,symbol,name,description__profile,ceo__profile,industry__profile,price__profile,currency__profile,mktCap__profile,image__profile,volAvg__profile,pe__quote,change__quote,volume__quote,ebitda__income_statement,netIncome__income_statement,annual_earnings,quaterly_earnings,eps__income_statement,epsdiluted__income_statement,totalAssets__balance_sheet_statement,totalCurrentAssets__balance_sheet_statement,cashAndShortTermInvestments__balance_sheet_statement,totalLiabilities__balance_sheet_statement,netReceivables__balance_sheet_statement,longTermInvestments__balance_sheet_statement,totalCurrentLiabilities__balance_sheet_statement,cashAndCashEquivalents__balance_sheet_statement,freeCashFlow__cash_flow_statement,growthEBITDA__income_statement_growth,growthNetIncome__income_statement_growth,growthEPS__income_statement_growth,dividend__historical-price-full/stock_dividend,date__historical-price-full/stock_dividend,derived__netIncomeMargin,derived__debtRatio
0,AACG,ATA Creativity Global American Depositary Shares,"ATA Creativity Global, together with its subsidiaries, provides educational services to individual students through its training center network in China and internationally. Its educational services include portfolio training, research-based learning, overseas study counselling, in-school art classes through cooperation with high schools, foreign language training services, junior art education, and other related educational services to its students. The company also offers online courses for students. As of December 31, 2021, it operated through 21 training centers in 20 cities in China. The company was formerly known as ATA Inc. and changed its name to ATA Creativity Global in September 2019. ATA Creativity Global was founded in 1999 and is headquartered in Beijing, China.",Mr. Xiaofeng  Ma,Education & Training Services,0.9448,USD,30200064,https://images.financialmodelingprep.com/symbol/AACG.png,42709,-5.25,0.0049,11668,-19511522,-33660245,"[{'period': '2023', 'revenue': 221.62, 'unit': 'M', 'net_profit': -33.66}, {'period': '2022', 'revenue': 206.82, 'unit': 'M', 'net_profit': -48.59}, {'period': '2021', 'revenue': 202.21, 'unit': 'M', 'net_profit': -36.41}, {'period': '2020', 'revenue': 162.17, 'unit': 'M', 'net_profit': -100.58}]","[{'period': ""Q3 '24"", 'revenue': 67.25, 'unit': 'M', 'net_profit': -14.65}, {'period': ""Q2 '24"", 'revenue': 51.76, 'unit': 'M', 'net_profit': -16.75}, {'period': ""Q1 '24"", 'revenue': 48.13, 'unit': 'M', 'net_profit': -17.95}, {'period': ""Q4 '23"", 'revenue': 83.61, 'unit': 'M', 'net_profit': 8.56}, {'period': ""Q3 '23"", 'revenue': 59.45, 'unit': 'M', 'net_profit': -7.25}, {'period': ""Q2 '23"", 'revenue': 36.24, 'unit': 'M', 'net_profit': -17.21}]",-1.08,-1.07,448939143,70444891,60167232,335965436,2235490,38000000,314402501,60167232,6511372,0.4260624620064456,0.3073201425905886,0.3032258064516129,"[5.98, 0.43]","['2018-08-27', '2011-06-28']",__nan__,0.748354072569698
1,AACQ,Artius Acquisition Inc. Class A Common Stock,,,,,,,,,0.0,0.3199997,3996043,,,[],"[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 62.53}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 16.18}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",,,726060750,1344274,1123407,721060740,0,0,220,1123407,,,,,__nan__,__nan__,__nan__,0.9931135101298342
2,AACQU,Artius Acquisition Inc. Unit ,,,,11.05,USD,1581255000,https://images.financialmodelingprep.com/symbol/AACQU.png,12570,0.0,0.5,4352,26820000,23798000,"[{'period': '2023', 'revenue': 28.8, 'unit': 'M', 'net_profit': 23.8}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 78.57}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -37.05}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.45}]","[{'period': ""Q3 '24"", 'revenue': 8.2, 'unit': 'M', 'net_profit': -36.76}, {'period': ""Q2 '24"", 'revenue': 7.03, 'unit': 'M', 'net_profit': -19.5}, {'period': ""Q1 '24"", 'revenue': 6.83, 'unit': 'M', 'net_profit': -13.91}, {'period': ""Q4 '23"", 'revenue': 13.06, 'unit': 'M', 'net_profit': -10.44}, {'period': ""Q3 '23"", 'revenue': 7.14, 'unit': 'M', 'net_profit': 30.93}, {'period': ""Q2 '23"", 'revenue': 6.9, 'unit': 'M', 'net_profit': -6.46}]",0.17,0.17,461834000,187112000,158263000,39327000,19577000,0,12862000,75502000,-170456000,-0.6641706944479226,-0.697107001489137,-0.7017543859649121,__nan__,__nan__,__nan__,0.08515397307257586
3,AACQW,Artius Acquisition Inc Warrant,,,,,,,,,0.0,0.07999992,534856,0,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 62.53}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",0,0,726060750,1344274,725839883,25357720,0,0,0,1123407,-562274,0,0,0,__nan__,__nan__,__nan__,0.0349250665319672
4,AAL,American Airlines Group Inc. Common Stock,"American Airlines Group Inc., through its subsidiaries, operates as a network air carrier. The company provides scheduled air transportation services for passengers and cargo through its hubs in Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C., as well as through partner gateways in London, Madrid, Seattle/Tacoma, Sydney, and Tokyo. As of December 31, 2021, it operated a mainline fleet of 865 aircraft. The company was formerly known as AMR Corporation and changed its name to American Airlines Group Inc. in December 2013. American Airlines Group Inc. was founded in 1930 and is headquartered in Fort Worth, Texas.",Mr. Robert D. Isom Jr.,"Airlines, Airports & Air Services",17.865,USD,11739645315,https://images.financialmodelingprep.com/symbol/AAL.png,27248585,41.55,,0,5202000000,822000000,"[{'period': '2023', 'revenue': 52790.0, 'unit': 'M', 'net_profit': 822.0}, {'period': '2022', 'revenue': 48970.0, 'unit': 'M', 'net_profit': 127.0}, {'period': '2021', 'revenue': 29.88, 'unit': 'B', 'net_profit': -1.99}, {'period': '2020', 'revenue': 17.34, 'unit': 'B', 'net_profit': -8.88}]","[{'period': ""Q3 '24"", 'revenue': 13650.0, 'unit': 'M', 'net_profit': -149.0}, {'period': ""Q2 '24"", 'revenue': 14330.0, 'unit': 'M', 'net_profit': 717.0}, {'period': ""Q1 '24"", 'revenue': 12570.0, 'unit': 'M', 'net_profit': -312.0}, {'period': ""Q4 '23"", 'revenue': 13060.0, 'unit': 'M', 'net_profit': 19.0}, {'period': ""Q3 '23"", 'revenue': 13480.0, 'unit': 'M', 'net_profit': -545.0}, {'period': ""Q2 '23"", 'revenue': 14.05, 'unit': 'B', 'net_profit': 1.34}]",1.26,1.14,63058000000,13572000000,7578000000,68260000000,2026000000,-807000000,22062000000,578000000,1207000000,0.2610909090909091,5.47244094488189,5.3,"[0.1, 0.1]","['2020-02-04', '2014-07-31']",__nan__,1.0824954803514224
5,AAME,Atlantic American Corporation Common Stock,"Atlantic American Corporation, through its subsidiaries, provides life and health, and property and casualty insurance products in the United States. The company operates through American Southern and Bankers Fidelity segments. It offers property and casualty insurance products, including business automobile insurance coverage for state governments, local municipalities, and other motor pools and fleets; and inland marine and general liability insurance products. The company also provides surety bond coverage for subdivision construction, school bus contracts, as well as performance and payment bonds. In addition, the company provides individual and group whole life insurance, as well as medicare supplement insurance products; and other accident and health insurance coverages, include various individual and group policies for the payment of standard benefits for the treatment of diagnosed cancer and other critical illnesses, as well as various other policies, such as short-term nursing facility care, accident expense, hospital indemnity, and disability coverages. It markets its products through independent agents and brokers. The company was founded in 1937 and is headquartered in Atlanta, Georgia.",Mr. Hilton Hatchett Howell Jr.,Insurance - Life,1.54,USD,31415692,https://images.financialmodelingprep.com/symbol/AAME.png,4680,-4.28,0.09,9369,3356000,-171000,"[{'period': '2023', 'revenue': 186790.0, 'unit': 'K', 'net_profit': -171.0}, {'period': '2022', 'revenue': 187.85, 'unit': 'M', 'net_profit': 1.52}, {'period': '2021', 'revenue': 199.55, 'unit': 'M', 'net_profit': 4.28}, {'period': '2020', 'revenue': 195.35, 'unit': 'M', 'net_profit': 12.17}]","[{'period': ""Q3 '24"", 'revenue': 44.52, 'unit': 'M', 'net_profit': -2.0}, {'period': ""Q2 '24"", 'revenue': 47670.0, 'unit': 'K', 'net_profit': -684.0}, {'period': ""Q1 '24"", 'revenue': 47.0, 'unit': 'M', 'net_profit': -2.0}, {'period': ""Q4 '23"", 'revenue': 46.74, 'unit': 'M', 'net_profit': -2.23}, {'period': ""Q3 '23"", 'revenue': 44.59, 'unit': 'M', 'net_profit': 1.76}, {'period': ""Q2 '23"", 'revenue': 49.19, 'unit': 'M', 'net_profit': 1.74}]",-0.0279,-0.0279,381265000,28301000,28301000,273990000,0,7619000,67440000,28301000,2542000,-0.3203726204941272,-1.1121311475409836,-1.5054347826086958,"[0.02, 0.2]","['2024-04-11', '1984-12-24']",__nan__,0.7186340209565525
6,AAOI,Applied Optoelectronics Inc. Common Stock,"Applied Optoelectronics, Inc. designs, manufactures, and sells various fiber-optic networking products worldwide. It offers optical modules, lasers, subassemblies, transmitters and transceivers, and turn-key equipment, as well as headend, node, and distribution equipment. The company sells its products to internet data center operators, cable television and telecom equipment manufacturers, and internet service providers through its direct and indirect sales channels. Applied Optoelectronics, Inc. was incorporated in 1997 and is headquartered in Sugar Land, Texas.",Dr. Chih-Hsiang  Lin Ph.D.,Semiconductors,33.93,USD,1625413257,https://images.financialmodelingprep.com/symbol/AAOI.png,3744461,-16.63,0,910770,-26184000,-56048000,"[{'period': '2023', 'revenue': 217.65, 'unit': 'M', 'net_profit': -56.05}, {'period': '2022', 'revenue': 222.82, 'unit': 'M', 'net_profit': -66.4}, {'period': '2021', 'revenue': 211.56, 'unit': 'M', 'net_profit': -54.16}, {'period': '2020', 'revenue': 234.62, 'unit': 'M', 'net_profit': -58.45}]","[{'period': ""Q3 '24"", 'revenue': 65.15, 'unit': 'M', 'net_profit': -17.76}, {'period': ""Q2 '24"", 'revenue': 43.27, 'unit': 'M', 'net_profit': -26.11}, {'period': ""Q1 '24"", 'revenue': 40.67, 'unit': 'M', 'net_profit': -23.17}, {'period': ""Q4 '23"", 'revenue': 60.45, 'unit': 'M', 'net_profit': -13.86}, {'period': ""Q3 '23"", 'revenue': 62.55, 'unit': 'M', 'net_profit': -8.95}, {'period': ""Q2 '23"", 'revenue': 41.62, 'unit': 'M', 'net_profit': -16.94}]",-1.75,-1.75,389186000,172605000,45366000,174317000,48290000,0,93358000,45366000,-17596000,0.2899254237288136,0.1558654758498125,0.2647058823529411,__nan__,__nan__,__nan__,0.4479015175263242
7,AAON,AAON Inc. Common Stock,"AAON, Inc., together with its subsidiaries, engages in engineering, manufacturing, marketing, and selling air conditioning and heating equipment in the United States and Canada. The company operates through three segments: AAON Oklahoma, AAON Coil Products, and BasX. It offers rooftop units, data center cooling solutions, cleanroom systems, chillers, packaged outdoor mechanical rooms, air handling units, makeup air units, energy recovery units, condensing units, geothermal/water-source heat pumps, coils, and controls. The company markets and sells its products to retail, manufacturing, educational, lodging, supermarket, data centers, medical and pharmaceutical, and other commercial industries. It sells its products through a network of independent manufacturer representative organizations and internal sales force. The company was incorporated in 1987 and is based in Tulsa, Oklahoma.",Mr. Gary D. Fields,Construction,121.64,USD,9886850544,https://images.financialmodelingprep.com/symbol/AAON.png,431224,53.35,-0.68,143285,274789000,177623000,"[{'period': '2023', 'revenue': 1170.0, 'unit': 'M', 'net_profit': 177.62}, {'period': '2022', 'revenue': 888.79, 'unit': 'M', 'net_profit': 100.38}, {'period': '2021', 'revenue': 534.52, 'unit': 'M', 'net_profit': 58.76}, {'period': '2020', 'revenue': 514.55, 'unit': 'M', 'net_profit': 79.01}]","[{'period': ""Q3 '24"", 'revenue': 327.25, 'unit': 'M', 'net_profit': 52.62}, {'period': ""Q2 '24"", 'revenue': 313.57, 'unit': 'M', 'net_profit': 52.23}, {'period': ""Q1 '24"", 'revenue': 262.1, 'unit': 'M', 'net_profit': 39.02}, {'period': ""Q4 '23"", 'revenue': 306.64, 'unit': 'M', 'net_profit': 47.05}, {'period': ""Q3 '23"", 'revenue': 311.97, 'unit': 'M', 'net_profit': 48.08}, {'period': ""Q2 '23"", 'revenue': 283.96, 'unit': 'M', 'net_profit': 45.68}]",2.19,2.13,941436000,408954000,287000,206212000,183302000,0,126749000,287000,49404000,0.6900731902331017,0.7695763927632103,0.738095238095238,"[0.08, 0.2]","['2024-11-29', '2006-06-08']",__nan__,0.2190398497614283
8,AAPL,Apple Inc. Common Stock,"Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. The company offers iPhone, a line of smartphones; Mac, a line of personal computers; iPad, a line of multi-purpose tablets; and wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod. It also provides AppleCare support and cloud services; and operates various platforms, including the App Store that allow customers to discover and download applications and digital content, such as books, music, video, games, and podcasts, as well as advertising services include third-party licensing arrangements and its own advertising platforms. In addition, the company offers various subscription-based services, such as Apple Arcade, a game subscription service; Apple Fitness+, a personalized fitness service; Apple Music, which offers users a curated listening experience with on-demand radio stations; Apple News+, a subscription news and magazine service; Apple TV+, which offers exclusive original content; Apple Card, a co-branded credit card; and Apple Pay, a cashless payment service, as well as licenses its intellectual property. The company serves consumers, and small and mid-sized businesses; and the education, enterprise, and government markets. It distributes third-party applications for its products through the App Store. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was founded in 1976 and is headquartered in Cupertino, California.",Mr. Timothy D. Cook,Consumer Electronics,244.11,USD,3689917938000,https://images.financialmodelingprep.com/symbol/AAPL.png,44102004,40.15,-0.895,11271951,134661000000,93736000000,"[{'period': '2024', 'revenue': 391.04, 'unit': 'B', 'net_profit': 93.74}, {'period': '2023', 'revenue': 383.29, 'unit': 'B', 'net_profit': 97.0}, {'period': '2022', 'revenue': 394.33, 'unit': 'B', 'net_profit': 99.8}, {'period': '2021', 'revenue': 365.82, 'unit': 'B', 'net_profit': 94.68}]","[{'period': ""Q4 '24"", 'revenue': 94.93, 'unit': 'B', 'net_profit': 14.74}, {'period': ""Q3 '24"", 'revenue': 85.78, 'unit': 'B', 'net_profit': 21.45}, {'period': ""Q2 '24"", 'revenue': 90.75, 'unit': 'B', 'net_profit': 23.64}, {'period': ""Q1 '24"", 'revenue': 119.58, 'unit': 'B', 'net_profit': 33.92}, {'period': ""Q4 '23"", 'revenue': 89.5, 'unit': 'B', 'net_profit': 22.96}, {'period': ""Q3 '23"", 'revenue': 81.8, 'unit': 'B', 'net_profit': 19.88}]",6.11,6.08,364980000000,152987000000,65171000000,308030000000,66243000000,91479000000,176392000000,29943000000,108807000000,0.07026704816404387,-0.033599670086086914,-0.008116883116883088,"[0.25, 0.12]","['2024-11-08', '1987-05-11']",__nan__,0.8439640528248123
9,AAWW,Atlas Air Worldwide Holdings NEW Common Stock,"Atlas Air Worldwide Holdings, Inc., through its subsidiaries, provides outsourced aircraft and aviation operating services. It operates through two segments, Airline Operations and Dry Leasing. The company offers outsourced cargo and passenger aircraft operating solutions, including contractual service arrangements, such as the provision of aircraft; and value-added services, including crew, maintenance, and insurance to aircraft and other customers. It also provides cargo and passenger aircraft charter services to the U.S. Military Air Mobility Command, charter brokers, freight forwarders, direct shippers, airlines, manufacturers, sports teams and fans, and private charter customers; and cargo and passenger aircraft and engines dry leasing services. In addition, the company offers administrative and management support services, and flight simulator training services. It also serves express delivery providers, e-commerce retailers, and airlines. The company has operations in Africa, Asia, Australia, Europe, the Middle East, North America, and South America. Atlas Air Worldwide Holdings, Inc. was founded in 1992 and is headquartered in Purchase, New York.",Mr. John W. Dietrich,"Airlines, Airports & Air Services",102.48,USD,2934330336,https://images.financialmodelingprep.com/symbol/AAWW.png,552884,9.732193732193732,0.02,1527211,914532000,355880000,"[{'period': '2022', 'revenue': 4550.0, 'unit': 'M', 'net_profit': 355.88}, {'period': '2021', 'revenue': 4030.0000000000005, 'unit': 'M', 'net_profit': 493.32}, {'period': '2020', 'revenue': 3210.0, 'unit': 'M', 'net_profit': 360.29}, {'period': '2019', 'revenue': 2740.0, 'unit': 'M', 'net_profit': -293.11}]","[{'period': ""Q4 '22"", 'revenue': 1210.0, 'unit': 'M', 'net_profit': 126.01}, {'period': ""Q3 '22"", 'revenue': 1120.0, 'unit': 'M', 'net_profit': 60.1}, {'period': ""Q2 '22"", 'revenue': 1180.0, 'unit': 'M', 'net_profit': 88.26}, {'period': ""Q1 '22"", 'revenue': 1040.0, 'unit': 'M', 'net_profit': 81.51}, {'period': ""Q4 '21"", 'revenue': 1160.0, 'unit': 'M', 'net_profit': 176.74}, {'period': ""Q3 '21"", 'revenue': 1020.0, 'unit': 'M', 'net_profit': 119.53}]",12.5,10.53,6696316000,1124918000,763314000,3631540000,253738000,0,1171283000,763314000,-8538000,-0.17628949641480052,-0.27859773735752064,-0.26729191090269633,__nan__,__nan__,__nan__,0.5423190900787836
10,ABCB,Ameris Bancorp Common Stock,"Ameris Bancorp operates as the bank holding company for Ameris Bank that provides range of banking services to retail and commercial customers primarily in Georgia, Alabama, Florida, North Carolina, and South Carolina. The company operates through five segments: Banking Division, Retail Mortgage Division, Warehouse Lending Division, SBA Division, and Premium Finance Division. It offers commercial and retail checking, regular interest-bearing savings, money market, individual retirement, and certificates of deposit accounts. The company also provides commercial real estate, residential real estate mortgage, agricultural, and commercial and industrial loans; consumer loans, including motor vehicle, home improvement, and home equity loans, as well as loans secured by savings accounts and small unsecured personal credit lines. In addition, it originates, administers, and services commercial insurance premium loans and small business administration loans. The company operates 165 full service domestic banking offices and 35 mortgage and loan production offices. Ameris Bancorp was founded in 1971 and is headquartered in Atlanta, Georgia.",Mr. H. Palmer Proctor Jr.,Banks - Regional,61.63,USD,4256580968,https://images.financialmodelingprep.com/symbol/ABCB.png,390050,12.89,-0.66,42513,0,269105000,"[{'period': '2023', 'revenue': 1450.0, 'unit': 'M', 'net_profit': 269.11}, {'period': '2022', 'revenue': 1090.0, 'unit': 'M', 'net_profit': 346.54}, {'period': '2021', 'revenue': 1020.0, 'unit': 'M', 'net_profit': 376.91}, {'period': '2020', 'revenue': 1080.0, 'unit': 'M', 'net_profit': 261.99}]","[{'period': ""Q3 '24"", 'revenue': 275.25, 'unit': 'M', 'net_profit': 99.21}, {'period': ""Q2 '24"", 'revenue': 347.32, 'unit': 'M', 'net_profit': 90.78}, {'period': ""Q1 '24"", 'revenue': 360.2, 'unit': 'M', 'net_profit': 74.31}, {'period': ""Q4 '23"", 'revenue': 388.46, 'unit': 'M', 'net_profit': 65.93}, {'period': ""Q3 '23"", 'revenue': 272.29, 'unit': 'M', 'net_profit': 80.11}, {'period': ""Q2 '23"", 'revenue': 276.04, 'unit': 'M', 'net_profit': 62.63}]",3.9,3.89,25203699000,2420007000,1167304000,21776952000,0,1616250000,9835950000,1167304000,551428000,0,-0.22345183817163963,-0.2215568862275449,"[0.2, 0.095]","['2024-12-31', '1994-07-11']",__nan__,0.8640379334795262
11,ABCL,AbCellera Biologics Inc. Common Shares,"AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.",Dr. Carl L.G. Hansen Ph.D.,Biotechnology,3.405,USD,1005721230,https://images.financialmodelingprep.com/symbol/ABCL.png,2460083,-5.58,0.095,2115296,-192158000,-146398000,"[{'period': '2023', 'revenue': 38.02, 'unit': 'M', 'net_profit': -146.4}, {'period': '2022', 'revenue': 485.42, 'unit': 'M', 'net_profit': 158.52}, {'period': '2021', 'revenue': 375.2, 'unit': 'M', 'net_profit': 153.46}, {'period': '2020', 'revenue': 233.16, 'unit': 'M', 'net_profit': 118.92}]","[{'period': ""Q3 '24"", 'revenue': 6.51, 'unit': 'M', 'net_profit': -51.11}, {'period': ""Q2 '24"", 'revenue': 7.32, 'unit': 'M', 'net_profit': -36.93}, {'period': ""Q1 '24"", 'revenue': 9.95, 'unit': 'M', 'net_profit': -40.61}, {'period': ""Q4 '23"", 'revenue': 9.18, 'unit': 'M', 'net_profit': -47.15}, {'period': ""Q3 '23"", 'revenue': 6.6, 'unit': 'M', 'net_profit': -28.61}, {'period': ""Q2 '23"", 'revenue': 10.06, 'unit': 'M', 'net_profit': -30.53}]",-0.51,-0.51,1488094000,871985000,760585000,335776000,64382000,65938000,119013000,133320000,-121384000,-1.7059415652403922,-1.9235359799140797,-1.9107142857142856,__nan__,__nan__,__nan__,0.2256416597338609
12,ABCM,Abcam plc American Depositary Shares,"Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.","Mr. Alan Thomas Hirzel BS, M.B.A., M.S.",Biotechnology,23.99,USD,5521322682,https://images.financialmodelingprep.com/symbol/ABCM.png,5816355,2399.0,0.01,7430229,42700000,-8500000,"[{'period': '2022', 'revenue': 361.7, 'unit': 'M', 'net_profit': -8.5}, {'period': '2021', 'revenue': 315.4, 'unit': 'M', 'net_profit': 4.4}, {'period': '2020', 'revenue': 297.7, 'unit': 'M', 'net_profit': 14.6}, {'period': '2019', 'revenue': 260.0, 'unit': 'M', 'net_profit': 12.5}]","[{'period': ""Q2 '23"", 'revenue': 101.6, 'unit': 'M', 'net_profit': 8.4}, {'period': ""Q1 '23"", 'revenue': 101.6, 'unit': 'M', 'net_profit': 8.4}, {'period': ""Q4 '22"", 'revenue': 166.7, 'unit': 'M', 'net_profit': -9.38}, {'period': ""Q3 '22"", 'revenue': 88.25, 'unit': 'M', 'net_profit': -7.15}, {'period': ""Q2 '22"", 'revenue': 92.6, 'unit': 'M', 'net_profit': 2.9}, {'period': ""Q1 '22"", 'revenue': 92.6, 'unit': 'M', 'net_profit': 2.9}]",-0.0372,-0.0372,1056600000,255400000,89000000,329700000,90300000,3200000,201800000,89000000,-12600000,-0.09915611814345991,-2.9318181818181817,-2.9375,"[0.044272, 0.035769]","['2020-03-19', '2014-03-19']",__nan__,0.31203861442362296
13,ABEO,Abeona Therapeutics Inc. Common Stock,"Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.","Dr. Vishwas  Seshadri M.B.A., Ph.D.",Biotechnology,6,USD,260826000,https://images.financialmodelingprep.com/symbol/ABEO.png,253229,-2.93,0,60920,-50572000,-54188000,"[{'period': '2023', 'revenue': 3.5, 'unit': 'M', 'net_profit': -54.19}, {'period': '2022', 'revenue': 1.41, 'unit': 'M', 'net_profit': -31.81}, {'period': '2021', 'revenue': 3.0, 'unit': 'M', 'net_profit': -88.61}, {'period': '2020', 'revenue': 10.0, 'unit': 'M', 'net_profit': -88.35}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.27}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.41}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.58}, {'period': ""Q4 '23"", 'revenue': 2.82, 'unit': 'M', 'net_profit': -16.59}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.84}, {'period': ""Q2 '23"", 'revenue': 3.5, 'unit': 'M', 'net_profit': -16.65}]",-2.53,-2.53,64002000,55737000,52226000,49176000,2444000,0,13422000,14473000,-37340000,-0.4708431492307245,-0.7035430224150397,0.37530864197530867,"[0.593, 0.593]","['2000-03-31', '2000-03-31']",__nan__,0.7683509890315927
14,ABGI,ABG Acquisition Corp. I Class A Ordinary Shares,"ABG Acquisition Corp. I does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. ABG Acquisition Corp. I was incorporated in 2020 and is based in New York, New York.",Mr. Fan  Yu,Shell Companies,10.19,USD,196999184,https://images.financialmodelingprep.com/symbol/ABGI.png,42875,1019.0,-0.03,2114,-750584,-742688,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -742.69}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.33}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 2.42}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -300.23}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -149.87}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -215.82}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.62}]",-0.0432,-0.0432,151524679,866783,510896,5469874,0,150657896,197124,510896,-979168,0,0,0,__nan__,__nan__,__nan__,0.03609889845072696
15,ABIO,ARCA biopharma Inc. Common Stock,"ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.",Mr. Thomas A. Keuer,Biotechnology,28.8,USD,34817184,https://images.financialmodelingprep.com/symbol/ABIO.png,13857,-4.8979591836734695,26.3,290850,-7296000,-5339000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.34}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.26}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.23}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.74}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.68}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.01}, {'period': ""Q3 '23"", 'revenue': 0.176, 'unit': 'M', 'net_profit': -1.09}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.42}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -958.0}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -896.0}]",-0.37,-0.37,37861000,37592000,37431000,841000,0,0,637000,37431000,-5014000,0.3114382785956965,0.42318496110630943,0.421875,"[1.613, 0.1325]","['2024-08-29', '2024-08-26']",__nan__,0.02221283114550593
16,ABMD,ABIOMED Inc. Common Stock,"Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.",Mr. Michael Minogue,Medical - Devices,381.02,USD,17180649405,https://images.financialmodelingprep.com/symbol/ABMD.png,1703123,65.35506003430531,0,15702662,400781000,136505000,"[{'period': '2022', 'revenue': 1030.0, 'unit': 'M', 'net_profit': 136.5}, {'period': '2021', 'revenue': 847.52, 'unit': 'M', 'net_profit': 225.53}, {'period': '2020', 'revenue': 840.88, 'unit': 'M', 'net_profit': 203.01}, {'period': '2019', 'revenue': 769.43, 'unit': 'M', 'net_profit': 259.02}]","[{'period': ""Q2 '23"", 'revenue': 265.92, 'unit': 'M', 'net_profit': 106.13}, {'period': ""Q1 '23"", 'revenue': 277.15, 'unit': 'M', 'net_profit': 54.55}, {'period': ""Q4 '22"", 'revenue': 269.85, 'unit': 'M', 'net_profit': 60.33}, {'period': ""Q3 '22"", 'revenue': 261.18, 'unit': 'M', 'net_profit': 45.75}, {'period': ""Q2 '22"", 'revenue': 248.14, 'unit': 'M', 'net_profit': 56.95}, {'period': ""Q1 '22"", 'revenue': 252.59, 'unit': 'M', 'net_profit': -26.52}]",3,2.98,1673393000,976473000,758607000,170067000,90608000,351938000,138457000,132818000,249627000,0.6230091075861455,-0.3947234231238222,-0.4,__nan__,__nan__,__nan__,0.10163004147860066
17,ABNB,Airbnb Inc. Class A Common Stock,"Airbnb, Inc., together with its subsidiaries, operates a platform that enables hosts to offer stays and experiences to guests worldwide. The company's marketplace model connects hosts and guests online or through mobile devices to book spaces and experiences. It primarily offers private rooms, primary homes, or vacation homes. The company was formerly known as AirBed & Breakfast, Inc. and changed its name to Airbnb, Inc. in November 2010. Airbnb, Inc. was founded in 2007 and is headquartered in San Francisco, California.",Mr. Brian  Chesky,Travel Services,133.65,USD,84736564773,https://images.financialmodelingprep.com/symbol/ABNB.png,4465472,46.41,-1.55,1274234,2229000000,4792000000,"[{'period': '2023', 'revenue': 9.92, 'unit': 'B', 'net_profit': 4.79}, {'period': '2022', 'revenue': 8.4, 'unit': 'B', 'net_profit': 1.89}, {'period': '2021', 'revenue': 5990.0, 'unit': 'M', 'net_profit': -352.0}, {'period': '2020', 'revenue': 3.38, 'unit': 'B', 'net_profit': -4.58}]","[{'period': ""Q3 '24"", 'revenue': 3.73, 'unit': 'B', 'net_profit': 1.37}, {'period': ""Q2 '24"", 'revenue': 2750.0, 'unit': 'M', 'net_profit': 555.0}, {'period': ""Q1 '24"", 'revenue': 2140.0, 'unit': 'M', 'net_profit': 264.0}, {'period': ""Q4 '23"", 'revenue': 2220.0, 'unit': 'M', 'net_profit': -349.0}, {'period': ""Q3 '23"", 'revenue': 3.4, 'unit': 'B', 'net_profit': 4.37}, {'period': ""Q2 '23"", 'revenue': 2480.0, 'unit': 'M', 'net_profit': 650.0}]",7.52,7.24,20645000000,16509000000,10071000000,12480000000,5869000000,95000000,9950000000,6874000000,3884000000,0.06026732626171336,1.5314315900686741,1.5319865319865316,__nan__,__nan__,__nan__,0.604504722693146
18,ABST,Absolute Software Corporation Common Stock,"Absolute Software Corporation develops, markets, and provides software services that support the management and security of computing devices, applications, data, and networks for various organizations. The company's Absolute platform offer Absolute Visibility that provides information on device hardware, software, and location; Absolute Control that provide remediation capabilities, such as the ability to remotely freeze devices and delete data; Absolute Resilience, which offer remote scripting, self-healing for critical apps, investigation and recovery services, and sensitive data identification; Absolute Ransomware Response that enables organizations to assess their ransomware preparedness for endpoints, monitors their endpoint cyber hygiene across the entire device fleet and allows for an expedited endpoint recovery; Absolute VPN an enterprise solution; Absolute ZTNA that protects networks and employees with real time risk analysis; and Absolute Insights for Network provides real-time data about device, application, and network performance in a single pane of glass. The company markets its solutions through device original equipment manufacturers, distributors, and value added resellers, as well as directly to healthcare organizations, educational institutions, governmental agencies, and individual consumers. It operates in North America, the United Kingdom, Vietnam, Germany, Australia, Japan, and Latin America. Absolute Software Corporation was incorporated in 1993 and is headquartered in Vancouver, Canada.",Ms. Christy  Wyatt,Software - Application,11.49,USD,610809526,https://images.financialmodelingprep.com/symbol/ABST.png,1570934,-22.98,-0.01,704052,18016000,-24485000,"[{'period': '2021', 'revenue': 197.31, 'unit': 'M', 'net_profit': -24.48}, {'period': '2020', 'revenue': 120.78, 'unit': 'M', 'net_profit': 3.73}, {'period': '2019', 'revenue': 104.67, 'unit': 'M', 'net_profit': 10.63}, {'period': '2018', 'revenue': 98.91, 'unit': 'M', 'net_profit': 7.58}]","[{'period': ""Q3 '22"", 'revenue': 58.77, 'unit': 'M', 'net_profit': -3.97}, {'period': ""Q2 '22"", 'revenue': 57.19, 'unit': 'M', 'net_profit': -7.0}, {'period': ""Q1 '22"", 'revenue': 53.56, 'unit': 'M', 'net_profit': -9.49}, {'period': ""Q4 '21"", 'revenue': 52.53, 'unit': 'M', 'net_profit': -5.34}, {'period': ""Q3 '21"", 'revenue': 51.98, 'unit': 'M', 'net_profit': -6.46}, {'period': ""Q2 '21"", 'revenue': 49.05, 'unit': 'M', 'net_profit': -5.12}]",-0.49,-0.49,555618000,136384000,64029000,552419000,63269000,0,174323000,63669000,37963000,0.5894133215703573,-7.560825294748124,-7.124999999999999,"[0.08, 0.05]","['2023-05-10', '2013-02-05']",__nan__,0.9942424471489405
19,ABTX,Allegiance Bancshares Inc. Common Stock,"Allegiance Bancshares, Inc. operates as the bank holding company for Allegiance Bank that provides a range of commercial banking services primarily to small and medium-sized businesses, professionals, and individual customers. It accepts deposit products, including checking accounts, commercial accounts, money market accounts, savings accounts, and other time deposits; and certificates of deposit. The company's loan portfolio comprises commercial and industrial loans; commercial real estate loans, including multi-family residential loans; commercial real estate construction and land development loans; residential real estate loans, such as 1-4 family residential mortgage loans; residential construction loans; and consumer and other loans. In addition, it offers automated teller machine services, drive-through services, and depository facilities; mobile banking services; and telephone, mail, and Internet banking services. Further, the company provides safe deposit boxes, debit cards, cash management and wire transfer services, night depository services, direct deposits, cashier's checks, and letters of credit. As of December 31, 2021, it operated 27 full-service banking locations, including 26 bank offices in the Houston metropolitan area and one office in Beaumont. The company was founded in 2007 and is headquartered in Houston, Texas.",Mr. Steven Retzloff,Banks - Regional,41.63,USD,0,https://images.financialmodelingprep.com/symbol/ABTX.png,0,11.190860215053764,-0.36,1609047,132064000,81553000,"[{'period': '2021', 'revenue': 237.13, 'unit': 'M', 'net_profit': 81.55}, {'period': '2020', 'revenue': 210.84, 'unit': 'M', 'net_profit': 45.53}, {'period': '2019', 'revenue': 192.96, 'unit': 'M', 'net_profit': 52.96}, {'period': '2018', 'revenue': 136.29, 'unit': 'M', 'net_profit': 37.31}]","[{'period': ""Q2 '22"", 'revenue': 60.19, 'unit': 'M', 'net_profit': 16.44}, {'period': ""Q1 '22"", 'revenue': 59.19, 'unit': 'M', 'net_profit': 18.66}, {'period': ""Q4 '21"", 'revenue': 60.56, 'unit': 'M', 'net_profit': 21.56}, {'period': ""Q3 '21"", 'revenue': 60.27, 'unit': 'M', 'net_profit': 19.06}, {'period': ""Q2 '21"", 'revenue': 58.87, 'unit': 'M', 'net_profit': 22.93}, {'period': ""Q1 '21"", 'revenue': 57.43, 'unit': 'M', 'net_profit': 18.01}]",3.97,3.97,7104954000,5029181000,2531274000,6288486000,33392000,1773765000,1753000,757509000,104449000,0.2860704269242755,0.7910352703474327,0.7882882882882882,"[0.14, 0.1]","['2022-08-30', '2020-02-28']",__nan__,0.8850846887960148
20,ABUS,Arbutus Biopharma Corporation Common Stock,"Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.",Mr. Michael J. McElhaugh,Biotechnology,3.29,USD,623428680,https://images.financialmodelingprep.com/symbol/ABUS.png,862698,-7.65,0.02,192881,-70986000,-72849000,"[{'period': '2023', 'revenue': 18.14, 'unit': 'M', 'net_profit': -72.85}, {'period': '2022', 'revenue': 39.02, 'unit': 'M', 'net_profit': -69.46}, {'period': '2021', 'revenue': 10.99, 'unit': 'M', 'net_profit': -77.35}, {'period': '2020', 'revenue': 6.91, 'unit': 'M', 'net_profit': -65.21}]","[{'period': ""Q3 '24"", 'revenue': 1.34, 'unit': 'M', 'net_profit': -19.72}, {'period': ""Q2 '24"", 'revenue': 1.73, 'unit': 'M', 'net_profit': -19.8}, {'period': ""Q1 '24"", 'revenue': 1.53, 'unit': 'M', 'net_profit': -17.88}, {'period': ""Q4 '23"", 'revenue': 2.15, 'unit': 'M', 'net_profit': -19.31}, {'period': ""Q3 '23"", 'revenue': 4.66, 'unit': 'M', 'net_profit': -20.1}, {'period': ""Q2 '23"", 'revenue': 4.65, 'unit': 'M', 'net_profit': -17.09}]",-0.44,-0.44,144401000,132026999,126003000,38383000,1776000,6284000,22487000,26285000,-86944000,-0.14754522381545127,-0.04885107118175536,0.04347826086956525,__nan__,__nan__,__nan__,0.2658084085290268
21,ACAC,Acies Acquisition Corp. Class A Ordinary Share,"Acri Capital Acquisition Corporation focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. It intends to complete a business combination with technology-enabled companies operating in the areas of Software-as-a-Service, artificial intelligence, cloud computing, and Internet of Things. The company was incorporated in 2022 and is based in Austin, Texas.",Ms. Yi  Hua,Shell Companies,11.2,USD,44482256,https://images.financialmodelingprep.com/symbol/ACAC.png,9876,-18.06451612903226,-0.52,4112,-801150,886366,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': 886.37}, {'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': 217.22}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -213.23}]","[{'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -245.3}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 102.65}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 158.9}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 272.86}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 90.94}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 363.66}]",0.14,0.14,36732926,60080,54289,5171858,0,36672846,2550421,54289,-849990,-0.12130657444095627,3.0804238942289985,5.9306930693069315,__nan__,__nan__,__nan__,0.14079624367522478
22,ACACU,Acies Acquisition Corp. Unit,"Acri Capital Acquisition Corporation focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. It intends to complete a business combination with technology-enabled companies operating in the areas of Software-as-a-Service, artificial intelligence, cloud computing, and Internet of Things. The company was incorporated in 2022 and is based in Austin, Texas.",Ms. Yi  Hua,Shell Companies,12.94,USD,44482246,https://images.financialmodelingprep.com/symbol/ACACU.png,1165,0.0,-0.01,404,-801150,886366,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': 886.37}, {'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': 217.22}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -213.23}]","[{'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -245.3}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 102.65}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 158.9}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 272.86}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 90.94}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 363.66}]",0.14,0.14,36732926,60080,54289,5171858,0,36672846,2550421,54289,-849990,-0.12130657444095627,3.0804238942289985,5.9306930693069315,__nan__,__nan__,__nan__,0.14079624367522478
23,ACACW,Acies Acquisition Corp. Warrant,"Acri Capital Acquisition Corp. operates as a blank check company. The company was founded on January 7, 2022 and is headquartered in Austin, TX.",Ms. Yi  Hua,Shell Companies,0.26,USD,44482256,https://images.financialmodelingprep.com/symbol/ACACW.png,0,0.0,0.08,13089,-801150,886366,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': 886.37}, {'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': 217.22}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -213.23}]","[{'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -245.3}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 102.65}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 158.9}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 272.86}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 90.94}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 363.66}]",0.14,0.14,36732926,60080,54289,5171858,0,36672846,2550421,54289,-849990,-0.12130657444095627,3.0804238942289985,5.9306930693069315,__nan__,__nan__,__nan__,0.14079624367522478
24,ACAD,ACADIA Pharmaceuticals Inc. Common Stock,"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.",Ms. Catherine E. Owen Adams,Biotechnology,17.53,USD,2916851760,https://images.financialmodelingprep.com/symbol/ACAD.png,2217272,22.47,0.07,471547,-67827000,-61286000,"[{'period': '2023', 'revenue': 726.44, 'unit': 'M', 'net_profit': -61.29}, {'period': '2022', 'revenue': 517.24, 'unit': 'M', 'net_profit': -215.97}, {'period': '2021', 'revenue': 484.14, 'unit': 'M', 'net_profit': -167.87}, {'period': '2020', 'revenue': 441.75, 'unit': 'M', 'net_profit': -281.58}]","[{'period': ""Q3 '24"", 'revenue': 250.4, 'unit': 'M', 'net_profit': 32.77}, {'period': ""Q2 '24"", 'revenue': 241.96, 'unit': 'M', 'net_profit': 33.39}, {'period': ""Q1 '24"", 'revenue': 205.83, 'unit': 'M', 'net_profit': 16.55}, {'period': ""Q4 '23"", 'revenue': 231.04, 'unit': 'M', 'net_profit': 45.8}, {'period': ""Q3 '23"", 'revenue': 211.7, 'unit': 'M', 'net_profit': -65.18}, {'period': ""Q2 '23"", 'revenue': 165.24, 'unit': 'M', 'net_profit': 1.11}]",-0.37,-0.37,748956000,616125000,438865000,317201000,102350000,5770000,254254000,188657000,-23348000,0.6938800379112696,0.7162356754253965,0.7238805970149254,__nan__,__nan__,__nan__,0.4235242123702861
25,ACAH,Atlantic Coastal Acquisition Corp. Class A Common Stock,"Atlantic Coastal Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in mobility sector. The company was incorporated in 2020 and is based in New York, New York.",Mr. Anthony  Porcheron,Shell Companies,10.45,USD,127046920,https://images.financialmodelingprep.com/symbol/ACAH.png,1254,40.19230769230769,-0.18,37960,-19071021,17994321,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.99}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.72}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': -12.0}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.81}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.95}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.9}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.59}]",0.42,0.42,350656275,1353445,1252410,19858039,0,348936724,6904706,1252410,393036,-2.446146765466579,2.851885459315284,2.8260869565217392,__nan__,__nan__,__nan__,0.056631066990031766
26,ACAHU,Atlantic Coastal Acquisition Corp. Unit,"Atlantic Coastal Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in mobility sector. The company was incorporated in 2020 and is based in New York, New York.",Mr. Anthony  Porcheron,Shell Companies,10.66,USD,127046914,https://images.financialmodelingprep.com/symbol/ACAHU.png,514,-2132.0,-0.05,3002,-19071021,17994321,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.99}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.72}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': -12.0}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.81}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.95}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.9}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.59}]",0.42,0.42,350656275,1353445,1252410,19858039,0,348936724,6904706,1252410,393036,-2.446146765466579,2.851885459315284,2.8260869565217392,__nan__,__nan__,__nan__,0.056631066990031766
27,ACAHW,Atlantic Coastal Acquisition Corp. Warrant,"Atlantic Coastal Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in San Francisco, California.",Mr. Anthony  Porcheron,Shell Companies,0.0161,USD,195077,https://images.financialmodelingprep.com/symbol/ACAHW.png,0,,,0,-19071021,17994321,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.99}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.72}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': -12.0}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.81}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.95}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.9}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.59}]",0.42,0.42,350656275,1353445,1252410,19858039,0,348936724,6904706,1252410,393036,-2.446146765466579,2.851885459315284,2.8260869565217392,__nan__,__nan__,__nan__,0.056631066990031766
28,ACBAU,Ace Global Business Acquisition Limited Unit,"Ace Global Business Acquisition Limited does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses. It intends to focus on businesses in the gaming and e-commerce sectors in Greater China, Japan, and Southeast Asia regions. The company was incorporated in 2020 and is based in Central, Hong Kong.",Mr. Eugene Tu  Wong,Shell Companies,12,USD,41124600,https://images.financialmodelingprep.com/symbol/ACBAU.png,3,-57.69230769230769,-0.69,202,-1462820,-227215,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': -227.22}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.93}, {'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -981.06}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -15.81}]","[{'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -23.64}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -5.47}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 117.33}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -589.09}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 609.09}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.86}]",-0.0611,-0.0611,23399064,68541,68541,6951262,0,23330523,5103586,68541,-1355983,0.470359280353089,-1.0460850009309692,-1.0754320987654322,__nan__,__nan__,__nan__,0.2970743616069429
29,ACBAW,Ace Global Business Acquisition Limited Warrant,"Ace Global Business Acquisition Limited focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was founded in 2020 and is based in Central, Hong Kong.",Mr. Eugene Tu  Wong,Shell Companies,0.02,USD,68541,https://images.financialmodelingprep.com/symbol/ACBAW.png,0,0,-0.0136,210387,-1462820,-227215,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': -227.22}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.93}, {'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -981.06}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -15.81}]","[{'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -23.64}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -5.47}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 117.33}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -589.09}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 609.09}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.86}]",-0.0611,-0.0611,23399064,68541,68541,6951262,0,23330523,5103586,68541,-1355983,0.470359280353089,-1.0460850009309692,-1.0754320987654322,__nan__,__nan__,__nan__,0.2970743616069429
30,ACBI,Atlantic Capital Bancshares Inc. Common Stock,"Atlantic Capital Bancshares, Inc. operates as the bank holding company for Atlantic Capital Bank, N.A. that provides banking products and services. The company offers non-interest and interest bearing demand, savings and money market, time, and brokered deposits. It also provides working capital and equipment loans, loans supported by owner-occupied real estate, revolving lines of credit, term loans, and letters of credit; secured installments and home equity lines of credit; and commercial real estate loans, including secured construction loans, secured mini-permanent loans, and secured or unsecured lines of credit, as well as small business administration and franchise finance loans. In addition, the company offers cash and treasury management, capital market, payment processing, commercial and not-for-profit banking, payroll, electronic payment, and online and mobile banking services. It serves small and medium sized businesses and commercial enterprises, franchisees, not for profit enterprises, commercial real estate developers and individual clients, and professional services businesses. The company primarily operates 5 additional locations located in Cobb County, Fulton County, and Athens-Clarke County, Georgia; and Hamilton County, Tennessee. Atlantic Capital Bancshares, Inc. was incorporated in 2006 and is headquartered in Atlanta, Georgia.",Mr. Douglas Williams,Banks - Regional,32.34,USD,0,https://images.financialmodelingprep.com/symbol/ACBI.png,106420,0,-0.03,81866,46330000,22540000,"[{'period': '2020', 'revenue': 97.26, 'unit': 'M', 'net_profit': 22.54}, {'period': '2019', 'revenue': 91.59, 'unit': 'M', 'net_profit': 49.85}, {'period': '2018', 'revenue': 84.61, 'unit': 'M', 'net_profit': 28.53}, {'period': '2017', 'revenue': 97.03, 'unit': 'M', 'net_profit': -3.73}]","[{'period': ""Q3 '21"", 'revenue': 29.38, 'unit': 'M', 'net_profit': 13.3}, {'period': ""Q2 '21"", 'revenue': 29.24, 'unit': 'M', 'net_profit': 11.82}, {'period': ""Q1 '21"", 'revenue': 26.91, 'unit': 'M', 'net_profit': 13.36}, {'period': ""Q4 '20"", 'revenue': 25.66, 'unit': 'M', 'net_profit': 9.95}, {'period': ""Q3 '20"", 'revenue': 24.22, 'unit': 'M', 'net_profit': 8.62}, {'period': ""Q2 '20"", 'revenue': 23.97, 'unit': 'M', 'net_profit': 1.85}]",1.05,1.05,3615617000,3009901000,988825000,3277031000,0,561471000,0,653402000,80963000,-0.472407588767167,-0.5478888777454618,-0.5047169811320755,__nan__,__nan__,__nan__,0.9063545724007825
31,ACCD,Accolade Inc. Common Stock,"Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.",Mr. Rajeev  Singh,Medical - Healthcare Information Services,3.405,USD,274228826,https://images.financialmodelingprep.com/symbol/ACCD.png,1280462,-3.34,-0.095,372405,-71193000,-99805000,"[{'period': '2024', 'revenue': 414.29, 'unit': 'M', 'net_profit': -99.81}, {'period': '2023', 'revenue': 363.14, 'unit': 'M', 'net_profit': -459.65}, {'period': '2022', 'revenue': 310.02, 'unit': 'M', 'net_profit': -123.12}, {'period': '2021', 'revenue': 170.36, 'unit': 'M', 'net_profit': -50.65}]","[{'period': ""Q2 '25"", 'revenue': 106.36, 'unit': 'M', 'net_profit': -23.93}, {'period': ""Q1 '25"", 'revenue': 110.47, 'unit': 'M', 'net_profit': -27.59}, {'period': ""Q4 '24"", 'revenue': 124.83, 'unit': 'M', 'net_profit': -7.51}, {'period': ""Q3 '24"", 'revenue': 99.37, 'unit': 'M', 'net_profit': -21.06}, {'period': ""Q2 '24"", 'revenue': 96.86, 'unit': 'M', 'net_profit': -32.83}, {'period': ""Q1 '24"", 'revenue': 93.23, 'unit': 'M', 'net_profit': -38.41}]",-1.33,-1.33,788151000,284912000,237033000,342686000,27702000,0,107850000,185718000,-28651000,0.35481444560242875,0.782867399108017,0.7937984496124031,__nan__,__nan__,__nan__,0.4347973928853735
32,ACER,Acer Therapeutics Inc. Common Stock (DE),"Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.",Mr. Christopher  Schelling,Biotechnology,0.6601,USD,0,https://images.financialmodelingprep.com/symbol/ACER.png,2387245,-0.342020725388601,-0.1444,574675,-24548224.000000004,-27860371,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -27.86}, {'period': '2021', 'revenue': 1.26, 'unit': 'M', 'net_profit': -14.73}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -22.9}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.88}]","[{'period': ""Q3 '23"", 'revenue': 0.37179, 'unit': 'M', 'net_profit': -14.73}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.09}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.86}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.24}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.99}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.67}]",-1.77,-1.77,11624226,3516698,2329218,28385498,0,0,18951700,2329218,-30423068,-0.5461036754204512,-0.8915723224152273,-0.7184466019417476,__nan__,__nan__,__nan__,2.4419258538159876
33,ACET,Adicet Bio Inc. Common Stock ,"Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.","Mr. Chen  Schor BA, CPA, M.B.A.",Biotechnology,1.035,USD,85285035,https://images.financialmodelingprep.com/symbol/ACET.png,572240,-0.61,-0.055,203753,-136535000,-142658000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -142.66}, {'period': '2022', 'revenue': 24.99, 'unit': 'M', 'net_profit': -67.03}, {'period': '2021', 'revenue': 9.73, 'unit': 'M', 'net_profit': -62.0}, {'period': '2020', 'revenue': 17.9, 'unit': 'M', 'net_profit': -36.68}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.48}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.9}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.02}, {'period': ""Q4 '23"", 'revenue': 12.89, 'unit': 'M', 'net_profit': -29.49}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -49.88}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -32.4}]",-3.31,-3.31,207295000,162272000,159711000,37120000,0,0,19287000,159711000,-98181000,-1.1102455912582494,-1.1283026749615839,-1.0306748466257671,"[0.0014, 0.0143]","['2018-09-21', '2009-06-11']",__nan__,0.17906847729081743
34,ACEV,ACE Convergence Acquisition Corp. Class A Ordinary Shares,"ACE Convergence Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. It intends to focus on businesses in the IT infrastructure software and semiconductor sectors. ACE Convergence Acquisition Corp. was incorporated in 2020 and is based in Wilmington, Delaware.",Mr. Behrooz  Abdi,Shell Companies,9.78,USD,258126474,https://images.financialmodelingprep.com/symbol/ACEV.png,39409,3.7906976744186047,0.65,31566,-31413000,-144851000,"[{'period': '2023', 'revenue': 12.05, 'unit': 'M', 'net_profit': -144.85}, {'period': '2022', 'revenue': 12.05, 'unit': 'M', 'net_profit': -192.82}, {'period': '2021', 'revenue': 17.36, 'unit': 'M', 'net_profit': -51.7}, {'period': '2020', 'revenue': 18.13, 'unit': 'M', 'net_profit': -16.97}]","[{'period': ""Q4 '23"", 'revenue': 2.77, 'unit': 'M', 'net_profit': -7.39}, {'period': ""Q3 '23"", 'revenue': 2.9, 'unit': 'M', 'net_profit': -48.33}, {'period': ""Q2 '23"", 'revenue': 2.39, 'unit': 'M', 'net_profit': -76.51}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.96}, {'period': ""Q4 '22"", 'revenue': 0.0039, 'unit': 'B', 'net_profit': 80.39}, {'period': ""Q3 '22"", 'revenue': 4.01, 'unit': 'M', 'net_profit': -23.62}]",-16.38,-16.38,20589000,13301000,7113000,46612000,2866000,0,44357000,7113000,-28827000,0.12731970218913213,0.2487838524649677,-750.3761467889908,__nan__,__nan__,__nan__,2.263927339841663
35,ACEVU,ACE Convergence Acquisition Corp. Unit,"ACE Convergence Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. It intends to focus on businesses in the IT infrastructure software and semiconductor sectors. ACE Convergence Acquisition Corp. was incorporated in 2020 and is based in Wilmington, Delaware.",Mr. Behrooz  Abdi,Shell Companies,9.769,USD,0,https://images.financialmodelingprep.com/symbol/ACEVU.png,1975,15.531001589825118,-0.011,858,-31413000,-144851000,"[{'period': '2023', 'revenue': 12.05, 'unit': 'M', 'net_profit': -144.85}, {'period': '2022', 'revenue': 12.05, 'unit': 'M', 'net_profit': -192.82}, {'period': '2021', 'revenue': 17.36, 'unit': 'M', 'net_profit': -51.7}, {'period': '2020', 'revenue': 18.13, 'unit': 'M', 'net_profit': -16.97}]","[{'period': ""Q4 '23"", 'revenue': 2.77, 'unit': 'M', 'net_profit': -7.39}, {'period': ""Q3 '23"", 'revenue': 2.9, 'unit': 'M', 'net_profit': -48.33}, {'period': ""Q2 '23"", 'revenue': 2.39, 'unit': 'M', 'net_profit': -76.51}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.96}, {'period': ""Q4 '22"", 'revenue': 0.0039, 'unit': 'B', 'net_profit': 80.39}, {'period': ""Q3 '22"", 'revenue': 4.01, 'unit': 'M', 'net_profit': -23.62}]",-16.38,-16.38,20589000,13301000,7113000,46612000,2866000,0,44357000,7113000,-28827000,0.12731970218913213,0.2487838524649677,-750.3761467889908,__nan__,__nan__,__nan__,2.263927339841663
36,ACEVW,ACE Convergence Acquisition Corp. Warrant,,,Shell Companies,0.1699,USD,0,https://images.financialmodelingprep.com/symbol/ACEVW.png,0,0,0.0199,132016,-31413000,-144851000,"[{'period': '2023', 'revenue': 12.05, 'unit': 'M', 'net_profit': -144.85}, {'period': '2022', 'revenue': 12.05, 'unit': 'M', 'net_profit': -192.82}, {'period': '2021', 'revenue': 17.36, 'unit': 'M', 'net_profit': -51.7}, {'period': '2020', 'revenue': 18.13, 'unit': 'M', 'net_profit': -16.97}]","[{'period': ""Q4 '23"", 'revenue': 2.77, 'unit': 'M', 'net_profit': -7.39}, {'period': ""Q3 '23"", 'revenue': 2.9, 'unit': 'M', 'net_profit': -48.33}, {'period': ""Q2 '23"", 'revenue': 2.39, 'unit': 'M', 'net_profit': -76.51}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.96}, {'period': ""Q4 '22"", 'revenue': 0.0039, 'unit': 'B', 'net_profit': 80.39}, {'period': ""Q3 '22"", 'revenue': 4.01, 'unit': 'M', 'net_profit': -23.62}]",-16.38,-16.38,20589000,13301000,7113000,46612000,2866000,0,44357000,7113000,-28827000,0.12731970218913213,0.2487838524649677,-750.3761467889908,__nan__,__nan__,__nan__,2.263927339841663
37,ACGL,Arch Capital Group Ltd. Common Stock,"Arch Capital Group Ltd., together with its subsidiaries, provides insurance, reinsurance, and mortgage insurance products worldwide. The company's Insurance segment offers primary and excess casualty coverages; loss sensitive primary casualty insurance programs; collateral protection, debt cancellation, and service contract reimbursement products; directors' and officers' liability, errors and omissions liability, employment practices and fiduciary liability, crime, professional indemnity, and other financial related coverages; medical professional and general liability insurance coverages; and workers' compensation and umbrella liability, as well as commercial automobile and inland marine products. It also provides property, energy, marine, and aviation insurance; travel insurance; accident, disability, and medical plan insurance coverages; captive insurance programs; employer's liability; and contract and commercial surety coverages. This segment markets its products through a group of licensed independent retail and wholesale brokers. Its Reinsurance segment provides casualty reinsurance for third party liability and workers' compensation exposures; marine and aviation; surety, accident and health, workers' compensation catastrophe, agriculture, trade credit, and political risk products; reinsurance protection for catastrophic losses, and personal lines and commercial property exposures; life reinsurance; casualty clash; and risk management solutions. This segment markets its reinsurance products through brokers. The company's Mortgage segment offers direct mortgage insurance and mortgage reinsurance. The company was incorporated in 1995 and is based in Pembroke, Bermuda.",Mr. Nicolas Alain Emmanuel Papadopoulo,Insurance - Diversified,92.97,USD,34979218740,https://images.financialmodelingprep.com/symbol/ACGL.png,1947666,6.24,2.23,695230,3335000000,4443000000,"[{'period': '2023', 'revenue': 13.63, 'unit': 'B', 'net_profit': 4.44}, {'period': '2022', 'revenue': 9.6, 'unit': 'B', 'net_profit': 1.48}, {'period': '2021', 'revenue': 8.93, 'unit': 'B', 'net_profit': 2.16}, {'period': '2020', 'revenue': 8.29, 'unit': 'B', 'net_profit': 1.41}]","[{'period': ""Q3 '24"", 'revenue': 4550.0, 'unit': 'M', 'net_profit': 988.0}, {'period': ""Q2 '24"", 'revenue': 4.06, 'unit': 'B', 'net_profit': 1.27}, {'period': ""Q1 '24"", 'revenue': 3.84, 'unit': 'B', 'net_profit': 1.12}, {'period': ""Q4 '23"", 'revenue': 3.87, 'unit': 'B', 'net_profit': 2.33}, {'period': ""Q3 '23"", 'revenue': 3290.0, 'unit': 'M', 'net_profit': 723.0}, {'period': ""Q2 '23"", 'revenue': 3090.0, 'unit': 'M', 'net_profit': 671.0}]",11.94,11.62,58906000000,14840000000,8026000000,40551000000,4644000000,7462000000,0,917000000,5697000000,1.0725832964079987,2.0101626016260163,2.0615384615384613,"[5, 5]","['2024-11-18', '2024-11-18']",__nan__,0.6884018605914508
38,ACGLO,Arch Capital Group Ltd. Depositary Shares Each Representing 1/1000th Interest in a Share of 5.45% Non-Cumulative Preferred Shares Series F,"Arch Capital Group Ltd., together with its subsidiaries, provides insurance, reinsurance, and mortgage insurance products worldwide. The company's Insurance segment offers primary and excess casualty coverages; loss sensitive primary casualty insurance programs; collateral protection, debt cancellation, and service contract reimbursement products; directors' and officers' liability, errors and omissions liability, employment practices and fiduciary liability, crime, professional indemnity, and other financial related coverages; medical professional and general liability insurance coverages; and workers' compensation and umbrella liability, as well as commercial automobile and inland marine products. It also provides property, energy, marine, and aviation insurance; travel insurance; accident, disability, and medical plan insurance coverages; captive insurance programs; employer's liability; and contract and commercial surety coverages. This segment markets its products through a group of licensed independent retail and wholesale brokers. Its Reinsurance segment provides casualty reinsurance for third party liability and workers' compensation exposures; marine and aviation; surety, accident and health, workers' compensation catastrophe, agriculture, trade credit, and political risk products; reinsurance protection for catastrophic losses, and personal lines and commercial property exposures; life reinsurance; casualty clash; and risk management solutions. This segment markets its reinsurance products through brokers. The company's Mortgage segment offers direct mortgage insurance and mortgage reinsurance. The company was incorporated in 1995 and is based in Pembroke, Bermuda.",Mr. Nicolas Alain Emmanuel Papadopoulo,Insurance - Diversified,21.7146,USD,34042046213,https://images.financialmodelingprep.com/symbol/ACGLO.png,31108,4.63,-0.2254,4396,3335000000,4443000000,"[{'period': '2023', 'revenue': 13.63, 'unit': 'B', 'net_profit': 4.44}, {'period': '2022', 'revenue': 9.6, 'unit': 'B', 'net_profit': 1.48}, {'period': '2021', 'revenue': 8.93, 'unit': 'B', 'net_profit': 2.16}, {'period': '2020', 'revenue': 8.29, 'unit': 'B', 'net_profit': 1.41}]","[{'period': ""Q3 '24"", 'revenue': 4550.0, 'unit': 'M', 'net_profit': 988.0}, {'period': ""Q2 '24"", 'revenue': 4.06, 'unit': 'B', 'net_profit': 1.27}, {'period': ""Q1 '24"", 'revenue': 3.84, 'unit': 'B', 'net_profit': 1.12}, {'period': ""Q4 '23"", 'revenue': 3.87, 'unit': 'B', 'net_profit': 2.33}, {'period': ""Q3 '23"", 'revenue': 3290.0, 'unit': 'M', 'net_profit': 723.0}, {'period': ""Q2 '23"", 'revenue': 3090.0, 'unit': 'M', 'net_profit': 671.0}]",11.94,11.62,58906000000,14840000000,8026000000,40551000000,4644000000,7462000000,0,917000000,5697000000,1.0725832964079987,2.0101626016260163,2.0615384615384613,"[0.34063, 0.507]","['2024-12-13', '2017-12-14']",__nan__,0.6884018605914508
39,ACGLP,Arch Capital Group Ltd. Depositary Shares Representing Interest in 5.25% Non-Cumulative Preferred Series E Shrs,"Arch Capital Group Ltd., together with its subsidiaries, provides insurance, reinsurance, and mortgage insurance products worldwide. The company's Insurance segment offers primary and excess casualty coverages; loss sensitive primary casualty insurance programs; collateral protection, debt cancellation, and service contract reimbursement products; directors' and officers' liability, errors and omissions liability, employment practices and fiduciary liability, crime, professional indemnity, and other financial related coverages; medical professional and general liability insurance coverages; and workers' compensation and umbrella liability, as well as commercial automobile and inland marine products. It also provides property, energy, marine, and aviation insurance; travel insurance; accident, disability, and medical plan insurance coverages; captive insurance programs; and contract and commercial surety coverages. This segment markets its products through a group of licensed independent retail and wholesale brokers. Its Reinsurance segment provides reinsurance for third party liability and workers' compensation exposures; marine and aviation reinsurance; surety, accident and health, workers' compensation catastrophe, agriculture, trade credit, and political risk products; reinsurance protection for catastrophic losses, and personal lines and commercial property exposures; life reinsurance; casualty clash; and risk management solutions. This segment markets its reinsurance products through brokers. The company's Mortgage segment offers private mortgage insurance covering one-to-four family residential mortgages; mortgage insurance to cover previously originated residential loans; quota share reinsurance; and credit risk-sharing products. This segment sells its products through direct basis and through brokers to mortgage originators. The company was founded in 1995 and is based in Pembroke, Bermuda.",Mr. Marc Grandisson,Insurance - Diversified,24.99,USD,15165357055,https://images.financialmodelingprep.com/symbol/ACGLP.png,29439,5.027157513578757,0.01,40244,3335000000,4443000000,"[{'period': '2023', 'revenue': 13.63, 'unit': 'B', 'net_profit': 4.44}, {'period': '2022', 'revenue': 9.6, 'unit': 'B', 'net_profit': 1.48}, {'period': '2021', 'revenue': 8.93, 'unit': 'B', 'net_profit': 2.16}, {'period': '2020', 'revenue': 8.29, 'unit': 'B', 'net_profit': 1.41}]","[{'period': ""Q3 '24"", 'revenue': 4550.0, 'unit': 'M', 'net_profit': 988.0}, {'period': ""Q2 '24"", 'revenue': 4.06, 'unit': 'B', 'net_profit': 1.27}, {'period': ""Q1 '24"", 'revenue': 3.84, 'unit': 'B', 'net_profit': 1.12}, {'period': ""Q4 '23"", 'revenue': 3.87, 'unit': 'B', 'net_profit': 2.33}, {'period': ""Q3 '23"", 'revenue': 3290.0, 'unit': 'M', 'net_profit': 723.0}, {'period': ""Q2 '23"", 'revenue': 3090.0, 'unit': 'M', 'net_profit': 671.0}]",11.94,11.62,58906000000,14840000000,8026000000,40551000000,4644000000,7462000000,0,917000000,5697000000,1.0725832964079987,2.0101626016260163,2.0615384615384613,"[0.32813, 0.343]","['2021-09-14', '2016-12-13']",__nan__,0.6884018605914508
40,ACHC,Acadia Healthcare Company Inc. Common Stock,"Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company offers behavioral healthcare services to its patients in various settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics. As of March 31, 2022, it operated a network of 238 behavioral healthcare facilities with approximately 10,600 beds. The company was founded in 2005 and is headquartered in Franklin, Tennessee.",Mr. Christopher Howal Hunter,Medical - Care Facilities,45.78,USD,4252289034,https://images.financialmodelingprep.com/symbol/ACHC.png,1737866,15.01,0.93,780447,189114000,-21667000,"[{'period': '2023', 'revenue': 2930.0, 'unit': 'M', 'net_profit': -21.67}, {'period': '2022', 'revenue': 2610.0, 'unit': 'M', 'net_profit': 273.14}, {'period': '2021', 'revenue': 2310.0, 'unit': 'M', 'net_profit': 190.63}, {'period': '2020', 'revenue': 2090.0, 'unit': 'M', 'net_profit': 143.19}]","[{'period': ""Q3 '24"", 'revenue': 815.63, 'unit': 'M', 'net_profit': 68.13}, {'period': ""Q2 '24"", 'revenue': 796.04, 'unit': 'M', 'net_profit': 78.48}, {'period': ""Q1 '24"", 'revenue': 768.05, 'unit': 'M', 'net_profit': 76.38}, {'period': ""Q4 '23"", 'revenue': 742.8, 'unit': 'M', 'net_profit': 57.73}, {'period': ""Q3 '23"", 'revenue': 750.33, 'unit': 'M', 'net_profit': -217.71}, {'period': ""Q2 '23"", 'revenue': 731.34, 'unit': 'M', 'net_profit': 72.3}]",-0.24,-0.24,5358841000,596000000,100073000,2471181000,429530000,0,885781000,100073000,38207000,-0.6633017134555399,-1.0793259109830526,-1.078688524590164,__nan__,__nan__,__nan__,0.4611409444691492
41,ACHL,Achilles Therapeutics plc American Depositary Shares,"Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.",Dr. Iraj  Ali Ph.D.,Biotechnology,1.1791,USD,48461057,https://images.financialmodelingprep.com/symbol/ACHL.png,165232,-0.71,0.0191,62247,-70442000,-69665000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -69.67}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -71.18}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -61.1}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -33.2}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.59}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.38}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.27}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.79}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.68}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.85}]",-1.74,-1.74,161456000,145633000,131539000,19087000,10351000,33000,16996000,131538999,-49549000,0.10131023308625595,0.02122906597729572,0.043956043956043994,__nan__,__nan__,__nan__,0.11821796650480626
42,ACHV,Achieve Life Sciences Inc. Common Shares,"Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.",Dr. Richard A. B. Stewart,Biotechnology,3.77,USD,129649923,https://images.financialmodelingprep.com/symbol/ACHV.png,142025,-3.37,0.22,378648,-26734000,-29815000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.82}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -41.88}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -32.9}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.66}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.51}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.46}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.49}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.48}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.11}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.24}]",-1.5,-1.5,19371000,16982000,15546000,20819000,111000,50000,20813000,15546000,-24500000,0.3370365778053317,0.288,0.620253164556962,__nan__,__nan__,__nan__,1.0747509163182076
43,ACIU,AC Immune SA Common Stock,"AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.",Dr. Andrea  Pfeifer Ph.D.,Biotechnology,2.955,USD,294555582,https://images.financialmodelingprep.com/symbol/ACIU.png,124787,-6.72,-0.025,54294,-51832000,-54233000,"[{'period': '2023', 'revenue': 14.8, 'unit': 'M', 'net_profit': -54.23}, {'period': '2022', 'revenue': 3.94, 'unit': 'M', 'net_profit': -70.75}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -73.0}, {'period': '2020', 'revenue': 15.43, 'unit': 'M', 'net_profit': -62.1}]","[{'period': ""Q3 '24"", 'revenue': 25.48, 'unit': 'M', 'net_profit': 5.5}, {'period': ""Q2 '24"", 'revenue': 0.687, 'unit': 'M', 'net_profit': -22.76}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.86}, {'period': ""Q4 '23"", 'revenue': 14.8, 'unit': 'M', 'net_profit': -4.74}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.14}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.83}]",-0.64,-0.64,182814000,125153000,103048000,22171000,15046000,361000,13576000,78494000,-61209000,0.24939902105598516,0.23348833265020563,0.24705882352941172,__nan__,__nan__,__nan__,0.12127626986992243
44,ACIW,ACI Worldwide Inc. Common Stock,"ACI Worldwide, Inc., a software company, develops, markets, installs, and supports a range of software products and solutions for facilitating digital payments to banks, merchants, and billers worldwide. The company offers ACI Acquiring, a merchant management system to deliver digital innovation, improve fraud prevention, and reduce interchange fees; ACI Issuing, a digital payments issuing solution; and ACI Enterprise Payments Platform that provides payment processing and orchestration capabilities for digital payments. It also provides ACI Low Value Real-Time Payments, a platform for processing real-time payments; and ACI High Value Real-Time Payments, a payments engine that offers multi-bank, multi-currency, 24x7 payment processing, and SWIFT messaging. In addition, the company offers ACI Omni Commerce, a scalable, omni-channel payment processing platform; ACI Secure eCommerce solution; ACI Fraud Management, a real-time approach to fraud management; ACI Digital Business Banking, a cloud-based digital banking platform; and ACI Speedpay, an integrated suite of digital billing, payment, disbursement, and communication services. The company offers electronic bill presentment and payment services to consumer finance, insurance, healthcare, higher education, utility, government, and mortgage sectors; implementation services, including product installations and configurations, and custom software modifications; and business and technical consultancy, on-site support, product education, and testing services, as well as distributes or acts as a sales agent for software developed by third parties. It markets its products under the ACI Worldwide brand. The company was formerly known as Transaction Systems Architects, Inc. and changed its name to ACI Worldwide, Inc. in July 2007. The company was founded in 1975 and is based in Coral Gables, Florida.",Mr. Thomas Woodrow Warsop III,Software - Infrastructure,51.27,USD,5377659030,https://images.financialmodelingprep.com/symbol/ACIW.png,682908,24.53,-1.46,142084,360106000,121509000,"[{'period': '2023', 'revenue': 1450.0, 'unit': 'M', 'net_profit': 121.51}, {'period': '2022', 'revenue': 1420.0, 'unit': 'M', 'net_profit': 142.18}, {'period': '2021', 'revenue': 1370.0, 'unit': 'M', 'net_profit': 127.79}, {'period': '2020', 'revenue': 1290.0, 'unit': 'M', 'net_profit': 72.66}]","[{'period': ""Q3 '24"", 'revenue': 451.75, 'unit': 'M', 'net_profit': 81.43}, {'period': ""Q2 '24"", 'revenue': 373.48, 'unit': 'M', 'net_profit': 30.89}, {'period': ""Q1 '24"", 'revenue': 316.02, 'unit': 'M', 'net_profit': -7.75}, {'period': ""Q4 '23"", 'revenue': 476.56, 'unit': 'M', 'net_profit': 122.62}, {'period': ""Q3 '23"", 'revenue': 363.01, 'unit': 'M', 'net_profit': 37.91}, {'period': ""Q2 '23"", 'revenue': 323.32, 'unit': 'M', 'net_profit': -6.71}]",1.12,1.12,3444739000,1406645000,164239000,2120442000,452337000,332483000,1037249000,164239000,130740000,-0.09564732591312733,-0.14536809751225585,-0.10399999999999991,__nan__,__nan__,__nan__,0.6155595532782019
45,ACKIT,Ackrell SPAC Partners I Co. Subunits,"Ackrell SPAC Partners I Co. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on alcoholic and non-alcoholic beverage and wellness sectors. Ackrell SPAC Partners I Co. was founded in 2018 and is Claymont, Delaware.",Mr. Jason M. Roth,Shell Companies,10.3801,USD,0,https://images.financialmodelingprep.com/symbol/ACKIT.png,0,-324.378125,0.0101004,8435,-1198210,-842789,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -842.79}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -115.54}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': -3.75}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -53.56}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -333.55}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.68}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -243.02}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -353.3}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 120.14}]",-0.0611,-0.0611,140981542,158964,86792,2777250,0,0,2492480,86792,-590338,-9.37016201620162,-6.294095755729419,-6.273809523809525,__nan__,__nan__,__nan__,0.01969938731412088
46,ACKIU,Ackrell SPAC Partners I Co. Units,"Ackrell SPAC Partners I Co. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on alcoholic and non-alcoholic beverage and wellness sectors. Ackrell SPAC Partners I Co. was founded in 2018 and is Claymont, Delaware.",Mr. Stephen N. Cannon,Shell Companies,10.36,USD,0,https://images.financialmodelingprep.com/symbol/ACKIU.png,0,-323.75,0.009999275,300,-1198210,-842789,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -842.79}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -115.54}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': -3.75}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -53.56}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -333.55}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.68}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -243.02}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -353.3}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 120.14}]",-0.0611,-0.0611,140981542,158964,86792,2777250,0,0,2492480,86792,-590338,-9.37016201620162,-6.294095755729419,-6.273809523809525,__nan__,__nan__,__nan__,0.01969938731412088
47,ACKIW,Ackrell SPAC Partners I Co. Warrants,"Ackrell SPAC Partners I Co., a blank check company, focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, and other similar business combination. The company was formerly known as Able Acquisition Corp. and changed its name to Ackrell SPAC Partners I Co. in September 2019. The company was incorporated in 2018 and is based in Claymont, Delaware.",Mr. Jason M. Roth,Shell Companies,0.0004,USD,0,https://images.financialmodelingprep.com/symbol/ACKIW.png,0,0,-0.0108,317451,-1198210,-842789,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -842.79}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -115.54}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': -3.75}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -53.56}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -333.55}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.68}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -243.02}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -353.3}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 120.14}]",-0.0611,-0.0611,140981542,158964,86792,2777250,0,0,2492480,86792,-590338,-9.37016201620162,-6.294095755729419,-6.273809523809525,__nan__,__nan__,__nan__,0.01969938731412088
48,ACLS,Axcelis Technologies Inc. Common Stock,"Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and Asia. The company offers high energy, high current, and medium current implanters for various application requirements. It also provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. It sells its equipment and services to semiconductor chip manufacturers through its direct sales force. The company was founded in 1978 and is headquartered in Beverly, Massachusetts.",Dr. Russell J. Low Ph.D.,Semiconductors,75.058,USD,2439842854,https://images.financialmodelingprep.com/symbol/ACLS.png,631695,11.1,0.608,138778,297015000,246263000,"[{'period': '2023', 'revenue': 1130.0, 'unit': 'M', 'net_profit': 246.26}, {'period': '2022', 'revenue': 920.0, 'unit': 'M', 'net_profit': 183.08}, {'period': '2021', 'revenue': 662.43, 'unit': 'M', 'net_profit': 98.65}, {'period': '2020', 'revenue': 474.56, 'unit': 'M', 'net_profit': 49.98}]","[{'period': ""Q3 '24"", 'revenue': 256.56, 'unit': 'M', 'net_profit': 48.58}, {'period': ""Q2 '24"", 'revenue': 256.51, 'unit': 'M', 'net_profit': 50.87}, {'period': ""Q1 '24"", 'revenue': 252.37, 'unit': 'M', 'net_profit': 51.59}, {'period': ""Q4 '23"", 'revenue': 310.29, 'unit': 'M', 'net_profit': 71.06}, {'period': ""Q3 '23"", 'revenue': 292.33, 'unit': 'M', 'net_profit': 65.93}, {'period': ""Q2 '23"", 'revenue': 273.97, 'unit': 'M', 'net_profit': 61.58}]",7.52,7.43,1281967000,1079991000,506148000,417085000,217964000,0,285129000,167297000,136213000,0.3374957220310896,0.34511877386264944,0.35740072202166057,__nan__,__nan__,__nan__,0.3253476883570326
49,ACMR,ACM Research Inc. Class A Common Stock,"ACM Research, Inc., together with its subsidiaries, develops, manufactures, and sells single-wafer wet cleaning equipment for enhancing the manufacturing process and yield for integrated chips worldwide. It offers space alternated phase shift technology for flat and patterned wafer surfaces, which employs alternating phases of megasonic waves to deliver megasonic energy in a uniform manner on a microscopic level; timely energized bubble oscillation technology for patterned wafer surfaces at advanced process nodes, which provides cleaning for 2D and 3D patterned wafers; Tahoe technology for delivering cleaning performance using less sulfuric acid and hydrogen peroxide; and electro-chemical plating technology for advanced metal plating. The company markets and sells its products under the Ultra C brand name through direct sales force and third-party representatives. ACM Research, Inc. was incorporated in 1998 and is headquartered in Fremont, California.",Dr. Hui  Wang Ph.D.,Semiconductors,16.08,USD,1007055715,https://images.financialmodelingprep.com/symbol/ACMR.png,1371454,12.09,0.21,232009,126989000,77349000,"[{'period': '2023', 'revenue': 557.72, 'unit': 'M', 'net_profit': 77.35}, {'period': '2022', 'revenue': 388.83, 'unit': 'M', 'net_profit': 39.26}, {'period': '2021', 'revenue': 259.75, 'unit': 'M', 'net_profit': 37.76}, {'period': '2020', 'revenue': 156.62, 'unit': 'M', 'net_profit': 18.78}]","[{'period': ""Q3 '24"", 'revenue': 203.98, 'unit': 'M', 'net_profit': 30.9}, {'period': ""Q2 '24"", 'revenue': 202.48, 'unit': 'M', 'net_profit': 24.21}, {'period': ""Q1 '24"", 'revenue': 152.19, 'unit': 'M', 'net_profit': 17.43}, {'period': ""Q4 '23"", 'revenue': 170.32, 'unit': 'M', 'net_profit': 17.7}, {'period': ""Q3 '23"", 'revenue': 168.57, 'unit': 'M', 'net_profit': 25.68}, {'period': ""Q2 '23"", 'revenue': 144.58, 'unit': 'M', 'net_profit': 26.82}]",1.29,1.19,1490908000,1176110000,283926000,564746000,325683000,68698000,500659000,182090000,-139660999,0.7072314910665072,0.9700226676514785,0.9545454545454545,__nan__,__nan__,__nan__,0.3787933259463361
50,ACNB,ACNB Corporation Common Stock,"ACNB Corporation, a financial holding company, provides banking, insurance, and financial services to individual, business, and government customers in the United States. The company offers checking, savings, and money market deposit accounts, as well as time deposits and debit cards. It also provides commercial lending products, such as commercial mortgages, real estate development and construction loans, accounts receivable and inventory financing, and agricultural and governmental loans; consumer lending products, including home equity loans and lines of credit, automobile and recreational vehicle loans, manufactured housing loans, and personal lines of credit; and mortgage lending programs include personal residential mortgages, and residential construction and investment mortgage loans. In addition, the company provides other services that are related to testamentary trusts, life insurance trusts, charitable remainder trusts, guardianships, powers of attorney, custodial accounts, and investment management and advisory accounts; and retail brokerage services. Further, it acts as a trustee to invest in, protect, manage, and distribute financial assets. Additionally, the company offers property and casualty, health, life, and disability insurance products to commercial and individual clients; and online, telephone, and mobile banking, as well as automated teller machine services. As of December 31, 2021, it operated through a network of 19 community banking offices located in Pennsylvania, including 12 offices in Adams county, five offices in York county, one office in Cumberland County, and one office in Franklin County; five community banking offices located in Frederick County; six community banking offices located in Carroll county, Maryland; and loan offices located in Lancaster and York, Pennsylvania, and Hunt Valley, Maryland. The company was founded in 1857 and is headquartered in Gettysburg, Pennsylvania.",Mr. James P. Helt,Banks - Regional,39.24,USD,335447849,https://images.financialmodelingprep.com/symbol/ACNB.png,16832,11.44,-0.06,4254,0,31688000,"[{'period': '2023', 'revenue': 105.92, 'unit': 'M', 'net_profit': 31.69}, {'period': '2022', 'revenue': 0.421, 'unit': 'M', 'net_profit': 35.75}, {'period': '2021', 'revenue': 93.93, 'unit': 'M', 'net_profit': 27.83}, {'period': '2020', 'revenue': 93.0, 'unit': 'M', 'net_profit': 18.39}]","[{'period': ""Q3 '24"", 'revenue': 27.24, 'unit': 'M', 'net_profit': 7.2}, {'period': ""Q2 '24"", 'revenue': 33.3, 'unit': 'M', 'net_profit': 11.28}, {'period': ""Q1 '24"", 'revenue': 31.65, 'unit': 'M', 'net_profit': 6.77}, {'period': ""Q4 '23"", 'revenue': 26.25, 'unit': 'M', 'net_profit': 4.1}, {'period': ""Q3 '23"", 'revenue': 28.03, 'unit': 'M', 'net_profit': 9.04}, {'period': ""Q2 '23"", 'revenue': 27.86, 'unit': 'M', 'net_profit': 9.52}]",3.71,3.71,2418847000,65958000,473135000,2141386000,0,518224000,1531652000,65958000,39434000,-1,-0.11367196240769747,-0.10602409638554225,"[0.32, 0.29]","['2024-11-29', '1994-05-27']",__nan__,0.8852920420349034
51,ACOR,Acorda Therapeutics Inc. Common Stock,"Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.",Dr. Ron  Cohen M.D.,Drug Manufacturers - Specialty & Generic,0.661,USD,821028,https://images.financialmodelingprep.com/symbol/ACOR.png,125680,-0.00324704033010758,-0.209,321668,8402000,-252854000,"[{'period': '2023', 'revenue': 117.63, 'unit': 'M', 'net_profit': -252.85}, {'period': '2022', 'revenue': 118.57, 'unit': 'M', 'net_profit': -65.92}, {'period': '2021', 'revenue': 129.07, 'unit': 'M', 'net_profit': -103.95}, {'period': '2020', 'revenue': 152.97, 'unit': 'M', 'net_profit': -99.59}]","[{'period': ""Q1 '24"", 'revenue': 20.29, 'unit': 'M', 'net_profit': -27.39}, {'period': ""Q4 '23"", 'revenue': 37.98, 'unit': 'M', 'net_profit': -217.76}, {'period': ""Q3 '23"", 'revenue': 27.71, 'unit': 'M', 'net_profit': -8.89}, {'period': ""Q2 '23"", 'revenue': 29.68, 'unit': 'M', 'net_profit': -9.38}, {'period': ""Q1 '23"", 'revenue': 22.26, 'unit': 'M', 'net_profit': -16.82}, {'period': ""Q4 '22"", 'revenue': 31.47, 'unit': 'M', 'net_profit': 19.14}]",-203.59,-203.59,117745000,74794000,30360000,275701000,17298000,255000,227773000,30360000,-14248000,1.8376869391824526,-2.8360033982644577,-2.043198804185351,__nan__,__nan__,__nan__,2.3415091935963313
52,ACQR,Independence Holdings Corp. Class A Ordinary Share,"Independence Holdings Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in New York, New York.",Mr. John Lawrence Furlong,Shell Companies,10.19,USD,631663803,https://images.financialmodelingprep.com/symbol/ACQR.png,522498,32.87096774193548,-0.015,100,-983472,1966648,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.97}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.2}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 10.53}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 16.04}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.8}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 837.39}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.33}]",0.0376,0.0376,498026595,2077765,1260014,34355832,0,495948830,91714,1260014,-1821586,0,0,0,__nan__,__nan__,__nan__,0.0689839304666049
53,ACQRU,Independence Holdings Corp. Units,"Independence Holdings Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in New York, New York.",Mr. John Lawrence Furlong,Shell Companies,10.19,USD,606006943,https://images.financialmodelingprep.com/symbol/ACQRU.png,1283,78.38461538461539,0,69,-983472,1966648,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.97}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.2}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 10.53}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 16.04}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.8}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 837.39}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.33}]",0.0376,0.0376,498026595,2077765,1260014,34355832,0,495948830,91714,1260014,-1821586,0,0,0,__nan__,__nan__,__nan__,0.0689839304666049
54,ACQRW,Independence Holdings Corp. Warrant,"Independence Holdings Corp. a blank check company, intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses or entities. The company was founded in 2020 and is based in New York, New York.",Mr. John Lawrence Furlong,Shell Companies,0.0003,USD,631663803,https://images.financialmodelingprep.com/symbol/ACQRW.png,0,0,0,64030,-983472,1966648,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.97}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.2}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 10.53}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 16.04}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.8}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 837.39}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.33}]",0.0376,0.0376,498026595,2077765,1260014,34355832,0,495948830,91714,1260014,-1821586,0,0,0,__nan__,__nan__,__nan__,0.0689839304666049
55,ACRS,Aclaris Therapeutics Inc. Common Stock,"Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.","Dr. Neal S. Walker D.O., M.D.",Medical - Diagnostics & Research,2.485,USD,177505787,https://images.financialmodelingprep.com/symbol/ACRS.png,2483127,-4.78,-0.045,173449,-117565000,-88481000,"[{'period': '2023', 'revenue': 31.25, 'unit': 'M', 'net_profit': -88.48}, {'period': '2022', 'revenue': 29.75, 'unit': 'M', 'net_profit': -88.66}, {'period': '2021', 'revenue': 6.76, 'unit': 'M', 'net_profit': -114.28}, {'period': '2020', 'revenue': 6.48, 'unit': 'M', 'net_profit': -51.15}]","[{'period': ""Q3 '24"", 'revenue': 4.35, 'unit': 'M', 'net_profit': -7.59}, {'period': ""Q2 '24"", 'revenue': 2.77, 'unit': 'M', 'net_profit': -10.99}, {'period': ""Q1 '24"", 'revenue': 2.4, 'unit': 'M', 'net_profit': -16.94}, {'period': ""Q4 '23"", 'revenue': 17.57, 'unit': 'M', 'net_profit': -1.49}, {'period': ""Q3 '23"", 'revenue': 9.28, 'unit': 'M', 'net_profit': -29.26}, {'period': ""Q2 '23"", 'revenue': 1.87, 'unit': 'M', 'net_profit': -29.57}]",-1.27,-1.27,197405000,128856000,119106000,40226000,298000,62771000,30952000,39878000,-79634000,-0.3936602771554228,0.0020414608287654236,0.06617647058823535,__nan__,__nan__,__nan__,0.203773967224741
56,ACRX,AcelRx Pharmaceuticals Inc. Common Stock,"AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.",Mr. Vincent J. Angotti,Drug Manufacturers - Specialty & Generic,0.86,USD,14578978,https://images.financialmodelingprep.com/symbol/ACRX.png,138824,-0.31272727272727274,0.06,240995,-16889000,-10287000,"[{'period': '2023', 'revenue': 0.651, 'unit': 'M', 'net_profit': -10.29}, {'period': '2022', 'revenue': 1.77, 'unit': 'M', 'net_profit': 47.76}, {'period': '2021', 'revenue': 2.82, 'unit': 'M', 'net_profit': -35.1}, {'period': '2020', 'revenue': 5.42, 'unit': 'M', 'net_profit': -40.38}]","[{'period': ""Q3 '23"", 'revenue': 0.117, 'unit': 'M', 'net_profit': -1.36}, {'period': ""Q2 '23"", 'revenue': 0.253, 'unit': 'M', 'net_profit': -4.37}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.34}, {'period': ""Q4 '22"", 'revenue': 0.252, 'unit': 'M', 'net_profit': -7.48}, {'period': ""Q3 '22"", 'revenue': 0.507, 'unit': 'M', 'net_profit': -6.75}, {'period': ""Q2 '22"", 'revenue': 0.5700000000000001, 'unit': 'M', 'net_profit': 70.66}]",-0.0007,-0.0007,20395000,11556000,9381000,6290000,0,0,4512000,5721000,-17592000,0.44044660901832156,-1.215411998743587,-1.0001221640488656,__nan__,__nan__,__nan__,0.3084089237558225
57,ACST,Acasti Pharma Inc. Class A Common Stock,"Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.",Mr. Prashant  Kohli,Biotechnology,3.37,USD,34171463,https://images.financialmodelingprep.com/symbol/ACST.png,33247,-2.3566433566433567,0.13,27682,-11301000,-12853000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.85}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -42.43}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.82}, {'period': '2020', 'revenue': 0.196, 'unit': 'M', 'net_profit': -19.68}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.62}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.17}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.39}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.72}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.02}, {'period': ""Q4 '22"", 'revenue': -0.032, 'unit': 'M', 'net_profit': -29.09}]",-1.35,-1.35,73300000,24010000,23005000,11557000,722000,0,1684000,23005000,-12355000,-1.713131823057992,0.6970703999622899,0.7635726795096321,__nan__,__nan__,__nan__,0.15766712141882674
58,ACTC,ArcLight Clean Transition Corp. Class A Ordinary Shares,,,,,,,,,,,,-1284331,-1284331,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}]","[{'period': ""Q2 '21"", 'revenue': 58.5, 'unit': 'M', 'net_profit': -189.03}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}]",-0.18,-0.18,278826627,1278085,278422424,10920462,0,0,1207962,873882,,0,0,0,__nan__,__nan__,__nan__,0.039165778812078805
59,ACTCU,ArcLight Clean Transition Corp. Unit,,,,,,,,,,,,-1284331,-1284331,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}]","[{'period': ""Q2 '21"", 'revenue': 58.5, 'unit': 'M', 'net_profit': -189.03}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}]",-0.18,-0.18,278826627,1278085,278422424,10920462,0,0,1207962,873882,,0,0,0,__nan__,__nan__,__nan__,0.039165778812078805
60,ACTCW,ArcLight Clean Transition Corp. Warrant,,,,,,,,,0,-0.44,254346,-1284331,-1284331,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}]","[{'period': ""Q2 '21"", 'revenue': 58.5, 'unit': 'M', 'net_profit': -189.03}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}]",-0.18,-0.18,278826627,1278085,278422424,10920462,0,0,1207962,873882,-543727,0,0,0,__nan__,__nan__,__nan__,0.039165778812078805
61,ACTDU,ArcLight Clean Transition Corp. II Unit,"ArcLight Clean Transition Corp. II intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities in energy and natural resources sectors. ArcLight Clean Transition Corp. II was incorporated in 2021 and is based in Boston, Massachusetts.",,Shell Companies,7.655,USD,0,https://images.financialmodelingprep.com/symbol/ACTDU.png,0,-25.687919463087248,-2.595,6040,-15732042,-26982181,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.98}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.31}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.16}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.21}]",-0.69,-0.69,312848614,1513189,811526,40766115,0,311175471,113261,811526,-1944632,0,0,0,__nan__,__nan__,__nan__,0.13030620298672635
62,ACTDW,ArcLight Clean Transition Corp. II Warrant,"ArcLight Clean Transition Corp. II intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Boston, Massachusetts.",Mr. John F. Erhard J.D.,Shell Companies,0.875,USD,0,https://images.financialmodelingprep.com/symbol/ACTDW.png,0,0,-0.10699999,24511,-15732042,-26982181,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.98}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.31}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.16}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.21}]",-0.69,-0.69,312848614,1513189,811526,40766115,0,311175471,113261,811526,-1944632,0,0,0,__nan__,__nan__,__nan__,0.13030620298672635
63,ACTG,Acacia Research Corporation (Acacia Tech) Common Stock,"Acacia Research Corporation, together with its subsidiaries, invests in intellectual property and related absolute return assets; and engages in the licensing and enforcement of patented technologies. The company operates through two segments, Intellectual Property Operations and Industrial Operations. The company owns or controls the rights to various patent portfolios, which include U.S. patents and foreign counterparts covering technologies used in a range of industries. It has executed approximately 1,600 license agreements, and approximately 200 patent portfolio licensing and enforcement programs. It also designs manufactures printers and parts, and consumable products through dealers and distributors for various industrial printing applications. In addition, the company offers supply-chain printing solutions for manufacturing, transportation and logistics, retail distribution, food and beverage distribution, and pharmaceutical distribution industries; and line matrix printers for mission critical applications within labeling and inventory management, build sheets, invoicing, manifests and bills of lading, and reporting industries. Acacia Research Corporation was incorporated in 1993 and is based in New York, New York.",Mr. Martin D. McNulty Jr.,Specialty Business Services,4.3,USD,418683260,https://images.financialmodelingprep.com/symbol/ACTG.png,263443,7.41,-0.04,39169,84329000,67060000,"[{'period': '2023', 'revenue': 125.1, 'unit': 'M', 'net_profit': 67.06}, {'period': '2022', 'revenue': 59.22, 'unit': 'M', 'net_profit': -110.94}, {'period': '2021', 'revenue': 88.05, 'unit': 'M', 'net_profit': 149.2}, {'period': '2020', 'revenue': 29.78, 'unit': 'M', 'net_profit': 109.23}]","[{'period': ""Q3 '24"", 'revenue': 23.31, 'unit': 'M', 'net_profit': -14.0}, {'period': ""Q2 '24"", 'revenue': 25.84, 'unit': 'M', 'net_profit': -8.45}, {'period': ""Q1 '24"", 'revenue': 24320.0, 'unit': 'K', 'net_profit': -186.0}, {'period': ""Q4 '23"", 'revenue': 92.31, 'unit': 'M', 'net_profit': 74.76}, {'period': ""Q3 '23"", 'revenue': 10.08, 'unit': 'M', 'net_profit': 1.64}, {'period': ""Q2 '23"", 'revenue': 7.9, 'unit': 'M', 'net_profit': -18.78}]",0.71,0.58,633545000,554512000,439909000,43936000,80555000,0,27636000,340091000,-28695000,1.7866217751820994,1.6044763338411199,1.2720306513409962,"[0.125, 0.125]","['2015-11-04', '2013-05-01']",__nan__,0.06934945426133897
64,ACVA,ACV Auctions Inc. Class A Common Stock,"ACV Auctions Inc. operates a digital marketplace that connects buyers and sellers for the online auction of wholesale vehicles. It also provides data services that offer insights into the condition and value of used vehicles, as well as offers customer financing services. ACV Auctions Inc. was incorporated in 2014 and is headquartered in Buffalo, New York.",Mr. George G. Chamoun,Auto - Dealerships,20.855,USD,3496131533,https://images.financialmodelingprep.com/symbol/ACVA.png,1385346,-44.37,-0.255,188622,-53885000,-75261000,"[{'period': '2023', 'revenue': 481.23, 'unit': 'M', 'net_profit': -75.26}, {'period': '2022', 'revenue': 421.53, 'unit': 'M', 'net_profit': -102.19}, {'period': '2021', 'revenue': 358.44, 'unit': 'M', 'net_profit': -78.18}, {'period': '2020', 'revenue': 208.36, 'unit': 'M', 'net_profit': -41.02}]","[{'period': ""Q3 '24"", 'revenue': 171.33, 'unit': 'M', 'net_profit': -16.03}, {'period': ""Q2 '24"", 'revenue': 160.62, 'unit': 'M', 'net_profit': -17.06}, {'period': ""Q1 '24"", 'revenue': 145.69, 'unit': 'M', 'net_profit': -20.47}, {'period': ""Q4 '23"", 'revenue': 118.38, 'unit': 'M', 'net_profit': -23.24}, {'period': ""Q3 '23"", 'revenue': 119.01, 'unit': 'M', 'net_profit': -18.24}, {'period': ""Q2 '23"", 'revenue': 124.22, 'unit': 'M', 'net_profit': -15.58}]",-0.47,-0.47,922924000,706899000,411332000,466396000,283043000,0,333941000,182571000,-46055000,0.3996033381987543,0.2635405556153553,0.276923076923077,__nan__,__nan__,__nan__,0.5053460523293359
65,ADAG,Adagene Inc. American Depositary Shares,"Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.",Dr. Peter P.  Luo Ph.D.,Biotechnology,1.875,USD,83007720,https://images.financialmodelingprep.com/symbol/ADAG.png,62496,-2.57,-0.125,10691,-14950785,-18946370,"[{'period': '2023', 'revenue': 18.11, 'unit': 'M', 'net_profit': -18.95}, {'period': '2022', 'revenue': 9.29, 'unit': 'M', 'net_profit': -79.97}, {'period': '2021', 'revenue': 10.18, 'unit': 'M', 'net_profit': -73.18}, {'period': '2020', 'revenue': 0.48, 'unit': 'M', 'net_profit': -16.44}]","[{'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.51}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.51}, {'period': ""Q4 '23"", 'revenue': 0.40787, 'unit': 'M', 'net_profit': -7.42}, {'period': ""Q3 '23"", 'revenue': 0.40787, 'unit': 'M', 'net_profit': -7.42}, {'period': ""Q2 '23"", 'revenue': 8.65, 'unit': 'M', 'net_profit': -2.05}, {'period': ""Q1 '23"", 'revenue': 8.65, 'unit': 'M', 'net_profit': -2.05}]",-0.43,-0.43,115728838,113443729,109934257,45169341,222027,0,31455647,109934257,-28539851,0.806812945220287,0.7630870023547162,0.7675675675675676,__nan__,__nan__,__nan__,0.3903032449008086
66,ADAP,Adaptimmune Therapeutics plc American Depositary Shares,"Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing a T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.",Mr. Adrian G.  Rawcliffe,Biotechnology,0.6501,USD,166349673,https://images.financialmodelingprep.com/symbol/ADAP.png,2130811,-3.82,0.0001,348279,-128198000,-113871000,"[{'period': '2023', 'revenue': 60.28, 'unit': 'M', 'net_profit': -113.87}, {'period': '2022', 'revenue': 27.15, 'unit': 'M', 'net_profit': -165.46}, {'period': '2021', 'revenue': 6.15, 'unit': 'M', 'net_profit': -158.09}, {'period': '2020', 'revenue': 3.96, 'unit': 'M', 'net_profit': -130.09}]","[{'period': ""Q3 '24"", 'revenue': 40.9, 'unit': 'M', 'net_profit': -17.62}, {'period': ""Q2 '24"", 'revenue': 128.23, 'unit': 'M', 'net_profit': 69.52}, {'period': ""Q1 '24"", 'revenue': 5.68, 'unit': 'M', 'net_profit': -48.5}, {'period': ""Q4 '23"", 'revenue': 0.23301, 'unit': 'M', 'net_profit': -48.33}, {'period': ""Q3 '23"", 'revenue': 7.32, 'unit': 'M', 'net_profit': -45.6}, {'period': ""Q2 '23"", 'revenue': 5.13, 'unit': 'M', 'net_profit': -21.39}]",-0.57,-0.57,282616000,207552000,146938000,243103000,46919000,0,72788000,143991000,-145760000,0.17606833212291043,0.3117747316507108,0.4466019417475729,__nan__,__nan__,__nan__,0.8601883828233362
67,ADBE,Adobe Inc. Common Stock,"Adobe Inc. operates as a diversified software company worldwide. It operates through three segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products, services, and solutions that enable individuals, teams, and enterprises to create, publish, and promote content; and Document Cloud, a unified cloud-based document services platform. Its flagship product is Creative Cloud, a subscription service that allows members to access its creative products. This segment serves content creators, workers, marketers, educators, enthusiasts, communicators, and consumers. The Digital Experience segment provides an integrated platform and set of applications and services that enable brands and businesses to create, manage, execute, measure, monetize, and optimize customer experiences from analytics to commerce. This segment serves marketers, advertisers, agencies, publishers, merchandisers, merchants, web analysts, data scientists, developers, and executives across the C-suite. The Publishing and Advertising segment offers products and services, such as e-learning solutions, technical document publishing, web conferencing, document and forms platform, web application development, and high-end printing, as well as Advertising Cloud offerings. The company offers its products and services directly to enterprise customers through its sales force and local field offices, as well as to end users through app stores and through its website at adobe.com. It also distributes products and services through a network of distributors, value-added resellers, systems integrators, software vendors and developers, retailers, and original equipment manufacturers. The company was formerly known as Adobe Systems Incorporated and changed its name to Adobe Inc. in October 2018. Adobe Inc. was founded in 1982 and is headquartered in San Jose, California.",Mr. Shantanu  Narayen,Software - Infrastructure,429.07,USD,188876614000,https://images.financialmodelingprep.com/symbol/ADBE.png,3514827,34.71,-2.18,1248812,6741000000,5560000000,"[{'period': '2024', 'revenue': 21.5, 'unit': 'B', 'net_profit': 5.56}, {'period': '2023', 'revenue': 19.41, 'unit': 'B', 'net_profit': 5.43}, {'period': '2022', 'revenue': 17.61, 'unit': 'B', 'net_profit': 4.76}, {'period': '2021', 'revenue': 15.79, 'unit': 'B', 'net_profit': 4.82}]","[{'period': ""Q4 '24"", 'revenue': 5.61, 'unit': 'B', 'net_profit': 1.68}, {'period': ""Q3 '24"", 'revenue': 5.41, 'unit': 'B', 'net_profit': 1.68}, {'period': ""Q2 '24"", 'revenue': 5.31, 'unit': 'B', 'net_profit': 1.57}, {'period': ""Q1 '24"", 'revenue': 5180.0, 'unit': 'M', 'net_profit': 620.0}, {'period': ""Q4 '23"", 'revenue': 5.05, 'unit': 'B', 'net_profit': 1.48}, {'period': ""Q3 '23"", 'revenue': 4.89, 'unit': 'B', 'net_profit': 1.4}]",12.44,12.36,30230000000,11232000000,7886000000,16125000000,2072000000,0,10521000000,7613000000,7824000000,0.01368421052631579,0.02431834929992631,0.04713804713804703,"[0.0125, 0.05]","['2005-03-24', '1990-01-08']",__nan__,0.5334105193516374
68,ADER,26 Capital Acquisition Corp. Class A Common Stock,"26 Capital Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Miami, Florida.",Mr. Jason N. Ader,Shell Companies,11.08,USD,114181616,https://images.financialmodelingprep.com/symbol/ADER.png,55398,-29.945945945945947,0.01,41942,-12035337,7258882,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.26}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.15}]","[{'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.09}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -692.92}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.67}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -519.52}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.94}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.17}]",0.21,0.21,35511910,805178,770820,21515475,0,34706732,5820854,770820,-1947734,0.10285697204853426,0.014834382459954354,-0.0454545454545455,__nan__,__nan__,__nan__,0.6058664543810794
69,ADERU,26 Capital Acquisition Corp. Unit,"26 Capital Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Miami, Florida.",Mr. Jason N. Ader,Shell Companies,11.08,USD,111652606,https://images.financialmodelingprep.com/symbol/ADERU.png,108,50.593607305936075,0.08,2000,-12035337,7258882,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.26}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.15}]","[{'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.09}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -692.92}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.67}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -519.52}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.94}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.17}]",0.21,0.21,35511910,805178,770820,21515475,0,34706732,5820854,770820,-1947734,0.10285697204853426,0.014834382459954354,-0.0454545454545455,__nan__,__nan__,__nan__,0.6058664543810794
70,ADERW,26 Capital Acquisition Corp. Warrant,"26 Capital Acquisition Corp. is a blank check company that focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, and similar business combination with one or more businesses. The company was founded in 2020 and is based in Miami, Florida.",Mr. Jason N. Ader,Shell Companies,0.0065,USD,0,https://images.financialmodelingprep.com/symbol/ADERW.png,0,0,0.0013,36027,-12035337,7258882,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.26}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.15}]","[{'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.09}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -692.92}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.67}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -519.52}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.94}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.17}]",0.21,0.21,35511910,805178,770820,21515475,0,34706732,5820854,770820,-1947734,0.10285697204853426,0.014834382459954354,-0.0454545454545455,__nan__,__nan__,__nan__,0.6058664543810794
71,ADES,Advanced Emissions Solutions Inc. Common Stock,"Advanced Emissions Solutions, Inc., together with its subsidiaries, provides environmental technologies and specialty chemicals in the United States. It operates through two segments, Refined Coal and Advanced Purification Technologies. The company offers CyClean technology, a pre-combustion coal treatment process to enhance combustion, as well as to reduce emissions of nitrogen oxide and mercury from coals burned in cyclone boilers; and M-45 and M-45-PC technologies, which are pre-combustion coal treatment technologies used to control emissions from circulating fluidized bed boilers and pulverized coal boilers. It also provides mercury and other air contaminants controls; and activated carbon products, such as powdered activated carbon and granular activated carbon, as well as owns an associated lignite mine that supplies the raw material for the powdered activated carbon plant. The company's products are used in removal of heavy metal pollutants; treatment of drinking and waste waters; industrial acid gas and odor removal; automotive gasoline emission control; soil and ground water remediation; and food and beverage process and product purifications. It serves customers in the coal-fired power generation and industrial boiler processes. Advanced Emissions Solutions, Inc. was founded in 1996 and is headquartered in Greenwood Village, Colorado.",Mr. Robert E. Rasmus,Industrial - Pollution & Treatment Controls,3.36,USD,111716976,https://images.financialmodelingprep.com/symbol/ADES.png,100316,-4.602739726027397,0.1,100969,-1234000,-12249000,"[{'period': '2023', 'revenue': 99.18, 'unit': 'M', 'net_profit': -12.25}, {'period': '2022', 'revenue': 102.99, 'unit': 'M', 'net_profit': -8.92}, {'period': '2021', 'revenue': 100.29, 'unit': 'M', 'net_profit': 60.4}, {'period': '2020', 'revenue': 61.58, 'unit': 'M', 'net_profit': -20.3}]","[{'period': ""Q4 '23"", 'revenue': 28.1, 'unit': 'M', 'net_profit': 3.29}, {'period': ""Q3 '23"", 'revenue': 29.83, 'unit': 'M', 'net_profit': -2.17}, {'period': ""Q2 '23"", 'revenue': 20.45, 'unit': 'M', 'net_profit': -5.86}, {'period': ""Q1 '23"", 'revenue': 20.8, 'unit': 'M', 'net_profit': -7.51}, {'period': ""Q4 '22"", 'revenue': 23.41, 'unit': 'M', 'net_profit': -3.17}, {'period': ""Q3 '22"", 'revenue': 28.44, 'unit': 'M', 'net_profit': -2.16}]",-0.42,-0.42,235502000,86461000,45361000,57102000,16192000,0,23048000,45361000,-44169000,0.36912065439672803,-0.37366827408321185,0.125,"[0.25, 0.25]","['2020-02-20', '2017-06-26']",__nan__,0.24246927839254018
72,ADI,Analog Devices Inc. Common Stock,"Analog Devices, Inc. designs, manufactures, tests, and markets integrated circuits (ICs), software, and subsystems that leverage analog, mixed-signal, and digital signal processing technologies. The company provides data converter products, which translate real-world analog signals into digital data, as well as translates digital data into analog signals; power management and reference products for power conversion, driver monitoring, sequencing, and energy management applications in the automotive, communications, industrial, and high-end consumer markets; and power ICs include performance, integration, and software design simulation tools for accurate power supply designs. It also offers high-performance amplifiers to condition analog signals; and radio frequency and microwave ICs to support cellular infrastructure; and microelectromechanical systems technology solutions, including accelerometers used to sense acceleration, gyroscopes for sense rotation, inertial measurement units to sense multiple degrees of freedom, and broadband switches for radio and instrument systems, as well as isolators. In addition, the company offers digital signal processing and system products for high-speed numeric calculations. It serves clients in the industrial, automotive, consumer, instrumentation, aerospace, and communications markets through a direct sales force, third-party distributors, and independent sales representatives in the United States, the rest of North and South America, Europe, Japan, China, and rest of Asia, as well as through its Website. Analog Devices, Inc. was incorporated in 1965 and is headquartered in Wilmington, Massachusetts.",Mr. Vincent T. Roche,Semiconductors,218.825,USD,108602191025,https://images.financialmodelingprep.com/symbol/ADI.png,2920991,66.92,0.825,1044514,2032798000,1635273000,"[{'period': '2024', 'revenue': 9.43, 'unit': 'B', 'net_profit': 1.64}, {'period': '2023', 'revenue': 12.31, 'unit': 'B', 'net_profit': 3.31}, {'period': '2022', 'revenue': 12.01, 'unit': 'B', 'net_profit': 2.75}, {'period': '2021', 'revenue': 7.32, 'unit': 'B', 'net_profit': 1.39}]","[{'period': ""Q4 '24"", 'revenue': 2440.0, 'unit': 'M', 'net_profit': 478.07}, {'period': ""Q3 '24"", 'revenue': 2310.0, 'unit': 'M', 'net_profit': 392.23}, {'period': ""Q2 '24"", 'revenue': 2160.0, 'unit': 'M', 'net_profit': 302.24}, {'period': ""Q1 '24"", 'revenue': 2510.0, 'unit': 'M', 'net_profit': 462.73}, {'period': ""Q4 '23"", 'revenue': 2720.0, 'unit': 'M', 'net_profit': 498.43}, {'period': ""Q3 '23"", 'revenue': 3080.0, 'unit': 'M', 'net_profit': 877.02}]",3.3,3.28,48228277000,5484654000,2363164000,13051960000,1336331000,0,2988280000,1991342000,3064299000,-0.6695081815827367,-0.50664232169455,-0.5,"[0.92, 0.04]","['2024-12-09', '2003-11-25']",__nan__,0.2706287848516753
73,ADIL,Adial Pharmaceuticals Inc Common Stock,"Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.",Mr. Cary John Claiborne MBA,Biotechnology,1.0599,USD,6862418,https://images.financialmodelingprep.com/symbol/ADIL.png,180308,-0.36,-0.0101,36895,-7001328,-7001890,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.0}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.73}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.42}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.86}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.19}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.46}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.48}, {'period': ""Q4 '23"", 'revenue': 0.03225, 'unit': 'M', 'net_profit': -1.92}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.38}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.09}]",-5.44,-5.44,4736605,3198679,2827082,653076,0,1534013,653076,2827082,0,0.4742613778482401,0.45003053862979575,0.5459098497495827,__nan__,__nan__,__nan__,0.137878501584996
74,ADILW,Adial Pharmaceuticals Inc Warrant,,None,,0.0009,USD,0,https://images.financialmodelingprep.com/symbol/ADILW.png,0,0,-0.0012,5182,-7001328,-7001890,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.0}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.73}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.42}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.86}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.19}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.46}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.48}, {'period': ""Q4 '23"", 'revenue': 0.03225, 'unit': 'M', 'net_profit': -1.92}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.38}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.09}]",-5.44,-5.44,4736605,3198679,2827082,653076,0,1534013,653076,2827082,0,0.4742613778482401,0.45003053862979575,0.5459098497495827,__nan__,__nan__,__nan__,0.137878501584996
75,ADMA,ADMA Biologics Inc Common Stock,"ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.",Mr. Adam S. Grossman,Biotechnology,18.35,USD,4337756500,https://images.financialmodelingprep.com/symbol/ADMA.png,3563187,67.96,-0.78,844739,5120000,-28239000,"[{'period': '2023', 'revenue': 258.21, 'unit': 'M', 'net_profit': -28.24}, {'period': '2022', 'revenue': 154.08, 'unit': 'M', 'net_profit': -85.18}, {'period': '2021', 'revenue': 80.94, 'unit': 'M', 'net_profit': -84.45}, {'period': '2020', 'revenue': 42.22, 'unit': 'M', 'net_profit': -87.61}]","[{'period': ""Q3 '24"", 'revenue': 119.84, 'unit': 'M', 'net_profit': 35.91}, {'period': ""Q2 '24"", 'revenue': 107.19, 'unit': 'M', 'net_profit': 32.06}, {'period': ""Q1 '24"", 'revenue': 81.88, 'unit': 'M', 'net_profit': 17.81}, {'period': ""Q4 '23"", 'revenue': 73.9, 'unit': 'M', 'net_profit': -17.64}, {'period': ""Q3 '23"", 'revenue': 67.27, 'unit': 'M', 'net_profit': 2.57}, {'period': ""Q2 '23"", 'revenue': 60.12, 'unit': 'M', 'net_profit': -6.37}]",-0.13,-0.13,329182000,257012999,51352000,193976000,27421000,0,49806000,51352000,3819000,1.128894034804209,0.668491448731109,0.6976744186046512,__nan__,__nan__,__nan__,0.5892667278283745
76,ADMP,Adamis Pharmaceuticals Corporation Common Stock,"Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.","Dr. Ebrahim  Versi M.D., Ph.D.",Drug Manufacturers - Specialty & Generic,0.775,USD,7253326,https://images.financialmodelingprep.com/symbol/ADMP.png,3113594,-0.07642998027613412,0.0065,119482,-24267629,-26199406,"[{'period': '2022', 'revenue': 4.76, 'unit': 'M', 'net_profit': -26.2}, {'period': '2021', 'revenue': 2.21, 'unit': 'M', 'net_profit': -34.6}, {'period': '2020', 'revenue': 16.53, 'unit': 'M', 'net_profit': -49.39}, {'period': '2019', 'revenue': 22.11, 'unit': 'M', 'net_profit': -29.31}]","[{'period': ""Q3 '23"", 'revenue': 9060.0, 'unit': 'K', 'net_profit': 348.2}, {'period': ""Q2 '23"", 'revenue': 0.0069500000000000004, 'unit': 'M', 'net_profit': -8.57}, {'period': ""Q1 '23"", 'revenue': 1450.0, 'unit': 'K', 'net_profit': 71.7}, {'period': ""Q4 '22"", 'revenue': 2.15, 'unit': 'M', 'net_profit': -3.4}, {'period': ""Q3 '22"", 'revenue': 1.51, 'unit': 'M', 'net_profit': -4.4}, {'period': ""Q2 '22"", 'revenue': 0.039850000000000003, 'unit': 'M', 'net_profit': -8.4}]",-12.24,-12.24,10930840,9272150,1081364,11738908,1085009,0,11395866,1081364,-26580923,0.20762511514149093,0.24279945930031407,0.27142857142857146,__nan__,__nan__,__nan__,1.0739255171606208
77,ADMS,Adamas Pharmaceuticals Inc. Common Stock,"Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.",Mr. Neil McFarlane,Drug Manufacturers - Specialty & Generic,8.22,USD,0,https://images.financialmodelingprep.com/symbol/ADMS.png,1338689,0,0,3151400,-43313000,-57403000,"[{'period': '2020', 'revenue': 74.46, 'unit': 'M', 'net_profit': -57.4}, {'period': '2019', 'revenue': 54.64, 'unit': 'M', 'net_profit': -105.19}, {'period': '2018', 'revenue': 34.05, 'unit': 'M', 'net_profit': -131.0}, {'period': '2017', 'revenue': 0.5710000000000001, 'unit': 'M', 'net_profit': -89.49}]","[{'period': ""Q3 '21"", 'revenue': 25.9, 'unit': 'M', 'net_profit': -19.52}, {'period': ""Q2 '21"", 'revenue': 21.97, 'unit': 'M', 'net_profit': -12.34}, {'period': ""Q1 '21"", 'revenue': 19.31, 'unit': 'M', 'net_profit': -12.57}, {'period': ""Q4 '20"", 'revenue': 21.01, 'unit': 'M', 'net_profit': -18.27}, {'period': ""Q3 '20"", 'revenue': 20.18, 'unit': 'M', 'net_profit': -11.92}, {'period': ""Q2 '20"", 'revenue': 18.79, 'unit': 'M', 'net_profit': -10.57}]",-1.63,-1.63,120029000,111736000,83365000,170005000,9294000,0,34867000,71660000,-50708000,0.5129430550557754,0.45427148099556974,0.5710526315789474,__nan__,__nan__,__nan__,1.416366044872489
78,ADN,Advent Technologies Holdings Inc. Class A Common Stock,"Advent Technologies Holdings, Inc., an advanced materials and technology development company, operates in the fuel cell and hydrogen technology markets. It develops, manufactures, and assembles fuel cell systems and critical components that determine the performance of hydrogen fuel cells and other energy systems. The company offers high-temperature proton exchange membrane (HT-PEM) fuel cells, HT-PEM based membrane electrode assemblies, membranes, and electrodes. It serves stationary and portable power, automotive, aviation, energy storage, and sensor markets. The company is headquartered in Boston, Massachusetts.",Mr. Gary L. Herman,Renewable Utilities,6.04,USD,15924520,https://images.financialmodelingprep.com/symbol/ADN.png,1231835,-0.18,-0.03,11024,-53226000,-71397000,"[{'period': '2023', 'revenue': 4.86, 'unit': 'M', 'net_profit': -71.4}, {'period': '2022', 'revenue': 7.84, 'unit': 'M', 'net_profit': -74.34}, {'period': '2021', 'revenue': 7.07, 'unit': 'M', 'net_profit': -20.52}, {'period': '2020', 'revenue': 882.65, 'unit': 'K', 'net_profit': -993.85}]","[{'period': ""Q3 '24"", 'revenue': 0.128, 'unit': 'M', 'net_profit': -18.52}, {'period': ""Q2 '24"", 'revenue': 0.805, 'unit': 'M', 'net_profit': -11.27}, {'period': ""Q1 '24"", 'revenue': 3.45, 'unit': 'M', 'net_profit': -9.36}, {'period': ""Q4 '23"", 'revenue': 1.51, 'unit': 'M', 'net_profit': -25.73}, {'period': ""Q3 '23"", 'revenue': 1.26, 'unit': 'M', 'net_profit': -11.85}, {'period': ""Q2 '23"", 'revenue': 1.11, 'unit': 'M', 'net_profit': -21.83}]",-37.24,-37.24,34737000,8835000,3562000,21289000,292000,0,11913000,3562000,-36741000,-0.19292662154287507,0.03954961862867751,0.13955637707948243,__nan__,__nan__,__nan__,0.6128623657771253
79,ADNWW,Advent Technologies Holdings Inc. Warrant,"Advent Technologies Holdings, Inc., an advanced materials and technology development company, operates in the fuel cell and hydrogen technology markets in North America, Europe, and Asia. It develops, manufactures, and assembles fuel cell systems and critical components that determine the performance of hydrogen fuel cells and other energy systems. The company offers high-temperature proton exchange membrane (HT-PEM) fuel cells, including membrane electrode assemblies, bipolar plates, and reformers, as well as provides fuel-cell stack assembly and testing services. It serves stationary power, portable power, automotive, aviation, energy storage, and sensor markets. The company is headquartered in Boston, Massachusetts.",Mr. Gary L. Herman,Renewable Utilities,0.0153,USD,19001591,https://images.financialmodelingprep.com/symbol/ADNWW.png,0,,0.0039,116571,-53226000,-71397000,"[{'period': '2023', 'revenue': 4.86, 'unit': 'M', 'net_profit': -71.4}, {'period': '2022', 'revenue': 7.84, 'unit': 'M', 'net_profit': -74.34}, {'period': '2021', 'revenue': 7.07, 'unit': 'M', 'net_profit': -20.52}, {'period': '2020', 'revenue': 882.65, 'unit': 'K', 'net_profit': -993.85}]","[{'period': ""Q3 '24"", 'revenue': 0.128, 'unit': 'M', 'net_profit': -18.52}, {'period': ""Q2 '24"", 'revenue': 0.805, 'unit': 'M', 'net_profit': -11.27}, {'period': ""Q1 '24"", 'revenue': 3.45, 'unit': 'M', 'net_profit': -9.36}, {'period': ""Q4 '23"", 'revenue': 1.51, 'unit': 'M', 'net_profit': -25.73}, {'period': ""Q3 '23"", 'revenue': 1.26, 'unit': 'M', 'net_profit': -11.85}, {'period': ""Q2 '23"", 'revenue': 1.11, 'unit': 'M', 'net_profit': -21.83}]",-37.24,-37.24,34737000,8835000,3562000,21289000,292000,0,11913000,3562000,-36741000,-0.19292662154287507,0.03954961862867751,0.13955637707948243,__nan__,__nan__,__nan__,0.6128623657771253
80,ADOC,Edoc Acquisition Corp. Class A Ordinary Share,"Edoc Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the health care and health care provider space in North America and the Asia-Pacific. The company was incorporated in 2020 and is based in Victor, New York.",Mr. Kevin  Chen,Shell Companies,2.85,USD,10317599,https://images.financialmodelingprep.com/symbol/ADOC.png,22081,-1.4766839378238341,-4.95,571568,-5141.406000000001,-7686.39,"[{'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -7.69}, {'period': '2021', 'revenue': 0.0, 'unit': '', 'net_profit': -899.88}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.7}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -252.47}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': -275.24}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': -431.05}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.04}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': '', 'net_profit': -230.12}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.85}]",-0.0013,-0.0013,21405267,86112,13726,4389775,0,21319155,4366518,13726,-1459672,-6.724006866929855,-7.541572209627951,-11.999999999999998,__nan__,__nan__,__nan__,0.2050791984982014
81,ADOCR,Edoc Acquisition Corp. Right,"Edoc Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the health care and health care provider space in North America and the Asia-Pacific. The company was incorporated in 2020 and is based in Victor, New York.",Mr. Kevin  Chen,Shell Companies,0.27,USD,1063080,https://images.financialmodelingprep.com/symbol/ADOCR.png,0,-0.4900181488203267,0.07,3483784,-5141.406000000001,-7686.39,"[{'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -7.69}, {'period': '2021', 'revenue': 0.0, 'unit': '', 'net_profit': -899.88}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.7}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -252.47}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': -275.24}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': -431.05}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.04}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': '', 'net_profit': -230.12}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.85}]",-0.0013,-0.0013,21405267,86112,13726,4389775,0,21319155,4366518,13726,-1459672,-6.724006866929855,-7.541572209627951,-11.999999999999998,"[0.285, 0.285]","['2022-03-15', '2022-03-15']",__nan__,0.2050791984982014
82,ADOCW,Edoc Acquisition Corp. Warrant,"Edoc Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the healthcare and healthcare provider space in North America and the Asia-Pacific. Edoc Acquisition Corp. was incorporated in 2020 and is based in Victor, New York.",Mr. Kevin  Chen,Shell Companies,0.045,USD,177180,https://images.financialmodelingprep.com/symbol/ADOCW.png,0,0,0.015,108311,-5141.406000000001,-7686.39,"[{'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -7.69}, {'period': '2021', 'revenue': 0.0, 'unit': '', 'net_profit': -899.88}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.7}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -252.47}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': -275.24}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': -431.05}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.04}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': '', 'net_profit': -230.12}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.85}]",-0.0013,-0.0013,21405267,86112,13726,4389775,0,21319155,4366518,13726,-1459672,-6.724006866929855,-7.541572209627951,-11.999999999999998,__nan__,__nan__,__nan__,0.2050791984982014
83,ADP,Automatic Data Processing Inc. Common Stock,"Automatic Data Processing, Inc. provides cloud-based human capital management solutions worldwide. It operates in two segments, Employer Services and Professional Employer Organization (PEO). The Employer Services segment offers strategic, cloud-based platforms, and human resources (HR) outsourcing solutions. Its offerings include payroll, benefits administration, talent management, HR management, workforce management, insurance, retirement, and compliance services, as well as integrated HCM solutions. The PEO Services segment provides HR outsourcing solutions to small and mid-sized businesses through a co-employment model. This segment offers benefits package, protection and compliance, talent engagement, expertise, comprehensive outsourcing, and recruitment process outsourcing services. The company was founded in 1949 and is headquartered in Roseland, New Jersey.",Ms. Maria  Black,Staffing & Employment Services,289.11,USD,117799893270,https://images.financialmodelingprep.com/symbol/ADP.png,1666525,31.36,1.98,345916,5800000000,3752000000,"[{'period': '2024', 'revenue': 19.2, 'unit': 'B', 'net_profit': 3.75}, {'period': '2023', 'revenue': 18.01, 'unit': 'B', 'net_profit': 3.41}, {'period': '2022', 'revenue': 16.5, 'unit': 'B', 'net_profit': 2.95}, {'period': '2021', 'revenue': 15.01, 'unit': 'B', 'net_profit': 2.6}]","[{'period': ""Q1 '25"", 'revenue': 4830.0, 'unit': 'M', 'net_profit': 956.3}, {'period': ""Q4 '24"", 'revenue': 4770.0, 'unit': 'M', 'net_profit': 829.3}, {'period': ""Q3 '24"", 'revenue': 5.25, 'unit': 'B', 'net_profit': 1.18}, {'period': ""Q2 '24"", 'revenue': 4670.0, 'unit': 'M', 'net_profit': 878.4}, {'period': ""Q1 '24"", 'revenue': 4510.0, 'unit': 'M', 'net_profit': 859.4}, {'period': ""Q4 '23"", 'revenue': 4480.0, 'unit': 'M', 'net_profit': 776.7}]",9.14,9.1,54362700000,45542500000,2913400000,49815100000,3428200000,0,45080000000,2913400000,3594200000,0.10589940128894482,0.09964830011723329,0.10787878787878795,"[1.54, 0.14]","['2024-12-13', '1983-06-14']",__nan__,0.9163470541382235
84,ADPT,Adaptive Biotechnologies Corporation Common Stock,"Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.",Mr. Chad M. Robins M.B.A.,Biotechnology,6.82,USD,1006488780,https://images.financialmodelingprep.com/symbol/ADPT.png,1176312,-5.09,-0.23,644617,-189273000,-225250000,"[{'period': '2023', 'revenue': 170.28, 'unit': 'M', 'net_profit': -225.25}, {'period': '2022', 'revenue': 185.31, 'unit': 'M', 'net_profit': -142.46}, {'period': '2021', 'revenue': 154.34, 'unit': 'M', 'net_profit': -205.61}, {'period': '2020', 'revenue': 98.38, 'unit': 'M', 'net_profit': -139.64}]","[{'period': ""Q3 '24"", 'revenue': 46.44, 'unit': 'M', 'net_profit': -32.07}, {'period': ""Q2 '24"", 'revenue': 43.19, 'unit': 'M', 'net_profit': -46.22}, {'period': ""Q1 '24"", 'revenue': 41.87, 'unit': 'M', 'net_profit': -47.51}, {'period': ""Q4 '23"", 'revenue': 45.78, 'unit': 'M', 'net_profit': -69.44}, {'period': ""Q3 '23"", 'revenue': 37.92, 'unit': 'M', 'net_profit': -50.3}, {'period': ""Q2 '23"", 'revenue': 48.93, 'unit': 'M', 'net_profit': -47.81}]",-1.56,-1.56,661134000,410188000,346401000,352856000,37969000,0,88015000,65063999,-167021000,-0.12673901525749628,-0.5811011904761905,-0.56,__nan__,__nan__,__nan__,0.5337132865652047
85,ADSK,Autodesk Inc. Common Stock,"Autodesk, Inc. provides 3D design, engineering, and entertainment software and services worldwide. The company offers AutoCAD Civil 3D, a surveying, design, analysis, and documentation solution for civil engineering, including land development, transportation, and environmental projects; BIM 360, a construction management cloud-based software; AutoCAD, a software for professional design, drafting, detailing, and visualization; AutoCAD LT, a drafting and detailing software; computer-aided manufacturing (CAM) software for computer numeric control machining, inspection, and modelling for manufacturing; Fusion 360, a 3D CAD, CAM, and computer-aided engineering tool; and Industry Collections tools for professionals in architecture, engineering and construction, product design and manufacturing, and media and entertainment collection industries. It also provides Inventor tools for 3D mechanical design, simulation, analysis, tooling, visualization, and documentation; Vault, a data management software to manage data in one central location, accelerate design processes, and streamline internal/external collaboration; Maya and 3ds Max software products that offer 3D modeling, animation, effects, rendering, and compositing solutions; and ShotGrid, a cloud-based software for review and production tracking in the media and entertainment industry. It sells its products and services to customers directly, as well as through a network of resellers and distributors. Autodesk, Inc. was incorporated in 1982 and is headquartered in San Rafael, California.",Dr. Andrew  Anagnost Ph.D.,Software - Application,292.68,USD,62926200000,https://images.financialmodelingprep.com/symbol/ADSK.png,1420627,58.54,0.17,224500,1219000000,906000000,"[{'period': '2024', 'revenue': 5440.0, 'unit': 'M', 'net_profit': 906.0}, {'period': '2023', 'revenue': 5000.0, 'unit': 'M', 'net_profit': 823.0}, {'period': '2022', 'revenue': 4390.0, 'unit': 'M', 'net_profit': 497.0}, {'period': '2021', 'revenue': 3.79, 'unit': 'B', 'net_profit': 1.21}]","[{'period': ""Q3 '25"", 'revenue': 1570.0, 'unit': 'M', 'net_profit': 275.0}, {'period': ""Q2 '25"", 'revenue': 1500.0, 'unit': 'M', 'net_profit': 282.0}, {'period': ""Q1 '25"", 'revenue': 1410.0, 'unit': 'M', 'net_profit': 252.0}, {'period': ""Q4 '24"", 'revenue': 1470.0, 'unit': 'M', 'net_profit': 282.0}, {'period': ""Q3 '24"", 'revenue': 1410.0, 'unit': 'M', 'net_profit': 241.0}, {'period': ""Q2 '24"", 'revenue': 1340.0, 'unit': 'M', 'net_profit': 222.0}]",4.19,4.19,9912000000,3579000000,2246000000,8057000000,876000000,234000000,4351000000,1892000000,1282000000,0.11121239744758432,0.10085054678007291,0.09973753280839903,"[0.015, 0.1]","['2005-03-22', '1989-07-14']",__nan__,0.8128531073446328
86,ADTN,ADTRAN Inc. Common Stock,"ADTRAN Holdings, Inc., through its subsidiaries, provides end-to-end fiber networking solutions for communications service provider, enterprises, and government customers in the United States, Germany, the United Kingdom, Mexico, and internationally. It operates through two segments, Network Solutions, and Services & Support. The company offers fiber access and fiber to the node platforms; transceivers, cables, and other miscellaneous materials; passive optical network optical line terminals; fiber to the distribution point Gfast distribution point units; cabinet and outside plant enclosures and services; packet optical transports; fixed wireless access platforms; and network management and subscriber services, and control and orchestration software. It also provides broadband customer premises solutions, ethernet switches and routers, residential gateways, cloud-based software-as-a-service management platforms, virtual wireless local area networks, Internet of Things gateways, pre-sale and post-sale technical support, and multi-gigabit mesh Wi-Fi gateways. In addition, the company offers time division multiplexed and asynchronous transfer mode-based aggregation systems and customer devices; and high-bit-rate and asymmetric digital subscriber line, and other technologies. Further, it provides other access and aggregation, subscriber and experience, and traditional and other products, software, and services. Additionally, the company engages in the provision of planning, engineering, program management, maintenance, installation, and commissioning services to implement customer network solutions; and customer devices solutions into consumer, small business, and enterprise locations. ADTRAN Holdings, Inc. is headquartered in Huntsville, Alabama.",Mr. Thomas R. Stanton,Communication Equipment,9.57,USD,758957463,https://images.financialmodelingprep.com/symbol/ADTN.png,635650,-1.47,-0.1,421401,-96062000,-267688000,"[{'period': '2023', 'revenue': 1150.0, 'unit': 'M', 'net_profit': -267.69}, {'period': '2022', 'revenue': 1030.0, 'unit': 'M', 'net_profit': -8.89}, {'period': '2021', 'revenue': 563.0, 'unit': 'M', 'net_profit': -8.63}, {'period': '2020', 'revenue': 506.51, 'unit': 'M', 'net_profit': 2.38}]","[{'period': ""Q3 '24"", 'revenue': 227.7, 'unit': 'M', 'net_profit': -31.24}, {'period': ""Q2 '24"", 'revenue': 225.99, 'unit': 'M', 'net_profit': -49.87}, {'period': ""Q1 '24"", 'revenue': 226.17, 'unit': 'M', 'net_profit': -324.55}, {'period': ""Q4 '23"", 'revenue': 225.48, 'unit': 'M', 'net_profit': -109.94}, {'period': ""Q3 '23"", 'revenue': 272.33, 'unit': 'M', 'net_profit': -72.73}, {'period': ""Q2 '23"", 'revenue': 327.38, 'unit': 'M', 'net_profit': -33.33}]",-3.41,-3.41,1682512000,736856000,87167000,636934000,241828000,27743000,279511000,87167000,-88725000,-25.46193022663611,-29.117911791179118,-23.357142857142854,"[0.09, 2]","['2023-08-18', '2003-07-29']",__nan__,0.37856134161301674
87,ADTX,ADiTx Therapeutics Inc. Common Stock,"Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.",Mr. Amro A. Albanna,Biotechnology,0.2022,USD,2878155,https://images.financialmodelingprep.com/symbol/ADTX.png,4602161,0,0.0062,14000695,-25457964,-32380839,"[{'period': '2023', 'revenue': 0.64518, 'unit': 'M', 'net_profit': -32.38}, {'period': '2022', 'revenue': 0.93372, 'unit': 'M', 'net_profit': -28.19}, {'period': '2021', 'revenue': 0.10503, 'unit': 'M', 'net_profit': -48.31}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.46}]","[{'period': ""Q3 '24"", 'revenue': 0.00685, 'unit': 'M', 'net_profit': -6.94}, {'period': ""Q2 '24"", 'revenue': 0.04428, 'unit': 'M', 'net_profit': -7.55}, {'period': ""Q1 '24"", 'revenue': 0.07968000000000001, 'unit': 'M', 'net_profit': -14.73}, {'period': ""Q4 '23"", 'revenue': 0.0813, 'unit': 'M', 'net_profit': -10.97}, {'period': ""Q3 '23"", 'revenue': 0.12449, 'unit': 'M', 'net_profit': -9.75}, {'period': ""Q2 '23"", 'revenue': 0.22097999999999998, 'unit': 'M', 'net_profit': -5.68}]",-108.15,-108.15,44578327,6912948,97102,28531558,5852954,22277211,25889814,97102,-18591218,-0.02538085009742904,-0.14850864093804406,0.8221334122755082,__nan__,__nan__,__nan__,0.6400320496549814
88,ADUS,Addus HomeCare Corporation Common Stock,"Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. It operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. As of December 31, 2021, the company served consumers through 206 offices located in 22 states. Addus HomeCare Corporation was founded in 1979 and is based in Frisco, Texas.",Mr. R. Dirk Allison CPA,Medical - Care Facilities,125.47,USD,2275160057,https://images.financialmodelingprep.com/symbol/ADUS.png,136969,28.71,-0.23,17118,106558000,62516000,"[{'period': '2023', 'revenue': 1060.0, 'unit': 'M', 'net_profit': 62.52}, {'period': '2022', 'revenue': 951.12, 'unit': 'M', 'net_profit': 46.02}, {'period': '2021', 'revenue': 864.5, 'unit': 'M', 'net_profit': 45.13}, {'period': '2020', 'revenue': 764.77, 'unit': 'M', 'net_profit': 33.13}]","[{'period': ""Q3 '24"", 'revenue': 289.79, 'unit': 'M', 'net_profit': 20.16}, {'period': ""Q2 '24"", 'revenue': 286.92, 'unit': 'M', 'net_profit': 18.08}, {'period': ""Q1 '24"", 'revenue': 280.75, 'unit': 'M', 'net_profit': 15.83}, {'period': ""Q4 '23"", 'revenue': 276.35, 'unit': 'M', 'net_profit': 19.58}, {'period': ""Q3 '23"", 'revenue': 270.72, 'unit': 'M', 'net_profit': 15.41}, {'period': ""Q2 '23"", 'revenue': 259.98, 'unit': 'M', 'net_profit': 14.85}]",3.85,3.83,1024425999,200004000,64791000,317732000,116076000,0,145117000,64791000,102793000,0.2817003055161298,0.3583052688756111,0.32758620689655177,__nan__,__nan__,__nan__,0.31015612675796606
89,ADV,Advantage Solutions Inc. Class A Common Stock,"Advantage Solutions Inc. provides outsourced solutions to consumer goods companies and retailers in North America and internationally. It operates in two segments, Sales and Marketing. The Sales segment offers brand-centric services, such as headquarter relationship management; analytics, insights, and intelligence; administration; and brand-centric merchandising services. This segment also provides retailer-centric services comprising retailer-centric merchandising, in-store media, and digital commerce. The Marketing segment offers brand-centric services, including shopper and consumer marketing, and brand experiential services; and retailer-centric services, such as retail experiential, private label, digital marketing, and digital media and advertising. The company was formerly known as Karman Holding Corp. and changed its name to Advantage Solutions Inc. in March 2016. Advantage Solutions Inc. was founded in 1987 and is headquartered in Irvine, California.",Mr. David A. Peacock,Advertising Agencies,2.6525,USD,850799985,https://images.financialmodelingprep.com/symbol/ADV.png,417200,-4.57,0.0025,95017,301173000,-63258000,"[{'period': '2023', 'revenue': 4220.0, 'unit': 'M', 'net_profit': -63.26}, {'period': '2022', 'revenue': 4.05, 'unit': 'B', 'net_profit': -1.38}, {'period': '2021', 'revenue': 3600.0, 'unit': 'M', 'net_profit': 54.49}, {'period': '2020', 'revenue': 3160.0, 'unit': 'M', 'net_profit': -161.71}]","[{'period': ""Q3 '24"", 'revenue': 939.27, 'unit': 'M', 'net_profit': -42.78}, {'period': ""Q2 '24"", 'revenue': 873.36, 'unit': 'M', 'net_profit': -114.01}, {'period': ""Q1 '24"", 'revenue': 879.0, 'unit': 'M', 'net_profit': -62.32}, {'period': ""Q4 '23"", 'revenue': 1080.0, 'unit': 'M', 'net_profit': 17.43}, {'period': ""Q3 '23"", 'revenue': 1100.0, 'unit': 'M', 'net_profit': -24.34}, {'period': ""Q2 '23"", 'revenue': 1040.0, 'unit': 'M', 'net_profit': -8.76}]",-0.2,-0.2,3779323000,1012034000,142842000,2675246000,714150000,211458000,541297000,126479000,192724000,1.2649955434171476,0.9540707417163535,0.9537037037037037,__nan__,__nan__,__nan__,0.7078638158209817
90,ADVM,Adverum Biotechnologies Inc. Common Stock,"Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.",Dr. Laurent  Fischer,Biotechnology,4.97,USD,103388425,https://images.financialmodelingprep.com/symbol/ADVM.png,218898,-0.87,0.18,26771,-118347000,-117165000,"[{'period': '2023', 'revenue': 3.6, 'unit': 'M', 'net_profit': -117.17}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -154.54}, {'period': '2021', 'revenue': 7.5, 'unit': 'M', 'net_profit': -145.54}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -117.51}]","[{'period': ""Q3 '24"", 'revenue': 1.0, 'unit': 'M', 'net_profit': -27.13}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.48}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.79}, {'period': ""Q4 '23"", 'revenue': -3.6, 'unit': 'M', 'net_profit': -23.71}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -32.88}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.51}]",-11.62,-11.62,173010000,102773000,96526000,89541000,0,1976000,24914000,75000000,-91710000,0.20000135195424987,0.24182714707252678,0.2536929993577393,__nan__,__nan__,__nan__,0.5175481186058609
91,ADVWW,Advantage Solutions Inc. Warrant,"Advantage Solutions Inc. provides business solutions to consumer goods manufacturers and retailers in North America and internationally. It operates in two segments, Sales and Marketing. The Sales segment offers brand-centric services, such as headquarter relationship management; analytics, insights, and intelligence; and brand-centric merchandising services. This segment also provides retailer-centric services comprising retailer-centric merchandising and in-store media services. The Marketing segment offers brand-centric services, including shopper and consumer marketing, and brand experiential services; retailer-centric services, such as retail experiential and private label services; and digital marketing, and digital media and advertising services. The company was formerly known as Karman Holding Corp. and changed its name to Advantage Solutions Inc. in March 2016. The company was founded in 1987 and is headquartered in Irvine, California.",Mr. David A. Peacock,Advertising Agencies,0.0137,USD,4394330,https://images.financialmodelingprep.com/symbol/ADVWW.png,0,,0.0011,5403,301173000,-63258000,"[{'period': '2023', 'revenue': 4220.0, 'unit': 'M', 'net_profit': -63.26}, {'period': '2022', 'revenue': 4.05, 'unit': 'B', 'net_profit': -1.38}, {'period': '2021', 'revenue': 3600.0, 'unit': 'M', 'net_profit': 54.49}, {'period': '2020', 'revenue': 3160.0, 'unit': 'M', 'net_profit': -161.71}]","[{'period': ""Q3 '24"", 'revenue': 939.27, 'unit': 'M', 'net_profit': -42.78}, {'period': ""Q2 '24"", 'revenue': 873.36, 'unit': 'M', 'net_profit': -114.01}, {'period': ""Q1 '24"", 'revenue': 879.0, 'unit': 'M', 'net_profit': -62.32}, {'period': ""Q4 '23"", 'revenue': 1080.0, 'unit': 'M', 'net_profit': 17.43}, {'period': ""Q3 '23"", 'revenue': 1100.0, 'unit': 'M', 'net_profit': -24.34}, {'period': ""Q2 '23"", 'revenue': 1040.0, 'unit': 'M', 'net_profit': -8.76}]",-0.2,-0.2,3779323000,1012034000,142842000,2675246000,714150000,211458000,541297000,126479000,192724000,1.2649955434171476,0.9540707417163535,0.9537037037037037,__nan__,__nan__,__nan__,0.7078638158209817
92,ADXN,Addex Therapeutics Ltd American Depositary Shares,"Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.",Mr. Timothy Mark Dyer,Biotechnology,8.4852,USD,14231462,https://images.financialmodelingprep.com/symbol/ADXN.png,38550,-0.4,-0.1148,6299,-10228668,-10556227,"[{'period': '2023', 'revenue': 1.61, 'unit': 'M', 'net_profit': -10.56}, {'period': '2022', 'revenue': 1.42, 'unit': 'M', 'net_profit': -20.8}, {'period': '2021', 'revenue': 2.92, 'unit': 'M', 'net_profit': -15.35}, {'period': '2020', 'revenue': 3.61, 'unit': 'M', 'net_profit': -12.86}]","[{'period': ""Q3 '24"", 'revenue': 0.053840000000000006, 'unit': 'M', 'net_profit': -1.53}, {'period': ""Q2 '24"", 'revenue': 0.11528000000000001, 'unit': 'M', 'net_profit': 12.88}, {'period': ""Q1 '24"", 'revenue': 0.23491, 'unit': 'M', 'net_profit': -3.09}, {'period': ""Q4 '23"", 'revenue': 0.15345, 'unit': 'M', 'net_profit': -2.86}, {'period': ""Q3 '23"", 'revenue': 0.32773, 'unit': 'M', 'net_profit': -2.62}, {'period': ""Q2 '23"", 'revenue': 0.63088, 'unit': 'M', 'net_profit': -2.68}]",-0.14,-0.14,4641885,4234605,3866329,3496420,151268,0,2893284,3865481,-7999253,0.49434707257049587,0.49259186108121467,0.6956521739130435,__nan__,__nan__,__nan__,0.7532327922815839
93,ADXS,Advaxis Inc. Common Stock,"Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.",Mr. Kenneth A. Berlin J.D.,Biotechnology,0.027,USD,1151102,https://images.financialmodelingprep.com/symbol/ADXS.png,1799,0,0,165,-35869000,-48072000,"[{'period': '2023', 'revenue': 0.013000000000000001, 'unit': 'M', 'net_profit': -48.07}, {'period': '2022', 'revenue': 0.25, 'unit': 'M', 'net_profit': -14.36}, {'period': '2021', 'revenue': 3.24, 'unit': 'M', 'net_profit': -17.86}, {'period': '2020', 'revenue': 0.253, 'unit': 'M', 'net_profit': -26.47}]","[{'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.67}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.34}, {'period': ""Q2 '23"", 'revenue': 0.009000000000000001, 'unit': 'M', 'net_profit': -8.7}, {'period': ""Q1 '23"", 'revenue': 0.004, 'unit': 'M', 'net_profit': -7.36}, {'period': ""Q4 '22"", 'revenue': 0.105, 'unit': 'M', 'net_profit': -9.59}, {'period': ""Q3 '22"", 'revenue': 0.25, 'unit': 'M', 'net_profit': -4.96}]",-7.99,-7.99,16579000,7528000,4882000,40996000,0,0,25018000,4882000,-29485000,-1.2736435091277891,-2.3478654502402674,-0.01139240506329112,__nan__,__nan__,__nan__,2.4727667531214186
94,AEAC,Authentic Equity Acquisition Corp. Class A ordinary share,"Authentic Equity Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to identify business opportunities in the field of the consumer in North America. The company was incorporated in 2020 and is based in Rye, New York.",Mr. David M. Hooper,Shell Companies,10.13,USD,0,https://images.financialmodelingprep.com/symbol/AEAC.png,34356,0,-0.02,4203,6962388,15491848,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.49}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -34.25}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.14}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.34}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.66}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.02}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.21}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.35}]",0.52,0.52,697.5339999999997,675.792,442.162,18737,0,230021,876.735,442.162,-1010801,204.28733685655055,453.32993664048587,473.7272727272727,__nan__,__nan__,__nan__,26.861773046188443
95,AEACU,Authentic Equity Acquisition Corp. Unit,"Authentic Equity Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to identify business opportunities in the field of the consumer in North America. The company was incorporated in 2020 and is based in Rye, New York.",Mr. David M. Hooper,Shell Companies,10.13,USD,0,https://images.financialmodelingprep.com/symbol/AEACU.png,4936,0,-0.0048,1300,6962388,15491848,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.49}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -34.25}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.14}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.34}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.66}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.02}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.21}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.35}]",0.52,0.52,697.5339999999997,675.792,442.162,18737,0,230021,876.735,442.162,-1010801,204.28733685655055,453.32993664048587,473.7272727272727,__nan__,__nan__,__nan__,26.861773046188443
96,AEACW,Authentic Equity Acquisition Corp. Warrant,"Authentic Equity Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded in 2020 and is based in Rye, New York.",Mr. David M. Hooper,Shell Companies,0.0009,USD,0,https://images.financialmodelingprep.com/symbol/AEACW.png,0,0,0,65887,6962388,15491848,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.49}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -34.25}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.14}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.34}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.66}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.02}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.21}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.35}]",0.52,0.52,697.5339999999997,675.792,442.162,18737,0,230021,876.735,442.162,-1010801,204.28733685655055,453.32993664048587,473.7272727272727,__nan__,__nan__,__nan__,26.861773046188443
97,AEHL,Antelope Enterprise Holdings Limited Common Stock (0.024 par),"Antelope Enterprise Holdings Limited, through its subsidiaries, manufactures and sells ceramic tiles for exterior siding and interior flooring, and design in residential and commercial buildings in the People's Republic of China. The company provides porcelain tiles, glazed tiles, glazed porcelain tiles, rustic tiles, and polished glazed tiles. It sells its products under the HD or Hengda brands through a network of distributors, as well as directly to property developers. The company was formerly known as China Ceramics Co., Ltd. and changed its name to Antelope Enterprise Holdings Limited in October 2020. Antelope Enterprise Holdings Limited was founded in 1993 and is headquartered in Jinjiang, the People's Republic of China.",Ms. Tingting  Zhang,Construction,0.225,USD,7496828,https://images.financialmodelingprep.com/symbol/AEHL.png,1735729,0.01,-0.006,850101,-85501000,-14340000,"[{'period': '2023', 'revenue': 510.55, 'unit': 'M', 'net_profit': -14.34}, {'period': '2022', 'revenue': 286.35, 'unit': 'M', 'net_profit': -5.65}, {'period': '2021', 'revenue': 216.27, 'unit': 'M', 'net_profit': -90.06}, {'period': '2020', 'revenue': 182.99, 'unit': 'M', 'net_profit': -193.09}]","[{'period': ""Q4 '23"", 'revenue': 201.3, 'unit': 'M', 'net_profit': -48.95}, {'period': ""Q2 '23"", 'revenue': 309.25, 'unit': 'M', 'net_profit': -37.85}, {'period': ""Q4 '22"", 'revenue': 168.1, 'unit': 'M', 'net_profit': -6.83}, {'period': ""Q2 '22"", 'revenue': 118.25, 'unit': 'M', 'net_profit': -3.09}, {'period': ""Q2 '21"", 'revenue': 50.11, 'unit': 'M', 'net_profit': -70.77}, {'period': ""Q4 '20"", 'revenue': 143.2, 'unit': 'M', 'net_profit': -81.59}]",-6.46,-6.46,121502000,34232000,4508000,19261000,15239000,0,11867000,3808000,-60846000,-15.566750629722922,-1.5380530973451327,-8.5,"[0.0032, 0.025]","['2014-12-10', '2013-06-11']",__nan__,0.15852413952033712
98,AEHR,Aehr Test Systems Common Stock,"Aehr Test Systems provides test systems for burning-in and testing logic, optical, and memory integrated circuits worldwide. It offers products, such as the ABTS and FOX-P families of test and burn-in systems and FOX WaferPak Aligner, FOX-XP WaferPak Contactor, FOX DiePak Carrier, and FOX DiePak Loader. The ABTS system is used in production and qualification testing of packaged parts for lower power and higher power logic devices, as well as various common types of memory devices. The FOX-XP and FOX-NP systems are wafer contact and singulated die/module test and burn-in systems used for burn-in and functional test of complex devices, such as memories, digital signal processors, microprocessors, microcontrollers, systems-on-a-chip, and integrated optical devices. The FOX-CP system is a single-wafer compact test and reliability verification solution for logic, memory, and photonic devices. The WaferPak Contactor contains a unique full wafer probe card capable of testing wafers up to 300mm that enables IC manufacturers to perform test and burn-in of full wafers on Aehr Test FOX systems. The DiePak Carrier is a reusable, temporary package that enables IC manufacturers to perform final test and burn-in of bare die and modules. Aehr Test Systems was incorporated in 1977 and is headquartered in Fremont, California.",Mr. Gayn  Erickson,Semiconductors,17.87,USD,529504183,https://images.financialmodelingprep.com/symbol/AEHR.png,1415366,18.23,1.02,939977,11441000,33156000,"[{'period': '2024', 'revenue': 66.22, 'unit': 'M', 'net_profit': 33.16}, {'period': '2023', 'revenue': 64.96, 'unit': 'M', 'net_profit': 14.56}, {'period': '2022', 'revenue': 50.83, 'unit': 'M', 'net_profit': 9.45}, {'period': '2021', 'revenue': 16.6, 'unit': 'M', 'net_profit': -2.03}]","[{'period': ""Q1 '25"", 'revenue': 13120.0, 'unit': 'K', 'net_profit': 660.0}, {'period': ""Q4 '24"", 'revenue': 16.6, 'unit': 'M', 'net_profit': 23.86}, {'period': ""Q3 '24"", 'revenue': 7.56, 'unit': 'M', 'net_profit': -1.47}, {'period': ""Q2 '24"", 'revenue': 21.43, 'unit': 'M', 'net_profit': 6.09}, {'period': ""Q1 '24"", 'revenue': 20.62, 'unit': 'M', 'net_profit': 4.67}, {'period': ""Q4 '23"", 'revenue': 22.27, 'unit': 'M', 'net_profit': 6.11}]",1.15,1.12,127912000,97848000,49159000,16319000,9996000,0,10508000,49159000,1007000,-0.17244122965641953,1.2776671017379955,1.2115384615384612,__nan__,__nan__,__nan__,0.12757989868034272
99,AEI,Alset EHome International Inc. Common Stock,"Alset EHome International Inc., through its subsidiaries, engages in the real estate development, financial services, digital transformation technologies, biohealth, and consumer products businesses in the United States, Singapore, Hong Kong, Australia, and South Korea. It operates through four segments: Real Estate, Digital Transformation Technology, Biohealth, and Other Business Activities segments. The Real Estate segment develops property projects and participates in third-party property development projects; and owns, operates, and manages real estate development projects with a focus on land subdivision developments and house rental projects. The Digital Transformation Technology segment provides consulting, implementation, and development services with various technologies, including blockchain, e-commerce, social media, and payment solutions. Its technology platform focuses on business-to-business solutions, such as communications and workflow, instant messaging, international calling, social media, e-commerce and payment systems, and direct marketing solutions. The Biohealth segment engages in developing, researching, testing, manufacturing, licensing, and distributing biohealth products and services. The Other Business Activities segment offers corporate strategy and business development, asset management, corporate restructuring, and leveraged buy-out expertise services. The company was formerly known as HF Enterprises Inc. and changed its name to Alset EHome International Inc. in February 2021. Alset EHome International Inc. was incorporated in 2018 and is based in Bethesda, Maryland.",Mr. Heng Fai  Chan,Real Estate - Development,1.04,USD,9604525,https://images.financialmodelingprep.com/symbol/AEI.png,895546,-0.26,-0.06,292949,-799785,-58946381,"[{'period': '2023', 'revenue': 22.09, 'unit': 'M', 'net_profit': -58.95}, {'period': '2022', 'revenue': 4.48, 'unit': 'M', 'net_profit': -40.49}, {'period': '2021', 'revenue': 19.8, 'unit': 'M', 'net_profit': -119.02}, {'period': '2020', 'revenue': 16.24, 'unit': 'M', 'net_profit': -3.98}]","[{'period': ""Q3 '24"", 'revenue': 4.96, 'unit': 'M', 'net_profit': 1.72}, {'period': ""Q2 '24"", 'revenue': 1.13, 'unit': 'M', 'net_profit': -1.24}, {'period': ""Q1 '24"", 'revenue': 6.09, 'unit': 'M', 'net_profit': -6.77}, {'period': ""Q4 '23"", 'revenue': 1.02, 'unit': 'M', 'net_profit': -33.27}, {'period': ""Q3 '23"", 'revenue': 0.9902000000000001, 'unit': 'M', 'net_profit': -16.01}, {'period': ""Q2 '23"", 'revenue': 19.15, 'unit': 'M', 'net_profit': -5.81}]",-6.52,-6.52,126314028,55461235,48545812,9066700,77517,0,8344684,26921727,7449718,0.8488923762147832,-0.4557919354696105,-0.04823151125401927,__nan__,__nan__,__nan__,0.07177904262541608
100,AEIS,Advanced Energy Industries Inc. Common Stock,"Advanced Energy Industries, Inc. designs, manufactures, sells, and supports precision power conversion, measurement, and control solutions worldwide. It offers plasma power solutions, including direct current (DC), pulsed DC, low frequency alternating current, high voltage, and radio frequency (RF) power supplies, as well as RF power supplies, RF matching networks, and RF instrumentation products; and remote plasma sources for reactive gas applications. The company also provides power control modules and thermal instrumentation products for rapid thermal processing, chemical vapor deposition, epitaxy, crystal growing, and chemical processing, as well as metal, carbon fiber, and glass manufacturing and other industrial power applications; high voltage DC-DC products for semiconductor wafer processing and metrology, electrostatic clamping of substrates, scientific instrumentation, mass spectrometry, and X-ray systems for industrial and analytical applications; and low voltage DC-DC board mounted solutions for use in healthcare, telecommunications, test and measurement, instrumentation, and industrial equipment applications, as well as distributed power in server and storage systems. In addition, it offers gas sensing and monitoring products for the energy market, air quality monitoring, and automobile emission monitoring and testing; and embedded power products for medical equipment or IEC 60950-1 for information technology equipment. Further, it offers conversions, upgrades, and refurbishments and used equipment to companies, as well as repair services. The company provides its products through a direct sales force, independent sales representatives, channel partners, and distributors. Advanced Energy Industries, Inc. was incorporated in 1981 and is headquartered in Denver, Colorado.",Mr. Stephen D. Kelley J.D.,Electrical Equipment & Parts,127.52,USD,4804073712,https://images.financialmodelingprep.com/symbol/AEIS.png,226716,106.27,6.28,78163,205560000,128284000,"[{'period': '2023', 'revenue': 1660.0, 'unit': 'M', 'net_profit': 128.28}, {'period': '2022', 'revenue': 1850.0, 'unit': 'M', 'net_profit': 199.66}, {'period': '2021', 'revenue': 1460.0, 'unit': 'M', 'net_profit': 134.74}, {'period': '2020', 'revenue': 1420.0, 'unit': 'M', 'net_profit': 134.68}]","[{'period': ""Q3 '24"", 'revenue': 374.22, 'unit': 'M', 'net_profit': -14.9}, {'period': ""Q2 '24"", 'revenue': 364.95, 'unit': 'M', 'net_profit': 15.03}, {'period': ""Q1 '24"", 'revenue': 327.48, 'unit': 'M', 'net_profit': 5.22}, {'period': ""Q4 '23"", 'revenue': 405.27, 'unit': 'M', 'net_profit': 37.5}, {'period': ""Q3 '23"", 'revenue': 409.99, 'unit': 'M', 'net_profit': 32.72}, {'period': ""Q2 '23"", 'revenue': 415.51, 'unit': 'M', 'net_profit': 27.14}]",3.41,3.4,2556757000,1711894000,1044556000,1412575000,282430000,0,335848000,1044556000,147932000,-0.3271864965976375,-0.3574877291395372,-0.3602251407129456,"[0.1, 0.1]","['2024-11-25', '2021-02-19']",__nan__,0.5524869981777697
101,AEMD,Aethlon Medical Inc. Common Stock,"Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.",Mr. James B. Frakes M.B.A.,Medical - Devices,0.8547,USD,11933321,https://images.financialmodelingprep.com/symbol/AEMD.png,3063403,-0.3,-0.0634,1259769,-11849117,-12208174,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.21}, {'period': '2023', 'revenue': 0.57425, 'unit': 'M', 'net_profit': -12.03}, {'period': '2022', 'revenue': 0.29417000000000004, 'unit': 'M', 'net_profit': -10.42}, {'period': '2021', 'revenue': 0.6591, 'unit': 'M', 'net_profit': -7.89}]","[{'period': ""Q2 '25"", 'revenue': 0.0, 'unit': 'B', 'net_profit': -2.81}, {'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.57}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.43}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.47}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.03}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.28}]",-4.86,-4.86,8245982,5947961,5441978,2479650,0,0,1829899,5441978,-10380677,-0.01641578054625654,-0.014828858967233498,0.1706484641638225,__nan__,__nan__,__nan__,0.30071009129052184
102,AEP,American Electric Power Company Inc. Common Stock,"American Electric Power Company, Inc., an electric public utility holding company, engages in the generation, transmission, and distribution of electricity for sale to retail and wholesale customers in the United States. It operates through Vertically Integrated Utilities, Transmission and Distribution Utilities, AEP Transmission Holdco, and Generation & Marketing segments. The company generates electricity using coal and lignite, natural gas, nuclear, hydro, solar, wind, and other energy sources. It also supplies and markets electric power at wholesale to other electric utility companies, rural electric cooperatives, municipalities, and other market participants. American Electric Power Company, Inc. was incorporated in 1906 and is headquartered in Columbus, Ohio.",Mr. William J. Fehrman,Regulated Electric,91.195,USD,48567265175,https://images.financialmodelingprep.com/symbol/AEP.png,2733827,18.39,0.875,620933,7205000000,2208100000,"[{'period': '2023', 'revenue': 18.98, 'unit': 'B', 'net_profit': 2.21}, {'period': '2022', 'revenue': 19.64, 'unit': 'B', 'net_profit': 2.31}, {'period': '2021', 'revenue': 16.79, 'unit': 'B', 'net_profit': 2.49}, {'period': '2020', 'revenue': 14.92, 'unit': 'B', 'net_profit': 2.2}]","[{'period': ""Q3 '24"", 'revenue': 5420.0, 'unit': 'M', 'net_profit': 944.4}, {'period': ""Q2 '24"", 'revenue': 4630.0, 'unit': 'M', 'net_profit': 340.3}, {'period': ""Q1 '24"", 'revenue': 5.03, 'unit': 'B', 'net_profit': 1.0}, {'period': ""Q4 '23"", 'revenue': 4580.0, 'unit': 'M', 'net_profit': 336.2}, {'period': ""Q3 '23"", 'revenue': 5340.0, 'unit': 'M', 'net_profit': 953.7}, {'period': ""Q2 '23"", 'revenue': 4370.0, 'unit': 'M', 'net_profit': 521.2}]",4.26,4.24,96684000000,6082100000,544400000,71398100000,2398700000,4196500000,11583600000,330100000,-2494300000,0.015046068017243808,-0.04295249653259362,-0.05543237250554324,"[0.93, 0.41]","['2024-11-08', '1970-02-04']",__nan__,0.7384686194199661
103,AEPPL,American Electric Power Company Inc. Corporate Unit,,,,,,,,,0,-0.6100006,1010987,6849100000,2396400000,"[{'period': '2021', 'revenue': 16.79, 'unit': 'B', 'net_profit': 2.4}, {'period': '2020', 'revenue': 14.92, 'unit': 'B', 'net_profit': 2.2}, {'period': '2019', 'revenue': 15.56, 'unit': 'B', 'net_profit': 1.92}, {'period': '2018', 'revenue': 16.2, 'unit': 'B', 'net_profit': 1.92}]","[{'period': ""Q1 '22"", 'revenue': 4590.0, 'unit': 'M', 'net_profit': 702.4}, {'period': ""Q4 '21"", 'revenue': 4059.9999999999995, 'unit': 'M', 'net_profit': 522.8}, {'period': ""Q3 '21"", 'revenue': 4620.0, 'unit': 'M', 'net_profit': 796.0}, {'period': ""Q2 '21"", 'revenue': 3830.0, 'unit': 'M', 'net_profit': 578.2}, {'period': ""Q1 '21"", 'revenue': 4280.0, 'unit': 'M', 'net_profit': 575.0}, {'period': ""Q4 '20"", 'revenue': 3610.0, 'unit': 'M', 'net_profit': 435.5}]",0,0,87668700000,7809200000,623800000,64988500000,2063100000,4419800000,12426700000,403400000,-1924200000,0.08490282111799274,0.08922321712649425,0,__nan__,__nan__,__nan__,0.7412964946440406
104,AEPPZ,American Electric Power Company Inc. Corporate Units,"American Electric Power Company, Inc., an electric public utility holding company, engages in the generation, transmission, and distribution of electricity for sale to retail and wholesale customers in the United States. It operates through Vertically Integrated Utilities, Transmission and Distribution Utilities, AEP Transmission Holdco, and Generation & Marketing segments. The company generates electricity using coal and lignite, natural gas, nuclear, hydro, solar, wind, and other energy sources. It also supplies and markets electric power at wholesale to other electric utility companies, rural electric cooperatives, municipalities, and other market participants. American Electric Power Company, Inc. was incorporated in 1906 and is headquartered in Columbus, Ohio.",Ms. Julia A. Sloat,Regulated Electric,47.12,USD,0,https://images.financialmodelingprep.com/symbol/AEPPZ.png,363570,9.026819923371647,-0.52,2100159,7205000000,2208100000,"[{'period': '2023', 'revenue': 18.98, 'unit': 'B', 'net_profit': 2.21}, {'period': '2022', 'revenue': 19.64, 'unit': 'B', 'net_profit': 2.31}, {'period': '2021', 'revenue': 16.79, 'unit': 'B', 'net_profit': 2.49}, {'period': '2020', 'revenue': 14.92, 'unit': 'B', 'net_profit': 2.2}]","[{'period': ""Q3 '24"", 'revenue': 5420.0, 'unit': 'M', 'net_profit': 944.4}, {'period': ""Q2 '24"", 'revenue': 4630.0, 'unit': 'M', 'net_profit': 340.3}, {'period': ""Q1 '24"", 'revenue': 5.03, 'unit': 'B', 'net_profit': 1.0}, {'period': ""Q4 '23"", 'revenue': 4580.0, 'unit': 'M', 'net_profit': 336.2}, {'period': ""Q3 '23"", 'revenue': 5340.0, 'unit': 'M', 'net_profit': 953.7}, {'period': ""Q2 '23"", 'revenue': 4370.0, 'unit': 'M', 'net_profit': 521.2}]",4.26,4.24,96684000000,6082100000,544400000,71398100000,2398700000,4196500000,11583600000,330100000,-2494300000,0.015046068017243808,-0.04295249653259362,-0.05543237250554324,"[0.76563, 0.774]","['2023-08-11', '2020-11-12']",__nan__,0.7384686194199661
105,AERI,Aerie Pharmaceuticals Inc. Common Stock,"Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.",Dr. Vicente Anido,Drug Manufacturers - Specialty & Generic,15.25,USD,0,https://images.financialmodelingprep.com/symbol/AERI.png,786842,0,0,1215184,-7813000,-74810000,"[{'period': '2021', 'revenue': 194.13, 'unit': 'M', 'net_profit': -74.81}, {'period': '2020', 'revenue': 83.14, 'unit': 'M', 'net_profit': -183.1}, {'period': '2019', 'revenue': 69.89, 'unit': 'M', 'net_profit': -199.58}, {'period': '2018', 'revenue': 24.18, 'unit': 'M', 'net_profit': -232.57}]","[{'period': ""Q3 '22"", 'revenue': 36.13, 'unit': 'M', 'net_profit': -26.83}, {'period': ""Q2 '22"", 'revenue': 33.31, 'unit': 'M', 'net_profit': -19.37}, {'period': ""Q1 '22"", 'revenue': 29.84, 'unit': 'M', 'net_profit': -35.89}, {'period': ""Q4 '21"", 'revenue': 114.67, 'unit': 'M', 'net_profit': 45.53}, {'period': ""Q3 '21"", 'revenue': 29.31, 'unit': 'M', 'net_profit': -39.69}, {'period': ""Q2 '21"", 'revenue': 27.18, 'unit': 'M', 'net_profit': -38.69}]",-1.61,-1.61,431391000,355650000,139801000,448724000,158828000,0,124991000,37187000,-102445000,0.9333486888126802,0.5914276819897215,0.5964912280701754,__nan__,__nan__,__nan__,1.0401793268751551
106,AESE,Allied Esports Entertainment Inc. Common Stock,"Allied Esports Entertainment Inc., a premier public esports and entertainment company, engages in the Allied Esports businesses worldwide. It operates esports properties to connect players and fans through a network of connected arenas; a flagship gaming arena located at the Luxor Hotel in Las Vegas, Nevada; a mobile esports truck that serves as a battleground and content generation hub; and a studio for recording and streaming gaming events. Allied Esports Entertainment Inc. was founded in 2018 and is based in Irvine, California.",Mr. Kenneth DeCubellis,Entertainment,1.3899,USD,0,https://images.financialmodelingprep.com/symbol/AESE.png,73781,0.864365671641791,0.0299,37968,-6771586000,-9092272000,"[{'period': '2022', 'revenue': 6.35, 'unit': 'B', 'net_profit': -9.09}, {'period': '2021', 'revenue': 4.96, 'unit': 'M', 'net_profit': -15.33}, {'period': '2020', 'revenue': 3.21, 'unit': 'M', 'net_profit': -45.06}, {'period': '2019', 'revenue': 26.07, 'unit': 'M', 'net_profit': -16.74}]","[{'period': ""Q3 '23"", 'revenue': 1120.0, 'unit': 'M', 'net_profit': 75.25}, {'period': ""Q2 '23"", 'revenue': 3270.0, 'unit': 'M', 'net_profit': -691.22}, {'period': ""Q1 '23"", 'revenue': 1.19, 'unit': 'B', 'net_profit': -1.13}, {'period': ""Q4 '22"", 'revenue': 6.35, 'unit': 'B', 'net_profit': -10.81}, {'period': ""Q3 '22"", 'revenue': 1.57, 'unit': 'M', 'net_profit': -1.67}, {'period': ""Q2 '22"", 'revenue': 1.16, 'unit': 'M', 'net_profit': -3.69}]",-232.71,-232.71,97729675000,82376852000,81167442000,9825607000,72739000,0,3298532000,11167442000,-10978860000,-102.91973922845533,-592.1574820578818,-595.6923076923077,__nan__,__nan__,__nan__,0.10053862350406875
107,AEY,ADDvantage Technologies Group Inc. Common Stock,"ADDvantage Technologies Group, Inc., through its subsidiaries, distributes and services electronics and hardware for the telecommunications industry in the United States and internationally. It operates through two segments, Wireless Infrastructure Services and Telecommunications. The Wireless Infrastructure Services segment provides turn-key wireless infrastructure services for U.S. wireless carriers, communication tower companies, national integrators, and original equipment manufacturers. This segment also offers installation and upgradation of technology on cell sites; and construction of new small cells for 5G. The Telecommunications segment provides central office equipment that include optical transport, switching, and data center equipment for communication networks; customer premise equipment, such as integrated access devices, channel banks, Internet protocol private branch exchange phones, and routers; and decommissioning services for surplus and obsolete telecom equipment. The company was formerly known as ADDvantage Media Group, Inc. and changed its name to ADDvantage Technologies Group, Inc. in December 1999. ADDvantage Technologies Group, Inc. was incorporated in 1989 and is headquartered in Carrollton, Texas.",Mr. Joseph E. Hart,Technology Distributors,0.36,USD,538096,https://images.financialmodelingprep.com/symbol/AEY.png,876776,-0.05625,-0.24,881062,1551000,471000,"[{'period': '2022', 'revenue': 97030.0, 'unit': 'K', 'net_profit': 471.0}, {'period': '2021', 'revenue': 62.16, 'unit': 'M', 'net_profit': -6.5}, {'period': '2020', 'revenue': 50.18, 'unit': 'M', 'net_profit': -17.33}, {'period': '2019', 'revenue': 55.12, 'unit': 'M', 'net_profit': -4.04}]","[{'period': ""Q3 '23"", 'revenue': 10.34, 'unit': 'M', 'net_profit': -2.73}, {'period': ""Q2 '23"", 'revenue': 12.09, 'unit': 'M', 'net_profit': -2.83}, {'period': ""Q1 '23"", 'revenue': 14.72, 'unit': 'M', 'net_profit': -2.99}, {'period': ""Q4 '22"", 'revenue': 19550.0, 'unit': 'K', 'net_profit': -493.0}, {'period': ""Q3 '22"", 'revenue': 25.93, 'unit': 'M', 'net_profit': 1.48}, {'period': ""Q2 '22"", 'revenue': 27790.0, 'unit': 'K', 'net_profit': 693.0}]",0.3,0.3,25426000,18130000,1837000,16111000,8688000,0,12788000,1837000,1944000,1.1922647824470063,1.072439249461704,1.0572519083969465,__nan__,__nan__,__nan__,0.6336427279163062
108,AEYE,AudioEye Inc. Common Stock,"AudioEye, Inc. provides patented, internet content publication, distribution software, and related services to Internet, print, broadcast, and other media to people regardless of their network connection, device, location, or disabilities in the United States. Its software and services enable conversion of digital content into accessible formats and allows for real time distribution to end users on any Internet connected device. The company offers AudioEye, an always-on testing, remediation, and monitoring solution that improves conformance with web content accessibility guidelines; identifies and fixes the common accessibility errors and addresses a range of disabilities including dyslexia, color blindness, epilepsy, and others; and provides additional solutions to provide for enhanced compliance and accessibility, including periodic manual auditing, manual remediations, and legal support services, as well as PDF remediation services and audit reports to help customers with their digital accessibility needs. The company serves small- and medium-sized businesses, corporate enterprises, non-profit organizations, and federal government agencies, as well as federal, state, and local governments and agencies through content management system partners, platform and agency partners, authorized resellers, and the marketplace. AudioEye, Inc. was incorporated in 2005 and is based in Tucson, Arizona.",Mr. David D. Moradi,Software - Application,15.465,USD,188334317,https://images.financialmodelingprep.com/symbol/AEYE.png,251709,-57.28,0.075,107863,-3246000,-5872000,"[{'period': '2023', 'revenue': 31.32, 'unit': 'M', 'net_profit': -5.87}, {'period': '2022', 'revenue': 29.91, 'unit': 'M', 'net_profit': -10.44}, {'period': '2021', 'revenue': 24.5, 'unit': 'M', 'net_profit': -12.63}, {'period': '2020', 'revenue': 20.48, 'unit': 'M', 'net_profit': -6.13}]","[{'period': ""Q3 '24"", 'revenue': 8.93, 'unit': 'M', 'net_profit': -1.2}, {'period': ""Q2 '24"", 'revenue': 8470.0, 'unit': 'K', 'net_profit': -735.0}, {'period': ""Q1 '24"", 'revenue': 8080.0, 'unit': 'K', 'net_profit': -829.0}, {'period': ""Q4 '23"", 'revenue': 7870.0, 'unit': 'K', 'net_profit': -533.0}, {'period': ""Q3 '23"", 'revenue': 7.84, 'unit': 'M', 'net_profit': -1.35}, {'period': ""Q2 '23"", 'revenue': 7.84, 'unit': 'M', 'net_profit': -1.97}]",-0.5,-0.5,25495000,14776000,9236000,18788000,4828000,0,11529000,9236000,-1838000,0.581808812161814,0.4373862220944716,0.45054945054945056,__nan__,__nan__,__nan__,0.736928809570504
109,AEZS,Aeterna Zentaris Inc. Common Stock,"Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.","Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc.",Biotechnology,5.72,USD,17512867,https://images.financialmodelingprep.com/symbol/AEZS.png,6037,-2.4761904761904763,0.12,7508,-2886878.486356,-16855544,"[{'period': '2023', 'revenue': 4.58, 'unit': 'M', 'net_profit': -16.86}, {'period': '2022', 'revenue': 5.64, 'unit': 'M', 'net_profit': -37.67}, {'period': '2021', 'revenue': 5.26, 'unit': 'M', 'net_profit': -8.37}, {'period': '2020', 'revenue': 3.65, 'unit': 'M', 'net_profit': -5.12}]","[{'period': ""Q1 '24"", 'revenue': 0.00398, 'unit': 'M', 'net_profit': -5.73}, {'period': ""Q4 '23"", 'revenue': 0.12434, 'unit': 'M', 'net_profit': -5.79}, {'period': ""Q3 '23"", 'revenue': 0.003, 'unit': 'M', 'net_profit': -4.14}, {'period': ""Q2 '23"", 'revenue': 2.25, 'unit': 'M', 'net_profit': -2.52}, {'period': ""Q1 '23"", 'revenue': 2.13, 'unit': 'M', 'net_profit': -4.36}, {'period': ""Q4 '22"", 'revenue': 2.48, 'unit': 'M', 'net_profit': -20.9}]",-3.47,-3.47,36826615,36180935,33841963,18723711,289505,330301,4516771,33841963,-17451271,0.6224822170320388,0.5525354004619183,0.5528350515463917,__nan__,__nan__,__nan__,0.5084287817384248
110,AFAQU,AF Acquisition Corp. Units,"AF Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. AF Acquisition Corp. was incorporated in 2021 and is based in Palm Beach, Florida.",Mr. Andrew Z. Scharf,Shell Companies,9.9,USD,0,https://images.financialmodelingprep.com/symbol/AFAQU.png,4280,0,-0.14,1900,9764932,20368433,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 20.37}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.75}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.04}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.57}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 19.81}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.07}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 18.79}]",0.73,0.73,225075028,991302,781302,15118434,0,224039393,225967,781302,-866877,0,0,0,__nan__,__nan__,__nan__,0.06717064142717778
111,AFAQW,AF Acquisition Corp. Warrants,"AF Acquisition Corp. is a blank check company that engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization. AF Acquisition Corp. was incorporated in 2021 and is based in Palm Beach, Florida.",Mr. Andrew Z. Scharf,Shell Companies,0.0053,USD,0,https://images.financialmodelingprep.com/symbol/AFAQW.png,0,0,0,101900,9764932,20368433,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 20.37}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.75}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.04}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.57}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 19.81}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.07}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 18.79}]",0.73,0.73,225075028,991302,781302,15118434,0,224039393,225967,781302,-866877,0,0,0,__nan__,__nan__,__nan__,0.06717064142717778
112,AFBI,Affinity Bancshares Inc. Common Stock (MD),"Affinity Bancshares, Inc. operates as the holding company for Affinity Bank that provides various banking products and services. The company accepts various deposit accounts, including savings accounts, checking accounts, certificates of deposit, and individual retirement accounts. It also offers commercial and industrial, commercial real estate, one- to four-family residential real estate, construction and land, and consumer loans. In addition, the company invests in U.S. treasury securities; securities issued by the U.S. government and its agencies, or government sponsored enterprises, including mortgage-backed securities and collateralized mortgage obligations; corporate and municipal bonds; certificates of deposit in other financial institutions; and federal and money market funds. It operates a main and a branch office in Covington, Georgia; a branch office in Atlanta, Georgia; and a commercial loan production office in Alpharetta, Georgia; out of an office in Monroe, Georgia. The company was founded in 1928 and is headquartered in Covington, Georgia.","Mr. Edward J. Cooney CPA, CPA",Banks - Regional,17.69,USD,113435887,https://images.financialmodelingprep.com/symbol/AFBI.png,10220,20.81,0.18,9783,0,6448000,"[{'period': '2023', 'revenue': 29.66, 'unit': 'M', 'net_profit': 6.45}, {'period': '2022', 'revenue': 32.16, 'unit': 'M', 'net_profit': 7.13}, {'period': '2021', 'revenue': 32.08, 'unit': 'M', 'net_profit': 7.57}, {'period': '2020', 'revenue': 27.01, 'unit': 'M', 'net_profit': 3.09}]","[{'period': ""Q3 '24"", 'revenue': 7.98, 'unit': 'M', 'net_profit': 1.73}, {'period': ""Q2 '24"", 'revenue': 12.93, 'unit': 'M', 'net_profit': 1.03}, {'period': ""Q1 '24"", 'revenue': 11.8, 'unit': 'M', 'net_profit': 1.33}, {'period': ""Q4 '23"", 'revenue': 11.69, 'unit': 'M', 'net_profit': 1.51}, {'period': ""Q3 '23"", 'revenue': 7.53, 'unit': 'M', 'net_profit': 1.62}, {'period': ""Q2 '23"", 'revenue': 7.37, 'unit': 'M', 'net_profit': 1.59}]",1,0.98,843258000,50025000,50025000,721742000,0,88201000,3040000,50025000,7344000,-1,-0.0961592374544435,-0.0654205607476636,__nan__,__nan__,__nan__,0.85589700898183
113,AFCG,AFC Gamma Inc. Common Stock,"AFC Gamma, Inc. originates, structures, underwrites, and invests in senior secured loans, and other types of loans and debt securities for established companies operating in the cannabis industry in states that have legalized medicinal and/or adult use cannabis. It primarily originates loans structured as senior loans secured by real estate, equipment, and licenses and/or other assets of the loan parties to the extent permitted by applicable laws and the regulations governing such loan parties. AFC Gamma, Inc. has elected and qualified to be taxed as a real estate investment trust for the United States federal income tax purposes under the Internal Revenue Code of 1986. The company was incorporated in 2020 and is based in West Palm Beach, Florida.",Mr. Daniel  Neville,REIT - Specialty,8.38,USD,183963626,https://images.financialmodelingprep.com/symbol/AFCG.png,170554,32.23,0,55033,26982412,20951999,"[{'period': '2023', 'revenue': 66.11, 'unit': 'M', 'net_profit': 20.95}, {'period': '2022', 'revenue': 71.54, 'unit': 'M', 'net_profit': 35.93}, {'period': '2021', 'revenue': 38.08, 'unit': 'M', 'net_profit': 21.0}, {'period': '2020', 'revenue': 5.6, 'unit': 'M', 'net_profit': 4.31}]","[{'period': ""Q3 '24"", 'revenue': 8.7, 'unit': 'M', 'net_profit': 1.38}, {'period': ""Q2 '24"", 'revenue': 16.96, 'unit': 'M', 'net_profit': 16.45}, {'period': ""Q1 '24"", 'revenue': 16270.0, 'unit': 'K', 'net_profit': -54.12}, {'period': ""Q4 '23"", 'revenue': 17.45, 'unit': 'M', 'net_profit': -9.19}, {'period': ""Q3 '23"", 'revenue': 14.85, 'unit': 'M', 'net_profit': 7.98}, {'period': ""Q2 '23"", 'revenue': 15.64, 'unit': 'M', 'net_profit': 12.14}]",1.02,1.02,466585055,133421789,121626453,146532830,5553445,0,58518272,121626453,21228934,-0.38358034062982865,-0.416905056459217,-0.43646408839779005,"[0.33, 0.38]","['2024-12-31', '2021-06-14']",__nan__,0.3140538438377543
114,AFIB,Acutus Medical Inc. Common Stock,"Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.",Mr. Takeo  Mukai,Medical - Devices,0.0488,USD,1459720,https://images.financialmodelingprep.com/symbol/AFIB.png,139951,-0.27,-0.0032,110,-13487000,-81663000,"[{'period': '2023', 'revenue': 7.16, 'unit': 'M', 'net_profit': -81.66}, {'period': '2022', 'revenue': 16.36, 'unit': 'M', 'net_profit': -39.62}, {'period': '2021', 'revenue': 17.26, 'unit': 'M', 'net_profit': -123.36}, {'period': '2020', 'revenue': 8.46, 'unit': 'M', 'net_profit': -101.98}]","[{'period': ""Q3 '24"", 'revenue': 5.27, 'unit': 'M', 'net_profit': -5.61}, {'period': ""Q2 '24"", 'revenue': 4130.0, 'unit': 'K', 'net_profit': -914.0}, {'period': ""Q1 '24"", 'revenue': 3.62, 'unit': 'M', 'net_profit': -1.62}, {'period': ""Q4 '23"", 'revenue': -7.53, 'unit': 'M', 'net_profit': -33.77}, {'period': ""Q3 '23"", 'revenue': 5.24, 'unit': 'M', 'net_profit': -13.24}, {'period': ""Q2 '23"", 'revenue': 5.29, 'unit': 'M', 'net_profit': -18.35}]",-2.81,-2.81,53960000,46252000,22403000,54839000,11353000,0,18942000,19170000,-63337000,-1.3830989916205085,-1.0613640953150243,-1.0215827338129497,__nan__,__nan__,__nan__,1.0162898443291326
115,AFIN,American Finance Trust Inc. Class A Common Stock,"American Finance Trust, Inc. (Nasdaq: AFIN) is a publicly traded real estate investment trust listed on the Nasdaq focused on acquiring and managing a diversified portfolio of primarily service-oriented and traditional retail and distribution related commercial real estate properties in the U.S.",Mr. Edward Weil,REIT - Diversified,8.23,USD,1176280980,https://images.financialmodelingprep.com/symbol/AFIN.png,1005844,-28.87719298245614,-0.03000069,629237,169805000,-121972000,"[{'period': '2021', 'revenue': 335.16, 'unit': 'M', 'net_profit': -121.97}, {'period': '2020', 'revenue': 305.22, 'unit': 'M', 'net_profit': -31.86}, {'period': '2019', 'revenue': 299.74, 'unit': 'M', 'net_profit': 4.15}, {'period': '2018', 'revenue': 291.21, 'unit': 'M', 'net_profit': -37.41}]","[{'period': ""Q4 '21"", 'revenue': 82.48, 'unit': 'M', 'net_profit': -57.24}, {'period': ""Q3 '21"", 'revenue': 91920.0, 'unit': 'K', 'net_profit': -569.0}, {'period': ""Q2 '21"", 'revenue': 81.58, 'unit': 'M', 'net_profit': -1.48}, {'period': ""Q1 '21"", 'revenue': 79.19, 'unit': 'M', 'net_profit': -3.75}, {'period': ""Q4 '20"", 'revenue': 77.24, 'unit': 'M', 'net_profit': -4.67}, {'period': ""Q3 '20"", 'revenue': 78.49, 'unit': 'M', 'net_profit': -3.47}]",-1.13,-1.13,3803786000,521728000,214853000,2103932000,70789000,0,48469000,214853000,131820000,-0.03371649689865134,-2.828133827129496,-2.8965517241379306,"[0.2125, 0.0916667]","['2022-04-08', '2018-10-10']",__nan__,0.5531152383441129
116,AFINO,American Finance Trust Inc. 7.375% Series C Cumulative Redeemable Preferred Stock,"American Finance Trust, Inc. (Nasdaq: AFIN) is a publicly traded real estate investment trust listed on the Nasdaq focused on acquiring and managing a diversified portfolio of primarily service-oriented and traditional retail and distribution related commercial real estate properties in the U.S.",,REIT - Diversified,25.66,USD,3407887382,https://images.financialmodelingprep.com/symbol/AFINO.png,13989,-90.03508771929825,0.02000046,11543,169805000,-121972000,"[{'period': '2021', 'revenue': 335.16, 'unit': 'M', 'net_profit': -121.97}, {'period': '2020', 'revenue': 305.22, 'unit': 'M', 'net_profit': -31.86}, {'period': '2019', 'revenue': 299.74, 'unit': 'M', 'net_profit': 4.15}, {'period': '2018', 'revenue': 291.21, 'unit': 'M', 'net_profit': -37.41}]","[{'period': ""Q4 '21"", 'revenue': 82.48, 'unit': 'M', 'net_profit': -57.24}, {'period': ""Q3 '21"", 'revenue': 91920.0, 'unit': 'K', 'net_profit': -569.0}, {'period': ""Q2 '21"", 'revenue': 81.58, 'unit': 'M', 'net_profit': -1.48}, {'period': ""Q1 '21"", 'revenue': 79.19, 'unit': 'M', 'net_profit': -3.75}, {'period': ""Q4 '20"", 'revenue': 77.24, 'unit': 'M', 'net_profit': -4.67}, {'period': ""Q3 '20"", 'revenue': 78.49, 'unit': 'M', 'net_profit': -3.47}]",-1.13,-1.13,3803786000,521728000,214853000,2103932000,70789000,0,48469000,214853000,131820000,-0.03371649689865134,-2.828133827129496,-2.8965517241379306,"[0.46875, 0.53]","['2022-04-07', '2021-04-01']",__nan__,0.5531152383441129
117,AFINP,American Finance Trust Inc. 7.50% Series A Cumulative Redeemable Perpetual Preferred Stock,"American Finance Trust, Inc. (Nasdaq: AFIN) is a publicly traded real estate investment trust listed on the Nasdaq focused on acquiring and managing a diversified portfolio of primarily service-oriented and traditional retail and distribution related commercial real estate properties in the U.S.",Mr. Edward Michael Weil Jr.,REIT - Diversified,25.91,USD,3441089714,https://images.financialmodelingprep.com/symbol/AFINP.png,15846,-90.91228070175438,-0.4699993,12257,169805000,-121972000,"[{'period': '2021', 'revenue': 335.16, 'unit': 'M', 'net_profit': -121.97}, {'period': '2020', 'revenue': 305.22, 'unit': 'M', 'net_profit': -31.86}, {'period': '2019', 'revenue': 299.74, 'unit': 'M', 'net_profit': 4.15}, {'period': '2018', 'revenue': 291.21, 'unit': 'M', 'net_profit': -37.41}]","[{'period': ""Q4 '21"", 'revenue': 82.48, 'unit': 'M', 'net_profit': -57.24}, {'period': ""Q3 '21"", 'revenue': 91920.0, 'unit': 'K', 'net_profit': -569.0}, {'period': ""Q2 '21"", 'revenue': 81.58, 'unit': 'M', 'net_profit': -1.48}, {'period': ""Q1 '21"", 'revenue': 79.19, 'unit': 'M', 'net_profit': -3.75}, {'period': ""Q4 '20"", 'revenue': 77.24, 'unit': 'M', 'net_profit': -4.67}, {'period': ""Q3 '20"", 'revenue': 78.49, 'unit': 'M', 'net_profit': -3.47}]",-1.13,-1.13,3803786000,521728000,214853000,2103932000,70789000,0,48469000,214853000,131820000,-0.03371649689865134,-2.828133827129496,-2.8965517241379306,"[0.46875, 0.5]","['2022-04-07', '2019-07-02']",__nan__,0.5531152383441129
118,AFMD,Affimed N.V.,"Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.","Dr. Shawn M. Leland Pharm.D., R.Ph.",Biotechnology,1.36,USD,20709400,https://images.financialmodelingprep.com/symbol/AFMD.png,292669,-0.29,0,135272,-102380000,-105938000,"[{'period': '2023', 'revenue': 8.28, 'unit': 'M', 'net_profit': -105.94}, {'period': '2022', 'revenue': 41.35, 'unit': 'M', 'net_profit': -86.0}, {'period': '2021', 'revenue': 40.37, 'unit': 'M', 'net_profit': -57.52}, {'period': '2020', 'revenue': 28.36, 'unit': 'M', 'net_profit': -41.37}]","[{'period': ""Q3 '24"", 'revenue': 0.155, 'unit': 'M', 'net_profit': -15.14}, {'period': ""Q2 '24"", 'revenue': 0.154, 'unit': 'M', 'net_profit': -15.45}, {'period': ""Q1 '24"", 'revenue': 0.155, 'unit': 'M', 'net_profit': -19.18}, {'period': ""Q4 '23"", 'revenue': 0.41300000000000003, 'unit': 'M', 'net_profit': -20.2}, {'period': ""Q3 '23"", 'revenue': 1.96, 'unit': 'M', 'net_profit': -24.36}, {'period': ""Q2 '23"", 'revenue': 1.39, 'unit': 'M', 'net_profit': -29.39}]",-7.09,-7.09,97157000,84188000,72898000,39350000,5327000,0,25907000,38529000,-113998000,-0.2566126201318228,-0.2317799172131529,-0.17384105960264898,__nan__,__nan__,__nan__,0.40501456405611536
119,AFRM,Affirm Holdings Inc. Class A Common Stock,"Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce in the United States and Canada. The company's platform includes point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. Its payments network and partnership with an originating bank, enables consumers to pay for a purchase over time with terms ranging from one to forty-eight months. As of June 30, 2021, the company had approximately 29,000 merchants integrated on its platform covering small businesses, large enterprises, direct-to-consumer brands, brick-and-mortar stores, and companies. Its merchants represent a range of industries, including sporting goods and outdoors, furniture and homewares, travel, apparel, accessories, consumer electronics, and jewelry. The company was founded in 2012 and is headquartered in San Francisco, California.",Mr. Max Roth Levchin,Software - Infrastructure,63.26,USD,19948958446,https://images.financialmodelingprep.com/symbol/AFRM.png,9453132,-44.87,-1.83,1722485,-2230000,-517756999,"[{'period': '2024', 'revenue': 2320.0, 'unit': 'M', 'net_profit': -517.76}, {'period': '2023', 'revenue': 1590.0, 'unit': 'M', 'net_profit': -985.35}, {'period': '2022', 'revenue': 1350.0, 'unit': 'M', 'net_profit': -707.42}, {'period': '2021', 'revenue': 870.46, 'unit': 'M', 'net_profit': -430.92}]","[{'period': ""Q1 '25"", 'revenue': 698.48, 'unit': 'M', 'net_profit': -100.22}, {'period': ""Q4 '24"", 'revenue': 659.18, 'unit': 'M', 'net_profit': -45.14}, {'period': ""Q3 '24"", 'revenue': 576.16, 'unit': 'M', 'net_profit': -133.94}, {'period': ""Q2 '24"", 'revenue': 591.11, 'unit': 'M', 'net_profit': -166.9}, {'period': ""Q1 '24"", 'revenue': 496.55, 'unit': 'M', 'net_profit': -171.78}, {'period': ""Q4 '23"", 'revenue': 445.82, 'unit': 'M', 'net_profit': -205.96}]",-1.67,-1.67,9519619000,2514229000,2144734000,6787630000,353028000,5503322000,124959000,1013106000,290842000,0.9966795612851735,0.47454242016755555,0.5,__nan__,__nan__,__nan__,0.7130148801123238
120,AFYA,Afya Limited Class A Common Shares,"Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. The company also provides digital health services, such as subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides medical postgraduate specialization programs; printed and digital content; and an online medical education platform and practical medical training services. As of December 31, 2021, it operated a network of 46 undergraduate and graduate medical school campuses consisted of 30 undergrad operating units and five approved units; and a network of 2,731 medical school seats that consisted of 2,481 operating seats and 278 approved seats. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.",Mr. Virgilio Deloy Capobianco Gibbon,Education & Training Services,15.01,USD,1353795249,https://images.financialmodelingprep.com/symbol/AFYA.png,120020,14.86,0.13,12120,1105389000,386324000,"[{'period': '2023', 'revenue': 2880.0, 'unit': 'M', 'net_profit': 386.32}, {'period': '2022', 'revenue': 2330.0, 'unit': 'M', 'net_profit': 373.57}, {'period': '2021', 'revenue': 1720.0, 'unit': 'M', 'net_profit': 223.33}, {'period': '2020', 'revenue': 1200.0, 'unit': 'M', 'net_profit': 292.07}]","[{'period': ""Q3 '24"", 'revenue': 841.18, 'unit': 'M', 'net_profit': 119.98}, {'period': ""Q2 '24"", 'revenue': 809.89, 'unit': 'M', 'net_profit': 158.21}, {'period': ""Q1 '24"", 'revenue': 804.24, 'unit': 'M', 'net_profit': 203.39}, {'period': ""Q4 '23"", 'revenue': 729.87, 'unit': 'M', 'net_profit': 98.06}, {'period': ""Q3 '23"", 'revenue': 723.48, 'unit': 'M', 'net_profit': 93.35}, {'period': ""Q2 '23"", 'revenue': 712.61, 'unit': 'M', 'net_profit': 82.79}]",4.27,4.27,7584481000,1203506000,553030000,3941469000,546438000,51834000,1058567000,553030000,798195000,0.2908190254651444,0.034143625407889844,0.02891566265060222,__nan__,__nan__,__nan__,0.519675505812461
121,AGBA,AGBA Acquisition Limited Ordinary Share,"AGBA Acquisition Limited does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare, education, entertainment, and financial services sectors in China. The company was incorporated in 2018 and is based in Tsim Sha Tsui, Hong Kong.",Mr. Wing Fai  Ng,Shell Companies,1.4,USD,66243100,https://images.financialmodelingprep.com/symbol/AGBA.png,376417,-1.044776119402985,0.18,4139318,-51426068,-49206019,"[{'period': '2023', 'revenue': 55.73, 'unit': 'M', 'net_profit': -49.21}, {'period': '2022', 'revenue': 31.08, 'unit': 'M', 'net_profit': -44.52}, {'period': '2021', 'revenue': 11.47, 'unit': 'M', 'net_profit': 96.46}, {'period': '2020', 'revenue': 14.05, 'unit': 'M', 'net_profit': -16.14}]","[{'period': ""Q2 '24"", 'revenue': 4.92, 'unit': 'M', 'net_profit': -11.37}, {'period': ""Q1 '24"", 'revenue': 7.66, 'unit': 'M', 'net_profit': -8.06}, {'period': ""Q4 '23"", 'revenue': 12.54, 'unit': 'M', 'net_profit': -13.63}, {'period': ""Q3 '23"", 'revenue': 13.44, 'unit': 'M', 'net_profit': -12.92}, {'period': ""Q2 '23"", 'revenue': 17.93, 'unit': 'M', 'net_profit': -10.59}, {'period': ""Q1 '23"", 'revenue': 13.22, 'unit': 'M', 'net_profit': -12.07}]",-0.75,-0.75,66588967,25618972,18678065,58486196,6940907,25724464,47840143,18678065,-42387005,-0.18785826868812192,-0.10524072713697817,0.050632911392405104,__nan__,__nan__,__nan__,0.8783166136215929
122,AGBAR,AGBA Acquisition Limited Right,,None,Shell Companies,0.551,USD,0,https://images.financialmodelingprep.com/symbol/AGBAR.png,0,0,0,244091,-51426068,-49206019,"[{'period': '2023', 'revenue': 55.73, 'unit': 'M', 'net_profit': -49.21}, {'period': '2022', 'revenue': 31.08, 'unit': 'M', 'net_profit': -44.52}, {'period': '2021', 'revenue': 11.47, 'unit': 'M', 'net_profit': 96.46}, {'period': '2020', 'revenue': 14.05, 'unit': 'M', 'net_profit': -16.14}]","[{'period': ""Q2 '24"", 'revenue': 4.92, 'unit': 'M', 'net_profit': -11.37}, {'period': ""Q1 '24"", 'revenue': 7.66, 'unit': 'M', 'net_profit': -8.06}, {'period': ""Q4 '23"", 'revenue': 12.54, 'unit': 'M', 'net_profit': -13.63}, {'period': ""Q3 '23"", 'revenue': 13.44, 'unit': 'M', 'net_profit': -12.92}, {'period': ""Q2 '23"", 'revenue': 17.93, 'unit': 'M', 'net_profit': -10.59}, {'period': ""Q1 '23"", 'revenue': 13.22, 'unit': 'M', 'net_profit': -12.07}]",-0.75,-0.75,66588967,25618972,18678065,58486196,6940907,25724464,47840143,18678065,-42387005,-0.18785826868812192,-0.10524072713697817,0.050632911392405104,"[0.285, 0.285]","['2022-03-15', '2022-03-15']",__nan__,0.8783166136215929
123,AGBAW,AGBA Acquisition Limited Warrant,"AGBA Group Holding Ltd. operates a wealth and health platform. Its group activities span a business-to-business platform, healthcare and wellness services, fintech businesses, as well as financial advisory services. It operates the TAG Business and OnePlatform brand, which offers a full-service platform to banks, other financial institutions, brokers, and individual financial advisors to advise and serve its retail clients. The company is headquartered in Hong Kong.",Mr. Wing Fai  Ng,Shell Companies,0.2001,USD,11596489,https://images.financialmodelingprep.com/symbol/AGBAW.png,0,0,-0.0147,79573,-51426068,-49206019,"[{'period': '2023', 'revenue': 55.73, 'unit': 'M', 'net_profit': -49.21}, {'period': '2022', 'revenue': 31.08, 'unit': 'M', 'net_profit': -44.52}, {'period': '2021', 'revenue': 11.47, 'unit': 'M', 'net_profit': 96.46}, {'period': '2020', 'revenue': 14.05, 'unit': 'M', 'net_profit': -16.14}]","[{'period': ""Q2 '24"", 'revenue': 4.92, 'unit': 'M', 'net_profit': -11.37}, {'period': ""Q1 '24"", 'revenue': 7.66, 'unit': 'M', 'net_profit': -8.06}, {'period': ""Q4 '23"", 'revenue': 12.54, 'unit': 'M', 'net_profit': -13.63}, {'period': ""Q3 '23"", 'revenue': 13.44, 'unit': 'M', 'net_profit': -12.92}, {'period': ""Q2 '23"", 'revenue': 17.93, 'unit': 'M', 'net_profit': -10.59}, {'period': ""Q1 '23"", 'revenue': 13.22, 'unit': 'M', 'net_profit': -12.07}]",-0.75,-0.75,66588967,25618972,18678065,58486196,6940907,25724464,47840143,18678065,-42387005,-0.18785826868812192,-0.10524072713697817,0.050632911392405104,__nan__,__nan__,__nan__,0.8783166136215929
124,AGC,Altimeter Growth Corp. Class A Ordinary Shares,"Altimeter Growth Corp. is a blank check company. The company was founded in in 2020 and is based in Menlo Park, California.",Mr. Bradley Thomas Gerstner J.D.,Shell Companies,11.01,USD,0,https://images.financialmodelingprep.com/symbol/AGC.png,4057663,0,-1.71,8848771,-212799,-212799,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.8}]","[{'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 49.39}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.87}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.8}]",-0.0034,-0.0034,501131563,1131563,855972,17564100,0,0,0,855972,,0,0,0,"[0.047, 0.047]","['2018-08-14', '2014-01-13']",__nan__,0.035048879968472474
125,AGCUU,Altimeter Growth Corp. Unit,"Altimeter Growth Corp. is a blank check company. The company was founded in in 2020 and is based in Menlo Park, California.",Mr. Bradley Thomas Gerstner,Shell Companies,11.87,USD,0,https://images.financialmodelingprep.com/symbol/AGCUU.png,137908,0,-1.6999998,150787,-212799,-212799,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.8}]","[{'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 49.39}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.87}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.8}]",-0.0034,-0.0034,501131563,1131563,855972,17564100,0,0,0,855972,,0,0,0,__nan__,__nan__,__nan__,0.035048879968472474
126,AGCWW,Altimeter Growth Corp. Warrant,,,,,,,,,0,-0.8699999,272398,-212799,-212799,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.8}]","[{'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 49.39}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.87}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.8}]",50,50,501131563,1131563,855972,17564100,0,0,0,855972,,0,0,0,__nan__,__nan__,__nan__,0.035048879968472474
127,AGEN,Agenus Inc. Common Stock,"Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGF TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.",Dr. Garo H. Armen Ph.D.,Biotechnology,3.572,USD,83795191,https://images.financialmodelingprep.com/symbol/AGEN.png,499761,-0.32,0.262,170169,-145924000,-245761000,"[{'period': '2023', 'revenue': 156.31, 'unit': 'M', 'net_profit': -245.76}, {'period': '2022', 'revenue': 98.02, 'unit': 'M', 'net_profit': -271.51}, {'period': '2021', 'revenue': 295.67, 'unit': 'M', 'net_profit': -94.7}, {'period': '2020', 'revenue': 88.17, 'unit': 'M', 'net_profit': -240.13}]","[{'period': ""Q3 '24"", 'revenue': 25.11, 'unit': 'M', 'net_profit': -66.39}, {'period': ""Q2 '24"", 'revenue': 23.51, 'unit': 'M', 'net_profit': -53.08}, {'period': ""Q1 '24"", 'revenue': 28.0, 'unit': 'M', 'net_profit': -61.89}, {'period': ""Q4 '23"", 'revenue': 83.8, 'unit': 'M', 'net_profit': -46.29}, {'period': ""Q3 '23"", 'revenue': 24.31, 'unit': 'M', 'net_profit': -62.2}, {'period': ""Q2 '23"", 'revenue': 25.3, 'unit': 'M', 'net_profit': -73.43}]",-13.75,-13.75,313913000,112416000,76110000,462295000,25836000,3222000,255897000,76110000,-234156000,0.0983830407730758,0.09485295471705062,0.28645563051375195,__nan__,__nan__,__nan__,1.472685107020098
128,AGFS,AgroFresh Solutions Inc. Common Stock,"AgroFresh Solutions, Inc. provides science-based solutions, data-driven technologies, and high-touch customer services. The company's flagship product is the SmartFresh system that regulates the post-harvest ripening effects of ethylene to preserve the texture, firmness, taste, and appearance of produce during storage, transportation, and retail display. It also provides Harvista technology for use in near-harvest management of apples, pears, cherries, and blueberries; FreshCloud, a digital technology service platform of produce monitoring and screening solutions; and LandSpring, a 1- methlycycloproprene technology targeted to transplanted vegetable seedlings. In addition, the company offers fungicides, disinfectants, coatings, and packinghouse equipment for the citrus market under the Actiseal, FreshStart, VitaFresh Botanicals, Teycer Originals, and Control-Tec brands. It supports growers, packers, and retailers with solutions across the food supply chain to enhance the shelf life of fresh produce. The company primarily operates in the United States, Canada, Argentina, Brazil, Chile, Columbia, Costa Rica, the Dominican Republic, Ecuador, Guatemala, Mexico, Peru, Uruguay, Europe, the Middle East, Africa, Australia, China, India, Japan, New Zealand, South Korea, and the Philippines. AgroFresh Solutions, Inc. was founded in 1994 and is headquartered in Philadelphia, Pennsylvania.","Mr. Clinton A. Lewis Jr., B.S.",Agricultural Farm Products,3,USD,161152800,https://images.financialmodelingprep.com/symbol/AGFS.png,157171,-2.608695652173913,0,0,42761000,-33804000,"[{'period': '2022', 'revenue': 161.94, 'unit': 'M', 'net_profit': -33.8}, {'period': '2021', 'revenue': 165.99, 'unit': 'M', 'net_profit': -6.08}, {'period': '2020', 'revenue': 157.64, 'unit': 'M', 'net_profit': -52.97}, {'period': '2019', 'revenue': 170.06, 'unit': 'M', 'net_profit': -61.51}]","[{'period': ""Q4 '22"", 'revenue': 48.53, 'unit': 'M', 'net_profit': -7.65}, {'period': ""Q3 '22"", 'revenue': 47.76, 'unit': 'M', 'net_profit': -4.61}, {'period': ""Q2 '22"", 'revenue': 25.75, 'unit': 'M', 'net_profit': -18.37}, {'period': ""Q1 '22"", 'revenue': 39.89, 'unit': 'M', 'net_profit': -3.17}, {'period': ""Q4 '21"", 'revenue': 55.9, 'unit': 'M', 'net_profit': 2.42}, {'period': ""Q3 '21"", 'revenue': 49180.0, 'unit': 'K', 'net_profit': 994.0}]",-0.65,-0.65,697710000,158730000,54355000,354544000,71187000,0,66435000,54355000,12137000,-0.3475487877447016,-4.558040118382111,-4.416666666666667,__nan__,__nan__,__nan__,0.5081538174886414
129,AGFY,Agrify Corporation Common Stock,"Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.",Mr. Benjamin  Kovler,Engineering & Construction,27.205,USD,41616849,https://images.financialmodelingprep.com/symbol/AGFY.png,582070,-12.95,-1.225,16142,-18260000,-18649000,"[{'period': '2023', 'revenue': 16.87, 'unit': 'M', 'net_profit': -18.65}, {'period': '2022', 'revenue': 58.26, 'unit': 'M', 'net_profit': -188.17}, {'period': '2021', 'revenue': 59.86, 'unit': 'M', 'net_profit': -32.33}, {'period': '2020', 'revenue': 12.09, 'unit': 'M', 'net_profit': -30.64}]","[{'period': ""Q3 '24"", 'revenue': 1.93, 'unit': 'M', 'net_profit': -18.65}, {'period': ""Q2 '24"", 'revenue': 2.99, 'unit': 'M', 'net_profit': -2.97}, {'period': ""Q1 '24"", 'revenue': 2600.0, 'unit': 'K', 'net_profit': -38.0}, {'period': ""Q4 '23"", 'revenue': 2860.0, 'unit': 'K', 'net_profit': 575.0}, {'period': ""Q3 '23"", 'revenue': 3.14, 'unit': 'M', 'net_profit': -2.09}, {'period': ""Q2 '23"", 'revenue': 5.07, 'unit': 'M', 'net_profit': -6.8}]",-187.63,-187.63,45270000,24009000,434000,59980000,1808000,0,41249000,430000,-31033000,0.8464604337114364,0.9008943897371037,0.9861343482116465,__nan__,__nan__,__nan__,1.3249392533686768
130,AGGR,Agile Growth Corp. Class A Ordinary Share,"Agile Growth Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company intends to acquire businesses in the technology industry, including infrastructure, and horizontal and vertical enterprise application software; healthcare IT; financial technology; robotics/automation; and education technology, as well as additional software and technology segments. Agile Growth Corp. was incorporated in 2021 and is based in Newton, Massachusetts.",Mr. Jay H. Bhatt,Shell Companies,10.21,USD,395637500,https://images.financialmodelingprep.com/symbol/AGGR.png,116575,340.3333333333333,0.02,2318,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
131,AGGRU,Agile Growth Corp. Units,"Agile Growth Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company intends to acquire businesses in the technology industry, including infrastructure, and horizontal and vertical enterprise application software; healthcare IT; financial technology; robotics/automation; and education technology, as well as additional software and technology segments. Agile Growth Corp. was incorporated in 2021 and is based in Newton, Massachusetts.",Mr. Jay H. Bhatt,Shell Companies,10.2,USD,420063193,https://images.financialmodelingprep.com/symbol/AGGRU.png,427,0,0,500,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
132,AGGRW,Agile Growth Corp. Warrant.,"Agile Growth Corp. is a blank check company. The company was incorporated in 2021 and is based in Newton, Massachusetts.",Mr. Jay H. Bhatt,Shell Companies,0.003,USD,395637500,https://images.financialmodelingprep.com/symbol/AGGRW.png,0,0,0,13436,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
133,AGIO,Agios Pharmaceuticals Inc. Common Stock,"Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.",Mr. Brian M. Goff M.B.A.,Biotechnology,34.43,USD,1963549786,https://images.financialmodelingprep.com/symbol/AGIO.png,0,2.95,0.89,344000,-384864000,-352088000,"[{'period': '2023', 'revenue': 26.82, 'unit': 'M', 'net_profit': -352.09}, {'period': '2022', 'revenue': 14.24, 'unit': 'M', 'net_profit': -74.56}, {'period': '2021', 'revenue': 0.0, 'unit': 'B', 'net_profit': 1.6}, {'period': '2020', 'revenue': 203.2, 'unit': 'M', 'net_profit': -335.22}]","[{'period': ""Q3 '24"", 'revenue': 8.96, 'unit': 'M', 'net_profit': 947.91}, {'period': ""Q2 '24"", 'revenue': 8.62, 'unit': 'M', 'net_profit': -96.12}, {'period': ""Q1 '24"", 'revenue': 8.19, 'unit': 'M', 'net_profit': -81.55}, {'period': ""Q4 '23"", 'revenue': 7.1, 'unit': 'M', 'net_profit': -95.94}, {'period': ""Q3 '23"", 'revenue': 7.4, 'unit': 'M', 'net_profit': -91.32}, {'period': ""Q2 '23"", 'revenue': 6.71, 'unit': 'M', 'net_profit': -83.81}]",-6.33,-6.33,937118000,833835000,776928000,126099000,2810000,29435000,67955000,88205000,-297061000,-0.011514312071761418,-3.7225269934947356,-3.654411764705882,__nan__,__nan__,__nan__,0.13456042888942482
134,AGLE,Aeglea BioTherapeutics Inc. Common Stock,"Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.",Mr. Jonathan D. Alspaugh M.B.A.,Biotechnology,12.01,USD,48627649,https://images.financialmodelingprep.com/symbol/AGLE.png,59537,-0.1619689817936615,0.75,43238,-84781000,-83815000,"[{'period': '2022', 'revenue': 2.33, 'unit': 'M', 'net_profit': -83.81}, {'period': '2021', 'revenue': 18.74, 'unit': 'M', 'net_profit': -65.8}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -80.3}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -75.69}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -40.11}, {'period': ""Q2 '23"", 'revenue': 0.6880000000000001, 'unit': 'M', 'net_profit': -217.08}, {'period': ""Q1 '23"", 'revenue': 0.198, 'unit': 'M', 'net_profit': -18.42}, {'period': ""Q4 '22"", 'revenue': 0.168, 'unit': 'M', 'net_profit': -18.82}, {'period': ""Q3 '22"", 'revenue': 0.17400000000000002, 'unit': 'M', 'net_profit': -18.23}, {'period': ""Q2 '22"", 'revenue': 0.625, 'unit': 'M', 'net_profit': -22.32}]",-24.86,-24.86,71144000,62258000,55711000,20839000,375000,0,14656000,34863000,-80182000,-0.2914286584715685,-0.2737648364006626,0.006394884092725825,__nan__,__nan__,__nan__,0.29291296525357025
135,AGMH,AGM Group Holdings Inc. Class A Ordinary Shares,"AGM Group Holdings Inc. operates as a technology company. The company offers MetaTrader 5, a futures trading solution; FXSC, a retail-orientated online trading education website; and foreign exchange trading system that provides services to financial institutions. It also engages in the research and development, manufacture, and sales of technology hardware. In addition, the company sells cryptocurrency mining machine and standardized computing equipment, and technical support plans, as well as delivers software customization services. It has a strategic partnership with HighSharp (Shenzhen Gaorui) Electronic Technology Co., Ltd. The company was incorporated in 2015 and is based in Wan Chai, Hong Kong.",Dr. Bo  Zhu,Software - Application,1.35,USD,32743980,https://images.financialmodelingprep.com/symbol/AGMH.png,94754,-4.35,-0.06,3084,-8767881,-7439280,"[{'period': '2023', 'revenue': 92.91, 'unit': 'M', 'net_profit': -7.44}, {'period': '2022', 'revenue': 242.4, 'unit': 'M', 'net_profit': 11.48}, {'period': '2021', 'revenue': 36.71, 'unit': 'M', 'net_profit': 3.55}, {'period': '2020', 'revenue': 0.0533, 'unit': 'M', 'net_profit': -1.1}]","[{'period': ""Q4 '23"", 'revenue': 28.16, 'unit': 'M', 'net_profit': -11.78}, {'period': ""Q3 '23"", 'revenue': 28.16, 'unit': 'M', 'net_profit': -11.78}, {'period': ""Q2 '23"", 'revenue': 36.59, 'unit': 'M', 'net_profit': 16.11}, {'period': ""Q1 '23"", 'revenue': 18.29, 'unit': 'M', 'net_profit': 8.06}, {'period': ""Q4 '22"", 'revenue': 128.87, 'unit': 'M', 'net_profit': -3.09}, {'period': ""Q3 '22"", 'revenue': 64.43, 'unit': 'M', 'net_profit': -1.55}]",-0.31,-0.31,97547345,87119145,2815995,78114845,8637179,1573,77981722,1601479,-1702426,-1.5302909533300735,-1.6482671683903616,-1.6595744680851066,__nan__,__nan__,__nan__,0.8007890424900852
136,AGNC,AGNC Investment Corp. Common Stock,"AGNC Investment Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It funds its investments primarily through collateralized borrowings structured as repurchase agreements. The company has elected to be taxed as a REIT under the Internal Revenue Code of 1986 and would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as American Capital Agency Corp. and changed its name to AGNC Investment Corp. in September 2016. AGNC Investment Corp. was incorporated in 2008 and is headquartered in Bethesda, Maryland.",Mr. Peter J. Federico,REIT - Mortgage,9.3001,USD,8236540564,https://images.financialmodelingprep.com/symbol/AGNC.png,18576208,6.24,-0.0199,8776209,2588000000,155000000,"[{'period': '2023', 'revenue': 251.0, 'unit': 'M', 'net_profit': 155.0}, {'period': '2022', 'revenue': 2.55, 'unit': 'B', 'net_profit': -1.19}, {'period': '2021', 'revenue': 837.0, 'unit': 'M', 'net_profit': 749.0}, {'period': '2020', 'revenue': -173.0, 'unit': 'M', 'net_profit': -266.0}]","[{'period': ""Q3 '24"", 'revenue': 376.0, 'unit': 'M', 'net_profit': 346.0}, {'period': ""Q2 '24"", 'revenue': 967.0, 'unit': 'M', 'net_profit': -48.0}, {'period': ""Q1 '24"", 'revenue': 1650.0, 'unit': 'M', 'net_profit': 443.0}, {'period': ""Q4 '23"", 'revenue': 440.0, 'unit': 'M', 'net_profit': 412.0}, {'period': ""Q3 '23"", 'revenue': -369.0, 'unit': 'M', 'net_profit': -392.0}, {'period': ""Q2 '23"", 'revenue': 309.0, 'unit': 'M', 'net_profit': 286.0}]",0.0517,0.0516,71596000000,518000000,518000000,63339000000,0,210000000,11334000000,518000000,-118000000,0.07788421491045398,1.1302521008403361,1.0232882882882883,"[0.12, 0.31]","['2024-12-31', '2008-06-30']",__nan__,0.8846723280630203
137,AGNCM,AGNC Investment Corp. Depositary Shares rep 6.875% Series D Fixed-to-Floating Cumulative Redeemable Preferred Stock,"AGNC Investment Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It funds its investments primarily through collateralized borrowings structured as repurchase agreements. The company has elected to be taxed as a REIT under the Internal Revenue Code of 1986 and would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as American Capital Agency Corp. and changed its name to AGNC Investment Corp. in September 2016. AGNC Investment Corp. was incorporated in 2008 and is headquartered in Bethesda, Maryland.",Mr. Peter J. Federico,REIT - Mortgage,25.197,USD,8251870501,https://images.financialmodelingprep.com/symbol/AGNCM.png,17259,-13.55,0.047,4856,2588000000,155000000,"[{'period': '2023', 'revenue': 251.0, 'unit': 'M', 'net_profit': 155.0}, {'period': '2022', 'revenue': 2.55, 'unit': 'B', 'net_profit': -1.19}, {'period': '2021', 'revenue': 837.0, 'unit': 'M', 'net_profit': 749.0}, {'period': '2020', 'revenue': -173.0, 'unit': 'M', 'net_profit': -266.0}]","[{'period': ""Q3 '24"", 'revenue': 376.0, 'unit': 'M', 'net_profit': 346.0}, {'period': ""Q2 '24"", 'revenue': 967.0, 'unit': 'M', 'net_profit': -48.0}, {'period': ""Q1 '24"", 'revenue': 1650.0, 'unit': 'M', 'net_profit': 443.0}, {'period': ""Q4 '23"", 'revenue': 440.0, 'unit': 'M', 'net_profit': 412.0}, {'period': ""Q3 '23"", 'revenue': -369.0, 'unit': 'M', 'net_profit': -392.0}, {'period': ""Q2 '23"", 'revenue': 309.0, 'unit': 'M', 'net_profit': 286.0}]",0.0517,0.0516,71596000000,518000000,518000000,63339000000,0,210000000,11334000000,518000000,-118000000,0.07788421491045398,1.1302521008403361,1.0232882882882883,"[0.59039, 0.186]","['2024-12-31', '2019-03-29']",__nan__,0.8846723280630203
138,AGNCN,AGNC Investment Corp. Depositary Shares Each Representing a 1/1000th Interest in a Share of 7.00% Series C Fixed-To-Floating Rate Cumulative Redeemable Preferred Stock,"AGNC Investment Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It funds its investments primarily through collateralized borrowings structured as repurchase agreements. The company has elected to be taxed as a REIT under the Internal Revenue Code of 1986 and would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as American Capital Agency Corp. and changed its name to AGNC Investment Corp. in September 2016. AGNC Investment Corp. was incorporated in 2008 and is headquartered in Bethesda, Maryland.",Mr. Peter J. Federico,REIT - Mortgage,25.5713,USD,8286329824,https://images.financialmodelingprep.com/symbol/AGNCN.png,24080,-13.75,-0.1687,42435,2588000000,155000000,"[{'period': '2023', 'revenue': 251.0, 'unit': 'M', 'net_profit': 155.0}, {'period': '2022', 'revenue': 2.55, 'unit': 'B', 'net_profit': -1.19}, {'period': '2021', 'revenue': 837.0, 'unit': 'M', 'net_profit': 749.0}, {'period': '2020', 'revenue': -173.0, 'unit': 'M', 'net_profit': -266.0}]","[{'period': ""Q3 '24"", 'revenue': 376.0, 'unit': 'M', 'net_profit': 346.0}, {'period': ""Q2 '24"", 'revenue': 967.0, 'unit': 'M', 'net_profit': -48.0}, {'period': ""Q1 '24"", 'revenue': 1650.0, 'unit': 'M', 'net_profit': 443.0}, {'period': ""Q4 '23"", 'revenue': 440.0, 'unit': 'M', 'net_profit': 412.0}, {'period': ""Q3 '23"", 'revenue': -369.0, 'unit': 'M', 'net_profit': -392.0}, {'period': ""Q2 '23"", 'revenue': 309.0, 'unit': 'M', 'net_profit': 286.0}]",0.0517,0.0516,71596000000,518000000,518000000,63339000000,0,210000000,11334000000,518000000,-118000000,0.07788421491045398,1.1302521008403361,1.0232882882882883,"[0.64016, 0.258]","['2024-12-31', '2017-09-28']",__nan__,0.8846723280630203
139,AGNCO,AGNC Investment Corp. Depositary Shares each representing a 1/1000th interest in a share of 6.50% Series E Fixed-to-Floating Cumulative Redeemable Preferred Stock,"AGNC Investment Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It funds its investments primarily through collateralized borrowings structured as repurchase agreements. The company has elected to be taxed as a REIT under the Internal Revenue Code of 1986 and would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as American Capital Agency Corp. and changed its name to AGNC Investment Corp. in September 2016. AGNC Investment Corp. was incorporated in 2008 and is headquartered in Bethesda, Maryland.",Mr. Peter J. Federico,REIT - Mortgage,25.23,USD,8357822636,https://images.financialmodelingprep.com/symbol/AGNCO.png,45475,-13.56,-0.02,25385,2588000000,155000000,"[{'period': '2023', 'revenue': 251.0, 'unit': 'M', 'net_profit': 155.0}, {'period': '2022', 'revenue': 2.55, 'unit': 'B', 'net_profit': -1.19}, {'period': '2021', 'revenue': 837.0, 'unit': 'M', 'net_profit': 749.0}, {'period': '2020', 'revenue': -173.0, 'unit': 'M', 'net_profit': -266.0}]","[{'period': ""Q3 '24"", 'revenue': 376.0, 'unit': 'M', 'net_profit': 346.0}, {'period': ""Q2 '24"", 'revenue': 967.0, 'unit': 'M', 'net_profit': -48.0}, {'period': ""Q1 '24"", 'revenue': 1650.0, 'unit': 'M', 'net_profit': 443.0}, {'period': ""Q4 '23"", 'revenue': 440.0, 'unit': 'M', 'net_profit': 412.0}, {'period': ""Q3 '23"", 'revenue': -369.0, 'unit': 'M', 'net_profit': -392.0}, {'period': ""Q2 '23"", 'revenue': 309.0, 'unit': 'M', 'net_profit': 286.0}]",0.0517,0.0516,71596000000,518000000,518000000,63339000000,0,210000000,11334000000,518000000,-118000000,0.07788421491045398,1.1302521008403361,1.0232882882882883,"[0.63262, 0.46]","['2024-12-31', '2019-12-30']",__nan__,0.8846723280630203
140,AGNCP,AGNC Investment Corp. Depositary Shares Each Representing a 1/1000th Interest in a Share of 6.125% Series F Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock,"AGNC Investment Corp. operates as a real estate investment trust (REIT) in the United States. The company invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It funds its investments primarily through collateralized borrowings structured as repurchase agreements. The company has elected to be taxed as a REIT under the Internal Revenue Code of 1986 and would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as American Capital Agency Corp. and changed its name to AGNC Investment Corp. in September 2016. AGNC Investment Corp. was incorporated in 2008 and is headquartered in Bethesda, Maryland.",Mr. Peter J. Federico,REIT - Mortgage,24.74,USD,8264184187,https://images.financialmodelingprep.com/symbol/AGNCP.png,47609,-13.3,0.03,16936,2588000000,155000000,"[{'period': '2023', 'revenue': 251.0, 'unit': 'M', 'net_profit': 155.0}, {'period': '2022', 'revenue': 2.55, 'unit': 'B', 'net_profit': -1.19}, {'period': '2021', 'revenue': 837.0, 'unit': 'M', 'net_profit': 749.0}, {'period': '2020', 'revenue': -173.0, 'unit': 'M', 'net_profit': -266.0}]","[{'period': ""Q3 '24"", 'revenue': 376.0, 'unit': 'M', 'net_profit': 346.0}, {'period': ""Q2 '24"", 'revenue': 967.0, 'unit': 'M', 'net_profit': -48.0}, {'period': ""Q1 '24"", 'revenue': 1650.0, 'unit': 'M', 'net_profit': 443.0}, {'period': ""Q4 '23"", 'revenue': 440.0, 'unit': 'M', 'net_profit': 412.0}, {'period': ""Q3 '23"", 'revenue': -369.0, 'unit': 'M', 'net_profit': -392.0}, {'period': ""Q2 '23"", 'revenue': 309.0, 'unit': 'M', 'net_profit': 286.0}]",0.0517,0.0516,71596000000,518000000,518000000,63339000000,0,210000000,11334000000,518000000,-118000000,0.07788421491045398,1.1302521008403361,1.0232882882882883,"[0.38281, 0.27222]","['2024-12-31', '2020-03-31']",__nan__,0.8846723280630203
141,AGRX,Agile Therapeutics Inc. Common Stock,"Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.",Mr. Alfred F. Altomari,Drug Manufacturers - Specialty & Generic,1.51,USD,10425795,https://images.financialmodelingprep.com/symbol/AGRX.png,143293,-0.888235294117647,0.05,119291,-19884000,-14465000,"[{'period': '2023', 'revenue': 19.59, 'unit': 'M', 'net_profit': -14.46}, {'period': '2022', 'revenue': 10.88, 'unit': 'M', 'net_profit': -25.41}, {'period': '2021', 'revenue': 4.1, 'unit': 'M', 'net_profit': -76.58}, {'period': '2020', 'revenue': 0.749, 'unit': 'M', 'net_profit': -54.69}]","[{'period': ""Q2 '24"", 'revenue': 5.58, 'unit': 'M', 'net_profit': -11.87}, {'period': ""Q1 '24"", 'revenue': 5.72, 'unit': 'M', 'net_profit': 1.28}, {'period': ""Q4 '23"", 'revenue': 3.61, 'unit': 'M', 'net_profit': -4.47}, {'period': ""Q3 '23"", 'revenue': 6660.0, 'unit': 'K', 'net_profit': -799.0}, {'period': ""Q2 '23"", 'revenue': 5.5, 'unit': 'M', 'net_profit': -3.81}, {'period': ""Q1 '23"", 'revenue': 3.81, 'unit': 'M', 'net_profit': -3.61}]",-6.71,-6.71,10255000,9530000,2557000,26573000,3392000,0,20777000,2557000,-9577000,0.5016541353383459,0.43078073351172674,0.88586494301752,__nan__,__nan__,__nan__,2.591223793271575
142,AGTC,Applied Genetic Technologies Corporation Common Stock,"Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.",Ms. Susan Washer,Biotechnology,0.3936,USD,0,https://images.financialmodelingprep.com/symbol/AGTC.png,1315880,-0.26958904109589044,0,764531,-64757000,-71424000,"[{'period': '2022', 'revenue': 0.325, 'unit': 'M', 'net_profit': -71.42}, {'period': '2021', 'revenue': 0.5, 'unit': 'M', 'net_profit': -57.83}, {'period': '2020', 'revenue': 2.45, 'unit': 'M', 'net_profit': -45.89}, {'period': '2019', 'revenue': 41.69, 'unit': 'M', 'net_profit': -2.01}]","[{'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.07}, {'period': ""Q4 '22"", 'revenue': 0.325, 'unit': 'M', 'net_profit': -18.97}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.91}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.44}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.12}, {'period': ""Q4 '21"", 'revenue': 0.5, 'unit': 'M', 'net_profit': -12.14}]",-1.59,-1.59,66684000,49561000,46366000,37207000,0,7807000,25207000,46366000,-67762000,-0.1366660230643661,-0.2350896608967819,0.10169491525423725,__nan__,__nan__,__nan__,0.5579599304180913
143,AGYS,Agilysys Inc. Common Stock,"Agilysys, Inc., together with its subsidiaries, operates as a developer and marketer of hardware and software products and services to the hospitality industry in North America, Europe, the Asia-Pacific, and India. It offers point of sale, property management systems, inventory and procurement, payments, reservations management, and seat solutions to enhance guest experience. The company also provides technical software support, maintenance, and subscription services; and professional services. It offers its solutions for gaming, hotels, resorts and cruise, corporate foodservice management, restaurants, universities, stadium, and healthcare. The company was formerly known as Pioneer-Standard Electronics, Inc. and changed its name to Agilysys, Inc. in 2003. Agilysys, Inc. was founded in 1932 and is headquartered in Alpharetta, Georgia.",Mr. Ramesh  Srinivasan,Software - Application,128.305,USD,3586188903,https://images.financialmodelingprep.com/symbol/AGYS.png,0,36.55,-1.845,43171,25946000,86195000,"[{'period': '2023', 'revenue': 237.46, 'unit': 'M', 'net_profit': 86.19}, {'period': '2022', 'revenue': 198.06, 'unit': 'M', 'net_profit': 14.58}, {'period': '2021', 'revenue': 162.64, 'unit': 'M', 'net_profit': 6.48}, {'period': '2020', 'revenue': 137.18, 'unit': 'M', 'net_profit': -21.0}]","[{'period': ""Q2 '24"", 'revenue': 68.28, 'unit': 'M', 'net_profit': 1.36}, {'period': ""Q1 '24"", 'revenue': 63.51, 'unit': 'M', 'net_profit': 14.11}, {'period': ""Q4 '23"", 'revenue': 62.22, 'unit': 'M', 'net_profit': 2.96}, {'period': ""Q3 '23"", 'revenue': 60.57, 'unit': 'M', 'net_profit': 77.14}, {'period': ""Q2 '23"", 'revenue': 58.62, 'unit': 'M', 'net_profit': 4.54}, {'period': ""Q1 '23"", 'revenue': 56.06, 'unit': 'M', 'net_profit': 1.55}]",3.31,3.17,350430000,188937000,144891000,113953000,31728000,0,89371000,144891000,40059000,0.34602614650342395,4.911054725003429,5.365384615384615,"[0.03, 0.0451]","['2009-07-16', '1985-01-10']",__nan__,0.32518049253773934
144,AHAC,Alpha Healthcare Acquisition Corp. Class A Common Stock,"Alpha Healthcare Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.",Mr. Rajiv Sarman Shukla,Shell Companies,10.96,USD,1130173280,https://images.financialmodelingprep.com/symbol/AHAC.png,222649,-72.10526315789474,0.8100004,295507,-96458000,-110776000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -110.78}, {'period': '2022', 'revenue': 1.56, 'unit': 'M', 'net_profit': 64.22}, {'period': '2021', 'revenue': 1.26, 'unit': 'M', 'net_profit': 37.54}, {'period': '2020', 'revenue': 1.49, 'unit': 'M', 'net_profit': -68.73}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -39.2}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -56.66}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.9}, {'period': ""Q4 '23"", 'revenue': 10.79, 'unit': 'M', 'net_profit': -25.11}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -22.71}]",-1.07,-1.07,128223000,83278000,80448000,114677000,0,0,18443000,80448000,-75585000,-39.738152610441766,-2.724972360204924,-2.725806451612903,__nan__,__nan__,__nan__,0.8943559267838064
145,AHACU,Alpha Healthcare Acquisition Corp. Unit,"Alpha Healthcare Acquisition Corp. is a blank check company. The company was incorporated in 2020 and is based in New York, New York.",Mr. Rajiv Sarman Shukla,Shell Companies,12.077,USD,0,https://images.financialmodelingprep.com/symbol/AHACU.png,1445,-79.45394736842105,0.877,2922,-96458000,-110776000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -110.78}, {'period': '2022', 'revenue': 1.56, 'unit': 'M', 'net_profit': 64.22}, {'period': '2021', 'revenue': 1.26, 'unit': 'M', 'net_profit': 37.54}, {'period': '2020', 'revenue': 1.49, 'unit': 'M', 'net_profit': -68.73}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -39.2}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -56.66}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.9}, {'period': ""Q4 '23"", 'revenue': 10.79, 'unit': 'M', 'net_profit': -25.11}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -22.71}]",-1.07,-1.07,128223000,83278000,80448000,114677000,0,0,18443000,80448000,-75585000,-39.738152610441766,-2.724972360204924,-2.725806451612903,__nan__,__nan__,__nan__,0.8943559267838064
146,AHACW,Alpha Healthcare Acquisition Corp. Warrant,,,,,,,,,0,0.5451,80740,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
147,AHCO,AdaptHealth Corp. Class A Common Stock,"AdaptHealth Corp., together with its subsidiaries, provides home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps to patients for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It serves beneficiaries of Medicare, Medicaid, and commercial insurance payors. AdaptHealth Corp. is headquartered in Plymouth Meeting, Pennsylvania.",Ms. Suzanne M. Foster,Medical - Devices,9.58,USD,1289036900,https://images.financialmodelingprep.com/symbol/AHCO.png,1122893,-5.81,0.04,119168,-171091000,-678895000,"[{'period': '2023', 'revenue': 3200.0, 'unit': 'M', 'net_profit': -678.89}, {'period': '2022', 'revenue': 2970.0, 'unit': 'M', 'net_profit': 69.32}, {'period': '2021', 'revenue': 2450.0, 'unit': 'M', 'net_profit': 156.18}, {'period': '2020', 'revenue': 1060.0, 'unit': 'M', 'net_profit': -58.72}]","[{'period': ""Q3 '24"", 'revenue': 805.86, 'unit': 'M', 'net_profit': 22.86}, {'period': ""Q2 '24"", 'revenue': 805.98, 'unit': 'M', 'net_profit': 19.43}, {'period': ""Q1 '24"", 'revenue': 792.5, 'unit': 'M', 'net_profit': -2.13}, {'period': ""Q4 '23"", 'revenue': 858.23, 'unit': 'M', 'net_profit': -254.5}, {'period': ""Q3 '23"", 'revenue': 804.03, 'unit': 'M', 'net_profit': -454.08}, {'period': ""Q2 '23"", 'revenue': 793.29, 'unit': 'M', 'net_profit': 13.98}]",-5.32,-5.31,4508650000,649022000,77132000,3041981000,388910000,986000,536999000,77132000,143203000,-1.2712466587819735,-10.794203358531941,-11.23076923076923,__nan__,__nan__,__nan__,0.6746988566422322
148,AHPI,Allied Healthcare Products Inc. Common Stock,"Allied Healthcare Products, Inc. manufactures and markets respiratory products for use in the health care industry in a range of hospitals and alternate site settings worldwide. The company offers respiratory care/anesthesia products, including air compressors, calibration equipment, humidifiers, croup tents, and equipment dryers, as well as respiratory disposable products, such as oxygen tubing products, facemasks, cannulas, and ventilator circuits; and home respiratory care products comprising aluminum oxygen cylinders, oxygen regulators, pneumatic nebulizers, portable suction equipment, and a line of respiratory disposable products. It also provides medical gas equipment, which include construction products consisting of in-wall medical system components, central station pumps and compressors, and headwalls; regulation devices and suction equipment comprising flowmeters, vacuum regulators, and pressure regulators, as well as related adapters, fittings, and hoses that measure, regulate, monitor, and transfer medical gases from walled piping or equipment to patients; and disposable oxygen cylinders to provide oxygen for short periods. In addition, the company offers emergency medical products that include respiratory/resuscitation products, such as demand resuscitation valves, portable resuscitation systems, bag masks and related products, emergency transport ventilators, precision oxygen regulators, minilators, multilators, and humidifiers; and trauma and patient handling products that include spine immobilization products, pneumatic anti-shock garments, and trauma burn kits. It serves hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, emergency medical products dealers, and others. The company was incorporated in 1979 and is headquartered in St. Louis, Missouri.",Mr. Daniel C. Dunn,Medical - Devices,0.004,USD,0,https://images.financialmodelingprep.com/symbol/AHPI.png,3110,-0.0029850746268656717,0,3311,-4119041,-5361428,"[{'period': '2022', 'revenue': 27.05, 'unit': 'M', 'net_profit': -5.36}, {'period': '2021', 'revenue': 36.28, 'unit': 'M', 'net_profit': 1.69}, {'period': '2020', 'revenue': 31.89, 'unit': 'M', 'net_profit': -3.01}, {'period': '2019', 'revenue': 31.38, 'unit': 'M', 'net_profit': -2.11}]","[{'period': ""Q4 '22"", 'revenue': 6.01, 'unit': 'M', 'net_profit': -1.94}, {'period': ""Q3 '22"", 'revenue': 6.87, 'unit': 'M', 'net_profit': -1.33}, {'period': ""Q2 '22"", 'revenue': 6.81, 'unit': 'M', 'net_profit': -1.2}, {'period': ""Q1 '22"", 'revenue': 7360.0, 'unit': 'K', 'net_profit': -984.01}, {'period': ""Q4 '21"", 'revenue': 7.02, 'unit': 'M', 'net_profit': 1.55}, {'period': ""Q3 '21"", 'revenue': 7970.0, 'unit': 'K', 'net_profit': -413.44}]",-1.34,-1.34,19670586,16081530,3317047,14436506,2369956,0,5982199,3317047,-4171392,-78.8896999035607,-4.177730045495819,-4.190476190476191,"[0.07, 0.06]","['1996-06-26', '1993-03-25']",__nan__,0.7339133668920692
149,AIH,Aesthetic Medical International Holdings Group Ltd. American Depositary Shares,"Aesthetic Medical International Holdings Group Limited provides aesthetic medical services. It offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments comprising minimally invasive and energy-based treatments, including laser, ultrasound, and ultraviolet light treatments. The company also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. It operates 15 treatment centers in China, Hong Kong, and Singapore. Aesthetic Medical International Holdings Group Limited was founded in 1997 and is headquartered in Shenzhen, the People's Republic of China.",Dr. Pengwu  Zhou,Medical - Care Facilities,0.3334,USD,15932519,https://images.financialmodelingprep.com/symbol/AIH.png,261827,-2.7783333333333333,-0.1656,178322,25467000,-37432000,"[{'period': '2023', 'revenue': 682.59, 'unit': 'M', 'net_profit': -37.43}, {'period': '2022', 'revenue': 670.09, 'unit': 'M', 'net_profit': -76.11}, {'period': '2021', 'revenue': 645.59, 'unit': 'M', 'net_profit': -669.52}, {'period': '2020', 'revenue': 901.57, 'unit': 'M', 'net_profit': -246.91}]","[{'period': ""Q4 '23"", 'revenue': 181.64, 'unit': 'M', 'net_profit': -13.68}, {'period': ""Q3 '23"", 'revenue': 181.64, 'unit': 'M', 'net_profit': -13.68}, {'period': ""Q2 '23"", 'revenue': 170.42, 'unit': 'M', 'net_profit': -10.56}, {'period': ""Q1 '23"", 'revenue': 148880.0, 'unit': 'K', 'net_profit': 182.0}, {'period': ""Q4 '22"", 'revenue': 503.04, 'unit': 'M', 'net_profit': -23.7}, {'period': ""Q3 '22"", 'revenue': -171.55, 'unit': 'M', 'net_profit': -48.66}]",-0.85,-0.85,560664000,111569000,62336000,527035000,12920000,-76938000,411380000,62336000,18827000,1.634153909805544,0.5081596720363704,0.6953405017921147,__nan__,__nan__,__nan__,0.9400193342179987
150,AIHS,Senmiao Technology Limited Common Stock,"Senmiao Technology Limited engages in the automobile transaction and related services business in the People's Republic of China. The company offers car rental services to individual customers; and auto finance solutions through financing leases. It also engages in automobile sales; the facilitation of automobile transaction and financing; and the provision of supporting services provided to online ride-hailing drivers, as well as management and guarantee services. The company was founded in 2014 and is headquartered in Chengdu, the People's Republic of China.",Mr. Xi  Wen,Financial - Credit Services,1,USD,10518000,https://images.financialmodelingprep.com/symbol/AIHS.png,22651,-2.63,0,12832,-3008405,-3668974,"[{'period': '2023', 'revenue': 6.81, 'unit': 'M', 'net_profit': -3.67}, {'period': '2022', 'revenue': 8.08, 'unit': 'M', 'net_profit': -3.11}, {'period': '2021', 'revenue': 4.91, 'unit': 'M', 'net_profit': -5.61}, {'period': '2020', 'revenue': 6.16, 'unit': 'M', 'net_profit': -12.6}]","[{'period': ""Q2 '24"", 'revenue': 745.88, 'unit': 'K', 'net_profit': -711.45}, {'period': ""Q1 '24"", 'revenue': 1120.0, 'unit': 'K', 'net_profit': -673.42}, {'period': ""Q4 '23"", 'revenue': 1.27, 'unit': 'M', 'net_profit': -1.38}, {'period': ""Q3 '23"", 'revenue': 1620.0, 'unit': 'K', 'net_profit': -934.0}, {'period': ""Q2 '23"", 'revenue': 1830.0, 'unit': 'K', 'net_profit': -925.96}, {'period': ""Q1 '23"", 'revenue': 2090.0, 'unit': 'K', 'net_profit': -427.83}]",-0.41,-0.41,9861484,2651160,792299,5573116,989064,0,5343210,792299,-664438,-0.23413845103656955,-0.1783139874151706,0.046511627906976785,__nan__,__nan__,__nan__,0.5651396889149747
151,AIKI,AIkido Pharma Inc. Common Stock,"AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.",Mr. Anthony C. Hayes Esq.,Biotechnology,3.56,USD,19526956,https://images.financialmodelingprep.com/symbol/AIKI.png,35256,0,0.03,31931,-14346000,-29868000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.87}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.9}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.34}, {'period': '2019', 'revenue': 0.009000000000000001, 'unit': 'M', 'net_profit': -4.18}]","[{'period': ""Q3 '23"", 'revenue': 0.963, 'unit': 'M', 'net_profit': -3.54}, {'period': ""Q2 '23"", 'revenue': 0.07100000000000001, 'unit': 'M', 'net_profit': -8.66}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.69}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.19}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.19}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.64}]",-5.6,-5.6,76236000,50656000,40304000,2469000,0,23103000,1789000,33174000,-10597000,-1.000557802259099,-5.094266476229341,-0.8855218855218853,"[0.0389, 0.0667]","['1980-05-12', '1978-05-15']",__nan__,0.03238627420116481
152,AIMC,Altra Industrial Motion Corp. Common Stock,"Altra Industrial Motion Corp. designs, produces, and markets a range of electromechanical power transmission motion control products for use in various motion-related applications, and high-volume manufacturing and non-manufacturing processes. The company operates in two segments, Power Transmission Technologies (PTT) and Automation & Specialty (A&S). The PTT segment offers couplings, such as gear couplings, diaphragm and disc couplings, elastomeric couplings, miniature and precision couplings, universal joints, mill spindles, and shaft locking devices under the Ameridrives, Bibby, Guardian, Huco, Lamiflex, Stromag, and TB Wood's brands; clutches and brakes under the Industrial Clutch, Formsprag, Stieber, Stromag, Svendborg, Twiflex, and Wichita brands; electromagnetic clutches and brakes under the Inertia Dynamics, Matrix, Stromag, and Warner Electric brands; and gears under the Bauer Gear Motor, Boston Gear, Delroyd, and Nuttall brands. The A&S segment provides rotary precision motion solutions, including servo and stepper motors, precision linear actuators, and electronic drives and motion controllers, as well as related software under the Kollmorgen brand; and miniature motors, and motion control products, such as brush and brushless DC, can stack, and disc magnet motors under the Portescap brand. This segment also offers linear bearings, guides, glides, lead and ball screws, industrial linear actuators, resolvers, and inductors for the transition of rotary motion to linear motion under the Thomson and Nook brands. It serves in North America, the rest of Europe, Germany, China, the rest of Asia, and internationally. The company was formerly known as Altra Holdings, Inc. and changed its name to Altra Industrial Motion Corp. in November 2013. Altra Industrial Motion Corp. was incorporated in 2004 and is headquartered in Braintree, Massachusetts. As of March 27, 2023, Altra Industrial Motion Corp. operates as a subsidiary of Regal Rexnord Corporation.",Mr. Carl R. Christenson,Industrial - Machinery,61.98,USD,4050845454,https://images.financialmodelingprep.com/symbol/AIMC.png,1348099,31.948453608247423,0,1844123,353400000,127000000,"[{'period': '2022', 'revenue': 1950.0, 'unit': 'M', 'net_profit': 127.0}, {'period': '2021', 'revenue': 1900.0, 'unit': 'M', 'net_profit': 27.7}, {'period': '2020', 'revenue': 1730.0, 'unit': 'M', 'net_profit': -25.5}, {'period': '2019', 'revenue': 1830.0, 'unit': 'M', 'net_profit': 127.2}]","[{'period': ""Q4 '22"", 'revenue': 469.4, 'unit': 'M', 'net_profit': 22.3}, {'period': ""Q3 '22"", 'revenue': 466.3, 'unit': 'M', 'net_profit': 33.6}, {'period': ""Q2 '22"", 'revenue': 498.1, 'unit': 'M', 'net_profit': 26.3}, {'period': ""Q1 '22"", 'revenue': 511.7, 'unit': 'M', 'net_profit': 44.8}, {'period': ""Q4 '21"", 'revenue': 469.8, 'unit': 'M', 'net_profit': -87.7}, {'period': ""Q3 '21"", 'revenue': 469.3, 'unit': 'M', 'net_profit': 35.4}]",1.95,1.94,3676600000,836400000,208900000,1674200000,253500000,0,377300000,208900000,69100000,-0.044864864864864865,3.5848375451263537,3.5348837209302326,"[0.09, 0.05]","['2023-03-15', '2012-06-14']",__nan__,0.4553663711037371
153,AINV,Apollo Investment Corporation Common Stock,"Apollo Investment Corporation is business development company and a closed-end, externally managed, non-diversified management investment company. It is elected to be treated as a business development company (""BDC"") under the Investment Company Act of 1940 (the ""1940 Act"") specializing in private equity investments in leveraged buyouts, acquisitions, recapitalizations, growth capital, refinancing and private middle market companies. It provides direct equity capital, mezzanine, first lien secured loans, stretch senior loans, unitranche loans, second lien secured loans and senior secured loans, unsecured debt, and subordinated debt and loans. It also seeks to invest in PIPES transactions. The fund may also invest in securities of public companies that are thinly traded and may acquire investments in the secondary market and structured products. It prefers to invest in preferred equity, common equity / interests and warrants and makes equity co-investments. It may invest in cash equivalents, U.S. government securities, high-quality debt investments that mature in one year or less, high-yield bonds, distressed debt, non-U.S. investments, or securities of public companies that are not thinly traded. It also focuses on other investments such as collateralized loan obligations (""CLOs"") and credit-linked notes (""CLNs""). The fund typically invests in construction and building materials, business services, plastics & rubber, advertising, capital equipment, education, cable television, chemicals, consumer products/goods durable and non-durable and customer services, direct marketing, energy  oil & gas, electricity and utilities. The fund also invest in aerospace & defense, wholesale, telecommunications, financial services, hotel, gaming, leisure, restaurants; environmental industries, healthcare and pharmaceuticals, high tech industries, beverages, food and tobacco, manufacturing, media  diversified & production, printing and publishing, retail, automation, aviation and consumer transport, transportation, cargo and distribution. It primarily invests in United States. It primarily invests between $20 million and $250 million in its portfolio companies. The fund seeks to make investments with stated maturities of five to 10 years.",Mr. Howard Widra,Asset Management,13.65,USD,893411610,https://images.financialmodelingprep.com/symbol/AINV.png,0,15.511363636363637,0.07999992,224490,137384000,82364000,"[{'period': '2022', 'revenue': 96.72, 'unit': 'M', 'net_profit': 82.36}, {'period': '2021', 'revenue': 126.73, 'unit': 'M', 'net_profit': 111.86}, {'period': '2020', 'revenue': 276.92, 'unit': 'M', 'net_profit': -116.06}, {'period': '2019', 'revenue': 255.08, 'unit': 'M', 'net_profit': 71.95}]","[{'period': ""Q1 '23"", 'revenue': 8.85, 'unit': 'M', 'net_profit': -10.72}, {'period': ""Q4 '22"", 'revenue': 7.83, 'unit': 'M', 'net_profit': 4.24}, {'period': ""Q3 '22"", 'revenue': 24.28, 'unit': 'M', 'net_profit': 6.41}, {'period': ""Q2 '22"", 'revenue': 28.73, 'unit': 'M', 'net_profit': 25.44}, {'period': ""Q1 '22"", 'revenue': 35.88, 'unit': 'M', 'net_profit': 32.14}, {'period': ""Q4 '21"", 'revenue': 45.95, 'unit': 'M', 'net_profit': 42.41}]",1.28,1.28,2600121000,59224000,30598000,1595289000,28626000,2523173000,26248000,30598000,-2677000,-0.17870358746271156,-0.26369333369091996,-0.25146198830409355,"[0.32, 0.045]","['2022-09-19', '2004-09-21']",__nan__,0.6135441389073816
154,AIRG,Airgain Inc. Common Stock,"Airgain, Inc. designs, develops, and engineers antenna products for original equipment and design manufacturers, vertical markets, chipset vendors, service providers, value-added resellers and software developers worldwide. The company's products include MaxBeam embedded antennas; profile embedded antennas; profile contour embedded antennas; ultra-embedded antennas; SmartMax embedded antennas; and MaxBeam carrier class antennas, as well as automotive, fleet, public safety, and machine-to-machine antennas under the Antenna Plus brand. It provides embedded antenna technologies to enable high performance wireless networking in a range of devices and markets, including consumer, enterprise, and automotive. The company was formerly known as AM Group and changed its name to Airgain, Inc. in 2004. Airgain, Inc. was incorporated in 1995 and is headquartered in San Diego, California.",Mr. Jacob  Suen,Communication Equipment,6.45,USD,73172670,https://images.financialmodelingprep.com/symbol/AIRG.png,0,-5.81,,0,-8770000,-12428000,"[{'period': '2023', 'revenue': 56.04, 'unit': 'M', 'net_profit': -12.43}, {'period': '2022', 'revenue': 75.89, 'unit': 'M', 'net_profit': -8.66}, {'period': '2021', 'revenue': 64.27, 'unit': 'M', 'net_profit': -10.09}, {'period': '2020', 'revenue': 48.5, 'unit': 'M', 'net_profit': -3.28}]","[{'period': ""Q3 '24"", 'revenue': 16.1, 'unit': 'M', 'net_profit': -1.76}, {'period': ""Q2 '24"", 'revenue': 15.18, 'unit': 'M', 'net_profit': -2.51}, {'period': ""Q1 '24"", 'revenue': 14.23, 'unit': 'M', 'net_profit': -2.46}, {'period': ""Q4 '23"", 'revenue': 10.07, 'unit': 'M', 'net_profit': -5.48}, {'period': ""Q3 '23"", 'revenue': 13.7, 'unit': 'M', 'net_profit': -1.88}, {'period': ""Q2 '23"", 'revenue': 15.83, 'unit': 'M', 'net_profit': -2.21}]",-1.2,-1.2,42229000,19081000,7881000,10816000,7375000,0,9991000,7881000,-3647000,-0.7974994875999181,-0.4352696616237441,-0.4117647058823529,__nan__,__nan__,__nan__,0.2561273058798456
155,AIRT,Air T Inc. Common Stock,"Air T, Inc., through its subsidiaries, provides overnight air cargo, ground equipment sale, and commercial jet engines and parts, and printing equipment and maintenance services in the United States and internationally. The company's Overnight Air Cargo segment offers air express delivery services. As of March 31, 2022, this segment had 72 aircraft under the dry-lease agreements with FedEx. Its Ground Equipment Sales segment manufactures, sells, and services aircraft deicers, scissor-type lifts, military and civilian decontamination units, flight-line tow tractors, glycol recovery vehicles, and other specialized equipment. This segment sells its products to passenger and cargo airlines, ground handling companies, the United States Air Force, airports, and industrial customers. Its Commercial Aircraft, Engines and Parts segment offers commercial aircraft trading, leasing, and parts solutions; commercial aircraft storage, storage maintenance, and aircraft disassembly/part-out services; commercial aircraft parts sales, exchanges, procurement services, consignment programs, and overhaul and repair services; and aircraft instrumentation, avionics, and a range of electrical accessories for civilian, military transport, regional/commuter and business/commercial jet, and turboprop aircraft. This segment also provides composite aircraft structures, and repair and support services. Air T, Inc. was incorporated in 1980 and is based in Denver, North Carolina.",Mr. Nicholas John Swenson,Integrated Freight & Logistics,20,USD,55201000,https://images.financialmodelingprep.com/symbol/AIRT.png,18454,-22.99,-0.42,3023,5851000,-6819000,"[{'period': '2024', 'revenue': 286.83, 'unit': 'M', 'net_profit': -6.82}, {'period': '2023', 'revenue': 247.32, 'unit': 'M', 'net_profit': -11.79}, {'period': '2022', 'revenue': 177.08, 'unit': 'M', 'net_profit': 10.93}, {'period': '2021', 'revenue': 175.12, 'unit': 'M', 'net_profit': -8.39}]","[{'period': ""Q2 '25"", 'revenue': 17.13, 'unit': 'M', 'net_profit': 2.52}, {'period': ""Q1 '25"", 'revenue': 66410.0, 'unit': 'K', 'net_profit': -335.0}, {'period': ""Q4 '24"", 'revenue': 72.68, 'unit': 'M', 'net_profit': -1.7}, {'period': ""Q3 '24"", 'revenue': 63.76, 'unit': 'M', 'net_profit': -2.98}, {'period': ""Q2 '24"", 'revenue': 78.97, 'unit': 'M', 'net_profit': -1.61}, {'period': ""Q1 '24"", 'revenue': 71430.0, 'unit': 'K', 'net_profit': -531.0}]",-2.42,-2.42,177167000,102877000,7100000,158371000,26004000,16653000,46841000,7100000,16102000,4.458022388059701,0.42138311412812895,0.4154589371980676,"[0.3, 0.01]","['2013-06-05', '1991-12-30']",__nan__,0.8939080076989507
156,AIRTP,Air T Inc. Air T Funding Alpha Income Trust Preferred Securities,"Air T, Inc., through its subsidiaries, provides overnight air cargo, ground equipment sale, and commercial jet engines and parts, and printing equipment and maintenance services in the United States and internationally. The company's Overnight Air Cargo segment offers air express delivery services. As of March 31, 2022, this segment had 72 aircraft under the dry-lease agreements with FedEx. Its Ground Equipment Sales segment manufactures, sells, and services aircraft deicers, scissor-type lifts, military and civilian decontamination units, flight-line tow tractors, glycol recovery vehicles, and other specialized equipment. This segment sells its products to passenger and cargo airlines, ground handling companies, the United States Air Force, airports, and industrial customers. Its Commercial Aircraft, Engines and Parts segment offers commercial aircraft trading, leasing, and parts solutions; commercial aircraft storage, storage maintenance, and aircraft disassembly/part-out services; commercial aircraft parts sales, exchanges, procurement services, consignment programs, and overhaul and repair services; and aircraft instrumentation, avionics, and a range of electrical accessories for civilian, military transport, regional/commuter and business/commercial jet, and turboprop aircraft. This segment also provides composite aircraft structures, and repair and support services. Air T, Inc. was incorporated in 1980 and is based in Denver, North Carolina.",Mr. Nicholas John Swenson,Integrated Freight & Logistics,17.2499,USD,415534549,https://images.financialmodelingprep.com/symbol/AIRTP.png,2416,51.34,0.1499,1201,5851000,-6819000,"[{'period': '2024', 'revenue': 286.83, 'unit': 'M', 'net_profit': -6.82}, {'period': '2023', 'revenue': 247.32, 'unit': 'M', 'net_profit': -11.79}, {'period': '2022', 'revenue': 177.08, 'unit': 'M', 'net_profit': 10.93}, {'period': '2021', 'revenue': 175.12, 'unit': 'M', 'net_profit': -8.39}]","[{'period': ""Q2 '25"", 'revenue': 17.13, 'unit': 'M', 'net_profit': 2.52}, {'period': ""Q1 '25"", 'revenue': 66410.0, 'unit': 'K', 'net_profit': -335.0}, {'period': ""Q4 '24"", 'revenue': 72.68, 'unit': 'M', 'net_profit': -1.7}, {'period': ""Q3 '24"", 'revenue': 63.76, 'unit': 'M', 'net_profit': -2.98}, {'period': ""Q2 '24"", 'revenue': 78.97, 'unit': 'M', 'net_profit': -1.61}, {'period': ""Q1 '24"", 'revenue': 71430.0, 'unit': 'K', 'net_profit': -531.0}]",-2.42,-2.42,177167000,102877000,7100000,158371000,26004000,16653000,46841000,7100000,16102000,4.458022388059701,0.42138311412812895,0.4154589371980676,"[0.5, 0.0433]","['2025-11-14', '2019-08-23']",__nan__,0.8939080076989507
157,AIRTW,Air T Inc. Air T Funding Warrants to Purchase Alpha Income Trust Preferred Expiring 08/30/2021,,None,Integrated Freight & Logistics,0.01,USD,0,https://images.financialmodelingprep.com/symbol/AIRTW.png,0,0.022779043280182234,-0.03,459631,5851000,-6819000,"[{'period': '2024', 'revenue': 286.83, 'unit': 'M', 'net_profit': -6.82}, {'period': '2023', 'revenue': 247.32, 'unit': 'M', 'net_profit': -11.79}, {'period': '2022', 'revenue': 177.08, 'unit': 'M', 'net_profit': 10.93}, {'period': '2021', 'revenue': 175.12, 'unit': 'M', 'net_profit': -8.39}]","[{'period': ""Q2 '25"", 'revenue': 17.13, 'unit': 'M', 'net_profit': 2.52}, {'period': ""Q1 '25"", 'revenue': 66410.0, 'unit': 'K', 'net_profit': -335.0}, {'period': ""Q4 '24"", 'revenue': 72.68, 'unit': 'M', 'net_profit': -1.7}, {'period': ""Q3 '24"", 'revenue': 63.76, 'unit': 'M', 'net_profit': -2.98}, {'period': ""Q2 '24"", 'revenue': 78.97, 'unit': 'M', 'net_profit': -1.61}, {'period': ""Q1 '24"", 'revenue': 71430.0, 'unit': 'K', 'net_profit': -531.0}]",-2.42,-2.42,177167000,102877000,7100000,158371000,26004000,16653000,46841000,7100000,16102000,4.458022388059701,0.42138311412812895,0.4154589371980676,__nan__,__nan__,__nan__,0.8939080076989507
158,AKAM,Akamai Technologies Inc. Common Stock,"Akamai Technologies, Inc. provides cloud services for securing, delivering, and optimizing content and business applications over the internet in the United States and internationally. The company offers cloud solutions to keep infrastructure, websites, applications, application programming interfaces, and users safe from various cyberattacks and online threats while enhancing performance. It also provides web and mobile performance solutions to enable dynamic websites and applications; media delivery solutions, including video streaming and video player services, game and software delivery, broadcast operations, authoritative domain name system, resolution, and data and analytics; and edge compute solutions to enable developers to deploy and distribute code at the edge. In addition, the company offers carrier offerings, including cybersecurity protection, parental controls, DNS infrastructure and content delivery solutions; and an array of service and support to assist customers with integrating, configuring, optimizing, and managing its offerings. It sells its solutions through direct sales and service organizations, as well as through various channel partners. Akamai Technologies, Inc. was incorporated in 1998 and is headquartered in Cambridge, Massachusetts.",Dr. F. Thomson Leighton,Software - Infrastructure,93.46,USD,14040215420,https://images.financialmodelingprep.com/symbol/AKAM.png,1787870,27.63,-0.01,264940,1241012000,547629000,"[{'period': '2023', 'revenue': 3810.0, 'unit': 'M', 'net_profit': 547.63}, {'period': '2022', 'revenue': 3620.0, 'unit': 'M', 'net_profit': 523.67}, {'period': '2021', 'revenue': 3460.0, 'unit': 'M', 'net_profit': 651.64}, {'period': '2020', 'revenue': 3200.0, 'unit': 'M', 'net_profit': 557.05}]","[{'period': ""Q3 '24"", 'revenue': 1000.0, 'unit': 'M', 'net_profit': 57.91}, {'period': ""Q2 '24"", 'revenue': 979.58, 'unit': 'M', 'net_profit': 131.69}, {'period': ""Q1 '24"", 'revenue': 986.97, 'unit': 'M', 'net_profit': 175.42}, {'period': ""Q4 '23"", 'revenue': 995.02, 'unit': 'M', 'net_profit': 161.16}, {'period': ""Q3 '23"", 'revenue': 965.48, 'unit': 'M', 'net_profit': 160.54}, {'period': ""Q2 '23"", 'revenue': 935.72, 'unit': 'M', 'net_profit': 128.82}]",3.59,3.52,9900037000,1804855000,864439000,5302882000,724302000,1431354000,836038000,489468000,618399000,-0.01651618690925171,0.04574810186528972,0.09118541033434645,__nan__,__nan__,__nan__,0.535642644567894
159,AKBA,Akebia Therapeutics Inc. Common Stock,"Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.",Mr. John P. Butler MBA,Biotechnology,1.89,USD,412362090,https://images.financialmodelingprep.com/symbol/AKBA.png,2111982,-9,0.02,781449,-6868000,-51925000,"[{'period': '2023', 'revenue': 194.62, 'unit': 'M', 'net_profit': -51.92}, {'period': '2022', 'revenue': 292.6, 'unit': 'M', 'net_profit': -106.01}, {'period': '2021', 'revenue': 213.58, 'unit': 'M', 'net_profit': -244.87}, {'period': '2020', 'revenue': 295.31, 'unit': 'M', 'net_profit': -349.87}]","[{'period': ""Q3 '24"", 'revenue': 37.43, 'unit': 'M', 'net_profit': -20.04}, {'period': ""Q2 '24"", 'revenue': 43.65, 'unit': 'M', 'net_profit': -8.58}, {'period': ""Q1 '24"", 'revenue': 32.61, 'unit': 'M', 'net_profit': -17.98}, {'period': ""Q4 '23"", 'revenue': 56200.0, 'unit': 'K', 'net_profit': 614.0}, {'period': ""Q3 '23"", 'revenue': 42.05, 'unit': 'M', 'net_profit': -14.49}, {'period': ""Q2 '23"", 'revenue': 56.38, 'unit': 'M', 'net_profit': -11.17}]",-0.28,-0.28,241703000,118149000,42925000,272287000,39290000,0,99870000,42925000,-23384000,0.8412353498693913,0.5101830976615193,0.5172413793103448,__nan__,__nan__,__nan__,1.1265354588068828
160,AKIC,Sports Ventures Acquisition Corp. Class A Ordinary Shares,"Sports Ventures Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on businesses operating in the sports, media, and entertainment sectors, including traditional and emerging sports, as well as film and television production and infrastructure. The company was incorporated in 2020 and is based in Bal Harbour, Florida.",Mr. Alan  Kestenbaum,Shell Companies,10.1085,USD,0,https://images.financialmodelingprep.com/symbol/AKIC.png,81373,0,0.0085,166542,4935531,11403001,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.4}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.81}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.28}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.52}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 10.76}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.08}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.52}]",0.39,0.39,230.849726,0.81696,0.440475,13.632732,0,230026577,0.7712910000000001,0.440475,-1221369,0,0,0,__nan__,__nan__,__nan__,0.059054573016907114
161,AKICU,Sports Ventures Acquisition Corp. Unit,"Sports Ventures Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on businesses operating in the sports, media, and entertainment sectors, including traditional and emerging sports, as well as film and television production and infrastructure. The company was incorporated in 2020 and is based in Bal Harbour, Florida.",,Shell Companies,10.1,USD,0,https://images.financialmodelingprep.com/symbol/AKICU.png,448,0,-0.01,295,4935531,11403001,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.4}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.81}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.28}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.52}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 10.76}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.08}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.52}]",0.39,0.39,230.849726,0.81696,0.440475,13.632732,0,230026577,0.7712910000000001,0.440475,-1221369,0,0,0,__nan__,__nan__,__nan__,0.059054573016907114
162,AKICW,Sports Ventures Acquisition Corp. Warrant,"Sports Ventures Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on businesses operating in the sports, media, and entertainment sectors, including traditional and emerging sports, as well as film and television production and infrastructure. The company was incorporated in 2020 and is based in Bal Harbour, Florida.",Mr. Alan  Kestenbaum,Shell Companies,0.0003,USD,0,https://images.financialmodelingprep.com/symbol/AKICW.png,0,0,0,6807,4935531,11403001,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.4}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.81}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 17.28}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.52}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 10.76}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.08}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.52}]",0.39,0.39,230.849726,0.81696,0.440475,13.632732,0,230026577,0.7712910000000001,0.440475,-1221369,0,0,0,__nan__,__nan__,__nan__,0.059054573016907114
163,AKRO,Akero Therapeutics Inc. Common Stock,"Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.","Dr. Andrew  Cheng M.D., Ph.D.",Biotechnology,27.37,USD,1910401367,https://images.financialmodelingprep.com/symbol/AKRO.png,602204,-7.24,-0.27,265688,-148631000,-151759000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -151.76}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -108.91}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -100.74}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -79.19}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -72.7}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -55.99}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -53.34}, {'period': ""Q4 '23"", 'revenue': 0.28400000000000003, 'unit': 'M', 'net_profit': -55.19}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -39.66}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.08}]",-2.89,-2.89,580271000,559962000,550010000,44965000,0,19283000,19128000,234207000,-145367000,-0.3386079939477998,-0.3934349462859242,-0.03584229390681007,__nan__,__nan__,__nan__,0.07748965569535614
164,AKTS,Akoustis Technologies Inc. Common Stock,"Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States. It operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and semiconductor wafer-manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company was incorporated in 2013 and is headquartered in Huntersville, North Carolina.",Mr. Kamran  Cheema,Communication Equipment,0.0372,USD,5750785,https://images.financialmodelingprep.com/symbol/AKTS.png,0,-0.02,,0,-152076000,-167950000,"[{'period': '2024', 'revenue': 27.38, 'unit': 'M', 'net_profit': -167.95}, {'period': '2023', 'revenue': 27.12, 'unit': 'M', 'net_profit': -63.56}, {'period': '2022', 'revenue': 15.35, 'unit': 'M', 'net_profit': -59.19}, {'period': '2021', 'revenue': 6.62, 'unit': 'M', 'net_profit': -46.92}]","[{'period': ""Q1 '25"", 'revenue': 9.03, 'unit': 'M', 'net_profit': -6.42}, {'period': ""Q4 '24"", 'revenue': 5.86, 'unit': 'M', 'net_profit': -108.8}, {'period': ""Q3 '24"", 'revenue': 7.51, 'unit': 'M', 'net_profit': -23.31}, {'period': ""Q2 '24"", 'revenue': 7.02, 'unit': 'M', 'net_profit': -15.71}, {'period': ""Q1 '24"", 'revenue': 7.0, 'unit': 'M', 'net_profit': -20.13}, {'period': ""Q4 '23"", 'revenue': 8.33, 'unit': 'M', 'net_profit': -17.77}]",-1.89,-1.89,69741000,36769000,24447000,126835000,5295000,0,84369000,24447000,-46338000,-1.922739852398524,-1.6425098730273613,-0.8899999999999999,__nan__,__nan__,__nan__,1.8186576045654637
165,AKTX,Akari Therapeutics plc ADR (0.01 USD),"Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barr syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.",Dr. Samir Rashmikant Patel M.D.,Biotechnology,1.3657,USD,15744587,https://images.financialmodelingprep.com/symbol/AKTX.png,56283,-0.5,-0.0343,15086,-16802000,-10008000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.01}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.97}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.61}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.6}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.9}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.56}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.57}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.5}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.5}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.0}]",-2.04,-2.04,4355000,4341000,3845000,4584000,0,0,4584000,3845000,-16432000,0.27213654479293015,-0.4354042280743725,0.08520179372197308,__nan__,__nan__,__nan__,1.0525832376578645
166,AKU,Akumin Inc. Common Shares,"Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures through a network of approximately 200 owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to approximately 1,000 hospitals and health systems across 46 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.",Mr. Riadh  Zine-El-Abidine,Medical - Diagnostics & Research,0.2887,USD,26271266,https://images.financialmodelingprep.com/symbol/AKU.png,3626464,-0.13182648401826483,-0.0628,7893176,139864000,-151587000,"[{'period': '2022', 'revenue': 749.63, 'unit': 'M', 'net_profit': -151.59}, {'period': '2021', 'revenue': 421.08, 'unit': 'M', 'net_profit': -34.81}, {'period': '2020', 'revenue': 251.28, 'unit': 'M', 'net_profit': -17.67}, {'period': '2019', 'revenue': 247.44, 'unit': 'M', 'net_profit': 8.65}]","[{'period': ""Q2 '23"", 'revenue': 184.84, 'unit': 'M', 'net_profit': -96.65}, {'period': ""Q1 '23"", 'revenue': 187.59, 'unit': 'M', 'net_profit': -29.19}, {'period': ""Q4 '22"", 'revenue': 184.63, 'unit': 'M', 'net_profit': -49.33}, {'period': ""Q3 '22"", 'revenue': 186.6, 'unit': 'M', 'net_profit': -49.74}, {'period': ""Q2 '22"", 'revenue': 192.13, 'unit': 'M', 'net_profit': -26.08}, {'period': ""Q1 '22"", 'revenue': 186.26, 'unit': 'M', 'net_profit': -26.43}]",-1.69,-1.69,1765115000,191945000,59424000,1623824000,114166000,0,168518000,59424000,20605000,1.3355041245032229,-3.3541965875797093,-2.7555555555555555,__nan__,__nan__,__nan__,0.9199536574104237
167,AKUS,Akouos Inc. Common Stock,"Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.","Dr. Emmanuel  Simons M.B.A., Ph.D.",Biotechnology,13.29,USD,0,https://images.financialmodelingprep.com/symbol/AKUS.png,725973,-4.692796610169491,0,1790496,-82924000,-86671000,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -86.67}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -48.6}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -25.74}, {'period': '2018', 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.01}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -20.36}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -20.83}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -27.24}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.94}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -22.91}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -22.74}]",-4.94,-4.94,278755000,236163000,232452000,45105000,0,0,16801000,121907000,-72752000,-0.696481178396072,-0.7833539094650206,-0.7833935018050543,__nan__,__nan__,__nan__,0.16180875679360013
168,AKYA,Akoya BioSciences Inc. Common Stock,"Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.",Mr. Brian  McKelligon,Medical - Instruments & Supplies,2.57,USD,127377938,https://images.financialmodelingprep.com/symbol/AKYA.png,225970,-2.22,0.1,32357,-45632000,-63323000,"[{'period': '2023', 'revenue': 96.63, 'unit': 'M', 'net_profit': -63.32}, {'period': '2022', 'revenue': 74.86, 'unit': 'M', 'net_profit': -70.64}, {'period': '2021', 'revenue': 54.92, 'unit': 'M', 'net_profit': -42.94}, {'period': '2020', 'revenue': 42.44, 'unit': 'M', 'net_profit': -16.71}]","[{'period': ""Q3 '24"", 'revenue': 18.81, 'unit': 'M', 'net_profit': -10.53}, {'period': ""Q2 '24"", 'revenue': 23.16, 'unit': 'M', 'net_profit': -13.15}, {'period': ""Q1 '24"", 'revenue': 18.35, 'unit': 'M', 'net_profit': -23.48}, {'period': ""Q4 '23"", 'revenue': 26.49, 'unit': 'M', 'net_profit': -10.8}, {'period': ""Q3 '23"", 'revenue': 25.21, 'unit': 'M', 'net_profit': -12.92}, {'period': ""Q2 '23"", 'revenue': 23.52, 'unit': 'M', 'net_profit': -20.8}]",-1.43,-1.43,180369000,121790000,83125000,126599000,16994000,0,35345000,83125000,-54552000,0.2241435008076171,0.1035942299797568,0.2352941176470589,__nan__,__nan__,__nan__,0.7018889055214588
169,ALAC,Alberton Acquisition Corporation Ordinary Shares,"Alberton Acquisition Corporation does not have significant operations. It focuses on the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more target businesses. The company was formerly known as Wisdom Resources Group Limited and changed its name to Alberton Acquisition Corporation in July 2018. Alberton Acquisition Corporation was founded in 2005 and is based in Wan Chai, Hong Kong.",Ms. Guan  Wang,Shell Companies,12.02,USD,0,https://images.financialmodelingprep.com/symbol/ALAC.png,0,-24.136546184738958,0.01000023,77891,-615039,-502026,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -502.03}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': 14.56}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.09}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': 341.71}]","[{'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -175.36}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -152.59}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -111.08}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -170.16}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -149.84}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",-0.12,-0.12,14870460,1276,1276,9831761,0,0,5399926,1276,-115916,-43.23588792748249,-35.47507210548002,-36.294117647058826,__nan__,__nan__,__nan__,0.661160515545585
170,ALACR,Alberton Acquisition Corporation Rights exp April 26 2021,,None,,0.035,USD,0,https://images.financialmodelingprep.com/symbol/ALACR.png,0,0,-0.035,5158411,-615039,-502026,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -502.03}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': 14.56}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.09}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': 341.71}]","[{'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -175.36}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -152.59}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -111.08}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -170.16}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -149.84}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",-0.12,-0.12,14870460,1276,1276,9831761,0,0,5399926,1276,-115916,-43.23588792748249,-35.47507210548002,-36.294117647058826,"[0.285, 0.285]","['2022-03-15', '2022-03-15']",__nan__,0.661160515545585
171,ALACU,Alberton Acquisition Corporation Unit,"Alberton Acquisition Corporation does not have significant operations. It focuses on the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more target businesses. The company was formerly known as Wisdom Resources Group Limited and changed its name to Alberton Acquisition Corporation in July 2018. Alberton Acquisition Corporation was founded in 2005 and is based in Wan Chai, Hong Kong.",Ms. Guan Wang,Shell Companies,11.8,USD,0,https://images.financialmodelingprep.com/symbol/ALACU.png,0,-23.694779116465863,0,0,-615039,-502026,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -502.03}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': 14.56}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.09}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': 341.71}]","[{'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -175.36}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -152.59}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -111.08}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -170.16}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -149.84}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",-0.12,-0.12,14870460,1276,1276,9831761,0,0,5399926,1276,-115916,-43.23588792748249,-35.47507210548002,-36.294117647058826,__nan__,__nan__,__nan__,0.661160515545585
172,ALACW,Alberton Acquisition Corporation Warrant,"Alberton Acquisition Corporation does not have significant operations. It focuses on the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more target businesses. The company was formerly known as Wisdom Resources Group Limited and changed its name to Alberton Acquisition Corporation in July 2018. Alberton Acquisition Corporation was founded in 2005 and is based in Wan Chai, Hong Kong.",Ms. Guan Wang,Shell Companies,0.01,USD,0,https://images.financialmodelingprep.com/symbol/ALACW.png,0,-0.020080321285140562,-0.0125,3069456,-615039,-502026,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -502.03}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': 14.56}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.09}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': 341.71}]","[{'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -175.36}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -152.59}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -111.08}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -170.16}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -149.84}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",-0.12,-0.12,14870460,1276,1276,9831761,0,0,5399926,1276,-115916,-43.23588792748249,-35.47507210548002,-36.294117647058826,__nan__,__nan__,__nan__,0.661160515545585
173,ALBO,Albireo Pharma Inc. Common Stock,"Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.",Mr. Ronald H. W. Cooper,Biotechnology,44.15,USD,915887335,https://images.financialmodelingprep.com/symbol/ALBO.png,566901,-6.629129129129129,0,1236106,-122129000,-151349000,"[{'period': '2021', 'revenue': 40.58, 'unit': 'M', 'net_profit': -151.35}, {'period': '2020', 'revenue': 8.31, 'unit': 'M', 'net_profit': -119.0}, {'period': '2019', 'revenue': 9.64, 'unit': 'M', 'net_profit': -71.7}, {'period': '2018', 'revenue': 12.74, 'unit': 'M', 'net_profit': -46.11}]","[{'period': ""Q3 '22"", 'revenue': 9.83, 'unit': 'M', 'net_profit': -38.41}, {'period': ""Q2 '22"", 'revenue': 8.21, 'unit': 'M', 'net_profit': -42.7}, {'period': ""Q1 '22"", 'revenue': 6.83, 'unit': 'M', 'net_profit': -45.31}, {'period': ""Q4 '21"", 'revenue': 32.52, 'unit': 'M', 'net_profit': -10.96}, {'period': ""Q3 '21"", 'revenue': 3.66, 'unit': 'M', 'net_profit': 57.09}, {'period': ""Q2 '21"", 'revenue': 2.43, 'unit': 'M', 'net_profit': -36.42}]",-7.87,-7.87,302051000,268930000,248107000,126443000,3272000,0,45347000,248107000,-108024000,0,-0.2718937770494559,-0.05637583892617449,__nan__,__nan__,__nan__,0.41861473724635906
174,ALCO,Alico Inc. Common Stock,"Alico, Inc., together with its subsidiaries, operates as an agribusiness and land management company in the United States. The company operates in two segments, Alico Citrus, and Land Management and Other Operations. The Alico Citrus segment cultivates citrus trees to produce citrus for delivery to the processed and fresh citrus markets. The Land Management and Other Operations segment owns and manages land in Collier, Glades, and Hendry Counties; and leasing of land for recreational and grazing purposes, conservation, and mining activities. As of September 30, 2021, it had 83,000 acres of land situated in eight counties in Florida, which include the Charlotte, Collier, DeSoto, Glades, Hardee, Hendry, Highlands, and Polk. The company was founded in 1960 and is headquartered in Fort Myers, Florida.",Mr. John E. Kiernan Esq.,Agricultural Farm Products,31.33,USD,239144083,https://images.financialmodelingprep.com/symbol/ALCO.png,48148,34.43,-0.06,51479,29500000,6973000,"[{'period': '2024', 'revenue': 46.64, 'unit': 'M', 'net_profit': 6.97}, {'period': '2023', 'revenue': 39.85, 'unit': 'M', 'net_profit': 1.83}, {'period': '2022', 'revenue': 91.95, 'unit': 'M', 'net_profit': 12.46}, {'period': '2021', 'revenue': 108.56, 'unit': 'M', 'net_profit': 34.86}]","[{'period': ""Q4 '24"", 'revenue': 0.935, 'unit': 'M', 'net_profit': -18.12}, {'period': ""Q3 '24"", 'revenue': 13.61, 'unit': 'M', 'net_profit': -2.04}, {'period': ""Q2 '24"", 'revenue': 18.11, 'unit': 'M', 'net_profit': -15.8}, {'period': ""Q1 '24"", 'revenue': 13.98, 'unit': 'M', 'net_profit': 42.95}, {'period': ""Q4 '23"", 'revenue': 680.0, 'unit': 'K', 'net_profit': 940.0}, {'period': ""Q3 '23"", 'revenue': 7.28, 'unit': 'M', 'net_profit': 11.83}]",0.91,0.91,398719000,40627000,3150000,142424000,771000,0,10651000,3150000,-48368000,0.29063306645666537,2.8,2.791666666666667,"[0.05, 1.2]","['2024-12-27', '1982-10-29']",__nan__,0.35720394563589897
175,ALDX,Aldeyra Therapeutics Inc. Common Stock,"Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.","Dr. Todd C. Brady M.D., Ph.D.",Biotechnology,5.165,USD,307573684,https://images.financialmodelingprep.com/symbol/ALDX.png,466708,-6.88,-0.11,152746,-35208295,-37542510,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -37.54}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -61.37}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -59.25}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -37.55}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.11}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.85}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.08}, {'period': ""Q4 '23"", 'revenue': 0.39262, 'unit': 'M', 'net_profit': -4.75}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.19}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.99}]",-0.64,-0.64,148326911,147810333,142823016,28531881,0,0,22260250,142823016,-30326128,0.41389675636822193,0.38825244582856067,0.3904761904761905,__nan__,__nan__,__nan__,0.19235808800737447
176,ALEC,Alector Inc. Common Stock,"Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.",Dr. Arnon  Rosenthal Ph.D.,Biotechnology,2.035,USD,199292841,https://images.financialmodelingprep.com/symbol/ALEC.png,1279062,-1.19,0.015,393255,-142892000,-130391000,"[{'period': '2023', 'revenue': 97.06, 'unit': 'M', 'net_profit': -130.39}, {'period': '2022', 'revenue': 133.62, 'unit': 'M', 'net_profit': -133.31}, {'period': '2021', 'revenue': 207.09, 'unit': 'M', 'net_profit': -28.01}, {'period': '2020', 'revenue': 21.1, 'unit': 'M', 'net_profit': -182.96}]","[{'period': ""Q3 '24"", 'revenue': 15.34, 'unit': 'M', 'net_profit': -42.22}, {'period': ""Q2 '24"", 'revenue': 15.08, 'unit': 'M', 'net_profit': -38.68}, {'period': ""Q1 '24"", 'revenue': 15.89, 'unit': 'M', 'net_profit': -36.08}, {'period': ""Q4 '23"", 'revenue': 15.19, 'unit': 'M', 'net_profit': -41.43}, {'period': ""Q3 '23"", 'revenue': 9.11, 'unit': 'M', 'net_profit': -44.48}, {'period': ""Q2 '23"", 'revenue': 56.21, 'unit': 'M', 'net_profit': 1.38}]",-1.56,-1.56,621827000,565807000,548861000,487669000,0,0,177948000,74555000,-186543000,-0.10459021969357307,0.021896331858075165,0.03703703703703707,__nan__,__nan__,__nan__,0.7842518899951273
177,ALF,ALFI Inc. Common Stock,"Alfi, Inc. provides Software as a Service (SaaS) solution for the digital out of home (DOOH) smart advertising segment in the United States. It offers Alfi, an artificial intelligence (AI) SaaS platform that transforms DOOH advertising into real-time audience-based marketing, as well as uses AI and computer vision to detect audience demographics, such as age and gender to serve relevant advertising. The company intends to market Alfi to advertisers, and other DOOH and out of home media operators as the first facial detection-based ad technology offering verified impressions and audience measurement based on eyes on screens. The company was formerly known as Lectrefy, Inc. and changed its name to Alfi, Inc. in January 2020. Alfi, Inc. was founded in 2018 and is based in Miami Beach, Florida. On October 14, 2022, Alfi, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.",Dr. Paul Antonio Pereira,Software - Infrastructure,10.1,USD,362968760,https://images.financialmodelingprep.com/symbol/ALF.png,37230,-6.82,-0.01,2059,-428391000000,0,"[{'period': '2021', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.56}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': 66.73}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.05}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 612.18}, {'period': ""Q2 '22"", 'revenue': 0.12930000000000003, 'unit': 'M', 'net_profit': -11.1}, {'period': ""Q1 '22"", 'revenue': 0.0633, 'unit': 'T', 'net_profit': -5.29}, {'period': ""Q4 '21"", 'revenue': -0.01839, 'unit': 'M', 'net_profit': 7.87}, {'period': ""Q3 '21"", 'revenue': 0.000112, 'unit': 'M', 'net_profit': -5.08}]",0,0,11373005,5323564,4391816,2362757,5578,0,2362757,4391816,-20566553,-143436.64031418995,1,1,"[0.015, 0.015]","['2019-12-19', '2019-12-19']",__nan__,0.20775133748732194
178,ALFIW,ALFI Inc. Warrant,"Alfi, Inc. provides interactive intelligent artificial intelligence and machine learning software solutions. Alfi, Inc. was formerly known as Lectrefy, Inc. and changed its name to Alfi, Inc. in January 2020. The company was founded in 2018 and is based in Miami Beach, Florida.",Dr. Paul Antonio Pereira,Software - Infrastructure,0.22,USD,0,https://images.financialmodelingprep.com/symbol/ALFIW.png,0,0,0.11,500,-428391000000,0,"[{'period': '2021', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.56}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': 66.73}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.05}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 612.18}, {'period': ""Q2 '22"", 'revenue': 0.12930000000000003, 'unit': 'M', 'net_profit': -11.1}, {'period': ""Q1 '22"", 'revenue': 0.0633, 'unit': 'T', 'net_profit': -5.29}, {'period': ""Q4 '21"", 'revenue': -0.01839, 'unit': 'M', 'net_profit': 7.87}, {'period': ""Q3 '21"", 'revenue': 0.000112, 'unit': 'M', 'net_profit': -5.08}]",0,0,11373005,5323564,4391816,2362757,5578,0,2362757,4391816,-20566553,-143436.64031418995,1,1,__nan__,__nan__,__nan__,0.20775133748732194
179,ALGM,Allegro MicroSystems Inc. Common Stock,"Allegro MicroSystems, Inc. designs, develops, manufactures, and markets sensor integrated circuits (ICs) and application-specific analog power ICs for motion control and energy-efficient systems. Its products include magnetic sensor ICs, such as position, speed, and current sensor ICs; power ICs comprising motor driver ICs, and regulator and LED driver ICs; and photonic and 3D sensing components, including photodiodes, eye-safe lasers, and readout ICs for LiDAR applications. The company sells its products to original equipment manufacturers and suppliers primarily in the automotive and industrial markets through its direct sales force, third party distributors, independent sales representatives, and consignment. It operates in the United States, rest of the Americas, Europe, Japan, Greater China, South Korea, and other Asian markets. The company was founded in 1990 and is headquartered in Manchester, New Hampshire. Allegro MicroSystems, Inc. is a subsidiary of Sanken Electric Co., Ltd.",Mr. Vineet A. Nargolwala,Semiconductors,25.18,USD,4632717120,https://images.financialmodelingprep.com/symbol/ALGM.png,1955975,-167.87,0.42,1116439,276942000,152697000,"[{'period': '2024', 'revenue': 1050.0, 'unit': 'M', 'net_profit': 152.7}, {'period': '2023', 'revenue': 973.65, 'unit': 'M', 'net_profit': 187.36}, {'period': '2022', 'revenue': 768.67, 'unit': 'M', 'net_profit': 119.41}, {'period': '2021', 'revenue': 591.21, 'unit': 'M', 'net_profit': 17.95}]","[{'period': ""Q2 '25"", 'revenue': 187.39, 'unit': 'M', 'net_profit': -33.67}, {'period': ""Q1 '25"", 'revenue': 166.92, 'unit': 'M', 'net_profit': -17.68}, {'period': ""Q4 '24"", 'revenue': 240.58, 'unit': 'M', 'net_profit': -7.12}, {'period': ""Q3 '24"", 'revenue': 254.98, 'unit': 'M', 'net_profit': 33.34}, {'period': ""Q2 '24"", 'revenue': 275.51, 'unit': 'M', 'net_profit': 65.62}, {'period': ""Q1 '24"", 'revenue': 278.29, 'unit': 'M', 'net_profit': 60.85}]",0.79,0.78,1530603000,572213000,212143000,398887000,125168000,26727000,117908000,212143000,56943000,0.04707928466104579,-0.18499442241282685,-0.1938775510204081,__nan__,__nan__,__nan__,0.2606077474041277
180,ALGN,Align Technology Inc. Common Stock,"Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.",Mr. Joseph M. Hogan,Medical - Devices,219.97,USD,16421442407,https://images.financialmodelingprep.com/symbol/ALGN.png,803820,37.47,1.09,244231,799039000,445053000,"[{'period': '2023', 'revenue': 3860.0, 'unit': 'M', 'net_profit': 445.05}, {'period': '2022', 'revenue': 3730.0, 'unit': 'M', 'net_profit': 361.57}, {'period': '2021', 'revenue': 3950.0, 'unit': 'M', 'net_profit': 772.02}, {'period': '2020', 'revenue': 2.47, 'unit': 'B', 'net_profit': 1.78}]","[{'period': ""Q3 '24"", 'revenue': 977.87, 'unit': 'M', 'net_profit': 115.96}, {'period': ""Q2 '24"", 'revenue': 1030.0, 'unit': 'M', 'net_profit': 96.56}, {'period': ""Q1 '24"", 'revenue': 997.43, 'unit': 'M', 'net_profit': 105.03}, {'period': ""Q4 '23"", 'revenue': 956.73, 'unit': 'M', 'net_profit': 124.01}, {'period': ""Q3 '23"", 'revenue': 960.21, 'unit': 'M', 'net_profit': 121.43}, {'period': ""Q2 '23"", 'revenue': 1000.0, 'unit': 'M', 'net_profit': 111.81}]",5.82,5.81,6083877000,2446618000,972742000,2453388000,903424000,8022000,2066610999,937438000,608060000,0.05780160105483752,0.23088007124425772,0.25974025974025977,__nan__,__nan__,__nan__,0.40326061818804027
181,ALGS,Aligos Therapeutics Inc. Common Stock,"Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR- agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.","Dr. Lawrence M. Blatt MBA, Ph.D.",Biotechnology,42.88,USD,148544896,https://images.financialmodelingprep.com/symbol/ALGS.png,417183,-5.91,-2.74,263484,-85058000,-87679000,"[{'period': '2023', 'revenue': 15.53, 'unit': 'M', 'net_profit': -87.68}, {'period': '2022', 'revenue': 13.91, 'unit': 'M', 'net_profit': -96.05}, {'period': '2021', 'revenue': 4.36, 'unit': 'M', 'net_profit': -128.33}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -108.54}]","[{'period': ""Q3 '24"", 'revenue': 1.27, 'unit': 'M', 'net_profit': -19.26}, {'period': ""Q2 '24"", 'revenue': 1.06, 'unit': 'M', 'net_profit': 5.06}, {'period': ""Q1 '24"", 'revenue': 0.986, 'unit': 'M', 'net_profit': -34.86}, {'period': ""Q4 '23"", 'revenue': 2.68, 'unit': 'M', 'net_profit': -27.89}, {'period': ""Q3 '23"", 'revenue': 3.24, 'unit': 'M', 'net_profit': -18.04}, {'period': ""Q2 '23"", 'revenue': 6.89, 'unit': 'M', 'net_profit': -18.79}]",-3.52,-3.52,151527000,141084000,135704000,59447000,0,0,23906000,135704000,-79016000,0.09421223577019328,0.08711450763175978,-0.5644444444444444,__nan__,__nan__,__nan__,0.392319520613488
182,ALGT,Allegiant Travel Company Common Stock,"Allegiant Travel Company, a leisure travel company, provides travel services and products to residents of under-served cities in the United States. The company offers scheduled air transportation on limited-frequency, nonstop flights between under-served cities and leisure destinations. As of February 14, 2022, it operated a fleet of 110 Airbus A320 series aircraft. The company also provides air-related services and products in conjunction with air transportation, including baggage fees, advance seat assignments, travel protection products, priority boarding, a customer convenience fee, food and beverage purchases on board, and other air-related services, as well as use of its call center for purchases. In addition, it offers third party travel products, such as hotel rooms and ground transportation, such as rental cars and hotel shuttle products; and air transportation services through fixed fee agreements and charter service on a year-round and ad-hoc basis. Further, the company operates a golf course. Allegiant Travel Company was founded in 1997 and is based in Las Vegas, Nevada.",Mr. Gregory Clark Anderson CPA,"Airlines, Airports & Air Services",98.69,USD,1810359491,https://images.financialmodelingprep.com/symbol/ALGT.png,384217,-64.93,0.57,82371,490235000,117596000,"[{'period': '2023', 'revenue': 2510.0, 'unit': 'M', 'net_profit': 117.6}, {'period': '2022', 'revenue': 2300.0, 'unit': 'M', 'net_profit': 2.49}, {'period': '2021', 'revenue': 1710.0, 'unit': 'M', 'net_profit': 151.85}, {'period': '2020', 'revenue': 990.07, 'unit': 'M', 'net_profit': -184.09}]","[{'period': ""Q3 '24"", 'revenue': 562.2, 'unit': 'M', 'net_profit': -36.79}, {'period': ""Q2 '24"", 'revenue': 666.28, 'unit': 'M', 'net_profit': 13.7}, {'period': ""Q1 '24"", 'revenue': 656.41, 'unit': 'M', 'net_profit': -1.27}, {'period': ""Q4 '23"", 'revenue': 611.0, 'unit': 'M', 'net_profit': -2.3}, {'period': ""Q3 '23"", 'revenue': 565.36, 'unit': 'M', 'net_profit': -25.07}, {'period': ""Q2 '23"", 'revenue': 683.81, 'unit': 'M', 'net_profit': 88.47}]",6.32,6.29,4869410000,1001130000,814673000,3540850000,70743000,56004000,1212307000,143259000,-447395000,0.6043506149244353,46.17047733654232,44.142857142857146,"[0.6, 0.75]","['2024-05-14', '2010-05-12']",__nan__,0.7271620175750245
183,ALHC,Alignment Healthcare Inc. Common Stock,"Alignment Healthcare, Inc., a tech-enabled Medicare advantage company, operates consumer-centric health care platform. It provides customized health care in the United States to seniors and those who need it through its Medicare advantage plans. The company owns Medicare advantage plans in the states of California, North Carolina, and Nevada. It also coordinates and provides covered health care services, including professional, institutional, and ancillary services to members enrolled in certain benefit plans of unaffiliated Medicare Advantage Health Maintenance Organizations. The company was founded in 2013 and is based in Orange, California.",Mr. John E. Kao,Medical - Healthcare Plans,11.63,USD,2229424480,https://images.financialmodelingprep.com/symbol/ALHC.png,1740396,-15.3,0.31,373947,-105296000,-148017000,"[{'period': '2023', 'revenue': 1820.0, 'unit': 'M', 'net_profit': -148.02}, {'period': '2022', 'revenue': 1430.0, 'unit': 'M', 'net_profit': -149.64}, {'period': '2021', 'revenue': 1170.0, 'unit': 'M', 'net_profit': -212.96}, {'period': '2020', 'revenue': 959.22, 'unit': 'M', 'net_profit': -39.12}]","[{'period': ""Q3 '24"", 'revenue': 692.43, 'unit': 'M', 'net_profit': -26.41}, {'period': ""Q2 '24"", 'revenue': 681.29, 'unit': 'M', 'net_profit': -24.01}, {'period': ""Q1 '24"", 'revenue': 628.6, 'unit': 'M', 'net_profit': -46.52}, {'period': ""Q4 '23"", 'revenue': 465.39, 'unit': 'M', 'net_profit': -47.21}, {'period': ""Q3 '23"", 'revenue': 456.71, 'unit': 'M', 'net_profit': -35.05}, {'period': ""Q2 '23"", 'revenue': 462.38, 'unit': 'M', 'net_profit': -28.48}]",-0.79,-0.79,591880000,483537000,318818000,433809000,119749000,0,263022000,202904000,-95182000,0.07248623651178154,0.0108394202046258,0.04819277108433726,__nan__,__nan__,__nan__,0.7329340406839224
184,ALIM,Alimera Sciences Inc. Common Stock,"Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.",Mr. Richard S. Eiswirth Jr.,Drug Manufacturers - Specialty & Generic,5.54,USD,301288468,https://images.financialmodelingprep.com/symbol/ALIM.png,866825,5.276190476190476,-0.01,2677974,7276000,-20132000,"[{'period': '2023', 'revenue': 80.75, 'unit': 'M', 'net_profit': -20.13}, {'period': '2022', 'revenue': 54.13, 'unit': 'M', 'net_profit': -18.11}, {'period': '2021', 'revenue': 59.03, 'unit': 'M', 'net_profit': -4.37}, {'period': '2020', 'revenue': 50.82, 'unit': 'M', 'net_profit': -5.34}]","[{'period': ""Q2 '24"", 'revenue': 27.0, 'unit': 'M', 'net_profit': -3.31}, {'period': ""Q1 '24"", 'revenue': 23.01, 'unit': 'M', 'net_profit': -6.25}, {'period': ""Q4 '23"", 'revenue': 26.31, 'unit': 'M', 'net_profit': -3.78}, {'period': ""Q3 '23"", 'revenue': 23.36, 'unit': 'M', 'net_profit': -1.35}, {'period': ""Q2 '23"", 'revenue': 17.54, 'unit': 'M', 'net_profit': -10.03}, {'period': ""Q1 '23"", 'revenue': 13.55, 'unit': 'M', 'net_profit': -8.3}]",-0.79,-0.79,153524000,52423000,12090000,107354000,34545000,0,21913000,12090000,-89793000,1.8144168345645848,-0.11183520185563595,0.6949806949806949,__nan__,__nan__,__nan__,0.699265261457492
185,ALJJ,ALJ Regional Holdings Inc. Common Stock,"ALJ Regional Holdings, Inc. provides call center, back-office, staffing, and toll collection services to government and commercial clients in the healthcare, utility, toll, transportation, and toll revenue collection industries in the United States. It operates through two segments, Faneuil and Phoenix. The Faneuil segment offers customer contact centers, fulfillment operations, and information technology services, as well as manual and electronic toll collection, violation processing, and medical device tracking services. This segment also provides customer relationship management; billing, payment, and claims processing; data entry; document management; operational expertise; workforce and support analytics; quality assurance; staffing; and system support and maintenance services. The Phoenix segment manufactures book components; educational materials and related products; heavily illustrated books; and specialty commercial products. This segment also provides label, printing, and packaging solutions. The company was formerly known as YouthStream Media Networks, Inc. and changed its name to ALJ Regional Holdings, Inc. in October 2006. ALJ Regional Holdings, Inc. was incorporated in 1999 and is based in New York, New York.",Mr. Jess Marshall Ravich J.D.,Specialty Business Services,1.92,USD,0,https://images.financialmodelingprep.com/symbol/ALJJ.png,28910,1.0607734806629834,0,184093,8920000,-3580000,"[{'period': '2021', 'revenue': 440.85, 'unit': 'M', 'net_profit': -3.58}, {'period': '2020', 'revenue': 389.15, 'unit': 'M', 'net_profit': -67.67}, {'period': '2019', 'revenue': 355.0, 'unit': 'M', 'net_profit': -15.98}, {'period': '2018', 'revenue': 369.78, 'unit': 'M', 'net_profit': -7.33}]","[{'period': ""Q3 '22"", 'revenue': 57.62, 'unit': 'M', 'net_profit': 105.87}, {'period': ""Q2 '22"", 'revenue': 68.51, 'unit': 'M', 'net_profit': -8.48}, {'period': ""Q1 '22"", 'revenue': 103.08, 'unit': 'M', 'net_profit': -9.39}, {'period': ""Q4 '21"", 'revenue': 111.67, 'unit': 'M', 'net_profit': 1.06}, {'period': ""Q3 '21"", 'revenue': 103.46, 'unit': 'M', 'net_profit': -3.5}, {'period': ""Q2 '21"", 'revenue': 114590.0, 'unit': 'K', 'net_profit': -115.0}]",-0.0846,-0.0846,214653000,89396000,2276000,202077000,68572000,0,58928000,2276000,3574000,20.349240780911064,0.9470993291367438,0.947125,__nan__,__nan__,__nan__,0.9414124191136393
186,ALKS,Alkermes plc Ordinary Shares,"Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.",Mr. Richard F. Pops,Biotechnology,28.3,USD,4579024900,https://images.financialmodelingprep.com/symbol/ALKS.png,1673374,12.36,-0.17,160609,519478000,355757000,"[{'period': '2023', 'revenue': 1660.0, 'unit': 'M', 'net_profit': 355.76}, {'period': '2022', 'revenue': 1110.0, 'unit': 'M', 'net_profit': -158.27}, {'period': '2021', 'revenue': 1170.0, 'unit': 'M', 'net_profit': -48.17}, {'period': '2020', 'revenue': 1040.0, 'unit': 'M', 'net_profit': -110.86}]","[{'period': ""Q3 '24"", 'revenue': 378.14, 'unit': 'M', 'net_profit': 92.38}, {'period': ""Q2 '24"", 'revenue': 399.13, 'unit': 'M', 'net_profit': 91.36}, {'period': ""Q1 '24"", 'revenue': 350.37, 'unit': 'M', 'net_profit': 36.83}, {'period': ""Q4 '23"", 'revenue': 377.48, 'unit': 'M', 'net_profit': 112.78}, {'period': ""Q3 '23"", 'revenue': 380.94, 'unit': 'M', 'net_profit': 47.76}, {'period': ""Q2 '23"", 'revenue': 617.4, 'unit': 'M', 'net_profit': 237.06}]",2.14,2.1,2136223000,1485506000,773491000,933537000,333183000,39887000,520220000,457469000,353305000,7.690701642854753,3.247828037430418,3.20618556701031,__nan__,__nan__,__nan__,0.43700353380709783
187,ALKT,Alkami Technology Inc. Common Stock,"Alkami Technology, Inc. offers a cloud-based digital banking platform in the United States. The company's platform allows financial institutions to onboard and engage new users, accelerate revenues, and enhance operational efficiency, with the support of a proprietary, cloud-based, multi-tenant architecture. It offers an end- to- end set of software products, which include Alkami Platform, Retail Banking Solutions, Business Banking Solutions, and The Alkami Difference. It serves community, regional, credit unions, and retail and business banking. Alkami Technology, Inc. was founded in 2009 and is headquartered in Plano, Texas.",Mr. Alex P. Shootman,Software - Application,35.08,USD,3525434760,https://images.financialmodelingprep.com/symbol/ALKT.png,855759,-77.96,-0.82,162670,-44854000,-62913000,"[{'period': '2023', 'revenue': 264.83, 'unit': 'M', 'net_profit': -62.91}, {'period': '2022', 'revenue': 204.27, 'unit': 'M', 'net_profit': -58.6}, {'period': '2021', 'revenue': 152.16, 'unit': 'M', 'net_profit': -46.82}, {'period': '2020', 'revenue': 112.14, 'unit': 'M', 'net_profit': -51.84}]","[{'period': ""Q3 '24"", 'revenue': 85.91, 'unit': 'M', 'net_profit': -9.44}, {'period': ""Q2 '24"", 'revenue': 82.16, 'unit': 'M', 'net_profit': -12.32}, {'period': ""Q1 '24"", 'revenue': 76.13, 'unit': 'M', 'net_profit': -11.43}, {'period': ""Q4 '23"", 'revenue': 71.37, 'unit': 'M', 'net_profit': -12.71}, {'period': ""Q3 '23"", 'revenue': 67.7, 'unit': 'M', 'net_profit': -15.48}, {'period': ""Q2 '23"", 'revenue': 65.76, 'unit': 'M', 'net_profit': -17.76}]",-0.67,-0.67,399825000,148585000,92123000,74884000,35499000,0,39430000,40927000,-23794000,0.04804957765609746,-0.07360068259385666,-0.04687500000000004,__nan__,__nan__,__nan__,0.18729194022384793
188,ALLK,Allakos Inc. Common Stock,"Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.",Dr. Robert  Alexander Ph.D.,Biotechnology,0.9976,USD,89129175,https://images.financialmodelingprep.com/symbol/ALLK.png,696190,-0.49,-0.0724,181843,-189915000,-185701000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -185.7}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -317.48}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -267.17}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -147.62}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.37}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.68}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -71.15}, {'period': ""Q4 '23"", 'revenue': 10.76, 'unit': 'M', 'net_profit': -62.55}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -45.63}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.12}]",-2.14,-2.14,243610000,179889000,170794000,74793000,0,0,36578000,66440000,-117072000,0.3977796662840328,0.41506890306323335,0.5737051792828685,__nan__,__nan__,__nan__,0.30701941628011986
189,ALLO,Allogene Therapeutics Inc. Common Stock,"Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.","Dr. David D. Chang M.D., Ph.D.",Biotechnology,2.265,USD,474907080,https://images.financialmodelingprep.com/symbol/ALLO.png,2438798,-1.46,0.105,970390,-300293000,-327265000,"[{'period': '2023', 'revenue': 0.095, 'unit': 'M', 'net_profit': -327.26}, {'period': '2022', 'revenue': 0.243, 'unit': 'M', 'net_profit': -329.81}, {'period': '2021', 'revenue': 38.49, 'unit': 'M', 'net_profit': -244.84}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -233.47}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -66.29}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -66.36}, {'period': ""Q1 '24"", 'revenue': 0.022, 'unit': 'M', 'net_profit': -65.0}, {'period': ""Q4 '23"", 'revenue': 0.021, 'unit': 'M', 'net_profit': -85.78}, {'period': ""Q3 '23"", 'revenue': 0.043000000000000003, 'unit': 'M', 'net_profit': -61.31}, {'period': ""Q2 '23"", 'revenue': 0.044, 'unit': 'M', 'net_profit': -77.99}]",-2.09,-2.09,642837000,459115000,448697000,130604000,0,3645000,37079000,83155000,-239249000,0.06520960898515445,0.007731607113078544,0.09130434782608694,__nan__,__nan__,__nan__,0.20316814371294745
190,ALLT,Allot Ltd. Ordinary Shares,"Allot Ltd. provides network intelligence and security solutions to protect and personalize the digital experience in Europe, Asia, Oceania, the Middle East, Africa, and the Americas. The company offers Allot Secure Management platform that includes Allot NetworkSecure, Allot HomeSecure, Allot DNSecure, EndPoint Secure, Allot BusinessSecure, Allot IoTSecure, and Allot Secure Cloud. It also provides Allot DDoS Secure/5G Protect, a solution that offers attack detection and mitigation services; integrated network intelligence solutions; and centralized management solutions, such as Allot NetXplorer for providing a central access point for network-wide monitoring, reporting, analytics, troubleshooting, accounting, and quality of service policy provisioning. The company markets its products through direct sales, distributors, resellers, original equipment manufacturers, and system integrators to carriers, mobile and fixed service providers, cable operators, satellite service providers, private networks, data centers, financial and educational institutions, and governments. Allot Ltd. was formerly known as Allot Communications Ltd. and changed its name to Allot Ltd. in October 2018. The company was incorporated in 1996 and is based in Hod Hasharon, Israel.",Mr. Eyal David Harari,Software - Infrastructure,6.7088,USD,257898348,https://images.financialmodelingprep.com/symbol/ALLT.png,428650,-10.32,-0.1912,577982,-55130000,-62804000,"[{'period': '2023', 'revenue': 93.15, 'unit': 'M', 'net_profit': -62.8}, {'period': '2022', 'revenue': 122.74, 'unit': 'M', 'net_profit': -32.03}, {'period': '2021', 'revenue': 145.6, 'unit': 'M', 'net_profit': -15.04}, {'period': '2020', 'revenue': 135.92, 'unit': 'M', 'net_profit': -9.35}]","[{'period': ""Q3 '24"", 'revenue': 23230.0, 'unit': 'K', 'net_profit': -244.0}, {'period': ""Q2 '24"", 'revenue': 22.16, 'unit': 'M', 'net_profit': -3.36}, {'period': ""Q1 '24"", 'revenue': 21.89, 'unit': 'M', 'net_profit': -2.51}, {'period': ""Q4 '23"", 'revenue': 24.34, 'unit': 'M', 'net_profit': -18.35}, {'period': ""Q3 '23"", 'revenue': 22.64, 'unit': 'M', 'net_profit': -12.36}, {'period': ""Q2 '23"", 'revenue': 25.05, 'unit': 'M', 'net_profit': -20.73}]",-1.66,-1.66,138163000,89912000,53045000,88400000,16580000,158000,39408000,14192000,-32225000,-1.4238294130578149,-0.9607867624102404,-0.9080459770114941,__nan__,__nan__,__nan__,0.6398239760283144
191,ALNA,Allena Pharmaceuticals Inc. Common Stock,"Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.",Dr. Louis Brenner,Biotechnology,0.075,USD,0,https://images.financialmodelingprep.com/symbol/ALNA.png,0,-0.11755485893416928,0.0023000017,252311606,-31972000,-33355000,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -33.35}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -32.84}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -47.34}, {'period': '2018', 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.65}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.55}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.06}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.68}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.69}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.97}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.64}]",-1.03,-1.03,34757000,33006000,29988000,15889000,0,0,15679000,29988000,-46345000,0.021634688943970134,-0.015527477546049627,-0.01980198019801982,__nan__,__nan__,__nan__,0.45714532324423857
192,ALNY,Alnylam Pharmaceuticals Inc. Common Stock,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","Dr. Yvonne L. Greenstreet M.B.A., MBChB",Biotechnology,236.41,USD,30492398210,https://images.financialmodelingprep.com/symbol/ALNY.png,765033,-90.58,3.26,163191,-258242000,-440242000,"[{'period': '2023', 'revenue': 1830.0, 'unit': 'M', 'net_profit': -440.24}, {'period': '2022', 'revenue': 1.04, 'unit': 'B', 'net_profit': -1.13}, {'period': '2021', 'revenue': 844.29, 'unit': 'M', 'net_profit': -852.82}, {'period': '2020', 'revenue': 492.85, 'unit': 'M', 'net_profit': -858.28}]","[{'period': ""Q3 '24"", 'revenue': 500.92, 'unit': 'M', 'net_profit': -111.57}, {'period': ""Q2 '24"", 'revenue': 659.83, 'unit': 'M', 'net_profit': -16.89}, {'period': ""Q1 '24"", 'revenue': 494.33, 'unit': 'M', 'net_profit': -65.94}, {'period': ""Q4 '23"", 'revenue': 439.72, 'unit': 'M', 'net_profit': -137.87}, {'period': ""Q3 '23"", 'revenue': 750.53, 'unit': 'M', 'net_profit': 147.75}, {'period': ""Q2 '23"", 'revenue': 318.75, 'unit': 'M', 'net_profit': -276.02}]",-3.52,-3.52,3829880000,2982697000,2439382000,4050524000,327787000,0,967786000,812688000,41945000,0.7212885985427772,0.6108034612378841,0.6215053763440861,__nan__,__nan__,__nan__,1.0576112045286015
193,ALOT,AstroNova Inc. Common Stock,"AstroNova, Inc. designs, develops, manufactures, and distributes specialty printers, and data acquisition and analysis systems in the United States, Europe, Asia, Canada, Central and South America, and internationally. The company operates in two segments, Product Identification (PI) and Test & Measurement (T&M). The PI segment offers tabletop and production-ready digital color label printers, and OEM printing systems under the QuickLabel brand; digital color label mini-presses and inline printing systems under the TrojanLabel brand; and label materials, tags, inks, toners, and thermal transfer ribbons under the GetLabels brand. This segment also develops and licenses various specialized software programs to design and manage labels and print images; and provides training and support. This segment serves chemicals, cosmetics, food and beverage, medical products, pharmaceuticals, and other industries; and brand owners, label converters, commercial printers, and packaging manufacturers. The T&M segment offers airborne printing solutions, such as ToughWriter used to print hard copies of navigation maps, arrival and departure procedures, flight itineraries, weather maps, performance data, passenger data, and various air traffic control data; ToughSwitch, an ethernet switches used to connect multiple computers or Ethernet devices; TMX data acquisition systems; Daxus DXS-100 distributed data acquisition platform; SmartCorder DDX100 portable data acquisition systems for facility maintenance and field testing; and Everest EV-500, a digital strip chart recording system used primarily in telemetry applications. This segment serves aerospace and defense, automotive, commercial airline, energy, manufacturing, and transportation industries. The company was formerly known as Astro-Med, Inc. and changed its name to AstroNova, Inc. in May 2016. AstroNova, Inc. was incorporated in 1969 and is headquartered in West Warwick, Rhode Island.",Mr. Gregory A. Woods,Computer Hardware,12,USD,90346080,https://images.financialmodelingprep.com/symbol/ALOT.png,18343,23.53,0,4739,13036000,4694000,"[{'period': '2024', 'revenue': 148.09, 'unit': 'M', 'net_profit': 4.69}, {'period': '2023', 'revenue': 142.53, 'unit': 'M', 'net_profit': 2.66}, {'period': '2022', 'revenue': 117.48, 'unit': 'M', 'net_profit': 6.43}, {'period': '2021', 'revenue': 116.03, 'unit': 'M', 'net_profit': 1.28}]","[{'period': ""Q3 '25"", 'revenue': 40420.0, 'unit': 'K', 'net_profit': 240.0}, {'period': ""Q2 '25"", 'revenue': 40540.0, 'unit': 'K', 'net_profit': -311.0}, {'period': ""Q1 '25"", 'revenue': 32.96, 'unit': 'M', 'net_profit': 1.18}, {'period': ""Q4 '24"", 'revenue': 39.59, 'unit': 'M', 'net_profit': 2.71}, {'period': ""Q3 '24"", 'revenue': 37.55, 'unit': 'M', 'net_profit': 2.75}, {'period': ""Q2 '24"", 'revenue': 35.52, 'unit': 'M', 'net_profit': -1.62}]",0.63,0.63,133251000,76674000,4527000,42969000,23056000,0,29761000,4527000,11479000,0.2959538721542897,0.7639984968057122,0.7500000000000001,"[0.07, 0.03]","['2020-03-25', '1991-05-10']",__nan__,0.3224666231397888
194,ALPN,Alpine Immune Sciences Inc. Common Stock,"Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.",Dr. Mitchell H. Gold M.D.,Biotechnology,64.97,USD,4456779835,https://images.financialmodelingprep.com/symbol/ALPN.png,2371991,-101.515625,0.01,4288333,-43674000,-32183999,"[{'period': '2023', 'revenue': 58.88, 'unit': 'M', 'net_profit': -32.18}, {'period': '2022', 'revenue': 30.06, 'unit': 'M', 'net_profit': -57.76}, {'period': '2021', 'revenue': 23.44, 'unit': 'M', 'net_profit': -50.33}, {'period': '2020', 'revenue': 9.34, 'unit': 'M', 'net_profit': -27.94}]","[{'period': ""Q1 '24"", 'revenue': 7.03, 'unit': 'M', 'net_profit': -17.92}, {'period': ""Q4 '23"", 'revenue': 30.85, 'unit': 'M', 'net_profit': 5.96}, {'period': ""Q3 '23"", 'revenue': 10.04, 'unit': 'M', 'net_profit': -11.72}, {'period': ""Q2 '23"", 'revenue': 8.59, 'unit': 'M', 'net_profit': -13.16}, {'period': ""Q1 '23"", 'revenue': 9.39, 'unit': 'M', 'net_profit': -11.01}, {'period': ""Q4 '22"", 'revenue': 2.78, 'unit': 'M', 'net_profit': -18.86}]",-0.64,-0.64,379852000,330034000,327412000,51911000,749000,40556000,41980000,43921000,-79499000,0.20529150593201834,0.44281709428343896,0.630057803468208,__nan__,__nan__,__nan__,0.13666112064698882
195,ALRM,Alarm.com Holdings Inc. Common Stock,"Alarm.com Holdings, Inc. provides cloud-based solutions for smart residential and commercial properties in the United States and internationally. It operates in two segments, Alarm.com and Other. The company provides interactive security solutions to control and monitor their security systems, as well as connected security devices, including door locks, motion sensors, door locks, garage doors, Internet of Things, thermostats, and video cameras; and video monitoring solutions, such as video analytics, live streaming, video doorbell, video clips, video alerts, continuous high definition recording, and commercial video surveillance solutions. It also offers intelligent automation and energy management solutions comprising scenes button; smart thermostat schedules; responsive savings; precision comfort; energy usage monitoring; heating, ventilation, and air conditioning monitoring services; whole home water safety solutions; geo-services; and demand response programs. In addition, the company provides commercial solutions, such as daily safeguards, commercial grade video, energy savings, protection for valuables and inventory, temperature monitoring, multi-site management and access control, early identification, simple to use, professionally supported, and easy to maintain. Further, it offers service provider solutions, including a permission-based online portal that offers account management, sales, marketing, training, and support tools; sales, marketing, and training services; and home builder programs, as well as wellness solutions. The company serves residential and commercial subscribers. Alarm.com Holdings, Inc. was founded in 2000 and is based in Tysons, Virginia.",Mr. Stephen S. Trundle,Software - Application,59.8496,USD,2958311863,https://images.financialmodelingprep.com/symbol/ALRM.png,401467,25.8,-0.8504,46615,145375000,81043000,"[{'period': '2023', 'revenue': 881.68, 'unit': 'M', 'net_profit': 81.04}, {'period': '2022', 'revenue': 842.56, 'unit': 'M', 'net_profit': 56.34}, {'period': '2021', 'revenue': 748.97, 'unit': 'M', 'net_profit': 52.26}, {'period': '2020', 'revenue': 618.0, 'unit': 'M', 'net_profit': 77.85}]","[{'period': ""Q3 '24"", 'revenue': 240.5, 'unit': 'M', 'net_profit': 36.68}, {'period': ""Q2 '24"", 'revenue': 233.81, 'unit': 'M', 'net_profit': 33.51}, {'period': ""Q1 '24"", 'revenue': 223.28, 'unit': 'M', 'net_profit': 23.59}, {'period': ""Q4 '23"", 'revenue': 226.24, 'unit': 'M', 'net_profit': 31.3}, {'period': ""Q3 '23"", 'revenue': 221.85, 'unit': 'M', 'net_profit': 19.52}, {'period': ""Q2 '23"", 'revenue': 223.88, 'unit': 'M', 'net_profit': 15.8}]",1.63,1.48,1439563000,956780000,696983000,714709000,130626000,0,175337000,696983000,121790000,0.4187771434148246,0.4385139692569846,0.4424778761061947,__nan__,__nan__,__nan__,0.4964763612290674
196,ALRN,Aileron Therapeutics Inc. Common Stock,"Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.",Dr. James Brian Windsor Ph.D.,Biotechnology,2.06,USD,44631754,https://images.financialmodelingprep.com/symbol/ALRN.png,96609,-0.72,-0.03,11551,-15613000,-15732000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.73}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -27.01}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -25.76}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.82}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.85}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.94}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.11}, {'period': ""Q4 '23"", 'revenue': 0.134, 'unit': 'M', 'net_profit': -7.34}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.83}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.79}]",-3.42,-3.42,106008000,18266000,17313000,99121000,0,0,4385000,17313000,-19808000,0.43179998544289977,0.41757061937729073,0.4252100840336135,__nan__,__nan__,__nan__,0.935033205041129
197,ALRS,Alerus Financial Corporation Common Stock,"Alerus Financial Corporation, through its subsidiary, Alerus Financial, National Association, provides various financial services to businesses and consumers. The company operates in four segments: Banking, Retirement and Benefit Services, Wealth Management, and Mortgage. It offers various deposit products, including demand deposits, interest-bearing transaction accounts, money market accounts, time and savings deposits, checking accounts, and certificates of deposit; and treasury management products, including electronic receivables management, remote deposit capture, cash vault services, merchant services, and other cash management services. The company also provides commercial loans, business term loans, lines of credit, and commercial real estate loans, as well as construction and land development loans; consumer lending products, including residential first mortgage loans; installment loans and lines of credit; and second mortgage loans. In addition, it offers retirement plan administration and investment advisory services, employee stock ownership plan, fiduciary services, payroll, health savings accounts, and other benefit services, as well as individual retirement accounts; and financial planning, investment management, personal and corporate trust, estate administration, and custody services. Further, the company provides debit and credit cards, online banking, mobile banking/wallet, payment, private banking, payroll accounts, flex spending accounts, administration, and government health insurance program services. It offers banking services through fourteen offices in North Dakota, Minnesota, and Arizona; and retirement and benefit plans in 50 states through offices located in Michigan, Minnesota, and Colorado. The company was formerly known as First National Bank North Dakota and changed its name to Alerus Financial Corporation in 2000. Alerus Financial Corporation was founded in 1879 and is headquartered in Grand Forks, North Dakota.",Ms. Katie A. Lorenson CPA,Banks - Regional,18.82,USD,476866806,https://images.financialmodelingprep.com/symbol/ALRS.png,101645,110.71,-0.18,32526,0,11696000,"[{'period': '2023', 'revenue': 166.01, 'unit': 'M', 'net_profit': 11.7}, {'period': '2022', 'revenue': 208.77, 'unit': 'M', 'net_profit': 40.01}, {'period': '2021', 'revenue': 230.24, 'unit': 'M', 'net_profit': 52.68}, {'period': '2020', 'revenue': 228.18, 'unit': 'M', 'net_profit': 44.67}]","[{'period': ""Q3 '24"", 'revenue': 50.22, 'unit': 'M', 'net_profit': 5.18}, {'period': ""Q2 '24"", 'revenue': 80.07, 'unit': 'M', 'net_profit': 6.21}, {'period': ""Q1 '24"", 'revenue': 74.15, 'unit': 'M', 'net_profit': 6.43}, {'period': ""Q4 '23"", 'revenue': 45.49, 'unit': 'M', 'net_profit': -14.75}, {'period': ""Q3 '23"", 'revenue': 48.11, 'unit': 'M', 'net_profit': 9.16}, {'period': ""Q2 '23"", 'revenue': 47.8, 'unit': 'M', 'net_profit': 9.1}]",0.59,0.58,3907713000,28893000,28893000,3538586000,0,0,2928999000,129893000,25809000,-1,-0.707636545431821,-0.7216981132075473,"[0.2, 0.23]","['2024-12-27', '2003-06-18']",__nan__,0.9055388663394676
198,ALSK,Alaska Communications Systems Group Inc. Common Stock,"Alaska Communications Systems Group, Inc., through its subsidiaries, provides broadband telecommunication and managed information technology services to business, wholesale, and consumer customers in the United States. Its services include voice and broadband services; and managed IT services comprising remote network monitoring and support service, managed IT security and IT professional services, and long distance services primarily over its own terrestrial network to business and wholesale customers. The company's business customers comprise enterprises; federal, state, and local governments; and small and medium business. It also provides voice and broadband services to residential customers in residential homes and multi-dwelling units; voice and broadband origination and termination services to inter and intrastate carriers; and access and support services. The company markets and sells its products through direct sales channels. Alaska Communications Systems Group, Inc. was incorporated in 1998 and is based in Anchorage, Alaska.",Mr. William Bishop,Telecommunications Services,3.4,USD,0,https://images.financialmodelingprep.com/symbol/ALSK.png,476388,0,0.00999999,878092,56156000,-1073000,"[{'period': '2020', 'revenue': 240.57, 'unit': 'M', 'net_profit': -1.07}, {'period': '2019', 'revenue': 231.69, 'unit': 'M', 'net_profit': 4.93}, {'period': '2018', 'revenue': 232.47, 'unit': 'M', 'net_profit': 9.08}, {'period': '2017', 'revenue': 226.91, 'unit': 'M', 'net_profit': -6.1}]","[{'period': ""Q1 '21"", 'revenue': 60670.0, 'unit': 'K', 'net_profit': 606.0}, {'period': ""Q4 '20"", 'revenue': 62.33, 'unit': 'M', 'net_profit': -8.2}, {'period': ""Q3 '20"", 'revenue': 60.51, 'unit': 'M', 'net_profit': 2.3}, {'period': ""Q2 '20"", 'revenue': 59.46, 'unit': 'M', 'net_profit': 2.44}, {'period': ""Q1 '20"", 'revenue': 58.27, 'unit': 'M', 'net_profit': 2.39}, {'period': ""Q4 '19"", 'revenue': 58.26, 'unit': 'M', 'net_profit': 2.64}]",-0.0199,-0.0199,569432000,77325000,20078000,403513000,42246000,0,62159000,19644000,8297000,-0.015290734376095953,-1.2177353896103895,-1.2191629955947136,"[0.09, 0.185]","['2020-04-17', '2004-12-29']",__nan__,0.7086236811419099
199,ALT,Altimmune Inc. Common Stock,"Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.",Dr. Vipin K. Garg Ph.D.,Biotechnology,7.195,USD,511741497,https://images.financialmodelingprep.com/symbol/ALT.png,3148040,-4.58,-0.055,1035894,-87935000,-88447000,"[{'period': '2023', 'revenue': 0.426, 'unit': 'M', 'net_profit': -88.45}, {'period': '2022', 'revenue': -0.068, 'unit': 'M', 'net_profit': -84.71}, {'period': '2021', 'revenue': 4.41, 'unit': 'M', 'net_profit': -96.17}, {'period': '2020', 'revenue': 8.19, 'unit': 'M', 'net_profit': -49.04}]","[{'period': ""Q3 '24"", 'revenue': 0.005, 'unit': 'M', 'net_profit': -22.84}, {'period': ""Q2 '24"", 'revenue': 0.005, 'unit': 'M', 'net_profit': -24.64}, {'period': ""Q1 '24"", 'revenue': 0.005, 'unit': 'M', 'net_profit': -24.39}, {'period': ""Q4 '23"", 'revenue': 0.037, 'unit': 'M', 'net_profit': -31.64}, {'period': ""Q3 '23"", 'revenue': 0.362, 'unit': 'M', 'net_profit': -20.67}, {'period': ""Q2 '23"", 'revenue': 0.006, 'unit': 'M', 'net_profit': -16.06}]",-1.66,-1.66,210640000,209626000,197815000,16541000,4853000,0,12143000,135117000,-75857000,-0.0418591976493448,-0.04407824064783445,0.08287292817679565,"[291, 291.0033]","['2017-02-06', '2017-01-20']",__nan__,0.07852734523357387
200,ALTA,Altabancorp Common Stock,"Altabancorp operates as the bank holding company for Altabank, a state-chartered bank that provides retail and commercial banking products and services. The company accepts various deposits, such as checking, rewards checking, savings, and money market deposit accounts, as well as individual retirement accounts and certificates of deposit. Its loan products include commercial and residential real estate lending comprising acquisition and development loans, construction loans, and mortgage financing; commercial and industrial loans; consumer loans consisting of home equity loans, home improvement loans, automobile loans, debt consolidation loans, and general consumer lending; and SBA loans. The company also offers credit and debit cards; investment securities, such as U.S. Agency issues, mortgage-backed securities, and municipal bonds; and mobile and Internet banking, automatic teller machine, treasury management, remote deposit capture, bill pay, cashier's checks, money orders, and safe deposit services. It serves real estate developers and contractors, small to medium sized businesses, individuals, and professionals and professional firms through 26 retail branches located in Utah and southern Idaho. The company was formerly known as People's Utah Bancorp and changed its name to Altabancorp in July 2020. Altabancorp was founded in 1905 and is headquartered in American Fork, Utah.",Mr. Len E. Williams,Banks - Regional,44.16,USD,0,https://images.financialmodelingprep.com/symbol/ALTA.png,80075,19.89189189189189,-0.5600014,410642,67922000,43502000,"[{'period': '2020', 'revenue': 126.14, 'unit': 'M', 'net_profit': 43.5}, {'period': '2019', 'revenue': 125.1, 'unit': 'M', 'net_profit': 44.32}, {'period': '2018', 'revenue': 123.31, 'unit': 'M', 'net_profit': 40.63}, {'period': '2017', 'revenue': 95.03, 'unit': 'M', 'net_profit': 19.85}]","[{'period': ""Q2 '21"", 'revenue': 30.59, 'unit': 'M', 'net_profit': 12.7}, {'period': ""Q1 '21"", 'revenue': 28.98, 'unit': 'M', 'net_profit': 9.44}, {'period': ""Q4 '20"", 'revenue': 31.37, 'unit': 'M', 'net_profit': 11.05}, {'period': ""Q3 '20"", 'revenue': 31.91, 'unit': 'M', 'net_profit': 11.34}, {'period': ""Q2 '20"", 'revenue': 31.91, 'unit': 'M', 'net_profit': 10.34}, {'period': ""Q1 '20"", 'revenue': 30.96, 'unit': 'M', 'net_profit': 10.77}]",2.31,2.31,3366228000,239.874,1557474000,2995090000,11336000,1323283000,71.943,237081000,49124000,-0.034568041618102736,-0.018545257648226694,-0.012820512820512739,"[0.17, 0.06]","['2021-09-24', '2015-07-30']",__nan__,0.889746624411656
201,ALTM,Altus Midstream Company Class A Common Stock,"Arcadium Lithium plc engages in the production of lithium chemicals products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America. The company offers battery-grade lithium hydroxide, lithium carbonate, butyllithium and high purity lithium metal for electric vehicles, greases, polymers, pharmaceutical, battery, and aerospace applications. It also owns 100% interest in the Sal de Vida property located in Argentina; the Cauchari property located in Argentina; the James Bay property located in northwestern Quebec, Canada; the Salar Del Hombre Muerto property located in Argentina; Mt Cattlin property located in Western Australia; owns 66.5% interest in the Salar de Olaroz property located in Jujuy Province, Argentina; and owns 50% interest in the Whabouchi Mine property located in Canada. The company was founded in 1944 and is based in Shannon, Ireland.",Mr. Paul W. Graves A.C.A.,Chemicals - Specialty,5.28,USD,5679326928,https://images.financialmodelingprep.com/symbol/ALTM.png,21929058,29.33,0.06,3769291,419400000,330100000,"[{'period': '2023', 'revenue': 882.5, 'unit': 'M', 'net_profit': 330.1}, {'period': '2022', 'revenue': 1210.0, 'unit': 'M', 'net_profit': 441.71}, {'period': '2021', 'revenue': 420400.0, 'unit': 'K', 'net_profit': 600.0}, {'period': '2020', 'revenue': 288.2, 'unit': 'M', 'net_profit': -16.3}]","[{'period': ""Q3 '24"", 'revenue': 203.1, 'unit': 'M', 'net_profit': 16.1}, {'period': ""Q2 '24"", 'revenue': 254.5, 'unit': 'M', 'net_profit': 85.7}, {'period': ""Q1 '24"", 'revenue': 283.49, 'unit': 'M', 'net_profit': 15.6}, {'period': ""Q4 '23"", 'revenue': 195.51, 'unit': 'M', 'net_profit': 37.7}, {'period': ""Q3 '23"", 'revenue': 211.4, 'unit': 'M', 'net_profit': 87.4}, {'period': ""Q2 '23"", 'revenue': 235.8, 'unit': 'M', 'net_profit': 90.2}]",0.66,0.66,3230100000,648200000,237600000,946300000,172300000,34800000,268600000,237600000,-29800000,0.1512489706286028,-0.2526787877141389,-0.38317757009345793,"[3, 3]","['2021-05-27', '2021-02-25']",__nan__,0.29296306615894246
202,ALTO,Alto Ingredients Inc. Common Stock,"Alto Ingredients, Inc. produces and markets specialty alcohols and essential ingredients in the United States. The company operates in three segments: Marketing and Distribution, Pekin Production, and Other Production. It offers specialty alcohols used in mouthwash, cosmetics, pharmaceuticals, hand sanitizers, disinfectants, and cleaners for health, home, and beauty markets; grain neutral spirits used in alcoholic beverages, flavor extracts, and vinegar, as well as corn germ used in corn oils and carbon dioxide for food and beverage markets; and essential ingredients include dried yeast, corn gluten meal, corn gluten feed, distillers grains, and liquid feed for commercial animal feed and pet food applications. The company also provides fuel-grade ethanol used as transportation fuel and distillers corn oil used as a biodiesel feedstock, as well as fuel-grade ethanol produced by third parties. In addition, it offers transportation, storage, and delivery services through third-party service providers. The company sells ethanol to integrated oil companies and gasoline marketers; essential ingredient feed products to dairies and feedlots; and corn oil to poultry and biodiesel customers. It operates five alcohol production facilities, including three plants in the Midwestern states of Illinois; and two facilities located in the Western states of Oregon and Idaho. The company was formerly known as Pacific Ethanol, Inc. and changed its name to Alto Ingredients, Inc. in January 2021. Alto Ingredients, Inc. was founded in 2003 and is headquartered in Pekin, Illinois.",Mr. Bryon T. McGregor,Chemicals - Specialty,1.78,USD,136430058,https://images.financialmodelingprep.com/symbol/ALTO.png,859985,-3.49,-0.05,341363,2597000,-28005000,"[{'period': '2023', 'revenue': 1220.0, 'unit': 'M', 'net_profit': -28.0}, {'period': '2022', 'revenue': 1340.0, 'unit': 'M', 'net_profit': -41.6}, {'period': '2021', 'revenue': 1210.0, 'unit': 'M', 'net_profit': 46.08}, {'period': '2020', 'revenue': 897.02, 'unit': 'M', 'net_profit': -17.28}]","[{'period': ""Q3 '24"", 'revenue': 251.81, 'unit': 'M', 'net_profit': -2.44}, {'period': ""Q2 '24"", 'revenue': 236.47, 'unit': 'M', 'net_profit': -3.11}, {'period': ""Q1 '24"", 'revenue': 240.63, 'unit': 'M', 'net_profit': -11.72}, {'period': ""Q4 '23"", 'revenue': 273.62, 'unit': 'M', 'net_profit': -18.95}, {'period': ""Q3 '23"", 'revenue': 318.13, 'unit': 'M', 'net_profit': -3.49}, {'period': ""Q2 '23"", 'revenue': 317.3, 'unit': 'M', 'net_profit': 7.59}]",-0.4,-0.4,454241000,168770000,30014000,174684000,58729000,0,65288000,30014000,-7506000,1.2036862745098038,0.32675433324518594,0.3103448275862068,__nan__,__nan__,__nan__,0.384562379882045
203,ALTR,Altair Engineering Inc. Class A Common Stock,"Altair Engineering Inc., together with its subsidiaries, provides software and cloud solutions in the areas of simulation, high-performance computing, data analytics, and artificial intelligence worldwide. The company operates in two segments, Software and Client Engineering Services. The Software segment includes solvers and optimization technology products, high-performance computing software applications and hardware products, modeling and visualization tools, data analytics and analysis products, and Internet of Things platform and analytics tools, as well as support and the complementary software products. This segment also offers software technologies in the areas of computational fluid dynamics and fatigue, manufacturing process simulation, and cost estimation for the applications in marine, motorcycle, aerospace, chemical, and architecture industries; and software-related services, such as consulting, implementation, and training services that focuses on the product design and development expertise and analysis from the component level up to complete product engineering at various stage of the lifecycle. The Client Engineering Services segment provides client engineering services. In addition, the company is involved in the development and sale of solid state lighting technology along with communication and control protocols based on its intellectual property for the direct replacement of fluorescent light tubes with LED lamps. Its integrated suite of software optimizes design performance across various disciplines, including structures, motion, fluids, thermal management, electromagnetics, system modeling, and embedded systems. The company's customers include universities, government agencies, manufacturers, pharmaceutical firms, banking, financial services, and insurance, weather prediction agencies, and electronics design companies. Altair Engineering Inc. was incorporated in 1985 and is headquartered in Troy, Michigan.",Mr. James R. Scapa,Software - Infrastructure,110,USD,9409861340,https://images.financialmodelingprep.com/symbol/ALTR.png,1019090,282.05,0.09,366027,57859000,-8926000,"[{'period': '2023', 'revenue': 612.7, 'unit': 'M', 'net_profit': -8.93}, {'period': '2022', 'revenue': 572.22, 'unit': 'M', 'net_profit': -43.43}, {'period': '2021', 'revenue': 532.18, 'unit': 'M', 'net_profit': -8.79}, {'period': '2020', 'revenue': 469.92, 'unit': 'M', 'net_profit': -10.5}]","[{'period': ""Q3 '24"", 'revenue': 151.45, 'unit': 'M', 'net_profit': 1.78}, {'period': ""Q2 '24"", 'revenue': 148.79, 'unit': 'M', 'net_profit': -5.15}, {'period': ""Q1 '24"", 'revenue': 172.91, 'unit': 'M', 'net_profit': 16.55}, {'period': ""Q4 '23"", 'revenue': 171.5, 'unit': 'M', 'net_profit': 19.68}, {'period': ""Q3 '23"", 'revenue': 134.0, 'unit': 'M', 'net_profit': -4.36}, {'period': ""Q2 '23"", 'revenue': 141.16, 'unit': 'M', 'net_profit': -22.28}]",-0.11,-0.11,1363493000,700623000,467459000,652162000,190461000,0,324110000,467459000,117114000,3.958776139869729,0.7944691335282875,0.8,"[0.18, 0.05]","['2015-11-06', '2009-08-06']",__nan__,0.4783024188609696
204,ALTU,Altitude Acquisition Corp. Class A Common Stock,"Altitude Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on travel, travel technology and travel-related businesses. The company was incorporated in 2020 and is based in Atlanta, Georgia.",Mr. Gary  Teplis,Shell Companies,10.12,USD,85771655,https://images.financialmodelingprep.com/symbol/ALTU.png,2354,56.22222222222222,-0.13,68972,-15405581,9342644,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.34}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.23}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.12}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -664.63}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.66}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -198.27}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.16}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -234.91}]",0.77,0.77,16977371,1575,760,18830171,0,16975796,1594065,760,-375360,0.41596786378693007,-0.3863950527751231,0.878048780487805,__nan__,__nan__,__nan__,1.10913350482828
205,ALTUU,Altitude Acquisition Corp. Unit,"Altitude Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on travel, travel technology and travel-related businesses. The company was incorporated in 2020 and is based in Atlanta, Georgia.",Mr. Gary  Teplis,Shell Companies,10.1,USD,85771654,https://images.financialmodelingprep.com/symbol/ALTUU.png,120,12.5,-0.16,3300,-15405581,9342644,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.34}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.23}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.12}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -664.63}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.66}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -198.27}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.16}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -234.91}]",0.77,0.77,16977371,1575,760,18830171,0,16975796,1594065,760,-375360,0.41596786378693007,-0.3863950527751231,0.878048780487805,__nan__,__nan__,__nan__,1.10913350482828
206,ALTUW,Altitude Acquisition Corp. Warrant,"Altitude Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. Altitude Acquisition Corp. was incorporated in 2020 and is based in Atlanta, Georgia. Altitude Acquisition Corp. operates as a subsidiary of Altitude Acquisition Holdco LLC.",Mr. Gary  Teplis,Shell Companies,0.0007,USD,85771655,https://images.financialmodelingprep.com/symbol/ALTUW.png,11998,0,-0.0217,2133842,-15405581,9342644,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.34}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.23}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.12}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -664.63}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.66}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -198.27}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.16}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -234.91}]",0.77,0.77,16977371,1575,760,18830171,0,16975796,1594065,760,-375360,0.41596786378693007,-0.3863950527751231,0.878048780487805,__nan__,__nan__,__nan__,1.10913350482828
207,ALVR,AlloVir Inc. Common Stock,"Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.",Dr. Diana M. Brainard M.D.,Biotechnology,0.4634,USD,53553748,https://images.financialmodelingprep.com/symbol/ALVR.png,375779,-0.53,-0.0095,343601,-190146000,-190418000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -190.42}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -168.71}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -171.96}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -68.38}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.13}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.08}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.3}, {'period': ""Q4 '23"", 'revenue': 8.38, 'unit': 'M', 'net_profit': -59.7}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -44.27}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -45.27}]",-1.83,-1.83,190796000,187635000,183943000,45015000,206000,0,28367000,90121000,-124451000,-0.14263565891472868,-0.1286704996739968,0.1681818181818182,__nan__,__nan__,__nan__,0.23593261913247657
208,ALXN,Alexion Pharmaceuticals Inc. Common Stock,"Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.",Dr. Ludwig Hantson,Biotechnology,182.5,USD,0,https://images.financialmodelingprep.com/symbol/ALXN.png,4222993,59.23401493021746,0,3,1003100000,603400000,"[{'period': '2020', 'revenue': 6070.0, 'unit': 'M', 'net_profit': 603.4}, {'period': '2019', 'revenue': 4.99, 'unit': 'B', 'net_profit': 2.4}, {'period': '2018', 'revenue': 4130.0, 'unit': 'M', 'net_profit': 77.6}, {'period': '2017', 'revenue': 3550.0, 'unit': 'M', 'net_profit': 443.3}]","[{'period': ""Q1 '21"", 'revenue': 1640.0, 'unit': 'M', 'net_profit': 636.0}, {'period': ""Q4 '20"", 'revenue': 1590.0, 'unit': 'M', 'net_profit': 535.8}, {'period': ""Q3 '20"", 'revenue': 1590.0, 'unit': 'M', 'net_profit': 578.1}, {'period': ""Q2 '20"", 'revenue': 1.44, 'unit': 'B', 'net_profit': -1.07}, {'period': ""Q1 '20"", 'revenue': 1440.0, 'unit': 'M', 'net_profit': 557.6}, {'period': ""Q4 '19"", 'revenue': 1380.0, 'unit': 'M', 'net_profit': 889.0}]",2.75,2.75,18103000000,5833000000,2999400000,6451800000,1409300000,0,1624700000,2964500000,2896200000,-0.6190855927698034,-0.7490329825728902,-0.7429906542056075,__nan__,__nan__,__nan__,0.3563939678506325
209,ALXO,ALX Oncology Holdings Inc. Common Stock,"ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.",Mr. Jason W. Lettmann,Biotechnology,1.86,USD,98102166,https://images.financialmodelingprep.com/symbol/ALXO.png,986837,-0.63,0.07,327360,-158404000,-160805000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -160.81}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -123.48}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -83.46}, {'period': '2020', 'revenue': 1.18, 'unit': 'M', 'net_profit': -45.74}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.71}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -39.4}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.58}, {'period': ""Q4 '23"", 'revenue': 2.48, 'unit': 'M', 'net_profit': -45.47}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -50.99}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -34.16}]",-3.74,-3.74,242553000,188659000,182736000,52841000,0,35411000,36001000,22406000,-131638000,-0.29890448701128314,-0.30225457961484264,-0.23432343234323447,__nan__,__nan__,__nan__,0.2178534176035753
210,ALYA,Alithya Group inc. Class A Subordinate Voting Shares,"Alithya Group Inc. provides strategy and digital technology services in Canada, the United States, and Europe. The company's business strategy services include strategic consulting, digital transformation, organizational performance, and enterprise architecture services. It also provides application services, such as digital applications DevOps, legacy systems modernization, control and software engineering, cloud infrastructure, quality assurance, and automated testing; enterprise solutions comprising enterprise resource planning, corporate performance management, customer relationship management, and human capital management; and data and analytics solutions, including business intelligence, data management, artificial intelligence (AI), and machine learning, as well as internet of things. In addition, the company provides AI-FI, an integrated artificial intelligence and fidelity solution; Alithya GoTest, solution allows clients to test the functionality of applications on various platforms; CASSI analytics for online weekly maintenance, outage management, petrochemical turnarounds, and maintenance and reliability; and SIDER, a secure solution that facilitates distribution of medical results to healthcare sectors and to centralized electronic medical records. It serves financial services, energy, manufacturing, telecommunications, transportation and logistics, professional services, healthcare, and government sectors. Alithya Group Inc. was founded in 1992 and is headquartered in Montreal, Canada.",Mr. Paul  Raymond,Information Technology Services,1.13,USD,110306527,https://images.financialmodelingprep.com/symbol/ALYA.png,42649,-3.4242424242424243,0.05,40583,17118000,-30097000,"[{'period': '2022', 'revenue': 522.7, 'unit': 'M', 'net_profit': -30.1}, {'period': '2021', 'revenue': 437.88, 'unit': 'M', 'net_profit': -15.55}, {'period': '2020', 'revenue': 287.64, 'unit': 'M', 'net_profit': -17.34}, {'period': '2019', 'revenue': 279.01, 'unit': 'M', 'net_profit': -39.67}]","[{'period': ""Q3 '23"", 'revenue': 120.5, 'unit': 'M', 'net_profit': -2.54}, {'period': ""Q2 '23"", 'revenue': 118.49, 'unit': 'M', 'net_profit': -9.18}, {'period': ""Q1 '23"", 'revenue': 131.59, 'unit': 'M', 'net_profit': -7.25}, {'period': ""Q4 '22"", 'revenue': 136.22, 'unit': 'M', 'net_profit': -19.99}, {'period': ""Q3 '22"", 'revenue': 130.78, 'unit': 'M', 'net_profit': -5.5}, {'period': ""Q2 '22"", 'revenue': 128930.0, 'unit': 'K', 'net_profit': -435.0}]",-0.32,-0.32,464101000,156080000,22583000,277033000,126654000,12108000,130219000,22583000,26297000,8.820998278829604,-0.935747363004888,-0.7777777777777779,"[1.15, 1.15]","['2018-11-02', '2018-11-02']",__nan__,0.5969239454342913
211,AMAL,Amalgamated Financial Corp. Common Stock (DE),"Amalgamated Financial Corp. operates as the bank holding company for Amalgamated Bank that provides commercial and retail banking, investment management, and trust and custody services for commercial and retail customers in the United States. The company accepts various deposit products, including non-interest bearing accounts, interest-bearing demand products, savings accounts, money market accounts, NOW accounts, and certificates of deposit. It also provides various commercial loans comprising commercial and industrial, multifamily mortgage, and commercial real estate loans; and retail loans, such as residential real estate, and consumer and other loans. In addition, the company offers online banking, bill payment, online cash management, and safe deposit box rental services; debit and ATM cards; and trust, custody, and investment management services comprising asset safekeeping, corporate actions, income collections, proxy, account transition, asset transfers, and conversion management services. Further, it provides investment products, such as equity, fixed-income, real estate, and alternative investment products; and brokerage, asset management, and insurance products. The company operates through its three branch offices across New York City, one branch office in Washington, D.C., one branch office in San Francisco, one commercial office in Boston, and digital banking platform. Amalgamated Financial Corp. was founded in 1923 and is headquartered in New York, New York.",Ms. Priscilla Sims Brown,Banks - Regional,33.045,USD,1013467019,https://images.financialmodelingprep.com/symbol/AMAL.png,182041,9.75,-0.375,30308,0,87978000,"[{'period': '2023', 'revenue': 274.58, 'unit': 'M', 'net_profit': 87.98}, {'period': '2022', 'revenue': 266.51, 'unit': 'M', 'net_profit': 81.48}, {'period': '2021', 'revenue': 202.54, 'unit': 'M', 'net_profit': 52.94}, {'period': '2020', 'revenue': 213.21, 'unit': 'M', 'net_profit': 46.19}]","[{'period': ""Q3 '24"", 'revenue': 78.5, 'unit': 'M', 'net_profit': 27.94}, {'period': ""Q2 '24"", 'revenue': 109.77, 'unit': 'M', 'net_profit': 26.75}, {'period': ""Q1 '24"", 'revenue': 105.09, 'unit': 'M', 'net_profit': 27.25}, {'period': ""Q4 '23"", 'revenue': 101.72, 'unit': 'M', 'net_profit': 22.69}, {'period': ""Q3 '23"", 'revenue': 91.24, 'unit': 'M', 'net_profit': 22.31}, {'period': ""Q2 '23"", 'revenue': 70.37, 'unit': 'M', 'net_profit': 21.64}]",2.88,2.86,7972324000,286224000,90170000,7386960000,0,102944000,0,2856000,115747000,-1,0.0797893884163629,0.09090909090909081,"[0.12, 0.06]","['2024-11-05', '2018-11-15']",__nan__,0.9265754879003915
212,AMAO,American Acquisition Opportunity Inc. Class A Common Stock,"American Acquisition Opportunity Inc. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more target businesses in the land holdings and resources industry in the United States. The company was incorporated in 2021 and is based in Fishers, Indiana.",Mr. Mark C. Jensen,Shell Companies,7.35,USD,22598090,https://images.financialmodelingprep.com/symbol/AMAO.png,17245,91.875,0.89,69810,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
213,AMAOU,American Acquisition Opportunity Inc. Units,"American Acquisition Opportunity Inc. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more target businesses in the land holdings and resources industry in the United States. The company was incorporated in 2021 and is based in Fishers, Indiana.",Mr. Mark C. Jensen,Shell Companies,7.19,USD,23514895,https://images.financialmodelingprep.com/symbol/AMAOU.png,581,0,0.71,4964,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
214,AMAOW,American Acquisition Opportunity Inc. Warrant,"American Acquisition Opportunity Inc. intends to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more target businesses. It intends to focus on companies in the land holdings and resources industry in the United States. The company was incorporated in 2021 and is based in Fishers, Indiana.",Mr. Mark C. Jensen,Shell Companies,0.0699,USD,244693,https://images.financialmodelingprep.com/symbol/AMAOW.png,0,0,0.0199,99089,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
215,AMAT,Applied Materials Inc. Common Stock,"Applied Materials, Inc. provides manufacturing equipment, services, and software to the semiconductor, display, and related industries. It operates through three segments: Semiconductor Systems, Applied Global Services, and Display and Adjacent Markets. The Semiconductor Systems segment develops, manufactures, and sells various manufacturing equipment that is used to fabricate semiconductor chips or integrated circuits. This segment also offers various technologies, including epitaxy, ion implantation, oxidation/nitridation, rapid thermal processing, physical vapor deposition, chemical vapor deposition, chemical mechanical planarization, electrochemical deposition, atomic layer deposition, etching, and selective deposition and removal, as well as metrology and inspection tools. The Applied Global Services segment provides integrated solutions to optimize equipment and fab performance and productivity comprising spares, upgrades, services, remanufactured earlier generation equipment, and factory automation software for semiconductor, display, and other products. The Display and Adjacent Markets segment offers products for manufacturing liquid crystal displays; organic light-emitting diodes; and other display technologies for TVs, monitors, laptops, personal computers, electronic tablets, smart phones, and other consumer-oriented devices. The company operates in the United States, China, Korea, Taiwan, Japan, Southeast Asia, and Europe. Applied Materials, Inc. was incorporated in 1967 and is headquartered in Santa Clara, California.",Mr. Gary E. Dickerson,Semiconductors,178.64,USD,145356688400,https://images.financialmodelingprep.com/symbol/AMAT.png,6674024,20.74,1.13,2087050,8259000000,7177000000,"[{'period': '2024', 'revenue': 27.18, 'unit': 'B', 'net_profit': 7.18}, {'period': '2023', 'revenue': 26.52, 'unit': 'B', 'net_profit': 6.86}, {'period': '2022', 'revenue': 25.79, 'unit': 'B', 'net_profit': 6.53}, {'period': '2021', 'revenue': 23.06, 'unit': 'B', 'net_profit': 5.89}]","[{'period': ""Q4 '24"", 'revenue': 7.04, 'unit': 'B', 'net_profit': 1.73}, {'period': ""Q3 '24"", 'revenue': 6.78, 'unit': 'B', 'net_profit': 1.71}, {'period': ""Q2 '24"", 'revenue': 6.65, 'unit': 'B', 'net_profit': 1.72}, {'period': ""Q1 '24"", 'revenue': 6.71, 'unit': 'B', 'net_profit': 2.02}, {'period': ""Q4 '23"", 'revenue': 6.72, 'unit': 'B', 'net_profit': 2.0}, {'period': ""Q3 '23"", 'revenue': 6.42, 'unit': 'B', 'net_profit': 1.56}]",8.68,8.61,34409000000,21220000000,9471000000,15408000000,5234000000,2787000000,8468000000,8022000000,7487000000,0.011017260374586852,0.04682030338389732,0.06372549019607837,"[0.4, 0.03]","['2025-02-20', '2005-05-16']",__nan__,0.4477898224301782
216,AMBA,Ambarella Inc. Ordinary Shares,"Ambarella, Inc. develops semiconductor solutions for video that enable high-definition (HD) and ultra HD compression, image processing, and deep neural network processing worldwide. The company's system-on-a-chip designs integrated HD video processing, image processing, artificial intelligence computer vision algorithms, audio processing, and system functions onto a single chip for delivering video and image quality, differentiated functionality, and low power consumption. Its solutions are used in automotive cameras, such as automotive video recorders, electronic mirrors, front advanced driver assistance system camera, cabin monitoring system and driver monitoring system camera, and central domain controllers for autonomous vehicle; and professional and home internet protocol security camera; robotics and industrial application, including identification/authentication cameras, robotic products, and sensing cameras, as well as cameras for the home, public spaces, and consumer leisure comprising wearable body cameras, sports action cameras, social media cameras, drones for capturing aerial video or photographs, video conferencing, and virtual reality applications. The company sells its solutions to original design manufacturers and original equipment manufacturers through its direct sales force and distributors. Ambarella, Inc. was incorporated in 2004 and is headquartered in Santa Clara, California.",Dr. Feng-Ming  Wang Ph.D.,Semiconductors,77.63,USD,3237326260,https://images.financialmodelingprep.com/symbol/AMBA.png,590490,-19.91,-0.55,299279,-129747000,-169417000,"[{'period': '2024', 'revenue': 226.47, 'unit': 'M', 'net_profit': -169.42}, {'period': '2023', 'revenue': 337.61, 'unit': 'M', 'net_profit': -65.39}, {'period': '2022', 'revenue': 331.86, 'unit': 'M', 'net_profit': -26.41}, {'period': '2021', 'revenue': 222.99, 'unit': 'M', 'net_profit': -59.79}]","[{'period': ""Q3 '25"", 'revenue': 82.65, 'unit': 'M', 'net_profit': -24.07}, {'period': ""Q2 '25"", 'revenue': 63.72, 'unit': 'M', 'net_profit': -34.89}, {'period': ""Q1 '25"", 'revenue': 54.47, 'unit': 'M', 'net_profit': -37.93}, {'period': ""Q4 '24"", 'revenue': 51.62, 'unit': 'M', 'net_profit': -60.61}, {'period': ""Q3 '24"", 'revenue': 50.59, 'unit': 'M', 'net_profit': -41.71}, {'period': ""Q2 '24"", 'revenue': 62.12, 'unit': 'M', 'net_profit': -31.2}]",-4.25,-4.25,657655000,280157000,219927000,97784000,24950000,0,82979000,144914000,7047000,-1.388479805603623,-1.591028660569541,-1.5,__nan__,__nan__,__nan__,0.14868586112779497
217,AMCX,AMC Networks Inc. Class A Common Stock,"AMC Networks Inc., an entertainment company, owns and operates a suite of video entertainment products that are delivered to audiences and a platform to distributors and advertisers in the United States and internationally. The company operates in two segments, Domestic Operations, and International and Other. The Domestic Operations segment operates various national programming networks, including the AMC, WE tv, BBC AMERICA, IFC, and SundanceTV; provides subscription streaming services comprising Acorn TV, Shudder, Sundance Now, ALLBLK, and HIDIVE, as well as AMC+ and other streaming initiatives; and engages in film distribution business under the IFC Films name. This segment also produces and licenses original programming for various programming networks, as well as services the national programming networks. The International and Other segment operates a portfolio of channels under the AMCNI name; and production and comedy venues activities under the Levity name. AMC Networks Inc. was founded in 1980 and is headquartered in New York, New York.",Ms. Kristin Aigner Dolan,Entertainment,9.68,USD,427089150,https://images.financialmodelingprep.com/symbol/AMCX.png,718543,13.63,-0.29,151499,1462269000,215464000,"[{'period': '2023', 'revenue': 2710.0, 'unit': 'M', 'net_profit': 215.46}, {'period': '2022', 'revenue': 3100.0, 'unit': 'M', 'net_profit': 11.03}, {'period': '2021', 'revenue': 3080.0, 'unit': 'M', 'net_profit': 250.6}, {'period': '2020', 'revenue': 2810.0, 'unit': 'M', 'net_profit': 239.98}]","[{'period': ""Q3 '24"", 'revenue': 599.61, 'unit': 'M', 'net_profit': 41.38}, {'period': ""Q2 '24"", 'revenue': 625.93, 'unit': 'M', 'net_profit': -29.23}, {'period': ""Q1 '24"", 'revenue': 596.46, 'unit': 'M', 'net_profit': 45.8}, {'period': ""Q4 '23"", 'revenue': 678.85, 'unit': 'M', 'net_profit': -21.81}, {'period': ""Q3 '23"", 'revenue': 636.95, 'unit': 'M', 'net_profit': 63.42}, {'period': ""Q2 '23"", 'revenue': 678.63, 'unit': 'M', 'net_profit': 70.24}]",4.92,4.9,4969787000,1623370000,570576000,3710544000,666760000,182499000,943423000,570576000,168712000,0.16632462366629153,18.537903518317012,17.923076923076923,__nan__,__nan__,__nan__,0.7466203279939362
218,AMD,Advanced Micro Devices Inc. Common Stock,"Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company operates in two segments, Computing and Graphics; and Enterprise, Embedded and Semi-Custom. Its products include x86 microprocessors as an accelerated processing unit, chipsets, discrete and integrated graphics processing units (GPUs), data center and professional GPUs, and development services; and server and embedded processors, and semi-custom System-on-Chip (SoC) products, development services, and technology for game consoles. The company provides processors for desktop and notebook personal computers under the AMD Ryzen, AMD Ryzen PRO, Ryzen Threadripper, Ryzen Threadripper PRO, AMD Athlon, AMD Athlon PRO, AMD FX, AMD A-Series, and AMD PRO A-Series processors brands; discrete GPUs for desktop and notebook PCs under the AMD Radeon graphics, AMD Embedded Radeon graphics brands; and professional graphics products under the AMD Radeon Pro and AMD FirePro graphics brands. It also offers Radeon Instinct, Radeon PRO V-series, and AMD Instinct accelerators for servers; chipsets under the AMD trademark; microprocessors for servers under the AMD EPYC; embedded processor solutions under the AMD Athlon, AMD Geode, AMD Ryzen, AMD EPYC, AMD R-Series, and G-Series processors brands; and customer-specific solutions based on AMD CPU, GPU, and multi-media technologies, as well as semi-custom SoC products. It serves original equipment manufacturers, public cloud service providers, original design manufacturers, system integrators, independent distributors, online retailers, and add-in-board manufacturers through its direct sales force, independent distributors, and sales representatives. The company was incorporated in 1969 and is headquartered in Santa Clara, California.",Dr. Lisa T. Su Ph.D.,Semiconductors,128.24,USD,208109154400,https://images.financialmodelingprep.com/symbol/AMD.png,0,113.49,-1.31,20561246,4149000000,854000000,"[{'period': '2023', 'revenue': 22680.0, 'unit': 'M', 'net_profit': 854.0}, {'period': '2022', 'revenue': 23.6, 'unit': 'B', 'net_profit': 1.32}, {'period': '2021', 'revenue': 16.43, 'unit': 'B', 'net_profit': 3.16}, {'period': '2020', 'revenue': 9.76, 'unit': 'B', 'net_profit': 2.49}]","[{'period': ""Q3 '24"", 'revenue': 6820.0, 'unit': 'M', 'net_profit': 771.0}, {'period': ""Q2 '24"", 'revenue': 5830.0, 'unit': 'M', 'net_profit': 265.0}, {'period': ""Q1 '24"", 'revenue': 5470.0, 'unit': 'M', 'net_profit': 123.0}, {'period': ""Q4 '23"", 'revenue': 6170.0, 'unit': 'M', 'net_profit': 667.0}, {'period': ""Q3 '23"", 'revenue': 5800.0, 'unit': 'M', 'net_profit': 299.0}, {'period': ""Q2 '23"", 'revenue': 5360.0, 'unit': 'M', 'net_profit': 27.0}]",0.53,0.53,67885000000,16768000000,5773000000,11993000000,5385000000,99000000,6689000000,3933000000,1121000000,-0.25027105168052044,-0.353030303030303,-0.37647058823529406,"[0.01, 0.01]","['1995-04-28', '1995-04-28']",__nan__,0.17666642115342124
219,AMED,Amedisys Inc Common Stock,"Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.",Mr. Richard M. Ashworth,Medical - Care Facilities,92.0525,USD,3015133611,https://images.financialmodelingprep.com/symbol/AMED.png,561248,36.53,,0,216913000,-9747000,"[{'period': '2023', 'revenue': 2240.0, 'unit': 'M', 'net_profit': -9.75}, {'period': '2022', 'revenue': 2220.0, 'unit': 'M', 'net_profit': 118.61}, {'period': '2021', 'revenue': 2210.0, 'unit': 'M', 'net_profit': 209.07}, {'period': '2020', 'revenue': 2070.0, 'unit': 'M', 'net_profit': 183.61}]","[{'period': ""Q3 '24"", 'revenue': 587.67, 'unit': 'M', 'net_profit': 41.46}, {'period': ""Q2 '24"", 'revenue': 591.19, 'unit': 'M', 'net_profit': 32.3}, {'period': ""Q1 '24"", 'revenue': 571.41, 'unit': 'M', 'net_profit': 14.4}, {'period': ""Q4 '23"", 'revenue': 570.79, 'unit': 'M', 'net_profit': 39.38}, {'period': ""Q3 '23"", 'revenue': 556.24, 'unit': 'M', 'net_profit': 25.96}, {'period': ""Q2 '23"", 'revenue': 552.97, 'unit': 'M', 'net_profit': -80.28}]",-0.3,-0.3,2060170000,496935000,126450000,940387000,313373000,66100000,473721000,126450000,124475000,0.04583259002830184,-1.082177575057542,-1.0821917808219177,__nan__,__nan__,__nan__,0.4564608745880194
220,AMEH,Apollo Medical Holdings Inc. Common Stock,"Apollo Medical Holdings, Inc., a physician-centric technology-powered healthcare company, provides medical care services. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients in California. The company was founded in 1994 and is headquartered in Alhambra, California.",Mr. Brandon  Sim,Medical - Care Facilities,40.82,USD,1830332062,https://images.financialmodelingprep.com/symbol/AMEH.png,208841,39.25,-0.88,313943,133350000,45171000,"[{'period': '2022', 'revenue': 1140.0, 'unit': 'M', 'net_profit': 45.17}, {'period': '2021', 'revenue': 773.91, 'unit': 'M', 'net_profit': 68.92}, {'period': '2020', 'revenue': 370.25, 'unit': 'M', 'net_profit': -23.75}, {'period': '2019', 'revenue': 560.62, 'unit': 'M', 'net_profit': 14.12}]","[{'period': ""Q3 '23"", 'revenue': 348.17, 'unit': 'M', 'net_profit': 22.06}, {'period': ""Q2 '23"", 'revenue': 348.21, 'unit': 'M', 'net_profit': 13.17}, {'period': ""Q1 '23"", 'revenue': 337.24, 'unit': 'M', 'net_profit': 13.13}, {'period': ""Q4 '22"", 'revenue': 294.21, 'unit': 'M', 'net_profit': -2.6}, {'period': ""Q3 '22"", 'revenue': 317.0, 'unit': 'M', 'net_profit': 23.18}, {'period': ""Q2 '22"", 'revenue': 269.7, 'unit': 'M', 'net_profit': 11.95}]",1,0.99,966213000,428125000,293594000,407666000,119733000,41195000,148610000,288027000,59188000,0.19699472191303724,-0.34461645604515184,-0.36305732484076436,__nan__,__nan__,__nan__,0.4219214603819241
221,AMGN,Amgen Inc. Common Stock,"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.",Mr. Robert A. Bradway,Drug Manufacturers - General,262.5737,USD,141142028682,https://images.financialmodelingprep.com/symbol/AMGN.png,3317817,33.84,3.9837,884208,14702000000,6717000000,"[{'period': '2023', 'revenue': 28.19, 'unit': 'B', 'net_profit': 6.72}, {'period': '2022', 'revenue': 26.32, 'unit': 'B', 'net_profit': 6.55}, {'period': '2021', 'revenue': 25.98, 'unit': 'B', 'net_profit': 5.89}, {'period': '2020', 'revenue': 25.42, 'unit': 'B', 'net_profit': 7.26}]","[{'period': ""Q3 '24"", 'revenue': 8.5, 'unit': 'B', 'net_profit': 2.83}, {'period': ""Q2 '24"", 'revenue': 8330.0, 'unit': 'M', 'net_profit': 746.0}, {'period': ""Q1 '24"", 'revenue': 7400.0, 'unit': 'M', 'net_profit': -113.0}, {'period': ""Q4 '23"", 'revenue': 8200.0, 'unit': 'M', 'net_profit': 767.0}, {'period': ""Q3 '23"", 'revenue': 6.9, 'unit': 'B', 'net_profit': 1.73}, {'period': ""Q2 '23"", 'revenue': 6.99, 'unit': 'B', 'net_profit': 1.38}]",12.56,12.49,97154000000,30332000000,10944000000,90922000000,7942000000,0,18392000000,10944000000,7359000000,0.21574464566278012,0.025183150183150184,0.03119868637110023,"[2.38, 0.28]","['2025-02-14', '2011-08-16']",__nan__,0.935854416699261
222,AMHC,Amplitude Healthcare Acquisition Corporation Class A Common Stock,"Amplitude Healthcare Acquisition Corporation does not have significant operations. It intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination with one or more businesses in the healthcare or healthcare related industries. The company was founded in 2019 and is based in New York, New York.",Mr. Balaji Venkataraman,Shell Companies,10.23,USD,1118364060,https://images.financialmodelingprep.com/symbol/AMHC.png,263450,0,-0.42000008,245352,-552250,-590701,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -590.7}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.57}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.5}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -513.8}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -282.06}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 38.86}]",-0.0473,-0.0473,101261021,921642,101109493,3769451,0,0,269451,770114,-640984,0,0,0,__nan__,__nan__,__nan__,0.03722509375053605
223,AMHCU,Amplitude Healthcare Acquisition Corporation Unit,"Amplitude Healthcare Acquisition Corporation does not have significant operations. It intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination with one or more businesses in the healthcare or healthcare related industries. The company was founded in 2019 and is based in New York, New York.",Mr. Balaji Venkataraman,Shell Companies,10.96,USD,0,https://images.financialmodelingprep.com/symbol/AMHCU.png,1193,0,0.35999966,4228,-552250,-590701,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -590.7}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.57}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.5}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -513.8}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -282.06}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 38.86}]",-0.0473,-0.0473,101261021,921642,101109493,3769451,0,0,269451,770114,-640984,0,0,0,__nan__,__nan__,__nan__,0.03722509375053605
224,AMHCW,Amplitude Healthcare Acquisition Corporation Warrants,,None,Shell Companies,1.57,USD,0,https://images.financialmodelingprep.com/symbol/AMHCW.png,0,0,0.05000007,92280,-552250,-590701,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -590.7}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.57}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.5}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -513.8}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -282.06}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 38.86}]",-0.0473,-0.0473,101261021,921642,101109493,3769451,0,0,269451,770114,-640984,0,0,0,__nan__,__nan__,__nan__,0.03722509375053605
225,AMKR,Amkor Technology Inc. Common Stock,"Amkor Technology, Inc. provides outsourced semiconductor packaging and test services in the United States, Japan, Europe, the Middle East, Africa, and the rest of the Asia Pacific. It offers turnkey packaging and test services, including semiconductor wafer bump, wafer probe, wafer back-grind, package design, packaging, and test and drop shipment services. The company also provides flip chip-scale package products for use in smartphones, tablets, and other mobile consumer electronic devices; flip-chip stacked chip-scale packages that are used to stack memory on top of digital baseband, and as applications processors in mobile devices; and flip-chip ball grid array packages for various networking, storage, computing, and consumer applications. In addition, it offers wafer-level CSP packages that are used in power management, transceivers, sensors, wireless charging, codecs, radar, and specialty silicon; wafer-level fan-out packages for use in ICs; and silicon wafer integrated fan-out technology, which replaces a laminate substrate with a thinner structure. Further, the company provides lead frame packages that are used in electronic devices for low to medium pin count analog and mixed-signal applications; substrate-based wirebond packages, which are used to connect a die to a substrate; micro-electro-mechanical systems (MEMS) packages that are miniaturized mechanical and electromechanical devices; and advanced system-in-package modules, which are used in radio frequency and front end modules, basebands, connectivity, fingerprint sensors, display and touch screen drivers, sensors and MEMS, and NAND memory and solid-state drives. It primarily serves integrated device manufacturers, fabless semiconductor companies, original equipment manufacturers, and contract foundries. Amkor Technology, Inc. was founded in 1968 and is headquartered in Tempe, Arizona.",Mr. Guillaume Marie Jean Rutten,Semiconductors,27.01,USD,6661503310,https://images.financialmodelingprep.com/symbol/AMKR.png,1304466,18.25,0.28,233562,1134349000,359813000,"[{'period': '2023', 'revenue': 6500.0, 'unit': 'M', 'net_profit': 359.81}, {'period': '2022', 'revenue': 7090.0, 'unit': 'M', 'net_profit': 765.82}, {'period': '2021', 'revenue': 6140.0, 'unit': 'M', 'net_profit': 643.0}, {'period': '2020', 'revenue': 5050.0, 'unit': 'M', 'net_profit': 338.14}]","[{'period': ""Q3 '24"", 'revenue': 1860.0, 'unit': 'M', 'net_profit': 122.57}, {'period': ""Q2 '24"", 'revenue': 1460.0, 'unit': 'M', 'net_profit': 66.9}, {'period': ""Q1 '24"", 'revenue': 1370.0, 'unit': 'M', 'net_profit': 58.9}, {'period': ""Q4 '23"", 'revenue': 1750.0, 'unit': 'M', 'net_profit': 117.56}, {'period': ""Q3 '23"", 'revenue': 1820.0, 'unit': 'M', 'net_profit': 132.61}, {'period': ""Q2 '23"", 'revenue': 1460.0, 'unit': 'M', 'net_profit': 64.29}]",1.46,1.46,6771125000,3195810000,1594687000,2776090000,1149493000,0,1384475000,1119818000,520553000,-0.25772069962184196,-0.5301616692107707,-0.5335463258785943,"[0.48815, 0.04]","['2024-12-04', '2020-12-17']",__nan__,0.40998947737635916
226,AMNB,American National Bankshares Inc. Common Stock,"American National Bankshares Inc. operates as the bank holding company for American National Bank and Trust Company that provides financial products and services. The company operates in two segments, Community Banking and Wealth Management. It accepts deposit products, including checking, money market, savings, and consumer and commercial time deposits. The company's loan products comprise commercial and residential real estate loans, commercial loans to small and medium-sized businesses, construction and land development loans, home equity loans, mortgage loans, and consumer loans. It also offers wealth management services, including estate planning, trust account administration, and retail brokerage services; investment management services, such as purchasing equity, fixed income, and mutual fund investments for customer accounts; online and telephone banking services; and insurance services, as well as operates 37 automated teller machines. As of December 31, 2021, the company operated 26 banking offices in south central Virginia and north central North Carolina; and one loan production office in Roanoke, Virginia. American National Bankshares Inc. was founded in 1909 and is based in Danville, Virginia.",Mr. Jeffrey Vernon Haley,Banks - Regional,47.76,USD,507722232,https://images.financialmodelingprep.com/symbol/AMNB.png,20507,19.414634146341463,-0.16,119440,0,26159000,"[{'period': '2023', 'revenue': 138.73, 'unit': 'M', 'net_profit': 26.16}, {'period': '2022', 'revenue': 109.27, 'unit': 'M', 'net_profit': 34.43}, {'period': '2021', 'revenue': 112.31, 'unit': 'M', 'net_profit': 43.53}, {'period': '2020', 'revenue': 100.77, 'unit': 'M', 'net_profit': 30.05}]","[{'period': ""Q4 '23"", 'revenue': 36.31, 'unit': 'M', 'net_profit': 4.08}, {'period': ""Q3 '23"", 'revenue': 25.44, 'unit': 'M', 'net_profit': 5.79}, {'period': ""Q2 '23"", 'revenue': 25.51, 'unit': 'M', 'net_profit': 7.14}, {'period': ""Q1 '23"", 'revenue': 27.7, 'unit': 'M', 'net_profit': 9.16}, {'period': ""Q4 '22"", 'revenue': 28.04, 'unit': 'M', 'net_profit': 8.03}, {'period': ""Q3 '22"", 'revenue': 28.77, 'unit': 'M', 'net_profit': 9.26}]",2.46,2.46,3090717000,76011000,-31500000,2747549000,0,47112000,903522000,66719000,16822000,0,-0.2401824096665505,-0.23839009287925697,"[0.3, 0.27]","['2024-02-16', '1995-06-06']",__nan__,0.8889681585211457
227,AMOT,Allied Motion Technologies Inc.,"Allied Motion Technologies Inc., together with its subsidiaries, designs, manufactures, and sells precision and specialty controlled motion components and systems that are used in a range of industries worldwide. The company offers brush and brushless DC motors, brushless servo and torque motors, coreless DC motors, integrated brushless motor-drives, gearmotors, gearing, modular digital servo drives, motion controllers, optical encoders, active, and passive filters. It also provides electronic power steering, drive-by-wire applications, drive systems and pumps, automated and remotely guided power steering, and HVAC systems, and construction and agricultural equipment. The company sells its products to end customers and original equipment manufacturers in vehicle, medical, aerospace and defense, and industrial markets through direct sales force, as well as authorized manufacturers' representatives, agents, and distributors. Allied Motion Technologies Inc. was incorporated in 1962 and is headquartered in Amherst, New York.",Mr. Richard S. Warzala,"Hardware, Equipment & Parts",34.08,USD,550906608,https://images.financialmodelingprep.com/symbol/AMOT.png,68443,23.50344827586207,0.69,84782,42314000,24097000,"[{'period': '2023', 'revenue': 578.63, 'unit': 'M', 'net_profit': 24.1}, {'period': '2022', 'revenue': 502.99, 'unit': 'M', 'net_profit': 17.39}, {'period': '2021', 'revenue': 403.52, 'unit': 'M', 'net_profit': 24.09}, {'period': '2020', 'revenue': 366.69, 'unit': 'M', 'net_profit': 13.64}]","[{'period': ""Q3 '23"", 'revenue': 145.32, 'unit': 'M', 'net_profit': 6.67}, {'period': ""Q2 '23"", 'revenue': 146.77, 'unit': 'M', 'net_profit': 6.77}, {'period': ""Q1 '23"", 'revenue': 145.55, 'unit': 'M', 'net_profit': 6.32}, {'period': ""Q4 '22"", 'revenue': 131.08, 'unit': 'M', 'net_profit': 3.7}, {'period': ""Q3 '22"", 'revenue': 134.41, 'unit': 'M', 'net_profit': 6.61}, {'period': ""Q2 '22"", 'revenue': 122.72, 'unit': 'M', 'net_profit': 4.58}]",1.48,1.48,597542000,248151000,31901000,345967000,85127000,0,95617000,31901000,33435000,-0.2558082273694578,0.38576111334751856,0.3097345132743364,"[0.03, 0.1]","['2023-08-16', '1987-02-13']",__nan__,0.5789835693557942
228,AMPG,Amplitech Group Inc. Common Stock,"AmpliTech Group, Inc. designs, engineers, and assembles micro-wave component-based amplifiers. The company's products include radio frequency (RF) amplifiers and related subsystems, such as low noise amplifiers for use in receivers of various communication systems comprising Wi-Fi, radar, satellite, base station, cell phone, radio, etc.; and medium power amplifiers that provide enhanced output power and gain in transceiver chains. It also provides specialty microwave block downconverters used as a test device on satellite access point antennas; specialty microwave 1:2 Tx protection switch panels that is used in satellite communication earth stations; desktop/benchtop and compact wideband power amplifiers; and waveguide to coaxial adapters for SATCOM and satellite internet gateway systems. In addition, the company offers cryogenic amplifiers for quantum computing, medical, RF imaging, research and development, space communications, accelerators, radiometry, and telephony applications; and cryogenic and non-cryogenic 4g/5g small cell subsystems for high-speed networks and airline Wi-Fi systems. Further, it provides custom assembly designs and non-recurring engineering services on a project-by-project basis, as well as IC packaging and lids products. The company serves aerospace, government, defense, commercial satellite, and wireless industries through sales representatives and distributors in the United States, Europe, the Middle East, and South Asia. AmpliTech Group, Inc. was founded in 2002 and is based in Bohemia, New York.",Mr. Fawad A. Maqbool,Communication Equipment,3.5087,USD,68968762,https://images.financialmodelingprep.com/symbol/AMPG.png,7541014,-4.28,-0.4713,4028813,-2046376,-2465439,"[{'period': '2023', 'revenue': 15.58, 'unit': 'M', 'net_profit': -2.47}, {'period': '2022', 'revenue': 19.39, 'unit': 'M', 'net_profit': -1.49}, {'period': '2021', 'revenue': 5.28, 'unit': 'M', 'net_profit': -5.06}, {'period': '2020', 'revenue': 3.46, 'unit': 'M', 'net_profit': -1.14}]","[{'period': ""Q3 '24"", 'revenue': 2.83, 'unit': 'M', 'net_profit': -1.19}, {'period': ""Q2 '24"", 'revenue': 2.53, 'unit': 'M', 'net_profit': -1.58}, {'period': ""Q1 '24"", 'revenue': 2.29, 'unit': 'M', 'net_profit': -4.66}, {'period': ""Q4 '23"", 'revenue': 4010.0, 'unit': 'K', 'net_profit': -523.0}, {'period': ""Q3 '23"", 'revenue': 3390.0, 'unit': 'K', 'net_profit': -887.71}, {'period': ""Q2 '23"", 'revenue': 4070.0000000000005, 'unit': 'K', 'net_profit': -472.76}]",-0.26,-0.26,31407629,17148636,6726013,4727898,2542710,348250,1499382,6726013,-4444239,-14.70178974362408,-0.6540442735308798,-0.625,__nan__,__nan__,__nan__,0.1505334261303201
229,AMPGW,Amplitech Group Inc. Warrants,"AmpliTech Group, Inc. designs, engineers, and assembles micro-wave component based amplifiers. The company's products include radio frequency amplifiers and related subsystems, such as low noise amplifiers for use in receivers of various communication systems comprise Wi-Fi, radar, satellite, base station, cell phone, radio, etc.; medium power amplifiers to provide increased output power and gain in transceiver chains; oscillators that consist of phase locked oscillators and dielectric resonator oscillators for transceiver applications; and filters that discriminate or block out frequencies in communication systems. It also provides custom assembly designs and non-recurring engineering services on a project-by-project basis. The company serves aerospace, government, defense, and commercial satellite industries. It sells its products through sales representatives or distributors in North America, Europe, and Asia. AmpliTech Group, Inc. was founded in 2002 and is based in Bohemia, New York.",Mr. Fawad A. Maqbool,Communication Equipment,0.888,USD,89064940,https://images.financialmodelingprep.com/symbol/AMPGW.png,50169,,0.108,3212,-2046376,-2465439,"[{'period': '2023', 'revenue': 15.58, 'unit': 'M', 'net_profit': -2.47}, {'period': '2022', 'revenue': 19.39, 'unit': 'M', 'net_profit': -1.49}, {'period': '2021', 'revenue': 5.28, 'unit': 'M', 'net_profit': -5.06}, {'period': '2020', 'revenue': 3.46, 'unit': 'M', 'net_profit': -1.14}]","[{'period': ""Q3 '24"", 'revenue': 2.83, 'unit': 'M', 'net_profit': -1.19}, {'period': ""Q2 '24"", 'revenue': 2.53, 'unit': 'M', 'net_profit': -1.58}, {'period': ""Q1 '24"", 'revenue': 2.29, 'unit': 'M', 'net_profit': -4.66}, {'period': ""Q4 '23"", 'revenue': 4010.0, 'unit': 'K', 'net_profit': -523.0}, {'period': ""Q3 '23"", 'revenue': 3390.0, 'unit': 'K', 'net_profit': -887.71}, {'period': ""Q2 '23"", 'revenue': 4070.0000000000005, 'unit': 'K', 'net_profit': -472.76}]",-0.26,-0.26,31407629,17148636,6726013,4727898,2542710,348250,1499382,6726013,-4444239,-14.70178974362408,-0.6540442735308798,-0.625,__nan__,__nan__,__nan__,0.1505334261303201
230,AMPH,Amphastar Pharmaceuticals Inc. Common Stock,"Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.",Dr. Yongfeng  Zhang Ph.D.,Drug Manufacturers - Specialty & Generic,35.47,USD,1705447258,https://images.financialmodelingprep.com/symbol/AMPH.png,464601,11.78,0.04,241667,240294000,137545000,"[{'period': '2023', 'revenue': 644.39, 'unit': 'M', 'net_profit': 137.54}, {'period': '2022', 'revenue': 498.99, 'unit': 'M', 'net_profit': 91.39}, {'period': '2021', 'revenue': 437.77, 'unit': 'M', 'net_profit': 62.12}, {'period': '2020', 'revenue': 349.85, 'unit': 'M', 'net_profit': 1.1}]","[{'period': ""Q3 '24"", 'revenue': 188.82, 'unit': 'M', 'net_profit': 40.43}, {'period': ""Q2 '24"", 'revenue': 182.39, 'unit': 'M', 'net_profit': 37.95}, {'period': ""Q1 '24"", 'revenue': 171.84, 'unit': 'M', 'net_profit': 43.18}, {'period': ""Q4 '23"", 'revenue': 178.1, 'unit': 'M', 'net_profit': 36.17}, {'period': ""Q3 '23"", 'revenue': 180.56, 'unit': 'M', 'net_profit': 49.22}, {'period': ""Q2 '23"", 'revenue': 145.71, 'unit': 'M', 'net_profit': 26.12}]",2.85,2.6,1512912000,489600000,256806000,873491000,114943000,15212000,225407000,144296000,145337000,1.2353554052671238,0.505099249337973,0.5159574468085107,"[0.3, 0.3]","['2010-06-11', '2009-06-11']",__nan__,0.577357440485633
231,AMRB,American River Bankshares Common Stock,"American River Bankshares operates as a bank holding company, which engages in financial services. The company is headquartered in Rancho Cordova, California and currently employs 104 full-time employees. The firm's banking subsidiary is American River Bank (the Bank). The Bank's primary business is serving the commercial banking needs of small to mid-sized businesses. The Bank accepts checking and savings deposits; offers money market deposit accounts and certificates of deposit; makes secured and unsecured commercial loans, secured real estate loans, and other installment and term loans, and offers other customary banking services. The Bank also conducts lease financing for various types of business equipment, from computer software to heavy earth-moving equipment. The company serves various communities located in Sacramento, Placer, Yolo, El Dorado, Sonoma and Amador counties. The company also serves Alameda, Contra Costa and Santa Clara Counties through loan production offices located in the Cities of San Jose and San Ramon. Its loans include real estate construction loans; lease financing receivable; agriculture loans, and consumer loans.",Mr. David Ritchie,Banks - Regional,20.91,USD,0,https://images.financialmodelingprep.com/symbol/AMRB.png,10735,13.930712858094603,0.40999985,115144,11580000,7055000,"[{'period': '2020', 'revenue': 27.84, 'unit': 'M', 'net_profit': 7.05}, {'period': '2019', 'revenue': 24.9, 'unit': 'M', 'net_profit': 5.5}, {'period': '2018', 'revenue': 22.16, 'unit': 'M', 'net_profit': 4.9}, {'period': '2017', 'revenue': 20.95, 'unit': 'M', 'net_profit': 3.2}]","[{'period': ""Q2 '21"", 'revenue': 7.66, 'unit': 'M', 'net_profit': 2.37}, {'period': ""Q1 '21"", 'revenue': 7.72, 'unit': 'M', 'net_profit': 2.65}, {'period': ""Q4 '20"", 'revenue': 7.25, 'unit': 'M', 'net_profit': 2.1}, {'period': ""Q3 '20"", 'revenue': 7.09, 'unit': 'M', 'net_profit': 1.78}, {'period': ""Q2 '20"", 'revenue': 6.86, 'unit': 'M', 'net_profit': 1.74}, {'period': ""Q1 '20"", 'revenue': 6.64, 'unit': 'M', 'net_profit': 1.43}]",1.2,1.2,30351000,14030000,349475000,775896000,9215000,306978000,7000000,42509000,6423000,0.14903750744195277,0.2827272727272727,0.2765957446808511,"[0.07, 0.125]","['2021-07-27', '1994-07-06']",__nan__,25.56410002965306
232,AMRK,A-Mark Precious Metals Inc. Common Stock,"A-Mark Precious Metals, Inc., together with its subsidiaries, operates as a precious metals trading company. It operates in three segments: Wholesale Sales & Ancillary Services, Direct-to-Consumer, and Secured Lending. The Wholesale Sales & Ancillary Services segment sells gold, silver, platinum, and palladium in the form of bars, plates, powders, wafers, grains, ingots, and coins. This segment also offers various ancillary services, including financing, storage, consignment, logistics, and various customized financial programs; and designs and produces minted silver products. The Direct-to-Consumer segment provides access to an array of gold, silver, copper, platinum, and palladium products through its websites and marketplaces. It operates five company-owned websites targeting specific niches within the precious metals retail market. This segment also operates as a direct retailer of precious metals to the investor community and markets its precious metal products on television, radio, and the internet, as well as through customer service outreach. The Secured Lending segment originates and acquires commercial loans secured by bullion and numismatic coins; and serves coin and precious metal dealers, investors, and collectors. The company serves customers, including financial institutions, bullion retailers, industrial manufacturers and fabricators, sovereign mints, refiners, coin and metal dealers, investors, collectors, and e-commerce and other retail customers. It has operations in the United States, rest of North America, Europe, the Asia Pacific, Africa, and Australia. A-Mark Precious Metals, Inc. was founded in 1965 and is headquartered in El Segundo, California.",Mr. Gregory N. Roberts,Financial - Capital Markets,27.5,USD,637562750,https://images.financialmodelingprep.com/symbol/AMRK.png,283285,11.27,-0.12,73163,133706000,68546000,"[{'period': '2024', 'revenue': 9700.0, 'unit': 'M', 'net_profit': 68.55}, {'period': '2023', 'revenue': 9320.0, 'unit': 'M', 'net_profit': 156.36}, {'period': '2022', 'revenue': 8160.0, 'unit': 'M', 'net_profit': 132.54}, {'period': '2021', 'revenue': 7610.0, 'unit': 'M', 'net_profit': 159.64}]","[{'period': ""Q1 '25"", 'revenue': 2720.0, 'unit': 'M', 'net_profit': 8.98}, {'period': ""Q4 '24"", 'revenue': 2520.0, 'unit': 'M', 'net_profit': 30.94}, {'period': ""Q3 '24"", 'revenue': 2630.0, 'unit': 'M', 'net_profit': 5.01}, {'period': ""Q2 '24"", 'revenue': 2080.0, 'unit': 'M', 'net_profit': 13.77}, {'period': ""Q1 '24"", 'revenue': 2480.0, 'unit': 'M', 'net_profit': 18.83}, {'period': ""Q4 '23"", 'revenue': 3160.0, 'unit': 'M', 'net_profit': 41.83}]",2.97,2.84,1827820000,1442203000,48636000,1165964000,36596000,50458000,883770000,48636000,45163000,-0.3623087489030486,-0.5616142235865951,-0.5553892215568862,"[0.2, 0.05]","['2025-01-14', '2015-03-10']",__nan__,0.6378986989966189
233,AMRN,Amarin Corporation plc,"Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.",Mr. Aaron D. Berg,Biotechnology,0.5404,USD,222245811,https://images.financialmodelingprep.com/symbol/AMRN.png,1456420,-5.4,0.0151,440319,-50901531,-59112000,"[{'period': '2023', 'revenue': 306.91, 'unit': 'M', 'net_profit': -59.11}, {'period': '2022', 'revenue': 369.19, 'unit': 'M', 'net_profit': -105.8}, {'period': '2021', 'revenue': 583.19, 'unit': 'M', 'net_profit': 7.73}, {'period': '2020', 'revenue': 614.06, 'unit': 'M', 'net_profit': -18.0}]","[{'period': ""Q3 '24"", 'revenue': 42.3, 'unit': 'M', 'net_profit': -25.13}, {'period': ""Q2 '24"", 'revenue': 67.57, 'unit': 'M', 'net_profit': 1.52}, {'period': ""Q1 '24"", 'revenue': 56.49, 'unit': 'M', 'net_profit': -9.95}, {'period': ""Q4 '23"", 'revenue': 75.36, 'unit': 'M', 'net_profit': -5.83}, {'period': ""Q3 '23"", 'revenue': 66.06, 'unit': 'M', 'net_profit': -19.31}, {'period': ""Q2 '23"", 'revenue': 80.17, 'unit': 'M', 'net_profit': -17.56}]",-0.15,-0.15,831684000,724981000,320659000,279587000,133562999,0,259277000,199252000,6347000,0.49425606430341723,0.44130128635293897,0.42307692307692313,__nan__,__nan__,__nan__,0.33616974716358616
234,AMRS,Amyris Inc. Common Stock,"Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.",Mr. Hermanus  Kieftenbeld,Chemicals - Specialty,0.05,USD,0,https://images.financialmodelingprep.com/symbol/AMRS.png,0,-0.04,0,46746028,-514205000,-535928000,"[{'period': '2022', 'revenue': 269.85, 'unit': 'M', 'net_profit': -535.93}, {'period': '2021', 'revenue': 341.82, 'unit': 'M', 'net_profit': -264.2}, {'period': '2020', 'revenue': 173.14, 'unit': 'M', 'net_profit': -324.14}, {'period': '2019', 'revenue': 152.56, 'unit': 'M', 'net_profit': -242.77}]","[{'period': ""Q1 '23"", 'revenue': 56.08, 'unit': 'M', 'net_profit': -201.78}, {'period': ""Q4 '22"", 'revenue': 75.8, 'unit': 'M', 'net_profit': -150.66}, {'period': ""Q3 '22"", 'revenue': 71.13, 'unit': 'M', 'net_profit': -167.27}, {'period': ""Q2 '22"", 'revenue': 65.21, 'unit': 'M', 'net_profit': -108.55}, {'period': ""Q1 '22"", 'revenue': 57.71, 'unit': 'M', 'net_profit': -109.44}, {'period': ""Q4 '21"", 'revenue': 64.78, 'unit': 'M', 'net_profit': 37.84}]",-1.58,-1.58,824932000,306361000,64437000,1292642000,97568000,10892000,387147000,64437000,-631841000,-1.6950371337075532,-1.0285165993557837,-0.7555555555555555,__nan__,__nan__,__nan__,1.5669679440244773
235,AMSC,American Superconductor Corporation Common Stock,"American Superconductor Corporation, together with its subsidiaries, provides megawatt-scale power resiliency solutions worldwide. The company operates in two segments, Grid and Wind. The Grid segment offers products and services that enable electric utilities, industrial facilities, and renewable energy project developers to connect, transmit, and distribute power under the Gridtec Solutions brand; and engineering planning services. It provides transmission planning services, which identify power grid congestion, poor power quality, and other risks; grid interconnection solutions for wind farms and solar power plants, power quality systems, and transmission and distribution cable systems; resilient electric grid systems, resilient electric grid systems; D-VAR systems used for controlling power flow and voltage in the AC transmission system; actiVAR system, a fast-switching medium-voltage reactive compensation solution; armorVAR system installed for reactive compensation, power factor correction, loss reduction, utility bill savings, and mitigation of common power quality concerns related to power converter-based generation and load devices; and D-VAR volt var optimization (VVO) that serves the distribution power grid market. This segment also offers ship protection systems, which reduce a naval ship's magnetic signature; and in board power delivery systems, power generation systems, and propulsion systems; and transformers and rectifiers systems. The Wind segment designs wind turbine systems and licenses these designs to third parties under the Windtec Solutions brand. It supplies power electronics and software-based control systems, engineered designs, and support services; and provides customer support services to wind turbine manufacturers. This segment's design portfolio comprises a range of drivetrains and power ratings of 2 megawatts and higher. The company was incorporated in 1987 and is headquartered in Ayer, Massachusetts.",Mr. Daniel Patrick McGahn,Industrial - Machinery,28.25,USD,1114552900,https://images.financialmodelingprep.com/symbol/AMSC.png,1415620,-941.67,-0.89,437805,-1966000,-11111000,"[{'period': '2023', 'revenue': 145.64, 'unit': 'M', 'net_profit': -11.11}, {'period': '2022', 'revenue': 105.98, 'unit': 'M', 'net_profit': -35.04}, {'period': '2021', 'revenue': 108.44, 'unit': 'M', 'net_profit': -19.19}, {'period': '2020', 'revenue': 87.12, 'unit': 'M', 'net_profit': -22.68}]","[{'period': ""Q2 '24"", 'revenue': 54.47, 'unit': 'M', 'net_profit': 4.89}, {'period': ""Q1 '24"", 'revenue': 40.29, 'unit': 'M', 'net_profit': -2.52}, {'period': ""Q4 '23"", 'revenue': 42.03, 'unit': 'M', 'net_profit': -1.58}, {'period': ""Q3 '23"", 'revenue': 39.35, 'unit': 'M', 'net_profit': -1.65}, {'period': ""Q2 '23"", 'revenue': 34.0, 'unit': 'M', 'net_profit': -2.48}, {'period': ""Q1 '23"", 'revenue': 30.25, 'unit': 'M', 'net_profit': -5.4}]",-0.37,-0.37,232771000,166467000,90522000,88200000,26325000,0,78808000,90522000,1204000,0.925895212966453,0.6829143003909706,0.7063492063492064,__nan__,__nan__,__nan__,0.37891318076564523
236,AMSF,AMERISAFE Inc. Common Stock,"AMERISAFE, Inc., an insurance holding company, underwrites workers' compensation insurance in the United States. The company's workers' compensation insurance policies provide benefits to injured employees for temporary or permanent disability, death, and medical and hospital expenses. It serves small to mid-sized employers engaged in hazardous industries, including construction, trucking, logging and lumber, agriculture, manufacturing, telecommunications, and maritime. The company was incorporated in 1985 and is based in DeRidder, Louisiana.",Ms. Gerry Janelle Frost,Insurance - Specialty,49.73,USD,947356500,https://images.financialmodelingprep.com/symbol/AMSF.png,119830,15.84,-0.13,20524,0,62108000,"[{'period': '2023', 'revenue': 306.91, 'unit': 'M', 'net_profit': 62.11}, {'period': '2022', 'revenue': 294.69, 'unit': 'M', 'net_profit': 55.6}, {'period': '2021', 'revenue': 316.01, 'unit': 'M', 'net_profit': 65.76}, {'period': '2020', 'revenue': 339.5, 'unit': 'M', 'net_profit': 86.6}]","[{'period': ""Q3 '24"", 'revenue': 78.71, 'unit': 'M', 'net_profit': 14.32}, {'period': ""Q2 '24"", 'revenue': 75.83, 'unit': 'M', 'net_profit': 10.99}, {'period': ""Q1 '24"", 'revenue': 80.49, 'unit': 'M', 'net_profit': 16.93}, {'period': ""Q4 '23"", 'revenue': 80.12, 'unit': 'M', 'net_profit': 19.18}, {'period': ""Q3 '23"", 'revenue': 72.66, 'unit': 'M', 'net_profit': 9.96}, {'period': ""Q2 '23"", 'revenue': 75.67, 'unit': 'M', 'net_profit': 15.63}]",3.24,3.23,1229162000,628625000,355746000,936711000,272879000,540722000,0,38682000,29289000,0,0.11701017948994641,0.12110726643598618,"[3.37, 0.08]","['2024-12-06', '2013-03-12']",__nan__,0.7620728593952628
237,AMST,Amesite Inc. Common Stock,"Amesite Inc., an artificial intelligence driven platform and course designer, provides online products in the United States. The company uses machine learning to offer a mass customized experience to learners. Its customers include businesses, universities and colleges, K-12 schools, and non-profit organizations. The company was incorporated in 2017 and is headquartered in Detroit, Michigan.",Dr. Ann Marie Sastry Ph.D.,Software - Application,2.8699,USD,8014024,https://images.financialmodelingprep.com/symbol/AMST.png,46759,-1.67,-1.1801,701616,-3869515,-4403182,"[{'period': '2024', 'revenue': 0.16688, 'unit': 'M', 'net_profit': -4.4}, {'period': '2023', 'revenue': 0.84501, 'unit': 'M', 'net_profit': -4.15}, {'period': '2022', 'revenue': 0.6970000000000001, 'unit': 'M', 'net_profit': -9.07}, {'period': '2021', 'revenue': 0.6745800000000001, 'unit': 'M', 'net_profit': -15.2}]","[{'period': ""Q1 '25"", 'revenue': 11.25, 'unit': 'K', 'net_profit': -908.04}, {'period': ""Q4 '24"", 'revenue': 0.02784, 'unit': 'M', 'net_profit': -1.18}, {'period': ""Q3 '24"", 'revenue': 0.03426, 'unit': 'M', 'net_profit': -1.43}, {'period': ""Q2 '24"", 'revenue': 41.44, 'unit': 'K', 'net_profit': -905.61}, {'period': ""Q1 '24"", 'revenue': 63.33, 'unit': 'K', 'net_profit': -890.69}, {'period': ""Q4 '23"", 'revenue': 123.0, 'unit': 'K', 'net_profit': -948.48}]",-1.73,-1.73,3314177,2604565,2071016,798465,30060,0,798465,2071016,-3189645,-0.09245841009027322,-0.060163922545501736,-0.029761904761904788,__nan__,__nan__,__nan__,0.24092406651787154
238,AMSWA,American Software Inc. Class A Common Stock,"American Software, Inc. develops, markets, and supports a range of computer business application software products in the United States and internationally. The company operates in three segments: Supply Chain Management (SCM), Information Technology Consulting (IT Consulting), and Other. The SCM segment offers Logility Digital Supply Chain Platform, a cloud-architected supply chain management platform that helps manage seven critical planning processes, such as product, demand, inventory, supply, deploy, integrated business planning, and supply chain data management. The IT Consulting segment provides IT staffing and consulting services, such as software enhancement, documentation, update, customer education, consulting, systems integration, maintenance, and support services. The Other segment offers American Software ERP, which provides purchasing and materials management, customer order processing, financial, e-commerce, and traditional manufacturing solutions. It also provides ongoing support and maintenance services; cloud hosting and managed services; and implementation and training services. The company markets its products through direct and indirect sales channels to the apparel and other soft goods, food and beverage, consumer packaged goods, consumer durable goods, wholesale distribution, specialty chemicals, and other process manufacturing industries. American Software, Inc. was incorporated in 1970 and is headquartered in Atlanta, Georgia.",Mr. H. Allan Dow,Software - Application,10.95,USD,388512570,https://images.financialmodelingprep.com/symbol/AMSWA.png,226237,40.55555555555556,-0.24,113503,8089000,11373000,"[{'period': '2024', 'revenue': 102.52, 'unit': 'M', 'net_profit': 11.37}, {'period': '2023', 'revenue': 123.66, 'unit': 'M', 'net_profit': 10.31}, {'period': '2022', 'revenue': 127.55, 'unit': 'M', 'net_profit': 12.8}, {'period': '2021', 'revenue': 111.41, 'unit': 'M', 'net_profit': 8.09}]","[{'period': ""Q1 '25"", 'revenue': 26.19, 'unit': 'M', 'net_profit': 2.05}, {'period': ""Q4 '24"", 'revenue': 25.39, 'unit': 'M', 'net_profit': 2.17}, {'period': ""Q3 '24"", 'revenue': 25.54, 'unit': 'M', 'net_profit': 4.09}, {'period': ""Q2 '24"", 'revenue': 25.69, 'unit': 'M', 'net_profit': 2.36}, {'period': ""Q1 '24"", 'revenue': 29.17, 'unit': 'M', 'net_profit': 2.75}, {'period': ""Q4 '23"", 'revenue': 29.91, 'unit': 'M', 'net_profit': 2.87}]",0.27,0.27,192444000,116196000,83773000,61963000,28339000,0,60343000,59512000,14283000,-0.35689298775640005,0.10288983708301008,-0.12903225806451607,"[0.11, 0.0237]","['2024-11-15', '1986-07-21']",__nan__,0.3219793810147368
239,AMTB,Amerant Bancorp Inc. Class A Common Stock,"Amerant Bancorp Inc. operates as the bank holding company for Amerant Bank, N.A. that provides banking products and services to individuals and businesses in the United States and internationally. The company offers checking, savings, and money market accounts; and certificates of deposits. It also provides variable and fixed rate commercial real estate loans; loans secured by owner-occupied properties; loans to domestic and foreign individuals primarily secured by personal residence; working capital loans, asset-based lending, participations in shared national credits, purchased receivables, and small business administration loans; loans to financial institutions and acceptances; and consumer loans and overdrafts, such as automobile, personal, or loans secured by cash or securities and revolving credit card agreements. In addition, the company offers trust and estate planning products and services to high-net-worth customers, brokerage and investment advisory services in global capital markets, and wealth management and fiduciary services. Further, it provides debit and credit cards, night depositories, direct deposits, cashier's checks, safe deposit boxes, letters of credit, and treasury management services, including wire transfer, remote deposit capture, and automated clearinghouse services; derivative instruments; and online and mobile banking, account balances, statements and other documents, online transfers and bill payment, and electronic delivery of customer statements services, as well as automated teller machines, and banking by mobile devices, telephone, and mail. As of December 31, 2021, the company operated 24 banking centers comprising 17 in Florida and 7 in Texas. It also operates loan production offices in Tampa, Florida. The company was formerly known as Mercantil Bank Holding Corporation and changed its name to Amerant Bancorp Inc. in June 2019. Amerant Bancorp Inc. was founded in 1979 and is headquartered in Coral Gables, Florida.","Mr. Gerald Paul Plush C.M.A., CPA",Banks - Regional,21.325,USD,897961630,https://images.financialmodelingprep.com/symbol/AMTB.png,246261,-14.41,-0.265,38688,0,32490000,"[{'period': '2023', 'revenue': 328.91, 'unit': 'M', 'net_profit': 32.49}, {'period': '2022', 'revenue': 266.67, 'unit': 'M', 'net_profit': 46.69}, {'period': '2021', 'revenue': 205.14, 'unit': 'M', 'net_profit': 79.21}, {'period': '2020', 'revenue': 263.1, 'unit': 'M', 'net_profit': -1.72}]","[{'period': ""Q3 '24"", 'revenue': 94.9, 'unit': 'M', 'net_profit': -48.16}, {'period': ""Q2 '24"", 'revenue': 163.28, 'unit': 'M', 'net_profit': 4.96}, {'period': ""Q1 '24"", 'revenue': 92.45, 'unit': 'M', 'net_profit': 10.57}, {'period': ""Q4 '23"", 'revenue': 57.15, 'unit': 'M', 'net_profit': -17.12}, {'period': ""Q3 '23"", 'revenue': 89.14, 'unit': 'M', 'net_profit': 22.12}, {'period': ""Q2 '23"", 'revenue': 83.88, 'unit': 'M', 'net_profit': 7.31}]",0.97,0.96,9716327000,53314000,53314000,8980259000,0,1446681000,0,296023000,15788000,-1,-0.3041187431729101,-0.2971014492753623,"[0.09, 0.06]","['2024-11-14', '2021-12-21']",__nan__,0.9242442128594478
240,AMTBB,Amerant Bancorp Inc. Class B Common Stock,"Amerant Bancorp Inc. operates as the bank holding company for Amerant Bank, N.A. that provides banking products and services to individuals and businesses in the United States and internationally. It offers a range of checking and savings accounts, certificates of deposit, and money market accounts. The company also provides variable and fixed rate commercial real estate loans; loans secured by owner-occupied properties; loans to domestic and foreign individuals primarily secured by personal residence; working capital loans, asset-based lending, participations in shared national credits, purchased receivables, and small business administration loans; loans to financial institutions and acceptances; and consumer loans and overdrafts. In addition, it offers trust and estate planning products and services, brokerage and investment advisory services in global capital markets, and wealth management and fiduciary services. Further, the company provides debit and credit cards; remote deposit capture, online and mobile banking, night depository, direct deposit, and treasury management services; and cashier's checks, safe deposit boxes, and letters of credit, as well as automated teller machines. As of April 10, 2020, it operated 27 banking centers comprising 19 in South Florida and 8 in Houston, Texas, as well as loan production offices in Dallas, Texas, and New York. The company was formerly known as Mercantil Bank Holding Corporation and changed its name to Amerant Bancorp Inc. in June 2019. Amerant Bancorp Inc. was founded in 1979 and is headquartered in Coral Gables, Florida.",Mr. Millar Wilson,Banks - Regional,28.72,USD,0,https://images.financialmodelingprep.com/symbol/AMTBB.png,18790,19.847961299239806,-0.3600006,3933,0,32490000,"[{'period': '2023', 'revenue': 328.91, 'unit': 'M', 'net_profit': 32.49}, {'period': '2022', 'revenue': 266.67, 'unit': 'M', 'net_profit': 46.69}, {'period': '2021', 'revenue': 205.14, 'unit': 'M', 'net_profit': 79.21}, {'period': '2020', 'revenue': 263.1, 'unit': 'M', 'net_profit': -1.72}]","[{'period': ""Q3 '24"", 'revenue': 94.9, 'unit': 'M', 'net_profit': -48.16}, {'period': ""Q2 '24"", 'revenue': 163.28, 'unit': 'M', 'net_profit': 4.96}, {'period': ""Q1 '24"", 'revenue': 92.45, 'unit': 'M', 'net_profit': 10.57}, {'period': ""Q4 '23"", 'revenue': 57.15, 'unit': 'M', 'net_profit': -17.12}, {'period': ""Q3 '23"", 'revenue': 89.14, 'unit': 'M', 'net_profit': 22.12}, {'period': ""Q2 '23"", 'revenue': 83.88, 'unit': 'M', 'net_profit': 7.31}]",0.97,0.96,9716327000,53314000,53314000,8980259000,0,1446681000,0,296023000,15788000,-1,-0.3041187431729101,-0.2971014492753623,__nan__,__nan__,__nan__,0.9242442128594478
241,AMTI,Applied Molecular Transport Inc. Common Stock,"Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.",Mr. Shawn M. Cross,Biotechnology,0.263,USD,11006287,https://images.financialmodelingprep.com/symbol/AMTI.png,320195,-0.13915343915343914,-0.0085,235210,-127219000,-125431000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -125.43}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -96.41}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -64.49}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.04}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.94}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.33}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.77}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -22.1}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.89}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.87}]",-3.23,-3.23,107446000,64019000,61145000,46608000,0,0,15087000,61145000,-98052000,-0.2622309974302751,-0.3010164920651385,-0.26171874999999994,__nan__,__nan__,__nan__,0.4337806898348938
242,AMTX,Aemetis Inc. Common Stock,"Aemetis, Inc. operates as a renewable natural gas and renewable fuels company in North America and India. It operates through three segments: California Ethanol, Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the acquisition, development, and commercialization of negative carbon intensity products and technologies that replace traditional petroleum-based products. It sells biodiesel primarily to government oil marketing companies, transport companies, resellers, distributors, and private refiners through its own sales force and independent sales agents, as well as to brokers who resell the product to end-users. The company also produces and sells ethanol; and wet distillers grains, distillers corn oil, and condensed distillers solubles to dairies and feedlots as animal feed. In addition, it produces dairy biogas; produces and sells high-grade alcohol and various feed products, as well as hand sanitizers; and researches and develops conversion technologies using waste feedstocks to produce biofuels and biochemicals. The company was formerly known as AE Biofuels, Inc. and changed its name to Aemetis, Inc. in November 2011. Aemetis, Inc. was founded in 2005 and is headquartered in Cupertino, California.",Mr. Eric A. McAfee,Oil & Gas Refining & Marketing,2.86,USD,142240956,https://images.financialmodelingprep.com/symbol/AMTX.png,725919,-1.25,-0.13,188858,-34843000,-46420000,"[{'period': '2023', 'revenue': 186.72, 'unit': 'M', 'net_profit': -46.42}, {'period': '2022', 'revenue': 256.51, 'unit': 'M', 'net_profit': -107.76}, {'period': '2021', 'revenue': 211.95, 'unit': 'M', 'net_profit': -47.15}, {'period': '2020', 'revenue': 165.56, 'unit': 'M', 'net_profit': -36.66}]","[{'period': ""Q3 '24"", 'revenue': 81.44, 'unit': 'M', 'net_profit': -17.93}, {'period': ""Q2 '24"", 'revenue': 66.56, 'unit': 'M', 'net_profit': -29.17}, {'period': ""Q1 '24"", 'revenue': 72.63, 'unit': 'M', 'net_profit': -24.23}, {'period': ""Q4 '23"", 'revenue': 70.76, 'unit': 'M', 'net_profit': -25.44}, {'period': ""Q3 '23"", 'revenue': 68.69, 'unit': 'M', 'net_profit': 30.71}, {'period': ""Q2 '23"", 'revenue': 45.11, 'unit': 'M', 'net_profit': -25.28}]",-1.22,-1.22,243406000,36400000,2667000,460383000,8633000,0,84389000,2667000,-19294000,0.4395348089049028,0.5692199187067317,0.608974358974359,__nan__,__nan__,__nan__,1.8914200964643435
243,AMWD,American Woodmark Corporation Common Stock,"American Woodmark Corporation manufactures and distributes kitchen, bath, office, home organization, and hardware products for the remodelling and new home construction markets in the United States. The company offers made-to-order and cash and carry products. It also provides turnkey installation services to its direct builder customers through a network of eight service centers. The company sells its products under the American Woodmark, Timberlake, Shenandoah Cabinetry, Waypoint Living Spaces, Estate, Stor-It-All, and Professional Cabinet Solutions brands, as well as Hampton Bay, Glacier Bay, Style Selections, Allen + Roth, Home Decorators Collection, and Project Source. It markets its products directly to home centers and builders, as well as through independent dealers and distributors. The company was incorporated in 1980 and is based in Winchester, Virginia.",Mr. M. Scott Culbreth,"Furnishings, Fixtures & Appliances",77.9775,USD,1173881083,https://images.financialmodelingprep.com/symbol/AMWD.png,152269,11.64,-0.9825,43992,238956000,116216000,"[{'period': '2024', 'revenue': 1850.0, 'unit': 'M', 'net_profit': 116.22}, {'period': '2023', 'revenue': 2070.0, 'unit': 'M', 'net_profit': 93.72}, {'period': '2022', 'revenue': 1860.0, 'unit': 'M', 'net_profit': -29.72}, {'period': '2021', 'revenue': 1740.0, 'unit': 'M', 'net_profit': 61.19}]","[{'period': ""Q2 '25"", 'revenue': 452.48, 'unit': 'M', 'net_profit': 27.69}, {'period': ""Q1 '25"", 'revenue': 459.13, 'unit': 'M', 'net_profit': 29.63}, {'period': ""Q4 '24"", 'revenue': 453.28, 'unit': 'M', 'net_profit': 26.8}, {'period': ""Q3 '24"", 'revenue': 422.1, 'unit': 'M', 'net_profit': 21.23}, {'period': ""Q2 '24"", 'revenue': 473.87, 'unit': 'M', 'net_profit': 30.34}, {'period': ""Q1 '24"", 'revenue': 498.25, 'unit': 'M', 'net_profit': 37.85}]",7.15,7.15,1593865000,402710000,87398000,683489000,132107000,0,195726000,87398000,139702000,0.045192105815662395,0.23999445173543313,0.26773049645390085,"[0.09, 0.005]","['2011-06-09', '1996-09-11']",__nan__,0.42882490047776944
244,AMYT,Amryt Pharma plc American Depositary Shares,"Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.",Dr. Joseph A. Wiley,Drug Manufacturers - Specialty & Generic,14.7,USD,0,https://images.financialmodelingprep.com/symbol/AMYT.png,0,39.73,0,2376385,29103000,-18171000,"[{'period': '2021', 'revenue': 222.54, 'unit': 'M', 'net_profit': -18.17}, {'period': '2020', 'revenue': 182.61, 'unit': 'M', 'net_profit': -104.53}, {'period': '2019', 'revenue': 58.12, 'unit': 'M', 'net_profit': -65.53}, {'period': '2018', 'revenue': 16.53, 'unit': 'M', 'net_profit': -29.49}]","[{'period': ""Q3 '22"", 'revenue': 61.13, 'unit': 'M', 'net_profit': -20.8}, {'period': ""Q2 '22"", 'revenue': 68.54, 'unit': 'M', 'net_profit': -7.05}, {'period': ""Q1 '22"", 'revenue': 59.13, 'unit': 'M', 'net_profit': -14.49}, {'period': ""Q4 '21"", 'revenue': 54.83, 'unit': 'M', 'net_profit': 22.37}, {'period': ""Q3 '21"", 'revenue': 56.52, 'unit': 'M', 'net_profit': -17.21}, {'period': ""Q2 '21"", 'revenue': 62.76, 'unit': 'M', 'net_profit': -6.8}]",-0.39,-0.37,783365000,282709000,112771000,445918000,53908000,0,157279000,112771000,13986000,30.788126919140225,0.8261597481990299,0.8664383561643835,__nan__,__nan__,__nan__,0.56923400968897
245,AMZN,Amazon.com Inc. Common Stock,"Amazon.com, Inc. engages in the retail sale of consumer products and subscriptions through online and physical stores in North America and internationally. The company operates through three segments: North America, International, and Amazon Web Services (AWS). Its products offered through its stores include merchandise and content purchased for resale; and products offered by third-party sellers The company also manufactures and sells electronic devices, including Kindle, Fire tablets, Fire TVs, Rings, Blink, eero, and Echo; and develops and produces media content. In addition, it offers programs that enable sellers to sell their products in its stores; and programs that allow authors, musicians, filmmakers, Twitch streamers, skill and app developers, and others to publish and sell content. Further, the company provides compute, storage, database, analytics, machine learning, and other services, as well as fulfillment, advertising, and digital content subscriptions. Additionally, it offers Amazon Prime, a membership program. The company serves consumers, sellers, developers, enterprises, content creators, and advertisers. Amazon.com, Inc. was incorporated in 1994 and is headquartered in Seattle, Washington.",Mr. Andrew R. Jassy,Specialty Retail,222.87,USD,2343478050000,https://images.financialmodelingprep.com/symbol/AMZN.png,37432196,47.52,-4.725,11456981,89402000000,30425000000,"[{'period': '2023', 'revenue': 574.78, 'unit': 'B', 'net_profit': 30.43}, {'period': '2022', 'revenue': 513.98, 'unit': 'B', 'net_profit': -2.72}, {'period': '2021', 'revenue': 469.82, 'unit': 'B', 'net_profit': 33.36}, {'period': '2020', 'revenue': 386.06, 'unit': 'B', 'net_profit': 21.33}]","[{'period': ""Q3 '24"", 'revenue': 158.88, 'unit': 'B', 'net_profit': 15.33}, {'period': ""Q2 '24"", 'revenue': 147.98, 'unit': 'B', 'net_profit': 13.48}, {'period': ""Q1 '24"", 'revenue': 143.31, 'unit': 'B', 'net_profit': 10.43}, {'period': ""Q4 '23"", 'revenue': 169.96, 'unit': 'B', 'net_profit': 10.62}, {'period': ""Q3 '23"", 'revenue': 143.08, 'unit': 'B', 'net_profit': 9.88}, {'period': ""Q2 '23"", 'revenue': 134.38, 'unit': 'B', 'net_profit': 6.75}]",2.95,2.9,527854000000,172351000000,86780000000,325979000000,52253000000,2206000000,164917000000,73387000000,32217000000,1.3310909470171046,12.177443056576047,11.925925925925926,__nan__,__nan__,__nan__,0.6175552330758126
246,ANAB,AnaptysBio Inc. Common Stock,"AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.",Mr. Daniel R. Faga,Biotechnology,15.22,USD,463124814,https://images.financialmodelingprep.com/symbol/ANAB.png,610974,-2.4,-0.08,123883,-143164000,-163619000,"[{'period': '2023', 'revenue': 17.16, 'unit': 'M', 'net_profit': -163.62}, {'period': '2022', 'revenue': 10.29, 'unit': 'M', 'net_profit': -128.72}, {'period': '2021', 'revenue': 63.17, 'unit': 'M', 'net_profit': -57.19}, {'period': '2020', 'revenue': 75.0, 'unit': 'M', 'net_profit': -19.92}]","[{'period': ""Q3 '24"", 'revenue': 30.02, 'unit': 'M', 'net_profit': -32.85}, {'period': ""Q2 '24"", 'revenue': 10.97, 'unit': 'M', 'net_profit': -46.66}, {'period': ""Q1 '24"", 'revenue': 7.18, 'unit': 'M', 'net_profit': -43.94}, {'period': ""Q4 '23"", 'revenue': 9.01, 'unit': 'M', 'net_profit': -42.21}, {'period': ""Q3 '23"", 'revenue': 3.32, 'unit': 'M', 'net_profit': -37.31}, {'period': ""Q2 '23"", 'revenue': 3.46, 'unit': 'M', 'net_profit': -39.84}]",-6.08,-6.08,452389000,406835000,390904000,364286000,6851000,27026000,37442000,35965000,-121607000,-0.3601375680477308,-0.2710838693639104,-0.3304157549234135,__nan__,__nan__,__nan__,0.8052494645095261
247,ANAT,American National Group Inc. Common Stock,"American National Group, Inc., together with its subsidiaries, provides life insurance, annuities, property and casualty insurance, health insurance, credit insurance, and pension products in the United States, the District of Columbia, and Puerto Rico. It operates through five segments: Life, Annuity, Health, Property and Casualty, and Corporate and Other. The Life segment offers whole life, term life, universal life, variable universal life, and credit life insurance products. The Annuity segment provides deferred, single premium immediate, and variable annuity products. The Health segment offers medicare supplement, supplemental, stop-loss, credit disability, and medical expense insurance products. The Property and Casualty segment provides personal lines insurance, such as auto, homeowners, boats, motorcycles, recreational vehicles, and other exposures; commercial lines of insurance, including property and casualty coverage tailored for a farm, ranch, or other agricultural business, as well as business owners' property and liability, workers' compensation insurance, and other commercial insurance; and specialty markets products comprising collateral or creditor protection insurance, and guaranteed auto protection or guaranteed asset protection insurance. The Corporate and Other segment engages in the investment activities. The company distributes its products through career, multiple-line, and independent agents, as well as direct marketing channels; brokers and financial institutions; managing general underwriters; and multiple-line and managing general agents. American National Group, Inc. was incorporated in 1905 and is headquartered in Galveston, Texas.",Mr. James Pozzi,Insurance - Diversified,188.99,USD,0,https://images.financialmodelingprep.com/symbol/ANAT.png,108431,6.725383438311804,-0.06999207,72185,915893000,696408000,"[{'period': '2021', 'revenue': 4390.0, 'unit': 'M', 'net_profit': 696.41}, {'period': '2020', 'revenue': 3790.0, 'unit': 'M', 'net_profit': 467.5}, {'period': '2019', 'revenue': 4070.0000000000005, 'unit': 'M', 'net_profit': 620.36}, {'period': '2018', 'revenue': 3330.0, 'unit': 'M', 'net_profit': 159.0}]","[{'period': ""Q1 '22"", 'revenue': 946.13, 'unit': 'M', 'net_profit': 111.55}, {'period': ""Q4 '21"", 'revenue': 1210.0, 'unit': 'M', 'net_profit': 249.64}, {'period': ""Q3 '21"", 'revenue': 975.23, 'unit': 'M', 'net_profit': 51.05}, {'period': ""Q2 '21"", 'revenue': 1170.0, 'unit': 'M', 'net_profit': 227.98}, {'period': ""Q1 '21"", 'revenue': 1040.0, 'unit': 'M', 'net_profit': 170.17}, {'period': ""Q4 '20"", 'revenue': 1190.0, 'unit': 'M', 'net_profit': 306.35}]",25.9,25.9,31312630000,2892645000,12151862000,24318262000,842183000,17571189000,149248000,1930882000,313637000,0.4385836777070444,0.48962684891070685,0.48936170212765945,"[0.82, 0.47]","['2022-03-03', '1985-06-10']",__nan__,0.7766278974330805
248,ANDA,Andina Acquisition Corp. III Ordinary Shares,"Andina Acquisition Corp. III is a blank check company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The company is headquartered in New York, New York. The firm's purpose is to enter into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.",Mr. Julio A. Torres Garca,Shell Companies,9.2,USD,335919600,https://images.financialmodelingprep.com/symbol/ANDA.png,30343,0,0.3000002,314275,-1139861,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.76}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': -14.77}, {'period': '2017', 'revenue': 0.0, 'unit': '', 'net_profit': -424.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -790.13}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -781.0}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 390.43}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 585.8}, {'period': ""Q4 '18"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -7.49}]",0,0,13743695,198192,13743695,8743689,0,0,0,198192,-254332,-1.646749093731613,-1,-1,__nan__,__nan__,__nan__,0.6361963795034742
249,ANDAR,Andina Acquisition Corp. III Right,"Andina Acquisition Corp. III is a blank check company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The company is headquartered in New York, New York. The firm's purpose is to enter into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.",Mr. Julio A. Torres Garca,Shell Companies,0.905,USD,0,https://images.financialmodelingprep.com/symbol/ANDAR.png,0,0,0.09499997,512197,-1139861,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.76}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': -14.77}, {'period': '2017', 'revenue': 0.0, 'unit': '', 'net_profit': -424.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -790.13}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -781.0}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 390.43}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 585.8}, {'period': ""Q4 '18"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -7.49}]",0,0,13743695,198192,13743695,8743689,0,0,0,198192,-254332,-1.646749093731613,-1,-1,__nan__,__nan__,__nan__,0.6361963795034742
250,ANDAU,Andina Acquisition Corp. III Unit,"Andina Acquisition Corp. III does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The company was founded in 2016 and is based in Bogot, Colombia.",Mr. Julio A. Torres Garca,Shell Companies,11.1,USD,405294300,https://images.financialmodelingprep.com/symbol/ANDAU.png,409,-17.34375,0,1123,-1139861,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.76}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': -14.77}, {'period': '2017', 'revenue': 0.0, 'unit': '', 'net_profit': -424.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -790.13}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -781.0}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 390.43}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 585.8}, {'period': ""Q4 '18"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -7.49}]",0,0,13743695,198192,13743695,8743689,0,0,0,198192,-254332,-1.646749093731613,-1,-1,__nan__,__nan__,__nan__,0.6361963795034742
251,ANDAW,Andina Acquisition Corp. III Warrant,,None,Shell Companies,1.27,USD,0,https://images.financialmodelingprep.com/symbol/ANDAW.png,0,0,0.14999998,666563,-1139861,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.76}, {'period': '2018', 'revenue': 0.0, 'unit': 'K', 'net_profit': -14.77}, {'period': '2017', 'revenue': 0.0, 'unit': '', 'net_profit': -424.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -790.13}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -781.0}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 390.43}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 585.8}, {'period': ""Q4 '18"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -7.49}]",0,0,13743695,198192,13743695,8743689,0,0,0,198192,-254332,-1.646749093731613,-1,-1,__nan__,__nan__,__nan__,0.6361963795034742
252,ANDE,Andersons Inc. (The) Common Stock,"The Andersons, Inc., an agriculture company, operates in trade, renewables, and plant nutrient sectors in the United States and internationally. The company's Trade segment operates grain elevators; stores commodities; and provides grain marketing, risk management, and origination services to its customers and affiliated ethanol facilities. This segment also engages in the commodity merchandising business, as well as offers logistics for physical commodities, such as whole grains, grain products, feed ingredients, domestic fuel products, and other agricultural commodities. Its Renewables segment produces, purchases, and sells ethanol, and co-products, as well as offers facility operations, risk management, and ethanol and coproducts marketing services to the ethanol plants it invests in and operates. The company's Plant Nutrient segment manufactures, distributes, and retails agricultural and related plant nutrients, corncob-based products, and pelleted lime and gypsum products; and crop nutrients, crop protection chemicals, and seed products, as well as provides application and agronomic services to commercial and family farmers. It also offers warehousing, packaging, and manufacturing services to nutrient producers and other distributors; and manufactures and distributes various industrial products, such as nitrogen reagents for air pollution control systems that are used in coal-fired power plants, and water treatment and dust abatement products. In addition, this segment produces corncob-based products for laboratory animal bedding and private-label cat litter, as well as absorbents, blast cleaners, carriers, and polishers; professional lawn care products for golf course and turf care markets; fertilizer and weed and pest control products; pelleted lime, gypsum, and value add soil amendments; and specialty ag liquids, seed starters, zinc, and industrial liquids. The Andersons, Inc. was founded in 1947 and is based in Maumee, Ohio.",Mr. William E. Krueger,Food Distribution,41.3,USD,1407091000,https://images.financialmodelingprep.com/symbol/ANDE.png,290732,11.83,0.53,67131,341536000,101190000,"[{'period': '2023', 'revenue': 14750.0, 'unit': 'M', 'net_profit': 101.19}, {'period': '2022', 'revenue': 17330.0, 'unit': 'M', 'net_profit': 131.08}, {'period': '2021', 'revenue': 12610.0, 'unit': 'M', 'net_profit': 103.99}, {'period': '2020', 'revenue': 8210.0, 'unit': 'M', 'net_profit': -14.21}]","[{'period': ""Q3 '24"", 'revenue': 2620.0, 'unit': 'M', 'net_profit': 27.36}, {'period': ""Q2 '24"", 'revenue': 2800.0, 'unit': 'M', 'net_profit': 35.98}, {'period': ""Q1 '24"", 'revenue': 2720.0, 'unit': 'M', 'net_profit': 5.58}, {'period': ""Q4 '23"", 'revenue': 3210.0, 'unit': 'M', 'net_profit': 51.19}, {'period': ""Q3 '23"", 'revenue': 3640.0, 'unit': 'M', 'net_profit': 9.71}, {'period': ""Q2 '23"", 'revenue': 4019.9999999999995, 'unit': 'M', 'net_profit': 55.05}]",3,2.94,3855007000,2806963000,643854000,2338620000,762549000,0,1636331000,643854000,796307000,-0.054833264148332644,-0.22802868477265792,-0.025974025974025997,"[0.195, 0.03]","['2025-01-02', '1996-12-30']",__nan__,0.6066448128369157
253,ANEB,Anebulo Pharmaceuticals Inc. Common Stock,"Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.",Mr. Richard Anthony Cunningham,Biotechnology,1.605,USD,41622786,https://images.financialmodelingprep.com/symbol/ANEB.png,26687,-5.35,0.035,4626,-8050473,-8201703,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.2}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.73}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.81}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.26}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.2}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.35}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.65}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.72}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.48}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.5}]",-0.32,-0.32,4073114,3507990,3094200,260583,0,0,260583,3094200,-8090849,0.31680694497496054,0.3009319199634378,0.3191489361702127,__nan__,__nan__,__nan__,0.06397635813777862
254,ANGI,Angi Inc. Class A Common Stock,"Angi Inc. connects home service professionals with consumers in the United States and internationally. Its Angi Ads business, which connects consumers with service professionals for local services through the Angi nationwide online directory of service professionals in various service categories; provides consumers with valuable tools, services, and content, including verified reviews, to help them research, shop, and hire for local services; and sells term-based website, and mobile and digital magazine advertising to service professionals, as well as provides quoting, invoicing, and payment services. The company also owns and operates Angi Leads digital marketplace service that connects consumers with service professionals for home repair, maintenance, and improvement projects; offers consumers with tools and resources to find local, pre-screened, and customer-rated service professionals, as well as online appointment booking; and connects consumers with service professionals by telephone, and home services-related resources. In addition, it operates Handy, a platform for household services, primarily cleaning and handyman services; Angi Roofing, which provides roof replacement and repair services; and home services marketplaces under the Travaux, MyHammer, Werkspot, MyBuilder, and Instapro names. As of December 31, 2021, it had a network of approximately 206,000 transacting service professionals; and approximately 38,000 advertising service professionals. The company was formerly known as ANGI Homeservices Inc. and changed its name to Angi Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Denver, Colorado. Angi Inc. is a subsidiary of IAC/InterActiveCorp.",Mr. Jeffrey W. Kip,Internet Content & Information,1.62,USD,805575427,https://images.financialmodelingprep.com/symbol/ANGI.png,931096,20.25,-0.03,124482,93491000,-40940000,"[{'period': '2023', 'revenue': 1360.0, 'unit': 'M', 'net_profit': -40.94}, {'period': '2022', 'revenue': 1890.0, 'unit': 'M', 'net_profit': -127.98}, {'period': '2021', 'revenue': 1690.0, 'unit': 'M', 'net_profit': -70.49}, {'period': '2020', 'revenue': 1470.0, 'unit': 'M', 'net_profit': -4.16}]","[{'period': ""Q3 '24"", 'revenue': 296.72, 'unit': 'M', 'net_profit': 35.16}, {'period': ""Q2 '24"", 'revenue': 315.13, 'unit': 'M', 'net_profit': 3.76}, {'period': ""Q1 '24"", 'revenue': 305.39, 'unit': 'M', 'net_profit': -1.63}, {'period': ""Q4 '23"", 'revenue': 300.43, 'unit': 'M', 'net_profit': -5.56}, {'period': ""Q3 '23"", 'revenue': 371.84, 'unit': 'M', 'net_profit': -5.36}, {'period': ""Q2 '23"", 'revenue': 375.07, 'unit': 'M', 'net_profit': -14.7}]",-0.0785,-0.0785,1856215000,487219000,364044000,811707000,51100000,0,258654999,364044000,57065000,4.549744746527366,0.6801112656467315,0.6859999999999999,__nan__,__nan__,__nan__,0.43729147754974507
255,ANGN,Angion Biomedica Corp. Common Stock,"Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.","Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D.",Biotechnology,1,USD,30113700,https://images.financialmodelingprep.com/symbol/ANGN.png,9772,-0.09891196834817013,0,224803,-20118000,-55700000,"[{'period': '2022', 'revenue': 2.3, 'unit': 'M', 'net_profit': -55.7}, {'period': '2021', 'revenue': 28.31, 'unit': 'M', 'net_profit': -53.77}, {'period': '2020', 'revenue': 2.88, 'unit': 'M', 'net_profit': -79.48}, {'period': '2019', 'revenue': 1.49, 'unit': 'M', 'net_profit': -42.37}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.66}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.56}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.47}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.51}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.47}, {'period': ""Q2 '22"", 'revenue': 0.653, 'unit': 'M', 'net_profit': -9.14}]",-1.85,-1.85,52790000,51430000,50487000,9018000,0,874000,6369000,50487000,-32760000,0.48818276642837155,-0.0358550918693744,0.02631578947368412,__nan__,__nan__,__nan__,0.17082780829702596
256,ANGO,AngioDynamics Inc. Common Stock,"AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.",Mr. James C. Clemmer,Medical - Instruments & Supplies,9.155,USD,372007017,https://images.financialmodelingprep.com/symbol/ANGO.png,533485,-1.51,-0.12,224475,-14292000,-184349000,"[{'period': '2024', 'revenue': 303.91, 'unit': 'M', 'net_profit': -184.35}, {'period': '2023', 'revenue': 338.75, 'unit': 'M', 'net_profit': -52.44}, {'period': '2022', 'revenue': 316.22, 'unit': 'M', 'net_profit': -26.55}, {'period': '2021', 'revenue': 291.01, 'unit': 'M', 'net_profit': -31.55}]","[{'period': ""Q1 '25"", 'revenue': 67.49, 'unit': 'M', 'net_profit': -12.8}, {'period': ""Q4 '24"", 'revenue': 70.98, 'unit': 'M', 'net_profit': -13.45}, {'period': ""Q3 '24"", 'revenue': 75.18, 'unit': 'M', 'net_profit': -187.74}, {'period': ""Q2 '24"", 'revenue': 79.07, 'unit': 'M', 'net_profit': -29.05}, {'period': ""Q1 '24"", 'revenue': 78.68, 'unit': 'M', 'net_profit': 45.88}, {'period': ""Q4 '23"", 'revenue': 91.07, 'unit': 'M', 'net_profit': -21.47}]",-4.59,-4.59,317671000,193253000,76056000,112085000,43610000,0,91155000,76056000,-33926000,-2.1720518287682467,-2.515293085694672,-2.451127819548872,__nan__,__nan__,__nan__,0.352833591986678
257,ANIK,Anika Therapeutics Inc. Common Stock,"Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.",Dr. Cheryl Renee Blanchard Ph.D.,Medical - Devices,15.84,USD,231986304,https://images.financialmodelingprep.com/symbol/ANIK.png,97762,-2.43,-0.07,30015,-11232000,-82667000,"[{'period': '2023', 'revenue': 166.66, 'unit': 'M', 'net_profit': -82.67}, {'period': '2022', 'revenue': 156.24, 'unit': 'M', 'net_profit': -14.86}, {'period': '2021', 'revenue': 147.79, 'unit': 'M', 'net_profit': 4.13}, {'period': '2020', 'revenue': 130.46, 'unit': 'M', 'net_profit': -23.98}]","[{'period': ""Q3 '24"", 'revenue': 38.75, 'unit': 'M', 'net_profit': -29.92}, {'period': ""Q2 '24"", 'revenue': 41920.0, 'unit': 'K', 'net_profit': -88.0}, {'period': ""Q1 '24"", 'revenue': 40.52, 'unit': 'M', 'net_profit': -4.51}, {'period': ""Q4 '23"", 'revenue': 42.97, 'unit': 'M', 'net_profit': -63.0}, {'period': ""Q3 '23"", 'revenue': 41.47, 'unit': 'M', 'net_profit': -6.58}, {'period': ""Q2 '23"", 'revenue': 44.3, 'unit': 'M', 'net_profit': -2.74}]",-5.64,-5.64,270632000,163309000,72867000,58367000,35961000,0,31059000,72867000,-7215000,-1.2861795237125992,-4.563429571303587,-4.529411764705881,__nan__,__nan__,__nan__,0.21566924827810457
258,ANIP,ANI Pharmaceuticals Inc.,"ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.",Mr. Nikhil  Lalwani,Drug Manufacturers - Specialty & Generic,54.31,USD,1141476718,https://images.financialmodelingprep.com/symbol/ANIP.png,256346,-115.55,-0.29,28553,106599300,18779000,"[{'period': '2023', 'revenue': 486.82, 'unit': 'M', 'net_profit': 18.78}, {'period': '2022', 'revenue': 316.38, 'unit': 'M', 'net_profit': -47.9}, {'period': '2021', 'revenue': 216.14, 'unit': 'M', 'net_profit': -42.6}, {'period': '2020', 'revenue': 208.47, 'unit': 'M', 'net_profit': -22.55}]","[{'period': ""Q3 '24"", 'revenue': 148.33, 'unit': 'M', 'net_profit': -24.17}, {'period': ""Q2 '24"", 'revenue': 138.04, 'unit': 'M', 'net_profit': -2.29}, {'period': ""Q1 '24"", 'revenue': 137.43, 'unit': 'M', 'net_profit': 18.21}, {'period': ""Q4 '23"", 'revenue': 131.65, 'unit': 'M', 'net_profit': 1.16}, {'period': ""Q3 '23"", 'revenue': 131.83, 'unit': 'M', 'net_profit': 9.94}, {'period': ""Q2 '23"", 'revenue': 116.55, 'unit': 'M', 'net_profit': 6.25}]",0.95,0.94,904422000,519816000,221121000,446823000,162079000,-200000,145477000,221121000,100448000,1.2176770408587834,1.3920786704526473,1.3220338983050848,__nan__,__nan__,__nan__,0.49404260400565225
259,ANIX,Anixa Biosciences Inc. Common Stock,"Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.",Dr. Amit  Kumar Ph.D.,Biotechnology,2.34,USD,75300028,https://images.financialmodelingprep.com/symbol/ANIX.png,105154,-6,-0.03,16593,-10965000,-9811000,"[{'period': '2023', 'revenue': 0.21, 'unit': 'M', 'net_profit': -9.81}, {'period': '2022', 'revenue': 2470.0, 'unit': 'M', 'net_profit': -13.49}, {'period': '2021', 'revenue': 0.5125, 'unit': 'M', 'net_profit': -12.95}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.13}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.28}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.14}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.25}, {'period': ""Q4 '23"", 'revenue': 0.156, 'unit': 'M', 'net_profit': -2.69}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.51}, {'period': ""Q2 '23"", 'revenue': 0.21, 'unit': 'M', 'net_profit': -2.04}]",-0.32,-0.32,25522000,25356000,23844000,2151000,270000,0,2028000,915000,-6209000,0.20132566100954186,0.27277444222073977,0.2727272727272727,__nan__,__nan__,__nan__,0.08428022882219262
260,ANNX,Annexon Inc. Common Stock,"Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barr syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.","Mr. Douglas  Love Esq., J.D.",Biotechnology,5.055,USD,538832670,https://images.financialmodelingprep.com/symbol/ANNX.png,1357827,-4.91,0.005,361515,-141575000,-134237000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -134.24}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -138.29}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -127.79}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -62.74}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -34.82}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.61}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -25.18}, {'period': ""Q4 '23"", 'revenue': 4.87, 'unit': 'M', 'net_profit': -27.89}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -32.48}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.19}]",-1.77,-1.77,297674000,263860000,259716000,47118000,0,0,17928000,225110000,-121335000,0.013366505683204058,0.02934307097147402,0.300395256916996,__nan__,__nan__,__nan__,0.1582872538414507
261,ANPC,AnPac Bio-Medical Science Co. Ltd. American Depositary Shares,"AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.",Dr. Chris Chang  Yu,Biotechnology,4.3,USD,26974846,https://images.financialmodelingprep.com/symbol/ANPC.png,22069,-0.37554585152838427,-0.14,35704,-78401000,-103598000,"[{'period': '2022', 'revenue': 12.04, 'unit': 'M', 'net_profit': -103.6}, {'period': '2021', 'revenue': 17.99, 'unit': 'M', 'net_profit': -120.09}, {'period': '2020', 'revenue': 20.51, 'unit': 'M', 'net_profit': -80.56}, {'period': '2019', 'revenue': 10.85, 'unit': 'M', 'net_profit': -101.62}]","[{'period': ""Q4 '22"", 'revenue': 0.437, 'unit': 'M', 'net_profit': -32.31}, {'period': ""Q3 '22"", 'revenue': 6.39, 'unit': 'M', 'net_profit': -20.2}, {'period': ""Q2 '22"", 'revenue': 3.25, 'unit': 'M', 'net_profit': -33.91}, {'period': ""Q1 '22"", 'revenue': 1.97, 'unit': 'M', 'net_profit': -14.9}, {'period': ""Q4 '21"", 'revenue': 4.31, 'unit': 'M', 'net_profit': -31.14}, {'period': ""Q3 '21"", 'revenue': 4.42, 'unit': 'M', 'net_profit': -30.55}]",-54.18,-54.18,40469000,13699000,1870000,49873000,5541000,1079000,42278000,1870000,-56652000,0.3005968045531995,0.1373087844645965,0.6930833286127004,__nan__,__nan__,__nan__,1.232375398453137
262,ANSS,ANSYS Inc. Common Stock,"ANSYS, Inc. develops and markets engineering simulation software and services worldwide. It offers ANSYS Workbench, a framework upon which its multiphysics engineering simulation technologies are built and enables engineers to simulate the interactions between structures, heat transfer, fluids, electronics, and optical elements in a unified engineering simulation environment; high-performance computing product suite; power analysis and optimization software suite that manages the power budget, power delivery integrity, and power-induced noise in an electronic design; and structural analysis product suite that provides simulation tools for product design and optimization. The company also provides electronics product suite that offers field simulation software for designing electronic and electromechanical products; SCADE product suite, a solution for embedded software simulation, code production, and automated certification; fluids product suite that enables modeling of fluid flow and other related physical phenomena; Ansys Granta products to give access to material intelligence; photonic design and simulation tools; and optical sensor and closed-loop, and real-time simulation, as well as safety-certified embedded software solutions. In addition, the company provides Discovery product family for use in the simulation of product design; and academic product suite used in research and teaching settings, which allows students to become familiar with its simulation software. It serves engineers, designers, researchers, and students in the aerospace and defense, automotive transportation and mobility, construction, consumer products, energy, healthcare, high-tech, industrial equipment, materials and chemical processing, and sports industries. The company was founded in 1970 and is headquartered in Canonsburg, Pennsylvania.",Dr. Ajei S. Gopal Ph.D.,Software - Application,337.415,USD,29506908009,https://images.financialmodelingprep.com/symbol/ANSS.png,463974,51.91,-1.235,144043,758639000,500412000,"[{'period': '2023', 'revenue': 2270.0, 'unit': 'M', 'net_profit': 500.41}, {'period': '2022', 'revenue': 2070.0, 'unit': 'M', 'net_profit': 523.71}, {'period': '2021', 'revenue': 1910.0, 'unit': 'M', 'net_profit': 454.63}, {'period': '2020', 'revenue': 1680.0, 'unit': 'M', 'net_profit': 433.89}]","[{'period': ""Q3 '24"", 'revenue': 601.89, 'unit': 'M', 'net_profit': 128.19}, {'period': ""Q2 '24"", 'revenue': 594.14, 'unit': 'M', 'net_profit': 130.03}, {'period': ""Q1 '24"", 'revenue': 466.61, 'unit': 'M', 'net_profit': 34.78}, {'period': ""Q4 '23"", 'revenue': 805.11, 'unit': 'M', 'net_profit': 274.76}, {'period': ""Q3 '23"", 'revenue': 458.8, 'unit': 'M', 'net_profit': 55.5}, {'period': ""Q2 '23"", 'revenue': 496.6, 'unit': 'M', 'net_profit': 69.53}]",5.76,5.73,7322875000,2049567000,860390000,1932511000,1140276000,634000,889294000,860201000,691804000,0.0727042890411908,-0.044486452425960936,-0.04318936877076409,__nan__,__nan__,__nan__,0.2639005854940853
263,ANTE,AirNet Technology Inc. American Depositary Shares,"AirNet Technology Inc. operates out-of-home advertising platforms in the People's Republic of China. It operates through two segments, Cryptocurrency Mining and Air Travel Media Network. The company provides in-flight solutions to connectivity, entertainment, and digital multimedia; and in-flight entertainment and advertising contents, such as sports, comedies, local attractions, reality shows, commentaries, documentaries. It also offers advertising time slots in the form of digital TV screens on airplanes; and media contents display in air travel. In addition, the company operates CIBN-AirNet channel to broadcast network TV programs to air travelers. Further, it engages in cryptocurrency mining business. The company was formerly known as AirMedia Group Inc. AirNet Technology Inc. was founded in 2005 and is headquartered in Beijing, the People's Republic of China.",Ms. Dan  Shao,Telecommunications Services,0.437,USD,6252522,https://images.financialmodelingprep.com/symbol/ANTE.png,261029,0.12,-0.0432,47423,1421000,-574000,"[{'period': '2023', 'revenue': 845.0, 'unit': 'K', 'net_profit': -574.0}, {'period': '2022', 'revenue': 2.87, 'unit': 'M', 'net_profit': -12.31}, {'period': '2021', 'revenue': 11.68, 'unit': 'M', 'net_profit': -17.79}, {'period': '2020', 'revenue': 23.43, 'unit': 'M', 'net_profit': 7.53}]","[{'period': ""Q2 '24"", 'revenue': 0.193, 'unit': 'M', 'net_profit': 19.89}, {'period': ""Q4 '23"", 'revenue': 0.31362, 'unit': 'M', 'net_profit': 3.75}, {'period': ""Q2 '23"", 'revenue': 0.538, 'unit': 'M', 'net_profit': -3.92}, {'period': ""Q4 '22"", 'revenue': 0.39405, 'unit': 'M', 'net_profit': -12.0}, {'period': ""Q2 '22"", 'revenue': 2.49, 'unit': 'M', 'net_profit': -1.76}, {'period': ""Q4 '21"", 'revenue': 2.9, 'unit': 'M', 'net_profit': -10.84}]",-0.0873,-0.0873,72174000,29915000,407000,93261000,22083000,32018000,84419000,150000,-1817000,1.3300046446818392,0.9533750304605637,0.9730555555555556,__nan__,__nan__,__nan__,1.2921689250976807
264,ANY,Sphere 3D Corp. Common Shares,"Sphere 3D Corp. focuses on operating as a carbon neutral bitcoin mining company. It also provides data management solutions through hybrid cloud, cloud, and on-premises implementations directly and through its reseller network and professional services organization. Its products portfolio includes HVE-STACK high density server, which provides computer and storage appliance for the data centers; HVE-VELOCITY, a high availability dual enclosure storage area network that offers reliability and integrity for optimal data storage, protection, and recovery; HVE 3DGFX, a virtual desktop infrastructure solution; HVE STAGE, a server virtualization platform; and HVE VAULT, an appliance designed to handle requirements for backup and replication storage. In addition, it offers self-service and support services. Sphere 3D Corp. is based in Toronto, Canada.",Ms. Patricia  Trompeter,Software - Application,1.105,USD,26863213,https://images.financialmodelingprep.com/symbol/ANY.png,881401,-1.45,0.045,1348875,-15944000,-23406000,"[{'period': '2023', 'revenue': 21.91, 'unit': 'M', 'net_profit': -23.41}, {'period': '2022', 'revenue': 6.08, 'unit': 'M', 'net_profit': -192.91}, {'period': '2021', 'revenue': 3.72, 'unit': 'M', 'net_profit': -17.29}, {'period': '2020', 'revenue': 4.85, 'unit': 'M', 'net_profit': -5.78}]","[{'period': ""Q3 '24"", 'revenue': 2350.0, 'unit': 'K', 'net_profit': 104.0}, {'period': ""Q2 '24"", 'revenue': 4.67, 'unit': 'M', 'net_profit': 2.12}, {'period': ""Q1 '24"", 'revenue': 6.95, 'unit': 'M', 'net_profit': -4.48}, {'period': ""Q4 '23"", 'revenue': 7.69, 'unit': 'M', 'net_profit': -8.77}, {'period': ""Q3 '23"", 'revenue': 5.72, 'unit': 'M', 'net_profit': -6.31}, {'period': ""Q2 '23"", 'revenue': 5.47, 'unit': 'M', 'net_profit': -4.83}]",-1.93,-1.93,45663000,13510000,586000,5346000,0,0,5346000,586000,-8143000,0.9030659703434397,0.8786700671808908,0.905252822778596,__nan__,__nan__,__nan__,0.11707509362065567
265,ANZU,Anzu Special Acquisition Corp I Class A Common Stock,"Anzu Special Acquisition Corp I does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify business opportunities in the field of industrial applications. The company was incorporated in 2020 and is based in Tampa, Florida.",Dr. Whitney Patrick Haring-Smith,Shell Companies,6.86,USD,102473308,https://images.financialmodelingprep.com/symbol/ANZU.png,35220,114.33333333333333,1.22,157285,-18238000,-29908000,"[{'period': '2023', 'revenue': 0.316, 'unit': 'M', 'net_profit': -29.91}, {'period': '2022', 'revenue': 0.23700000000000002, 'unit': 'M', 'net_profit': -15.92}, {'period': '2021', 'revenue': 0.31, 'unit': 'M', 'net_profit': -8.68}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': -701.0}]","[{'period': ""Q3 '24"", 'revenue': 0.056, 'unit': 'M', 'net_profit': -5.96}, {'period': ""Q2 '24"", 'revenue': 0.068, 'unit': 'M', 'net_profit': -3.95}, {'period': ""Q1 '24"", 'revenue': 0.059000000000000004, 'unit': 'M', 'net_profit': -6.27}, {'period': ""Q4 '23"", 'revenue': 0.095, 'unit': 'M', 'net_profit': -4.88}, {'period': ""Q3 '23"", 'revenue': 0.08, 'unit': 'M', 'net_profit': 1.56}, {'period': ""Q2 '23"", 'revenue': 0.063, 'unit': 'M', 'net_profit': -13.25}]",-2.38,-2.38,7640000,6825000,4218000,9402000,70000,0,6636000,4218000,-17807000,-1.1130807554165218,-0.8782892670979087,-0.5159235668789808,__nan__,__nan__,__nan__,1.2306282722513089
266,ANZUU,Anzu Special Acquisition Corp I Units,"Anzu Special Acquisition Corp I does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify business opportunities in the field of industrial applications. The company was incorporated in 2020 and is based in Tampa, Florida.",Dr. Whitney Patrick Haring-Smith,Shell Companies,7.09,USD,104595615,https://images.financialmodelingprep.com/symbol/ANZUU.png,741,27.587548638132297,0.49,3436,-18238000,-29908000,"[{'period': '2023', 'revenue': 0.316, 'unit': 'M', 'net_profit': -29.91}, {'period': '2022', 'revenue': 0.23700000000000002, 'unit': 'M', 'net_profit': -15.92}, {'period': '2021', 'revenue': 0.31, 'unit': 'M', 'net_profit': -8.68}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': -701.0}]","[{'period': ""Q3 '24"", 'revenue': 0.056, 'unit': 'M', 'net_profit': -5.96}, {'period': ""Q2 '24"", 'revenue': 0.068, 'unit': 'M', 'net_profit': -3.95}, {'period': ""Q1 '24"", 'revenue': 0.059000000000000004, 'unit': 'M', 'net_profit': -6.27}, {'period': ""Q4 '23"", 'revenue': 0.095, 'unit': 'M', 'net_profit': -4.88}, {'period': ""Q3 '23"", 'revenue': 0.08, 'unit': 'M', 'net_profit': 1.56}, {'period': ""Q2 '23"", 'revenue': 0.063, 'unit': 'M', 'net_profit': -13.25}]",-2.38,-2.38,7640000,6825000,4218000,9402000,70000,0,6636000,4218000,-17807000,-1.1130807554165218,-0.8782892670979087,-0.5159235668789808,__nan__,__nan__,__nan__,1.2306282722513089
267,ANZUW,Anzu Special Acquisition Corp I Warrant,"Anzu Special Acquisition Corp I is a blank check company. The company was incorporated in 2020 and is based in Tampa, Florida.",Dr. Whitney Patrick Haring-Smith,Shell Companies,0.085,USD,0,https://images.financialmodelingprep.com/symbol/ANZUW.png,0,0,-0.035,16473,-18238000,-29908000,"[{'period': '2023', 'revenue': 0.316, 'unit': 'M', 'net_profit': -29.91}, {'period': '2022', 'revenue': 0.23700000000000002, 'unit': 'M', 'net_profit': -15.92}, {'period': '2021', 'revenue': 0.31, 'unit': 'M', 'net_profit': -8.68}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': -701.0}]","[{'period': ""Q3 '24"", 'revenue': 0.056, 'unit': 'M', 'net_profit': -5.96}, {'period': ""Q2 '24"", 'revenue': 0.068, 'unit': 'M', 'net_profit': -3.95}, {'period': ""Q1 '24"", 'revenue': 0.059000000000000004, 'unit': 'M', 'net_profit': -6.27}, {'period': ""Q4 '23"", 'revenue': 0.095, 'unit': 'M', 'net_profit': -4.88}, {'period': ""Q3 '23"", 'revenue': 0.08, 'unit': 'M', 'net_profit': 1.56}, {'period': ""Q2 '23"", 'revenue': 0.063, 'unit': 'M', 'net_profit': -13.25}]",-2.38,-2.38,7640000,6825000,4218000,9402000,70000,0,6636000,4218000,-17807000,-1.1130807554165218,-0.8782892670979087,-0.5159235668789808,__nan__,__nan__,__nan__,1.2306282722513089
268,AOSL,Alpha and Omega Semiconductor Limited Common Shares,"Alpha and Omega Semiconductor Limited designs, develops, and supplies power semiconductor products for computing, consumer electronics, communication, and industrial applications in Hong Kong, China, South Korea, the United States, and internationally. It offers power discrete products, including metal-oxide-semiconductor field-effect transistors (MOSFET), SRFETs, XSFET, electrostatic discharge, protected MOSFETs, high and mid-voltage MOSFETs, and insulated gate bipolar transistors for use in smart phone chargers, battery packs, notebooks, desktop and servers, data centers, base stations, graphics card, game boxes, TVs, AC adapters, power supplies, motor control, power tools, e-vehicles, white goods and industrial motor drives, UPS systems, solar inverters, and industrial welding. The company also provides power ICs that deliver power, as well as control and regulate the power management variables, such as the flow of current and level of voltage. Its power ICs are used in flat panel displays, TVs, Notebooks, graphic cards, servers, DVD/Blu-Ray players, set-top boxes, and networking equipment. In addition, the company offers aMOS5 MOSFET for quick charger, adapter, PC power, server, industrial power, telecom, and datacenter applications; and Transient Voltage Suppressors for laptops, televisions, and other electronic devices. Further, it provides EZBuck regulators; SOA MOSFET for hot swap applications; RigidCSP for battery management; and Type-C power delivery protection switches. The company was incorporated in 2000 and is headquartered in Sunnyvale, California.",Mr. Stephen Chunping Chang,Semiconductors,39.635,USD,1150635758,https://images.financialmodelingprep.com/symbol/AOSL.png,632985,-57.44,-0.925,159823,50001000,-11081000,"[{'period': '2024', 'revenue': 657.27, 'unit': 'M', 'net_profit': -11.08}, {'period': '2023', 'revenue': 691.32, 'unit': 'M', 'net_profit': 12.36}, {'period': '2022', 'revenue': 777.55, 'unit': 'M', 'net_profit': 453.16}, {'period': '2021', 'revenue': 656.9, 'unit': 'M', 'net_profit': 58.12}]","[{'period': ""Q1 '25"", 'revenue': 181.89, 'unit': 'M', 'net_profit': -2.5}, {'period': ""Q4 '24"", 'revenue': 161.3, 'unit': 'M', 'net_profit': -2.73}, {'period': ""Q3 '24"", 'revenue': 150.06, 'unit': 'M', 'net_profit': -11.21}, {'period': ""Q2 '24"", 'revenue': 165.28, 'unit': 'M', 'net_profit': -2.92}, {'period': ""Q1 '24"", 'revenue': 180.63, 'unit': 'M', 'net_profit': 5.79}, {'period': ""Q4 '23"", 'revenue': 161.53, 'unit': 'M', 'net_profit': -1.1}]",-0.39,-0.39,1145013000,398001000,175127000,253406000,15951000,356139000,154233000,175127000,-11378000,-0.23936655713764146,-1.8962309932060821,-1.8666666666666667,__nan__,__nan__,__nan__,0.2213127711213759
269,AOUT,American Outdoor Brands Inc. Common Stock ,"American Outdoor Brands, Inc. provides outdoor products and accessories for rugged outdoor enthusiasts in the United States and internationally. It offers hunting, fishing, camping, shooting, and personal security and defense products. The company also provides shooting sports accessories products include rests, vaults, and other related accessories; outdoor lifestyle products, such as premium sportsmen knives and tools for fishing and hunting; land management tools for hunting preparedness; harvesting products for post-hunt or post-fishing activities; outdoor cooking products; and camping, survival, and emergency preparedness products. In addition, it offers electro-optical devices, including hunting optics, firearm aiming devices, flashlights, and laser grips; and reloading, gunsmithing, and firearm cleaning supplies. The company sells its products through e-commerce and traditional distribution channels under the Adventurer, Harvester, Marksman, and Defender brand lanes. American Outdoor Brands, Inc. was incorporated in 2020 and is headquartered in Columbia, Missouri.",Mr. Brian Daniel Murphy,Leisure,15.6,USD,199116840,https://images.financialmodelingprep.com/symbol/AOUT.png,72146,-27.37,-0.47,17373,3604000,-12248000,"[{'period': '2024', 'revenue': 201.1, 'unit': 'M', 'net_profit': -12.25}, {'period': '2023', 'revenue': 191.21, 'unit': 'M', 'net_profit': -12.02}, {'period': '2022', 'revenue': 247.53, 'unit': 'M', 'net_profit': -64.88}, {'period': '2021', 'revenue': 276.69, 'unit': 'M', 'net_profit': 18.41}]","[{'period': ""Q2 '25"", 'revenue': 60.23, 'unit': 'M', 'net_profit': 3.11}, {'period': ""Q1 '25"", 'revenue': 41.64, 'unit': 'M', 'net_profit': -2.37}, {'period': ""Q4 '24"", 'revenue': 46.3, 'unit': 'M', 'net_profit': -5.3}, {'period': ""Q3 '24"", 'revenue': 53.42, 'unit': 'M', 'net_profit': -2.91}, {'period': ""Q2 '24"", 'revenue': 57930.0, 'unit': 'K', 'net_profit': 77.0}, {'period': ""Q1 '24"", 'revenue': 43.45, 'unit': 'M', 'net_profit': -4.11}]",-0.94,-0.94,240597000,155374000,29698000,62672000,25951000,0,29383000,29698000,18384000,-0.27905581116223244,-0.018629407850964737,-0.04444444444444436,__nan__,__nan__,__nan__,0.26048537596063126
270,APA,APA Corporation Common Stock,"APA Corporation, through its subsidiaries, explores for, develops, and produces oil and gas properties. It has operations in the United States, Egypt, and the United Kingdom, as well as has exploration activities offshore Suriname. The company also operates gathering, processing, and transmission assets in West Texas, as well as holds ownership in four Permian-to-Gulf Coast pipelines. APA Corporation was founded in 1954 and is based in Houston, Texas.",Mr. John J. Christmann IV,Oil & Gas Exploration & Production,23.865,USD,8828785155,https://images.financialmodelingprep.com/symbol/APA.png,6319120,3.39,0.205,1855062,4750000000,2855000000,"[{'period': '2023', 'revenue': 8.28, 'unit': 'B', 'net_profit': 2.85}, {'period': '2022', 'revenue': 11.07, 'unit': 'B', 'net_profit': 3.6}, {'period': '2021', 'revenue': 7.99, 'unit': 'B', 'net_profit': 1.14}, {'period': '2020', 'revenue': 4.43, 'unit': 'B', 'net_profit': -4.9}]","[{'period': ""Q3 '24"", 'revenue': 2530.0, 'unit': 'M', 'net_profit': -223.0}, {'period': ""Q2 '24"", 'revenue': 2540.0, 'unit': 'M', 'net_profit': 541.0}, {'period': ""Q1 '24"", 'revenue': 1950.0, 'unit': 'M', 'net_profit': 132.0}, {'period': ""Q4 '23"", 'revenue': 2.17, 'unit': 'B', 'net_profit': 1.77}, {'period': ""Q3 '23"", 'revenue': 2310.0, 'unit': 'M', 'net_profit': 459.0}, {'period': ""Q2 '23"", 'revenue': 1800.0, 'unit': 'M', 'net_profit': 381.0}]",9.27,9.24,15244000000,2462000000,87000000,11553000000,1610000000,437000000,2404000000,87000000,772000000,-0.37606725338237224,-0.20782463928967815,-0.16260162601626021,"[0.25, 0.06]","['2025-01-22', '1982-03-25']",__nan__,0.7578719496195224
271,APDN,Applied DNA Sciences Inc. Common Stock,"Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.","Dr. James A. Hayward Ph.D., Sc.D.",Medical - Diagnostics & Research,0.2348,USD,12278725,https://images.financialmodelingprep.com/symbol/APDN.png,6119314,-0.13,-0.0056,2696249,-14024765,-7225608,"[{'period': '2024', 'revenue': 3.43, 'unit': 'M', 'net_profit': -7.23}, {'period': '2023', 'revenue': 13.37, 'unit': 'M', 'net_profit': -9.95}, {'period': '2022', 'revenue': 18.17, 'unit': 'M', 'net_profit': -8.38}, {'period': '2021', 'revenue': 9.03, 'unit': 'M', 'net_profit': -16.03}]","[{'period': ""Q4 '24"", 'revenue': 0.81311, 'unit': 'M', 'net_profit': -3.3}, {'period': ""Q3 '24"", 'revenue': 0.79752, 'unit': 'M', 'net_profit': 1.88}, {'period': ""Q2 '24"", 'revenue': 0.9296300000000001, 'unit': 'M', 'net_profit': -4.47}, {'period': ""Q1 '24"", 'revenue': 0.89116, 'unit': 'M', 'net_profit': -1.18}, {'period': ""Q4 '23"", 'revenue': 0.77974, 'unit': 'M', 'net_profit': -3.59}, {'period': ""Q3 '23"", 'revenue': 2.92, 'unit': 'M', 'net_profit': -3.1}]",-1.82,-1.82,12789040,8047670,6431095,3820955,362013,0,2398124,6431095,-14119301,-0.4622776609963402,0.2735935315151946,0.8803418803418803,__nan__,__nan__,__nan__,0.2987679294145612
272,APEI,American Public Education Inc. Common Stock,"American Public Education, Inc., together with its subsidiaries, provides online and campus-based postsecondary education. The company operates through three segments: American Public University System, Rasmussen University, and Hondros College of Nursing. It offers 130 degree programs and 111 certificate programs in various fields of study, including business administration, health science, technology, criminal justice, education, and liberal arts, as well as national security, military studies, intelligence, and homeland security. The company also provides nursing-and health sciences-focused postsecondary education, diploma in practical nursing, an associate degree in nursing, and an associate degree in medical laboratory technology. American Public Education, Inc. was incorporated in 1991 and is headquartered in Charles Town, West Virginia.",Ms. Angela K. Selden,Education & Training Services,20.39,USD,361149719,https://images.financialmodelingprep.com/symbol/APEI.png,118695,38.47,-0.63,27515,-20490000,-47286000,"[{'period': '2023', 'revenue': 600.54, 'unit': 'M', 'net_profit': -47.29}, {'period': '2022', 'revenue': 606.33, 'unit': 'M', 'net_profit': -114.97}, {'period': '2021', 'revenue': 418.8, 'unit': 'M', 'net_profit': 17.75}, {'period': '2020', 'revenue': 321.79, 'unit': 'M', 'net_profit': 18.82}]","[{'period': ""Q3 '24"", 'revenue': 153.12, 'unit': 'M', 'net_profit': 2.26}, {'period': ""Q2 '24"", 'revenue': 152900.0, 'unit': 'K', 'net_profit': 371.0}, {'period': ""Q1 '24"", 'revenue': 154430.0, 'unit': 'K', 'net_profit': 516.0}, {'period': ""Q4 '23"", 'revenue': 152.8, 'unit': 'M', 'net_profit': 13.01}, {'period': ""Q3 '23"", 'revenue': 150.84, 'unit': 'M', 'net_profit': -3.33}, {'period': ""Q2 '23"", 'revenue': 147.21, 'unit': 'M', 'net_profit': -51.23}]",-2.94,-2.93,557386000,217382000,116660000,265410000,51447000,2600000,73989000,116660000,31619000,0.7979150434448138,0.5887172528963573,0.5180327868852459,__nan__,__nan__,__nan__,0.4761691179900464
273,APEN,Apollo Endosurgery Inc. Common Stock,"Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.",Mr. Charles S. McKhann,Medical - Devices,10,USD,579718970,https://images.financialmodelingprep.com/symbol/APEN.png,1329953,-9.433962264150944,0,1639528,-31422000,-39839000,"[{'period': '2022', 'revenue': 76.86, 'unit': 'M', 'net_profit': -39.84}, {'period': '2021', 'revenue': 62.99, 'unit': 'M', 'net_profit': -24.68}, {'period': '2020', 'revenue': 42.05, 'unit': 'M', 'net_profit': -22.61}, {'period': '2019', 'revenue': 50.71, 'unit': 'M', 'net_profit': -27.43}]","[{'period': ""Q4 '22"", 'revenue': 21.31, 'unit': 'M', 'net_profit': -9.55}, {'period': ""Q3 '22"", 'revenue': 19.57, 'unit': 'M', 'net_profit': -11.45}, {'period': ""Q2 '22"", 'revenue': 19.31, 'unit': 'M', 'net_profit': -10.43}, {'period': ""Q1 '22"", 'revenue': 16.66, 'unit': 'M', 'net_profit': -8.41}, {'period': ""Q4 '21"", 'revenue': 16.17, 'unit': 'M', 'net_profit': -10.4}, {'period': ""Q3 '21"", 'revenue': 16.35, 'unit': 'M', 'net_profit': -6.66}]",-0.98,-0.98,110231000,92878000,57002000,77637000,14991000,0,39536000,57002000,-34007000,-0.8284550480069829,-0.6140912405801799,-0.19512195121951226,__nan__,__nan__,__nan__,0.7043118541970952
274,API,Agora Inc. American Depositary Shares,"Agora, Inc. provides Real-Time Engagement Platform-as-a-Service (RTE-PaaS) in the People's Republic of China, the United States, and internationally. The company RTE-PaaS offers developers with software tools to embed real-time video, voice, and messaging functionalities into applications. Its products include video calling, voice calling, interactive live streaming, chat, signaling. Acceleration products; and extensions, which comprise interactive whiteboard, recording, analytics, and extensions marketplace products to enable developers to launch RTE in specific use cases and verticals. The company also provides Flexible Classroom that offers a low-code application Platform as a Service; and App Builder, no-code application platform. Its real-time engagement products are delivered through its Software-Defined Real-Time Network, which is a virtual network overlay on top of the public internet. The company serves social, entertainment, gaming, education, enterprise solutions, e-commerce, financial services, healthcare, and IoT industries. Agora, Inc. was incorporated in 2013 and is headquartered in Shanghai, the People's Republic of China.",Mr. Bin  Zhao,Software - Application,4.27,USD,393160237,https://images.financialmodelingprep.com/symbol/API.png,1629095,-8.37,-0.08,383305,-78266000,-87219000,"[{'period': '2023', 'revenue': 141.54, 'unit': 'M', 'net_profit': -87.22}, {'period': '2022', 'revenue': 160.67, 'unit': 'M', 'net_profit': -120.62}, {'period': '2021', 'revenue': 167.98, 'unit': 'M', 'net_profit': -72.69}, {'period': '2020', 'revenue': 133.56, 'unit': 'M', 'net_profit': -3.11}]","[{'period': ""Q3 '24"", 'revenue': 31.57, 'unit': 'M', 'net_profit': -24.18}, {'period': ""Q2 '24"", 'revenue': 34.21, 'unit': 'M', 'net_profit': -9.24}, {'period': ""Q1 '24"", 'revenue': 33.02, 'unit': 'M', 'net_profit': -9.46}, {'period': ""Q4 '23"", 'revenue': 36.04, 'unit': 'M', 'net_profit': -2.61}, {'period': ""Q3 '23"", 'revenue': 35.02, 'unit': 'M', 'net_profit': -22.51}, {'period': ""Q2 '23"", 'revenue': 34.04, 'unit': 'M', 'net_profit': -45.29}]",-0.88,-0.88,674595000,261429000,216654000,69846000,40583000,207020000,56894000,36894000,-30460000,0.24798462647129474,0.2769349383207322,0.18518518518518523,__nan__,__nan__,__nan__,0.10353767816245303
275,APLS,Apellis Pharmaceuticals Inc. Common Stock,"Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.","Dr. Cedric  Francois M.D., Ph.D.",Biotechnology,34.9,USD,4341315700,https://images.financialmodelingprep.com/symbol/APLS.png,3126267,-16.7,0.52,501911,-495211000,-528628000,"[{'period': '2023', 'revenue': 396.59, 'unit': 'M', 'net_profit': -528.63}, {'period': '2022', 'revenue': 75.42, 'unit': 'M', 'net_profit': -652.17}, {'period': '2021', 'revenue': 66.56, 'unit': 'M', 'net_profit': -746.35}, {'period': '2020', 'revenue': 250.65, 'unit': 'M', 'net_profit': -344.87}]","[{'period': ""Q3 '24"", 'revenue': 196.83, 'unit': 'M', 'net_profit': -57.45}, {'period': ""Q2 '24"", 'revenue': 199.69, 'unit': 'M', 'net_profit': -37.66}, {'period': ""Q1 '24"", 'revenue': 172.32, 'unit': 'M', 'net_profit': -66.42}, {'period': ""Q4 '23"", 'revenue': 146.38, 'unit': 'M', 'net_profit': -88.58}, {'period': ""Q3 '23"", 'revenue': 99.18, 'unit': 'M', 'net_profit': -140.24}, {'period': ""Q2 '23"", 'revenue': 94.97, 'unit': 'M', 'net_profit': -122.04}]",-4.45,-4.45,788730000,766331000,352299000,594209000,206442000,3240000,247593000,351185000,-595508000,0.1978959814703834,0.1894346890084211,0.2764227642276423,__nan__,__nan__,__nan__,0.7533744120294651
276,APLT,Applied Therapeutics Inc. Common Stock,"Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.",Mr. Les D. Funtleyder,Biotechnology,0.8223,USD,95679539,https://images.financialmodelingprep.com/symbol/APLT.png,5600896,-0.58,-0.0519,3025945,-64534000,-119763000,"[{'period': '2023', 'revenue': 9.99, 'unit': 'M', 'net_profit': -119.76}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -81.69}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -104.61}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -93.02}]","[{'period': ""Q3 '24"", 'revenue': 0.122, 'unit': 'M', 'net_profit': -68.59}, {'period': ""Q2 '24"", 'revenue': 0.14400000000000002, 'unit': 'M', 'net_profit': 2.9}, {'period': ""Q1 '24"", 'revenue': 0.19, 'unit': 'M', 'net_profit': -83.94}, {'period': ""Q4 '23"", 'revenue': -0.667, 'unit': 'M', 'net_profit': -37.68}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -42.37}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.58}]",-1.42,-1.42,54833000,54386000,49898000,71979000,285000,0,71182000,49898000,-55173000,0.2136425116063704,-0.4660847849771695,0.34259259259259267,__nan__,__nan__,__nan__,1.312694909999453
277,APM,Aptorum Group Limited Class A Ordinary Shares,"Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.",Mr. Chung Yuen  Huen,Biotechnology,1.64,USD,7765161,https://images.financialmodelingprep.com/symbol/APM.png,2277753,5.29,0.03,385905,-9598997,-2824647,"[{'period': '2023', 'revenue': 0.43138, 'unit': 'M', 'net_profit': -2.82}, {'period': '2022', 'revenue': 1.3, 'unit': 'M', 'net_profit': -5.31}, {'period': '2021', 'revenue': 1.54, 'unit': 'M', 'net_profit': -25.29}, {'period': '2020', 'revenue': 0.91151, 'unit': 'M', 'net_profit': 7.07}]","[{'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.66}, {'period': ""Q2 '23"", 'revenue': 0.43138, 'unit': 'M', 'net_profit': -5.49}, {'period': ""Q4 '22"", 'revenue': 0.76843, 'unit': 'M', 'net_profit': -7.91}, {'period': ""Q2 '22"", 'revenue': 0.52746, 'unit': 'M', 'net_profit': -1.89}, {'period': ""Q4 '21"", 'revenue': 0.9039900000000001, 'unit': 'M', 'net_profit': -8.97}, {'period': ""Q2 '21"", 'revenue': 0.63778, 'unit': 'M', 'net_profit': -16.08}]",-0.62,-0.62,20640091,2476092,2005351,5256738,70945,16098846,2098753,2005351,-7727379,0.4542668793277321,0.46849563396919863,0.9583613163196777,__nan__,__nan__,__nan__,0.25468579571669525
278,APOG,Apogee Enterprises Inc. Common Stock,"Apogee Enterprises, Inc. designs and develops glass and metal products and services in the United States, Canada, and Brazil. The company operates in four segments: Architectural Framing Systems, Architectural Glass, Architectural Services, and Large-Scale Optical Technologies (LSO). The Architectural Framing Systems segment designs, engineers, fabricates, and finishes the aluminum frames used in customized aluminum and glass window; curtain wall; storefront; and entrance systems, such as the outside skin and entrances of commercial, institutional, and multi-family residential buildings. The Architectural Glass segment fabricates coated and high-performance glass used in customized window and wall systems, including the outside skin of commercial, institutional, and multi-family residential buildings. The Architectural Services segment offers full-service installation of the walls of glass, windows, and other curtain wall products making up the outside skin of commercial and institutional buildings. The LSO segment manufactures value-added glass and acrylic products for framing and display applications. The company's products and services are primarily used in commercial buildings, such as office buildings, hotels, and retail centers; and institutional buildings comprising education facilities, health care facilities, and government buildings, as well as multi-family residential buildings. It markets its architectural products and services through direct sales force, independent sales representatives, and distributors to glazing subcontractors and general contractors; and value-added glass and acrylics through retail chains, picture-framing shops, and independent distributors to museums, galleries, and other customers. The company was incorporated in 1949 and is based in Minneapolis, Minnesota.",Mr. Ty R. Silberhorn,Construction,59.82,USD,1312630260,https://images.financialmodelingprep.com/symbol/APOG.png,159690,12.62,-11.31,485428,178830000,99613000,"[{'period': '2024', 'revenue': 1420.0, 'unit': 'M', 'net_profit': 99.61}, {'period': '2023', 'revenue': 1440.0, 'unit': 'M', 'net_profit': 104.11}, {'period': '2022', 'revenue': 1310.0, 'unit': 'M', 'net_profit': 3.49}, {'period': '2021', 'revenue': 1230.0, 'unit': 'M', 'net_profit': 15.44}]","[{'period': ""Q3 '25"", 'revenue': 341.34, 'unit': 'M', 'net_profit': 20.99}, {'period': ""Q2 '25"", 'revenue': 342.44, 'unit': 'M', 'net_profit': 30.57}, {'period': ""Q1 '25"", 'revenue': 331.52, 'unit': 'M', 'net_profit': 31.01}, {'period': ""Q4 '24"", 'revenue': 361.84, 'unit': 'M', 'net_profit': 15.74}, {'period': ""Q3 '24"", 'revenue': 339.71, 'unit': 'M', 'net_profit': 26.97}, {'period': ""Q2 '24"", 'revenue': 353.68, 'unit': 'M', 'net_profit': 33.33}]",4.55,4.51,884064000,358639000,41306000,413039000,223059000,8106999,244705000,37216000,160974000,-0.002821519382611411,-0.043167126129847175,-0.03805496828752655,"[0.25, 0.0603]","['2024-10-22', '1985-02-04']",__nan__,0.4672048629963442
279,APOP,Cellect Biotechnology Ltd. American Depositary Shares,,Dr. Shai Yarkoni,Biotechnology,13.17,USD,129021222,https://images.financialmodelingprep.com/symbol/APOP.png,1950309,-15.421545667447306,0.05000019,17433,17241000,16808000,"[{'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': 16.81}, {'period': '2018', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2017', 'revenue': 0.0, 'unit': 'M', 'net_profit': 28.22}, {'period': '2016', 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.32}]",[],0.32,0.32,19394000,18106000,18106000,6483000,0,0,0,18106000,-20460000,36.56209150326797,0,0,__nan__,__nan__,__nan__,0.33427864287924103
280,APOPW,Cellect Biotechnology Ltd. Warrants to Purchase ADRs,,None,,0.0876,USD,0,https://images.financialmodelingprep.com/symbol/APOPW.png,0,0,-0.0005,51821,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
281,APP,Applovin Corporation Class A Common Stock,"AppLovin Corporation engages in building a software-based platform for mobile app developers to enhance the marketing and monetization of their apps in the United States and internationally. The company's software solutions include AppDiscovery, a marketing software solution, which matches advertiser demand with publisher supply through auctions; Adjust, an analytics platform that helps marketers grow their mobile apps with solutions for measuring, optimizing campaigns, and protecting user data; and MAX, an in-app bidding software that optimizes the value of an app's advertising inventory by running a real-time competitive auction. Its business clients include various advertisers, publishers, internet platforms, and others. The company was incorporated in 2011 and is headquartered in Palo Alto, California.",Mr. Adam Arash Foroughi,Software - Application,320.1299,USD,107432971936,https://images.financialmodelingprep.com/symbol/APP.png,5773661,97.01,-34.8001,3852275,1145243000,356711000,"[{'period': '2023', 'revenue': 3280.0, 'unit': 'M', 'net_profit': 356.71}, {'period': '2022', 'revenue': 2820.0, 'unit': 'M', 'net_profit': -217.41}, {'period': '2021', 'revenue': 2790.0, 'unit': 'M', 'net_profit': 35.45}, {'period': '2020', 'revenue': 1450.0, 'unit': 'M', 'net_profit': -125.93}]","[{'period': ""Q3 '24"", 'revenue': 1200.0, 'unit': 'M', 'net_profit': 434.42}, {'period': ""Q2 '24"", 'revenue': 1080.0, 'unit': 'M', 'net_profit': 309.97}, {'period': ""Q1 '24"", 'revenue': 1060.0, 'unit': 'M', 'net_profit': 236.18}, {'period': ""Q4 '23"", 'revenue': 953.26, 'unit': 'M', 'net_profit': 172.23}, {'period': ""Q3 '23"", 'revenue': 864.26, 'unit': 'M', 'net_profit': 108.64}, {'period': ""Q2 '23"", 'revenue': 750.16, 'unit': 'M', 'net_profit': 80.36}]",1.01,0.98,5359187000,1616163000,502152000,4102858000,953810000,56700000,944122000,502152000,1057264000,1.2290966818403113,2.6407521376956584,2.7118644067796613,__nan__,__nan__,__nan__,0.7655747037750316
282,APPF,AppFolio Inc. Class A Common Stock,"AppFolio, Inc., together with its subsidiaries, provides cloud business management solutions for the real estate industry. The company offers AppFolio Property Manager, a platform to leverage process automation, easy to use interface, and the optimization of common workflows for property management companies, as well as completes and records critical transactions in the system and give its customers access to the data they need to run their business; AppFolio Property Manager Plus, which offers customizable workflows that allow customers to digitize their existing processes, performance insights, intelligent revenue management, and integrations through selected partners and dedicated strategic account managers; and AppFolio Investment Management, a solution that is designed to enable real estate investment management organizations to manage investor relationships through enhancing transparency and streamlining certain business processes. It also provides value added services that are designed to enhance, automate, and streamline processes and workflows for property management businesses, such as electronic payment, tenant screening, and insurance services. AppFolio, Inc. was incorporated in 2006 and is headquartered in Santa Barbara, California.",Mr. Shane  Trigg,Software - Application,247.51,USD,9355600541,https://images.financialmodelingprep.com/symbol/APPF.png,220832,68.94,-3.54,38705,29951000,2702000,"[{'period': '2023', 'revenue': 620.45, 'unit': 'M', 'net_profit': 2.7}, {'period': '2022', 'revenue': 471.88, 'unit': 'M', 'net_profit': -68.12}, {'period': '2021', 'revenue': 359.37, 'unit': 'M', 'net_profit': 1.03}, {'period': '2020', 'revenue': 310.06, 'unit': 'M', 'net_profit': 158.4}]","[{'period': ""Q3 '24"", 'revenue': 205.73, 'unit': 'M', 'net_profit': 33.01}, {'period': ""Q2 '24"", 'revenue': 197.38, 'unit': 'M', 'net_profit': 29.66}, {'period': ""Q1 '24"", 'revenue': 187.43, 'unit': 'M', 'net_profit': 38.66}, {'period': ""Q4 '23"", 'revenue': 171.83, 'unit': 'M', 'net_profit': 30.27}, {'period': ""Q3 '23"", 'revenue': 165.44, 'unit': 'M', 'net_profit': 26.45}, {'period': ""Q2 '23"", 'revenue': 147.07, 'unit': 'M', 'net_profit': -18.9}]",0.0758,0.0742,408889000,272357000,211705000,111577000,20709000,0,69766000,49509000,51242000,1.7807262205771186,1.039665878829695,1.0388717948717947,__nan__,__nan__,__nan__,0.27287845845694064
283,APPH,AppHarvest Inc. Common Stock,"AppHarvest, Inc., an applied agricultural technology company, develops and operates indoor farms to grow non-GMO produce free of chemical pesticide residues. Its products include tomatoes; and other fruits and vegetables, such as berries, peppers, cucumbers, and salad greens. The company was incorporated in 2018 and is based in Morehead, Kentucky.",Mr. Anthony  Martin,Agricultural Farm Products,0.0666,USD,10330259,https://images.financialmodelingprep.com/symbol/APPH.png,4291016,-0.14170212765957446,-0.0127,9356857,-107795000,-176646000,"[{'period': '2022', 'revenue': 14.59, 'unit': 'M', 'net_profit': -176.65}, {'period': '2021', 'revenue': 9.05, 'unit': 'M', 'net_profit': -166.19}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.45}]","[{'period': ""Q1 '23"", 'revenue': 13.01, 'unit': 'M', 'net_profit': -33.63}, {'period': ""Q4 '22"", 'revenue': 4.55, 'unit': 'M', 'net_profit': -93.32}, {'period': ""Q3 '22"", 'revenue': 0.524, 'unit': 'M', 'net_profit': -23.98}, {'period': ""Q2 '22"", 'revenue': 4.36, 'unit': 'M', 'net_profit': -28.7}, {'period': ""Q1 '22"", 'revenue': 5.16, 'unit': 'M', 'net_profit': -30.64}, {'period': ""Q4 '21"", 'revenue': 3.07, 'unit': 'M', 'net_profit': -88.39}]",-1.69,-1.69,595328000,114112000,54334000,335037000,2786000,5000000,42968000,54334000,-266870000,0.16367318121513527,-0.06294152335335107,0.028735632183908073,__nan__,__nan__,__nan__,0.5627771581380349
284,APPHW,AppHarvest Inc. Warrants,,,Agricultural Farm Products,0.0101,USD,10330259,https://images.financialmodelingprep.com/symbol/APPHW.png,0,,0.0101,3961,-107795000,-176646000,"[{'period': '2022', 'revenue': 14.59, 'unit': 'M', 'net_profit': -176.65}, {'period': '2021', 'revenue': 9.05, 'unit': 'M', 'net_profit': -166.19}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.45}]","[{'period': ""Q1 '23"", 'revenue': 13.01, 'unit': 'M', 'net_profit': -33.63}, {'period': ""Q4 '22"", 'revenue': 4.55, 'unit': 'M', 'net_profit': -93.32}, {'period': ""Q3 '22"", 'revenue': 0.524, 'unit': 'M', 'net_profit': -23.98}, {'period': ""Q2 '22"", 'revenue': 4.36, 'unit': 'M', 'net_profit': -28.7}, {'period': ""Q1 '22"", 'revenue': 5.16, 'unit': 'M', 'net_profit': -30.64}, {'period': ""Q4 '21"", 'revenue': 3.07, 'unit': 'M', 'net_profit': -88.39}]",-1.69,-1.69,595328000,114112000,54334000,335037000,2786000,5000000,42968000,54334000,-266870000,0.16367318121513527,-0.06294152335335107,0.028735632183908073,__nan__,__nan__,__nan__,0.5627771581380349
285,APPN,Appian Corporation Class A Common Stock,"Appian Corporation provides low-code automation platform in the United States and internationally. The company's platform automates the creation of forms, workflows, data structures, reports, user interfaces, and other software elements that are needed to be manually coded. The company also offers professional and customer support services. It serves to financial services, government, life sciences, insurance, manufacturing, energy, healthcare, telecommunications, and transportation industries. The company was incorporated in 1999 and is headquartered in McLean, Virginia.",Mr. Matthew W. Calkins,Software - Infrastructure,35.05,USD,2589749234,https://images.financialmodelingprep.com/symbol/APPN.png,492919,-28.27,0.2,187224,-80897000,-111441000,"[{'period': '2023', 'revenue': 545.36, 'unit': 'M', 'net_profit': -111.44}, {'period': '2022', 'revenue': 467.99, 'unit': 'M', 'net_profit': -150.92}, {'period': '2021', 'revenue': 369.26, 'unit': 'M', 'net_profit': -88.64}, {'period': '2020', 'revenue': 304.57, 'unit': 'M', 'net_profit': -33.48}]","[{'period': ""Q3 '24"", 'revenue': 154.05, 'unit': 'M', 'net_profit': -2.1}, {'period': ""Q2 '24"", 'revenue': 146.45, 'unit': 'M', 'net_profit': -43.59}, {'period': ""Q1 '24"", 'revenue': 149.84, 'unit': 'M', 'net_profit': -32.92}, {'period': ""Q4 '23"", 'revenue': 145.32, 'unit': 'M', 'net_profit': -10.01}, {'period': ""Q3 '23"", 'revenue': 137.09, 'unit': 'M', 'net_profit': -22.25}, {'period': ""Q2 '23"", 'revenue': 127.72, 'unit': 'M', 'net_profit': -42.35}]",-1.52,-1.52,627503000,414355000,159004000,575162000,171561000,0,371172000,149351000,-120079000,0.42731031162836797,0.2615889212827988,0.2692307692307693,__nan__,__nan__,__nan__,0.9165884465891
286,APPS,Digital Turbine Inc. Common Stock,"Digital Turbine, Inc., through its subsidiaries, operates a mobile growth platform for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The company operates through three segments: On Device Media, In App Media  AdColony, and In App Media  Fyber. Its application media platform delivers mobile applications to various publishers, carriers, OEMs, and devices; and content media platform offers news, weather, sports, and other content, as well as programmatic advertising, and sponsored and editorial content media. The company also provides an end-to-end platform for brands, agencies, publishers, and application developers to deliver advertising to consumers on mobile devices; and a platform that allows mobile application developers and digital publishers to monetize their content through display, native, and video advertising. It operates in the United States, Canada, Europe, the Middle East, Africa, the Asia Pacific, China, Mexico, Central America, and South America. The company is headquartered in Austin, Texas.",Mr. William Gordon Stone III,Software - Application,2.078,USD,215542628,https://images.financialmodelingprep.com/symbol/APPS.png,3817298,-0.7,0.048,2534164,54566000,-420228000,"[{'period': '2024', 'revenue': 544.48, 'unit': 'M', 'net_profit': -420.23}, {'period': '2023', 'revenue': 665.92, 'unit': 'M', 'net_profit': 16.67}, {'period': '2022', 'revenue': 747.6, 'unit': 'M', 'net_profit': 35.55}, {'period': '2021', 'revenue': 313.58, 'unit': 'M', 'net_profit': 54.88}]","[{'period': ""Q2 '25"", 'revenue': 118.73, 'unit': 'M', 'net_profit': -24.99}, {'period': ""Q1 '25"", 'revenue': 117.99, 'unit': 'M', 'net_profit': -25.16}, {'period': ""Q4 '24"", 'revenue': 112.22, 'unit': 'M', 'net_profit': -236.51}, {'period': ""Q3 '24"", 'revenue': 142.63, 'unit': 'M', 'net_profit': -14.06}, {'period': ""Q2 '24"", 'revenue': 143.26, 'unit': 'M', 'net_profit': -161.48}, {'period': ""Q1 '24"", 'revenue': 146.37, 'unit': 'M', 'net_profit': -8.18}]",-4.16,-4.16,865540000,242341000,33605000,651608000,191015000,17637000,236024000,33605000,4398000,0.18197768872522474,-26.204102441072394,-25.470588235294116,__nan__,__nan__,__nan__,0.7528340689049611
287,APR,Apria Inc. Common Stock,"Apria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. Apria, Inc. was incorporated in 2018 and is headquartered in Indianapolis, Indiana. As of March 29, 2022, Apria, Inc. operates as a subsidiary of Byram Healthcare Centers, Inc.",Mr. Daniel J. Starck,Medical - Instruments & Supplies,37.5,USD,0,https://images.financialmodelingprep.com/symbol/APR.png,435036,22.59036144578313,0,436727,215859000,65668000,"[{'period': '2021', 'revenue': 1150.0, 'unit': 'M', 'net_profit': 65.67}, {'period': '2020', 'revenue': 1110.0, 'unit': 'M', 'net_profit': 46.14}, {'period': '2019', 'revenue': 1090.0, 'unit': 'M', 'net_profit': 15.62}, {'period': '2018', 'revenue': 1110.0, 'unit': 'M', 'net_profit': 13.13}]","[{'period': ""Q4 '21"", 'revenue': 296.52, 'unit': 'M', 'net_profit': 17.74}, {'period': ""Q3 '21"", 'revenue': 287.2, 'unit': 'M', 'net_profit': 22.81}, {'period': ""Q2 '21"", 'revenue': 286.28, 'unit': 'M', 'net_profit': 20.58}, {'period': ""Q1 '21"", 'revenue': 275.27, 'unit': 'M', 'net_profit': 4.54}, {'period': ""Q4 '20"", 'revenue': 293.79, 'unit': 'M', 'net_profit': 25.87}, {'period': ""Q3 '20"", 'revenue': 276.76, 'unit': 'M', 'net_profit': 5.7}]",1.86,1.86,775429000,333277000,219561000,735696000,81720000,2809000,306829000,219561000,92849000,0.15509214666409812,0.42326448340882983,0.41984732824427484,__nan__,__nan__,__nan__,0.9487599767354586
288,APRE,Aprea Therapeutics Inc. Common stock,"Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.",Dr. Oren  Gilad Ph.D.,Biotechnology,4.18,USD,22717882,https://images.financialmodelingprep.com/symbol/APRE.png,29200,-1.49,-0.115,9884,-14279708,-14286756,"[{'period': '2023', 'revenue': 0.58323, 'unit': 'M', 'net_profit': -14.29}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -224.88}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -36.54}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -53.92}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.78}, {'period': ""Q2 '24"", 'revenue': 0.56157, 'unit': 'M', 'net_profit': -3.47}, {'period': ""Q1 '24"", 'revenue': 0.38057, 'unit': 'M', 'net_profit': -2.81}, {'period': ""Q4 '23"", 'revenue': 0.014070000000000001, 'unit': 'M', 'net_profit': -3.44}, {'period': ""Q3 '23"", 'revenue': 0.31947000000000003, 'unit': 'M', 'net_profit': -3.2}, {'period': ""Q2 '23"", 'revenue': 0.24969, 'unit': 'M', 'net_profit': -3.26}]",-3.95,-3.95,22650174,22521095,21606820,5696668,0,40717,4385605,21606820,-12270701,0.8730417105806411,0.9364681204528622,0.9985446801612274,__nan__,__nan__,__nan__,0.2515065888677058
289,APTO,Aptose Biosciences Inc. Common Shares,"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.",Dr. William G. Rice Ph.D.,Biotechnology,0.2249,USD,13534752,https://images.financialmodelingprep.com/symbol/APTO.png,6609233,-0.08,-0.0027,505949,-52268000,-51207000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -51.21}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -41.05}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -65.26}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -54.71}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.95}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.25}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.6}, {'period': ""Q4 '23"", 'revenue': 0.71221, 'unit': 'M', 'net_profit': -12.29}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.45}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.13}]",-7.58,-7.58,12989000,11894000,9252000,15890000,0,0,15269000,9252000,-44619000,-0.3179426105939761,-0.2473388059337929,-0.13643178410794604,__nan__,__nan__,__nan__,1.2233428285472323
290,APTX,Aptinyx Inc. Common Stock,"Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.",Mr. Craig R. Jalbert CIRA,Biotechnology,0.096,USD,0,https://images.financialmodelingprep.com/symbol/APTX.png,132918,-0.09795918367346938,0.003,231126,-61708000,-64112000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -64.11}, {'period': '2021', 'revenue': 1.0, 'unit': 'M', 'net_profit': -74.36}, {'period': '2020', 'revenue': 1.56, 'unit': 'M', 'net_profit': -49.63}, {'period': '2019', 'revenue': 3.67, 'unit': 'M', 'net_profit': -56.95}]","[{'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.81}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 25.97}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.1}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.23}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -20.27}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.61}]",-0.95,-0.95,66684000,64030000,56205000,28399000,0,0,6291000,56205000,-59684000,0,0.13781603012372243,0.14414414414414425,__nan__,__nan__,__nan__,0.42587427268910083
291,APVO,Aptevo Therapeutics Inc. Common Stock,"Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.",Mr. Marvin L. White,Biotechnology,5.3101,USD,7744462,https://images.financialmodelingprep.com/symbol/APVO.png,337518,-0.01,0.2101,92351,-28311000,-17411000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.41}, {'period': '2022', 'revenue': 3.11, 'unit': 'M', 'net_profit': 42.67}, {'period': '2021', 'revenue': 12.29, 'unit': 'M', 'net_profit': -27.31}, {'period': '2020', 'revenue': 4.31, 'unit': 'M', 'net_profit': -18.45}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.1}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.88}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.83}, {'period': ""Q4 '23"", 'revenue': 0.902, 'unit': 'M', 'net_profit': -5.9}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.33}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.95}]",-62.62,-62.62,24842000,19066000,16904000,12621000,0,0,7224000,16904000,-11730000,-0.020583994232155733,-1.4080479973751436,-1.170761637261051,__nan__,__nan__,__nan__,0.5080508815715321
292,APWC,Asia Pacific Wire & Cable Corporation Ltd. Ordinary Shares (Bermuda),"Asia Pacific Wire & Cable Corporation Limited, through its subsidiaries, manufactures and distributes enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, the People's Republic of China, Hong Kong, and other markets in the Asia Pacific region. The company offers copper rods; and telecommunications cable products, including copper-based and fiber optic cables for telephone and data transmissions; and armored and unarmored low voltage power transmission cable, which is used to transmit electricity to and within commercial and residential buildings, as well as to outdoor installations, such as streetlights, traffic signals, and other signs. It also provides enameled wire for use in the assembly of a range of electrical products consisting of oil-filled transformers, refrigerator motors, telephones, radios, televisions, fan motors, air conditioner compressors, and other electric appliances. In addition, the company distributes wire and cable products; and offers project engineering services in the supply, delivery, and installation of power cables, as well as fabrication services for converting raw materials to wire and cable products. It serves government organizations, electric contracting firms, electrical dealers, and wire and cable factories. The company was incorporated in 1996 and is headquartered in Taipei, Taiwan. Asia Pacific Wire & Cable Corporation Limited is a subsidiary of Pacific Electric Wire & Cable Co., Ltd.",Mr. Chun-Tang  Yuan M.S.,Electrical Equipment & Parts,1.495,USD,30821219,https://images.financialmodelingprep.com/symbol/APWC.png,13287,8.31,0.095,18411,8623000,3867000,"[{'period': '2023', 'revenue': 425.77, 'unit': 'M', 'net_profit': 3.87}, {'period': '2022', 'revenue': 433.89, 'unit': 'M', 'net_profit': 3.87}, {'period': '2021', 'revenue': 476.66, 'unit': 'M', 'net_profit': -8.51}, {'period': '2020', 'revenue': 313.56, 'unit': 'M', 'net_profit': 3.71}]","[{'period': ""Q3 '24"", 'revenue': 122.23, 'unit': 'M', 'net_profit': 1.41}, {'period': ""Q2 '24"", 'revenue': 107170.0, 'unit': 'K', 'net_profit': -255.0}, {'period': ""Q1 '24"", 'revenue': 107170.0, 'unit': 'K', 'net_profit': -255.0}, {'period': ""Q4 '23"", 'revenue': 131.56, 'unit': 'M', 'net_profit': 2.75}, {'period': ""Q3 '23"", 'revenue': 100.73, 'unit': 'M', 'net_profit': 1.1}, {'period': ""Q2 '23"", 'revenue': 96740.0, 'unit': 'K', 'net_profit': 7.5}]",0.19,0.19,366664000,294950000,38277000,152043000,121939000,3712000,140573000,37970000,-10384000,-0.4203025210084034,-0.0018069179143004647,0,"[0.08, 0.1]","['2018-09-13', '2017-10-30']",__nan__,0.4146657430235856
293,APXT,Apex Technology Acquisition Corporation Class A Common Stock,"Apex Technology Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company has not conducted any business operations. The Company has generated no revenues.",Mr. Jeff Epstein,Shell Companies,12.11,USD,2260585907,https://images.financialmodelingprep.com/symbol/APXT.png,745248,0,-0.14000034,747560,-3839770,-4251085,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.25}]","[{'period': ""Q2 '21"", 'revenue': 45.34, 'unit': 'M', 'net_profit': -11.06}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 58.52}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -155.24}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 815.68}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.0}]",-0.0954,-0.0954,352608027,749707,197628,17639744,0,0,4489744,197628,-2419063,0,0,0,__nan__,__nan__,__nan__,0.05002649585172376
294,APXTU,Apex Technology Acquisition Corporation Unit,"Apex Technology Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the software and internet technology industries. The company was founded in 2019 and is based in Burlingame, California.",Mr. Jeffrey Emanuel Epstein,Shell Companies,13.61,USD,2540592419,https://images.financialmodelingprep.com/symbol/APXTU.png,573,0,0,1,-3839770,-4251085,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.25}]","[{'period': ""Q2 '21"", 'revenue': 45.34, 'unit': 'M', 'net_profit': -11.06}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 58.52}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -155.24}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 815.68}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.0}]",-0.0954,-0.0954,352608027,749707,197628,17639744,0,0,4489744,197628,-2419063,0,0,0,__nan__,__nan__,__nan__,0.05002649585172376
295,APXTW,Apex Technology Acquisition Corporation Warrant,,None,Shell Companies,3.39,USD,0,https://images.financialmodelingprep.com/symbol/APXTW.png,0,0,0.02000022,161823,-3839770,-4251085,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.25}]","[{'period': ""Q2 '21"", 'revenue': 45.34, 'unit': 'M', 'net_profit': -11.06}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 58.52}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -155.24}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 815.68}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -1.0}]",-0.0954,-0.0954,352608027,749707,197628,17639744,0,0,4489744,197628,-2419063,0,0,0,__nan__,__nan__,__nan__,0.05002649585172376
296,APYX,Apyx Medical Corporation Common Stock,"Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.",Mr. Charles D. Goodwin II,Medical - Devices,1.7,USD,63994630,https://images.financialmodelingprep.com/symbol/APYX.png,58332,-2.07,-0.02,89903,-18112000,-18713000,"[{'period': '2023', 'revenue': 52.35, 'unit': 'M', 'net_profit': -18.71}, {'period': '2022', 'revenue': 44.51, 'unit': 'M', 'net_profit': -23.28}, {'period': '2021', 'revenue': 48.52, 'unit': 'M', 'net_profit': -15.2}, {'period': '2020', 'revenue': 27.71, 'unit': 'M', 'net_profit': -11.91}]","[{'period': ""Q3 '24"", 'revenue': 11.49, 'unit': 'M', 'net_profit': -4.7}, {'period': ""Q2 '24"", 'revenue': 12.15, 'unit': 'M', 'net_profit': -6.56}, {'period': ""Q1 '24"", 'revenue': 14.54, 'unit': 'M', 'net_profit': -7.58}, {'period': ""Q4 '23"", 'revenue': 14.66, 'unit': 'M', 'net_profit': -9.61}, {'period': ""Q3 '23"", 'revenue': 15.97, 'unit': 'M', 'net_profit': -4.63}, {'period': ""Q2 '23"", 'revenue': 13570.0, 'unit': 'K', 'net_profit': -994.0}]",-0.54,-0.54,79240000,70362000,43652000,52318000,14053000,0,12740000,43652000,-5782000,0.17695174043442696,0.1961079130509494,0.19402985074626866,__nan__,__nan__,__nan__,0.6602473498233216
297,AQB,AquaBounty Technologies Inc. Common Stock,"AquaBounty Technologies, Inc., a biotechnology company, focuses on enhancing productivity in the commercial aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It offers AquAdvantage Salmon, a bioengineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Maynard, Massachusetts.",Mr. David A. Frank M.B.A.,Agricultural Farm Products,0.7801,USD,3015695,https://images.financialmodelingprep.com/symbol/AQB.png,437196,-0.04,-0.0014,44228,-25158368,-27557901,"[{'period': '2023', 'revenue': 2.47, 'unit': 'M', 'net_profit': -27.56}, {'period': '2022', 'revenue': 3.14, 'unit': 'M', 'net_profit': -21.99}, {'period': '2021', 'revenue': 1.17, 'unit': 'M', 'net_profit': -22.75}, {'period': '2020', 'revenue': 0.12766, 'unit': 'M', 'net_profit': -16.55}]","[{'period': ""Q3 '24"", 'revenue': 4.781e-05, 'unit': 'B', 'net_profit': -3.4}, {'period': ""Q2 '24"", 'revenue': 0.18018, 'unit': 'M', 'net_profit': -50.51}, {'period': ""Q1 '24"", 'revenue': 0.47726999999999997, 'unit': 'M', 'net_profit': -11.16}, {'period': ""Q4 '23"", 'revenue': 0.55325, 'unit': 'M', 'net_profit': -8.42}, {'period': ""Q3 '23"", 'revenue': 0.7331300000000001, 'unit': 'M', 'net_profit': -6.14}, {'period': ""Q2 '23"", 'revenue': 0.78843, 'unit': 'M', 'net_profit': -6.51}]",-7.17,-7.17,187551428,11637745,8213520,22534710,85988,0,14572603,8203868,-93125785,-0.26798397377985794,-0.25315294741649846,-0.1583198707592891,__nan__,__nan__,__nan__,0.12015216434395797
298,AQMS,Aqua Metals Inc. Common Stock,"Aqua Metals, Inc. engages in the recycling of lead primarily in the United States. It produces and sells hard lead, lead compounds, and plastics. Aqua Metals, Inc. was incorporated in 2014 and is headquartered in Reno, Nevada.",Mr. Stephen  Cotton,Waste Management,2.6499,USD,18898530,https://images.financialmodelingprep.com/symbol/AQMS.png,195061,-0.57,-0.0901,55318,-22046000,-23938000,"[{'period': '2023', 'revenue': 0.025, 'unit': 'M', 'net_profit': -23.94}, {'period': '2022', 'revenue': 0.004, 'unit': 'M', 'net_profit': -15.43}, {'period': '2021', 'revenue': 0.17300000000000001, 'unit': 'M', 'net_profit': -18.19}, {'period': '2020', 'revenue': 0.108, 'unit': 'M', 'net_profit': -25.76}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.21}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.15}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.75}, {'period': ""Q4 '23"", 'revenue': 0.024, 'unit': 'M', 'net_profit': -10.03}, {'period': ""Q3 '23"", 'revenue': 0.025, 'unit': 'M', 'net_profit': -4.55}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.76}]",-5.1,-5.1,33600000,18299000,16521999,7536000,667000,0,4613000,16521999,-13076000,-0.5478480657164924,-0.551292852051066,-0.2530712530712529,__nan__,__nan__,__nan__,0.22428571428571428
299,AQST,Aquestive Therapeutics Inc. Common Stock,"Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.",Mr. Daniel  Barber,Drug Manufacturers - Specialty & Generic,3.325,USD,303167515,https://images.financialmodelingprep.com/symbol/AQST.png,1506564,-7.39,0.025,1143575,1182000,-7870000,"[{'period': '2023', 'revenue': 50.58, 'unit': 'M', 'net_profit': -7.87}, {'period': '2022', 'revenue': 47.68, 'unit': 'M', 'net_profit': -60.2}, {'period': '2021', 'revenue': 50.83, 'unit': 'M', 'net_profit': -90.04}, {'period': '2020', 'revenue': 45.85, 'unit': 'M', 'net_profit': -65.36}]","[{'period': ""Q3 '24"", 'revenue': 13.54, 'unit': 'M', 'net_profit': -11.51}, {'period': ""Q2 '24"", 'revenue': 20.1, 'unit': 'M', 'net_profit': -2.75}, {'period': ""Q1 '24"", 'revenue': 12.05, 'unit': 'M', 'net_profit': -12.83}, {'period': ""Q4 '23"", 'revenue': 13.21, 'unit': 'M', 'net_profit': -8.11}, {'period': ""Q3 '23"", 'revenue': 13.0, 'unit': 'M', 'net_profit': -2.04}, {'period': ""Q2 '23"", 'revenue': 13.24, 'unit': 'M', 'net_profit': -5.79}]",-0.13,-0.13,57418000,40966000,23872000,163905000,8471000,0,18308000,23872000,-7375000,1.0298635674583123,0.8692734460649147,0.8951612903225805,__nan__,__nan__,__nan__,2.854592636455467
300,ARAV,Aravive Inc. Common Stock,"Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.",Dr. Fredric N. Eshelman Pharm.D.,Biotechnology,0.0401,USD,2949860,https://images.financialmodelingprep.com/symbol/ARAV.png,2242572,-0.052763157894736845,-0.0062,4040076,-70837000,-80921000,"[{'period': '2022', 'revenue': 9.14, 'unit': 'M', 'net_profit': -80.92}, {'period': '2021', 'revenue': 7.44, 'unit': 'M', 'net_profit': -38.14}, {'period': '2020', 'revenue': 5.68, 'unit': 'M', 'net_profit': -34.24}, {'period': '2019', 'revenue': 4.75, 'unit': 'M', 'net_profit': -20.25}]","[{'period': ""Q3 '23"", 'revenue': 2.76, 'unit': 'M', 'net_profit': 21.23}, {'period': ""Q2 '23"", 'revenue': 1.27, 'unit': 'M', 'net_profit': 18.01}, {'period': ""Q1 '23"", 'revenue': 1.49, 'unit': 'M', 'net_profit': -82.0}, {'period': ""Q4 '22"", 'revenue': 1.47, 'unit': 'M', 'net_profit': -38.38}, {'period': ""Q3 '22"", 'revenue': 4.96, 'unit': 'M', 'net_profit': -14.63}, {'period': ""Q2 '22"", 'revenue': 1.61, 'unit': 'M', 'net_profit': -17.28}]",-2.22,-2.22,62153000,56134000,53689000,51496000,85000,0,20538000,53689000,-65090000,-0.7426504957071515,-1.1216832721552177,-0.1684210526315791,__nan__,__nan__,__nan__,0.8285360320499413
301,ARAY,Accuray Incorporated Common Stock,"Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.",Ms. Suzanne  Winter M.B.A.,Medical - Specialties,2.135,USD,214706275,https://images.financialmodelingprep.com/symbol/ARAY.png,627835,-12.56,-0.055,295253,5709000,-15545000,"[{'period': '2024', 'revenue': 446.55, 'unit': 'M', 'net_profit': -15.54}, {'period': '2023', 'revenue': 447.61, 'unit': 'M', 'net_profit': -9.28}, {'period': '2022', 'revenue': 429.91, 'unit': 'M', 'net_profit': -5.35}, {'period': '2021', 'revenue': 396.29, 'unit': 'M', 'net_profit': -6.31}]","[{'period': ""Q1 '25"", 'revenue': 101.55, 'unit': 'M', 'net_profit': -3.95}, {'period': ""Q4 '24"", 'revenue': 134.29, 'unit': 'M', 'net_profit': 3.39}, {'period': ""Q3 '24"", 'revenue': 101.13, 'unit': 'M', 'net_profit': -6.34}, {'period': ""Q2 '24"", 'revenue': 107.24, 'unit': 'M', 'net_profit': -9.62}, {'period': ""Q1 '24"", 'revenue': 103.89, 'unit': 'M', 'net_profit': -2.97}, {'period': ""Q4 '23"", 'revenue': 118.29, 'unit': 'M', 'net_profit': -2.56}]",-0.16,-0.16,468627000,323236000,68570000,423543000,92001000,9826000,195267000,68570000,-15505000,-0.4058694973462379,-0.6751077586206896,-0.6359918200408998,__nan__,__nan__,__nan__,0.9037955559538823
302,ARBG,Aequi Acquisition Corp. Class A Common Stock,"Aequi Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Greenwich, Connecticut.",Ms. Hope Schefler Taitz,Shell Companies,10.24,USD,95631759,https://images.financialmodelingprep.com/symbol/ARBG.png,1045,170.66666666666666,-0.01,2821,-7602071,6860102,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.86}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.35}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -596.51}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 342.88}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 826.43}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.56}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'T', 'net_profit': 4.31}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 434.55}]",1.19,0.26,36667491,213552,170652,9164506,0,36453939,776639,170652,-1103975,0.08013317978969103,0.08024137209400102,0.08181818181818168,__nan__,__nan__,__nan__,0.24993545372384493
303,ARBGU,Aequi Acquisition Corp. Unit,"Aequi Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Greenwich, Connecticut.",Ms. Hope Schefler Taitz,Shell Companies,10.26,USD,0,https://images.financialmodelingprep.com/symbol/ARBGU.png,19,35.25773195876289,0.01,600,-7602071,6860102,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.86}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.35}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -596.51}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 342.88}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 826.43}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.56}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'T', 'net_profit': 4.31}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 434.55}]",1.19,0.26,36667491,213552,170652,9164506,0,36453939,776639,170652,-1103975,0.08013317978969103,0.08024137209400102,0.08181818181818168,__nan__,__nan__,__nan__,0.24993545372384493
304,ARBGW,Aequi Acquisition Corp. warrants,,,Shell Companies,0.0007,USD,0,https://images.financialmodelingprep.com/symbol/ARBGW.png,0,0,0.0001,37830,-7602071,6860102,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.86}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.35}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -596.51}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 342.88}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 826.43}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.56}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'T', 'net_profit': 4.31}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 434.55}]",1.19,0.26,36667491,213552,170652,9164506,0,36453939,776639,170652,-1103975,0.08013317978969103,0.08024137209400102,0.08181818181818168,__nan__,__nan__,__nan__,0.24993545372384493
305,ARCB,ArcBest Corporation Common Stock,"ArcBest Corporation provides freight transportation and integrated logistics services. It operates through three segments: Asset-Based, ArcBest, and FleetNet. The Asset-Based segment transports general commodities, such as food, textiles, apparel, furniture, appliances, chemicals, nonbulk petroleum products, rubber, plastics, metal and metal products, wood, glass, automotive parts, machinery, and miscellaneous manufactured products through less-than-truckload services. It also offers motor carrier freight transportation services to customers in Mexico through arrangements with trucking companies. The ArcBest segment provides expedite freight transportation services to commercial and government customers; premium logistics services, such as deployment of specialized equipment to meet linehaul requirements; and international freight transportation with air, ocean, and ground services. It also offers third-party transportation brokerage services by sourcing various capacity solutions, including dry van over the road and intermodal, temperature-controlled and refrigerated, flatbed, intermodal or container shipping, and specialized equipment; full-container and less-than-container load ocean transportation services; warehousing and distribution services; managed transportation services; and moving services to 'do-it-yourself' consumer, as well as provides final mile, time critical, product launch, warehousing, retail logistics, supply chain optimization, and trade show shipping services. The FleetNet segment provides roadside repair solutions and vehicle maintenance management services for commercial and private fleets through a network of third-party service providers. The company was formerly known as Arkansas Best Corporation and changed its name to ArcBest Corporation in May 2014. ArcBest Corporation was founded in 1923 and is headquartered in Fort Smith, Arkansas.",Ms. Judy R. McReynolds CPA,Trucking,94.8075,USD,2218457577,https://images.financialmodelingprep.com/symbol/ARCB.png,260348,11.81,-1.8925,55399,341358000,142164000,"[{'period': '2023', 'revenue': 4430.0, 'unit': 'M', 'net_profit': 142.16}, {'period': '2022', 'revenue': 5320.0, 'unit': 'M', 'net_profit': 298.21}, {'period': '2021', 'revenue': 3980.0, 'unit': 'M', 'net_profit': 213.52}, {'period': '2020', 'revenue': 2940.0, 'unit': 'M', 'net_profit': 71.1}]","[{'period': ""Q3 '24"", 'revenue': 1060.0, 'unit': 'M', 'net_profit': 100.31}, {'period': ""Q2 '24"", 'revenue': 1080.0, 'unit': 'M', 'net_profit': 46.92}, {'period': ""Q1 '24"", 'revenue': 1040.0, 'unit': 'M', 'net_profit': -3.12}, {'period': ""Q4 '23"", 'revenue': 1090.0, 'unit': 'M', 'net_profit': 48.79}, {'period': ""Q3 '23"", 'revenue': 1130.0, 'unit': 'M', 'net_profit': 34.92}, {'period': ""Q2 '23"", 'revenue': 1100.0, 'unit': 'M', 'net_profit': 40.44}]",8.14,7.93,2485094000,884783000,330068000,1242731000,482246000,6337000,701563000,262226000,90169000,-0.3609777831025781,-0.5232739454543626,-0.32893652102225884,"[0.12, 0.01]","['2024-11-13', '1992-07-30']",__nan__,0.5000740414648299
306,ARCC,Ares Capital Corporation Common Stock,"Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.",Mr. Robert Kipp DeVeer III,Asset Management,22.135,USD,14300892260,https://images.financialmodelingprep.com/symbol/ARCC.png,3948751,8.51,0.015,1126960,2124000000,1522000000,"[{'period': '2023', 'revenue': 2.61, 'unit': 'B', 'net_profit': 1.52}, {'period': '2022', 'revenue': 741.0, 'unit': 'M', 'net_profit': 600.0}, {'period': '2021', 'revenue': 1.68, 'unit': 'B', 'net_profit': 1.57}, {'period': '2020', 'revenue': 541.0, 'unit': 'M', 'net_profit': 484.0}]","[{'period': ""Q3 '24"", 'revenue': 751.0, 'unit': 'M', 'net_profit': 394.0}, {'period': ""Q2 '24"", 'revenue': 767.0, 'unit': 'M', 'net_profit': 322.0}, {'period': ""Q1 '24"", 'revenue': 495.0, 'unit': 'M', 'net_profit': 449.0}, {'period': ""Q4 '23"", 'revenue': 444.0, 'unit': 'M', 'net_profit': 413.0}, {'period': ""Q3 '23"", 'revenue': 528.0, 'unit': 'M', 'net_profit': 500.0}, {'period': ""Q2 '23"", 'revenue': 361.0, 'unit': 'M', 'net_profit': 331.0}]",2.78,2.68,23800000000,796000000,535000000,12599000000,261000000,22874000000,681000000,535000000,511000000,0.826311263972485,1.5366666666666666,1.3166666666666667,"[0.48, 0.3]","['2024-12-13', '2004-12-22']",__nan__,0.5293697478991597
307,ARCE,Arco Platform Limited Class A Common Shares,"Arco Platform Limited, a technology company in the education sector, provides a pedagogical system with technology-enabled features to deliver educational content to private schools in Brazil. The company's curriculum solutions provide educational content from basic to secondary education K-12 curriculum in printed and digital formats delivered through its platform. As of March 31, 2022, it had a network consisted of 8,056 partner schools and 1,614,648 enrolled students. The company's activities also comprise editing, publishing, advertising, and sale of educational content for private schools. It serves students, teachers, administrators, and parents. Arco Platform Limited was founded in 1941 and is headquartered in Sao Paulo, Brazil.",Mr. Ari  de Sa Cavalcante Neto,Education & Training Services,13.98,USD,927434556,https://images.financialmodelingprep.com/symbol/ARCE.png,237541,-73.57894736842105,-0.01,470862,983859000,39489000,"[{'period': '2022', 'revenue': 1780.0, 'unit': 'M', 'net_profit': 39.49}, {'period': '2021', 'revenue': 1230.0, 'unit': 'M', 'net_profit': -158.08}, {'period': '2020', 'revenue': 1000.0, 'unit': 'M', 'net_profit': 16.78}, {'period': '2019', 'revenue': 572.84, 'unit': 'M', 'net_profit': -9.43}]","[{'period': ""Q2 '23"", 'revenue': 470.96, 'unit': 'M', 'net_profit': -74.04}, {'period': ""Q1 '23"", 'revenue': 534.91, 'unit': 'M', 'net_profit': 90.62}, {'period': ""Q4 '22"", 'revenue': 679.33, 'unit': 'M', 'net_profit': 22.64}, {'period': ""Q3 '22"", 'revenue': 253.92, 'unit': 'M', 'net_profit': -72.46}, {'period': ""Q2 '22"", 'revenue': 412.14, 'unit': 'M', 'net_profit': -13.34}, {'period': ""Q1 '22"", 'revenue': 430.04, 'unit': 'M', 'net_profit': 102.66}]",0.71,-1.49,5753408000,1872729000,608145000,3855978000,928009000,142492000,1533589000,216360000,-280297000,3.9582419908380326,1.2497991561394963,1.22397476340694,__nan__,__nan__,__nan__,0.6702076404106923
308,ARCT,Arcturus Therapeutics Holdings Inc. Common Stock,"Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.",Mr. Joseph E. Payne M.Sc.,Biotechnology,19.985,USD,541341689,https://images.financialmodelingprep.com/symbol/ARCT.png,397116,-8.58,,0,-24166000,-29725000,"[{'period': '2023', 'revenue': 157.75, 'unit': 'M', 'net_profit': -29.73}, {'period': '2022', 'revenue': 205.75, 'unit': 'M', 'net_profit': 9.35}, {'period': '2021', 'revenue': 12.36, 'unit': 'M', 'net_profit': -206.86}, {'period': '2020', 'revenue': 9.54, 'unit': 'M', 'net_profit': -71.36}]","[{'period': ""Q3 '24"", 'revenue': 38.81, 'unit': 'M', 'net_profit': -6.9}, {'period': ""Q2 '24"", 'revenue': 45.98, 'unit': 'M', 'net_profit': -17.22}, {'period': ""Q1 '24"", 'revenue': 32.6, 'unit': 'M', 'net_profit': -26.82}, {'period': ""Q4 '23"", 'revenue': 28.21, 'unit': 'M', 'net_profit': -8.57}, {'period': ""Q3 '23"", 'revenue': 43.38, 'unit': 'M', 'net_profit': -16.22}, {'period': ""Q2 '23"", 'revenue': 9.56, 'unit': 'M', 'net_profit': -52.55}]",-1.12,-1.12,429402000,386590000,292005000,150889000,32064000,0,81989000,292005000,-21000000,-2.763426736719206,-4.179484436838164,-4.200000000000001,"[0.0085, 0.0029]","['2013-01-08', '2012-03-06']",__nan__,0.35139333305387493
309,ARDS,Aridis Pharmaceuticals Inc. Common Stock,"Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.",Dr. Vu L. Truong Ph.D.,Biotechnology,0.0001,USD,4457,https://images.financialmodelingprep.com/symbol/ARDS.png,16801,0,0,350,-29506000,-30749000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.75}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -42.28}, {'period': '2020', 'revenue': 1.0, 'unit': 'M', 'net_profit': -21.92}, {'period': '2019', 'revenue': 1.02, 'unit': 'M', 'net_profit': -28.99}]","[{'period': ""Q3 '23"", 'revenue': 417.0, 'unit': 'K', 'net_profit': -83.0}, {'period': ""Q2 '23"", 'revenue': 19.65, 'unit': 'M', 'net_profit': 12.14}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.34}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.39}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.07}, {'period': ""Q2 '22"", 'revenue': 0.292, 'unit': 'M', 'net_profit': -8.22}]",-1.64,-1.64,14695000,11626000,4876000,38927000,1240000,0,36898000,4876000,-29209000,0.3359440055814372,0.2727466237790024,0.5232558139534884,__nan__,__nan__,__nan__,2.6489962572303503
310,ARDX,Ardelyx Inc. Common Stock,"Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.",Mr. Michael G. Raab,Biotechnology,5.255,USD,1244667770,https://images.financialmodelingprep.com/symbol/ARDX.png,4381066,-16.42,0.255,2513517,-55354000,-66067000,"[{'period': '2023', 'revenue': 124.46, 'unit': 'M', 'net_profit': -66.07}, {'period': '2022', 'revenue': 52.16, 'unit': 'M', 'net_profit': -67.21}, {'period': '2021', 'revenue': 10.1, 'unit': 'M', 'net_profit': -158.16}, {'period': '2020', 'revenue': 7.57, 'unit': 'M', 'net_profit': -94.31}]","[{'period': ""Q3 '24"", 'revenue': 98240.0, 'unit': 'K', 'net_profit': -809.0}, {'period': ""Q2 '24"", 'revenue': 73.22, 'unit': 'M', 'net_profit': -16.45}, {'period': ""Q1 '24"", 'revenue': 46.02, 'unit': 'M', 'net_profit': -26.52}, {'period': ""Q4 '23"", 'revenue': 34.36, 'unit': 'M', 'net_profit': -28.8}, {'period': ""Q3 '23"", 'revenue': 56.39, 'unit': 'M', 'net_profit': 6.63}, {'period': ""Q2 '23"", 'revenue': 22.33, 'unit': 'M', 'net_profit': -17.12}]",-0.3,-0.3,297579000,246111000,184299000,130763000,22031000,0,50393000,21470000,-90061000,0.09228952805745957,0.016962518785245583,0.2857142857142857,__nan__,__nan__,__nan__,0.43942280873314316
311,AREC,American Resources Corporation Class A Common Stock,"American Resources Corporation engages in the extraction, processing, transportation, distribution, and sale of metallurgical coal to the steel industries. The company supplies raw materials; and sells coal used in pulverized coal injections. It has a portfolio of operations located in the Pike, Knott, and Letcher Counties in Kentucky; and Wyoming County, West Virginia. American Resources Corporation was founded in 2006 and is headquartered in Fishers, Indiana.",Mr. Mark C. Jensen,Coal,0.7806,USD,60435067,https://images.financialmodelingprep.com/symbol/AREC.png,381070,-3.12,-0.0044,221798,-7210803,-11455086,"[{'period': '2023', 'revenue': 16.74, 'unit': 'M', 'net_profit': -11.46}, {'period': '2022', 'revenue': 39.47, 'unit': 'M', 'net_profit': 22.53}, {'period': '2021', 'revenue': 7.76, 'unit': 'M', 'net_profit': -36.33}, {'period': '2020', 'revenue': 1.06, 'unit': 'M', 'net_profit': -16.13}]","[{'period': ""Q3 '24"", 'revenue': 0.23544, 'unit': 'M', 'net_profit': -9.21}, {'period': ""Q2 '24"", 'revenue': 0.00409, 'unit': 'M', 'net_profit': -6.62}, {'period': ""Q1 '24"", 'revenue': 0.09401999999999999, 'unit': 'M', 'net_profit': -6.23}, {'period': ""Q4 '23"", 'revenue': 0.0664, 'unit': 'M', 'net_profit': -10.84}, {'period': ""Q3 '23"", 'revenue': 5.83, 'unit': 'M', 'net_profit': 3.48}, {'period': ""Q2 '23"", 'revenue': 1980.0, 'unit': 'K', 'net_profit': -999.92}]",-0.15,-0.15,91746164,34885493,2666638,91522320,0,18780000,18070562,2666638,-14515241,-2.5274736704303438,-1.5083879837066758,-1.441176470588235,__nan__,__nan__,__nan__,0.9975601813717248
312,ARGX,argenx SE American Depositary Shares,"argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S..R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Universit Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.","Mr. Timothy  Van Hauwermeiren EMBA, M.Sc.",Biotechnology,651.49,USD,39328887724,https://images.financialmodelingprep.com/symbol/ARGX.png,260356,-775.58,6.12,117575,-216023048,-295053000,"[{'period': '2023', 'revenue': 1230.0, 'unit': 'M', 'net_profit': -295.05}, {'period': '2022', 'revenue': 410.75, 'unit': 'M', 'net_profit': -709.59}, {'period': '2021', 'revenue': 497.28, 'unit': 'M', 'net_profit': -408.26}, {'period': '2020', 'revenue': 44.85, 'unit': 'M', 'net_profit': -651.23}]","[{'period': ""Q3 '24"", 'revenue': 573.24, 'unit': 'M', 'net_profit': 91.41}, {'period': ""Q2 '24"", 'revenue': 877.26, 'unit': 'M', 'net_profit': -32.48}, {'period': ""Q1 '24"", 'revenue': 401.0, 'unit': 'M', 'net_profit': -61.6}, {'period': ""Q4 '23"", 'revenue': 407.43, 'unit': 'M', 'net_profit': -99.32}, {'period': ""Q3 '23"", 'revenue': 329.79, 'unit': 'M', 'net_profit': -72.64}, {'period': ""Q2 '23"", 'revenue': 270.55, 'unit': 'M', 'net_profit': -94.37}]",-5.16,-5.16,4542458000,4123737000,3179844000,444951000,499271000,47155000,422993000,2048844000,-464139000,0.6288322969200211,0.5841946239680719,0.6045977011494253,__nan__,__nan__,__nan__,0.09795379505985526
313,ARKO,ARKO Corp. Common Stock,"Arko Corp. operates convenience stores in the United States. It operates through three segments: Retail, Wholesale, and GPM Petroleum. The Retail segment engages in the sale of fuel and merchandise to retail consumers. The Wholesale segment supplies fuel to third-party dealers and consignment agents. The GPM Petroleum segment supplies fuel to independent dealers, and bulk and spot purchasers. It operates approximately 3,000 locations comprising approximately 1,400 company-operated stores and approximately 1,650 dealer sites. The company is based in Richmond, Virginia.",Mr. Arie  Kotler,Specialty Retail,6.295,USD,728778445,https://images.financialmodelingprep.com/symbol/ARKO.png,285319,39.34,-0.175,83102,265884000,34369000,"[{'period': '2023', 'revenue': 9410.0, 'unit': 'M', 'net_profit': 34.37}, {'period': '2022', 'revenue': 9140.0, 'unit': 'M', 'net_profit': 71.75}, {'period': '2021', 'revenue': 7420.0, 'unit': 'M', 'net_profit': 59.2}, {'period': '2020', 'revenue': 3910.0, 'unit': 'M', 'net_profit': 31.39}]","[{'period': ""Q3 '24"", 'revenue': 2280.0, 'unit': 'M', 'net_profit': 26.25}, {'period': ""Q2 '24"", 'revenue': 2390.0, 'unit': 'M', 'net_profit': 14.06}, {'period': ""Q1 '24"", 'revenue': 2069999.9999999998, 'unit': 'K', 'net_profit': -594.0}, {'period': ""Q4 '23"", 'revenue': 2230.0, 'unit': 'M', 'net_profit': 1.08}, {'period': ""Q3 '23"", 'revenue': 2620.0, 'unit': 'M', 'net_profit': 21.44}, {'period': ""Q2 '23"", 'revenue': 2470.0, 'unit': 'M', 'net_profit': 14.43}]",0.24,0.24,3650364000,749113000,222012000,3274247000,200274000,2885000,486224000,218120000,24885000,-0.013465027661003366,-0.5209695178892497,-0.5555555555555556,"[0.03, 0.02]","['2024-11-19', '2022-03-14']",__nan__,0.8969645218942549
314,ARKOW,ARKO Corp. Warrant,"Arko Corp. operates convenience stores in the United States. It operates through three segments: Retail, Wholesale, and GPM Petroleum. The Retail segment engages in the sale of fuel and merchandise to retail consumers. The Wholesale segment supplies fuel to third-party dealers and consignment agents. The GPM Petroleum segment supplies fuel to independent dealers, and bulk and spot purchasers. It operates approximately 3,000 locations comprising approximately 1,400 company-operated stores and approximately 1,650 dealer sites. The company is based in Richmond, Virginia.",Mr. Arie  Kotler,Specialty Retail,0.589,USD,68189119,https://images.financialmodelingprep.com/symbol/ARKOW.png,0,1.08,-0.031,1101,265884000,34369000,"[{'period': '2023', 'revenue': 9410.0, 'unit': 'M', 'net_profit': 34.37}, {'period': '2022', 'revenue': 9140.0, 'unit': 'M', 'net_profit': 71.75}, {'period': '2021', 'revenue': 7420.0, 'unit': 'M', 'net_profit': 59.2}, {'period': '2020', 'revenue': 3910.0, 'unit': 'M', 'net_profit': 31.39}]","[{'period': ""Q3 '24"", 'revenue': 2280.0, 'unit': 'M', 'net_profit': 26.25}, {'period': ""Q2 '24"", 'revenue': 2390.0, 'unit': 'M', 'net_profit': 14.06}, {'period': ""Q1 '24"", 'revenue': 2069999.9999999998, 'unit': 'K', 'net_profit': -594.0}, {'period': ""Q4 '23"", 'revenue': 2230.0, 'unit': 'M', 'net_profit': 1.08}, {'period': ""Q3 '23"", 'revenue': 2620.0, 'unit': 'M', 'net_profit': 21.44}, {'period': ""Q2 '23"", 'revenue': 2470.0, 'unit': 'M', 'net_profit': 14.43}]",0.24,0.24,3650364000,749113000,222012000,3274247000,200274000,2885000,486224000,218120000,24885000,-0.013465027661003366,-0.5209695178892497,-0.5555555555555556,__nan__,__nan__,__nan__,0.8969645218942549
315,ARKR,Ark Restaurants Corp. Common Stock,"Ark Restaurants Corp., through its subsidiaries, owns and operates restaurants and bars in the United States. As of December 20, 2021, it owned and operated 17 restaurants and bars, including four restaurants located in New York City; one in Washington, D.C.; five in Las Vegas, Nevada; one in Atlantic City, New Jersey; four on the east coast of Florida; and two on the gulf coast of Alabama, as well as had 17 fast food concepts and catering operations. The company was incorporated in 1983 and is based in New York, New York.",Mr. Michael  Weinstein,Restaurants,16.21,USD,58423434,https://images.financialmodelingprep.com/symbol/ARKR.png,9453,-15.01,0.01,17736,151000,-3896000,"[{'period': '2024', 'revenue': 183.54, 'unit': 'M', 'net_profit': -3.9}, {'period': '2023', 'revenue': 184.79, 'unit': 'M', 'net_profit': -5.93}, {'period': '2022', 'revenue': 183.67, 'unit': 'M', 'net_profit': 9.28}, {'period': '2021', 'revenue': 131.87, 'unit': 'M', 'net_profit': 12.89}]","[{'period': ""Q4 '24"", 'revenue': 43.41, 'unit': 'M', 'net_profit': -4.46}, {'period': ""Q3 '24"", 'revenue': 50400.0, 'unit': 'K', 'net_profit': 640.0}, {'period': ""Q2 '24"", 'revenue': 42.26, 'unit': 'M', 'net_profit': -1.45}, {'period': ""Q1 '24"", 'revenue': 47.49, 'unit': 'M', 'net_profit': 1.37}, {'period': ""Q4 '23"", 'revenue': 44.4, 'unit': 'M', 'net_profit': -10.36}, {'period': ""Q3 '23"", 'revenue': 51.05, 'unit': 'M', 'net_profit': 3.19}]",-1.08,-1.08,156041000,18225000,10273000,112400000,3516000,0,28884000,10273000,2189000,-0.7618296529968455,0.3427800269905533,0.3454545454545454,"[0.1875, 0.35]","['2024-05-31', '2004-10-20']",__nan__,0.7203235047199134
316,ARLP,Alliance Resource Partners L.P. Common Units representing Limited Partners Interests,"Alliance Resource Partners, L.P., a diversified natural resource company, produces and markets coal primarily to utilities and industrial users in the United States. The company operates through four segments: Illinois Basin Coal Operations, Appalachia Coal Operations, Oil & Gas Royalties, and Coal Royalties. It produces a range of thermal and metallurgical coal with sulfur and heat contents. The company operates seven underground mining complexes in Illinois, Indiana, Kentucky, Maryland, Pennsylvania, and West Virginia. In addition, it leases land and operates a coal loading terminal on the Ohio River at Mt. Vernon, Indiana; and buys and resells coal, as well as owns mineral and royalty interests in approximately 1.5 million gross acres of oil and gas producing regions primarily in the Permian, Anadarko, and Williston Basins. Further, the company offers various mining technology products and services, including data network, communication and tracking systems, mining proximity detection systems, industrial collision avoidance systems, and data and analytics software. As of December 31, 2021, it had approximately 547.1 million tons of proven and probable coal mineral reserves, as well as 1.17 billion tons of measured, indicated, and inferred coal mineral resources in Illinois, Indiana, Kentucky, Maryland, Pennsylvania, and West Virginia. The company was founded in 1971 and is headquartered in Tulsa, Oklahoma.",Mr. Joseph W. Craft III,Coal,26.06,USD,3337295720,https://images.financialmodelingprep.com/symbol/ARLP.png,301877,7.4,-0.22,34814,948523000,630118000,"[{'period': '2023', 'revenue': 2570.0, 'unit': 'M', 'net_profit': 630.12}, {'period': '2022', 'revenue': 2410.0, 'unit': 'M', 'net_profit': 586.2}, {'period': '2021', 'revenue': 1570.0, 'unit': 'M', 'net_profit': 182.77}, {'period': '2020', 'revenue': 1330.0, 'unit': 'M', 'net_profit': -129.05}]","[{'period': ""Q3 '24"", 'revenue': 613.57, 'unit': 'M', 'net_profit': 86.28}, {'period': ""Q2 '24"", 'revenue': 593.35, 'unit': 'M', 'net_profit': 100.19}, {'period': ""Q1 '24"", 'revenue': 651.7, 'unit': 'M', 'net_profit': 158.06}, {'period': ""Q4 '23"", 'revenue': 625.42, 'unit': 'M', 'net_profit': 115.44}, {'period': ""Q3 '23"", 'revenue': 636.52, 'unit': 'M', 'net_profit': 153.7}, {'period': ""Q2 '23"", 'revenue': 641.84, 'unit': 'M', 'net_profit': 169.79}]",4.81,4.81,2788426000,516121000,59813000,929829000,292300000,139044000,227467000,59813000,451304000,0.01537531043932517,0.07491982258614807,0.09567198177676536,"[0.7, 0.23]","['2024-11-07', '1999-10-27']",__nan__,0.3334601671337163
317,ARNA,Arena Pharmaceuticals Inc. Common Stock,"Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.",Mr. Amit Munshi,Biotechnology,99.99,USD,0,https://images.financialmodelingprep.com/symbol/ARNA.png,1472638,-9.858030168589174,0,0,-608402000,-620592000,"[{'period': '2021', 'revenue': 0.054, 'unit': 'M', 'net_profit': -620.59}, {'period': '2020', 'revenue': 0.319, 'unit': 'M', 'net_profit': -404.73}, {'period': '2019', 'revenue': 806.43, 'unit': 'M', 'net_profit': 397.56}, {'period': '2018', 'revenue': 17.97, 'unit': 'M', 'net_profit': -29.4}]","[{'period': ""Q4 '21"", 'revenue': 0.054, 'unit': 'M', 'net_profit': -156.61}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -196.31}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -146.09}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -118.42}, {'period': ""Q4 '20"", 'revenue': 0.037, 'unit': 'M', 'net_profit': -122.16}, {'period': ""Q3 '20"", 'revenue': 0.02, 'unit': 'M', 'net_profit': -97.44}]",-11.33,-11.33,784705000,569465000,550469000,111468000,0,160796000,66316000,224572000,-523004000,-0.5350003658355053,-0.5333330038988571,-0.5331529093369419,__nan__,__nan__,__nan__,0.1420508343899937
318,AROW,Arrow Financial Corporation Common Stock,"Arrow Financial Corporation, a bank holding company, provides commercial and consumer banking, and financial products and services. The company's deposit products include demand deposits, interest-bearing checking accounts, savings deposits, time deposits, and other time deposits. Its lending activities comprise commercial loans, such as term loans, time notes, and lines of credit; and commercial real estate loans to finance real estate purchases, refinancing, expansions, and improvements to commercial properties, as well as commercial construction and land development loans to finance projects. The company's lending activities also include consumer installment loans to finance personal expenditures, personal lines of credit, overdraft protection, and automobile loans; and residential real estate loans, fixed home equity loans, and home equity lines of credit for consumers to finance home improvements, debt consolidation, education, and other uses. In addition, it maintains an indirect lending program; and sells residential real estate loan originations into the secondary market. Further, the company provides retirement planning, trust, and estate administration services for individuals; and pension, profit-sharing, and employee benefit plan administration services for corporations. Additionally, it offers insurance agency services comprising group health care policies and life insurance, and property and casualty insurance products; and investment advisory services to its proprietary mutual funds, as well as holds a real estate investment trust. The company operates in the northeastern region of New York State in Warren, Washington, Saratoga, Essex, Clinton, Rensselaer, Albany, and Schenectady counties, as well as surrounding areas. It owns 26 branch banking offices; and leases 12 branch banking offices, as well as two residential loan origination offices. Arrow Financial Corporation was founded in 1851 and is headquartered in Glens Falls, New York.",Mr. David S. DeMarco,Banks - Regional,26.52,USD,443918280,https://images.financialmodelingprep.com/symbol/AROW.png,0,13.53,,0,0,30075000,"[{'period': '2023', 'revenue': 133.95, 'unit': 'M', 'net_profit': 30.07}, {'period': '2022', 'revenue': 149.24, 'unit': 'M', 'net_profit': 48.8}, {'period': '2021', 'revenue': 142.72, 'unit': 'M', 'net_profit': 49.86}, {'period': '2020', 'revenue': 131.86, 'unit': 'M', 'net_profit': 40.83}]","[{'period': ""Q3 '24"", 'revenue': 36.57, 'unit': 'M', 'net_profit': 8.97}, {'period': ""Q2 '24"", 'revenue': 55.83, 'unit': 'M', 'net_profit': 8.6}, {'period': ""Q1 '24"", 'revenue': 54.53, 'unit': 'M', 'net_profit': 7.66}, {'period': ""Q4 '23"", 'revenue': 51.81, 'unit': 'M', 'net_profit': 7.72}, {'period': ""Q3 '23"", 'revenue': 33.4, 'unit': 'M', 'net_profit': 7.74}, {'period': ""Q2 '23"", 'revenue': 32.68, 'unit': 'M', 'net_profit': 6.05}]",1.77,1.77,4169868000,142536000,142536000,3790096000,0,117038000,0,142536000,13499000,-1,-0.3836963872210496,-0.3832752613240418,"[0.28, 8.2136]","['2024-10-15', '1985-01-17']",__nan__,0.9089246949783543
319,ARPO,Aerpio Pharmaceuticals Inc. Common Stock,"Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.",,Biotechnology,2.2,USD,53669220,https://images.financialmodelingprep.com/symbol/ARPO.png,401776,0,-0.01999998,826006,-36054000,-36917000,"[{'period': '2022', 'revenue': 5.51, 'unit': 'M', 'net_profit': -36.92}, {'period': '2021', 'revenue': 4.47, 'unit': 'M', 'net_profit': -23.16}, {'period': '2020', 'revenue': 0.8230000000000001, 'unit': 'M', 'net_profit': -22.18}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.48}]","[{'period': ""Q3 '23"", 'revenue': 1.23, 'unit': 'M', 'net_profit': -31.16}, {'period': ""Q2 '23"", 'revenue': 0.98, 'unit': 'M', 'net_profit': -3.55}, {'period': ""Q1 '23"", 'revenue': 0.796, 'unit': 'M', 'net_profit': -14.49}, {'period': ""Q4 '22"", 'revenue': 1.05, 'unit': 'M', 'net_profit': -10.31}, {'period': ""Q3 '22"", 'revenue': 1.34, 'unit': 'M', 'net_profit': -8.61}, {'period': ""Q2 '22"", 'revenue': 1.88, 'unit': 'M', 'net_profit': -9.21}]",-1.08,-1.08,95834000,27047000,14852000,59754000,0,0,24873000,14852000,-34692000,-0.5915772745331744,-0.5943424746275102,-0.1250000000000001,__nan__,__nan__,__nan__,0.6235156624997391
320,ARQT,Arcutis Biotherapeutics Inc. Common Stock,"Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.",Mr. Todd Franklin Watanabe M.A.,Biotechnology,15.655,USD,1832339475,https://images.financialmodelingprep.com/symbol/ARQT.png,2041320,-9.37,0.945,1311271,-227434000,-262140000,"[{'period': '2023', 'revenue': 59.61, 'unit': 'M', 'net_profit': -262.14}, {'period': '2022', 'revenue': 3.69, 'unit': 'M', 'net_profit': -321.29}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -205.9}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -135.68}]","[{'period': ""Q3 '24"", 'revenue': 44.76, 'unit': 'M', 'net_profit': -41.54}, {'period': ""Q2 '24"", 'revenue': 30.86, 'unit': 'M', 'net_profit': -52.33}, {'period': ""Q1 '24"", 'revenue': 49.57, 'unit': 'M', 'net_profit': -35.38}, {'period': ""Q4 '23"", 'revenue': 13.53, 'unit': 'M', 'net_profit': -66.28}, {'period': ""Q3 '23"", 'revenue': 38.11, 'unit': 'M', 'net_profit': -44.77}, {'period': ""Q2 '23"", 'revenue': 5.19, 'unit': 'M', 'net_profit': -70.99}]",-3.78,-3.78,341365000,330431000,271861000,252698000,25807000,0,46668000,88398000,-247485000,0.22786731080654415,0.18409905101014973,0.3527397260273973,__nan__,__nan__,__nan__,0.7402574956424941
321,ARRW,Arrowroot Acquisition Corp. Class A common stock,"Arrowroot Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to identify and acquire a business focusing on the enterprise software sector. The company was incorporated in 2020 and is based in Marina Del Rey, California.",Mr. Matthew J. Safaii,Shell Companies,18,USD,59292648,https://images.financialmodelingprep.com/symbol/ARRW.png,0,-48.65,0,44582,19115000,-4407000,"[{'period': '2023', 'revenue': 420.58, 'unit': 'M', 'net_profit': -4.41}, {'period': '2022', 'revenue': 309.17, 'unit': 'M', 'net_profit': 11.47}, {'period': '2021', 'revenue': 217.87, 'unit': 'M', 'net_profit': 4.84}, {'period': '2020', 'revenue': 141.75, 'unit': 'M', 'net_profit': 6.86}]","[{'period': ""Q2 '24"", 'revenue': 135.54, 'unit': 'M', 'net_profit': -314.03}, {'period': ""Q1 '24"", 'revenue': 124.94, 'unit': 'M', 'net_profit': -4.24}, {'period': ""Q4 '23"", 'revenue': 115670.0, 'unit': 'K', 'net_profit': 949.69}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 275.54}, {'period': ""Q2 '23"", 'revenue': 195.22, 'unit': 'M', 'net_profit': -5.38}, {'period': ""Q1 '23"", 'revenue': 93980.0, 'unit': 'K', 'net_profit': -374.84}]",-0.05,-0.046,47004462,80832000,4763000,24744253,74007000,0,12871753,4763000,-16190000,0.592253227821741,-1.3843537414965987,-1.131578947368421,__nan__,__nan__,__nan__,0.5264234914549176
322,ARRWU,Arrowroot Acquisition Corp. Unit,"Arrowroot Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to identify and acquire a business focusing on the enterprise software sector. The company was incorporated in 2020 and is based in Marina Del Rey, California.",Mr. Matthew J. Safaii,Shell Companies,17,USD,137576274,https://images.financialmodelingprep.com/symbol/ARRWU.png,1553,67.46031746031746,4.66,6933,19115000,-4407000,"[{'period': '2023', 'revenue': 420.58, 'unit': 'M', 'net_profit': -4.41}, {'period': '2022', 'revenue': 309.17, 'unit': 'M', 'net_profit': 11.47}, {'period': '2021', 'revenue': 217.87, 'unit': 'M', 'net_profit': 4.84}, {'period': '2020', 'revenue': 141.75, 'unit': 'M', 'net_profit': 6.86}]","[{'period': ""Q2 '24"", 'revenue': 135.54, 'unit': 'M', 'net_profit': -314.03}, {'period': ""Q1 '24"", 'revenue': 124.94, 'unit': 'M', 'net_profit': -4.24}, {'period': ""Q4 '23"", 'revenue': 115670.0, 'unit': 'K', 'net_profit': 949.69}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 275.54}, {'period': ""Q2 '23"", 'revenue': 195.22, 'unit': 'M', 'net_profit': -5.38}, {'period': ""Q1 '23"", 'revenue': 93980.0, 'unit': 'K', 'net_profit': -374.84}]",-0.05,-0.046,47004462,80832000,4763000,24744253,74007000,0,12871753,4763000,-16190000,0.592253227821741,-1.3843537414965987,-1.131578947368421,__nan__,__nan__,__nan__,0.5264234914549176
323,ARRWW,Arrowroot Acquisition Corp. Warrant,"Arrowroot Acquisition Corp. is a blank check company. The company was incorporated in 2020 and is based in Marina Del Rey, California.",Mr. Matthew J. Safaii,Shell Companies,0.289,USD,2338797,https://images.financialmodelingprep.com/symbol/ARRWW.png,0,0,0.0296,274799,19115000,-4407000,"[{'period': '2023', 'revenue': 420.58, 'unit': 'M', 'net_profit': -4.41}, {'period': '2022', 'revenue': 309.17, 'unit': 'M', 'net_profit': 11.47}, {'period': '2021', 'revenue': 217.87, 'unit': 'M', 'net_profit': 4.84}, {'period': '2020', 'revenue': 141.75, 'unit': 'M', 'net_profit': 6.86}]","[{'period': ""Q2 '24"", 'revenue': 135.54, 'unit': 'M', 'net_profit': -314.03}, {'period': ""Q1 '24"", 'revenue': 124.94, 'unit': 'M', 'net_profit': -4.24}, {'period': ""Q4 '23"", 'revenue': 115670.0, 'unit': 'K', 'net_profit': 949.69}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 275.54}, {'period': ""Q2 '23"", 'revenue': 195.22, 'unit': 'M', 'net_profit': -5.38}, {'period': ""Q1 '23"", 'revenue': 93980.0, 'unit': 'K', 'net_profit': -374.84}]",-0.05,-0.046,47004462,80832000,4763000,24744253,74007000,0,12871753,4763000,-16190000,0.592253227821741,-1.3843537414965987,-1.131578947368421,__nan__,__nan__,__nan__,0.5264234914549176
324,ARRY,Array Technologies Inc. Common Stock,"Array Technologies, Inc. manufactures and supplies solar tracking systems and related products in the United States and internationally. Its products include DuraTrack HZ v3, a single-axis solar tracking system; and SmarTrack, a machine learning software that is used to identify the optimal position for a solar array in real time to increase energy production. The company was founded in 1989 and is headquartered in Albuquerque, New Mexico.",Mr. Kevin G. Hostetler,Solar,6.725,USD,1021816675,https://images.financialmodelingprep.com/symbol/ARRY.png,6699416,-6.86,0.085,1572739,276212000,137240000,"[{'period': '2023', 'revenue': 1580.0, 'unit': 'M', 'net_profit': 137.24}, {'period': '2022', 'revenue': 1640.0, 'unit': 'M', 'net_profit': 4.43}, {'period': '2021', 'revenue': 853.32, 'unit': 'M', 'net_profit': -50.4}, {'period': '2020', 'revenue': 872.66, 'unit': 'M', 'net_profit': 59.07}]","[{'period': ""Q3 '24"", 'revenue': 231.41, 'unit': 'M', 'net_profit': -141.35}, {'period': ""Q2 '24"", 'revenue': 255.77, 'unit': 'M', 'net_profit': 25.7}, {'period': ""Q1 '24"", 'revenue': 153.4, 'unit': 'M', 'net_profit': 2.17}, {'period': ""Q4 '23"", 'revenue': 341.62, 'unit': 'M', 'net_profit': 23.09}, {'period': ""Q3 '23"", 'revenue': 350.44, 'unit': 'M', 'net_profit': 23.21}, {'period': ""Q2 '23"", 'revenue': 507.73, 'unit': 'M', 'net_profit': 64.81}]",0.57,0.56,1706741000,832281000,249080000,1096233000,332152000,0,335691000,249080000,214966000,2.401290513249926,29.965703971119133,18.256756756756754,__nan__,__nan__,__nan__,0.6422960484338279
325,ARTAU,Artisan Acquisition Corp. Units,"Artisan Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to search for a target with operations or prospects focusing on healthcare, consumer, and technology sectors. The company was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.",Mr. Cheng Yin Pan,Shell Companies,10.15,USD,0,https://images.financialmodelingprep.com/symbol/ARTAU.png,8262,0,0,1240,0,0,"[{'period': '2021', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'T', 'net_profit': 5.56}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.1}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.54}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",0,0,340178214,610487,102212,27888846,0,0,3278431,102212,-1372731,0,0,0,__nan__,__nan__,__nan__,0.08198304551037475
326,ARTL,Artelo Biosciences Inc. Common Stock,"Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.",Mr. Gregory D. Gorgas M.B.A.,Biotechnology,1.14,USD,3679578,https://images.financialmodelingprep.com/symbol/ARTL.png,31540,-0.4,-0.01,34169,-10285000,-9874000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.87}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.44}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.65}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.17}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.45}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.6}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.04}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.2}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.26}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.43}]",-3.49,-3.49,20424000,18322000,17533000,1021000,0,-1495000,998000,6888000,-8008000,-0.38183528147252455,-0.32768589485007393,0.4154103852596314,__nan__,__nan__,__nan__,0.04999020759890325
327,ARTLW,Artelo Biosciences Inc. Warrant,"Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.",Mr. Gregory D. Gorgas M.B.A.,Biotechnology,0.0056,USD,13069,https://images.financialmodelingprep.com/symbol/ARTLW.png,0,0,0,29400,-10285000,-9874000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.87}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.44}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.65}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.17}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.45}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.6}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.04}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.2}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.26}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.43}]",-3.49,-3.49,20424000,18322000,17533000,1021000,0,-1495000,998000,6888000,-8008000,-0.38183528147252455,-0.32768589485007393,0.4154103852596314,__nan__,__nan__,__nan__,0.04999020759890325
328,ARTNA,Artesian Resources Corporation Class A Common Stock,"Artesian Resources Corporation, through its subsidiaries, provides water, wastewater, and other services in Delaware, Maryland, and Pennsylvania. The company distributes and sells water to residential, commercial, industrial, governmental, municipal, and utility customers, as well as for public and private fire protection in the states of Delaware, Maryland, and Pennsylvania; and offers wastewater collection, treatment infrastructure, and wastewater services to customers in Delaware. It also provides contract water and wastewater services; water, sewer, and internal service line protection plans; and wastewater management services, as well as design, construction, and engineering services. In addition, the company offers services to other water utilities, including operations and billing functions; owns real estate properties, including land for office buildings, a water treatment plant, and wastewater facility; and provides design, installation, maintenance, and repair services related to existing or proposed storm water management systems. As of December 31, 2021, it served approximately 91,700 customers in Delaware, 2,500 customers in Maryland, and 40 customers in Pennsylvania through 1,368 miles of transmission and distribution mains. Artesian Resources Corporation was founded in 1905 and is headquartered in Newark, Delaware.",Ms. Dian C. Taylor,Regulated Water,30.08,USD,309753673,https://images.financialmodelingprep.com/symbol/ARTNA.png,32206,15.43,-0.19,17508,42129000,16699000,"[{'period': '2023', 'revenue': 98.86, 'unit': 'M', 'net_profit': 16.7}, {'period': '2022', 'revenue': 98.9, 'unit': 'M', 'net_profit': 18.0}, {'period': '2021', 'revenue': 90.86, 'unit': 'M', 'net_profit': 16.83}, {'period': '2020', 'revenue': 88.14, 'unit': 'M', 'net_profit': 16.82}]","[{'period': ""Q3 '24"", 'revenue': 29.14, 'unit': 'M', 'net_profit': 6.81}, {'period': ""Q2 '24"", 'revenue': 27.42, 'unit': 'M', 'net_profit': 5.33}, {'period': ""Q1 '24"", 'revenue': 24.54, 'unit': 'M', 'net_profit': 4.41}, {'period': ""Q4 '23"", 'revenue': 24.55, 'unit': 'M', 'net_profit': 3.48}, {'period': ""Q3 '23"", 'revenue': 26.57, 'unit': 'M', 'net_profit': 5.07}, {'period': ""Q2 '23"", 'revenue': 25.25, 'unit': 'M', 'net_profit': 4.44}]",1.67,1.67,766832000,30617000,2505000,536435000,16562999,0,22414000,2505000,-30326000,-0.006485237241769645,-0.07217468607623069,-0.12105263157894737,"[0.3014, 0.15]","['2024-11-15', '1994-05-05']",__nan__,0.699546967262712
329,ARTW,Art's-Way Manufacturing Co. Inc. Common Stock,"Art's-Way Manufacturing Co., Inc. manufactures and sells agricultural equipment, specialized modular science buildings, and steel cutting tools in the United States and internationally. The company operates through three segments: Agricultural Products, Modular Buildings, and Tools. The Agricultural Products segment offers various specialized farm machinery, including portable and stationary animal feed processing equipment and related attachments; hay and forage equipment, such as forage boxes, bale processors, running gears, and dump boxes; manure spreaders; sugar beet harvesting equipment; dirt work equipment; and after-market service parts. The Modular Buildings segment produces, sells, and leases swine buildings, complex containment research laboratories, and research facilities for academic research institutions, government research and diagnostic centers, public health institutions, and private research and pharmaceutical companies. This segment also designs, manufactures, delivers, installs, and rents building units. The Tools segment offers standard single point brazed carbide tipped tools, polycrystalline diamond and cubic boron nitride inserts and tools, and original equipment manufacturer (OEM) specialty tools to the automotive, aerospace, oil and gas piping, and appliances industries. The company markets and sells its products through independent farm equipment dealers, manufacturers' representatives, direct sales, and OEM sales channels. Art's-Way Manufacturing Co., Inc. was founded in 1956 and is based in Armstrong, Iowa.",Mr. Marc H. McConnell,Agricultural - Machinery,1.9093,USD,9606567,https://images.financialmodelingprep.com/symbol/ARTW.png,156009,-17.36,-0.0407,72053,2483571,266969,"[{'period': '2023', 'revenue': 30280.0, 'unit': 'K', 'net_profit': 266.97}, {'period': '2022', 'revenue': 28400.0, 'unit': 'K', 'net_profit': 97.8}, {'period': '2021', 'revenue': 24970.0, 'unit': 'K', 'net_profit': 212.63}, {'period': '2020', 'revenue': 22.41, 'unit': 'M', 'net_profit': -2.1}]","[{'period': ""Q3 '24"", 'revenue': 5880.0, 'unit': 'K', 'net_profit': -26.2}, {'period': ""Q2 '24"", 'revenue': 6730.0, 'unit': 'K', 'net_profit': -33.34}, {'period': ""Q1 '24"", 'revenue': 5720.0, 'unit': 'K', 'net_profit': -465.04}, {'period': ""Q4 '23"", 'revenue': 6850.0, 'unit': 'K', 'net_profit': -307.88}, {'period': ""Q3 '23"", 'revenue': 8119.999999999999, 'unit': 'K', 'net_profit': -74.03}, {'period': ""Q2 '23"", 'revenue': 9010.0, 'unit': 'K', 'net_profit': 306.66}]",0.0534,0.0534,24402114,15085494,4014,12760859,3721498,0,9395023,4014,-896978,0.9621556153889911,1.7298281133368099,1.5673076923076925,"[0.05, 0.1]","['2015-02-10', '1989-02-01']",__nan__,0.5229407173493247
330,ARVL,Arrival Ordinary Shares,"Arrival engages in the research and development, and design of commercial electric vehicles (EVs), EVs components, robotic manufacturing processes for EVs, and associated software in the United Kingdom, the United States, Russia, and internationally. Its products portfolio includes commercial EV vans, buses, and cars. The company was formerly known as Arrival Group S.A. and changed its name to Arrival. The company was founded in 2015 and is based in Howald, Luxembourg. Arrival is a subsidiary of Kinetik S. r.l.",Mr. Igor  Torgov,Auto - Manufacturers,0.49,USD,9003799,https://images.financialmodelingprep.com/symbol/ARVL.png,174108,-0.07324364723467862,-0.249,2343693,-187182000,-1304404595,"[{'period': '2021', 'revenue': 0.0, 'unit': 'B', 'net_profit': -1.3}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.3}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': 31.09}]","[{'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -53.51}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.79}]",-95.78,-95.77,1770701523,1017542628,901092593,544484952,44199633,41116603,81634247,901092593,-585656180,-0.949690644334729,-244.98412065323978,-10.68048780487805,__nan__,__nan__,__nan__,0.3074967434813688
331,ARVLW,Arrival Warrant,,,,,,,,,0,0,758400,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
332,ARVN,Arvinas Inc. Common Stock,"Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.",Dr. John G. Houston Ph.D.,Biotechnology,19.83,USD,1362580773,https://images.financialmodelingprep.com/symbol/ARVN.png,771995,-4.14,-0.08,244034,-394800000,-367300000,"[{'period': '2023', 'revenue': 78.5, 'unit': 'M', 'net_profit': -367.3}, {'period': '2022', 'revenue': 131.4, 'unit': 'M', 'net_profit': -271.9}, {'period': '2021', 'revenue': 46.7, 'unit': 'M', 'net_profit': -183.2}, {'period': '2020', 'revenue': 21.8, 'unit': 'M', 'net_profit': -111.79}]","[{'period': ""Q3 '24"", 'revenue': 102.4, 'unit': 'M', 'net_profit': -49.2}, {'period': ""Q2 '24"", 'revenue': 76.5, 'unit': 'M', 'net_profit': -35.2}, {'period': ""Q1 '24"", 'revenue': 25.3, 'unit': 'M', 'net_profit': -69.4}, {'period': ""Q4 '23"", 'revenue': -43.1, 'unit': 'M', 'net_profit': -154.8}, {'period': ""Q3 '23"", 'revenue': 34.6, 'unit': 'M', 'net_profit': -64.0}, {'period': ""Q2 '23"", 'revenue': 54.5, 'unit': 'M', 'net_profit': -66.6}]",-6.62,-6.62,1304600000,1280200000,1261000000,644600000,7200000,0,257100000,311700000,-350700000,-0.536784747126449,-0.35086428834130196,-0.2954990215264187,__nan__,__nan__,__nan__,0.49409780775716694
333,ARWR,Arrowhead Pharmaceuticals Inc. Common Stock,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",Dr. Christopher R. Anzalone Ph.D.,Biotechnology,19.69,USD,2450105460,https://images.financialmodelingprep.com/symbol/ARWR.png,1453875,-3.99,0.19,405492,-561513000,-599493000,"[{'period': '2024', 'revenue': 3.55, 'unit': 'M', 'net_profit': -599.49}, {'period': '2023', 'revenue': 240.74, 'unit': 'M', 'net_profit': -205.28}, {'period': '2022', 'revenue': 243.23, 'unit': 'M', 'net_profit': -176.49}, {'period': '2021', 'revenue': 138.29, 'unit': 'M', 'net_profit': -140.85}]","[{'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -170.54}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -170.79}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -125.3}, {'period': ""Q1 '24"", 'revenue': 3.55, 'unit': 'M', 'net_profit': -132.86}, {'period': ""Q4 '23"", 'revenue': 16.1, 'unit': 'M', 'net_profit': -109.68}, {'period': ""Q3 '23"", 'revenue': 15.82, 'unit': 'M', 'net_profit': -102.95}]",-5,-5,1139802000,695471000,680961000,948739000,0,0,103168000,102685000,-604320000,-2.1963716471606176,-1.9204384362440627,-1.617801047120419,__nan__,__nan__,__nan__,0.8323717628149451
334,ARYA,ARYA Sciences Acquisition Corp III Class A Ordinary Shares,,,,,,,,,,,,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
335,ARYD,ARYA Sciences Acquisition Corp IV Class A Odinary Shares,"ARYA Sciences Acquisition Corp IV does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.",Mr. Adam Leo Stone,Shell Companies,6.64,USD,50042486,https://images.financialmodelingprep.com/symbol/ARYD.png,30382,-25.53846153846154,-2.46,90405,-4752270,-2133335,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.13}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.14}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.56}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -13.54}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -245.85}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.22}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -455.07}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 381.51}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.29}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.14}]",-0.22,-0.22,40652687,76738,20191,14969477,0,40575949,12353227,20191,-725858,-3.709559009344257,-1.6785326022998421,-2.375,__nan__,__nan__,__nan__,0.3682284765088222
336,ASAX,Astrea Acquisition Corp. Class A Common Stock,"Astrea Acquisition Corp. does not have significant operations. It intends to enter a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company focuses on the businesses in the food and beverage/hospitality, financial services, technology, consumer, real estate and transportation, telecom and media, and industrial sectors. The company was incorporated in 2020 and is based in Key Biscayne, Florida.",Mr. Felipe  Gonzalez,Shell Companies,10.08,USD,0,https://images.financialmodelingprep.com/symbol/ASAX.png,67834,0,0.01,7296,-1589100,-1565898,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.57}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 218.28}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 370.83}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -207.91}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -797.81}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -291.37}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -158.19}]",-0.0783,-0.0783,172973428,412348,67689,1552178,0,0,1209988,67689,-1541075,0,0,0,__nan__,__nan__,__nan__,0.008973505456572209
337,ASAXU,Astrea Acquisition Corp. Unit,"Astrea Acquisition Corp. does not have significant operations. It intends to enter a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company focuses on the businesses in the food and beverage/hospitality, financial services, technology, consumer, real estate and transportation, telecom and media, and industrial sectors. The company was incorporated in 2020 and is based in Key Biscayne, Florida.",Mr. Felipe  Gonzalez,Shell Companies,10,USD,0,https://images.financialmodelingprep.com/symbol/ASAXU.png,336,0,0,0,-1589100,-1565898,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.57}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 218.28}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 370.83}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -207.91}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -797.81}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -291.37}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -158.19}]",-0.0783,-0.0783,172973428,412348,67689,1552178,0,0,1209988,67689,-1541075,0,0,0,__nan__,__nan__,__nan__,0.008973505456572209
338,ASAXW,Astrea Acquisition Corp. Warrant,"Astrea Acquisition Corp. does not have significant operations. It intends to enter a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The company was founded 2020 and is based in Key Biscayne, Florida.",Mr. Felipe  Gonzalez,Shell Companies,0.0013,USD,0,https://images.financialmodelingprep.com/symbol/ASAXW.png,0,0,0,14061,-1589100,-1565898,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.57}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 218.28}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 370.83}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -207.91}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -797.81}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -291.37}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -158.19}]",-0.0783,-0.0783,172973428,412348,67689,1552178,0,0,1209988,67689,-1541075,0,0,0,__nan__,__nan__,__nan__,0.008973505456572209
339,ASLE,AerSale Corporation Common Stock,"AerSale Corporation provides aftermarket commercial aircraft, engines, and its parts to passenger and cargo airlines, leasing companies, original equipment manufacturers, and government and defense contractors, as well as maintenance, repair, and overhaul (MRO) service providers worldwide. It operates in two segments, Asset Management Solutions and Technical Operations (TechOps). The Asset Management Solutions segment engages in the sale and lease of aircraft, engines, and airframes, as well as disassembly of these assets for component parts. The TechOps segment provides internal and third-party aviation services, including internally developed engineered solutions, heavy aircraft maintenance and modification, and component MRO, as well as end-of-life disassembly services. This segment also provides aircraft modifications, cargo and tanker conversions of aircraft, and aircraft storage; and MRO services for landing gear, thrust reversers, hydraulic systems, and other aircraft components. The company was founded in 2008 and is headquartered in Coral Gables, Florida.",Mr. Nicolas  Finazzo,"Airlines, Airports & Air Services",6.09,USD,324032457,https://images.financialmodelingprep.com/symbol/ASLE.png,433516,-304.5,-0.03,77861,48000,-5563000,"[{'period': '2023', 'revenue': 334.5, 'unit': 'M', 'net_profit': -5.56}, {'period': '2022', 'revenue': 408.54, 'unit': 'M', 'net_profit': 43.86}, {'period': '2021', 'revenue': 340.44, 'unit': 'M', 'net_profit': 36.12}, {'period': '2020', 'revenue': 208.94, 'unit': 'M', 'net_profit': 8.09}]","[{'period': ""Q3 '24"", 'revenue': 82680.0, 'unit': 'K', 'net_profit': 509.0}, {'period': ""Q2 '24"", 'revenue': 77.1, 'unit': 'M', 'net_profit': -3.64}, {'period': ""Q1 '24"", 'revenue': 90.54, 'unit': 'M', 'net_profit': 6.28}, {'period': ""Q4 '23"", 'revenue': 94.42, 'unit': 'M', 'net_profit': -2.73}, {'period': ""Q3 '23"", 'revenue': 92480.0, 'unit': 'K', 'net_profit': -148.0}, {'period': ""Q2 '23"", 'revenue': 69.33, 'unit': 'M', 'net_profit': -2.69}]",-0.15,-0.15,553938000,264774000,5873000,108923000,32866999,0,45713000,5873000,-185509000,-0.9992823717613288,-1.1268324935591985,-1.1764705882352942,__nan__,__nan__,__nan__,0.19663391931949062
340,ASLEW,AerSale Corporation Warrants,"AerSale Corporation provides aftermarket commercial aircraft, engines, and its parts to passenger and cargo airlines, leasing companies, original equipment manufacturers, and government and defense contractors, as well as maintenance, repair, and overhaul (MRO) service providers worldwide. It operates in two segments, Asset Management Solutions and Technical Operations (TechOps). The Asset Management Solutions segment engages in the sale and lease of aircraft, engines, and airframes, as well as disassembly of these assets for component parts. The TechOps segment provides internal and third-party aviation services, including internally developed engineered solutions, heavy aircraft maintenance and modification, and component MRO, as well as end-of-life disassembly services. This segment also provides aircraft modifications, cargo and tanker conversions of aircraft, and aircraft storage; and MRO services for landing gear, thrust reversers, hydraulic systems, and other aircraft components. The company was founded in 2008 and is headquartered in Coral Gables, Florida.",Mr. Nicolas  Finazzo,"Airlines, Airports & Air Services",6.48,USD,0,https://images.financialmodelingprep.com/symbol/ASLEW.png,0,8.307692307692308,0.15999985,48476,48000,-5563000,"[{'period': '2023', 'revenue': 334.5, 'unit': 'M', 'net_profit': -5.56}, {'period': '2022', 'revenue': 408.54, 'unit': 'M', 'net_profit': 43.86}, {'period': '2021', 'revenue': 340.44, 'unit': 'M', 'net_profit': 36.12}, {'period': '2020', 'revenue': 208.94, 'unit': 'M', 'net_profit': 8.09}]","[{'period': ""Q3 '24"", 'revenue': 82680.0, 'unit': 'K', 'net_profit': 509.0}, {'period': ""Q2 '24"", 'revenue': 77.1, 'unit': 'M', 'net_profit': -3.64}, {'period': ""Q1 '24"", 'revenue': 90.54, 'unit': 'M', 'net_profit': 6.28}, {'period': ""Q4 '23"", 'revenue': 94.42, 'unit': 'M', 'net_profit': -2.73}, {'period': ""Q3 '23"", 'revenue': 92480.0, 'unit': 'K', 'net_profit': -148.0}, {'period': ""Q2 '23"", 'revenue': 69.33, 'unit': 'M', 'net_profit': -2.69}]",-0.15,-0.15,553938000,264774000,5873000,108923000,32866999,0,45713000,5873000,-185509000,-0.9992823717613288,-1.1268324935591985,-1.1764705882352942,__nan__,__nan__,__nan__,0.19663391931949062
341,ASLN,ASLAN Pharmaceuticals Limited American Depositary Shares,"ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.","Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.",Biotechnology,0.6,USD,1697010,https://images.financialmodelingprep.com/symbol/ASLN.png,102493,-0.0375,-0.0999,769822,-43387100,-44219604,"[{'period': '2023', 'revenue': 12.0, 'unit': 'M', 'net_profit': -44.22}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -51.38}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -34.71}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.91}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.92}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.51}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.71}, {'period': ""Q2 '23"", 'revenue': 12.0, 'unit': 'M', 'net_profit': -1.89}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.11}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.48}]",-2.69,-2.69,24626525,24129992,21252058,37913456,171441,235567,13114904,21252058,-46370623,0.08865003160110863,0.13940202540491622,0.2690217391304348,__nan__,__nan__,__nan__,1.539537389055094
342,ASMB,Assembly Biosciences Inc. Common Stock,"Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.",Mr. Jason A. Okazaki,Biotechnology,16.9863,USD,107969849,https://images.financialmodelingprep.com/symbol/ASMB.png,34840,-2.47,-0.3637,9059,-64196000,-61228000,"[{'period': '2023', 'revenue': 7.16, 'unit': 'M', 'net_profit': -61.23}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -92.07}, {'period': '2021', 'revenue': 6.25, 'unit': 'M', 'net_profit': -129.85}, {'period': '2020', 'revenue': 79.11, 'unit': 'M', 'net_profit': -59.53}]","[{'period': ""Q3 '24"", 'revenue': 6.84, 'unit': 'M', 'net_profit': -9.61}, {'period': ""Q2 '24"", 'revenue': 8.53, 'unit': 'M', 'net_profit': -11.15}, {'period': ""Q1 '24"", 'revenue': 5.79, 'unit': 'M', 'net_profit': -9.08}, {'period': ""Q4 '23"", 'revenue': 7.16, 'unit': 'M', 'net_profit': -10.96}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.42}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.9}]",-13.38,-13.38,136823000,133787000,130247000,95726000,43000,0,39225000,19841000,22488000,0.30669373825517854,0.3349842511132834,0.4136722173531989,__nan__,__nan__,__nan__,0.6996338334929069
343,ASML,ASML Holding N.V. New York Registry Shares,"ASML Holding N.V. develops, produces, markets, sells, and services advanced semiconductor equipment systems consisting of lithography, metrology, and inspection related systems for memory and logic chipmakers. The company provides extreme ultraviolet lithography systems; and deep ultraviolet lithography systems comprising immersion and dry lithography solutions to manufacture various range of semiconductor nodes and technologies. It also offers metrology and inspection systems, including YieldStar optical metrology solutions to measure the quality of patterns on the wafers; and HMI e-beam solutions to locate and analyze individual chip defects. In addition, the company provides computational lithography and software solutions to create applications that enhance the setup of the lithography system; and mature products and services that refurbish used lithography equipment and offers associated services. It operates in Japan, South Korea, Singapore, Taiwan, China, the Netherlands, Europe, the United States, and rest of Asia. The company was formerly known as ASM Lithography Holding N.V. and changed its name to ASML Holding N.V. in 2001. ASML Holding N.V. was founded in 1984 and is headquartered in Veldhoven, the Netherlands.",Mr. Christophe D. Fouquet,Semiconductors,762,USD,299787672966,https://images.financialmodelingprep.com/symbol/ASML.png,2074124,41.82,-6.51,795824,9698700000,7839000000,"[{'period': '2023', 'revenue': 27.56, 'unit': 'B', 'net_profit': 7.84}, {'period': '2022', 'revenue': 21.17, 'unit': 'B', 'net_profit': 5.62}, {'period': '2021', 'revenue': 18.61, 'unit': 'B', 'net_profit': 5.88}, {'period': '2020', 'revenue': 13.98, 'unit': 'B', 'net_profit': 3.55}]","[{'period': ""Q3 '24"", 'revenue': 7.47, 'unit': 'B', 'net_profit': 2.08}, {'period': ""Q2 '24"", 'revenue': 6.24, 'unit': 'B', 'net_profit': 1.58}, {'period': ""Q1 '24"", 'revenue': 5.29, 'unit': 'B', 'net_profit': 1.22}, {'period': ""Q4 '23"", 'revenue': 7.24, 'unit': 'B', 'net_profit': 2.05}, {'period': ""Q3 '23"", 'revenue': 6.67, 'unit': 'B', 'net_profit': 1.89}, {'period': ""Q2 '23"", 'revenue': 6.9, 'unit': 'B', 'net_profit': 1.94}]",19.89,19.89,39957500000,24393900000,7010100000,26505100000,5953400000,919600000,16274700000,7004700000,3247200000,0.38600377272207614,0.3937982290814694,0.40664780763790664,"[1.64136, 2.1868]","['2024-10-29', '2007-10-01']",__nan__,0.6633322905587187
344,ASND,Ascendis Pharma A/S American Depositary Shares,"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 /g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.",Mr. Jan Moller Mikkelsen,Biotechnology,138.83,USD,8296538276,https://images.financialmodelingprep.com/symbol/ASND.png,426233,-17.98,-1.45,109855,-411168000,-481447000,"[{'period': '2023', 'revenue': 266.72, 'unit': 'M', 'net_profit': -481.45}, {'period': '2022', 'revenue': 51.17, 'unit': 'M', 'net_profit': -583.19}, {'period': '2021', 'revenue': 7.78, 'unit': 'M', 'net_profit': -383.58}, {'period': '2020', 'revenue': 6.95, 'unit': 'M', 'net_profit': -418.95}]","[{'period': ""Q3 '24"", 'revenue': 57.83, 'unit': 'M', 'net_profit': -99.2}, {'period': ""Q2 '24"", 'revenue': 36.0, 'unit': 'M', 'net_profit': -109.38}, {'period': ""Q1 '24"", 'revenue': 95.89, 'unit': 'M', 'net_profit': -131.03}, {'period': ""Q4 '23"", 'revenue': 137.7, 'unit': 'M', 'net_profit': -86.88}, {'period': ""Q3 '23"", 'revenue': 48.03, 'unit': 'M', 'net_profit': -162.22}, {'period': ""Q2 '23"", 'revenue': 47.39, 'unit': 'M', 'net_profit': -121.43}]",-8.55,-8.55,825587000,702721000,399439000,971284000,55773000,5686000,197344000,392164000,-469803000,0.2605424070210776,0.17446510080693559,0.17788461538461534,__nan__,__nan__,__nan__,1.1764768582838634
345,ASO,Academy Sports and Outdoors Inc. Common Stock,"Academy Sports and Outdoors, Inc., through its subsidiaries, operates as a sporting goods and outdoor recreational products retailer in the United States. The company sells coolers and drinkware, camping accessories, camping equipment, sunglasses, backpacks, and sports bags; marine equipment and fishing rods, reels, baits, and equipment; firearms, ammunition, archery and archery equipment, camouflage apparel, waders, shooting accessories, optics, airguns, and hunting equipment; team sports equipment, including baseball, football, basketball, soccer, golf, racket sports, and volleyball; fitness equipment and accessories, and nutrition supplies; and patio furniture, outdoor cooking, wheeled goods, trampolines, playsets, watersports, and pet equipment, as well as electronics products, watches, consumables, batteries, etc. It also offers outdoor apparel, seasonal apparel, denim, work apparel, graphic t-shirts, and accessories; boys and girls outdoor and athletic apparel; sporting apparel and apparel for fitness; professional and collegiate team licensed apparel and accessories; casual shoes and slippers, work and western boots, youth footwear, socks, and hunting and seasonal footwear; and boys and girls athletic footwear, running shoes, athletic lifestyle and training shoes, team and specialty sports footwear, and slides. The company sells its products under the Academy Sports + Outdoors, Magellan Outdoors, BCG, O'rageous, Outdoor Gourmet, and Freely brand names. As of June 14, 2022, it operated 260 retail locations in 16 contiguous states. The company also sells merchandise to customers through the academy.com website. Academy Sports and Outdoors, Inc. was founded in 1938 and is headquartered in Katy, Texas.",Mr. Steven Paul Lawrence,Specialty Retail,57.615,USD,3998313917,https://images.financialmodelingprep.com/symbol/ASO.png,1546366,9.52,1.015,452602,788791000,519190000,"[{'period': '2023', 'revenue': 6160.0, 'unit': 'M', 'net_profit': 519.19}, {'period': '2022', 'revenue': 6400.0, 'unit': 'M', 'net_profit': 628.0}, {'period': '2021', 'revenue': 6770.0, 'unit': 'M', 'net_profit': 671.38}, {'period': '2020', 'revenue': 5690.0, 'unit': 'M', 'net_profit': 308.76}]","[{'period': ""Q3 '24"", 'revenue': 1340.0, 'unit': 'M', 'net_profit': 65.76}, {'period': ""Q2 '24"", 'revenue': 1550.0, 'unit': 'M', 'net_profit': 142.59}, {'period': ""Q1 '24"", 'revenue': 1360.0, 'unit': 'M', 'net_profit': 76.47}, {'period': ""Q4 '23"", 'revenue': 1790.0, 'unit': 'M', 'net_profit': 168.17}, {'period': ""Q3 '23"", 'revenue': 1400.0, 'unit': 'M', 'net_profit': 99.98}, {'period': ""Q2 '23"", 'revenue': 1580.0, 'unit': 'M', 'net_profit': 157.07}]",6.89,6.7,4676713000,1644900000,347920000,2722063000,19371000,0,879858000,347920000,327489000,-0.18807481572443638,-0.17326564766616614,-0.10519480519480526,"[0.11, 0.075]","['2024-12-18', '2022-03-16']",__nan__,0.5820461935551743
346,ASPC,Alpha Capital Acquisition Company One Class A Ordinary Share,"A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.",Mr. Sze Wai  Tsang CFA,Shell Companies,9.97,USD,80308350,https://images.financialmodelingprep.com/symbol/ASPC.png,335400,90.64,0,219,-2650,-2650,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': -2.65}, {'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -102.73}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.91}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -38.78}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -8.0}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -2.65}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 26.56}]",0,0,0,0,0,140576,0,0,140576,0,0,0.9742039735615065,0.9742039735615065,0,__nan__,__nan__,__nan__,__nan__
347,ASPCU,Alpha Capital Acquisition Company Unit,"A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.",Mr. Sze Wai  Tsang CFA,Shell Companies,10.0822,USD,82031330,https://images.financialmodelingprep.com/symbol/ASPCU.png,73387,89.22,-0.0078,5743,-2650,-2650,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': -2.65}, {'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -102.73}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.91}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -38.78}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -8.0}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -2.65}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 26.56}]",0,0,0,0,0,140576,0,0,140576,0,0,0.9742039735615065,0.9742039735615065,0,__nan__,__nan__,__nan__,__nan__
348,ASPCW,Alpha Capital Acquisition Company Warrant,"Alpha Capital Acquisition Company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.",Mr. Alec  Oxenford,Shell Companies,0.2892,USD,0,https://images.financialmodelingprep.com/symbol/ASPCW.png,0,0,-0.0108,106229,-2650,-2650,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': -2.65}, {'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -102.73}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.91}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -38.78}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -8.0}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -2.65}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 26.56}]",0,0,0,0,0,140576,0,0,140576,0,0,0.9742039735615065,0.9742039735615065,0,__nan__,__nan__,__nan__,__nan__
349,ASPS,Altisource Portfolio Solutions S.A. Common Stock,"Altisource Portfolio Solutions S.A. operates as an integrated service provider and marketplace for the real estate and mortgage industries in the United States, India, Luxembourg, Uruguay, and internationally. It provides property preservation and inspection services, payment management technologies, and a vendor management oversight software-as-a-service (SaaS) platform. The company also offers Hubzu, an online real estate auction platform, as well as real estate auction, real estate brokerage, and asset management services; and Equator, a SaaS-based technology to manage real estate owned, short sales, foreclosure, bankruptcy, and eviction processes. In addition, it provides mortgage loan fulfillment, certification and certification insurance services, technologies, title insurance agent, settlement, real estate valuation services, residential and commercial construction inspection and risk mitigation, foreclosure trustee, and commercial loan servicing technology services. Further, the company operates TrelixTM Connect, Vendorly, RentRange, REALSynergy, Lenders One Loan Automation, and other platform solutions. It serves financial institutions, government-sponsored enterprises, banks, asset managers, servicers, investors, originators, correspondent lenders, and mortgage bankers. Altisource Portfolio Solutions S.A. was incorporated in 1999 and is headquartered in Luxembourg City, Luxembourg.",Mr. William B. Shepro,Real Estate - Services,0.7343,USD,19992052,https://images.financialmodelingprep.com/symbol/ASPS.png,187677,-0.53,-0.0037,21889,-6900000,-56290000,"[{'period': '2023', 'revenue': 145.07, 'unit': 'M', 'net_profit': -56.29}, {'period': '2022', 'revenue': 153.12, 'unit': 'M', 'net_profit': -52.83}, {'period': '2021', 'revenue': 178.45, 'unit': 'M', 'net_profit': 11.81}, {'period': '2020', 'revenue': 365.55, 'unit': 'M', 'net_profit': -66.31}]","[{'period': ""Q3 '24"", 'revenue': 40.53, 'unit': 'M', 'net_profit': -9.36}, {'period': ""Q2 '24"", 'revenue': 41.34, 'unit': 'M', 'net_profit': -8.31}, {'period': ""Q1 '24"", 'revenue': 42.01, 'unit': 'M', 'net_profit': -9.2}, {'period': ""Q4 '23"", 'revenue': 36.03, 'unit': 'M', 'net_profit': -13.15}, {'period': ""Q3 '23"", 'revenue': 36.21, 'unit': 'M', 'net_profit': -11.34}, {'period': ""Q2 '23"", 'revenue': 35.23, 'unit': 'M', 'net_profit': -18.85}]",-2.51,-2.51,154858000,55540000,32522000,279913000,11682000,0,35760000,32522000,-21833000,0.6484792908451781,-0.06543258948005981,0.23708206686930097,__nan__,__nan__,__nan__,1.8075462681940875
350,ASPU,Aspen Group Inc. Common Stock,"Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.",Mr. Michael D. Mathews,Education & Training Services,0.13,USD,3310099,https://images.financialmodelingprep.com/symbol/ASPU.png,37494,-0.34,0.0049,15000,-1852318,-8347605,"[{'period': '2023', 'revenue': 66.32, 'unit': 'M', 'net_profit': -8.35}, {'period': '2022', 'revenue': 76.69, 'unit': 'M', 'net_profit': -9.59}, {'period': '2021', 'revenue': 67.81, 'unit': 'M', 'net_profit': -10.45}, {'period': '2020', 'revenue': 49.06, 'unit': 'M', 'net_profit': -5.66}]","[{'period': ""Q3 '24"", 'revenue': 12.06, 'unit': 'M', 'net_profit': -3.88}, {'period': ""Q2 '24"", 'revenue': 13.83, 'unit': 'M', 'net_profit': -1.61}, {'period': ""Q1 '24"", 'revenue': 14640.0, 'unit': 'K', 'net_profit': -639.44}, {'period': ""Q4 '23"", 'revenue': 14780.0, 'unit': 'K', 'net_profit': -783.95}, {'period': ""Q3 '23"", 'revenue': 15.57, 'unit': 'M', 'net_profit': -1.56}, {'period': ""Q2 '23"", 'revenue': 17.07, 'unit': 'M', 'net_profit': -2.29}]",-0.33,-0.33,80867215,28632189,5724467,45320433,19228904,13004428,17818921,5724467,-7001215,0.6345926150667978,0.12916798328691215,0.13157894736842102,__nan__,__nan__,__nan__,0.5604302435789337
351,ASRT,Assertio Holdings Inc. Common Stock,"Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.",Mr. Brendan P. O'Grady,Drug Manufacturers - Specialty & Generic,0.8611,USD,82215934,https://images.financialmodelingprep.com/symbol/ASRT.png,0,-1.96,-0.0187,302480,-222447000,-331942000,"[{'period': '2023', 'revenue': 152.07, 'unit': 'M', 'net_profit': -331.94}, {'period': '2022', 'revenue': 156.23, 'unit': 'M', 'net_profit': 109.62}, {'period': '2021', 'revenue': 111.01, 'unit': 'M', 'net_profit': -1.28}, {'period': '2020', 'revenue': 106.28, 'unit': 'M', 'net_profit': -28.14}]","[{'period': ""Q3 '24"", 'revenue': 29.2, 'unit': 'M', 'net_profit': -2.92}, {'period': ""Q2 '24"", 'revenue': 31.13, 'unit': 'M', 'net_profit': -3.67}, {'period': ""Q1 '24"", 'revenue': 32.45, 'unit': 'M', 'net_profit': -4.51}, {'period': ""Q4 '23"", 'revenue': 32.98, 'unit': 'M', 'net_profit': -57.38}, {'period': ""Q3 '23"", 'revenue': 35.63, 'unit': 'M', 'net_profit': -279.54}, {'period': ""Q2 '23"", 'revenue': 40.99, 'unit': 'M', 'net_profit': 8.47}]",-4.67,-4.67,286419000,171062000,73441000,148416000,47663000,0,93443000,73441000,48976000,-4.066753980836838,-4.027977194982896,-3.004291845493562,__nan__,__nan__,__nan__,0.5181779141746882
352,ASRV,AmeriServ Financial Inc. Common Stock,"AmeriServ Financial, Inc. operates as the bank holding company for AmeriServ Financial Bank that provides various consumer, mortgage, and commercial financial products. It offers retail banking services, such as demand, savings, and time deposits; checking and money market accounts; secured and unsecured consumer loans, and mortgage loans; and safe deposit boxes, holiday club accounts, and money orders. The company also provides lending, depository, and related financial services, such as commercial real estate mortgage loans, short and medium-term loans, revolving credit arrangements, lines of credit, inventory and accounts receivable financing, real estate-construction loans, business savings accounts, certificates of deposit, wire transfers, night depository, and lock box services to commercial, industrial, financial, and governmental customers. In addition, the company offers personal trust products and services, including personal portfolio investment management, estate planning and administration, custodial services, and pre-need trusts; institutional trust products and services comprising 401(k) plans, defined benefit and defined contribution employee benefit plans, and individual retirement accounts; financial services consisting of the sale of mutual funds, annuities, and insurance products; and union collective investment funds to invest union pension dollars in construction projects that utilize union labor. Further, it engages in underwriting as reinsurer of credit life and disability insurance. The company operates through a network of 17 banking locations in Allegheny, Cambria, Centre, Somerset, and Westmoreland counties, Pennsylvania, and Washington County, Maryland; and operates 18 automated bank teller machines. AmeriServ Financial, Inc. is headquartered in Johnstown, Pennsylvania.",Mr. Jeffrey A. Stopko CPA,Banks - Regional,2.751,USD,45444594,https://images.financialmodelingprep.com/symbol/ASRV.png,11269,-17.19,0.021,10593,0,-3346000,"[{'period': '2023', 'revenue': 44.98, 'unit': 'M', 'net_profit': -3.35}, {'period': '2022', 'revenue': 8.2, 'unit': 'M', 'net_profit': 7.45}, {'period': '2021', 'revenue': 56.84, 'unit': 'M', 'net_profit': 7.07}, {'period': '2020', 'revenue': 52.64, 'unit': 'M', 'net_profit': 4.6}]","[{'period': ""Q3 '24"", 'revenue': 13.14, 'unit': 'M', 'net_profit': 1.18}, {'period': ""Q2 '24"", 'revenue': 20880.0, 'unit': 'K', 'net_profit': -375.0}, {'period': ""Q1 '24"", 'revenue': 21.17, 'unit': 'M', 'net_profit': 1.9}, {'period': ""Q4 '23"", 'revenue': 18.73, 'unit': 'M', 'net_profit': -5.32}, {'period': ""Q3 '23"", 'revenue': 13050.0, 'unit': 'K', 'net_profit': 647.0}, {'period': ""Q2 '23"", 'revenue': 12970.0, 'unit': 'K', 'net_profit': -187.0}]",-0.2,-0.2,1389638000,19556000,14027000,1287361000,5529000,16396000,1025381000,14027000,4907000,-1,-1.449248120300752,-1.4545454545454546,"[0.03, 0.22]","['2024-11-04', '1987-02-27']",__nan__,0.9264002567575153
353,ASRVP,AmeriServ Financial Inc. AmeriServ Financial Trust I - 8.45% Beneficial Unsecured Securities Series A,,None,Asset Management,27.31,USD,0,https://images.financialmodelingprep.com/symbol/ASRVP.png,2364,0,2.06,1092,-2707000,4598000,"[{'period': '2020', 'revenue': 46.88, 'unit': 'M', 'net_profit': 4.6}, {'period': '2019', 'revenue': 35.44, 'unit': 'M', 'net_profit': 6.03}, {'period': '2018', 'revenue': 35.49, 'unit': 'M', 'net_profit': 7.77}, {'period': '2017', 'revenue': 35.56, 'unit': 'M', 'net_profit': 3.29}]","[{'period': ""Q2 '21"", 'revenue': 11.84, 'unit': 'M', 'net_profit': 1.71}, {'period': ""Q4 '20"", 'revenue': 26.29, 'unit': 'M', 'net_profit': 1.48}, {'period': ""Q1 '20"", 'revenue': 8.75, 'unit': 'M', 'net_profit': 1.41}, {'period': ""Q4 '19"", 'revenue': 8960.0, 'unit': 'K', 'net_profit': 669.0}, {'period': ""Q3 '19"", 'revenue': 8.76, 'unit': 'M', 'net_profit': 1.69}, {'period': ""Q2 '19"", 'revenue': 9.06, 'unit': 'M', 'net_profit': 1.79}]",0.27,0.27,34701000,20427000,20427000,1175314000,0,0,24702000,20427000,-1373000,-1.1144076750771312,-0.23722627737226276,-0.22857142857142848,"[0.528, 0.35208]","['2021-06-28', '1998-06-25']",__nan__,33.869744387769806
354,ASTC,Astrotech Corporation (DE) Common Stock,"Astrotech Corporation operates as a science and technology development and commercialization company worldwide. It operates through three segments, Astrotech Technologies, Inc. (ATI), 1st Detect Corporation (1st Detect), and AgLAB Inc (AgLAB). The ATI segment owns and licenses the AMS Technology, the platform mass spectrometry technology. The 1st Detect segment manufactures explosives and narcotics trace detectors for use at airports, secured facilities, and borders. This segment provides TRACER 1000, a mass spectrometer based explosives trace detector to replace the explosives trace detectors used at airports, cargo and secured facilities, and borders. The AgLAB segment develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. It also develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. Astrotech Corporation was incorporated in 1984 is based in Austin, Texas.",Mr. Thomas Boone Pickens III,Aerospace & Defense,6.933,USD,11798094,https://images.financialmodelingprep.com/symbol/ASTC.png,23238,-0.94,0.083,1438,-12406000,-11666000,"[{'period': '2024', 'revenue': 1.66, 'unit': 'M', 'net_profit': -11.67}, {'period': '2023', 'revenue': 0.75, 'unit': 'M', 'net_profit': -9.64}, {'period': '2022', 'revenue': 0.869, 'unit': 'M', 'net_profit': -7.56}, {'period': '2021', 'revenue': 0.334, 'unit': 'M', 'net_profit': -7.61}]","[{'period': ""Q1 '25"", 'revenue': 0.034, 'unit': 'M', 'net_profit': -3.28}, {'period': ""Q4 '24"", 'revenue': 0.074, 'unit': 'M', 'net_profit': -2.96}, {'period': ""Q3 '24"", 'revenue': 0.05, 'unit': 'M', 'net_profit': -3.15}, {'period': ""Q2 '24"", 'revenue': 1.11, 'unit': 'M', 'net_profit': -2.64}, {'period': ""Q1 '24"", 'revenue': 0.425, 'unit': 'M', 'net_profit': -2.91}, {'period': ""Q4 '23"", 'revenue': 0.41400000000000003, 'unit': 'M', 'net_profit': -2.32}]",-7.12,-7.12,37640000,34728000,31916000,2833000,77000,0,2528000,10442000,-10304000,-0.16008976996446606,-0.20991495540344327,-0.19663865546218487,__nan__,__nan__,__nan__,0.07526567481402763
355,ASTE,Astec Industries Inc. Common Stock,"Astec Industries, Inc. designs, engineers, manufactures, and markets equipment and components used primarily in road building and related construction activities in the United States and internationally. The company operates in two segments, Infrastructure Solutions and Materials Solutions. The Infrastructure Solutions segment offers asphalt plants and related components, heaters, concrete dust control systems, asphalt pavers, vaporizers, concrete material handling systems, screeds, heat recovery units, paste back-fill plants, asphalt storage tanks, hot oil heaters, bagging plants, fuel storage tanks, industrial and asphalt burners and systems, custom batch plants, material transfer vehicles, soil stabilizing-reclaiming machinery, blower trucks and trailers, milling machines, soil remediation plants, wood chippers and grinders, pump trailers, concrete batch plants, control systems, liquid terminals, storage equipment and related parts, construction and retrofits, polymer plants, and concrete mixers, as well as engineering and environmental permitting services. This segment provides its products to asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, contractors in the construction and demolition recycling markets, and governmental agencies. The Materials Solutions segment designs and manufactures crushing equipment, mobile plants, bulk material handling solutions, vibrating equipment, screening equipment, electrical control centers, modular plants and systems, conveying equipment, plant automation products, portable plants, and mineral processing equipment, as well as offers consulting and engineering services. Astec Industries, Inc. was incorporated in 1972 and is headquartered in Chattanooga, Tennessee.",Mr. Jaco G. van der Merwe,Agricultural - Machinery,32.67,USD,744934806,https://images.financialmodelingprep.com/symbol/ASTE.png,131701,-363,-0.55,32518,77300000,33500000,"[{'period': '2023', 'revenue': 1340.0, 'unit': 'M', 'net_profit': 33.5}, {'period': '2022', 'revenue': 1270000.0, 'unit': 'K', 'net_profit': -600.0}, {'period': '2021', 'revenue': 1100.0, 'unit': 'M', 'net_profit': 15.8}, {'period': '2020', 'revenue': 1020.0, 'unit': 'M', 'net_profit': 46.0}]","[{'period': ""Q3 '24"", 'revenue': 291.4, 'unit': 'M', 'net_profit': -6.2}, {'period': ""Q2 '24"", 'revenue': 345.5, 'unit': 'M', 'net_profit': -14.0}, {'period': ""Q1 '24"", 'revenue': 309.2, 'unit': 'M', 'net_profit': 3.4}, {'period': ""Q4 '23"", 'revenue': 337.2, 'unit': 'M', 'net_profit': 14.9}, {'period': ""Q3 '23"", 'revenue': 303.1, 'unit': 'M', 'net_profit': -6.6}, {'period': ""Q2 '23"", 'revenue': 350.0, 'unit': 'M', 'net_profit': 13.1}]",1.47,1.47,1059300000,719500000,68900000,405600000,152700000,13800000,299000000,63200000,-6300000,0.08720112517580872,56.833333333333336,56.893536121673,"[0.13, 1]","['2024-11-13', '2012-11-16']",__nan__,0.3828943642027754
356,ASTS,AST SpaceMobile Inc. Class A Common Stock,"AST SpaceMobile, Inc. operates space-based cellular broadband network for mobile phones. Its SpaceMobile service provides mobile broadband services for users traveling in and out of areas without terrestrial mobile services on land, at sea, or in flight. The company is headquartered in Midland, Texas.",Mr. Abel  Avellan,Communication Equipment,23.13,USD,6715421696,https://images.financialmodelingprep.com/symbol/ASTS.png,9145795,-10.23,-1.01,2678275,-166527000,-87561000,"[{'period': '2023', 'revenue': 24.34, 'unit': 'M', 'net_profit': -87.56}, {'period': '2022', 'revenue': 13.82, 'unit': 'M', 'net_profit': -103.11}, {'period': '2021', 'revenue': 12.4, 'unit': 'M', 'net_profit': -73.26}, {'period': '2020', 'revenue': 5.97, 'unit': 'M', 'net_profit': -24.41}]","[{'period': ""Q3 '24"", 'revenue': 1.1, 'unit': 'M', 'net_profit': -171.95}, {'period': ""Q2 '24"", 'revenue': 0.9, 'unit': 'M', 'net_profit': -72.55}, {'period': ""Q1 '24"", 'revenue': 0.5, 'unit': 'M', 'net_profit': -19.73}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.93}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -50.22}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.41}]",-1.07,-1.07,360892000,106882000,85622000,147333000,1152000,0,46221000,85622000,-267749000,-0.18059878201810667,0.15082482325216026,0.4338624338624338,__nan__,__nan__,__nan__,0.4082467885129069
357,ASTSW,AST SpaceMobile Inc. Warrant,"AST SpaceMobile, Inc., together with its subsidiaries, operates space-based cellular broadband network for mobile phones in the United States. Its SpaceMobile service provides mobile broadband services to end-users who are out of terrestrial cellular coverage. AST SpaceMobile, Inc. was founded in 2017 and is based in Midland, Texas.",Mr. Abel  Avellan,Telecommunications Services,13.5,USD,1749411756,https://images.financialmodelingprep.com/symbol/ASTSW.png,0,,1.21,375766,-166527000,-87561000,"[{'period': '2023', 'revenue': 24.34, 'unit': 'M', 'net_profit': -87.56}, {'period': '2022', 'revenue': 13.82, 'unit': 'M', 'net_profit': -103.11}, {'period': '2021', 'revenue': 12.4, 'unit': 'M', 'net_profit': -73.26}, {'period': '2020', 'revenue': 5.97, 'unit': 'M', 'net_profit': -24.41}]","[{'period': ""Q3 '24"", 'revenue': 1.1, 'unit': 'M', 'net_profit': -171.95}, {'period': ""Q2 '24"", 'revenue': 0.9, 'unit': 'M', 'net_profit': -72.55}, {'period': ""Q1 '24"", 'revenue': 0.5, 'unit': 'M', 'net_profit': -19.73}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.93}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -50.22}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.41}]",-1.07,-1.07,360892000,106882000,85622000,147333000,1152000,0,46221000,85622000,-267749000,-0.18059878201810667,0.15082482325216026,0.4338624338624338,__nan__,__nan__,__nan__,0.4082467885129069
358,ASUR,Asure Software Inc Common Stock,"Asure Software, Inc. provides cloud-based human capital management solutions the United States. It helps various small and mid-sized businesses to build productive teams to help them stay compliant and allocate resources to grow their business. The company's solutions include Asure Payroll & Tax, an integrated cloud-based solution automates regulations associated with payroll and taxes, including wages, benefits, overtime, garnishments, tips, direct deposits, and fair labor standard act, as well as federal, state, and local payroll taxes; Asure (human resource) HR, a cloud-based functionality that handles HR complexities, such as employee self-service that enable employees to access information, pay history, and company documents; and Asure Time & Attendance that provides cost savings and return on investment gains come in the form of strategic use of labor dollars and the elimination of time theft. It also provides HR services that offers services comprising on-demand HR resource library, phone and email support for any HR issues, and compliance and policy updates; support for strategic HR decision making; and HR outsourcing solution, as well as data integration with related third-party systems, such as 401(k), benefits, and insurance provider systems. Asure Software, Inc. was incorporated in 1985 and is headquartered in Austin, Texas.",Mr. Patrick F. Goepel,Software - Application,10.84,USD,287844276,https://images.financialmodelingprep.com/symbol/ASUR.png,105561,-21.68,0.84,236080,15808000,-9214000,"[{'period': '2023', 'revenue': 119.08, 'unit': 'M', 'net_profit': -9.21}, {'period': '2022', 'revenue': 95.83, 'unit': 'M', 'net_profit': -14.47}, {'period': '2021', 'revenue': 76.06, 'unit': 'M', 'net_profit': 3.19}, {'period': '2020', 'revenue': 65.51, 'unit': 'M', 'net_profit': -16.31}]","[{'period': ""Q3 '24"", 'revenue': 29.3, 'unit': 'M', 'net_profit': -3.9}, {'period': ""Q2 '24"", 'revenue': 28.04, 'unit': 'M', 'net_profit': -4.36}, {'period': ""Q1 '24"", 'revenue': 31650.0, 'unit': 'K', 'net_profit': -308.0}, {'period': ""Q4 '23"", 'revenue': 26.26, 'unit': 'M', 'net_profit': -3.58}, {'period': ""Q3 '23"", 'revenue': 29.33, 'unit': 'M', 'net_profit': -2.21}, {'period': ""Q2 '23"", 'revenue': 30.42, 'unit': 'M', 'net_profit': -3.77}]",-0.42,-0.42,443868000,267220000,30317000,252213000,14202000,0,241340000,30317000,2637000,0.5063846007242233,0.36305820544725564,0.4166666666666667,__nan__,__nan__,__nan__,0.5682162264457
359,ASYS,Amtech Systems Inc. Common Stock,"Amtech Systems, Inc. manufactures and sells capital equipment and related consumables for use in fabricating silicon carbide (SiC), silicon power devices, analog and discrete devices, electronic assemblies, and light-emitting diodes (LEDs) worldwide. The company operates in Semiconductor and Material and Substrate segments. The Semiconductor segment designs, manufactures, sells, and services thermal processing equipment, including solder reflow ovens, diffusion furnaces, and customer high-temp belt furnaces for use by semiconductor manufacturers, as well as in electronics, automotive and other industries; and wafer polishing equipment and related services. Its products include horizontal diffusion furnaces; and belt furnaces. The Material and Substrate segment manufactures and sells consumables and machinery for lapping and polishing of materials, such as silicon wafers for semiconductor products; sapphire substrates for LED lighting and mobile devices; silicon carbide wafers for LED and power device applications; various glass and silica components for 3D image transmission; quartz and ceramic components for telecommunications devices; and medical device components, and optical and photonics applications. This segment also offers substrate process chemicals for use in various manufacturing processes, including semiconductors, silicon and compound semiconductor wafers, and optics. The company sells its products through sales personnel, as well as a network of independent sales representatives and distributors. The company was formerly known as Quartz Engineering & Materials, Inc. and changed its name to Amtech Systems, Inc. in 1987. Amtech Systems, Inc. was incorporated in 1981 and is headquartered in Tempe, Arizona.",Mr. Robert C. Daigle,Semiconductors,5.7,USD,81379470,https://images.financialmodelingprep.com/symbol/ASYS.png,42961,-9.34,0.02,14905,-3925000,-8486000,"[{'period': '2024', 'revenue': 101.21, 'unit': 'M', 'net_profit': -8.49}, {'period': '2023', 'revenue': 113.31, 'unit': 'M', 'net_profit': -12.58}, {'period': '2022', 'revenue': 106.3, 'unit': 'M', 'net_profit': 17.37}, {'period': '2021', 'revenue': 85.2, 'unit': 'M', 'net_profit': 1.51}]","[{'period': ""Q4 '24"", 'revenue': 24110.0, 'unit': 'K', 'net_profit': -536.0}, {'period': ""Q3 '24"", 'revenue': 26750.0, 'unit': 'K', 'net_profit': 438.0}, {'period': ""Q2 '24"", 'revenue': 25430.0, 'unit': 'K', 'net_profit': 970.0}, {'period': ""Q1 '24"", 'revenue': 24.92, 'unit': 'M', 'net_profit': -9.36}, {'period': ""Q4 '23"", 'revenue': 27.71, 'unit': 'M', 'net_profit': -12.02}, {'period': ""Q3 '23"", 'revenue': 30.74, 'unit': 'M', 'net_profit': -1.03}]",-0.6,-0.6,118953000,64376000,11086000,36595000,21989000,0,19599000,11086000,4964000,0.5932642487046632,0.3255444285487204,0.3258426966292135,__nan__,__nan__,__nan__,0.30764251427034206
360,ATAX,America First Multifamily Investors L.P. Beneficial Unit Certificates (BUCs) representing Limited Partnership Interests,"America First Multifamily Investors, L.P. acquires, holds, sells, and deals in a portfolio of mortgage revenue bonds (MRBs) that are issued to provide construction and/or permanent financing for multifamily and student housing, and residential and commercial properties. It operates through five segments: Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, Market-Rate Joint Venture Investments, and Public Housing Capital Fund Trusts. As of December 31, 2021, the company owned 74 MRBs issued by state and local housing authorities in order to provide construction or permanent financing for 76 multifamily and seniors housing properties comprising a total of 12,584 rental units located in 17 states; and nine governmental issuer loans related to affordable multifamily properties containing a total of 1,832 rental units located in six states in the United States. America First Capital Associates Limited Partnership Two serves as the general partner of the company. America First Multifamily Investors, L.P. was incorporated in 1998 and is based in Omaha, Nebraska.",Mr. Chad Daffer,Financial - Mortgages,18.6,USD,419223540,https://images.financialmodelingprep.com/symbol/ATAX.png,36184,6.503496503496503,0,27807,124626773000,54011696000,"[{'period': '2023', 'revenue': 104.9, 'unit': 'B', 'net_profit': 54.01}, {'period': '2022', 'revenue': 81.07, 'unit': 'M', 'net_profit': 65.56}, {'period': '2021', 'revenue': 62.01, 'unit': 'M', 'net_profit': 38.1}, {'period': '2020', 'revenue': 35.73, 'unit': 'M', 'net_profit': 7.21}]","[{'period': ""Q3 '23"", 'revenue': 26.47, 'unit': 'B', 'net_profit': 9.73}, {'period': ""Q2 '23"", 'revenue': 28.3, 'unit': 'M', 'net_profit': 21.29}, {'period': ""Q1 '23"", 'revenue': 24.94, 'unit': 'M', 'net_profit': 16.79}, {'period': ""Q4 '22"", 'revenue': 80.99, 'unit': 'M', 'net_profit': 65.5}, {'period': ""Q3 '22"", 'revenue': 25.15, 'unit': 'M', 'net_profit': 18.52}, {'period': ""Q2 '22"", 'revenue': 23.1, 'unit': 'M', 'net_profit': 17.61}]",2.37,2.37,1198966000,654989000,600000,34000,40000000,0,34000,600000,24138618000,1261.7742349449916,822.8241549249608,-0.1883561643835616,"[0.1, 0.142]","['2022-12-29', '1986-04-24']",__nan__,2.835776827699868e-05
361,ATCOL,Atlas Corp. 7.125% Notes due 2027,"Atlas Corp. operates as an asset manager and operator of containerships. The company, through its subsidiaries, operates as an independent charter owner and manager of containerships. The company charters its containerships under long-term and fixed-rate time charters to various container liner companies. It also provides electricity to oil and gas, mining, and other industries, as well as government backed and private utilities; and power solutions comprising plant design, fast-tracked installation of generating equipment and balance of plant, plant operation, and service and maintenance. As of March 10, 2022, the company operated a fleet of 132 vessels, 30 gas turbines, and 414 diesel generators. Atlas Corp. was incorporated in 2019 and is based in London, the United Kingdom.",Mr. Bing  Chen CPA,Asset Management,25.2,USD,5148564019,https://images.financialmodelingprep.com/symbol/ATCOL.png,1456,14.52,0.05,1587,1110100000,622300000,"[{'period': '2022', 'revenue': 1700.0, 'unit': 'M', 'net_profit': 622.3}, {'period': '2021', 'revenue': 1650.0, 'unit': 'M', 'net_profit': 400.5}, {'period': '2020', 'revenue': 1420.0, 'unit': 'M', 'net_profit': 192.6}, {'period': '2019', 'revenue': 1130.0, 'unit': 'M', 'net_profit': 230.8}]","[{'period': ""Q1 '23"", 'revenue': 417.2, 'unit': 'M', 'net_profit': 58.8}, {'period': ""Q4 '22"", 'revenue': 436.4, 'unit': 'M', 'net_profit': 127.2}, {'period': ""Q3 '22"", 'revenue': 439.6, 'unit': 'M', 'net_profit': 185.7}, {'period': ""Q2 '22"", 'revenue': 413.3, 'unit': 'M', 'net_profit': 140.0}, {'period': ""Q1 '22"", 'revenue': 408.1, 'unit': 'M', 'net_profit': 169.4}, {'period': ""Q4 '21"", 'revenue': 428.2, 'unit': 'M', 'net_profit': 142.3}]",2.1,1.96,11302400000,593200000,280000000,7173500000,119600000,0,1038500000,280000000,-429600000,0.05583032147612707,0.5538077403245942,0.5441176470588235,"[0.44531, 0.445]","['2025-01-15', '2021-07-14']",__nan__,0.6346882078142695
362,ATCX,Atlas Technical Consultants Inc. Class A Common Stock,"Atlas Technical Consultants, Inc. provides professional testing, inspection, engineering, environmental, and program management and consulting services in the United States. The company provides a range of technical services that helps its clients test, inspect, plan, design, certify, and manage various projects across various end markets. It offers testing, inspection, and certification services, such as construction materials testing; non-destructive testing and evaluations, materials testing and inspection, laboratory, and geophysics; construction quality assurance; owner verification and inspection; forensic and structural investigations; and materials laboratory services. The company also provides environmental services, including environmental permitting, compliance assistance, and auditing and compliance management system implementation; air quality; water, hazardous material permitting, and registration; underground storage tank management; leak detection and repair program management; water resource management; industrial hygiene and building science; and disaster response and recovery. In addition, it offers engineering and design services comprising civil site, transportation, and geotechnical engineering; hydrogeology; water/wastewater; solid waste/landfill; land acquisition; subsurface utility engineering; surveying and mapping; and geographic information system asset inventory and assessments. Further, the company offers program management/construction management/quality management services consisting of programmatic planning and phasing; contract document preparation; bid evaluation and award analysis; alternative/value engineering; project estimating and scheduling; project cost/schedule control; contract administration; project management; community relations/affairs; asset management; construction management; quality management and assurance; and construction engineering and inspection. The company is headquartered in Austin, Texas.",Mr. L. Joseph Boyer,Engineering & Construction,12.25,USD,0,https://images.financialmodelingprep.com/symbol/ATCX.png,233488,-58.333333333333336,0,380049,70700000,-8070000,"[{'period': '2022', 'revenue': 604.76, 'unit': 'M', 'net_profit': -8.07}, {'period': '2021', 'revenue': 538.8, 'unit': 'M', 'net_profit': -29.7}, {'period': '2020', 'revenue': 468.22, 'unit': 'M', 'net_profit': -27.06}, {'period': '2019', 'revenue': 471.05, 'unit': 'M', 'net_profit': 8.03}]","[{'period': ""Q4 '22"", 'revenue': 150.96, 'unit': 'M', 'net_profit': -4.22}, {'period': ""Q3 '22"", 'revenue': 162.12, 'unit': 'M', 'net_profit': 1.91}, {'period': ""Q2 '22"", 'revenue': 156.5, 'unit': 'M', 'net_profit': -1.41}, {'period': ""Q1 '22"", 'revenue': 135.19, 'unit': 'M', 'net_profit': -4.42}, {'period': ""Q4 '21"", 'revenue': 145.25, 'unit': 'M', 'net_profit': -7.61}, {'period': ""Q3 '21"", 'revenue': 138.72, 'unit': 'M', 'net_profit': -2.53}]",-0.22,-0.22,487360000,180755000,5799000,613720000,160620000,0,78556000,5799000,-6212000,0.37776478612491476,0.7283285642147787,0.7943925233644861,__nan__,__nan__,__nan__,1.259274458305975
363,ATEC,Alphatec Holdings Inc. Common Stock,"Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.",Mr. Patrick S. Miles,Medical - Devices,9.315,USD,1320568920,https://images.financialmodelingprep.com/symbol/ATEC.png,1948791,-7.39,,0,-110592000,-186638000,"[{'period': '2023', 'revenue': 482.26, 'unit': 'M', 'net_profit': -186.64}, {'period': '2022', 'revenue': 350.87, 'unit': 'M', 'net_profit': -152.15}, {'period': '2021', 'revenue': 243.21, 'unit': 'M', 'net_profit': -144.33}, {'period': '2020', 'revenue': 144.86, 'unit': 'M', 'net_profit': -78.99}]","[{'period': ""Q3 '24"", 'revenue': 150.72, 'unit': 'M', 'net_profit': -39.62}, {'period': ""Q2 '24"", 'revenue': 145.57, 'unit': 'M', 'net_profit': -40.68}, {'period': ""Q1 '24"", 'revenue': 138.48, 'unit': 'M', 'net_profit': -48.49}, {'period': ""Q4 '23"", 'revenue': 137.97, 'unit': 'M', 'net_profit': -49.08}, {'period': ""Q3 '23"", 'revenue': 118.26, 'unit': 'M', 'net_profit': -42.65}, {'period': ""Q2 '23"", 'revenue': 116.92, 'unit': 'M', 'net_profit': -51.38}]",-1.54,-1.54,805208000,451091000,220970000,703489000,72613000,0,157574000,220970000,-165460000,-0.07814693495554516,-0.22667911060867965,-0.047619047619047665,__nan__,__nan__,__nan__,0.8736736346385033
364,ATER,Aterian Inc. Common Stock,"Aterian, Inc., together with its subsidiaries, operates as a technology-enabled consumer products company in North America and internationally. The company provides Artificial Intelligence Marketplace e-Commerce Engine, a software technology platform, which uses machine learning, natural language processing, and data analytics to design, develop, market, and sell products. Its platform offers home and kitchen appliances; kitchenware; heating, cooling, and health and beauty products; and air quality appliances, such as dehumidifiers, humidifiers, and air conditioners under the hOmeLabs, Vremi, Squatty Potty, Xtava, RIF6, Aussie Health, Holonix, Truweo, Mueller, Pursteam, Pohl and Schmitt, Healing Solutions, Photo Paper Direct, and Spiralizer brands. The company also sells essential oils. It primarily serves individual online consumers through Amazon and other e-commerce platforms, as well as through its owned and operated websites and other marketplaces. The company was formerly known as Mohawk Group Holdings, Inc. and changed its name to Aterian, Inc. in April 2021. Aterian, Inc. was founded in 2014 and is headquartered in New York, New York.",Mr. Arturo  Rodriguez,"Furnishings, Fixtures & Appliances",2.535,USD,22194407,https://images.financialmodelingprep.com/symbol/ATER.png,55979,-0.97,-0.005,10023,-69420000,-74564000,"[{'period': '2023', 'revenue': 142.57, 'unit': 'M', 'net_profit': -74.56}, {'period': '2022', 'revenue': 221.17, 'unit': 'M', 'net_profit': -196.29}, {'period': '2021', 'revenue': 247.77, 'unit': 'M', 'net_profit': -234.72}, {'period': '2020', 'revenue': 185.7, 'unit': 'M', 'net_profit': -63.13}]","[{'period': ""Q3 '24"", 'revenue': 26.24, 'unit': 'M', 'net_profit': -1.77}, {'period': ""Q2 '24"", 'revenue': 27.98, 'unit': 'M', 'net_profit': -3.63}, {'period': ""Q1 '24"", 'revenue': 20.21, 'unit': 'M', 'net_profit': -5.16}, {'period': ""Q4 '23"", 'revenue': 32.75, 'unit': 'M', 'net_profit': -7.71}, {'period': ""Q3 '23"", 'revenue': 39.67, 'unit': 'M', 'net_profit': -6.27}, {'period': ""Q2 '23"", 'revenue': 35.26, 'unit': 'M', 'net_profit': -34.79}]",-11.45,-11.45,61869000,49636000,20023000,25838000,4225000,0,25447000,20023000,-13507000,0.6276769767928303,0.6201373464022986,0.6766450155323355,__nan__,__nan__,__nan__,0.41762433528907855
365,ATEX,Anterix Inc. Common Stock,"Anterix Inc. operates as a wireless communications company. The company focuses on commercializing its spectrum assets to enable the targeted utility and critical infrastructure customers to deploy private broadband networks, technologies, and solutions. It holds licensed spectrum in the 900 MHz band with coverage throughout the United States, Alaska, Hawaii, and Puerto Rico. The company was formerly known as pdvWireless, Inc. and changed its name to Anterix Inc. in August 2019. Anterix Inc. was incorporated in 1997 and is headquartered in Woodland Park, New Jersey.",Mr. Scott A. Lang,Telecommunications Services,29.66,USD,552218778,https://images.financialmodelingprep.com/symbol/ATEX.png,118895,-14.68,0,34540,-51622000,-9128000,"[{'period': '2024', 'revenue': 4.19, 'unit': 'M', 'net_profit': -9.13}, {'period': '2023', 'revenue': 1.92, 'unit': 'M', 'net_profit': -16.32}, {'period': '2022', 'revenue': 1.08, 'unit': 'M', 'net_profit': -37.52}, {'period': '2021', 'revenue': 0.921, 'unit': 'M', 'net_profit': -54.43}]","[{'period': ""Q2 '25"", 'revenue': 1.55, 'unit': 'M', 'net_profit': -12.77}, {'period': ""Q1 '25"", 'revenue': 1.52, 'unit': 'M', 'net_profit': -15.52}, {'period': ""Q4 '24"", 'revenue': 1.26, 'unit': 'M', 'net_profit': -9.41}, {'period': ""Q3 '24"", 'revenue': 1270.0, 'unit': 'K', 'net_profit': 328.0}, {'period': ""Q2 '24"", 'revenue': 1.05, 'unit': 'M', 'net_profit': 2.07}, {'period': ""Q1 '24"", 'revenue': 0.608, 'unit': 'M', 'net_profit': -2.12}]",-0.49,-0.49,324894000,73011000,60578000,163862000,8521000,0,17951000,60578000,24655000,0.03383866741530975,0.44058344058344057,0.4367816091954023,__nan__,__nan__,__nan__,0.5043552666408121
366,ATHA,Athira Pharma Inc. Common Stock,"Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.","Dr. Mark J. Litton M.B.A., Ph.D.",Biotechnology,0.5895,USD,22795434,https://images.financialmodelingprep.com/symbol/ATHA.png,4816683,-0.21,0.0165,80035,-116703000,-117672000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -117.67}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -87.26}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -54.37}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.63}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.74}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.86}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.34}, {'period': ""Q4 '23"", 'revenue': 1.66, 'unit': 'M', 'net_profit': -27.29}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -32.97}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.6}]",-3.1,-3.09,160245000,154729000,147419000,30057000,1628000,0,28840000,90584000,-101057000,-0.23376431161526995,-0.34849075198826523,-0.341991341991342,__nan__,__nan__,__nan__,0.18756903491528598
367,ATHE,Alterity Therapeutics Limited American Depositary Shares,"Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.",Dr. David A. Stamler M.D.,Biotechnology,3.99,USD,35380260,https://images.financialmodelingprep.com/symbol/ATHE.png,63024,-0.57,0,62068,-19571603,-19123464,"[{'period': '2024', 'revenue': 4.02, 'unit': 'M', 'net_profit': -19.12}, {'period': '2023', 'revenue': 3.92, 'unit': 'M', 'net_profit': -13.81}, {'period': '2022', 'revenue': 5.12, 'unit': 'M', 'net_profit': -12.85}, {'period': '2021', 'revenue': 4.34, 'unit': 'M', 'net_profit': -15.31}]","[{'period': ""Q4 '24"", 'revenue': 2.12, 'unit': 'M', 'net_profit': -12.62}, {'period': ""Q2 '24"", 'revenue': 1.9, 'unit': 'M', 'net_profit': -6.51}, {'period': ""Q4 '23"", 'revenue': 1.53, 'unit': 'M', 'net_profit': -5.77}, {'period': ""Q2 '23"", 'revenue': 2.39, 'unit': 'M', 'net_profit': -8.03}, {'period': ""Q4 '22"", 'revenue': 2.76, 'unit': 'M', 'net_profit': -6.26}, {'period': ""Q2 '22"", 'revenue': 2.36, 'unit': 'M', 'net_profit': -6.58}]",-0.0052,-0.0052,19223743,19036860,12638885,5425686,4041675,0,5373772,12638885,-12611546,-0.11748192391216591,-0.3851043510980142,0.08771929824561411,__nan__,__nan__,__nan__,0.28223879189396156
368,ATHX,Athersys Inc. Common Stock,"Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.",Ms. Z. Kasey Rosado,Biotechnology,0.0135,USD,0,https://images.financialmodelingprep.com/symbol/ATHX.png,1772562,-0.008181818181818182,-0.0068,6462682,-75589000,-68061000,"[{'period': '2022', 'revenue': 5.33, 'unit': 'M', 'net_profit': -68.06}, {'period': '2021', 'revenue': 5.51, 'unit': 'M', 'net_profit': -86.95}, {'period': '2020', 'revenue': 1.43, 'unit': 'M', 'net_profit': -78.77}, {'period': '2019', 'revenue': 5.52, 'unit': 'M', 'net_profit': -44.58}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.77}, {'period': ""Q2 '23"", 'revenue': 0.049, 'unit': 'M', 'net_profit': -12.92}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.29}, {'period': ""Q4 '22"", 'revenue': 0.032, 'unit': 'M', 'net_profit': -12.4}, {'period': ""Q3 '22"", 'revenue': 0.065, 'unit': 'M', 'net_profit': -10.62}, {'period': ""Q2 '22"", 'revenue': 2.32, 'unit': 'M', 'net_profit': -23.04}]",-5.7,-5.7,27731000,13535000,9038000,51582000,716000,0,42363000,9038000,-59347000,0.11727061461386647,0.21728480248404347,0.41176470588235287,__nan__,__nan__,__nan__,1.8600843820994555
369,ATIF,ATIF Holdings Limited Ordinary Shares,"ATIF Holdings Limited operates as a consulting company in Asia and North America. It offers IPO advisory services to small and medium-sized enterprises (SMEs). The company primarily helps clients going public on the OTC markets and exchanges in the United States. It also operates IPOEX.com, an internet-based financial information service platform that provides membership services, including market information, pre-IPO education, and IR media and matchmaking services to SMEs and financing institutions; and chinacnnm.com, a news and financial information platform. In addition, the company offers public consulting, M&A consulting, and financial consulting services. The company was incorporated in 2015 and is headquartered in Shenzhen, China.",Mr. Jun  Liu,Financial - Capital Markets,0.6401,USD,7628392,https://images.financialmodelingprep.com/symbol/ATIF.png,0,-2.06,,0,-1960009,-3184924,"[{'period': '2024', 'revenue': 0.62, 'unit': 'M', 'net_profit': -3.18}, {'period': '2023', 'revenue': 2.45, 'unit': 'M', 'net_profit': -2.88}, {'period': '2022', 'revenue': 1.67, 'unit': 'M', 'net_profit': -4.07}, {'period': '2021', 'revenue': 0.9369299999999999, 'unit': 'M', 'net_profit': -8.82}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -367.07}, {'period': ""Q4 '24"", 'revenue': 0.27, 'unit': 'M', 'net_profit': -1.35}, {'period': ""Q3 '24"", 'revenue': 200.0, 'unit': 'K', 'net_profit': -807.59}, {'period': ""Q2 '24"", 'revenue': 25.0, 'unit': 'K', 'net_profit': -407.64}, {'period': ""Q1 '24"", 'revenue': 125.0, 'unit': 'K', 'net_profit': -625.46}, {'period': ""Q4 '23"", 'revenue': 0.15, 'unit': 'M', 'net_profit': -3.24}]",-0.31,-0.31,3012588,2898748,1673524,1258834,200000,0,988417,1249376,-125569,0.13965072613584237,-0.10499431183232552,-0.03333333333333337,__nan__,__nan__,__nan__,0.417858001160464
370,ATLC,Atlanticus Holdings Corporation Common Stock,"Atlanticus Holdings Corporation provides credit and related financial services and products to customers the United States. It operates in two segments, Credit as a Service, and Auto Finance. The Credit as a Service segment originates a range of consumer loan products, such as private label and general purpose credit cards originated by lenders through various channels, including retail and healthcare, direct mail solicitation, digital marketing, and partnerships with third parties; and offers credit to their customers for the purchase of various goods and services, including consumer electronics, furniture, elective medical procedures, healthcare, educational services, and home-improvements by partnering with retailers and service providers. In addition, it offers loan servicing, such as risk management and customer service outsourcing for third parties; and engages in testing and investment activities in consumer finance technology platforms. The Auto Finance segment purchases and/or services loans secured by automobiles from or for a pre-qualified network of independent automotive dealers and automotive finance companies in the buy-here, pay-here, and used car business. This segment also provides floor plan financing and installment lending products. Further, the company invests in and services portfolios of credit card receivables. Atlanticus Holdings Corporation was founded in 1996 and is headquartered in Atlanta, Georgia.",Mr. Jeffrey A. Howard,Financial - Credit Services,54.93,USD,809607777,https://images.financialmodelingprep.com/symbol/ATLC.png,40566,12.34,0,34812,241943000,102845000,"[{'period': '2023', 'revenue': 1160.0, 'unit': 'M', 'net_profit': 102.84}, {'period': '2022', 'revenue': 292.56, 'unit': 'M', 'net_profit': 135.6}, {'period': '2021', 'revenue': 399.8, 'unit': 'M', 'net_profit': 177.9}, {'period': '2020', 'revenue': 340.27, 'unit': 'M', 'net_profit': 94.12}]","[{'period': ""Q3 '24"", 'revenue': 350.95, 'unit': 'M', 'net_profit': 29.54}, {'period': ""Q2 '24"", 'revenue': 316.02, 'unit': 'M', 'net_profit': 24.28}, {'period': ""Q1 '24"", 'revenue': 290.71, 'unit': 'M', 'net_profit': 19.88}, {'period': ""Q4 '23"", 'revenue': 309.09, 'unit': 'M', 'net_profit': 19.96}, {'period': ""Q3 '23"", 'revenue': 294.91, 'unit': 'M', 'net_profit': 38.54}, {'period': ""Q2 '23"", 'revenue': 64.98, 'unit': 'M', 'net_profit': 25.09}]",5.52,4.24,2706445000,2655837000,383653000,2173778000,2272184000,0,147460000,383653000,455325000,0,-0.24153926709292978,-0.2688741721854305,"[0.5, 0.5]","['2009-12-29', '2009-12-29']",__nan__,0.8031857288805057
371,ATLO,Ames National Corporation Common Stock,"Ames National Corporation operates as a multi-bank holding company that provides banking products and services primarily in Boone, Clarke, Hancock, Marshall, Polk, Story, and Union counties in central, north-central, and south-central Iowa. The company accepts a range of deposits, including checking and savings accounts; and time deposits, such as money market accounts and certificates of deposit. It also provides loans, such as short-term and medium-term commercial and agricultural real estate, residential real estate loans, equipment, vehicle, and home improvement loans; personal loans and lines of credit; agricultural and business operating loans and lines of credit; and originates mortgage loans for sale into the secondary market. In addition, the company offers cash management, merchant credit card processing, safe deposit box, wire transfer, direct deposit of payroll and social security check, and automated/video teller machine access services; and automatic drafts for various accounts, as well as wealth management services. Further, it provides farm management, investment, and custodial services for individuals, businesses, and non-profit organizations; and online, mobile, and private banking services. Ames National Corporation was founded in 1903 and is based in Ames, Iowa.",Mr. John P. Nelson,Banks - Regional,16.3916,USD,147396054,https://images.financialmodelingprep.com/symbol/ATLO.png,20880,16.73,-0.0584,9400,0,10817000,"[{'period': '2023', 'revenue': 52.28, 'unit': 'M', 'net_profit': 10.82}, {'period': '2022', 'revenue': 62.93, 'unit': 'M', 'net_profit': 19.29}, {'period': '2021', 'revenue': 66.53, 'unit': 'M', 'net_profit': 23.91}, {'period': '2020', 'revenue': 65.46, 'unit': 'M', 'net_profit': 18.85}]","[{'period': ""Q3 '24"", 'revenue': 23.12, 'unit': 'M', 'net_profit': 2.22}, {'period': ""Q2 '24"", 'revenue': 23.15, 'unit': 'M', 'net_profit': 2.18}, {'period': ""Q1 '24"", 'revenue': 22.29, 'unit': 'M', 'net_profit': 2.3}, {'period': ""Q4 '23"", 'revenue': 22.14, 'unit': 'M', 'net_profit': 2.14}, {'period': ""Q3 '23"", 'revenue': 13.05, 'unit': 'M', 'net_profit': 2.92}, {'period': ""Q2 '23"", 'revenue': 13.62, 'unit': 'M', 'net_profit': 2.56}]",1.2,1.2,2155481000,877352000,800394000,1989693000,12953000,736389000,10441000,64005000,14313000,-1,-0.43933032706162856,-0.4392523364485982,"[0.2, 0.38]","['2025-01-31', '2000-04-04']",__nan__,0.9230853809428151
372,ATNF,180 Life Sciences Corp. Common Stock,"1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.",Sir Marc  Feldmann Ph.D.,Biotechnology,1.6975,USD,5392956,https://images.financialmodelingprep.com/symbol/ATNF.png,2379245,0.21,,0,-22134027,-19935112,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.94}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -38.73}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -20.32}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.01}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -836.72}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 11.78}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.07}, {'period': ""Q4 '23"", 'revenue': 0.16603, 'unit': 'M', 'net_profit': -1.23}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.27}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.68}]",-52.6,-52.59,5259476,3639906,1975799,5387209,0,0,5062616,1975799,-10922223,-0.2442563115406234,0.48523011220887613,0.864173939988638,__nan__,__nan__,__nan__,1.0242862596958329
373,ATNFW,180 Life Sciences Corp. Warrant,"180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.",Sir Marc  Feldmann Ph.D.,Medical - Pharmaceuticals,0.0103,USD,6117796,https://images.financialmodelingprep.com/symbol/ATNFW.png,0,,0.0011,118060,-22134027,-19935112,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.94}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -38.73}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -20.32}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.01}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -836.72}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 11.78}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.07}, {'period': ""Q4 '23"", 'revenue': 0.16603, 'unit': 'M', 'net_profit': -1.23}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.27}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.68}]",-52.6,-52.59,5259476,3639906,1975799,5387209,0,0,5062616,1975799,-10922223,-0.2442563115406234,0.48523011220887613,0.864173939988638,__nan__,__nan__,__nan__,1.0242862596958329
374,ATNI,ATN International Inc. Common Stock,"ATN International, Inc., through its subsidiaries, provides telecommunications services. It operates in three segments: International Telecom, US Telecom, and Renewable Energy. The International Telecom segment provides fixed data and voice; fixed, carrier, managed, and mobility services to customers in Bermuda, the Cayman Islands, Guyana, and the US Virgin Islands, as well as video services in Bermuda, the Cayman Islands, and the US Virgin Islands. This segment also offers mobile, data, and voice services to retail and business customers in Bermuda, Guyana, and US Virgin Islands under the One, GTT+, and Viya brands; roaming services; and handsets and accessories. The US Telecom segment provides carrier services, such as wholesale roaming services; fixed, mobility, carrier, and managed services to business and consumer; private network services to enterprise and consumer customers; and site maintenance services and international long-distance services, as well as leases critical network infrastructure, including towers and transport facilities. The Renewable Energy segment provides distributed generation solar power to commercial and industrial customers in India. As of December 31, 2021, it operated seven retail stores in the US Telecom segment and twenty-one retail stores in the International Telecom segment. The company was formerly known as Atlantic Tele-Network, Inc. and changed its name to ATN International, Inc. in June 2016. ATN International, Inc. was incorporated in 1987 and is headquartered in Beverly, Massachusetts.",Mr. Brad W. Martin,Telecommunications Services,15.945,USD,240995919,https://images.financialmodelingprep.com/symbol/ATNI.png,82917,-5.93,-0.585,27532,169410000,-14538000,"[{'period': '2023', 'revenue': 762.22, 'unit': 'M', 'net_profit': -14.54}, {'period': '2022', 'revenue': 725.75, 'unit': 'M', 'net_profit': -7.58}, {'period': '2021', 'revenue': 602.71, 'unit': 'M', 'net_profit': -20.81}, {'period': '2020', 'revenue': 455440.0, 'unit': 'K', 'net_profit': -708.0}]","[{'period': ""Q3 '24"", 'revenue': 178.45, 'unit': 'M', 'net_profit': -32.69}, {'period': ""Q2 '24"", 'revenue': 183.28, 'unit': 'M', 'net_profit': 9.0}, {'period': ""Q1 '24"", 'revenue': 186.79, 'unit': 'M', 'net_profit': -6.32}, {'period': ""Q4 '23"", 'revenue': 198.97, 'unit': 'M', 'net_profit': -7.32}, {'period': ""Q3 '23"", 'revenue': 191.04, 'unit': 'M', 'net_profit': -3.58}, {'period': ""Q2 '23"", 'revenue': 186440.0, 'unit': 'K', 'net_profit': 767.0}]",-0.93,-0.93,1783714000,281272000,49525000,1059993999,149481000,0,293194000,49225000,-51665000,0.05542195696325554,-0.9171831728867202,-0.9375000000000002,"[0.24, 0.08]","['2024-12-31', '1992-03-04']",__nan__,0.5942623083072734
375,ATNX,Athenex Inc. Common Stock,"Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.","Dr. Yiu-Nam  Lau F.R.C.P., M.B.B.S., M.D., Ph.D.",Drug Manufacturers - Specialty & Generic,0.2031,USD,2333680,https://images.financialmodelingprep.com/symbol/ATNX.png,263314,-0.019435406698564594,0,1754889,-69572000,-98975000,"[{'period': '2022', 'revenue': 102.82, 'unit': 'M', 'net_profit': -98.97}, {'period': '2021', 'revenue': 120.18, 'unit': 'M', 'net_profit': -194.31}, {'period': '2020', 'revenue': 144.39, 'unit': 'M', 'net_profit': -148.43}, {'period': '2019', 'revenue': 101.23, 'unit': 'M', 'net_profit': -125.53}]","[{'period': ""Q4 '22"", 'revenue': 25.06, 'unit': 'M', 'net_profit': -28.77}, {'period': ""Q3 '22"", 'revenue': 33.53, 'unit': 'M', 'net_profit': -19.62}, {'period': ""Q2 '22"", 'revenue': 31.52, 'unit': 'M', 'net_profit': -24.03}, {'period': ""Q1 '22"", 'revenue': 29.72, 'unit': 'M', 'net_profit': -30.47}, {'period': ""Q4 '21"", 'revenue': 24.94, 'unit': 'M', 'net_profit': -97.35}, {'period': ""Q3 '21"", 'revenue': 32.3, 'unit': 'M', 'net_profit': -36.06}]",-15.13,-15.13,204055000,124929000,36691000,204055000,27865000,0,114879000,35620000,-77074000,0.39369749363823336,0.4906204163557294,0.5953463492912543,__nan__,__nan__,__nan__,1.0
376,ATOM,Atomera Incorporated Common Stock,"Atomera Incorporated develops, commercializes, and licenses proprietary materials, processes, and technologies for the semiconductor industry in North America and the Asia Pacific. The company's lead technology is the Mears Silicon Technology, a thin film of reengineered silicon that can be applied as a transistor channel enhancement to CMOS-type transistors. Its customers include foundries, integrated device manufacturers, fabless semiconductor manufacturers, original equipment manufacturers, and electronic design automation companies. The company was formerly known as Mears Technologies, Inc. and changed its name to Atomera Incorporated in January 2016. Atomera Incorporated was incorporated in 2001 and is headquartered in Los Gatos, California.",Mr. Scott A. Bibaud,Semiconductors,16.17,USD,465341877,https://images.financialmodelingprep.com/symbol/ATOM.png,581119,-23.1,-0.38,546000,-18157000,-19790000,"[{'period': '2023', 'revenue': 0.55, 'unit': 'M', 'net_profit': -19.79}, {'period': '2022', 'revenue': 0.382, 'unit': 'M', 'net_profit': -17.36}, {'period': '2021', 'revenue': 0.4, 'unit': 'M', 'net_profit': -15.71}, {'period': '2020', 'revenue': 0.062, 'unit': 'M', 'net_profit': -14.66}]","[{'period': ""Q3 '24"", 'revenue': 0.022, 'unit': 'M', 'net_profit': -4.59}, {'period': ""Q2 '24"", 'revenue': 0.07200000000000001, 'unit': 'M', 'net_profit': -4.36}, {'period': ""Q1 '24"", 'revenue': 0.018000000000000002, 'unit': 'M', 'net_profit': -4.82}, {'period': ""Q4 '23"", 'revenue': 0.55, 'unit': 'M', 'net_profit': -4.58}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.04}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.15}]",-0.8,-0.8,24029000,20404000,19531000,5859000,629000,0,3814000,12591000,-14588000,-0.15797193877551022,-0.14023968656372435,-0.06666666666666672,__nan__,__nan__,__nan__,0.24383037163427526
377,ATOS,Atossa Therapeutics Inc. Common Stock,"Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.","Dr. Steven C. Quay FCAP, M.D., Ph.D.",Biotechnology,0.9614,USD,120945081,https://images.financialmodelingprep.com/symbol/ATOS.png,749988,-4.58,0.0011,332617,-31354000,-30094000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.09}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.23}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -20.61}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.1}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.23}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.05}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.88}, {'period': ""Q4 '23"", 'revenue': 0.018000000000000002, 'unit': 'M', 'net_profit': -7.75}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.23}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.83}]",-0.24,-0.24,96252000,92219000,88460000,5236000,0,1710000,5236000,88460000,-20955,-0.1326084600657443,-0.14735598002211292,-0.14285714285714285,__nan__,__nan__,__nan__,0.05439886963387774
378,ATRA,Atara Biotherapeutics Inc. Common Stock,"Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.",Dr. Anhco  Nguyen Ph.D.,Biotechnology,18,USD,103675500,https://images.financialmodelingprep.com/symbol/ATRA.png,110737,-0.65,0,105354,-265997000,-276126000,"[{'period': '2023', 'revenue': 8.57, 'unit': 'M', 'net_profit': -276.13}, {'period': '2022', 'revenue': 0.06357, 'unit': 'B', 'net_profit': -2.28}, {'period': '2021', 'revenue': 0.02034, 'unit': 'B', 'net_profit': -3.4}, {'period': '2020', 'revenue': 0.0, 'unit': 'B', 'net_profit': -3.07}]","[{'period': ""Q3 '24"", 'revenue': 40.19, 'unit': 'M', 'net_profit': -21.91}, {'period': ""Q2 '24"", 'revenue': 28.64, 'unit': 'M', 'net_profit': -19.05}, {'period': ""Q1 '24"", 'revenue': 27.36, 'unit': 'M', 'net_profit': -317.52}, {'period': ""Q4 '23"", 'revenue': 4.25, 'unit': 'M', 'net_profit': -604.5}, {'period': ""Q3 '23"", 'revenue': 2.14, 'unit': 'M', 'net_profit': -697.97}, {'period': ""Q2 '23"", 'revenue': 0.9570000000000001, 'unit': 'M', 'net_profit': -711.08}]",-65.18,-65.18,165504000,101869000,51725000,264735000,34108000,0,142226000,25841000,-194200000,-0.24459344381954126,0.8790523079079465,-0.16476054324517522,__nan__,__nan__,__nan__,1.599568590487239
379,ATRC,AtriCure Inc. Common Stock,"AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.",Mr. Michael H. Carrel,Medical - Instruments & Supplies,32.31,USD,1575219123,https://images.financialmodelingprep.com/symbol/ATRC.png,499261,-38.93,-1.18,141688,-8109000,-30438000,"[{'period': '2023', 'revenue': 399.25, 'unit': 'M', 'net_profit': -30.44}, {'period': '2022', 'revenue': 330.38, 'unit': 'M', 'net_profit': -46.47}, {'period': '2021', 'revenue': 274.33, 'unit': 'M', 'net_profit': 50.2}, {'period': '2020', 'revenue': 206.53, 'unit': 'M', 'net_profit': -48.16}]","[{'period': ""Q3 '24"", 'revenue': 115.91, 'unit': 'M', 'net_profit': -7.85}, {'period': ""Q2 '24"", 'revenue': 116.27, 'unit': 'M', 'net_profit': -8.01}, {'period': ""Q1 '24"", 'revenue': 108.85, 'unit': 'M', 'net_profit': -13.27}, {'period': ""Q4 '23"", 'revenue': 106.54, 'unit': 'M', 'net_profit': -9.79}, {'period': ""Q3 '23"", 'revenue': 98.29, 'unit': 'M', 'net_profit': -9.05}, {'period': ""Q2 '23"", 'revenue': 100.92, 'unit': 'M', 'net_profit': -5.12}]",-0.66,-0.66,613932000,266245999,137285000,147764000,52501000,0,74569000,84310000,-37514000,0.7251372788285539,0.3449403865191753,0.3529411764705882,__nan__,__nan__,__nan__,0.24068463608347504
380,ATRI,Atrion Corporation Common Stock,"Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and products for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.",Mr. David A. Battat,Medical - Instruments & Supplies,459.92,USD,809436204,https://images.financialmodelingprep.com/symbol/ATRI.png,27595,64.50490883590463,0.26,29517,37677000,19411000,"[{'period': '2023', 'revenue': 169.33, 'unit': 'M', 'net_profit': 19.41}, {'period': '2022', 'revenue': 183.51, 'unit': 'M', 'net_profit': 35.01}, {'period': '2021', 'revenue': 165.01, 'unit': 'M', 'net_profit': 33.05}, {'period': '2020', 'revenue': 147.59, 'unit': 'M', 'net_profit': 32.12}]","[{'period': ""Q2 '24"", 'revenue': 48770.0, 'unit': 'K', 'net_profit': 402.0}, {'period': ""Q1 '24"", 'revenue': 47.33, 'unit': 'M', 'net_profit': 2.79}, {'period': ""Q4 '23"", 'revenue': 43.58, 'unit': 'M', 'net_profit': 6.42}, {'period': ""Q3 '23"", 'revenue': 41.91, 'unit': 'M', 'net_profit': 2.94}, {'period': ""Q2 '23"", 'revenue': 43.84, 'unit': 'M', 'net_profit': 6.56}, {'period': ""Q1 '23"", 'revenue': 39.99, 'unit': 'M', 'net_profit': 3.48}]",11.02,11.02,260825000,114765000,6256000,17936000,23029000,8164999,12621000,3565000,-2313000,-0.3077771041172904,-0.44552673674588666,-0.4374680959673303,"[2.2, 0.55035]","['2024-06-14', '1985-02-08']",__nan__,0.0687664142624365
381,ATRO,Astronics Corporation Common Stock,"Astronics Corporation, through its subsidiaries, designs and manufactures products for the aerospace, defense, and electronics industries in the United States, rest of North America, Asia, Europe, South America, and internationally. It operates in two segments, Aerospace and Test Systems. The Aerospace segment offers lighting and safety systems, electrical power generation systems, distribution and seat motions systems, aircraft structures, avionics products, system certification, and other products. This segment serves airframe manufacturers (OEM) that build aircraft for the commercial, military, and general aviation markets; suppliers to OEMs; and aircraft operators, such as airlines; suppliers to the aircraft operators; and branches of the U.S. Department of Defense. The Test Systems segment designs, develops, manufactures, and maintains automated test systems that support the aerospace and defense, and communications and mass transit industries; and provides wireless communication testing for the civil land mobile radio market, as well as training and simulation devices for commercial and military applications. It serves OEMs and prime government contractors for electronics and military products. The company was incorporated in 1968 and is headquartered in East Aurora, New York.",Mr. Peter J. Gundermann,Aerospace & Defense,15.75,USD,555744751,https://images.financialmodelingprep.com/symbol/ATRO.png,324379,-98.44,-0.02,95941,19433000,-26421000,"[{'period': '2023', 'revenue': 689.21, 'unit': 'M', 'net_profit': -26.42}, {'period': '2022', 'revenue': 534.89, 'unit': 'M', 'net_profit': -35.75}, {'period': '2021', 'revenue': 444.91, 'unit': 'M', 'net_profit': -25.58}, {'period': '2020', 'revenue': 502.59, 'unit': 'M', 'net_profit': -115.78}]","[{'period': ""Q3 '24"", 'revenue': 203.7, 'unit': 'M', 'net_profit': -11.74}, {'period': ""Q2 '24"", 'revenue': 198.11, 'unit': 'M', 'net_profit': 1.53}, {'period': ""Q1 '24"", 'revenue': 185.07, 'unit': 'M', 'net_profit': -3.18}, {'period': ""Q4 '23"", 'revenue': 195.29, 'unit': 'M', 'net_profit': 6.98}, {'period': ""Q3 '23"", 'revenue': 162.92, 'unit': 'M', 'net_profit': -16.98}, {'period': ""Q2 '23"", 'revenue': 174.45, 'unit': 'M', 'net_profit': -12.0}]",-0.8,-0.8,633792000,389782000,4756000,384274000,172108000,0,143334000,4756000,-31593000,9.57212174680194,0.2608890256525023,0.2792792792792793,"[4.516, 0.0022]","['2012-10-25', '1994-01-25']",__nan__,0.6063093254569323
382,ATRS,Antares Pharma Inc. Common Stock,"Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.",Mr. Robert Apple,Medical - Instruments & Supplies,5.59,USD,0,https://images.financialmodelingprep.com/symbol/ATRS.png,5230217,14.946524064171124,0.01000023,1763417,66172000,46289000,"[{'period': '2021', 'revenue': 183.98, 'unit': 'M', 'net_profit': 46.29}, {'period': '2020', 'revenue': 149.6, 'unit': 'M', 'net_profit': 56.2}, {'period': '2019', 'revenue': 123.86, 'unit': 'M', 'net_profit': -2.03}, {'period': '2018', 'revenue': 63.55, 'unit': 'M', 'net_profit': -6.51}]","[{'period': ""Q1 '22"", 'revenue': 41.56, 'unit': 'M', 'net_profit': -2.32}, {'period': ""Q4 '21"", 'revenue': 48.73, 'unit': 'M', 'net_profit': 32.68}, {'period': ""Q3 '21"", 'revenue': 48.19, 'unit': 'M', 'net_profit': 5.39}, {'period': ""Q2 '21"", 'revenue': 44.98, 'unit': 'M', 'net_profit': 6.71}, {'period': ""Q1 '21"", 'revenue': 42.08, 'unit': 'M', 'net_profit': 3.79}, {'period': ""Q4 '20"", 'revenue': 44.13, 'unit': 'M', 'net_profit': 51.39}]",0.27,0.27,257505000,161710000,67158000,81747000,83008000,0,58930000,65913000,30002000,3.0509335782063056,-0.1763669685592783,-0.1818181818181818,__nan__,__nan__,__nan__,0.317457913438574
383,ATSG,Air Transport Services Group Inc,"Air Transport Services Group, Inc., together with its subsidiaries, provides aircraft leasing and air cargo transportation and related services in the United States and internationally. The company offers aircraft, flight crews, aircraft maintenance, aircraft hull and liability insurance, and aviation fuel services; and aircraft maintenance and modification services, including airframe modification and heavy maintenance, component repairs, engineering services, and aircraft line maintenance. It also provides equipment maintenance services; cargo load transfer and package sorting services; crew training services; and airline express operation, line and heavy maintenance, and ground handling services. The company's ground support services include labor and management for cargo load transfer and sorting; design, installation, and maintenance of material handling equipment; leasing and maintenance of ground support equipment; and general facilities maintenance. In addition, it offers equipment installation and maintenance, vehicle maintenance and repair, jet fuel, and deicing services. Further, the company operates cargo and passenger transportation business; resells and brokers aircraft parts; and performs passenger-to-freighter and passenger-to-combi conversions of aircrafts. It provides its services to delivery companies, freight forwarders, airlines, air transportation, e-commerce, package delivery, and logistics industries, as well as government customers. As of December 31, 2021, the company's in-service aircraft fleet consisted of 107 owned aircraft and ten leased aircraft. The company was formerly known as ABX Holdings, Inc. Air Transport Services Group, Inc. was founded in 1980 and is based in Wilmington, Ohio.",Mr. Joseph C. Hete,"Airlines, Airports & Air Services",22.03,USD,1464384769,https://images.financialmodelingprep.com/symbol/ATSG.png,1316466,-2203,0.04,253132,507654000,60327000,"[{'period': '2023', 'revenue': 2070.0, 'unit': 'M', 'net_profit': 60.33}, {'period': '2022', 'revenue': 2050.0, 'unit': 'M', 'net_profit': 198.58}, {'period': '2021', 'revenue': 2050.0, 'unit': 'M', 'net_profit': 231.42}, {'period': '2020', 'revenue': 1730.0, 'unit': 'M', 'net_profit': 231.42}]","[{'period': ""Q3 '24"", 'revenue': 471.25, 'unit': 'M', 'net_profit': -7.05}, {'period': ""Q2 '24"", 'revenue': 488.41, 'unit': 'M', 'net_profit': 7.43}, {'period': ""Q1 '24"", 'revenue': 485.52, 'unit': 'M', 'net_profit': 8.62}, {'period': ""Q4 '23"", 'revenue': 517.04, 'unit': 'M', 'net_profit': -15.01}, {'period': ""Q3 '23"", 'revenue': 523.14, 'unit': 'M', 'net_profit': 17.17}, {'period': ""Q2 '23"", 'revenue': 529.34, 'unit': 'M', 'net_profit': 38.02}]",0.9,0.82,3882090000,345701000,53555000,2513388000,215581000,22700000,400189000,53555000,-139366000,-0.20483127957482736,-0.6962096071628202,-0.6666666666666667,__nan__,__nan__,__nan__,0.6474316669628989
384,ATSPT,Archimedes Tech SPAC Partners Co. Subunit,"Archimedes Tech SPAC Partners Co. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses. It intends to focus on the artificial intelligence, cloud services, and automotive technology sectors. The company was incorporated in 2020 and is based in Claymont, Delaware.",Mr. Stephen N. Cannon,Shell Companies,8.18,USD,0,https://images.financialmodelingprep.com/symbol/ATSPT.png,52693,0,-1.4299994,108356,-981884,-948508,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -948.51}]","[{'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -280.85}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -70.54}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -84.03}]",0,0,0.333361,0.33336099999999996,0.23529499999999998,0.497198,0,133.01058300000003,0.249684,0.23529499999999998,-864358,0,0,0,__nan__,__nan__,__nan__,1.491470207972738
385,ATSPU,Archimedes Tech SPAC Partners Co. Unit,"Archimedes Tech SPAC Partners Co. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses. It intends to focus on the artificial intelligence, cloud services, and automotive technology sectors. The company was incorporated in 2020 and is based in Claymont, Delaware.",Mr. Stephen N. Cannon,Shell Companies,8.1,USD,0,https://images.financialmodelingprep.com/symbol/ATSPU.png,3313,0,-1.7999992,21081,-981884,-948508,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -948.51}]","[{'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -280.85}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -70.54}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -84.03}]",0,0,0.333361,0.33336099999999996,0.23529499999999998,0.497198,0,133.01058300000003,0.249684,0.23529499999999998,-864358,0,0,0,__nan__,__nan__,__nan__,1.491470207972738
386,ATSPW,Archimedes Tech SPAC Partners Co. Warrant,"Archimedes Tech SPAC Partners Co. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on the technology industry. The company was founded in 2020 and is based in Claymont, Delaware.",Mr. Stephen N. Cannon,Shell Companies,0.6893,USD,0,https://images.financialmodelingprep.com/symbol/ATSPW.png,0,0,-0.01069999,89693,-981884,-948508,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -948.51}]","[{'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -280.85}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -70.54}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -84.03}]",0,0,0.333361,0.33336099999999996,0.23529499999999998,0.497198,0,133.01058300000003,0.249684,0.23529499999999998,-864358,0,0,0,__nan__,__nan__,__nan__,1.491470207972738
387,ATVCU,Tribe Capital Growth Corp I Units,"Tribe Capital Growth Corp I does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in San Francisco, California.",Mr. Arjun  Sethi,Shell Companies,9.83,USD,321109238,https://images.financialmodelingprep.com/symbol/ATVCU.png,2119,33.435374149659864,0,5940,4369659000,11273590000,"[{'period': '2021', 'revenue': 0.0, 'unit': 'B', 'net_profit': 11.27}]","[{'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'B', 'net_profit': 8.22}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'B', 'net_profit': 11.28}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -161.06}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.96}]",326.77,326.77,276438,421.922,336.228,21569,0,276016,1380.389,336.228,-1215879000,0,0,0,__nan__,__nan__,__nan__,0.07802472887229686
388,ATVCW,Tribe Capital Growth Corp I Warrant,"Tribe Capital Growth Corp I focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in San Francisco, California.",Mr. Arjun  Sethi,Shell Companies,0.1242,USD,4057148,https://images.financialmodelingprep.com/symbol/ATVCW.png,0,0,0.0141,46446,4369659000,11273590000,"[{'period': '2021', 'revenue': 0.0, 'unit': 'B', 'net_profit': 11.27}]","[{'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'B', 'net_profit': 8.22}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'B', 'net_profit': 11.28}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -161.06}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.96}]",326.77,326.77,276438,421.922,336.228,21569,0,276016,1380.389,336.228,-1215879000,0,0,0,__nan__,__nan__,__nan__,0.07802472887229686
389,ATVI,Activision Blizzard Inc. Common Stock,"Activision Blizzard, Inc., together with its subsidiaries, develops and publishes interactive entertainment content and services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through three segments: Activision, Blizzard, and King. It develops and distributes content and services on video game consoles, personal computers, and mobile devices, including subscription, full-game, and in-game sales, as well as by licensing software to third-party or related-party companies that distribute Activision and Blizzard products. The company also maintains a proprietary online gaming service, Battle.net that facilitates digital distribution of content, online social connectivity, and the creation of user-generated content. In addition, it operates esports leagues and offer digital advertising content; and provides warehousing, logistics, and sales distribution services to third-party publishers of interactive entertainment software, as well as manufacturers of interactive entertainment hardware products. The company's key product franchises include Call of Duty, World of Warcraft, Diablo, Hearthstone, Overwatch, Overwatch League, and Candy Crush. It serves retailers and distributors, including mass-market retailers, consumer electronics stores, discount warehouses, and game specialty stores through third-party distribution and licensing arrangements. The company is headquartered in Santa Monica, California.",Mr. Robert A. Kotick,Electronic Gaming & Multimedia,94.42,USD,74289468671,https://images.financialmodelingprep.com/symbol/ATVI.png,9578042,34.586080586080584,-0.05,7127746,2248000000,1513000000,"[{'period': '2022', 'revenue': 7.53, 'unit': 'B', 'net_profit': 1.51}, {'period': '2021', 'revenue': 8.8, 'unit': 'B', 'net_profit': 2.7}, {'period': '2020', 'revenue': 8.09, 'unit': 'B', 'net_profit': 2.2}, {'period': '2019', 'revenue': 6.49, 'unit': 'B', 'net_profit': 1.5}]","[{'period': ""Q2 '23"", 'revenue': 2210.0, 'unit': 'M', 'net_profit': 587.0}, {'period': ""Q1 '23"", 'revenue': 2380.0, 'unit': 'M', 'net_profit': 740.0}, {'period': ""Q4 '22"", 'revenue': 2330.0, 'unit': 'M', 'net_profit': 403.0}, {'period': ""Q3 '22"", 'revenue': 1780.0, 'unit': 'M', 'net_profit': 435.0}, {'period': ""Q2 '22"", 'revenue': 1640.0, 'unit': 'M', 'net_profit': 280.0}, {'period': ""Q1 '22"", 'revenue': 1770.0, 'unit': 'M', 'net_profit': 395.0}]",1.92,1.92,27383000000,14469000000,11992000000,8140000000,1204000000,0,3555000000,7060000000,2129000000,-0.4048186391315859,-0.4394220081511671,-0.4466858789625361,"[0.99, 0.15]","['2023-08-01', '2010-02-18']",__nan__,0.297264726290034
390,ATXI,Avenue Therapeutics Inc. Common Stock,"Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.",Dr. Alexandra  MacLean M.D.,Biotechnology,2.06,USD,4231075,https://images.financialmodelingprep.com/symbol/ATXI.png,50285,0.08,0.07,21799,4052000,-10377000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.38}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.05}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.72}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.09}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.08}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.19}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.34}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 640.0}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 526.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.01}]",-73.6,-73.48,1850000,1850000,1783000,1196000,0,0,1196000,1783000,-12451000,0,-6.06689453125,-79.29787234042553,__nan__,__nan__,__nan__,0.6464864864864864
391,AUB,Atlantic Union Bankshares Corporation Common Stock,"Atlantic Union Bankshares Corporation operates as the holding company for Atlantic Union Bank that provides banking and related financial services to consumers and businesses. The company accepts various deposit products, including checking, savings, NOW, time deposit, and money market accounts; certificates of deposit; and other depository services. It also provides loans for commercial, industrial, residential mortgage, and consumer purposes. In addition, the company offers credit cards, automated teller machine (ATM) services, mobile and internet banking services, and online bill payment services, as well as financial planning, trust, and wealth management services. Further, it provides securities, brokerage, and investment advisory products and services; and originates and sells residential loan products in the secondary market. As of February 25, 2022, it operated 130 branches and approximately 150 ATMs in Virginia, Maryland, and North Carolina. The company was formerly known as Union Bankshares Corporation and changed its name to Atlantic Union Bankshares Corporation in May 2019. Atlantic Union Bankshares Corporation was founded in 1902 and is headquartered in Richmond, Virginia.",Mr. John C. Asbury,Banks - Regional,36.38,USD,3265865342,https://images.financialmodelingprep.com/symbol/AUB.png,1026246,15.16,-0.61,120659,261595000,201818000,"[{'period': '2023', 'revenue': 696.27, 'unit': 'M', 'net_profit': 201.82}, {'period': '2022', 'revenue': 696.21, 'unit': 'M', 'net_profit': 234.51}, {'period': '2021', 'revenue': 677.07, 'unit': 'M', 'net_profit': 263.92}, {'period': '2020', 'revenue': 686.78, 'unit': 'M', 'net_profit': 158.23}]","[{'period': ""Q3 '24"", 'revenue': 215.77, 'unit': 'M', 'net_profit': 76.42}, {'period': ""Q2 '24"", 'revenue': 344.7, 'unit': 'M', 'net_profit': 25.16}, {'period': ""Q1 '24"", 'revenue': 172.05, 'unit': 'M', 'net_profit': 49.77}, {'period': ""Q4 '23"", 'revenue': -515.45, 'unit': 'M', 'net_profit': 56.91}, {'period': ""Q3 '23"", 'revenue': 177.65, 'unit': 'M', 'net_profit': 54.02}, {'period': ""Q2 '23"", 'revenue': 176.28, 'unit': 'M', 'net_profit': 55.24}]",2.53,2.53,21166197000,2428015000,2428015000,18609870000,0,3068639000,810000000,364355000,258871000,-0.19604715630051692,-0.13940556905888873,-0.14814814814814828,"[0.34, 0.25]","['2024-11-08', '1994-05-27']",__nan__,0.8792259658170998
392,AUBAP,Atlantic Union Bankshares Corporation Depositary Shares each representing a 1/400th ownership interest in a share of 6.875% Perpetual Non-Cumulative Preferred Stock Series A,"Atlantic Union Bankshares Corporation operates as the holding company for Atlantic Union Bank that provides banking and related financial services to consumers and businesses. The company accepts various deposit products, including checking, savings, NOW, time deposit, and money market accounts; certificates of deposit; and other depository services. It also provides loans for commercial, industrial, residential mortgage, and consumer purposes. In addition, the company offers credit cards, automated teller machine (ATM) services, mobile and internet banking services, and online bill payment services, as well as financial planning, trust, and wealth management services. Further, it provides securities, brokerage, and investment advisory products and services; and originates and sells residential loan products in the secondary market. As of February 25, 2022, it operated 130 branches and approximately 150 ATMs in Virginia, Maryland, and North Carolina. The company was formerly known as Union Bankshares Corporation and changed its name to Atlantic Union Bankshares Corporation in May 2019. Atlantic Union Bankshares Corporation was founded in 1902 and is headquartered in Richmond, Virginia.",Mr. John C. Asbury,Banks - Regional,25.27,USD,3341272885,https://images.financialmodelingprep.com/symbol/AUBAP.png,11359,8.08,0.27,10394,261595000,201818000,"[{'period': '2023', 'revenue': 696.27, 'unit': 'M', 'net_profit': 201.82}, {'period': '2022', 'revenue': 696.21, 'unit': 'M', 'net_profit': 234.51}, {'period': '2021', 'revenue': 677.07, 'unit': 'M', 'net_profit': 263.92}, {'period': '2020', 'revenue': 686.78, 'unit': 'M', 'net_profit': 158.23}]","[{'period': ""Q3 '24"", 'revenue': 215.77, 'unit': 'M', 'net_profit': 76.42}, {'period': ""Q2 '24"", 'revenue': 344.7, 'unit': 'M', 'net_profit': 25.16}, {'period': ""Q1 '24"", 'revenue': 172.05, 'unit': 'M', 'net_profit': 49.77}, {'period': ""Q4 '23"", 'revenue': -515.45, 'unit': 'M', 'net_profit': 56.91}, {'period': ""Q3 '23"", 'revenue': 177.65, 'unit': 'M', 'net_profit': 54.02}, {'period': ""Q2 '23"", 'revenue': 176.28, 'unit': 'M', 'net_profit': 55.24}]",2.53,2.53,21166197000,2428015000,2428015000,18609870000,0,3068639000,810000000,364355000,258871000,-0.19604715630051692,-0.13940556905888873,-0.14814814814814828,"[0.43, 0.39]","['2024-11-15', '2020-08-13']",__nan__,0.8792259658170998
393,AUBN,Auburn National Bancorporation Inc. Common Stock,"Auburn National Bancorporation, Inc. operates as the bank holding company for AuburnBank that provides various banking products and services in East Alabama. The company's deposit products include checking, savings, and transaction deposit accounts, as well as certificates of deposit. It also provides commercial, financial, agricultural, real estate construction, and consumer loan products; and other financial services. In addition, the company offers automated teller services; debit cards; online banking, bill payment, and other electronic services; and safe deposit boxes. It operates through seven full-service branches in Auburn, Opelika, Notasulga, and Valley, Alabama; as well as loan production offices in Auburn and Phenix City, Alabama. Auburn National Bancorporation, Inc. was founded in 1907 and is headquartered in Auburn, Alabama.",Mr. David A. Hedges CPA,Banks - Regional,22.65,USD,79132305,https://images.financialmodelingprep.com/symbol/AUBN.png,4164,94.38,-0.58,1031,2318000,1395000,"[{'period': '2023', 'revenue': 23.35, 'unit': 'M', 'net_profit': 1.4}, {'period': '2022', 'revenue': 3.23, 'unit': 'M', 'net_profit': 10.35}, {'period': '2021', 'revenue': 28.28, 'unit': 'M', 'net_profit': 8.04}, {'period': '2020', 'revenue': 29.71, 'unit': 'M', 'net_profit': 7.45}]","[{'period': ""Q3 '24"", 'revenue': 7.64, 'unit': 'M', 'net_profit': 1.73}, {'period': ""Q2 '24"", 'revenue': 10.48, 'unit': 'M', 'net_profit': 1.73}, {'period': ""Q1 '24"", 'revenue': 10.12, 'unit': 'M', 'net_profit': 1.37}, {'period': ""Q4 '23"", 'revenue': 0.63, 'unit': 'M', 'net_profit': -3.98}, {'period': ""Q3 '23"", 'revenue': 7.14, 'unit': 'M', 'net_profit': 1.49}, {'period': ""Q2 '23"", 'revenue': 7.68, 'unit': 'M', 'net_profit': 1.93}]",0.4,0.4,975255000,71369000,310867000,898748000,0,270910000,866043000,39957000,11451000,-0.8387702580510538,-0.865165281268123,-0.864406779661017,"[0.27, 0.27]","['2024-12-10', '1995-12-20']",__nan__,0.9215517992730107
394,AUDC,AudioCodes Ltd. Common Stock,"AudioCodes Ltd. provides advanced communications software, products, and productivity solutions for the digital workplace. The company offers solutions, products, and services for unified communications, contact centers, VoiceAI business line, and service provider business. Its products include session border controllers, life cycle management solutions, VoIP network routing solutions, media gateways and servers, multi-service business routers, IP phones solutions, and value-added applications, as well as professional services. The company also offers One Voice Operations Center, a voice network management solution; Device Manager for administering business phones and meeting room solutions; AudioCodes Routing Manager for handling call routing in VoIP networks; and User Management Pack 365 simplifies user lifecycle and identity management across Microsoft Teams and Skype for Business deployments. In addition, it provides AudioCodes Live for Microsoft Teams, a portfolio of managed services for simplifying Teams adoption; appliances for Microsoft Skype/Teams for Business such as survivable branch appliances, CCE, and CloudBond 365; and a range of value-added voice applications comprising SmartTAP, Voca, VoiceAI Connect, and Meeting Insights. Further, the company offers managed services; and AudioCodes Live Cloud, a Microsoft Teams software as a service solution that enables service providers to offer their business customers a seamless migration to Microsoft Teams. It primarily markets and sells its products through a direct sales force and sales representatives to original equipment manufacturers, network equipment providers, and systems integrators and distributors in the telecommunications and networking industries. The company primarily operates in the Americas, Europe, the Far East, and Israel. AudioCodes Ltd. was incorporated in 1992 and is headquartered in Lod, Israel.",Mr. Shabtai  Adlersberg,Communication Equipment,10.27,USD,307582392,https://images.financialmodelingprep.com/symbol/AUDC.png,88851,25.05,0,22436,18533000,8780000,"[{'period': '2023', 'revenue': 244.38, 'unit': 'M', 'net_profit': 8.78}, {'period': '2022', 'revenue': 275.09, 'unit': 'M', 'net_profit': 28.47}, {'period': '2021', 'revenue': 248.92, 'unit': 'M', 'net_profit': 33.75}, {'period': '2020', 'revenue': 220.77, 'unit': 'M', 'net_profit': 27.25}]","[{'period': ""Q3 '24"", 'revenue': 60.24, 'unit': 'M', 'net_profit': 2.68}, {'period': ""Q2 '24"", 'revenue': 60.3, 'unit': 'M', 'net_profit': 3.77}, {'period': ""Q1 '24"", 'revenue': 60.08, 'unit': 'M', 'net_profit': 2.08}, {'period': ""Q4 '23"", 'revenue': 63.56, 'unit': 'M', 'net_profit': 3.65}, {'period': ""Q3 '23"", 'revenue': 61.59, 'unit': 'M', 'net_profit': 4.25}, {'period': ""Q2 '23"", 'revenue': 60.02, 'unit': 'M', 'net_profit': 1.05}]",0.28,0.28,337517000,142661000,38196000,149405000,51125000,68462000,84197000,30546000,8926000,-0.45972655452875844,-0.6915618632754865,-0.6853932584269663,"[0.18, 0.2]","['2024-08-15', '2018-08-03']",__nan__,0.4426591845744066
395,AUPH,Aurinia Pharmaceuticals Inc Ordinary Shares,"Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.",Mr. Peter S. Greenleaf M.B.A.,Biotechnology,8.48,USD,1214157920,https://images.financialmodelingprep.com/symbol/AUPH.png,1293674,-56.53,0.1,538378,-63047000,-78020000,"[{'period': '2023', 'revenue': 175.51, 'unit': 'M', 'net_profit': -78.02}, {'period': '2022', 'revenue': 134.03, 'unit': 'M', 'net_profit': -108.18}, {'period': '2021', 'revenue': 45.6, 'unit': 'M', 'net_profit': -180.97}, {'period': '2020', 'revenue': 50.12, 'unit': 'M', 'net_profit': -102.68}]","[{'period': ""Q3 '24"", 'revenue': 67.77, 'unit': 'M', 'net_profit': 14.35}, {'period': ""Q2 '24"", 'revenue': 57190.0, 'unit': 'K', 'net_profit': 722.0}, {'period': ""Q1 '24"", 'revenue': 50.3, 'unit': 'M', 'net_profit': -10.75}, {'period': ""Q4 '23"", 'revenue': 45.09, 'unit': 'M', 'net_profit': -26.88}, {'period': ""Q3 '23"", 'revenue': 54.52, 'unit': 'M', 'net_profit': -13.45}, {'period': ""Q2 '23"", 'revenue': 41.49, 'unit': 'M', 'net_profit': -11.49}]",-0.54,-0.54,548062000,424800000,350489000,170108000,24089000,201000,77188000,48875000,-34179000,0.39170831484090074,0.2787946015899427,0.28947368421052627,__nan__,__nan__,__nan__,0.3103809423021483
396,AURC,Aurora Acquisition Corp. Class A Ordinary Shares,"Aurora Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in London, the United Kingdom.",Mr. Arnaud  Massenet,Shell Companies,17.4425,USD,140531938,https://images.financialmodelingprep.com/symbol/AURC.png,332406,-134.17307692307693,-6.9075,113455,-8577543,26048627,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 26.05}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.32}]","[{'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -831.13}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.57}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.26}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.48}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.2}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.01}]",2.49,2.49,282703802,419183,285307,15496897,0,0,15024385,285307,-1152438,-0.1605445514279328,5.897499981198625,14.833333333333336,__nan__,__nan__,__nan__,0.054816726518591354
397,AURCU,Aurora Acquisition Corp. Unit,"Aurora Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in London, the United Kingdom.",Mr. Arnaud  Massenet,Shell Companies,16.6,USD,148896788,https://images.financialmodelingprep.com/symbol/AURCU.png,588,-286.2068965517241,-9.21,1037,-8577543,26048627,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 26.05}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.32}]","[{'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -831.13}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.57}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.26}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.48}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.2}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.01}]",2.49,2.49,282703802,419183,285307,15496897,0,0,15024385,285307,-1152438,-0.1605445514279328,5.897499981198625,14.833333333333336,__nan__,__nan__,__nan__,0.054816726518591354
398,AURCW,Aurora Acquisition Corp. Warrant,"Aurora Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the technology and media companies in Europe, the Middle East, and Africa. The company was incorporated in 2020 and is based in London, the United Kingdom.",Mr. Arnaud  Massenet,Shell Companies,0.3,USD,4485395,https://images.financialmodelingprep.com/symbol/AURCW.png,0,0,0.0474,26069,-8577543,26048627,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 26.05}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.32}]","[{'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -831.13}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.57}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 15.26}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.48}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.2}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.01}]",2.49,2.49,282703802,419183,285307,15496897,0,0,15024385,285307,-1152438,-0.1605445514279328,5.897499981198625,14.833333333333336,__nan__,__nan__,__nan__,0.054816726518591354
399,AUTL,Autolus Therapeutics plc American Depositary Share,"Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.",Dr. Christian Martin Itin Ph.D.,Biotechnology,2.545,USD,677273496,https://images.financialmodelingprep.com/symbol/AUTL.png,1870548,-2.16,-0.055,388383,-156770000,-208383000,"[{'period': '2023', 'revenue': 1.7, 'unit': 'M', 'net_profit': -208.38}, {'period': '2022', 'revenue': 6.19, 'unit': 'M', 'net_profit': -148.84}, {'period': '2021', 'revenue': 2.33, 'unit': 'M', 'net_profit': -142.1}, {'period': '2020', 'revenue': 0.242, 'unit': 'M', 'net_profit': -142.09}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -82.09}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -58.27}, {'period': ""Q1 '24"", 'revenue': 10.09, 'unit': 'M', 'net_profit': -52.69}, {'period': ""Q4 '23"", 'revenue': 1.77, 'unit': 'M', 'net_profit': -77.17}, {'period': ""Q3 '23"", 'revenue': 0.406, 'unit': 'M', 'net_profit': -45.85}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -45.55}]",-1.2,-1.2,375381000,275302000,239566000,263907000,1046999,0,44737000,239566000,-156573000,-0.1566668634163617,-0.4000564368209945,0.23566878980891726,__nan__,__nan__,__nan__,0.7030377136828981
400,AUTO,AutoWeb Inc. Common Stock,"AutoWeb, Inc. operates as a digital marketing company for the automotive industry in the United States. It assists automotive retail dealers and manufacturers to market and sell new and used vehicles to consumers through its programs. The company's products include new vehicle lead program, which allows consumers to submit requests for pricing and availability of specific makes and models; and used vehicle lead program, which allows consumers to search for used vehicles according to specific search parameters, such as price, make, model, mileage, year, and location of the vehicle. Its products and services also comprise WebLeads+ that offers various coupon options, which display marketing messages to consumers visiting the dealer's website; and Payment Pro, a dealer website conversion tool that offers consumers real-time online monthly payment information, as well as sells fixed placement advertising across its Website to automotive advertisers. It owns and operates automotive websites that offers consumers with the information and tools to aid them with their automotive purchase decisions; direct marketing platform that enables manufacturers to selectively target in-market consumers during the often-extended vehicle shopping process; and click traffic referral program, a pay-per-click advertising program that offer targeted offers to consumers based on make, model, and geographic location. The company was formerly known as Autobytel Inc. and changed its name to AutoWeb, Inc. in October 2017. AutoWeb, Inc. was founded in 1995 and is headquartered in Tampa, Florida.",Mr. Jared Rowe,Internet Content & Information,0.388,USD,0,https://images.financialmodelingprep.com/symbol/AUTO.png,0,-0.503242542153048,0.003,97457,-2164000,-6670000,"[{'period': '2021', 'revenue': 71.58, 'unit': 'M', 'net_profit': -6.67}, {'period': '2020', 'revenue': 76.57, 'unit': 'M', 'net_profit': -6.82}, {'period': '2019', 'revenue': 113.98, 'unit': 'M', 'net_profit': -15.23}, {'period': '2018', 'revenue': 125.59, 'unit': 'M', 'net_profit': -38.82}]","[{'period': ""Q2 '22"", 'revenue': 17.2, 'unit': 'M', 'net_profit': -4.68}, {'period': ""Q1 '22"", 'revenue': 19.06, 'unit': 'M', 'net_profit': -4.31}, {'period': ""Q4 '21"", 'revenue': 17.81, 'unit': 'M', 'net_profit': -2.87}, {'period': ""Q3 '21"", 'revenue': 17.16, 'unit': 'M', 'net_profit': -3.06}, {'period': ""Q2 '21"", 'revenue': 18740.0, 'unit': 'K', 'net_profit': -304.0}, {'period': ""Q1 '21"", 'revenue': 17880.0, 'unit': 'K', 'net_profit': 310.0}]",-0.51,-0.51,35132000,25136000,7315000,22375000,11433000,0,20943000,7315000,-3460000,0.32077840552416825,0.021994134897360705,0.019230769230769246,__nan__,__nan__,__nan__,0.6368837527040875
401,AUUD,Auddia Inc. Common Stock,"Auddia Inc., a technology company, develops software products for the audio and podcast markets. The company's flagship product is Faidr, a subscription based mobile application that enables users to listen to various streaming AM/FM radio stations without commercials. It also provides Vodacast, an interactive podcasting platform and application; and Vodcast Hub, a content management system. The company was formerly known as Clip Interactive, LLC and changed its name to Auddia Inc. in November 2019. Auddia Inc. was founded in 2012 and is headquartered in Boulder, Colorado.",Mr. Michael Thomas Lawless,Software - Application,0.55,USD,3120520,https://images.financialmodelingprep.com/symbol/AUUD.png,461929,-0.11,-0.0499,435916,-7450978,-8807496,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.81}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.07}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.93}, {'period': '2020', 'revenue': 0.11092, 'unit': 'M', 'net_profit': -5.72}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.95}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.3}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.21}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.21}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.12}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.32}]",-12.93,-12.93,4403048,834043,804556,3982628,494,0,3982628,804556,-5535773,-0.29971462362065177,-0.24567299043119045,0.08427762039660054,__nan__,__nan__,__nan__,0.9045161442709686
402,AUUDW,Auddia Inc. Warrants,"Auddia Inc. develops software technologies for audio media companies and consumers of audio media. The company's flagship product is Auddia App, a subscription based commercial free AM/FM software application. It also provides Vodacast, an interactive podcasting platform and application. The company was founded in 2012 and is headquartered in Boulder, Colorado.",Mr. Michael Thomas Lawless,Software - Application,0.023,USD,3710126,https://images.financialmodelingprep.com/symbol/AUUDW.png,0,,0.0019,472,-7450978,-8807496,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.81}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.07}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.93}, {'period': '2020', 'revenue': 0.11092, 'unit': 'M', 'net_profit': -5.72}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.95}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.3}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.21}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.21}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.12}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.32}]",-12.93,-12.93,4403048,834043,804556,3982628,494,0,3982628,804556,-5535773,-0.29971462362065177,-0.24567299043119045,0.08427762039660054,__nan__,__nan__,__nan__,0.9045161442709686
403,AUVI,Applied UV Inc. Common Stock,"Applied UV, Inc., through its subsidiaries, develops, acquires, and commercializes technology that addresses air purification and infection control in the healthcare, hospitality, commercial, municipal, and residential markets in the United States, Canada, and Europe. It operates through Disinfection and Hospitality segments. The company offers science-based solutions and products in air purification under the Airocide brand; and disinfection of hard surfaces under the Lumicide brand. It also manufactures and supplies fine decorative framed mirrors, framed arts, and bathroom vanities. The company was incorporated in 2019 and is headquartered in Mount Vernon, New York.",Mr. Max  Munn,"Furnishings, Fixtures & Appliances",0.2926,USD,1367759,https://images.financialmodelingprep.com/symbol/AUVI.png,347986,-0.007315,0.0001,5561130,-9054290,-13203852,"[{'period': '2023', 'revenue': 40.72, 'unit': 'M', 'net_profit': -13.2}, {'period': '2022', 'revenue': 20.14, 'unit': 'M', 'net_profit': -22.05}, {'period': '2021', 'revenue': 11.67, 'unit': 'M', 'net_profit': -7.39}, {'period': '2020', 'revenue': 5.73, 'unit': 'M', 'net_profit': -3.37}]","[{'period': ""Q4 '23"", 'revenue': 7.77, 'unit': 'M', 'net_profit': -3.1}, {'period': ""Q3 '23"", 'revenue': 11.45, 'unit': 'M', 'net_profit': -2.57}, {'period': ""Q2 '23"", 'revenue': 10.84, 'unit': 'M', 'net_profit': -2.99}, {'period': ""Q1 '23"", 'revenue': 10.65, 'unit': 'M', 'net_profit': -5.95}, {'period': ""Q4 '22"", 'revenue': 5.0, 'unit': 'M', 'net_profit': -15.18}, {'period': ""Q3 '22"", 'revenue': 5.88, 'unit': 'M', 'net_profit': -3.06}]",-35.63,-35.63,58386231,17023926,1130947,33502612,7187052,0,27871423,1130947,-8777006,-0.02083431986019505,0.40118900054766155,0.8351149983803046,__nan__,__nan__,__nan__,0.5738101505473097
404,AVAH,Aveanna Healthcare Holdings Inc. Common Stock,"Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides private duty nursing (PDN), adult home health and hospice, home-based pediatric therapy, and enteral nutrition services in the United States. Its patient- centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers PDN services, which include in-home skilled nursing services to medically fragile children; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and employer of record support and personal care services, as well as in-clinic and home-based pediatric therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.",Mr. Jeffrey S. Shaner,Medical - Care Facilities,4.41,USD,852122250,https://images.financialmodelingprep.com/symbol/AVAH.png,265967,-12.97,-0.1,73370,44348000,-134524000,"[{'period': '2023', 'revenue': 1900.0, 'unit': 'M', 'net_profit': -134.52}, {'period': '2022', 'revenue': 1790.0, 'unit': 'M', 'net_profit': -662.03}, {'period': '2021', 'revenue': 1680.0, 'unit': 'M', 'net_profit': -117.04}, {'period': '2020', 'revenue': 1500.0, 'unit': 'M', 'net_profit': -57.05}]","[{'period': ""Q3 '24"", 'revenue': 509.02, 'unit': 'M', 'net_profit': -42.84}, {'period': ""Q2 '24"", 'revenue': 504.96, 'unit': 'M', 'net_profit': 13.91}, {'period': ""Q1 '24"", 'revenue': 490.65, 'unit': 'M', 'net_profit': -11.17}, {'period': ""Q4 '23"", 'revenue': 478.84, 'unit': 'M', 'net_profit': -25.74}, {'period': ""Q3 '23"", 'revenue': 478.01, 'unit': 'M', 'net_profit': -102.39}, {'period': ""Q2 '23"", 'revenue': 471.94, 'unit': 'M', 'net_profit': 25.6}]",-0.71,-0.71,1612985000,314886000,43942000,1740420000,245808000,0,354758000,43942000,16556000,1.0857333969079168,0.7968019769377404,0.8011204481792717,__nan__,__nan__,__nan__,1.0790056944112933
405,AVAV,AeroVironment Inc. Common Stock,"AeroVironment, Inc. designs, develops, produces, delivers, and supports a portfolio of robotic systems and related services for government agencies and businesses in the United States and internationally. It operates through four segments: Unmanned Aircraft Systems (UAS), Tactical Missile System (TMS), Medium Unmanned Aircraft Systems (MUAS), and High Altitude Pseudo-Satellite Systems (HAPS). The company supplies UAS, TMS, unmanned ground vehicle, and related services primarily to organizations within the U.S. Department of Defense and to international allied governments. It also designs, engineers, tools, and manufactures unmanned aerial and aircraft systems, including airborne platforms, payloads and payload integration, ground control systems, and ground support equipment and other items and services related to unmanned aircraft systems. In addition, the company offers small UAS products, including spare equipment, alternative payload modules, batteries, chargers, repair services, and customer support, as well as multiple aircraft, hand-held ground control system, and spare parts and accessories. Further, it develops high-altitude pseudo-satellite UAS systems. The company was incorporated in 1971 and is headquartered in Arlington, Virginia.",Mr. Wahid  Nawabi,Aerospace & Defense,164.29,USD,4633700876,https://images.financialmodelingprep.com/symbol/AVAV.png,447243,96.08,0.56,124934,103200000,59666000,"[{'period': '2024', 'revenue': 716.72, 'unit': 'M', 'net_profit': 59.67}, {'period': '2023', 'revenue': 540.54, 'unit': 'M', 'net_profit': -173.71}, {'period': '2022', 'revenue': 445.73, 'unit': 'M', 'net_profit': -8.77}, {'period': '2021', 'revenue': 394.91, 'unit': 'M', 'net_profit': 33.83}]","[{'period': ""Q2 '25"", 'revenue': 188.46, 'unit': 'M', 'net_profit': 7.54}, {'period': ""Q1 '25"", 'revenue': 189.48, 'unit': 'M', 'net_profit': 21.17}, {'period': ""Q4 '24"", 'revenue': 196.98, 'unit': 'M', 'net_profit': 6.05}, {'period': ""Q3 '24"", 'revenue': 186.58, 'unit': 'M', 'net_profit': 13.88}, {'period': ""Q2 '24"", 'revenue': 180.82, 'unit': 'M', 'net_profit': 17.84}, {'period': ""Q1 '24"", 'revenue': 152.35, 'unit': 'M', 'net_profit': 21.89}]",2.19,2.18,1015860000,515581000,73301000,193115000,269779000,21112000,144879000,73301000,-9191000,2.304925080609471,1.343472604395731,1.3155619596541788,__nan__,__nan__,__nan__,0.19010001378142657
406,AVCO,Avalon GloboCare Corp. Common Stock,"Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.",Dr. David K. Jin,Real Estate - Services,0.5259,USD,5258180,https://images.financialmodelingprep.com/symbol/AVCO.png,189950,-5.155882352941177,-0.1041,432165,-15025558,-16707010,"[{'period': '2023', 'revenue': 1.26, 'unit': 'M', 'net_profit': -16.71}, {'period': '2022', 'revenue': 1.2, 'unit': 'M', 'net_profit': -12.68}, {'period': '2021', 'revenue': 1.39, 'unit': 'M', 'net_profit': -9.23}, {'period': '2020', 'revenue': 1.38, 'unit': 'M', 'net_profit': -12.79}]","[{'period': ""Q3 '24"", 'revenue': 0.34516, 'unit': 'M', 'net_profit': -1.68}, {'period': ""Q2 '24"", 'revenue': 0.32789, 'unit': 'M', 'net_profit': -2.13}, {'period': ""Q1 '24"", 'revenue': 0.31459, 'unit': 'M', 'net_profit': -1.37}, {'period': ""Q4 '23"", 'revenue': 0.32132, 'unit': 'M', 'net_profit': -9.56}, {'period': ""Q3 '23"", 'revenue': 0.33129000000000003, 'unit': 'M', 'net_profit': -1.49}, {'period': ""Q2 '23"", 'revenue': 0.3069, 'unit': 'M', 'net_profit': -2.54}]",-1.59,-1.59,20582536,850867,285400,13213760,234660,12095020,6762686,285400,-6526877,-0.9048065644105594,-0.3175773562633349,-0.1691176470588235,__nan__,__nan__,__nan__,0.6419889172063151
407,AVCT,American Virtual Cloud Technologies Inc. Common Stock ,"American Virtual Cloud Technologies, Inc., a pure-play cloud communications and collaboration company, provides cloud-based enterprise services worldwide. The company's Kandy cloud communications platform is a cloud-based, real-time communications platform, which offers proprietary unified communications as a service, communications platform as a service, contact center as a service, Microsoft Teams Direct Routing as a Service, and SIP Trunking as a Service capabilities. Its cloud-based, real-time communications platform enables service providers, enterprises, software vendors, systems integrators, partners, and developers to enrich their applications and services with real-time contextual communications empowering the application programming interface economy. American Virtual Cloud Technologies, Inc. also has strategic partnerships with AT&T, IBM, and Etisalat to sell various solutions. The company was founded in 1987 and is based in Atlanta, Georgia.",Mr. Darrell J. Mays,Information Technology Services,0.598,USD,0,https://images.financialmodelingprep.com/symbol/AVCT.png,2857270,0,0,5956527,-57166000,-39427000,"[{'period': '2022', 'revenue': 16.81, 'unit': 'M', 'net_profit': -39.43}, {'period': '2021', 'revenue': 20.05, 'unit': 'M', 'net_profit': -162.56}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.02}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': 989.8}]","[{'period': ""Q1 '23"", 'revenue': 4.06, 'unit': 'M', 'net_profit': -9.88}, {'period': ""Q4 '22"", 'revenue': 4.25, 'unit': 'M', 'net_profit': -7.6}, {'period': ""Q3 '22"", 'revenue': 4.74, 'unit': 'M', 'net_profit': -25.55}, {'period': ""Q2 '22"", 'revenue': 3.72, 'unit': 'M', 'net_profit': 8.35}, {'period': ""Q1 '22"", 'revenue': 4.09, 'unit': 'M', 'net_profit': -14.63}, {'period': ""Q4 '21"", 'revenue': -62.19, 'unit': 'M', 'net_profit': -55.0}]",-0.0029,-0.0029,31909000,26402000,12627000,13418000,7390000,0,11104000,12627000,-64359000,0.5450522864373597,0.757460368235533,0.9999576147325344,__nan__,__nan__,__nan__,0.42050832053652576
408,AVCTW,American Virtual Cloud Technologies Inc. Warrant expiring 4/7/2025,,None,,0.0161,USD,0,https://images.financialmodelingprep.com/symbol/AVCTW.png,0,0,0,574251,-57166000,-39427000,"[{'period': '2022', 'revenue': 16.81, 'unit': 'M', 'net_profit': -39.43}, {'period': '2021', 'revenue': 20.05, 'unit': 'M', 'net_profit': -162.56}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.02}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': 989.8}]","[{'period': ""Q1 '23"", 'revenue': 4.06, 'unit': 'M', 'net_profit': -9.88}, {'period': ""Q4 '22"", 'revenue': 4.25, 'unit': 'M', 'net_profit': -7.6}, {'period': ""Q3 '22"", 'revenue': 4.74, 'unit': 'M', 'net_profit': -25.55}, {'period': ""Q2 '22"", 'revenue': 3.72, 'unit': 'M', 'net_profit': 8.35}, {'period': ""Q1 '22"", 'revenue': 4.09, 'unit': 'M', 'net_profit': -14.63}, {'period': ""Q4 '21"", 'revenue': -62.19, 'unit': 'M', 'net_profit': -55.0}]",-0.0029,-0.0029,31909000,26402000,12627000,13418000,7390000,0,11104000,12627000,-64359000,0.5450522864373597,0.757460368235533,0.9999576147325344,__nan__,__nan__,__nan__,0.42050832053652576
409,AVDL,Avadel Pharmaceuticals plc American Depositary Shares,"Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.",Mr. Gregory J. Divis Jr.,Drug Manufacturers - Specialty & Generic,10.86,USD,1046485890,https://images.financialmodelingprep.com/symbol/AVDL.png,1200512,-14.48,0.17,372099,-149125000,-160276000,"[{'period': '2023', 'revenue': 27.96, 'unit': 'M', 'net_profit': -160.28}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -137.46}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -77.33}, {'period': '2020', 'revenue': 22.33, 'unit': 'M', 'net_profit': 7.03}]","[{'period': ""Q3 '24"", 'revenue': 50.02, 'unit': 'M', 'net_profit': -2.62}, {'period': ""Q2 '24"", 'revenue': 41.5, 'unit': 'M', 'net_profit': -13.82}, {'period': ""Q1 '24"", 'revenue': 27.18, 'unit': 'M', 'net_profit': -27.34}, {'period': ""Q4 '23"", 'revenue': 19.45, 'unit': 'M', 'net_profit': -28.79}, {'period': ""Q3 '23"", 'revenue': 7.01, 'unit': 'M', 'net_profit': -36.27}, {'period': ""Q2 '23"", 'revenue': 1.5, 'unit': 'M', 'net_profit': -64.43}]",-2,-2,164698000,134202000,105111000,76959000,13425000,0,36855000,31167000,-128511000,-0.5278574648579977,-0.16594890298550893,0.12663755458515286,__nan__,__nan__,__nan__,0.46727343380004616
410,AVEO,AVEO Pharmaceuticals Inc. Common Stock,"AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.",Mr. Michael P. Bailey,Biotechnology,15,USD,0,https://images.financialmodelingprep.com/symbol/AVEO.png,564056,0,0,245298,-57387000,-61175000,"[{'period': '2021', 'revenue': 38.87, 'unit': 'M', 'net_profit': -61.17}, {'period': '2020', 'revenue': 6.02, 'unit': 'M', 'net_profit': -35.58}, {'period': '2019', 'revenue': 28.8, 'unit': 'M', 'net_profit': 9.39}, {'period': '2018', 'revenue': 5.41, 'unit': 'M', 'net_profit': -5.33}]","[{'period': ""Q3 '22"", 'revenue': 30.45, 'unit': 'M', 'net_profit': -4.36}, {'period': ""Q2 '22"", 'revenue': 25.3, 'unit': 'M', 'net_profit': -9.48}, {'period': ""Q1 '22"", 'revenue': 20.92, 'unit': 'M', 'net_profit': -11.39}, {'period': ""Q4 '21"", 'revenue': 14.22, 'unit': 'M', 'net_profit': -15.29}, {'period': ""Q3 '21"", 'revenue': 15.17, 'unit': 'M', 'net_profit': -10.37}, {'period': ""Q2 '21"", 'revenue': 7.56, 'unit': 'M', 'net_profit': -13.6}]",-2.86,-2.86,105341000,104736000,70542000,59471000,9811000,16784000,18731000,70542000,-57257000,-0.689940514753519,-0.7191715377697842,-0.7228915662650602,__nan__,__nan__,__nan__,0.5645570100910376
411,AVGO,Broadcom Inc. Common Stock,"Broadcom Inc. designs, develops, and supplies various semiconductor devices with a focus on complex digital and mixed signal complementary metal oxide semiconductor based devices and analog III-V based products worldwide. The company operates in two segments, Semiconductor Solutions and Infrastructure Software. It provides set-top box system-on-chips (SoCs); cable, digital subscriber line, and passive optical networking central office/consumer premise equipment SoCs; wireless local area network access point SoCs; Ethernet switching and routing merchant silicon products; embedded processors and controllers; serializer/deserializer application specific integrated circuits; optical and copper, and physical layers; and fiber optic transmitter and receiver components. The company also offers RF front end modules, filters, and power amplifiers; Wi-Fi, Bluetooth, and global positioning system/global navigation satellite system SoCs; custom touch controllers; serial attached small computer system interface, and redundant array of independent disks controllers and adapters; peripheral component interconnect express switches; fiber channel host bus adapters; read channel based SoCs; custom flash controllers; preamplifiers; and optocouplers, industrial fiber optics, and motion control encoders and subsystems. Its products are used in various applications, including enterprise and data center networking, home connectivity, set-top boxes, broadband access, telecommunication equipment, smartphones and base stations, data center servers and storage systems, factory automation, power generation and alternative energy systems, and electronic displays. Broadcom Inc. was incorporated in 2018 and is headquartered in San Jose, California.",Mr. Hock E. Tan,Semiconductors,231.68,USD,1085967564800,https://images.financialmodelingprep.com/symbol/AVGO.png,28381453,181,-4.73,12570946,23722000000,5895000000,"[{'period': '2024', 'revenue': 51.57, 'unit': 'B', 'net_profit': 5.89}, {'period': '2023', 'revenue': 35.82, 'unit': 'B', 'net_profit': 14.08}, {'period': '2022', 'revenue': 33.2, 'unit': 'B', 'net_profit': 11.49}, {'period': '2021', 'revenue': 27.45, 'unit': 'B', 'net_profit': 6.74}]","[{'period': ""Q4 '24"", 'revenue': 14.05, 'unit': 'B', 'net_profit': 4.32}, {'period': ""Q3 '24"", 'revenue': 13.07, 'unit': 'B', 'net_profit': -1.88}, {'period': ""Q2 '24"", 'revenue': 12.49, 'unit': 'B', 'net_profit': 2.12}, {'period': ""Q1 '24"", 'revenue': 11.96, 'unit': 'B', 'net_profit': 1.32}, {'period': ""Q4 '23"", 'revenue': 9.29, 'unit': 'B', 'net_profit': 3.52}, {'period': ""Q3 '23"", 'revenue': 8.88, 'unit': 'B', 'net_profit': 3.3}]",1.33,1.29,165645000000,19595000000,9348000000,97967000000,4416000000,0,16697000000,9348000000,19414000000,0.15413058285491876,-0.5813804857264593,-0.6076696165191741,"[0.59, 0.07]","['2024-12-23', '2010-12-13']",__nan__,0.5914274502701561
412,AVGOP,Broadcom Inc. 8.00% Mandatory Convertible Preferred Stock Series A,"Broadcom Inc. designs, develops, and supplies various semiconductor devices with a focus on complex digital and mixed signal complementary metal oxide semiconductor based devices and analog III-V based products worldwide. The company operates in two segments, Semiconductor Solutions and Infrastructure Software. It provides set-top box system-on-chips (SoCs); cable, digital subscriber line, and passive optical networking central office/consumer premise equipment SoCs; wireless local area network access point SoCs; Ethernet switching and routing merchant silicon products; embedded processors and controllers; serializer/deserializer application specific integrated circuits; optical and copper, and physical layers; and fiber optic transmitter and receiver components. The company also offers RF front end modules, filters, and power amplifiers; Wi-Fi, Bluetooth, and global positioning system/global navigation satellite system SoCs; custom touch controllers; serial attached small computer system interface, and redundant array of independent disks controllers and adapters; peripheral component interconnect express switches; fiber channel host bus adapters; read channel based SoCs; custom flash controllers; preamplifiers; and optocouplers, industrial fiber optics, and motion control encoders and subsystems. Its products are used in various applications, including enterprise and data center networking, home connectivity, set-top boxes, broadband access, telecommunication equipment, smartphones and base stations, data center servers and storage systems, factory automation, power generation and alternative energy systems, and electronic displays. Broadcom Inc. was incorporated in 2018 and is headquartered in San Jose, California.",Mr. Hock E. Tan,Semiconductors,1406.7,USD,0,https://images.financialmodelingprep.com/symbol/AVGOP.png,0,0,-37.3201,36980,23722000000,5895000000,"[{'period': '2024', 'revenue': 51.57, 'unit': 'B', 'net_profit': 5.89}, {'period': '2023', 'revenue': 35.82, 'unit': 'B', 'net_profit': 14.08}, {'period': '2022', 'revenue': 33.2, 'unit': 'B', 'net_profit': 11.49}, {'period': '2021', 'revenue': 27.45, 'unit': 'B', 'net_profit': 6.74}]","[{'period': ""Q4 '24"", 'revenue': 14.05, 'unit': 'B', 'net_profit': 4.32}, {'period': ""Q3 '24"", 'revenue': 13.07, 'unit': 'B', 'net_profit': -1.88}, {'period': ""Q2 '24"", 'revenue': 12.49, 'unit': 'B', 'net_profit': 2.12}, {'period': ""Q1 '24"", 'revenue': 11.96, 'unit': 'B', 'net_profit': 1.32}, {'period': ""Q4 '23"", 'revenue': 9.29, 'unit': 'B', 'net_profit': 3.52}, {'period': ""Q3 '23"", 'revenue': 8.88, 'unit': 'B', 'net_profit': 3.3}]",1.33,1.29,165645000000,19595000000,9348000000,97967000000,4416000000,0,16697000000,9348000000,19414000000,0.15413058285491876,-0.5813804857264593,-0.6076696165191741,"[20, 20]","['2022-09-14', '2019-12-12']",__nan__,0.5914274502701561
413,AVGR,Avinger Inc. Common Stock,"Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.",Mr. Himanshu N. Patel,Medical - Instruments & Supplies,0.73,USD,2415884,https://images.financialmodelingprep.com/symbol/AVGR.png,2066359,-0.08,-0.04,221608,-16346000,-18320000,"[{'period': '2023', 'revenue': 7.65, 'unit': 'M', 'net_profit': -18.32}, {'period': '2022', 'revenue': 8.27, 'unit': 'M', 'net_profit': -17.43}, {'period': '2021', 'revenue': 10.13, 'unit': 'M', 'net_profit': -20.71}, {'period': '2020', 'revenue': 8.76, 'unit': 'M', 'net_profit': -19.82}]","[{'period': ""Q3 '24"", 'revenue': 1.65, 'unit': 'M', 'net_profit': -3.71}, {'period': ""Q2 '24"", 'revenue': 1.85, 'unit': 'M', 'net_profit': -4.36}, {'period': ""Q1 '24"", 'revenue': 1.86, 'unit': 'M', 'net_profit': -5.52}, {'period': ""Q4 '23"", 'revenue': 1.91, 'unit': 'M', 'net_profit': -5.02}, {'period': ""Q3 '23"", 'revenue': 1.82, 'unit': 'M', 'net_profit': -2.04}, {'period': ""Q2 '23"", 'revenue': 2.04, 'unit': 'M', 'net_profit': -4.18}]",-23.31,-23.31,13770000,12162000,5275000,19972000,1014000,0,19300000,5275000,-14440000,-0.03711693420468244,-0.051242325127675445,0.4427444417881903,__nan__,__nan__,__nan__,1.45039941902687
414,AVID,Avid Technology Inc. Common Stock,"Avid Technology, Inc., together with its subsidiaries, develops, markets, sells, and supports software and integrated solutions for video and audio content creation, management, and distribution worldwide. The company's video products and solutions include the Media Composer, a cloud-enabled solution used to edit video content; Avid NEXIS shared storage systems; Maestro solutions for the integration of virtual sets, augmented reality, and video wall control into existing workflows; AirSpeed 5000 and AirSpeed 5500 on-air server solutions; and MediaCentral, a media production suite. Its audio products and solutions comprise Pro Tools digital audio software solutions to facilitate the audio production process; Sibelius solution to create, edit, and publish musical scores; S6 line of complementary control surfaces and consoles; S1 and S4 audio control surfaces; and VENUE | S6L live sound system for mixing audio for live sound reinforcement. The company also provides Avid Link, a mobile application to connect with other artists, producers, mixers, composers, editors, videographers, movie makers, and graphic designers; FastServe video server that assists broadcasters in making the move to UHD and IP based workflows with a new and modular architecture; and hardware products, such as I/O devices, interfaces, and audio and video processing equipment. In addition, it offers various maintenance contracts and support services; professional services, such as workflow design and consulting, program and project management, system installation and commissioning, and custom development and role-based product level training; and public and private training to customers and alliance partners, as well as develops and licenses curriculum content for use by third party Avid Learning partners to deliver training to customers, users, and alliance partners. The company was incorporated in 1987 and is headquartered in Burlington, Massachusetts.",Mr. Jeffrey  Rosica,Electronic Gaming & Multimedia,27.045,USD,1191107777,https://images.financialmodelingprep.com/symbol/AVID.png,676342,37.5625,0.005,412361,63524000,55241000,"[{'period': '2022', 'revenue': 417.41, 'unit': 'M', 'net_profit': 55.24}, {'period': '2021', 'revenue': 409.94, 'unit': 'M', 'net_profit': 41.39}, {'period': '2020', 'revenue': 360.47, 'unit': 'M', 'net_profit': 11.06}, {'period': '2019', 'revenue': 411.79, 'unit': 'M', 'net_profit': 7.6}]","[{'period': ""Q3 '23"", 'revenue': 91.01, 'unit': 'M', 'net_profit': -7.33}, {'period': ""Q2 '23"", 'revenue': 108.54, 'unit': 'M', 'net_profit': -4.6}, {'period': ""Q1 '23"", 'revenue': 97810.0, 'unit': 'K', 'net_profit': -381.0}, {'period': ""Q4 '22"", 'revenue': 116.1, 'unit': 'M', 'net_profit': 25.26}, {'period': ""Q3 '22"", 'revenue': 102.98, 'unit': 'M', 'net_profit': 12.02}, {'period': ""Q2 '22"", 'revenue': 97.68, 'unit': 'M', 'net_profit': 7.37}]",1.24,1.23,287453000,178971000,35247000,406235000,109144000,0,190617000,35247000,32768000,0.05043489764196184,0.3347105441190683,0.3478260869565217,__nan__,__nan__,__nan__,1.413222335477452
415,AVIR,Atea Pharmaceuticals Inc. Common Stock,"Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.",Dr. Jean-Pierre  Sommadossi Ph.D.,Biotechnology,3.39,USD,286329909,https://images.financialmodelingprep.com/symbol/AVIR.png,302390,-1.64,-0.01,77095,-119593000,-135956000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -135.96}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -115.91}, {'period': '2021', 'revenue': 351.37, 'unit': 'M', 'net_profit': 121.19}, {'period': '2020', 'revenue': 48.63, 'unit': 'M', 'net_profit': -10.86}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.15}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -40.52}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -63.17}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -39.16}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -33.14}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.18}]",-1.63,-1.63,594968000,590455000,578106000,39776000,0,0,32375999,143823000,-85395000,-0.07893074952185053,-0.17295464545462388,-0.17266187050359713,__nan__,__nan__,__nan__,0.06685401567815412
416,AVNW,Aviat Networks Inc. Common Stock,"Aviat Networks, Inc. provides wireless transport solutions worldwide. It offers a comprehensive suite of products and localized professional and support services enabling customers to simplify their networks and lives. The company's products and solutions include wireless transmission systems for microwave and millimeter wave networking applications. It serves communications service providers and private network operators, including state/local government, utility, federal government, and defense organizations. The company markets its products through a direct sales, service, and support organization; indirect sales channels comprising dealers, resellers, and sales representatives; and through online. Aviat Networks, Inc. was incorporated in 2006 and is headquartered in Austin, Texas.",Mr. Peter A. Smith Ph.D.,Communication Equipment,19.0875,USD,242228010,https://images.financialmodelingprep.com/symbol/AVNW.png,229279,-50.23,-0.2925,128792,28261000,10760000,"[{'period': '2024', 'revenue': 408.08, 'unit': 'M', 'net_profit': 10.76}, {'period': '2023', 'revenue': 346.59, 'unit': 'M', 'net_profit': 11.53}, {'period': '2022', 'revenue': 302.96, 'unit': 'M', 'net_profit': 21.16}, {'period': '2021', 'revenue': 274.91, 'unit': 'M', 'net_profit': 110.14}]","[{'period': ""Q1 '25"", 'revenue': 88.43, 'unit': 'M', 'net_profit': -11.88}, {'period': ""Q4 '24"", 'revenue': 113870.0, 'unit': 'K', 'net_profit': 447.0}, {'period': ""Q3 '24"", 'revenue': 111.61, 'unit': 'M', 'net_profit': 3.42}, {'period': ""Q2 '24"", 'revenue': 95.04, 'unit': 'M', 'net_profit': 2.89}, {'period': ""Q1 '24"", 'revenue': 87.57, 'unit': 'M', 'net_profit': 4.0}, {'period': ""Q4 '23"", 'revenue': 91.18, 'unit': 'M', 'net_profit': 3.34}]",0.88,0.86,535223000,405223000,64622000,279338000,248538000,0,218857000,64622000,27865000,-0.16414776256247968,-0.06662040249826509,-0.12871287128712872,__nan__,__nan__,__nan__,0.521909559193084
417,AVO,Mission Produce Inc. Common Stock,"Mission Produce, Inc. engages in sourcing, producing, packaging, and distributing avocados in the United States and internationally. The company operates through two segments, Marketing and Distribution, and International Farming. It also provides value-added services, including ripening, bagging, custom packing, and logistical management. The company serves retail, wholesale, and foodservice customers. The company was founded in 1983 and is headquartered in Oxnard, California.",Mr. Stephen J. Barnard,Food Distribution,12.83,USD,909836884,https://images.financialmodelingprep.com/symbol/AVO.png,0,24.67,-0.37,121156,110700000,36700000,"[{'period': '2024', 'revenue': 1230.0, 'unit': 'M', 'net_profit': 36.7}, {'period': '2023', 'revenue': 953.9, 'unit': 'M', 'net_profit': -2.8}, {'period': '2022', 'revenue': 1050.0, 'unit': 'M', 'net_profit': -34.9}, {'period': '2021', 'revenue': 891.7, 'unit': 'M', 'net_profit': 44.9}]","[{'period': ""Q4 '24"", 'revenue': 354.4, 'unit': 'M', 'net_profit': 17.3}, {'period': ""Q3 '24"", 'revenue': 324.0, 'unit': 'M', 'net_profit': 12.4}, {'period': ""Q2 '24"", 'revenue': 297.6, 'unit': 'M', 'net_profit': 7.0}, {'period': ""Q1 '24"", 'revenue': 258.7, 'unit': 'M', 'net_profit': 2.0}, {'period': ""Q4 '23"", 'revenue': 257.9, 'unit': 'M', 'net_profit': 3.7}, {'period': ""Q3 '23"", 'revenue': 261.4, 'unit': 'M', 'net_profit': 6.6}]",0.52,0.52,971500000,279000000,58000000,394400000,-1700000,0,149100000,58000000,61200000,1.5448275862068965,14.107142857142858,14.13131313131313,__nan__,__nan__,__nan__,0.4059701492537313
418,AVRO,AVROBIO Inc. Common Stock,"AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",Mr. Erik John Ostrowski M.B.A.,Biotechnology,1.4,USD,5237596,https://images.financialmodelingprep.com/symbol/AVRO.png,19048,0.16908212560386474,-0.02,204382,-71050000,12157000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': 12.16}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -106.05}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -117.73}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -118.5}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.81}, {'period': ""Q4 '23"", 'revenue': 3.6, 'unit': 'M', 'net_profit': -8.79}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.58}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 67.48}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.12}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 32.57}]",0.27,0.27,101093000,100261000,98303000,6354000,0,400000,6354000,98303000,-63198000,0.3261187093347497,1.1146378492555187,1.1115702479338843,__nan__,__nan__,__nan__,0.06285301652933438
419,AVT,Avnet Inc. Common Stock,"Avnet, Inc., a technology solutions company, markets, sells, and distributes electronic components. The company operates through two segments, Electronic Components and Farnell. The Electronic Components segment markets, sells, and distributes semiconductors; interconnect, passive, and electromechanical devices; and other integrated components from electronic component manufacturers. It also offers design chain support that provides engineers with technical design solutions; engineering and technical resources to support product design, bill of materials development, and technical education and training; and supply chain solutions that provide support and logistical services to original equipment manufacturers, electronic manufacturing service providers, and electronic component manufacturers. In addition, this segment provides integrated solutions, such as technical design, integration, and assembly of embedded products, and systems and solutions primarily for industrial applications, as well as for intelligent and innovative embedded display solutions comprising touch and passive displays. Further, it develops and manufactures standard board and industrial subsystems, and application-specific devices that enable it to produce systems tailored to specific customer requirements. This segment serves various markets, such as automotive, medical, defense, aerospace, telecommunications, industrial, and digital editing. The Farnell segment distributes kits, tools, and electronic and industrial automation components, as well as test and measurement products to engineers and entrepreneurs. It has operations in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Avnet, Inc. was founded in 1921 and is headquartered in Phoenix, Arizona.",Mr. Philip R. Gallagher,Technology Distributors,52.59,USD,4572227190,https://images.financialmodelingprep.com/symbol/AVT.png,736570,13.7,0.39,163383,1055626000,498699000,"[{'period': '2024', 'revenue': 23760.0, 'unit': 'M', 'net_profit': 498.7}, {'period': '2023', 'revenue': 26540.0, 'unit': 'M', 'net_profit': 770.83}, {'period': '2022', 'revenue': 24310.0, 'unit': 'M', 'net_profit': 692.38}, {'period': '2021', 'revenue': 19530.0, 'unit': 'M', 'net_profit': 193.11}]","[{'period': ""Q1 '25"", 'revenue': 5600.0, 'unit': 'M', 'net_profit': 58.96}, {'period': ""Q4 '24"", 'revenue': 5560.0, 'unit': 'M', 'net_profit': 82.67}, {'period': ""Q3 '24"", 'revenue': 5650.0, 'unit': 'M', 'net_profit': 88.83}, {'period': ""Q2 '24"", 'revenue': 6200.0, 'unit': 'M', 'net_profit': 117.93}, {'period': ""Q1 '24"", 'revenue': 6340.0, 'unit': 'M', 'net_profit': 209.27}, {'period': ""Q4 '23"", 'revenue': 6550.0, 'unit': 'M', 'net_profit': 155.26}]",5.51,5.43,12209147000,10370552000,310941000,7283643000,4391187000,0,4465269000,310941000,463506000,-0.23324786635191574,-0.3530346588343963,-0.34169653524492233,"[0.33, 0.25]","['2024-12-04', '1982-03-01']",__nan__,0.596572635254535
420,AVXL,Anavex Life Sciences Corp. Common Stock,"Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.","Dr. Christopher U. Missling M.B.A., M.S., Ph.D.",Biotechnology,13.7899,USD,1169597263,https://images.financialmodelingprep.com/symbol/AVXL.png,0,-26.47,0.655,973903,0,-43002000,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -43.0}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -47.51}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -47.98}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -37.91}]","[{'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.62}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.21}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.55}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.62}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.15}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.28}]",-0.52,-0.52,135567000,135567000,132187000,15304000,2449000,0,15304000,132187000,-30812000,1,0.09479002210293654,0.13333333333333328,__nan__,__nan__,__nan__,0.11288882987747756
421,AWH,Aspira Women's Health Inc. Common Stock,"Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.",Ms. Nicole  Sandford CPA,Medical - Diagnostics & Research,0.7501,USD,12502142,https://images.financialmodelingprep.com/symbol/AWH.png,102474,-0.65,0.0001,25015,-16491000,-16690000,"[{'period': '2023', 'revenue': 9.15, 'unit': 'M', 'net_profit': -16.69}, {'period': '2022', 'revenue': 8.18, 'unit': 'M', 'net_profit': -21.57}, {'period': '2021', 'revenue': 6.81, 'unit': 'M', 'net_profit': -31.71}, {'period': '2020', 'revenue': 4.65, 'unit': 'M', 'net_profit': -17.63}]","[{'period': ""Q3 '24"", 'revenue': 2.26, 'unit': 'M', 'net_profit': -3.55}, {'period': ""Q2 '24"", 'revenue': 2.42, 'unit': 'M', 'net_profit': -3.53}, {'period': ""Q1 '24"", 'revenue': 2.15, 'unit': 'M', 'net_profit': -4.63}, {'period': ""Q4 '23"", 'revenue': 2.13, 'unit': 'M', 'net_profit': -3.09}, {'period': ""Q3 '23"", 'revenue': 2.22, 'unit': 'M', 'net_profit': -4.71}, {'period': ""Q2 '23"", 'revenue': 2.49, 'unit': 'M', 'net_profit': -2.32}]",-1.81,-1.81,6262000,5280000,2597000,8627000,1459000,0,5119000,2597000,-15918000,0.4658612424693917,0.22641946697566628,0.956553048487758,"[0.0173, 0.012]","['2016-12-16', '2009-05-21']",__nan__,1.3776748642606196
422,AWRE,Aware Inc. Common Stock,"Aware, Inc. provides biometrics software products and solutions in the United States, Brazil, the United Kingdom, and internationally. It offers biometrics software products, including biometric search and matching software development kits (SDKs); biometric enrollment SDKs and application programming interfaces (APIs); and imaging products for medical and advanced imaging applications, such as JPEG2000 product to compress, store, and display images, as well as software maintenance services. The company also provides Knomi mobile biometric authentication framework; AwareABIS, an automated biometric identification system; AFIX suite of products for small-scale law enforcement focused biometric identification; BioSP, a biometric services platform; WebEnroll, a browser-based biometric enrollment and data management solution; AwareID, a software-as-a-service that provides biometric face and voice analysis for liveness-verification, and document validation; and Fortress Identity Biometric Authenticator and Onboarding Authentication Platform, which offers multi-factor authentication through passive and active biometrics for multiple modalities, including voice, fingerprint, face, and behavior to enable online onboarding and identity proofing. In addition, it offers program management and software engineering services, including project planning and management; system and architecture design; software design, development, customization, configuration, and testing; and software integration and installation. The company's software portfolio enables government agencies and commercial entities to enroll, identify, authenticate, and enable using biometrics, such as fingerprints, faces, irises, and voices. The company sells its products through systems integrators, original equipment manufacturers, value added resellers, and partners, as well as directly to end user customers. Aware, Inc. was incorporated in 1986 and is headquartered in Bedford, Massachusetts.",Mr. Robert A. Eckel,Software - Application,1.67,USD,35410513,https://images.financialmodelingprep.com/symbol/AWRE.png,63538,-4.77,-0.01,14511,-6079000,-7314000,"[{'period': '2023', 'revenue': 18.24, 'unit': 'M', 'net_profit': -7.31}, {'period': '2022', 'revenue': 16.01, 'unit': 'M', 'net_profit': -1.73}, {'period': '2021', 'revenue': 16.85, 'unit': 'M', 'net_profit': -5.82}, {'period': '2020', 'revenue': 11.31, 'unit': 'M', 'net_profit': -7.61}]","[{'period': ""Q3 '24"", 'revenue': 3.85, 'unit': 'M', 'net_profit': -1.17}, {'period': ""Q2 '24"", 'revenue': 4.32, 'unit': 'M', 'net_profit': -1.09}, {'period': ""Q1 '24"", 'revenue': 4420.0, 'unit': 'K', 'net_profit': -982.0}, {'period': ""Q4 '23"", 'revenue': 4.37, 'unit': 'M', 'net_profit': -4.24}, {'period': ""Q3 '23"", 'revenue': 6.38, 'unit': 'M', 'net_profit': 1.14}, {'period': ""Q2 '23"", 'revenue': 3.18, 'unit': 'M', 'net_profit': -2.65}]",-0.35,-0.35,46296000,35824000,30915000,11998000,3855000,0,7549000,10002000,1807000,0.15989496959646213,-3.2375434530706837,-3.3749999999999996,"[1.75, 1.15]","['2014-07-25', '2012-05-09']",__nan__,0.2591584586141351
423,AXAS,Abraxas Petroleum Corporation Common Stock,"Abraxas Petroleum Corporation, an independent energy company, engages in the acquisition, exploration, exploitation, development, and production of oil and gas properties in the United States. The company operates oil and gas assets in the Permian/Delaware Basin and the Rocky Mountain regions. As of December 31, 2021, its estimated net proved reserves were 14.8 million barrels of oil equivalent. The company was founded in 1977 and is based in San Antonio, Texas.",Mr. Stephen T. Wendel,Oil & Gas Exploration & Production,0.0347,USD,10271546,https://images.financialmodelingprep.com/symbol/AXAS.png,10824,0.07081632653061225,-0.0673,683,21455000,59653000,"[{'period': '2022', 'revenue': 49.74, 'unit': 'M', 'net_profit': 59.65}, {'period': '2021', 'revenue': 78.86, 'unit': 'M', 'net_profit': -80.34}, {'period': '2020', 'revenue': 43.04, 'unit': 'M', 'net_profit': -205.73}, {'period': '2019', 'revenue': 129.15, 'unit': 'M', 'net_profit': -77.73}]","[{'period': ""Q4 '22"", 'revenue': 9.76, 'unit': 'M', 'net_profit': -24.99}, {'period': ""Q3 '22"", 'revenue': 13.25, 'unit': 'M', 'net_profit': 2.43}, {'period': ""Q2 '22"", 'revenue': 14.54, 'unit': 'M', 'net_profit': 6.75}, {'period': ""Q1 '22"", 'revenue': 12.19, 'unit': 'M', 'net_profit': 40.06}, {'period': ""Q4 '21"", 'revenue': 22.88, 'unit': 'M', 'net_profit': -19.66}, {'period': ""Q3 '21"", 'revenue': 20.86, 'unit': 'M', 'net_profit': -1.25}]",2.31,2.31,70547000,11213000,2876000,9410000,4878000,15091000,6369000,2876000,18768000,-0.4169044707161299,1.7425068459049042,1.24163179916318,__nan__,__nan__,__nan__,0.13338625313620706
424,AXDX,Accelerate Diagnostics Inc. Common Stock,"Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.",Mr. Jack  Phillips,Medical - Devices,1.16,USD,29050808,https://images.financialmodelingprep.com/symbol/AXDX.png,67390,-0.45,-0.06,12223,-49771000,-61618000,"[{'period': '2023', 'revenue': 12.06, 'unit': 'M', 'net_profit': -61.62}, {'period': '2022', 'revenue': 12.75, 'unit': 'M', 'net_profit': -62.49}, {'period': '2021', 'revenue': 11.78, 'unit': 'M', 'net_profit': -77.7}, {'period': '2020', 'revenue': 11.16, 'unit': 'M', 'net_profit': -78.21}]","[{'period': ""Q3 '24"", 'revenue': 2.98, 'unit': 'M', 'net_profit': -14.64}, {'period': ""Q2 '24"", 'revenue': 2.99, 'unit': 'M', 'net_profit': -11.59}, {'period': ""Q1 '24"", 'revenue': 2.92, 'unit': 'M', 'net_profit': -14.23}, {'period': ""Q4 '23"", 'revenue': 3.0, 'unit': 'M', 'net_profit': -13.0}, {'period': ""Q3 '23"", 'revenue': 3300.0, 'unit': 'K', 'net_profit': 910.0}, {'period': ""Q2 '23"", 'revenue': 2.92, 'unit': 'M', 'net_profit': -25.98}]",-4.94,-4.94,31366000,24466000,13219000,51254000,2622000,0,12034000,12138000,-41230999,0.10803060986756036,0.014001568175635672,0.3508541392904073,__nan__,__nan__,__nan__,1.634062360517758
425,AXGN,Axogen Inc. Common Stock,"AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.","Mr. Nir  Naor C.F.A., CPA, L.L.M., M.B.A.",Medical - Devices,14.1,USD,620517030,https://images.financialmodelingprep.com/symbol/AXGN.png,381093,-42.73,-0.46,127335,-13328000,-21716000,"[{'period': '2023', 'revenue': 159.01, 'unit': 'M', 'net_profit': -21.72}, {'period': '2022', 'revenue': 138.58, 'unit': 'M', 'net_profit': -27.34}, {'period': '2021', 'revenue': 127.36, 'unit': 'M', 'net_profit': -28.06}, {'period': '2020', 'revenue': 112.3, 'unit': 'M', 'net_profit': -24.8}]","[{'period': ""Q3 '24"", 'revenue': 48.64, 'unit': 'M', 'net_profit': -1.86}, {'period': ""Q2 '24"", 'revenue': 47.91, 'unit': 'M', 'net_profit': -1.92}, {'period': ""Q1 '24"", 'revenue': 41.38, 'unit': 'M', 'net_profit': -6.63}, {'period': ""Q4 '23"", 'revenue': 42.92, 'unit': 'M', 'net_profit': -3.89}, {'period': ""Q3 '23"", 'revenue': 41.27, 'unit': 'M', 'net_profit': -4.09}, {'period': ""Q2 '23"", 'revenue': 38.16, 'unit': 'M', 'net_profit': -6.66}]",-0.51,-0.51,196827000,88004000,31024000,101162000,25147000,0,30430000,31024000,-20634000,0.4321503131524008,0.20556063654655204,0.2153846153846154,"[1, 0.04172]","['2010-01-27', '1992-07-10']",__nan__,0.5139640394864525
426,AXLA,Axcella Health Inc. Common Stock,"Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.",Mr. Craig R. Jalbert CIRA,Biotechnology,4.58,USD,0,https://images.financialmodelingprep.com/symbol/AXLA.png,0,-0.25095890410958904,4.1791,0,-67009000,-81186000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -81.19}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -67.12}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -58.81}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -59.97}]","[{'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.41}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.77}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.26}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.59}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.99}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.75}]",-1.49,-1.49,18927000,17147000,17147000,14763000,0,0,14148000,17147000,-70014000,-0.08348155094913172,-0.2096010012217289,0.1534090909090909,__nan__,__nan__,__nan__,0.7799968299255032
427,AXNX,Axonics Inc. Common Stock,"Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.",Mr. Raymond W. Cohen,Medical - Devices,70.98,USD,3627731016,https://images.financialmodelingprep.com/symbol/AXNX.png,0,-709.8,,0,7775000,-6088000,"[{'period': '2023', 'revenue': 366.38, 'unit': 'M', 'net_profit': -6.09}, {'period': '2022', 'revenue': 273.7, 'unit': 'M', 'net_profit': -59.7}, {'period': '2021', 'revenue': 180.29, 'unit': 'M', 'net_profit': -80.07}, {'period': '2020', 'revenue': 111.53, 'unit': 'M', 'net_profit': -54.91}]","[{'period': ""Q3 '24"", 'revenue': 116190.0, 'unit': 'K', 'net_profit': -21.0}, {'period': ""Q2 '24"", 'revenue': 114.56, 'unit': 'M', 'net_profit': 6.9}, {'period': ""Q1 '24"", 'revenue': 91.41, 'unit': 'M', 'net_profit': -19.11}, {'period': ""Q4 '23"", 'revenue': 109.73, 'unit': 'M', 'net_profit': 6.57}, {'period': ""Q3 '23"", 'revenue': 93.1, 'unit': 'M', 'net_profit': 3.93}, {'period': ""Q2 '23"", 'revenue': 22.7, 'unit': 'M', 'net_profit': -7.34}]",-0.12,-0.12,719923000,491422000,344960000,82359000,57243000,0,45816000,104811000,-5566000,1.1648607959966921,0.898020034171999,0.9062500000000001,__nan__,__nan__,__nan__,0.11439973441604172
428,AXON,Axon Enterprise Inc. Common Stock,"Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include TASER 7, TASER X26P, TASER X2, TASER Consumer devices, and related cartridges; on-officer body cameras, Axon Fleet in-car systems, and other devices; Axon Evidence digital evidence management software; Axon Signal enabled devices, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. It sells its products through its direct sales force, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand the capabilities of Axon Respond and the Fusus Real Time Crime Center in the Cloud solution to provide agencies real-time operations situational awareness, including streamlined investigative workflows. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.",Mr. Patrick W. Smith,Aerospace & Defense,560.99,USD,42778180252,https://images.financialmodelingprep.com/symbol/AXON.png,893351,145.71,-9.72,365154,194633000,174227000,"[{'period': '2023', 'revenue': 1560.0, 'unit': 'M', 'net_profit': 174.23}, {'period': '2022', 'revenue': 1190.0, 'unit': 'M', 'net_profit': 147.14}, {'period': '2021', 'revenue': 863.38, 'unit': 'M', 'net_profit': -60.02}, {'period': '2020', 'revenue': 681.0, 'unit': 'M', 'net_profit': -1.72}]","[{'period': ""Q3 '24"", 'revenue': 544.27, 'unit': 'M', 'net_profit': 67.03}, {'period': ""Q2 '24"", 'revenue': 504.1, 'unit': 'M', 'net_profit': 40.8}, {'period': ""Q1 '24"", 'revenue': 460.74, 'unit': 'M', 'net_profit': 133.22}, {'period': ""Q4 '23"", 'revenue': 432.14, 'unit': 'M', 'net_profit': 57.27}, {'period': ""Q3 '23"", 'revenue': 413.6, 'unit': 'M', 'net_profit': 59.4}, {'period': ""Q2 '23"", 'revenue': 374.61, 'unit': 'M', 'net_profit': 12.42}]",2.35,2.31,3436845000,2396649000,1320539000,1824811000,693469000,231730000,799969000,598545000,128993000,-0.1449363863213018,0.18409802975417802,0.13526570048309192,__nan__,__nan__,__nan__,0.5309552802061193
429,AXSM,Axsome Therapeutics Inc. Common Stock,"Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.",Dr. Herriot  Tabuteau M.D.,Biotechnology,86.55,USD,4194420720,https://images.financialmodelingprep.com/symbol/AXSM.png,582101,-13.36,1.42,132279,-224991000,-239238000,"[{'period': '2023', 'revenue': 270.6, 'unit': 'M', 'net_profit': -239.24}, {'period': '2022', 'revenue': 50.04, 'unit': 'M', 'net_profit': -197.77}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -134.94}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -105.39}]","[{'period': ""Q3 '24"", 'revenue': 104.76, 'unit': 'M', 'net_profit': -64.6}, {'period': ""Q2 '24"", 'revenue': 87.17, 'unit': 'M', 'net_profit': -79.34}, {'period': ""Q1 '24"", 'revenue': 75.0, 'unit': 'M', 'net_profit': -68.36}, {'period': ""Q4 '23"", 'revenue': 71.53, 'unit': 'M', 'net_profit': -98.65}, {'period': ""Q3 '23"", 'revenue': 57.79, 'unit': 'M', 'net_profit': -62.2}, {'period': ""Q2 '23"", 'revenue': 46.7, 'unit': 'M', 'net_profit': -67.17}]",-5.27,-5.27,588236000,504263000,386193000,397259000,94820000,0,138854000,386193000,-145662000,-0.2913085911235616,-0.2096994578105368,-0.08436213991769531,__nan__,__nan__,__nan__,0.6753394895926125
430,AXTI,AXT Inc Common Stock,"AXT, Inc. designs, develops, manufactures, and distributes compound and single element semiconductor substrates. It produces semiconductor substrates using its proprietary vertical gradient freeze technology. The company offers indium phosphide for use in data center connectivity using light/lasers, 5G communications, fiber optic lasers and detectors, passive optical networks, silicon photonics, photonic integrated circuits, terrestrial solar cells, RF amplifier and switching, infrared light-emitting diode (LEDS) motion control, lidar for robotics and autonomous vehicles, and infrared thermal imaging. It also provides semi-insulating gallium arsenide (GaAs) substrates for use in Wi-Fi and IoT devices, transistors, direct broadcast television, power amplifiers, satellite communications, and solar cells; and semi-conducting GaAs substrates that are used in LED, screen displays, printer head lasers and LEDs, 3-D sensing using VCSELs, data center communication using VCSELs, sensors for industrial robotics/near-infrared sensors, optical couplers, solar cells, night vision goggles, lidar for robotics and autonomous vehicles, and other lasers, as well as laser machining, cutting, and drilling. In addition, the company offers germanium substrates for use in multi-junction solar cells for satellites, optical sensors and detectors, terrestrial concentrated photo voltaic cells, infrared detectors, and carrier wafer for LED. Further, it provides 6N+ and 7N+ purified gallium, boron trioxide, gallium-magnesium alloy, pyrolytic boron nitride (pBN) crucibles, and pBN insulating parts. AXT, Inc. sells its products through direct salesforce in the United States, China, and Europe, as well as through independent sales representatives and distributors in Japan, Taiwan, Korea, and internationally. The company was formerly known as American Xtal Technology, Inc. and changed its name to AXT, Inc. in July 2000. AXT, Inc. was incorporated in 1986 and is headquartered in Fremont, California.",Dr. Morris S. Young Ph.D.,Semiconductors,2.22,USD,99346332,https://images.financialmodelingprep.com/symbol/AXTI.png,376304,-9.65,-0.03,79014,-8784000,-17881000,"[{'period': '2023', 'revenue': 75.8, 'unit': 'M', 'net_profit': -17.88}, {'period': '2022', 'revenue': 141.12, 'unit': 'M', 'net_profit': 15.81}, {'period': '2021', 'revenue': 137.39, 'unit': 'M', 'net_profit': 14.57}, {'period': '2020', 'revenue': 95.36, 'unit': 'M', 'net_profit': 5.04}]","[{'period': ""Q3 '24"", 'revenue': 23.64, 'unit': 'M', 'net_profit': -2.94}, {'period': ""Q2 '24"", 'revenue': 27.92, 'unit': 'M', 'net_profit': -1.52}, {'period': ""Q1 '24"", 'revenue': 22.69, 'unit': 'M', 'net_profit': -2.08}, {'period': ""Q4 '23"", 'revenue': 20.43, 'unit': 'M', 'net_profit': -3.62}, {'period': ""Q3 '23"", 'revenue': 17.37, 'unit': 'M', 'net_profit': -5.82}, {'period': ""Q2 '23"", 'revenue': 18.59, 'unit': 'M', 'net_profit': -5.09}]",-0.42,-0.42,358701000,170656000,39892000,89555000,19256000,12476000,81557000,37752000,-7072000,-1.4249020461471484,-2.130921510340902,-2.135135135135135,__nan__,__nan__,__nan__,0.24966476257384285
431,AY,Atlantica Sustainable Infrastructure plc Ordinary Shares,"Atlantica Sustainable Infrastructure plc owns, manages, and invests in renewable energy, storage, natural gas and heat, electric transmission lines, and water assets in the United States, Canada, Mexico, Peru, Chile, Colombia, Uruguay, Spain, Italy, Algeria, and South Africa. It owns 39 assets comprising 2,044 megawatts (MW) of aggregate renewable energy installed generation capacity; 343 MW of natural gas-fired power generation capacity; 55 thermal megawatts of district heating capacity; 1,229 miles of electric transmission lines; and 17.5 million cubic feet per day of water desalination assets. The company was formerly known as Atlantica Yield plc and changed its name to Atlantica Sustainable Infrastructure plc in May 2020. Atlantica Sustainable Infrastructure plc was incorporated in 2013 and is based in Brentford, the United Kingdom.",Mr. Santiago  Seage Medela,Renewable Utilities,21.99,USD,2554578300,https://images.financialmodelingprep.com/symbol/AY.png,0,87.96,,0,828502000,43380000,"[{'period': '2023', 'revenue': 1100.0, 'unit': 'M', 'net_profit': 43.38}, {'period': '2022', 'revenue': 1100.0, 'unit': 'M', 'net_profit': -2.09}, {'period': '2021', 'revenue': 1210.0, 'unit': 'M', 'net_profit': -10.92}, {'period': '2020', 'revenue': 1010.0, 'unit': 'M', 'net_profit': 16.87}]","[{'period': ""Q3 '24"", 'revenue': 347.55, 'unit': 'M', 'net_profit': 16.64}, {'period': ""Q2 '24"", 'revenue': 328.26, 'unit': 'M', 'net_profit': 21.43}, {'period': ""Q1 '24"", 'revenue': 242.93, 'unit': 'M', 'net_profit': -5.39}, {'period': ""Q4 '23"", 'revenue': 241.31, 'unit': 'M', 'net_profit': -2.67}, {'period': ""Q3 '23"", 'revenue': 303.96, 'unit': 'M', 'net_profit': 21.39}, {'period': ""Q2 '23"", 'revenue': 312.11, 'unit': 'M', 'net_profit': 35.65}]",0.37,0.37,8714333000,982182000,460215000,7125524001,273766000,230307000,607782000,448301000,303839000,0.12241851139350259,21.785816962146622,21.32967032967033,"[0.2225, 0.037]","['2024-11-29', '2014-11-25']",__nan__,0.8176786451699746
432,AYLA,Ayala Pharmaceuticals Inc. Common Stock,"Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.","Dr. Roni  Mamluk M.D., Ph.D.",Biotechnology,0.5339,USD,0,https://images.financialmodelingprep.com/symbol/AYLA.png,50544,0,0,137793,-37503000,-38013000,"[{'period': '2022', 'revenue': 0.6920000000000001, 'unit': 'M', 'net_profit': -38.01}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -38.7}, {'period': '2020', 'revenue': 3.71, 'unit': 'M', 'net_profit': -30.15}, {'period': '2019', 'revenue': 2.33, 'unit': 'M', 'net_profit': -17.79}]","[{'period': ""Q4 '22"", 'revenue': 0.105, 'unit': 'M', 'net_profit': -9.59}, {'period': ""Q3 '22"", 'revenue': 0.091, 'unit': 'M', 'net_profit': -10.19}, {'period': ""Q2 '22"", 'revenue': 0.038, 'unit': 'M', 'net_profit': -8.21}, {'period': ""Q1 '22"", 'revenue': 0.458, 'unit': 'M', 'net_profit': -10.03}, {'period': ""Q4 '21"", 'revenue': -2.36, 'unit': 'M', 'net_profit': -8.5}, {'period': ""Q3 '21"", 'revenue': 0.625, 'unit': 'M', 'net_profit': -9.8}]",-2.46,-2.46,4581000,3188000,2408000,5680000,0,0,7536000,2408000,-34512000,0.08220351426753462,0.01780269753501111,0.37244897959183676,__nan__,__nan__,__nan__,1.2399039511023795
433,AYRO,AYRO Inc. Common Stock,"Ayro, Inc. designs and manufactures electric vehicles for closed campus mobility, urban and community transport, local on-demand and last mile delivery, and government use. The company provides four-wheeled purpose-built electric vehicles for universities, business and medical campuses, last mile delivery services, and food service providers. It also offers AYRO vehicles to internal combustion engine vehicles for light duty uses, including low-speed logistics, maintenance, and cargo services; and Club Car 411 for low-speed logistics and cargo services for campus. The company was formerly known as AEV Technologies, Inc. Ayro, Inc. was founded in 2017 and is headquartered in Round Rock, Texas.",Mr. Joshua N. Silverman,Auto - Manufacturers,0.7516,USD,5084273,https://images.financialmodelingprep.com/symbol/AYRO.png,540233,-0.21,0.0126,173651,-26915439,-34160455,"[{'period': '2023', 'revenue': 0.49892000000000003, 'unit': 'M', 'net_profit': -34.16}, {'period': '2022', 'revenue': 2.99, 'unit': 'M', 'net_profit': -45.87}, {'period': '2021', 'revenue': 2.68, 'unit': 'M', 'net_profit': -33.13}, {'period': '2020', 'revenue': 1.6, 'unit': 'M', 'net_profit': -11.33}]","[{'period': ""Q3 '24"", 'revenue': 5.43, 'unit': 'K', 'net_profit': 550.56}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.91}, {'period': ""Q1 '24"", 'revenue': 0.058350000000000006, 'unit': 'M', 'net_profit': -3.64}, {'period': ""Q4 '23"", 'revenue': 0.15789, 'unit': 'M', 'net_profit': -10.09}, {'period': ""Q3 '23"", 'revenue': 0.08839, 'unit': 'M', 'net_profit': -12.59}, {'period': ""Q2 '23"", 'revenue': 0.13954, 'unit': 'M', 'net_profit': -6.0}]",-8.19,-8.19,52863778,48979631,33440867,27532112,219000,0,4309481,33440867,-28365005,-0.22456120795317125,0.2552882225095903,0.1727272727272728,__nan__,__nan__,__nan__,0.5208124171526295
434,AYTU,Aytu BioPharma Inc.  Common Stock,"Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.",Mr. Joshua R. Disbrow,Drug Manufacturers - Specialty & Generic,1.81,USD,11130360,https://images.financialmodelingprep.com/symbol/AYTU.png,34367,-1.06,-0.045,27583,-1012000,-15844000,"[{'period': '2024', 'revenue': 81.0, 'unit': 'M', 'net_profit': -15.84}, {'period': '2023', 'revenue': 107.4, 'unit': 'M', 'net_profit': -17.05}, {'period': '2022', 'revenue': 96.67, 'unit': 'M', 'net_profit': -108.78}, {'period': '2021', 'revenue': 65.63, 'unit': 'M', 'net_profit': -58.29}]","[{'period': ""Q1 '25"", 'revenue': 16.57, 'unit': 'M', 'net_profit': 1.47}, {'period': ""Q4 '24"", 'revenue': 17.98, 'unit': 'M', 'net_profit': -4.62}, {'period': ""Q3 '24"", 'revenue': 17.99, 'unit': 'M', 'net_profit': -2.89}, {'period': ""Q2 '24"", 'revenue': 22930.0, 'unit': 'K', 'net_profit': -220.0}, {'period': ""Q1 '24"", 'revenue': 22.1, 'unit': 'M', 'net_profit': -8.12}, {'period': ""Q4 '23"", 'revenue': 30.73, 'unit': 'M', 'net_profit': -2.46}]",-2.86,-2.86,118095000,61891000,20006000,90379000,23617000,0,62228000,20006000,-1388000,0.7120091064314172,0.07073313782991203,0.44031311154598834,__nan__,__nan__,__nan__,0.7653075913459503
435,AZN,AstraZeneca PLC American Depositary Shares,"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.","Mr. Pascal  Soriot D.V.M., M.B.A.",Drug Manufacturers - General,66.98,USD,207680867200,https://images.financialmodelingprep.com/symbol/AZN.png,5642264,32.36,0.14,1740081,13422000000,5955000000,"[{'period': '2023', 'revenue': 45.81, 'unit': 'B', 'net_profit': 5.96}, {'period': '2022', 'revenue': 44.35, 'unit': 'B', 'net_profit': 3.29}, {'period': '2021', 'revenue': 37420.0, 'unit': 'M', 'net_profit': 112.0}, {'period': '2020', 'revenue': 26.62, 'unit': 'B', 'net_profit': 3.2}]","[{'period': ""Q3 '24"", 'revenue': 13.56, 'unit': 'B', 'net_profit': 1.43}, {'period': ""Q2 '24"", 'revenue': 12.94, 'unit': 'B', 'net_profit': 1.93}, {'period': ""Q1 '24"", 'revenue': 12.68, 'unit': 'B', 'net_profit': 2.18}, {'period': ""Q4 '23"", 'revenue': 12020.0, 'unit': 'M', 'net_profit': 960.0}, {'period': ""Q3 '23"", 'revenue': 11.49, 'unit': 'B', 'net_profit': 1.37}, {'period': ""Q2 '23"", 'revenue': 11.42, 'unit': 'B', 'net_profit': 1.82}]",1.92,1.91,101119000000,25054000000,5860000000,61953000000,8407000000,1777000000,30542000000,5840000000,6567000000,0.47738029719317554,0.8111313868613139,-0.09433962264150951,"[0.49, 0.579]","['2024-08-09', '1993-09-24']",__nan__,0.6126741759708858
436,AZPN,Aspen Technology Inc. Common Stock,"Aspen Technology, Inc. provides enterprise asset performance management, asset performance monitoring, and asset optimization solutions worldwide. The company's solutions address complex environments where it is critical to optimize the asset design, operation, and maintenance lifecycle. It serves bulk chemicals, consumer packaged goods, downstream, food and beverage, metals and mining, midstream and LNG, pharmaceuticals, polymers, pulp and paper, specialty chemicals, transportation, upstream, and water and wastewater industries; power generation, transmission, and distribution industries; and engineering, procurement, and construction industries. The company was incorporated in 2021 and is headquartered in Bedford, Massachusetts.",Mr. Antonio J. Pietri,Software - Application,250.285,USD,15830455670,https://images.financialmodelingprep.com/symbol/AZPN.png,423959,-431.53,-2.615,97376,403469000,-9771000,"[{'period': '2024', 'revenue': 1130.0, 'unit': 'M', 'net_profit': -9.77}, {'period': '2023', 'revenue': 1040.0, 'unit': 'M', 'net_profit': -107.76}, {'period': '2022', 'revenue': 482.31, 'unit': 'M', 'net_profit': 41.94}, {'period': '2021', 'revenue': 709.38, 'unit': 'M', 'net_profit': 319.8}]","[{'period': ""Q1 '25"", 'revenue': 215.88, 'unit': 'M', 'net_profit': -60.46}, {'period': ""Q4 '24"", 'revenue': 342.9, 'unit': 'M', 'net_profit': 44.7}, {'period': ""Q3 '24"", 'revenue': 278.11, 'unit': 'M', 'net_profit': 1.56}, {'period': ""Q2 '24"", 'revenue': 257.16, 'unit': 'M', 'net_profit': -21.5}, {'period': ""Q1 '24"", 'revenue': 249.31, 'unit': 'M', 'net_profit': -34.52}, {'period': ""Q4 '23"", 'revenue': 320.64, 'unit': 'M', 'net_profit': 27.32}]",-0.15,-0.15,14071707000,876066000,236970000,1258852000,603193000,0,337401000,236970000,335271000,0.30846040589711826,0.909326280623608,0.9101796407185629,"[0.525, 0.525]","['2024-02-15', '2024-02-15']",__nan__,0.08945979332855637
437,AZRX,AzurRx BioPharma Inc. Common Stock,"AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).",Mr. James Sapirstein,Biotechnology,3.45,USD,3432760,https://images.financialmodelingprep.com/symbol/AZRX.png,713030,-1.8449197860962567,0.06999993,629030,-26830851.962203,-32671466,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -32.67}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.18}, {'period': '2018', 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.53}, {'period': '2017', 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.1}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.28}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.69}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -5.31}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.7}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.26}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.28}]",-5.902903309999999,-5.902903309999999,9942.161,7869.784,6062.141,15564,0,0,15545,6062.141,-11225705,-1955073.0694658824,-2152597.62405903,-871919.7252584934,__nan__,__nan__,__nan__,1.5654544318886006
438,AZYO,Aziyo Biologics Inc. Class A Common Stock,"Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.",Dr. C. Randal Mills Ph.D.,Medical - Devices,1.49,USD,24212202,https://images.financialmodelingprep.com/symbol/AZYO.png,432734,-0.6834862385321101,0.03,8103,-22381000,-32897000,"[{'period': '2022', 'revenue': 49.19, 'unit': 'M', 'net_profit': -32.9}, {'period': '2021', 'revenue': 47.39, 'unit': 'M', 'net_profit': -24.83}, {'period': '2020', 'revenue': 42.68, 'unit': 'M', 'net_profit': -21.82}, {'period': '2019', 'revenue': 42.9, 'unit': 'M', 'net_profit': -11.94}]","[{'period': ""Q3 '23"", 'revenue': 6.13, 'unit': 'M', 'net_profit': -9.75}, {'period': ""Q2 '23"", 'revenue': 10.3, 'unit': 'M', 'net_profit': -10.62}, {'period': ""Q1 '23"", 'revenue': 13.05, 'unit': 'M', 'net_profit': -7.97}, {'period': ""Q4 '22"", 'revenue': 12.66, 'unit': 'M', 'net_profit': -5.44}, {'period': ""Q3 '22"", 'revenue': 12.39, 'unit': 'M', 'net_profit': -9.91}, {'period': ""Q2 '22"", 'revenue': 12.64, 'unit': 'M', 'net_profit': -9.4}]",-2.38,-2.38,68841000,50699000,16989000,73874000,6830000,0,42615000,16989000,-21974000,-0.15051662982573383,-0.32478253865979384,0,__nan__,__nan__,__nan__,1.0731105010095727
439,BAND,Bandwidth Inc. Class A Common Stock,"Bandwidth Inc. operates as a cloud-based software-powered communications platform-as-a-service (CPaaS) provider in the United States. The company operates in two segments, CPaaS and Other. Its platform enables enterprises to create, scale, and operate voice or messaging communications services across various mobile applications or connected devices. The company also provides SIP trunking, data resale, and hosted voice over Internet protocol services. It serves large enterprises, communications service providers, conferencing providers, contact centers, small and medium-sized businesses, emerging technology companies, and many other businesses. Bandwidth Inc. was founded in 2000 and is headquartered in Raleigh, North Carolina.",Mr. David Andrew Morken J.D.,Software - Infrastructure,16.3986,USD,451127241,https://images.financialmodelingprep.com/symbol/BAND.png,261017,-26.88,-1.0714,86795,32545000,-16343000,"[{'period': '2023', 'revenue': 601.12, 'unit': 'M', 'net_profit': -16.34}, {'period': '2022', 'revenue': 573.15, 'unit': 'M', 'net_profit': 19.57}, {'period': '2021', 'revenue': 490.91, 'unit': 'M', 'net_profit': -27.36}, {'period': '2020', 'revenue': 343.11, 'unit': 'M', 'net_profit': -43.98}]","[{'period': ""Q3 '24"", 'revenue': 193880.0, 'unit': 'K', 'net_profit': 413.0}, {'period': ""Q2 '24"", 'revenue': 173.6, 'unit': 'M', 'net_profit': 4.05}, {'period': ""Q1 '24"", 'revenue': 171.03, 'unit': 'M', 'net_profit': -9.23}, {'period': ""Q4 '23"", 'revenue': 165.39, 'unit': 'M', 'net_profit': -10.93}, {'period': ""Q3 '23"", 'revenue': 152.01, 'unit': 'M', 'net_profit': -5.13}, {'period': ""Q2 '23"", 'revenue': 145.87, 'unit': 'M', 'net_profit': -3.89}]",-0.64,-0.64,1101048000,252775000,153475000,803658000,78155000,0,122771000,131987000,19102000,-0.48283806583248157,-1.8351047521716914,-1.8311688311688312,__nan__,__nan__,__nan__,0.7299027835298734
440,BANF,BancFirst Corporation Common Stock,"BancFirst Corporation operates as the bank holding company for BancFirst that provides a range of commercial banking services to retail customers, and small to medium-sized businesses. It operates through Metropolitan Banks, Community Banks, Pegasus Bank, and Other Financial Services segments. The company offers checking accounts, negotiable order of withdrawal accounts, savings accounts, money market accounts, sweep accounts, club accounts, individual retirement accounts, and certificates of deposit, as well as overdraft protection and auto draft services. It also provides commercial, financial, and other loans for working capital, facilities acquisition or expansion, purchase of equipment, and other needs; lending services that include private banking, energy, commercial and residential real estate, and commercial and industrial loans; and loans to finance purchases of consumer goods, such as automobiles, boats, household goods, vacations, and education. In addition, the company engages in the investment management and administration of trusts for individuals, corporations, and employee benefit plans, as well as bond trustee and paying agent business for various Oklahoma municipalities and governmental entities; and provision of item processing, research, and other correspondent banking services. Further, it is involved in real estate investment and insurance agency services; and providing funds transfer, collection, safe deposit box, cash management, and other services. The company serves customers in non-metropolitan trade centers and cities in the metropolitan statistical areas of Oklahoma. It operates through 108 banking locations in Oklahoma and 3 banking locations in Dallas, Texas. The company was formerly known as United Community Corporation and changed its name to BancFirst Corporation in November 1988. BancFirst Corporation was incorporated in 1984 and is headquartered in Oklahoma City, Oklahoma.",Mr. David R. Harlow,Banks - Regional,114.59,USD,3796240651,https://images.financialmodelingprep.com/symbol/BANF.png,96706,18.42,-1.64,22759,292137000,212465000,"[{'period': '2023', 'revenue': 623.94, 'unit': 'M', 'net_profit': 212.47}, {'period': '2022', 'revenue': 557.42, 'unit': 'M', 'net_profit': 193.1}, {'period': '2021', 'revenue': 485.69, 'unit': 'M', 'net_profit': 167.63}, {'period': '2020', 'revenue': 443.89, 'unit': 'M', 'net_profit': 99.59}]","[{'period': ""Q3 '24"", 'revenue': 187.65, 'unit': 'M', 'net_profit': 58.9}, {'period': ""Q2 '24"", 'revenue': 220.66, 'unit': 'M', 'net_profit': 50.64}, {'period': ""Q1 '24"", 'revenue': 148.8, 'unit': 'M', 'net_profit': 50.33}, {'period': ""Q4 '23"", 'revenue': 142.35, 'unit': 'M', 'net_profit': 48.93}, {'period': ""Q3 '23"", 'revenue': 148.76, 'unit': 'M', 'net_profit': 50.99}, {'period': ""Q2 '23"", 'revenue': 153.9, 'unit': 'M', 'net_profit': 55.01}]",6.45,6.34,12372042000,2398779000,1779367000,10938151000,0,1555095000,88064000,225462000,210541000,0.1258555572683829,0.10028482651475919,0.09507640067911724,"[0.46, 0.15]","['2024-12-31', '1991-02-22']",__nan__,0.8841023171437665
441,BANFP,BancFirst Corporation - BFC Capital Trust II Cumulative Trust Preferred Securities,"BFC Capital Trust II provides a full range of commercial banking services to retail customers and small to medium-sized businesses in both the non-metropolitan trade centers and cities in the metropolitan statistical areas of Oklahoma. BancFirst operates as a super community bank, managing its community banking offices on a decentralized basis, which permits them to be responsive to local customer needs. Underwriting, funding, customer service, and pricing decisions are made by presidents in each market within BancFirsts strategic parameters.",None,Banks,25.45,USD,3851304395,https://images.financialmodelingprep.com/symbol/BANFP.png,804,,-0.13,1255,292137000,212465000,"[{'period': '2023', 'revenue': 623.94, 'unit': 'M', 'net_profit': 212.47}, {'period': '2022', 'revenue': 557.42, 'unit': 'M', 'net_profit': 193.1}, {'period': '2021', 'revenue': 485.69, 'unit': 'M', 'net_profit': 167.63}, {'period': '2020', 'revenue': 443.89, 'unit': 'M', 'net_profit': 99.59}]","[{'period': ""Q3 '24"", 'revenue': 187.65, 'unit': 'M', 'net_profit': 58.9}, {'period': ""Q2 '24"", 'revenue': 220.66, 'unit': 'M', 'net_profit': 50.64}, {'period': ""Q1 '24"", 'revenue': 148.8, 'unit': 'M', 'net_profit': 50.33}, {'period': ""Q4 '23"", 'revenue': 142.35, 'unit': 'M', 'net_profit': 48.93}, {'period': ""Q3 '23"", 'revenue': 148.76, 'unit': 'M', 'net_profit': 50.99}, {'period': ""Q2 '23"", 'revenue': 153.9, 'unit': 'M', 'net_profit': 55.01}]",6.45,6.34,12372042000,2398779000,1779367000,10938151000,0,1555095000,88064000,225462000,210541000,0.1258555572683829,0.10028482651475919,0.09507640067911724,"[0.45, 0.45]","['2024-12-31', '2004-03-29']",__nan__,0.8841023171437665
442,BANR,Banner Corporation Common Stock,"Banner Corporation operates as the bank holding company for Banner Bank that provide commercial banking and financial products and services to individuals, businesses, and public sector entities in the United States. It accepts various deposit instruments, including interest-bearing and non-interest-bearing checking accounts, money market deposit accounts, regular savings accounts, and certificates of deposit, as well as treasury management services and retirement savings plans. The company also provides commercial real estate loans, including owner-occupied, investment properties, and multifamily residential real estate loans; construction, land, and land development loans; residential mortgage loans; commercial business loans; agricultural loans; and consumer and other loans, such as home equity lines of credit, automobile, and boat and recreational vehicle loans, as well as loans secured by deposit accounts. In addition, it engages in the mortgage banking operations through the origination and sale of one-to four-family and multi-family residential loans, as well as small business administration loans. Further, the company provides electronic and digital banking services. As of December 31, 2021, it operated 150 branch offices and 18 loan production offices located in Washington, Oregon, California, Idaho, and Utah. Banner Corporation was founded in 1890 and is headquartered in Walla Walla, Washington.",Mr. Mark J. Grescovich,Banks - Regional,66.06,USD,2276361540,https://images.financialmodelingprep.com/symbol/BANR.png,229222,13.82,-0.67,66555,248716000,183624000,"[{'period': '2023', 'revenue': 620.41, 'unit': 'M', 'net_profit': 183.62}, {'period': '2022', 'revenue': 623.75, 'unit': 'M', 'net_profit': 195.38}, {'period': '2021', 'revenue': 607.16, 'unit': 'M', 'net_profit': 201.05}, {'period': '2020', 'revenue': 598.67, 'unit': 'M', 'net_profit': 115.93}]","[{'period': ""Q3 '24"", 'revenue': 152.75, 'unit': 'M', 'net_profit': 45.15}, {'period': ""Q2 '24"", 'revenue': 206.18, 'unit': 'M', 'net_profit': 39.8}, {'period': ""Q1 '24"", 'revenue': 184.69, 'unit': 'M', 'net_profit': 37.56}, {'period': ""Q4 '23"", 'revenue': 197.6, 'unit': 'M', 'net_profit': 42.62}, {'period': ""Q3 '23"", 'revenue': 153.75, 'unit': 'M', 'net_profit': 45.85}, {'period': ""Q2 '23"", 'revenue': 150.73, 'unit': 'M', 'net_profit': 39.59}]",5.35,5.33,15670391000,254464000,254464000,14017700000,0,3432838000,198392000,254464000,242548000,-0.054265039716792085,-0.06016030464023585,-0.06140350877192992,"[0.48, 0.0087]","['2024-11-05', '1995-12-27']",__nan__,0.8945341568056598
443,BANX,StoneCastle Financial Corp Common Stock,"StoneCastle Financial Corp. is a closed ended balanced mutual fund launched and managed by StoneCastle Asset Management LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating across the banking sector. It invests in dividend paying growth and value stocks of companies. For its fixed income portion, the fund invests in subordinated debt securities which are rated BBB- or better by Kroll Ratings. The fund employs fundamental analysis with bottom-up security picking approach by focusing on factors such as review of historical and prospective financial information, interviews with management and key employees of the prospective bank, financial models and projections, changes in interest rates, changes in unemployment rates, changes in home prices, changes in economic activity to create its portfolio. It employs proprietary research to create its portfolio. StoneCastle Financial Corp. was formed on February 7, 2013 and is domiciled in the United States.",Mr. Sanjai Suryaji Bhonsle,Asset Management,21,USD,149497320,https://images.financialmodelingprep.com/symbol/BANX.png,24856,8.05,0.02,2520,22163800,20247926,"[{'period': '2023', 'revenue': 23.25, 'unit': 'M', 'net_profit': 20.25}, {'period': '2022', 'revenue': 7.86, 'unit': 'M', 'net_profit': 5.37}, {'period': '2021', 'revenue': 14.42, 'unit': 'M', 'net_profit': 12.63}, {'period': '2020', 'revenue': 9.85, 'unit': 'M', 'net_profit': 7.78}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q3 '22"", 'revenue': 1.9, 'unit': 'M', 'net_profit': 1.41}, {'period': ""Q2 '22"", 'revenue': -231.5, 'unit': 'K', 'net_profit': -845.57}]",2.85,2.85,203696545,0,807308,51260994,5560779,196542458,5953858,443413,15099720,1.8799524317587137,2.7734058522667446,2.75,"[0.65, 0.28]","['2024-12-26', '2013-12-19']",__nan__,0.25165372343453346
444,BAOS,Baosheng Media Group Holdings Limited Ordinary shares,"Baosheng Media Group Holdings Limited operates as an online marketing solution provider in the People's Republic of China. The company connects advertisers, online media, and helping advertisers to manage their online marketing activities in various ways, including advising on advertising strategies, budget, and choice of advertising channels; procures ad inventory; offers ad optimization services; and administrates and fine-tunes the ad placement process. It also serves media businesses in various ways, including identifying advertisers to buy their ad inventory; facilitating payment arrangements with advertisers; assisting advertisers in handling ad deployment logistics with media; and engaging in other marketing and promotion activities aimed at educating and inducing advertisers to use online advertising. The company's advertising services comprise search engine marketing (SEM) services, such as the deployment of ranked search ads and other display search ads offered by search engine operators; and non-SEM services consisting of social media marketing, in-feed advertising, and mobile app advertising through deploying ads on media, such as social media platforms, short-video platforms, news portals, and mobile apps. Baosheng Media Group Holdings Limited was incorporated in 2014 and is headquartered in Beijing, the People's Republic of China.",Ms. Shasha  Mi,Advertising Agencies,3.5826,USD,5497464,https://images.financialmodelingprep.com/symbol/BAOS.png,1159435,-1.54,-0.6774,261672,-1946935,-1845170,"[{'period': '2023', 'revenue': 0.92183, 'unit': 'M', 'net_profit': -1.85}, {'period': '2022', 'revenue': 2.42, 'unit': 'M', 'net_profit': -23.41}, {'period': '2021', 'revenue': 3.91, 'unit': 'M', 'net_profit': -6.6}, {'period': '2020', 'revenue': 11.91, 'unit': 'M', 'net_profit': 6.94}]","[{'period': ""Q2 '24"", 'revenue': 23.09, 'unit': 'K', 'net_profit': -870.21}, {'period': ""Q1 '24"", 'revenue': 23.09, 'unit': 'K', 'net_profit': -870.21}, {'period': ""Q4 '23"", 'revenue': -274.3, 'unit': 'K', 'net_profit': -920.54}, {'period': ""Q3 '23"", 'revenue': -274.3, 'unit': 'K', 'net_profit': -920.54}, {'period': ""Q2 '23"", 'revenue': 1470.0, 'unit': 'K', 'net_profit': -4.08}, {'period': ""Q1 '23"", 'revenue': 735.22, 'unit': 'K', 'net_profit': -2.04}]",-1.2,-1.2,48827742,39520805,5870381,6467631,28709213,6848964,6467631,3316062,2229358,0.9159523456769658,0.9211831872274022,0.921875,__nan__,__nan__,__nan__,0.13245812186031458
445,BATRA,Liberty Media Corporation Series A Liberty Braves Common Stock,"The Liberty Braves Group, through its subsidiary, Braves Holdings, LLC, owns the Atlanta Braves Major League Baseball Club, various assets and liabilities associated with ANLBC's stadium, and mixed-use development project. The company is based in Englewood, Colorado. The Liberty Braves Group is a subsidiary of Liberty Media Corporation.",Mr. Terence Foster McGuirk,Entertainment,39.75,USD,2292075710,https://images.financialmodelingprep.com/symbol/BATRA.png,41248,-55.21,-0.36,15101,-20505000,-125294000,"[{'period': '2023', 'revenue': 640.67, 'unit': 'M', 'net_profit': -125.29}, {'period': '2022', 'revenue': 588.0, 'unit': 'M', 'net_profit': -35.0}, {'period': '2021', 'revenue': 568.0, 'unit': 'M', 'net_profit': -11.0}, {'period': '2020', 'revenue': 178.0, 'unit': 'M', 'net_profit': -78.0}]","[{'period': ""Q3 '24"", 'revenue': 290.67, 'unit': 'M', 'net_profit': 10.02}, {'period': ""Q2 '24"", 'revenue': 282.88, 'unit': 'M', 'net_profit': 29.11}, {'period': ""Q1 '24"", 'revenue': 37.08, 'unit': 'M', 'net_profit': -51.27}, {'period': ""Q4 '23"", 'revenue': 67.75, 'unit': 'M', 'net_profit': -32.36}, {'period': ""Q3 '23"", 'revenue': 271.82, 'unit': 'M', 'net_profit': -6.05}, {'period': ""Q2 '23"", 'revenue': 270.12, 'unit': 'M', 'net_profit': -28.91}]",-2.02,-2.02,1504330000,218019000,125148000,963688000,62922000,99213000,233673000,125148000,-67410000,-1.2939279263782575,-2.5798285714285716,-2.5438596491228074,"[0.25, 0.25]","['2022-02-10', '2022-02-10']",__nan__,0.6406094407477083
446,BATRK,Liberty Media Corporation Series C Liberty Braves Common Stock,"The Liberty Braves Group, through its subsidiary, Braves Holdings, LLC, owns the Atlanta Braves Major League Baseball Club, various assets and liabilities associated with ANLBC's stadium, and mixed-use development project. The company is based in Englewood, Colorado. The Liberty Braves Group is a subsidiary of Liberty Media Corporation.",Mr. Terence Foster McGuirk,Entertainment,37.07,USD,2295495619,https://images.financialmodelingprep.com/symbol/BATRK.png,279109,-51.49,-0.28,62750,-20505000,-125294000,"[{'period': '2023', 'revenue': 640.67, 'unit': 'M', 'net_profit': -125.29}, {'period': '2022', 'revenue': 588.0, 'unit': 'M', 'net_profit': -35.0}, {'period': '2021', 'revenue': 568.0, 'unit': 'M', 'net_profit': -11.0}, {'period': '2020', 'revenue': 178.0, 'unit': 'M', 'net_profit': -78.0}]","[{'period': ""Q3 '24"", 'revenue': 290.67, 'unit': 'M', 'net_profit': 10.02}, {'period': ""Q2 '24"", 'revenue': 282.88, 'unit': 'M', 'net_profit': 29.11}, {'period': ""Q1 '24"", 'revenue': 37.08, 'unit': 'M', 'net_profit': -51.27}, {'period': ""Q4 '23"", 'revenue': 67.75, 'unit': 'M', 'net_profit': -32.36}, {'period': ""Q3 '23"", 'revenue': 271.82, 'unit': 'M', 'net_profit': -6.05}, {'period': ""Q2 '23"", 'revenue': 270.12, 'unit': 'M', 'net_profit': -28.91}]",-2.02,-2.02,1504330000,218019000,125148000,963688000,62922000,99213000,233673000,125148000,-67410000,-1.2939279263782575,-2.5798285714285716,-2.5438596491228074,__nan__,__nan__,__nan__,0.6406094407477083
447,BBBY,Bed Bath & Beyond Inc. Common Stock,"Bed Bath & Beyond Inc., together with its subsidiaries, operates a chain of retail stores. It sells a range of domestics merchandise, including bed linens and related items, bath items, and kitchen textiles; and home furnishings, such as kitchen and tabletop items, fine tabletop, basic housewares, general home furnishings, consumables, and various juvenile products. As of February 26, 2022, the company had 953 stores, which included 771 Bed Bath & Beyond stores in 50 states, the District of Columbia, Puerto Rico, and Canada; 130 buybuy BABY stores in 37 states and Canada; and 52 stores in 6 states under the names Harmon, Harmon Face Values or Face Values. It also offers products through various Websites and applications comprising bedbathandbeyond.com, bedbathandbeyond.ca, harmondiscount.com, facevalues.com, buybuybaby.com, buybuybaby.ca, and decorist.com. In addition, the company operates Decorist, an online interior design platform that provides personalized home design services. Bed Bath & Beyond Inc. was incorporated in 1971 and is headquartered in Union, New Jersey.",Ms. Sue Ellen Gove,Specialty Retail,0.0751,USD,41961072,https://images.financialmodelingprep.com/symbol/BBBY.png,121625124,-0.0051615120274914085,0,192179915,-2992286000,-3498801000,"[{'period': '2022', 'revenue': 5.34, 'unit': 'B', 'net_profit': -3.5}, {'period': '2021', 'revenue': 7870.0, 'unit': 'M', 'net_profit': -559.62}, {'period': '2020', 'revenue': 9230.0, 'unit': 'M', 'net_profit': -150.77}, {'period': '2019', 'revenue': 11160.0, 'unit': 'M', 'net_profit': -613.82}]","[{'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q4 '22"", 'revenue': 1.19, 'unit': 'B', 'net_profit': -2.38}, {'period': ""Q3 '22"", 'revenue': 1260.0, 'unit': 'M', 'net_profit': -392.97}, {'period': ""Q2 '22"", 'revenue': 1440.0, 'unit': 'M', 'net_profit': -366.16}, {'period': ""Q1 '22"", 'revenue': 1460.0, 'unit': 'M', 'net_profit': -357.67}]",-36.03,-36.03,2225217000,1096909000,65853000,5025225000,16100000,15262000,2495884000,65853000,-1323865000,-25.17281878606132,-5.252067910003699,-5.388297872340426,"[0.17, 0.125]","['2020-03-12', '2016-06-15']",__nan__,2.2583078414374866
448,BBCP,Concrete Pumping Holdings Inc. Common Stock,"Concrete Pumping Holdings, Inc. provides concrete pumping and waste management services in the United States and the United Kingdom. The company offers concrete pumping services to general contractors and concrete finishing companies in the commercial, infrastructure, and residential sectors under the Brundage-Bone and Camfaud brands; and industrial cleanup and containment services primarily to customers in the construction industry under the Eco-Pan brand. It also leases and rents concrete pumping equipment, pans, and containers. As of October 31, 2021, the company owned a fleet of approximately 820 boom pumps, 70 placing booms, 20 telebelts, 250 stationary pumps, and 90 waste management trucks. Concrete Pumping Holdings, Inc. was founded in 1983 and is headquartered in Thornton, Colorado.",Mr. Bruce F. Young,Engineering & Construction,6.55,USD,350643115,https://images.financialmodelingprep.com/symbol/BBCP.png,78280,26.2,-0.07,12263,132853000,31790000,"[{'period': '2023', 'revenue': 442.24, 'unit': 'M', 'net_profit': 31.79}, {'period': '2022', 'revenue': 401.29, 'unit': 'M', 'net_profit': 28.68}, {'period': '2021', 'revenue': 315.81, 'unit': 'M', 'net_profit': -15.07}, {'period': '2020', 'revenue': 304.3, 'unit': 'M', 'net_profit': -61.25}]","[{'period': ""Q3 '24"", 'revenue': 109.62, 'unit': 'M', 'net_profit': 7.56}, {'period': ""Q2 '24"", 'revenue': 107.06, 'unit': 'M', 'net_profit': 3.05}, {'period': ""Q1 '24"", 'revenue': 97.71, 'unit': 'M', 'net_profit': -3.83}, {'period': ""Q4 '23"", 'revenue': 120.2, 'unit': 'M', 'net_profit': 9.39}, {'period': ""Q3 '23"", 'revenue': 120.67, 'unit': 'M', 'net_profit': 10.34}, {'period': ""Q2 '23"", 'revenue': 107.79, 'unit': 'M', 'net_profit': 5.59}]",0.55,0.54,904525000,94270000,15861000,596285000,62976000,0,83976000,15861000,41570000,0.09392651878201011,0.1085925512623797,0.14583333333333348,__nan__,__nan__,__nan__,0.6592244548243553
449,BBGI,Beasley Broadcast Group Inc. Class A Common Stock,"Beasley Broadcast Group, Inc., a multi-platform media company, owns and operates radio stations in the United States. It also operates Houston Outlaws, an esports team that competes in the Overwatch League. The company was founded in 1961 and is headquartered in Naples, Florida.",Ms. Barbara Caroline Beasley,Broadcasting,9.5561,USD,16931756,https://images.financialmodelingprep.com/symbol/BBGI.png,6800,5.14,0.3661,9286,-63841714,-75120138,"[{'period': '2023', 'revenue': 247.11, 'unit': 'M', 'net_profit': -75.12}, {'period': '2022', 'revenue': 256.38, 'unit': 'M', 'net_profit': -43.38}, {'period': '2021', 'revenue': 241.43, 'unit': 'M', 'net_profit': -1.4}, {'period': '2020', 'revenue': 206.14, 'unit': 'M', 'net_profit': -18.71}]","[{'period': ""Q3 '24"", 'revenue': 58.19, 'unit': 'M', 'net_profit': -3.56}, {'period': ""Q2 '24"", 'revenue': 60440.0, 'unit': 'K', 'net_profit': -276.02}, {'period': ""Q1 '24"", 'revenue': 54380.0, 'unit': 'K', 'net_profit': 7.97}, {'period': ""Q4 '23"", 'revenue': 65.75, 'unit': 'M', 'net_profit': 6.38}, {'period': ""Q3 '23"", 'revenue': 60.12, 'unit': 'M', 'net_profit': -67.54}, {'period': ""Q2 '23"", 'revenue': 63.46, 'unit': 'M', 'net_profit': -10.43}]",-2.51,-2.51,574267938,86646783,26733921,425289303,53424196,1800000,48295856,26733921,-8868103,-1.7759663943156134,-0.731561605458005,-0.7074829931972788,"[0.05, 0.0625]","['2020-03-30', '2005-12-29']",__nan__,0.7405764362906153
450,BBI,Brickell Biotech Inc. Common Stock,"Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.",Mr. Robert Brown,Biotechnology,2.35,USD,7080973,https://images.financialmodelingprep.com/symbol/BBI.png,0,-5.595238095238095,0.049999952,31317,-40244000,-39543000,"[{'period': '2021', 'revenue': 0.404, 'unit': 'M', 'net_profit': -39.54}, {'period': '2020', 'revenue': 1.82, 'unit': 'M', 'net_profit': -20.91}, {'period': '2019', 'revenue': 7.92, 'unit': 'M', 'net_profit': -23.88}, {'period': '2018', 'revenue': 1.62, 'unit': 'M', 'net_profit': -16.25}]","[{'period': ""Q2 '22"", 'revenue': 4.32, 'unit': 'M', 'net_profit': -1.15}, {'period': ""Q1 '22"", 'revenue': 0.092, 'unit': 'M', 'net_profit': -9.41}, {'period': ""Q4 '21"", 'revenue': 0.10400000000000001, 'unit': 'M', 'net_profit': -6.07}, {'period': ""Q3 '21"", 'revenue': 0.132, 'unit': 'M', 'net_profit': -13.25}, {'period': ""Q2 '21"", 'revenue': 0.151, 'unit': 'M', 'net_profit': -11.15}, {'period': ""Q1 '21"", 'revenue': 0.017, 'unit': 'M', 'net_profit': -9.01}]",-22.16,-22.16,29717000,29600000,26884000,4810000,0,0,4810000,26884000,-36184000,-0.9185736079328757,-0.8908334528762014,0.42276634540244856,__nan__,__nan__,__nan__,0.16186021469192718
451,BBIG,Vinco Ventures Inc. Common Stock,"Vinco Ventures, Inc. develops and commercializes end-to-end consumer products in North America. It offers kitchenware, small appliances, toys, pet care, baby products, health and beauty aids, entertainment venue merchandise, and housewares to retailers, mass-market retailers, and e-commerce sites; and personal protective equipment to governmental agencies, hospitals, and distributors. The company also offers Lomotif app that allows its users to create their own music videos; Cortex, a real-time analytics for marketing spend and revenue optimization; and delivers ad-campaign creation, optimalization, and monetization at scale. In addition, it provides Non-Fungible Token, a platform for artists and content owners to distribute their intellectual property, and digital marketing services for brands and influencers. The company was formerly known as Edison Nation, Inc. and changed its name to Vinco Ventures, Inc. in November 2020. Vinco Ventures, Inc. was incorporated in 2017 and is based in Fairport, New York.",Mr. James  Robertson,Leisure,0.0011,USD,13694,https://images.financialmodelingprep.com/symbol/BBIG.png,15209,0,0.0001,265,-639202096,-713172942,"[{'period': '2021', 'revenue': 9.79, 'unit': 'M', 'net_profit': -713.17}, {'period': '2020', 'revenue': 15.78, 'unit': 'M', 'net_profit': -5.07}, {'period': '2019', 'revenue': 19.63, 'unit': 'M', 'net_profit': -14.2}, {'period': '2018', 'revenue': 16.5, 'unit': 'M', 'net_profit': -5.34}]","[{'period': ""Q3 '22"", 'revenue': 5.56, 'unit': 'M', 'net_profit': -241.63}, {'period': ""Q2 '22"", 'revenue': 10.37, 'unit': 'M', 'net_profit': 145.93}, {'period': ""Q1 '22"", 'revenue': 11.53, 'unit': 'M', 'net_profit': -372.95}, {'period': ""Q4 '21"", 'revenue': 2.3, 'unit': 'M', 'net_profit': 75.43}, {'period': ""Q3 '21"", 'revenue': 2.23, 'unit': 'M', 'net_profit': -542.46}, {'period': ""Q2 '21"", 'revenue': 2.69, 'unit': 'M', 'net_profit': -183.67}]",-224.72,-224.72,405142729,219741467,87790176,271455687,21072224,1000000,70089546,87612176,-47897324,-114.7477431799234,-139.79896414465333,-22.31120331950207,__nan__,__nan__,__nan__,0.6700248272257652
452,BBIO,BridgeBio Pharma Inc. Common Stock,"BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.",Dr. Neil  Kumar Ph.D.,Biotechnology,28.42,USD,5371095800,https://images.financialmodelingprep.com/symbol/BBIO.png,1955467,-11.74,0.16,331334,-565468000,-643202000,"[{'period': '2023', 'revenue': 9.3, 'unit': 'M', 'net_profit': -643.2}, {'period': '2022', 'revenue': 77.65, 'unit': 'M', 'net_profit': -493.96}, {'period': '2021', 'revenue': 69.72, 'unit': 'M', 'net_profit': -639.3}, {'period': '2020', 'revenue': 8.25, 'unit': 'M', 'net_profit': -483.93}]","[{'period': ""Q3 '24"", 'revenue': 2.73, 'unit': 'M', 'net_profit': -162.04}, {'period': ""Q2 '24"", 'revenue': 2.17, 'unit': 'M', 'net_profit': -73.46}, {'period': ""Q1 '24"", 'revenue': 211.12, 'unit': 'M', 'net_profit': -35.22}, {'period': ""Q4 '23"", 'revenue': 1.75, 'unit': 'M', 'net_profit': -168.15}, {'period': ""Q3 '23"", 'revenue': 4.09, 'unit': 'M', 'net_profit': -177.0}, {'period': ""Q2 '23"", 'revenue': 1.64, 'unit': 'M', 'net_profit': -157.9}]",-3.95,-3.95,546380000,477593000,434884000,1888915000,1751000,0,143844000,375935000,-529026000,-0.42276502542502953,-0.3021232316525091,-0.17910447761194032,__nan__,__nan__,__nan__,3.4571452102932025
453,BBQ,BBQ Holdings Inc. Common Stock,"BBQ Holdings, Inc. develops, owns, operates, and franchises casual and fast dining restaurants under the Famous Dave's, Village Inn, Clark Crew BBQ, Granite City, Tahoe Joe's Steakhouse, Bakers Square, and Real Urban Barbecue names in the United States, Canada, and the United Arab Emirates. It offers smoked, barbequed, and grilled meats, as well as entre items, and side dishes and appetizers. The company operates full-service and counter-service restaurants. As of March 14, 2022, it had 100 company owned locations and approximately 200 franchised locations, including ghost kitchens operating out of the kitchen of another restaurant location or shared kitchen space. BBQ Holdings, Inc. was incorporated in 1994 and is based in Minnetonka, Minnesota.",Mr. Jeffery Crivello,Restaurants,17.24,USD,185504124,https://images.financialmodelingprep.com/symbol/BBQ.png,0,15.531531531531531,0,14040,23554000,24021000,"[{'period': '2021', 'revenue': 206.44, 'unit': 'M', 'net_profit': 24.02}, {'period': '2020', 'revenue': 121.44, 'unit': 'M', 'net_profit': 4.95}, {'period': '2019', 'revenue': 82.27, 'unit': 'M', 'net_profit': -1.25}, {'period': '2018', 'revenue': 54.89, 'unit': 'M', 'net_profit': 4.86}]","[{'period': ""Q2 '22"", 'revenue': 79.94, 'unit': 'M', 'net_profit': 4.18}, {'period': ""Q1 '22"", 'revenue': 64180.00000000001, 'unit': 'K', 'net_profit': 767.0}, {'period': ""Q4 '21"", 'revenue': 68.39, 'unit': 'M', 'net_profit': 2.6}, {'period': ""Q3 '21"", 'revenue': 55.38, 'unit': 'M', 'net_profit': 4.83}, {'period': ""Q2 '21"", 'revenue': 45.52, 'unit': 'M', 'net_profit': 15.79}, {'period': ""Q1 '21"", 'revenue': 37320.0, 'unit': 'K', 'net_profit': 799.0}]",2.44,2.42,204423000,54172000,40309000,140076000,5476000,0,48074000,40309000,21032000,12.677739216658404,3.8556701030927836,3.518518518518518,__nan__,__nan__,__nan__,0.6852262220982962
454,BBSI,Barrett Business Services Inc. Common Stock,"Barrett Business Services, Inc. provides business management solutions for small and mid-sized companies in the United States. The company develops a management platform that integrates a knowledge-based approach from the management consulting industry with tools from the human resource outsourcing industry. It offers professional employer services under which it enters into a client services agreement to establish a co-employment relationship with each client company, assuming responsibility for payroll, payroll taxes, workers' compensation coverage, and other administration functions for the client's existing workforce. The company also provides staffing and recruiting services, such as on-demand or short-term staffing assignment, contract staffing, direct placement, and long-term or indefinite-term on-site management services. It serves electronics manufacturers, light-manufacturing industries, agriculture-based companies, transportation and shipping enterprises, food processors, telecommunications companies, public utilities, general contractors in various construction-related fields, and professional services firms. The company was incorporated in 1965 and is headquartered in Vancouver, Washington.",Mr. Gary Edward Kramer,Staffing & Employment Services,41.38,USD,1073277198,https://images.financialmodelingprep.com/symbol/BBSI.png,120827,21.89,-0.79,24423,76264000,50612000,"[{'period': '2023', 'revenue': 1070.0, 'unit': 'M', 'net_profit': 50.61}, {'period': '2022', 'revenue': 1050.0, 'unit': 'M', 'net_profit': 47.27}, {'period': '2021', 'revenue': 955.17, 'unit': 'M', 'net_profit': 38.08}, {'period': '2020', 'revenue': 880.82, 'unit': 'M', 'net_profit': 33.77}]","[{'period': ""Q3 '24"", 'revenue': 294.28, 'unit': 'M', 'net_profit': 19.63}, {'period': ""Q2 '24"", 'revenue': 279.65, 'unit': 'M', 'net_profit': 16.7}, {'period': ""Q1 '24"", 'revenue': 265780.0, 'unit': 'K', 'net_profit': -136.0}, {'period': ""Q4 '23"", 'revenue': 276.68, 'unit': 'M', 'net_profit': 14.56}, {'period': ""Q3 '23"", 'revenue': 273.33, 'unit': 'M', 'net_profit': 18.22}, {'period': ""Q2 '23"", 'revenue': 264.63, 'unit': 'M', 'net_profit': 17.02}]",1.88,1.85,721538000,447502000,152195000,522398000,179394000,-4218000,343252000,71168000,55395000,-0.030053289582458953,0.07074553609207075,0.1325301204819277,"[0.08, 0.035]","['2024-11-22', '2006-11-28']",__nan__,0.7240062200466226
455,BCAB,BioAtla Inc. Common Stock,"BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.",Dr. Jay M. Short Ph.D.,Biotechnology,0.6385,USD,37048771,https://images.financialmodelingprep.com/symbol/BCAB.png,1101979,-0.42,0.0369,719578,-122241000,-123462000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -123.46}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -105.28}, {'period': '2021', 'revenue': 0.25, 'unit': 'M', 'net_profit': -95.41}, {'period': '2020', 'revenue': 0.429, 'unit': 'M', 'net_profit': -37.24}]","[{'period': ""Q3 '24"", 'revenue': 11.0, 'unit': 'M', 'net_profit': -10.59}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.07}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -23.23}, {'period': ""Q4 '23"", 'revenue': 1.71, 'unit': 'M', 'net_profit': -26.93}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -33.33}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.75}]",-2.58,-2.58,119658000,116406000,111471000,48986000,0,0,28344000,111471000,-104113000,-0.14799684453710485,-0.17266795209103084,0.04444444444444448,__nan__,__nan__,__nan__,0.4093834093834094
456,BCAC,Brookline Capital Acquisition Corp. Common Stock,"Brookline Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to acquire companies in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.",James Jiayuan Tong,Shell Companies,22.71,USD,559613007,https://images.financialmodelingprep.com/symbol/BCAC.png,0,-61.04838709677419,12.719999,586499,-484062,-364939,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -364.94}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.57}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.46}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -280.95}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 316.75}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -399.63}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -170.0}]",-0.0491,-0.0491,58316,230.826,217.409,236.363,0,58085,186.703,217.409,-451526,0,0,0,__nan__,__nan__,__nan__,0.004053141504904314
457,BCACU,Brookline Capital Acquisition Corp. Units,"Brookline Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to acquire companies in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.",James Jiayuan Tong,Shell Companies,23.2,USD,0,https://images.financialmodelingprep.com/symbol/BCACU.png,0,-62.365591397849464,13.910001,9932,-484062,-364939,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -364.94}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.57}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.46}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -280.95}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 316.75}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -399.63}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -170.0}]",-0.0491,-0.0491,58316,230.826,217.409,236.363,0,58085,186.703,217.409,-451526,0,0,0,__nan__,__nan__,__nan__,0.004053141504904314
458,BCACW,Brookline Capital Acquisition Corp. Warrant,,,Shell Companies,0.55,USD,0,https://images.financialmodelingprep.com/symbol/BCACW.png,0,0,0.31,901118,-484062,-364939,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -364.94}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.57}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.46}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -280.95}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 316.75}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -399.63}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -170.0}]",-0.0491,-0.0491,58316,230.826,217.409,236.363,0,58085,186.703,217.409,-451526,0,0,0,__nan__,__nan__,__nan__,0.004053141504904314
459,BCBP,BCB Bancorp Inc. (NJ) Common Stock,"BCB Bancorp, Inc. operates as a bank holding company for BCB Community Bank that provides banking products and services to businesses and individuals in the United States. The company offers deposit products, including savings and club accounts, interest and non-interest-bearing demand accounts, money market accounts, certificates of deposit, and individual retirement accounts. It also provides loans, such as commercial and multi-family real estate, one-to-four family mortgage, commercial business, small business administration, construction, home equity and lines of credit, and consumer loans, as well as residential loans secured by one-to-four family dwellings, condominiums, and cooperative units. In addition, the company offers retail and commercial banking services comprising wire transfers, money orders, safe deposit boxes, night depository services, debit cards, online and mobile banking services, fraud detection services, and automated teller services. As of December 31, 2021, it operated 29 branch offices in Bayonne, Carteret, Edison, Hoboken, Fairfield, Holmdel, Jersey City, Lyndhurst, Maplewood, Monroe Township, Newark, Parsippany, Plainsboro, River Edge, Rutherford, South Orange, Union, and Woodbridge, New Jersey, as well as three branches in Staten Island and Hicksville, New York. The company was founded in 2000 and is headquartered in Bayonne, New Jersey.",Mr. Michael A. Shriner,Banks - Regional,11.16,USD,190255680,https://images.financialmodelingprep.com/symbol/BCBP.png,43895,9.54,-0.3,10047,0,29483000,"[{'period': '2023', 'revenue': 102.05, 'unit': 'M', 'net_profit': 29.48}, {'period': '2022', 'revenue': 115.54, 'unit': 'M', 'net_profit': 45.58}, {'period': '2021', 'revenue': 105.72, 'unit': 'M', 'net_profit': 34.24}, {'period': '2020', 'revenue': 88.52, 'unit': 'M', 'net_profit': 20.86}]","[{'period': ""Q3 '24"", 'revenue': 26.17, 'unit': 'M', 'net_profit': 6.67}, {'period': ""Q2 '24"", 'revenue': 46.21, 'unit': 'M', 'net_profit': 2.82}, {'period': ""Q1 '24"", 'revenue': 51.39, 'unit': 'M', 'net_profit': 5.87}, {'period': ""Q4 '23"", 'revenue': 52.93, 'unit': 'M', 'net_profit': 6.06}, {'period': ""Q3 '23"", 'revenue': 27.09, 'unit': 'M', 'net_profit': 6.71}, {'period': ""Q2 '23"", 'revenue': 28.11, 'unit': 'M', 'net_profit': 8.6}]",1.71,1.7,3832397000,295595000,279523000,3518342000,16072000,289865000,2689230000,279523000,30631000,-1,-0.35314508874701067,-0.3522727272727273,"[0.16, 0.3]","['2024-11-01', '2006-08-30']",__nan__,0.9180525921505522
460,BCDA,BioCardia Inc. Common Stock,"BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.",Dr. Peter A. Altman Ph.D.,Biotechnology,2.3999,USD,11001838,https://images.financialmodelingprep.com/symbol/BCDA.png,49137,-0.6,0.0299,33470,-11560000,-11571000,"[{'period': '2023', 'revenue': 0.47700000000000004, 'unit': 'M', 'net_profit': -11.57}, {'period': '2022', 'revenue': 1.35, 'unit': 'M', 'net_profit': -11.91}, {'period': '2021', 'revenue': 1.01, 'unit': 'M', 'net_profit': -12.62}, {'period': '2020', 'revenue': 0.145, 'unit': 'M', 'net_profit': -15.01}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.74}, {'period': ""Q2 '24"", 'revenue': 0.003, 'unit': 'M', 'net_profit': -1.65}, {'period': ""Q1 '24"", 'revenue': 0.055, 'unit': 'M', 'net_profit': -2.27}, {'period': ""Q4 '23"", 'revenue': 0.013000000000000001, 'unit': 'M', 'net_profit': -2.07}, {'period': ""Q3 '23"", 'revenue': 0.357, 'unit': 'M', 'net_profit': -2.57}, {'period': ""Q2 '23"", 'revenue': 0.043000000000000003, 'unit': 'M', 'net_profit': -3.42}]",-8.19,-8.19,2987000,1461000,1103000,4590000,63000,0,3608000,1103000,-9986000,0.021913867501480666,0.028708133971291867,0.18750000000000006,__nan__,__nan__,__nan__,1.5366588550385
461,BCDAW,BioCardia Inc. Warrant,"BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.",Dr. Peter A. Altman Ph.D.,Biotechnology,0.0061,USD,10116,https://images.financialmodelingprep.com/symbol/BCDAW.png,0,0,-0.0002,18712,-11560000,-11571000,"[{'period': '2023', 'revenue': 0.47700000000000004, 'unit': 'M', 'net_profit': -11.57}, {'period': '2022', 'revenue': 1.35, 'unit': 'M', 'net_profit': -11.91}, {'period': '2021', 'revenue': 1.01, 'unit': 'M', 'net_profit': -12.62}, {'period': '2020', 'revenue': 0.145, 'unit': 'M', 'net_profit': -15.01}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.74}, {'period': ""Q2 '24"", 'revenue': 0.003, 'unit': 'M', 'net_profit': -1.65}, {'period': ""Q1 '24"", 'revenue': 0.055, 'unit': 'M', 'net_profit': -2.27}, {'period': ""Q4 '23"", 'revenue': 0.013000000000000001, 'unit': 'M', 'net_profit': -2.07}, {'period': ""Q3 '23"", 'revenue': 0.357, 'unit': 'M', 'net_profit': -2.57}, {'period': ""Q2 '23"", 'revenue': 0.043000000000000003, 'unit': 'M', 'net_profit': -3.42}]",-8.19,-8.19,2987000,1461000,1103000,4590000,63000,0,3608000,1103000,-9986000,0.021913867501480666,0.028708133971291867,0.18750000000000006,__nan__,__nan__,__nan__,1.5366588550385
462,BCEL,Atreca Inc. Class A Common Stock,"Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.",Mr. John A. Orwin M.B.A.,Biotechnology,0.09,USD,3568788,https://images.financialmodelingprep.com/symbol/BCEL.png,267000,-0.036,-0.0012,122115,-90444000,-90525000,"[{'period': '2022', 'revenue': 0.77, 'unit': 'M', 'net_profit': -90.53}, {'period': '2021', 'revenue': 0.851, 'unit': 'M', 'net_profit': -109.33}, {'period': '2020', 'revenue': 1.35, 'unit': 'M', 'net_profit': -86.33}, {'period': '2019', 'revenue': 2.13, 'unit': 'M', 'net_profit': -67.48}]","[{'period': ""Q3 '23"", 'revenue': 0.08, 'unit': 'M', 'net_profit': -36.22}, {'period': ""Q2 '23"", 'revenue': 0.07100000000000001, 'unit': 'M', 'net_profit': -19.19}, {'period': ""Q1 '23"", 'revenue': 0.092, 'unit': 'M', 'net_profit': -18.76}, {'period': ""Q4 '22"", 'revenue': 0.02, 'unit': 'M', 'net_profit': -20.91}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -23.29}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.03}]",-2.35,-2.35,155030000,78026000,70495000,76624000,3985000,1115000,16293000,30819000,-81606000,0.1361192034003534,0.17197190055430547,0.2033898305084746,__nan__,__nan__,__nan__,0.4942527252789783
463,BCLI,Brainstorm Cell Therapeutics Inc. Common Stock,"Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.",Mr. Chaim  Lebovits,Biotechnology,2.285,USD,13032338,https://images.financialmodelingprep.com/symbol/BCLI.png,114030,-0.66,-0.005,28706,-16927000,-17192000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.19}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -23.73}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.38}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.94}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.71}, {'period': ""Q2 '24"", 'revenue': 0.365, 'unit': 'M', 'net_profit': -2.54}, {'period': ""Q1 '24"", 'revenue': -0.5690000000000001, 'unit': 'M', 'net_profit': -3.4}, {'period': ""Q4 '23"", 'revenue': 0.343, 'unit': 'M', 'net_profit': -5.58}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.23}, {'period': ""Q2 '23"", 'revenue': 0.154, 'unit': 'M', 'net_profit': -5.33}]",-0.4,-0.4,4208000,1899000,1300000,9066000,51000,0,7800000,1300000,-20476,0.29447315771923976,0.2755772796224507,0.3846153846153846,__nan__,__nan__,__nan__,2.154467680608365
464,BCML,BayCom Corp Common Stock,"BayCom Corp operates as the bank holding company for United Business Bank that provides various financial services to small and mid-sized businesses, service professionals, and individuals. The company offers demand, savings, money market, and time deposit accounts. It also provides commercial and multifamily real estate loans, including owner-occupied and investor real estate loans; commercial and industrial loans, such as equipment loans and working capital lines of credit; small business administration loans; construction and land loans; agriculture-related loans; and consumer loans comprising installment loans, unsecured and secured personal lines of credit, and overdraft protection. In addition, the company offers online and mobile banking, automated teller machine, remote deposit capture, night depository, courier, direct deposit, treasury management, wire transfer, automated clearing house services, debit cards, cashier's and travelers checks, letters of credit, lockbox, positive pay, reverse positive pay, and account reconciliation services, as well as zero balance accounts and sweep accounts, including loan sweep. As of December 31, 2021, it operated through a network of 33 full-service banking branches in Northern and Southern California; Denver, Colorado; Custer, Delta, and Grand counties, Colorado; and Seattle, Washington and Central New Mexico. The company was formerly known as Bay Commercial Bank and changed its name to BayCom Corp in January 2017. BayCom Corp was incorporated in 2004 and is headquartered in Walnut Creek, California.",Mr. George J. Guarini,Banks - Regional,25.52,USD,283820680,https://images.financialmodelingprep.com/symbol/BCML.png,27825,12.15,-0.28,5289,41121000,27425000,"[{'period': '2023', 'revenue': 102.84, 'unit': 'M', 'net_profit': 27.43}, {'period': '2022', 'revenue': 105.31, 'unit': 'M', 'net_profit': 23.73}, {'period': '2021', 'revenue': 84.06, 'unit': 'M', 'net_profit': 20.69}, {'period': '2020', 'revenue': 87.03, 'unit': 'M', 'net_profit': 13.73}]","[{'period': ""Q3 '24"", 'revenue': 33.43, 'unit': 'M', 'net_profit': 6.02}, {'period': ""Q2 '24"", 'revenue': 33.89, 'unit': 'M', 'net_profit': 5.6}, {'period': ""Q1 '24"", 'revenue': 33.81, 'unit': 'M', 'net_profit': 5.88}, {'period': ""Q4 '23"", 'revenue': 34.87, 'unit': 'M', 'net_profit': 6.4}, {'period': ""Q3 '23"", 'revenue': 26.46, 'unit': 'M', 'net_profit': 6.63}, {'period': ""Q2 '23"", 'revenue': 25.37, 'unit': 'M', 'net_profit': 7.21}]",2.27,2.27,2551960000,141239000,141239000,2239091000,0,185697000,3054000,17901000,28679000,0.12793153578188002,0.15571007163927517,0.25414364640883974,"[0.15, 0.05]","['2024-12-12', '2022-03-10']",__nan__,0.8774005078449505
465,BCOR,Blucora Inc. Common Stock,"Blucora, Inc. provides technology-enabled financial solutions to consumers, small business owners, tax professionals, financial advisors, and certified public accounting firms in the United States. The company operates through two segments, Wealth Management and Tax Preparation. The Wealth Management segment offers an integrated platform of brokerage, investment advisory, and insurance services to financial advisors. The Tax Preparation segment provides digital do-it-yourself tax preparation solutions through TaxAct.com; and ancillary services, including refund payment transfer, audit defense, stored value cards, retirement plan services, and e-filing services. This segment also offers professional tax preparer software that allows professional tax preparers to prepare and file individual and business returns. The company was formerly known as InfoSpace, Inc. and changed its name to Blucora, Inc. in June 2012. Blucora, Inc. was founded in 1996 and is headquartered in Dallas, Texas.",Mr. Christopher W. Walters,Asset Management,27.19,USD,1324661480,https://images.financialmodelingprep.com/symbol/BCOR.png,395637,-3.8059910414333706,-0.08,254725,-11338000,3121000,"[{'period': '2022', 'revenue': 666.5, 'unit': 'M', 'net_profit': 3.12}, {'period': '2021', 'revenue': 885.2, 'unit': 'M', 'net_profit': 7.76}, {'period': '2020', 'revenue': 754.95, 'unit': 'M', 'net_profit': -342.75}, {'period': '2019', 'revenue': 717.95, 'unit': 'M', 'net_profit': 48.15}]","[{'period': ""Q3 '23"", 'revenue': 192.34, 'unit': 'M', 'net_profit': -3.63}, {'period': ""Q2 '23"", 'revenue': 186.93, 'unit': 'M', 'net_profit': 7.73}, {'period': ""Q1 '23"", 'revenue': 177980.0, 'unit': 'K', 'net_profit': -111.0}, {'period': ""Q4 '22"", 'revenue': 172.39, 'unit': 'M', 'net_profit': -1.6}, {'period': ""Q3 '22"", 'revenue': 171.7, 'unit': 'M', 'net_profit': -21.84}, {'period': ""Q2 '22"", 'revenue': 256.88, 'unit': 'M', 'net_profit': 39.42}]",0.0635,0.0635,963515000,323751000,263928000,220317000,24117000,0,142294000,263928000,91730000,-1.1576517700714704,-0.5976537321129303,-0.603125,"[9, 6.3]","['2008-01-09', '2007-05-16']",__nan__,0.22865964722915574
466,BCOV,Brightcove Inc. Common Stock,"Brightcove Inc. provides cloud-based services for video. Its flagship product includes Video Cloud, an online video platform that enables its customers to publish and distribute video to Internet-connected devices. The company also offers Brightcove Live, a solution for live streaming; Brightcove Beacon, an application that enables companies to launch over-the-top video experiences on multiple monetization models; Brightcove Player, a video player technology with a cloud-based service for creating and managing experiences; and Zencoder, a cloud-based video encoding technology. In addition, it provides video solutions, such as Brightcove CorpTV, an application that enables marketing videos, product announcements, training programs, and other live and on-demand content; Video Marketing Suite, a suite of video technologies to drive awareness, engagement, and conversion; Enterprise Video Suite, an enterprise-class platform for internal communications, employee training, live streaming, marketing, and e-commerce videos; and Virtual Events Experience, a platform to create customized, live, and virtual experiences. The company serves media, broadcasters, publishers, sports and entertainment companies, fashion, faith-based institutions, retail and e-commerce platforms, and hi-tech organizations, governments, educational institutions, and hospitality brands. It also sells its products in the America, Europe, Asia Pacific, Japan, and the Middle East. Brightcove Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.",Mr. Marc  DeBevoise,Software - Application,4.375,USD,198691500,https://images.financialmodelingprep.com/symbol/BCOV.png,572908,-20.83,0.005,113054,-5158999,-22886000,"[{'period': '2023', 'revenue': 201.19, 'unit': 'M', 'net_profit': -22.89}, {'period': '2022', 'revenue': 211.01, 'unit': 'M', 'net_profit': -9.02}, {'period': '2021', 'revenue': 211.09, 'unit': 'M', 'net_profit': 5.4}, {'period': '2020', 'revenue': 197.35, 'unit': 'M', 'net_profit': -5.81}]","[{'period': ""Q3 '24"", 'revenue': 49.95, 'unit': 'M', 'net_profit': -2.96}, {'period': ""Q2 '24"", 'revenue': 49.25, 'unit': 'M', 'net_profit': -5.25}, {'period': ""Q1 '24"", 'revenue': 50.48, 'unit': 'M', 'net_profit': 1.57}, {'period': ""Q4 '23"", 'revenue': 50.16, 'unit': 'M', 'net_profit': -2.51}, {'period': ""Q3 '23"", 'revenue': 50.98, 'unit': 'M', 'net_profit': -2.42}, {'period': ""Q2 '23"", 'revenue': 50.99, 'unit': 'M', 'net_profit': -6.24}]",-0.53,-0.53,216107000,70399000,18615000,122194000,33451000,0,104629000,18615000,-11145000,-4.122880750605327,-1.5386577925679423,-1.4090909090909094,__nan__,__nan__,__nan__,0.5654328642755672
467,BCOW,1895 Bancorp of Wisconsin Inc. Common Stock,"1895 Bancorp of Wisconsin, Inc. operates as a holding company for PyraMax Bank, FSB that provides a range of financial services. The company offers checking, savings, and certificate of deposits accounts. Its loan products include one- to four-family residential real estate, residential real estate construction, commercial real estate, and land development loans; commercial loans and lines of credit secured by non-real estate business assets; and consumer loans, such as home equity lines of credit, new and used automobile loans, boat loans, recreational vehicle loans, and loans secured by certificates of deposit. It also provides insurance and risk products for personal and business needs. The company operates through a network of three full-service banking offices in Milwaukee County, two full-service banking offices in Waukesha County, and one full service banking office in Ozaukee County, Wisconsin. 1895 Bancorp of Wisconsin, Inc. was founded in 1895 and is headquartered in Greenfield, Wisconsin.",Mr. David R. Ball,Banks - Regional,10.03,USD,59761348,https://images.financialmodelingprep.com/symbol/BCOW.png,3774,-16.72,-0.48,176,-5912000,-6792000,"[{'period': '2023', 'revenue': 9.98, 'unit': 'M', 'net_profit': -6.79}, {'period': '2022', 'revenue': 16180.0, 'unit': 'K', 'net_profit': -148.0}, {'period': '2021', 'revenue': 16970.0, 'unit': 'K', 'net_profit': 85.0}, {'period': '2020', 'revenue': 19.23, 'unit': 'M', 'net_profit': 1.32}]","[{'period': ""Q3 '24"", 'revenue': 3660.0, 'unit': 'K', 'net_profit': -159.0}, {'period': ""Q2 '24"", 'revenue': 6880.0, 'unit': 'K', 'net_profit': -516.0}, {'period': ""Q1 '24"", 'revenue': 6600.0, 'unit': 'K', 'net_profit': -306.0}, {'period': ""Q4 '23"", 'revenue': 3.7, 'unit': 'M', 'net_profit': -2.28}, {'period': ""Q3 '23"", 'revenue': 5.37, 'unit': 'M', 'net_profit': -3.64}, {'period': ""Q2 '23"", 'revenue': 3990.0, 'unit': 'K', 'net_profit': -508.0}]",-1.23,-1.23,557607000,14804000,13250000,484846000,1554000,2838000,0,11220000,-1521000,0,-44.891891891891895,-47.04687499999999,__nan__,__nan__,__nan__,0.8695120398416806
468,BCPC,Balchem Corporation Common Stock,"Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York.",Mr. Theodore L. Harris,Chemicals - Specialty,156.92,USD,5101108284,https://images.financialmodelingprep.com/symbol/BCPC.png,127627,42.64,-0.24,29316,214809000,108543000,"[{'period': '2023', 'revenue': 922.44, 'unit': 'M', 'net_profit': 108.54}, {'period': '2022', 'revenue': 942.36, 'unit': 'M', 'net_profit': 105.37}, {'period': '2021', 'revenue': 799.02, 'unit': 'M', 'net_profit': 96.1}, {'period': '2020', 'revenue': 703.64, 'unit': 'M', 'net_profit': 84.62}]","[{'period': ""Q3 '24"", 'revenue': 239.94, 'unit': 'M', 'net_profit': 33.84}, {'period': ""Q2 '24"", 'revenue': 234.08, 'unit': 'M', 'net_profit': 32.07}, {'period': ""Q1 '24"", 'revenue': 239.66, 'unit': 'M', 'net_profit': 28.99}, {'period': ""Q4 '23"", 'revenue': 228.7, 'unit': 'M', 'net_profit': 26.65}, {'period': ""Q3 '23"", 'revenue': 229.95, 'unit': 'M', 'net_profit': 29.07}, {'period': ""Q2 '23"", 'revenue': 231.25, 'unit': 'M', 'net_profit': 30.11}]",3.38,3.35,1597211000,314242000,64447000,543227001,125284000,4075999,148491000,64447000,145869000,0.08724964696235783,0.030142264655916937,0.027355623100303907,"[0.87, 0.03]","['2024-12-26', '1988-11-17']",__nan__,0.34010972939705525
469,BCRX,BioCryst Pharmaceuticals Inc. Common Stock,"BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.",Mr. Jon P. Stonehouse,Biotechnology,8.14,USD,1686062620,https://images.financialmodelingprep.com/symbol/BCRX.png,2009385,-13.13,0.31,555892,-116335000,-226539000,"[{'period': '2023', 'revenue': 331.41, 'unit': 'M', 'net_profit': -226.54}, {'period': '2022', 'revenue': 270.83, 'unit': 'M', 'net_profit': -247.12}, {'period': '2021', 'revenue': 157.17, 'unit': 'M', 'net_profit': -184.06}, {'period': '2020', 'revenue': 17.81, 'unit': 'M', 'net_profit': -196.57}]","[{'period': ""Q3 '24"", 'revenue': 117.08, 'unit': 'M', 'net_profit': -14.03}, {'period': ""Q2 '24"", 'revenue': 109.33, 'unit': 'M', 'net_profit': -12.67}, {'period': ""Q1 '24"", 'revenue': 92.76, 'unit': 'M', 'net_profit': -35.38}, {'period': ""Q4 '23"", 'revenue': 93.4, 'unit': 'M', 'net_profit': -61.73}, {'period': ""Q3 '23"", 'revenue': 86.74, 'unit': 'M', 'net_profit': -36.15}, {'period': ""Q2 '23"", 'revenue': 82.49, 'unit': 'M', 'net_profit': -75.33}]",-1.18,-1.18,516960000,495966000,388987000,972488000,56950000,0,149988000,110643000,-97309000,0.19129812170673044,0.08327229611884249,0.11278195488721814,__nan__,__nan__,__nan__,1.881166821417518
470,BCTG,BCTG Acquisition Corp. Common Stock,"BCTG Acquisition Corp. intends to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses primarily located in North America and Europe in the biotechnology industry. The company was founded in 2020 and is based in San Diego, California.","Mr. Aaron I. Davis B.A., M.A.",Shell Companies,10.2,USD,899409480,https://images.financialmodelingprep.com/symbol/BCTG.png,25308,-204,0,151857,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
471,BCTX,BriaCell Therapeutics Corp. Common Shares,"BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.",Dr. William V. Williams M.D.,Biotechnology,0.4331,USD,19144839,https://images.financialmodelingprep.com/symbol/BCTX.png,1557503,-0.49,-0.0269,986882,-4771736,-4791466,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.79}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -20.3}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.58}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.89}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.8}, {'period': ""Q4 '24"", 'revenue': 0.022670000000000003, 'unit': 'M', 'net_profit': -1.2}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.72}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.36}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.0}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.42}]",-0.29,-0.29,5872261,3653854,862089,8557193,1369588,418490,7461157,862089,-24582929,0.8443952110726825,0.7639950244291388,0.7769230769230769,__nan__,__nan__,__nan__,1.4572228652643335
472,BCTXW,BriaCell Therapeutics Corp. Warrant,"BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.",Dr. William V. Williams M.D.,Biotechnology,0.2399,USD,4400322,https://images.financialmodelingprep.com/symbol/BCTXW.png,0,,0.0099,7054,-4791466,-4791466,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.79}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -20.3}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.55}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.69}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.8}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.21}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.72}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.29}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.0}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.42}]",-0.29,-0.29,5872261,3653854,862089,8557193,1369016,418490,7461157,862089,-24582929,0.7857679902064671,0.7639950244291388,0.7786259541984732,__nan__,__nan__,__nan__,1.4572228652643335
473,BCYC,Bicycle Therapeutics plc American Depositary Shares,"Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.","Dr. Kevin  Lee M.B.A., Ph.D.",Biotechnology,15.39,USD,1062155794,https://images.financialmodelingprep.com/symbol/BCYC.png,0,-4.69,0.51,85827,-183400000,-180664000,"[{'period': '2023', 'revenue': 26.98, 'unit': 'M', 'net_profit': -180.66}, {'period': '2022', 'revenue': 14.46, 'unit': 'M', 'net_profit': -112.72}, {'period': '2021', 'revenue': 11.7, 'unit': 'M', 'net_profit': -66.82}, {'period': '2020', 'revenue': 10.39, 'unit': 'M', 'net_profit': -51.01}]","[{'period': ""Q3 '24"", 'revenue': 2.68, 'unit': 'M', 'net_profit': -50.8}, {'period': ""Q2 '24"", 'revenue': 9.37, 'unit': 'M', 'net_profit': -39.86}, {'period': ""Q1 '24"", 'revenue': 19.52, 'unit': 'M', 'net_profit': -26.55}, {'period': ""Q4 '23"", 'revenue': 5.33, 'unit': 'M', 'net_profit': -49.1}, {'period': ""Q3 '23"", 'revenue': 5.35, 'unit': 'M', 'net_profit': -49.9}, {'period': ""Q2 '23"", 'revenue': 11.4, 'unit': 'M', 'net_profit': -42.6}]",-5.08,-5.08,595344000,561868000,526423000,224412000,24039000,0,69537000,526423000,-63557000,-0.6235260791048476,-0.6028105787059628,-0.336842105263158,__nan__,__nan__,__nan__,0.3769450939288882
474,BCYP,Big Cypress Acquisition Corp. Common stock,"Big Cypress Acquisition Corp. intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It intends to focus on life science companies in the United States and Israel. The company was founded in 2020 and is based in Miami Beach, Florida.",Mr. Samuel J. Reich,Biotechnology,8.44,USD,425357432,https://images.financialmodelingprep.com/symbol/BCYP.png,2267566,0,-2.0100002,15335164,0,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2019', 'revenue': 3.44, 'unit': 'M', 'net_profit': -8.99}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.2}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",0,0,322205,87094,84836,306201,0,0,306201,84836,-2726907,1,1,1,__nan__,__nan__,__nan__,0.9503297590043606
475,BCYPU,Big Cypress Acquisition Corp. Unit,,,Biotechnology,8.57,USD,0,https://images.financialmodelingprep.com/symbol/BCYPU.png,1730,0,-2.28,32880,0,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2019', 'revenue': 3.44, 'unit': 'M', 'net_profit': -8.99}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.2}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",0,0,322205,87094,84836,306201,0,0,306201,84836,-2726907,1,1,1,__nan__,__nan__,__nan__,0.9503297590043606
476,BCYPW,Big Cypress Acquisition Corp. Warrant,"Big Cypress Acquisition Corp. intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It intends to focus on life science companies in the United States and Israel. The company was founded in 2020 and is based in Miami Beach, Florida.",Mr. Samuel J. Reich,Shell Companies,1.1001,USD,0,https://images.financialmodelingprep.com/symbol/BCYPW.png,0,0,-0.14989996,3600913,0,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': '2019', 'revenue': 3.44, 'unit': 'M', 'net_profit': -8.99}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.2}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",0,0,322205,87094,84836,306201,0,0,306201,84836,-2726907,1,1,1,__nan__,__nan__,__nan__,0.9503297590043606
477,BDSI,BioDelivery Sciences International Inc. Common Stock,"BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.",Mr. Herm Cukier,Drug Manufacturers - Specialty & Generic,5.59,USD,577050110,https://images.financialmodelingprep.com/symbol/BDSI.png,3352473,6.817073170731708,-0.005,2107479,44542000,84860000,"[{'period': '2021', 'revenue': 166.7, 'unit': 'M', 'net_profit': 84.86}, {'period': '2020', 'revenue': 156.47, 'unit': 'M', 'net_profit': 25.71}, {'period': '2019', 'revenue': 111.39, 'unit': 'M', 'net_profit': -15.3}, {'period': '2018', 'revenue': 55.64, 'unit': 'M', 'net_profit': -33.87}]","[{'period': ""Q4 '21"", 'revenue': 43.15, 'unit': 'M', 'net_profit': 63.89}, {'period': ""Q3 '21"", 'revenue': 41.09, 'unit': 'M', 'net_profit': 6.67}, {'period': ""Q2 '21"", 'revenue': 41.44, 'unit': 'M', 'net_profit': 9.06}, {'period': ""Q1 '21"", 'revenue': 41.02, 'unit': 'M', 'net_profit': 5.24}, {'period': ""Q4 '20"", 'revenue': 42.17, 'unit': 'M', 'net_profit': 10.2}, {'period': ""Q3 '20"", 'revenue': 39.44, 'unit': 'M', 'net_profit': 9.38}]",0.82,0.82,324596000,202065000,114309000,136774000,56867000,0,82378000,114309000,40622000,0.0999382639832078,2.3005328458636383,2.1538461538461537,__nan__,__nan__,__nan__,0.4213668683532761
478,BDSX,Biodesix Inc. Common Stock,"Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.",Mr. Scott  Hutton,Medical - Diagnostics & Research,1.43,USD,208017810,https://images.financialmodelingprep.com/symbol/BDSX.png,419824,-3.97,-0.02,157686,-37103000,-52146000,"[{'period': '2023', 'revenue': 49.09, 'unit': 'M', 'net_profit': -52.15}, {'period': '2022', 'revenue': 38.21, 'unit': 'M', 'net_profit': -80.39}, {'period': '2021', 'revenue': 54.51, 'unit': 'M', 'net_profit': -44.48}, {'period': '2020', 'revenue': 45.56, 'unit': 'M', 'net_profit': -36.47}]","[{'period': ""Q3 '24"", 'revenue': 18.15, 'unit': 'M', 'net_profit': -10.26}, {'period': ""Q2 '24"", 'revenue': 17.93, 'unit': 'M', 'net_profit': -10.81}, {'period': ""Q1 '24"", 'revenue': 14.82, 'unit': 'M', 'net_profit': -13.61}, {'period': ""Q4 '23"", 'revenue': 14.67, 'unit': 'M', 'net_profit': -9.14}, {'period': ""Q3 '23"", 'revenue': 13.49, 'unit': 'M', 'net_profit': -10.95}, {'period': ""Q2 '23"", 'revenue': 11.87, 'unit': 'M', 'net_profit': -13.36}]",-0.64,-0.64,99096000,39683000,26284000,94516000,7679000,0,33415999,26284000,-45932000,0.3100710327643274,0.35132109270040307,0.6649214659685865,__nan__,__nan__,__nan__,0.9537821910067006
479,BDTX,Black Diamond Therapeutics Inc. Common Stock,"Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.","Dr. Mark A. Velleca M.D., Ph.D.",Biotechnology,2.12,USD,119960412,https://images.financialmodelingprep.com/symbol/BDTX.png,575280,-1.59,-0.01,128835,-86023000,-82442000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -82.44}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -84.52}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -123.2}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -65.48}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.56}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.91}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.23}, {'period': ""Q4 '23"", 'revenue': 4.89, 'unit': 'M', 'net_profit': -19.41}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -23.01}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.15}]",-1.88,-1.88,158567000,134034000,131400000,41831000,0,0,19646000,56221000,-66750000,0.0682084055459272,0.024585896829152864,0.1931330472103005,__nan__,__nan__,__nan__,0.2638064666670871
480,BEAM,Beam Therapeutics Inc. Common Stock,"Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.",Mr. John M. Evans M.B.A.,Biotechnology,27.01,USD,2236579256,https://images.financialmodelingprep.com/symbol/BEAM.png,1142298,-17.09,0.65,551786,-156473000,-132526999,"[{'period': '2023', 'revenue': 377.71, 'unit': 'M', 'net_profit': -132.53}, {'period': '2022', 'revenue': 60.92, 'unit': 'M', 'net_profit': -263.59}, {'period': '2021', 'revenue': 51.84, 'unit': 'M', 'net_profit': -341.36}, {'period': '2020', 'revenue': 0.024, 'unit': 'M', 'net_profit': -256.42}]","[{'period': ""Q3 '24"", 'revenue': 14.27, 'unit': 'M', 'net_profit': -96.67}, {'period': ""Q2 '24"", 'revenue': 11.77, 'unit': 'M', 'net_profit': -91.05}, {'period': ""Q1 '24"", 'revenue': 7.41, 'unit': 'M', 'net_profit': -98.67}, {'period': ""Q4 '23"", 'revenue': 316.19, 'unit': 'M', 'net_profit': 142.8}, {'period': ""Q3 '23"", 'revenue': 17.19, 'unit': 'M', 'net_profit': -96.09}, {'period': ""Q2 '23"", 'revenue': 20.12, 'unit': 'M', 'net_profit': -82.78}]",-1.72,-1.72,1459714000,1211043000,1189876000,478385000,0,0,205565000,435895000,-182927000,0.5175530012456372,0.4972191488231634,0.5425531914893618,"[0.225, 0.19]","['2014-02-04', '2011-11-07']",__nan__,0.32772515711981937
481,BECN,Beacon Roofing Supply Inc. Common Stock,"Beacon Roofing Supply, Inc., together with its subsidiaries, distributes residential and non-residential roofing materials, and complementary building products to contractors, home builders, building owners, lumberyards, and retailers. It offers pitched roofing and low slope roof products; gutters and sidings; building materials, such as lumber and composite, skylights and window, plywood and OSB, decking and railing, and HVAC products; and foam board, spray foam, roll, batt, mineral wool, fiberglass, and commercial insulation products, as well as radiant barriers and blown-in insulation and equipment. The company also provides above grade and below grade membranes and coatings, deck and floor coatings, plaza deck waterproofing products, damp proofing coatings, and air and vapor barriers; tools and equipment, including power and hand tools, ladders and scaffolding, air tools and compressors, nails, screws and fasteners, generators, work wear and safety gear, job site supplies, tool bags and belts, welding and soldering, cleaning supplies, drill bits, and saw blades; and solar panels, mounting hardware, inverters, and storage and batteries. As of September 30, 2021, it operated approximately 446 branches in 50 states of the United States and 6 provinces in Canada. Beacon Roofing Supply, Inc. was founded in 1928 and is headquartered in Herndon, Virginia.",Mr. Julian G. Francis,Construction,100.72,USD,6233359360,https://images.financialmodelingprep.com/symbol/BECN.png,678253,17.22,-1.26,149908,895800000,435000000,"[{'period': '2023', 'revenue': 9120.0, 'unit': 'M', 'net_profit': 435.0}, {'period': '2022', 'revenue': 8430.0, 'unit': 'M', 'net_profit': 458.4}, {'period': '2021', 'revenue': 6820.0, 'unit': 'M', 'net_profit': 243.0}, {'period': '2020', 'revenue': 6940.0, 'unit': 'M', 'net_profit': -80.9}]","[{'period': ""Q1 '24"", 'revenue': 1910.0, 'unit': 'M', 'net_profit': 5.6}, {'period': ""Q4 '23"", 'revenue': 2300.0, 'unit': 'M', 'net_profit': 95.3}, {'period': ""Q3 '23"", 'revenue': 2580.0, 'unit': 'M', 'net_profit': -262.8}, {'period': ""Q2 '23"", 'revenue': 2500.0, 'unit': 'M', 'net_profit': 123.6}, {'period': ""Q1 '23"", 'revenue': 1730.0, 'unit': 'M', 'net_profit': 16.3}, {'period': ""Q4 '22"", 'revenue': 1970.0, 'unit': 'M', 'net_profit': 73.3}]",-0.43,-0.43,6207700000,2896700000,84000000,4384200000,1512000000,0,1567300000,84000000,664900000,0.03848829121261303,-0.051047120418848166,-1.0664605873261206,__nan__,__nan__,__nan__,0.7062519129468241
482,BEEM,Beam Global Common Stock,"Beam Global, a cleantech company, designs, develops, engineers, manufactures, and sells renewably energized products for electric vehicle (EV) charging infrastructure, outdoor media and branding, and energy security products. The company's product portfolio include EV ARC (electric vehicle autonomous renewable charger), an infrastructure product that uses integrated solar power and battery storage to provide a source of power for factory installed electric vehicle charging stations; Solar Tree DCFC, an off-grid, renewably energized, and single-column mounted smart generation and energy storage system to provide a 50kW DC fast charge to one or more electric vehicles or larger vehicles; and EV ARC DCFC, a DC fast charging system for charging EVs. It is also developing EV-Standard, a lamp standard, EV charging, and emergency power product that uses an existing streetlamp's foundation and a combination of solar, wind, grid connection, and onboard energy storage to provide curbside charging; and UAV ARC, an off-grid and renewably energized product and network used to charge aerial drone (UAV) fleets. The company was formerly known as Envision Solar International, Inc. and changed its name to Beam Global in September 2020. Beam Global was incorporated in 2006 and is headquartered in San Diego, California.",Mr. Desmond  Wheatley,Solar,3.68,USD,54367952,https://images.financialmodelingprep.com/symbol/BEEM.png,216696,-3.72,-0.07,132797,-14174000,-16059999,"[{'period': '2023', 'revenue': 67.35, 'unit': 'M', 'net_profit': -16.06}, {'period': '2022', 'revenue': 22.0, 'unit': 'M', 'net_profit': -19.68}, {'period': '2021', 'revenue': 9.0, 'unit': 'M', 'net_profit': -6.6}, {'period': '2020', 'revenue': 6.21, 'unit': 'M', 'net_profit': -5.21}]","[{'period': ""Q3 '24"", 'revenue': 11.48, 'unit': 'M', 'net_profit': 1.3}, {'period': ""Q2 '24"", 'revenue': 14.81, 'unit': 'M', 'net_profit': -4.92}, {'period': ""Q1 '24"", 'revenue': 14.56, 'unit': 'M', 'net_profit': -3.04}, {'period': ""Q4 '23"", 'revenue': 20.03, 'unit': 'M', 'net_profit': -5.07}, {'period': ""Q3 '23"", 'revenue': 16.49, 'unit': 'M', 'net_profit': -3.63}, {'period': ""Q2 '23"", 'revenue': 17.82, 'unit': 'M', 'net_profit': -3.53}]",-1.3,-1.3,77643000,40722000,10393000,28101000,16059000,0,16874000,10393000,-14364000,0.2363146551724138,0.18402606442434713,0.34673366834170855,__nan__,__nan__,__nan__,0.3619257370271628
483,BEEMW,Beam Global Warrant,"Beam Global, a cleantech company, designs, develops, engineers, manufactures, and sells renewably energized infrastructure products for electric vehicle (EV) charging infrastructure, energy storage, energy security, disaster preparedness, and outdoor media advertising. The company's product portfolio includes EV ARC (electric vehicle autonomous renewable charger), an infrastructure product that uses integrated solar power and battery storage to provide a source of power for factory installed electric vehicle charging stations; Solar Tree DCFC, an off-grid, renewably energized, and single-column mounted smart generation and energy storage system to provide a 50kW DC fast charge to one or more electric vehicles or larger vehicles; and EV ARC DCFC, a DC fast charging system for charging EVs. It is also developing EV-Standard, a lamp standard, EV charging, and emergency power product that uses an existing streetlamp's foundation and a combination of solar, wind, grid connection, and onboard energy storage to provide curbside charging; and UAV ARC, an off-grid and renewably energized product and network used to charge aerial drone (UAV) fleets. The company was formerly known as Envision Solar International, Inc. and changed its name to Beam Global in September 2020. Beam Global was incorporated in 2006 and is headquartered in San Diego, California.",Mr. Desmond  Wheatley,Solar,0.0997,USD,1334957,https://images.financialmodelingprep.com/symbol/BEEMW.png,0,0,-0.0502,32367,-14174000,-16059999,"[{'period': '2023', 'revenue': 67.35, 'unit': 'M', 'net_profit': -16.06}, {'period': '2022', 'revenue': 22.0, 'unit': 'M', 'net_profit': -19.68}, {'period': '2021', 'revenue': 9.0, 'unit': 'M', 'net_profit': -6.6}, {'period': '2020', 'revenue': 6.21, 'unit': 'M', 'net_profit': -5.21}]","[{'period': ""Q3 '24"", 'revenue': 11.48, 'unit': 'M', 'net_profit': 1.3}, {'period': ""Q2 '24"", 'revenue': 14.81, 'unit': 'M', 'net_profit': -4.92}, {'period': ""Q1 '24"", 'revenue': 14.56, 'unit': 'M', 'net_profit': -3.04}, {'period': ""Q4 '23"", 'revenue': 20.03, 'unit': 'M', 'net_profit': -5.07}, {'period': ""Q3 '23"", 'revenue': 16.49, 'unit': 'M', 'net_profit': -3.63}, {'period': ""Q2 '23"", 'revenue': 17.82, 'unit': 'M', 'net_profit': -3.53}]",-1.3,-1.3,77643000,40722000,10393000,28101000,16059000,0,16874000,10393000,-14364000,0.2363146551724138,0.18402606442434713,0.34673366834170855,__nan__,__nan__,__nan__,0.3619257370271628
484,BELFA,Bel Fuse Inc. Class A Common Stock,"Bel Fuse Inc. designs, manufactures, markets, and sells products that are used in the networking, telecommunication, high-speed data transmission, commercial aerospace, military, broadcasting, transportation, e-Mobility and broadcasting, and consumer electronic industries in the United States, Macao, the United Kingdom, Slovakia, Germany, Switzerland, and internationally. It offers magnetic products, such as integrated connector modules; power transformers; SMD power inductors and SMPS transformers; and ethernet discrete components. The company also provides power solutions and protection products comprising front-end power supplies; board-mount power; industrial power; external power; and circuit protection products. In addition, it offers connectivity solutions, which includes expanded beam fiber optic connectors, cable assemblies, and active optical devices; copper-based connectors/cable assemblies; radio frequency connectors, cable assemblies, microwave devices, and low loss cables; and ethernet, I/O, and industrial and power connectivity. The company sells its products under the Bel, TRP Connector, MagJack, Signal, Bel Power Solutions, Melcher, CUI, Stratos, Fibreco, Cinch, Johnson, Trompeter, Midwest Microwave, Semflex, and Stewart Connector brands through direct strategic account managers, regional sales managers working with independent sales representative organizations, and authorized distributors. Bel Fuse Inc. was incorporated in 1949 and is headquartered in Jersey City, New Jersey.",Mr. Daniel  Bernstein,"Hardware, Equipment & Parts",87.01,USD,1002742133,https://images.financialmodelingprep.com/symbol/BELFA.png,11025,21.12,-2.49,12252,99462000,73831000,"[{'period': '2023', 'revenue': 639.81, 'unit': 'M', 'net_profit': 73.83}, {'period': '2022', 'revenue': 654.23, 'unit': 'M', 'net_profit': 52.69}, {'period': '2021', 'revenue': 543.49, 'unit': 'M', 'net_profit': 24.82}, {'period': '2020', 'revenue': 465.77, 'unit': 'M', 'net_profit': 12.79}]","[{'period': ""Q3 '24"", 'revenue': 123.64, 'unit': 'M', 'net_profit': 8.08}, {'period': ""Q2 '24"", 'revenue': 133.21, 'unit': 'M', 'net_profit': 18.81}, {'period': ""Q1 '24"", 'revenue': 128.09, 'unit': 'M', 'net_profit': 15.87}, {'period': ""Q4 '23"", 'revenue': 140.01, 'unit': 'M', 'net_profit': 12.04}, {'period': ""Q3 '23"", 'revenue': 158.68, 'unit': 'M', 'net_profit': 19.45}, {'period': ""Q2 '23"", 'revenue': 168.78, 'unit': 'M', 'net_profit': 27.77}]",5.78,5.78,571631000,381478000,126919000,231073000,96922000,10282000,110609000,89371000,96223000,0.1730669434353918,0.401260225094422,0.5663956639566397,"[0.06, 0.05]","['2025-01-15', '2000-07-12']",__nan__,0.40423454991069413
485,BELFB,Bel Fuse Inc. Class B Common Stock,"Bel Fuse Inc. designs, manufactures, markets, and sells products that are used in the networking, telecommunication, high-speed data transmission, commercial aerospace, military, broadcasting, transportation, e-Mobility and broadcasting, and consumer electronic industries in the United States, Macao, the United Kingdom, Slovakia, Germany, Switzerland, and internationally. It offers magnetic products, such as integrated connector modules; power transformers; SMD power inductors and SMPS transformers; and ethernet discrete components. The company also provides power solutions and protection products comprising front-end power supplies; board-mount power; industrial power; external power; and circuit protection products. In addition, it offers connectivity solutions, which includes expanded beam fiber optic connectors, cable assemblies, and active optical devices; copper-based connectors/cable assemblies; radio frequency connectors, cable assemblies, microwave devices, and low loss cables; and ethernet, I/O, and industrial and power connectivity. The company sells its products under the Bel, TRP Connector, MagJack, Signal, Bel Power Solutions, Melcher, CUI, Stratos, Fibreco, Cinch, Johnson, Trompeter, Midwest Microwave, Semflex, and Stewart Connector brands through direct strategic account managers, regional sales managers working with independent sales representative organizations, and authorized distributors. Bel Fuse Inc. was incorporated in 1949 and is headquartered in Jersey City, New Jersey.",Mr. Daniel  Bernstein,"Hardware, Equipment & Parts",79.565,USD,1016427678,https://images.financialmodelingprep.com/symbol/BELFB.png,66838,19.31,-1.175,24769,99462000,73831000,"[{'period': '2023', 'revenue': 639.81, 'unit': 'M', 'net_profit': 73.83}, {'period': '2022', 'revenue': 654.23, 'unit': 'M', 'net_profit': 52.69}, {'period': '2021', 'revenue': 543.49, 'unit': 'M', 'net_profit': 24.82}, {'period': '2020', 'revenue': 465.77, 'unit': 'M', 'net_profit': 12.79}]","[{'period': ""Q3 '24"", 'revenue': 123.64, 'unit': 'M', 'net_profit': 8.08}, {'period': ""Q2 '24"", 'revenue': 133.21, 'unit': 'M', 'net_profit': 18.81}, {'period': ""Q1 '24"", 'revenue': 128.09, 'unit': 'M', 'net_profit': 15.87}, {'period': ""Q4 '23"", 'revenue': 140.01, 'unit': 'M', 'net_profit': 12.04}, {'period': ""Q3 '23"", 'revenue': 158.68, 'unit': 'M', 'net_profit': 19.45}, {'period': ""Q2 '23"", 'revenue': 168.78, 'unit': 'M', 'net_profit': 27.77}]",5.78,5.78,571631000,381478000,126919000,231073000,96922000,10282000,110609000,89371000,96223000,0.1730669434353918,0.401260225094422,0.5663956639566397,"[0.07, 0.1]","['2025-01-15', '1999-01-07']",__nan__,0.40423454991069413
486,BENE,Benessere Capital Acquisition Corp. Class A Common Stock,"Benessere Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology-focused companies in the North, Central, and South America. The company was incorporated in 2020 and is based in Miami, Florida.",,Shell Companies,10.44,USD,0,https://images.financialmodelingprep.com/symbol/BENE.png,30136,-62.142857142857146,0,20259,2057947,5787234,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.79}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -38.77}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.45}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.2}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.63}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 839.92}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -941.35}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.16}]",0.39,0.39,220.02000000000044,160.457,117.191,11352,0,116784,876.128,117.191,-997685,54.08091307712149,150.2709311323188,151,__nan__,__nan__,__nan__,51.59530951731651
487,BENER,Benessere Capital Acquisition Corp. Right,,,,0.0028,USD,0,https://images.financialmodelingprep.com/symbol/BENER.png,74426,0,-0.0012,328803,2057947,5787234,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.79}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -38.77}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.45}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.2}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.63}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 839.92}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -941.35}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.16}]",0.39,0.39,220.02000000000044,160.457,117.191,11352,0,116784,876.128,117.191,-997685,54.08091307712149,150.2709311323188,151,__nan__,__nan__,__nan__,51.59530951731651
488,BENEU,Benessere Capital Acquisition Corp. Unit,"Benessere Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology-focused companies in the North, Central, and South America. The company was incorporated in 2020 and is based in Miami, Florida.",Mr. Patrick F.  Orlando,Shell Companies,10.4201,USD,0,https://images.financialmodelingprep.com/symbol/BENEU.png,58,-62.02440476190476,-0.5249,1078,2057947,5787234,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.79}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -38.77}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.45}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.2}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.63}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 839.92}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -941.35}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.16}]",0.39,0.39,220.02000000000044,160.457,117.191,11352,0,116784,876.128,117.191,-997685,54.08091307712149,150.2709311323188,151,__nan__,__nan__,__nan__,51.59530951731651
489,BENEW,Benessere Capital Acquisition Corp. Warrant,,,Shell Companies,0.0025,USD,0,https://images.financialmodelingprep.com/symbol/BENEW.png,100921,0,0,419955,2057947,5787234,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.79}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -38.77}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.45}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.2}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.63}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 839.92}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -941.35}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.16}]",0.39,0.39,220.02000000000044,160.457,117.191,11352,0,116784,876.128,117.191,-997685,54.08091307712149,150.2709311323188,151,__nan__,__nan__,__nan__,51.59530951731651
490,BFC,Bank First Corporation Common Stock,"Bank First Corporation operates as a holding company for Bank First N.A. that provides consumer and commercial financial services to businesses, professionals, consumers, associations, individuals, and governmental authorities in Wisconsin. The company offers checking, savings, money market, cash management, retirement, and health savings accounts; other time deposits; certificates of deposit; and residential mortgage products. It also provides credit cards; ATM processing; insurance; data processing and other information technology; investment and safekeeping; treasury management; and online, telephone, and mobile banking services. The company's loan products include real estate loans, including commercial real estate, residential mortgage, and home equity loans; commercial and industrial loans for working capital, accounts receivable, inventory financing, and other business purposes; construction and development loans; residential 1-4 family loans; and consumer loans for personal and household purposes, including secured and unsecured installment loans, and revolving lines of credit. It operates through 21 offices in Manitowoc, Outagamie, Brown, Winnebago, Sheboygan, Waupaca, Ozaukee, Monroe, and Jefferson counties in Wisconsin. The company was formerly known as Bank First National Corporation and changed its name to Bank First Corporation in June 2019. Bank First Corporation was founded in 1894 and is headquartered in Manitowoc, Wisconsin.",Mr. Michael B. Molepske,Banks - Regional,96.135,USD,962513234,https://images.financialmodelingprep.com/symbol/BFC.png,17219,11.81,-0.715,6190,107191000,74514000,"[{'period': '2023', 'revenue': 179.01, 'unit': 'M', 'net_profit': 74.51}, {'period': '2022', 'revenue': 118.32, 'unit': 'M', 'net_profit': 45.21}, {'period': '2021', 'revenue': 108.48, 'unit': 'M', 'net_profit': 45.44}, {'period': '2020', 'revenue': 103.15, 'unit': 'M', 'net_profit': 38.05}]","[{'period': ""Q3 '24"", 'revenue': 39.71, 'unit': 'M', 'net_profit': 16.55}, {'period': ""Q2 '24"", 'revenue': 54.31, 'unit': 'M', 'net_profit': 16.06}, {'period': ""Q1 '24"", 'revenue': 52.7, 'unit': 'M', 'net_profit': 15.41}, {'period': ""Q4 '23"", 'revenue': 42.87, 'unit': 'M', 'net_profit': 34.9}, {'period': ""Q3 '23"", 'revenue': 37.68, 'unit': 'M', 'net_profit': 14.8}, {'period': ""Q2 '23"", 'revenue': 36.62, 'unit': 'M', 'net_profit': 14.13}]",7.28,7.26,4221842000,247468000,247468000,3602044000,0,234799000,0,247468000,39461000,0.6852076029367837,0.6480293714336267,0.30465949820788535,"[0.45, 0.105]","['2024-12-23', '2010-11-24']",__nan__,0.8531925164418753
491,BFI,BurgerFi International Inc. Common Stock ,"BurgerFi International, Inc., together with its subsidiaries, owns and franchises fast-casual and premium-casual dining restaurants. Its restaurants offer burgers, hot dogs, crispy chicken, frozen custard, hand-cut fries, shakes, beer, wine, pizza, coal fired chicken wings, homemade meatballs, and a variety of handcrafted sandwiches and salads. As of March 31, 2022, the company has 185 franchised and corporate-owned restaurants. The company was formerly known as Opes Acquisition Corp. and changed its name to BurgerFi International, Inc. in December 2020. BurgerFi International, Inc. was founded in 2011 and is headquartered in Fort Lauderdale, Florida.",Mr. Carl J. Bachmann,Restaurants,0.083,USD,2274491,https://images.financialmodelingprep.com/symbol/BFI.png,0,-0.08,,0,-913000,-30708000,"[{'period': '2023', 'revenue': 170.1, 'unit': 'M', 'net_profit': -30.71}, {'period': '2022', 'revenue': 178.72, 'unit': 'M', 'net_profit': -103.43}, {'period': '2021', 'revenue': 68.87, 'unit': 'M', 'net_profit': -121.49}, {'period': '2020', 'revenue': 32299.999999999996, 'unit': 'K', 'net_profit': 488.0}]","[{'period': ""Q1 '24"", 'revenue': 42.88, 'unit': 'M', 'net_profit': -6.54}, {'period': ""Q4 '23"", 'revenue': 41.47, 'unit': 'M', 'net_profit': -10.6}, {'period': ""Q3 '23"", 'revenue': 39.48, 'unit': 'M', 'net_profit': -4.96}, {'period': ""Q2 '23"", 'revenue': 43.43, 'unit': 'M', 'net_profit': -6.0}, {'period': ""Q1 '23"", 'revenue': 45.73, 'unit': 'M', 'net_profit': -13.38}, {'period': ""Q4 '22"", 'revenue': 45.23, 'unit': 'M', 'net_profit': -26.16}]",-1.2,-1.2,258476000,12500000,7556000,145597000,1368000,149633000,82692000,7556000,-7886000,0.9903750869721056,0.7031092891948333,0.7424892703862661,__nan__,__nan__,__nan__,0.5632902087621288
492,BFIIW,BurgerFi International Inc. Warrant ,"BurgerFi International, Inc., together with its subsidiaries, owns and franchises fast-casual and premium-casual dining restaurants. Its restaurants offer burgers, hot dogs, crispy chicken, frozen custard, hand-cut fries, shakes, beer, wine, pizza, coal fired chicken wings, homemade meatballs, and a variety of handcrafted sandwiches and salads. The company was formerly known as Opes Acquisition Corp. and changed its name to BurgerFi International, Inc. in December 2020. The company was founded in 2011 and is headquartered in Fort Lauderdale, Florida.",Mr. Carl J. Bachmann,Restaurants,0.009,USD,242318,https://images.financialmodelingprep.com/symbol/BFIIW.png,0,0,0.0014,121426,-913000,-30708000,"[{'period': '2023', 'revenue': 170.1, 'unit': 'M', 'net_profit': -30.71}, {'period': '2022', 'revenue': 178.72, 'unit': 'M', 'net_profit': -103.43}, {'period': '2021', 'revenue': 68.87, 'unit': 'M', 'net_profit': -121.49}, {'period': '2020', 'revenue': 32299.999999999996, 'unit': 'K', 'net_profit': 488.0}]","[{'period': ""Q1 '24"", 'revenue': 42.88, 'unit': 'M', 'net_profit': -6.54}, {'period': ""Q4 '23"", 'revenue': 41.47, 'unit': 'M', 'net_profit': -10.6}, {'period': ""Q3 '23"", 'revenue': 39.48, 'unit': 'M', 'net_profit': -4.96}, {'period': ""Q2 '23"", 'revenue': 43.43, 'unit': 'M', 'net_profit': -6.0}, {'period': ""Q1 '23"", 'revenue': 45.73, 'unit': 'M', 'net_profit': -13.38}, {'period': ""Q4 '22"", 'revenue': 45.23, 'unit': 'M', 'net_profit': -26.16}]",-1.2,-1.2,258476000,12500000,7556000,145597000,1368000,149633000,82692000,7556000,-7886000,0.9903750869721056,0.7031092891948333,0.7424892703862661,__nan__,__nan__,__nan__,0.5632902087621288
493,BFIN,BankFinancial Corporation Common Stock,"BankFinancial Corporation operates as the bank holding company for BankFinancial, National Association that provides various commercial, family, and personal banking products and services. The company accepts various deposit products, including savings, NOW, checking, money market, IRA, and other retirement accounts, as well as certificates of deposit. Its loan products include multi-family and nonresidential real estate, construction and land, and commercial loans and leases; one-to-four family residential mortgage loans, including home equity loans and lines of credit; and consumer loans. The company also provides cash management, funds transfer, bill payment, other online and mobile banking transactions, automated teller machines, safe deposit boxes, trust, wealth management, and general insurance agency services. In addition, it offers financial planning services; and sells property and casualty, and other insurance products on an agency basis. The company operates 19 full-service banking offices located in Cook, DuPage, Lake, and Will Counties, Illinois. BankFinancial Corporation was founded in 1924 and is headquartered in Burr Ridge, Illinois.",Mr. F. Morgan Gasior,Banks - Regional,12,USD,149528400,https://images.financialmodelingprep.com/symbol/BFIN.png,14661,19.05,-0.25,9588,0,9393000,"[{'period': '2023', 'revenue': 55.93, 'unit': 'M', 'net_profit': 9.39}, {'period': '2022', 'revenue': 56.79, 'unit': 'M', 'net_profit': 10.49}, {'period': '2021', 'revenue': 49.46, 'unit': 'M', 'net_profit': 7.41}, {'period': '2020', 'revenue': 51.25, 'unit': 'M', 'net_profit': 9.16}]","[{'period': ""Q3 '24"", 'revenue': 13.16, 'unit': 'M', 'net_profit': 1.99}, {'period': ""Q2 '24"", 'revenue': 18.94, 'unit': 'M', 'net_profit': 2.13}, {'period': ""Q1 '24"", 'revenue': 18.77, 'unit': 'M', 'net_profit': 1.71}, {'period': ""Q4 '23"", 'revenue': 18.57, 'unit': 'M', 'net_profit': 2.08}, {'period': ""Q3 '23"", 'revenue': 16.89, 'unit': 'M', 'net_profit': 2.37}, {'period': ""Q2 '23"", 'revenue': 14.17, 'unit': 'M', 'net_profit': 2.31}]",0.74,0.74,1487384000,178484000,178484000,1332001000,7542000,166193000,0,178484000,8037000,-1,-0.10491709548313322,-0.07500000000000007,"[0.1, 0.06]","['2024-11-15', '2006-05-01']",__nan__,0.8955326936419916
494,BFRA,Biofrontera AG American Depositary Shares,"Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.",Dr. Hermann Lbbert,Biotechnology,2.67,USD,0,https://images.financialmodelingprep.com/symbol/BFRA.png,30523,-4.348534201954397,-0.07999992,4951,-4284000,-13023000,"[{'period': '2020', 'revenue': 30.35, 'unit': 'M', 'net_profit': -13.02}, {'period': '2019', 'revenue': 31.27, 'unit': 'M', 'net_profit': -7.64}, {'period': '2018', 'revenue': 21.11, 'unit': 'M', 'net_profit': -8.88}, {'period': '2017', 'revenue': 12.03, 'unit': 'M', 'net_profit': -16.1}]","[{'period': ""Q3 '21"", 'revenue': 5.38, 'unit': 'M', 'net_profit': -5.73}, {'period': ""Q2 '21"", 'revenue': 7.62, 'unit': 'M', 'net_profit': -4.0}, {'period': ""Q1 '21"", 'revenue': 5.48, 'unit': 'M', 'net_profit': -4.88}, {'period': ""Q4 '20"", 'revenue': 9.52, 'unit': 'M', 'net_profit': -2.12}, {'period': ""Q3 '20"", 'revenue': 4.71, 'unit': 'M', 'net_profit': -5.5}, {'period': ""Q2 '20"", 'revenue': 9640.0, 'unit': 'K', 'net_profit': 93.0}]",-0.47,-0.47,56390000,26126000,17077000,49016000,3506000,0,8286000,16546000,-3623000,-6.3283582089552235,-0.7036891679748822,-0.4242424242424241,"[0.1039, 0.0221]","['2021-02-24', '2020-03-18']",__nan__,0.8692321333569782
495,BFST,Business First Bancshares Inc. Common Stock,"Business First Bancshares, Inc. operates as the bank holding company for b1BANK that provides various banking products and services. It offers various deposit products and services, including checking, demand, money market, time, and savings accounts; and certificates of deposits, remote deposit capture, and direct deposit services. The company also provides commercial and industrial loans, such as commercial lines of credit, letters of credit, working capital, term, equipment financing, asset acquisition, expansion and development, borrowing base, and other loan products; construction and development loans; commercial real estate loans; residential real estate loans comprising first and second lien 1-4 family mortgage loans, and home equity lines of credit; and consumer loans, including secured and unsecured installment and term loans. In addition, it offers wealth management products, including mutual funds, annuities, individual retirement accounts, and other financial products, as well as other fiduciary services and private banking products and services. Further, the company provides a range of other financial services comprising debit and credit cards, treasury and cash management, merchant, automated clearing house, lock-box, receivables factoring, correspondent banking, and other treasury services, as well as employee and payroll benefits solutions; and drive-through banking facilities, automated teller machines, night depository, personalized checks, electronic funds transfer, domestic and foreign wire transfer, traveler's checks, vault, loan and deposit sweep accounts, online and mobile banking, e-statements, and bank-by-mail services. As of March 01, 2022, it operates approximately 48 full-service banking centers and three loan production offices across Louisiana, and in the Dallas and Houston markets. Business First Bancshares, Inc. was incorporated in 2006 and is headquartered in Baton Rouge, Louisiana.",Mr. David R. Melville III,Banks - Regional,24.5,USD,723766750,https://images.financialmodelingprep.com/symbol/BFST.png,99503,10.56,-0.43,69591,0,71043000,"[{'period': '2023', 'revenue': 247.42, 'unit': 'M', 'net_profit': 71.04}, {'period': '2022', 'revenue': 227.54, 'unit': 'M', 'net_profit': 54.26}, {'period': '2021', 'revenue': 186.56, 'unit': 'M', 'net_profit': 52.14}, {'period': '2020', 'revenue': 149.21, 'unit': 'M', 'net_profit': 29.99}]","[{'period': ""Q3 '24"", 'revenue': 66.55, 'unit': 'M', 'net_profit': 17.84}, {'period': ""Q2 '24"", 'revenue': 111.65, 'unit': 'M', 'net_profit': 17.21}, {'period': ""Q1 '24"", 'revenue': 105.1, 'unit': 'M', 'net_profit': 13.57}, {'period': ""Q4 '23"", 'revenue': 100.56, 'unit': 'M', 'net_profit': 15.82}, {'period': ""Q3 '23"", 'revenue': 63.74, 'unit': 'M', 'net_profit': 20.45}, {'period': ""Q2 '23"", 'revenue': 61.53, 'unit': 'M', 'net_profit': 19.74}]",2.62,2.59,6584550000,377244000,377244000,5940291000,0,913513000,0,226110000,80779000,0,0.30942770251589713,0.11965811965811977,"[0.14, 0.08]","['2024-11-15', '2018-05-14']",__nan__,0.9021559559878807
496,BGCP,BGC Partners Inc Class A Common Stock,"BGC Partners, Inc. operates as a financial brokerage and technology company in the United States, France, other Europe, the United Kingdom, other Americas, Asia, Australia, Africa, and the Middle East. It offers various brokerage products, such as fixed income, such as government bonds, corporate bonds, and other debt instruments, as well as related interest rate derivatives and credit derivatives; and fixed income, equity derivatives and cash equities, energy and commodities, shipping, insurance, and futures and options. The company also provides trade execution, brokerage, clearing, trade compression, post-trade, information, consulting, and other back office services to financial and non-financial institutions. In addition, it offers electronic and hybrid brokerage, other financial technology solutions, market data and related information services, and analytics related to financial instrument and markets under the Fenics, FMX, BGC Trader, CreditMatch, Fenics Market Data, Fenics GO, BGC Market Data, kACE2, Capitalab, Swaptioniser, CBID, Lucera, and LumeAlfa brand names. Further, the company provides screen-based market solutions, which enable its clients to develop a marketplace, trade with their customers, issue debt, trade odd lots, access program trading interfaces, and access its network and intellectual property; option pricing and analysis tools; and software and technology infrastructure for the transactional and technology related elements. It primarily serves banks, broker-dealers, investment banks, trading firms, hedge funds, governments, and corporations, as well as investment firms. BGC Partners, Inc. was founded in 1945 and is headquartered in New York, New York.",Mr. Howard W. Lutnick,Financial - Capital Markets,4.43,USD,1734216446,https://images.financialmodelingprep.com/symbol/BGCP.png,2433100,40.27272727272727,0.06,3475885,1740376000,34070000,"[{'period': '2023', 'revenue': 2029.9999999999998, 'unit': 'M', 'net_profit': 34.07}, {'period': '2022', 'revenue': 1800.0, 'unit': 'M', 'net_profit': 48.71}, {'period': '2021', 'revenue': 2020.0, 'unit': 'M', 'net_profit': 124.01}, {'period': '2020', 'revenue': 2060.0, 'unit': 'M', 'net_profit': 48.91}]","[{'period': ""Q3 '23"", 'revenue': 482.69, 'unit': 'M', 'net_profit': 15.97}, {'period': ""Q2 '23"", 'revenue': 493.08, 'unit': 'M', 'net_profit': -19.7}, {'period': ""Q1 '23"", 'revenue': 532.87, 'unit': 'M', 'net_profit': 18.98}, {'period': ""Q4 '22"", 'revenue': 436.51, 'unit': 'M', 'net_profit': 3.6}, {'period': ""Q3 '22"", 'revenue': 416.57, 'unit': 'M', 'net_profit': 8.22}, {'period': ""Q2 '22"", 'revenue': 435.76, 'unit': 'M', 'net_profit': 14.76}]",0.0695,0.0695,3175937000,1005677000,655641000,0,350036000,0,0,655641000,29441000,10.12687006112063,-0.3005830185580555,-0.46538461538461534,"[0.01, 0.2021]","['2023-05-16', '2008-09-11']",__nan__,0.0
497,BGFV,Big 5 Sporting Goods Corporation Common Stock,"Big 5 Sporting Goods Corporation operates as a sporting goods retailer in the western United States. The company's products include athletic shoes, apparel, and accessories. It also offers a selection of outdoor and athletic equipment for team sports, fitness, camping, hunting, fishing, tennis, golf, and winter and summer recreation, as well as home recreation. The company also provides private label items, such as shoes, apparel, camping equipment, fishing supplies, and snow sport equipment. It sells private label merchandise under its own trademarks comprising Golden Bear, Harsh, Pacifica, and Rugged Exposure. As of May 03, 2022, the company operated 431 stores. It also operates an e-commerce platform under the Big 5 Sporting Goods name. The company was founded in 1955 and is headquartered in El Segundo, California.",Mr. Steven G. Miller,Specialty Retail,1.855,USD,42108129,https://images.financialmodelingprep.com/symbol/BGFV.png,308053,-0.71,-0.005,154453,8176000,-7083000,"[{'period': '2023', 'revenue': 884.75, 'unit': 'M', 'net_profit': -7.08}, {'period': '2022', 'revenue': 995.54, 'unit': 'M', 'net_profit': 26.13}, {'period': '2021', 'revenue': 1160.0, 'unit': 'M', 'net_profit': 102.39}, {'period': '2020', 'revenue': 1040.0, 'unit': 'M', 'net_profit': 55.94}]","[{'period': ""Q3 '24"", 'revenue': 220.6, 'unit': 'M', 'net_profit': -29.9}, {'period': ""Q2 '24"", 'revenue': 199.82, 'unit': 'M', 'net_profit': -10.0}, {'period': ""Q1 '24"", 'revenue': 193.43, 'unit': 'M', 'net_profit': -8.29}, {'period': ""Q4 '23"", 'revenue': 196.35, 'unit': 'M', 'net_profit': -8.85}, {'period': ""Q3 '23"", 'revenue': 239.89, 'unit': 'M', 'net_profit': 1.86}, {'period': ""Q2 '23"", 'revenue': 223570.0, 'unit': 'K', 'net_profit': -282.0}]",-0.33,-0.33,644683000,310175000,9201000,400269000,9163000,0,190699000,9201000,7516000,-0.836440745778987,-1.2710262493303743,-1.2727272727272727,"[0.05, 0.07]","['2024-05-31', '2004-11-29']",__nan__,0.620877237339902
498,BGNE,BeiGene Ltd. American Depositary Shares,"BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.",Mr. John V. Oyler,Biotechnology,184.71,USD,20209121100,https://images.financialmodelingprep.com/symbol/BGNE.png,369150,-22.55,0.9,329397,-1124611000,-881708000,"[{'period': '2023', 'revenue': 2460.0, 'unit': 'M', 'net_profit': -881.71}, {'period': '2022', 'revenue': 1.42, 'unit': 'B', 'net_profit': -2.0}, {'period': '2021', 'revenue': 1.18, 'unit': 'B', 'net_profit': -1.41}, {'period': '2020', 'revenue': 0.30887000000000003, 'unit': 'B', 'net_profit': -1.6}]","[{'period': ""Q3 '24"", 'revenue': 1000.0, 'unit': 'M', 'net_profit': -121.35}, {'period': ""Q2 '24"", 'revenue': 929.17, 'unit': 'M', 'net_profit': -120.41}, {'period': ""Q1 '24"", 'revenue': 751.65, 'unit': 'M', 'net_profit': -251.15}, {'period': ""Q4 '23"", 'revenue': 634.41, 'unit': 'M', 'net_profit': -367.55}, {'period': ""Q3 '23"", 'revenue': 781.31, 'unit': 'M', 'net_profit': 215.41}, {'period': ""Q2 '23"", 'revenue': 595.26, 'unit': 'M', 'net_profit': -381.14}]",-8.45,-8.45,5805275000,4203413999,3174400000,2267948000,395886000,89644000,1810113000,3171800000,-1738714000,0.3489660610053241,0.5599853279868651,0.5651055069480185,__nan__,__nan__,__nan__,0.39067020942160363
499,BHAT,Blue Hat Interactive Entertainment Technology Ordinary Shares,"Fujian Blue Hat Interactive Entertainment Technology Ltd. engages in the designing, producing, promoting, and selling animated toys with mobile games features, intellectual property, and peripheral derivatives features worldwide. It offers AR Racer, a car-racing mobile game; AR Crazy Bug, a combat game played using a ladybug-shaped electronic toy; AR 3D Magic Box, which uses AR recognition technology to allow children to draw shapes or objects onto a physical card while the mobile game captures the drawings and animates them onto a set background; AR Dinosaur, an educational toy; 'Talking Tom and Friends' Bouncing Bubble, which enables children to bounce and play with bubbles; and AR Shake Bouncing Bubble, which helps children to improve concentration and reaction. The company also holds license to sell products with WUHUANGWANSHUI brand images. Its distribution channels include domestic distributors, e-commerce platforms, supermarkets, and export distributors. Fujian Blue Hat Interactive Entertainment Technology Ltd. was incorporated in 2010 and is based in Xiamen, China.",Mr. Xiaodong  Chen,Electronic Gaming & Multimedia,0.1102,USD,6435493,https://images.financialmodelingprep.com/symbol/BHAT.png,6419629,-0.17,0.0207,106981998,-28397097,-26687328,"[{'period': '2023', 'revenue': 73.69, 'unit': 'M', 'net_profit': -26.69}, {'period': '2022', 'revenue': 7.38, 'unit': 'M', 'net_profit': -9.41}, {'period': '2021', 'revenue': 15.16, 'unit': 'M', 'net_profit': -61.55}, {'period': '2020', 'revenue': 30.19, 'unit': 'M', 'net_profit': 8.17}]","[{'period': ""Q4 '23"", 'revenue': 13.69, 'unit': 'M', 'net_profit': -11.16}, {'period': ""Q3 '23"", 'revenue': 13.69, 'unit': 'M', 'net_profit': -11.16}, {'period': ""Q2 '23"", 'revenue': 23.15, 'unit': 'M', 'net_profit': -2.19}, {'period': ""Q1 '23"", 'revenue': 23.15, 'unit': 'M', 'net_profit': -2.19}, {'period': ""Q4 '22"", 'revenue': 0.69589, 'unit': 'M', 'net_profit': -3.77}, {'period': ""Q3 '22"", 'revenue': 0.69589, 'unit': 'M', 'net_profit': -3.77}]",-0.65,-0.65,49262838,39282300,407588,8640763,21291384,1694269,5664392,407588,-2111571,-2.7676663236501486,-1.8375436638982694,0.47154471544715443,__nan__,__nan__,__nan__,0.1754012426161887
500,BHF,Brighthouse Financial Inc. Common Stock,"Brighthouse Financial, Inc. provides annuity and life insurance products in the United States. It operates through three segments: Annuities, Life, and Run-off. The Annuities segment offers variable, fixed, index-linked, and income annuities for contract holders' needs for protected wealth accumulation on a tax-deferred basis, wealth transfer, and income security. The Life segment provides term, universal, whole, and variable life policies for policyholders' needs for financial security and protected wealth transfer. The Run-off segment manages structured settlements, pension risk transfer contracts, certain company-owned life insurance policies, funding agreements, and universal life with secondary guarantees. The company was incorporated in 2016 and is based in Charlotte, North Carolina.",Mr. Eric Thomas Steigerwalt,Insurance - Life,48.52,USD,2879865784,https://images.financialmodelingprep.com/symbol/BHF.png,368480,-2.41,0.48,91688,0,-1112000000,"[{'period': '2023', 'revenue': 4.12, 'unit': 'B', 'net_profit': -1.11}, {'period': '2022', 'revenue': 8470.0, 'unit': 'M', 'net_profit': 10.0}, {'period': '2021', 'revenue': 7140.0, 'unit': 'M', 'net_profit': -103.0}, {'period': '2020', 'revenue': 8.5, 'unit': 'B', 'net_profit': -1.06}]","[{'period': ""Q3 '24"", 'revenue': 2020.0, 'unit': 'M', 'net_profit': 176.0}, {'period': ""Q2 '24"", 'revenue': 1430.0, 'unit': 'M', 'net_profit': 34.0}, {'period': ""Q1 '24"", 'revenue': 74.0, 'unit': 'M', 'net_profit': -493.0}, {'period': ""Q4 '23"", 'revenue': 737.0, 'unit': 'M', 'net_profit': -917.0}, {'period': ""Q3 '23"", 'revenue': 1170.0, 'unit': 'M', 'net_profit': 479.0}, {'period': ""Q2 '23"", 'revenue': 263.0, 'unit': 'M', 'net_profit': -175.0}]",-19.12,-18.39,236340000000,3851000000,3851000000,231332000000,0,9110000000,0,3851000000,-137000000,0,-112.2,-137.57142857142858,__nan__,__nan__,__nan__,0.9788101887111789
501,BHFAL,Brighthouse Financial Inc. 6.25% Junior Subordinated Debentures due 2058,"Brighthouse Financial, Inc. operates as a holding company, which engages in the provision of life insurance and annuities through independent distribution channels and marketing arrangements with a diverse network of distribution partners. It operates through the following segments: Annuities, Life, Run-Off, and Corporate & Others. The Annuities segment product offerings include fixed, structured, income and variable annuities. The Life segment manufactures products to serve its target segments through a broad independent distribution network. The Run-Off segment includes structured settlements, pension risk transfer contracts, certain company-owned life insurance policies, funding agreements and universal life with secondary guarantees. The Corporate & Other segment refers to the general account investments and the separate account assets of the company. The company was founded in June 1863 and is headquartered in Charlotte, NC.",None,Insurance - Life,23.72,USD,2784466772,https://images.financialmodelingprep.com/symbol/BHFAL.png,24056,-4.88,-0.48,5470,0,-1112000000,"[{'period': '2023', 'revenue': 4.12, 'unit': 'B', 'net_profit': -1.11}, {'period': '2022', 'revenue': 8470.0, 'unit': 'M', 'net_profit': 10.0}, {'period': '2021', 'revenue': 7140.0, 'unit': 'M', 'net_profit': -103.0}, {'period': '2020', 'revenue': 8.5, 'unit': 'B', 'net_profit': -1.06}]","[{'period': ""Q3 '24"", 'revenue': 2020.0, 'unit': 'M', 'net_profit': 176.0}, {'period': ""Q2 '24"", 'revenue': 1430.0, 'unit': 'M', 'net_profit': 34.0}, {'period': ""Q1 '24"", 'revenue': 74.0, 'unit': 'M', 'net_profit': -493.0}, {'period': ""Q4 '23"", 'revenue': 737.0, 'unit': 'M', 'net_profit': -917.0}, {'period': ""Q3 '23"", 'revenue': 1170.0, 'unit': 'M', 'net_profit': 479.0}, {'period': ""Q2 '23"", 'revenue': 263.0, 'unit': 'M', 'net_profit': -175.0}]",-19.12,-18.39,236340000000,3851000000,3851000000,231332000000,0,9110000000,0,3851000000,-137000000,0,-112.2,-137.57142857142858,"[0.39063, 0.391]","['2024-11-29', '2019-02-28']",__nan__,0.9788101887111789
502,BHFAN,Brighthouse Financial Inc. Depositary shares each representing a 1/1000th interest in a share of 5.375% Non-Cumulative Preferred Stock Series C,"Brighthouse Financial, Inc. provides annuity and life insurance products in the United States. It operates through three segments: Annuities, Life, and Run-off. The Annuities segment offers variable, fixed, index-linked, and income annuities for contract holders' needs for protected wealth accumulation on a tax-deferred basis, wealth transfer, and income security. The Life segment provides term, universal, whole, and variable life policies for policyholders' needs for financial security and protected wealth transfer. The Run-off segment manages structured settlements, pension risk transfer contracts, certain company-owned life insurance policies, funding agreements, and universal life with secondary guarantees. The company was incorporated in 2016 and is based in Charlotte, North Carolina.",Mr. Eric Thomas Steigerwalt,Insurance - Life,19.01,USD,1128323342,https://images.financialmodelingprep.com/symbol/BHFAN.png,67479,1.51,-0.52,22875,0,-1112000000,"[{'period': '2023', 'revenue': 4.12, 'unit': 'B', 'net_profit': -1.11}, {'period': '2022', 'revenue': 8470.0, 'unit': 'M', 'net_profit': 10.0}, {'period': '2021', 'revenue': 7140.0, 'unit': 'M', 'net_profit': -103.0}, {'period': '2020', 'revenue': 8.5, 'unit': 'B', 'net_profit': -1.06}]","[{'period': ""Q3 '24"", 'revenue': 2020.0, 'unit': 'M', 'net_profit': 176.0}, {'period': ""Q2 '24"", 'revenue': 1430.0, 'unit': 'M', 'net_profit': 34.0}, {'period': ""Q1 '24"", 'revenue': 74.0, 'unit': 'M', 'net_profit': -493.0}, {'period': ""Q4 '23"", 'revenue': 737.0, 'unit': 'M', 'net_profit': -917.0}, {'period': ""Q3 '23"", 'revenue': 1170.0, 'unit': 'M', 'net_profit': 479.0}, {'period': ""Q2 '23"", 'revenue': 263.0, 'unit': 'M', 'net_profit': -175.0}]",-19.12,-18.39,236340000000,3851000000,3851000000,231332000000,0,9110000000,0,3851000000,-137000000,0,-112.2,-137.57142857142858,"[0.33594, 0.467]","['2024-12-10', '2021-03-09']",__nan__,0.9788101887111789
503,BHFAO,Brighthouse Financial Inc. Depositary Shares 6.75% Non-Cumulative Preferred Stock Series B,"Brighthouse Financial, Inc. provides annuity and life insurance products in the United States. It operates through three segments: Annuities, Life, and Run-off. The Annuities segment offers variable, fixed, index-linked, and income annuities for contract holders' needs for protected wealth accumulation on a tax-deferred basis, wealth transfer, and income security. The Life segment provides term, universal, whole, and variable life policies for policyholders' needs for financial security and protected wealth transfer. The Run-off segment manages structured settlements, pension risk transfer contracts, certain company-owned life insurance policies, funding agreements, and universal life with secondary guarantees. The company was incorporated in 2016 and is based in Charlotte, North Carolina.",Mr. Eric Thomas Steigerwalt,Insurance - Life,23.17,USD,1375236814,https://images.financialmodelingprep.com/symbol/BHFAO.png,41054,1.84,-0.4,13644,0,-1112000000,"[{'period': '2023', 'revenue': 4.12, 'unit': 'B', 'net_profit': -1.11}, {'period': '2022', 'revenue': 8470.0, 'unit': 'M', 'net_profit': 10.0}, {'period': '2021', 'revenue': 7140.0, 'unit': 'M', 'net_profit': -103.0}, {'period': '2020', 'revenue': 8.5, 'unit': 'B', 'net_profit': -1.06}]","[{'period': ""Q3 '24"", 'revenue': 2020.0, 'unit': 'M', 'net_profit': 176.0}, {'period': ""Q2 '24"", 'revenue': 1430.0, 'unit': 'M', 'net_profit': 34.0}, {'period': ""Q1 '24"", 'revenue': 74.0, 'unit': 'M', 'net_profit': -493.0}, {'period': ""Q4 '23"", 'revenue': 737.0, 'unit': 'M', 'net_profit': -917.0}, {'period': ""Q3 '23"", 'revenue': 1170.0, 'unit': 'M', 'net_profit': 479.0}, {'period': ""Q2 '23"", 'revenue': 263.0, 'unit': 'M', 'net_profit': -175.0}]",-19.12,-18.39,236340000000,3851000000,3851000000,231332000000,0,9110000000,0,3851000000,-137000000,0,-112.2,-137.57142857142858,"[0.42188, 0.595]","['2024-12-10', '2020-09-09']",__nan__,0.9788101887111789
504,BHFAP,Brighthouse Financial Inc. Depositary Shares 6.6% Non-Cumulative Preferred Stock Series A,"Brighthouse Financial, Inc. provides annuity and life insurance products in the United States. It operates through three segments: Annuities, Life, and Run-off. The Annuities segment offers variable, fixed, index-linked, and income annuities for contract holders' needs for protected wealth accumulation on a tax-deferred basis, wealth transfer, and income security. The Life segment provides term, universal, whole, and variable life policies for policyholders' needs for financial security and protected wealth transfer. The Run-off segment manages structured settlements, pension risk transfer contracts, certain company-owned life insurance policies, funding agreements, and universal life with secondary guarantees. The company was incorporated in 2016 and is based in Charlotte, North Carolina.",Mr. Eric Thomas Steigerwalt,Insurance - Life,22.3,USD,2788848258,https://images.financialmodelingprep.com/symbol/BHFAP.png,37038,1.77,-0.5,20654,0,-1112000000,"[{'period': '2023', 'revenue': 4.12, 'unit': 'B', 'net_profit': -1.11}, {'period': '2022', 'revenue': 8470.0, 'unit': 'M', 'net_profit': 10.0}, {'period': '2021', 'revenue': 7140.0, 'unit': 'M', 'net_profit': -103.0}, {'period': '2020', 'revenue': 8.5, 'unit': 'B', 'net_profit': -1.06}]","[{'period': ""Q3 '24"", 'revenue': 2020.0, 'unit': 'M', 'net_profit': 176.0}, {'period': ""Q2 '24"", 'revenue': 1430.0, 'unit': 'M', 'net_profit': 34.0}, {'period': ""Q1 '24"", 'revenue': 74.0, 'unit': 'M', 'net_profit': -493.0}, {'period': ""Q4 '23"", 'revenue': 737.0, 'unit': 'M', 'net_profit': -917.0}, {'period': ""Q3 '23"", 'revenue': 1170.0, 'unit': 'M', 'net_profit': 479.0}, {'period': ""Q2 '23"", 'revenue': 263.0, 'unit': 'M', 'net_profit': -175.0}]",-19.12,-18.39,236340000000,3851000000,3851000000,231332000000,0,9110000000,0,3851000000,-137000000,0,-112.2,-137.57142857142858,"[0.4125, 0.413]","['2024-12-10', '2019-06-07']",__nan__,0.9788101887111789
505,BHSE,Bull Horn Holdings Corp. Ordinary Shares,"Bull Horn Holdings Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the sports, entertainment, and brand sectors. The company was incorporated in 2018 and is based in Miami Beach, Florida.",,Shell Companies,11.95,USD,234718303,https://images.financialmodelingprep.com/symbol/BHSE.png,27407,11.95,3.69,1176367,-20157618,-21266537,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.27}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -40.97}, {'period': '2021', 'revenue': 0.075, 'unit': 'M', 'net_profit': -14.42}, {'period': '2020', 'revenue': 0.030760000000000003, 'unit': 'M', 'net_profit': -7.01}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.83}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.04}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.0}, {'period': ""Q4 '23"", 'revenue': 1.5, 'unit': 'M', 'net_profit': -3.76}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.26}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.11}]",-0.83,-0.83,4571089,1749713,1469134,3757125,38978,0,2988696,1469134,-7239510,0.44552500380834004,0.4808957697686124,0.7108013937282229,__nan__,__nan__,__nan__,0.821932147897361
506,BHSEU,Bull Horn Holdings Corp. Unit,"Bull Horn Holdings Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the sports, entertainment, and brand sectors. The company was incorporated in 2018 and is based in Miami Beach, Florida.",Mr. Robert  Striar,Shell Companies,12.96,USD,0,https://images.financialmodelingprep.com/symbol/BHSEU.png,743,27.99136069114471,3.36,5787,-20157618,-21266537,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.27}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -40.97}, {'period': '2021', 'revenue': 0.075, 'unit': 'M', 'net_profit': -14.42}, {'period': '2020', 'revenue': 0.030760000000000003, 'unit': 'M', 'net_profit': -7.01}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.83}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.04}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.0}, {'period': ""Q4 '23"", 'revenue': 1.5, 'unit': 'M', 'net_profit': -3.76}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.26}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.11}]",-0.83,-0.83,4571089,1749713,1469134,3757125,38978,0,2988696,1469134,-7239510,0.44552500380834004,0.4808957697686124,0.7108013937282229,__nan__,__nan__,__nan__,0.821932147897361
507,BHSEW,Bull Horn Holdings Corp. Warrants,"Bull Horn Holdings Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the sports, entertainment, and brands sectors. The company was founded in 2018 and is based in Miami Beach, Florida.",Mr. Robert  Striar,Shell Companies,0.12,USD,0,https://images.financialmodelingprep.com/symbol/BHSEW.png,0,0,0.0497,1777079,-20157618,-21266537,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.27}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -40.97}, {'period': '2021', 'revenue': 0.075, 'unit': 'M', 'net_profit': -14.42}, {'period': '2020', 'revenue': 0.030760000000000003, 'unit': 'M', 'net_profit': -7.01}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.83}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.04}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.0}, {'period': ""Q4 '23"", 'revenue': 1.5, 'unit': 'M', 'net_profit': -3.76}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.26}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.11}]",-0.83,-0.83,4571089,1749713,1469134,3757125,38978,0,2988696,1469134,-7239510,0.44552500380834004,0.4808957697686124,0.7108013937282229,__nan__,__nan__,__nan__,0.821932147897361
508,BHTG,BioHiTech Global Inc. Common Stock,"BioHiTech Global, Inc. engages in the provision of waste management services. The company is headquartered in Chestnut Ridge, New York and currently employs 27 full-time employees. The Company, through its subsidiaries, BioHiTech America, LLC and BioHiTech Europe Limited, offers its customers various technologies integrating technological, biological and mechanical engineering solutions for the control, reduction and/or reuse of organic waste. The company has a distribution license to sell, lease, use, distribute and manufacture the Eco-Safe Digester product. The Eco-Safe Digester is a data-driven, network-based mechanical/biological technology, which transforms food waste into nutrient-neutral water that can be disposed of via conventional sanitary sewer systems. The Eco-Safe Digester may be used by businesses in food service, hospitality, healthcare, government, conference centers, education centers or stadiums. Its Internet enabled system, the BioHiTech Cloud, streams data from the digesters, collects information from system users and integrates business application data.",Mr. Frank E. Celli,Industrial - Pollution & Treatment Controls,0.837,USD,29461982,https://images.financialmodelingprep.com/symbol/BHTG.png,447030,-2.551829268292683,-0.01309997,164762,-17517852,-15741839,"[{'period': '2020', 'revenue': 5.88, 'unit': 'M', 'net_profit': -15.74}, {'period': '2019', 'revenue': 4.22, 'unit': 'M', 'net_profit': -7.62}, {'period': '2018', 'revenue': 3.36, 'unit': 'M', 'net_profit': -14.67}, {'period': '2017', 'revenue': 2.42, 'unit': 'M', 'net_profit': -8.35}]","[{'period': ""Q3 '21"", 'revenue': 3940.0, 'unit': 'K', 'net_profit': 25.79}, {'period': ""Q2 '21"", 'revenue': 3.45, 'unit': 'M', 'net_profit': -2.38}, {'period': ""Q1 '21"", 'revenue': 3.04, 'unit': 'M', 'net_profit': -1.63}, {'period': ""Q4 '20"", 'revenue': 2500.0, 'unit': 'K', 'net_profit': -7.21}, {'period': ""Q3 '20"", 'revenue': 0.74288, 'unit': 'M', 'net_profit': -3.29}, {'period': ""Q2 '20"", 'revenue': 1.27, 'unit': 'M', 'net_profit': -2.66}]",-0.65,-0.65,56686425,6741981,3115161,52605248,1574047,711302,18349491,2403859,-8758207,-5.96236997610565,-1.0650592133122252,-0.32653061224489804,__nan__,__nan__,__nan__,0.9280043326069689
509,BIDU,Baidu Inc. ADS,"Baidu, Inc. offers internet search services in China. It operates through Baidu Core and iQIYI segments. The company offers Baidu App to access search, feed, and other services using mobile devices; Baidu Search to access its search and other services; Baidu Feed that provides users with personalized timeline based on their demographics and interests; and Haokan, a short video app. It also provides Baidu Knows, an online community where users can ask questions to other users; Baidu Wiki; Baidu Healthcare Wiki; Baidu Wenku; Baidu Scholar; Baidu Experience; Baidu Post; Baidu Maps, a voice-enabled mobile app that provides travel-related services; Baidu Drive; Baijiahao; and DuerOS, a smart assistant platform. In addition, it offers online marketing services, which include pay for performance, an auction-based services that allow customers to bid for priority placement of paid sponsored links and reach users who search for information related to their products or services; other marketing services that include display-based marketing services and other online marketing services based on performance criteria other than cost per click; mobile ecosystem, a portfolio of apps, including Baidu App, Haokan, and Baidu Post; various cloud services and solutions, such as platform as a service, software as a service, and infrastructure as a service; self-driving services, including maps, automated valet parking, autonomous navigation pilot, electric vehicles, and robotaxi fleets, as well as Xiaodu smart devices. Further, the company provides iQIYI, AN online entertainment service, including original and licensed content; other video content and membership; and online advertising services. Baidu, Inc. has strategic partnership with Zhejiang Geely Holding Group. The company was formerly known as Baidu.com, Inc. Baidu, Inc. was incorporated in 2000 and is headquartered in Beijing, China.",Mr. Yanhong  Li,Internet Content & Information,82.865,USD,28946235241,https://images.financialmodelingprep.com/symbol/BIDU.png,3370775,11.05,-0.515,1510755,36535000000,20315000000,"[{'period': '2023', 'revenue': 134.6, 'unit': 'B', 'net_profit': 20.32}, {'period': '2022', 'revenue': 123.67, 'unit': 'B', 'net_profit': 7.56}, {'period': '2021', 'revenue': 124.49, 'unit': 'B', 'net_profit': 7.59}, {'period': '2020', 'revenue': 107.07, 'unit': 'B', 'net_profit': 22.47}]","[{'period': ""Q3 '24"", 'revenue': 33.56, 'unit': 'B', 'net_profit': 7.63}, {'period': ""Q2 '24"", 'revenue': 33.93, 'unit': 'B', 'net_profit': 5.49}, {'period': ""Q1 '24"", 'revenue': 34.95, 'unit': 'B', 'net_profit': 2.6}, {'period': ""Q4 '23"", 'revenue': 34.95, 'unit': 'B', 'net_profit': 2.6}, {'period': ""Q3 '23"", 'revenue': 34.45, 'unit': 'B', 'net_profit': 6.68}, {'period': ""Q2 '23"", 'revenue': 34.06, 'unit': 'B', 'net_profit': 5.21}]",425.55,442.11,406759000000,230255000000,193901000000,144151000000,16620000000,72623000000,76451000000,25231000000,25320000000,1.5180922186229238,1.6875248048683689,20.2775,__nan__,__nan__,__nan__,0.3543892083518742
510,BIGC,BigCommerce Holdings Inc. Series 1 Common Stock,"BigCommerce Holdings, Inc. operates a software-as-a-service platform for small businesses, mid-markets, and large enterprises in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company's platform provides various services for launching and scaling e-commerce operation, including store design, catalog management, hosting, checkout, order management, reporting, and pre-integrations. As of December 31, 2021, it served approximately 60,000 online stores across industries. BigCommerce Holdings, Inc. was founded in 2009 and is headquartered in Austin, Texas.",Mr. Christopher Travis Hess,Software - Application,6.36,USD,498496800,https://images.financialmodelingprep.com/symbol/BIGC.png,905685,-17.67,-0.26,238008,-49306000,-64671000,"[{'period': '2023', 'revenue': 309.39, 'unit': 'M', 'net_profit': -64.67}, {'period': '2022', 'revenue': 279.07, 'unit': 'M', 'net_profit': -139.92}, {'period': '2021', 'revenue': 219.85, 'unit': 'M', 'net_profit': -76.68}, {'period': '2020', 'revenue': 152.37, 'unit': 'M', 'net_profit': -37.56}]","[{'period': ""Q3 '24"", 'revenue': 83.71, 'unit': 'M', 'net_profit': -6.99}, {'period': ""Q2 '24"", 'revenue': 81.83, 'unit': 'M', 'net_profit': -11.26}, {'period': ""Q1 '24"", 'revenue': 80.36, 'unit': 'M', 'net_profit': -6.39}, {'period': ""Q4 '23"", 'revenue': 84.15, 'unit': 'M', 'net_profit': -3.18}, {'period': ""Q3 '23"", 'revenue': 78.05, 'unit': 'M', 'net_profit': -20.31}, {'period': ""Q2 '23"", 'revenue': 75.44, 'unit': 'M', 'net_profit': -19.07}]",-0.86,-0.86,444058000,341986000,270134000,418525000,37713000,0,70750000,71719000,-28422000,0.6061003083707479,0.5377968681880231,0.5497382198952879,__nan__,__nan__,__nan__,0.9425007544059559
511,BIIB,Biogen Inc. Common Stock,"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.",Mr. Christopher A. Viehbacher,Drug Manufacturers - General,154.2,USD,22469869800,https://images.financialmodelingprep.com/symbol/BIIB.png,0,13.85,1.02,401764,2377000000,1161100000,"[{'period': '2023', 'revenue': 9.84, 'unit': 'B', 'net_profit': 1.16}, {'period': '2022', 'revenue': 10.17, 'unit': 'B', 'net_profit': 3.05}, {'period': '2021', 'revenue': 10.98, 'unit': 'B', 'net_profit': 1.56}, {'period': '2020', 'revenue': 13.44, 'unit': 'B', 'net_profit': 4.0}]","[{'period': ""Q3 '24"", 'revenue': 2470.0, 'unit': 'M', 'net_profit': 388.5}, {'period': ""Q2 '24"", 'revenue': 2350.0, 'unit': 'M', 'net_profit': 583.6}, {'period': ""Q1 '24"", 'revenue': 2200.0, 'unit': 'M', 'net_profit': 393.4}, {'period': ""Q4 '23"", 'revenue': 2390.0, 'unit': 'M', 'net_profit': 249.7}, {'period': ""Q3 '23"", 'revenue': 2530.0, 'unit': 'M', 'net_profit': -68.1}, {'period': ""Q2 '23"", 'revenue': 2460.0, 'unit': 'M', 'net_profit': 591.6}]",8.02,7.97,26844800000,6859300000,1049900000,12045400000,2100000000,460700000,3434300000,1049900000,1235800000,-0.45445365036377405,-0.6189241524172109,-0.6175488793514544,__nan__,__nan__,__nan__,0.44870514960066754
512,BILI,Bilibili Inc. American Depositary Shares,"Bilibili Inc. provides online entertainment services for the young generations in the People's Republic of China. Its platform offers a range of content, including video services, mobile games, and value-added service, as well as ACG-related comic and audio content. The company's video services include professional user generated videos, occupationally generated videos, and live broadcasting. Bilibili Inc. was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.",Mr. Rui  Chen,Electronic Gaming & Multimedia,17.45,USD,7274793966,https://images.financialmodelingprep.com/symbol/BILI.png,6071546,-19.39,0.46,3381499,-1668395000,-4822321000,"[{'period': '2023', 'revenue': 22.53, 'unit': 'B', 'net_profit': -4.82}, {'period': '2022', 'revenue': 21.9, 'unit': 'B', 'net_profit': -7.51}, {'period': '2021', 'revenue': 19.38, 'unit': 'B', 'net_profit': -6.81}, {'period': '2020', 'revenue': 12.0, 'unit': 'B', 'net_profit': -3.05}]","[{'period': ""Q3 '24"", 'revenue': 7310.0, 'unit': 'M', 'net_profit': -79.52}, {'period': ""Q2 '24"", 'revenue': 6130.0, 'unit': 'M', 'net_profit': -608.7}, {'period': ""Q1 '24"", 'revenue': 5660.0, 'unit': 'M', 'net_profit': -748.54}, {'period': ""Q4 '23"", 'revenue': 6.35, 'unit': 'B', 'net_profit': -1.3}, {'period': ""Q3 '23"", 'revenue': 5.81, 'unit': 'B', 'net_profit': -1.35}, {'period': ""Q2 '23"", 'revenue': 5.3, 'unit': 'B', 'net_profit': -1.55}]",-11.67,-11.67,33159067000,18727039000,15039777000,18754800000,2506192000,4366632000,18103695000,7191821000,-1063522000,0.6677276418011988,0.3576792907184176,0.46245969599263015,__nan__,__nan__,__nan__,0.5656009561427044
513,BIMI,BOQI International Medical Inc. Common Stock,"BIMI International Medical Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. The company operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies. It distributes Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment to drug stores, private clinics, pharmaceutical dealers, and hospitals in the Southwest region of the People's Republic of China. The company also distributes generic drugs, Chinese herbal medicine, biochemical drugs, raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines. In addition, it offers prescription and over-the-counter drugs, nutritional supplements, health foods, sundry products, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items under the Lijiantang Pharmacy brand name. Further, the company provides medical services in the hospitals, as well as IT research and development services. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BOQI International Medical Inc. and changed its name to BIMI International Medical Inc. in June 2021. BIMI International Medical Inc. was incorporated in 2000 and is based in Chongqing, the People's Republic of China.",Mr. Tiewei  Song,Medical - Pharmaceuticals,0.0001,USD,1396,https://images.financialmodelingprep.com/symbol/BIMI.png,2566,0,-0.001,601,-17967485,-22352754,"[{'period': '2022', 'revenue': 11.83, 'unit': 'M', 'net_profit': -22.35}, {'period': '2021', 'revenue': 27.08, 'unit': 'M', 'net_profit': -34.92}, {'period': '2020', 'revenue': 12.84, 'unit': 'M', 'net_profit': -3.79}, {'period': '2019', 'revenue': 0.15797999999999998, 'unit': 'M', 'net_profit': -3.9}]","[{'period': ""Q3 '23"", 'revenue': 2.52, 'unit': 'M', 'net_profit': -3.13}, {'period': ""Q2 '23"", 'revenue': 5.56, 'unit': 'M', 'net_profit': 1.05}, {'period': ""Q1 '23"", 'revenue': 3200.0, 'unit': 'K', 'net_profit': -884.21}, {'period': ""Q4 '22"", 'revenue': -5.43, 'unit': 'M', 'net_profit': -11.03}, {'period': ""Q3 '22"", 'revenue': 7.31, 'unit': 'M', 'net_profit': -3.71}, {'period': ""Q2 '22"", 'revenue': 2.83, 'unit': 'M', 'net_profit': -6.54}]",-8.4,-8.4,35714490,23235675,2336636,30497257,4175182,1800000,25362347,2336636,-10255206,0.43810519061142184,0.359918755491743,0.9974202345743848,__nan__,__nan__,__nan__,0.8539183115872577
514,BIOC,Biocept Inc. Common Stock,"Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.",Mr. Darrell  Taylor Esq.,Medical - Diagnostics & Research,0.4349,USD,0,https://images.financialmodelingprep.com/symbol/BIOC.png,2157634,-0.009028440938343367,-0.0701,671569,-30328000,-32087000,"[{'period': '2022', 'revenue': 25.86, 'unit': 'M', 'net_profit': -32.09}, {'period': '2021', 'revenue': 61.25, 'unit': 'M', 'net_profit': -2.82}, {'period': '2020', 'revenue': 27.46, 'unit': 'M', 'net_profit': -17.04}, {'period': '2019', 'revenue': 5.53, 'unit': 'M', 'net_profit': -24.61}]","[{'period': ""Q2 '23"", 'revenue': 0.589, 'unit': 'M', 'net_profit': -3.63}, {'period': ""Q1 '23"", 'revenue': 0.673, 'unit': 'M', 'net_profit': -7.24}, {'period': ""Q4 '22"", 'revenue': -10.29, 'unit': 'M', 'net_profit': -18.52}, {'period': ""Q3 '22"", 'revenue': 5.59, 'unit': 'M', 'net_profit': -5.51}, {'period': ""Q2 '22"", 'revenue': 10.61, 'unit': 'M', 'net_profit': -5.41}, {'period': ""Q1 '22"", 'revenue': 19.95, 'unit': 'M', 'net_profit': -2.77}]",-56.78,-56.78,30873000,16343000,12897000,22013000,2151000,0,5506000,12897000,-14096000,-11.589456205894562,-10.362252124645892,-8.909249563699824,__nan__,__nan__,__nan__,0.7130178473099472
515,BIOL,Biolase Inc. Common Stock,"BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.",Mr. John R. Beaver,Medical - Devices,0.02,USD,731942,https://images.financialmodelingprep.com/symbol/BIOL.png,201374,0.0012360939431396787,0.0043,2672966,-15139000,-20632000,"[{'period': '2023', 'revenue': 49.16, 'unit': 'M', 'net_profit': -20.63}, {'period': '2022', 'revenue': 48.46, 'unit': 'M', 'net_profit': -28.63}, {'period': '2021', 'revenue': 39.19, 'unit': 'M', 'net_profit': -16.16}, {'period': '2020', 'revenue': 22.78, 'unit': 'M', 'net_profit': -16.83}]","[{'period': ""Q2 '24"", 'revenue': 11.55, 'unit': 'M', 'net_profit': -2.8}, {'period': ""Q1 '24"", 'revenue': 10.13, 'unit': 'M', 'net_profit': -6.49}, {'period': ""Q4 '23"", 'revenue': 13.49, 'unit': 'M', 'net_profit': -5.33}, {'period': ""Q3 '23"", 'revenue': 10.92, 'unit': 'M', 'net_profit': -4.59}, {'period': ""Q2 '23"", 'revenue': 14.29, 'unit': 'M', 'net_profit': -4.87}, {'period': ""Q1 '23"", 'revenue': 10.47, 'unit': 'M', 'net_profit': -5.85}]",-16.14,-16.14,35101000,24863000,6566000,35348000,5483000,0,19663000,6566000,-15402000,0.3905639869570468,0.2794579870084515,0.9609380672329921,"[0.01, 0.01]","['2005-06-24', '2004-08-12']",__nan__,1.007036836557363
516,BIOT,Biotech Acquisition Company Class A Ordinary Shares,"Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.",Dr. Michael  Shleifer Ph.D.,Shell Companies,10.15,USD,0,https://images.financialmodelingprep.com/symbol/BIOT.png,103991,0,-0.08,44124,-6864581,-12158997,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.16}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.77}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 20.03}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.68}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.24}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.94}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.07}]",-0.42,-0.42,230.320701,0.29946300000000003,0.091407,27.469212,0,230.021238,0.31381200000000004,0.091407,-1465214,0,0,0,__nan__,__nan__,__nan__,0.11926505902741238
517,BIOTU,Biotech Acquisition Company Unit,"Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.",Dr. Michael  Shleifer Ph.D.,Shell Companies,10.14,USD,0,https://images.financialmodelingprep.com/symbol/BIOTU.png,797,0,-0.05,1342,-6864581,-12158997,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.16}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.77}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 20.03}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.68}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.24}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.94}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.07}]",-0.42,-0.42,230.320701,0.29946300000000003,0.091407,27.469212,0,230.021238,0.31381200000000004,0.091407,-1465214,0,0,0,__nan__,__nan__,__nan__,0.11926505902741238
518,BIOTW,Biotech Acquisition Company Warrant,"Biotech Acquisition Company is a blank check company. The company was incorporated in 2020 and is based in New York, New York.",Mr. Michael  Shleifer Ph.D.,Shell Companies,0.0073,USD,0,https://images.financialmodelingprep.com/symbol/BIOTW.png,0,0,0,414459,-6864581,-12158997,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.16}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.77}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 20.03}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.68}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.24}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.94}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.07}]",-0.42,-0.42,230.320701,0.29946300000000003,0.091407,27.469212,0,230.021238,0.31381200000000004,0.091407,-1465214,0,0,0,__nan__,__nan__,__nan__,0.11926505902741238
519,BIOX,Bioceres Crop Solutions Corp. Ordinary Shares,"Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment develops and commercializes seed technology, biotechnological events, germplasm, and seed treatments. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. The company also offers HB4, a drought tolerant seed technology program. It operates in Argentina, Uruguay, France, South Africa, and internationally. The company was founded in 2001 and is headquartered in Rosario, Argentina. Bioceres Crop Solutions Corp. is a subsidiary of Bioceres LLC.",Dr. Federico  Trucco Ph.D.,Agricultural Inputs,6.85,USD,430540995,https://images.financialmodelingprep.com/symbol/BIOX.png,193075,342.5,0.24,122479,55455336,3243361,"[{'period': '2024', 'revenue': 464.83, 'unit': 'M', 'net_profit': 3.24}, {'period': '2023', 'revenue': 419.45, 'unit': 'M', 'net_profit': 18.78}, {'period': '2022', 'revenue': 328.46, 'unit': 'M', 'net_profit': -7.2}, {'period': '2021', 'revenue': 206.7, 'unit': 'M', 'net_profit': -6.87}]","[{'period': ""Q1 '25"", 'revenue': 92.6, 'unit': 'M', 'net_profit': -5.5}, {'period': ""Q4 '24"", 'revenue': 124.31, 'unit': 'M', 'net_profit': -1.53}, {'period': ""Q3 '24"", 'revenue': 84.0, 'unit': 'M', 'net_profit': 9.5}, {'period': ""Q2 '24"", 'revenue': 140300.0, 'unit': 'K', 'net_profit': 108.45}, {'period': ""Q1 '24"", 'revenue': 116.18, 'unit': 'M', 'net_profit': -4.59}, {'period': ""Q4 '23"", 'revenue': 105.07, 'unit': 'M', 'net_profit': -1.71}]",0.0516,0.0511,850628347,408668037,56168798,501063986,216033262,40420906,329505846,44473270,18934175,-0.09217614789664848,-0.8272959310274466,-0.828,__nan__,__nan__,__nan__,0.5890515967016087
520,BIVI,BioVie Inc. Class A Common Stock,"BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.",Mr. Cuong Viet  Do M.B.A.,Biotechnology,2.43,USD,44837388,https://images.financialmodelingprep.com/symbol/BIVI.png,6298879,-0.48,0.2,2280794,-31950208,-32120533,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -32.12}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -50.26}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.08}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -183.85}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.15}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.94}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.95}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.4}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.71}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.11}]",-7.3,-7.3,25208345,24048190,23843798,9702130,0,0,9352236,23843798,-27945024,0.3006996919137094,0.3608593624610279,0.5281189398836459,__nan__,__nan__,__nan__,0.38487770617230127
521,BJRI,BJ's Restaurants Inc. Common Stock,"BJ's Restaurants, Inc. owns and operates casual dining restaurants in the United States. The company's restaurants offer pizzas, craft and other beers, appetizers, entres, pastas, sandwiches, specialty salads, and desserts. As of April 19, 2022, it operated 213 restaurants in 29 states. The company was founded in 1978 and is based in Huntington Beach, California.",Mr. Carl Bradford Richmond CPA,Restaurants,35.475,USD,809415338,https://images.financialmodelingprep.com/symbol/BJRI.png,291354,28.15,-1.175,74548,86007000,19660000,"[{'period': '2023', 'revenue': 1330.0, 'unit': 'M', 'net_profit': 19.66}, {'period': '2022', 'revenue': 1280.0, 'unit': 'M', 'net_profit': 4.08}, {'period': '2021', 'revenue': 1090.0, 'unit': 'M', 'net_profit': -3.61}, {'period': '2020', 'revenue': 778.51, 'unit': 'M', 'net_profit': -57.88}]","[{'period': ""Q3 '24"", 'revenue': 325.7, 'unit': 'M', 'net_profit': -2.93}, {'period': ""Q2 '24"", 'revenue': 349.93, 'unit': 'M', 'net_profit': 17.16}, {'period': ""Q1 '24"", 'revenue': 337.33, 'unit': 'M', 'net_profit': 7.72}, {'period': ""Q4 '23"", 'revenue': 323.63, 'unit': 'M', 'net_profit': 8.05}, {'period': ""Q3 '23"", 'revenue': 318.64, 'unit': 'M', 'net_profit': -3.8}, {'period': ""Q2 '23"", 'revenue': 349.67, 'unit': 'M', 'net_profit': 11.93}]",0.84,0.82,1058454000,83021000,29070000,692693000,19469000,4770000,199325000,29070000,6923000,0.2687831000044256,3.8233562315996075,3.9411764705882346,"[0.13, 0.11]","['2020-03-09', '2017-11-10']",__nan__,0.6544384545762026
522,BKCC,BlackRock Capital Investment Corporation Common Stock,"BlackRock Capital Investment Corporation, formerly known as BlackRock Kelso Capital Corporation, is a Business Development Company specializing in investments in middle market companies. The fund invests in all industries. It prefers to invest between $10 million and $50 million and can invest more or less in companies with EBITDA or operating cash flow between $10 million and $50 million. The fund invests in the form of senior and junior secured, unsecured, and subordinated debt securities and loans including cash flow, asset backed, and junior lien facilities and equity securities. It's equity investments can be structured in the form of warrants, preferred stock, common equity co-investments, and direct investments in common stock. The fund's debt investments are principally structured to provide for current cash interest and to a lesser extent non-cash interest, particularly with subordinated debt investments, through a pay-in-kind (PIK) feature. It can also make non-control investments.",Mr. James Edward Keenan C.F.A.,Asset Management,3.68,USD,267064607,https://images.financialmodelingprep.com/symbol/BKCC.png,226764,10.222222222222221,0.01,143336,47947890,26236270,"[{'period': '2023', 'revenue': 32.94, 'unit': 'M', 'net_profit': 26.24}, {'period': '2022', 'revenue': 10.37, 'unit': 'M', 'net_profit': 3.49}, {'period': '2021', 'revenue': 73.9, 'unit': 'M', 'net_profit': 66.49}, {'period': '2020', 'revenue': -101.37, 'unit': 'M', 'net_profit': -103.85}]","[{'period': ""Q4 '23"", 'revenue': 6.98, 'unit': 'M', 'net_profit': 5.39}, {'period': ""Q3 '23"", 'revenue': 12.7, 'unit': 'M', 'net_profit': 10.83}, {'period': ""Q2 '23"", 'revenue': 3.27, 'unit': 'M', 'net_profit': 1.5}, {'period': ""Q1 '23"", 'revenue': 9.99, 'unit': 'M', 'net_profit': 8.52}, {'period': ""Q4 '22"", 'revenue': -3.55, 'unit': 'M', 'net_profit': -5.1}, {'period': ""Q3 '22"", 'revenue': 7.19, 'unit': 'M', 'net_profit': 5.61}]",0.36,0.36,627285472,17581928000000,9359280,311555613,8222648000000,604527268,11355040,9359280,28789624,1.8836709622123848,6.5240753019235,6.199999999999999,"[0.1, 0.42]","['2024-03-14', '2007-09-12']",__nan__,0.4966727700653651
523,BKEP,Blueknight Energy Partners L.P. Common Units,"Blueknight Energy Partners, L.P. provides integrated terminalling services for companies engaged in the production, distribution, and handling of liquid asphalt in the United States. As of March 1, 2022, it had 54 terminals located in 26 states. Blueknight Energy Partners G.P., L.L.C. operates as a general partner of Blueknight Energy Partners, L.P. The company was formerly known as SemGroup Energy Partners, L.P. and changed its name to Blueknight Energy Partners, L.P. in December 2009. Blueknight Energy Partners, L.P. was incorporated in 2007 and is headquartered in Tulsa, Oklahoma.",Mr. Mark Hurley,Oil & Gas Midstream,4.63,USD,0,https://images.financialmodelingprep.com/symbol/BKEP.png,0,0,-0.0050001144,2143538,-4956000,-4970000,"[{'period': '2021', 'revenue': 5.29, 'unit': 'M', 'net_profit': -4.97}, {'period': '2020', 'revenue': 110.25, 'unit': 'M', 'net_profit': -13.48}, {'period': '2019', 'revenue': 371.07, 'unit': 'M', 'net_profit': 18.41}, {'period': '2018', 'revenue': 384.83, 'unit': 'M', 'net_profit': -42.05}]","[{'period': ""Q2 '22"", 'revenue': 29.51, 'unit': 'M', 'net_profit': 6.34}, {'period': ""Q1 '22"", 'revenue': 28.46, 'unit': 'M', 'net_profit': 6.64}, {'period': ""Q4 '21"", 'revenue': 30.24, 'unit': 'M', 'net_profit': -30.8}, {'period': ""Q3 '21"", 'revenue': 30.34, 'unit': 'M', 'net_profit': 12.6}, {'period': ""Q2 '21"", 'revenue': 27.76, 'unit': 'M', 'net_profit': 7.28}, {'period': ""Q1 '21"", 'revenue': 27.07, 'unit': 'M', 'net_profit': 81.65}]",-0.12,-0.12,136898000,7644000,1172000,136898000,2989000,0,-89691000,1172000,40900000,-1.1493490838958533,0.6313056379821959,0.6363636363636364,"[0.043, 0.11]","['2022-08-04', '2012-02-01']",__nan__,1.0
524,BKEPP,Blueknight Energy Partners L.P. Series A Preferred Units,"Blueknight Energy Partners, L.P. provides integrated terminalling services for companies engaged in the production, distribution, and handling of liquid asphalt in the United States. As of March 1, 2022, it had 54 terminals located in 26 states. Blueknight Energy Partners G.P., L.L.C. operates as a general partner of Blueknight Energy Partners, L.P. The company was formerly known as SemGroup Energy Partners, L.P. and changed its name to Blueknight Energy Partners, L.P. in December 2009. Blueknight Energy Partners, L.P. was incorporated in 2007 and is headquartered in Tulsa, Oklahoma.",Mr. Mark A. Hurley,Oil & Gas Midstream,8.735,USD,0,https://images.financialmodelingprep.com/symbol/BKEPP.png,0,35.221774193548384,-0.0050001144,19523,-4956000,-4970000,"[{'period': '2021', 'revenue': 5.29, 'unit': 'M', 'net_profit': -4.97}, {'period': '2020', 'revenue': 110.25, 'unit': 'M', 'net_profit': -13.48}, {'period': '2019', 'revenue': 371.07, 'unit': 'M', 'net_profit': 18.41}, {'period': '2018', 'revenue': 384.83, 'unit': 'M', 'net_profit': -42.05}]","[{'period': ""Q2 '22"", 'revenue': 29.51, 'unit': 'M', 'net_profit': 6.34}, {'period': ""Q1 '22"", 'revenue': 28.46, 'unit': 'M', 'net_profit': 6.64}, {'period': ""Q4 '21"", 'revenue': 30.24, 'unit': 'M', 'net_profit': -30.8}, {'period': ""Q3 '21"", 'revenue': 30.34, 'unit': 'M', 'net_profit': 12.6}, {'period': ""Q2 '21"", 'revenue': 27.76, 'unit': 'M', 'net_profit': 7.28}, {'period': ""Q1 '21"", 'revenue': 27.07, 'unit': 'M', 'net_profit': 81.65}]",-0.12,-0.12,136898000,7644000,1172000,136898000,2989000,0,-89691000,1172000,40900000,-1.1493490838958533,0.6313056379821959,0.6363636363636364,"[0.179, 0.179]","['2022-08-04', '2012-05-02']",__nan__,1.0
525,BKNG,Booking Holdings Inc. Common Stock,"Booking Holdings Inc. provides travel and restaurant online reservation and related services worldwide. The company operates Booking.com, which offers online accommodation reservations; Rentalcars.com that provides online rental car reservation services; Priceline, which offer online travel reservation services, and consumers hotel, flight, and rental car reservation services, as well as vacation packages, cruises, and hotel distribution services. It also operates Agoda that provides online accommodation reservation services, as well as flight, ground transportation and activities reservation services. In addition, the company operates KAYAK, an online price comparison service that allows consumers to search and compare travel itineraries and prices, comprising airline ticket, accommodation reservation, and rental car reservation information; and OpenTable for booking online restaurant reservations. Further, it offers travel-related insurance products, and restaurant management services to consumers, travel service providers, and restaurants. The company was formerly known as The Priceline Group Inc. and changed its name to Booking Holdings Inc. in February 2018. The company was founded in 1997 and is headquartered in Norwalk, Connecticut.",Mr. Glenn D. Fogel,Travel Services,4808.57,USD,159147798719,https://images.financialmodelingprep.com/symbol/BKNG.png,215522,32.58,-101.2202,81019,7043000000,4289000000,"[{'period': '2023', 'revenue': 21.36, 'unit': 'B', 'net_profit': 4.29}, {'period': '2022', 'revenue': 17.09, 'unit': 'B', 'net_profit': 3.06}, {'period': '2021', 'revenue': 10.96, 'unit': 'B', 'net_profit': 1.17}, {'period': '2020', 'revenue': 6800.0, 'unit': 'M', 'net_profit': 59.0}]","[{'period': ""Q3 '24"", 'revenue': 7.99, 'unit': 'B', 'net_profit': 2.52}, {'period': ""Q2 '24"", 'revenue': 5.86, 'unit': 'B', 'net_profit': 1.52}, {'period': ""Q1 '24"", 'revenue': 4420.0, 'unit': 'M', 'net_profit': 776.0}, {'period': ""Q4 '23"", 'revenue': 4780.0, 'unit': 'M', 'net_profit': 222.0}, {'period': ""Q3 '23"", 'revenue': 7.34, 'unit': 'B', 'net_profit': 2.51}, {'period': ""Q2 '23"", 'revenue': 5.46, 'unit': 'B', 'net_profit': 1.29}]",118.68,117.41,24342000000,17034000000,12683000000,27086000000,3253000000,440000000,13330000000,12107000000,6999000000,0.4312131680552733,0.4025506867233486,0.5473272490221643,"[8.75, 8.75]","['2024-12-06', '2024-03-07']",__nan__,1.112726973954482
526,BKSC,Bank of South Carolina Corp. Common Stock,"Bank of South Carolina Corporation operates as a bank holding company for The Bank of South Carolina that provides a range of financial products and services primarily in Charleston, Berkeley, and Dorchester counties of South Carolina. Its deposits include non-interest-bearing demand accounts, NOW accounts, money market accounts, time deposits, and savings accounts, as well as certificates of deposit. The company offers secured and unsecured commercial loans, commercial real estate construction loans, consumer construction loans, home equity lines of credit, and mortgage originations, as well as paycheck protection program loans. It operates five banking house locations. The company was founded in 1986 and is headquartered in Charleston, South Carolina.",Mr. Eugene H. Walpole IV,Banks - Regional,13.49,USD,74834966,https://images.financialmodelingprep.com/symbol/BKSC.png,0,11.63,0.29,228,7287089,5493616,"[{'period': '2023', 'revenue': 26.08, 'unit': 'M', 'net_profit': 5.49}, {'period': '2022', 'revenue': 20.96, 'unit': 'M', 'net_profit': 6.66}, {'period': '2021', 'revenue': 21.25, 'unit': 'M', 'net_profit': 6.74}, {'period': '2020', 'revenue': 20.34, 'unit': 'M', 'net_profit': 6.46}]","[{'period': ""Q3 '24"", 'revenue': 7.33, 'unit': 'M', 'net_profit': 1.8}, {'period': ""Q2 '24"", 'revenue': 7.17, 'unit': 'M', 'net_profit': 1.75}, {'period': ""Q1 '24"", 'revenue': 7.02, 'unit': 'M', 'net_profit': 1.38}, {'period': ""Q4 '23"", 'revenue': 6.9, 'unit': 'M', 'net_profit': 1.36}, {'period': ""Q3 '23"", 'revenue': 6.63, 'unit': 'M', 'net_profit': 1.26}, {'period': ""Q2 '23"", 'revenue': 5.04, 'unit': 'M', 'net_profit': 1.28}]",0.99,0.98,633815719,24297032,-21916060,586734857,0,2130899,520233800,-21916060,5711865,-0.1895817316359428,-0.1745303629976229,-0.175,"[0.19, 0.4921]","['2024-12-31', '1989-06-26']",__nan__,0.9257183743024209
527,BKYI,BIO-key International Inc. Common Stock,"BIO-key International, Inc. develops and markets fingerprint identification biometric technology and software solutions, and enterprise-ready identity access management solutions for commercial, government, and education customers in the United States and internationally. The company offers BIO-key PortalGuard and PortalGuard IDaaS solutions, a customer-controlled and neutral-by-design cloud-based identity platform that allows customers to integrate with any cloud or on-premises SaaS application, as well as windows device authentication through IAM platform. Its solutions enable its customers to secure their workforces and student populations; and make their partner networks more collaborative. In addition, it provides BIO-key VST and WEB-key products; and Civil and Large-Scale ID Infrastructure solutions that develops finger-based biometric technology. Further, it offers finger scanners for enterprise and consumer markets under SideSwipe, EcoID, and SidePass brand names. The company was formerly known as SAC Technologies and changed its name to BIO-key International, Inc. in 2002. BIO-key International, Inc. was founded in 1993 and is headquartered in Wall, New Jersey.",Mr. Michael W. DePasquale,Security & Protection Services,1.5807,USD,4942928,https://images.financialmodelingprep.com/symbol/BKYI.png,2294601,-0.26,0.0407,572038,-7847438,-8521837,"[{'period': '2023', 'revenue': 7.75, 'unit': 'M', 'net_profit': -8.52}, {'period': '2022', 'revenue': 7.02, 'unit': 'M', 'net_profit': -10.74}, {'period': '2021', 'revenue': 5.11, 'unit': 'M', 'net_profit': -4.57}, {'period': '2020', 'revenue': 2.84, 'unit': 'M', 'net_profit': -13.59}]","[{'period': ""Q3 '24"", 'revenue': 2140.0, 'unit': 'K', 'net_profit': -738.96}, {'period': ""Q2 '24"", 'revenue': 1.14, 'unit': 'M', 'net_profit': -1.67}, {'period': ""Q1 '24"", 'revenue': 2180.0, 'unit': 'K', 'net_profit': -510.29}, {'period': ""Q4 '23"", 'revenue': 0.9251, 'unit': 'M', 'net_profit': -6.17}, {'period': ""Q3 '23"", 'revenue': 1830.0, 'unit': 'K', 'net_profit': -749.09}, {'period': ""Q2 '23"", 'revenue': 1.93, 'unit': 'M', 'net_profit': -1.42}]",-15.21,-15.21,4517035,2622157,511399,3453470,1300846,0,3213389,511399,-3794456,0.31004631496320245,0.20673273568130784,0.36279849183074986,"[0.1111, 0.1111]","['1997-07-25', '1997-07-25']",__nan__,0.7645435556731351
528,BL,BlackLine Inc. Common Stock,"BlackLine, Inc. provides cloud-based solutions to automate and streamline accounting and finance operations worldwide. It offers financial close management solutions, such as account reconciliations that provides a centralized workspace for users to collaborate on account reconciliations; transaction matching that analyzes and reconciles high volumes of individual transactions; and task management to create and manage processes and task lists. The company's financial close management solutions also include journal entry that allows users to generate, review, and post manual journal entries; variance analysis that monitors and identifies anomalous fluctuations in balance sheet and income statement account balances; consolidation integrity manager that manages the automated system-to-system tie-out process that occurs during the consolidation phase of the financial close; and compliance, an integrated solution that facilitates compliance-related initiatives, consolidates project management, and provides visibility over control self-assessments and testing. In addition, it offers accounts receivable automation solutions, which include cash application, credit and risk management, collections management, disputes and deductions, team and task management, and AR intelligence solutions. Further, the company provides intercompany workflow that stores permissions by entity and transaction type thereby ensuring both the initiator and the approver of the intercompany transaction are authorized to conduct business; intercompany processing, which records an organization's intercompany transactions; and netting and settlement that generates a real-time settlement matrix, which shows the balance of transactions. The company sells its solutions primarily through direct sales force to multinational corporations, large domestic enterprises, and mid-market companies across various industries. BlackLine, Inc. was incorporated in 2001 and is headquartered in Woodland Hills, California.",Mr. Owen M. Ryan CPA,Software - Application,57.89,USD,3617285595,https://images.financialmodelingprep.com/symbol/BL.png,608593,59.07,-1.06,154325,116506000,52833000,"[{'period': '2023', 'revenue': 590.0, 'unit': 'M', 'net_profit': 52.83}, {'period': '2022', 'revenue': 522.94, 'unit': 'M', 'net_profit': -33.89}, {'period': '2021', 'revenue': 425.71, 'unit': 'M', 'net_profit': -100.99}, {'period': '2020', 'revenue': 351.74, 'unit': 'M', 'net_profit': -39.4}]","[{'period': ""Q3 '24"", 'revenue': 165.91, 'unit': 'M', 'net_profit': 17.24}, {'period': ""Q2 '24"", 'revenue': 160.51, 'unit': 'M', 'net_profit': 76.69}, {'period': ""Q1 '24"", 'revenue': 157.46, 'unit': 'M', 'net_profit': 10.83}, {'period': ""Q4 '23"", 'revenue': 155.73, 'unit': 'M', 'net_profit': 22.07}, {'period': ""Q3 '23"", 'revenue': 150.71, 'unit': 'M', 'net_profit': 11.92}, {'period': ""Q2 '23"", 'revenue': 144.57, 'unit': 'M', 'net_profit': 30.85}]",0.87,0.73,2100764999,1407324000,1204472000,1809821000,171608000,0,642565000,271117000,99016000,91.83346613545817,2.558909444985394,2.5263157894736845,__nan__,__nan__,__nan__,0.8615056900041203
529,BLBD,Blue Bird Corporation Common Stock,"Blue Bird Corporation designs, engineers, manufactures, and sells school buses and related parts in the United States, Canada, and internationally. It operates through two segments, Bus and Parts. The company offers Type C, Type D, and specialty buses; and alternative fuel applications through its propane powered, gasoline powered, compressed natural gas powered, and electric powered school buses. Blue Bird Corporation sells its products through a network of dealers, as well as directly to fleet operators, the United States government, and state governments; and maintains a parts distribution center. Blue Bird Corporation was formerly known as Hennessy Capital Acquisition Corp. The company was founded in 1927 and is headquartered in Macon, Georgia.",Mr. Philip  Horlock,Auto - Manufacturers,41.47,USD,1338153960,https://images.financialmodelingprep.com/symbol/BLBD.png,774920,13.12,-0.92,317723,152335000,105547000,"[{'period': '2024', 'revenue': 1350.0, 'unit': 'M', 'net_profit': 105.55}, {'period': '2023', 'revenue': 1130.0, 'unit': 'M', 'net_profit': 23.81}, {'period': '2022', 'revenue': 800.64, 'unit': 'M', 'net_profit': -41.6}, {'period': '2021', 'revenue': 684000.0, 'unit': 'K', 'net_profit': -787.0}]","[{'period': ""Q4 '24"", 'revenue': 350.21, 'unit': 'M', 'net_profit': 24.66}, {'period': ""Q3 '24"", 'revenue': 333.37, 'unit': 'M', 'net_profit': 28.71}, {'period': ""Q2 '24"", 'revenue': 345.92, 'unit': 'M', 'net_profit': 26.02}, {'period': ""Q1 '24"", 'revenue': 317.66, 'unit': 'M', 'net_profit': 26.15}, {'period': ""Q4 '23"", 'revenue': 302.96, 'unit': 'M', 'net_profit': 18.62}, {'period': ""Q3 '23"", 'revenue': 294.28, 'unit': 'M', 'net_profit': 9.36}]",3.27,3.16,524894000,323379000,127687000,365330000,59099000,32089000,235973000,127687000,95849000,1.5006976706009816,3.432513018646061,3.4189189189189193,__nan__,__nan__,__nan__,0.6960071938334216
530,BLCM,Bellicum Pharmaceuticals Inc. Common Stock,"Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.",Mr. David M. Maggio,Biotechnology,0.07475,USD,778326,https://images.financialmodelingprep.com/symbol/BLCM.png,28581,-0.11156716417910448,-0.0053,6059,-26981000,-24973000,"[{'period': '2022', 'revenue': 1.5, 'unit': 'M', 'net_profit': -24.97}, {'period': '2021', 'revenue': 6.2, 'unit': 'M', 'net_profit': -9.58}, {'period': '2020', 'revenue': 0.5, 'unit': 'M', 'net_profit': -8.62}, {'period': '2019', 'revenue': 7.14, 'unit': 'M', 'net_profit': -126.09}]","[{'period': ""Q3 '23"", 'revenue': 1000.0, 'unit': 'K', 'net_profit': -763.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.35}, {'period': ""Q1 '23"", 'revenue': 0.008, 'unit': 'M', 'net_profit': -7.49}, {'period': ""Q4 '22"", 'revenue': 0.5, 'unit': 'M', 'net_profit': -6.2}, {'period': ""Q3 '22"", 'revenue': 1.0, 'unit': 'M', 'net_profit': -7.26}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.47}]",-0.81,-0.81,23823000,23801000,21837000,21808000,0,0,3772000,21837000,-25804000,-0.1080947882869933,-1.60732929630403,0.024096385542168565,__nan__,__nan__,__nan__,0.9154178734836083
531,BLCT,BlueCity Holdings Limited American Depositary Shares,"BlueCity Holdings Limited operates a platform for LGBTQ community primarily under BlueCity brand in the People's Republic of China, India, South Korea, Thailand, and Vietnam. The company operates Blued, Finka, and LESDO mobile applications that offer mobile-based social and entertainment services, including live streaming, advertising, membership, merchandise sales, and other services. It also offers online health services. BlueCity Holdings Limited was founded in 2000 and is based in Beijing, China.",Mr. Baoli  Ma,Internet Content & Information,1.54,USD,0,https://images.financialmodelingprep.com/symbol/BLCT.png,104877,-1.289782244556114,0,167054,240150069000,-309623944,"[{'period': '2021', 'revenue': 1080.0, 'unit': 'M', 'net_profit': -309.62}, {'period': '2020', 'revenue': 1030.0, 'unit': 'M', 'net_profit': -221.85}, {'period': '2019', 'revenue': 758.89, 'unit': 'M', 'net_profit': -52.93}, {'period': '2018', 'revenue': 501.29, 'unit': 'M', 'net_profit': -144.56}]","[{'period': ""Q4 '21"", 'revenue': 243.58, 'unit': 'M', 'net_profit': -148.7}, {'period': ""Q3 '21"", 'revenue': 270.0, 'unit': 'M', 'net_profit': -73.83}, {'period': ""Q2 '21"", 'revenue': 291.88, 'unit': 'M', 'net_profit': -35.01}, {'period': ""Q1 '21"", 'revenue': 271.13, 'unit': 'M', 'net_profit': -52.08}, {'period': ""Q4 '20"", 'revenue': 278.79, 'unit': 'M', 'net_profit': -73.08}, {'period': ""Q3 '20"", 'revenue': 297.62, 'unit': 'M', 'net_profit': -137.81}]",-9.85,-9.85,610162588,469842783,349785624,164216062,12878562,0,152312966,349785624,-217906243,0.7166759079298974,-0.39562743711075105,-0.5836012861736335,__nan__,__nan__,__nan__,0.2691349244113276
532,BLDE,Blade Air Mobility Inc. Class A Common Stock,"Blade Air Mobility, Inc. provides air transportation alternatives to the congested ground routes in the United States. It provides its services through charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes. The company was founded in 2014 and is headquartered in New York, New York.",Mr. Robert S. Wiesenthal,"Airlines, Airports & Air Services",4.64,USD,363376960,https://images.financialmodelingprep.com/symbol/BLDE.png,957933,-6.72,-0.27,620176,-68117000,-56076000,"[{'period': '2023', 'revenue': 225.18, 'unit': 'M', 'net_profit': -56.08}, {'period': '2022', 'revenue': 146.12, 'unit': 'M', 'net_profit': -27.26}, {'period': '2021', 'revenue': 50.53, 'unit': 'M', 'net_profit': -40.05}, {'period': '2020', 'revenue': 23.43, 'unit': 'M', 'net_profit': -10.16}]","[{'period': ""Q3 '24"", 'revenue': 74.88, 'unit': 'M', 'net_profit': -1.95}, {'period': ""Q2 '24"", 'revenue': 67.94, 'unit': 'M', 'net_profit': -11.33}, {'period': ""Q1 '24"", 'revenue': 51.51, 'unit': 'M', 'net_profit': -4.23}, {'period': ""Q4 '23"", 'revenue': 47.48, 'unit': 'M', 'net_profit': -33.94}, {'period': ""Q3 '23"", 'revenue': 71440.0, 'unit': 'K', 'net_profit': 289.0}, {'period': ""Q2 '23"", 'revenue': 60.99, 'unit': 'M', 'net_profit': -12.23}]",-0.76,-0.76,294938000,206261000,166137000,60638000,21005000,0,35491000,27873000,-34458000,0.02504759042180142,-1.0570799706529714,-1,__nan__,__nan__,__nan__,0.20559575232760782
533,BLDEW,Blade Air Mobility Inc. Warrants,"Blade Air Mobility, Inc. provides air transportation alternatives to the congested ground routes in the United States. It provides its services through charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes. The company was founded in 2014 and is headquartered in New York, New York.",Mr. Robert S. Wiesenthal,"Airlines, Airports & Air Services",0.5075,USD,372413819,https://images.financialmodelingprep.com/symbol/BLDEW.png,0,,-0.0125,34271,-68117000,-56076000,"[{'period': '2023', 'revenue': 225.18, 'unit': 'M', 'net_profit': -56.08}, {'period': '2022', 'revenue': 146.12, 'unit': 'M', 'net_profit': -27.26}, {'period': '2021', 'revenue': 50.53, 'unit': 'M', 'net_profit': -40.05}, {'period': '2020', 'revenue': 23.43, 'unit': 'M', 'net_profit': -10.16}]","[{'period': ""Q3 '24"", 'revenue': 74.88, 'unit': 'M', 'net_profit': -1.95}, {'period': ""Q2 '24"", 'revenue': 67.94, 'unit': 'M', 'net_profit': -11.33}, {'period': ""Q1 '24"", 'revenue': 51.51, 'unit': 'M', 'net_profit': -4.23}, {'period': ""Q4 '23"", 'revenue': 47.48, 'unit': 'M', 'net_profit': -33.94}, {'period': ""Q3 '23"", 'revenue': 71440.0, 'unit': 'K', 'net_profit': 289.0}, {'period': ""Q2 '23"", 'revenue': 60.99, 'unit': 'M', 'net_profit': -12.23}]",-0.76,-0.76,294938000,206261000,166137000,60638000,21005000,0,35491000,27873000,-34458000,0.02504759042180142,-1.0570799706529714,-1,__nan__,__nan__,__nan__,0.20559575232760782
534,BLDP,Ballard Power Systems Inc. Common Shares,"Ballard Power Systems Inc. engages in the design, development, manufacture, sale, and service of proton exchange membrane (PEM) fuel cell products. The company offers its products for power product markets, consisting of heavy-duty motives, such as bus, truck, rail, and marine applications; material handling; and backup power. It also provides technology solutions, including engineering and technology transfer, as well as licenses and sells intellectual property portfolio and fundamental knowledge for various PEM fuel cell applications; and hydrogen fuel cell powertrain and vehicle systems integration solutions. It operates in China, Germany, the United States, the United Kingdom, Canada, Denmark, Norway, Belgium, Japan, France, Spain, Taiwan, Poland, India, Ukraine, Sweden, and internationally. The company has a strategic alliance with Linamar Corporation for the co-development and sale of fuel cell powertrains and components for class 1 and 2 vehicles in North America and Europe. Ballard Power Systems Inc. was founded in 1979 and is headquartered in Burnaby, Canada.","Mr. R. Randall MacEwen BA, LLB",Industrial - Machinery,1.965,USD,588362265,https://images.financialmodelingprep.com/symbol/BLDP.png,5864266,-1.8,-0.015,7677562,-122267866,-177716000,"[{'period': '2023', 'revenue': 102.37, 'unit': 'M', 'net_profit': -177.72}, {'period': '2022', 'revenue': 83.8, 'unit': 'M', 'net_profit': -173.49}, {'period': '2021', 'revenue': 104.5, 'unit': 'M', 'net_profit': -114.4}, {'period': '2020', 'revenue': 103.88, 'unit': 'M', 'net_profit': -49.47}]","[{'period': ""Q3 '24"", 'revenue': 14.76, 'unit': 'M', 'net_profit': -205.02}, {'period': ""Q2 '24"", 'revenue': 16.0, 'unit': 'M', 'net_profit': -31.46}, {'period': ""Q1 '24"", 'revenue': 14.39, 'unit': 'M', 'net_profit': -41.11}, {'period': ""Q4 '23"", 'revenue': 47.42, 'unit': 'M', 'net_profit': -52.66}, {'period': ""Q3 '23"", 'revenue': 27.57, 'unit': 'M', 'net_profit': -62.45}, {'period': ""Q2 '23"", 'revenue': 15.31, 'unit': 'M', 'net_profit': -30.1}]",-0.61,-0.61,1077542000,864741000,753243000,86326000,58565000,54246000,70586000,751130000,-145938000,0.1573660873041033,-0.024335135509008957,-0.05172413793103453,__nan__,__nan__,__nan__,0.08011381458912971
535,BLDR,Builders FirstSource Inc. Common Stock,"Builders FirstSource, Inc., together with its subsidiaries, manufactures and supplies building materials, manufactured components, and construction services to professional homebuilders, sub-contractors, remodelers, and consumers in the United States. It offers lumber and lumber sheet goods comprising dimensional lumber, plywood, and oriented strand board products that are used in on-site house framing; manufactured products, such as wood floor and roof trusses, steel roof trusses, wall panels, stairs, and engineered wood products; and windows, and interior and exterior door units, as well as interior and exterior trims and custom products under the Synboard brand name. The company also offers gypsum, roofing, and insulation products, including wallboards, ceilings, joint treatments, and finishes; and siding, metal, and concrete products, such as vinyl, composite, and wood siding products, as well as exterior trims, other exteriors, metal studs, and cement products. In addition, it provides other building products and services, such as cabinets and hardware, as well as turn-key framing, shell construction, design assistance, and professional installation services. The company was formerly known as BSL Holdings, Inc. and changed its name to Builders FirstSource, Inc. in October 1999. Builders FirstSource, Inc. was founded in 1998 and is based in Dallas, Texas.",Mr. Peter M. Jackson CPA,Construction,142.88,USD,16443344800,https://images.financialmodelingprep.com/symbol/BLDR.png,1283574,13.98,-2.77,460021,2734594000,1540555000,"[{'period': '2023', 'revenue': 17.1, 'unit': 'B', 'net_profit': 1.54}, {'period': '2022', 'revenue': 22.73, 'unit': 'B', 'net_profit': 2.75}, {'period': '2021', 'revenue': 19.89, 'unit': 'B', 'net_profit': 1.73}, {'period': '2020', 'revenue': 8560.0, 'unit': 'M', 'net_profit': 313.54}]","[{'period': ""Q3 '24"", 'revenue': 4230.0, 'unit': 'M', 'net_profit': 284.78}, {'period': ""Q2 '24"", 'revenue': 4460.0, 'unit': 'M', 'net_profit': 344.09}, {'period': ""Q1 '24"", 'revenue': 3890.0, 'unit': 'M', 'net_profit': 258.78}, {'period': ""Q4 '23"", 'revenue': 4150.0, 'unit': 'M', 'net_profit': 350.69}, {'period': ""Q3 '23"", 'revenue': 4530.0, 'unit': 'M', 'net_profit': 451.46}, {'period': ""Q2 '23"", 'revenue': 4530.0, 'unit': 'M', 'net_profit': 404.62}]",12.06,11.94,10499452000,3300728000,66156000,5767101000,1892904000,0,1863437000,66156000,1830537000,-0.35918156156074527,-0.4396696114635758,-0.28975265017667845,__nan__,__nan__,__nan__,0.5492763812816136
536,BLFS,BioLife Solutions Inc. Common Stock,"BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.",Mr. Roderick  de Greef,Medical - Instruments & Supplies,26.77,USD,1241785344,https://images.financialmodelingprep.com/symbol/BLFS.png,385279,-24.12,-0.49,104827,-45238000,-66427000,"[{'period': '2023', 'revenue': 143.27, 'unit': 'M', 'net_profit': -66.43}, {'period': '2022', 'revenue': 161.76, 'unit': 'M', 'net_profit': -139.81}, {'period': '2021', 'revenue': 119.16, 'unit': 'M', 'net_profit': -8.38}, {'period': '2020', 'revenue': 48.09, 'unit': 'M', 'net_profit': 2.67}]","[{'period': ""Q3 '24"", 'revenue': 30.57, 'unit': 'M', 'net_profit': -1.7}, {'period': ""Q2 '24"", 'revenue': 28.33, 'unit': 'M', 'net_profit': -20.72}, {'period': ""Q1 '24"", 'revenue': 31.73, 'unit': 'M', 'net_profit': -10.22}, {'period': ""Q4 '23"", 'revenue': 32.73, 'unit': 'M', 'net_profit': -13.38}, {'period': ""Q3 '23"", 'revenue': 33.33, 'unit': 'M', 'net_profit': -29.13}, {'period': ""Q2 '23"", 'revenue': 39.51, 'unit': 'M', 'net_profit': -10.2}]",-1.52,-1.52,412714000,120604000,51695000,75051000,18657000,5617000,42178000,35407000,-18879000,-0.9507546356188012,0.524859625907514,0.5379939209726444,__nan__,__nan__,__nan__,0.181847477914488
537,BLI,Berkeley Lights Inc. Common Stock,"Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. Berkeley Lights, Inc. was incorporated in 2011 and is headquartered in Emeryville, California.","Dr. Siddhartha Chandrakant Kadia B.E., M.S., Ph.D.",Biotechnology,1.2,USD,86608685,https://images.financialmodelingprep.com/symbol/BLI.png,815455,-0.9022556390977443,-0.075,2288364,-93517000,-98040000,"[{'period': '2022', 'revenue': 78.59, 'unit': 'M', 'net_profit': -98.04}, {'period': '2021', 'revenue': 85.39, 'unit': 'M', 'net_profit': -71.72}, {'period': '2020', 'revenue': 64.3, 'unit': 'M', 'net_profit': -41.58}, {'period': '2019', 'revenue': 56.69, 'unit': 'M', 'net_profit': -18.3}]","[{'period': ""Q2 '23"", 'revenue': 14.06, 'unit': 'M', 'net_profit': -50.24}, {'period': ""Q1 '23"", 'revenue': 18.52, 'unit': 'M', 'net_profit': -23.42}, {'period': ""Q4 '22"", 'revenue': 17.84, 'unit': 'M', 'net_profit': -29.3}, {'period': ""Q3 '22"", 'revenue': 21.4, 'unit': 'M', 'net_profit': -21.57}, {'period': ""Q2 '22"", 'revenue': 19.15, 'unit': 'M', 'net_profit': -25.75}, {'period': ""Q1 '22"", 'revenue': 20.21, 'unit': 'M', 'net_profit': -21.43}]",-1.42,-1.42,226094000,176952000,132774000,84039000,18534000,0,45490000,86522000,-55615000,-0.32445331973714026,-0.3669064748201439,-0.31481481481481466,__nan__,__nan__,__nan__,0.3716993816731094
538,BLIN,Bridgeline Digital Inc. Common Stock,"Bridgeline Digital, Inc. operates as a digital engagement company in the United States. The company's Bridgeline's Unbound platform enables companies and developers to create websites, web applications, and online stores. It offers Bridgeline Unbound Experience Manager, a marketing automation engine and content management system; Bridgeline Unbound Content Manager that enables non-technical users to create, edit, and publish content via a browser-based interface; and Bridgeline Unbound Commerce, an online B2B and B2C commerce solution that allows users to manage domestic and international commerce initiatives. The company also provides Bridgeline Unbound Marketing, an online marketing management solution that helps marketers drive to their sites through personalized and targeted marketing automation flows; and Bridgeline Unbound Insights to manage, measure, and optimize web properties by recording detailed events and mining data for statistical analysis. In addition, it offers Bridgeline Unbound Social, a social media management solution that empowers customers to set up customized watch lists; and Bridgeline Unbound Franchises, a web content management and e-commerce platform to multi-unit organizations and franchises. Further, the company provides digital strategy, web design and development, usability engineering, information architecture, and search engine optimization services; application monitoring, emergency response, version control, load balancing, managed firewall security, and virus protection services; and shared, dedicated, and Software as a Service hosting services. Further, it offers OrchestraCMS by Bridgeline and Celebros Search by Bridgeline digital solutions. It serves vertical markets, such as financial services, retail brand names, health services and life sciences, technology, credit unions and regional banks, and associations and foundations through its direct sales force. The company was formerly known as Bridgeline Software, Inc. Bridgeline Digital, Inc. was founded in 2000 and is based in Burlington, Massachusetts.",Mr. Roger E. Kahn Ph.D.,Software - Infrastructure,1.95,USD,20314320,https://images.financialmodelingprep.com/symbol/BLIN.png,148185,-10.26,-0.4,882953,-979000,-1961000,"[{'period': '2024', 'revenue': 15.36, 'unit': 'M', 'net_profit': -1.96}, {'period': '2023', 'revenue': 15.88, 'unit': 'M', 'net_profit': -9.44}, {'period': '2022', 'revenue': 16.82, 'unit': 'M', 'net_profit': 2.15}, {'period': '2021', 'revenue': 13.26, 'unit': 'M', 'net_profit': -6.69}]","[{'period': ""Q4 '24"", 'revenue': 3860.0, 'unit': 'K', 'net_profit': -432.0}, {'period': ""Q3 '24"", 'revenue': 3940.0, 'unit': 'K', 'net_profit': -305.0}, {'period': ""Q2 '24"", 'revenue': 3800.0, 'unit': 'K', 'net_profit': -602.0}, {'period': ""Q1 '24"", 'revenue': 3750.0, 'unit': 'K', 'net_profit': -622.0}, {'period': ""Q4 '23"", 'revenue': 3.8, 'unit': 'M', 'net_profit': -8.06}, {'period': ""Q3 '23"", 'revenue': 3910.0, 'unit': 'K', 'net_profit': -781.0}]",-0.19,-0.19,15602000,2947000,1390000,5596000,1288000,0,4728000,1390000,-794000,-0.1125,0.792156862745098,0.7912087912087912,__nan__,__nan__,__nan__,0.3586719651326753
539,BLKB,Blackbaud Inc. Common Stock,"Blackbaud, Inc. provides cloud software solutions to higher education institutions, K12 schools, healthcare organizations, faith communities, arts and cultural organizations, foundations, companies, and individual change agents in the United States and internationally. The company offers fundraising and relationship management solutions, such as Blackbaud Raiser's Edge NXT and Blackbaud CRM, Blackbaud eTapestry, Blackbaud TeamRaiser, JustGiving, and Blackbaud Guided Fundraising and Blackbaud Volunteer Network Fundraising; marketing and engagement solutions, including Blackbaud Luminate Online, Blackbaud Online Express, and Blackbaud School Website System; and financial management solutions comprising Blackbaud Financial Edge NXT, Blackbaud Tuition Management, and Blackbaud Financial Aid Management. It also provides grant and award management solutions, consisting of Blackbaud Grantmaking and Blackbaud Award Management; organizational and program management, such as Blackbaud Student Information System, Blackbaud Learning Management System, Blackbaud Enrollment Management System, Blackbaud Altru, and Blackbaud Church Management; social responsibility solutions, which includes YourCause GrantsConnect and YourCause CSRconnect; Blackbaud Merchant Services and Blackbaud Purchase Cards payment services; and Blackbaud's Intelligence for Good solutions, as well as donor acquisition, prospect research, data enrichment, and benchmarking and performance management solutions and services. It sells its solutions and related services through its direct sales force. Blackbaud, Inc. was founded in 1981 and is headquartered in Charleston, South Carolina.",Mr. Michael P. Gianoni,Software - Application,74.845,USD,3795966257,https://images.financialmodelingprep.com/symbol/BLKB.png,205211,74.1,-0.365,31089,167053000,1820000,"[{'period': '2023', 'revenue': 1110.0, 'unit': 'M', 'net_profit': 1.82}, {'period': '2022', 'revenue': 1060.0, 'unit': 'M', 'net_profit': -45.41}, {'period': '2021', 'revenue': 927.74, 'unit': 'M', 'net_profit': 5.7}, {'period': '2020', 'revenue': 913.22, 'unit': 'M', 'net_profit': 7.72}]","[{'period': ""Q3 '24"", 'revenue': 286.73, 'unit': 'M', 'net_profit': 20.54}, {'period': ""Q2 '24"", 'revenue': 287.16, 'unit': 'M', 'net_profit': 21.8}, {'period': ""Q1 '24"", 'revenue': 279.25, 'unit': 'M', 'net_profit': 5.25}, {'period': ""Q4 '23"", 'revenue': 295.01, 'unit': 'M', 'net_profit': 5.4}, {'period': ""Q3 '23"", 'revenue': 277.63, 'unit': 'M', 'net_profit': 9.02}, {'period': ""Q2 '23"", 'revenue': 271.04, 'unit': 'M', 'net_profit': 2.1}]",0.0346,0.0339,2912279000,929757000,31251000,2103574000,102215000,0,1197137000,31251000,135506000,0.8958089812408503,1.0400819256942762,1.0393181818181818,"[0.12, 0.05]","['2020-02-27', '2005-02-10']",__nan__,0.7223119762907332
540,BLMN,Bloomin' Brands Inc. Common Stock,"Bloomin' Brands, Inc., through its subsidiaries, owns and operates casual, upscale casual, and fine dining restaurants in the United States and internationally. The company operates through two segments, U.S. and International. Its restaurant portfolio has four concepts, including Outback Steakhouse, a casual steakhouse restaurant; Carrabba's Italian Grill, a casual Italian restaurant; Bonefish Grill; and Fleming's Prime Steakhouse & Wine Bar, a contemporary steakhouse. As of December 26, 2021, the company owned and operated 1,013 full-service restaurants and franchised 157 restaurants across 47 states; and 156 full-service restaurants and franchised 172 restaurants across 17 countries and Guam. The company was founded in 1988 and is based in Tampa, Florida.",Mr. Michael  Spanos,Restaurants,12.07,USD,1024056217,https://images.financialmodelingprep.com/symbol/BLMN.png,1848416,-150.87,-0.55,570213,516315000,247386000,"[{'period': '2023', 'revenue': 4670.0, 'unit': 'M', 'net_profit': 247.39}, {'period': '2022', 'revenue': 4420.0, 'unit': 'M', 'net_profit': 101.91}, {'period': '2021', 'revenue': 4120.0, 'unit': 'M', 'net_profit': 215.56}, {'period': '2020', 'revenue': 3170.0, 'unit': 'M', 'net_profit': -158.79}]","[{'period': ""Q3 '24"", 'revenue': 1040.0, 'unit': 'M', 'net_profit': 6.91}, {'period': ""Q2 '24"", 'revenue': 1120.0, 'unit': 'M', 'net_profit': 28.4}, {'period': ""Q1 '24"", 'revenue': 1200.0, 'unit': 'M', 'net_profit': -83.87}, {'period': ""Q4 '23"", 'revenue': 1190.0, 'unit': 'M', 'net_profit': 43.27}, {'period': ""Q3 '23"", 'revenue': 1080.0, 'unit': 'M', 'net_profit': 44.53}, {'period': ""Q2 '23"", 'revenue': 1150.0, 'unit': 'M', 'net_profit': 68.28}]",2.84,2.56,3424081000,343314000,111519000,3012078000,102843000,0,1002335000,111519000,208166000,0.0017714327845060748,1.4275663104595366,1.4695652173913045,"[0.24, 0.06]","['2024-11-25', '2015-03-02']",__nan__,0.8796748675045947
541,BLNK,Blink Charging Co. Common Stock,"Blink Charging Co., through its subsidiaries, owns, operates, and provides electric vehicle (EV) charging equipment and networked EV charging services in the United States and internationally. The company offers residential and commercial EV charging equipment that enable EV drivers to recharge at various location types. It also provides Blink Network, a cloud-based system that operates, maintains, and manages various Blink charging stations and associated charging data, back-end operations, and payment processing, as well as offers property owners, managers, parking companies, and state and municipal entities with cloud-based services that enable the remote monitoring and management of EV charging stations; and provides EV drivers with station information, including station location, availability, and applicable fees. In addition, the company provides EV charging hardware, software services, and service plans. It has strategic partnerships across transit/destination locations, including airports, auto dealers, healthcare/medicals, hotels, mixed-use, municipal locations, multifamily residential and condos, parks and recreation areas, parking lots, religious institutions, restaurants, retailers, schools and universities, stadiums, supermarkets, transportation hubs, and workplace locations. The company offers its services through direct sales force and resellers, as well as sells residential Level 2 chargers through various internet channels. As of March 10, 2022, it deployed approximately 30,000 charging ports. Blink Charging Co. was founded in 2009 and is headquartered in Miami Beach, Florida.",Mr. Brendan S. Jones,Engineering & Construction,1.6875,USD,170732813,https://images.financialmodelingprep.com/symbol/BLNK.png,4941148,-1.18,0.0175,4715700,-93119000,-203693000,"[{'period': '2023', 'revenue': 140.6, 'unit': 'M', 'net_profit': -203.69}, {'period': '2022', 'revenue': 61.14, 'unit': 'M', 'net_profit': -91.56}, {'period': '2021', 'revenue': 20.94, 'unit': 'M', 'net_profit': -53.89}, {'period': '2020', 'revenue': 6.23, 'unit': 'M', 'net_profit': -18.0}]","[{'period': ""Q3 '24"", 'revenue': 24.2, 'unit': 'M', 'net_profit': -87.39}, {'period': ""Q2 '24"", 'revenue': 33.26, 'unit': 'M', 'net_profit': -20.06}, {'period': ""Q1 '24"", 'revenue': 37.57, 'unit': 'M', 'net_profit': -17.17}, {'period': ""Q4 '23"", 'revenue': 42.71, 'unit': 'M', 'net_profit': -19.69}, {'period': ""Q3 '23"", 'revenue': 43.38, 'unit': 'M', 'net_profit': -112.72}, {'period': ""Q2 '23"", 'revenue': 32.65, 'unit': 'M', 'net_profit': -41.48}]",-3.21,-3.21,428519000,221734000,121691000,139122000,45447000,0,69701000,121691000,-105122000,-0.16801715919923738,-1.2246941896024466,-0.6461538461538462,__nan__,__nan__,__nan__,0.324657716460647
542,BLNKW,Blink Charging Co. Warrant,"Blink Charging Co., through its subsidiaries, owns, operates, manufactures, and provides electric vehicle (EV) charging equipment and networked EV charging services in the United States and internationally. The company offers residential and commercial EV charging equipment that enable EV drivers to recharge at various location types. It also provides Blink Network, a cloud-based system that operates, maintains, and manages various Blink charging stations and associated charging data, back-end operations, and payment processing, as well as offers fleets, property owners, managers, parking companies, and state and municipal entities with cloud-based services that enable the remote monitoring and management of EV charging stations; and EV drivers with station information, including station location, availability, and applicable fees. In addition, the company offers EV charging hardware, software services, and service plans. It has strategic partnerships across transit/destination locations, including airports, auto dealers, healthcare/medicals, hotels, mixed-use and municipal locations, multifamily residential and condos, parks and recreation areas, parking lots, religious institutions, restaurants, retailers, schools and universities, stadiums, supermarkets, transportation hubs, and workplace locations. Blink Charging Co. was founded in 2009 and is headquartered in Bowie, Maryland.",None,Electrical Equipment & Parts,10.0499,USD,0,https://images.financialmodelingprep.com/symbol/BLNKW.png,0,0,0,997,-93119000,-203693000,"[{'period': '2023', 'revenue': 140.6, 'unit': 'M', 'net_profit': -203.69}, {'period': '2022', 'revenue': 61.14, 'unit': 'M', 'net_profit': -91.56}, {'period': '2021', 'revenue': 20.94, 'unit': 'M', 'net_profit': -53.89}, {'period': '2020', 'revenue': 6.23, 'unit': 'M', 'net_profit': -18.0}]","[{'period': ""Q3 '24"", 'revenue': 24.2, 'unit': 'M', 'net_profit': -87.39}, {'period': ""Q2 '24"", 'revenue': 33.26, 'unit': 'M', 'net_profit': -20.06}, {'period': ""Q1 '24"", 'revenue': 37.57, 'unit': 'M', 'net_profit': -17.17}, {'period': ""Q4 '23"", 'revenue': 42.71, 'unit': 'M', 'net_profit': -19.69}, {'period': ""Q3 '23"", 'revenue': 43.38, 'unit': 'M', 'net_profit': -112.72}, {'period': ""Q2 '23"", 'revenue': 32.65, 'unit': 'M', 'net_profit': -41.48}]",-3.21,-3.21,428519000,221734000,121691000,139122000,45447000,0,69701000,121691000,-105122000,-0.16801715919923738,-1.2246941896024466,-0.6461538461538462,__nan__,__nan__,__nan__,0.324657716460647
543,BLPH,Bellerophon Therapeutics Inc. Common Stock,"Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.",Mr. Craig R. Jalbert CIRA,Biotechnology,0.012,USD,146791,https://images.financialmodelingprep.com/symbol/BLPH.png,0,-0.01,,0,-22183000,-19831000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.83}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.76}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.73}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.27}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.92}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.14}, {'period': ""Q1 '23"", 'revenue': 5.64, 'unit': 'M', 'net_profit': 2.82}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.43}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.07}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.11}]",-2.08,-2.08,7935000,7563000,7329000,5401000,0,0,5401000,6924000,-17770000,-0.10029264421407669,-0.11686190583464744,-0.11229946524064169,"[0.018965, 0.018965]","['2024-12-19', '2024-12-19']",__nan__,0.6806553245116572
544,BLRX,BioLineRx Ltd. American Depositary Shares,"BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.","Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA",Biotechnology,0.1528,USD,19651146,https://images.financialmodelingprep.com/symbol/BLRX.png,3600304,-0.51,-0.0091,12461638,-57061000,-60614000,"[{'period': '2023', 'revenue': 4.8, 'unit': 'M', 'net_profit': -60.61}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.87}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.14}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.93}]","[{'period': ""Q3 '24"", 'revenue': 4.94, 'unit': 'M', 'net_profit': -5.82}, {'period': ""Q2 '24"", 'revenue': 5390.0, 'unit': 'K', 'net_profit': 484.0}, {'period': ""Q1 '24"", 'revenue': 6860.0, 'unit': 'K', 'net_profit': -696.0}, {'period': ""Q4 '23"", 'revenue': 4.8, 'unit': 'M', 'net_profit': -13.88}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.02}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.55}]",-0.94,-0.94,63925000,47183000,42994000,50702000,708000,0,30852000,4255000,-22905000,-1.0019296214433568,-2.2118482407799913,-1.5405405405405403,__nan__,__nan__,__nan__,0.7931482205709817
545,BLSA,BCLS Acquisition Corp. Class A Ordinary Shares,"BCLS Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Boston, Massachusetts.",Mr. Jeffrey Lawrence Schwartz M.B.A.,Shell Companies,10.035,USD,0,https://images.financialmodelingprep.com/symbol/BLSA.png,29954,-218.15217391304347,0,4694,-847038,-837545,"[{'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -837.54}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -166.75}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -55.75}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -233.65}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -627.45}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -164.3}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -242.92}]",-0.0442,-0.0442,144595871,835474,639686,5448349,0,143760397,417099,639686,-329114,-4.079596768873723,-4.0226682578424375,-4.0227272727272725,__nan__,__nan__,__nan__,0.037679838036315715
546,BLTS,Bright Lights Acquisition Corp. Class A Common Stock,"Bright Lights Acquisition Corp. is a blank check company. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It intends to focus for a target business operating in the consumer products, media, entertainment, and sports sectors. The company was incorporated in 2020 and is based in Los Angeles, California.",,Shell Companies,10.01,USD,0,https://images.financialmodelingprep.com/symbol/BLTS.png,106688,18.537037037037038,-0.04,1200,-1341378,4494420,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.49}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.4}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.34}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.93}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.93}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.89}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.17}]",0.16,0.16,230701499,687074,87074,28025185,0,230014425,5976435,87074,-2004860,0,0,0,__nan__,__nan__,__nan__,0.12147812268874768
547,BLTSU,Bright Lights Acquisition Corp. Unit,"Bright Lights Acquisition Corp. is a blank check company. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It intends to focus for a target business operating in the consumer products, media, entertainment, and sports sectors. The company was incorporated in 2020 and is based in Los Angeles, California.",,Shell Companies,10.03,USD,0,https://images.financialmodelingprep.com/symbol/BLTSU.png,1898,-44.776785714285715,-0.01,300,-1341378,4494420,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.49}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.4}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.34}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.93}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.93}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.89}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.17}]",0.16,0.16,230701499,687074,87074,28025185,0,230014425,5976435,87074,-2004860,0,0,0,__nan__,__nan__,__nan__,0.12147812268874768
548,BLTSW,Bright Lights Acquisition Corp. Warrant,"Bright Lights Acquisition Corp. is a blank check company. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was incorporated in 2020 and is based in Los Angeles, California.",Mr. Michael  Mahan,Shell Companies,0.0095,USD,0,https://images.financialmodelingprep.com/symbol/BLTSW.png,0,0,0,1060,-1341378,4494420,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.49}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.4}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.34}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.93}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.93}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.89}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.17}]",0.16,0.16,230701499,687074,87074,28025185,0,230014425,5976435,87074,-2004860,0,0,0,__nan__,__nan__,__nan__,0.12147812268874768
549,BLU,BELLUS Health Inc. Common Shares,"BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.",Mr. Roberto Francesco Bellini,Biotechnology,14.745,USD,1869842940,https://images.financialmodelingprep.com/symbol/BLU.png,5381551,-20.198630136986303,0.005,2839350,-72763000,-76080000,"[{'period': '2022', 'revenue': 0.016, 'unit': 'M', 'net_profit': -76.08}, {'period': '2021', 'revenue': 0.016, 'unit': 'M', 'net_profit': -71.22}, {'period': '2020', 'revenue': 0.015, 'unit': 'M', 'net_profit': -31.8}, {'period': '2019', 'revenue': 0.02679, 'unit': 'M', 'net_profit': -26.41}]","[{'period': ""Q3 '23"", 'revenue': 1650.0, 'unit': 'M', 'net_profit': -42.7}, {'period': ""Q2 '23"", 'revenue': 1520.0, 'unit': 'M', 'net_profit': -22.19}, {'period': ""Q1 '23"", 'revenue': 0.003, 'unit': 'M', 'net_profit': -25.06}, {'period': ""Q4 '22"", 'revenue': 0.004, 'unit': 'M', 'net_profit': -18.25}, {'period': ""Q3 '22"", 'revenue': 0.004, 'unit': 'M', 'net_profit': -24.71}, {'period': ""Q2 '22"", 'revenue': 0.004, 'unit': 'M', 'net_profit': -18.78}]",-0.66,-0.66,407820000,355893000,337057000,16808000,1643000,23493740,15876000,87250000,-97982032,0.001303906228554174,-0.06817926541615187,0.26666666666666666,__nan__,__nan__,__nan__,0.04121426119366387
550,BLUE,bluebird bio Inc. Common Stock,"bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent -thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with -thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.",Mr. Andrew  Obenshain,Biotechnology,9.36,USD,90999979,https://images.financialmodelingprep.com/symbol/BLUE.png,413890,-0.24,-0.56,225356,-167161000,-211913000,"[{'period': '2023', 'revenue': 29.5, 'unit': 'M', 'net_profit': -211.91}, {'period': '2022', 'revenue': 3.6, 'unit': 'M', 'net_profit': -266.58}, {'period': '2021', 'revenue': 3.66, 'unit': 'M', 'net_profit': -562.64}, {'period': '2020', 'revenue': 250.73, 'unit': 'M', 'net_profit': -618.7}]","[{'period': ""Q3 '24"", 'revenue': 10.61, 'unit': 'M', 'net_profit': -60.81}, {'period': ""Q2 '24"", 'revenue': 16.1, 'unit': 'M', 'net_profit': -81.39}, {'period': ""Q1 '24"", 'revenue': 18.57, 'unit': 'M', 'net_profit': -69.8}, {'period': ""Q4 '23"", 'revenue': 7.83, 'unit': 'M', 'net_profit': -88.51}, {'period': ""Q3 '23"", 'revenue': 12.39, 'unit': 'M', 'net_profit': -71.73}, {'period': ""Q2 '23"", 'revenue': 6.89, 'unit': 'M', 'net_profit': -72.91}]",-1.93,-1.93,619161000,281685000,221755000,424624000,13009000,0,200113000,221755000,-244103000,0.2245232163815939,0.20506193309275333,0.4306784660766962,__nan__,__nan__,__nan__,0.6858054690137138
551,BLUW,Blue Water Acquisition Corp. Class A Common Stock,"Blue Water Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded in 2020 and is based in Greenwich, Connecticut.",Mr. Joseph  Hernandez,Shell Companies,9.63,USD,0,https://images.financialmodelingprep.com/symbol/BLUW.png,717768,0,0.6999998,5919992,,,[],"[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",,,59473560,823512,655371,19131980,0,0,420845,655371,29526000,,,,__nan__,__nan__,__nan__,0.32168883113773583
552,BLUWU,Blue Water Acquisition Corp. Unit,"Blue Water Acquisition Corp. is a blank check company. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. The company was founded in 2020 and is based in Greenwich, Connecticut.",,Shell Companies,10.35,USD,0,https://images.financialmodelingprep.com/symbol/BLUWU.png,4373,0,0.75,7616,,,[],"[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",,,59473560,823512,655371,19131980,0,0,420845,655371,29526000,,,,__nan__,__nan__,__nan__,0.32168883113773583
553,BLUWW,Blue Water Acquisition Corp. Warrant,"Blue Water Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded in 2020 and is based in Greenwich, Connecticut.",Mr. Joseph  Hernandez,Shell Companies,0.8801,USD,0,https://images.financialmodelingprep.com/symbol/BLUWW.png,0,0,0.0201,277090,,,[],"[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",,,59473560,823512,655371,19131980,0,0,420845,655371,29526000,,,,__nan__,__nan__,__nan__,0.32168883113773583
554,BMBL,Bumble Inc. Class A Common Stock,"Bumble Inc. provides online dating and social networking platforms in North America, Europe, internationally. It owns and operates websites and applications that offers subscription and in-app purchases dating products. The company operates two apps, Bumble and Badoo with approximately 40 million users on monthly basis, as well as Fruitz, an online dating app. Bumble Inc. was founded in 2014 in and is headquartered in Austin, Texas.",Ms. Lidiane S. Jones,Software - Application,8.13,USD,879519660,https://images.financialmodelingprep.com/symbol/BMBL.png,2306651,-1.72,-0.1,493885,121401000,-4213000,"[{'period': '2023', 'revenue': 1050.0, 'unit': 'M', 'net_profit': -4.21}, {'period': '2022', 'revenue': 903.5, 'unit': 'M', 'net_profit': -114.12}, {'period': '2021', 'revenue': 765.66, 'unit': 'M', 'net_profit': 309.81}, {'period': '2020', 'revenue': 488.94, 'unit': 'M', 'net_profit': 98.12}]","[{'period': ""Q3 '24"", 'revenue': 273.61, 'unit': 'M', 'net_profit': -613.2}, {'period': ""Q2 '24"", 'revenue': 268.62, 'unit': 'M', 'net_profit': 27.39}, {'period': ""Q1 '24"", 'revenue': 267.77, 'unit': 'M', 'net_profit': 24.62}, {'period': ""Q4 '23"", 'revenue': 273.64, 'unit': 'M', 'net_profit': -26.03}, {'period': ""Q3 '23"", 'revenue': 275.51, 'unit': 'M', 'net_profit': 16.67}, {'period': ""Q2 '23"", 'revenue': 259.74, 'unit': 'M', 'net_profit': 6.75}]",-0.03,-0.0312,3625127000,493051000,355642000,1287854000,106900000,1735000,244909000,355642000,167151000,14.98012373305252,0.9630840138796397,0.9659090909090908,__nan__,__nan__,__nan__,0.35525762269845995
555,BMEA,Biomea Fusion Inc. Common Stock,"Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.",Mr. Thomas Andrew Butler,Biotechnology,4.055,USD,146947929,https://images.financialmodelingprep.com/symbol/BMEA.png,871429,-1.01,0.135,1084039,-124620000,-117255000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -117.25}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -80.02}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -41.22}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.32}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -32.79}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -37.28}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -39.06}, {'period': ""Q4 '23"", 'revenue': 6.14, 'unit': 'M', 'net_profit': -34.88}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.43}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.89}]",-3.44,-3.44,199927000,179181000,176866000,30690000,0,0,22860000,176866000,-99962000,-0.5024776051022992,-0.46528454674964387,-0.26007326007326004,__nan__,__nan__,__nan__,0.15350602970084082
556,BMRA,Biomerica Inc. Common Stock,"Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.",Mr. Zackary S. Irani,Medical - Devices,0.3625,USD,6097830,https://images.financialmodelingprep.com/symbol/BMRA.png,929132,-0.98,0.0003,135766,-5993000,-5978000,"[{'period': '2024', 'revenue': 5.42, 'unit': 'M', 'net_profit': -5.98}, {'period': '2023', 'revenue': 5.34, 'unit': 'M', 'net_profit': -7.14}, {'period': '2022', 'revenue': 18.87, 'unit': 'M', 'net_profit': -4.53}, {'period': '2021', 'revenue': 7.2, 'unit': 'M', 'net_profit': -6.47}]","[{'period': ""Q1 '25"", 'revenue': 1.81, 'unit': 'M', 'net_profit': -1.32}, {'period': ""Q4 '24"", 'revenue': 1.12, 'unit': 'M', 'net_profit': -1.42}, {'period': ""Q3 '24"", 'revenue': 1.02, 'unit': 'M', 'net_profit': -1.92}, {'period': ""Q2 '24"", 'revenue': 1.57, 'unit': 'M', 'net_profit': -1.51}, {'period': ""Q1 '24"", 'revenue': 1.71, 'unit': 'M', 'net_profit': -1.13}, {'period': ""Q4 '23"", 'revenue': 1.11, 'unit': 'M', 'net_profit': -1.79}]",-0.36,-0.36,9254000,7731000,4170000,2663000,947000,165000,2204000,4170000,-5476000,0.11056693380825171,0.1627450980392157,0.28,__nan__,__nan__,__nan__,0.2877674519126864
557,BMRC,Bank of Marin Bancorp Common Stock,"Bank of Marin Bancorp operates as the holding company for Bank of Marin that provides a range of financial services primarily to small to medium-sized businesses, professionals, not-for-profit organizations, and individuals in California, the United States. It offers personal and business checking and savings accounts; and individual retirement, health savings, and demand deposit marketplace accounts, as well as time certificates of deposit, certificate of deposit account registry and insured cash sweep services. The company also provides commercial real estate, commercial and industrial, and consumer loans, as well as construction financing and home equity lines of credit. In addition, it offers merchant and payroll, and cash management services; credit cards; fraud detection tools; and mobile deposit, remote deposit capture, automated clearing house, wire transfer, and image lockbox services. Further, the company provides wealth management and trust services comprising customized investment portfolio management, financial planning, trust administration, estate settlement, and custody services, as well as 401(k) plan services; and automated teller machines, and telephone and digital banking services. It operates through 12 branch offices in Marin, southern Sonoma counties, and north of San Francisco, California; and a loan production office in San Francisco. The company was incorporated in 1989 and is headquartered in Novato, California.",Mr. Timothy D. Myers,Banks - Regional,23.09,USD,371354138,https://images.financialmodelingprep.com/symbol/BMRC.png,61356,-26.54,-0.45,13854,0,19895000,"[{'period': '2023', 'revenue': 104.97, 'unit': 'M', 'net_profit': 19.89}, {'period': '2022', 'revenue': 138.4, 'unit': 'M', 'net_profit': 46.59}, {'period': '2021', 'revenue': 115.08, 'unit': 'M', 'net_profit': 33.23}, {'period': '2020', 'revenue': 105.21, 'unit': 'M', 'net_profit': 30.24}]","[{'period': ""Q3 '24"", 'revenue': 39.21, 'unit': 'M', 'net_profit': 4.57}, {'period': ""Q2 '24"", 'revenue': 4.58, 'unit': 'M', 'net_profit': -21.9}, {'period': ""Q1 '24"", 'revenue': 36.9, 'unit': 'M', 'net_profit': 2.92}, {'period': ""Q4 '23"", 'revenue': 32140.0, 'unit': 'K', 'net_profit': 610.0}, {'period': ""Q3 '23"", 'revenue': 27.07, 'unit': 'M', 'net_profit': 5.29}, {'period': ""Q2 '23"", 'revenue': 26.87, 'unit': 'M', 'net_profit': 4.55}]",1.24,1.24,3803903000,30453000,30453000,3364841000,0,1477226000,2752000,30123000,33910000,-1,-0.5729403683510067,-0.5767918088737202,"[0.25, 0.4]","['2024-11-07', '2004-05-25']",__nan__,0.884575921099986
558,BMRN,BioMarin Pharmaceutical Inc. Common Stock,"BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.",Mr. Alexander  Hardy,Biotechnology,68.37,USD,13030159710,https://images.financialmodelingprep.com/symbol/BMRN.png,1426279,41.19,1.3,422322,310284000,167645000,"[{'period': '2023', 'revenue': 2420.0, 'unit': 'M', 'net_profit': 167.65}, {'period': '2022', 'revenue': 2100.0, 'unit': 'M', 'net_profit': 141.56}, {'period': '2021', 'revenue': 1850.0, 'unit': 'M', 'net_profit': -64.08}, {'period': '2020', 'revenue': 1860.0, 'unit': 'M', 'net_profit': 854.03}]","[{'period': ""Q3 '24"", 'revenue': 745.74, 'unit': 'M', 'net_profit': 106.08}, {'period': ""Q2 '24"", 'revenue': 708.66, 'unit': 'M', 'net_profit': 107.17}, {'period': ""Q1 '24"", 'revenue': 648.83, 'unit': 'M', 'net_profit': 88.66}, {'period': ""Q4 '23"", 'revenue': 646.21, 'unit': 'M', 'net_profit': 20.38}, {'period': ""Q3 '23"", 'revenue': 585.97, 'unit': 'M', 'net_profit': 40.38}, {'period': ""Q2 '23"", 'revenue': 594.6, 'unit': 'M', 'net_profit': 56.04}]",0.89,0.87,6841603000,2956088000,1073810000,1890054000,633704000,611135000,1177024000,755127000,51648000,0.15987514718800816,0.1842597890661976,0.17105263157894737,__nan__,__nan__,__nan__,0.27625894106980486
559,BMTC,Bryn Mawr Bank Corporation Common Stock,"Bryn Mawr Bank Corporation operates as a bank holding company for The Bryn Mawr Trust Company that provides commercial and retail banking services to individual and business customers. It operates in two segments, Wealth Management and Banking. The company accepts deposit products, including interest-bearing demand accounts, wholesale time deposits, retail time deposits, savings accounts, noninterest-bearing deposits, money market accounts, and wholesale non-maturity deposits. It also provides commercial mortgages, home equity lines and loans, and residential mortgages, as well as construction, commercial and industrial, and consumer loans; and leasing services. In addition, the company offers wealth management services comprising trust administration and other related fiduciary, custody, investment management and advisory, employee benefits and IRA administration, estate settlement, financial planning, and brokerage services, as well as estate administration, retirement planning, and tax planning and preparation services. Further, it provides insurance and related products and services that include casualty, property, and allied insurance lines, as well as life insurance, annuities, medical insurance, and accident and health insurance for groups and individuals. Additionally, the company offers a small-ticket equipment financing service. It provides its services through 41 banking locations, seven wealth management offices, and two insurance and risk management locations in the Montgomery, Chester, Delaware, Philadelphia, and Dauphin Counties in Pennsylvania; New Castle County in Delaware; and Mercer and Camden Counties in New Jersey. Bryn Mawr Bank Corporation was founded in 1889 and is headquartered in Bryn Mawr, Pennsylvania.",Mr. Francis Leto,Banks - Regional,45.01,USD,0,https://images.financialmodelingprep.com/symbol/BMTC.png,89506,12.46124031007752,-0.7200012,743295,78519000,32573000,"[{'period': '2020', 'revenue': 222.45, 'unit': 'M', 'net_profit': 32.57}, {'period': '2019', 'revenue': 229.01, 'unit': 'M', 'net_profit': 59.21}, {'period': '2018', 'revenue': 224.38, 'unit': 'M', 'net_profit': 63.79}, {'period': '2017', 'revenue': 173.97, 'unit': 'M', 'net_profit': 23.02}]","[{'period': ""Q3 '21"", 'revenue': 57.28, 'unit': 'M', 'net_profit': 18.38}, {'period': ""Q2 '21"", 'revenue': 55.99, 'unit': 'M', 'net_profit': 21.34}, {'period': ""Q1 '21"", 'revenue': 54.31, 'unit': 'M', 'net_profit': 17.08}, {'period': ""Q4 '20"", 'revenue': 54.45, 'unit': 'M', 'net_profit': 15.54}, {'period': ""Q3 '20"", 'revenue': 55.94, 'unit': 'M', 'net_profit': 13.16}, {'period': ""Q2 '20"", 'revenue': 57.7, 'unit': 'M', 'net_profit': 15.04}]",1.63,1.63,5432022000,3922469000,1271277000,4809700000,167837000,1216088000,39602000,96313000,69928000,-0.42437704809870463,-0.4498361652535216,-0.4436860068259386,"[0.28, 5.76]","['2021-10-29', '1985-10-16']",__nan__,0.8854345582547346
560,BNFT,Benefitfocus Inc. Common Stock,"Benefitfocus, Inc. provides cloud-based benefits management technology solutions for employers and health plans in the United States. Its products for employers comprise Benefitplace, a cloud-based benefits management portal that streamlines online enrollment, employee communication, and benefit administration; Health Insights, a data analytics solution; ACA Management and Reporting, a solution for employers to manage ACA compliance; Billing & Payments, an application that synchronizes enrollment and billing information to streamline the monthly billing process, automate adjustments, and enhance accuracy of payments; and COBRA Administration, a solution that simplifies management of Consolidated Omnibus Budget Reconciliation Act, benefits. The company's products for health plans include Enrollment that provides platform for carriers to automate enrollment across all segments of their commercial group business; Billing & Payments, an electronic invoice presentment and payment solution; Exchange, a solution that bridges the integration gap between health plan and employer systems; and Quoting that gives health plans and brokers tools to organize and proactively manage accounts, track leads, generate quotes, and create proposals for multiple products. Its products for brokers consist of Health Insights that support strategic decisions for their clients with on-demand health plan analytics; Benefit Catalog, which allows brokers to offer products to their clients; and benefit catalog consultative support for brokers through benefit advisors. The company also provides implementation services to its customers in order to help ensure seamless deployment and effective utilization of its solutions; and employers with expanded support services. The company was incorporated in 2000 and is headquartered in Charleston, South Carolina.",Mr. Matthew C. Levin,Software - Application,10.5,USD,0,https://images.financialmodelingprep.com/symbol/BNFT.png,597401,0,0,381982,-5710000,-32166000,"[{'period': '2021', 'revenue': 263.1, 'unit': 'M', 'net_profit': -32.17}, {'period': '2020', 'revenue': 268.14, 'unit': 'M', 'net_profit': -24.3}, {'period': '2019', 'revenue': 295.69, 'unit': 'M', 'net_profit': -45.52}, {'period': '2018', 'revenue': 258.72, 'unit': 'M', 'net_profit': -52.63}]","[{'period': ""Q3 '22"", 'revenue': 56.19, 'unit': 'M', 'net_profit': -6.99}, {'period': ""Q2 '22"", 'revenue': 56.59, 'unit': 'M', 'net_profit': -12.16}, {'period': ""Q1 '22"", 'revenue': 61.23, 'unit': 'M', 'net_profit': -2.28}, {'period': ""Q4 '21"", 'revenue': 75.1, 'unit': 'M', 'net_profit': 3.0}, {'period': ""Q3 '21"", 'revenue': 62.03, 'unit': 'M', 'net_profit': -18.05}, {'period': ""Q2 '21"", 'revenue': 60.9, 'unit': 'M', 'net_profit': -15.02}]",-0.97,-0.97,260841000,112156000,68050000,257965000,16491000,0,72236000,31001000,21726000,-1.239815203695926,-0.3238671440918632,-0.2933333333333333,__nan__,__nan__,__nan__,0.9889741260001303
561,BNGO,Bionano Genomics Inc. Common Stock,"Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.","Dr. Robert Erik Holmlin M.B.A., Ph.D.",Medical - Diagnostics & Research,0.2607,USD,26589575,https://images.financialmodelingprep.com/symbol/BNGO.png,6318679,-0.13,-0.019,9306830,-213604000,-232493000,"[{'period': '2023', 'revenue': 36.12, 'unit': 'M', 'net_profit': -232.49}, {'period': '2022', 'revenue': 27.8, 'unit': 'M', 'net_profit': -132.6}, {'period': '2021', 'revenue': 17.98, 'unit': 'M', 'net_profit': -72.44}, {'period': '2020', 'revenue': 8.5, 'unit': 'M', 'net_profit': -41.14}]","[{'period': ""Q3 '24"", 'revenue': 6.07, 'unit': 'M', 'net_profit': -44.25}, {'period': ""Q2 '24"", 'revenue': 7.77, 'unit': 'M', 'net_profit': -16.22}, {'period': ""Q1 '24"", 'revenue': 8.77, 'unit': 'M', 'net_profit': -31.42}, {'period': ""Q4 '23"", 'revenue': 10.72, 'unit': 'M', 'net_profit': -43.89}, {'period': ""Q3 '23"", 'revenue': 9.32, 'unit': 'M', 'net_profit': -112.57}, {'period': ""Q2 '23"", 'revenue': 8.66, 'unit': 'M', 'net_profit': -38.91}]",-6.81,-6.81,214404000,140118000,101888000,118247000,9661000,400000,100028000,17948000,-126872000,-0.7753729792627686,-0.7533937675344656,-0.4868995633187772,__nan__,__nan__,__nan__,0.5515148971101286
562,BNGOW,Bionano Genomics Inc. Warrant,,None,,0.0036,USD,0,https://images.financialmodelingprep.com/symbol/BNGOW.png,0,0,-0.0015,63789,-213604000,-232493000,"[{'period': '2023', 'revenue': 36.12, 'unit': 'M', 'net_profit': -232.49}, {'period': '2022', 'revenue': 27.8, 'unit': 'M', 'net_profit': -132.6}, {'period': '2021', 'revenue': 17.98, 'unit': 'M', 'net_profit': -72.44}, {'period': '2020', 'revenue': 8.5, 'unit': 'M', 'net_profit': -41.14}]","[{'period': ""Q3 '24"", 'revenue': 6.07, 'unit': 'M', 'net_profit': -44.25}, {'period': ""Q2 '24"", 'revenue': 7.77, 'unit': 'M', 'net_profit': -16.22}, {'period': ""Q1 '24"", 'revenue': 8.77, 'unit': 'M', 'net_profit': -31.42}, {'period': ""Q4 '23"", 'revenue': 10.72, 'unit': 'M', 'net_profit': -43.89}, {'period': ""Q3 '23"", 'revenue': 9.32, 'unit': 'M', 'net_profit': -112.57}, {'period': ""Q2 '23"", 'revenue': 8.66, 'unit': 'M', 'net_profit': -38.91}]",-6.81,-6.81,214404000,140118000,101888000,118247000,9661000,400000,100028000,17948000,-126872000,-0.7753729792627686,-0.7533937675344656,-0.4868995633187772,__nan__,__nan__,__nan__,0.5515148971101286
563,BNR,Burning Rock Biotech Limited American Depositary Shares,"Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.",Mr. Yusheng  Han,Medical - Diagnostics & Research,7.0501,USD,70255840,https://images.financialmodelingprep.com/symbol/BNR.png,27346,-1.24,0.0001,3546,-517901000,-653689000,"[{'period': '2023', 'revenue': 537.43, 'unit': 'M', 'net_profit': -653.69}, {'period': '2022', 'revenue': 563.24, 'unit': 'M', 'net_profit': -971.23}, {'period': '2021', 'revenue': 507.86, 'unit': 'M', 'net_profit': -796.7}, {'period': '2020', 'revenue': 429.9, 'unit': 'M', 'net_profit': -373.71}]","[{'period': ""Q3 '24"", 'revenue': 128.64, 'unit': 'M', 'net_profit': -35.74}, {'period': ""Q2 '24"", 'revenue': 135.53, 'unit': 'M', 'net_profit': -108.04}, {'period': ""Q1 '24"", 'revenue': 125.62, 'unit': 'M', 'net_profit': -121.55}, {'period': ""Q4 '23"", 'revenue': 121.08, 'unit': 'M', 'net_profit': -162.21}, {'period': ""Q3 '23"", 'revenue': 127.57, 'unit': 'M', 'net_profit': -174.98}, {'period': ""Q2 '23"", 'revenue': 146.27, 'unit': 'M', 'net_profit': -131.24}]",-63.84,-63.84,1040001000,884096000,615096000,271591000,149606000,337000,263363999,615096000,-265167000,0.3951952036117719,0.32694935200925007,-5.827807486631016,__nan__,__nan__,__nan__,0.26114494120678733
564,BNSO,Bonso Electronics International Inc. Common Stock,"Bonso Electronics International Inc., together with its subsidiaries, designs, develops, produces, and sells electronic sensor-based and wireless products. It operates in four segments: Scales, Pet Electronic Products, Rental and Management, and Others. The Scales segment provides sensor-based scales products that include bathroom, kitchen, office, jewelry, laboratory, postal, and industrial scales for consumer, commercial, and industrial applications. The Pet Electronic Products segment develops and produces pet-related electronic products for use in consumer applications. The Rental and Management segment offers leasing of factories and machineries to third parties. The Others segment sells cordless leaf blowers, food vacuum sealers, and hydroponics growing systems, as well as scrap materials; and provides tooling and molding charges for scales. It serves private label original equipment, original brand manufacturers, and original design manufacturers primarily in the United States, Germany, and the People's Republic of China. The company also sells its pet electronic products through online platforms. The company was formerly known as Golden Virtue Limited and changed its name to Bonso Electronics International Inc. in September 1988. Bonso Electronics International Inc. was incorporated in 1988 and is based in Tsim Sha Tsui, Hong Kong.",Mr. Chun Bong  So,"Hardware, Equipment & Parts",1.12,USD,5440053,https://images.financialmodelingprep.com/symbol/BNSO.png,35383,-2.4347826086956523,-0.07,22990,-1042000,-2760000,"[{'period': '2022', 'revenue': 14.8, 'unit': 'M', 'net_profit': -2.76}, {'period': '2021', 'revenue': 15.59, 'unit': 'M', 'net_profit': 1.77}, {'period': '2020', 'revenue': 13100.0, 'unit': 'K', 'net_profit': 217.0}, {'period': '2019', 'revenue': 9990.0, 'unit': 'K', 'net_profit': -479.0}]","[{'period': ""Q4 '22"", 'revenue': -2.66, 'unit': 'M', 'net_profit': -2.78}, {'period': ""Q4 '20"", 'revenue': 8690.0, 'unit': 'K', 'net_profit': 986.0}, {'period': ""Q2 '20"", 'revenue': 4410.0, 'unit': 'K', 'net_profit': -588.0}, {'period': ""Q4 '19"", 'revenue': 4360.0, 'unit': 'K', 'net_profit': -375.0}, {'period': ""Q2 '19"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q4 '18"", 'revenue': 5310.0, 'unit': 'K', 'net_profit': -684.0}]",-0.57,-0.57,23750000,11522000,7135000,8407000,2260000,0,4648000,6740000,-3187000,-1.4926713947990544,-2.5584415584415585,-2.583333333333333,"[0.05, 0.1]","['2006-09-27', '2001-01-29']",__nan__,0.35397894736842106
565,BNTC,Benitec Biopharma Inc. Common Stock,"Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.","Dr. Jerel A. Banks M.D., Ph.D.",Biotechnology,11.795,USD,273837438,https://images.financialmodelingprep.com/symbol/BNTC.png,56101,-4.01,0.305,22322,-22490000,-21751000,"[{'period': '2024', 'revenue': 0.216, 'unit': 'M', 'net_profit': -21.75}, {'period': '2023', 'revenue': 0.075, 'unit': 'M', 'net_profit': -19.56}, {'period': '2022', 'revenue': 0.073, 'unit': 'M', 'net_profit': -18.56}, {'period': '2021', 'revenue': 0.059000000000000004, 'unit': 'M', 'net_profit': -13.78}]","[{'period': ""Q1 '25"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.06}, {'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.72}, {'period': ""Q3 '24"", 'revenue': 0.006, 'unit': 'M', 'net_profit': -4.28}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.8}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.95}, {'period': ""Q4 '23"", 'revenue': 0.007, 'unit': 'M', 'net_profit': -4.66}]",-5.36,-5.36,52210000,51674000,50866000,4962000,229000,0,4924000,50866000,-19582000,-0.20267379679144384,-0.11190062365811267,0.6203966005665721,"[0.003, 0.003]","['2018-06-01', '2018-06-01']",__nan__,0.0950392645087148
566,BNTX,BioNTech SE American Depositary Share,"BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.",Dr. Ugur  Sahin M.D.,Biotechnology,127.565,USD,30582401464,https://images.financialmodelingprep.com/symbol/BNTX.png,792303,-63.78,7.355,973879,1087600000,930300000,"[{'period': '2023', 'revenue': 3820.0, 'unit': 'M', 'net_profit': 930.3}, {'period': '2022', 'revenue': 17.31, 'unit': 'B', 'net_profit': 9.43}, {'period': '2021', 'revenue': 18.98, 'unit': 'B', 'net_profit': 10.29}, {'period': '2020', 'revenue': 482.32, 'unit': 'M', 'net_profit': 15.2}]","[{'period': ""Q3 '24"", 'revenue': 1240.0, 'unit': 'M', 'net_profit': 198.1}, {'period': ""Q2 '24"", 'revenue': 128.7, 'unit': 'M', 'net_profit': -807.8}, {'period': ""Q1 '24"", 'revenue': 187.6, 'unit': 'M', 'net_profit': -315.1}, {'period': ""Q4 '23"", 'revenue': 1480.0, 'unit': 'M', 'net_profit': 457.9}, {'period': ""Q3 '23"", 'revenue': 895.3, 'unit': 'M', 'net_profit': 160.6}, {'period': ""Q2 '23"", 'revenue': 167.7, 'unit': 'M', 'net_profit': -190.4}]",3.83,3.83,23006300000,19527300000,16549000000,2760400000,2160600000,1176100000,2070500000,11663700000,4665900000,-0.9124815926483251,-0.9013927753752226,-0.899422268907563,"[2.111, 2.111]","['2022-06-02', '2022-06-02']",__nan__,0.11998452597766698
567,BOCH,Bank of Commerce Holdings (CA) Common Stock,"Bank of Commerce Holdings operates as the bank holding company for Merchants Bank of Commerce that provides a range of financial services and products for small to medium-sized businesses, and retail customers in California. The company accepts various deposit products, such as checking, interest bearing checking, money market, and savings accounts, as well as certificates of deposit. Its loan products include commercial loans, commercial real estate loans, residential real estate loans, consumer loans, construction loans, term loans, and small business administration loans. In addition, it provides sweep arrangements, safe deposit boxes, collection, electronic banking, payroll processing, and ATM and point of sale services. The company operates ten full service offices and one limited service office in northern California. Bank of Commerce Holdings is headquartered in Sacramento, California.",Mr. Randall Eslick,Banks - Regional,15.17,USD,0,https://images.financialmodelingprep.com/symbol/BOCH.png,107447,0,-0.23999977,431040,25909000,14164000,"[{'period': '2020', 'revenue': 59.51, 'unit': 'M', 'net_profit': 14.16}, {'period': '2019', 'revenue': 57.72, 'unit': 'M', 'net_profit': 14.96}, {'period': '2018', 'revenue': 51.56, 'unit': 'M', 'net_profit': 15.73}, {'period': '2017', 'revenue': 46.19, 'unit': 'M', 'net_profit': 7.34}]","[{'period': ""Q2 '21"", 'revenue': 15.1, 'unit': 'M', 'net_profit': 4.14}, {'period': ""Q1 '21"", 'revenue': 15.27, 'unit': 'M', 'net_profit': 4.92}, {'period': ""Q4 '20"", 'revenue': 15.57, 'unit': 'M', 'net_profit': 5.07}, {'period': ""Q3 '20"", 'revenue': 15.32, 'unit': 'M', 'net_profit': 4.33}, {'period': ""Q2 '20"", 'revenue': 14.74, 'unit': 'M', 'net_profit': 3.85}, {'period': ""Q1 '20"", 'revenue': 13880.0, 'unit': 'K', 'net_profit': 916.0}]",0.85,0.85,35590000,19875000,553866000,1586252000,7279000,455632000,15000000,106986000,21640000,-0.09342524231078764,-0.0532718401176392,0.024096385542168697,"[0.3, 1]","['2021-10-12', '1997-10-20']",__nan__,44.57016015734757
568,BOKF,BOK Financial Corporation Common Stock,"BOK Financial Corporation operates as the financial holding company for BOKF, NA that provides various financial products and services in Oklahoma, Texas, New Mexico, Northwest Arkansas, Colorado, Arizona, and Kansas/Missouri. It operates through three segments: Commercial Banking, Consumer Banking, and Wealth Management. The Commercial Banking segment offers lending, treasury, cash management, and customer commodity risk management products for small businesses, middle market, and larger commercial customers, as well as operates TransFund electronic funds transfer network. The Consumer Banking segment provides lending and deposit services to small business customers through consumer branch network; and engages in the mortgage loan origination and servicing activities. The Wealth Management segment offers fiduciary, private bank, insurance, and investment advisory services; and brokerage and trading services primarily related to providing liquidity to the mortgage markets through trading of U.S. government agency mortgage-backed securities and related derivative contracts, as well as underwrites state and municipal securities. The company also provides commercial loans, such as loans for working capital, facilities acquisition or expansion, purchases of equipment, and other needs of commercial customers; and service, healthcare, manufacturing, wholesale/retail, energy, and other sector loans. In addition, it offers commercial real estate loans for the construction of buildings or other enhancements to real estate and property held by borrowers for investment purposes; and residential mortgage and personal loans. Further, the company provides automated teller machine (ATM), call center, and Internet and mobile banking services. As of December 31, 2021, it operated 2,593 TransFund ATM locations. The company was founded in 1910 and is headquartered in Tulsa, Oklahoma.",Mr. Stacy C. Kymes,Banks - Regional,108.45,USD,6953640372,https://images.financialmodelingprep.com/symbol/BOKF.png,158541,14.88,-0.41,59361,765830000,530746000,"[{'period': '2023', 'revenue': 1970.0, 'unit': 'M', 'net_profit': 530.75}, {'period': '2022', 'revenue': 1820.0, 'unit': 'M', 'net_profit': 520.27}, {'period': '2021', 'revenue': 1830.0, 'unit': 'M', 'net_profit': 618.12}, {'period': '2020', 'revenue': 1890.0, 'unit': 'M', 'net_profit': 435.03}]","[{'period': ""Q3 '24"", 'revenue': 680.31, 'unit': 'M', 'net_profit': 138.62}, {'period': ""Q2 '24"", 'revenue': 932.67, 'unit': 'M', 'net_profit': 163.71}, {'period': ""Q1 '24"", 'revenue': 814.35, 'unit': 'M', 'net_profit': 83.7}, {'period': ""Q4 '23"", 'revenue': 453.02, 'unit': 'M', 'net_profit': 82.58}, {'period': ""Q3 '23"", 'revenue': 490.69, 'unit': 'M', 'net_profit': 134.5}, {'period': ""Q2 '23"", 'revenue': 523.01, 'unit': 'M', 'net_profit': 151.31}]",8.02,8.02,49824830000,203808000,203808000,44679411000,709832000,19724339000,0,1348265000,66183000,0.36769034046261767,0.020129816461742202,0.044270833333333315,"[0.57, 0.1]","['2024-11-15', '2005-05-11']",__nan__,0.8967298232628189
569,BOKFL,BOK Financial Corporation 5.375% Subordinated Notes due 2056,"BOK Financial Corporation operates as the financial holding company for BOKF, NA that provides various financial products and services in Oklahoma, Texas, New Mexico, Northwest Arkansas, Colorado, Arizona, and Kansas/Missouri. It operates through three segments: Commercial Banking, Consumer Banking, and Wealth Management. The Commercial Banking segment offers lending, treasury, and cash management services, as well as customer risk management products for small businesses, middle market, and larger commercial customers. This segment also operates TransFund electronic funds transfer network. The Consumer Banking segment provides lending and deposit services to small business customers through the retail branch network; and mortgage banking services. The Wealth Management segment offers fiduciary, private banking, and investment advisory services; insurance services; and brokerage and trading services, as well as underwrites state and municipal securities. The company also provides commercial loans, such as loans for working capital, facilities acquisition or expansion, purchases of equipment, and other needs of commercial customers; and service, healthcare, manufacturing, wholesale/retail, energy, and other sector loans. In addition, it offers commercial real estate loans for the construction of buildings or other enhancements to real estate and property held by borrowers for investment purposes; and residential mortgage, personal, and home equity loans. Further, the company provides automated teller machine (ATM), call center, and Internet and mobile banking services. As of December 31, 2019, it operated 2,463 TransFund ATM locations. BOK Financial Corporation was founded in 1910 and is headquartered in Tulsa, Oklahoma.",Mr. Steven Glen Bradshaw,Banks - Regional,25.19,USD,0,https://images.financialmodelingprep.com/symbol/BOKFL.png,14082,0,-0.01000023,7673,765830000,530746000,"[{'period': '2023', 'revenue': 1970.0, 'unit': 'M', 'net_profit': 530.75}, {'period': '2022', 'revenue': 1820.0, 'unit': 'M', 'net_profit': 520.27}, {'period': '2021', 'revenue': 1830.0, 'unit': 'M', 'net_profit': 618.12}, {'period': '2020', 'revenue': 1890.0, 'unit': 'M', 'net_profit': 435.03}]","[{'period': ""Q3 '24"", 'revenue': 680.31, 'unit': 'M', 'net_profit': 138.62}, {'period': ""Q2 '24"", 'revenue': 932.67, 'unit': 'M', 'net_profit': 163.71}, {'period': ""Q1 '24"", 'revenue': 814.35, 'unit': 'M', 'net_profit': 83.7}, {'period': ""Q4 '23"", 'revenue': 453.02, 'unit': 'M', 'net_profit': 82.58}, {'period': ""Q3 '23"", 'revenue': 490.69, 'unit': 'M', 'net_profit': 134.5}, {'period': ""Q2 '23"", 'revenue': 523.01, 'unit': 'M', 'net_profit': 151.31}]",8.02,8.02,49824830000,203808000,203808000,44679411000,709832000,19724339000,0,1348265000,66183000,0.36769034046261767,0.020129816461742202,0.044270833333333315,"[0.336, 0.336]","['2021-03-12', '2017-09-14']",__nan__,0.8967298232628189
570,BOLT,Bolt Biotherapeutics Inc. Common Stock,"Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.",Mr. William P. Quinn,Biotechnology,0.5816,USD,22259577,https://images.financialmodelingprep.com/symbol/BOLT.png,155080,-0.34,-0.0346,41156,-74342000,-69197000,"[{'period': '2023', 'revenue': 7.88, 'unit': 'M', 'net_profit': -69.2}, {'period': '2022', 'revenue': 5.73, 'unit': 'M', 'net_profit': -85.88}, {'period': '2021', 'revenue': 1.26, 'unit': 'M', 'net_profit': -104.39}, {'period': '2020', 'revenue': 0.231, 'unit': 'M', 'net_profit': -72.27}]","[{'period': ""Q3 '24"", 'revenue': 1.14, 'unit': 'M', 'net_profit': -15.18}, {'period': ""Q2 '24"", 'revenue': 1.27, 'unit': 'M', 'net_profit': -21.2}, {'period': ""Q1 '24"", 'revenue': 5.27, 'unit': 'M', 'net_profit': -10.81}, {'period': ""Q4 '23"", 'revenue': 2.09, 'unit': 'M', 'net_profit': -17.9}, {'period': ""Q3 '23"", 'revenue': 2.53, 'unit': 'M', 'net_profit': -16.26}, {'period': ""Q2 '23"", 'revenue': 1.43, 'unit': 'M', 'net_profit': -18.06}]",-1.83,-1.83,159784000,105708000,102189000,47043000,0,26413000,20456000,10810000,-69731000,0.16144605493203992,0.19421251819505095,0.20434782608695642,"[0.09, 0.05]","['2014-08-29', '2012-03-06']",__nan__,0.29441621188604616
571,BOMN,Boston Omaha Corporation Class A Common Stock,"Boston Omaha Corporation, together with its subsidiaries, engages in the outdoor billboard advertising business in the southeast United States. It is also involved in the surety insurance and related brokerage, broadband, and investment businesses. The company provides high-speed internet service to approximately 7,000 subscribers in communities in southern Arizona; and 10,000 subscribers in Salt Lake City, Park City, Ogden, Provo, and surrounding communities. As of March 26, 2021, it operated approximately 3,200 billboards containing approximately 6,000 advertising faces of which 60 are digital displays. The company was formerly known as REO Plus, Inc. and changed its name to Boston Omaha Corporation in March 2015. Boston Omaha Corporation was incorporated in 2009 and is headquartered in Omaha, Nebraska.",Mr. Adam Peterson,Advertising Agencies,25.76,USD,765030784,https://images.financialmodelingprep.com/symbol/BOMN.png,119377,8.65010073875084,0,86968,17271237,-7004009,"[{'period': '2023', 'revenue': 96.25, 'unit': 'M', 'net_profit': -7.0}, {'period': '2022', 'revenue': 81.23, 'unit': 'M', 'net_profit': 7.14}, {'period': '2021', 'revenue': 56.97, 'unit': 'M', 'net_profit': 52.75}, {'period': '2020', 'revenue': 45.74, 'unit': 'M', 'net_profit': -5.57}]","[{'period': ""Q3 '24"", 'revenue': 27.7, 'unit': 'M', 'net_profit': -1.6}, {'period': ""Q2 '24"", 'revenue': 27.09, 'unit': 'M', 'net_profit': -2.24}, {'period': ""Q1 '24"", 'revenue': 25.55, 'unit': 'M', 'net_profit': -2.81}, {'period': ""Q4 '23"", 'revenue': 24.67, 'unit': 'M', 'net_profit': -3.58}, {'period': ""Q3 '23"", 'revenue': 24.55, 'unit': 'M', 'net_profit': -1.64}, {'period': ""Q2 '23"", 'revenue': 24.22, 'unit': 'M', 'net_profit': 1.54}]",-0.23,-0.23,768207092,131387549,96023049,151754831,12326726,181349060,51385752,21946884,-35807215,-0.4189810640079906,-1.9810157449743317,-1.9583333333333333,__nan__,__nan__,__nan__,0.19754416820718443
572,BOOM,DMC Global Inc. Common Stock,"DMC Global Inc. provides a suite of technical products for the energy, industrial, and infrastructure markets worldwide. The company operates through three segments: Arcadia, DynaEnergetics, and NobelClad. The Arcadia segment manufactures, assembles, and sells architectural building materials, including storefronts and entrances, windows, curtain walls, and interior partitions; architectural components, architectural framing systems, and sun control products; sliding and glazing systems; and engineered steel, aluminum, and wood door and window systems. It sells its products through a national in-house sales force for buildings, such as office towers, hotels, education and athletic facilities, health care facilities, government buildings, retail centers, luxury homes, mixed use, and multi-family residential buildings. The DynaEnergetics segment designs, manufactures, markets, and sells perforating systems, including initiation systems, shaped charges, detonating cords, gun hardware, and control panels; and associated hardware for the oil and gas industry. It sells its products through direct selling, distributors, and independent sales representatives. The NobelClad segment produces and sells explosion-welded clad metal plates for use in the construction of heavy, corrosion resistant pressure vessels, and heat exchangers for oil and gas, chemical and petrochemical, alternative energy, hydrometallurgy, aluminum production, shipbuilding, power generation, and industrial refrigeration industries. It sells its products through direct sales personnel, program managers, and independent sales representatives. The company was formerly known as Dynamic Materials Corporation and changed its name to DMC Global Inc. in November 2016. DMC Global Inc. was founded in 1965 and is headquartered in Broomfield, Colorado.",Mr. James  O'Leary,Oil & Gas Equipment & Services,7.99,USD,160011735,https://images.financialmodelingprep.com/symbol/BOOM.png,255130,-0.96,0.41,110260,95902000,26259000,"[{'period': '2023', 'revenue': 719.19, 'unit': 'M', 'net_profit': 26.26}, {'period': '2022', 'revenue': 654.09, 'unit': 'M', 'net_profit': 14.18}, {'period': '2021', 'revenue': 260.12, 'unit': 'M', 'net_profit': -1.01}, {'period': '2020', 'revenue': 229.16, 'unit': 'M', 'net_profit': -1.41}]","[{'period': ""Q3 '24"", 'revenue': 152.43, 'unit': 'M', 'net_profit': -163.01}, {'period': ""Q2 '24"", 'revenue': 171.18, 'unit': 'M', 'net_profit': 4.8}, {'period': ""Q1 '24"", 'revenue': 166870.0, 'unit': 'K', 'net_profit': 256.0}, {'period': ""Q4 '23"", 'revenue': 174040.0, 'unit': 'K', 'net_profit': 183.0}, {'period': ""Q3 '23"", 'revenue': 172.15, 'unit': 'M', 'net_profit': 7.62}, {'period': ""Q2 '23"", 'revenue': 188.66, 'unit': 'M', 'net_profit': 13.81}]",1.08,1.08,884495000,326812000,43659000,286440000,106205000,0,126461000,31040000,49953000,0.17846127379299329,0.8513113367174281,0.4794520547945207,"[0.125, 0.2]","['2020-03-30', '2005-06-22']",__nan__,0.3238458103211437
573,BOSC,B.O.S. Better Online Solutions Common Stock,"B.O.S. Better Online Solutions Ltd. provides intelligent robotics, radio frequency identification (RFID), and supply chain solutions for enterprises worldwide. The Intelligent Robotics Division provides custom-made machines for industrial automation and assembly of products and packing that offer technological solutions. The RFID Division provides hardware products, such as thermal and barcode printers; RFID and barcode scanners and readers; wireless, mobile, and forklift terminals; wireless infrastructure; active and passive RFID tags; ribbons, labels, and tags; and RFID systems for libraries. It also develops Warehouse Management System, a data collection solution for logistics management in logistic centers and warehouses; RFID-based systems for tracking inventory in a produce packing house; automatic systems for industrial packing lines; automatic systems to track the production line; and automatic systems to identify and track vehicles for transportation-related settings. In addition, this segment provides maintenance and repair services for data collection equipment, as well as warehouse and on-site service plans; on-site inventory count services in various fields; and asset tagging and counting services for corporate and governmental entities. The Supply Chain Division offers electro-mechanical components, electronics components, communications products, and components consolidation services to aerospace, defense, and other industries. This segment also provides inventory and quality control management of components entering production lines; and inventory management services for ongoing projects. The company markets its products through direct sales and sales agents, as well as through distributors. B.O.S. Better Online Solutions Ltd. was incorporated in 1990 and is headquartered in Rishon LeZion, Israel.",Mr. Eyal  Cohen,Communication Equipment,3.91,USD,22525510,https://images.financialmodelingprep.com/symbol/BOSC.png,33458,10.29,-0.14,79661,2960000,2005000,"[{'period': '2023', 'revenue': 44.18, 'unit': 'M', 'net_profit': 2.0}, {'period': '2022', 'revenue': 41.51, 'unit': 'M', 'net_profit': 1.28}, {'period': '2021', 'revenue': 33630.0, 'unit': 'K', 'net_profit': 451.0}, {'period': '2020', 'revenue': 33.55, 'unit': 'M', 'net_profit': -1.04}]","[{'period': ""Q3 '24"", 'revenue': 9830.0, 'unit': 'K', 'net_profit': 574.0}, {'period': ""Q2 '24"", 'revenue': 8450.0, 'unit': 'K', 'net_profit': 501.0}, {'period': ""Q1 '24"", 'revenue': 11290.0, 'unit': 'K', 'net_profit': 741.0}, {'period': ""Q4 '23"", 'revenue': 10890.0, 'unit': 'K', 'net_profit': 427.0}, {'period': ""Q3 '23"", 'revenue': 9810.0, 'unit': 'K', 'net_profit': 313.0}, {'period': ""Q2 '23"", 'revenue': 11340.0, 'unit': 'K', 'net_profit': 609.0}]",0.35,0.34,32481000,22018000,2344000,13642000,12424000,0,10904000,2344000,1488000,0.2925764192139738,0.5713166144200627,0.5217391304347825,__nan__,__nan__,__nan__,0.41999938425541083
574,BOTJ,Bank of the James Financial Group Inc. Common Stock,"Bank of the James Financial Group, Inc. operates as the bank holding company for Bank of the James that provides general retail and commercial banking services to individuals, businesses, associations and organizations, and governmental authorities in Virginia, the Unites States. It offers checking, savings, individual retirement, and health care saving accounts, as well as other time deposits, including money market accounts and certificates of deposit. The company also offers loans to small- and medium-sized businesses for the purchases of equipment, facilities upgrades, inventory acquisition, and various working capital purposes; commercial and residential construction and development loans; commercial real estate mortgage loans; residential mortgage loans; and secured and unsecured consumer loans, such as lines of credit and overdraft lines of credit, as well as personal, automobile, installment, demand, and home equity loans for personal, family, or household purposes. In addition, it provides other banking services, including safe deposit boxes, traveler's checks, direct deposit of payroll and social security checks, automatic drafts for various accounts, treasury management, and credit card merchant services. Further, the company offers securities brokerage and investment services; and telephone and internet banking services comprising online bill pay, as well as acts as an agent for insurance and annuity products. It operates through a network of 16 full-service offices, 2 limited-service offices, and 1 residential mortgage loan production office. The company was founded in 1998 and is headquartered in Lynchburg, Virginia.",Mr. Robert R. Chapman III,Banks - Regional,15.51,USD,70467203,https://images.financialmodelingprep.com/symbol/BOTJ.png,6577,8.34,0.37,2091,12246000,8704000,"[{'period': '2023', 'revenue': 39.36, 'unit': 'M', 'net_profit': 8.7}, {'period': '2022', 'revenue': 42.02, 'unit': 'M', 'net_profit': 8.96}, {'period': '2021', 'revenue': 37.19, 'unit': 'M', 'net_profit': 7.59}, {'period': '2020', 'revenue': 35.01, 'unit': 'M', 'net_profit': 4.98}]","[{'period': ""Q3 '24"", 'revenue': 11.14, 'unit': 'M', 'net_profit': 1.99}, {'period': ""Q2 '24"", 'revenue': 15.13, 'unit': 'M', 'net_profit': 2.15}, {'period': ""Q1 '24"", 'revenue': 13.82, 'unit': 'M', 'net_profit': 2.19}, {'period': ""Q4 '23"", 'revenue': 13.67, 'unit': 'M', 'net_profit': 2.11}, {'period': ""Q3 '23"", 'revenue': 10.35, 'unit': 'M', 'net_profit': 2.08}, {'period': ""Q2 '23"", 'revenue': 10.58, 'unit': 'M', 'net_profit': 2.53}]",1.91,1.91,969371000,77673000,74838000,909332000,2835000,220132000,480000,25613000,7918000,-0.10736934178876012,-0.028462998102466792,0,"[0.1, 0.05]","['2024-11-22', '2014-06-17']",__nan__,0.9380639610634112
575,BOWX,BowX Acquisition Corp. Class A Common Stock,"Bowx Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It primarily focuses on businesses in the technology, media, and telecommunications industries. The company was founded in 2020 and is based in Menlo Park, California.",Mr. Vivek Y. Ranadiv,Shell Companies,10.38,USD,0,https://images.financialmodelingprep.com/symbol/BOWX.png,903658,0,1.0100002,3408386,-792000000,-2034000000,"[{'period': '2022', 'revenue': 3.25, 'unit': 'B', 'net_profit': -2.03}, {'period': '2021', 'revenue': 2.57, 'unit': 'B', 'net_profit': -4.44}, {'period': '2020', 'revenue': 3.42, 'unit': 'B', 'net_profit': -3.13}, {'period': '2019', 'revenue': 3.46, 'unit': 'B', 'net_profit': -3.26}]","[{'period': ""Q3 '23"", 'revenue': 794.0, 'unit': 'M', 'net_profit': -788.0}, {'period': ""Q2 '23"", 'revenue': 844.0, 'unit': 'M', 'net_profit': -349.0}, {'period': ""Q1 '23"", 'revenue': 849.0, 'unit': 'M', 'net_profit': -264.0}, {'period': ""Q4 '22"", 'revenue': 848.0, 'unit': 'M', 'net_profit': -454.0}, {'period': ""Q3 '22"", 'revenue': 817.0, 'unit': 'M', 'net_profit': -568.0}, {'period': ""Q2 '22"", 'revenue': 815.0, 'unit': 'M', 'net_profit': -577.0}]",-106.79,-106.79,17863000000,689000000,287000000,21318000000,173000000,63000000,2230000000,287000000,-1071000000,0.5818373812038015,0.5417886911466546,0.8414708371064235,__nan__,__nan__,__nan__,1.193416559368527
576,BOWXU,BowX Acquisition Corp. Unit,"Bowx Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It primarily focuses on businesses in the technology, media, and telecommunications industries. The company was founded in 2020 and is based in Menlo Park, California.",Mr. Vivek Y. Ranadiv,Shell Companies,11.18,USD,0,https://images.financialmodelingprep.com/symbol/BOWXU.png,965,0,1.06,3270,-792000000,-2034000000,"[{'period': '2022', 'revenue': 3.25, 'unit': 'B', 'net_profit': -2.03}, {'period': '2021', 'revenue': 2.57, 'unit': 'B', 'net_profit': -4.44}, {'period': '2020', 'revenue': 3.42, 'unit': 'B', 'net_profit': -3.13}, {'period': '2019', 'revenue': 3.46, 'unit': 'B', 'net_profit': -3.26}]","[{'period': ""Q3 '23"", 'revenue': 794.0, 'unit': 'M', 'net_profit': -788.0}, {'period': ""Q2 '23"", 'revenue': 844.0, 'unit': 'M', 'net_profit': -349.0}, {'period': ""Q1 '23"", 'revenue': 849.0, 'unit': 'M', 'net_profit': -264.0}, {'period': ""Q4 '22"", 'revenue': 848.0, 'unit': 'M', 'net_profit': -454.0}, {'period': ""Q3 '22"", 'revenue': 817.0, 'unit': 'M', 'net_profit': -568.0}, {'period': ""Q2 '22"", 'revenue': 815.0, 'unit': 'M', 'net_profit': -577.0}]",-106.79,-106.79,17863000000,689000000,287000000,21318000000,173000000,63000000,2230000000,287000000,-1071000000,0.5818373812038015,0.5417886911466546,0.8414708371064235,__nan__,__nan__,__nan__,1.193416559368527
577,BOWXW,BowX Acquisition Corp. Warrant,,,,,,,,,0,0.25,327201,-136972,90079,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': 90.08}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.18}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.91}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 90.08}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -61.02}]",-0.02,-0.02,484520512,1293461,484148100,17116262,0,0,211262,921049,-599792,0,0,0,__nan__,__nan__,__nan__,0.03532618656194271
578,BOXL,Boxlight Corporation Class A Common Stock,"Boxlight Corporation develops, sells, and services interactive classroom technology products and solutions for the K-12 education market worldwide. The company provides interactive and non-interactive projectors, interactive flat panel displays, interactive touch projectors, touchboards, and MimioTeach that could turn any whiteboard interactive; and accessory document cameras, teacher pads for remote control, and assessment systems under the Mimio and Clevertouch brands. It also offers MimioStudio Interactive Instructional software that enables the creation, editing, and presentation of interactive instructional lessons and activities; MimioMobile, a software accessory for MimioStudio; Oktopus Instructional and Whiteboarding software that enables the creation, editing, and presentation of interactive instructional lessons and activities; Notes+, a software accessory for use with Oktopus software; and GameZones and MimioInteract, which are multi-student interactive gaming software. In addition, the company provides MimioClarity, a classroom audio solution; Mimio MyBot system that bridges the gap between learning about robotics in the classroom and the application of robotics; Robo3D printers; MyStemKits, which offers standards-driven lesson plans for grades K-12 math and science teachers; MimioView document camera; MimioVote, a student assessment system; and MimioPad, a wireless pen tablet, as well as peripherals and accessories, such as amplified speaker systems, mobile carts, installation accessories, and wall-mount accessories for interactive and standard projectors, and LED flat panels. Further, it offers classroom training, professional development, and educator certification services. The company was formerly known as Logical Choice Corporation. Boxlight Corporation was founded in 1985 and is headquartered in Lawrenceville, Georgia.",Mr. Dale W. Strang,Communication Equipment,1.13,USD,11108386,https://images.financialmodelingprep.com/symbol/BOXL.png,3949669,-0.36,-0.55,4951588,-17591000,-39156000,"[{'period': '2023', 'revenue': 176.72, 'unit': 'M', 'net_profit': -39.16}, {'period': '2022', 'revenue': 221.78, 'unit': 'M', 'net_profit': -3.74}, {'period': '2021', 'revenue': 185.18, 'unit': 'M', 'net_profit': -13.8}, {'period': '2020', 'revenue': 54.89, 'unit': 'M', 'net_profit': -16.15}]","[{'period': ""Q3 '24"", 'revenue': 36.29, 'unit': 'M', 'net_profit': -3.06}, {'period': ""Q2 '24"", 'revenue': 38.51, 'unit': 'M', 'net_profit': -1.48}, {'period': ""Q1 '24"", 'revenue': 37.09, 'unit': 'M', 'net_profit': -7.09}, {'period': ""Q4 '23"", 'revenue': 38.81, 'unit': 'M', 'net_profit': -17.67}, {'period': ""Q3 '23"", 'revenue': 49.67, 'unit': 'M', 'net_profit': -18.07}, {'period': ""Q2 '23"", 'revenue': 47050.0, 'unit': 'K', 'net_profit': -811.0}]",-4.28,-4.28,158571000,100378000,17253000,113311000,29523000,0,46232000,17253000,10260000,-2.144800208251985,-9.46112743788405,-8.953488372093023,__nan__,__nan__,__nan__,0.7145758051598338
579,BPFH,Boston Private Financial Holdings Inc. Common Stock,"Boston Private Financial Holdings, Inc. operates as the bank holding company for Boston Private Bank & Trust Company that provides a range of banking products and services in the United States. It operates in two segments, Private Banking; and Wealth Management and Trust. The company offers deposit products, such as checking, savings and NOW, and money market accounts; and certificates of deposit. Its loan products include loans to individuals, such as residential mortgage loans, mortgage loans on investment or vacation properties, unsecured and secured personal lines of credits, home equity loans, and overdraft protection; and loans to businesses consisting of commercial and mortgage loans, revolving lines of credit, working capital loans, equipment financing, community lending programs, and construction and land loans. In addition, the company provides wealth management solutions comprising planning-based financial strategies, wealth management, family office, financial planning, tax planning, and trust services to individuals, families, institutions, and nonprofit institutions. It operates offices in Boston, Miami, New York, Los Angeles, San Francisco, and Florida. Boston Private Financial Holdings, Inc. was founded in 1987 and is headquartered in Boston, Massachusetts.",Mr. Anthony DeChellis,Banks - Regional,14.75,USD,0,https://images.financialmodelingprep.com/symbol/BPFH.png,885418,0,0.01000023,1370858,116068000,45153000,"[{'period': '2020', 'revenue': 327.31, 'unit': 'M', 'net_profit': 45.15}, {'period': '2019', 'revenue': 329.62, 'unit': 'M', 'net_profit': 80.03}, {'period': '2018', 'revenue': 366.42, 'unit': 'M', 'net_profit': 80.38}, {'period': '2017', 'revenue': 379.92, 'unit': 'M', 'net_profit': 40.59}]","[{'period': ""Q1 '21"", 'revenue': 64.89, 'unit': 'M', 'net_profit': 10.65}, {'period': ""Q4 '20"", 'revenue': 86.06, 'unit': 'M', 'net_profit': 24.97}, {'period': ""Q3 '20"", 'revenue': 80.87, 'unit': 'M', 'net_profit': 22.68}, {'period': ""Q2 '20"", 'revenue': 81.6, 'unit': 'M', 'net_profit': -3.3}, {'period': ""Q1 '20"", 'revenue': 78780.0, 'unit': 'K', 'net_profit': 800.0}, {'period': ""Q4 '19"", 'revenue': 82.92, 'unit': 'M', 'net_profit': 21.24}]",0.55,0.55,1122251000,1055588000,2299281000,9180725000,28991000,1320368000,6774000,1055588000,49662000,-0.4395963595104169,-0.43578497525865945,-0.4210526315789473,"[0.06, 0.03]","['2021-05-06', '2000-01-27']",__nan__,8.180634278784336
580,BPMC,Blueprint Medicines Corporation Common Stock,"Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.",Ms. Kathryn  Haviland M.B.A.,Biotechnology,93.18,USD,5919334044,https://images.financialmodelingprep.com/symbol/BPMC.png,628640,-44.58,3.64,156167,-470356000,-506984000,"[{'period': '2023', 'revenue': 249.38, 'unit': 'M', 'net_profit': -506.98}, {'period': '2022', 'revenue': 204.04, 'unit': 'M', 'net_profit': -557.52}, {'period': '2021', 'revenue': 180.08, 'unit': 'M', 'net_profit': -644.09}, {'period': '2020', 'revenue': 793.74, 'unit': 'M', 'net_profit': 313.88}]","[{'period': ""Q3 '24"", 'revenue': 128.18, 'unit': 'M', 'net_profit': -56.28}, {'period': ""Q2 '24"", 'revenue': 138.16, 'unit': 'M', 'net_profit': -49.99}, {'period': ""Q1 '24"", 'revenue': 96.12, 'unit': 'M', 'net_profit': 89.14}, {'period': ""Q4 '23"", 'revenue': 71.96, 'unit': 'M', 'net_profit': -110.92}, {'period': ""Q3 '23"", 'revenue': 56.57, 'unit': 'M', 'net_profit': -133.71}, {'period': ""Q2 '23"", 'revenue': 57.57, 'unit': 'M', 'net_profit': -132.79}]",-8.37,-8.37,1049250000,808393000,710641000,918641000,43178000,84319000,214923000,71286000,-452909000,0.08742275641958422,0.09063938857469817,0.10481283422459899,__nan__,__nan__,__nan__,0.8755215630212057
581,BPOP,Popular Inc. Common Stock,"Popular, Inc., through its subsidiaries, provides various retail, mortgage, and commercial banking products and services in Puerto Rico, the United States, and British Virgin Islands. The company provides savings, NOW, money market, and other interest-bearing demand accounts; non-interest bearing demand deposits; and certificates of deposit. It also offers commercial and industrial, commercial multi-family, commercial real estate, and residential mortgage loans; consumer loans, including personal loans, credit cards, automobile loans, home equity lines of credit, and other loans to individual borrowers; construction loans; and lease financing comprising automobile loans/leases. In addition, the company provides investment banking, auto and equipment leasing and financing, broker-dealer, and insurance services; debit cards; and online banking services. As of December 31, 2021, it operated 169 branches; and 616 ATMs in Puerto Rico, 23 ATMs in the Virgin Islands, and 91 ATMs in the United States Mainland. Popular, Inc. was founded in 1893 and is headquartered in Hato Rey, Puerto Rico.",Mr. Ignacio  Alvarez Esq.,Banks - Regional,94.415,USD,6732365432,https://images.financialmodelingprep.com/symbol/BPOP.png,534183,12.83,-0.095,114819,741418000,541342000,"[{'period': '2023', 'revenue': 2640.0, 'unit': 'M', 'net_profit': 541.34}, {'period': '2022', 'revenue': 2.94, 'unit': 'B', 'net_profit': 1.1}, {'period': '2021', 'revenue': 2550.0, 'unit': 'M', 'net_profit': 934.89}, {'period': '2020', 'revenue': 2320.0, 'unit': 'M', 'net_profit': 506.62}]","[{'period': ""Q3 '24"", 'revenue': 702.24, 'unit': 'M', 'net_profit': 155.32}, {'period': ""Q2 '24"", 'revenue': 1090.0, 'unit': 'M', 'net_profit': 177.79}, {'period': ""Q1 '24"", 'revenue': 1060.0, 'unit': 'M', 'net_profit': 103.28}, {'period': ""Q4 '23"", 'revenue': 1040.0, 'unit': 'M', 'net_profit': 94.59}, {'period': ""Q3 '23"", 'revenue': 655.67, 'unit': 'M', 'net_profit': 136.61}, {'period': ""Q2 '23"", 'revenue': 655.34, 'unit': 'M', 'net_profit': 151.16}]",7.53,7.52,70758155000,8091890000,7419333000,65611202000,0,7412573000,530908000,7419333000,478568000,-0.4280466345905356,-0.5090496362823439,-0.48600682593856653,"[0.7, 0.33]","['2024-12-06', '1986-12-08']",__nan__,0.9272599320883932
582,BPOPM,Popular Inc. Popular Capital Trust II - 6.125% Cumulative Monthly Income Trust Preferred Securities,Popular Capital Trust II is a statutory trust. It is engaged in issuing capital securities.,None,Banks,25.71,USD,2495751381,https://images.financialmodelingprep.com/symbol/BPOPM.png,3198,,-0.18,990,113951000,934889000,"[{'period': '2021', 'revenue': 2120.0, 'unit': 'M', 'net_profit': 934.89}, {'period': '2020', 'revenue': 2090.0, 'unit': 'M', 'net_profit': 506.62}, {'period': '2019', 'revenue': 2260.0, 'unit': 'M', 'net_profit': 409.39}, {'period': '2018', 'revenue': 19.24, 'unit': 'M', 'net_profit': 618.16}]","[{'period': ""Q3 '22"", 'revenue': 651.24, 'unit': 'M', 'net_profit': 422.39}, {'period': ""Q2 '22"", 'revenue': 571.76, 'unit': 'M', 'net_profit': 211.42}, {'period': ""Q1 '22"", 'revenue': 529.72, 'unit': 'M', 'net_profit': 211.69}, {'period': ""Q4 '21"", 'revenue': 1980.0, 'unit': 'M', 'net_profit': 189.07}, {'period': ""Q3 '21"", 'revenue': 530.16, 'unit': 'M', 'net_profit': 248.11}, {'period': ""Q2 '21"", 'revenue': 529.76, 'unit': 'M', 'net_profit': 218.08}]",9.63,9.63,75097899000,17544242000,17544242000,69128502000,0,0,75000000,7523000,784849000,0.30649285132826565,0.8453383390377835,0.6377551020408165,"[0.1276, 0.128]","['2025-01-15', '2008-12-11']",__nan__,0.9205117975404346
583,BPOPN,Popular Inc. 6.70% Cumulative Monthly Income Trust Preferred Securities,,None,Banks,25.23,USD,0,https://images.financialmodelingprep.com/symbol/BPOPN.png,11440,0,0.1099987,11833,1412922000,671135000,"[{'period': '2019', 'revenue': 285.21, 'unit': 'M', 'net_profit': 671.13}, {'period': '2018', 'revenue': 19.24, 'unit': 'M', 'net_profit': 618.16}, {'period': '2017', 'revenue': 1500.0, 'unit': 'M', 'net_profit': 107.68}, {'period': '2016', 'revenue': 1420.0, 'unit': 'M', 'net_profit': 216.69}]","[{'period': ""Q1 '20"", 'revenue': 581.87, 'unit': 'M', 'net_profit': 573.6}, {'period': ""Q4 '19"", 'revenue': 75.56, 'unit': 'M', 'net_profit': 166.78}, {'period': ""Q3 '19"", 'revenue': 71.31, 'unit': 'M', 'net_profit': 165.32}, {'period': ""Q2 '19"", 'revenue': 74.03, 'unit': 'M', 'net_profit': 171.11}, {'period': ""Q1 '19"", 'revenue': 64.31, 'unit': 'M', 'net_profit': 167.93}, {'period': ""Q4 '18"", 'revenue': -1240.0, 'unit': 'M', 'net_profit': 106.4}]",6.92,6.92,52115324000,571682000,390811000,46098545000,180871000,3262286000,262971000,388311000,629702000,0.20301101416106423,0.08570139025944823,0.13442622950819677,"[0.13958, 0.1396]","['2021-09-14', '2003-12-11']",__nan__,0.8845487557556008
584,BPRN,The Bank of Princeton Common Stock,"The Bank of Princeton provides various banking products and services. It accepts various deposit products, including checking, savings, attorney trust, and money market accounts, as well as certificates of deposit. The company also offers various loan products comprising commercial real estate and multi-family, commercial and industrial, construction, residential first-lien mortgage, paycheck protection program, home equity, and consumer loans. In addition, it provides debit and credit cards, and money orders, direct deposit, automated teller machines, cashier's checks, safe deposit boxes, wire transfers, night depository, remote deposit capture, debit cards, bank-by-mail, online, and automated telephone banking services, as well as payroll-related services and merchant credit card processing services. Further, the company offers full on-line statements, on-line bill payment, account inquiries, transaction histories and details, and account-to-account transfer services. The company operates 21 branches in Princeton, including parts of Mercer, Somerset, Hunterdon, Ocean, Burlington, Camden, Gloucester, and Middlesex Counties in central New Jersey, as well as in additional areas in portions of Philadelphia, Montgomery, and Bucks counties in Pennsylvania. The Bank of Princeton was incorporated in 2007 and is headquartered in Princeton, New Jersey.",Mr. Edward J. Dietzler,Banks - Regional,32.7801,USD,224509266,https://images.financialmodelingprep.com/symbol/BPRN.png,9758,20.62,-0.5599,6236,32313000,25765000,"[{'period': '2023', 'revenue': 69.33, 'unit': 'M', 'net_profit': 25.77}, {'period': '2022', 'revenue': 72.94, 'unit': 'M', 'net_profit': 26.49}, {'period': '2021', 'revenue': 67.27, 'unit': 'M', 'net_profit': 22.49}, {'period': '2020', 'revenue': 53.66, 'unit': 'M', 'net_profit': 13.81}]","[{'period': ""Q3 '24"", 'revenue': 14.56, 'unit': 'M', 'net_profit': -4.46}, {'period': ""Q2 '24"", 'revenue': 31.5, 'unit': 'M', 'net_profit': 5.13}, {'period': ""Q1 '24"", 'revenue': 30.05, 'unit': 'M', 'net_profit': 4.34}, {'period': ""Q4 '23"", 'revenue': 29.33, 'unit': 'M', 'net_profit': 5.28}, {'period': ""Q3 '23"", 'revenue': 19.09, 'unit': 'M', 'net_profit': 7.6}, {'period': ""Q2 '23"", 'revenue': 17.53, 'unit': 'M', 'net_profit': 6.79}]",4.1,4.03,1916497000,150557000,150557000,1676286000,6089000,99841000,1412981000,34532000,21400000,-0.10500221582096167,-0.0275156639239073,-0.02147971360381879,"[0.3, 0.03]","['2024-11-05', '2018-11-02']",__nan__,0.8746614265506286
585,BPTH,Bio-Path Holdings Inc. Common Stock,"Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.",Mr. Peter H. Nielsen MBA,Biotechnology,1.06,USD,4565303,https://images.financialmodelingprep.com/symbol/BPTH.png,3202832,-0.13,-0.03,128958,-15761000,-16078000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.08}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.84}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.44}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.86}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.12}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.87}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.16}, {'period': ""Q4 '23"", 'revenue': 0.274, 'unit': 'M', 'net_profit': -3.37}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.2}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.23}]",-33.64,-33.64,3220000,3042000,1052000,2779000,0,0,1906000,1052000,-11535000,-0.1512783053323594,-0.1621250451752801,0.11543518275046018,__nan__,__nan__,__nan__,0.8630434782608696
586,BPTS,Biophytis SA American Depositary Share,"Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.",Mr. Stanislas  Veillet Ph.D.,Biotechnology,8.22,USD,2608625,https://images.financialmodelingprep.com/symbol/BPTS.png,9044,-0.06402367785653089,-1.28,17954,-13804000,-17026000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.03}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.22}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.16}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -25.52}]","[{'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.91}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.91}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.63}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.63}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.88}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.88}]",-12.55,-12.54,11960000,8850000,5567000,15849000,0,134000,12365000,5567000,-13093000,0.3439266150769498,0.24979070279797314,-95.46153846153845,__nan__,__nan__,__nan__,1.3251672240802677
587,BPY,Brookfield Property Partners L.P. Limited Partnership Units,"Brookfield Property Partners, through Brookfield Property Partners L.P. and its subsidiary Brookfield Property REIT Inc., is one of the world's premier real estate companies, with approximately $88 billion in total assets. We own and operate iconic properties in the world's major markets, and our global portfolio includes office, retail, multifamily, logistics, hospitality, self-storage, triple net lease, manufactured housing and student housing. Brookfield Property Partners is the flagship listed real estate company of Brookfield Asset Management Inc., a leading global alternative asset manager with over $540 billion in assets under management. More information is available at www.brookfield.com.",Mr. Brian Kingston,Real Estate - Services,18.59,USD,0,https://images.financialmodelingprep.com/symbol/BPY.png,4292488,-11.280339805825243,-0.04999924,5400819,14495000000,-47000000,"[{'period': '2022', 'revenue': 8070.0, 'unit': 'M', 'net_profit': -47.0}, {'period': '2021', 'revenue': 7720.0, 'unit': 'M', 'net_profit': 530.0}, {'period': '2020', 'revenue': 7.25, 'unit': 'B', 'net_profit': -1.1}, {'period': '2019', 'revenue': 9120.0, 'unit': 'M', 'net_profit': 884.0}]","[{'period': ""Q2 '23"", 'revenue': 2420.0, 'unit': 'M', 'net_profit': -191.0}, {'period': ""Q1 '23"", 'revenue': 2400.0, 'unit': 'M', 'net_profit': -83.0}, {'period': ""Q4 '22"", 'revenue': 1960.0, 'unit': 'M', 'net_profit': -428.0}, {'period': ""Q3 '22"", 'revenue': 1880.0, 'unit': 'M', 'net_profit': -14.0}, {'period': ""Q2 '21"", 'revenue': 1660.0, 'unit': 'M', 'net_profit': 319.0}, {'period': ""Q1 '21"", 'revenue': 1450.0, 'unit': 'M', 'net_profit': 124.0}]",-0.16,-0.16,112516000000,4020000000,4020000000,41262000000,0,0,0,4020000000,-53000000,0.04853877314814815,-1.088679245283019,-1.0903954802259888,"[0.3325, 0.1277]","['2021-02-25', '2013-05-29']",__nan__,0.3667211774325429
588,BPYPN,Brookfield Property Partners L.P. 5.750% Class A Cumulative Redeemable Perpetual Preferred Units Series 3,"Brookfield Property Partners, through Brookfield Property Partners L.P. and its subsidiary Brookfield Property REIT Inc., is one of the world's premier real estate companies, with approximately $88 billion in total assets. We own and operate iconic properties in the world's major markets, and our global portfolio includes office, retail, multifamily, logistics, hospitality, self-storage, triple net lease, manufactured housing and student housing. Brookfield Property Partners is the flagship listed real estate company of Brookfield Asset Management Inc., a leading global alternative asset manager with over $540 billion in assets under management. More information is available at www.brookfield.com. As of July 26, 2021, Brookfield Property Partners L.P. operates as a subsidiary of Brookfield Asset Management Inc.",Mr. Brian William Kingston,Real Estate - Services,13,USD,4442478625,https://images.financialmodelingprep.com/symbol/BPYPN.png,20232,5.92,0,20873,2995000000,-442000000,"[{'period': '2023', 'revenue': 9480.0, 'unit': 'M', 'net_profit': -442.0}, {'period': '2022', 'revenue': 7370.0, 'unit': 'M', 'net_profit': 996.0}, {'period': '2021', 'revenue': 7.1, 'unit': 'B', 'net_profit': 3.5}, {'period': '2020', 'revenue': 6.59, 'unit': 'B', 'net_profit': -2.06}]","[{'period': ""Q3 '24"", 'revenue': 2470.0, 'unit': 'M', 'net_profit': -150.0}, {'period': ""Q2 '24"", 'revenue': 2420.0, 'unit': 'M', 'net_profit': -173.0}, {'period': ""Q1 '24"", 'revenue': 2320.0, 'unit': 'M', 'net_profit': -138.0}, {'period': ""Q4 '23"", 'revenue': 2480.0, 'unit': 'M', 'net_profit': -105.0}, {'period': ""Q3 '23"", 'revenue': 2430.0, 'unit': 'M', 'net_profit': -63.0}, {'period': ""Q2 '23"", 'revenue': 2330.0, 'unit': 'M', 'net_profit': -191.0}]",-1.38,-1.38,131577000000,9041000000,2341000000,82990000000,2720000000,22764000000,35255000000,2341000000,-1199000000,-0.29579120620738303,-1.4437751004016064,-1.4144144144144144,"[0.35938, 0.527]","['2024-12-02', '2020-05-29']",__nan__,0.6307333348533558
589,BPYPO,Brookfield Property Partners L.P. 6.375% Class A Cumulative Redeemable Perpetual Preferred Units Series 2,"Brookfield Property Partners, through Brookfield Property Partners L.P. and its subsidiary Brookfield Property REIT Inc., is one of the world's premier real estate companies, with approximately $88 billion in total assets. We own and operate iconic properties in the world's major markets, and our global portfolio includes office, retail, multifamily, logistics, hospitality, self-storage, triple net lease, manufactured housing and student housing. Brookfield Property Partners is the flagship listed real estate company of Brookfield Asset Management Inc., a leading global alternative asset manager with over $540 billion in assets under management. More information is available at www.brookfield.com. As of July 26, 2021, Brookfield Property Partners L.P. operates as a subsidiary of Brookfield Asset Management Inc.",Mr. Brian William Kingston,Real Estate - Services,13.82,USD,4722696508,https://images.financialmodelingprep.com/symbol/BPYPO.png,12480,6.29,-0.31,6412,2995000000,-442000000,"[{'period': '2023', 'revenue': 9480.0, 'unit': 'M', 'net_profit': -442.0}, {'period': '2022', 'revenue': 7370.0, 'unit': 'M', 'net_profit': 996.0}, {'period': '2021', 'revenue': 7.1, 'unit': 'B', 'net_profit': 3.5}, {'period': '2020', 'revenue': 6.59, 'unit': 'B', 'net_profit': -2.06}]","[{'period': ""Q3 '24"", 'revenue': 2470.0, 'unit': 'M', 'net_profit': -150.0}, {'period': ""Q2 '24"", 'revenue': 2420.0, 'unit': 'M', 'net_profit': -173.0}, {'period': ""Q1 '24"", 'revenue': 2320.0, 'unit': 'M', 'net_profit': -138.0}, {'period': ""Q4 '23"", 'revenue': 2480.0, 'unit': 'M', 'net_profit': -105.0}, {'period': ""Q3 '23"", 'revenue': 2430.0, 'unit': 'M', 'net_profit': -63.0}, {'period': ""Q2 '23"", 'revenue': 2330.0, 'unit': 'M', 'net_profit': -191.0}]",-1.38,-1.38,131577000000,9041000000,2341000000,82990000000,2720000000,22764000000,35255000000,2341000000,-1199000000,-0.29579120620738303,-1.4437751004016064,-1.4144144144144144,"[0.39844, 0.58]","['2024-12-02', '2019-11-29']",__nan__,0.6307333348533558
590,BPYPP,Brookfield Property Partners L.P. 6.50% Class A Cumulative Redeemable Perpetual Preferred Units,"Brookfield Property Partners, through Brookfield Property Partners L.P. and its subsidiary Brookfield Property REIT Inc., is one of the world's premier real estate companies, with approximately $88 billion in total assets. We own and operate iconic properties in the world's major markets, and our global portfolio includes office, retail, multifamily, logistics, hospitality, self-storage, triple net lease, manufactured housing and student housing. Brookfield Property Partners is the flagship listed real estate company of Brookfield Asset Management Inc., a leading global alternative asset manager with over $540 billion in assets under management. More information is available at www.brookfield.com. As of July 26, 2021, Brookfield Property Partners L.P. operates as a subsidiary of Brookfield Asset Management Inc.",Mr. Brian William Kingston,Real Estate - Services,13.965,USD,4772247231,https://images.financialmodelingprep.com/symbol/BPYPP.png,16950,6.36,-0.245,21486,2995000000,-442000000,"[{'period': '2023', 'revenue': 9480.0, 'unit': 'M', 'net_profit': -442.0}, {'period': '2022', 'revenue': 7370.0, 'unit': 'M', 'net_profit': 996.0}, {'period': '2021', 'revenue': 7.1, 'unit': 'B', 'net_profit': 3.5}, {'period': '2020', 'revenue': 6.59, 'unit': 'B', 'net_profit': -2.06}]","[{'period': ""Q3 '24"", 'revenue': 2470.0, 'unit': 'M', 'net_profit': -150.0}, {'period': ""Q2 '24"", 'revenue': 2420.0, 'unit': 'M', 'net_profit': -173.0}, {'period': ""Q1 '24"", 'revenue': 2320.0, 'unit': 'M', 'net_profit': -138.0}, {'period': ""Q4 '23"", 'revenue': 2480.0, 'unit': 'M', 'net_profit': -105.0}, {'period': ""Q3 '23"", 'revenue': 2430.0, 'unit': 'M', 'net_profit': -63.0}, {'period': ""Q2 '23"", 'revenue': 2330.0, 'unit': 'M', 'net_profit': -191.0}]",-1.38,-1.38,131577000000,9041000000,2341000000,82990000000,2720000000,22764000000,35255000000,2341000000,-1199000000,-0.29579120620738303,-1.4437751004016064,-1.4144144144144144,"[0.40625, 0.447]","['2024-12-02', '2019-05-30']",__nan__,0.6307333348533558
591,BPYU,Brookfield Property REIT Inc. Class A Common Stock,"Brookfield Property REIT Inc. (?BPYU?) is a subsidiary of Brookfield Property Partners L.P., (NASDAQ: BPY; TSX: BPY.UN) (?BPY?) one of the world's premier real estate companies, with approximately $88 billion in total assets. BPYU was created as a public security that is intended to offer economic equivalence to an investment in BPY in the form of a U.S. REIT stock.",,REIT - Retail,18.52,USD,0,https://images.financialmodelingprep.com/symbol/BPYU.png,680367,-0.778543803598453,-0.15999985,9009668,589440000,-711461000,"[{'period': '2020', 'revenue': 1530.0, 'unit': 'M', 'net_profit': -711.46}, {'period': '2019', 'revenue': 1560.0, 'unit': 'M', 'net_profit': 432.88}, {'period': '2018', 'revenue': 2.06, 'unit': 'B', 'net_profit': 4.09}, {'period': '2017', 'revenue': 2330.0, 'unit': 'M', 'net_profit': 657.33}]","[{'period': ""Q2 '21"", 'revenue': 470550000.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q1 '21"", 'revenue': 368.4, 'unit': 'M', 'net_profit': -229.12}, {'period': ""Q4 '20"", 'revenue': 384.47, 'unit': 'M', 'net_profit': -249.96}, {'period': ""Q3 '20"", 'revenue': 366.98, 'unit': 'M', 'net_profit': -170.62}, {'period': ""Q2 '20"", 'revenue': 374.46, 'unit': 'M', 'net_profit': -209.05}, {'period': ""Q1 '20"", 'revenue': 403.63, 'unit': 'M', 'net_profit': -81.83}]",-17.04,-17.04,21879964000,1298891000,204541000,17790368000,641451000,4342995000,800644000,204541000,-8430000,-0.634374866249458,-2.643552485677324,-3.520710059171597,"[0.3325, 0.315]","['2021-02-25', '2018-08-30']",__nan__,0.813089454808975
592,BPYUP,Brookfield Property REIT Inc. 6.375% Series A Preferred Stock,"Brookfield Property REIT Inc. (?BPYU?) is a subsidiary of Brookfield Property Partners L.P., (NASDAQ: BPY; TSX: BPY.UN) (?BPY?) one of the world's premier real estate companies, with approximately $88 billion in total assets. BPYU was created as a public security that is intended to offer economic equivalence to an investment in BPY in the form of a U.S. REIT stock.",Mr. Brian William Kingston,REIT - Retail,25.2,USD,0,https://images.financialmodelingprep.com/symbol/BPYUP.png,35433,-0.9692680487711066,0,28091,589440000,-711461000,"[{'period': '2020', 'revenue': 1530.0, 'unit': 'M', 'net_profit': -711.46}, {'period': '2019', 'revenue': 1560.0, 'unit': 'M', 'net_profit': 432.88}, {'period': '2018', 'revenue': 2.06, 'unit': 'B', 'net_profit': 4.09}, {'period': '2017', 'revenue': 2330.0, 'unit': 'M', 'net_profit': 657.33}]","[{'period': ""Q2 '21"", 'revenue': 470550000.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q1 '21"", 'revenue': 368.4, 'unit': 'M', 'net_profit': -229.12}, {'period': ""Q4 '20"", 'revenue': 384.47, 'unit': 'M', 'net_profit': -249.96}, {'period': ""Q3 '20"", 'revenue': 366.98, 'unit': 'M', 'net_profit': -170.62}, {'period': ""Q2 '20"", 'revenue': 374.46, 'unit': 'M', 'net_profit': -209.05}, {'period': ""Q1 '20"", 'revenue': 403.63, 'unit': 'M', 'net_profit': -81.83}]",-17.04,-17.04,21879964000,1298891000,204541000,17790368000,641451000,4342995000,800644000,204541000,-8430000,-0.634374866249458,-2.643552485677324,-3.520710059171597,"[0.3984, 0.398]","['2021-06-14', '2018-09-14']",__nan__,0.813089454808975
593,BREZ,Breeze Holdings Acquisition Corp. Common Stock,"Breeze Holdings Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on businesses in the energy industry in North America. The company was incorporated in 2020 and is based in Irving, Texas.","Dr. J. Douglas Ramsey Jr., Jr.",Shell Companies,11.39,USD,48968799,https://images.financialmodelingprep.com/symbol/BREZ.png,2258,-2.0485611510791366,-0.03,46403,-2070139,-2549111,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.55}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.79}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.7}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.54}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -22.02}, {'period': ""Q4 '23"", 'revenue': 3130.0, 'unit': 'K', 'net_profit': 692.04}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.08}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.51}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -654.26}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.05}]",-0.58,-0.58,13243673,266145,4228,10277665,18672,12977528,8077415,4228,-2024603,0.7546009237291611,-1.6729039782230406,-2.4146341463414633,__nan__,__nan__,__nan__,0.7760433982324993
594,BREZR,Breeze Holdings Acquisition Corp. Right,"Breeze Holdings Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on businesses in the energy industry in North America. The company was incorporated in 2020 and is based in Irving, Texas.","Dr. J. Douglas Ramsey Jr., Jr.",Shell Companies,0.175,USD,785225,https://images.financialmodelingprep.com/symbol/BREZR.png,0,0.4654255319148936,-0.025,165006,-2070139,-2549111,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.55}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.79}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.7}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.54}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -22.02}, {'period': ""Q4 '23"", 'revenue': 3130.0, 'unit': 'K', 'net_profit': 692.04}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.08}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.51}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -654.26}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.05}]",-0.58,-0.58,13243673,266145,4228,10277665,18672,12977528,8077415,4228,-2024603,0.7546009237291611,-1.6729039782230406,-2.4146341463414633,"[0.285, 0.285]","['2022-03-15', '2022-03-15']",__nan__,0.7760433982324993
595,BREZW,Breeze Holdings Acquisition Corp. Warrant,"Breeze Holdings Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in North Richland Hills, Texas.","Dr. J. Douglas Ramsey Jr., Jr.",Shell Companies,0.3488,USD,1565066,https://images.financialmodelingprep.com/symbol/BREZW.png,0,0,-0.1022,13144,-2070139,-2549111,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.55}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.79}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.7}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.54}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -22.02}, {'period': ""Q4 '23"", 'revenue': 3130.0, 'unit': 'K', 'net_profit': 692.04}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.08}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.51}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -654.26}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.05}]",-0.58,-0.58,13243673,266145,4228,10277665,18672,12977528,8077415,4228,-2024603,0.7546009237291611,-1.6729039782230406,-2.4146341463414633,__nan__,__nan__,__nan__,0.7760433982324993
596,BRID,Bridgford Foods Corporation Common Stock,"Bridgford Foods Corporation, together with its subsidiaries, manufactures, markets, and distributes frozen, refrigerated, and snack food products in the United States. It operates in two segments, Frozen Food Products and Snack Food Products. The company primarily offers biscuits, bread dough items, roll dough items, and dry sausage and beef jerky products. It provides approximately 130 frozen food products to food service and retail customers through wholesalers, cooperatives, and distributors; and 170 snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. The company was founded in 1932 and is headquartered in Dallas, Texas. Bridgford Foods Corporation is a subsidiary of Bridgford Industries Incorporated.",Mr. Baron R. H. Bridgford II,Packaged Foods,10.665,USD,96804392,https://images.financialmodelingprep.com/symbol/BRID.png,7743,-96.95,0.125,272,11632000,3474000,"[{'period': '2023', 'revenue': 251.64, 'unit': 'M', 'net_profit': 3.47}, {'period': '2022', 'revenue': 265.9, 'unit': 'M', 'net_profit': 45.07}, {'period': '2021', 'revenue': 240.43, 'unit': 'M', 'net_profit': -5.5}, {'period': '2020', 'revenue': 197.97, 'unit': 'M', 'net_profit': 7.32}]","[{'period': ""Q3 '24"", 'revenue': 49.26, 'unit': 'M', 'net_profit': -1.77}, {'period': ""Q2 '24"", 'revenue': 47.31, 'unit': 'M', 'net_profit': -2.19}, {'period': ""Q1 '24"", 'revenue': 54.84, 'unit': 'M', 'net_profit': 1.24}, {'period': ""Q4 '23"", 'revenue': 80.31, 'unit': 'M', 'net_profit': 1.71}, {'period': ""Q3 '23"", 'revenue': 54190.0, 'unit': 'K', 'net_profit': 684.0}, {'period': ""Q2 '23"", 'revenue': 55510.0, 'unit': 'K', 'net_profit': 149.0}]",0.38,0.38,166998000,87477000,15708000,37463000,30761000,0,17981000,15708000,1382000,-0.8318977975605526,-0.9229130608440953,-0.9235412474849095,"[0.05, 0.05]","['2012-11-23', '1987-12-02']",__nan__,0.22433202792847817
597,BRIVU,B. Riley Principal 250 Merger Corp. Units,"B. Riley Principal 250 Merger Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York. B. Riley Principal 250 Merger Corp. is a subsidiary of B. Riley Financial, Inc.",Mr. Daniel  Shribman,Shell Companies,10.16,USD,225032824,https://images.financialmodelingprep.com/symbol/BRIVU.png,1336,125.4320987654321,0,0,-5765524,5439084,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.44}, {'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': 166.25}]","[{'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.62}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.17}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.18}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.27}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.25}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.31}]",0.3,1.26,175601511,1164265,442978,993420,558497,174437246,812920,442978,-607166,-3.405626157183651,31.7155075968097,6.317073170731708,__nan__,__nan__,__nan__,0.005657240614518402
598,BRKL,Brookline Bancorp Inc. Common Stock,"Brookline Bancorp, Inc. operates as a bank holding company for the Brookline Bank that provide commercial, business, and retail banking services to corporate, municipal, and retail customers in the United States. Its deposit products include demand checking, NOW, money market, and savings accounts. The company's loan portfolio primarily comprises first mortgage loans secured by commercial, multi-family, and residential real estate properties; loans to business entities comprising commercial lines of credit; loans to condominium associations; loans and leases used to finance equipment for small businesses; financing for construction and development projects; and home equity and other consumer loans. It also provides term loans, letters of credit, foreign exchange, cash management, investment advisory, and online and mobile banking services, as well as invests in debt and equity securities. As of December 31, 2021, the company operated 50 full-service banking offices in greater Boston, Massachusetts, and greater Providence, Rhode Island. Brookline Bancorp, Inc. was founded in 1871 and is headquartered in Boston, Massachusetts.",Mr. Paul A. Perrault,Banks - Regional,11.515,USD,1036128912,https://images.financialmodelingprep.com/symbol/BRKL.png,696100,13.87,-0.225,169170,109913000,74999000,"[{'period': '2023', 'revenue': 333.44, 'unit': 'M', 'net_profit': 75.0}, {'period': '2022', 'revenue': 328.12, 'unit': 'M', 'net_profit': 109.74}, {'period': '2021', 'revenue': 309.36, 'unit': 'M', 'net_profit': 115.44}, {'period': '2020', 'revenue': 284.81, 'unit': 'M', 'net_profit': 47.63}]","[{'period': ""Q3 '24"", 'revenue': 89.53, 'unit': 'M', 'net_profit': 20.14}, {'period': ""Q2 '24"", 'revenue': 161.65, 'unit': 'M', 'net_profit': 16.37}, {'period': ""Q1 '24"", 'revenue': 161.31, 'unit': 'M', 'net_profit': 14.66}, {'period': ""Q4 '23"", 'revenue': 160.35, 'unit': 'M', 'net_profit': 22.89}, {'period': ""Q3 '23"", 'revenue': 89.49, 'unit': 'M', 'net_profit': 22.7}, {'period': ""Q2 '23"", 'revenue': 91.37, 'unit': 'M', 'net_profit': 21.85}]",0.85,0.85,11382256000,24727000,133026999,10183612000,0,307840000,0,133027000,104240000,-0.24958694613231378,-0.31660045196092723,-0.4014084507042253,"[0.135, 0.1095]","['2024-11-15', '1998-07-29']",__nan__,0.894691878306023
599,BRKR,Bruker Corporation Common Stock,"Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.",Dr. Frank H. Laukien Ph.D.,Medical - Devices,61.27,USD,9288409460,https://images.financialmodelingprep.com/symbol/BRKR.png,1407817,29.6,0.62,211866,599000000,427200000,"[{'period': '2023', 'revenue': 2960.0, 'unit': 'M', 'net_profit': 427.2}, {'period': '2022', 'revenue': 2530.0, 'unit': 'M', 'net_profit': 296.6}, {'period': '2021', 'revenue': 2420.0, 'unit': 'M', 'net_profit': 277.1}, {'period': '2020', 'revenue': 1990.0, 'unit': 'M', 'net_profit': 157.8}]","[{'period': ""Q3 '24"", 'revenue': 864.4, 'unit': 'M', 'net_profit': 40.9}, {'period': ""Q2 '24"", 'revenue': 800.7, 'unit': 'M', 'net_profit': 7.6}, {'period': ""Q1 '24"", 'revenue': 721.7, 'unit': 'M', 'net_profit': 50.9}, {'period': ""Q4 '23"", 'revenue': 854.5, 'unit': 'M', 'net_profit': 205.5}, {'period': ""Q3 '23"", 'revenue': 742.8, 'unit': 'M', 'net_profit': 88.1}, {'period': ""Q2 '23"", 'revenue': 681.9, 'unit': 'M', 'net_profit': 57.1}]",2.92,2.9,4249899999,2164200000,488300000,2836600000,621800000,8300000,1202100000,488300000,243200000,0.0984779020722538,0.4403236682400539,0.45999999999999996,"[0.05, 0.04]","['2024-12-02', '2016-03-02']",__nan__,0.6674509990040827
600,BRKS,Brooks Automation Inc.,"Brooks Automation, Inc. provides automation and cryogenic solutions worldwide. The company operates in two segments, Brooks Semiconductor Solutions Group and Brooks Life Science Systems. The Brooks Semiconductor Solutions Group segment offers wafer automation and contamination controls solutions and services. Its products include atmospheric and vacuum robots, robotic modules, and tool automation systems that offer precision handling and clean wafer environments; and automated cleaning and inspection systems for wafer carriers, reticle pod cleaners, and stockers. This segment also offers repair, diagnostic, and installation services, as well as spare parts and productivity enhancement upgrade services. The Brooks Life Science Systems segment provides automated cold storage systems; consumables, including various formats of racks, tubes, caps, plates, and foils; and instruments used for labeling, bar coding, capping, de-capping, auditing, sealing, peeling, and piercing tubes and plates. It also provides sample management services, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery, and business continuity, as well as project management and consulting. In addition, this segment offers sample intelligence software solutions and customer technology integration; laboratory work flow scheduling for life science tools and instrument work cells, sample inventory and logistics, environmental and temperature monitoring, and clinical trial and consent management, as well as planning, data management, virtualization, and visualization services; and gene sequencing analysis and synthesis services. The company serves the semiconductor capital equipment and life sciences sample management markets in approximately 50 countries. Brooks Automation, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.",Dr. Stephen Schwartz,Semiconductors,113.1,USD,7815594540,https://images.financialmodelingprep.com/symbol/BRKS.png,620741,0,-3.1800003,999754,153943000,110747000,"[{'period': '2021', 'revenue': 513.7, 'unit': 'M', 'net_profit': 110.75}, {'period': '2020', 'revenue': 897.27, 'unit': 'M', 'net_profit': 64.85}, {'period': '2019', 'revenue': 780.85, 'unit': 'M', 'net_profit': 437.42}, {'period': '2018', 'revenue': 631.56, 'unit': 'M', 'net_profit': 116.58}]","[{'period': ""Q3 '21"", 'revenue': 136.94, 'unit': 'M', 'net_profit': 21.8}, {'period': ""Q2 '21"", 'revenue': 315.35, 'unit': 'M', 'net_profit': 39.17}, {'period': ""Q1 '21"", 'revenue': 286.59, 'unit': 'M', 'net_profit': 23.75}, {'period': ""Q4 '20"", 'revenue': 249.5, 'unit': 'M', 'net_profit': 26.03}, {'period': ""Q3 '20"", 'revenue': 246.2, 'unit': 'M', 'net_profit': 28.97}, {'period': ""Q2 '20"", 'revenue': 220.35, 'unit': 'M', 'net_profit': 13.7}]",1.49,1.49,1819512000,777366000,227508000,494178000,119877000,3598000,345088000,227427000,97052000,0.07479578300635342,0.7076619431637704,0.6931818181818181,"[0.1, 0.08]","['2021-12-02', '2011-09-07']",__nan__,0.27159919802672366
601,BRLI,Brilliant Acquisition Corporation Ordinary Shares,"Brilliant Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2019 and is based in Shanghai, China.",Dr. Peng  Jiang,Shell Companies,4.7,USD,8529090,https://images.financialmodelingprep.com/symbol/BRLI.png,36586,-18.8,-3.98,370983,-1372235,-732829,"[{'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -732.83}, {'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -594.49}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -314.68}, {'period': '2019', 'revenue': 0.0, 'unit': '', 'net_profit': -35.42}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -126.06}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -122.36}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -80.23}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 321.6}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -676.64}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 73.5}]",-0.16,-0.16,6111545,6111545,6110807,3976493,0,0,3965850,6110807,-1132761,-1.045315657995934,-0.23269575924359076,-0.644398766700925,__nan__,__nan__,__nan__,0.6506526582067219
602,BRLIR,Brilliant Acquisition Corporation Rights,,Dr. Peng  Jiang,Shell Companies,0.4501,USD,816898,https://images.financialmodelingprep.com/symbol/BRLIR.png,0,0,0.1501,1136776,-1372235,-732829,"[{'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -732.83}, {'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -594.49}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -314.68}, {'period': '2019', 'revenue': 0.0, 'unit': '', 'net_profit': -35.42}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -126.06}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -122.36}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -80.23}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 321.6}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -676.64}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 73.5}]",-0.16,-0.16,6111545,6111545,6110807,3976493,0,0,3965850,6110807,-1132761,-1.045315657995934,-0.23269575924359076,-0.644398766700925,__nan__,__nan__,__nan__,0.6506526582067219
603,BRLIW,Brilliant Acquisition Corporation Warrants,,,Shell Companies,0.16,USD,8529090,https://images.financialmodelingprep.com/symbol/BRLIW.png,0,0,-0.0399,76470,-1372235,-732829,"[{'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -732.83}, {'period': '2021', 'revenue': 0.0, 'unit': 'K', 'net_profit': -594.49}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -314.68}, {'period': '2019', 'revenue': 0.0, 'unit': '', 'net_profit': -35.42}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -126.06}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -122.36}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -80.23}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 321.6}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -676.64}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 73.5}]",-0.16,-0.16,6111545,6111545,6110807,3976493,0,0,3965850,6110807,-1132761,-1.045315657995934,-0.23269575924359076,-0.644398766700925,__nan__,__nan__,__nan__,0.6506526582067219
604,BROG,Brooge Energy Limited Ordinary Shares,"Brooge Energy Limited, through its subsidiaries, provides oil storage and related services at the Port of Fujairah in the emirate of Fujairah in the United Arab Emirates. The company operates phase I facility that comprises 14 storage tanks with an aggregate geometric capacity of 399,324 cbm for the storage, heating, and blending of fuel oil and clean petroleum products, including aviation fuel, gas oil, gasoline, marine gas oil, and naphtha. It also provides ancillary services that comprise blending and circulation, heating, throughput, and intertank transfer. The company was formerly known as Brooge Holdings Limited and changed its name to Brooge Energy Limited in April 2020. Brooge Energy Limited was incorporated in 2019 and is headquartered in Fujairah, the United Arab Emirates.",Mr. Saif  Alhazaimeh,Oil & Gas Midstream,1.37,USD,120608498,https://images.financialmodelingprep.com/symbol/BROG.png,24629,-2.49,-0.17,75715,-14978464,-48328195,"[{'period': '2023', 'revenue': 105.7, 'unit': 'M', 'net_profit': -48.33}, {'period': '2022', 'revenue': 81.54, 'unit': 'M', 'net_profit': 27.23}, {'period': '2021', 'revenue': 41.76, 'unit': 'M', 'net_profit': 12.8}, {'period': '2020', 'revenue': 41.83, 'unit': 'M', 'net_profit': 9.65}]","[{'period': ""Q2 '23"", 'revenue': 31.46, 'unit': 'M', 'net_profit': 18.68}, {'period': ""Q1 '23"", 'revenue': 31.46, 'unit': 'M', 'net_profit': 18.68}, {'period': ""Q2 '22"", 'revenue': 14.2, 'unit': 'M', 'net_profit': 1.95}, {'period': ""Q1 '22"", 'revenue': 14.2, 'unit': 'M', 'net_profit': 1.95}, {'period': ""Q4 '21"", 'revenue': 18.48, 'unit': 'M', 'net_profit': 14.62}, {'period': ""Q2 '21"", 'revenue': 23.29, 'unit': 'M', 'net_profit': 11.07}]",0,0,485984047,22216805,7718655,429217550,1889560,0,342606730,7718655,45290915,-1.226338615895049,-2.7748609631137944,-1,__nan__,__nan__,__nan__,0.8831926740179601
605,BROGW,Brooge Holdings Limited Warrant expiring 12/20/2024,"Brooge Energy Limited, through its subsidiaries, provides oil storage and related services at the Port of Fujairah in the United Arab Emirates. It operates phase I and phase II facilities comprising 22 tanks with a capacity of approximately 1,001,388 cubic meters for offering storage, heating, and blending of fuel oil and clean petroleum products, including aviation fuel, gas oil, gasoline, marine gas oil, and naphtha. The company was formerly known as Brooge Holdings Limited and changed its name to Brooge Energy Limited in April 2020. Brooge Energy Limited was incorporated in 2019 and is headquartered in Dubai, the United Arab Emirates.",Mr. Saif  Alhazaimeh,Oil & Gas Midstream,0.0007,USD,61450,https://images.financialmodelingprep.com/symbol/BROGW.png,0,,-0.0004,249364,-14978464,-48328195,"[{'period': '2023', 'revenue': 105.7, 'unit': 'M', 'net_profit': -48.33}, {'period': '2022', 'revenue': 81.54, 'unit': 'M', 'net_profit': 27.23}, {'period': '2021', 'revenue': 41.76, 'unit': 'M', 'net_profit': 12.8}, {'period': '2020', 'revenue': 41.83, 'unit': 'M', 'net_profit': 9.65}]","[{'period': ""Q2 '23"", 'revenue': 31.46, 'unit': 'M', 'net_profit': 18.68}, {'period': ""Q1 '23"", 'revenue': 31.46, 'unit': 'M', 'net_profit': 18.68}, {'period': ""Q2 '22"", 'revenue': 14.2, 'unit': 'M', 'net_profit': 1.95}, {'period': ""Q1 '22"", 'revenue': 14.2, 'unit': 'M', 'net_profit': 1.95}, {'period': ""Q4 '21"", 'revenue': 18.48, 'unit': 'M', 'net_profit': 14.62}, {'period': ""Q2 '21"", 'revenue': 23.29, 'unit': 'M', 'net_profit': 11.07}]",0,0,485984047,22216805,7718655,429217550,1889560,0,342606730,7718655,45290915,-1.226338615895049,-2.7748609631137944,-1,__nan__,__nan__,__nan__,0.8831926740179601
606,BRP,BRP Group Inc. (Insurance Company) Class A Common Stock,"BRP Group, Inc. markets and sells insurance products and services in the United States. The company operates through four segments: Middle Market, Specialty, MainStreet, and Medicare. The Middle Market segment provides commercial risk management, employee benefits solutions, and private risk management for mid-to-large size businesses and high net worth individuals, as well as its families. The Specialty segment delivers specialty insurers, professionals, individuals, and industry businesses the access to specialty markets, as well as capabilities and programs requiring underwriting and placement. This segment also operates as a managing general agent of the Future platform, which delivers proprietary, technology-enabled insurance solutions. The MainStreet segment offers personal insurance, commercial insurance, and life and health solutions to individuals and businesses in its communities. The Medicare segment provides consultation for government assistance programs and solutions, including Medicare and Medicare Advantage to seniors and Medicare-eligible individuals through a network of primarily independent contractor agents. The company was founded in 2011 and is headquartered in Tampa, Florida.",Mr. Trevor Lowry Baldwin,Insurance - Brokers,32.66,USD,2160187922,https://images.financialmodelingprep.com/symbol/BRP.png,359205,-35.11827956989247,0.15,694652,116216000,-90141000,"[{'period': '2023', 'revenue': 1220.0, 'unit': 'M', 'net_profit': -90.14}, {'period': '2022', 'revenue': 980.72, 'unit': 'M', 'net_profit': -76.75}, {'period': '2021', 'revenue': 567.29, 'unit': 'M', 'net_profit': -58.12}, {'period': '2020', 'revenue': 240.92, 'unit': 'M', 'net_profit': -29.89}]","[{'period': ""Q1 '24"", 'revenue': 380.37, 'unit': 'M', 'net_profit': 21.58}, {'period': ""Q4 '23"", 'revenue': 284.65, 'unit': 'M', 'net_profit': -34.48}, {'period': ""Q3 '23"", 'revenue': 306.27, 'unit': 'M', 'net_profit': -17.63}, {'period': ""Q2 '23"", 'revenue': 297.19, 'unit': 'M', 'net_profit': -23.9}, {'period': ""Q1 '23"", 'revenue': 330.45, 'unit': 'M', 'net_profit': -25.85}, {'period': ""Q4 '22"", 'revenue': 246.04, 'unit': 'M', 'net_profit': -91.47}]",-1.5,-1.5,3501937000,925905000,116209000,2483055000,627791000,2600000,1033440000,116209000,23268000,0.0220924505734187,-0.17450617605670507,-0.11111111111111104,"[0.5, 0.5]","['2008-12-30', '2008-12-30']",__nan__,0.7090518761474007
607,BRPA,Big Rock Partners Acquisition Corp. Common Stock,,,,,,,,,0,-3.27,287782,-416571,-398730,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -398.73}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'B', 'net_profit': -16.01}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -398.73}]",-0.15,-0.15,6050405,82458,5968413,3281546,0,0,1809889,466,-598617,0,0,0,__nan__,__nan__,__nan__,0.5423679902419756
608,BRPAR,Big Rock Partners Acquisition Corp. Right,,,,,,,,,,,,-416571,-398730,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -398.73}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': 408.43}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'B', 'net_profit': -16.01}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -398.73}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -211.16}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 408.43}]",2.74,2.74,6050.405,82.458,5968.4130000000005,3281.546,0,5967.947,2419.398,0.466,-598617,-2.2848365775196546,-1.9762576910929004,25.90909090909091,__nan__,__nan__,__nan__,0.5423679902419756
609,BRPAU,Big Rock Partners Acquisition Corp. Unit,,,,,,,,,,,,-416571,-434412,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -434.41}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': 408.43}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'B', 'net_profit': -16.01}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -893.72}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -432.35}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -125.78}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -149.5}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 273.22}]",2.74,2.74,6050405,82458,5968413,3281546,0,0,609509,466,-598617,-1.8456010864071226,-2.063622140553881,0,__nan__,__nan__,__nan__,0.5423679902419756
610,BRPAW,Big Rock Partners Acquisition Corp. Warrant,,,,,,,,,0,-0.6,63415,-416571,-398730,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -398.73}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'B', 'net_profit': -16.01}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -398.73}]",2.74,2.74,6050405,82458,5968413,3281546,0,0,1809889,466,-598617,0,0,0,__nan__,__nan__,__nan__,0.5423679902419756
611,BRPM,B. Riley Principal 150 Merger Corp. Class A Common Stock,"B. Riley Principal 150 Merger Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York. B. Riley Principal 150 Merger Corp. is a subsidiary of B. Riley Financial, Inc.",,Shell Companies,13.02,USD,944038536,https://images.financialmodelingprep.com/symbol/BRPM.png,0,-72.73743016759776,1.9700003,743455,-6867161,-10288632,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.29}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': 8.85}]","[{'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.61}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.99}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.3}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.82}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.85}, {'period': ""Q3 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 466.8}]",-3.47,-3.47,173171973,655773,43324,11412401,0,0,2813168,43324,-1246.42,0,0,0,__nan__,__nan__,__nan__,0.06590212493565573
612,BRPMU,B. Riley Principal 150 Merger Corp. Unit,"As of July 19, 2022, B. Riley Principal 150 Merger Corp. was acquired by FaZe Holdings Inc., in a reverse merger transaction. B. Riley Principal 150 Merger Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York. B. Riley Principal 150 Merger Corp. is a subsidiary of B. Riley Financial, Inc.",Mr. Daniel  Shribman,Shell Companies,13.45,USD,0,https://images.financialmodelingprep.com/symbol/BRPMU.png,0,-75.13966480446928,2.41,1784,-6867161,-10288632,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.29}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': 8.85}]","[{'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.61}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.99}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.3}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.82}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.85}, {'period': ""Q3 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 466.8}]",-3.47,-3.47,173171973,655773,43324,11412401,0,0,2813168,43324,-1246.42,0,0,0,__nan__,__nan__,__nan__,0.06590212493565573
613,BRPMW,B. Riley Principal 150 Merger Corp. Warrant,,,,,,,,,0,0.305,570885,-6867161,-10288632,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.29}]","[{'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.61}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.99}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.82}]",-0.58,-0.58,173171973,655773,43324,11412401,0,0,2813168,43324,-1246420,0,0,0,__nan__,__nan__,__nan__,0.06590212493565573
614,BRQS,Borqs Technologies Inc. Ordinary Shares,"Borqs Technologies, Inc. provides Android-based smart connected devices and cloud service solutions in the United States, India, China, and internationally. The company offers commercial grade Android platform software and service solutions to address vertical market segment needs through the targeted BorqsWare software platform solutions. Its BorqsWare software platform consists of BorqsWare Client software that has been used in Android phones, tablets, watches, and various Internet-of-things devices; and BorqsWare Server software platform, which includes back-end server software that allows customers to develop their own mobile end-to-end services for their devices. In addition, it provides IVI solutions, machine to machine solutions, smart appliance solution, mobile operator services, and google mobile services (GMS). The company primarily serves mobile chipset manufacturers, mobile device original equipment manufacturers, and mobile operators, as well as product solutions of mobile connected devices for enterprise and consumer applications. Borqs Technologies, Inc. was founded in 2007 and is headquartered in Kwun Tong, Hong Kong.",Mr. Sek Yuen  Chan,Software - Application,0.43,USD,6284579,https://images.financialmodelingprep.com/symbol/BRQS.png,113330,-0.028666666666666667,-0.1365,889356,-3952000,-28945000,"[{'period': '2022', 'revenue': 52.54, 'unit': 'M', 'net_profit': -28.95}, {'period': '2021', 'revenue': 29.56, 'unit': 'M', 'net_profit': -56.6}, {'period': '2020', 'revenue': 26.75, 'unit': 'M', 'net_profit': -36.09}, {'period': '2019', 'revenue': 98.96, 'unit': 'M', 'net_profit': -31.58}]","[{'period': ""Q4 '21"", 'revenue': -11.45, 'unit': 'M', 'net_profit': 16.61}, {'period': ""Q4 '20"", 'revenue': -14.26, 'unit': 'M', 'net_profit': 37.57}, {'period': ""Q4 '19"", 'revenue': 57.94, 'unit': 'M', 'net_profit': 42.08}, {'period': ""Q2 '19"", 'revenue': 27.19, 'unit': 'M', 'net_profit': -1.21}, {'period': ""Q4 '18"", 'revenue': -14.47, 'unit': 'M', 'net_profit': -70.24}, {'period': ""Q3 '18"", 'revenue': 28.29, 'unit': 'M', 'net_profit': -2.51}]",-1.26,-1.26,30143000,27991000,12741000,41295000,3482000,0,37940000,11305000,-6241000,0.8250088558271342,0.4886223101657185,0.8359375,__nan__,__nan__,__nan__,1.369969810569618
615,BRY,Berry Corporation (bry) Common Stock,"Berry Corporation, an independent upstream energy company, engages in the development and production of conventional oil reserves located in the western United States. It operates in two segments, Development and Production, and Well Servicing and Abandonment. The company's properties are located in the San Joaquin and Ventura basins, California; and Uinta basin, Utah. As of December 31, 2021, it had a total of 3,417 net productive wells. The company was formerly known as Berry Petroleum Corporation and changed its name to Berry Corporation in February 2020. Berry Corporation was founded in 1909 and is headquartered in Dallas, Texas.",Mr. Fernando  Araujo,Oil & Gas Exploration & Production,4.365,USD,335838735,https://images.financialmodelingprep.com/symbol/BRY.png,1344908,4.04,0.065,353531,251379000,37400000,"[{'period': '2023', 'revenue': 863.45, 'unit': 'M', 'net_profit': 37.4}, {'period': '2022', 'revenue': 1060.0, 'unit': 'M', 'net_profit': 250.17}, {'period': '2021', 'revenue': 701.35, 'unit': 'M', 'net_profit': -15.54}, {'period': '2020', 'revenue': 406.05, 'unit': 'M', 'net_profit': -262.89}]","[{'period': ""Q3 '24"", 'revenue': 184.35, 'unit': 'M', 'net_profit': 69.86}, {'period': ""Q2 '24"", 'revenue': 203.66, 'unit': 'M', 'net_profit': -8.77}, {'period': ""Q1 '24"", 'revenue': 202.31, 'unit': 'M', 'net_profit': -40.08}, {'period': ""Q4 '23"", 'revenue': 336.4, 'unit': 'M', 'net_profit': 62.55}, {'period': ""Q3 '23"", 'revenue': 222.08, 'unit': 'M', 'net_profit': -45.06}, {'period': ""Q2 '23"", 'revenue': 208.49, 'unit': 'M', 'net_profit': 25.77}]",0.49,0.48,1594158000,140800000,4835000,836182000,86918000,0,223182000,4835000,117586000,-0.3732822410147992,-0.8505004636884014,-0.8463949843260189,"[0.03, 0.09]","['2024-11-15', '2018-09-13']",__nan__,0.5245289362785872
616,BSBK,Bogota Financial Corp. Common Stock,"Bogota Financial Corp. operates as the bank holding company for Bogota Savings Bank that provides banking products and services in the United States. It offers deposit accounts, including demand accounts, savings accounts, money market accounts, and certificate of deposit accounts. The company also provides one-to four-family residential real estate loans, and commercial real estate and multi-family loans, as well as consumer loans, such as home equity loans and lines of credit, commercial and industrial loans, and construction loans; and buys, sells, and holds investment securities. It operates through various offices located in Bogota, Hasbrouck Heights, Newark, Oak Ridge, Parsippany, and Teaneck, as well as through a loan production office in Spring Lake, New Jersey. The company was founded in 1893 and is based in Teaneck, New Jersey. Bogota Financial Corp. operates as a subsidiary of Bogota Financial, MHC.",Mr. Kevin  Pace,Banks - Regional,7.564,USD,98898544,https://images.financialmodelingprep.com/symbol/BSBK.png,6680,-39.81,0.024,3216,0,642535,"[{'period': '2023', 'revenue': 16110.0, 'unit': 'K', 'net_profit': 642.53}, {'period': '2022', 'revenue': 31.47, 'unit': 'M', 'net_profit': 6.88}, {'period': '2021', 'revenue': 27.61, 'unit': 'M', 'net_profit': 7.52}, {'period': '2020', 'revenue': 24.38, 'unit': 'M', 'net_profit': 2.07}]","[{'period': ""Q3 '24"", 'revenue': 10950.0, 'unit': 'K', 'net_profit': -366.96}, {'period': ""Q2 '24"", 'revenue': 10780.0, 'unit': 'K', 'net_profit': -432.48}, {'period': ""Q1 '24"", 'revenue': 10360.0, 'unit': 'K', 'net_profit': -440.98}, {'period': ""Q4 '23"", 'revenue': 9.85, 'unit': 'M', 'net_profit': -1.18}, {'period': ""Q3 '23"", 'revenue': 9580.0, 'unit': 'K', 'net_profit': -29.05}, {'period': ""Q2 '23"", 'revenue': 9690.0, 'unit': 'K', 'net_profit': 856.64}]",0.0498,0.0498,939324203,57724512,24929471,802151000,3932785,20217966,0,24929471,1119316,-1,-0.9065656554640263,-0.9023529411764706,__nan__,__nan__,__nan__,0.8539660720314688
617,BSET,Bassett Furniture Industries Incorporated Common Stock,"Bassett Furniture Industries, Incorporated engages in the manufacture, marketing, and retail of home furnishings in the United States and internationally. It operates through three segments: Wholesale, Retail company-owned Stores, and Logistical Services. The company engages in the design, manufacture, sourcing, sale, and distribution of furniture products to a network of company-owned retail stores and licensee-owned stores, and independent furniture retailers; and wood and upholstery operations. As of November 27, 2021, it operated a network of 63 company-owned stores and 34 licensee-owned stores. It also provides shipping, and warehousing services to customers in the furniture industry. In addition, the company owns and leases retail store properties; and distributes its products through other multi-line furniture stores, Bassett galleries or design centers, mass merchants, and specialty stores, as well as sells its products online. Bassett Furniture Industries, Incorporated was incorporated in 1902 and is based in Bassett, Virginia.",Mr. Robert H. Spilman Jr.,"Furnishings, Fixtures & Appliances",13.85,USD,121895789,https://images.financialmodelingprep.com/symbol/BSET.png,13543,-7.1,0,3327,7675000,-3171000,"[{'period': '2023', 'revenue': 390.14, 'unit': 'M', 'net_profit': -3.17}, {'period': '2022', 'revenue': 485.6, 'unit': 'M', 'net_profit': 25.36}, {'period': '2021', 'revenue': 486.53, 'unit': 'M', 'net_profit': 18.04}, {'period': '2020', 'revenue': 385.86, 'unit': 'M', 'net_profit': -10.42}]","[{'period': ""Q3 '24"", 'revenue': 75.62, 'unit': 'M', 'net_profit': -4.5}, {'period': ""Q2 '24"", 'revenue': 83.41, 'unit': 'M', 'net_profit': -7.2}, {'period': ""Q1 '24"", 'revenue': 86.55, 'unit': 'M', 'net_profit': -1.19}, {'period': ""Q4 '23"", 'revenue': 94.7, 'unit': 'M', 'net_profit': -4.1}, {'period': ""Q3 '23"", 'revenue': 87.22, 'unit': 'M', 'net_profit': -2.59}, {'period': ""Q2 '23"", 'revenue': 100.52, 'unit': 'M', 'net_profit': 2.08}]",-0.36,-0.36,370424000,157954000,70182000,186983000,16310000,0,77890000,52407000,1235000,-0.7924778282500541,-1.1250394321766561,-1.1333333333333333,"[0.2, 0.2001]","['2024-11-15', '1986-02-10']",__nan__,0.5047810077100836
618,BSGM,BioSig Technologies Inc. Common Stock,"BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.",Mr. Anthony  Amato,Medical - Devices,1.43,USD,24645907,https://images.financialmodelingprep.com/symbol/BSGM.png,335164,-1.16,-0.02,17032,-28151000,-29041000,"[{'period': '2023', 'revenue': 0.018000000000000002, 'unit': 'M', 'net_profit': -29.04}, {'period': '2022', 'revenue': 0.28600000000000003, 'unit': 'M', 'net_profit': -27.27}, {'period': '2021', 'revenue': 0.441, 'unit': 'M', 'net_profit': -31.36}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -52.17}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.91}, {'period': ""Q2 '24"", 'revenue': 0.013000000000000001, 'unit': 'M', 'net_profit': -3.92}, {'period': ""Q1 '24"", 'revenue': 0.014, 'unit': 'M', 'net_profit': -3.4}, {'period': ""Q4 '23"", 'revenue': 0.012, 'unit': 'M', 'net_profit': -6.05}, {'period': ""Q3 '23"", 'revenue': 0.001, 'unit': 'M', 'net_profit': -4.57}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.09}]",-3.95,-3.95,1798000,528000,190000,4685000,127000,0,4582000,190000,-17499000,-0.043711997627168916,-0.06490411059367093,0.37598736176935227,__nan__,__nan__,__nan__,2.6056729699666294
619,BSKYU,Big Sky Growth Partners Inc. Unit,"Big Sky Growth Partners, Inc. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It focuses on pursuing opportunities in internet retail and direct-to-consumer companies. The company was incorporated in 2021 and is based in Seattle, Washington.",,Shell Companies,10.14,USD,0,https://images.financialmodelingprep.com/symbol/BSKYU.png,34178,42.25,0.09,2439,5132991,10963259,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 10.96}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.66}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.11}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'T', 'net_profit': 7.09}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.58}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.72}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 588.02}]",0.29,0.29,301455581,1440975,1004964,20369003,0,300014606,341003,1004964,-929097,0,0,0,__nan__,__nan__,__nan__,0.06756883694914907
620,BSPE,Bespoke Capital Acquisition Corp. Class A Restricted Voting Shares,,,,,,,,,0,,,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
621,BSQR,BSQUARE Corporation Common Stock,"BSQUARE Corporation develops and deploys technologies for the makers and operators of connected devices in North America, Europe, and Asia. The company operates through two segments, Partner Solutions and Edge to Cloud. It offers software that connect devices to create intelligent systems; and embedded operating system software and services for makers of connected and intelligent devices, such as point-of-sale terminals, kiosks, tablets and handheld data collection devices, smart vending machines, ATMs, essential equipment in buildings and facilities environments, digital signs, and in-vehicle telematics and entertainment devices. The company also resells Windows IoT, Windows Embedded, and Windows Server IoT software, as well as system utility software for Adobe and McAfee; and provides license compliance services, technical support, and manufacturing support. In addition, it provides operating system configuration and device hardening, fleet transition, 24/7 IoT operations, data engineering, and software utilities and professional services, as well as device management solutions. The company serves original equipment manufacturers, original design manufacturers, silicon vendors, and peripheral vendors. BSQUARE Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.",Mr. Ralph C. Derrickson,Software - Application,1.89,USD,37555245,https://images.financialmodelingprep.com/symbol/BSQR.png,170701,-14.538461538461538,0.01,22363,-3626000,-3031000,"[{'period': '2022', 'revenue': 36.49, 'unit': 'M', 'net_profit': -3.03}, {'period': '2021', 'revenue': 40.37, 'unit': 'M', 'net_profit': -1.76}, {'period': '2020', 'revenue': 47.14, 'unit': 'M', 'net_profit': -1.26}, {'period': '2019', 'revenue': 59.28, 'unit': 'M', 'net_profit': -9.18}]","[{'period': ""Q3 '23"", 'revenue': 9.29, 'unit': 'M', 'net_profit': -1.13}, {'period': ""Q2 '23"", 'revenue': 6530.0, 'unit': 'K', 'net_profit': -260.0}, {'period': ""Q1 '23"", 'revenue': 8140.000000000001, 'unit': 'K', 'net_profit': 306.0}, {'period': ""Q4 '22"", 'revenue': 7.96, 'unit': 'M', 'net_profit': -1.21}, {'period': ""Q3 '22"", 'revenue': 8.41, 'unit': 'M', 'net_profit': -1.1}, {'period': ""Q2 '22"", 'revenue': 10390.0, 'unit': 'K', 'net_profit': -625.0}]",-0.15,-0.15,42171000,40037000,35421000,6772000,3985000,0,5712000,35414000,-4243000,0.0683453237410072,-0.7250996015936255,-0.3636363636363636,__nan__,__nan__,__nan__,0.16058428778070238
622,BSRR,Sierra Bancorp Common Stock,"Sierra Bancorp operates as the bank holding company for Bank of the Sierra that provides retail and commercial banking services to individuals and businesses in California. The company accepts various deposit products, such as checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. Its loan products include agricultural, commercial, consumer, real estate, construction, and mortgage loans. The company also offers automated teller machines; electronic point-of-sale payment alternatives; online and automated telephone banking services; and remote deposit capture and automated payroll services for business customers. As of December 31, 2021, it operated 35 full-service branches, an online branch, a loan production office, an agricultural credit center, and an SBA center. Sierra Bancorp was founded in 1977 and is headquartered in Porterville, California.",Mr. Kevin J. McPhaill,Banks - Regional,28.23,USD,406331328,https://images.financialmodelingprep.com/symbol/BSRR.png,41738,11.2,-0.46,18566,49696000,34844000,"[{'period': '2023', 'revenue': 139.12, 'unit': 'M', 'net_profit': 34.84}, {'period': '2022', 'revenue': 130.09, 'unit': 'M', 'net_profit': 33.66}, {'period': '2021', 'revenue': 127.56, 'unit': 'M', 'net_profit': 43.01}, {'period': '2020', 'revenue': 130.99, 'unit': 'M', 'net_profit': 35.44}]","[{'period': ""Q3 '24"", 'revenue': 37.22, 'unit': 'M', 'net_profit': 10.6}, {'period': ""Q2 '24"", 'revenue': 51.12, 'unit': 'M', 'net_profit': 10.26}, {'period': ""Q1 '24"", 'revenue': 45.75, 'unit': 'M', 'net_profit': 9.33}, {'period': ""Q4 '23"", 'revenue': 64.99, 'unit': 'M', 'net_profit': 6.29}, {'period': ""Q3 '23"", 'revenue': 33.63, 'unit': 'M', 'net_profit': 9.88}, {'period': ""Q2 '23"", 'revenue': 33.65, 'unit': 'M', 'net_profit': 9.92}]",2.37,2.36,3729799000,78602000,78602000,3391702000,0,0,2060810000,78602000,51830000,0.025696064064725185,0.03520603701833091,0.05333333333333338,"[0.24, 0.39]","['2024-10-31', '1994-04-28']",__nan__,0.9093524878954603
623,BSVN,Bank7 Corp. Common stock,"Bank7 Corp. operates as a bank holding company for Bank7 that provides banking and financial services to individual and corporate customers. It offers commercial deposit services, including commercial checking, money market, and other deposit accounts; and retail deposit services, such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. The company also provides commercial real estate, hospitality, energy, and commercial and industrial lending services; consumer lending services to individuals for personal and household purposes comprising secured and unsecured term loans, and home improvement loans. As of March 8, 2022, it operated through a network of twelve full-service branches in Oklahoma, the Dallas/Fort Worth, Texas metropolitan area, and Kansas. The company was formerly known as Haines Financial Corp.Bank7 Corp. was founded in 1901 and is headquartered in Oklahoma City, Oklahoma.",Mr. Thomas L. Travis,Banks - Regional,43.65,USD,407830244,https://images.financialmodelingprep.com/symbol/BSVN.png,30159,11.52,-1.07,5337,38525000,28275000,"[{'period': '2023', 'revenue': 130.79, 'unit': 'M', 'net_profit': 28.27}, {'period': '2022', 'revenue': 72.37, 'unit': 'M', 'net_profit': 29.64}, {'period': '2021', 'revenue': 55.49, 'unit': 'M', 'net_profit': 23.16}, {'period': '2020', 'revenue': 48.83, 'unit': 'M', 'net_profit': 19.27}]","[{'period': ""Q3 '24"", 'revenue': 33.49, 'unit': 'M', 'net_profit': 11.78}, {'period': ""Q2 '24"", 'revenue': 35.6, 'unit': 'M', 'net_profit': 11.52}, {'period': ""Q1 '24"", 'revenue': 35.3, 'unit': 'M', 'net_profit': 11.29}, {'period': ""Q4 '23"", 'revenue': 39.17, 'unit': 'M', 'net_profit': 1.07}, {'period': ""Q3 '23"", 'revenue': 21.75, 'unit': 'M', 'net_profit': 7.85}, {'period': ""Q2 '23"", 'revenue': 21.29, 'unit': 'M', 'net_profit': 9.75}]",3.09,3.05,1771666000,181042000,181042000,1601340000,0,170770000,1417573000,198721000,46291000,-0.05257851117723729,-0.04598825831702544,-0.052147239263803664,"[0.24, 0.1]","['2024-12-20', '2019-09-30']",__nan__,0.9038611115187626
624,BSY,Bentley Systems Incorporated Class B Common Stock,"Bentley Systems, Incorporated, together with its subsidiaries, provides infrastructure engineering software solutions in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company offers open modeling and open simulation applications for infrastructure design integration, which include MicroStation, OpenRoads, OpenRail, OpenPlant, OpenBuildings, OpenBridge, OpenSite, OpenFlows, STAAD and RAM, SACS, MOSES, AutoPIPE, SITEOPS, CUBE, DYNAMEQ, EMME, and LEGION; and geoprofessional applications for modeling and simulation of near and deep subsurface conditions, including Leapfrog, AGS Workbench, GeoStudio, Imago, MX Deposit, Oasis montaj, PLAXIS, and OpenGround. It also provides project delivery systems that support collaboration, work-sharing, and 4D construction modeling for infrastructure project delivery enterprises, such as ProjectWise, ProjectWise Design Review Service, and SYNCHRO; and asset and network performance systems, such as AssetWise ALIM, AssetWise Asset Reliability, AssetWise Enterprise Interoperability, AssetWise 4D Analytics, AssetWise Linear, and Seequent Central. In addition, it offers industry solutions comprising AssetWise Linear SUPERLOAD, AssetWise Linear Analytics, AssetWise Inspections, ContextCapture, OpenCities, OpenUtilities, OpenTower, OpenWindPower, Power Line, SPIDA, OrbitGT, sensemetrics, PlantSight, and WaterSight. The company serves civil, structural, geotechnical, geoscience subsurface engineers, architects, geospatial professionals, city and regional planners, contractors, fabricators, and operations and maintenance engineers. Bentley Systems, Incorporated was incorporated in 1984 and is headquartered in Exton, Pennsylvania.",Mr. Nicholas H. Cumins,Software - Application,46.93,USD,13643114160,https://images.financialmodelingprep.com/symbol/BSY.png,0,42.28,0.06,298767,288445000,326787000,"[{'period': '2023', 'revenue': 1230.0, 'unit': 'M', 'net_profit': 326.79}, {'period': '2022', 'revenue': 1100.0, 'unit': 'M', 'net_profit': 174.78}, {'period': '2021', 'revenue': 965.05, 'unit': 'M', 'net_profit': 93.19}, {'period': '2020', 'revenue': 801.54, 'unit': 'M', 'net_profit': 126.52}]","[{'period': ""Q3 '24"", 'revenue': 335.17, 'unit': 'M', 'net_profit': 42.34}, {'period': ""Q2 '24"", 'revenue': 330.34, 'unit': 'M', 'net_profit': 72.05}, {'period': ""Q1 '24"", 'revenue': 337.76, 'unit': 'M', 'net_profit': 70.31}, {'period': ""Q4 '23"", 'revenue': 310.64, 'unit': 'M', 'net_profit': 179.59}, {'period': ""Q3 '23"", 'revenue': 306.61, 'unit': 'M', 'net_profit': 53.03}, {'period': ""Q2 '23"", 'revenue': 296.75, 'unit': 'M', 'net_profit': 48.69}]",1.07,1,3319850000,419557000,68412000,2435868000,293536000,23480000,760363000,68412000,391694000,-0.030857208134959967,0.8697047717130106,0.8771929824561406,"[0.06, 0.03]","['2024-12-03', '2020-12-04']",__nan__,0.7337283310992967
625,BTAI,BioXcel Therapeutics Inc. Common Stock,"BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment nave to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.",Dr. Vimal D. Mehta Ph.D.,Biotechnology,0.485,USD,24070065,https://images.financialmodelingprep.com/symbol/BTAI.png,769106,-0.24,-0.0882,1162144,-165421000,-179053000,"[{'period': '2023', 'revenue': 1.38, 'unit': 'M', 'net_profit': -179.05}, {'period': '2022', 'revenue': 0.375, 'unit': 'M', 'net_profit': -171.85}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -106.63}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -82.01}]","[{'period': ""Q3 '24"", 'revenue': 0.214, 'unit': 'M', 'net_profit': -13.65}, {'period': ""Q2 '24"", 'revenue': 1.1, 'unit': 'M', 'net_profit': -8.3}, {'period': ""Q1 '24"", 'revenue': 0.582, 'unit': 'M', 'net_profit': -26.79}, {'period': ""Q4 '23"", 'revenue': 0.376, 'unit': 'M', 'net_profit': -22.26}, {'period': ""Q3 '23"", 'revenue': 0.341, 'unit': 'M', 'net_profit': -50.49}, {'period': ""Q2 '23"", 'revenue': 0.457, 'unit': 'M', 'net_profit': -53.52}]",-6.15,-6.15,73702000,72143000,65221000,130210000,71000,0,27267000,65221000,-155026000,-0.05106618207695827,-0.041920523250062555,-0.0032626427406199777,__nan__,__nan__,__nan__,1.766709180212206
626,BTAQ,Burgundy Technology Acquisition Corporation Class A Ordinary shares,"Burgundy Technology Acquisition Corporation does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on public and private opportunities in the technology sector, primarily companies in enterprise software or technology-enabled services. The company was incorporated in 2020 and is based in George Town, the Cayman Islands.",Mr. Leo  Apotheker,Shell Companies,10.04,USD,0,https://images.financialmodelingprep.com/symbol/BTAQ.png,159077,-101.41414141414141,0,28012,-336288,-336288,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -336.29}]","[{'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.03}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.87}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -336.29}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -143.58}]",-0.0078,-0.0078,347848218,1111451,347711582,12164352,0,0,89352,974815,,0,0,0,__nan__,__nan__,__nan__,0.03497028695429453
627,BTAQU,Burgundy Technology Acquisition Corporation Unit,"Burgundy Technology Acquisition Corporation does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on public and private opportunities in the technology sector, primarily companies in enterprise software or technology-enabled services. The company was incorporated in 2020 and is based in George Town, the Cayman Islands.",Mr. Leo  Apotheker,Shell Companies,10.03,USD,0,https://images.financialmodelingprep.com/symbol/BTAQU.png,1124,-101.31313131313131,0,4,-336288,-336288,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -336.29}]","[{'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.03}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.87}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -336.29}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -143.58}]",-0.0078,-0.0078,347848218,1111451,347711582,12164352,0,0,89352,974815,,0,0,0,__nan__,__nan__,__nan__,0.03497028695429453
628,BTAQW,Burgundy Technology Acquisition Corporation Warrant,,,,,,,,,0,-0.0084,3484708,-336288,-336288,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -336.29}]","[{'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.03}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.87}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 14.49}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -336.29}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -121.02}]",-0.04,-0.04,347848218,1111451,347711582,12164352,0,0,89352,974815,-439484,0,0,0,__nan__,__nan__,__nan__,0.03497028695429453
629,BTBT,Bit Digital Inc. Ordinary Shares,"Bit Digital, Inc., together with its subsidiaries, engages in the bitcoin mining business. It is also involved in the treasury management activities. The company was formerly known as Golden Bull Limited and changed its name to Bit Digital, Inc. in September 2020. Bit Digital, Inc. was incorporated in 2017 and is headquartered in New York, New York.",Mr. Samir  Tabar,Financial - Capital Markets,3.555,USD,545724495,https://images.financialmodelingprep.com/symbol/BTBT.png,17713035,-118.5,-0.325,13108081,-12309046,-13893281,"[{'period': '2023', 'revenue': 44.92, 'unit': 'M', 'net_profit': -13.89}, {'period': '2022', 'revenue': 32.3, 'unit': 'M', 'net_profit': -105.3}, {'period': '2021', 'revenue': 96.08, 'unit': 'M', 'net_profit': 4.86}, {'period': '2020', 'revenue': 21.07, 'unit': 'M', 'net_profit': -1.1}]","[{'period': ""Q3 '24"", 'revenue': 22.71, 'unit': 'M', 'net_profit': -38.8}, {'period': ""Q2 '24"", 'revenue': 28.95, 'unit': 'M', 'net_profit': -11.95}, {'period': ""Q1 '24"", 'revenue': 30.29, 'unit': 'M', 'net_profit': 50.08}, {'period': ""Q4 '23"", 'revenue': 16.05, 'unit': 'M', 'net_profit': -2.02}, {'period': ""Q3 '23"", 'revenue': 11.56, 'unit': 'M', 'net_profit': -7.18}, {'period': ""Q2 '23"", 'revenue': 13.48, 'unit': 'M', 'net_profit': -2.43}]",-0.16,-0.16,189328382,83346183,64752555,36624526,13855949,4773685,27081262,16860934,-65554014,-0.37334460656596624,0.8680557529476995,0.8805970149253732,__nan__,__nan__,__nan__,0.19344445673232447
630,BTNB,Bridgetown 2 Holdings Limited Class A Ordinary Shares,"Bridgetown 2 Holdings Limited does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Central, Hong Kong.",,Shell Companies,8.33,USD,0,https://images.financialmodelingprep.com/symbol/BTNB.png,131465,0,0,162786,,,[],"[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.86}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.91}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",,,67500,25000,25000,52500,0,0,52500,25000,,,,,__nan__,__nan__,__nan__,0.7777777777777778
631,BTRS,BTRS Holdings Inc. Class 1 Common Stock,"BTRS Holdings Inc. provides cloud-based software and integrated payment processing solutions that automates business-to-business (B2B) commerce worldwide. The company operates in two segments, Print, and Software and Payments. The company offers solutions that span credit decisioning and monitoring, online ordering, invoicing, cash application, and collections. Its products include credit Application, a B2B credit application module, which provides a digital process that delivers credit-related information in real-time to streamline prospect evaluation and new customer onboarding during initial sales activity; Credit Management, a credit management module, which provides ongoing risk assessment for its customers' customers; order/E-commerce module that offers B2B wholesale distributors with e-commerce capabilities; and invoicing module, which enables its customers to optimize invoice delivery across various distribution channels. The company's products also comprise integrated B2B payments, an integrated payment capabilities that enable customers to facilitate payments at every possible touchpoint across solution set; cash application module, which enables revenue reconciliation through line item reconciliation within accounting and ERP systems; collections module that enables customers to shift from a reactive recovery-centric model to a strategic customer touchpoint-centric operation, preventing payment delays, and driving positive customer experiences; and business payments network, which makes accepting electronic payments through connecting suppliers and their underlying systems, AP portals, payment card issuers, banks, and payment processors. It serves customers across various industry verticals comprising technology, healthcare, industrial, wholesale distribution, consumer packaged goods, and others. The company was incorporated in 2001 and is headquartered in Lawrenceville, New Jersey. As of December 16, 2022, BTRS Holdings Inc. was taken private.",Mr. Flint A. Lane,Software - Application,9.49,USD,0,https://images.financialmodelingprep.com/symbol/BTRS.png,1623187,-22.488151658767773,0,1,-64265000,-61200000,"[{'period': '2021', 'revenue': 166.41, 'unit': 'M', 'net_profit': -61.2}, {'period': '2020', 'revenue': 145.69, 'unit': 'M', 'net_profit': -4.45}, {'period': '2019', 'revenue': 136.47, 'unit': 'M', 'net_profit': -22.8}, {'period': '2018', 'revenue': 120.52, 'unit': 'M', 'net_profit': -18.23}]","[{'period': ""Q3 '22"", 'revenue': 51.36, 'unit': 'M', 'net_profit': -21.21}, {'period': ""Q2 '22"", 'revenue': 49.28, 'unit': 'M', 'net_profit': -15.8}, {'period': ""Q1 '22"", 'revenue': 45.63, 'unit': 'M', 'net_profit': -29.03}, {'period': ""Q4 '21"", 'revenue': 42.88, 'unit': 'M', 'net_profit': -16.48}, {'period': ""Q3 '21"", 'revenue': 41.36, 'unit': 'M', 'net_profit': -11.19}, {'period': ""Q2 '21"", 'revenue': 40.23, 'unit': 'M', 'net_profit': -10.74}]",-0.39,-0.39,470649,299663,187672,161015,34394,45117,88825,187672,-11193000,-12.014304971048137,-12.743667133771693,-11.703583061889251,__nan__,__nan__,__nan__,0.34211269969765157
632,BTRSW,BTRS Holdings Inc. Warrants,,,,,,,,,0,0.13999987,28096,-4450315,-4447670,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.45}, {'period': '2019', 'revenue': 136.47, 'unit': 'M', 'net_profit': -22.8}, {'period': '2018', 'revenue': 120.52, 'unit': 'M', 'net_profit': -18.23}]","[{'period': ""Q3 '21"", 'revenue': 41.36, 'unit': 'M', 'net_profit': -11.19}, {'period': ""Q2 '21"", 'revenue': 40.23, 'unit': 'M', 'net_profit': -10.74}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.45}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': -225.89}, {'period': ""Q2 '20"", 'revenue': 34.59, 'unit': 'M', 'net_profit': -2.9}]",0.02,0.02,253568166,1275211,253310357,12741227,0,252292955,4770852,1017402,-1071206,0.7082717141920681,0.80495241854142,0,__nan__,__nan__,__nan__,0.05024773890583726
633,BTWN,Bridgetown Holdings Limited Class A Ordinary Shares,"Bridgetown Holdings Limited does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the technology, financial services, or media sectors. The company was incorporated in 2020 and is based in Central, Hong Kong.",Mr. Daniel  Wong,Shell Companies,6.15,USD,184302591,https://images.financialmodelingprep.com/symbol/BTWN.png,74873,-87.85714285714286,-0.26,159230,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
634,BTWNU,Bridgetown Holdings Limited Units,"Bridgetown Holdings Limited does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the technology, financial services, or media sectors. The company was incorporated in 2020 and is based in Central, Hong Kong.",Mr. Daniel  Wong,Shell Companies,6.14,USD,179469744,https://images.financialmodelingprep.com/symbol/BTWNU.png,1715,8.175765645805592,0.0205,2000,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
635,BTWNW,Bridgetown Holdings Limited Warrants,"As of October 12, 2023, Bridgetown Holdings Limited was acquired by MoneyHero Limited, in a reverse merger transaction. Bridgetown Holdings Limited does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company focuses its search on target companies operating in the technology, financial services, and media sectors in Southeast Asia. Bridgetown Holdings Limited was incorporated in 2020 and is based in Central, Hong Kong.",,Shell Companies,0.1901,USD,2869186,https://images.financialmodelingprep.com/symbol/BTWNW.png,62660,0,-0.0299,64930,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
636,BUSE,First Busey Corporation Class A Common Stock,"First Busey Corporation operates as the bank holding company for Busey Bank that provides retail and commercial banking products and services to individual, corporate, institutional, and governmental customers in the United States. The company operates through three segments: Banking, FirsTech, and Wealth Management. It offers customary types of demand and savings deposits; and commercial, agricultural, real estate construction, commercial and residential real estate, and consumer loans, as well as home equity lines of credit. The company also provides money transfer, safe deposit, IRA, and other fiduciary services through banking center, ATM and technology-based networks. In addition, it offers investment management, trust, estate advisory, and financial planning services, as well as business succession and employee retirement planning services; investment strategy consulting and fiduciary services; and security brokerage services. Further, the company provides asset management, philanthropic advisory, tax preparation, and professional farm management services; and commercial depository services, such as cash management services. Additionally, it offers payment technology solutions through its payment platform, such as walk-in payment processing for customers at retail pay agents; online bill payment solutions; customer service payments accepted over the telephone; mobile bill pay; direct debit services; electronic concentration of payments delivered to automated clearing house network; money management and credit card networks; and lockbox remittance processing to make payments by mail, as well as provides tools related to billing, reconciliation, bill reminders, and treasury services. The company has 46 banking centers in Illinois; 8 in Missouri; 3 in southwest Florida; and 1 in Indianapolis, Indiana. First Busey Corporation was founded in 1868 and is headquartered in Champaign, Illinois.",Mr. Van A. Dukeman CFA,Banks - Regional,22.84,USD,1299098088,https://images.financialmodelingprep.com/symbol/BUSE.png,269967,11.71,-0.42,57566,0,122565000,"[{'period': '2023', 'revenue': 50.82, 'unit': 'M', 'net_profit': 122.56}, {'period': '2022', 'revenue': 450.24, 'unit': 'M', 'net_profit': 128.31}, {'period': '2021', 'revenue': 403.5, 'unit': 'M', 'net_profit': 123.45}, {'period': '2020', 'revenue': 401.2, 'unit': 'M', 'net_profit': 100.34}]","[{'period': ""Q3 '24"", 'revenue': 118.49, 'unit': 'M', 'net_profit': 32.0}, {'period': ""Q2 '24"", 'revenue': 165.78, 'unit': 'M', 'net_profit': 27.36}, {'period': ""Q1 '24"", 'revenue': 160.73, 'unit': 'M', 'net_profit': 26.23}, {'period': ""Q4 '23"", 'revenue': 128.7, 'unit': 'M', 'net_profit': 25.75}, {'period': ""Q3 '23"", 'revenue': 108.8, 'unit': 'M', 'net_profit': 30.67}, {'period': ""Q2 '23"", 'revenue': 106.68, 'unit': 'M', 'net_profit': 29.36}]",2.21,2.18,12283415000,2222251000,2222251000,11011434000,0,2970011000,4770338000,719581000,163857000,1,-0.04478181917372634,-0.047413793103448225,"[0.24, 0.1]","['2024-10-18', '1998-10-16']",__nan__,0.8964472827792597
637,BVS,Bioventus Inc. Class A Common Stock,"Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.",Mr. Robert E. Claypoole,Medical - Devices,9.5294,USD,622915913,https://images.financialmodelingprep.com/symbol/BVS.png,384566,-15.62,-0.3006,270419,-23070000,-156230000,"[{'period': '2023', 'revenue': 512.35, 'unit': 'M', 'net_profit': -156.23}, {'period': '2022', 'revenue': 512.12, 'unit': 'M', 'net_profit': -213.39}, {'period': '2021', 'revenue': 430.9, 'unit': 'M', 'net_profit': 9.59}, {'period': '2020', 'revenue': 321.16, 'unit': 'M', 'net_profit': 16.41}]","[{'period': ""Q3 '24"", 'revenue': 138.96, 'unit': 'M', 'net_profit': -4.82}, {'period': ""Q2 '24"", 'revenue': 151.22, 'unit': 'M', 'net_profit': -23.99}, {'period': ""Q1 '24"", 'revenue': 129.46, 'unit': 'M', 'net_profit': -4.57}, {'period': ""Q4 '23"", 'revenue': 135.42, 'unit': 'M', 'net_profit': -6.1}, {'period': ""Q3 '23"", 'revenue': 120.79, 'unit': 'M', 'net_profit': -7.3}, {'period': ""Q2 '23"", 'revenue': 137.07, 'unit': 'M', 'net_profit': -3.68}]",-2.49,-2.49,810910000,267999000,36964000,589792000,123046000,0,175497000,36964000,7982000,0.7887459365413672,0.2678697789503775,0.2844827586206896,__nan__,__nan__,__nan__,0.7273211577117066
638,BVXV,BiondVax Pharmaceuticals Ltd. American Depositary Shares,"BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Gttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.","Mr. Amir  Reichman M.B.A., M.Sc.",Biotechnology,1.36,USD,4966625,https://images.financialmodelingprep.com/symbol/BVXV.png,38939,-0.5787234042553191,0.01,22668,-10499000,-531000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'K', 'net_profit': -531.0}, {'period': '2021', 'revenue': 2.75, 'unit': 'M', 'net_profit': -50.81}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.82}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -124.11}]","[{'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.76}, {'period': ""Q1 '23"", 'revenue': 2.02, 'unit': 'M', 'net_profit': -3.84}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.6}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.79}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.07}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.42}]",0,0,27067000,14370000,14075000,28827000,110000,0,2338000,14075000,-8101000,0.6763962520034521,0.989549301318638,1,__nan__,__nan__,__nan__,1.0650238297557912
639,BWAC,Better World Acquisition Corp. Common Stock,"Better World Acquisition Corp. does not have significant operations. It intends to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities in the healthy living industries. Better World Acquisition Corp. was incorporated in 2020 and is based in New York, New York.",Ms. Rosemary L. Ripley,Shell Companies,10.85,USD,0,https://images.financialmodelingprep.com/symbol/BWAC.png,6527,-29.324324324324323,-0.02,193,-4350522,3250075,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.25}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.1}]","[{'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -607.37}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -157.18}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 844.15}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 915.7}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.85}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -107.03}]",0.41,0.41,44743088,46464,2369,3861285,0,44696624,3332727,2369,-1334539,0.3201626350897442,0.5474904331587646,-0.3166666666666667,__nan__,__nan__,__nan__,0.08629902790795307
640,BWACU,Better World Acquisition Corp. Unit,"Better World Acquisition Corp. does not have significant operations. It intends to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities in the healthy living industries. Better World Acquisition Corp. was incorporated in 2020 and is based in New York, New York.",Ms. Rosemary L. Ripley,Shell Companies,10.02,USD,0,https://images.financialmodelingprep.com/symbol/BWACU.png,91,55.35911602209945,-0.92,198,-4350522,3250075,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.25}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.1}]","[{'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -607.37}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -157.18}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 844.15}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 915.7}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.85}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -107.03}]",0.41,0.41,44743088,46464,2369,3861285,0,44696624,3332727,2369,-1334539,0.3201626350897442,0.5474904331587646,-0.3166666666666667,__nan__,__nan__,__nan__,0.08629902790795307
641,BWACW,Better World Acquisition Corp. Warrants,,Ms. Rosemary L. Ripley,Shell Companies,0.0035,USD,0,https://images.financialmodelingprep.com/symbol/BWACW.png,0,0,0.0015,300,-4350522,3250075,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.25}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.1}]","[{'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -607.37}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -157.18}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 844.15}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 915.7}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.85}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -107.03}]",0.41,0.41,44743088,46464,2369,3861285,0,44696624,3332727,2369,-1334539,0.3201626350897442,0.5474904331587646,-0.3166666666666667,__nan__,__nan__,__nan__,0.08629902790795307
642,BWAY,BrainsWay Ltd. American Depositary Shares,"Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.",Mr. Hadar  Levy,Medical - Devices,9.65,USD,181547380,https://images.financialmodelingprep.com/symbol/BWAY.png,79000,120.63,0.09,20706,-2311000,-4197000,"[{'period': '2023', 'revenue': 31.79, 'unit': 'M', 'net_profit': -4.2}, {'period': '2022', 'revenue': 27.18, 'unit': 'M', 'net_profit': -13.35}, {'period': '2021', 'revenue': 29.66, 'unit': 'M', 'net_profit': -6.46}, {'period': '2020', 'revenue': 22.06, 'unit': 'M', 'net_profit': -5.38}]","[{'period': ""Q3 '24"", 'revenue': 10500.0, 'unit': 'K', 'net_profit': 662.0}, {'period': ""Q2 '24"", 'revenue': 10010.0, 'unit': 'K', 'net_profit': 600.0}, {'period': ""Q1 '24"", 'revenue': 9100.0, 'unit': 'K', 'net_profit': 111.0}, {'period': ""Q4 '23"", 'revenue': 9030.0, 'unit': 'K', 'net_profit': 127.0}, {'period': ""Q3 '23"", 'revenue': 8300.0, 'unit': 'K', 'net_profit': -230.0}, {'period': ""Q2 '23"", 'revenue': 7.83, 'unit': 'M', 'net_profit': -1.66}]",-0.25,-0.25,62972000,55465000,45985000,21391000,3780000,0,9761000,10520000,-1103000,0.7982364239566964,0.6855944265488052,0.41860465116279066,__nan__,__nan__,__nan__,0.3396906561646446
643,BWB,Bridgewater Bancshares Inc. Common Stock,"Bridgewater Bancshares, Inc. operates as the bank holding company for Bridgewater Bank that provides banking products and services to commercial real estate investors, small business entrepreneurs, and high net worth individuals in the United States. The company offers savings and money market accounts, demand deposits, time and brokered deposits, and interest and noninterest bearing transaction, as well as certificates of deposit. It also provides commercial loans to sole proprietorships, partnerships, corporations, and other business enterprises to finance accounts receivable or inventory, capital assets, or other business-related purposes; paycheck protection program loans; construction and land development loans; 1-4 family mortgage loans; multifamily lending products; owner and non-owner occupied commercial real estate loans; and consumer and other loans. In addition, the company online, mobile, and direct banking services. It operates through seven full-service offices located in Bloomington, Greenwood, Minneapolis, St. Louis Park, Orono, and St. Paul, Minnesota. The company was incorporated in 2005 and is headquartered in Saint Louis Park, Minnesota.",Mr. Gerald John Baack,Banks - Regional,13.025,USD,357219743,https://images.financialmodelingprep.com/symbol/BWB.png,69554,12.4,-0.235,13235,55665000,39960000,"[{'period': '2023', 'revenue': 111.84, 'unit': 'M', 'net_profit': 39.96}, {'period': '2022', 'revenue': 136.03, 'unit': 'M', 'net_profit': 53.39}, {'period': '2021', 'revenue': 114.82, 'unit': 'M', 'net_profit': 45.69}, {'period': '2020', 'revenue': 93.8, 'unit': 'M', 'net_profit': 27.19}]","[{'period': ""Q3 '24"", 'revenue': 0.0009599999999999999, 'unit': 'M', 'net_profit': 8.68}, {'period': ""Q2 '24"", 'revenue': 62.11, 'unit': 'M', 'net_profit': 8.12}, {'period': ""Q1 '24"", 'revenue': 59.73, 'unit': 'M', 'net_profit': 7.83}, {'period': ""Q4 '23"", 'revenue': 59.96, 'unit': 'M', 'net_profit': 8.87}, {'period': ""Q3 '23"", 'revenue': 26.6, 'unit': 'M', 'net_profit': 9.63}, {'period': ""Q2 '23"", 'revenue': 27.29, 'unit': 'M', 'net_profit': 9.82}]",1.29,1.27,4611990000,128562000,128562000,4186475000,0,604104000,1798317000,128562000,27045000,-0.2574336672758561,-0.251573269403656,-0.2752808988764045,__nan__,__nan__,__nan__,0.9077372240616307
644,BWEN,Broadwind Inc. Common Stock,"Broadwind, Inc. manufactures and sells structures, equipment, and components for clean tech and other specialized applications primarily in the United States. It operates through three segments: Heavy Fabrications, Gearing, and Industrial Solutions. The Heavy Fabrications segment provides fabrications to various industrial markets. It offers steel towers and adapters primarily to wind turbine manufacturers. The Gearing segment provides gearing, and gearboxes and systems for onshore and offshore oil and gas fracking and drilling, surface and underground mining, wind energy, steel, material handling, and other infrastructure markets. This segment also offers heat treat services for aftermarket and original equipment manufacturer applications. The Industrial Solutions segment provides supply chain solutions for offering instrumentation and controls, valve assemblies, sensor devices, fuel system components, electrical junction boxes and wiring, energy storage services, and electromechanical devices; light fabrication, inventory management, and kitting and assembly services; packaging solutions; and fabricating services for panels and sub-assemblies to combined cycle natural gas turbine market. The company sells its products to the energy, mining, and infrastructure sector customers through its direct sales force and independent sales agents. The company was formerly known as Broadwind Energy, Inc. and changed its name to Broadwind, Inc. in May 2020. Broadwind, Inc. is headquartered in Cicero, Illinois.",Mr. Eric B. Blashford,Industrial - Machinery,2.1,USD,46439400,https://images.financialmodelingprep.com/symbol/BWEN.png,183606,15,-0.04,266436,17474000,7649000,"[{'period': '2023', 'revenue': 203.48, 'unit': 'M', 'net_profit': 7.65}, {'period': '2022', 'revenue': 176.76, 'unit': 'M', 'net_profit': -9.73}, {'period': '2021', 'revenue': 145.62, 'unit': 'M', 'net_profit': 2.85}, {'period': '2020', 'revenue': 198.5, 'unit': 'M', 'net_profit': -1.49}]","[{'period': ""Q3 '24"", 'revenue': 35500.0, 'unit': 'K', 'net_profit': 74.0}, {'period': ""Q2 '24"", 'revenue': 36450.0, 'unit': 'K', 'net_profit': 482.0}, {'period': ""Q1 '24"", 'revenue': 37.62, 'unit': 'M', 'net_profit': 1.51}, {'period': ""Q4 '23"", 'revenue': 46.6, 'unit': 'M', 'net_profit': 1.07}, {'period': ""Q3 '23"", 'revenue': 57.16, 'unit': 'M', 'net_profit': 4.39}, {'period': ""Q2 '23"", 'revenue': 50.84, 'unit': 'M', 'net_profit': 1.42}]",0.36,0.36,135156000,69746000,1099000,79137000,27742000,0,53612000,1099000,-13351000,42.90407673860911,1.7861253854059609,1.75,__nan__,__nan__,__nan__,0.585523395187783
645,BWFG,Bankwell Financial Group Inc. Common Stock,"Bankwell Financial Group, Inc. operates as the bank holding company for Bankwell Bank that provides various banking services for individual and commercial customers. It offers various traditional depository products, including checking, savings, money market, and certificates of deposit. The company also provides first mortgage loans secured by one-to-four family owner occupied residential properties for personal use; home equity loans and home equity lines of credit secured by owner occupied one-to-four family residential properties; loans secured by commercial real estate, multi-family dwellings, and investor-owned one-to-four family dwellings; commercial construction loans for commercial development projects, including apartment buildings and condominiums, as well as office buildings, retail, and other income producing properties; land loans; commercial business loans secured by assignments of corporate assets and personal guarantees of the business owners; loans secured by savings or certificate accounts and automobiles; and unsecured personal loans and overdraft lines of credit. It operates branches in New Canaan, Stamford, Fairfield, Wilton, Westport, Darien, Norwalk, and Hamden, Connecticut. The company was formerly known as BNC Financial Group, Inc. and changed its name to Bankwell Financial Group, Inc. in September 2013. Bankwell Financial Group, Inc. was founded in 2002 and is headquartered in New Canaan, Connecticut.",Mr. Christopher R. Gruseke,Banks - Regional,28.58,USD,224597931,https://images.financialmodelingprep.com/symbol/BWFG.png,15617,14.66,-0.9,5738,51666000,36663000,"[{'period': '2023', 'revenue': 99.31, 'unit': 'M', 'net_profit': 36.66}, {'period': '2022', 'revenue': 97.78, 'unit': 'M', 'net_profit': 37.43}, {'period': '2021', 'revenue': 73.54, 'unit': 'M', 'net_profit': 26.59}, {'period': '2020', 'revenue': 57.72, 'unit': 'M', 'net_profit': 5.9}]","[{'period': ""Q3 '24"", 'revenue': 21.87, 'unit': 'M', 'net_profit': 1.93}, {'period': ""Q2 '24"", 'revenue': 48.55, 'unit': 'M', 'net_profit': 1.12}, {'period': ""Q1 '24"", 'revenue': 49.23, 'unit': 'M', 'net_profit': 3.76}, {'period': ""Q4 '23"", 'revenue': 50.52, 'unit': 'M', 'net_profit': 8.52}, {'period': ""Q3 '23"", 'revenue': 23.48, 'unit': 'M', 'net_profit': 9.78}, {'period': ""Q2 '23"", 'revenue': 25.39, 'unit': 'M', 'net_profit': 7.98}]",4.71,4.67,3215482000,269157000,269157000,2949730000,0,14515000,34690000,267521000,29882000,0.006173440573331516,-0.02046541451815437,-0.026859504132231385,"[0.2, 0.05]","['2024-11-08', '2015-12-09']",__nan__,0.9173523596151371
646,BWMN,Bowman Consulting Group Ltd. Common Stock,"Bowman Consulting Group Ltd. provides a range of real estate, energy, infrastructure, and environmental management solutions in the United States. It offers civil and site engineering services, such as conceptual land planning, environmental consulting and permitting, planning/zoning and entitlements, roadway and highway designs, erosion and sediment designs, stormwater management designs, construction administration, traffic studies, floodplain studies, and utility relocation designs; and commissioning and energy efficiency services comprise construction observation, direct systems functional performance testing, system development readiness checklist, post occupancy review, review of construction documents, deferred/seasonal functional testing, final commissioning report, and commissioning review of submittals. The company also provides construction management services, including constructability review, value engineering, budgeting and cost estimating, interagency and utility coordination, onsite observation and report evaluation, public communication and outreach, and resident engineer services, as well as bid solicitation, documentation, and preparation services; and environmental consulting services consisting of wetlands and waters of the U.S. delineations, natural resources inventories, wildlife and vegetation surveys, threatened and endangered species surveys, endangered species conservation and management, wetland creation and enhancement design, NEPA documentation, section 404/401 permitting and compliance, NPDES permitting, and phase I environmental site assessment. In addition, it offers landscape architecture, land procurement and right-of-way acquisition, structural engineering, surveying and geospatial engineering, and transportation and water resources engineering services, as well as mechanical, electrical, and plumbing engineering services. Bowman Consulting Group Ltd. was incorporated in 1995 and is headquartered in Reston, Virginia.",Mr. Gary P. Bowman,Engineering & Construction,24.775,USD,434300795,https://images.financialmodelingprep.com/symbol/BWMN.png,81709,-31.36,-0.525,13540,17656000,-6624000,"[{'period': '2023', 'revenue': 346.26, 'unit': 'M', 'net_profit': -6.62}, {'period': '2022', 'revenue': 261.71, 'unit': 'M', 'net_profit': 5.0}, {'period': '2021', 'revenue': 149970.0, 'unit': 'K', 'net_profit': 299.0}, {'period': '2020', 'revenue': 122020.0, 'unit': 'K', 'net_profit': 990.0}]","[{'period': ""Q3 '24"", 'revenue': 113930.0, 'unit': 'K', 'net_profit': 771.0}, {'period': ""Q2 '24"", 'revenue': 104.5, 'unit': 'M', 'net_profit': -2.08}, {'period': ""Q1 '24"", 'revenue': 94.91, 'unit': 'M', 'net_profit': -1.56}, {'period': ""Q4 '23"", 'revenue': 92.97, 'unit': 'M', 'net_profit': -7.71}, {'period': ""Q3 '23"", 'revenue': 94.43, 'unit': 'M', 'net_profit': 1.18}, {'period': ""Q2 '23"", 'revenue': 82750.0, 'unit': 'K', 'net_profit': -634.0}]",-0.53,-0.53,402785000,154777000,20687000,239504000,122284000,0,126756000,20687000,9629000,0.021227370004048816,-2.3234765234765233,-2.358974358974359,__nan__,__nan__,__nan__,0.5946199585386744
647,BWMX,Betterware de Mexico S.A.B. de C.V. Ordinary Shares,"Betterware de Mxico, S.A.P.I. de C.V. operates as a direct-to-consumer company in Mexico. It focuses on the home organization segment with a product portfolio, including home solutions, kitchen and food preservation, technology and mobility, bedroom, bathroom, laundry and cleaning, and other categories. The company sells its products through twelve catalogues. Betterware de Mxico, S.A.P.I. de C.V. was incorporated in 1995 and is based in Zapopan, Mexico. Betterware de Mxico, S.A.P.I. de C.V. is a subsidiary of Campalier, S.A. de C.V.",Mr. Andres Campos Chevallier,Specialty Retail,10.85,USD,404884025,https://images.financialmodelingprep.com/symbol/BWMX.png,28658,9.52,-0.13,10198,2626518000,1049461000,"[{'period': '2023', 'revenue': 13.01, 'unit': 'B', 'net_profit': 1.05}, {'period': '2022', 'revenue': 11500.0, 'unit': 'M', 'net_profit': 872.56}, {'period': '2021', 'revenue': 10.04, 'unit': 'B', 'net_profit': 1.75}, {'period': '2020', 'revenue': 7260.0, 'unit': 'M', 'net_profit': 298.44}]","[{'period': ""Q3 '24"", 'revenue': 3330.0, 'unit': 'M', 'net_profit': -115.61}, {'period': ""Q2 '24"", 'revenue': 3390.0, 'unit': 'M', 'net_profit': 300.77}, {'period': ""Q1 '24"", 'revenue': 3600.0, 'unit': 'M', 'net_profit': 294.15}, {'period': ""Q4 '23"", 'revenue': 3400.0, 'unit': 'M', 'net_profit': 406.1}, {'period': ""Q3 '23"", 'revenue': 3120.0, 'unit': 'M', 'net_profit': 196.99}, {'period': ""Q2 '23"", 'revenue': 3220.0, 'unit': 'M', 'net_profit': 258.37}]",28.16,28.16,11088140000,3992087000,549730000,9615127000,1102021000,0,3826235000,549730000,2235713000,0.18423270227290864,0.20274205581984903,0.3055169216504404,"[0.3378, 0.131]","['2024-11-08', '2020-05-28']",__nan__,0.8671541845611618
648,BXRX,Baudax Bio Inc. Common Stock,"Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.",Dr. Geraldine A. Henwood Ph.D.,Biotechnology,0.0218,USD,0,https://images.financialmodelingprep.com/symbol/BXRX.png,424847,-0.00023159460320832891,0.0015,310872,-35578000,-58795000,"[{'period': '2022', 'revenue': 1.27, 'unit': 'M', 'net_profit': -58.8}, {'period': '2021', 'revenue': 1.08, 'unit': 'M', 'net_profit': -19.77}, {'period': '2020', 'revenue': 0.493, 'unit': 'M', 'net_profit': -76.1}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.0}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.93}, {'period': ""Q2 '23"", 'revenue': 0.03, 'unit': 'M', 'net_profit': -7.38}, {'period': ""Q1 '23"", 'revenue': -0.014, 'unit': 'M', 'net_profit': 11.4}, {'period': ""Q4 '22"", 'revenue': 0.31, 'unit': 'M', 'net_profit': -9.25}, {'period': ""Q3 '22"", 'revenue': 0.23800000000000002, 'unit': 'M', 'net_profit': -29.2}, {'period': ""Q2 '22"", 'revenue': 0.3, 'unit': 'M', 'net_profit': -7.53}]",-177.3,-177.3,10032000,6347000,5259000,34274000,335000,0,21460000,5259000,-27813000,0.2627849150435143,-1.974100864990642,0.5090818473806623,__nan__,__nan__,__nan__,3.416467304625199
649,BYFC,Broadway Financial Corporation Common Stock,"Broadway Financial Corporation operates as the holding company for City First Bank, National Association that provides various banking products and services in the United States. It accepts various deposit accounts, including savings accounts, checking accounts, NOW accounts, money market accounts, and fixed-term certificates of deposit. The company also offers mortgage loans, which are secured by multi-family residential properties; single family residential properties; and commercial real estate, including charter schools, community facilities, and churches, as well as commercial business, construction, and consumer loans. In addition, it invests in securities issued by federal government agencies, residential mortgage-backed securities, and other investments. The company operates through three branch offices. Broadway Financial Corporation was founded in 1946 and is headquartered in Los Angeles, California.",Mr. Brian E. Argrett,Banks - Regional,7.49,USD,68251614,https://images.financialmodelingprep.com/symbol/BYFC.png,7812,26.75,0.39,9904,7298000,4514000,"[{'period': '2023', 'revenue': 33.89, 'unit': 'M', 'net_profit': 4.51}, {'period': '2022', 'revenue': 34.05, 'unit': 'M', 'net_profit': 5.64}, {'period': '2021', 'revenue': 24.22, 'unit': 'M', 'net_profit': -3.95}, {'period': '2020', 'revenue': 13080.0, 'unit': 'K', 'net_profit': -642.0}]","[{'period': ""Q3 '24"", 'revenue': 16580.0, 'unit': 'K', 'net_profit': 522.0}, {'period': ""Q2 '24"", 'revenue': 15760.0, 'unit': 'K', 'net_profit': 269.0}, {'period': ""Q1 '24"", 'revenue': 15100.0, 'unit': 'K', 'net_profit': -168.0}, {'period': ""Q4 '23"", 'revenue': 17.09, 'unit': 'M', 'net_profit': 2.61}, {'period': ""Q3 '23"", 'revenue': 12260.0, 'unit': 'K', 'net_profit': 91.0}, {'period': ""Q2 '23"", 'revenue': 7530.0, 'unit': 'K', 'net_profit': 243.0}]",0.52,0.51,1375404000,105195000,105195000,1093307001,4938000,316950000,12859000,105195000,7386000,-0.18275475923852183,-0.19907735982966643,-0.16129032258064513,"[0.01, 0.05]","['2010-04-08', '1996-04-11']",__nan__,0.7948988086409521
650,BYND,Beyond Meat Inc. Common Stock,"Beyond Meat, Inc. manufactures, markets, and sells plant-based meat products in the United States and internationally. The company sells a range of plant-based meat products across the platforms of beef, pork, and poultry. It sells its products through grocery, mass merchandiser, club store, convenience store and natural retailer channels, and direct-to-consumer, as well as various food-away-from-home channels, including restaurants, foodservice outlets, and schools. The company was formerly known as Savage River, Inc. and changed its name to Beyond Meat, Inc. in September 2018. Beyond Meat, Inc. was founded in 2009 and is headquartered in El Segundo, California.",Mr. Ethan  Brown,Packaged Foods,3.745,USD,244186359,https://images.financialmodelingprep.com/symbol/BYND.png,3285380,-0.89,-0.165,1508728,-282188000,-338144000,"[{'period': '2023', 'revenue': 343.38, 'unit': 'M', 'net_profit': -338.14}, {'period': '2022', 'revenue': 418.93, 'unit': 'M', 'net_profit': -347.19}, {'period': '2021', 'revenue': 464.7, 'unit': 'M', 'net_profit': -179.13}, {'period': '2020', 'revenue': 406.79, 'unit': 'M', 'net_profit': -52.75}]","[{'period': ""Q3 '24"", 'revenue': 81.01, 'unit': 'M', 'net_profit': -26.58}, {'period': ""Q2 '24"", 'revenue': 93.19, 'unit': 'M', 'net_profit': -34.48}, {'period': ""Q1 '24"", 'revenue': 75.6, 'unit': 'M', 'net_profit': -54.36}, {'period': ""Q4 '23"", 'revenue': 73.68, 'unit': 'M', 'net_profit': -155.11}, {'period': ""Q3 '23"", 'revenue': 75.31, 'unit': 'M', 'net_profit': -70.49}, {'period': ""Q2 '23"", 'revenue': 102.15, 'unit': 'M', 'net_profit': -53.51}]",-5.26,-5.26,774450000,372844000,190505000,1287818000,31730000,1673000,74354000,190505000,-118389000,0.0761322935287223,0.026052092664226114,0.03663003663003666,__nan__,__nan__,__nan__,1.662880754083543
651,BYRN,Byrna Technologies Inc. Common Stock,"Byrna Technologies Inc., a less-lethal defense technology company, develops and manufactures less-lethal munitions. It offers a Byrna line of handheld personal security devices, including the Byrna SD and Byrna SD .68 caliber handheld personal security devices that are designed to be used by civilians and private security professionals, as well as Byrna HD magazines, shoulder-fired launchers, and projectiles. The company also offers accessories and related safety products, including the Byrna Banshee, Byrna Shield, compressed carbon dioxide canisters, sighting systems, holsters, and Byrna-branded apparels. It operates in the United States and South Africa. The company was formerly known as Security Devices International, Inc. and changed its name to Byrna Technologies Inc. in March 2020. Byrna Technologies Inc. was incorporated in 2005 and is headquartered in Andover, Massachusetts.",Mr. Bryan Scott Ganz J.D.,Aerospace & Defense,26.73,USD,600863670,https://images.financialmodelingprep.com/symbol/BYRN.png,580732,243,-0.87,180939,-6528000,-8192000,"[{'period': '2023', 'revenue': 42.64, 'unit': 'M', 'net_profit': -8.19}, {'period': '2022', 'revenue': 48.04, 'unit': 'M', 'net_profit': -7.88}, {'period': '2021', 'revenue': 42.16, 'unit': 'M', 'net_profit': -3.28}, {'period': '2020', 'revenue': 16.57, 'unit': 'M', 'net_profit': -12.55}]","[{'period': ""Q3 '24"", 'revenue': 20.85, 'unit': 'M', 'net_profit': 1.02}, {'period': ""Q2 '24"", 'revenue': 20.27, 'unit': 'M', 'net_profit': 2.08}, {'period': ""Q1 '24"", 'revenue': 16650.0, 'unit': 'K', 'net_profit': 17.0}, {'period': ""Q4 '23"", 'revenue': 15640.0, 'unit': 'K', 'net_profit': -829.0}, {'period': ""Q3 '23"", 'revenue': 7.08, 'unit': 'M', 'net_profit': -4.09}, {'period': ""Q2 '23"", 'revenue': 11.51, 'unit': 'M', 'net_profit': -1.12}]",-0.37,-0.37,52314000,38201000,20498000,9995000,2945000,0,8646000,20498000,2989000,0.0506108202443281,-0.03893468611287254,-0.0571428571428572,__nan__,__nan__,__nan__,0.1910578430248117
652,BYSI,BeyondSpring Inc. Ordinary Shares,"BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.",Dr. Lan  Huang Ph.D.,Biotechnology,1.7,USD,68510680,https://images.financialmodelingprep.com/symbol/BYSI.png,25066,-4.25,0.04,1458,-21540000,-21026000,"[{'period': '2023', 'revenue': 1.75, 'unit': 'M', 'net_profit': -21.03}, {'period': '2022', 'revenue': 1.35, 'unit': 'M', 'net_profit': -36.28}, {'period': '2021', 'revenue': 1.35, 'unit': 'M', 'net_profit': -68.21}, {'period': '2020', 'revenue': 0.18, 'unit': 'M', 'net_profit': -61.06}]","[{'period': ""Q2 '24"", 'revenue': 0.5, 'unit': 'M', 'net_profit': -3.63}, {'period': ""Q1 '24"", 'revenue': 0.5, 'unit': 'M', 'net_profit': -3.63}, {'period': ""Q4 '23"", 'revenue': 0.438, 'unit': 'M', 'net_profit': -4.15}, {'period': ""Q3 '23"", 'revenue': 0.438, 'unit': 'M', 'net_profit': -4.15}, {'period': ""Q2 '23"", 'revenue': 0.4375, 'unit': 'M', 'net_profit': -6.36}, {'period': ""Q1 '23"", 'revenue': 0.4375, 'unit': 'M', 'net_profit': -6.36}]",-0.54,-0.54,24808000,18419000,8002000,48269000,0,0,7958000,7809000,-16574000,0.38379677308616544,0.42045203969128997,0.41935483870967744,__nan__,__nan__,__nan__,1.94570299903257
653,BYTS,BYTE Acquisition Corp. Class A Ordinary Shares,"BYTE Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus its search for targets in the Israeli technology industry, including cybersecurity, automotive technology, fintech, enterprise software, cloud computing, semiconductors, medical technology, artificial intelligence, and robotics. The company was incorporated in 2021 and is based in New York, New York.",Mr. Samuel  Gloor,Shell Companies,6.49,USD,71129751,https://images.financialmodelingprep.com/symbol/BYTS.png,13482,-108.16666666666667,-3.97,320028,-1397009,22658937,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 22.66}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.02}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.49}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.82}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.0}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 12.2}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.29}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.12}]",0.55,0.55,329414104,1187672,1054581,13099122,0,328226432,433834,1054581,-608523,0.8233500405773849,3.5132182149763014,2.666666666666667,__nan__,__nan__,__nan__,0.039764909398050545
654,BYTSU,BYTE Acquisition Corp. Units,"BYTE Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus its search for targets in the Israeli technology industry, including cybersecurity, automotive technology, fintech, enterprise software, cloud computing, semiconductors, medical technology, artificial intelligence, and robotics. The company was incorporated in 2021 and is based in New York, New York.",Mr. Samuel  Gloor,Shell Companies,6.36,USD,59631360,https://images.financialmodelingprep.com/symbol/BYTSU.png,368,23.043478260869566,-3.69,14185,-1397009,22658937,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 22.66}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.02}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.49}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.82}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.0}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 12.2}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.29}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.12}]",0.55,0.55,329414104,1187672,1054581,13099122,0,328226432,433834,1054581,-608523,0.8233500405773849,3.5132182149763014,2.666666666666667,__nan__,__nan__,__nan__,0.039764909398050545
655,BYTSW,BYTE Acquisition Corp. Warrants,"BYTE Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded in 2021 and is based in New York, New York.",Mr. Samuel  Gloor,Shell Companies,0.12,USD,1125120,https://images.financialmodelingprep.com/symbol/BYTSW.png,0,0,0.045,141015,-1397009,22658937,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 22.66}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.02}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.49}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.82}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.0}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 12.2}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.29}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.12}]",0.55,0.55,329414104,1187672,1054581,13099122,0,328226432,433834,1054581,-608523,0.8233500405773849,3.5132182149763014,2.666666666666667,__nan__,__nan__,__nan__,0.039764909398050545
656,BZUN,Baozun Inc. American Depositary Shares,"Baozun Inc., through its subsidiaries, provides e-commerce solutions to brand partners in the People's Republic of China. The company offers IT infrastructure setup and integration, online store design and setup, online store operations, visual merchandising and marketing campaigns, customer services, and warehousing and order fulfilment. It serves brand partners in various categories, including apparel and accessories; appliances; electronics; home and furnishings; food and health products; beauty and cosmetics; fast moving consumer goods, and mother and baby products; and automobiles. The company was formerly known as Baozun Cayman Inc. and changed its name to Baozun Inc. in March 2015. Baozun Inc. was founded in 2007 and is headquartered in Shanghai, the People's Republic of China.",Mr. Wenbin  Qiu,Specialty Retail,3.04,USD,169176708,https://images.financialmodelingprep.com/symbol/BZUN.png,667438,-4.9,,0,75946000,-278422000,"[{'period': '2023', 'revenue': 8810.0, 'unit': 'M', 'net_profit': -278.42}, {'period': '2022', 'revenue': 8400.0, 'unit': 'M', 'net_profit': -606.79}, {'period': '2021', 'revenue': 9400.0, 'unit': 'M', 'net_profit': -209.26}, {'period': '2020', 'revenue': 8850.0, 'unit': 'M', 'net_profit': 425.99}]","[{'period': ""Q3 '24"", 'revenue': 2060.0, 'unit': 'M', 'net_profit': -88.07}, {'period': ""Q2 '24"", 'revenue': 2390.0, 'unit': 'M', 'net_profit': -30.62}, {'period': ""Q1 '24"", 'revenue': 1980.0, 'unit': 'M', 'net_profit': -66.64}, {'period': ""Q4 '23"", 'revenue': 2780.0, 'unit': 'M', 'net_profit': -48.41}, {'period': ""Q3 '23"", 'revenue': 1820.0, 'unit': 'M', 'net_profit': -126.43}, {'period': ""Q2 '23"", 'revenue': 2320.0, 'unit': 'M', 'net_profit': -20.03}]",-4.68,-4.68,10474476000,7290784000,2870053000,4622740000,2271390000,359129000,3757960000,2149531000,283248000,1.2323587722733502,0.541154406481341,0.5287009063444109,__nan__,__nan__,__nan__,0.44133377173235205
657,CAAS,China Automotive Systems Inc. Common Stock,"China Automotive Systems, Inc., through its subsidiaries, manufactures and sells automotive systems and components in the People's Republic of China. It produces rack and pinion power steering gears for cars and light-duty vehicles; integral power steering gears for heavy-duty vehicles; power steering parts for light duty vehicles; sensor modules; automobile steering systems and columns; and automobile electronic and hydraulic power steering systems and parts. The company also offers automotive motors and electromechanical integrated systems; polymer materials; and intelligent automotive technology research and development services. In addition, it provides after sales services, and research and development support services, as well as markets automotive parts in North America and Brazil. The company primarily sells its products to the original equipment manufacturing customers. China Automotive Systems, Inc. was incorporated in 1999 and is headquartered in Jingzhou, the People's Republic of China.",Mr. Qizhou  Wu,Auto - Parts,4,USD,120742800,https://images.financialmodelingprep.com/symbol/CAAS.png,49322,3.85,-0.01,25066,68177000,37658000,"[{'period': '2023', 'revenue': 576.35, 'unit': 'M', 'net_profit': 37.66}, {'period': '2022', 'revenue': 529.55, 'unit': 'M', 'net_profit': 21.18}, {'period': '2021', 'revenue': 497.99, 'unit': 'M', 'net_profit': 4.39}, {'period': '2020', 'revenue': 417.64, 'unit': 'M', 'net_profit': -14.36}]","[{'period': ""Q3 '24"", 'revenue': 164.22, 'unit': 'M', 'net_profit': 5.5}, {'period': ""Q2 '24"", 'revenue': 158.61, 'unit': 'M', 'net_profit': 7.14}, {'period': ""Q1 '24"", 'revenue': 139.39, 'unit': 'M', 'net_profit': 8.27}, {'period': ""Q4 '23"", 'revenue': 159.16, 'unit': 'M', 'net_profit': 10.88}, {'period': ""Q3 '23"", 'revenue': 137.54, 'unit': 'M', 'net_profit': 9.49}, {'period': ""Q2 '23"", 'revenue': 137.41, 'unit': 'M', 'net_profit': 10.47}]",1.25,1.25,766440000,564075000,125744000,398018000,269406000,68820000,383739000,114660000,-1774000,0.3639218981314768,0.7779141683584344,0.8115942028985509,"[0.8, 0.18]","['2024-07-30', '2014-06-24']",__nan__,0.519307447419237
658,CABA,Cabaletta Bio Inc. Common Stock,"Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.",Dr. Steven A. Nichtberger M.D.,Biotechnology,2.675,USD,130746510,https://images.financialmodelingprep.com/symbol/CABA.png,2420264,-1.24,0.015,720853,-73234000,-67675000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -67.67}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -51.81}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -45.53}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -32.49}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.63}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -27.6}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -25.05}, {'period': ""Q4 '23"", 'revenue': 4.01, 'unit': 'M', 'net_profit': -20.89}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.45}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.49}]",-1.65,-1.65,253650000,244490000,241249000,17452000,0,0,15994000,193238000,-54236000,-0.38279111043975755,-0.3061898052537106,0.06779661016949158,__nan__,__nan__,__nan__,0.06880346934752612
659,CAC,Camden National Corporation Common Stock,"Camden National Corporation operates as the bank holding company for Camden National Bank that provides various commercial and consumer banking products and services for consumer, institutional, municipal, non-profit, and commercial customers. The company accepts checking, savings, time, and brokered deposits, as well as deposits with the certificate of deposit account registry system. It also offers non-owner-occupied commercial estate loans, owner-occupied commercial real estate loans, unsecured fully-guaranteed commercial loans backed by the U.S. small business administration, loans secured by one-to four-family properties, and consumer and home equity loans. In addition, the company provides brokerage and insurance services through its financial offerings consisting of college, retirement, estate planning, mutual funds, strategic asset management accounts, and variable and fixed annuities. Further, it offers a range of fiduciary and asset management, wealth management, investment management, financial planning, and trustee services. As of December 31, 2021, the company had 57 branches within Maine; one residential mortgage lending office in Braintree, Massachusetts; two locations in New Hampshire, including a branch in Portsmouth and a commercial loan production office in Manchester; and an online residential mortgage and small commercial digital loan platform, as well as 66 ATMs. Camden National Corporation was founded in 1875 and is headquartered in Camden, Maine.",Mr. Simon R. Griffiths,Banks - Regional,41.545,USD,605609774,https://images.financialmodelingprep.com/symbol/CAC.png,59143,12.98,-0.315,25869,57799000,43383000,"[{'period': '2023', 'revenue': 161.2, 'unit': 'M', 'net_profit': 43.38}, {'period': '2022', 'revenue': 183.79, 'unit': 'M', 'net_profit': 61.44}, {'period': '2021', 'revenue': 182.86, 'unit': 'M', 'net_profit': 69.01}, {'period': '2020', 'revenue': 183.04, 'unit': 'M', 'net_profit': 59.49}]","[{'period': ""Q3 '24"", 'revenue': 43.62, 'unit': 'M', 'net_profit': 13.07}, {'period': ""Q2 '24"", 'revenue': 72.94, 'unit': 'M', 'net_profit': 11.99}, {'period': ""Q1 '24"", 'revenue': 70.5, 'unit': 'M', 'net_profit': 13.27}, {'period': ""Q4 '23"", 'revenue': 59.8, 'unit': 'M', 'net_profit': 8.48}, {'period': ""Q3 '23"", 'revenue': 57.67, 'unit': 'M', 'net_profit': 9.79}, {'period': ""Q2 '23"", 'revenue': 41.54, 'unit': 'M', 'net_profit': 12.39}]",2.98,2.97,5714506000,703457000,703457000,5219442000,0,1175386000,3008828000,99804000,64886000,-0.2878563859934452,-0.2938849916177021,-0.2870813397129186,"[0.42, 0.35]","['2025-01-15', '1997-10-21']",__nan__,0.9133671396967646
660,CACC,Credit Acceptance Corporation Common Stock,"Credit Acceptance Corporation provides financing programs, and related products and services to independent and franchised automobile dealers in the United States. The company advances money to dealers in exchange for the right to service the underlying consumer loans; and buys the consumer loans from the dealers and keeps various amounts collected from the consumers. It is also involved in the business of reinsuring coverage under vehicle service contracts sold to consumers by dealers on vehicles financed by the company. The company was founded in 1972 and is headquartered in Southfield, Michigan.",Mr. Kenneth S. Booth,Financial - Credit Services,468.94,USD,5679848174,https://images.financialmodelingprep.com/symbol/CACC.png,65461,31.41,-1.85,16756,373900000,286100000,"[{'period': '2023', 'revenue': 1900.0, 'unit': 'M', 'net_profit': 286.1}, {'period': '2022', 'revenue': 1180.0, 'unit': 'M', 'net_profit': 535.8}, {'period': '2021', 'revenue': 1800.0, 'unit': 'M', 'net_profit': 958.3}, {'period': '2020', 'revenue': 1620.0, 'unit': 'M', 'net_profit': 421.0}]","[{'period': ""Q3 '24"", 'revenue': 543.6, 'unit': 'M', 'net_profit': 78.8}, {'period': ""Q2 '24"", 'revenue': 538.2, 'unit': 'M', 'net_profit': -47.1}, {'period': ""Q1 '24"", 'revenue': 508.0, 'unit': 'M', 'net_profit': 64.3}, {'period': ""Q4 '23"", 'revenue': 491.6, 'unit': 'M', 'net_profit': 93.6}, {'period': ""Q3 '23"", 'revenue': 473.2, 'unit': 'M', 'net_profit': 70.8}, {'period': ""Q2 '23"", 'revenue': 460.8, 'unit': 'M', 'net_profit': 22.2}]",22.09,21.99,7610200000,13200000,13200000,5856500000,4300000,86300000,399800000,13200000,1199800000,-0.4746381902487003,-0.4660321015304218,-0.44075949367088607,__nan__,__nan__,__nan__,0.769559275708917
661,CAHC,CA Healthcare Acquisition Corp. Class A Common Stock,"CA Healthcare Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more operating businesses. CA Healthcare Acquisition Corp. was founded in 2020 and is based in Boston, Massachusetts.",Mr. Larry J. Neiterman,Shell Companies,9.94,USD,0,https://images.financialmodelingprep.com/symbol/CAHC.png,243436,0,-0.03000069,1383727,,,[],"[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.37}]",,,150698,9498,9498,127961,0,0,127961,9498,,,,,__nan__,__nan__,__nan__,0.8491220852300628
662,CAHCU,CA Healthcare Acquisition Corp. Unit,,,,,,,,,0,0.19999981,1,,,[],"[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.37}]",,,150698,9498,9498,127961,0,0,127961,9498,,,,,__nan__,__nan__,__nan__,0.8491220852300628
663,CAHCW,CA Healthcare Acquisition Corp. Warrant,"CA Healthcare Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more operating businesses. CA Healthcare Acquisition Corp. was founded in 2020 and is based in Boston, Massachusetts.",Mr. Larry J. Neiterman,Shell Companies,1.31,USD,0,https://images.financialmodelingprep.com/symbol/CAHCW.png,0,0,0.07999992,67091,,,[],"[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.37}]",,,150698,9498,9498,127961,0,0,127961,9498,,,,,__nan__,__nan__,__nan__,0.8491220852300628
664,CAKE,Cheesecake Factory Incorporated (The) Common Stock,"The Cheesecake Factory Incorporated operates restaurants. It operates two bakeries that produces cheesecakes and other baked products for its restaurants, international licensees, third-party bakery customers, external foodservice operators, retailers, and distributors. The company owns and operates 306 restaurants throughout the United States and Canada under brands, including 208 The Cheesecake Factory and 29 North Italia; and a collection of Fox Restaurant Concepts, as well as 29 The Cheesecake Factory restaurants under licensing agreements internationally. The Cheesecake Factory Incorporated was founded in 1972 and is headquartered in Calabasas, California.",Mr. David M. Overton,Restaurants,50.3,USD,2567296910,https://images.financialmodelingprep.com/symbol/CAKE.png,1144206,19.05,,0,202902000,101351000,"[{'period': '2023', 'revenue': 3440.0, 'unit': 'M', 'net_profit': 101.35}, {'period': '2022', 'revenue': 3300.0, 'unit': 'M', 'net_profit': 43.12}, {'period': '2021', 'revenue': 2930.0, 'unit': 'M', 'net_profit': 72.37}, {'period': '2020', 'revenue': 1980.0, 'unit': 'M', 'net_profit': -253.37}]","[{'period': ""Q3 '24"", 'revenue': 865.47, 'unit': 'M', 'net_profit': 29.99}, {'period': ""Q2 '24"", 'revenue': 904.04, 'unit': 'M', 'net_profit': 52.44}, {'period': ""Q1 '24"", 'revenue': 891.22, 'unit': 'M', 'net_profit': 33.19}, {'period': ""Q4 '23"", 'revenue': 877.01, 'unit': 'M', 'net_profit': 12.68}, {'period': ""Q3 '23"", 'revenue': 830.21, 'unit': 'M', 'net_profit': 17.95}, {'period': ""Q2 '23"", 'revenue': 866.17, 'unit': 'M', 'net_profit': 42.67}]",2.1,2.07,2840383000,300798000,56290000,2522321000,79428000,0,660671000,56290000,65178000,0.16296211383045797,1.350277114300953,1.4137931034482758,"[0.27, 0.12]","['2024-11-13', '2012-08-06']",__nan__,0.8880214393622269
665,CALA,Calithera Biosciences Inc. Common Stock,"Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.",Ms. Stephanie  Wong CPA,Biotechnology,0.0003,USD,1462,https://images.financialmodelingprep.com/symbol/CALA.png,2957,0,0,10000,-38265000,-18866000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.87}, {'period': '2021', 'revenue': 9.75, 'unit': 'M', 'net_profit': -165.34}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -88.52}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -86.35}]","[{'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.94}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.8}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 10.22}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.84}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -120.02}, {'period': ""Q3 '21"", 'revenue': 6.75, 'unit': 'M', 'net_profit': -11.17}]",-7.94,-7.94,28676000,26624000,25451000,8284000,0,0,7390000,25451000,-43741000,0.6685090052238095,0.8858943497562569,0.8226490953763682,__nan__,__nan__,__nan__,0.28888268935695355
666,CALB,California BanCorp Common Stock,"California BanCorp operates as the bank holding company for California Bank of Commerce that provides commercial banking services in California. It accepts various deposit products, including commercial checking, savings, and money market accounts, as well as certificates of deposit. The company also offers asset-based lending loans; standby letters of credit; construction and development loans; real estate loans, such as commercial real estate loans and other loans; small business administration (SBA) loans, including SBA 7(a) and SBA 504 loans; consumer loans, such as secured and unsecured installment loans, and revolving lines of credit; and commercial and industrial loans, including term loans, working capital, accounts receivable and inventory financing, and other business loans to the dental and veterinary industries, contractors, and emerging companies. In addition, it provides foreign exchange, treasury and cash management, and online and mobile banking services. The company has a full-service branch in California located in Contra Costa County, California; and 4 loan production offices in Alameda, Contra Costa, Sacramento, and Santa Clara. California BanCorp was incorporated in 2007 and is headquartered in Oakland, California.",Mr. Steven E. Shelton,Banks - Regional,25.09,USD,212563484,https://images.financialmodelingprep.com/symbol/CALB.png,53288,24.359223300970875,0.26,122789,945000,21633000,"[{'period': '2023', 'revenue': 114.08, 'unit': 'M', 'net_profit': 21.63}, {'period': '2022', 'revenue': 78.35, 'unit': 'M', 'net_profit': 21.11}, {'period': '2021', 'revenue': 58.9, 'unit': 'M', 'net_profit': 13.37}, {'period': '2020', 'revenue': 48.93, 'unit': 'M', 'net_profit': 4.3}]","[{'period': ""Q2 '24"", 'revenue': 28.27, 'unit': 'M', 'net_profit': -5.86}, {'period': ""Q1 '24"", 'revenue': 29.09, 'unit': 'M', 'net_profit': 3.82}, {'period': ""Q4 '23"", 'revenue': 29.74, 'unit': 'M', 'net_profit': 5.34}, {'period': ""Q3 '23"", 'revenue': 19.87, 'unit': 'M', 'net_profit': 5.4}, {'period': ""Q2 '23"", 'revenue': 19.78, 'unit': 'M', 'net_profit': 5.44}, {'period': ""Q1 '23"", 'revenue': 19.86, 'unit': 'M', 'net_profit': 5.45}]",2.58,2.56,1990383000,220219000,-27520000,1793922000,0,5000000,993471000,27520000,28070000,-0.9770697854993691,0.024872086412734508,0.015748031496063006,__nan__,__nan__,__nan__,0.901294876413233
667,CALM,Cal-Maine Foods Inc. Common Stock,"Cal-Maine Foods, Inc., together with its subsidiaries, produces, grades, packages, markets, and distributes shell eggs. The company offers specialty shell eggs, such as nutritionally enhanced, cage free, organic, and brown eggs under the Egg-Land's Best, Land O' Lakes, Farmhouse Eggs, and 4-Grain brand names, as well as under private labels. It sells its products to various customers, including national and regional grocery store chains, club stores, independent supermarkets, foodservice distributors, and egg product consumers primarily in the southwestern, southeastern, mid-western, and mid-Atlantic regions of the United States. Cal-Maine Foods, Inc. was founded in 1957 and is headquartered in Ridgeland, Mississippi.",Mr. Sherman L. Miller,Agricultural Farm Products,105.668,USD,5152621902,https://images.financialmodelingprep.com/symbol/CALM.png,0,12.1,0.918,249113,440761000,277888000,"[{'period': '2024', 'revenue': 2330.0, 'unit': 'M', 'net_profit': 277.89}, {'period': '2023', 'revenue': 3150.0, 'unit': 'M', 'net_profit': 758.02}, {'period': '2022', 'revenue': 1780.0, 'unit': 'M', 'net_profit': 132.65}, {'period': '2021', 'revenue': 1350.0, 'unit': 'M', 'net_profit': 2.06}]","[{'period': ""Q1 '25"", 'revenue': 785.87, 'unit': 'M', 'net_profit': 149.98}, {'period': ""Q4 '24"", 'revenue': 640.79, 'unit': 'M', 'net_profit': 113.24}, {'period': ""Q3 '24"", 'revenue': 703.08, 'unit': 'M', 'net_profit': 146.71}, {'period': ""Q2 '24"", 'revenue': 523.23, 'unit': 'M', 'net_profit': 17.01}, {'period': ""Q1 '24"", 'revenue': 459340.0, 'unit': 'K', 'net_profit': 926.0}, {'period': ""Q4 '23"", 'revenue': 688.68, 'unit': 'M', 'net_profit': 110.93}]",5.7,5.69,2184761000,1241839000,812377000,387718000,162442000,11195000,227743000,237878000,307282000,-0.5885994248469478,-0.6334047470792481,-0.6341463414634145,"[1.019, 0.04]","['2024-10-30', '1998-02-05']",__nan__,0.17746472039733407
668,CALT,Calliditas Therapeutics AB American Depositary Shares,"Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.",Ms. Renee  Aguiar-Lucander,Biotechnology,40.0001,USD,1080670702,https://images.financialmodelingprep.com/symbol/CALT.png,7730,-22.727329545454545,-0.0399,9795,-367803000,-466185000,"[{'period': '2023', 'revenue': 1210.0, 'unit': 'M', 'net_profit': -466.19}, {'period': '2022', 'revenue': 802.88, 'unit': 'M', 'net_profit': -412.27}, {'period': '2021', 'revenue': 229.35, 'unit': 'M', 'net_profit': -509.54}, {'period': '2020', 'revenue': 0.874, 'unit': 'M', 'net_profit': -436.51}]","[{'period': ""Q2 '24"", 'revenue': 559.78, 'unit': 'M', 'net_profit': -47.48}, {'period': ""Q1 '24"", 'revenue': 295.48, 'unit': 'M', 'net_profit': -246.16}, {'period': ""Q4 '23"", 'revenue': 451.56, 'unit': 'M', 'net_profit': -18.37}, {'period': ""Q3 '23"", 'revenue': 294.59, 'unit': 'M', 'net_profit': -168.36}, {'period': ""Q2 '23"", 'revenue': 269.38, 'unit': 'M', 'net_profit': -91.93}, {'period': ""Q1 '23"", 'revenue': 191.35, 'unit': 'M', 'net_profit': -187.53}]",-8.69,-8.69,1900549000,1275152000,973733000,1565743000,188189000,24201000,407144000,973733000,-447442000,0.05404599078743985,-0.13078143343650248,-0.11696658097686366,__nan__,__nan__,__nan__,0.8238372175618729
669,CAMP,CalAmp Corp. Common Stock,"CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.",Mr. Joshua  Mandel-Brehm,Biotechnology,4.58,USD,92337719,https://images.financialmodelingprep.com/symbol/CAMP.png,122100,-1.73,0.08,18929,-8721000,-93261000,"[{'period': '2024', 'revenue': 186.23, 'unit': 'M', 'net_profit': -93.26}, {'period': '2023', 'revenue': 294.95, 'unit': 'M', 'net_profit': -32.49}, {'period': '2022', 'revenue': 295.84, 'unit': 'M', 'net_profit': -31.15}, {'period': '2021', 'revenue': 308.59, 'unit': 'M', 'net_profit': -21.16}]","[{'period': ""Q3 '24"", 'revenue': 53.62, 'unit': 'M', 'net_profit': -85.0}, {'period': ""Q2 '24"", 'revenue': 61.71, 'unit': 'M', 'net_profit': -4.22}, {'period': ""Q1 '24"", 'revenue': 70.89, 'unit': 'M', 'net_profit': -4.03}, {'period': ""Q4 '23"", 'revenue': 78.51, 'unit': 'M', 'net_profit': -8.09}, {'period': ""Q3 '23"", 'revenue': 78.89, 'unit': 'M', 'net_profit': -4.73}, {'period': ""Q2 '23"", 'revenue': 72.83, 'unit': 'M', 'net_profit': -7.49}]",-2.52,-2.52,380120000,174795000,41928000,365813000,82946000,0,106500000,41928000,-34032000,-32.59782608695652,-1.8704524469067405,-1.8,__nan__,__nan__,__nan__,0.9623618857202989
670,CAMT,Camtek Ltd. Ordinary Shares,"Camtek Ltd., together with its subsidiaries, develops, manufactures, and sells inspection and metrology equipment for the advanced interconnect packaging, memory, complementary metal oxide semiconductor image sensors, micro-electro mechanical systems, radio frequency, and other segments of the semiconductor industry. It provides inspection and metrology systems, including Eagle-i, a system that delivers 2D inspection and metrology capabilities; Eagle-AP, which addresses the advanced packaging market using software and hardware technologies that deliver superior 2D and 3D inspection and metrology capabilities on the same platform; and Golden Eagle, a panel inspection and metrology system to support fanout wafer level packaging applications. The company sells its products in the Asia Pacific, the United States, and Europe. Camtek Ltd. was incorporated in 1987 and is headquartered in Migdal HaEmek, Israel.",Mr. Rafi  Amit,Semiconductors,91.635,USD,4157131737,https://images.financialmodelingprep.com/symbol/CAMT.png,500748,42.03,3.135,272927,95885000,78632000,"[{'period': '2023', 'revenue': 315.38, 'unit': 'M', 'net_profit': 78.63}, {'period': '2022', 'revenue': 320.91, 'unit': 'M', 'net_profit': 79.95}, {'period': '2021', 'revenue': 269.66, 'unit': 'M', 'net_profit': 60.28}, {'period': '2020', 'revenue': 155.86, 'unit': 'M', 'net_profit': 21.78}]","[{'period': ""Q3 '24"", 'revenue': 112.34, 'unit': 'M', 'net_profit': 32.74}, {'period': ""Q2 '24"", 'revenue': 102.59, 'unit': 'M', 'net_profit': 27.96}, {'period': ""Q1 '24"", 'revenue': 97.01, 'unit': 'M', 'net_profit': 24.8}, {'period': ""Q4 '23"", 'revenue': 88.69, 'unit': 'M', 'net_profit': 20.79}, {'period': ""Q3 '23"", 'revenue': 80.47, 'unit': 'M', 'net_profit': 22.06}, {'period': ""Q2 '23"", 'revenue': 73.76, 'unit': 'M', 'net_profit': 18.54}]",1.78,1.63,787667000,546787000,354034000,311519000,87300000,73576000,96674000,119968000,71054000,0.17653193943409654,-0.016473001538480782,-0.01657458563535913,"[1.33, 0.14]","['2024-04-03', '2017-11-21']",__nan__,0.39549581231662617
671,CAN,Canaan Inc. American Depositary Shares,"Canaan Inc. engages in the research, design, and sale of integrated circuits (IC), and lease of final mining equipment by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts; and distribution of artificial intelligence products, as well as mining business. The company has operations in the United States, Australia, Kazakhstan, Canada, Indonesia, Mainland China, Malaysia, Thailand, Cyprus, and internationally. Canaan Inc. was founded in 2013 and is headquartered in Singapore.",Mr. Nangeng  Zhang,Computer Hardware,2.125,USD,581701416,https://images.financialmodelingprep.com/symbol/CAN.png,17166341,-1.54,-0.215,9709378,-330114000,-414153000,"[{'period': '2023', 'revenue': 211.48, 'unit': 'M', 'net_profit': -414.15}, {'period': '2022', 'revenue': 656.32, 'unit': 'M', 'net_profit': 70.4}, {'period': '2021', 'revenue': 771.14, 'unit': 'M', 'net_profit': 308.44}, {'period': '2020', 'revenue': 68.58, 'unit': 'M', 'net_profit': -32.95}]","[{'period': ""Q3 '24"", 'revenue': 73.61, 'unit': 'M', 'net_profit': -75.58}, {'period': ""Q2 '24"", 'revenue': 71.86, 'unit': 'M', 'net_profit': -41.88}, {'period': ""Q1 '24"", 'revenue': 35.03, 'unit': 'M', 'net_profit': -39.33}, {'period': ""Q4 '23"", 'revenue': 104.53, 'unit': 'M', 'net_profit': -223.86}, {'period': ""Q3 '23"", 'revenue': 33.3, 'unit': 'M', 'net_profit': -80.05}, {'period': ""Q2 '23"", 'revenue': 18.65, 'unit': 'M', 'net_profit': -26.34}]",-0.1606666666506,-0.1606666666506,493297000,363680000,96154000,145110000,58400000,2824000,135193000,96154000,-126932000,-4.90639717889854,-6.883035198023462,-6.8780487804878065,"[0.38, 0.38]","['2021-11-15', '2021-11-15']",__nan__,0.2941635566403201
672,CAPA,HighCape Capital Acquisition Corp. Class A Common Stock,,,,,,,,,0,,,-263139,-263139,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -263.14}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.7}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -263.14}]",-0.08,-0.08,116186042,1183890,1034163,4171558,0,0,146558,1034163,,0,0,0,__nan__,__nan__,__nan__,0.03590412349187349
673,CAPAU,HighCape Capital Acquisition Corp. Unit,,,,,,,,,,,,-263139,-263139,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -263.14}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.7}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -212.89}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -50.25}]",-0.08,-0.08,116186042,1183890,1034163,4171558,0,0,146558,1034163,-268460,0,0,0,__nan__,__nan__,__nan__,0.03590412349187349
674,CAPAW,HighCape Capital Acquisition Corp. Warrant,,,,,,,,,0,0.1001,26005,-263139,-263139,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -263.14}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.7}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -263.14}]",-0.08,-0.08,116186042,1183890,1034163,4171558,0,0,146558,1034163,,0,0,0,__nan__,__nan__,__nan__,0.03590412349187349
675,CAPR,Capricor Therapeutics Inc. Common Stock,"Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.",Dr. Linda  Marbn Ph.D.,Biotechnology,14.42,USD,655675958,https://images.financialmodelingprep.com/symbol/CAPR.png,1714977,-14.14,-0.58,389648,-23008977,-22287542,"[{'period': '2023', 'revenue': 25.18, 'unit': 'M', 'net_profit': -22.29}, {'period': '2022', 'revenue': 2.55, 'unit': 'M', 'net_profit': -29.02}, {'period': '2021', 'revenue': 0.2449, 'unit': 'M', 'net_profit': -19.41}, {'period': '2020', 'revenue': 0.31025, 'unit': 'M', 'net_profit': -13.48}]","[{'period': ""Q3 '24"", 'revenue': 2.26, 'unit': 'M', 'net_profit': -12.56}, {'period': ""Q2 '24"", 'revenue': 3.97, 'unit': 'M', 'net_profit': -11.0}, {'period': ""Q1 '24"", 'revenue': 4.91, 'unit': 'M', 'net_profit': -9.79}, {'period': ""Q4 '23"", 'revenue': 12090.0, 'unit': 'K', 'net_profit': -762.09}, {'period': ""Q3 '23"", 'revenue': 6.19, 'unit': 'M', 'net_profit': -6.39}, {'period': ""Q2 '23"", 'revenue': 3.92, 'unit': 'M', 'net_profit': -7.37}]",-0.83,-0.83,58734327,50855472,39487703,36132860,10371993,0,31269818,14694857,-27644078,0.21105547298110028,0.23196340263600532,0.2966101694915254,__nan__,__nan__,__nan__,0.6151915216462768
676,CAR,Avis Budget Group Inc. Common Stock,"Avis Budget Group, Inc., together with its subsidiaries, provides car and truck rentals, car sharing, and ancillary products and services to businesses and consumers. It operates the Avis brand, that offers vehicle rental and other mobility solutions to the premium commercial and leisure segments of the travel industry; the Budget Truck brand, a local, and one-way truck and cargo van rental businesses with a fleet of approximately 20,000 vehicles, which are rented through a network of approximately 465 dealer-operated and 385 company-operated locations that serve the consumer and light commercial sectors in the continental United States; and the Zipcar brand, a car sharing network. The company also operates various other car rental brands, such as Budget, Payless, Apex, Maggiore, MoriniRent, FranceCars, Amicoblue, Turiscar, and ACL Hire. In addition, it offers optional insurance products and coverages, such as supplemental liability, personal accident, personal effects protection, emergency sickness protection, and automobile towing protection and cargo insurance products; fuel service options, roadside assistance services, electronic toll collection services, curbside delivery, tablet rentals, access to satellite radio, portable navigation units, and child safety seat rentals; automobile towing equipment and other moving accessories, such as hand trucks, furniture pads, and moving supplies; and Business Intelligence solution, an online portal for corporate travel. Avis Budget Group, Inc. operates in approximately 10,400 locations worldwide. The company was formerly known as Cendant Corporation and changed its name to Avis Budget Group, Inc. in September 2006. Avis Budget Group, Inc. was founded in 1946 and is headquartered in Parsippany, New Jersey.",Mr. Joseph A. Ferraro,Rental & Leasing Services,86.04,USD,3023376768,https://images.financialmodelingprep.com/symbol/CAR.png,685995,7.4,1.31,201102,5660000000,1632000000,"[{'period': '2023', 'revenue': 12.01, 'unit': 'B', 'net_profit': 1.63}, {'period': '2022', 'revenue': 11.99, 'unit': 'B', 'net_profit': 2.76}, {'period': '2021', 'revenue': 9.31, 'unit': 'B', 'net_profit': 1.28}, {'period': '2020', 'revenue': 5400.0, 'unit': 'M', 'net_profit': -684.0}]","[{'period': ""Q3 '24"", 'revenue': 3480.0, 'unit': 'M', 'net_profit': 237.0}, {'period': ""Q2 '24"", 'revenue': 3050.0, 'unit': 'M', 'net_profit': 14.0}, {'period': ""Q1 '24"", 'revenue': 2550.0, 'unit': 'M', 'net_profit': -114.0}, {'period': ""Q4 '23"", 'revenue': 2760.0, 'unit': 'M', 'net_profit': 259.0}, {'period': ""Q3 '23"", 'revenue': 3560.0, 'unit': 'M', 'net_profit': 626.0}, {'period': ""Q2 '23"", 'revenue': 3120.0, 'unit': 'M', 'net_profit': 435.0}]",42.61,42.06,32569000000,2139000000,555000000,32912000000,1092000000,1304000000,2659000000,555000000,-11630000000,-0.20805932559115714,-0.40955137481910275,-0.27087611225188224,"[10, 5]","['2023-12-14', '1989-06-07']",__nan__,1.0105314869968376
677,CARA,Cara Therapeutics Inc. Common Stock,"Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.",Mr. Christopher A. Posner,Biotechnology,4.87,USD,22262182,https://images.financialmodelingprep.com/symbol/CARA.png,138414,-0.23,-0.3,71136,-117650000,-118513000,"[{'period': '2023', 'revenue': 20.97, 'unit': 'M', 'net_profit': -118.51}, {'period': '2022', 'revenue': 41.87, 'unit': 'M', 'net_profit': -83.41}, {'period': '2021', 'revenue': 23.03, 'unit': 'M', 'net_profit': -88.19}, {'period': '2020', 'revenue': 135.08, 'unit': 'M', 'net_profit': 8.41}]","[{'period': ""Q3 '24"", 'revenue': 2.56, 'unit': 'M', 'net_profit': -12.48}, {'period': ""Q2 '24"", 'revenue': 0.991, 'unit': 'M', 'net_profit': -20.02}, {'period': ""Q1 '24"", 'revenue': 2.13, 'unit': 'M', 'net_profit': -30.7}, {'period': ""Q4 '23"", 'revenue': 3.0, 'unit': 'M', 'net_profit': -32.34}, {'period': ""Q3 '23"", 'revenue': 4.87, 'unit': 'M', 'net_profit': -28.03}, {'period': ""Q2 '23"", 'revenue': 6.93, 'unit': 'M', 'net_profit': -31.48}]",-2.19,-2.19,125844000,116158000,100758000,68759000,4017000,0,25592000,51775000,-94453000,-0.40387093694811704,-0.42079771738218263,-0.41290322580645156,__nan__,__nan__,__nan__,0.5463828231779028
678,CARE,Carter Bankshares Inc. Common Stock,"Carter Bankshares, Inc. operates as the bank holding company for Carter Bank & Trust that provides various banking products and services. It accepts various deposit products, including checking, savings, retirement, and money market accounts, as well as longer-term certificates of deposits. The company also offers commercial loans comprising secured and unsecured loans; consumer loans, such as secured and unsecured loans for financing automobiles, home improvements, education, overdraft protection, and personal investments, as well as residential mortgages; real estate construction and acquisition loans; home equity lines of credit; and credit cards, as well as originates and holds fixed and variable rate mortgage loans. In addition, it provides other banking services that include safe deposit boxes, direct deposit of payroll and social security checks, online banking, bill pay, online account opening, mobile deposit, mobile banking, debit cards, e-statements, and ATM services; title insurance and other financial institution-related products and services; and treasury and corporate cash management services. It operates through 69 branches in Virginia and North Carolina. Carter Bankshares, Inc. was founded in 1974 and is headquartered in Martinsville, Virginia.",Mr. Litz H. Van Dyke,Banks - Regional,16.97,USD,391531840,https://images.financialmodelingprep.com/symbol/CARE.png,71841,27.37,-0.24,28331,0,23384000,"[{'period': '2023', 'revenue': 136.61, 'unit': 'M', 'net_profit': 23.38}, {'period': '2022', 'revenue': 0.073, 'unit': 'M', 'net_profit': 50.12}, {'period': '2021', 'revenue': 133.66, 'unit': 'M', 'net_profit': 31.59}, {'period': '2020', 'revenue': 127.95, 'unit': 'M', 'net_profit': -45.86}]","[{'period': ""Q3 '24"", 'revenue': 33.33, 'unit': 'M', 'net_profit': 5.63}, {'period': ""Q2 '24"", 'revenue': 60.12, 'unit': 'M', 'net_profit': 4.8}, {'period': ""Q1 '24"", 'revenue': 59.09, 'unit': 'M', 'net_profit': 5.81}, {'period': ""Q4 '23"", 'revenue': 55.11, 'unit': 'M', 'net_profit': -1.89}, {'period': ""Q3 '23"", 'revenue': 31.85, 'unit': 'M', 'net_profit': 3.63}, {'period': ""Q2 '23"", 'revenue': 30.97, 'unit': 'M', 'net_profit': 5.7}]",1,1,4512539000,54529000,54529000,4161296000,0,779003000,0,54529000,36932000,-1,-0.5334211261423042,-0.5073891625615763,"[0.14, 0.1]","['2020-02-14', '2007-08-07']",__nan__,0.9221628887861135
679,CARG,CarGurus Inc. Class A Common Stock ,"CarGurus, Inc. operates an online automotive marketplace connecting buyers and sellers of new and used cars in the United States and internationally. The company provides consumers an online automotive marketplace where they can search for new and used car listings from its dealers, as well as sell their car in the United States marketplace. Its marketplace connects dealers to a large audience of informed and engaged consumers. The company operates online marketplaces under the CarGurus brand in Canada and the United Kingdom; and the Autolist and PistonHeads online marketplaces as independent brands in the United States and the United Kingdom. CarGurus, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.",Mr. Jason M. Trevisan,Internet Content & Information,36.525,USD,3787935978,https://images.financialmodelingprep.com/symbol/CARG.png,618527,-81.17,-0.425,132460,81101000,31104000,"[{'period': '2023', 'revenue': 914.24, 'unit': 'M', 'net_profit': 31.1}, {'period': '2022', 'revenue': 1660.0, 'unit': 'M', 'net_profit': 84.39}, {'period': '2021', 'revenue': 951.37, 'unit': 'M', 'net_profit': 109.24}, {'period': '2020', 'revenue': 551.45, 'unit': 'M', 'net_profit': 77.55}]","[{'period': ""Q3 '24"", 'revenue': 231.36, 'unit': 'M', 'net_profit': 22.51}, {'period': ""Q2 '24"", 'revenue': 218.69, 'unit': 'M', 'net_profit': -68.72}, {'period': ""Q1 '24"", 'revenue': 215.8, 'unit': 'M', 'net_profit': 21.3}, {'period': ""Q4 '23"", 'revenue': 223.12, 'unit': 'M', 'net_profit': -17.91}, {'period': ""Q3 '23"", 'revenue': 219.42, 'unit': 'M', 'net_profit': 22.3}, {'period': ""Q2 '23"", 'revenue': 239.74, 'unit': 'M', 'net_profit': 16.41}]",0.19,0.19,918927000,391191000,312087000,302075000,39963000,0,115178000,291363000,83316000,-0.5165739763833503,-0.6314124213445199,-0.7323943661971831,__nan__,__nan__,__nan__,0.3287257856173559
680,CARV,Carver Bancorp Inc. Common Stock,"Carver Bancorp, Inc. operates as the holding company for Carver Federal Savings Bank that provides consumer and commercial banking services for consumers, businesses, non-profit organizations, and governmental and quasi-governmental agencies primarily in New York. It accepts various deposit products, including demand, savings, and time deposits; passbook and statement accounts, and certificates of deposit; and individual retirement accounts. The company also provides lending products, such as one-to-four family residential, multifamily real estate, and commercial real estate lending; and construction, business and small business administration, and consumer and other loans. In addition, it offers other consumer and commercial banking products and services, including debit cards, online account opening and banking, online bill pay, and telephone banking, as well as check cashing, wire transfer, bill payment, reloadable prepaid card, and money order services. The company operates through one administrative office, seven branches, and four ATMs. Carver Bancorp, Inc. was founded in 1948 and is headquartered in New York, New York.",Mr. Donald  Felix,Banks - Regional,1.89,USD,9657390,https://images.financialmodelingprep.com/symbol/CARV.png,25129,-2.3,-0.01,3060,0,-2977000,"[{'period': '2024', 'revenue': 29.2, 'unit': 'M', 'net_profit': -2.98}, {'period': '2023', 'revenue': 26.38, 'unit': 'M', 'net_profit': -3.34}, {'period': '2022', 'revenue': 27.82, 'unit': 'M', 'net_profit': -3.25}, {'period': '2021', 'revenue': 22.09, 'unit': 'M', 'net_profit': -3.9}]","[{'period': ""Q2 '25"", 'revenue': 6.58, 'unit': 'M', 'net_profit': -2.11}, {'period': ""Q1 '25"", 'revenue': 6.21, 'unit': 'M', 'net_profit': -2.21}, {'period': ""Q4 '24"", 'revenue': 10660.0, 'unit': 'K', 'net_profit': 11.0}, {'period': ""Q3 '24"", 'revenue': 9610.0, 'unit': 'K', 'net_profit': 15.0}, {'period': ""Q2 '24"", 'revenue': 8.01, 'unit': 'M', 'net_profit': -1.59}, {'period': ""Q1 '24"", 'revenue': 6.24, 'unit': 'M', 'net_profit': -1.42}]",-0.61,-0.61,756796000,59025000,59025000,714487000,0,0,0,59025000,-6931000,0,0.1094825007478313,0.21794871794871798,"[0.025, 0.05]","['2010-08-25', '1997-07-10']",__nan__,0.944094577666901
681,CASA,Casa Systems Inc. Common Stock,"Casa Systems, Inc., a communications technology company, provides solutions for next-generation physical, virtualized, and cloud native architectures for cable broadband, fixed-line broadband, and wireless networks in North America, Latin America, the Asia-Pacific, Europe, the Middle East, and Africa. It offers converged cable access platforms; wireless network core products, such as virtual evolved packet and 5G core products, as well as small cell solutions, axyom element management system, and fixed wireless access devices; and virtual, centralized, and distributed deployment, and bandwidth capacity expansion systems. The company also provides optical access solutions, virtualized broadband network gateway router and multiservice router, fiber extension, and residential broadband gateways; and machine-to-machine and industrial internet of things routers. The company was incorporated in 2003 and is headquartered in Andover, Massachusetts.",Mr. Michael  Glickman,Communication Equipment,0.035,USD,3468815,https://images.financialmodelingprep.com/symbol/CASA.png,1322293,-0.03211009174311927,-0.02,28327484,-52055000,-79205000,"[{'period': '2022', 'revenue': 286.54, 'unit': 'M', 'net_profit': -79.2}, {'period': '2021', 'revenue': 401.32, 'unit': 'M', 'net_profit': 3.21}, {'period': '2020', 'revenue': 393.25, 'unit': 'M', 'net_profit': 24.8}, {'period': '2019', 'revenue': 282.3, 'unit': 'M', 'net_profit': -48.21}]","[{'period': ""Q3 '23"", 'revenue': 62.09, 'unit': 'M', 'net_profit': -25.62}, {'period': ""Q2 '23"", 'revenue': 58.0, 'unit': 'M', 'net_profit': -51.14}, {'period': ""Q1 '23"", 'revenue': 45.3, 'unit': 'M', 'net_profit': -31.66}, {'period': ""Q4 '22"", 'revenue': 84.4, 'unit': 'M', 'net_profit': 1.24}, {'period': ""Q3 '22"", 'revenue': 66.9, 'unit': 'M', 'net_profit': -31.16}, {'period': ""Q2 '22"", 'revenue': 70.84, 'unit': 'M', 'net_profit': -16.7}]",-0.86,-0.86,398294000,291779000,126312000,348893000,74484000,3113000,323912000,126312000,-13053000,-2.4361980962891434,-25.697536638603054,-23.872340425531913,__nan__,__nan__,__nan__,0.8759685056767111
682,CASH,Meta Financial Group Inc. Common Stock,"Pathward Financial, Inc. operates as the holding company for Pathward, National Association that provides various banking products and services in the United States. It operates through three segments: Consumer, Commercial, and Corporate Services/Other. The company offers demand deposit accounts, savings accounts, money market savings accounts, and certificate accounts. It also provides commercial finance product comprising term lending, asset based lending, factoring, lease financing, insurance premium finance, government guaranteed lending, and other commercial finance products; consumer credit products; other consumer financing services; short-term taxpayer advance loans; and warehouse financing services. In addition, the company issues prepaid cards and consumer credit products; sponsors merchant acquiring and automated teller machines (ATMs) in various debit networks; and offers tax refund-transfer services, and other payment industry products and services. The company was formerly known as Meta Financial Group, Inc. and changed its name to Pathward Financial, Inc. in July 2022. Pathward Financial, Inc. was founded in 1954 and is headquartered in Sioux Falls, South Dakota.",Mr. Brett L. Pharr,Banks - Regional,74.08,USD,1786772560,https://images.financialmodelingprep.com/symbol/CASH.png,206911,11.19,-0.42,56921,0,168357000,"[{'period': '2024', 'revenue': 299.59, 'unit': 'M', 'net_profit': 168.36}, {'period': '2023', 'revenue': 577.38, 'unit': 'M', 'net_profit': 163.62}, {'period': '2022', 'revenue': 501.28, 'unit': 'M', 'net_profit': 156.39}, {'period': '2021', 'revenue': 508.27, 'unit': 'M', 'net_profit': 141.71}]","[{'period': ""Q4 '24"", 'revenue': 171.76, 'unit': 'M', 'net_profit': 33.6}, {'period': ""Q3 '24"", 'revenue': 179.81, 'unit': 'M', 'net_profit': 41.84}, {'period': ""Q2 '24"", 'revenue': 212.55, 'unit': 'M', 'net_profit': 65.27}, {'period': ""Q1 '24"", 'revenue': 127.99, 'unit': 'M', 'net_profit': 27.66}, {'period': ""Q4 '23"", 'revenue': 131.41, 'unit': 'M', 'net_profit': 35.91}, {'period': ""Q3 '23"", 'revenue': 136.89, 'unit': 'M', 'net_profit': 45.1}]",6.63,6.62,7549336000,189722000,1899558000,6709731000,0,724884000,377000000,158337000,176783000,-1,0.02898267273782966,0.1031613976705491,"[0.05, 0.075]","['2024-12-10', '1994-12-09']",__nan__,0.8887842586420845
683,CASI,CASI Pharmaceuticals Inc. Common Stock,"CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.",Dr. Wei-Wu  He Ph.D.,Biotechnology,3.06,USD,41008284,https://images.financialmodelingprep.com/symbol/CASI.png,45895,-1.37,-0.02,13664,-21539000,-26938000,"[{'period': '2023', 'revenue': 33.88, 'unit': 'M', 'net_profit': -26.94}, {'period': '2022', 'revenue': 43.11, 'unit': 'M', 'net_profit': -39.41}, {'period': '2021', 'revenue': 30.17, 'unit': 'M', 'net_profit': -37.77}, {'period': '2020', 'revenue': 15.14, 'unit': 'M', 'net_profit': -62.57}]","[{'period': ""Q3 '24"", 'revenue': 7.79, 'unit': 'M', 'net_profit': -8.39}, {'period': ""Q2 '24"", 'revenue': 3.98, 'unit': 'M', 'net_profit': -6.96}, {'period': ""Q1 '24"", 'revenue': 3.41, 'unit': 'M', 'net_profit': -9.53}, {'period': ""Q4 '23"", 'revenue': 6.09, 'unit': 'M', 'net_profit': -5.46}, {'period': ""Q3 '23"", 'revenue': 8.84, 'unit': 'M', 'net_profit': -4.63}, {'period': ""Q2 '23"", 'revenue': 9.82, 'unit': 'M', 'net_profit': -10.24}]",-2.02,-2.02,75268000,59344000,30769000,51103000,10138000,1686000,16726000,17083000,-22208000,0.10511446258672982,0.3164852452361016,0.30103806228373703,__nan__,__nan__,__nan__,0.6789472285699102
684,CASS,Cass Information Systems Inc Common Stock,"Cass Information Systems, Inc. provides payment and information processing services to manufacturing, distribution, and retail enterprises in the United States. It operates through two segments, Information Services and Banking Services. The company's services include freight invoice rating, payment processing, auditing, and the generation of accounting and transportation information. It also processes and pays facility-related invoices, such as electricity, gas, waste, and telecommunications expenses; and provides telecom expense management solutions. In addition, the company, through its banking subsidiary, Cass Commercial Bank, provides a range of banking products and services, such as checking, savings, and time deposit accounts; commercial, industrial, and real estate loans; and cash management services to privately-owned businesses and faith-related ministries. Further, it provides B2B payment platform for clients that require an agile fintech partner. It operates through its banking facility near downtown St. Louis, Missouri; operating branch in the Bridgeton, Missouri; and leased facilities in Fenton, Missouri and Colorado Springs, Colorado. The company was formerly known as Cass Commercial Corporation and changed its name to Cass Information Systems, Inc. in January 2001. Cass Information Systems, Inc. was founded in 1906 and is headquartered in St. Louis, Missouri.",Mr. Martin H. Resch,Specialty Business Services,40.995,USD,556269354,https://images.financialmodelingprep.com/symbol/CASS.png,41198,24.4,0.655,40704,58591000,30059000,"[{'period': '2023', 'revenue': 213.23, 'unit': 'M', 'net_profit': 30.06}, {'period': '2022', 'revenue': 183.83, 'unit': 'M', 'net_profit': 34.9}, {'period': '2021', 'revenue': 154.02, 'unit': 'M', 'net_profit': 28.6}, {'period': '2020', 'revenue': 144.96, 'unit': 'M', 'net_profit': 25.18}]","[{'period': ""Q3 '24"", 'revenue': 22.77, 'unit': 'M', 'net_profit': 2.94}, {'period': ""Q2 '24"", 'revenue': 54.3, 'unit': 'M', 'net_profit': 4.48}, {'period': ""Q1 '24"", 'revenue': 54.95, 'unit': 'M', 'net_profit': 7.15}, {'period': ""Q4 '23"", 'revenue': 50.52, 'unit': 'M', 'net_profit': 8.41}, {'period': ""Q3 '23"", 'revenue': 49.35, 'unit': 'M', 'net_profit': 7.39}, {'period': ""Q2 '23"", 'revenue': 48.09, 'unit': 'M', 'net_profit': 7.14}]",2.18,2.18,2478622000,483119000,372468000,2248813000,110651000,627117000,1071369000,372468000,22612000,0,-0.1388093055237222,-0.15503875968992245,"[0.31, 0.0638]","['2024-12-03', '1996-09-03']",__nan__,0.9072835632056845
685,CASY,Casey's General Stores Inc. Common Stock,"Casey's General Stores, Inc., together with its subsidiaries, operates convenience stores under the Casey's and Casey's General Store names. Its stores offer a selection of food, including freshly prepared foods, such as pizza, donuts, and sandwiches; beverages; tobacco and nicotine products; health and beauty aids; automotive products; and other nonfood items. The company's stores also provide motor fuel for sale on a self-service basis; and gasoline and diesel fuel. In addition, its stores offer various products, include soft drinks, energy, water, sports drinks, juices, coffee, and tea and dairy products; beer, wine, and spirits; snacks, candy, packaged bakery, and other food items; ice, ice cream, meals, and appetizers; health and beauty aids, electronic accessories, housewares, and pet supplies; and lotto/lottery and prepaid cards. Further, the company operates two stores that sells tobacco and nicotine products; one liquor store; and one grocery store. As of April 30, 2022, it operated 2,452 convenience stores. Casey's General Stores, Inc. was founded in 1959 and is headquartered in Ankeny, Iowa.",Mr. Darren M. Rebelez,Specialty Retail,393.2494,USD,14596473929,https://images.financialmodelingprep.com/symbol/CASY.png,224138,27.37,-3.5106,68941,1071134000,501972000,"[{'period': '2024', 'revenue': 14860.0, 'unit': 'M', 'net_profit': 501.97}, {'period': '2023', 'revenue': 15090.0, 'unit': 'M', 'net_profit': 446.69}, {'period': '2022', 'revenue': 12950.0, 'unit': 'M', 'net_profit': 339.79}, {'period': '2021', 'revenue': 8710.0, 'unit': 'M', 'net_profit': 312.9}]","[{'period': ""Q2 '25"", 'revenue': 3950.0, 'unit': 'M', 'net_profit': 180.92}, {'period': ""Q1 '25"", 'revenue': 4100.0, 'unit': 'M', 'net_profit': 180.2}, {'period': ""Q4 '24"", 'revenue': 3600.0, 'unit': 'M', 'net_profit': 87.02}, {'period': ""Q3 '24"", 'revenue': 3330.0, 'unit': 'M', 'net_profit': 86.93}, {'period': ""Q2 '24"", 'revenue': 4059.9999999999995, 'unit': 'M', 'net_profit': 158.78}, {'period': ""Q1 '24"", 'revenue': 3870.0, 'unit': 'M', 'net_profit': 169.24}]",13.51,13.43,6347433000,829854000,206482000,3332052000,168859000,0,953466000,206482000,370949000,0.11543111590597395,0.12375669086684084,0.12677231025854876,"[0.5, 0.025]","['2025-02-03', '1990-07-26']",__nan__,0.5249448083973474
686,CATB,Catabasis Pharmaceuticals Inc. Common Stock,"Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.",Dr. Jill Milne,Biotechnology,8.54,USD,234861102,https://images.financialmodelingprep.com/symbol/CATB.png,528916,0,-0.64000034,98872,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
687,CATC,Cambridge Bancorp Common Stock,"Cambridge Bancorp operates as the bank holding company for Cambridge Trust Company that provides commercial and consumer banking, and investment management and trust services. The company accepts various deposits, such as checking, savings, money market, trust, and individual retirement accounts; and time and demand deposits, and certificates of deposit. Its loan products include residential and commercial real estate loans; home equity lines of credit and term loans; commercial and industrial loans; secured and unsecured loans, lines of credit, and personal installment loans; and construction loans. The company also offers cash management, online and mobile banking, and payments services. It serves commercial enterprises, non-profit organizations, and individuals. The company operates through a network of 19 banking offices in Eastern Massachusetts and New Hampshire; and two wealth management offices located in Massachusetts, as well as three wealth management offices located in New Hampshire. Cambridge Bancorp was founded in 1890 and is headquartered in Cambridge, Massachusetts.",Mr. Denis K. Sheahan,Banks - Regional,220,USD,0,https://images.financialmodelingprep.com/symbol/CATC.png,3,60.61,0,0,46409000,34109000,"[{'period': '2023', 'revenue': 161.63, 'unit': 'M', 'net_profit': 34.11}, {'period': '2022', 'revenue': 186.22, 'unit': 'M', 'net_profit': 52.91}, {'period': '2021', 'revenue': 172.31, 'unit': 'M', 'net_profit': 54.02}, {'period': '2020', 'revenue': 159.76, 'unit': 'M', 'net_profit': 31.96}]","[{'period': ""Q1 '24"", 'revenue': 37.64, 'unit': 'M', 'net_profit': 6.89}, {'period': ""Q4 '23"", 'revenue': 56.95, 'unit': 'M', 'net_profit': 8.03}, {'period': ""Q3 '23"", 'revenue': 55.7, 'unit': 'M', 'net_profit': 6.54}, {'period': ""Q2 '23"", 'revenue': 39.79, 'unit': 'M', 'net_profit': 7.12}, {'period': ""Q1 '23"", 'revenue': 51.74, 'unit': 'M', 'net_profit': 12.42}, {'period': ""Q4 '22"", 'revenue': 50.95, 'unit': 'M', 'net_profit': 11.32}]",4.36,4.35,5417666000,48769000,32503999,4897716000,15765000,1097170000,2678118000,32503999,31718000,-0.4770168696965258,-0.3553270710087131,-0.4068027210884353,"[0.67, 0.5]","['2024-05-08', '2001-02-28']",__nan__,0.9040269370610887
688,CATM,Cardtronics plc Class A Ordinary Shares (UK),"Cardtronics plc provides automated consumer financial services through its network of automated teller machines (ATMs) and multi-function financial services kiosks. The company offers cash dispensing and balance inquiries; and financial related services to cardholders, as well as ATM management and ATM equipment-related services to large retail merchants, smaller retailers, financial institutions, and operators of facilities, such as shopping malls, airports, train stations, and casinos. It also provides transaction processing, cash and cash delivery management, supply, and telecommunications, as well as routine and technical maintenance services for ATMs; and owns and operates electronic funds transfer transaction processing platforms that offer transaction processing services to its network of ATMS, as well as other ATMs under managed services arrangements. In addition, the company provides processing services for issuers of debit cards; and owns and operates Allpoint network, a surcharge-free ATM network, which offers surcharge-free ATM access to participating banks, credit unions, digital banks, financial technology companies, and stored-value debit card issuers. As of April 1, 2020, it provided services to approximately 285,000 ATMs in North America, Europe, the Asia-Pacific, and Africa. The company was founded in 1989 and is based in Houston, Texas.",Mr. Edward West,Business Equipment & Supplies,39.01,USD,0,https://images.financialmodelingprep.com/symbol/CATM.png,475200,0,0,460335,221777000,19144000,"[{'period': '2020', 'revenue': 1090.0, 'unit': 'M', 'net_profit': 19.14}, {'period': '2019', 'revenue': 1350.0, 'unit': 'M', 'net_profit': 48.27}, {'period': '2018', 'revenue': 1350.0, 'unit': 'M', 'net_profit': 3.68}, {'period': '2017', 'revenue': 1510.0, 'unit': 'M', 'net_profit': -145.35}]","[{'period': ""Q1 '21"", 'revenue': 267.83, 'unit': 'M', 'net_profit': 5.88}, {'period': ""Q4 '20"", 'revenue': 274.81, 'unit': 'M', 'net_profit': 9.58}, {'period': ""Q3 '20"", 'revenue': 279.4, 'unit': 'M', 'net_profit': 5.73}, {'period': ""Q2 '20"", 'revenue': 233.19, 'unit': 'M', 'net_profit': -1.92}, {'period': ""Q1 '20"", 'revenue': 306.6, 'unit': 'M', 'net_profit': 5.75}, {'period': ""Q4 '19"", 'revenue': 338.81, 'unit': 'M', 'net_profit': 12.62}]",0.42,0.42,1831445000,462013000,174242000,1452029000,89867000,0,475985000,174242000,191207000,-0.1826510943955303,-0.6034304180304098,-0.6000000000000001,__nan__,__nan__,__nan__,0.7928324355904763
689,CATY,Cathay General Bancorp Common Stock,"Cathay General Bancorp operates as the holding company for Cathay Bank that offers various commercial banking products and services to individuals, professionals, and small to medium-sized businesses in the United States. The company offers various deposit products, including passbook accounts, checking accounts, money market deposit accounts, certificates of deposit, individual retirement accounts, and public funds deposits. It also provides loan products, such as commercial mortgage loans, commercial loans, small business administration loans, residential mortgage loans, real estate construction loans, and home equity lines of credit, as well as installment loans to individuals for household, and other consumer expenditures. In addition, the company offers trade financing, letter of credit, wire transfer, forward currency spot and forward contract, traveler's check, safe deposit, night deposit, social security payment deposit, collection, bank-by-mail, drive-up and walk-up window, automatic teller machine, Internet banking, investment, and other customary bank services, as well as securities and insurance products. As of March 1, 2022, it operated 31 branches in Southern California, 16 branches in Northern California, 10 branches in New York, four branches in Washington, two branches in Illinois, and two branches in Texas, as well as one branch each in Maryland, Massachusetts, Nevada, and New Jersey, and Hong Kong; and a representative office each in Beijing, Taipei, and Shanghai. The company was founded in 1962 and is headquartered in Los Angeles, California.",Mr. Chang Ming Liu,Banks - Regional,46.64,USD,3320702704,https://images.financialmodelingprep.com/symbol/CATY.png,313877,11.78,-0.83,82187,0,354124000,"[{'period': '2023', 'revenue': 784.06, 'unit': 'M', 'net_profit': 354.12}, {'period': '2022', 'revenue': 790.51, 'unit': 'M', 'net_profit': 360.64}, {'period': '2021', 'revenue': 652.36, 'unit': 'M', 'net_profit': 298.3}, {'period': '2020', 'revenue': 594.93, 'unit': 'M', 'net_profit': 228.86}]","[{'period': ""Q3 '24"", 'revenue': 189.52, 'unit': 'M', 'net_profit': 67.51}, {'period': ""Q2 '24"", 'revenue': 344.59, 'unit': 'M', 'net_profit': 66.83}, {'period': ""Q1 '24"", 'revenue': 339.0, 'unit': 'M', 'net_profit': 71.44}, {'period': ""Q4 '23"", 'revenue': 356.17, 'unit': 'M', 'net_profit': 82.53}, {'period': ""Q3 '23"", 'revenue': 193.48, 'unit': 'M', 'net_profit': 82.37}, {'period': ""Q2 '23"", 'revenue': 204.64, 'unit': 'M', 'net_profit': 93.22}]",4.88,4.86,23081534000,926474000,828801000,20344959000,97673000,2615472000,0,173988000,381341000,-1,-0.018073324793008026,0.00618556701030933,"[0.34, 0.601]","['2024-11-27', '1991-01-07']",__nan__,0.8814387726569647
690,CBAN,Colony Bankcorp Inc. Common Stock,"Colony Bankcorp, Inc. operates as the bank holding company for Colony Bank that provides various banking products and services to commercial and consumer customers. The company offers various deposit products, including demand, savings, and time deposits. It also provides loans to small and medium-sized businesses; residential and commercial construction, and land development loans; commercial real estate loans; commercial loans; agri-business and production loans; residential mortgage loans; home equity loans; and consumer loans. In addition, the company offers internet banking services, electronic bill payment services, safe deposit box rentals, telephone banking, credit and debit card services, and remote depository products, as well as access to a network of ATMs. As of January 20, 2022, it operated 39 locations throughout Georgia. The company was founded in 1975 and is headquartered in Fitzgerald, Georgia.",Mr. T. Heath Fountain CPA,Banks - Regional,15.41,USD,270091070,https://images.financialmodelingprep.com/symbol/CBAN.png,36398,12.23,-0.33,15275,31113000,21747000,"[{'period': '2023', 'revenue': 160.74, 'unit': 'M', 'net_profit': 21.75}, {'period': '2022', 'revenue': 115.7, 'unit': 'M', 'net_profit': 19.54}, {'period': '2021', 'revenue': 102.48, 'unit': 'M', 'net_profit': 18.66}, {'period': '2020', 'revenue': 79.49, 'unit': 'M', 'net_profit': 11.81}]","[{'period': ""Q3 '24"", 'revenue': 28.62, 'unit': 'M', 'net_profit': 5.63}, {'period': ""Q2 '24"", 'revenue': 42.83, 'unit': 'M', 'net_profit': 5.47}, {'period': ""Q1 '24"", 'revenue': 42.8, 'unit': 'M', 'net_profit': 5.33}, {'period': ""Q4 '23"", 'revenue': 42.51, 'unit': 'M', 'net_profit': 5.6}, {'period': ""Q3 '23"", 'revenue': 29.34, 'unit': 'M', 'net_profit': 5.8}, {'period': ""Q2 '23"", 'revenue': 28.13, 'unit': 'M', 'net_profit': 5.3}]",1.24,1.24,3053422000,83322000,83322000,2798487000,0,873281000,0,25339000,22517000,-0.09767698152605783,0.11283389622351858,0.08771929824561413,"[0.1125, 0.1719]","['2024-11-06', '1998-06-26']",__nan__,0.9165084289037021
691,CBAT,CBAK Energy Technology Inc. Common Stock,"CBAK Energy Technology, Inc., together with its subsidiaries, develops, manufactures, and sells lithium batteries in Mainland China, the United States, Korea, Europe, and internationally. Its products are used in various applications, including electric vehicles, such as electric cars, electric buses, and hybrid electric cars and buses; light electric vehicles that include electric bicycles, electric motors, and sight-seeing cars; and electric tools, energy storage, uninterruptible power supply, and other high power applications, as well as cordless power tools. The company was formerly known as China BAK Battery, Inc. and changed its name to CBAK Energy Technology, Inc. in January 2017. CBAK Energy Technology, Inc. was incorporated in 1999 and is based in Dalian, China.",Mr. Zhiguang  Hu,Electrical Equipment & Parts,1.01,USD,90838592,https://images.financialmodelingprep.com/symbol/CBAT.png,577496,8.42,-0.03,201027,10154271,-2449057,"[{'period': '2023', 'revenue': 204.44, 'unit': 'M', 'net_profit': -2.45}, {'period': '2022', 'revenue': 248.73, 'unit': 'M', 'net_profit': -11.33}, {'period': '2021', 'revenue': 52.67, 'unit': 'M', 'net_profit': 61.49}, {'period': '2020', 'revenue': 37.57, 'unit': 'M', 'net_profit': -6.5}]","[{'period': ""Q3 '24"", 'revenue': 44630.0, 'unit': 'K', 'net_profit': 17.65}, {'period': ""Q2 '24"", 'revenue': 47.79, 'unit': 'M', 'net_profit': 6.45}, {'period': ""Q1 '24"", 'revenue': 58.82, 'unit': 'M', 'net_profit': 9.84}, {'period': ""Q4 '23"", 'revenue': 56.18, 'unit': 'M', 'net_profit': -4.77}, {'period': ""Q3 '23"", 'revenue': 63.44, 'unit': 'M', 'net_profit': 6.33}, {'period': ""Q2 '23"", 'revenue': 42.42, 'unit': 'M', 'net_profit': -2.63}]",-0.0274,-0.0274,281155260,128423485,4751759,167696919,33978433,2565005,160495555,4643267,15366359,1.9499312359574064,0.7838013893416831,0.7892307692307692,__nan__,__nan__,__nan__,0.5964566304041404
692,CBAY,CymaBay Therapeutics Inc. Common Stock,"CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.",Mr. Sujal A. Shah,Biotechnology,32.48,USD,3728216800,https://images.financialmodelingprep.com/symbol/CBAY.png,3944615,-32.80808080808081,0.01,8354629,-85744000,-105370000,"[{'period': '2023', 'revenue': 31.07, 'unit': 'M', 'net_profit': -105.37}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -118.89}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -92.58}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -48.66}]","[{'period': ""Q4 '23"", 'revenue': 0.057, 'unit': 'M', 'net_profit': -41.9}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -33.88}, {'period': ""Q2 '23"", 'revenue': 31020.0, 'unit': 'K', 'net_profit': -808.0}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.08}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -36.38}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -27.65}]",-0.99,-0.99,434686000,403802000,394255000,142430000,0,22360000,36843000,206535000,-72976000,0.07204467484118138,0.11372601794921398,0.2666666666666667,__nan__,__nan__,__nan__,0.32766180645339393
693,CBFV,CB Financial Services Inc. Common Stock,"CB Financial Services, Inc. operates as the bank holding company for Community Bank that provides various banking products and services for individuals and businesses in southwestern Pennsylvania, West Virginia, and Ohio. The company's primary deposit products include demand deposits, NOW accounts, money market accounts, and savings accounts, as well as time deposit products. Its loan products comprise residential real estate loans, such as one- to four-family mortgage loans, home equity installment loans, and home equity lines of credit; commercial real estate loans that are secured primarily by improved properties, such as retail facilities, office buildings, and other non-residential buildings; construction loans to individuals to finance the construction of residential dwellings, as well as for the construction of commercial properties, including hotels, apartment buildings, housing developments, and owner-occupied properties used for businesses; commercial and industrial loans, and lines of credit; consumer loans consisting of indirect auto loans, secured and unsecured loans, and lines of credit; and other loans. In addition, the company conducts insurance agency activities by offering property and casualty, commercial liability, surety, and other insurance products. It operates through its main office and 13 branch offices in Greene, Allegheny, Washington, Fayette, and Westmoreland counties in southwestern Pennsylvania; Marshall and Ohio counties in West Virginia; and Belmont County in Ohio, as well as one loan production offices in Allegheny County. The company was founded in 1901 and is headquartered in Carmichaels, Pennsylvania.",Mr. John H. Montgomery,Banks - Regional,28.02,USD,143563832,https://images.financialmodelingprep.com/symbol/CBFV.png,5917,6.34,-0.25,867,0,22550000,"[{'period': '2023', 'revenue': 68.73, 'unit': 'M', 'net_profit': 22.55}, {'period': '2022', 'revenue': 0.538, 'unit': 'M', 'net_profit': 11.25}, {'period': '2021', 'revenue': 47.22, 'unit': 'M', 'net_profit': 11.57}, {'period': '2020', 'revenue': 49.39, 'unit': 'M', 'net_profit': -10.64}]","[{'period': ""Q3 '24"", 'revenue': 12.14, 'unit': 'M', 'net_profit': 3.22}, {'period': ""Q2 '24"", 'revenue': 19.59, 'unit': 'M', 'net_profit': 2.65}, {'period': ""Q1 '24"", 'revenue': 19.65, 'unit': 'M', 'net_profit': 4.2}, {'period': ""Q4 '23"", 'revenue': 8.88, 'unit': 'M', 'net_profit': 12.96}, {'period': ""Q3 '23"", 'revenue': 12.84, 'unit': 'M', 'net_profit': 2.67}, {'period': ""Q2 '23"", 'revenue': 12.96, 'unit': 'M', 'net_profit': 2.76}]",4.41,4.4,1456091000,68223000,68223000,1316257000,0,207095000,12635000,68223000,10943000,-1,1.004979105539255,1.0136986301369864,"[0.25, 0.19]","['2024-11-15', '2003-12-05']",__nan__,0.9039661669497305
694,CBIO,Catalyst Biosciences Inc. Common Stock,"Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.",Dr. Nassim  Usman Ph.D.,Biotechnology,0.5113,USD,19418203,https://images.financialmodelingprep.com/symbol/CBIO.png,437269,-0.02470048309178744,-0.0139,460710,-52153000,-8242000,"[{'period': '2022', 'revenue': 0.794, 'unit': 'M', 'net_profit': -8.24}, {'period': '2021', 'revenue': 7.34, 'unit': 'M', 'net_profit': -87.89}, {'period': '2020', 'revenue': 20.95, 'unit': 'M', 'net_profit': -55.54}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -52.89}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.58}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.47}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 260.0}, {'period': ""Q4 '22"", 'revenue': -0.794, 'unit': 'M', 'net_profit': -40.45}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.6}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 51.63}]",-0.26,-0.26,28444000,28206000,21666000,50133000,5000000,0,16824000,21666000,-33096000,0.40467330258892287,0.9062279564020297,0.9094076655052266,"[0.016, 0.1443]","['2023-01-13', '2015-08-20']",__nan__,1.7625158205596962
695,CBLI,Cleveland BioLabs Inc. Common Stock,"Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.",Dr. Yakov Kogan,Biotechnology,3.17,USD,226388720,https://images.financialmodelingprep.com/symbol/CBLI.png,156953,0,-0.25,116255,-2387011,-2398457,"[{'period': '2020', 'revenue': 0.26294, 'unit': 'M', 'net_profit': -2.4}, {'period': '2019', 'revenue': 1.11, 'unit': 'M', 'net_profit': -2.65}, {'period': '2018', 'revenue': 1.14, 'unit': 'M', 'net_profit': -3.61}, {'period': '2017', 'revenue': 1.95, 'unit': 'M', 'net_profit': -9.71}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -659.51}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -538.1}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -694.7}, {'period': ""Q3 '20"", 'revenue': 43.65, 'unit': 'K', 'net_profit': -745.39}, {'period': ""Q2 '20"", 'revenue': 63.26, 'unit': 'K', 'net_profit': -369.84}, {'period': ""Q1 '20"", 'revenue': 156.04, 'unit': 'K', 'net_profit': -588.53}]",-0.19,-0.19,2318021,2314306,2271288,304611,11512,0,304611,1946418,-2372985,0.0934959488532036,0.09389165870478397,0.1739130434782609,__nan__,__nan__,__nan__,0.13140993977190024
696,CBMB,CBM Bancorp Inc. Common Stock,"CBM Bancorp, Inc. operates as a bank holding company for the Chesapeake Bank of Maryland. Its deposit products include savings, money market, certificate of deposit, and retirement, as well as small business and corporate checking accounts. The company's loan portfolio comprises one-to four-family residential real estate loans, nonresidential real estate loans, construction and land development loans, home equity loans and lines of credit, commercial loans, and consumer loans. It also invests in various investment securities; online and mobile banking services; and mortgages. The company operates through a main office located in Baltimore County, Maryland; and three branch offices situated in Arbutus, Bel Air, and Pasadena, Maryland. CBM Bancorp, Inc. was founded in 1913 and is based in Baltimore, Maryland.",Mr. Joseph M. Solomon,Banks - Regional,17.71,USD,0,https://images.financialmodelingprep.com/symbol/CBMB.png,5143,70.84,0,4514,2987288,942557,"[{'period': '2020', 'revenue': 8860.0, 'unit': 'K', 'net_profit': 942.56}, {'period': '2019', 'revenue': 8230.0, 'unit': 'K', 'net_profit': 907.71}, {'period': '2018', 'revenue': 7310.0, 'unit': 'K', 'net_profit': 673.12}, {'period': '2017', 'revenue': 6940000.0, 'unit': '', 'net_profit': 986.0}]","[{'period': ""Q2 '21"", 'revenue': 2080.0, 'unit': 'K', 'net_profit': 104.29}, {'period': ""Q1 '21"", 'revenue': 2009.9999999999998, 'unit': 'K', 'net_profit': 121.72}, {'period': ""Q4 '20"", 'revenue': 2330.0, 'unit': 'K', 'net_profit': 387.34}, {'period': ""Q3 '20"", 'revenue': 2190.0, 'unit': 'K', 'net_profit': 250.84}, {'period': ""Q2 '20"", 'revenue': 2200.0, 'unit': 'K', 'net_profit': 130.62}, {'period': ""Q1 '20"", 'revenue': 2140.0, 'unit': 'K', 'net_profit': 173.76}]",0.26,0.26,234803603,71234672,70629339,181240888,605333,16543524,1029677,54085815,-2456296,0.052444892893141165,0.03838658254316067,0.13043478260869565,"[0.5, 0.5]","['2022-02-28', '2020-04-03']",__nan__,0.7718829084577548
697,CBNK,Capital Bancorp Inc. Common Stock,"Capital Bancorp, Inc. operates as the bank holding company for Capital Bank, N.A. that provides various banking products and services to businesses, not-for-profit associations, and entrepreneurs in the United States. It operates through Commercial Banking, Capital Bank Home Loans, and OpenSky segments. The company offers a range of deposit products and services, including checking and savings, time, interest bearing demand, and money market accounts, as well as certificates of deposit; and credit cards. It originates residential mortgages and offers residential and commercial real estate, construction, and commercial business loans, as well as other consumer loans, such as term loans, car loans, and boat loans to small to medium-sized businesses, professionals, real estate investors, and small residential builders and individuals. It operates through four commercial bank branches, four mortgage offices, and one loan production office. The company was founded in 1974 and is headquartered in Rockville, Maryland.",Mr. Edward F. Barry,Banks - Regional,27.365,USD,453098724,https://images.financialmodelingprep.com/symbol/CBNK.png,50609,11.69,-0.305,15335,46698000,35871000,"[{'period': '2023', 'revenue': 156.99, 'unit': 'M', 'net_profit': 35.87}, {'period': '2022', 'revenue': 169.98, 'unit': 'M', 'net_profit': 41.8}, {'period': '2021', 'revenue': 167.33, 'unit': 'M', 'net_profit': 39.98}, {'period': '2020', 'revenue': 145.13, 'unit': 'M', 'net_profit': 25.82}]","[{'period': ""Q3 '24"", 'revenue': 44.99, 'unit': 'M', 'net_profit': 8.67}, {'period': ""Q2 '24"", 'revenue': 57.51, 'unit': 'M', 'net_profit': 8.21}, {'period': ""Q1 '24"", 'revenue': 54.34, 'unit': 'M', 'net_profit': 6.56}, {'period': ""Q4 '23"", 'revenue': 52.91, 'unit': 'M', 'net_profit': 9.03}, {'period': ""Q3 '23"", 'revenue': 43.14, 'unit': 'M', 'net_profit': 9.79}, {'period': ""Q2 '23"", 'revenue': 42.03, 'unit': 'M', 'net_profit': 7.32}]",2.56,2.55,2226176000,256960000,245466000,1971316000,11494000,50878000,5583000,53557000,45262000,-0.16110372579312326,-0.14192421777820305,-0.14093959731543623,"[0.1, 0.05]","['2024-11-04', '2021-07-29']",__nan__,0.8855166887074517
698,CBRL,Cracker Barrel Old Country Store Inc Common Stock,"Cracker Barrel Old Country Store, Inc. develops and operates the Cracker Barrel Old Country Store concept in the United States. The company's Cracker Barrel stores consist of a restaurant with a gift shop. Its restaurants serve breakfast, lunch, and dinner, as well as dine-in, pick-up, and delivery services. The company's gift shops comprise various decorative and functional items, such as rocking chairs, seasonal gifts, apparel, toys, cookware, and various other gift items, as well as various candies, preserves, and other food items. As of September 15, 2021, it operated 664 Cracker Barrel stores in 45 states. The company was founded in 1969 and is headquartered in Lebanon, Tennessee.",Ms. Julie Felss Masino,Restaurants,57.165,USD,1272447168,https://images.financialmodelingprep.com/symbol/CBRL.png,679601,30.09,-1.925,271287,156865000,40930000,"[{'period': '2024', 'revenue': 3470.0, 'unit': 'M', 'net_profit': 40.93}, {'period': '2023', 'revenue': 3440.0, 'unit': 'M', 'net_profit': 99.05}, {'period': '2022', 'revenue': 3270.0, 'unit': 'M', 'net_profit': 131.88}, {'period': '2021', 'revenue': 2820.0, 'unit': 'M', 'net_profit': 254.51}]","[{'period': ""Q1 '25"", 'revenue': 845.09, 'unit': 'M', 'net_profit': 4.84}, {'period': ""Q4 '24"", 'revenue': 894.39, 'unit': 'M', 'net_profit': 18.14}, {'period': ""Q3 '24"", 'revenue': 817.13, 'unit': 'M', 'net_profit': -9.2}, {'period': ""Q2 '24"", 'revenue': 935.4, 'unit': 'M', 'net_profit': 26.53}, {'period': ""Q1 '24"", 'revenue': 823.84, 'unit': 'M', 'net_profit': 5.46}, {'period': ""Q4 '23"", 'revenue': 836.73, 'unit': 'M', 'net_profit': 37.46}]",1.84,1.83,2161494000,278214000,12035000,1721345000,49086000,0,454207000,12035000,40685000,-0.3439383356824104,-0.5867743563856638,-0.5883668903803132,"[0.25, 0.0353]","['2025-01-17', '1985-03-08']",__nan__,0.7963681601706968
699,CBSH,Commerce Bancshares Inc. Common Stock,"Commerce Bancshares, Inc. operates as the bank holding company for Commerce Bank that provides retail, mortgage banking, corporate, investment, trust, and asset management products and services to individuals and businesses in the United States. It operates through three segments: Consumer, Commercial, and Wealth. The Consumer segment offers various banking products and services, including consumer deposits; consumer loans, such as automobile, motorcycle, marine, tractor/trailer, recreational vehicle, fixed rate and revolving home equity, and other consumer loans; patient health care financing; real estate loans; indirect and other consumer financing; personal mortgage banking; consumer installment lending; and consumer debit and credit bank cards. The Commercial segment provides corporate lending, leasing, international, merchant and commercial bank card, and securities safekeeping and bond accounting services; and business products, government deposits, and related commercial cash management services, as well as sells fixed income securities to correspondent banks, corporations, public institutions, municipalities, and individuals. The Wealth segment provides traditional trust and estate planning, advisory and discretionary investment portfolio management, and brokerage services, as well as private banking accounts. The company also offers private equity investment, securities brokerage, insurance agency, specialty lending, and leasing services, as well as online and mobile banking services. It operates through a network of 287 locations in Missouri, Kansas, Illinois, Oklahoma, and Colorado, as well as commercial offices. Commerce Bancshares, Inc. was founded in 1865 and is headquartered in Kansas City, Missouri.",Mr. John W. Kemper,Banks - Regional,62.25,USD,8381277750,https://images.financialmodelingprep.com/symbol/CBSH.png,566612,17.01,-0.56,172543,669239000,477060000,"[{'period': '2023', 'revenue': 1380.0, 'unit': 'M', 'net_profit': 477.06}, {'period': '2022', 'revenue': 1510.0, 'unit': 'M', 'net_profit': 488.4}, {'period': '2021', 'revenue': 1430.0, 'unit': 'M', 'net_profit': 530.76}, {'period': '2020', 'revenue': 1350.0, 'unit': 'M', 'net_profit': 354.06}]","[{'period': ""Q3 '24"", 'revenue': 534.97, 'unit': 'M', 'net_profit': 138.01}, {'period': ""Q2 '24"", 'revenue': 524.84, 'unit': 'M', 'net_profit': 139.55}, {'period': ""Q1 '24"", 'revenue': 499.87, 'unit': 'M', 'net_profit': 112.66}, {'period': ""Q4 '23"", 'revenue': 515.09, 'unit': 'M', 'net_profit': 109.22}, {'period': ""Q3 '23"", 'revenue': 395.79, 'unit': 'M', 'net_profit': 120.6}, {'period': ""Q2 '23"", 'revenue': 400.54, 'unit': 'M', 'net_profit': 127.79}]",3.64,3.64,31701061000,2687182000,10391911000,28736831000,0,9902958000,0,443147000,400695000,-0.014715105545364336,-0.023216673252811737,-0.010869565217391313,"[0.27, 0.4951]","['2024-12-03', '1985-02-25']",__nan__,0.9064942968312638
700,CBTX,CBTX Inc. Common Stock,"CBTX, Inc. operates as the bank holding company for CommunityBank of Texas, National Association that provides commercial banking products and services to small and mid-sized businesses, and professionals in the United States. The company offers demand, money market, savings, and time deposit accounts, as well as certificates of deposit; commercial and industrial, commercial real estate, construction and development, 1-4 family residential mortgage, multi-family residential, consumer, and agricultural loans; and treasury and online banking services. It operates through 34 banking locations, including 18 branches in Houston; 15 branches in Beaumont; and one branch in Dallas. The company was formerly known as CBFH, Inc. and changed its name to CBTX, Inc. in September 2017. CBTX, Inc. was incorporated in 2007 and is headquartered in Beaumont, Texas.",Mr. Robert Franklin,Banks - Regional,29.25,USD,1548933750,https://images.financialmodelingprep.com/symbol/CBTX.png,0,19.763513513513512,-0.42,5324146,0,130497000,"[{'period': '2023', 'revenue': 590.82, 'unit': 'M', 'net_profit': 130.5}, {'period': '2022', 'revenue': 322.99, 'unit': 'M', 'net_profit': 51.43}, {'period': '2021', 'revenue': 142.43, 'unit': 'M', 'net_profit': 35.6}, {'period': '2020', 'revenue': 143.39, 'unit': 'M', 'net_profit': 26.36}]","[{'period': ""Q3 '23"", 'revenue': 151.27, 'unit': 'M', 'net_profit': 30.91}, {'period': ""Q2 '23"", 'revenue': 146.96, 'unit': 'M', 'net_profit': 35.17}, {'period': ""Q4 '22"", 'revenue': 200.54, 'unit': 'M', 'net_profit': 16.38}, {'period': ""Q3 '22"", 'revenue': 46.08, 'unit': 'M', 'net_profit': 12.75}, {'period': ""Q2 '22"", 'revenue': 38.42, 'unit': 'M', 'net_profit': 11.71}, {'period': ""Q1 '22"", 'revenue': 37.96, 'unit': 'M', 'net_profit': 10.6}]",5.334,5.334,10647139000,1560928000,1516684000,0,44244000,0,0,121004000,168217000,0,1.5372725151656557,2.6040540540540538,"[0.13, 0.05]","['2022-09-28', '2017-12-30']",__nan__,0.0
701,CCAP,Crescent Capital BDC Inc. Common stock,"Crescent Capital BDC, Inc. is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.",Mr. Jason A. Breaux,Asset Management,18.87,USD,699350505,https://images.financialmodelingprep.com/symbol/CCAP.png,106325,7.37,-0.07,30952,0,83837000,"[{'period': '2023', 'revenue': 184.13, 'unit': 'M', 'net_profit': 83.84}, {'period': '2022', 'revenue': 20.22, 'unit': 'M', 'net_profit': 15.54}, {'period': '2021', 'revenue': 81.33, 'unit': 'M', 'net_profit': 83.63}, {'period': '2020', 'revenue': 46.53, 'unit': 'M', 'net_profit': 54.67}]","[{'period': ""Q3 '24"", 'revenue': 51.63, 'unit': 'M', 'net_profit': 15.27}, {'period': ""Q2 '24"", 'revenue': 45.4, 'unit': 'M', 'net_profit': 20.39}, {'period': ""Q1 '24"", 'revenue': 50.2, 'unit': 'M', 'net_profit': 28.0}, {'period': ""Q4 '23"", 'revenue': 33.03, 'unit': 'M', 'net_profit': 30.86}, {'period': ""Q3 '23"", 'revenue': 48.15, 'unit': 'M', 'net_profit': 22.62}, {'period': ""Q2 '23"", 'revenue': 24.52, 'unit': 'M', 'net_profit': 22.58}]",2.33,2.33,1627379000,43849000,7780000,884785000,14251000,1587203000,35891000,7780000,92298000,-1,4.393528049408132,3.66,"[0.42, 0.41]","['2024-12-31', '2020-03-30']",__nan__,0.543687118980889
702,CCB,Coastal Financial Corporation Common Stock,"Coastal Financial Corporation operates as the bank holding company for Coastal Community Bank that provides various banking products and services to small to medium-sized businesses, professionals, and individuals in the Puget Sound region in Washington. It accepts a range of deposit products, including demand and savings accounts, time deposits, and money market accounts. The company offers commercial and industrial loans, including term loans, small business administration loans, commercial lines of credit, working capital loans, equipment financing, borrowing base loans, and other loan products; owner-occupied and non-owner-occupied real estate loans, and multi-family residential loans; construction and land development loans; residential real estate loans; and consumer and other loans, including automobile, boat and recreational vehicle, and secured term loans, as well as overdraft protection. It also provides remote deposit capture, online and mobile banking, and direct and reciprocal deposit services, as well as debit cards. In addition, the company offers business accounts and cash management services, including business checking and savings accounts, and treasury services, as well as banking as a service (BaaS), a platform that allows broker dealers and digital financial service providers to offer their clients banking services. It operates 14 full-service banking locations. Coastal Financial Corporation was founded in 1997 and is headquartered in Everett, Washington.",Mr. Eric M. Sprink,Banks - Regional,83.55,USD,1246933620,https://images.financialmodelingprep.com/symbol/CCB.png,102375,28.04,-1.2,25098,59461000,44579000,"[{'period': '2023', 'revenue': 330.37, 'unit': 'M', 'net_profit': 44.58}, {'period': '2022', 'revenue': 213.59, 'unit': 'M', 'net_profit': 40.62}, {'period': '2021', 'revenue': 101.81, 'unit': 'M', 'net_profit': 27.0}, {'period': '2020', 'revenue': 65.57, 'unit': 'M', 'net_profit': 15.15}]","[{'period': ""Q3 '24"", 'revenue': 117.56, 'unit': 'M', 'net_profit': 13.46}, {'period': ""Q2 '24"", 'revenue': 167.4, 'unit': 'M', 'net_profit': 11.6}, {'period': ""Q1 '24"", 'revenue': 177.41, 'unit': 'M', 'net_profit': 6.8}, {'period': ""Q4 '23"", 'revenue': 88.24, 'unit': 'M', 'net_profit': 9.01}, {'period': ""Q3 '23"", 'revenue': 70.95, 'unit': 'M', 'net_profit': 10.27}, {'period': ""Q2 '23"", 'revenue': 97.38, 'unit': 'M', 'net_profit': 12.91}]",3.36,3.27,3753366000,626956000,582632000,3458388000,35907000,160591000,3281310000,483128000,190268000,0,0.09732923076923077,0.07006369426751584,__nan__,__nan__,__nan__,0.9214097426150287
703,CCBG,Capital City Bank Group Common Stock,"Capital City Bank Group, Inc. operates as the financial holding company for Capital City Bank that provides a range of banking and banking-related services to individual and corporate clients. The company offers financing for commercial business properties, equipment, inventories, and accounts receivable, as well as commercial leasing and letters of credit; treasury management services; and merchant credit card transaction processing services. It also provides commercial and residential real estate lending products, as well as fixed- and adjustable-rate residential mortgage loans; personal, automobile, boat/RV, and home equity loans; and credit card programs. In addition, the company offers institutional banking services, including customized checking and savings accounts, cash management systems, tax-exempt loans, lines of credit, and term loans to meet the needs of state and local governments, public schools and colleges, charities, membership, and not-for-profit associations. Further, it provides consumer banking services comprising checking accounts, savings programs, interactive/automated teller machines, debit/credit cards, night deposit services, safe deposit facilities, and online and mobile banking services. Additionally, the company provides asset management for individuals through agency, personal trust, IRA, and personal investment management accounts; and various retail securities products, such as the U.S. government bonds, tax-free municipal bonds, stocks, mutual funds, unit investment trusts, annuities, life insurance, and long-term health care. As of December 31, 2021, it operated through 57 banking offices and 86 ATMs/ITMs in Florida, Georgia, and Alabama. The company was founded in 1895 and is headquartered in Tallahassee, Florida.",Mr. William Godfrey Smith Jr.,Banks - Regional,34.86,USD,590685270,https://images.financialmodelingprep.com/symbol/CCBG.png,27627,11.47,-0.48,9824,-3172000,52258000,"[{'period': '2023', 'revenue': 223.61, 'unit': 'M', 'net_profit': 52.26}, {'period': '2022', 'revenue': 212.55, 'unit': 'M', 'net_profit': 33.41}, {'period': '2021', 'revenue': 203.84, 'unit': 'M', 'net_profit': 33.4}, {'period': '2020', 'revenue': 206.66, 'unit': 'M', 'net_profit': 42.65}]","[{'period': ""Q3 '24"", 'revenue': 68.84, 'unit': 'M', 'net_profit': 13.12}, {'period': ""Q2 '24"", 'revenue': 68.18, 'unit': 'M', 'net_profit': 14.15}, {'period': ""Q1 '24"", 'revenue': 55.53, 'unit': 'M', 'net_profit': 12.56}, {'period': ""Q4 '23"", 'revenue': 62.84, 'unit': 'M', 'net_profit': 11.72}, {'period': ""Q3 '23"", 'revenue': 59.33, 'unit': 'M', 'net_profit': 12.65}, {'period': ""Q2 '23"", 'revenue': 61.01, 'unit': 'M', 'net_profit': 14.17}]",3.08,3.07,4304477000,312067000,421020000,3856445000,0,966374000,3175787000,83118000,50207000,-1.054828617357786,0.5640488447264456,0.2995780590717299,"[0.23, 0.11]","['2024-12-09', '1994-07-05']",__nan__,0.895914881180687
704,CCCC,C4 Therapeutics Inc. Common Stock,"C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.",Mr. Andrew J. Hirsch M.B.A.,Biotechnology,3.8588,USD,272388833,https://images.financialmodelingprep.com/symbol/CCCC.png,1351250,-2.26,-0.2312,233595,-122103000,-132493000,"[{'period': '2023', 'revenue': 20.76, 'unit': 'M', 'net_profit': -132.49}, {'period': '2022', 'revenue': 31.1, 'unit': 'M', 'net_profit': -126.5}, {'period': '2021', 'revenue': 45.78, 'unit': 'M', 'net_profit': -86.04}, {'period': '2020', 'revenue': 33.2, 'unit': 'M', 'net_profit': -66.33}]","[{'period': ""Q2 '24"", 'revenue': 15.36, 'unit': 'M', 'net_profit': -24.67}, {'period': ""Q1 '24"", 'revenue': 12.01, 'unit': 'M', 'net_profit': -17.72}, {'period': ""Q4 '23"", 'revenue': 3.04, 'unit': 'M', 'net_profit': -28.36}, {'period': ""Q3 '23"", 'revenue': 3.26, 'unit': 'M', 'net_profit': -34.75}, {'period': ""Q2 '23"", 'revenue': 11.07, 'unit': 'M', 'net_profit': -27.04}, {'period': ""Q1 '23"", 'revenue': 2.66, 'unit': 'M', 'net_profit': -35.92}]",-2.67,-2.67,376451000,271189000,253681000,130336999,11799000,28008000,42766000,126590000,-108546000,0.01754061295591513,-0.047383773784773,-0.030888030888030917,__nan__,__nan__,__nan__,0.34622566814804584
705,CCD,Calamos Dynamic Convertible & Income Fund Common Stock,"Calamos Dynamic Convertible and Income Fund is a closed ended fixed income mutual fund launched by Calamos Investments LLC. It is managed by Calamos Advisors LLC. The fund invests in the fixed income markets of the United States. It primarily invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities. The fund also invests through derivatives such as options. It employs fundamental analysis with a top-down global macroeconomic approach to create its portfolio. Calamos Dynamic Convertible and Income Fund was formed on March 11, 2014 and is domiciled in the United States.",Mr. John Peter Calamos Sr.,Asset Management - Income,24.27,USD,626110179,https://images.financialmodelingprep.com/symbol/CCD.png,59819,5.59,-0.06,21979,0,115378765,"[{'period': '2024', 'revenue': 115.87, 'unit': 'M', 'net_profit': 115.38}, {'period': '2023', 'revenue': -16.53, 'unit': 'M', 'net_profit': -17.07}, {'period': '2022', 'revenue': -232.16, 'unit': 'M', 'net_profit': -232.78}, {'period': '2021', 'revenue': 221.19, 'unit': 'M', 'net_profit': 220.62}]","[{'period': ""Q2 '24"", 'revenue': 8.26, 'unit': 'M', 'net_profit': 69.74}, {'period': ""Q4 '23"", 'revenue': 38.35, 'unit': 'M', 'net_profit': -23.31}, {'period': ""Q2 '23"", 'revenue': 50.37, 'unit': 'M', 'net_profit': 6.24}, {'period': ""Q4 '22"", 'revenue': -2.24, 'unit': 'M', 'net_profit': -67.68}, {'period': ""Q2 '22"", 'revenue': 63.47, 'unit': 'M', 'net_profit': -165.1}, {'period': ""Q4 '21"", 'revenue': -31.43, 'unit': 'M', 'net_profit': 38.15}]",0,0,824073068,0,0,307075585,4263323,800822422,0,0,56246270,1,7.7585192932075975,1,"[0.195, 0.167]","['2024-12-30', '2015-06-08']",__nan__,0.3726315018949266
706,CCLP,CSI Compressco LP Common Units,"CSI Compressco LP provides contract services for natural gas compression and treating in the United States, Latin America, Canada, Egypt, and internationally. The company offers natural gas compression services through low-, medium-, and high-horsepower compressor packages for oil and natural gas production, gathering, artificial lift, transmission, processing, and storage. It also provides treating services for natural gas producers and midstream companies, such as providing equipment for lease or sale, equipment installation services, and the operation of equipment for removal of contaminants from a natural gas stream, and natural gas cooling to reduce the temperature of produced gas and liquids; well monitoring and sand separation services; and operation, maintenance, overhaul, and reconfiguration services for compression equipment. In addition, the company sells engine parts, compressor package parts, and other parts manufactured by third-party suppliers. CSI Compressco GP LLC serves as the general partner of CSI Compressco LP. The company was formerly known as Compressco Partners, L.P. and changed its name to CSI Compressco LP in December 2014. CSI Compressco LP was incorporated in 2008 and is headquartered in The Woodlands, Texas.",Mr. John Earl Jackson,Oil & Gas Equipment & Services,2.42,USD,344842721,https://images.financialmodelingprep.com/symbol/CCLP.png,224392,-34.57142857142857,0.09,3018771,125601000,-9480000,"[{'period': '2023', 'revenue': 386.13, 'unit': 'M', 'net_profit': -9.48}, {'period': '2022', 'revenue': 353.4, 'unit': 'M', 'net_profit': -22.27}, {'period': '2021', 'revenue': 304.17, 'unit': 'M', 'net_profit': -49.66}, {'period': '2020', 'revenue': 301.59, 'unit': 'M', 'net_profit': -62.95}]","[{'period': ""Q4 '23"", 'revenue': 98.27, 'unit': 'M', 'net_profit': -3.33}, {'period': ""Q3 '23"", 'revenue': 99710.0, 'unit': 'K', 'net_profit': -947.0}, {'period': ""Q2 '23"", 'revenue': 96.78, 'unit': 'M', 'net_profit': -2.57}, {'period': ""Q1 '23"", 'revenue': 91.37, 'unit': 'M', 'net_profit': -2.61}, {'period': ""Q4 '22"", 'revenue': 93.97, 'unit': 'M', 'net_profit': -4.25}, {'period': ""Q3 '22"", 'revenue': 94.89, 'unit': 'M', 'net_profit': -4.53}]",-0.0668,-0.0668,687036000,120023000,7012000,725895000,59428000,0,70372000,7012000,4299000,2.7881831342743393,0.5742769894018322,0.5825,"[0.01, 0.047]","['2024-01-30', '2011-07-28']",__nan__,1.0565603549158995
707,CCMP,CMC Materials Inc. Common Stock,"CMC Materials, Inc., together with its subsidiaries, provides consumable materials to semiconductor manufacturers, and pipeline and adjacent industry customers in North America, Asia, Europe, the Middle East, Africa, and South America. The company operates in two segments, Electronic Materials and Performance Materials. The Electronic Materials segment develops, produces, and sells chemical mechanical planarization (CMP) slurries for polishing various materials used in IC devices, including tungsten, dielectric materials, copper, tantalum, and aluminum; and various materials that are used in the production of disk substrates and magnetic heads for hard disk drives; and CMP pads, which are used in conjunction with slurries in the CMP process. This segment also offers sulfuric, phosphoric, nitric, and hydrofluoric acids, as well as ammonium hydroxide, hydrogen peroxide, isopropyl alcohol, other specialty organic solvents, and various blends of chemicals; and develops and manufactures consumable products for cleaning advanced probe cards and test sockets. The Performance Materials segment provides pipeline and industrial materials comprising polymer-based drag-reducing agents for crude oil transmission, valve greases, cleaners and sealants, and related services and equipment; and routine and emergency maintenance services, as well as training services. This segment also offers precision polishing and metrology systems for advanced optics applications; and magneto-rheological polishing fluids, consumables, and spare and replacement parts, as well as optical polishing services and other customer support services; and engages in the wood treatment business. The company was formerly known as Cabot Microelectronics Corporation and changed its name to CMC Materials, Inc. in October 2020. CMC Materials, Inc. was incorporated in 1999 and is headquartered in Aurora, Illinois.",Mr. David Li,Semiconductors,173.69,USD,0,https://images.financialmodelingprep.com/symbol/CCMP.png,448476,0,0,0,115736000,-68577000,"[{'period': '2021', 'revenue': 1200.0, 'unit': 'M', 'net_profit': -68.58}, {'period': '2020', 'revenue': 1120.0, 'unit': 'M', 'net_profit': 142.83}, {'period': '2019', 'revenue': 1040.0, 'unit': 'M', 'net_profit': 39.22}, {'period': '2018', 'revenue': 590.12, 'unit': 'M', 'net_profit': 110.04}]","[{'period': ""Q2 '22"", 'revenue': 324.13, 'unit': 'M', 'net_profit': 34.57}, {'period': ""Q1 '22"", 'revenue': 317.05, 'unit': 'M', 'net_profit': 27.43}, {'period': ""Q4 '21"", 'revenue': 311.92, 'unit': 'M', 'net_profit': 16.06}, {'period': ""Q3 '21"", 'revenue': 309.52, 'unit': 'M', 'net_profit': 33.64}, {'period': ""Q2 '21"", 'revenue': 290.53, 'unit': 'M', 'net_profit': -149.81}, {'period': ""Q1 '21"", 'revenue': 287.86, 'unit': 'M', 'net_profit': 31.53}]",-2.35,-2.35,2150885000,534981000,185979000,1271948000,150099000,0,205858000,185979000,228510000,-0.66316059069716,-1.4801369479373792,-1.486542443064182,"[0.46, 15]","['2022-03-22', '2012-03-02']",__nan__,0.5913603005274572
708,CCNC,Code Chain New Continent Limited Common Stock,"Code Chain New Continent Limited, through its subsidiaries, focuses on research, development, and application of Internet of Things (IoT) and electronic token digital door signs. It creates digital door signs which is the digitalization of a physical store by means of animation and other technical services; and offers electronic tokens, that are used for purchasing virtual real estate properties. The company also offers Wuge Manor, a game that combines Internet of Things and e-commerce based on code chain platform that provides players with access to vendors and business owners in approximately 100 cities in China. Code Chain New Continent Limited is based in Chengdu, China.",Mr. Wei  Xu,Electronic Gaming & Multimedia,3.015,USD,0,https://images.financialmodelingprep.com/symbol/CCNC.png,27372,0,0.215,31337,-423443,-424652,"[{'period': '2022', 'revenue': 153.3, 'unit': 'K', 'net_profit': -424.65}, {'period': '2021', 'revenue': 25.03, 'unit': 'M', 'net_profit': -15.82}, {'period': '2020', 'revenue': 11.85, 'unit': 'M', 'net_profit': 2.51}, {'period': '2019', 'revenue': 19.58, 'unit': 'M', 'net_profit': -16.83}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -102.48}, {'period': ""Q2 '23"", 'revenue': 206.8, 'unit': 'K', 'net_profit': -155.5}, {'period': ""Q1 '23"", 'revenue': 75.37, 'unit': 'K', 'net_profit': -20.62}, {'period': ""Q4 '22"", 'revenue': -7.46, 'unit': 'M', 'net_profit': 19.02}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.09}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -20.37}]",-0.28,-0.28,3800908,1609921,389108,333784,194520,0,333784,389108,-886211,0.9710893352601512,0.9731637578145613,0.9765494137353434,__nan__,__nan__,__nan__,0.08781691111702783
709,CCNE,CNB Financial Corporation Common Stock,"CNB Financial Corporation operates as the bank holding company for CNB Bank that provides a range of banking products and services for individual, business, governmental, and institutional customers. The company accepts checking, savings, and time deposit accounts; and offers real estate, commercial, industrial, residential, and consumer loans, as well as various other specialized financial services. It also provides wealth and asset management services, including the administration of trusts and estates, retirement plans, and other employee benefit plans, as well as a range of wealth management services. In addition, the company invests in debt and equity securities; sells nonproprietary annuities and other insurance products; and small balance unsecured loans and secured loans primarily collateralized by automobiles and equipment. As of February 8, 2022, the company operated a private banking division; three loan production office; one drive-up office; and 45 full-service offices in Pennsylvania, Ohio, New York, and Virginia. CNB Financial Corporation was founded in 1865 and is headquartered in Clearfield, Pennsylvania.",Mr. Michael D. Peduzzi CPA,Banks - Regional,23.91,USD,501959367,https://images.financialmodelingprep.com/symbol/CCNE.png,50046,10.26,-0.42,12586,79568000,58020000,"[{'period': '2023', 'revenue': 218.14, 'unit': 'M', 'net_profit': 58.02}, {'period': '2022', 'revenue': 219.62, 'unit': 'M', 'net_profit': 63.19}, {'period': '2021', 'revenue': 189.38, 'unit': 'M', 'net_profit': 57.71}, {'period': '2020', 'revenue': 159.63, 'unit': 'M', 'net_profit': 32.74}]","[{'period': ""Q3 '24"", 'revenue': 56.08, 'unit': 'M', 'net_profit': 13.95}, {'period': ""Q2 '24"", 'revenue': 89.52, 'unit': 'M', 'net_profit': 12.96}, {'period': ""Q1 '24"", 'revenue': 86.86, 'unit': 'M', 'net_profit': 12.6}, {'period': ""Q4 '23"", 'revenue': 88.34, 'unit': 'M', 'net_profit': 13.98}, {'period': ""Q3 '23"", 'revenue': 53.89, 'unit': 'M', 'net_profit': 13.73}, {'period': ""Q2 '23"", 'revenue': 53.98, 'unit': 'M', 'net_profit': 13.83}]",2.56,2.55,5752957000,221873000,221873000,5181710000,0,740224000,3550000,221873000,36051000,-0.06155424770306769,-0.08178768120529215,-0.21472392638036802,"[0.18, 0.27]","['2024-11-29', '1994-08-31']",__nan__,0.9007037598229919
710,CCNEP,CNB Financial Corporation Depositary Shares each representing a 1/40th ownership interest in a share of 7.125% Series A Fixed-Rate Non-Cumulative Perpetual Preferred Stock,"CNB Financial Corporation operates as the bank holding company for CNB Bank that provides a range of banking products and services for individual, business, governmental, and institutional customers. The company accepts checking, savings, and time deposit accounts; and offers real estate, commercial, industrial, residential, and consumer loans, as well as various other specialized financial services. It also provides wealth and asset management services, including the administration of trusts and estates, retirement plans, and other employee benefit plans, as well as a range of wealth management services. In addition, the company invests in debt and equity securities; sells nonproprietary annuities and other insurance products; and small balance unsecured loans and secured loans primarily collateralized by automobiles and equipment. As of February 8, 2022, the company operated a private banking division; three loan production office; one drive-up office; and 45 full-service offices in Pennsylvania, Ohio, New York, and Virginia. CNB Financial Corporation was founded in 1865 and is headquartered in Clearfield, Pennsylvania.",Mr. Michael D. Peduzzi CPA,Banks - Regional,25.1,USD,526941870,https://images.financialmodelingprep.com/symbol/CCNEP.png,1887,7.8,-0.34,2104,79568000,58020000,"[{'period': '2023', 'revenue': 218.14, 'unit': 'M', 'net_profit': 58.02}, {'period': '2022', 'revenue': 219.62, 'unit': 'M', 'net_profit': 63.19}, {'period': '2021', 'revenue': 189.38, 'unit': 'M', 'net_profit': 57.71}, {'period': '2020', 'revenue': 159.63, 'unit': 'M', 'net_profit': 32.74}]","[{'period': ""Q3 '24"", 'revenue': 56.08, 'unit': 'M', 'net_profit': 13.95}, {'period': ""Q2 '24"", 'revenue': 89.52, 'unit': 'M', 'net_profit': 12.96}, {'period': ""Q1 '24"", 'revenue': 86.86, 'unit': 'M', 'net_profit': 12.6}, {'period': ""Q4 '23"", 'revenue': 88.34, 'unit': 'M', 'net_profit': 13.98}, {'period': ""Q3 '23"", 'revenue': 53.89, 'unit': 'M', 'net_profit': 13.73}, {'period': ""Q2 '23"", 'revenue': 53.98, 'unit': 'M', 'net_profit': 13.83}]",2.56,2.55,5752957000,221873000,221873000,5181710000,0,740224000,3550000,221873000,36051000,-0.06155424770306769,-0.08178768120529215,-0.21472392638036802,"[0.44531, 0.475]","['2024-11-15', '2020-11-16']",__nan__,0.9007037598229919
711,CCOI,Cogent Communications Holdings Inc.,"Cogent Communications Holdings, Inc., through its subsidiaries, provides high-speed Internet access, private network, and data center colocation space services in North America, Europe, Asia, South America, Australia, and Africa. The company offers on-net Internet access and private network services to law firms, financial services firms, and advertising and marketing firms, as well as heath care providers, educational institutions and other professional services businesses, other Internet service providers, telephone companies, cable television companies, Web hosting companies, media service providers, mobile phone operators, content delivery network companies, and commercial content and application service providers. It also provides Internet access and private network services to customers that are not located in buildings directly connected to its network; and on-net services to customers located in buildings that are physically connected to its network. In addition, the company offers off-net services to corporate customers using other carriers' circuits to provide the last mile portion of the link from the customers' premises to the network. Further, it operates data centers that allow its customers to collocate their equipment and access the network. The company operates 54 data centers and provides facilities to 3,035 buildings and on-net services to 1,817 to multi-tenant office buildings. It serves primarily to small and medium-sized businesses, communications service providers, and other bandwidth-intensive organizations. Cogent Communications Holdings, Inc. was founded in 1999 and is headquartered in Washington, the District of Columbia.",Mr. David  Schaeffer Ph.D.,Telecommunications Services,73.825,USD,3619218948,https://images.financialmodelingprep.com/symbol/CCOI.png,401788,106.99,-1.955,148881,1558469000,1273441000,"[{'period': '2023', 'revenue': 0.94092, 'unit': 'B', 'net_profit': 1.27}, {'period': '2022', 'revenue': 599.6, 'unit': 'M', 'net_profit': 5.15}, {'period': '2021', 'revenue': 589.8, 'unit': 'M', 'net_profit': 48.19}, {'period': '2020', 'revenue': 568.1, 'unit': 'M', 'net_profit': 6.22}]","[{'period': ""Q3 '24"", 'revenue': 257.2, 'unit': 'M', 'net_profit': -63.11}, {'period': ""Q2 '24"", 'revenue': 260.44, 'unit': 'M', 'net_profit': -32.34}, {'period': ""Q1 '24"", 'revenue': 266.17, 'unit': 'M', 'net_profit': -65.31}, {'period': ""Q4 '23"", 'revenue': 272.1, 'unit': 'M', 'net_profit': 200.15}, {'period': ""Q3 '23"", 'revenue': 275.43, 'unit': 'M', 'net_profit': -56.72}, {'period': ""Q2 '23"", 'revenue': 0.23981, 'unit': 'B', 'net_profit': 1.12}]",26.88,26.62,3211619000,513626999,75092000,2602063000,319258000,0,373324000,75092000,-112287000,6.47721766164977,246.4623008161679,243.36363636363635,"[0.995, 0.1]","['2024-11-22', '2012-08-20']",__nan__,0.8102028914388661
712,CCRC,China Customer Relations Centers Inc. Ordinary Shares,"China Customer Relations Centers, Inc. is a business process outsourcing service provider company, which focuses on the voice-based customer care services including inbound and outbound. The company is headquartered in Taian, Shandong and currently employs 11,101 full-time employees. The firm's customers are the provincial subsidiaries of various telecommunications carriers in the PRC. The company also provides outsourcing services to its clients whereby they can lease its employees to work at their offices. The firm operates its business through contractual arrangements between its subsidiary, wholly foreign owned enterprise (WFOE) and its variable interest entity, Shandong Taiying Technology Co., Ltd (Taiying). Its line of services includes Inbound Customer Care Service and Outbound Customer Care Service. The firm's inbound customer support service offers answering service hotlines in China, round the clock.",Mr. Gary Wang,Information Technology Services,6.5,USD,0,https://images.financialmodelingprep.com/symbol/CCRC.png,51535,4.793510324483776,0.01999998,147697,32177280,24860799,"[{'period': '2020', 'revenue': 240.32, 'unit': 'M', 'net_profit': 24.86}, {'period': '2019', 'revenue': 173.41, 'unit': 'M', 'net_profit': 13.06}, {'period': '2018', 'revenue': 141.43, 'unit': 'M', 'net_profit': 16.09}, {'period': '2017', 'revenue': 88.97, 'unit': 'M', 'net_profit': 8.77}]","[{'period': ""Q2 '20"", 'revenue': 48.86, 'unit': 'M', 'net_profit': 5.15}, {'period': ""Q4 '19"", 'revenue': 100.13, 'unit': 'M', 'net_profit': 8.07}, {'period': ""Q2 '19"", 'revenue': 73.27, 'unit': 'M', 'net_profit': 4.99}, {'period': ""Q4 '18"", 'revenue': 75.4, 'unit': 'M', 'net_profit': 5.08}, {'period': ""Q2 '18"", 'revenue': 66.04, 'unit': 'M', 'net_profit': 11.01}, {'period': ""Q4 '17"", 'revenue': 54.23, 'unit': 'M', 'net_profit': 4.73}]",1.36,1.36,143957860,114870576,43669538,48442062,64763837,3678171,40805723,43669538,18715270,0.7242617708497107,0.9041651316137166,0.9154929577464791,__nan__,__nan__,__nan__,0.33650168181160794
713,CCRN,Cross Country Healthcare Inc. Common Stock $0.0001 Par Value,"Cross Country Healthcare, Inc. provides talent management and other consultative services for healthcare clients in the United States. The company operates in two segments, Nurse and Allied Staffing and Physician Staffing. The Nurse and Allied Staffing segment offers traditional staffing, including temporary and permanent placement of travel nurses and allied professionals, local nurses, and allied staffing; staffing solutions for registered nurses, licensed practical nurses, certified nurse assistants, practitioners, pharmacists, and other allied professionals on per diem and short-term assignments; and clinical and non-clinical professionals on long-term contract assignments, as well as workforce solutions, including MSP, RPO, and consulting services. It also provides retained search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services. This segment serves public and private acute care and non-acute care hospitals, government facilities, local and national healthcare plans, managed care providers, public and charter schools, outpatient clinics, ambulatory care facilities, physician practice groups, and other healthcare providers under the Cross Country brand. The Physician Staffing segment provides physicians in various specialties, certified registered nurse anesthetists, nurse practitioners, and physician assistants under the Cross Country Locums brand as independent contractors on temporary assignments at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations. The company was founded in 1986 and is headquartered in Boca Raton, Florida.",Mr. John A. Martins,Medical - Care Facilities,18.195,USD,587287293,https://images.financialmodelingprep.com/symbol/CCRN.png,910219,-363.9,-0.035,169771,129335000,72631000,"[{'period': '2023', 'revenue': 2020.0, 'unit': 'M', 'net_profit': 72.63}, {'period': '2022', 'revenue': 2810.0, 'unit': 'M', 'net_profit': 188.46}, {'period': '2021', 'revenue': 1680.0, 'unit': 'M', 'net_profit': 132.0}, {'period': '2020', 'revenue': 836.42, 'unit': 'M', 'net_profit': -12.14}]","[{'period': ""Q3 '24"", 'revenue': 315.12, 'unit': 'M', 'net_profit': 2.56}, {'period': ""Q2 '24"", 'revenue': 339.77, 'unit': 'M', 'net_profit': -16.05}, {'period': ""Q1 '24"", 'revenue': 379.17, 'unit': 'M', 'net_profit': 2.69}, {'period': ""Q4 '23"", 'revenue': 414.04, 'unit': 'M', 'net_profit': 9.04}, {'period': ""Q3 '23"", 'revenue': 442.29, 'unit': 'M', 'net_profit': 12.81}, {'period': ""Q2 '23"", 'revenue': 540.7, 'unit': 'M', 'net_profit': 21.34}]",2.07,2.05,679317000,415153000,17094000,205924000,388347000,33000,148587000,17094000,234524000,-0.5464189772113544,-0.614609919293647,-0.593320235756385,__nan__,__nan__,__nan__,0.30313388300307514
714,CCXI,ChemoCentryx Inc. Common Stock,"ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.",Dr. Thomas Schall,Biotechnology,51.99,USD,0,https://images.financialmodelingprep.com/symbol/CCXI.png,2020634,-25.930174563591024,0,656224,-131311000,-129060000,"[{'period': '2021', 'revenue': 32.22, 'unit': 'M', 'net_profit': -129.06}, {'period': '2020', 'revenue': 64.89, 'unit': 'M', 'net_profit': -55.36}, {'period': '2019', 'revenue': 35.95, 'unit': 'M', 'net_profit': -55.49}, {'period': '2018', 'revenue': 42.88, 'unit': 'M', 'net_profit': -37.97}]","[{'period': ""Q2 '22"", 'revenue': 11.76, 'unit': 'M', 'net_profit': -32.24}, {'period': ""Q1 '22"", 'revenue': 5.46, 'unit': 'M', 'net_profit': -39.2}, {'period': ""Q4 '21"", 'revenue': 2.61, 'unit': 'M', 'net_profit': -35.78}, {'period': ""Q3 '21"", 'revenue': 17.69, 'unit': 'M', 'net_profit': -22.31}, {'period': ""Q2 '21"", 'revenue': 1.7, 'unit': 'M', 'net_profit': -39.21}, {'period': ""Q1 '21"", 'revenue': 10.22, 'unit': 'M', 'net_profit': -29.71}]",-1.96,-1.96,425652000,269177000,264492000,139532000,411000,97856000,63017000,49978000,-94641000,-1.52929732645042,-1.3314545848688488,-1.3333333333333335,__nan__,__nan__,__nan__,0.3278076926691288
715,CD,Chindata Group Holdings Limited American Depositary Shares,"Chindata Group Holdings Limited provides carrier-neutral hyper scale data center solutions in China, India, Malaysia, and Southeast Asia. It offers artificial intelligence, cloud computing, smart cities and homes, online entertainment, and other on-demand services. The company also provides internet data center colocation and rental services; and technical and consulting services. Its integrated data center solutions include infrastructure, power supply, connectivity and operation and maintenance, tailor-made to their scale and requirements throughout the planning, design, construction, and operation process. The company was formerly known as BCPE Bridge Stack Limited and changed its name to Chindata Group Holdings Limited in April 2020. Chindata Group Holdings Limited was founded in 2015 and is headquartered in Beijing, China.",Mr. Huapeng  Wu,Information Technology Services,8.45,USD,3097770000,https://images.financialmodelingprep.com/symbol/CD.png,2173064,26.40625,-0.14,11291061,2098286000,651630000,"[{'period': '2022', 'revenue': 4550.0, 'unit': 'M', 'net_profit': 651.63}, {'period': '2021', 'revenue': 2850.0, 'unit': 'M', 'net_profit': 316.42}, {'period': '2020', 'revenue': 1830.0, 'unit': 'M', 'net_profit': -283.35}, {'period': '2019', 'revenue': 853.01, 'unit': 'M', 'net_profit': -169.7}]","[{'period': ""Q2 '23"", 'revenue': 1550.0, 'unit': 'M', 'net_profit': 219.22}, {'period': ""Q1 '23"", 'revenue': 1440.0, 'unit': 'M', 'net_profit': 252.97}, {'period': ""Q4 '22"", 'revenue': 1390.0, 'unit': 'M', 'net_profit': 116.46}, {'period': ""Q3 '22"", 'revenue': 1200.0, 'unit': 'M', 'net_profit': 241.04}, {'period': ""Q2 '22"", 'revenue': 1040.0, 'unit': 'M', 'net_profit': 199.56}, {'period': ""Q1 '22"", 'revenue': 920.61, 'unit': 'M', 'net_profit': 94.57}]",1.78,1.78,23100231000,6756422000,3115914000,12190677000,2375271000,0,4255680000,3115914000,-3824620000,0.560046542231871,1.059383098413501,1.0227272727272727,__nan__,__nan__,__nan__,0.5277296577683573
716,CDAK,Codiak BioSciences Inc. Common Stock,"Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.",Dr. Douglas Edward Williams Ph.D.,Biotechnology,0.057,USD,0,https://images.financialmodelingprep.com/symbol/CDAK.png,1599191,-0.12391304347826088,0,12929980,-61326000,-41633000,"[{'period': '2021', 'revenue': 22.93, 'unit': 'M', 'net_profit': -41.63}, {'period': '2020', 'revenue': 2.92, 'unit': 'M', 'net_profit': -88.93}, {'period': '2019', 'revenue': 0.388, 'unit': 'M', 'net_profit': -79.25}, {'period': '2018', 'revenue': 0.0, 'unit': 'M', 'net_profit': -44.54}]","[{'period': ""Q3 '22"", 'revenue': 0.028, 'unit': 'M', 'net_profit': -17.16}, {'period': ""Q2 '22"", 'revenue': 13.14, 'unit': 'M', 'net_profit': -6.53}, {'period': ""Q1 '22"", 'revenue': 12.7, 'unit': 'M', 'net_profit': -7.8}, {'period': ""Q4 '21"", 'revenue': 7.7, 'unit': 'M', 'net_profit': 2.26}, {'period': ""Q3 '21"", 'revenue': 1.16, 'unit': 'M', 'net_profit': -21.7}, {'period': ""Q2 '21"", 'revenue': 0.89, 'unit': 'M', 'net_profit': -21.81}]",-1.91,-1.91,171670000,90171000,76938000,118165000,0,0,27165000,76938000,-77389000,0.31677046312904555,0.5318505358086606,0.863960113960114,__nan__,__nan__,__nan__,0.6883264402632958
717,CDEV,Centennial Resource Development Inc. Class A Common Stock,"Centennial Resource Development, Inc., an independent oil and natural gas company, focuses on the development of crude oil and related liquids-rich natural gas reserves in the United States. Its assets primarily focus on the Delaware Basin, a sub-basin of the Permian Basin. The company's properties consist of acreage blocks primarily in Reeves County, West Texas and Lea County, New Mexico. As of December 31, 2021, it leased or acquired approximately 73,675 net acres; and owned 991 net mineral acres in the Delaware Basin. The company was formerly known as Silver Run Acquisition Corporation and changed its name to Centennial Resource Development, Inc. in October 2016. The company was incorporated in 2015 and is headquartered in Denver, Colorado.",Mr. Mark Papa,Oil & Gas Exploration & Production,7.62,USD,4181414109,https://images.financialmodelingprep.com/symbol/CDEV.png,0,5.521739130434782,-0.60999966,17581515,2220433000,476306000,"[{'period': '2023', 'revenue': 3120.0, 'unit': 'M', 'net_profit': 476.31}, {'period': '2022', 'revenue': 2130.0, 'unit': 'M', 'net_profit': 749.84}, {'period': '2021', 'revenue': 1030.0, 'unit': 'M', 'net_profit': 138.18}, {'period': '2020', 'revenue': 580.46, 'unit': 'M', 'net_profit': -685.2}]","[{'period': ""Q3 '24"", 'revenue': 1220.0, 'unit': 'M', 'net_profit': 386.38}, {'period': ""Q2 '24"", 'revenue': 1250.0, 'unit': 'M', 'net_profit': 235.1}, {'period': ""Q1 '24"", 'revenue': 1240.0, 'unit': 'M', 'net_profit': 146.57}, {'period': ""Q4 '23"", 'revenue': 1120.0, 'unit': 'M', 'net_profit': 255.35}, {'period': ""Q3 '23"", 'revenue': 758.54, 'unit': 'M', 'net_profit': 45.43}, {'period': ""Q2 '23"", 'revenue': 623.4, 'unit': 'M', 'net_profit': 73.4}]",1.38,1.24,14965578000,650392000,73290000,5735830000,481060000,0,1241553000,73290000,419829000,0.5742671691050051,-0.36478982182865677,-0.47328244274809167,__nan__,__nan__,__nan__,0.3832681905102496
718,CDK,CDK Global Inc. Common Stock,"CDK Global, Inc., together with its subsidiaries, provides integrated data and technology solutions to the automotive, heavy truck, recreation, and heavy equipment industries in the United States and internationally. It offers subscription-based software and technology solutions to automotive retailers, as well as to retailers and manufacturers of heavy trucks, construction and agricultural equipment, motorcycles, boats, and other marine and recreational vehicles. The company's flagship Dealer Management System provides software solutions that facilitates the sale of new and used vehicles, consumer financing, repair and maintenance services, and vehicle and parts inventory management. It also provides a portfolio of layered software applications and services to address the needs of automotive retail workflows. In addition, the company offers data management and business intelligence solutions to automotive retailers and original equipment manufacturers through its Neuron intelligent data platform. Further, it offers professional services, custom programming, consulting, implementation, and training solutions, as well as customer support solutions. The company serves approximately 15,000 retail locations. CDK Global, Inc. was incorporated in 2014 and is headquartered in Hoffman Estates, Illinois.",Mr. Brian Krzanich,Software - Application,54.76,USD,0,https://images.financialmodelingprep.com/symbol/CDK.png,1874131,28.08205128205128,0,16774575,1352100000,1034300000,"[{'period': '2021', 'revenue': 1.67, 'unit': 'B', 'net_profit': 1.03}, {'period': '2020', 'revenue': 1960.0, 'unit': 'M', 'net_profit': 207.5}, {'period': '2019', 'revenue': 1910.0, 'unit': 'M', 'net_profit': 124.0}, {'period': '2018', 'revenue': 2270.0, 'unit': 'M', 'net_profit': 380.8}]","[{'period': ""Q3 '22"", 'revenue': 459.7, 'unit': 'M', 'net_profit': 70.1}, {'period': ""Q2 '22"", 'revenue': 436.7, 'unit': 'M', 'net_profit': 63.8}, {'period': ""Q1 '22"", 'revenue': 440.0, 'unit': 'M', 'net_profit': 71.7}, {'period': ""Q4 '21"", 'revenue': 420.1, 'unit': 'M', 'net_profit': 49.4}, {'period': ""Q3 '21"", 'revenue': 433.1, 'unit': 'M', 'net_profit': 860.9}, {'period': ""Q2 '21"", 'revenue': 406.3, 'unit': 'M', 'net_profit': 68.3}]",8.44,8.44,2712600000,562300000,157000000,2217700000,236400000,0,368300000,157000000,121300000,1.3646379853095487,3.984578313253012,3.964705882352941,"[0.15, 0.12]","['2022-06-16', '2014-11-26']",__nan__,0.8175551131755512
719,CDLX,Cardlytics Inc. Common Stock,"Cardlytics, Inc. operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing. The company was incorporated in 2008 and is headquartered in Atlanta, Georgia.",Mr. Amit  Gupta,Advertising Agencies,3.515,USD,178640736,https://images.financialmodelingprep.com/symbol/CDLX.png,0,-0.55,,0,-99004000,-134702000,"[{'period': '2023', 'revenue': 309.2, 'unit': 'M', 'net_profit': -134.7}, {'period': '2022', 'revenue': 298.54, 'unit': 'M', 'net_profit': -465.26}, {'period': '2021', 'revenue': 267.12, 'unit': 'M', 'net_profit': -128.56}, {'period': '2020', 'revenue': 186.89, 'unit': 'M', 'net_profit': -58.47}]","[{'period': ""Q3 '24"", 'revenue': 67.06, 'unit': 'M', 'net_profit': -145.18}, {'period': ""Q2 '24"", 'revenue': 69.64, 'unit': 'M', 'net_profit': -4.26}, {'period': ""Q1 '24"", 'revenue': 67.61, 'unit': 'M', 'net_profit': -24.27}, {'period': ""Q4 '23"", 'revenue': 89.17, 'unit': 'M', 'net_profit': -100.84}, {'period': ""Q3 '23"", 'revenue': 79.0, 'unit': 'M', 'net_profit': -23.97}, {'period': ""Q2 '23"", 'revenue': 76.7, 'unit': 'M', 'net_profit': -23.51}]",-3.69,-3.69,574144000,223928000,91830000,439346000,126001000,0,171149000,91830000,-12577000,0.7637000687390209,0.7104826507101345,0.7349137931034483,__nan__,__nan__,__nan__,0.7652191784639394
720,CDMO,Avid Bioservices Inc. Common Stock,"Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.","Mr. Nicholas Stewart Green B.Sc., MBA",Biotechnology,12.35,USD,789946755,https://images.financialmodelingprep.com/symbol/CDMO.png,1900538,-5.12,-0.01,484372,-11481000,-140753000,"[{'period': '2024', 'revenue': 139.91, 'unit': 'M', 'net_profit': -140.75}, {'period': '2023', 'revenue': 149270.0, 'unit': 'K', 'net_profit': 560.0}, {'period': '2022', 'revenue': 119.6, 'unit': 'M', 'net_profit': 127.67}, {'period': '2021', 'revenue': 95.87, 'unit': 'M', 'net_profit': 11.21}]","[{'period': ""Q2 '25"", 'revenue': 33.48, 'unit': 'M', 'net_profit': -17.41}, {'period': ""Q1 '25"", 'revenue': 40.17, 'unit': 'M', 'net_profit': -5.53}, {'period': ""Q4 '24"", 'revenue': 42.98, 'unit': 'M', 'net_profit': -123.1}, {'period': ""Q3 '24"", 'revenue': 33.81, 'unit': 'M', 'net_profit': -6.01}, {'period': ""Q2 '24"", 'revenue': 25.39, 'unit': 'M', 'net_profit': -9.51}, {'period': ""Q1 '24"", 'revenue': 37.73, 'unit': 'M', 'net_profit': -2.09}]",-2.23,-2.23,336557000,104002000,38106000,275668000,29008000,0,70566000,38106000,-20853000,-2.0522408578498763,-252.34464285714284,-248.77777777777777,"[0.66, 0.66]","['2018-03-16', '2018-03-16']",__nan__,0.8190826516756449
721,CDNA,CareDx Inc. Common Stock,"CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.",Mr. John Walter Hanna Jr.,Medical - Diagnostics & Research,22.325,USD,1197376818,https://images.financialmodelingprep.com/symbol/CDNA.png,805687,-8.3,-1.015,177236,-89657000,-190284000,"[{'period': '2023', 'revenue': 280.32, 'unit': 'M', 'net_profit': -190.28}, {'period': '2022', 'revenue': 321.79, 'unit': 'M', 'net_profit': -76.61}, {'period': '2021', 'revenue': 296.4, 'unit': 'M', 'net_profit': -30.66}, {'period': '2020', 'revenue': 192.19, 'unit': 'M', 'net_profit': -18.71}]","[{'period': ""Q3 '24"", 'revenue': 82.88, 'unit': 'M', 'net_profit': -7.41}, {'period': ""Q2 '24"", 'revenue': 92.27, 'unit': 'M', 'net_profit': -1.39}, {'period': ""Q1 '24"", 'revenue': 72.05, 'unit': 'M', 'net_profit': -16.66}, {'period': ""Q4 '23"", 'revenue': 65.57, 'unit': 'M', 'net_profit': -118.1}, {'period': ""Q3 '23"", 'revenue': 67.19, 'unit': 'M', 'net_profit': -23.48}, {'period': ""Q2 '23"", 'revenue': 70.3, 'unit': 'M', 'net_profit': -24.95}]",-3.54,-3.54,466826000,313713000,235418000,205498001,51061000,586000,78072000,82197000,-27628000,-0.4644093819417222,-1.4837038100583453,-1.4583333333333335,__nan__,__nan__,__nan__,0.4402025615539837
722,CDNS,Cadence Design Systems Inc. Common Stock,"Cadence Design Systems, Inc. provides software, hardware, services, and reusable integrated circuit (IC) design blocks worldwide. The company offers functional verification services, including emulation and prototyping hardware. Its functional verification offering consists of JasperGold, a formal verification platform; Xcelium, a parallel logic simulation platform; Palladium, an enterprise emulation platform; and Protium, a prototyping platform for chip verification. The company also provides digital IC design and sign off products, including Genus logic synthesis and Joules RTL power solutions, as well as Modus software solution to reduce systems-on-chip design-for-test time; physical implementation tools, such as place and route, optimization, and multiple patterning preparation; and signoff products to signoff the design as ready for silicon manufacturing. In addition, it offers custom IC design and simulation products to create schematic and physical representations of circuits down to the transistor level for analog, mixed-signal, custom digital, memory, and radio frequency designs; and system design and analysis products to develop printed circuit boards and IC packages, as well as to analyze electromagnetic, electro-thermal, and other multi-physics effects. Further, the company provides intellectual property (IP) products comprising pre-verified and customizable functional blocks to integrate into customer's ICs; and verification IP and memory models to emulate and model the expected behavior and interaction of standard industry system interface protocols. Additionally, it offers services related to methodology, education, and hosted design solutions, as well as technical support and maintenance services. The company serves 5G communications, aerospace and defense, automotive, industrial and healthcare, mobile, consumer, and hyperscale computing markets. Cadence Design Systems, Inc. was incorporated in 1987 and is headquartered in San Jose, California.",Dr. Anirudh  Devgan Ph.D.,Software - Application,301.895,USD,82798628385,https://images.financialmodelingprep.com/symbol/CDNS.png,1829790,79.45,-6.245,642975,1419630000,1041144000,"[{'period': '2023', 'revenue': 4.09, 'unit': 'B', 'net_profit': 1.04}, {'period': '2022', 'revenue': 3560.0, 'unit': 'M', 'net_profit': 848.95}, {'period': '2021', 'revenue': 2990.0, 'unit': 'M', 'net_profit': 695.96}, {'period': '2020', 'revenue': 2680.0, 'unit': 'M', 'net_profit': 590.64}]","[{'period': ""Q3 '24"", 'revenue': 1220.0, 'unit': 'M', 'net_profit': 238.11}, {'period': ""Q2 '24"", 'revenue': 1060.0, 'unit': 'M', 'net_profit': 229.52}, {'period': ""Q1 '24"", 'revenue': 1010.0, 'unit': 'M', 'net_profit': 247.64}, {'period': ""Q4 '23"", 'revenue': 1070.0, 'unit': 'M', 'net_profit': 323.9}, {'period': ""Q3 '23"", 'revenue': 1020.0, 'unit': 'M', 'net_profit': 254.32}, {'period': ""Q2 '23"", 'revenue': 976.58, 'unit': 'M', 'net_profit': 221.12}]",3.86,3.82,5669491000,1976217000,1138511000,2265220000,506778000,249421000,1590867000,1008152000,1246673000,0.18264556788030506,0.22638735758912165,0.23322683706070288,__nan__,__nan__,__nan__,0.39954556767088967
723,CDTX,Cidara Therapeutics Inc. Common Stock,"Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.",Dr. Jeffrey L. Stein Ph.D.,Biotechnology,26.78,USD,188708751,https://images.financialmodelingprep.com/symbol/CDTX.png,59391,-1.12,-0.03,118635,-24365000,-22931000,"[{'period': '2023', 'revenue': 63.91, 'unit': 'M', 'net_profit': -22.93}, {'period': '2022', 'revenue': 64.29, 'unit': 'M', 'net_profit': -29.8}, {'period': '2021', 'revenue': 49.57, 'unit': 'M', 'net_profit': -43.91}, {'period': '2020', 'revenue': 12.07, 'unit': 'M', 'net_profit': -72.37}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.54}, {'period': ""Q2 '24"", 'revenue': 0.302, 'unit': 'M', 'net_profit': -89.41}, {'period': ""Q1 '24"", 'revenue': 8.46, 'unit': 'M', 'net_profit': -10.33}, {'period': ""Q4 '23"", 'revenue': 17.58, 'unit': 'M', 'net_profit': -5.61}, {'period': ""Q3 '23"", 'revenue': 12.72, 'unit': 'M', 'net_profit': -8.17}, {'period': ""Q2 '23"", 'revenue': 7.61, 'unit': 'M', 'net_profit': -12.36}]",-5.25,-5.25,67030000,60855000,35778000,75240000,16245999,0,67418000,35778000,-22937000,0.26963429256594723,0.2304775328031142,0.3845252051582649,__nan__,__nan__,__nan__,1.1224824705355811
724,CDW,CDW Corporation Common Stock,"CDW Corporation provides information technology (IT) solutions in the United States, the United Kingdom, and Canada. It operates through three segments: Corporate, Small Business, and Public. The company offers discrete hardware and software products and services, as well as integrated IT solutions, including on-premise, hybrid, and cloud capabilities across data center and networking, digital workspace, and security. Its hardware products comprise notebooks/mobile devices, network communications, desktop computers, video monitors, enterprise and data storage, and others; and software products consists of application suites, security, virtualization, operating systems, and network management. The company also provides advisory and design, software development, implementation, managed, professional, configuration, and telecom services, as well as warranties; mission critical software, systems, and network solutions; and implementation and installation, and repair services to its customers through various third-party service providers. It serves government, education, and healthcare customers; and small, medium, and large business customers. The company was founded in 1984 and is headquartered in Vernon Hills, Illinois.",Ms. Christine A. Leahy J.D.,Information Technology Services,182.21,USD,24282033440,https://images.financialmodelingprep.com/symbol/CDW.png,1305898,22.3,2.92,636661,1947800000,1104300000,"[{'period': '2023', 'revenue': 21.38, 'unit': 'B', 'net_profit': 1.1}, {'period': '2022', 'revenue': 23.75, 'unit': 'B', 'net_profit': 1.11}, {'period': '2021', 'revenue': 20820.0, 'unit': 'M', 'net_profit': 988.6}, {'period': '2020', 'revenue': 18470.0, 'unit': 'M', 'net_profit': 788.5}]","[{'period': ""Q3 '24"", 'revenue': 5520.0, 'unit': 'M', 'net_profit': 316.4}, {'period': ""Q2 '24"", 'revenue': 5420.0, 'unit': 'M', 'net_profit': 281.1}, {'period': ""Q1 '24"", 'revenue': 4870.0, 'unit': 'M', 'net_profit': 216.1}, {'period': ""Q4 '23"", 'revenue': 5020.0, 'unit': 'M', 'net_profit': 296.1}, {'period': ""Q3 '23"", 'revenue': 5630.0, 'unit': 'M', 'net_profit': 315.5}, {'period': ""Q2 '23"", 'revenue': 5630.0, 'unit': 'M', 'net_profit': 262.6}]",8.2,8.1,13284600000,6705000000,588700000,11242100000,5038000000,0,5442000000,588700000,1450500000,-0.03483474555274763,-0.009152086137281292,-0.004854368932038947,"[0.625, 0.0425]","['2024-11-25', '2013-11-13']",__nan__,0.8462505457446968
725,CDXC,ChromaDex Corporation Common Stock,"ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.",Mr. Robert N. Fried,Biotechnology,5.32,USD,406359156,https://images.financialmodelingprep.com/symbol/CDXC.png,1317437,266,-0.06,174581,-3894000,-4938000,"[{'period': '2023', 'revenue': 83.57, 'unit': 'M', 'net_profit': -4.94}, {'period': '2022', 'revenue': 72.05, 'unit': 'M', 'net_profit': -14.45}, {'period': '2021', 'revenue': 67.45, 'unit': 'M', 'net_profit': -25.56}, {'period': '2020', 'revenue': 59.26, 'unit': 'M', 'net_profit': -18.48}]","[{'period': ""Q3 '24"", 'revenue': 34.92, 'unit': 'M', 'net_profit': 1.88}, {'period': ""Q2 '24"", 'revenue': 22740.0, 'unit': 'K', 'net_profit': -15.0}, {'period': ""Q1 '24"", 'revenue': 22150.0, 'unit': 'K', 'net_profit': -492.0}, {'period': ""Q4 '23"", 'revenue': 21200.0, 'unit': 'K', 'net_profit': 114.0}, {'period': ""Q3 '23"", 'revenue': 19500.0, 'unit': 'K', 'net_profit': -959.0}, {'period': ""Q2 '23"", 'revenue': 20.32, 'unit': 'M', 'net_profit': -2.19}]",-0.0659,-0.0659,54964000,49534000,27325000,26508000,5234000,0,20622000,27173000,6969000,0.767439082656474,0.6582462454149076,0.6861904761904762,__nan__,__nan__,__nan__,0.48227931009387964
726,CDXS,Codexis Inc. Common Stock,"Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.","Dr. Stephen George Dilly MBBS, Ph.D.",Biotechnology,5.02,USD,408516556,https://images.financialmodelingprep.com/symbol/CDXS.png,672798,-6.05,-0.12,153537,-49283000,-76240000,"[{'period': '2023', 'revenue': 70.14, 'unit': 'M', 'net_profit': -76.24}, {'period': '2022', 'revenue': 138.59, 'unit': 'M', 'net_profit': -33.59}, {'period': '2021', 'revenue': 104.75, 'unit': 'M', 'net_profit': -21.28}, {'period': '2020', 'revenue': 69.06, 'unit': 'M', 'net_profit': -24.01}]","[{'period': ""Q3 '24"", 'revenue': 12.83, 'unit': 'M', 'net_profit': -20.64}, {'period': ""Q2 '24"", 'revenue': 7.98, 'unit': 'M', 'net_profit': -22.75}, {'period': ""Q1 '24"", 'revenue': 17.07, 'unit': 'M', 'net_profit': -11.51}, {'period': ""Q4 '23"", 'revenue': 26.56, 'unit': 'M', 'net_profit': -7.19}, {'period': ""Q3 '23"", 'revenue': 9.28, 'unit': 'M', 'net_profit': -34.91}, {'period': ""Q2 '23"", 'revenue': 21.32, 'unit': 'M', 'net_profit': -11.52}]",-1.12,-1.12,136561000,93466000,65116000,49946000,19928000,9700000,35830000,65116000,-57056000,-1.13670062865814,-1.2695879971421766,-1.1960784313725492,__nan__,__nan__,__nan__,0.3657413170670982
727,CDZI,CADIZ Inc. Common Stock,"Cadiz Inc., together with its subsidiaries, operates as a natural resources development company in the United States. It engages in the water resource and agricultural development activities in San Bernardino County properties. The company owns approximately 35,000 acres of land in the Cadiz and Fenner valleys of eastern San Bernardino County; and approximately 11,000 acres of land in the eastern Mojave Desert portion of San Bernardino County. It is also involved in the cultivation of lemons, and spring and fall plantings of vegetables and grains. Cadiz Inc. was founded in 1983 and is headquartered in Los Angeles, California.",Ms. Susan P. Kennedy,Regulated Water,4.845,USD,364266965,https://images.financialmodelingprep.com/symbol/CDZI.png,467388,-9.69,-0.135,214998,-24491000,-31446000,"[{'period': '2023', 'revenue': 1.99, 'unit': 'M', 'net_profit': -31.45}, {'period': '2022', 'revenue': 1.5, 'unit': 'M', 'net_profit': -24.83}, {'period': '2021', 'revenue': 0.5640000000000001, 'unit': 'M', 'net_profit': -30.31}, {'period': '2020', 'revenue': 0.541, 'unit': 'M', 'net_profit': -35.65}]","[{'period': ""Q3 '24"", 'revenue': 3.22, 'unit': 'M', 'net_profit': -6.79}, {'period': ""Q2 '24"", 'revenue': 0.513, 'unit': 'M', 'net_profit': -8.87}, {'period': ""Q1 '24"", 'revenue': 1.12, 'unit': 'M', 'net_profit': -6.85}, {'period': ""Q4 '23"", 'revenue': 0.684, 'unit': 'M', 'net_profit': -6.75}, {'period': ""Q3 '23"", 'revenue': 0.368, 'unit': 'M', 'net_profit': -6.94}, {'period': ""Q2 '23"", 'revenue': 0.809, 'unit': 'M', 'net_profit': -7.06}]",-0.56,-0.56,107374000,8020000,4502000,67407000,904000,0,5835000,4502000,-26711000,-0.5412838263058527,-0.26634987113402064,-0.1200000000000001,__nan__,__nan__,__nan__,0.6277776742973159
728,CECE,CECO Environmental Corp. Common Stock,"CECO Environmental Corp. provides industrial air quality and fluid handling systems worldwide. It operates in two segments: Engineered Systems Segment and Industrial Process Solutions Segment. The company engineers, designs, builds, and installs systems that capture, clean, and destroy air- and water-borne emissions from industrial facilities as well as fluid handling, gas separation, and filtration systems. It offers dampers and diverters, selective catalytic reduction and selective non-catalytic reduction systems, cyclonic technology, thermal oxidizers, filtration systems, scrubbers, and water and fluid handling equipment, as well as plant engineering services and engineered design build fabrication. The company markets its products and services to natural gas processors, transmission and distribution companies, refineries, power generators, industrial manufacturing, engineering and construction companies, semiconductor manufacturers, compressor manufacturers, beverage can manufacturers, metals and minerals, and electric vehicle producer companies. CECO Environmental Corp. was incorporated in 1966 and is headquartered in Dallas, Texas.",Mr. Dennis Sadlowski,Industrial - Pollution & Treatment Controls,11.65,USD,400991835,https://images.financialmodelingprep.com/symbol/CECE.png,316688,58.25,0.25,201410,47448000,12911000,"[{'period': '2023', 'revenue': 544.85, 'unit': 'M', 'net_profit': 12.91}, {'period': '2022', 'revenue': 422.63, 'unit': 'M', 'net_profit': 17.42}, {'period': '2021', 'revenue': 324.14, 'unit': 'M', 'net_profit': 1.98}, {'period': '2020', 'revenue': 316.01, 'unit': 'M', 'net_profit': 8.21}]","[{'period': ""Q3 '24"", 'revenue': 135.51, 'unit': 'M', 'net_profit': 2.09}, {'period': ""Q2 '24"", 'revenue': 137.52, 'unit': 'M', 'net_profit': 4.49}, {'period': ""Q1 '24"", 'revenue': 126.33, 'unit': 'M', 'net_profit': 1.51}, {'period': ""Q4 '23"", 'revenue': 153.71, 'unit': 'M', 'net_profit': 3.88}, {'period': ""Q3 '23"", 'revenue': 149.39, 'unit': 'M', 'net_profit': 3.33}, {'period': ""Q2 '23"", 'revenue': 129.18, 'unit': 'M', 'net_profit': 3.72}]",0.37,0.37,600291000,281437000,54779000,362800000,179307000,0,203106000,54779000,36263000,0.23794614902943018,-0.25871275190905435,-0.26,"[0.075, 0.025]","['2017-09-15', '2011-09-13']",__nan__,0.6043735454971005
729,CELC,Celcuity Inc. Common Stock,"Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.",Mr. Brian F. Sullivan,Biotechnology,13.18,USD,489368128,https://images.financialmodelingprep.com/symbol/CELC.png,247462,-5.07,0.01,139466,-58309957,-63779116,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -63.78}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -41.35}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.56}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.09}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.79}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -23.72}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.61}, {'period': ""Q4 '23"", 'revenue': 0.22965000000000002, 'unit': 'M', 'net_profit': -18.85}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.4}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.59}]",-2.69,-2.69,191219398,190590597,180582748,51450076,805882,0,14188743,30662774,-53909897,-0.4882516470766987,-0.5424588978463295,-0.0037313432835820097,__nan__,__nan__,__nan__,0.2690630581317906
730,CELH,Celsius Holdings Inc. Common Stock,"Celsius Holdings, Inc. develops, processes, markets, distributes, and sells functional drinks and liquid supplements in North America, Europe, Asia, and internationally. It offers various carbonated and non-carbonated functional energy drinks under the CELSIUS Originals name; dietary supplement in carbonated flavors, including apple jack'd, orangesicle, inferno punch, cherry lime, blueberry pomegranate, strawberry dragon fruit, tangerine grapefruit, and jackfruit under the CELSIUS HEAT name; and branched-chain amino acids functional energy drink that fuels muscle recovery under the CELSIUS BCCA+ENERGY name. The company also provides CELSIUS On-the-Go, a powdered form of the active ingredients in functional energy drinks in individual On-The-Go packets and canisters; and sparkling grapefruit, cucumber lime, and orange pomegranate, as well as pineapple coconut, watermelon berry, and strawberries and cream non-carbonated functional energy drinks under the CELSIUS Sweetened. It distributes its products through direct-to-store delivery distributors and direct to retailers, including supermarkets, convenience stores, drug stores, nutritional stores, and mass merchants, as well as health clubs, spas, gyms, the military, and e-commerce websites. The company was formerly known as Vector Ventures, Inc. and changed its name to Celsius Holdings, Inc. in January 2007. Celsius Holdings, Inc. was founded in 2004 and is headquartered in Boca Raton, Florida.",Mr. John  Fieldly CPA,Beverages - Non-Alcoholic,29.2401,USD,6872329943,https://images.financialmodelingprep.com/symbol/CELH.png,9025748,40.61,0.3101,4124561,269592000,226801000,"[{'period': '2023', 'revenue': 1320.0, 'unit': 'M', 'net_profit': 226.8}, {'period': '2022', 'revenue': 653.6, 'unit': 'M', 'net_profit': -187.28}, {'period': '2021', 'revenue': 314.27, 'unit': 'M', 'net_profit': 3.94}, {'period': '2020', 'revenue': 130.73, 'unit': 'M', 'net_profit': 8.52}]","[{'period': ""Q3 '24"", 'revenue': 265.75, 'unit': 'M', 'net_profit': 6.36}, {'period': ""Q2 '24"", 'revenue': 401.98, 'unit': 'M', 'net_profit': 79.78}, {'period': ""Q1 '24"", 'revenue': 355.71, 'unit': 'M', 'net_profit': 77.81}, {'period': ""Q4 '23"", 'revenue': 347.44, 'unit': 'M', 'net_profit': 39.08}, {'period': ""Q3 '23"", 'revenue': 384.76, 'unit': 'M', 'net_profit': 83.95}, {'period': ""Q2 '23"", 'revenue': 325.88, 'unit': 'M', 'net_profit': 40.86}]",0.79,0.77,1536396000,1204904000,755981000,447868000,186021000,0,276613000,755981000,123785000,2.7084302380846763,2.2110133381745176,1.951807228915663,__nan__,__nan__,__nan__,0.2915055753855126
731,CEMI,Chembio Diagnostics Inc. Common Stock,"Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.",Mr. Richard L. Eberly,Medical - Diagnostics & Research,0.455,USD,16710285,https://images.financialmodelingprep.com/symbol/CEMI.png,538392,-0.6319444444444444,0.001,351642,-14612706,-23290657,"[{'period': '2022', 'revenue': 48.34, 'unit': 'M', 'net_profit': -23.29}, {'period': '2021', 'revenue': 36.93, 'unit': 'M', 'net_profit': -33.9}, {'period': '2020', 'revenue': 30.45, 'unit': 'M', 'net_profit': -25.52}, {'period': '2019', 'revenue': 34.46, 'unit': 'M', 'net_profit': -13.68}]","[{'period': ""Q4 '22"", 'revenue': 9160.0, 'unit': 'K', 'net_profit': -855.12}, {'period': ""Q3 '22"", 'revenue': 11.2, 'unit': 'M', 'net_profit': -8.33}, {'period': ""Q2 '22"", 'revenue': 9.16, 'unit': 'M', 'net_profit': -6.95}, {'period': ""Q1 '22"", 'revenue': 18.82, 'unit': 'M', 'net_profit': -8.79}, {'period': ""Q4 '21"", 'revenue': 17.71, 'unit': 'M', 'net_profit': -13.97}, {'period': ""Q3 '21"", 'revenue': 9.66, 'unit': 'M', 'net_profit': -6.37}]",-0.96,-0.96,62611405,48451695,18178985,44813048,18722737,0,39300116,18178985,-14145186,0.3066137228332239,0.3130314841266229,0.3142857142857143,__nan__,__nan__,__nan__,0.7157329882630808
732,CENH,Centricus Acquisition Corp. Class A Ordinary Share,"Centricus Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in London, the United Kingdom.",Mr. Garth  Ritchie,Shell Companies,8.35,USD,0,https://images.financialmodelingprep.com/symbol/CENH.png,314168,0,-0.03999996,150445,0,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.69}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",0,0,216584,0,0,196584,0,0,196584,0,,0,0,0,__nan__,__nan__,__nan__,0.9076570753148894
733,CENHU,Centricus Acquisition Corp. Unit,,,,,,,,,0,-0.53499985,7211,0,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.69}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",0,0,216584,0,0,196584,0,0,196584,0,,0,0,0,__nan__,__nan__,__nan__,0.9076570753148894
734,CENHW,Centricus Acquisition Corp. Warrant,"Centricus Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in London, the United Kingdom.",Mr. Garth  Ritchie,Shell Companies,1.01,USD,0,https://images.financialmodelingprep.com/symbol/CENHW.png,0,0,0.01999998,149625,0,0,"[{'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.69}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",0,0,216584,0,0,196584,0,0,196584,0,,0,0,0,__nan__,__nan__,__nan__,0.9076570753148894
735,CENT,Central Garden & Pet Company Common Stock,"Central Garden & Pet Company produces and distributes various products for the lawn and garden, and pet supplies markets in the United States. It operates through two segments, Pet and Garden. The Pet segment provides dog and cat supplies, such as dog treats and chews, toys, pet beds and grooming products, waste management and training pads, and pet containment; supplies for aquatics, small animals, reptiles, and pet birds, including toys, cages and habitats, bedding, and food and supplements; animal and household health and insect control products; live fish and products for fish, reptiles, and other aquarium-based pets, such as aquariums, furniture and lighting fixtures, pumps, filters, water conditioners, food, and supplements; and products for horses and livestock, as well as outdoor cushions and pillows. This segment sells its products under the Aqueon, Cadet, Comfort Zone, Farnam, Four Paws, Kaytee, K&H Pet Products, Nylabone, and Zilla brands. The Garden segment offers lawn and garden supplies products that include grass seed; wild bird feed, bird feeders, bird houses, and other birding accessories; fertilizers; decorative outdoor lifestyle products; live plants; and weed and grass, as well as other herbicides, insecticide, and pesticide products. This segment sells its lawn and garden supplies products under the AMDRO, Ferry-Morse, Pennington, and Sevin brands, as well as under Bell Nursery, Lilly Miller, and Over-N-Out other brand names. Central Garden & Pet Company was founded in 1955 and is based in Walnut Creek, California.",Mr. Nicholas  Lahanas,Packaged Foods,36.03,USD,2069069373,https://images.financialmodelingprep.com/symbol/CENT.png,0,22.24,,0,290759000,107983000,"[{'period': '2024', 'revenue': 3200.0, 'unit': 'M', 'net_profit': 107.98}, {'period': '2023', 'revenue': 3310.0, 'unit': 'M', 'net_profit': 125.64}, {'period': '2022', 'revenue': 3340.0, 'unit': 'M', 'net_profit': 152.15}, {'period': '2021', 'revenue': 3300.0, 'unit': 'M', 'net_profit': 151.75}]","[{'period': ""Q4 '24"", 'revenue': 669.49, 'unit': 'M', 'net_profit': -34.16}, {'period': ""Q3 '24"", 'revenue': 996.35, 'unit': 'M', 'net_profit': 79.72}, {'period': ""Q2 '24"", 'revenue': 900.09, 'unit': 'M', 'net_profit': 61.99}, {'period': ""Q1 '24"", 'revenue': 634530.0, 'unit': 'K', 'net_profit': 430.0}, {'period': ""Q4 '23"", 'revenue': 750.15, 'unit': 'M', 'net_profit': 2.83}, {'period': ""Q3 '23"", 'revenue': 1020.0, 'unit': 'M', 'net_profit': 83.13}]",1.64,1.62,3495750000,1886806000,753550000,1940096000,326220000,0,515384000,753550000,351757000,-0.05342644138424976,-0.14055697492100636,-0.30212765957446813,"[29.2, 29.2]","['2007-02-06', '2007-02-06']",__nan__,0.5549870557105057
736,CENTA,Central Garden & Pet Company Class A Common Stock Nonvoting,"Central Garden & Pet Company produces and distributes various products for the lawn and garden, and pet supplies markets in the United States. It operates through two segments, Pet and Garden. The Pet segment provides dog and cat supplies, such as dog treats and chews, toys, pet beds and grooming products, waste management and training pads, and pet containment; supplies for aquatics, small animals, reptiles, and pet birds, including toys, cages and habitats, bedding, and food and supplements; animal and household health and insect control products; live fish and products for fish, reptiles, and other aquarium-based pets, such as aquariums, furniture and lighting fixtures, pumps, filters, water conditioners, food, and supplements; and products for horses and livestock, as well as outdoor cushions and pillows. This segment sells its products under the Aqueon, Cadet, Comfort Zone, Farnam, Four Paws, Kaytee, K&H Pet Products, Nylabone, and Zilla brands. The Garden segment offers lawn and garden supplies products that include grass seed; wild bird feed, bird feeders, bird houses, and other birding accessories; fertilizers; decorative outdoor lifestyle products; live plants; and weed and grass, as well as other herbicides, insecticide, and pesticide products. This segment sells its lawn and garden supplies products under the AMDRO, Ferry-Morse, Pennington, and Sevin brands, as well as under Bell Nursery, Lilly Miller, and Over-N-Out other brand names. Central Garden & Pet Company was founded in 1955 and is based in Walnut Creek, California.",Mr. Nicholas  Lahanas,Packaged Foods,30.495,USD,2063517668,https://images.financialmodelingprep.com/symbol/CENTA.png,303719,18.82,-1.475,105617,290759000,107983000,"[{'period': '2024', 'revenue': 3200.0, 'unit': 'M', 'net_profit': 107.98}, {'period': '2023', 'revenue': 3310.0, 'unit': 'M', 'net_profit': 125.64}, {'period': '2022', 'revenue': 3340.0, 'unit': 'M', 'net_profit': 152.15}, {'period': '2021', 'revenue': 3300.0, 'unit': 'M', 'net_profit': 151.75}]","[{'period': ""Q4 '24"", 'revenue': 669.49, 'unit': 'M', 'net_profit': -34.16}, {'period': ""Q3 '24"", 'revenue': 996.35, 'unit': 'M', 'net_profit': 79.72}, {'period': ""Q2 '24"", 'revenue': 900.09, 'unit': 'M', 'net_profit': 61.99}, {'period': ""Q1 '24"", 'revenue': 634530.0, 'unit': 'K', 'net_profit': 430.0}, {'period': ""Q4 '23"", 'revenue': 750.15, 'unit': 'M', 'net_profit': 2.83}, {'period': ""Q3 '23"", 'revenue': 1020.0, 'unit': 'M', 'net_profit': 83.13}]",1.64,1.62,3495750000,1886806000,753550000,1940096000,326220000,0,515384000,753550000,351757000,-0.05342644138424976,-0.14055697492100636,-0.30212765957446813,__nan__,__nan__,__nan__,0.5549870557105057
737,CENX,Century Aluminum Company Common Stock,"Century Aluminum Company, together with its subsidiaries, produces standard-grade and value-added primary aluminum products in the United States and Iceland. It also owns and operates a carbon anode production facility in the Netherlands. The company was incorporated in 1981 and is headquartered in Chicago, Illinois.",Mr. Jesse E. Gary J.D.,Aluminum,18.38,USD,1705641944,https://images.financialmodelingprep.com/symbol/CENX.png,1092951,5.41,-0.3,391034,43400000,-43100000,"[{'period': '2023', 'revenue': 2190.0, 'unit': 'M', 'net_profit': -43.1}, {'period': '2022', 'revenue': 2780.0, 'unit': 'M', 'net_profit': -14.0}, {'period': '2021', 'revenue': 2210.0, 'unit': 'M', 'net_profit': -167.0}, {'period': '2020', 'revenue': 1610.0, 'unit': 'M', 'net_profit': -123.2}]","[{'period': ""Q3 '24"", 'revenue': 539.1, 'unit': 'M', 'net_profit': 47.3}, {'period': ""Q2 '24"", 'revenue': 560.8, 'unit': 'M', 'net_profit': -2.5}, {'period': ""Q1 '24"", 'revenue': 489.5, 'unit': 'M', 'net_profit': 246.8}, {'period': ""Q4 '23"", 'revenue': 512.3, 'unit': 'M', 'net_profit': 30.0}, {'period': ""Q3 '23"", 'revenue': 545.2, 'unit': 'M', 'net_profit': -42.0}, {'period': ""Q2 '23"", 'revenue': 575.5, 'unit': 'M', 'net_profit': 7.5}]",-0.47,-0.47,1846500000,767100000,88800000,1502400000,169400000,0,763000000,88800000,10600000,-0.4745762711864407,-2.0785714285714287,-2.1333333333333333,"[0.05, 0.05]","['2002-09-18', '1996-06-12']",__nan__,0.8136474411047928
738,CERC,Cerecor Inc. Common Stock,"Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.",Mr. Michael Cola,Biotechnology,2.93,USD,38629413,https://images.financialmodelingprep.com/symbol/CERC.png,639167,-3.3794694348327567,-0.04999995,258592,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
739,CERE,Cerevel Therapeutics Holdings Inc. Common Stock,"Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.","Mr. Ronald C. Renaud Jr., M.B.A.",Biotechnology,44.96,USD,8191487560,https://images.financialmodelingprep.com/symbol/CERE.png,2056487,-16.468864468864467,0.33,15033754,-441638000,-432842000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -432.84}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -351.51}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -222.45}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -152.14}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -131.91}, {'period': ""Q4 '23"", 'revenue': 8.25, 'unit': 'M', 'net_profit': -132.66}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -96.36}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -99.53}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -104.29}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -92.81}]",-2.67,-2.67,1243298000,1006938000,990965000,569553000,5291000,187159000,92179000,990965000,-346109000,-0.20059916052282464,-0.2313754050371112,-0.1508620689655173,__nan__,__nan__,__nan__,0.4580985411381664
740,CEREW,Cerevel Therapeutics Holdings Inc. Warrant,,,,,,,,,0,-0.610001,406,-151769000,-152142000,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -152.14}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -128.39}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -53.24}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -50.98}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -69.33}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.89}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.72}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -53.21}]",0,0,445273000,390560000,383623000,60753000,0,0,29548000,383623000,-136694000,-0.18415036631894324,-0.18500806143828522,0,__nan__,__nan__,__nan__,0.13643989193146677
741,CERN,Cerner Corporation Common Stock,"Cerner Corporation, together with its subsidiaries, provides health care information technology solutions and tech-enabled services in the United States and internationally. It offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. The company also provides HealtheIntent platform, a cloud-based platform to aggregate, transform, and reconcile data across the continuum of care; and CareAware, an EHR agnostic platform that facilitates connectivity of health care devices to EHRs. In addition, it offers a portfolio of clinical and financial healthcare information technology solutions, as well as departmental and care coordination solutions. Further, the company provides tech-enabled services, such as implementation and training, remote hosting, application management, revenue cycle, support and maintenance, health care data analysis, real-world evidence, clinical process optimization, transaction processing, employer health centers, and data-driven services; and complementary hardware and devices for third parties. It serves integrated delivery networks, physician groups and networks, managed care organizations, hospitals, medical centers, free-standing reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employers, governments, and public health organizations. The company was founded in 1979 and is headquartered in North Kansas City, Missouri. As of June 8, 2022, Cerner Corporation operates as a subsidiary of Oracle Corporation.",Mr. Brent Shafer,Medical - Healthcare Information Services,94.92,USD,0,https://images.financialmodelingprep.com/symbol/CERN.png,3526650,55.83529411764706,0,38200339,1461788000,555596000,"[{'period': '2021', 'revenue': 5760.0, 'unit': 'M', 'net_profit': 555.6}, {'period': '2020', 'revenue': 5510.0, 'unit': 'M', 'net_profit': 780.09}, {'period': '2019', 'revenue': 5690.0, 'unit': 'M', 'net_profit': 529.45}, {'period': '2018', 'revenue': 5370.0, 'unit': 'M', 'net_profit': 630.06}]","[{'period': ""Q1 '22"", 'revenue': 1430.0, 'unit': 'M', 'net_profit': 206.13}, {'period': ""Q4 '21"", 'revenue': 1450.0, 'unit': 'M', 'net_profit': 174.84}, {'period': ""Q3 '21"", 'revenue': 1470.0, 'unit': 'M', 'net_profit': 175.79}, {'period': ""Q2 '21"", 'revenue': 1460.0, 'unit': 'M', 'net_profit': 32.71}, {'period': ""Q1 '21"", 'revenue': 1390.0, 'unit': 'M', 'net_profit': 172.25}, {'period': ""Q4 '20"", 'revenue': 1400.0, 'unit': 'M', 'net_profit': 141.5}]",1.81,1.81,7434158000,2449454000,842469000,3753696000,1161361000,461984000,1626258000,589847000,1144403000,-0.14912199006272497,-0.28777778917250363,-0.28174603174603174,"[0.27, 0.18]","['2022-03-25', '2019-06-17']",__nan__,0.5049255073674787
742,CERS,Cerus Corporation Common Stock,"Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.",Mr. William M. Greenman,Medical - Devices,1.66,USD,308286900,https://images.financialmodelingprep.com/symbol/CERS.png,1593541,-15.09,-0.04,887625,-26536000,-37489000,"[{'period': '2023', 'revenue': 156.37, 'unit': 'M', 'net_profit': -37.49}, {'period': '2022', 'revenue': 162.05, 'unit': 'M', 'net_profit': -42.83}, {'period': '2021', 'revenue': 130.86, 'unit': 'M', 'net_profit': -54.38}, {'period': '2020', 'revenue': 91.92, 'unit': 'M', 'net_profit': -59.86}]","[{'period': ""Q3 '24"", 'revenue': 46.02, 'unit': 'M', 'net_profit': -2.93}, {'period': ""Q2 '24"", 'revenue': 45.08, 'unit': 'M', 'net_profit': -5.78}, {'period': ""Q1 '24"", 'revenue': 38.37, 'unit': 'M', 'net_profit': -9.69}, {'period': ""Q4 '23"", 'revenue': 46.77, 'unit': 'M', 'net_profit': -1.33}, {'period': ""Q3 '23"", 'revenue': 39.77, 'unit': 'M', 'net_profit': -7.27}, {'period': ""Q2 '23"", 'revenue': 38.85, 'unit': 'M', 'net_profit': -13.28}]",-0.21,-0.21,197748000,144441000,65852000,144304000,35500000,0,67521000,11647000,-47765000,0.22138434905079077,0.12460011675423234,0.125,__nan__,__nan__,__nan__,0.7297368367821672
743,CERT,Certara Inc. Common Stock,"Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.",Dr. William F. Feehery Ph.D.,Medical - Healthcare Information Services,11.22,USD,1806285360,https://images.financialmodelingprep.com/symbol/CERT.png,1201827,-56.1,-0.11,207299,23843999,-55357000,"[{'period': '2023', 'revenue': 354.34, 'unit': 'M', 'net_profit': -55.36}, {'period': '2022', 'revenue': 335.64, 'unit': 'M', 'net_profit': 14.73}, {'period': '2021', 'revenue': 286.1, 'unit': 'M', 'net_profit': -13.27}, {'period': '2020', 'revenue': 243.53, 'unit': 'M', 'net_profit': -49.4}]","[{'period': ""Q3 '24"", 'revenue': 94.82, 'unit': 'M', 'net_profit': -1.37}, {'period': ""Q2 '24"", 'revenue': 93.31, 'unit': 'M', 'net_profit': -12.57}, {'period': ""Q1 '24"", 'revenue': 96.65, 'unit': 'M', 'net_profit': -4.68}, {'period': ""Q4 '23"", 'revenue': 88.01, 'unit': 'M', 'net_profit': -12.46}, {'period': ""Q3 '23"", 'revenue': 85.58, 'unit': 'M', 'net_profit': -48.97}, {'period': ""Q2 '23"", 'revenue': 90.45, 'unit': 'M', 'net_profit': 4.71}]",-0.35,-0.35,1563140000,340201000,234951000,516300001,93256000,1151000,130023000,234951000,67433000,-0.7320838782893998,-4.757857579254633,-4.727369542066027,__nan__,__nan__,__nan__,0.3302967111071305
744,CETX,Cemtrex Inc. Common Stock,"Cemtrex, Inc. operates as a technology company in the United States and internationally. The company operates through Advanced Technologies and Industrial Services segments. The Advanced Technologies segment provides Internet of Things products and smart devices under the SmartDesk name for mobile, web, virtual and augmented reality, wearables, and television markets; and security and video surveillance solutions, and virtual and augmented reality solutions for various commercial and industrial applications. This segment also offers browser-based video monitoring systems and analytics-based recognition systems, cameras, servers, and access control systems for security and surveillance in industrial and commercial facilities, federal prisons, hospitals, universities, schools, and federal and state government offices. The Industrial Services segment offers single-source services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly; installs high precision equipment in various industrial markets comprising automotive, printing and graphics, industrial automation, packaging, chemicals and others; and provides maintenance and contracting solutions for the machinery, packaging, printing, chemical, and other manufacturing markets. The company was formerly known as Diversified American Holding, Inc. and changed its name to Cemtrex, Inc. in December 2004. Cemtrex, Inc. was incorporated in 1998 and is based in Brooklyn, New York.",Mr. Saagar  Govil,Software - Infrastructure,3.256,USD,5613865,https://images.financialmodelingprep.com/symbol/CETX.png,510635,-0.01,0.106,105738,-3978139,-7229491,"[{'period': '2024', 'revenue': 43.33, 'unit': 'M', 'net_profit': -7.23}, {'period': '2023', 'revenue': 59.37, 'unit': 'M', 'net_profit': -9.2}, {'period': '2022', 'revenue': 50.27, 'unit': 'M', 'net_profit': -13.29}, {'period': '2021', 'revenue': 43130.0, 'unit': 'K', 'net_profit': 393.78}]","[{'period': ""Q4 '24"", 'revenue': 18.14, 'unit': 'M', 'net_profit': 4.43}, {'period': ""Q3 '24"", 'revenue': 14.69, 'unit': 'M', 'net_profit': -8.98}, {'period': ""Q2 '24"", 'revenue': 17.16, 'unit': 'M', 'net_profit': -1.47}, {'period': ""Q1 '24"", 'revenue': 16.88, 'unit': 'M', 'net_profit': -1.21}, {'period': ""Q4 '23"", 'revenue': 16.59, 'unit': 'M', 'net_profit': -1.18}, {'period': ""Q3 '23"", 'revenue': 14.73, 'unit': 'M', 'net_profit': -1.15}]",-17.69,-17.69,44115458,26696279,3911382,39154616,11159676,1200000,18592822,3897511,-5246706,-454.0084639139459,0.21391874957526333,-1.303385416666667,"[0.4083, 0.4083]","['2017-03-29', '2017-03-29']",__nan__,0.8875486683148569
745,CETXP,Cemtrex Inc. Series 1 Preferred Stock,"Cemtrex, Inc. operates as a technology company in the United States and internationally. The company operates through Advanced Technologies and Industrial Services segments. The Advanced Technologies segment provides Internet of Things products and smart devices under the SmartDesk name for mobile, web, virtual and augmented reality, wearables, and television markets; and security and video surveillance solutions, and virtual and augmented reality solutions for various commercial and industrial applications. This segment also offers browser-based video monitoring systems and analytics-based recognition systems, cameras, servers, and access control systems for security and surveillance in industrial and commercial facilities, federal prisons, hospitals, universities, schools, and federal and state government offices. The Industrial Services segment offers single-source services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly; installs high precision equipment in various industrial markets comprising automotive, printing and graphics, industrial automation, packaging, chemicals and others; and provides maintenance and contracting solutions for the machinery, packaging, printing, chemical, and other manufacturing markets. The company was formerly known as Diversified American Holding, Inc. and changed its name to Cemtrex, Inc. in December 2004. Cemtrex, Inc. was incorporated in 1998 and is based in Brooklyn, New York.",Mr. Saagar  Govil,Software - Infrastructure,0.112,USD,510812,https://images.financialmodelingprep.com/symbol/CETXP.png,1260,-0.14,0,10001,-3978139,-7229491,"[{'period': '2024', 'revenue': 43.33, 'unit': 'M', 'net_profit': -7.23}, {'period': '2023', 'revenue': 59.37, 'unit': 'M', 'net_profit': -9.2}, {'period': '2022', 'revenue': 50.27, 'unit': 'M', 'net_profit': -13.29}, {'period': '2021', 'revenue': 43130.0, 'unit': 'K', 'net_profit': 393.78}]","[{'period': ""Q4 '24"", 'revenue': 18.14, 'unit': 'M', 'net_profit': 4.43}, {'period': ""Q3 '24"", 'revenue': 14.69, 'unit': 'M', 'net_profit': -8.98}, {'period': ""Q2 '24"", 'revenue': 17.16, 'unit': 'M', 'net_profit': -1.47}, {'period': ""Q1 '24"", 'revenue': 16.88, 'unit': 'M', 'net_profit': -1.21}, {'period': ""Q4 '23"", 'revenue': 16.59, 'unit': 'M', 'net_profit': -1.18}, {'period': ""Q3 '23"", 'revenue': 14.73, 'unit': 'M', 'net_profit': -1.15}]",-17.69,-17.69,44115458,26696279,3911382,39154616,11159676,1200000,18592822,3897511,-5246706,-454.0084639139459,0.21391874957526333,-1.303385416666667,"[1.182, 1.182]","['2017-03-22', '2017-03-22']",__nan__,0.8875486683148569
746,CETXW,Cemtrex Inc. Series 1 Warrant,,None,,0.0129,USD,0,https://images.financialmodelingprep.com/symbol/CETXW.png,0,0,-0.0067,116198,-2305167,-7807995,"[{'period': '2021', 'revenue': 43.13, 'unit': 'M', 'net_profit': -7.81}, {'period': '2020', 'revenue': 43.52, 'unit': 'M', 'net_profit': -9.71}, {'period': '2019', 'revenue': 39.27, 'unit': 'M', 'net_profit': -22.36}, {'period': '2018', 'revenue': 89.94, 'unit': 'M', 'net_profit': -9.24}]","[{'period': ""Q1 '22"", 'revenue': 10.67, 'unit': 'M', 'net_profit': -5.94}, {'period': ""Q4 '21"", 'revenue': 14.71, 'unit': 'M', 'net_profit': -9.67}, {'period': ""Q3 '21"", 'revenue': 10.33, 'unit': 'M', 'net_profit': 1.1}, {'period': ""Q2 '21"", 'revenue': 9.26, 'unit': 'M', 'net_profit': 2.45}, {'period': ""Q1 '21"", 'revenue': 8.84, 'unit': 'M', 'net_profit': -1.69}, {'period': ""Q4 '20"", 'revenue': 59.16, 'unit': 'K', 'net_profit': 11.03}]",-1.09,-1.09,52939888,34742294,15441957,29385212,9298051,500000,19653402,15426976,-11120448,0.3333991692528712,0.19560427537425595,0.19852941176470587,__nan__,__nan__,__nan__,0.555067513554241
747,CEVA,CEVA Inc. Common Stock,"CEVA, Inc. operates as a licensor of wireless connectivity and smart sensing technologies to semiconductor and original equipment manufacturer (OEM) companies worldwide. It designs and licenses various digital signal processors, AI processors, wireless platforms, and complementary software for sensor fusion, image enhancement, computer vision, voice input, and artificial intelligence (AI). The company licenses a family of wireless connectivity and smart sensing technologies, and integrated IP solutions, including DSP-based platforms for 5G baseband processing in mobile, IoT, and infrastructure; imaging and computer vision for any camera-enabled devices; audio/voice/speech and ultra-low power always-on/sensing applications for multiple IoT markets; sensor fusion software and inertial measurement unit solutions for hearables, wearables, AR/VR, PC, robotics, remote controls, and IoT; and wireless IoT for Bluetooth, Wi-Fi 4/5/6/6E, Ultra-wideband (UWB), and NB-IoT. Its technologies are licensed to companies, which design, manufacture, market, and sell application-specific integrated circuits and application-specific standard products to mobile, consumer, automotive, robotics, industrial, aerospace and defense, and IoT companies for incorporation into various end products. The company delivers its DSP cores, platforms, and AI processors in the form of a hardware description language definition; and offers development platforms, software development kits, and software debug tools that facilitate system design, debug, and software development. The company licenses its technology through a direct sales force. The company was formerly known as ParthusCeva, Inc. and changed its name to CEVA, Inc. in December 2003. CEVA, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.",Mr. Amir  Panush,Semiconductors,33,USD,779681100,https://images.financialmodelingprep.com/symbol/CEVA.png,195738,-50.77,-0.14,63868,-8584000,-11878000,"[{'period': '2023', 'revenue': 97.42, 'unit': 'M', 'net_profit': -11.88}, {'period': '2022', 'revenue': 134.65, 'unit': 'M', 'net_profit': -23.18}, {'period': '2021', 'revenue': 122710.0, 'unit': 'K', 'net_profit': 396.0}, {'period': '2020', 'revenue': 100.33, 'unit': 'M', 'net_profit': -2.38}]","[{'period': ""Q3 '24"", 'revenue': 27.21, 'unit': 'M', 'net_profit': -1.31}, {'period': ""Q2 '24"", 'revenue': 28440.0, 'unit': 'K', 'net_profit': -291.0}, {'period': ""Q1 '24"", 'revenue': 22.07, 'unit': 'M', 'net_profit': -5.45}, {'period': ""Q4 '23"", 'revenue': 24.16, 'unit': 'M', 'net_profit': 3.77}, {'period': ""Q3 '23"", 'revenue': 24.07, 'unit': 'M', 'net_profit': -4.96}, {'period': ""Q2 '23"", 'revenue': 26.17, 'unit': 'M', 'net_profit': -5.82}]",-0.51,-0.51,304085000,209371000,166538000,39744000,30307000,406000,26887000,23287000,-9215000,-1.5717711316858722,0.4876418064961394,0.49,__nan__,__nan__,__nan__,0.13070029761415394
748,CFAC,CF Finance Acquisition Corp. III Common Stock,,,,,,,,,,,,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
749,CFACU,CF Finance Acquisition Corp. III Unit,"CF Finance Acquisition Corp. III focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2016 and is based in New York, New York.",Mr. Howard W. Lutnick,Shell Companies,8.89,USD,0,https://images.financialmodelingprep.com/symbol/CFACU.png,2709,-88.01980198019803,0.01000023,1312,-152883,-152883,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -152.88}, {'period': '2019', 'revenue': 0.0, 'unit': '', 'net_profit': -548.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.91}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -152.38}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': -505.0}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q3 '19"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",0,0,230804152,438750,1250,484647,0,0,484647,1250,0,-277.9835766423358,-277.9835766423358,0,__nan__,__nan__,__nan__,0.002099819244152939
750,CFACW,CF Finance Acquisition Corp. III Warrant,,,,,,,,,0,0.03000009,34051,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
751,CFB,CrossFirst Bankshares Inc. Common Stock,"CrossFirst Bankshares, Inc. operates as the bank holding company for CrossFirst Bank that provides various banking and financial services to businesses, business owners, professionals, and its personal networks. The company offers commercial real estate, construction and development, 1-4 family real estate, commercial, energy, and consumer loans. It also provides a range of deposit products consisting of noninterest-bearing demand and interest-bearing deposits, which include transaction accounts, savings accounts, money market accounts, and certificates of deposit; and personal and business checking and savings accounts, as well as negotiable order of withdrawal accounts; and brokered and reciprocal deposits. In addition, the company offers international banking services; treasury management services; automated teller machine access; and mobile banking services. Further, it holds investments in marketable securities. As of December 31, 2021, it had nine full-service banking offices in Kansas, Missouri, Oklahoma, Arizona, and Texas. CrossFirst Bankshares, Inc. was founded in 2007 and is headquartered in Leawood, Kansas.",Mr. Michael J. Maddox,Banks - Regional,14.665,USD,723201542,https://images.financialmodelingprep.com/symbol/CFB.png,214779,9.98,-0.305,55556,93570000,66669000,"[{'period': '2023', 'revenue': 231.02, 'unit': 'M', 'net_profit': 66.67}, {'period': '2022', 'revenue': 0.077, 'unit': 'M', 'net_profit': 61.6}, {'period': '2021', 'revenue': 182.35, 'unit': 'M', 'net_profit': 69.41}, {'period': '2020', 'revenue': 171.98, 'unit': 'M', 'net_profit': 12.6}]","[{'period': ""Q3 '24"", 'revenue': 67.13, 'unit': 'M', 'net_profit': 19.65}, {'period': ""Q2 '24"", 'revenue': 128.69, 'unit': 'M', 'net_profit': 18.62}, {'period': ""Q1 '24"", 'revenue': 124.44, 'unit': 'M', 'net_profit': 18.22}, {'period': ""Q4 '23"", 'revenue': 122.36, 'unit': 'M', 'net_profit': 17.65}, {'period': ""Q3 '23"", 'revenue': 61.11, 'unit': 'M', 'net_profit': 16.86}, {'period': ""Q2 '23"", 'revenue': 60.32, 'unit': 'M', 'net_profit': 16.05}]",1.35,1.34,7380680000,234029000,234029000,6672537000,0,11881000,2662652000,234029000,90401000,0.1290225273598224,0.08230653095017776,0.08870967741935491,__nan__,__nan__,__nan__,0.9040545044630034
752,CFBK,CF Bankshares Inc. Common Stock,"CF Bankshares Inc. operates as the bank holding company for CFBank, National Association that provides various banking products and services in the United States. The company accepts savings, retail and business checking accounts, and money market accounts, as well as certificates of deposit. It also offers single-family mortgage loans; commercial real estate and multi-family residential mortgage loans; commercial loans; construction and land loans; and consumer loans, such as home equity lines of credit, home improvement loans, and loans secured by deposits and purchased loans, as well as other loans. In addition, the company provides Internet and mobile banking, remote deposit, and treasury management depository services. As of December 31, 2021, it operated five branch offices located in Franklin, Cuyahoga, Hamilton, and Summit counties, Ohio; and a loan production office located in Franklin County, Ohio. The company was formerly known as Central Federal Corporation and changed its name to CF Bankshares Inc. in July 2020. CF Bankshares Inc. was founded in 1892 and is based in Worthington, Ohio.",Mr. Timothy T. O'Dell,Banks - Regional,23.99,USD,153214150,https://images.financialmodelingprep.com/symbol/CFBK.png,23362,11.76,-0.84,15027,0,16937000,"[{'period': '2023', 'revenue': 49.35, 'unit': 'M', 'net_profit': 16.94}, {'period': '2022', 'revenue': 51.31, 'unit': 'M', 'net_profit': 18.16}, {'period': '2021', 'revenue': 53.33, 'unit': 'M', 'net_profit': 18.45}, {'period': '2020', 'revenue': 87.5, 'unit': 'M', 'net_profit': 29.61}]","[{'period': ""Q3 '24"", 'revenue': 12.51, 'unit': 'M', 'net_profit': 4.07}, {'period': ""Q2 '24"", 'revenue': 30.53, 'unit': 'M', 'net_profit': 1.7}, {'period': ""Q1 '24"", 'revenue': 29.99, 'unit': 'M', 'net_profit': 3.07}, {'period': ""Q4 '23"", 'revenue': 30.71, 'unit': 'M', 'net_profit': 4.24}, {'period': ""Q3 '23"", 'revenue': 12.82, 'unit': 'M', 'net_profit': 4.03}, {'period': ""Q2 '23"", 'revenue': 12.28, 'unit': 'M', 'net_profit': 4.22}]",2.64,2.63,2058614999,258295000,258295000,1903241000,13497000,13092000,2806000,261595000,17390000,0,-0.06755120017617265,-0.07042253521126751,"[0, 0.0018]","['2025-01-16', '1999-06-22']",__nan__,0.9245249844796258
753,CFFE,CF Acquisition Corp. VIII Class A Common Stock,"CF Acquisition Corp. VIII does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.",Mr. Howard W. Lutnick,Shell Companies,16.52,USD,123839206,https://images.financialmodelingprep.com/symbol/CFFE.png,46759,-6.661290322580645,3.12,16936,605000,-11047000,"[{'period': '2023', 'revenue': 166.57, 'unit': 'M', 'net_profit': -11.05}, {'period': '2022', 'revenue': 180.49, 'unit': 'M', 'net_profit': -7.93}, {'period': '2021', 'revenue': 205.95, 'unit': 'M', 'net_profit': -12.73}, {'period': '2020', 'revenue': 217.54, 'unit': 'M', 'net_profit': -28.38}]","[{'period': ""Q3 '24"", 'revenue': 35.33, 'unit': 'M', 'net_profit': -1.23}, {'period': ""Q2 '24"", 'revenue': 36.11, 'unit': 'M', 'net_profit': -4.72}, {'period': ""Q1 '24"", 'revenue': 40.35, 'unit': 'M', 'net_profit': -2.21}, {'period': ""Q3 '23"", 'revenue': 40.24, 'unit': 'M', 'net_profit': -2.89}, {'period': ""Q2 '23"", 'revenue': 42370.0, 'unit': 'K', 'net_profit': -558.0}, {'period': ""Q1 '23"", 'revenue': 42.8, 'unit': 'M', 'net_profit': -2.51}]",-0.49,-0.49,104430000,49867000,6905000,116998000,32395000,1498000,82071000,6905000,-3360999,-0.7070217917675545,-0.39324000504477236,-0.8846153846153845,__nan__,__nan__,__nan__,1.1203485588432442
754,CFFEU,CF Acquisition Corp. VIII Unit,"CF Acquisition Corp. VIII does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.",Mr. Howard W. Lutnick,Shell Companies,16.59,USD,119816663,https://images.financialmodelingprep.com/symbol/CFFEU.png,2681,149.45945945945945,5.04,13380,605000,-11047000,"[{'period': '2023', 'revenue': 166.57, 'unit': 'M', 'net_profit': -11.05}, {'period': '2022', 'revenue': 180.49, 'unit': 'M', 'net_profit': -7.93}, {'period': '2021', 'revenue': 205.95, 'unit': 'M', 'net_profit': -12.73}, {'period': '2020', 'revenue': 217.54, 'unit': 'M', 'net_profit': -28.38}]","[{'period': ""Q3 '24"", 'revenue': 35.33, 'unit': 'M', 'net_profit': -1.23}, {'period': ""Q2 '24"", 'revenue': 36.11, 'unit': 'M', 'net_profit': -4.72}, {'period': ""Q1 '24"", 'revenue': 40.35, 'unit': 'M', 'net_profit': -2.21}, {'period': ""Q3 '23"", 'revenue': 40.24, 'unit': 'M', 'net_profit': -2.89}, {'period': ""Q2 '23"", 'revenue': 42370.0, 'unit': 'K', 'net_profit': -558.0}, {'period': ""Q1 '23"", 'revenue': 42.8, 'unit': 'M', 'net_profit': -2.51}]",-0.49,-0.49,104430000,49867000,6905000,116998000,32395000,1498000,82071000,6905000,-3360999,-0.7070217917675545,-0.39324000504477236,-0.8846153846153845,__nan__,__nan__,__nan__,1.1203485588432442
755,CFFEW,CF Acquisition Corp. VIII Warrant,"CF Acquisition Corp. VIII focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.",Mr. Howard W. Lutnick,Shell Companies,0.11,USD,123839206,https://images.financialmodelingprep.com/symbol/CFFEW.png,0,0,0.059,220969,605000,-11047000,"[{'period': '2023', 'revenue': 166.57, 'unit': 'M', 'net_profit': -11.05}, {'period': '2022', 'revenue': 180.49, 'unit': 'M', 'net_profit': -7.93}, {'period': '2021', 'revenue': 205.95, 'unit': 'M', 'net_profit': -12.73}, {'period': '2020', 'revenue': 217.54, 'unit': 'M', 'net_profit': -28.38}]","[{'period': ""Q3 '24"", 'revenue': 35.33, 'unit': 'M', 'net_profit': -1.23}, {'period': ""Q2 '24"", 'revenue': 36.11, 'unit': 'M', 'net_profit': -4.72}, {'period': ""Q1 '24"", 'revenue': 40.35, 'unit': 'M', 'net_profit': -2.21}, {'period': ""Q3 '23"", 'revenue': 40.24, 'unit': 'M', 'net_profit': -2.89}, {'period': ""Q2 '23"", 'revenue': 42370.0, 'unit': 'K', 'net_profit': -558.0}, {'period': ""Q1 '23"", 'revenue': 42.8, 'unit': 'M', 'net_profit': -2.51}]",-0.49,-0.49,104430000,49867000,6905000,116998000,32395000,1498000,82071000,6905000,-3360999,-0.7070217917675545,-0.39324000504477236,-0.8846153846153845,__nan__,__nan__,__nan__,1.1203485588432442
756,CFFI,C&F Financial Corporation Common Stock,"C&F Financial Corporation operates as a bank holding company for Citizens and Farmers Bank that provides banking services to individuals and businesses. The company's Retail Banking offers various banking services, including checking and savings deposit accounts, as well as business, real estate, development, mortgage, home equity, and installment loans. It also provides ATMs, Internet and mobile banking, and debit and credit cards, as well as safe deposit box rentals, notary public, electronic transfer, and other customary bank services. This segment offers its services through its main office in West Point, Virginia, as well as through 30 Virginia branches located 1 each in Albermarle, Goochland, Hanover, Middlesex, Powhatan, Stafford, York, Charlottesville, Hampton, Montross, Newport News, Richmond, Warsaw, and Williamsburg; 2 each in the counties of Cumberland, James City, King George, and New Kent; and four each in the counties of Chesterfield and Henrico. The company's Mortgage Banking segment provides various residential mortgage loans; originates conventional mortgage loans, mortgage loans insured by the Federal Housing Administration, and mortgage loans guaranteed by the United States Department of Agriculture and the Veterans Administration; and ancillary mortgage loan origination services for residential appraisals, as well as various mortgage origination functions to third parties. It provides mortgage loan origination services through 11 offices in Virginia, 1 office in Maryland, and 2 offices in North Carolina, as well as through 1 each in South Carolina and West Virginia. The company's Consumer Finance segment provides automobile loans through its offices in Richmond and Hampton, Virginia. It also offers brokerage and wealth management services; and insurance products. In addition, the company provides title and settlement agency, and insurance services. C&F Financial Corporation was founded in 1927 and is headquartered in West Point, Virginia.",Mr. Thomas F. Cherry,Banks - Regional,70.622,USD,228395079,https://images.financialmodelingprep.com/symbol/CFFI.png,9400,12.48,-0.978,6990,0,23604000,"[{'period': '2023', 'revenue': 119.05, 'unit': 'M', 'net_profit': 23.6}, {'period': '2022', 'revenue': 1.68, 'unit': 'M', 'net_profit': 29.16}, {'period': '2021', 'revenue': 134.53, 'unit': 'M', 'net_profit': 28.67}, {'period': '2020', 'revenue': 138.95, 'unit': 'M', 'net_profit': 22.12}]","[{'period': ""Q3 '24"", 'revenue': 29.76, 'unit': 'M', 'net_profit': 5.39}, {'period': ""Q2 '24"", 'revenue': 41.64, 'unit': 'M', 'net_profit': 5.01}, {'period': ""Q1 '24"", 'revenue': 40.2, 'unit': 'M', 'net_profit': 3.4}, {'period': ""Q4 '23"", 'revenue': 40.21, 'unit': 'M', 'net_profit': 5.07}, {'period': ""Q3 '23"", 'revenue': 30.48, 'unit': 'M', 'net_profit': 5.79}, {'period': ""Q2 '23"", 'revenue': 32.11, 'unit': 'M', 'net_profit': 6.31}]",6.92,6.92,2438498000,489224000,478826000,2220982000,10398000,462444000,1243493000,75159000,37352000,-1,-0.1905072190404335,-0.1652593486127864,"[0.44, 0.22]","['2024-12-13', '1998-06-26']",__nan__,0.9107991886809012
757,CFFN,Capitol Federal Financial Inc. Common Stock,"Capitol Federal Financial, Inc. operates as the holding company for Capitol Federal Savings Bank that provides various retail banking products and services in the United States. The company accepts a range of deposit products, including savings accounts, money market deposit accounts, interest-bearing and non-interest-bearing checking accounts, and certificates of deposit. It also provides various loan products, such as one- to four-family residential real estate loans, commercial real estate, commercial and industrial, and construction loans, as well as consumer loans, which include home equity, loans and lines of credit, home improvement loans, vehicle loans, and loans secured by saving deposits. In addition, the company offers mobile, telephone, and online banking services, as well as bill payment services; operates a call center; and invests in various securities. It operates a network of 54 branches, including 45 traditional branches and nine in-store branches located in nine counties throughout Kansas and two counties in Missouri. The company serves the metropolitan areas of Topeka, Wichita, Lawrence, Manhattan, Emporia, and Salina, Kansas, and a portion of the metropolitan area of greater Kansas City. Capitol Federal Financial, Inc. was founded in 1893 and is headquartered in Topeka, Kansas.",Mr. John B. Dicus,Banks - Regional,5.725,USD,760131150,https://images.financialmodelingprep.com/symbol/CFFN.png,757296,19.74,-0.135,199698,0,38010000,"[{'period': '2024', 'revenue': 164.59, 'unit': 'M', 'net_profit': 38.01}, {'period': '2023', 'revenue': -25.02, 'unit': 'M', 'net_profit': -101.61}, {'period': '2022', 'revenue': 220.05, 'unit': 'M', 'net_profit': 84.45}, {'period': '2021', 'revenue': 210.66, 'unit': 'M', 'net_profit': 76.08}]","[{'period': ""Q4 '24"", 'revenue': 45.03, 'unit': 'M', 'net_profit': 12.06}, {'period': ""Q3 '24"", 'revenue': 99.7, 'unit': 'M', 'net_profit': 9.65}, {'period': ""Q2 '24"", 'revenue': 97.93, 'unit': 'M', 'net_profit': 13.76}, {'period': ""Q1 '24"", 'revenue': 30.58, 'unit': 'M', 'net_profit': 2.54}, {'period': ""Q4 '23"", 'revenue': -157.93, 'unit': 'M', 'net_profit': -140.32}, {'period': ""Q3 '23"", 'revenue': 39.24, 'unit': 'M', 'net_profit': 8.3}]",0.29,0.29,9527608000,217666000,217307000,8495338000,359000,293313000,0,217307000,28719000,1,1.3740847177387607,1.381578947368421,"[0.085, 0.1]","['2024-11-01', '1999-05-03']",__nan__,0.8916548623746905
758,CFFVU,CF Acquisition Corp. V Unit,,,,,,,,,0,-2.43,1406,,,[],"[{'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.21}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.3}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",,,156695,25000,25000,132200,0,0,132200,25000,,,,,__nan__,__nan__,__nan__,0.843677207313571
759,CFFVW,CF Acquisition Corp. V Warrant,"CF Acquisition Corp. V, a blank check company, intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.",Mr. Howard W. Lutnick,Shell Companies,0.5492,USD,0,https://images.financialmodelingprep.com/symbol/CFFVW.png,0,0,-0.10290003,33876,,,[],[],,,156695,25000,25000,132200,0,0,132200,25000,,,,,__nan__,__nan__,__nan__,0.843677207313571
760,CFIV,CF Acquisition Corp. IV Class A common stock,"CF Acquisition Corp. IV does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the financial services, healthcare, real estate, technology, and software industries. CF Acquisition Corp. IV was incorporated in 2020 and is based in New York, New York.",Mr. Howard W. Lutnick,Shell Companies,10.58,USD,221290222,https://images.financialmodelingprep.com/symbol/CFIV.png,43612,529,0.015,441,13291770,11070791,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.07}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.45}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -6.32}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 513.7}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 179.72}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.02}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.19}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.54}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.08}]",0.17,0.17,104549809,370444,370444,7812963,0,0,5466319,370444,13686,6.931072180773213,0.3093958108241567,0.30769230769230776,__nan__,__nan__,__nan__,0.07472957698086277
761,CFIVU,CF Acquisition Corp. IV Unit,"CF Acquisition Corp. IV does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the financial services, healthcare, real estate, technology, and software industries. CF Acquisition Corp. IV was incorporated in 2020 and is based in New York, New York.",Mr. Howard W. Lutnick,Shell Companies,10.395,USD,221290215,https://images.financialmodelingprep.com/symbol/CFIVU.png,268,102.92079207920793,-0.215,200,13291770,11070791,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.07}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.45}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -6.32}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 513.7}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 179.72}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.02}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.19}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.54}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.08}]",0.17,0.17,104549809,370444,370444,7812963,0,0,5466319,370444,13686,6.931072180773213,0.3093958108241567,0.30769230769230776,__nan__,__nan__,__nan__,0.07472957698086277
762,CFIVW,CF Acquisition Corp. IV Warrant,"CF Acquisition Corp. IV focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.",Mr. Howard W. Lutnick,Shell Companies,0.0005,USD,221290222,https://images.financialmodelingprep.com/symbol/CFIVW.png,21272,0,0.0001,154877,13291770,11070791,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.07}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.45}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -6.32}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 513.7}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 179.72}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.02}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.19}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.54}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.08}]",0.17,0.17,104549809,370444,370444,7812963,0,0,5466319,370444,13686,6.931072180773213,0.3093958108241567,0.30769230769230776,__nan__,__nan__,__nan__,0.07472957698086277
763,CFMS,Conformis Inc. Common Stock,"Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.",Mr. Mark A. Augusti,Medical - Devices,2.27,USD,17881902,https://images.financialmodelingprep.com/symbol/CFMS.png,156850,-0.39824561403508774,0.01,7081,-46225000,-50473000,"[{'period': '2022', 'revenue': 62.05, 'unit': 'M', 'net_profit': -50.47}, {'period': '2021', 'revenue': 99.86, 'unit': 'M', 'net_profit': -2.41}, {'period': '2020', 'revenue': 68.76, 'unit': 'M', 'net_profit': -24.29}, {'period': '2019', 'revenue': 77.43, 'unit': 'M', 'net_profit': -28.48}]","[{'period': ""Q2 '23"", 'revenue': 13.02, 'unit': 'M', 'net_profit': -13.01}, {'period': ""Q1 '23"", 'revenue': 12.84, 'unit': 'M', 'net_profit': -9.57}, {'period': ""Q4 '22"", 'revenue': 17.42, 'unit': 'M', 'net_profit': -3.72}, {'period': ""Q3 '22"", 'revenue': 13.78, 'unit': 'M', 'net_profit': -15.2}, {'period': ""Q2 '22"", 'revenue': 15.29, 'unit': 'M', 'net_profit': -15.52}, {'period': ""Q1 '22"", 'revenue': 15.55, 'unit': 'M', 'net_profit': -16.03}]",-6.99,-6.99,94048000,79269000,48667000,39869000,9773000,0,14073000,48667000,-52071000,-11.648468094909006,-19.91711562370493,-18.416666666666668,__nan__,__nan__,__nan__,0.42392182715209253
764,CFRX,ContraFect Corporation Common Stock,"ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.",Mr. Michael  Messinger CPA,Biotechnology,0.05,USD,0,https://images.financialmodelingprep.com/symbol/CFRX.png,262784,-0.0046168051708217915,-0.0194,910216,-53203000,-65153000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -65.15}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.85}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -27.99}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.63}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.36}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.57}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.12}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.22}, {'period': ""Q3 '22"", 'revenue': 4.83, 'unit': 'M', 'net_profit': -12.23}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.09}]",-124.97,-124.97,20679000,17706000,13682000,32531000,0,0,20840000,8907000,-46036000,-0.12563207447371205,-10.512775587677034,-9.38724832214765,__nan__,__nan__,__nan__,1.5731418347115431
765,CFV,CF Acquisition Corp. V Class A Common Stock,"CF Acquisition Corp. V, a blank check company, intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.",Mr. Howard W. Lutnick,Shell Companies,8.65,USD,0,https://images.financialmodelingprep.com/symbol/CFV.png,79506,0,-3.6800003,53899,,,[],[],,,156695,25000,25000,132200,0,0,132200,25000,,,,,__nan__,__nan__,__nan__,0.843677207313571
766,CFVI,CF Acquisition Corp. VI Class A Common Stock,"CF Acquisition Corp. VI does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the financial services, healthcare, real estate services, technology, and software industries CF Acquisition Corp. VI was incorporated in 2020 and is based in New York, New York.",Mr. Howard W. Lutnick,Shell Companies,12.04,USD,3360725007,https://images.financialmodelingprep.com/symbol/CFVI.png,0,-18.55161787365177,0.42000008,2829591,-131467263,-116420462,"[{'period': '2023', 'revenue': 80.96, 'unit': 'M', 'net_profit': -116.42}, {'period': '2022', 'revenue': 39.38, 'unit': 'M', 'net_profit': -11.4}, {'period': '2021', 'revenue': 9.47, 'unit': 'M', 'net_profit': -13.41}, {'period': '2020', 'revenue': 4.56, 'unit': 'M', 'net_profit': -1.26}]","[{'period': ""Q3 '24"", 'revenue': 25.06, 'unit': 'M', 'net_profit': -31.54}, {'period': ""Q2 '24"", 'revenue': 22.47, 'unit': 'M', 'net_profit': -26.78}, {'period': ""Q1 '24"", 'revenue': 17.73, 'unit': 'M', 'net_profit': -43.29}, {'period': ""Q4 '23"", 'revenue': 20.39, 'unit': 'M', 'net_profit': -29.28}, {'period': ""Q3 '23"", 'revenue': 17.98, 'unit': 'M', 'net_profit': -29.02}, {'period': ""Q2 '23"", 'revenue': 24.97, 'unit': 'M', 'net_profit': -29.45}]",-0.58,-0.58,295712888,238004377,219473858,44089740,5440447,0,33556581,218338658,-110399331,-2.9925433820416356,-9.208744585449624,-11.340425531914892,__nan__,__nan__,__nan__,0.14909644384522058
767,CFVIU,CF Acquisition Corp. VI Unit,"CF Acquisition Corp. VI does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the financial services, healthcare, real estate services, technology, and software industries CF Acquisition Corp. VI was incorporated in 2020 and is based in New York, New York.",Mr. Howard W. Lutnick,Shell Companies,13.1,USD,0,https://images.financialmodelingprep.com/symbol/CFVIU.png,0,-20.184899845916796,0.46000004,623,-131467263,-116420462,"[{'period': '2023', 'revenue': 80.96, 'unit': 'M', 'net_profit': -116.42}, {'period': '2022', 'revenue': 39.38, 'unit': 'M', 'net_profit': -11.4}, {'period': '2021', 'revenue': 9.47, 'unit': 'M', 'net_profit': -13.41}, {'period': '2020', 'revenue': 4.56, 'unit': 'M', 'net_profit': -1.26}]","[{'period': ""Q3 '24"", 'revenue': 25.06, 'unit': 'M', 'net_profit': -31.54}, {'period': ""Q2 '24"", 'revenue': 22.47, 'unit': 'M', 'net_profit': -26.78}, {'period': ""Q1 '24"", 'revenue': 17.73, 'unit': 'M', 'net_profit': -43.29}, {'period': ""Q4 '23"", 'revenue': 20.39, 'unit': 'M', 'net_profit': -29.28}, {'period': ""Q3 '23"", 'revenue': 17.98, 'unit': 'M', 'net_profit': -29.02}, {'period': ""Q2 '23"", 'revenue': 24.97, 'unit': 'M', 'net_profit': -29.45}]",-0.58,-0.58,295712888,238004377,219473858,44089740,5440447,0,33556581,218338658,-110399331,-2.9925433820416356,-9.208744585449624,-11.340425531914892,__nan__,__nan__,__nan__,0.14909644384522058
768,CFVIW,CF Acquisition Corp. VI Warrant,"CF Acquisition Corp. VI does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is New York, New York.",Mr. Howard W. Lutnick,Shell Companies,3.86,USD,0,https://images.financialmodelingprep.com/symbol/CFVIW.png,0,0,0.31,260729,-131467263,-116420462,"[{'period': '2023', 'revenue': 80.96, 'unit': 'M', 'net_profit': -116.42}, {'period': '2022', 'revenue': 39.38, 'unit': 'M', 'net_profit': -11.4}, {'period': '2021', 'revenue': 9.47, 'unit': 'M', 'net_profit': -13.41}, {'period': '2020', 'revenue': 4.56, 'unit': 'M', 'net_profit': -1.26}]","[{'period': ""Q3 '24"", 'revenue': 25.06, 'unit': 'M', 'net_profit': -31.54}, {'period': ""Q2 '24"", 'revenue': 22.47, 'unit': 'M', 'net_profit': -26.78}, {'period': ""Q1 '24"", 'revenue': 17.73, 'unit': 'M', 'net_profit': -43.29}, {'period': ""Q4 '23"", 'revenue': 20.39, 'unit': 'M', 'net_profit': -29.28}, {'period': ""Q3 '23"", 'revenue': 17.98, 'unit': 'M', 'net_profit': -29.02}, {'period': ""Q2 '23"", 'revenue': 24.97, 'unit': 'M', 'net_profit': -29.45}]",-0.58,-0.58,295712888,238004377,219473858,44089740,5440447,0,33556581,218338658,-110399331,-2.9925433820416356,-9.208744585449624,-11.340425531914892,__nan__,__nan__,__nan__,0.14909644384522058
769,CG,The Carlyle Group Inc. Common Stock,"The Carlyle Group Inc. is an investment firm specializing in direct and fund of fund investments. Within direct investments, it specializes in management-led/ Leveraged buyouts, privatizations, divestitures, strategic minority equity investments, structured credit, global distressed and corporate opportunities, small and middle market, equity private placements, consolidations and buildups, senior debt, mezzanine and leveraged finance, and venture and growth capital financings, seed/startup, early venture, emerging growth, turnaround, mid venture, late venture, PIPES. The firm invests across four segments which include Corporate Private Equity, Real Assets, Global Market Strategies, and Solutions. The firm typically invests in industrial, agribusiness, ecological sector, fintech, airports, parking, Plastics, Rubber, diversified natural resources, minerals, farming, aerospace, defense, automotive, consumer, retail, industrial, infrastructure, energy, power, healthcare, software, software enabled services, semiconductors, communications infrastructure, financial technology, utilities, gaming, systems and related supply chain, electronic systems, systems, oil and gas, processing facilities, power generation assets, technology, systems, real estate, financial services, transportation, business services, telecommunications, media, and logistics sectors. Within the industrial sector, the firm invests in manufacturing, building products, packaging, chemicals, metals and mining, forestry and paper products, and industrial consumables and services. In consumer and retail sectors, it invests in food and beverage, retail, restaurants, consumer products, domestic consumption, consumer services, personal care products, direct marketing, and education. Within aerospace, defense, business services, and government services sectors, it seeks to invest in defense electronics, manufacturing and services, government contracting and services, information technology, distribution companies. In telecommunication and media sectors, it invests in cable TV, directories, publishing, entertainment and content delivery services, wireless infrastructure/services, fixed line networks, satellite services, broadband and Internet, and infrastructure. Within real estate, the firm invests in office, hotel, industrial, retail, for sale residential, student housing, hospitality, multifamily residential, homebuilding and building products, and senior living sectors. The firm seeks to make investments in growing business including those with overleveraged balance sheets. The firm seeks to hold its investments for four to six years. In the healthcare sector, it invests in healthcare services, outsourcing services, companies running clinical trials for pharmaceutical companies, managed care, pharmaceuticals, pharmaceutical related services, healthcare IT, medical, products, and devices. It seeks to invest in companies based in Sub-Saharan focusing on Ghana, Kenya, Mozambique, Botswana, Nigeria, Uganda, West Africa, North Africa and South Africa focusing on Tanzania and Zambia; Asia focusing on Pakistan, India, South East Asia, Indonesia, Philippines, Vietnam, Korea, and Japan; Australia; New Zealand; Europe focusing on France, Italy, Denmark, United Kingdom, Germany, Austria, Belgium, Finland, Iceland, Ireland, Netherlands, Norway, Portugal, Spain, Benelux , Sweden, Switzerland, Hungary, Poland, and Russia; Middle East focusing on Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey, and UAE; North America focusing on United States which further invest in Southeastern United States, Texas, Boston, San Francisco Bay Area and Pacific Northwest; Asia Pacific; Soviet Union, Central-Eastern Europe, and Israel; Nordic region; and South America focusing on Mexico, Argentina, Brazil, Chile, and Peru. The firm seeks to invest in food, financial, and healthcare industries in Western China. In the real estate sector, the firm seeks to invest in various locations across Europe focusing on France and Central Europe, United States, Asia focusing on China, and Latin America. It typically invests between $1 million and $50 million for venture investments and between $50 million and $2 billion for buyouts in companies with enterprise value of between $31.57 million and $1000 million and sales value of $10 million and $500 million. It seeks to invest in companies with market capitalization greater than $50 million and EBITDA between $5 million to $25 million. It prefers to take a majority or a minority stake. It typically holds its investments for three to five years. Within automotive and transportation sectors, the firm seeks to hold its investments in for four to six years. While investing in Japan, it does not invest in companies with more than 1,000 employees and prefers companies' worth between $100 million and $150 million. The firm originates, structures, and acts as lead equity investor in the transactions. The Carlyle Group Inc. was founded in 1987 and is based in Washington, District of Columbia with additional offices in 21 countries across 5 continents (North America, South America, Asia, Australia and Europe).",Mr. Harvey Mitchell Schwartz,Asset Management,51.97,USD,18588681570,https://images.financialmodelingprep.com/symbol/CG.png,2412250,173.23,-0.73,999595,0,-608400000,"[{'period': '2023', 'revenue': 2640.0, 'unit': 'M', 'net_profit': -608.4}, {'period': '2022', 'revenue': 3.36, 'unit': 'B', 'net_profit': 1.23}, {'period': '2021', 'revenue': 5.53, 'unit': 'B', 'net_profit': 2.97}, {'period': '2020', 'revenue': 1880.0, 'unit': 'M', 'net_profit': 348.2}]","[{'period': ""Q3 '24"", 'revenue': 1830.0, 'unit': 'M', 'net_profit': 595.7}, {'period': ""Q2 '24"", 'revenue': 1040.0, 'unit': 'M', 'net_profit': 148.2}, {'period': ""Q1 '24"", 'revenue': 681.4, 'unit': 'M', 'net_profit': 65.6}, {'period': ""Q4 '23"", 'revenue': 921.2, 'unit': 'M', 'net_profit': -692.0}, {'period': ""Q3 '23"", 'revenue': 627.3, 'unit': 'M', 'net_profit': 81.3}, {'period': ""Q2 '23"", 'revenue': 437.1, 'unit': 'M', 'net_profit': -98.4}]",-1.68,-1.68,21176000000,2272900000,1440300000,15391500000,832600000,17208400000,0,1786300000,138300000,-1,-1.4966530612244897,-1.4955752212389382,"[0.35, 0.11]","['2024-11-18', '2012-08-16']",__nan__,0.7268369852663392
770,CGABL,The Carlyle Group Inc. 4.625% Subordinated Notes due 2061,,,Financial - Credit Services,18.29,USD,6542141339,https://images.financialmodelingprep.com/symbol/CGABL.png,27359,,-0.42,55977,-1088600000,-608400000,"[{'period': '2023', 'revenue': 2960.0, 'unit': 'M', 'net_profit': -608.4}, {'period': '2022', 'revenue': 4.44, 'unit': 'B', 'net_profit': 1.28}, {'period': '2021', 'revenue': 8.78, 'unit': 'B', 'net_profit': 3.04}, {'period': '2020', 'revenue': 2930.0, 'unit': 'M', 'net_profit': 382.0}]","[{'period': ""Q3 '24"", 'revenue': 1830.0, 'unit': 'M', 'net_profit': 595.7}, {'period': ""Q2 '24"", 'revenue': 1070.0, 'unit': 'M', 'net_profit': 148.2}, {'period': ""Q1 '24"", 'revenue': 688.4, 'unit': 'M', 'net_profit': 65.6}, {'period': ""Q4 '23"", 'revenue': 926.2, 'unit': 'M', 'net_profit': -716.6}, {'period': ""Q3 '23"", 'revenue': 716.6, 'unit': 'M', 'net_profit': 81.3}, {'period': ""Q2 '23"", 'revenue': 462.1, 'unit': 'M', 'net_profit': -98.4}]",-1.68,-1.68,21176000000,2131900000,1440300000,15391500000,691600000,0,140300000,1440300000,889100000,-1.5815792285500587,-1.473573596948704,-1.4786324786324785,"[0.28906, 0.302]","['2025-01-31', '2021-07-29']",__nan__,0.7268369852663392
771,CGBD,TCG BDC Inc. Common Stock,"TCG BDC, Inc. is business development company specializing in first lien debt, senior secured loans, second lien senior secured loan unsecured debt, mezzanine debt and investments in equities. It specializes in directly investing. It specializes in middle market. It targets healthcare and pharmaceutical, aerospace and defense, high tech industries, business services, software, beverage food and tobacco, hotel gamming and leisure, banking finance insurance and in real estate sector. The fund seeks to invest across United States of America, Luxembourg, Cayman Islands, Cyprus, and United Kingdom. It invests in companies with EBITDA between $25 million and $100 million.","Mr. Justin V. Plouffe CFA, J.D.",Asset Management,17.93,USD,912749959,https://images.financialmodelingprep.com/symbol/CGBD.png,193212,10.36,-0.17,97251,169963000,92280000,"[{'period': '2023', 'revenue': 241.63, 'unit': 'M', 'net_profit': 92.28}, {'period': '2022', 'revenue': 162.16, 'unit': 'M', 'net_profit': 85.64}, {'period': '2021', 'revenue': 169.89, 'unit': 'M', 'net_profit': 160.35}, {'period': '2020', 'revenue': 17.12, 'unit': 'M', 'net_profit': 6.83}]","[{'period': ""Q3 '24"", 'revenue': 44.49, 'unit': 'M', 'net_profit': 19.61}, {'period': ""Q2 '24"", 'revenue': 62.46, 'unit': 'M', 'net_profit': 18.75}, {'period': ""Q1 '24"", 'revenue': 42.82, 'unit': 'M', 'net_profit': 29.26}, {'period': ""Q4 '23"", 'revenue': 62.9, 'unit': 'M', 'net_profit': 29.59}, {'period': ""Q3 '23"", 'revenue': 51.03, 'unit': 'M', 'net_profit': 29.99}, {'period': ""Q2 '23"", 'revenue': 7.49, 'unit': 'M', 'net_profit': 4.71}]",1.7,1.64,1942578000,102330000,60447000,1029766000,35394000,1841881000,46970000,60447000,230609000,0.13435714667093812,0.07757161040204584,-0.15000000000000002,"[0.45, 0.37]","['2024-12-31', '2017-06-28']",__nan__,0.5301027809436738
772,CGC,Canopy Growth Corporation Common Shares,"Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.",Ms. Judy Eunjoo Hong,Drug Manufacturers - Specialty & Generic,2.9,USD,362314040,https://images.financialmodelingprep.com/symbol/CGC.png,5938188,-0.59,-0.02,2795052,-312827000,-657269000,"[{'period': '2023', 'revenue': 297.15, 'unit': 'M', 'net_profit': -657.27}, {'period': '2022', 'revenue': 0.4029, 'unit': 'B', 'net_profit': -3.31}, {'period': '2021', 'revenue': 520.33, 'unit': 'M', 'net_profit': -320.49}, {'period': '2020', 'revenue': 0.54665, 'unit': 'B', 'net_profit': -1.67}]","[{'period': ""Q2 '24"", 'revenue': 62.99, 'unit': 'M', 'net_profit': -128.29}, {'period': ""Q1 '24"", 'revenue': 66.21, 'unit': 'M', 'net_profit': -127.14}, {'period': ""Q4 '23"", 'revenue': 72.79, 'unit': 'M', 'net_profit': -92.34}, {'period': ""Q3 '23"", 'revenue': 78.5, 'unit': 'M', 'net_profit': -216.8}, {'period': ""Q2 '23"", 'revenue': 69.59, 'unit': 'M', 'net_profit': -310.01}, {'period': ""Q1 '23"", 'revenue': 108.73, 'unit': 'M', 'net_profit': -38.12}]",-6.47,-8.79,1300330000,371180000,203461000,799823000,44943000,136221000,234715000,170300000,-285946000,0.8913783069811887,0.8014020654192449,0.9093456634440241,__nan__,__nan__,__nan__,0.6150923227180792
773,CGEM,Cullinan Oncology Inc. Common Stock,"Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.",Mr. Nadim  Ahmed,Biotechnology,11.49,USD,669035124,https://images.financialmodelingprep.com/symbol/CGEM.png,508906,-4.35,-0.29,95851,-190339000,-153162000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -153.16}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 111.21}, {'period': '2021', 'revenue': 18.94, 'unit': 'M', 'net_profit': -65.04}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -50.85}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -40.56}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -42.03}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -37.15}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -23.8}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -39.18}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -32.21}]",-3.69,-3.69,484182000,480191000,467067000,30287000,0,0,28137000,98434000,-134483000,-2.257118136966759,-2.3771827287931377,-2.5,__nan__,__nan__,__nan__,0.06255292431358456
774,CGEN,Compugen Ltd. Ordinary Shares,"Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.",Dr. Anat  Cohen-Dayag Ph.D.,Biotechnology,1.59,USD,142362876,https://images.financialmodelingprep.com/symbol/CGEN.png,358406,53,-0.01,109461,-12516000,-18754000,"[{'period': '2023', 'revenue': 33.46, 'unit': 'M', 'net_profit': -18.75}, {'period': '2022', 'revenue': 7.5, 'unit': 'M', 'net_profit': -33.69}, {'period': '2021', 'revenue': 6.0, 'unit': 'M', 'net_profit': -32.87}, {'period': '2020', 'revenue': 2.0, 'unit': 'M', 'net_profit': -27.26}]","[{'period': ""Q3 '24"", 'revenue': 17.13, 'unit': 'M', 'net_profit': 1.28}, {'period': ""Q2 '24"", 'revenue': 6.7, 'unit': 'M', 'net_profit': -2.12}, {'period': ""Q1 '24"", 'revenue': 2.56, 'unit': 'M', 'net_profit': -7.27}, {'period': ""Q4 '23"", 'revenue': 33.46, 'unit': 'M', 'net_profit': 9.71}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.85}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.28}]",-0.21,-0.21,121334000,114579000,50685000,55775000,61318000,0,26266000,13890000,-36058000,0.6461808107649686,0.443402386181516,0.46153846153846156,__nan__,__nan__,__nan__,0.4596815402113175
775,CGNT,Cognyte Software Ltd. Ordinary Shares,"Cognyte Software Ltd. provides an investigative analytics software to governments and enterprises worldwide. Its Actionable Intelligence for a Safer World, an open software designed to help governments and enterprises accelerate and enhance the effectiveness of investigations. The company also offers network intelligence analytics, open source and threat intelligence analytics, and operational intelligence analytics solutions. Its solutions are designed to support various use cases and support a range of users, including data analysts, investigation managers, and security operations center operators, as well as operational field teams. In addition, the company provides customer support, professional, and integration services. Its government customers include national, regional, and local government agencies; and enterprise customers consist of commercial and physical security customers. The company was incorporated in 2020 and is headquartered in Herzliya, Israel.",Mr. Elad  Sharon,Software - Infrastructure,8.71,USD,626205450,https://images.financialmodelingprep.com/symbol/CGNT.png,258300,-48.39,-0.2,62787,572999,-15570000,"[{'period': '2024', 'revenue': 313.4, 'unit': 'M', 'net_profit': -15.57}, {'period': '2023', 'revenue': 312.06, 'unit': 'M', 'net_profit': -109.95}, {'period': '2022', 'revenue': 474.04, 'unit': 'M', 'net_profit': -10.26}, {'period': '2021', 'revenue': 443.46, 'unit': 'M', 'net_profit': 20.31}]","[{'period': ""Q3 '25"", 'revenue': 89.0, 'unit': 'M', 'net_profit': -3.77}, {'period': ""Q2 '25"", 'revenue': 84.41, 'unit': 'M', 'net_profit': -1.93}, {'period': ""Q1 '25"", 'revenue': 82.71, 'unit': 'M', 'net_profit': -5.12}, {'period': ""Q4 '24"", 'revenue': 83.69, 'unit': 'M', 'net_profit': -2.61}, {'period': ""Q3 '24"", 'revenue': 79.39, 'unit': 'M', 'net_profit': 5.22}, {'period': ""Q2 '24"", 'revenue': 77.05, 'unit': 'M', 'net_profit': -9.43}]",-0.22,-0.22,472082000,264981000,74477000,257349000,122119000,7323000,190467000,74477000,25492000,1.0074080648497699,0.8583914652890833,0.8641975308641976,__nan__,__nan__,__nan__,0.5451362263335607
776,CGNX,Cognex Corporation Common Stock,"Cognex Corporation provides machine vision products that capture and analyze visual information in order to automate manufacturing and distribution tasks worldwide. Its machine vision products are used to automate the manufacturing and tracking of discrete items, including mobile phones, aspirin bottles, and automobile tires by locating, identifying, inspecting, and measuring them during the manufacturing or distribution process. The company offers VisionPro software, a suite of patented vision tools for advanced programming; QuickBuild that allows customers to build vision applications with a graphical, flowchart-based programming interface; and Cognex deep learning vision software. It also provides a range of inspection tasks, including part location, identification, measurement, assembly verification, and robotic guidance; vision sensors for vision applications, such as checking the presence and size of parts; and the In-Sight product line of vision systems and sensors. In addition, the company offers DataMan, an image-based barcode readers and barcode verifiers. It sells its products to consumer electronics, automotive, consumer products, food and beverage, pharmaceuticals, and medical devices industries, as well as through a network of distributors and integrators. Cognex Corporation was incorporated in 1981 and is headquartered in Natick, Massachusetts.",Mr. Robert J. Willett,"Hardware, Equipment & Parts",37.47,USD,6426667050,https://images.financialmodelingprep.com/symbol/CGNX.png,1127240,73.47,0.84,480540,144582000,113234000,"[{'period': '2023', 'revenue': 837.55, 'unit': 'M', 'net_profit': 113.23}, {'period': '2022', 'revenue': 1010.0, 'unit': 'M', 'net_profit': 215.53}, {'period': '2021', 'revenue': 1040.0, 'unit': 'M', 'net_profit': 279.88}, {'period': '2020', 'revenue': 811.02, 'unit': 'M', 'net_profit': 176.19}]","[{'period': ""Q3 '24"", 'revenue': 234.74, 'unit': 'M', 'net_profit': 29.59}, {'period': ""Q2 '24"", 'revenue': 239.29, 'unit': 'M', 'net_profit': 36.21}, {'period': ""Q1 '24"", 'revenue': 210.8, 'unit': 'M', 'net_profit': 12.02}, {'period': ""Q4 '23"", 'revenue': 196.67, 'unit': 'M', 'net_profit': 11.23}, {'period': ""Q3 '23"", 'revenue': 197.24, 'unit': 'M', 'net_profit': 18.92}, {'period': ""Q2 '23"", 'revenue': 242.51, 'unit': 'M', 'net_profit': 57.47}]",0.66,0.65,2017812000,678997000,332047000,513060000,116566000,244230000,151884000,202655000,89839000,-0.4984772066628279,-0.47461315392645864,-0.46774193548387094,"[0.08, 0.06]","['2024-11-14', '2003-08-27']",__nan__,0.25426551135586467
777,CGO,Calamos Global Total Return Fund Common Stock,"Calamos Global Total Return Fund is a closed ended balanced mutual fund launched by Calamos Investments LLC. It is managed by Calamos Advisors LLC. The fund invests in public equity and fixed income markets across the globe. It seeks to invest in securities of companies operating across diversified sectors. The fund primarily invests in equities, convertible bonds, and high yield corporate bonds. It employs both fundamental and quantitative analysis to create its portfolio. The fund benchmarks the performance of its portfolio against MSCI World Index. Calamos Global Total Return Fund was formed on March 30, 2004 and is domiciled in the United States.",Mr. John Peter Calamos Sr.,Asset Management - Global,11.337,USD,111339317,https://images.financialmodelingprep.com/symbol/CGO.png,22758,3.11,-0.063,25366,0,35751085,"[{'period': '2024', 'revenue': 36.14, 'unit': 'M', 'net_profit': 35.75}, {'period': '2023', 'revenue': 5.28, 'unit': 'M', 'net_profit': 4.8}, {'period': '2022', 'revenue': -47.89, 'unit': 'M', 'net_profit': -48.46}, {'period': '2021', 'revenue': 45.4, 'unit': 'M', 'net_profit': 44.94}]","[{'period': ""Q4 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q4 '22"", 'revenue': -2.8, 'unit': 'M', 'net_profit': -16.63}, {'period': ""Q2 '22"", 'revenue': 7.91, 'unit': 'M', 'net_profit': -31.83}, {'period': ""Q4 '21"", 'revenue': 2.56, 'unit': 'M', 'net_profit': 9.31}, {'period': ""Q2 '21"", 'revenue': 12.15, 'unit': 'M', 'net_profit': 35.63}]",0,0,179473766,18,18,63556611,1466932,171043168,0,18,-2804795,-1,6.444231385093082,-1,"[0.08, 0.1]","['2024-12-30', '2005-12-28']",__nan__,0.35412758319229787
778,CGRN,Capstone Green Energy Corporation Common Stock,"Capstone Green Energy Corporation develops, manufactures, markets, and services microturbine technology solutions for use in stationary distributed power generation and distribution networks applications worldwide. It offers microturbines, components, and accessories for various applications, including cogeneration combined heat and power (CHP), integrated CHP, and combined cooling, heat, and power, as well as renewable energy, natural resources, and critical power supply. The company's microturbines are also used as battery charging generators for use in hybrid electric vehicles. It also provides various accessories, including rotary gas compressors with digital controls; integrated heat recovery modules for CHP applications; dual mode controllers that allow automatic transition between grid connect and stand-alone modes; batteries with digital controls for stand-alone or dual-mode operations; power servers for multipacked installations; protocol converters for Internet access; packaging options; and miscellaneous parts, such as frames, exhaust ducting, backflow dampers, and installation hardware. In addition, the company offers rental solutions and aftermarket spare parts. Further, it provides energy conversion products including hybrid energy stations, baker hughes, and industrial gas turbines; hydrogen energy solutions, such as hydrogen-based combined heat and power products; and energy storage products comprising microgrid storage systems and lithium-ion battery energy storage systems. The company markets and sells its products primarily through distributors and original equipment manufacturers. The company was formerly known as Capstone Turbine Corporation and changed its name to Capstone Green Energy Corporation in April 2021. Capstone Green Energy Corporation was founded in 1988 and is headquartered in Van Nuys, California.",Mr. Robert C. Flexon,Industrial - Machinery,0.37,USD,6788686,https://images.financialmodelingprep.com/symbol/CGRN.png,210565,-0.42045454545454547,0.06,1584043,-14566000,-20211000,"[{'period': '2022', 'revenue': 69.64, 'unit': 'M', 'net_profit': -20.21}, {'period': '2021', 'revenue': 67.64, 'unit': 'M', 'net_profit': -18.39}, {'period': '2020', 'revenue': 68.93, 'unit': 'M', 'net_profit': -21.9}, {'period': '2019', 'revenue': 83.41, 'unit': 'M', 'net_profit': -16.66}]","[{'period': ""Q3 '23"", 'revenue': 19.61, 'unit': 'M', 'net_profit': -7.07}, {'period': ""Q2 '23"", 'revenue': 20.77, 'unit': 'M', 'net_profit': -4.92}, {'period': ""Q1 '23"", 'revenue': 18.65, 'unit': 'M', 'net_profit': -2.06}, {'period': ""Q4 '22"", 'revenue': 15.76, 'unit': 'M', 'net_profit': -6.89}, {'period': ""Q3 '22"", 'revenue': 20.61, 'unit': 'M', 'net_profit': -5.15}, {'period': ""Q2 '22"", 'revenue': 17.2, 'unit': 'M', 'net_profit': -5.99}]",-1.37,-1.37,100773000,71208000,22559000,95359000,25877000,0,37620000,22559000,-37422000,-0.6311310190369541,-0.0992005221080111,0.15950920245398761,__nan__,__nan__,__nan__,0.946275291992895
779,CHCI,Comstock Holding Companies Inc. Class A Common Stock,"Comstock Holding Companies, Inc. develops, operates, and manages of mixed-use and transit-oriented properties primarily in the Washington, D.C. metropolitan area. The company operates a portfolio of 34 operating assets, which include 14 commercial assets totaling approximately 2.2 million square feet; 6 multifamily assets totaling 1,636 units; and 14 commercial garages with approximately 11,000 parking spaces. It also has 18 development pipeline assets consisting of approximately 2.0 million square feet of additional planned commercial development; approximately 1,900 multifamily units; and 2 hotel assets. In addition, the company provides real estate development and management services. It primarily serves private and institutional owners; investors in commercial, residential, and mixed-use real estate; and various governmental bodies. The company was formerly known as Comstock Homebuilding Companies, Inc. and changed its name to Comstock Holding Companies, Inc. in June 2012. Comstock Holding Companies, Inc. was founded in 1985 and is headquartered in Reston, Virginia.",Mr. Christopher  Clemente,Real Estate - Diversified,8.12,USD,78510494,https://images.financialmodelingprep.com/symbol/CHCI.png,25174,13.76,0.06,2634,9376000,7784000,"[{'period': '2023', 'revenue': 44.72, 'unit': 'M', 'net_profit': 7.78}, {'period': '2022', 'revenue': 39.31, 'unit': 'M', 'net_profit': 7.35}, {'period': '2021', 'revenue': 31.09, 'unit': 'M', 'net_profit': 13.61}, {'period': '2020', 'revenue': 28.73, 'unit': 'M', 'net_profit': 2.08}]","[{'period': ""Q3 '24"", 'revenue': 12.99, 'unit': 'M', 'net_profit': 2.38}, {'period': ""Q2 '24"", 'revenue': 10750.0, 'unit': 'K', 'net_profit': 946.0}, {'period': ""Q1 '24"", 'revenue': 10640.0, 'unit': 'K', 'net_profit': 910.0}, {'period': ""Q4 '23"", 'revenue': 11.02, 'unit': 'M', 'net_profit': 1.87}, {'period': ""Q3 '23"", 'revenue': 14.46, 'unit': 'M', 'net_profit': 4.68}, {'period': ""Q2 '23"", 'revenue': 8970.0, 'unit': 'K', 'net_profit': 475.0}]",0.81,0.77,49939000,24386000,18788000,12723000,5245000,7077000,6373000,18788000,8756000,0.14930129933807307,0.05948005988838982,-0.012195121951219388,__nan__,__nan__,__nan__,0.2547708204008891
780,CHCO,City Holding Company Common Stock,"City Holding Company operates as a holding company for City National Bank of West Virginia that provides various banking, trust and investment management, and other financial solutions in the United States. The company offers checking, savings, and money market accounts, as well as certificates of deposit and individual retirement accounts. It also provides commercial and industrial loans that consist of loans to corporate and other legal entity borrowers primarily in small to mid-size industrial and commercial companies; commercial real estate loans comprising commercial mortgages, which are secured by nonresidential and multi-family residential properties; residential real estate loans to consumers for the purchase or refinance of residence; first-priority home equity loans; consumer loans that are secured and unsecured by automobiles, boats, recreational vehicles, certificates of deposit, and other personal property; and demand deposit account overdrafts. In addition, the company offers mortgage banking services, including fixed and adjustable-rate mortgages, construction financing, land loans, production of conventional and government insured mortgages, secondary marketing, and mortgage servicing. Further, it provides deposit services for commercial customers comprising treasury management, lockbox, and other cash management services; merchant credit card services; wealth management, trust, investment, and custodial services for commercial and individual customers; and corporate trust and institutional custody, financial and estate planning, and retirement plan services, as well as automated-teller-machine, interactive-teller-machine, mobile banking, interactive voice response systems, and credit and debit card services. The company operates through a network of 94 branches and 905 full-time equivalent associates in West Virginia, Virginia, Kentucky, and Ohio. City Holding Company was founded in 1957 and is headquartered in Charleston, West Virginia.",Mr. Charles R. Hageboeck,Banks - Regional,116.25,USD,1709119125,https://images.financialmodelingprep.com/symbol/CHCO.png,56282,14.9,-1.45,15723,0,114365000,"[{'period': '2023', 'revenue': 286.63, 'unit': 'M', 'net_profit': 114.36}, {'period': '2022', 'revenue': 246.08, 'unit': 'M', 'net_profit': 102.07}, {'period': '2021', 'revenue': 218.76, 'unit': 'M', 'net_profit': 88.08}, {'period': '2020', 'revenue': 231.43, 'unit': 'M', 'net_profit': 89.59}]","[{'period': ""Q3 '24"", 'revenue': 74.75, 'unit': 'M', 'net_profit': 29.53}, {'period': ""Q2 '24"", 'revenue': 94.53, 'unit': 'M', 'net_profit': 29.11}, {'period': ""Q1 '24"", 'revenue': 91.44, 'unit': 'M', 'net_profit': 29.52}, {'period': ""Q4 '23"", 'revenue': 85.78, 'unit': 'M', 'net_profit': 27.45}, {'period': ""Q3 '23"", 'revenue': 70.84, 'unit': 'M', 'net_profit': 29.84}, {'period': ""Q2 '23"", 'revenue': 74.07, 'unit': 'M', 'net_profit': 32.73}]",7.62,7.61,6168052000,156276000,156276000,5490986000,0,1369103000,0,156276000,134618000,-1,0.12044557219974332,0.11894273127753312,"[0.79, 0.385]","['2025-01-15', '1987-07-06']",__nan__,0.8902301731567762
781,CHDN,Churchill Downs Incorporated Common Stock,"Churchill Downs Incorporated operates as a racing, online wagering, and gaming entertainment company in the United States. It operates through three segments: Live and Historical Racing, TwinSpires, and Gaming. As of December 31, 2021, the company owned and operated three pari-mutuel gaming entertainment venues with approximately 3,050 historical racing machines (HRMs) in Kentucky; TwinSpires, an online wagering platform for horse racing, sports, and iGaming; nine retail sportsbooks; and casino gaming in eight states with approximately 11,000 slot machines and video lottery terminals, and 200 table games. It also offers streaming video of live horse races, replays, and an assortment of racing and handicapping information; and provides the Bloodstock Research Information Services platform for horse racing statistical data. In addition, the company manufactures and operates pari-mutuel wagering systems for racetracks, off-track betting facilities, and other pari-mutuel wagering businesses. Churchill Downs Incorporated was founded in 1875 and is headquartered in Louisville, Kentucky.",Mr. William C. Carstanjen,"Gambling, Resorts & Casinos",129.63,USD,9527377221,https://images.financialmodelingprep.com/symbol/CHDN.png,438588,23.44,-3.19,97250,1005400000,417300000,"[{'period': '2023', 'revenue': 2460.0, 'unit': 'M', 'net_profit': 417.3}, {'period': '2022', 'revenue': 1810.0, 'unit': 'M', 'net_profit': 439.4}, {'period': '2021', 'revenue': 1600.0, 'unit': 'M', 'net_profit': 249.1}, {'period': '2020', 'revenue': 1050.0, 'unit': 'M', 'net_profit': 13.3}]","[{'period': ""Q3 '24"", 'revenue': 628.5, 'unit': 'M', 'net_profit': 64.4}, {'period': ""Q2 '24"", 'revenue': 890.7, 'unit': 'M', 'net_profit': 209.3}, {'period': ""Q1 '24"", 'revenue': 590.9, 'unit': 'M', 'net_profit': 80.4}, {'period': ""Q4 '23"", 'revenue': 561.2, 'unit': 'M', 'net_profit': 57.6}, {'period': ""Q3 '23"", 'revenue': 572.5, 'unit': 'M', 'net_profit': 61.0}, {'period': ""Q2 '23"", 'revenue': 768.5, 'unit': 'M', 'net_profit': 143.0}]",5.55,5.48,6955500000,400800000,144500000,6061900000,119500000,655900000,755800000,144500000,-70700000,0.14889726888355617,-0.05029585798816568,-0.04310344827586207,"[0.409, 0.5]","['2024-12-06', '1993-12-27']",__nan__,0.8715261304004026
782,CHEF,The Chefs' Warehouse Inc. Common Stock,"The Chefs' Warehouse, Inc., together with its subsidiaries, engages in distribution of specialty food products in the United States and Canada. The company's product portfolio includes approximately 50,000 stock-keeping units, such as specialty food products, such as artisan charcuterie, specialty cheeses, unique oils and vinegars, truffles, caviar, chocolate, and pastry products. It also offers a line of center-of-the-plate products, including custom cut beef, seafood, and hormone-free poultry, as well as food products, such as cooking oils, butter, eggs, milk, and flour. The company serves menu-driven independent restaurants, fine dining establishments, country clubs, hotels, caterers, culinary schools, bakeries, patisseries, chocolatiers, cruise lines, casinos, and specialty food stores. It markets its center-of-the-plate products directly to consumers through a mail and e-commerce platform. The company was founded in 1985 and is headquartered in Ridgefield, Connecticut.",Mr. Christopher  Pappas,Food Distribution,50.25,USD,1987613625,https://images.financialmodelingprep.com/symbol/CHEF.png,369011,43.32,-0.21,112164,156549000,34590000,"[{'period': '2023', 'revenue': 3430.0, 'unit': 'M', 'net_profit': 34.59}, {'period': '2022', 'revenue': 2610.0, 'unit': 'M', 'net_profit': 27.75}, {'period': '2021', 'revenue': 1750.0, 'unit': 'M', 'net_profit': -4.92}, {'period': '2020', 'revenue': 1110.0, 'unit': 'M', 'net_profit': -82.9}]","[{'period': ""Q3 '24"", 'revenue': 931.45, 'unit': 'M', 'net_profit': 14.1}, {'period': ""Q2 '24"", 'revenue': 954.7, 'unit': 'M', 'net_profit': 15.52}, {'period': ""Q1 '24"", 'revenue': 874.49, 'unit': 'M', 'net_profit': 1.93}, {'period': ""Q4 '23"", 'revenue': 950.47, 'unit': 'M', 'net_profit': 16.0}, {'period': ""Q3 '23"", 'revenue': 881.83, 'unit': 'M', 'net_profit': 7.32}, {'period': ""Q2 '23"", 'revenue': 881.82, 'unit': 'M', 'net_profit': 9.87}]",1.06,0.88,1705306000,730943000,49878000,1250634000,334015000,0,385777000,49878000,4212000,0.8258998343791552,0.2464864864864865,0.4133333333333334,__nan__,__nan__,__nan__,0.7333780564895684
783,CHEK,Check-Cap Ltd. Ordinary Share,"Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.",Dr. Yoav  Kimchy Ph.D.,Medical - Diagnostics & Research,1.5803,USD,9245324,https://images.financialmodelingprep.com/symbol/CHEK.png,1219696,-0.74,0.2303,2175686,-17649000,-17568000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.57}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.25}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.09}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.76}]","[{'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.66}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.59}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.88}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.03}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.15}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.46}]",-3,-3,25017000,24856000,24756000,1330000,0,0,1330000,8844000,-17037000,0.055748756085816704,0.08756622000623247,0.11504424778761065,__nan__,__nan__,__nan__,0.05316384858296359
784,CHEKZ,Check-Cap Ltd. Series C Warrant,,None,,0.0101,USD,0,https://images.financialmodelingprep.com/symbol/CHEKZ.png,0,0,0,48250,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
785,CHI,Calamos Convertible Opportunities and Income Fund Common Stock,"Calamos Convertible Opportunities and Income Fund is a closed ended fixed income mutual fund launched by Calamos Investments LLC. It is managed by Calamos Advisors LLC. The fund invests in the fixed income markets of the United States. It primarily invests in a diversified portfolio of convertible securities and high yield corporate bonds rated Ba or lower by Moody's or BB or lower by Standard & Poor's. The fund employs both fundamental and quantitative analysis with a focus on such factors as financial soundness, ability to make interest and dividend payments, earnings and cash-flow forecast, and quality of management to create its portfolio. Calamos Convertible Opportunities and Income Fund was formed on April 17, 2002 and is domiciled in the United States.",Mr. John Peter Calamos Sr.,Asset Management - Income,11.69,USD,864646174,https://images.financialmodelingprep.com/symbol/CHI.png,0,5.34,-0.14,211251,0,164031248,"[{'period': '2024', 'revenue': 164.71, 'unit': 'M', 'net_profit': 164.03}, {'period': '2023', 'revenue': -9.13, 'unit': 'M', 'net_profit': -9.83}, {'period': '2022', 'revenue': -297.27, 'unit': 'M', 'net_profit': -298.1}, {'period': '2021', 'revenue': 287.78, 'unit': 'M', 'net_profit': 287.01}]","[{'period': ""Q2 '24"", 'revenue': 13.31, 'unit': 'M', 'net_profit': 98.68}, {'period': ""Q4 '23"", 'revenue': 50.8, 'unit': 'M', 'net_profit': -28.7}, {'period': ""Q2 '23"", 'revenue': 61.44, 'unit': 'M', 'net_profit': 18.87}, {'period': ""Q4 '22"", 'revenue': 7.8, 'unit': 'M', 'net_profit': -90.76}, {'period': ""Q2 '22"", 'revenue': 81.64, 'unit': 'M', 'net_profit': -207.33}, {'period': ""Q4 '21"", 'revenue': -25.95, 'unit': 'M', 'net_profit': 52.31}]",0,0,1215431322,0,0,456224884,10564437,1176563182,0,0,83193972,-1,17.686396402609986,1,"[0.095, 0.0969]","['2024-12-30', '2002-08-15']",__nan__,0.37536047964378527
786,CHK,Chesapeake Energy Corporation Common Stock,"Chesapeake Energy Corporation, an independent exploration and production company, engages in the acquisition, exploration, and development of properties for the production of oil, natural gas, and natural gas liquids from underground reservoirs in the United States. The company holds interests in natural gas resource plays in the Marcellus Shale in the northern Appalachian Basin in Pennsylvania and the Haynesville/Bossier Shales in northwestern Louisiana; and the liquids-rich resource play in the Eagle Ford Shale in South Texas. As of December 31, 2021, it owned interests in approximately 8,200 gross productive wells, including 6,500 wells with working interest and 1,700 wells with an overriding or royalty interest; and had estimated proved reserves of 661 million barrels of oil equivalent. The company was founded in 1989 and is headquartered in Oklahoma City, Oklahoma.",Mr. Domenic J. Dell'Osso Jr.,Oil & Gas Exploration & Production,81.46,USD,10695127780,https://images.financialmodelingprep.com/symbol/CHK.png,2329734,26.884488448844884,-0.79,2992655,4756000000,2419000000,"[{'period': '2023', 'revenue': 7.78, 'unit': 'B', 'net_profit': 2.42}, {'period': '2022', 'revenue': 11.44, 'unit': 'B', 'net_profit': 4.94}, {'period': '2021', 'revenue': 7.3, 'unit': 'B', 'net_profit': 6.33}, {'period': '2020', 'revenue': 5.21, 'unit': 'B', 'net_profit': -9.75}]","[{'period': ""Q2 '24"", 'revenue': 514.0, 'unit': 'M', 'net_profit': -227.0}, {'period': ""Q1 '24"", 'revenue': 1070.0, 'unit': 'M', 'net_profit': 26.0}, {'period': ""Q4 '23"", 'revenue': 1810.0, 'unit': 'M', 'net_profit': 569.0}, {'period': ""Q3 '23"", 'revenue': 1510.0, 'unit': 'M', 'net_profit': 70.0}, {'period': ""Q2 '23"", 'revenue': 1420.0, 'unit': 'M', 'net_profit': 391.0}, {'period': ""Q1 '23"", 'revenue': 3.04, 'unit': 'B', 'net_profit': 1.39}]",18.21,16.92,14376000000,2609000000,1079000000,3647000000,626000000,312000000,1314000000,1079000000,551000000,-0.14567989940722112,-0.5099270664505673,-0.5295789201756652,"[0.575, 0.34375]","['2024-08-15', '2021-05-21']",__nan__,0.2536867000556483
787,CHKEL,Chesapeake Energy Corporation Class C Warrants,"Chesapeake Energy Corporation engages in the acquisition, exploration, and development of properties for the production of oil, natural gas, and natural gas liquids (NGL) from underground reservoirs in the United States. The company holds interests in natural gas resource plays, including the Marcellus in Northern Appalachian Basin in Pennsylvania; Haynesville located in Northwestern Louisiana; Eagle Ford in South Texas; Brazos Valley in Southeast Texas; Powder River Basin in Wyoming; and Mid-Continent in Anadarko Basin of northwestern Oklahoma. As of December 31, 2019, it owned interests in approximately 13,500 oil and natural gas wells; and had estimated proved reserves of 1,572 one million barrels of oil equivalent. The company was founded in 1989 and is headquartered in Oklahoma City, Oklahoma.",Mr. Domenic J. Dell'Osso Jr.,Oil & Gas Exploration & Production,62.5,USD,8205426750,https://images.financialmodelingprep.com/symbol/CHKEL.png,196,0,-0.19,1799,4756000000,2419000000,"[{'period': '2023', 'revenue': 6.04, 'unit': 'B', 'net_profit': 2.42}, {'period': '2022', 'revenue': 11.44, 'unit': 'B', 'net_profit': 4.94}, {'period': '2021', 'revenue': 5550.0, 'unit': 'K', 'net_profit': 945.0}, {'period': '2020', 'revenue': 5.21, 'unit': 'B', 'net_profit': -9.75}]","[{'period': ""Q2 '24"", 'revenue': 514.0, 'unit': 'M', 'net_profit': -227.0}, {'period': ""Q1 '24"", 'revenue': 922.0, 'unit': 'M', 'net_profit': 26.0}, {'period': ""Q4 '23"", 'revenue': 1090.0, 'unit': 'M', 'net_profit': 569.0}, {'period': ""Q3 '23"", 'revenue': 1510.0, 'unit': 'M', 'net_profit': 70.0}, {'period': ""Q2 '23"", 'revenue': 1420.0, 'unit': 'M', 'net_profit': 391.0}, {'period': ""Q1 '23"", 'revenue': 3.04, 'unit': 'B', 'net_profit': 1.39}]",18.21,16.92,14866000000,2609000000,1790000000,4137000000,593000000,312000000,1314000000,1153000000,551000000,-0.14567989940722112,-0.5099270664505673,-0.5295789201756652,__nan__,__nan__,__nan__,0.2782860217946993
788,CHKEW,Chesapeake Energy Corporation Class A Warrants,"Chesapeake Energy Corporation engages in the acquisition, exploration, and development of properties for the production of oil, natural gas, and natural gas liquids (NGL) from underground reservoirs in the United States. The company holds interests in natural gas resource plays, including the Marcellus in Northern Appalachian Basin in Pennsylvania; Haynesville located in Northwestern Louisiana; Eagle Ford in South Texas; Brazos Valley in Southeast Texas; Powder River Basin in Wyoming; and Mid-Continent in Anadarko Basin of northwestern Oklahoma. As of December 31, 2019, it owned interests in approximately 13,500 oil and natural gas wells; and had estimated proved reserves of 1,572 one million barrels of oil equivalent. The company was founded in 1989 and is headquartered in Oklahoma City, Oklahoma.",Mr. Domenic J. Dell'Osso Jr.,Oil & Gas Exploration & Production,71.89,USD,9438210065,https://images.financialmodelingprep.com/symbol/CHKEW.png,35,0,-3.07,3,4756000000,2419000000,"[{'period': '2023', 'revenue': 6.04, 'unit': 'B', 'net_profit': 2.42}, {'period': '2022', 'revenue': 11.44, 'unit': 'B', 'net_profit': 4.94}, {'period': '2021', 'revenue': 5550.0, 'unit': 'K', 'net_profit': 945.0}, {'period': '2020', 'revenue': 5.21, 'unit': 'B', 'net_profit': -9.75}]","[{'period': ""Q2 '24"", 'revenue': 514.0, 'unit': 'M', 'net_profit': -227.0}, {'period': ""Q1 '24"", 'revenue': 1070.0, 'unit': 'M', 'net_profit': 26.0}, {'period': ""Q4 '23"", 'revenue': 1090.0, 'unit': 'M', 'net_profit': 569.0}, {'period': ""Q3 '23"", 'revenue': 1510.0, 'unit': 'M', 'net_profit': 70.0}, {'period': ""Q2 '23"", 'revenue': 1420.0, 'unit': 'M', 'net_profit': 391.0}, {'period': ""Q1 '23"", 'revenue': 3.04, 'unit': 'B', 'net_profit': 1.39}]",18.21,16.92,14866000000,2609000000,1790000000,4137000000,593000000,312000000,1314000000,1153000000,551000000,-0.14567989940722112,-0.5099270664505673,-0.5295789201756652,__nan__,__nan__,__nan__,0.2782860217946993
789,CHKEZ,Chesapeake Energy Corporation Class B Warrants,"Chesapeake Energy Corporation engages in the acquisition, exploration, and development of properties for the production of oil, natural gas, and natural gas liquids (NGL) from underground reservoirs in the United States. The company holds interests in natural gas resource plays, including the Marcellus in Northern Appalachian Basin in Pennsylvania; Haynesville located in Northwestern Louisiana; Eagle Ford in South Texas; Brazos Valley in Southeast Texas; Powder River Basin in Wyoming; and Mid-Continent in Anadarko Basin of northwestern Oklahoma. As of December 31, 2019, it owned interests in approximately 13,500 oil and natural gas wells; and had estimated proved reserves of 1,572 one million barrels of oil equivalent. The company was founded in 1989 and is headquartered in Oklahoma City, Oklahoma.",Mr. Domenic J. Dell'Osso Jr.,Oil & Gas Exploration & Production,64.04,USD,8407608465,https://images.financialmodelingprep.com/symbol/CHKEZ.png,338,0,2.04,100,4756000000,2419000000,"[{'period': '2023', 'revenue': 6.04, 'unit': 'B', 'net_profit': 2.42}, {'period': '2022', 'revenue': 11.44, 'unit': 'B', 'net_profit': 4.94}, {'period': '2021', 'revenue': 5550.0, 'unit': 'K', 'net_profit': 945.0}, {'period': '2020', 'revenue': 5.21, 'unit': 'B', 'net_profit': -9.75}]","[{'period': ""Q2 '24"", 'revenue': 514.0, 'unit': 'M', 'net_profit': -227.0}, {'period': ""Q1 '24"", 'revenue': 1070.0, 'unit': 'M', 'net_profit': 26.0}, {'period': ""Q4 '23"", 'revenue': 1090.0, 'unit': 'M', 'net_profit': 569.0}, {'period': ""Q3 '23"", 'revenue': 1510.0, 'unit': 'M', 'net_profit': 70.0}, {'period': ""Q2 '23"", 'revenue': 1420.0, 'unit': 'M', 'net_profit': 391.0}, {'period': ""Q1 '23"", 'revenue': 3.04, 'unit': 'B', 'net_profit': 1.39}]",18.21,16.92,14866000000,2609000000,1790000000,4137000000,593000000,312000000,1314000000,1153000000,551000000,-0.14567989940722112,-0.5099270664505673,-0.5295789201756652,__nan__,__nan__,__nan__,0.2782860217946993
790,CHKP,Check Point Software Technologies Ltd. Ordinary Shares,"Check Point Software Technologies Ltd. develops, markets, and supports a range of products and services for IT security worldwide. The company offers a portfolio of network security, endpoint security, data security, and management solutions. It provides Check Point Infinity Architecture, a cyber security architecture that protects against 5th and 6th generation cyber-attacks across various networks, endpoint, cloud, workloads, Internet of Things, and mobile. The company also offers security gateways and software platforms that support small and medium sized business (SMB) to large enterprise data center and telco-grade environments; and threat prevention technologies and zero-day protections. In addition, the company provides cloud network security, security and posture management, cloud workload protection, and cloud web application protection for web applications and APIs; and Check Point Harmony that delivers endpoint and secure connectivity for remote user access. Further, the company provides technical customer support programs and plans; professional services in implementing, upgrading, and optimizing Check Point products comprising design planning and security implementation; and certification and educational training services on Check Point products. It sells its products through multiple distribution channels, including distributors, resellers, system integrators, original equipment manufacturers, and managed security service providers. Check Point Software Technologies Ltd. was incorporated in 1993 and is headquartered in Tel Aviv, Israel.",Brig.Gen. Nadav  Zafrir,Software - Infrastructure,183.54,USD,20186279820,https://images.financialmodelingprep.com/symbol/CHKP.png,730429,25.18,3.66,378162,1023000000,840300000,"[{'period': '2023', 'revenue': 2410.0, 'unit': 'M', 'net_profit': 840.3}, {'period': '2022', 'revenue': 2330.0, 'unit': 'M', 'net_profit': 796.9}, {'period': '2021', 'revenue': 2170.0, 'unit': 'M', 'net_profit': 815.6}, {'period': '2020', 'revenue': 2060.0, 'unit': 'M', 'net_profit': 846.6}]","[{'period': ""Q3 '24"", 'revenue': 635.1, 'unit': 'M', 'net_profit': 206.9}, {'period': ""Q2 '24"", 'revenue': 627.4, 'unit': 'M', 'net_profit': 197.4}, {'period': ""Q1 '24"", 'revenue': 598.8, 'unit': 'M', 'net_profit': 183.9}, {'period': ""Q4 '23"", 'revenue': 663.5, 'unit': 'M', 'net_profit': 249.2}, {'period': ""Q3 '23"", 'revenue': 596.3, 'unit': 'M', 'net_profit': 205.0}, {'period': ""Q2 '23"", 'revenue': 588.7, 'unit': 'M', 'net_profit': 202.0}]",7.19,7.1,5695500000,2257700000,1530000000,2874500000,657700000,1429700000,1916100000,537700000,1019300000,0.11135252580119501,0.05446103651650144,0.13050314465408805,__nan__,__nan__,__nan__,0.50469669036959
791,CHMA,Chiasma Inc. Common Stock,"Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.",Mr. Raj Kannan,Biotechnology,3.76,USD,0,https://images.financialmodelingprep.com/symbol/CHMA.png,996380,-2.390336935791481,-0.24000001,8196718,-68651000,-74779000,"[{'period': '2020', 'revenue': 1.11, 'unit': 'M', 'net_profit': -74.78}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -36.32}, {'period': '2018', 'revenue': 0.0, 'unit': 'M', 'net_profit': -31.26}, {'period': '2017', 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.83}]","[{'period': ""Q1 '21"", 'revenue': 1.92, 'unit': 'M', 'net_profit': -30.55}, {'period': ""Q4 '20"", 'revenue': 0.964, 'unit': 'M', 'net_profit': -19.81}, {'period': ""Q3 '20"", 'revenue': 0.14200000000000002, 'unit': 'M', 'net_profit': -18.46}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.13}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.39}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.05}]",-1.43,-1.43,176338000,153358000,135421000,84553000,538000,0,16731000,15462000,-75698000,-0.9260724405914205,-1.0588931718061674,-0.3490566037735848,__nan__,__nan__,__nan__,0.47949392643672945
792,CHMG,Chemung Financial Corp Common Stock,"Chemung Financial Corporation operates as the holding company for Chemung Canal Trust Company that provides a range of banking, financing, fiduciary, and other financial services. The company provides demand, savings, and time deposits; non-interest and interest-bearing checking accounts; and insured money market accounts. It also offers commercial and agricultural loans comprising loans to small to mid-sized businesses; commercial mortgage loans; residential mortgage loans; consumer loans, including home equity lines of credit and home equity term loans; and interest rate swaps, letters of credit, wealth management, employee benefit plans, mutual fund, insurance products, and brokerage services. Further, it provides securities, insurance, and tax preparation services. Additionally, it offers guardian, custodian, and trustee services, as well as acts as an agent for pension, profit-sharing, and other employee benefit trusts; and various investment, pension, estate planning, and employee benefit administrative services. The company operates 31 branch offices located in 13 counties in New York and Bradford County in Pennsylvania. Chemung Financial Corporation was founded in 1833 and is headquartered in Elmira, New York.",Mr. Anders M. Tomson,Banks - Regional,46.84,USD,222891419,https://images.financialmodelingprep.com/symbol/CHMG.png,14722,10.36,-0.26,1482,34303000,25000000,"[{'period': '2023', 'revenue': 95.74, 'unit': 'M', 'net_profit': 25.0}, {'period': '2022', 'revenue': 94.61, 'unit': 'M', 'net_profit': 28.78}, {'period': '2021', 'revenue': 88.42, 'unit': 'M', 'net_profit': 26.43}, {'period': '2020', 'revenue': 82.87, 'unit': 'M', 'net_profit': 19.26}]","[{'period': ""Q3 '24"", 'revenue': 32.36, 'unit': 'M', 'net_profit': 5.72}, {'period': ""Q2 '24"", 'revenue': 36.96, 'unit': 'M', 'net_profit': 4.99}, {'period': ""Q1 '24"", 'revenue': 36.73, 'unit': 'M', 'net_profit': 7.05}, {'period': ""Q4 '23"", 'revenue': 35.7, 'unit': 'M', 'net_profit': 3.8}, {'period': ""Q3 '23"", 'revenue': 25.58, 'unit': 'M', 'net_profit': 7.65}, {'period': ""Q2 '23"", 'revenue': 23.73, 'unit': 'M', 'net_profit': 6.28}]",5.28,5.28,2710529000,630169000,630169000,2515288000,0,587824000,0,36847000,30419000,-0.1405987723913316,-0.13143174790675052,-0.13866231647634578,"[0.31, 0.24]","['2024-12-19', '1995-03-17']",__nan__,0.927969411137088
793,CHNG,Change Healthcare Inc. Common Stock,"Change Healthcare Inc., an independent healthcare technology company, provides data and analytics-driven solutions to enhance clinical, financial, administrative, and patient engagement outcomes in the United States healthcare system. It operates through three segments: Software and Analytics, Network Solutions, and Technology-Enabled Services. The Software and Analytics segment offers software and analytics solutions for revenue cycle management, provider network management, payment accuracy, clinical decision support, value-based payment, consumer engagement, risk adjustment and quality performance, and imaging and clinical workflow. The Network Solutions segment provides solutions for financial, administrative, and clinical and pharmacy transactions; connected consumer health; network; electronic payments; data; pharmacy; and aggregation and analytics of clinical and financial data. The Technology-Enabled Services segment offers solutions for financial and administrative management, value-based care, communication and payment, pharmacy benefits administration, and healthcare consulting. The company serves commercial insurers, private insurers, BlueCross Blue Shield plans, Medicare/Medicaid plans, provider-sponsored payers, third party administrators, emerging technology and data-driven health plans, and other specialty health benefits insurers, as well as hospitals and health systems, physician practices, dentists, pharmacies, skilled nursing facilities, home health agencies, telehealth providers, senior care facilities, laboratories, and other healthcare providers. Change Healthcare Inc. was incorporated in 2016 and is headquartered in Nashville, Tennessee.",Mr. Neil E. de Crescenzo IV,Medical - Healthcare Information Services,27.49,USD,0,https://images.financialmodelingprep.com/symbol/CHNG.png,0,-152.72222222222223,0.07,28984942,907273000,-154612000,"[{'period': '2022', 'revenue': 3480.0, 'unit': 'M', 'net_profit': -154.61}, {'period': '2021', 'revenue': 3090.0, 'unit': 'M', 'net_profit': -112.21}, {'period': '2020', 'revenue': 196.79, 'unit': 'M', 'net_profit': -947.6}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -52.01}]","[{'period': ""Q1 '23"", 'revenue': 884.47, 'unit': 'M', 'net_profit': -41.79}, {'period': ""Q4 '22"", 'revenue': 920.13, 'unit': 'M', 'net_profit': -19.51}, {'period': ""Q3 '22"", 'revenue': 866.07, 'unit': 'M', 'net_profit': -24.47}, {'period': ""Q2 '22"", 'revenue': 826.76, 'unit': 'M', 'net_profit': -36.4}, {'period': ""Q1 '22"", 'revenue': 867.86, 'unit': 'M', 'net_profit': -3.6}, {'period': ""Q4 '21"", 'revenue': 855.16, 'unit': 'M', 'net_profit': -13.09}]",-0.48,-0.48,9932495000,1312907000,252298000,6656388000,720122000,-563606000000,1079666000,252298000,420602000,-0.3668358085837371,-0.3778807592906158,-0.37142857142857144,"[2, 2]","['2022-09-30', '2022-09-30']",__nan__,0.6701627335327126
794,CHNGU,Change Healthcare Inc. Tangible Equity Units,,None,Medical - Healthcare Information Services,73.71,USD,0,https://images.financialmodelingprep.com/symbol/CHNGU.png,39262,0,0,275964,907273000,-154612000,"[{'period': '2022', 'revenue': 3480.0, 'unit': 'M', 'net_profit': -154.61}, {'period': '2021', 'revenue': 3090.0, 'unit': 'M', 'net_profit': -112.21}, {'period': '2020', 'revenue': 196.79, 'unit': 'M', 'net_profit': -947.6}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -52.01}]","[{'period': ""Q1 '23"", 'revenue': 884.47, 'unit': 'M', 'net_profit': -41.79}, {'period': ""Q4 '22"", 'revenue': 920.13, 'unit': 'M', 'net_profit': -19.51}, {'period': ""Q3 '22"", 'revenue': 866.07, 'unit': 'M', 'net_profit': -24.47}, {'period': ""Q2 '22"", 'revenue': 826.76, 'unit': 'M', 'net_profit': -36.4}, {'period': ""Q1 '22"", 'revenue': 867.86, 'unit': 'M', 'net_profit': -3.6}, {'period': ""Q4 '21"", 'revenue': 855.16, 'unit': 'M', 'net_profit': -13.09}]",-0.48,-0.48,9932495000,1312907000,252298000,6656388000,720122000,-563606000000,1079666000,252298000,420602000,-0.3668358085837371,-0.3778807592906158,-0.37142857142857144,"[0.75, 0.742]","['2022-06-14', '2019-09-13']",__nan__,0.6701627335327126
795,CHNR,China Natural Resources Inc. Common Stock,"China Natural Resources, Inc., through its subsidiaries, engages in the exploration and mining of metal properties in the People's Republic of China. It explores for lead, silver, and other nonferrous metals. The company holds interest in the Moruogu Tong mine that covers an area of 7.81 square kilometers located in Bayannaoer City, Inner Mongolia. It also offers equipment for rural wastewater treatment; and engineering, procurement, and construction services related to wastewater treatment. The company was incorporated in 1993 and is headquartered in Sheung Wan, Hong Kong. China Natural Resources, Inc. is a subsidiary of Feishang Group Limited.",Mr. Wah On  Wong,Waste Management,0.69,USD,6807379,https://images.financialmodelingprep.com/symbol/CHNR.png,58550,-17.25,,0,-12340000,-12443000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.44}, {'period': '2022', 'revenue': 20.31, 'unit': 'M', 'net_profit': -22.3}, {'period': '2021', 'revenue': 18.73, 'unit': 'M', 'net_profit': -54.97}, {'period': '2020', 'revenue': 6.87, 'unit': 'M', 'net_profit': 24.34}]","[{'period': ""Q2 '23"", 'revenue': 1.76, 'unit': 'M', 'net_profit': -1.55}, {'period': ""Q1 '23"", 'revenue': 6.11, 'unit': 'M', 'net_profit': -5.37}, {'period': ""Q4 '22"", 'revenue': 0.6063500000000001, 'unit': 'M', 'net_profit': -3.81}, {'period': ""Q3 '22"", 'revenue': 2.12, 'unit': 'M', 'net_profit': -13.29}, {'period': ""Q2 '22"", 'revenue': 8039.999999999999, 'unit': 'K', 'net_profit': 974.5}, {'period': ""Q1 '22"", 'revenue': 8039.999999999999, 'unit': 'K', 'net_profit': 974.5}]",-0.68,-1.01,253807000,5878000,4753000,177812000,0,0,177812000,4753000,13316000,0.4896186615931839,0.4419178327951202,0.9500367376928729,__nan__,__nan__,__nan__,0.7005795742434212
796,CHPM,CHP Merger Corp. Class A Common Stock,"CHP Merger Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses with a focus on the healthcare sector. The company was incorporated in 2019 and is based in Summit, New Jersey.",Mr. James T. Olsen,Shell Companies,10.18,USD,0,https://images.financialmodelingprep.com/symbol/CHPM.png,114092,10.241448692152918,-0.00999928,87931,22287767,48112294,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 48.11}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': 959.91}]","[{'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.27}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.61}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 36.41}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -133.0}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 400.86}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 751.95}]",1.28,1.28,188792288,401198,98614,25697392,0,0,4253225,98614,-1769146,5.7102804329211825,49.12151517897976,48.99999999999999,__nan__,__nan__,__nan__,0.13611462773309893
797,CHPMW,CHP Merger Corp. Warrant,,None,Shell Companies,0.0041,USD,0,https://images.financialmodelingprep.com/symbol/CHPMW.png,0,0,0.0003,665347,22287767,48112294,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 48.11}, {'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': 959.91}]","[{'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.27}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.61}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 36.41}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -133.0}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 400.86}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 751.95}]",1.28,1.28,188792288,401198,98614,25697392,0,0,4253225,98614,-1769146,5.7102804329211825,49.12151517897976,48.99999999999999,__nan__,__nan__,__nan__,0.13611462773309893
798,CHRS,Coherus BioSciences Inc. Common Stock,"Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.",Mr. Dennis M. Lanfear,Biotechnology,1.61,USD,185492930,https://images.financialmodelingprep.com/symbol/CHRS.png,5091266,-17.89,-0.01,738943,-193939000,-237892000,"[{'period': '2023', 'revenue': 257.24, 'unit': 'M', 'net_profit': -237.89}, {'period': '2022', 'revenue': 211.04, 'unit': 'M', 'net_profit': -326.63}, {'period': '2021', 'revenue': 326.55, 'unit': 'M', 'net_profit': -306.32}, {'period': '2020', 'revenue': 475.82, 'unit': 'M', 'net_profit': 132.24}]","[{'period': ""Q3 '24"", 'revenue': 70.77, 'unit': 'M', 'net_profit': -10.75}, {'period': ""Q2 '24"", 'revenue': 64.98, 'unit': 'M', 'net_profit': -12.92}, {'period': ""Q1 '24"", 'revenue': 77.06, 'unit': 'M', 'net_profit': 102.88}, {'period': ""Q4 '23"", 'revenue': 91.52, 'unit': 'M', 'net_profit': -79.65}, {'period': ""Q3 '23"", 'revenue': 74.57, 'unit': 'M', 'net_profit': -39.64}, {'period': ""Q2 '23"", 'revenue': 58.72, 'unit': 'M', 'net_profit': -42.87}]",-2.53,-2.53,629604000,475631000,117748000,823029000,260522000,0,331771000,102891000,-175170000,0.2411838125682269,0.271672973535643,0.39904988123515445,__nan__,__nan__,__nan__,1.3072169173003982
799,CHRW,C.H. Robinson Worldwide Inc. Common Stock,"C.H. Robinson Worldwide, Inc., together with its subsidiaries, provides freight transportation services and logistics solutions to companies in various industries worldwide. The company operates in two segments, North American Surface Transportation and Global Forwarding. It offers transportation and logistics services, such as truckload; less than truckload transportation brokerage services, which include the shipment of single or multiple pallets of freight; intermodal transportation that comprise the shipment service of freight in containers or trailers by a combination of truck and rail; and non-vessel ocean common carrier and freight forwarding services, as well as organizes air shipments and provides door-to-door services. The company also offers customs broker services; and other logistics services, such as fee-based managed, warehousing, small parcel, and other services. It has contractual relationships with approximately 85,000 transportation companies, including motor carriers, railroads, and air and ocean carriers. In addition, the company is involved in buying, selling, and/or marketing of fresh produce, including fresh fruits, vegetables, and other value-added perishable items under the Robinson Fresh name. Further, it provides transportation management services or managed TMS; and other surface transportation services. The company offers its fresh produce to grocery retailers, restaurants, produce wholesalers, and foodservice distributors through a network of independent produce growers and suppliers. C.H. Robinson Worldwide, Inc. was founded in 1905 and is headquartered in Eden Prairie, Minnesota.",Mr. David P. Bozeman,Integrated Freight & Logistics,104.61,USD,12365425050,https://images.financialmodelingprep.com/symbol/CHRW.png,1161027,36.45,1.09,190014,613592000,325129000,"[{'period': '2023', 'revenue': 17600.0, 'unit': 'M', 'net_profit': 325.13}, {'period': '2022', 'revenue': 24700.0, 'unit': 'M', 'net_profit': 940.52}, {'period': '2021', 'revenue': 23100.0, 'unit': 'M', 'net_profit': 844.25}, {'period': '2020', 'revenue': 16210.0, 'unit': 'M', 'net_profit': 506.42}]","[{'period': ""Q3 '24"", 'revenue': 4640.0, 'unit': 'M', 'net_profit': 97.23}, {'period': ""Q2 '24"", 'revenue': 4480.0, 'unit': 'M', 'net_profit': 126.25}, {'period': ""Q1 '24"", 'revenue': 4410.0, 'unit': 'M', 'net_profit': 92.9}, {'period': ""Q4 '23"", 'revenue': 4220.0, 'unit': 'M', 'net_profit': 30.97}, {'period': ""Q3 '23"", 'revenue': 4340.0, 'unit': 'M', 'net_profit': 81.95}, {'period': ""Q2 '23"", 'revenue': 4420.0, 'unit': 'M', 'net_profit': 97.32}]",2.74,2.72,5225280000,2880694000,145524000,3806583000,2571863000,0,2051993000,145524000,647835000,-0.5486827336531431,-0.6543107884540958,-0.6336898395721925,"[0.62, 0.06]","['2024-12-06', '1997-12-10']",__nan__,0.728493592687856
800,CHSCL,CHS Inc Class B Cumulative Redeemable Preferred Stock Series 4,"CHS Inc., an integrated agricultural company, provides grains, foods, and energy resources to businesses and consumers in North America, South America, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Energy, Ag, Nitrogen Production, and Foods. It is involved in the operation of petroleum refineries and pipelines; supply, marketing, and distribution of refined fuels, including gasoline, diesel fuel, and other energy products; blending, sale, and distribution of lubricants; and the supply of propane and other natural gas liquids. The company also processes and sells crude oil into refined petroleum products under the Cenex brand name to member cooperatives and other independent retailers through a network of approximately 1,500 sites; and provides transportation services. In addition, it markets grains and oilseeds; and offers seeds, crop nutrients, crop protection products, animal feed, animal health products, refined and renewable fuels, and propane, as well as refined oils, meal, soy flour, and processed sunflower products. Further, the company produces and sells nitrogen-based products, including methanol, UAN and urea, and related products; manufactures, packages, and distributes vegetable oil-based products, such as packaged oils, margarine, mayonnaise, flavored dressings, sauces, and other food products; and offers cooperatives with various loans that meet commercial agriculture needs and loans to individual producers, as well as consulting and commodity risk management services. CHS Inc. was incorporated in 1936 and is headquartered in Inver Grove Heights, Minnesota.",Mr. Jay D. Debertin,Agricultural Farm Products,25.6001,USD,350159883,https://images.financialmodelingprep.com/symbol/CHSCL.png,30691,,-0.2199,16162,1683575000,1102319000,"[{'period': '2024', 'revenue': 39.26, 'unit': 'B', 'net_profit': 1.1}, {'period': '2023', 'revenue': 45.59, 'unit': 'B', 'net_profit': 1.73}, {'period': '2022', 'revenue': 47.79, 'unit': 'B', 'net_profit': 1.68}, {'period': '2021', 'revenue': 38450.0, 'unit': 'M', 'net_profit': 553.95}]","[{'period': ""Q4 '24"", 'revenue': 9170.0, 'unit': 'M', 'net_profit': 111.81}, {'period': ""Q3 '24"", 'revenue': 9610.0, 'unit': 'M', 'net_profit': 255.11}, {'period': ""Q2 '24"", 'revenue': 9090.0, 'unit': 'M', 'net_profit': 170.31}, {'period': ""Q1 '24"", 'revenue': 11390.0, 'unit': 'M', 'net_profit': 522.92}, {'period': ""Q4 '23"", 'revenue': 9490.0, 'unit': 'M', 'net_profit': 278.02}, {'period': ""Q3 '23"", 'revenue': 12030.0, 'unit': 'M', 'net_profit': 547.5}]",0,0,18715075000,8708783000,1374783000,7225008000,3549917000,3878192000,5400814000,794865000,441369000,-0.35491157298772796,-0.3634726320469808,0,"[0.46875, 0.37]","['2024-12-17', '2015-03-13']",__nan__,0.386052847771115
801,CHSCM,CHS Inc Class B Reset Rate Cumulative Redeemable Preferred Stock Series 3,"CHS Inc., an integrated agricultural company, provides grains, foods, and energy resources to businesses and consumers in North America, South America, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Energy, Ag, Nitrogen Production, and Foods. It is involved in the operation of petroleum refineries and pipelines; supply, marketing, and distribution of refined fuels, including gasoline, diesel fuel, and other energy products; blending, sale, and distribution of lubricants; and the supply of propane and other natural gas liquids. The company also processes and sells crude oil into refined petroleum products under the Cenex brand name to member cooperatives and other independent retailers through a network of approximately 1,500 sites; and provides transportation services. In addition, it markets grains and oilseeds; and offers seeds, crop nutrients, crop protection products, animal feed, animal health products, refined and renewable fuels, and propane, as well as refined oils, meal, soy flour, and processed sunflower products. Further, the company produces and sells nitrogen-based products, including methanol, UAN and urea, and related products; manufactures, packages, and distributes vegetable oil-based products, such as packaged oils, margarine, mayonnaise, flavored dressings, sauces, and other food products; and offers cooperatives with various loans that meet commercial agriculture needs and loans to individual producers, as well as consulting and commodity risk management services. CHS Inc. was incorporated in 1936 and is headquartered in Inver Grove Heights, Minnesota.",Mr. Jay D. Debertin,Agricultural Farm Products,25.03,USD,350559017,https://images.financialmodelingprep.com/symbol/CHSCM.png,26964,,0.02,10403,1683575000,1102319000,"[{'period': '2024', 'revenue': 39.26, 'unit': 'B', 'net_profit': 1.1}, {'period': '2023', 'revenue': 45.59, 'unit': 'B', 'net_profit': 1.73}, {'period': '2022', 'revenue': 47.79, 'unit': 'B', 'net_profit': 1.68}, {'period': '2021', 'revenue': 38450.0, 'unit': 'M', 'net_profit': 553.95}]","[{'period': ""Q4 '24"", 'revenue': 9170.0, 'unit': 'M', 'net_profit': 111.81}, {'period': ""Q3 '24"", 'revenue': 9610.0, 'unit': 'M', 'net_profit': 255.11}, {'period': ""Q2 '24"", 'revenue': 9090.0, 'unit': 'M', 'net_profit': 170.31}, {'period': ""Q1 '24"", 'revenue': 11390.0, 'unit': 'M', 'net_profit': 522.92}, {'period': ""Q4 '23"", 'revenue': 9490.0, 'unit': 'M', 'net_profit': 278.02}, {'period': ""Q3 '23"", 'revenue': 12030.0, 'unit': 'M', 'net_profit': 547.5}]",0,0,18715075000,8708783000,1374783000,7225008000,3549917000,3878192000,5400814000,794865000,441369000,-0.35491157298772796,-0.3634726320469808,0,"[0.42188, 0.497]","['2024-12-17', '2014-12-15']",__nan__,0.386052847771115
802,CHSCN,CHS Inc Preferred Class B Series 2 Reset Rate,"CHS Inc., an integrated agricultural company, provides grains, foods, and energy resources to businesses and consumers in North America, South America, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Energy, Ag, Nitrogen Production, and Foods. It is involved in the operation of petroleum refineries and pipelines; supply, marketing, and distribution of refined fuels, including gasoline, diesel fuel, and other energy products; blending, sale, and distribution of lubricants; and the supply of propane and other natural gas liquids. The company also processes and sells crude oil into refined petroleum products under the Cenex brand name to member cooperatives and other independent retailers through a network of approximately 1,500 sites; and provides transportation services. In addition, it markets grains and oilseeds; and offers seeds, crop nutrients, crop protection products, animal feed, animal health products, refined and renewable fuels, and propane, as well as refined oils, meal, soy flour, and processed sunflower products. Further, the company produces and sells nitrogen-based products, including methanol, UAN and urea, and related products; manufactures, packages, and distributes vegetable oil-based products, such as packaged oils, margarine, mayonnaise, flavored dressings, sauces, and other food products; and offers cooperatives with various loans that meet commercial agriculture needs and loans to individual producers, as well as consulting and commodity risk management services. CHS Inc. was incorporated in 1936 and is headquartered in Inver Grove Heights, Minnesota.",Mr. Jay D. Debertin,Agricultural Farm Products,25.525,USD,350635751,https://images.financialmodelingprep.com/symbol/CHSCN.png,20645,,-0.175,1875,1683575000,1102319000,"[{'period': '2024', 'revenue': 39.26, 'unit': 'B', 'net_profit': 1.1}, {'period': '2023', 'revenue': 45.59, 'unit': 'B', 'net_profit': 1.73}, {'period': '2022', 'revenue': 47.79, 'unit': 'B', 'net_profit': 1.68}, {'period': '2021', 'revenue': 38450.0, 'unit': 'M', 'net_profit': 553.95}]","[{'period': ""Q4 '24"", 'revenue': 9170.0, 'unit': 'M', 'net_profit': 111.81}, {'period': ""Q3 '24"", 'revenue': 9610.0, 'unit': 'M', 'net_profit': 255.11}, {'period': ""Q2 '24"", 'revenue': 9090.0, 'unit': 'M', 'net_profit': 170.31}, {'period': ""Q1 '24"", 'revenue': 11390.0, 'unit': 'M', 'net_profit': 522.92}, {'period': ""Q4 '23"", 'revenue': 9490.0, 'unit': 'M', 'net_profit': 278.02}, {'period': ""Q3 '23"", 'revenue': 12030.0, 'unit': 'M', 'net_profit': 547.5}]",0,0,18715075000,8708783000,1374783000,7225008000,3549917000,3878192000,5400814000,794865000,441369000,-0.35491157298772796,-0.3634726320469808,0,"[0.44375, 0.404]","['2024-12-17', '2014-06-12']",__nan__,0.386052847771115
803,CHSCO,CHS Inc. Class B Cumulative Redeemable Preferred Stock,"CHS Inc., an integrated agricultural company, provides grains, foods, and energy resources to businesses and consumers in North America, South America, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Energy, Ag, Nitrogen Production, and Foods. It is involved in the operation of petroleum refineries and pipelines; supply, marketing, and distribution of refined fuels, including gasoline, diesel fuel, and other energy products; blending, sale, and distribution of lubricants; and the supply of propane and other natural gas liquids. The company also processes and sells crude oil into refined petroleum products under the Cenex brand name to member cooperatives and other independent retailers through a network of approximately 1,500 sites; and provides transportation services. In addition, it markets grains and oilseeds; and offers seeds, crop nutrients, crop protection products, animal feed, animal health products, refined and renewable fuels, and propane, as well as refined oils, meal, soy flour, and processed sunflower products. Further, the company produces and sells nitrogen-based products, including methanol, UAN and urea, and related products; manufactures, packages, and distributes vegetable oil-based products, such as packaged oils, margarine, mayonnaise, flavored dressings, sauces, and other food products; and offers cooperatives with various loans that meet commercial agriculture needs and loans to individual producers, as well as consulting and commodity risk management services. CHS Inc. was incorporated in 1936 and is headquartered in Inver Grove Heights, Minnesota.",Mr. Jay D. Debertin,Agricultural Farm Products,26.96,USD,351500706,https://images.financialmodelingprep.com/symbol/CHSCO.png,25008,,-0.01,17170,1683575000,1102319000,"[{'period': '2024', 'revenue': 39.26, 'unit': 'B', 'net_profit': 1.1}, {'period': '2023', 'revenue': 45.59, 'unit': 'B', 'net_profit': 1.73}, {'period': '2022', 'revenue': 47.79, 'unit': 'B', 'net_profit': 1.68}, {'period': '2021', 'revenue': 38450.0, 'unit': 'M', 'net_profit': 553.95}]","[{'period': ""Q4 '24"", 'revenue': 9170.0, 'unit': 'M', 'net_profit': 111.81}, {'period': ""Q3 '24"", 'revenue': 9610.0, 'unit': 'M', 'net_profit': 255.11}, {'period': ""Q2 '24"", 'revenue': 9090.0, 'unit': 'M', 'net_profit': 170.31}, {'period': ""Q1 '24"", 'revenue': 11390.0, 'unit': 'M', 'net_profit': 522.92}, {'period': ""Q4 '23"", 'revenue': 9490.0, 'unit': 'M', 'net_profit': 278.02}, {'period': ""Q3 '23"", 'revenue': 12030.0, 'unit': 'M', 'net_profit': 547.5}]",0,0,18715075000,8708783000,1374783000,7225008000,3549917000,3878192000,5400814000,794865000,441369000,-0.35491157298772796,-0.3634726320469808,0,"[0.49219, 0.492]","['2024-12-17', '2013-12-12']",__nan__,0.386052847771115
804,CHSCP,CHS Inc. 8%  Cumulative Redeemable Preferred Stock,"CHS Inc., an integrated agricultural company, provides grains, foods, and energy resources to businesses and consumers in North America, South America, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Energy, Ag, Nitrogen Production, and Foods. It is involved in the operation of petroleum refineries and pipelines; supply, marketing, and distribution of refined fuels, including gasoline, diesel fuel, and other energy products; blending, sale, and distribution of lubricants; and the supply of propane and other natural gas liquids. The company also processes and sells crude oil into refined petroleum products under the Cenex brand name to member cooperatives and other independent retailers through a network of approximately 1,500 sites; and provides transportation services. In addition, it markets grains and oilseeds; and offers seeds, crop nutrients, crop protection products, animal feed, animal health products, refined and renewable fuels, and propane, as well as refined oils, meal, soy flour, and processed sunflower products. Further, the company produces and sells nitrogen-based products, including methanol, UAN and urea, and related products; manufactures, packages, and distributes vegetable oil-based products, such as packaged oils, margarine, mayonnaise, flavored dressings, sauces, and other food products; and offers cooperatives with various loans that meet commercial agriculture needs and loans to individual producers, as well as consulting and commodity risk management services. CHS Inc. was incorporated in 1936 and is headquartered in Inver Grove Heights, Minnesota.",Mr. Jay D. Debertin,Agricultural Farm Products,28.26,USD,346806720,https://images.financialmodelingprep.com/symbol/CHSCP.png,14890,,-0.34,10337,1683575000,1102319000,"[{'period': '2024', 'revenue': 39.26, 'unit': 'B', 'net_profit': 1.1}, {'period': '2023', 'revenue': 45.59, 'unit': 'B', 'net_profit': 1.73}, {'period': '2022', 'revenue': 47.79, 'unit': 'B', 'net_profit': 1.68}, {'period': '2021', 'revenue': 38450.0, 'unit': 'M', 'net_profit': 553.95}]","[{'period': ""Q4 '24"", 'revenue': 9170.0, 'unit': 'M', 'net_profit': 111.81}, {'period': ""Q3 '24"", 'revenue': 9610.0, 'unit': 'M', 'net_profit': 255.11}, {'period': ""Q2 '24"", 'revenue': 9090.0, 'unit': 'M', 'net_profit': 170.31}, {'period': ""Q1 '24"", 'revenue': 11390.0, 'unit': 'M', 'net_profit': 522.92}, {'period': ""Q4 '23"", 'revenue': 9490.0, 'unit': 'M', 'net_profit': 278.02}, {'period': ""Q3 '23"", 'revenue': 12030.0, 'unit': 'M', 'net_profit': 547.5}]",0,0,18715075000,8708783000,1374783000,7225008000,3549917000,3878192000,5400814000,794865000,441369000,-0.35491157298772796,-0.3634726320469808,0,"[0.5, 0.5]","['2024-12-17', '2003-06-13']",__nan__,0.386052847771115
805,CHTR,Charter Communications Inc. Class A Common Stock New,"Charter Communications, Inc. operates as a broadband connectivity and cable operator company serving residential and commercial customers in the United States. The company offers subscription-based video services, including video on demand, high-definition television, digital video recorder, pay-per-view services. It provides Internet services, such as security suite that protects computers from viruses and spyware, and threats from malicious actors; in-home WiFi, which provides customers with high performance wireless routers to enhance their in-home wireless Internet experience; out-of-home WiFi; and Spectrum WiFi services, as well as video services. The company also offers voice communications services using voice over Internet protocol technology; and broadband communications solutions, such as Internet access, data networking, fiber connectivity, video entertainment, and business telephone services to cellular towers and office buildings for business and carrier organizations. In addition, it provides mobile services; offers video programming, static IP and business WiFi, email and security, and multi-line telephone services, as well as Web-based service management; sells local advertising across various platforms for networks, such as TBS, CNN, and ESPN; sells advertising inventory to local sports and news channels; and offers Audience App for optimizes linear inventory. Further, the company offers communications products and managed service solutions; data connectivity services to mobile and wireline carriers on a wholesale basis; and owns and operates regional sports and news networks. It serves approximately 32 million customers in 41 states. The company was founded in 1993 and is headquartered in Stamford, Connecticut.",Mr. Christopher L. Winfrey,Telecommunications Services,346.25,USD,49235365000,https://images.financialmodelingprep.com/symbol/CHTR.png,1163593,10.86,-3.3,340144,20738000000,4557000000,"[{'period': '2023', 'revenue': 54.61, 'unit': 'B', 'net_profit': 4.56}, {'period': '2022', 'revenue': 54.02, 'unit': 'B', 'net_profit': 5.05}, {'period': '2021', 'revenue': 51.68, 'unit': 'B', 'net_profit': 4.65}, {'period': '2020', 'revenue': 48.1, 'unit': 'B', 'net_profit': 3.22}]","[{'period': ""Q3 '24"", 'revenue': 13.79, 'unit': 'B', 'net_profit': 1.28}, {'period': ""Q2 '24"", 'revenue': 13.69, 'unit': 'B', 'net_profit': 1.23}, {'period': ""Q1 '24"", 'revenue': 13.68, 'unit': 'B', 'net_profit': 1.11}, {'period': ""Q4 '23"", 'revenue': 13.71, 'unit': 'B', 'net_profit': 1.06}, {'period': ""Q3 '23"", 'revenue': 13.58, 'unit': 'B', 'net_profit': 1.25}, {'period': ""Q2 '23"", 'revenue': 13.66, 'unit': 'B', 'net_profit': 1.22}]",30.54,29.99,147193000000,4132000000,709000000,132475000000,2965000000,833000000,13214000000,709000000,3490000000,-0.00874719181683476,-0.09851632047477744,-0.02428115015974446,__nan__,__nan__,__nan__,0.9000088319417363
806,CHUY,Chuy's Holdings Inc. Common Stock,"Chuy's Holdings, Inc., through its subsidiaries, owns and operates full-service restaurants under the Chuy's name in the United States. As of December 26, 2021, it operated 96 restaurants in 17 states, including the Southeastern and Midwestern United States. The company was founded in 1982 and is headquartered in Austin, Texas.",Mr. Steven J. Hislop,Restaurants,37.48,USD,645874100,https://images.financialmodelingprep.com/symbol/CHUY.png,468834,24.18064516129032,0.01,999863,68111000,31510000,"[{'period': '2023', 'revenue': 461.31, 'unit': 'M', 'net_profit': 31.51}, {'period': '2022', 'revenue': 422.21, 'unit': 'M', 'net_profit': 20.86}, {'period': '2021', 'revenue': 396.47, 'unit': 'M', 'net_profit': 30.18}, {'period': '2020', 'revenue': 320.95, 'unit': 'M', 'net_profit': -3.29}]","[{'period': ""Q2 '24"", 'revenue': 119.8, 'unit': 'M', 'net_profit': 7.41}, {'period': ""Q1 '24"", 'revenue': 110.46, 'unit': 'M', 'net_profit': 6.92}, {'period': ""Q4 '23"", 'revenue': 116.35, 'unit': 'M', 'net_profit': 5.48}, {'period': ""Q3 '23"", 'revenue': 113.46, 'unit': 'M', 'net_profit': 7.07}, {'period': ""Q2 '23"", 'revenue': 119.0, 'unit': 'M', 'net_profit': 10.73}, {'period': ""Q1 '23"", 'revenue': 112.5, 'unit': 'M', 'net_profit': 8.22}]",1.77,1.76,476634000,80370000,67774000,226787000,3284000,0,48766000,67774000,20473000,0.2858410420993015,0.5109086549988012,0.5803571428571427,__nan__,__nan__,__nan__,0.47580953100282397
807,CHW,Calamos Global Dynamic Income Fund Common Stock,"Calamos Global Dynamic Income Fund is a closed ended balanced mutual fund launched by Calamos Investments LLC. The fund is managed by Calamos Advisors LLC. It invests in public equity and fixed income markets across the globe. The fund seeks to invest in securities of companies operating across diversified sectors. It primarily invests in growth stocks of companies across all market capitalizations, as well as in higher yield corporate bonds, government bonds, convertibles, and alternative investments such as arbitrage and call writes. The fund employs both fundamental and quantitative analysis, focusing on such factors as source, sustainability, and risk of investment opportunities to create its portfolio. It benchmarks the performance of its portfolio against the MSCI World Index and Merrill Lynch Global Broad Markets Index. The fund was formerly known as Calamos Global Diversified Income & Opportunities Fund. Calamos Global Dynamic Income Fund was formed on April 10, 2007 and is domiciled in the United States.",Mr. John Peter Calamos Sr.,Asset Management - Income,6.765,USD,431827539,https://images.financialmodelingprep.com/symbol/CHW.png,151895,2.9,-0.075,127612,0,148775830,"[{'period': '2024', 'revenue': 149.86, 'unit': 'M', 'net_profit': 148.78}, {'period': '2023', 'revenue': 31.16, 'unit': 'M', 'net_profit': 30.08}, {'period': '2022', 'revenue': -195.99, 'unit': 'M', 'net_profit': -197.49}, {'period': '2021', 'revenue': 177.05, 'unit': 'M', 'net_profit': 175.66}]","[{'period': ""Q2 '24"", 'revenue': 49.08, 'unit': 'M', 'net_profit': 94.64}, {'period': ""Q4 '23"", 'revenue': 30.97, 'unit': 'M', 'net_profit': -17.57}, {'period': ""Q2 '23"", 'revenue': 1.07, 'unit': 'M', 'net_profit': 47.65}, {'period': ""Q4 '22"", 'revenue': -23.94, 'unit': 'M', 'net_profit': -71.86}, {'period': ""Q2 '22"", 'revenue': 40.47, 'unit': 'M', 'net_profit': -125.63}, {'period': ""Q4 '21"", 'revenue': 22.89, 'unit': 'M', 'net_profit': 32.19}]",0,0,760309835,14967,14967,266976769,6639674,731384974,0,14967,-8120750,-1,3.9455666595507193,-1,"[0.05, 0.11]","['2024-12-30', '2007-08-09']",__nan__,0.3511420696011383
808,CHX,ChampionX Corporation Common Stock ,"ChampionX Corporation provides chemistry solutions, and engineered equipment and technologies to oil and gas companies worldwide. The company's Production Chemical Technologies segment offers onshore and offshore chemical solutions, such as corrosion inhibitors, scale inhibitors, emulsion breakers, and biocides to oil and natural gas production and midstream markets to manage and control corrosion, oil and water separation, flow assurance, sour gas treatment, and water-related issues. The company's Production & Automation Technologies segment provides artificial lift equipment, end-to-end automation and digital solutions, and other production equipment, including electrical submersible pumping systems, gas lift systems, jet pumps, multiplex surface pumps, plunger lift equipment, progressive cavity pumping systems, downhole rod lift systems, emissions monitoring solutions, chemical injection systems, flow control valves, and gauges under the Harbison-Fischer, Norris, Alberta Oil Tool, Oil Lift Technology, PCS Ferguson, Pro-Rod, Upco, Unbridled ESP, Norriseal-Wellmark, Quartzdyne, Spirit, Theta, Timberline, and Windrock brands. The company's Drilling Technologies segment offers polycrystalline diamond cutter inserts, bearings, valves, and mining tools under the US Synthetic brand for use in oil and gas drill bits, renewable energy applications, mixers, and agitators; and high-density ceramic roof bolt mining tools for underground mining operations. The company's Reservoir Chemical Technologies segment provides chemistry-oriented solutions and technologies for well drilling, cementing, fracturing, acidizing, and other well interventions, as well as fracturing fluid packages, drilling and cement additives, and products for acidizing activities. ChampionX Corporation is headquartered in The Woodlands, Texas.",Mr. Sivasankaran  Somasundaram,Oil & Gas Equipment & Services,27.9455,USD,5323617750,https://images.financialmodelingprep.com/symbol/CHX.png,1713154,17.25,0.5255,578092,719356000,314238000,"[{'period': '2023', 'revenue': 3760.0, 'unit': 'M', 'net_profit': 314.24}, {'period': '2022', 'revenue': 3810.0, 'unit': 'M', 'net_profit': 154.97}, {'period': '2021', 'revenue': 3070.0, 'unit': 'M', 'net_profit': 113.3}, {'period': '2020', 'revenue': 1900.0, 'unit': 'M', 'net_profit': -742.35}]","[{'period': ""Q3 '24"", 'revenue': 906.53, 'unit': 'M', 'net_profit': 72.01}, {'period': ""Q2 '24"", 'revenue': 893.27, 'unit': 'M', 'net_profit': 52.57}, {'period': ""Q1 '24"", 'revenue': 922.14, 'unit': 'M', 'net_profit': 112.92}, {'period': ""Q4 '23"", 'revenue': 943.55, 'unit': 'M', 'net_profit': 77.2}, {'period': ""Q3 '23"", 'revenue': 939.78, 'unit': 'M', 'net_profit': 77.71}, {'period': ""Q2 '23"", 'revenue': 926.6, 'unit': 'M', 'net_profit': 95.8}]",1.6,1.57,3241702000,1425417000,288557000,1580671000,534534000,0,782749000,288557000,397947000,0.1670960666099902,1.0277474849808672,1.077922077922078,"[0.095, 0.075]","['2025-01-03', '2022-04-07']",__nan__,0.4876052764874748
809,CHY,Calamos Convertible and High Income Fund Common Stock,"Calamos Convertible and High Income Fund is a closed ended fixed income mutual fund launched by Calamos Investments LLC. It is managed by Calamos Advisors LLC. The fund invests in the fixed income markets of the United States. It primarily invests in a diversified portfolio of convertible securities and high yield corporate bonds rated Ba or lower by Moody's or BB or lower by Standard & Poor's. The fund employs both fundamental and quantitative analysis to create its portfolio. Calamos Convertible and High Income Fund was formed on March 12, 2003 and is domiciled in the United States.",Mr. John Peter Calamos Sr.,Asset Management - Income,11.9908,USD,911406319,https://images.financialmodelingprep.com/symbol/CHY.png,143553,5.12,-0.0092,134957,0,178731198,"[{'period': '2024', 'revenue': 179.45, 'unit': 'M', 'net_profit': 178.73}, {'period': '2023', 'revenue': -8.88, 'unit': 'M', 'net_profit': -9.61}, {'period': '2022', 'revenue': -324.71, 'unit': 'M', 'net_profit': -325.57}, {'period': '2021', 'revenue': 317.51, 'unit': 'M', 'net_profit': 316.68}]","[{'period': ""Q2 '24"", 'revenue': 14.06, 'unit': 'M', 'net_profit': 107.85}, {'period': ""Q4 '23"", 'revenue': -139.33, 'unit': 'M', 'net_profit': -31.53}, {'period': ""Q2 '23"", 'revenue': 69.57, 'unit': 'M', 'net_profit': 21.92}, {'period': ""Q4 '22"", 'revenue': 11.17, 'unit': 'M', 'net_profit': -97.56}, {'period': ""Q2 '22"", 'revenue': 89.95, 'unit': 'M', 'net_profit': -228.01}, {'period': ""Q4 '21"", 'revenue': 11.43, 'unit': 'M', 'net_profit': 59.12}]",0,0,1314506363,0,0,494924155,11472767,1274581172,0,0,95171811,1,19.595845474793293,1,"[0.1, 0.1219]","['2024-12-30', '2003-08-14']",__nan__,0.3765095163712037
810,CIDM,Cinedigm Corp. Class A Common Stock,"Cinedigm Corp., together with its subsidiaries, operates as distributor and aggregator of independent movie, television, and other short form content in the United States. The company operates through two segments, Cinema Equipment Business and Content and Entertainment Business. The company distributes its products for various brands, such as Hallmark, Televisa, ITV, Nelvana, ZDF, Konami, NFL, and NHL, as well as international and domestic content creators, movie producers, television producers, and other short form digital content producers. It also collaborates with producers, various brands, and other content owners to market, source, curate, and distribute content to targeted audiences through existing and emerging digital home entertainment platforms, including Apple, Amazon Prime, Netflix, Hulu, Xbox, Tubi, PlutoTV, Vudu, and cable/satellite video-on-demand; and distributes DVD and Blu-ray discs to wholesalers and retailers with sales coverage to approximately 48,000 retail storefronts, including Walmart, Target, Best Buy, and Amazon. In addition, the company operates various branded and curated over-the-top (OTT) entertainment channels and applications, including Docurama, CONtv, Dove Channel, Viewster Anime, Fandor, and Screambox; and Matchpoint, a software-as-a-service platform to automate the distribution of streaming content and OTT channels. Further, it provides monitoring, billing, collection, and verification support services to music and movie screens as well as directly to exhibitors and other third-party customers. The company was formerly known as Cinedigm Digital Cinema Corp. and changed its name to Cinedigm Corp. in September 2013. Cinedigm Corp. was incorporated in 2000 and is headquartered in New York, New York.",Mr. Christopher J. McGurk,Entertainment,0.2945,USD,55046470,https://images.financialmodelingprep.com/symbol/CIDM.png,681225,-4.908333333333333,0.0025,1093691,-2628000,-9694000,"[{'period': '2023', 'revenue': 68.03, 'unit': 'M', 'net_profit': -9.69}, {'period': '2022', 'revenue': 56.05, 'unit': 'M', 'net_profit': 1.65}, {'period': '2021', 'revenue': 31.42, 'unit': 'M', 'net_profit': -62.91}, {'period': '2020', 'revenue': 39.29, 'unit': 'M', 'net_profit': -14.72}]","[{'period': ""Q3 '24"", 'revenue': 13.28, 'unit': 'M', 'net_profit': -2.86}, {'period': ""Q2 '24"", 'revenue': 13010.0, 'unit': 'K', 'net_profit': -445.0}, {'period': ""Q1 '24"", 'revenue': 12.98, 'unit': 'M', 'net_profit': -3.64}, {'period': ""Q4 '23"", 'revenue': 12.55, 'unit': 'M', 'net_profit': -3.07}, {'period': ""Q3 '23"", 'revenue': 27.88, 'unit': 'M', 'net_profit': 5.01}, {'period': ""Q2 '23"", 'revenue': 14.01, 'unit': 'M', 'net_profit': -6.24}]",-1.09,-1.09,87988000,37577000,7152000,48915000,25387000,5200000,45331000,7152000,-10068000,-1.4424987371611382,-6.864488808227465,-6.45,__nan__,__nan__,__nan__,0.5559280811019685
811,CIGI,Colliers International Group Inc. Subordinate Voting Shares,"Colliers International Group Inc. provides commercial real estate professional and investment management services to corporate and institutional clients in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers sales brokerage services, including real estate sales, debt origination and placement, equity capital raising, market value opinions, acquisition advisory, and transaction management services; and landlord and tenant representation services. The company provides outsourcing and advisory services, such as corporate and workplace solutions; valuation and advisory services; workplace strategy services; loan servicing; property marketing; research services; and engineering design services for property and building, infrastructure, transportation, environmental and telecommunications end-markets. It also offers property management services comprising building operations and maintenance, facilities management, lease administration, property accounting and financial reporting, contract management and, construction management; and project management services, which include bid document review, construction monitoring and delivery management, contract administration and integrated cost control, development management, facility and engineering functionality, milestone and performance monitoring, quality assurance, risk management and strategic project consulting. In addition, the company provides investment management services that consists of asset management advisory and administration, transaction, and incentive services. The company was founded in 1972 and is headquartered in Toronto, Canada.",Mr. Jay Stewart Hennick CM,Real Estate - Services,136.215,USD,6690158861,https://images.financialmodelingprep.com/symbol/CIGI.png,97130,42.83,-0.955,30846,509390000,65543000,"[{'period': '2023', 'revenue': 4340.0, 'unit': 'M', 'net_profit': 65.54}, {'period': '2022', 'revenue': 4460.0, 'unit': 'M', 'net_profit': 194.54}, {'period': '2021', 'revenue': 4090.0, 'unit': 'M', 'net_profit': -237.56}, {'period': '2020', 'revenue': 2790.0, 'unit': 'M', 'net_profit': 94.49}]","[{'period': ""Q3 '24"", 'revenue': 1180.0, 'unit': 'M', 'net_profit': 37.23}, {'period': ""Q2 '24"", 'revenue': 1140.0, 'unit': 'M', 'net_profit': 36.72}, {'period': ""Q1 '24"", 'revenue': 997.5, 'unit': 'M', 'net_profit': 12.66}, {'period': ""Q4 '23"", 'revenue': 1270.0, 'unit': 'M', 'net_profit': 67.43}, {'period': ""Q3 '23"", 'revenue': 1060.0, 'unit': 'M', 'net_profit': 25.11}, {'period': ""Q2 '23"", 'revenue': 1080.0, 'unit': 'M', 'net_profit': -6.85}]",1.41,1.42,5482126000,1474264000,204655000,3559570000,726764000,48225000,1441213000,181134000,81137000,-0.17023269451616319,-0.6630942100501686,-0.6852678571428571,"[0.15, 5]","['2024-12-31', '2007-07-23']",__nan__,0.6493046675687498
812,CIH,China Index Holdings Limited American Depository Shares,"China Index Holdings Limited, together with its subsidiaries, operates a real estate information and analytics service platform in China. The company offers promotion services, including number of online and offline themed campaigns, such as industry forums, periodic updates, and online promotions to its customers to promote their brands. It provides listing services comprising commercial property listing and agent services for commercial properties; access and analytics tools, including appraisal and rating, and land modules, based on proprietary database of commercial real estate information; customized research reports; and data monitoring and survey services. The company serves real estate developers, commercial banks and other financial institutions, academic institutions, property managers, brokers, agents, consultants, and other participants in real estate related business. The company was formerly known as Selovo Investments Limited and changed its name to China Index Holdings Limited. China Index Holdings Limited was incorporated in 2007 and is based in Beijing, China.",Ms. Yu  Huang,Software - Application,0.9477,USD,85696152,https://images.financialmodelingprep.com/symbol/CIH.png,54746,2.7077142857142857,0,228927,306775000,279182000,"[{'period': '2021', 'revenue': 620.95, 'unit': 'M', 'net_profit': 279.18}, {'period': '2020', 'revenue': 635.91, 'unit': 'M', 'net_profit': 294.34}, {'period': '2019', 'revenue': 579.65, 'unit': 'M', 'net_profit': 245.45}, {'period': '2018', 'revenue': 421.02, 'unit': 'M', 'net_profit': 165.42}]","[{'period': ""Q3 '22"", 'revenue': 97.67, 'unit': 'M', 'net_profit': 27.6}, {'period': ""Q2 '22"", 'revenue': 110.22, 'unit': 'M', 'net_profit': 21.13}, {'period': ""Q1 '22"", 'revenue': 118.51, 'unit': 'M', 'net_profit': 41.83}, {'period': ""Q4 '21"", 'revenue': 173.78, 'unit': 'M', 'net_profit': 82.51}, {'period': ""Q3 '21"", 'revenue': 160.78, 'unit': 'M', 'net_profit': 72.86}, {'period': ""Q2 '21"", 'revenue': 152.66, 'unit': 'M', 'net_profit': 67.37}]",3.1,3.08,480797000,436269000,361521000,469942000,49217000,0,365084000,361521000,214329000,2.350378779541943,-0.051495044829261497,-0.05487804878048772,__nan__,__nan__,__nan__,0.9774229040530619
813,CINF,Cincinnati Financial Corporation Common Stock,"Cincinnati Financial Corporation, together with its subsidiaries, provides property casualty insurance products in the United States. The company operates through five segments: Commercial Lines Insurance, Personal Lines Insurance, Excess and Surplus Lines Insurance, Life Insurance, and Investments. The Commercial Lines Insurance segment offers coverage for commercial casualty, commercial property, commercial auto, and workers' compensation. It also provides director and officer liability insurance, contract and commercial surety bonds, and fidelity bonds; and machinery and equipment coverage. The Personal Lines Insurance segment offers personal auto insurance; homeowner insurance; and dwelling fire, inland marine, personal umbrella liability, and watercraft coverages to individuals. The Excess and Surplus Lines Insurance segment offers commercial casualty insurance that covers businesses for third-party liability from accidents occurring on their premises or arising out of their operations, such as injuries sustained from products; and commercial property insurance, which insures buildings, inventory, equipment, and business income from loss or damage due to various causes, such as fire, wind, hail, water, theft, and vandalism. The Life Insurance segment provides term life insurance products; universal life insurance products; worksite products, such as term life; and whole life insurance products. The Investments segment invests in fixed-maturity investments, including taxable and tax-exempt bonds, and redeemable preferred stocks; and equity investments comprising common and nonredeemable preferred stocks. The company also offers commercial leasing and financing services; and insurance brokerage services. Cincinnati Financial Corporation was founded in 1950 and is headquartered in Fairfield, Ohio.",Mr. Stephen Michael Spray,Insurance - Property & Casualty,142.8,USD,22321782000,https://images.financialmodelingprep.com/symbol/CINF.png,579122,7.36,1.05,138662,2442000000,1843000000,"[{'period': '2023', 'revenue': 10.01, 'unit': 'B', 'net_profit': 1.84}, {'period': '2022', 'revenue': 6560.0, 'unit': 'M', 'net_profit': -486.0}, {'period': '2021', 'revenue': 9.63, 'unit': 'B', 'net_profit': 2.97}, {'period': '2020', 'revenue': 7.54, 'unit': 'B', 'net_profit': 1.22}]","[{'period': ""Q3 '24"", 'revenue': 3320.0, 'unit': 'M', 'net_profit': 820.0}, {'period': ""Q2 '24"", 'revenue': 2540.0, 'unit': 'M', 'net_profit': 312.0}, {'period': ""Q1 '24"", 'revenue': 2940.0, 'unit': 'M', 'net_profit': 755.0}, {'period': ""Q4 '23"", 'revenue': 3.36, 'unit': 'B', 'net_profit': 1.18}, {'period': ""Q3 '23"", 'revenue': 1810.0, 'unit': 'M', 'net_profit': -99.0}, {'period': ""Q2 '23"", 'revenue': 2600.0, 'unit': 'M', 'net_profit': 534.0}]",11.74,11.66,32769000000,962000000,907000000,20671000000,0,478000000,0,907000000,2034000000,5.750972762645914,4.792181069958848,4.836601307189543,"[0.81, 4.1887]","['2024-12-19', '1984-12-20']",__nan__,0.6308096066404224
814,CIVB,Civista Bancshares Inc. Common Stock,"Civista Bancshares, Inc. operates as the financial holding company for Civista Bank that provides community banking services. It collects a range of customer deposits; and offers commercial and agriculture, commercial and residential real estate, farm real estate, real estate construction, consumer, and other loans, as well as letters of credit. The company also purchases securities; and provides trust and third-party insurance services. It operates approximately 42 locations in Northern, Central, Southwestern, and Northwestern Ohio, as well as Southeastern Indiana and Northern Kentucky. The company was formerly known as First Citizens Banc Corp and changed its name to Civista Bancshares, Inc. in May 2015. Civista Bancshares, Inc. was founded in 1884 and is headquartered in Sandusky, Ohio.",Mr. Dennis G. Shaffer,Banks - Regional,19.94,USD,313785810,https://images.financialmodelingprep.com/symbol/CIVB.png,58187,9.97,-0.02,14044,0,42964000,"[{'period': '2023', 'revenue': 158.22, 'unit': 'M', 'net_profit': 42.96}, {'period': '2022', 'revenue': 137.03, 'unit': 'M', 'net_profit': 39.43}, {'period': '2021', 'revenue': 124.56, 'unit': 'M', 'net_profit': 40.55}, {'period': '2020', 'revenue': 116.04, 'unit': 'M', 'net_profit': 32.19}]","[{'period': ""Q3 '24"", 'revenue': 62.43, 'unit': 'M', 'net_profit': 8.19}, {'period': ""Q2 '24"", 'revenue': 61.14, 'unit': 'M', 'net_profit': 7.06}, {'period': ""Q1 '24"", 'revenue': 58.63, 'unit': 'M', 'net_profit': 6.36}, {'period': ""Q4 '23"", 'revenue': 57.42, 'unit': 'M', 'net_profit': 9.65}, {'period': ""Q3 '23"", 'revenue': 39.01, 'unit': 'M', 'net_profit': 10.39}, {'period': ""Q2 '23"", 'revenue': 39.87, 'unit': 'M', 'net_profit': 10.03}]",2.73,2.73,3861418000,82781000,8331000,3489416000,0,60551000,30359000,60406000,59269000,-1,0.08971009714155274,0.049999999999999954,"[0.16, 0.14]","['2024-11-05', '1997-01-16']",__nan__,0.9036618154263537
815,CIZN,Citizens Holding Company Common Stock,"Citizens Holding Company operates as the bank holding company for The Citizens Bank of Philadelphia that provides various commercial and personal banking products and services. It offers demand deposits; and savings and time deposit accounts. The company also provides secured and unsecured loans; mortgage loans; single and multi-family housing, farm, residential and commercial construction, and commercial real estate loans; commercial, industrial, and agricultural production loans; and consumer loans, as well as issues letters of credit. In addition, it offers personal and corporate trust services; credit life and title insurance; and online and mobile banking services. The company was founded in 1908 and is headquartered in Philadelphia, Mississippi.",Mr. Stacy M. Brantley,Banks - Regional,8.92,USD,50282575,https://images.financialmodelingprep.com/symbol/CIZN.png,2251,27.03,-0.28,200,0,1854000,"[{'period': '2023', 'revenue': 37.66, 'unit': 'M', 'net_profit': 1.85}, {'period': '2022', 'revenue': 44.97, 'unit': 'M', 'net_profit': 9.62}, {'period': '2021', 'revenue': 45.68, 'unit': 'M', 'net_profit': 7.49}, {'period': '2020', 'revenue': 43.59, 'unit': 'M', 'net_profit': 6.93}]","[{'period': ""Q4 '23"", 'revenue': 8029.999999999999, 'unit': 'K', 'net_profit': -793.0}, {'period': ""Q3 '23"", 'revenue': 10.62, 'unit': 'M', 'net_profit': 1.21}, {'period': ""Q2 '23"", 'revenue': 9680.0, 'unit': 'K', 'net_profit': 300.0}, {'period': ""Q1 '23"", 'revenue': 10.04, 'unit': 'M', 'net_profit': 1.14}, {'period': ""Q4 '22"", 'revenue': 11.31, 'unit': 'M', 'net_profit': 2.46}, {'period': ""Q3 '22"", 'revenue': 0.20500000000000002, 'unit': 'M', 'net_profit': 2.58}]",0.33,0.33,1404597000,277502000,272271000,1361824000,5231000,565594000,0,94476000,4805000,0,-0.8072765072765072,-0.8092485549132947,"[0.16, 0.2551]","['2024-12-16', '1999-12-13']",__nan__,0.9695478489559639
816,CJJD,China Jo-Jo Drugstores Inc. Common Stock,"China Jo-Jo Drugstores, Inc., together with its subsidiaries, operates as a retailer and distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company operates through four segments: Retail Drugstores, Online Pharmacy, Drug Wholesale, and Herb Farming. Its stores provide various pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as convenience products, such as consumable, seasonal, and promotional items. The company also operates licensed doctors of Western medicine and TCM on site for consultation, examination, and treatment of common ailments at scheduled hours. In addition, it operates online drugstore that retails OTC drugs and nutritional supplements, as well as sells products through third-party platforms. Further, the company distributes third-party pharmaceutical products primarily to trading companies, as well as cultivates and wholesales herbs used for TCM. As of March 31, 2021, it had 109 retail pharmacies under the Jiuzhou Grand Pharmacy name, as well as 4 drugstores. The company was founded in 2003 and is headquartered in Hangzhou, the People's Republic of China.",Mr. Lei  Liu M.D.,Medical - Pharmaceuticals,2.1,USD,13973568,https://images.financialmodelingprep.com/symbol/CJJD.png,11225,-0.72,-0.05,31260,1226845,-4234228,"[{'period': '2024', 'revenue': 154.54, 'unit': 'M', 'net_profit': -4.23}, {'period': '2023', 'revenue': 148.81, 'unit': 'M', 'net_profit': -21.14}, {'period': '2022', 'revenue': 164.39, 'unit': 'M', 'net_profit': -3.2}, {'period': '2021', 'revenue': 133.13, 'unit': 'M', 'net_profit': -8.38}]","[{'period': ""Q4 '24"", 'revenue': 37.98, 'unit': 'M', 'net_profit': -1.65}, {'period': ""Q3 '24"", 'revenue': 37.98, 'unit': 'M', 'net_profit': -1.65}, {'period': ""Q2 '24"", 'revenue': 39290.0, 'unit': 'K', 'net_profit': -462.12}, {'period': ""Q1 '24"", 'revenue': 39290.0, 'unit': 'K', 'net_profit': -462.12}, {'period': ""Q4 '23"", 'revenue': 38.04, 'unit': 'M', 'net_profit': -10.27}, {'period': ""Q3 '23"", 'revenue': 38.04, 'unit': 'M', 'net_profit': -10.27}]",-2.93,-2.93,95057090,69682362,20149806,80763953,19075498,1195261,74360095,20149806,-4079077,1.061464000966314,0.799693804423974,0.9293294741919923,__nan__,__nan__,__nan__,0.8496362869934267
817,CKPT,Checkpoint Therapeutics Inc. Common Stock,"Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.","Mr. James F. Oliviero III, C.F.A.",Biotechnology,3.5,USD,168463750,https://images.financialmodelingprep.com/symbol/CKPT.png,1431858,-1.91,-0.16,787269,-52148000,-51847000,"[{'period': '2023', 'revenue': 0.10300000000000001, 'unit': 'M', 'net_profit': -51.85}, {'period': '2022', 'revenue': 0.192, 'unit': 'M', 'net_profit': -66.92}, {'period': '2021', 'revenue': 0.268, 'unit': 'M', 'net_profit': -56.62}, {'period': '2020', 'revenue': 1.07, 'unit': 'M', 'net_profit': -22.96}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.72}, {'period': ""Q2 '24"", 'revenue': 0.041, 'unit': 'M', 'net_profit': -6.67}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.95}, {'period': ""Q4 '23"", 'revenue': 0.006, 'unit': 'M', 'net_profit': -19.13}, {'period': ""Q3 '23"", 'revenue': 0.031, 'unit': 'M', 'net_profit': -5.72}, {'period': ""Q2 '23"", 'revenue': 0.031, 'unit': 'M', 'net_profit': -16.52}]",-2.77,-2.77,5378000,5378000,4928000,18425000,0,0,18425000,4928000,-47590000,0.10602917730958462,0.22518120002988867,0.6340819022457068,__nan__,__nan__,__nan__,3.42599479360357
818,CLAR,Clarus Corporation Common Stock,"Clarus Corporation develops, manufactures, and distributes outdoor equipment and lifestyle products focusing on the outdoor and consumer markets in the United States, Canada, Europe, the Middle East, Asia, Australia, New Zealand, Africa, and South America. Its Outdoor segment offers activity-based apparel, such as shells, insulation, midlayers, pants, and logowear; rock-climbing footwear and equipment, including carabiners, protection devices, harnesses, belay devices, helmets, and ice-climbing gears; technical backpacks and day packs; trekking poles; headlamps and lanterns; gloves and mittens; skincare and other products; and skis, ski poles, ski skins, and snow safety products, such as avalanche airbag systems, avalanche transceivers, shovels, and probes. This segment offers its products for climbing, mountaineering, trail running, backpacking, skiing, and other outdoor recreation activities under the Black Diamond Equipment, PIEPS, and SKINourishment brands. The company's Precision Sport segment manufactures bullets and ammunition products for precision target shooting, hunting, and military and law enforcement purposes under the Sierra and Barnes brands. The company sells its products to mountain, rock, ice, and gym climbers; and winter outdoor enthusiasts, trail runners, backpackers, competitive shooters, hunters, and outdoor consumers. Its Adventure segment offers engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, and accessories under the Rhino-Rack brand; and overlanding and off-road vehicle recovery and extraction tracks for the overland and the off-road market under the MAXTRAX brand. It markets and distributes its products through independent specialty stores and specialty chains, sporting goods and outdoor recreation stores, distributors, and original equipment manufacturers; and independent distributors, as well as through its websites. The company was incorporated in 1991 and is headquartered in Salt Lake City, Utah.",Mr. Warren B. Kanders,Leisure,4.491,USD,172284640,https://images.financialmodelingprep.com/symbol/CLAR.png,223209,-7.74,-0.079,39751,1494000,-10146000,"[{'period': '2023', 'revenue': 286.02, 'unit': 'M', 'net_profit': -10.15}, {'period': '2022', 'revenue': 448.11, 'unit': 'M', 'net_profit': -69.78}, {'period': '2021', 'revenue': 375.79, 'unit': 'M', 'net_profit': 26.09}, {'period': '2020', 'revenue': 224.01, 'unit': 'M', 'net_profit': 5.54}]","[{'period': ""Q3 '24"", 'revenue': 67.11, 'unit': 'M', 'net_profit': -3.16}, {'period': ""Q2 '24"", 'revenue': 56.35, 'unit': 'M', 'net_profit': -5.49}, {'period': ""Q1 '24"", 'revenue': 69.25, 'unit': 'M', 'net_profit': 21.88}, {'period': ""Q4 '23"", 'revenue': 4.83, 'unit': 'M', 'net_profit': -8.39}, {'period': ""Q3 '23"", 'revenue': 100.08, 'unit': 'M', 'net_profit': -1.26}, {'period': ""Q2 '23"", 'revenue': 83.73, 'unit': 'M', 'net_profit': -2.09}]",-0.27,-0.27,495338000,299745000,11324000,203218000,54863000,0,170934000,11324000,25957000,-0.879126213592233,0.8546001719690456,0.8563829787234042,"[0.025, 0.025]","['2024-11-18', '2018-08-17']",__nan__,0.4102612761387174
819,CLBK,Columbia Financial Inc. Common Stock,"Columbia Financial, Inc., a bank holding company, provides financial services to businesses and consumers in the United States. The company offers non-interest-bearing demand deposits, such as individual and commercial checking accounts; interest bearing demand accounts comprising interest earning checking accounts and municipal accounts; and savings and club accounts, money market accounts, and certificates of deposit. It also provides loans, including multifamily and commercial real estate loans, commercial business loans, one-to-four family residential loans, construction loans, home equity loans and advances, and other consumer loans that include automobiles and personal loans, as well as unsecured and overdraft lines of credit. In addition, the company offers title insurance products; wealth management services; and cash management services, including remote deposit, lockbox service, and sweep accounts. As of December 31, 2021, it operated 62 full-service banking offices in 12 of New Jersey's 21 counties; and 2 branch offices in Freehold, New Jersey. The company was founded in 1927 and is headquartered in Fair Lawn, New Jersey. Columbia Financial, Inc. is a subsidiary of Columbia Bank MHC.",Mr. Thomas J. Kemly,Banks - Regional,15.48,USD,1621112040,https://images.financialmodelingprep.com/symbol/CLBK.png,75991,103.2,-0.21,27967,-239000,36086000,"[{'period': '2023', 'revenue': 233.25, 'unit': 'M', 'net_profit': 36.09}, {'period': '2022', 'revenue': 297.18, 'unit': 'M', 'net_profit': 86.17}, {'period': '2021', 'revenue': 271.96, 'unit': 'M', 'net_profit': 92.05}, {'period': '2020', 'revenue': 252.84, 'unit': 'M', 'net_profit': 57.6}]","[{'period': ""Q3 '24"", 'revenue': 54.25, 'unit': 'M', 'net_profit': 6.18}, {'period': ""Q2 '24"", 'revenue': 122.36, 'unit': 'M', 'net_profit': 4.54}, {'period': ""Q1 '24"", 'revenue': 115.73, 'unit': 'M', 'net_profit': -1.16}, {'period': ""Q4 '23"", 'revenue': 118.35, 'unit': 'M', 'net_profit': 6.57}, {'period': ""Q3 '23"", 'revenue': 57.12, 'unit': 'M', 'net_profit': 9.13}, {'period': ""Q2 '23"", 'revenue': 50.6, 'unit': 'M', 'net_profit': 1.66}]",0.35,0.35,10645568000,885843000,423249000,9605233000,0,1498790000,107713000,423249000,33081000,-1.0018352568975712,-0.5812377426804219,-0.573170731707317,__nan__,__nan__,__nan__,0.90227529428209
820,CLBS,Caladrius Biosciences Inc. Common Stock,"Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.",Dr. David Mazzo,Biotechnology,0.4264,USD,3351368,https://images.financialmodelingprep.com/symbol/CLBS.png,0,-1.0822335025380712,-0.08579999,26946654,-28919000,-27466000,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -27.47}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.14}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.36}, {'period': '2018', 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.17}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.63}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.23}, {'period': ""Q4 '21"", 'revenue': 125.59, 'unit': 'M', 'net_profit': -6.79}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.93}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.68}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.06}]",-1.78,-1.78,97008000,94970000,95121000,5008000,0,0,4523000,94970000,-22305000,-0.5253441637217153,-2.3737870040535562,-2.3584905660377355,"[0.0021, 0.0002]","['2013-10-28', '2011-04-04']",__nan__,0.051624608279729506
821,CLDB,Cortland Bancorp Common Stock,"Cortland Bancorp, Inc. is a bank holding company, which provides commercial and retail banking services through its subsidiary, The Cortland Savings and Banking Company. The company is headquartered in Cortland, Ohio and currently employs 144 full-time employees. The firm's principal activity is to own, manage and supervise The Cortland Savings and Banking Company (Cortland Banks or the Bank). The firm operates through the commercial banking segment. The Bank is a state chartered bank engaged in commercial and retail banking. The Bank's services include checking accounts, savings accounts, time deposit accounts, commercial, mortgage and installment loans, night depository, automated teller services, safe deposit boxes and other miscellaneous services. The Bank provides brokerage and investment services through an arrangement with Investment Professionals, Inc. Under this arrangement, financial advisors offer customers a range of investment products and services, such as estate planning, annuities, life insurance, fixed income, and equity securities and equity research and recommendations. The Bank, through Investment Professionals, Inc., also offers asset management services to customers.",Mr. James Gasior,Banks - Regional,28.47,USD,0,https://images.financialmodelingprep.com/symbol/CLDB.png,7221,12.29805615550756,0.389999,206,16296000,8263000,"[{'period': '2020', 'revenue': 30.78, 'unit': 'M', 'net_profit': 8.26}, {'period': '2019', 'revenue': 29.11, 'unit': 'M', 'net_profit': 7.28}, {'period': '2018', 'revenue': 29.06, 'unit': 'M', 'net_profit': 8.84}, {'period': '2017', 'revenue': 25.47, 'unit': 'M', 'net_profit': 4.35}]","[{'period': ""Q2 '21"", 'revenue': 7.68, 'unit': 'M', 'net_profit': 2.0}, {'period': ""Q1 '21"", 'revenue': 8.18, 'unit': 'M', 'net_profit': 2.77}, {'period': ""Q4 '20"", 'revenue': 8.53, 'unit': 'M', 'net_profit': 2.8}, {'period': ""Q3 '20"", 'revenue': 7.77, 'unit': 'M', 'net_profit': 2.16}, {'period': ""Q2 '20"", 'revenue': 7.33, 'unit': 'M', 'net_profit': 1.93}, {'period': ""Q1 '20"", 'revenue': 7.16, 'unit': 'M', 'net_profit': 1.37}]",1.97,1.97,821305000,9728000,203983000,740300000,0,167875000,5155000,36108000,9512000,-0.008638520501277528,0.13471573743477067,0.17261904761904764,"[0.15, 0.29135]","['2021-08-06', '1999-12-08']",__nan__,0.9013703800658708
822,CLDX,Celldex Therapeutics Inc.,"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.",Mr. Anthony S. Marucci M.B.A.,Biotechnology,28.315,USD,1878536023,https://images.financialmodelingprep.com/symbol/CLDX.png,983662,-10.97,1.735,316387,-139034000,-141429000,"[{'period': '2023', 'revenue': 6.88, 'unit': 'M', 'net_profit': -141.43}, {'period': '2022', 'revenue': 2.36, 'unit': 'M', 'net_profit': -122.78}, {'period': '2021', 'revenue': 4.65, 'unit': 'M', 'net_profit': -70.51}, {'period': '2020', 'revenue': 7.42, 'unit': 'M', 'net_profit': -59.78}]","[{'period': ""Q3 '24"", 'revenue': 3.19, 'unit': 'M', 'net_profit': -42.12}, {'period': ""Q2 '24"", 'revenue': 2.5, 'unit': 'M', 'net_profit': -35.84}, {'period': ""Q1 '24"", 'revenue': 0.156, 'unit': 'M', 'net_profit': -32.81}, {'period': ""Q4 '23"", 'revenue': 4.13, 'unit': 'M', 'net_profit': -43.31}, {'period': ""Q3 '23"", 'revenue': 1.52, 'unit': 'M', 'net_profit': -38.26}, {'period': ""Q2 '23"", 'revenue': 0.268, 'unit': 'M', 'net_profit': -30.5}]",-2.92,-2.92,465627000,431693000,423598000,36456000,2628000,0,31125000,34814000,-109109000,-0.33429942418426106,-0.15186141403940284,-0.11450381679389306,__nan__,__nan__,__nan__,0.07829442880245346
823,CLEU,China Liberal Education Holdings Limited Ordinary Shares,"China Liberal Education Holdings Limited provides educational services and products under the China Liberal brand name in the People's Republic of China. The company offers Sino-foreign jointly managed academic programs, including undergraduate and postgraduate education; and diploma and non-degree higher education, and senior secondary education programs in the areas of languages, liberal arts, and businesses. It also provides overseas study consulting and technological consulting services for Chinese universities to enhance their campus information and data management system, as well as to optimize their teaching, operating, and management environment. The company's consulting services include campus intranet solution buildout, school management software customization, smart devices, installation and testing, and school management data collection and analysis. In addition, it sells textbooks and other course materials, and AI-space products to students enrolled under the Sino-foreign Jointly Managed Academic Programs, as well as offers job readiness training to graduating students. The company was founded in 2011 and is headquartered in Beijing, the People's Republic of China.",Ms. Ngai Ngai  Lam,Education & Training Services,3.6705,USD,820070,https://images.financialmodelingprep.com/symbol/CLEU.png,348220,-0.07,0.0905,502758,-3458636,-4958744,"[{'period': '2023', 'revenue': 2.89, 'unit': 'M', 'net_profit': -4.96}, {'period': '2022', 'revenue': 11.6, 'unit': 'M', 'net_profit': -1.69}, {'period': '2021', 'revenue': 3.91, 'unit': 'M', 'net_profit': -1.25}, {'period': '2020', 'revenue': 5.02, 'unit': 'M', 'net_profit': 1.21}]","[{'period': ""Q2 '24"", 'revenue': 0.8857999999999999, 'unit': 'M', 'net_profit': -4.72}, {'period': ""Q2 '23"", 'revenue': 9020.0, 'unit': 'K', 'net_profit': 376.21}, {'period': ""Q1 '23"", 'revenue': 4510.0, 'unit': 'K', 'net_profit': 188.11}, {'period': ""Q4 '22"", 'revenue': 8.87, 'unit': 'M', 'net_profit': -3.19}, {'period': ""Q3 '22"", 'revenue': 4.43, 'unit': 'M', 'net_profit': -1.6}, {'period': ""Q2 '22"", 'revenue': 2.74, 'unit': 'M', 'net_profit': 1.5}]",-1.65,-2.14,72801367,65594477,20337847,6264432,41453230,0,6231907,20337847,-3784615,-1.158676621299936,-1.9360738893826348,-0.14583333333333331,__nan__,__nan__,__nan__,0.08604827434078265
824,CLFD,Clearfield Inc. Common Stock,"Clearfield, Inc. manufactures, markets, and sells standard and custom passive connectivity products to the fiber-to-the-premises, enterprises, and original equipment manufacturers markets in the United States and internationally. The company offers FieldSmart, a series of panels, cabinets, wall boxes, and other enclosures. It also provides WaveSmart, which are optical components integrated for signal coupling, splitting, termination, multiplexing, demultiplexing, and attenuation for integration within its fiber management platform; and outdoor cabinet and fiber active cabinet products. The company offers StreetSmart, a portfolio of fiber management products; FieldShield, a fiber pathway and protection method for reducing the cost of broadband deployment; and YOURx platform that consists of hardened terminals, test access points, and various drop cable options for portions of the access network across various fiber drop cable media. It also provides CraftSmart, a line of optical protection field enclosures, including CraftSmart Fiber Protection Pedestals and CraftSmart Fiber Protection Vaults integrated solutions optimized to house FieldSmart products at the last mile access point of the network in above-grade or below-grade installations. The company offers fiber and copper assemblies with an industry-standard or customer-specified configuration; and designs and manufactures custom solutions for in-the-box and network connectivity assemblies specific to that customer's product line. It provides its fiber to anywhere platform for various incumbent local exchange carriers, competitive local exchange carriers, wireless operators, and multiple systems operators and cable TV companies, as well as the utility/municipality, enterprise, and data center markets. The company was formerly known as APA Enterprises, Inc. and changed its name to Clearfield, Inc. in January 2008. Clearfield, Inc. was founded in 1979 and is headquartered in Minneapolis, Minnesota.",Ms. Cheryl P. Beranek,Communication Equipment,34.1893,USD,488517232,https://images.financialmodelingprep.com/symbol/CLFD.png,123798,-40.22,-0.7907,46131,-8339000,-12453000,"[{'period': '2024', 'revenue': 166.71, 'unit': 'M', 'net_profit': -12.45}, {'period': '2023', 'revenue': 268.72, 'unit': 'M', 'net_profit': 32.53}, {'period': '2022', 'revenue': 270.88, 'unit': 'M', 'net_profit': 49.36}, {'period': '2021', 'revenue': 140.76, 'unit': 'M', 'net_profit': 20.33}]","[{'period': ""Q4 '24"", 'revenue': 46770.0, 'unit': 'K', 'net_profit': -827.0}, {'period': ""Q3 '24"", 'revenue': 48790.0, 'unit': 'K', 'net_profit': -447.0}, {'period': ""Q2 '24"", 'revenue': 36.91, 'unit': 'M', 'net_profit': -5.91}, {'period': ""Q1 '24"", 'revenue': 34.23, 'unit': 'M', 'net_profit': -5.27}, {'period': ""Q4 '23"", 'revenue': 49.69, 'unit': 'M', 'net_profit': 2.7}, {'period': ""Q3 '23"", 'revenue': 61.28, 'unit': 'M', 'net_profit': 5.22}]",-0.85,-0.85,315275000,229595000,130992000,39512000,21309000,24505000,24352000,16167000,12656000,-1.1924044207563278,-1.3827805612762425,-1.391705069124424,__nan__,__nan__,__nan__,0.1253255094758544
825,CLGN,CollPlant Biotechnologies Ltd American Depositary Shares,"CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.",Mr. Yehiel  Tal,Biotechnology,4.47,USD,51201615,https://images.financialmodelingprep.com/symbol/CLGN.png,14850,-2.92,0.04,5987,-6410000,-7019000,"[{'period': '2023', 'revenue': 10.96, 'unit': 'M', 'net_profit': -7.02}, {'period': '2022', 'revenue': 0.299, 'unit': 'M', 'net_profit': -16.75}, {'period': '2021', 'revenue': 15640.0, 'unit': 'K', 'net_profit': 409.0}, {'period': '2020', 'revenue': 6.14, 'unit': 'M', 'net_profit': -5.81}]","[{'period': ""Q3 '24"", 'revenue': 0.004, 'unit': 'M', 'net_profit': -4.33}, {'period': ""Q2 '24"", 'revenue': 0.249, 'unit': 'M', 'net_profit': -4.21}, {'period': ""Q1 '24"", 'revenue': 0.098, 'unit': 'M', 'net_profit': -4.2}, {'period': ""Q4 '23"", 'revenue': 0.299, 'unit': 'M', 'net_profit': -4.69}, {'period': ""Q3 '23"", 'revenue': 0.043000000000000003, 'unit': 'M', 'net_profit': -4.38}, {'period': ""Q2 '23"", 'revenue': 10.18, 'unit': 'M', 'net_profit': 5.76}]",-0.62,-0.62,34126000,28022000,26674000,5786000,393000,0,3251000,26674000,-3717000,0.5999001310779601,0.5810302632364353,0.5921052631578947,__nan__,__nan__,__nan__,0.16954814510930083
826,CLIR,ClearSign Technologies Corporation Common Stock,"ClearSign Technologies Corporation designs and develops products and technologies to enhance operational performance, energy efficiency, emission reduction, safety, and overall cost-effectiveness of industrial and commercial systems in the United States and the People's Republic of China. Its ClearSign Core Burner Technology consists of an industrial burner body and a downstream porous ceramic structure or metal flame stabilizing device; ClearSign Core Plug & Play technology provides direct burner replacement for traditional refinery process heaters; and ClearSign Eye Flame Sensor, an electrical flame sensor for industrial applications. The company also provides ClearSign Core Boiler Burner; and ClearSign Core Flaring Burners technologies. It serves energy, institutional, commercial and industrial boiler, chemical, and petrochemical industries. The company was formerly known as ClearSign Combustion Corporation and changed its name ClearSign Technologies Corporation in November 2019. ClearSign Technologies Corporation was incorporated in 2008 and is headquartered in Tulsa, Oklahoma.",Dr. Colin James Deller Ph.D.,Industrial - Pollution & Treatment Controls,1.1,USD,55257840,https://images.financialmodelingprep.com/symbol/CLIR.png,155167,-10,-0.22,315169,-5682000,-5194000,"[{'period': '2023', 'revenue': 2.4, 'unit': 'M', 'net_profit': -5.19}, {'period': '2022', 'revenue': 0.374, 'unit': 'M', 'net_profit': -5.4}, {'period': '2021', 'revenue': 0.607, 'unit': 'M', 'net_profit': -7.89}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.84}]","[{'period': ""Q3 '24"", 'revenue': 1.86, 'unit': 'M', 'net_profit': -1.16}, {'period': ""Q2 '24"", 'revenue': 0.045, 'unit': 'M', 'net_profit': -1.87}, {'period': ""Q1 '24"", 'revenue': 1.1, 'unit': 'M', 'net_profit': -1.11}, {'period': ""Q4 '23"", 'revenue': 1270.0, 'unit': 'K', 'net_profit': -955.0}, {'period': ""Q3 '23"", 'revenue': 0.085, 'unit': 'M', 'net_profit': -1.33}, {'period': ""Q2 '23"", 'revenue': 0.15, 'unit': 'M', 'net_profit': -1.48}]",-0.13,-0.13,7620000,6509000,5684000,2428000,475000,0,2256000,5684000,-3433000,-0.03951701427003293,0.03796999444341545,0.13333333333333328,__nan__,__nan__,__nan__,0.3186351706036745
827,CLLS,Cellectis S.A. American Depositary Shares,"Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.",Dr. Andre  Choulika Ph.D.,Biotechnology,2.141,USD,130260626,https://images.financialmodelingprep.com/symbol/CLLS.png,101761,-1.85,0.011,274826,-92636000,-101059000,"[{'period': '2023', 'revenue': 0.755, 'unit': 'M', 'net_profit': -101.06}, {'period': '2022', 'revenue': 19.17, 'unit': 'M', 'net_profit': -98.69}, {'period': '2021', 'revenue': 73.95, 'unit': 'M', 'net_profit': -86.28}, {'period': '2020', 'revenue': 73.95, 'unit': 'M', 'net_profit': -72.57}]","[{'period': ""Q3 '24"", 'revenue': 16.2, 'unit': 'M', 'net_profit': -23.06}, {'period': ""Q2 '24"", 'revenue': 8.06, 'unit': 'M', 'net_profit': -25.27}, {'period': ""Q1 '24"", 'revenue': 4.53, 'unit': 'M', 'net_profit': 5.64}, {'period': ""Q4 '23"", 'revenue': 0.28300000000000003, 'unit': 'M', 'net_profit': -42.86}, {'period': ""Q3 '23"", 'revenue': 0.155, 'unit': 'M', 'net_profit': -17.48}, {'period': ""Q2 '23"", 'revenue': 0.178, 'unit': 'M', 'net_profit': -10.65}]",-1.77,-1.77,334270000,233006000,203815000,249575000,23130000,7853000,155144000,136708000,-25819000,-0.21286234255937575,-0.02402521076523995,0.184331797235023,__nan__,__nan__,__nan__,0.7466269781912825
828,CLMT,Calumet Specialty Products Partners L.P. Common Units,"Calumet Specialty Products Partners, L.P. manufactures, formulates, and markets slate of specialty branded products to various consumer-facing and industrial markets in North America and internationally. Its Specialty Products and Solutions segment offers various solvents, waxes, customized lubricating oils, white oils, petrolatums, gels, esters, and other products. The company's Montana/Renewables segment focuses on processing renewable feedstocks into renewable hydrogen, renewable natural gas, renewable propane, renewable naphtha, renewable kerosene/aviation fuel, and renewable diesel. This segment also processes Canadian crude oil into conventional gasoline, diesel, jet fuel, and specialty grades of asphalt. Its Performance Brands segment blends, packages, and markets high performance products through Royal Purple, Bel-Ray, and TruFuel brands. Calumet GP, LLC serves as the general partner for Calumet Specialty Products Partners, L.P. The company was founded in 1916 and is headquartered in Indianapolis, Indiana.",Mr. Louis Todd Borgmann,Oil & Gas Exploration & Production,21.6,USD,1855528560,https://images.financialmodelingprep.com/symbol/CLMT.png,761588,-7.66,-0.84,204429,418200000,48100000,"[{'period': '2023', 'revenue': 4180.0, 'unit': 'M', 'net_profit': 48.1}, {'period': '2022', 'revenue': 4690.0, 'unit': 'M', 'net_profit': -171.8}, {'period': '2021', 'revenue': 3150.0, 'unit': 'M', 'net_profit': -260.1}, {'period': '2020', 'revenue': 2270.0, 'unit': 'M', 'net_profit': -149.0}]","[{'period': ""Q3 '24"", 'revenue': 1100.0, 'unit': 'M', 'net_profit': -100.6}, {'period': ""Q2 '24"", 'revenue': 1130.0, 'unit': 'M', 'net_profit': -38.3}, {'period': ""Q1 '24"", 'revenue': 1010.0, 'unit': 'M', 'net_profit': -40.8}, {'period': ""Q4 '23"", 'revenue': 976.5, 'unit': 'M', 'net_profit': -47.0}, {'period': ""Q3 '23"", 'revenue': 2040.0, 'unit': 'M', 'net_profit': 103.1}, {'period': ""Q2 '23"", 'revenue': 1020.0, 'unit': 'M', 'net_profit': -18.5}]",0.59,0.59,2751300000,794700000,7900000,2996000000,286200000,0,1112700000,7900000,-286700000,2.282574568288854,1.279976717112922,1.271889400921659,"[0.685, 0.3]","['2016-01-29', '2006-04-28']",__nan__,1.0889397739250537
829,CLNE,Clean Energy Fuels Corp. Common Stock,"Clean Energy Fuels Corp. provides natural gas as an alternative fuel for vehicle fleets and related fueling solutions, primarily in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. As of December 31, 2021, the company served approximately 1,000 fleet customers operating approximately 48,000 vehicles; and owned, operated, or supplied approximately 548 fueling stations in 42 states in the United States and 25 fueling stations in Canada. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California.",Mr. Andrew J. Littlefair,Oil & Gas Refining & Marketing,3.06,USD,683778420,https://images.financialmodelingprep.com/symbol/CLNE.png,1885637,-9.27,,0,-32625999,-99497000,"[{'period': '2023', 'revenue': 425.16, 'unit': 'M', 'net_profit': -99.5}, {'period': '2022', 'revenue': 420.16, 'unit': 'M', 'net_profit': -59.59}, {'period': '2021', 'revenue': 255.65, 'unit': 'M', 'net_profit': -94.16}, {'period': '2020', 'revenue': 291.72, 'unit': 'M', 'net_profit': -11.53}]","[{'period': ""Q3 '24"", 'revenue': 104.88, 'unit': 'M', 'net_profit': -18.18}, {'period': ""Q2 '24"", 'revenue': 97.89, 'unit': 'M', 'net_profit': -16.29}, {'period': ""Q1 '24"", 'revenue': 102.09, 'unit': 'M', 'net_profit': -18.44}, {'period': ""Q4 '23"", 'revenue': 106.71, 'unit': 'M', 'net_profit': -18.69}, {'period': ""Q3 '23"", 'revenue': 95.57, 'unit': 'M', 'net_profit': -25.81}, {'period': ""Q2 '23"", 'revenue': 90.55, 'unit': 'M', 'net_profit': -16.3}]",-0.45,-0.45,1259458000,470175000,263130000,525811000,118196000,258773000,163823000,104963000,-77505000,-7.5095768156424585,-0.6696929014935392,-0.6666666666666666,__nan__,__nan__,__nan__,0.4174899043874429
830,CLNN,Clene Inc. Common Stock,"Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.",Mr. Robert  Etherington MBA,Biotechnology,5.99,USD,47798583,https://images.financialmodelingprep.com/symbol/CLNN.png,81093,-1.13,0.44,109381,-43241000,-49504000,"[{'period': '2023', 'revenue': 0.654, 'unit': 'M', 'net_profit': -49.5}, {'period': '2022', 'revenue': 0.47300000000000003, 'unit': 'M', 'net_profit': -15.28}, {'period': '2021', 'revenue': 0.723, 'unit': 'M', 'net_profit': -9.74}, {'period': '2020', 'revenue': 0.20600000000000002, 'unit': 'M', 'net_profit': -19.28}]","[{'period': ""Q3 '24"", 'revenue': 0.08700000000000001, 'unit': 'M', 'net_profit': -7.99}, {'period': ""Q2 '24"", 'revenue': 0.091, 'unit': 'M', 'net_profit': -6.79}, {'period': ""Q1 '24"", 'revenue': 0.073, 'unit': 'M', 'net_profit': -11.08}, {'period': ""Q4 '23"", 'revenue': 0.17, 'unit': 'M', 'net_profit': -10.17}, {'period': ""Q3 '23"", 'revenue': 0.108, 'unit': 'M', 'net_profit': -2.42}, {'period': ""Q2 '23"", 'revenue': 0.269, 'unit': 'M', 'net_profit': -25.14}]",-9.43,-9.43,52341000,38852000,35000000,38951000,1338000,0,25330000,28821000,-30501000,-0.7149599428888712,-2.2400026179723804,-1.0106609808102343,__nan__,__nan__,__nan__,0.7441776045547468
831,CLNNW,Clene Inc. Warrant,"Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.",Mr. Robert  Etherington MBA,Biotechnology,0.0498,USD,42441290,https://images.financialmodelingprep.com/symbol/CLNNW.png,0,,0.0132,8676,-43241000,-49504000,"[{'period': '2023', 'revenue': 0.654, 'unit': 'M', 'net_profit': -49.5}, {'period': '2022', 'revenue': 0.47300000000000003, 'unit': 'M', 'net_profit': -15.28}, {'period': '2021', 'revenue': 0.723, 'unit': 'M', 'net_profit': -9.74}, {'period': '2020', 'revenue': 0.20600000000000002, 'unit': 'M', 'net_profit': -19.28}]","[{'period': ""Q3 '24"", 'revenue': 0.08700000000000001, 'unit': 'M', 'net_profit': -7.99}, {'period': ""Q2 '24"", 'revenue': 0.091, 'unit': 'M', 'net_profit': -6.79}, {'period': ""Q1 '24"", 'revenue': 0.073, 'unit': 'M', 'net_profit': -11.08}, {'period': ""Q4 '23"", 'revenue': 0.17, 'unit': 'M', 'net_profit': -10.17}, {'period': ""Q3 '23"", 'revenue': 0.108, 'unit': 'M', 'net_profit': -2.42}, {'period': ""Q2 '23"", 'revenue': 0.269, 'unit': 'M', 'net_profit': -25.14}]",-9.43,-9.43,52341000,38852000,35000000,38951000,1338000,0,25330000,28821000,-30501000,-0.7149599428888712,-2.2400026179723804,-1.0106609808102343,__nan__,__nan__,__nan__,0.7441776045547468
832,CLOV,Clover Health Investments Corp. Class A Common Stock,"Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.",Mr. Andrew  Toy,Medical - Healthcare Plans,3.575,USD,1791463763,https://images.financialmodelingprep.com/symbol/CLOV.png,6143514,-18.82,0.195,4899890,-210845000,-213361000,"[{'period': '2023', 'revenue': 2029.9999999999998, 'unit': 'M', 'net_profit': -213.36}, {'period': '2022', 'revenue': 3480.0, 'unit': 'M', 'net_profit': -305.4}, {'period': '2021', 'revenue': 1470.0, 'unit': 'M', 'net_profit': -604.67}, {'period': '2020', 'revenue': 672.89, 'unit': 'M', 'net_profit': -148.69}]","[{'period': ""Q3 '24"", 'revenue': 330.99, 'unit': 'M', 'net_profit': -9.15}, {'period': ""Q2 '24"", 'revenue': 356.24, 'unit': 'M', 'net_profit': 7.41}, {'period': ""Q1 '24"", 'revenue': 346.45, 'unit': 'M', 'net_profit': -19.17}, {'period': ""Q4 '23"", 'revenue': 505.44, 'unit': 'M', 'net_profit': -70.47}, {'period': ""Q3 '23"", 'revenue': 482.07, 'unit': 'M', 'net_profit': -41.47}, {'period': ""Q2 '23"", 'revenue': 513.63, 'unit': 'M', 'net_profit': -28.81}]",-0.44,-0.44,570671000,427970000,242685000,284277000,113832000,119822000,261115000,122863000,-116455000,0.3743787405383111,0.3013742587614317,0.3125,__nan__,__nan__,__nan__,0.4981451659537632
833,CLOVW,Clover Health Investments Corp. Warrants,,,,,,,,,0,0.09000003,789074,-6744840000000,-6744840000000,"[{'period': '2020', 'revenue': 0.0, 'unit': 'T', 'net_profit': -6.74}]","[{'period': ""Q2 '21"", 'revenue': 412.47, 'unit': 'M', 'net_profit': -317.61}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'T', 'net_profit': -6.74}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -2.29}, {'period': ""Q2 '20"", 'revenue': 172.08, 'unit': 'M', 'net_profit': 5.4}]",-0.32,-0.32,856420161000000,28302906000000,856120495000000,62913978000000,0,828117255000000,33933978000000,28003240000000,-2227118000000,0,0,0,__nan__,__nan__,__nan__,0.07346157980043162
834,CLPS,CLPS Incorporation Common Stock,"CLPS Incorporation provides information technology, consulting, and solutions to institutions operating in banking, insurance, and financial sectors in the People's Republic of China and internationally. It offers IT consulting services in credit card business areas, such as credit card application, account setup, authorization and activation, settlement, collection, promotion, point system, anti-fraud, statement, reporting, and risk management. The company also provides banking services, including business analysis, system design, development, testing, system maintenance, and operation support; and services in loans, deposit, general ledger, wealth management, debit card, anti-money-laundering, statement and reporting, and risk management, as well as architecture consulting services for banking systems, and online and mobile banking. In addition, it offers solutions in the field of wealth management; e-commerce solutions in online platforms, cross-border e-commerce, logistics, and back-end technology, such as big data analysis and intelligent decision-making among others; and driving, automatic control, and other AI-driven technology solutions for the automotive industry. Further, the company provides IT consulting services to its clients in the banking, wealth management, e-commerce, and automotive industries, among others; and software project development, maintenance, and testing services. Additionally, it offers CLPS Virtual Banking platform, a training platform for IT talents; recruitment and headhunting, as well as fee-for-service training services; and sells product and third-party software. The company was founded in 2005 and is headquartered in Kwun Tong, Hong Kong.",Mr. Ming Hui  Lin,Information Technology Services,1.1,USD,30624770,https://images.financialmodelingprep.com/symbol/CLPS.png,37525,-12.22,-0.08,13830,-1285922,-2329965,"[{'period': '2024', 'revenue': 142.81, 'unit': 'M', 'net_profit': -2.33}, {'period': '2023', 'revenue': 150360.0, 'unit': 'K', 'net_profit': 192.53}, {'period': '2022', 'revenue': 152.02, 'unit': 'M', 'net_profit': 4.46}, {'period': '2021', 'revenue': 126.06, 'unit': 'M', 'net_profit': 6.82}]","[{'period': ""Q2 '24"", 'revenue': 71.77, 'unit': 'M', 'net_profit': -1.49}, {'period': ""Q4 '23"", 'revenue': 73.6, 'unit': 'M', 'net_profit': -1.07}, {'period': ""Q2 '23"", 'revenue': 76.76, 'unit': 'M', 'net_profit': 1.27}, {'period': ""Q4 '22"", 'revenue': 76.1, 'unit': 'M', 'net_profit': -1.81}, {'period': ""Q2 '22"", 'revenue': 75.92, 'unit': 'M', 'net_profit': 6.26}, {'period': ""Q4 '21"", 'revenue': 67.74, 'unit': 'M', 'net_profit': 1.96}]",-0.0924,-0.0924,110029816,78076408,31240512,46110203,42338318,2988105,39795803,29116431,6807952,-1.3495549156627227,-13.101891143671862,-12.132530120481928,"[0.13, 0.05]","['2024-11-04', '2022-12-28']",__nan__,0.4190700727882704
835,CLPT,ClearPoint Neuro Inc. Common Stock,"ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.",Mr. Joseph Michael Burnett,Medical - Devices,15.605,USD,430459244,https://images.financialmodelingprep.com/symbol/CLPT.png,241054,-22.62,-0.145,53309,-20989000,-22089000,"[{'period': '2023', 'revenue': 23.95, 'unit': 'M', 'net_profit': -22.09}, {'period': '2022', 'revenue': 20.55, 'unit': 'M', 'net_profit': -16.54}, {'period': '2021', 'revenue': 16.3, 'unit': 'M', 'net_profit': -15.32}, {'period': '2020', 'revenue': 12.83, 'unit': 'M', 'net_profit': -9.11}]","[{'period': ""Q3 '24"", 'revenue': 8.12, 'unit': 'M', 'net_profit': -4.97}, {'period': ""Q2 '24"", 'revenue': 7.86, 'unit': 'M', 'net_profit': -4.41}, {'period': ""Q1 '24"", 'revenue': 7.64, 'unit': 'M', 'net_profit': -4.15}, {'period': ""Q4 '23"", 'revenue': 6.81, 'unit': 'M', 'net_profit': -4.62}, {'period': ""Q3 '23"", 'revenue': 5.76, 'unit': 'M', 'net_profit': -4.81}, {'period': ""Q2 '23"", 'revenue': 5.95, 'unit': 'M', 'net_profit': -7.05}]",-0.9,-0.9,42661000,36172000,23140000,21488000,3944000,0,7430000,23140000,-14771000,-0.3474353213070553,-0.3356512274761156,-0.32352941176470584,__nan__,__nan__,__nan__,0.5036918965800146
836,CLRB,Cellectar Biosciences Inc.  Common Stock,"Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.",Mr. James V. Caruso,Biotechnology,0.3401,USD,14035859,https://images.financialmodelingprep.com/symbol/CLRB.png,1881585,-0.24,-0.0098,398392,-38768268,-37983496,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -37.98}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.6}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -23.97}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.76}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.66}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -919.37}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.58}, {'period': ""Q4 '23"", 'revenue': 0.33037, 'unit': 'M', 'net_profit': -7.45}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.73}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.22}]",-3.11,-3.11,12075580,10453213,9564988,25852525,0,0,25358522,9564988,-33241012,-0.35244412607309916,-0.3280360364618978,0.23209876543209876,__nan__,__nan__,__nan__,2.1408930254281784
837,CLRM,Clarim Acquisition Corp. Class A Common Stock,"Clarim Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on the consumer-facing e-commerce sector. The company was incorporated in 2020 and is based in New York, New York.",Mr. James F. McCann,Shell Companies,10.07,USD,0,https://images.financialmodelingprep.com/symbol/CLRM.png,92853,38.73076923076923,0.01,7200,-2360223,7291007,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.29}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.96}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.89}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 12.45}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -583.35}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.74}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.13}]",0.2,0.2,288120,499.625,107.125,20636,0,0,1281.21,107.125,-1504523,0,0,0,__nan__,__nan__,__nan__,0.07162293488824101
838,CLRMU,Clarim Acquisition Corp. Unit,"Clarim Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on the consumer-facing e-commerce sector. The company was incorporated in 2020 and is based in New York, New York.",,Shell Companies,10.15,USD,0,https://images.financialmodelingprep.com/symbol/CLRMU.png,14466,70,0.09,257,-2360223,7291007,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.29}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.96}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.89}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 12.45}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -583.35}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.74}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.13}]",0.2,0.2,288120,499.625,107.125,20636,0,0,1281.21,107.125,-1504523,0,0,0,__nan__,__nan__,__nan__,0.07162293488824101
839,CLRMW,Clarim Acquisition Corp. Warrant,"Clarim Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded in 2020 and is based in New York, New York.",Mr. James F. McCann,Shell Companies,0.0009,USD,0,https://images.financialmodelingprep.com/symbol/CLRMW.png,0,0,-0.0017,3790,-2360223,7291007,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.29}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.96}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.89}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 12.45}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -583.35}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.74}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.13}]",0.2,0.2,288120,499.625,107.125,20636,0,0,1281.21,107.125,-1504523,0,0,0,__nan__,__nan__,__nan__,0.07162293488824101
840,CLRO,ClearOne Inc. (DE) Common Stock,"ClearOne, Inc., together with its subsidiaries, designs, develops, and sells conferencing, collaboration, and network streaming solutions for voice and visual communications in the United States and internationally. The company offers a range of audio conferencing products, including professional audio conferencing and sound-reinforcement products for use in enterprise, healthcare, education and distance learning, government, legal, and finance organizations; mid-tier premium conferencing products for smaller rooms, and small and medium businesses, which interface with video and Web conferencing systems; USB-based personal and group speakerphones that could be used with PCs, laptops, tablets, smartphones, and other portable devices; and traditional tabletop conferencing phones used in conference rooms and offices. It also provides video products, such as video conferencing and collaboration solutions; and AV networking, which deliver the IP A/V experience by streaming time sensitive high definition audio and video, and control over TCP/IP networks. In addition, the company offers professional microphones consisting of beamforming microphones, ceiling microphones, and wireless microphones. ClearOne, Inc. sells its commercial products to a network of independent professional audiovisual, information technology, and telecommunications distributors, as well as systems integrators, dealers, value-added resellers, and end-users. The company was incorporated in 1983 and is headquartered in Salt Lake City, Utah.",Mr. Derek L. Graham,Communication Equipment,0.9121,USD,21862216,https://images.financialmodelingprep.com/symbol/CLRO.png,400161,-5.37,-0.1879,542818,1563000,-560000,"[{'period': '2023', 'revenue': 18700.0, 'unit': 'K', 'net_profit': -560.0}, {'period': '2022', 'revenue': 25.2, 'unit': 'M', 'net_profit': 20.56}, {'period': '2021', 'revenue': 28.97, 'unit': 'M', 'net_profit': -7.69}, {'period': '2020', 'revenue': 29070.0, 'unit': 'K', 'net_profit': 505.0}]","[{'period': ""Q3 '24"", 'revenue': 2.5, 'unit': 'M', 'net_profit': -2.06}, {'period': ""Q2 '24"", 'revenue': 2.3, 'unit': 'M', 'net_profit': -2.82}, {'period': ""Q1 '24"", 'revenue': 3.62, 'unit': 'M', 'net_profit': -1.9}, {'period': ""Q4 '23"", 'revenue': 4.15, 'unit': 'M', 'net_profit': 2.64}, {'period': ""Q3 '23"", 'revenue': 4.89, 'unit': 'M', 'net_profit': -1.35}, {'period': ""Q2 '23"", 'revenue': 5.48, 'unit': 'M', 'net_profit': -1.02}]",-0.0234,-0.0234,50694000,43317000,21315000,6009000,3279000,916000,4265000,17835000,54253000,-0.9499871992188403,-1.0272426542128819,-1.0272093023255813,"[0.5, 0.1]","['2024-04-11', '2014-12-10']",__nan__,0.11853473783879749
841,CLSD,Clearside Biomedical Inc. Common Stock,"Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.","Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.",Biotechnology,0.9968,USD,75600801,https://images.financialmodelingprep.com/symbol/CLSD.png,711183,-2.22,0.0043,143672,-23058000,-32485000,"[{'period': '2023', 'revenue': 8.23, 'unit': 'M', 'net_profit': -32.48}, {'period': '2022', 'revenue': 1.33, 'unit': 'M', 'net_profit': -34.07}, {'period': '2021', 'revenue': 29570.0, 'unit': 'K', 'net_profit': 376.0}, {'period': '2020', 'revenue': 7.89, 'unit': 'M', 'net_profit': -18.03}]","[{'period': ""Q3 '24"", 'revenue': 1.04, 'unit': 'M', 'net_profit': -7.69}, {'period': ""Q2 '24"", 'revenue': 0.09, 'unit': 'M', 'net_profit': -7.59}, {'period': ""Q1 '24"", 'revenue': 0.23, 'unit': 'M', 'net_profit': -11.76}, {'period': ""Q4 '23"", 'revenue': 6.34, 'unit': 'M', 'net_profit': -4.83}, {'period': ""Q3 '23"", 'revenue': 0.859, 'unit': 'M', 'net_profit': -9.27}, {'period': ""Q2 '23"", 'revenue': 1.02, 'unit': 'M', 'net_profit': -9.11}]",-0.53,-0.53,34018000,30123000,28920000,49930000,170000,0,6813000,28920000,-19912000,0.21739130434782608,0.04655945026880801,0.0701754385964911,__nan__,__nan__,__nan__,1.4677523663942618
842,CLSK,CleanSpark Inc. Common Stock,"CleanSpark, Inc. provides bitcoin mining and energy technology solutions worldwide. It operates in two segments, Digital Currency Mining and Energy. The Digital Currency Mining segment engages in mining of bitcoin. The energy segment provides engineering, design and software, custom hardware, open automated demand response, solar, and energy storage solutions for microgrids and distributed energy systems to military, commercial, and residential customers; and develops platforms that enables designing, building, operating, and managing of energy assets. This segment also offers microgrid energy modeling, energy market communications, and energy management solutions comprising mPulse and mVoult, which are control platforms that enables integration and optimization of multiple energy sources; Canvas, a middleware for grid operators and aggregators to administrate load shifting programs; Plaid, a middleware for controls and Internet-of-Things products companies to participate in load shifting programs; and mVSO, an energy modeling software for internal microgrid design, as well as owns gasification energy technologies for various applications, such as feedstock for the generation of di-methyl ether. In addition, it provides design, software development, and other technology-based consulting services; data center services, including rack space, power, and equipment; and various cloud services, such as virtual, virtual storage, and data backup services. The company was formerly known as Stratean Inc. and changed its name to CleanSpark, Inc. in November 2016. CleanSpark, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.",Mr. Zachary K. Bradford CPA,Software - Application,10.8025,USD,3160401005,https://images.financialmodelingprep.com/symbol/CLSK.png,35528001,-15.66,-0.6275,13784301,6299000,-145777000,"[{'period': '2024', 'revenue': 378.97, 'unit': 'M', 'net_profit': -145.78}, {'period': '2023', 'revenue': 168.41, 'unit': 'M', 'net_profit': -136.59}, {'period': '2022', 'revenue': 131.52, 'unit': 'M', 'net_profit': -57.66}, {'period': '2021', 'revenue': 49.44, 'unit': 'M', 'net_profit': -22.51}]","[{'period': ""Q4 '24"", 'revenue': 89.28, 'unit': 'M', 'net_profit': -62.18}, {'period': ""Q3 '24"", 'revenue': 104.11, 'unit': 'M', 'net_profit': -236.24}, {'period': ""Q2 '24"", 'revenue': 111.8, 'unit': 'M', 'net_profit': 126.73}, {'period': ""Q1 '24"", 'revenue': 73.79, 'unit': 'M', 'net_profit': 25.91}, {'period': ""Q4 '23"", 'revenue': 51.76, 'unit': 'M', 'net_profit': -74.88}, {'period': ""Q3 '23"", 'revenue': 45.38, 'unit': 'M', 'net_profit': -14.22}]",-0.67,-0.66,1962662000,705430000,553801000,201821000,138746000,0,187887000,121222000,-1040058000,1.8290339563042906,-0.06726749591841218,0.49624060150375937,"[0.12, 0.12]","['2021-06-21', '2021-06-21']",__nan__,0.1028302377077663
843,CLSN,Celsion Corporation Common Stock,"Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.",Michael Tardugno,Biotechnology,1.9466,USD,14471628,https://images.financialmodelingprep.com/symbol/CLSN.png,0,-0.49057459677419357,-0.013400078,56809,-19878279,-19514977,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -19.51}, {'period': '2022', 'revenue': 0.5, 'unit': 'M', 'net_profit': -35.9}, {'period': '2021', 'revenue': 0.5, 'unit': 'M', 'net_profit': -20.77}, {'period': '2020', 'revenue': 0.5, 'unit': 'M', 'net_profit': -21.48}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'B', 'net_profit': -4.85}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.79}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.93}, {'period': ""Q4 '23"", 'revenue': 7.05, 'unit': 'M', 'net_profit': -4.89}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.48}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.56}]",-2.16,-2.16,21918069,18240704,15695653,8530427,0,0,7391134,5838566,-19473907,0.373024082123041,0.45637704050364925,0.5705765407554672,__nan__,__nan__,__nan__,0.38919610117113873
844,CLVR,Clever Leaves Holdings Inc. Common Shares,"Clever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally. The Non-Cannabinoid segment is engaged in formulating, manufacturing, marketing, selling, distributing, and commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. The company was founded in 2017 and is based in Boca Raton, Florida.",Mr. Andres  Fajardo,Drug Manufacturers - Specialty & Generic,0.0002,USD,351,https://images.financialmodelingprep.com/symbol/CLVR.png,668,0,0,10,-16835000,-17899000,"[{'period': '2023', 'revenue': 17.42, 'unit': 'M', 'net_profit': -17.9}, {'period': '2022', 'revenue': 17.8, 'unit': 'M', 'net_profit': -66.1}, {'period': '2021', 'revenue': 15.37, 'unit': 'M', 'net_profit': -45.63}, {'period': '2020', 'revenue': 12.12, 'unit': 'M', 'net_profit': -41.41}]","[{'period': ""Q4 '23"", 'revenue': 4.64, 'unit': 'M', 'net_profit': -5.08}, {'period': ""Q3 '23"", 'revenue': 3.82, 'unit': 'M', 'net_profit': -5.14}, {'period': ""Q2 '23"", 'revenue': 4.98, 'unit': 'M', 'net_profit': -3.6}, {'period': ""Q1 '23"", 'revenue': 3.98, 'unit': 'M', 'net_profit': -4.08}, {'period': ""Q4 '22"", 'revenue': 4.61, 'unit': 'M', 'net_profit': -28.82}, {'period': ""Q3 '22"", 'revenue': 2.87, 'unit': 'M', 'net_profit': -20.16}]",-11.42,-11.42,31243000,13940000,6831000,7026000,2079000,0,5811000,6831000,-11539000,0.5298011395374819,0.7292174097214869,0.7788964181994191,__nan__,__nan__,__nan__,0.22488237365169797
845,CLVRW,Clever Leaves Holdings Inc. Warrant,"Clever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally. The Non-Cannabinoid segment is engaged in formulating, manufacturing, marketing, selling, distributing, and commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. The company was founded in 2017 and is based in Boca Raton, Florida.",Mr. Andres  Fajardo,Drug Manufacturers - Specialty & Generic,0.025,USD,41528,https://images.financialmodelingprep.com/symbol/CLVRW.png,0,-0.01,0,1100,-16835000,-17899000,"[{'period': '2023', 'revenue': 17.42, 'unit': 'M', 'net_profit': -17.9}, {'period': '2022', 'revenue': 17.8, 'unit': 'M', 'net_profit': -66.1}, {'period': '2021', 'revenue': 15.37, 'unit': 'M', 'net_profit': -45.63}, {'period': '2020', 'revenue': 12.12, 'unit': 'M', 'net_profit': -41.41}]","[{'period': ""Q4 '23"", 'revenue': 4.64, 'unit': 'M', 'net_profit': -5.08}, {'period': ""Q3 '23"", 'revenue': 3.82, 'unit': 'M', 'net_profit': -5.14}, {'period': ""Q2 '23"", 'revenue': 4.98, 'unit': 'M', 'net_profit': -3.6}, {'period': ""Q1 '23"", 'revenue': 3.98, 'unit': 'M', 'net_profit': -4.08}, {'period': ""Q4 '22"", 'revenue': 4.61, 'unit': 'M', 'net_profit': -28.82}, {'period': ""Q3 '22"", 'revenue': 2.87, 'unit': 'M', 'net_profit': -20.16}]",-11.42,-11.42,31243000,13940000,6831000,7026000,2079000,0,5811000,6831000,-11539000,0.5298011395374819,0.7292174097214869,0.7788964181994191,__nan__,__nan__,__nan__,0.22488237365169797
846,CLVS,Clovis Oncology Inc. Common Stock,"Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.",Mr. Patrick Mahaffy,Biotechnology,0.0812,USD,0,https://images.financialmodelingprep.com/symbol/CLVS.png,5971191,-0.038963531669865645,0,24212259,-114354000,-264524000,"[{'period': '2021', 'revenue': 148.76, 'unit': 'M', 'net_profit': -264.52}, {'period': '2020', 'revenue': 164.52, 'unit': 'M', 'net_profit': -369.21}, {'period': '2019', 'revenue': 143.01, 'unit': 'M', 'net_profit': -400.42}, {'period': '2018', 'revenue': 95.39, 'unit': 'M', 'net_profit': -368.01}]","[{'period': ""Q3 '22"", 'revenue': 1.34, 'unit': 'M', 'net_profit': -56.01}, {'period': ""Q2 '22"", 'revenue': 32.14, 'unit': 'M', 'net_profit': -71.33}, {'period': ""Q1 '22"", 'revenue': 34.25, 'unit': 'M', 'net_profit': -60.17}, {'period': ""Q4 '21"", 'revenue': 35.97, 'unit': 'M', 'net_profit': -64.39}, {'period': ""Q3 '21"", 'revenue': 37.92, 'unit': 'M', 'net_profit': -67.41}, {'period': ""Q2 '21"", 'revenue': 36.82, 'unit': 'M', 'net_profit': -66.45}]",-2.18,-2.18,472833000,198087000,143428000,751673000,26868000,0,125214000,143428000,-196369000,0.6617446091046233,0.28354441350768667,0.502283105022831,__nan__,__nan__,__nan__,1.5897219525709922
847,CLWT,Euro Tech Holdings Company Limited Common Stock,"Euro Tech Holdings Company Limited primarily distributes water treatment equipment, laboratory instruments, analyzers, test kits and related supplies, and power generation equipment to commercial customers, and governmental agencies in Hong Kong and the People's Republic of China. The company operates in two segments, Trading and Manufacturing, and Engineering. It sells analytical instruments, such as spectrophotometers, colorimeters, chromatographs, mass spectrometers, flow injector analyzers, automated sample preparation workstations, and atomic spectrometers; environmental monitoring instruments comprising air and water quality monitoring instruments; sample pre-treatment equipment; and general-purpose laboratory instruments consisting of water quality monitoring and analysis equipment. The company also distributes general testing and measuring equipment comprising multi-channel digital and analogue recorders, signal amplifiers, and calibration equipment for energy conservation, renewable energy equipment, power quality analyzers, and continuous emissions monitoring systems; and air pollution control systems to power plants, railway and aero-space industries, utilities, educational institutions, and telecommunications companies. In addition, it offers process control systems, including sensors, temperature and pressure gauges, power and energy consumption meters, flow meters, valves, temperature and pressure transmitters and control devices, and temperature and pressure calibrators, as well as moisture, power, energy, and harmonic analyzers; systems engineering services; and maintenance, installation assistance, and calibration services. Further, the company distributes programmable logic controllers, telemetry units, and supervisory control and data acquisition systems and software; and designs, operates, and manages various wastewater, water, and power generation projects. The company was founded in 1971 and is headquartered in Hong Kong, Hong Kong.",Mr. Y. L.  Leung,Industrial - Pollution & Treatment Controls,1.43,USD,11034309,https://images.financialmodelingprep.com/symbol/CLWT.png,7430,5.11,0.02,5314,1717000,1828000,"[{'period': '2023', 'revenue': 17.94, 'unit': 'M', 'net_profit': 1.83}, {'period': '2022', 'revenue': 14950.0, 'unit': 'K', 'net_profit': 539.0}, {'period': '2021', 'revenue': 21.39, 'unit': 'M', 'net_profit': 1.37}, {'period': '2020', 'revenue': 13360.0, 'unit': 'K', 'net_profit': 402.0}]","[{'period': ""Q4 '23"", 'revenue': 4.99, 'unit': 'M', 'net_profit': 1.04}, {'period': ""Q3 '23"", 'revenue': 4.99, 'unit': 'M', 'net_profit': 1.04}, {'period': ""Q2 '23"", 'revenue': 7960.0, 'unit': 'K', 'net_profit': -255.0}, {'period': ""Q1 '23"", 'revenue': 3980.0, 'unit': 'K', 'net_profit': -127.5}, {'period': ""Q4 '22"", 'revenue': 4110.0, 'unit': 'K', 'net_profit': 276.5}, {'period': ""Q3 '22"", 'revenue': 4110.0, 'unit': 'K', 'net_profit': 276.5}]",0.24,0.24,22120000,10545000,5453000,5640000,3068000,9856000,5596000,5453000,-85000,9.664596273291925,2.391465677179963,2.443328550932568,"[0.08, 0.42]","['2024-06-13', '2018-06-14']",__nan__,0.2549728752260398
848,CLXT,Calyxt Inc. Common Stock,"Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.",Mr. Michael Allen Carr,Packaged Foods,6.3,USD,31334247,https://images.financialmodelingprep.com/symbol/CLXT.png,22518,-1.6449086161879896,0.33,254088,-22370000,-9803000,"[{'period': '2022', 'revenue': 0.157, 'unit': 'M', 'net_profit': -9.8}, {'period': '2021', 'revenue': 25.99, 'unit': 'M', 'net_profit': -29.09}, {'period': '2020', 'revenue': 23.85, 'unit': 'M', 'net_profit': -46.4}, {'period': '2019', 'revenue': 7.3, 'unit': 'M', 'net_profit': -41.1}]","[{'period': ""Q3 '23"", 'revenue': 0.47500000000000003, 'unit': 'M', 'net_profit': -26.43}, {'period': ""Q2 '23"", 'revenue': 0.197, 'unit': 'M', 'net_profit': -18.69}, {'period': ""Q1 '23"", 'revenue': 0.042, 'unit': 'M', 'net_profit': -6.33}, {'period': ""Q4 '22"", 'revenue': 0.042, 'unit': 'M', 'net_profit': -1.98}, {'period': ""Q3 '22"", 'revenue': 0.042, 'unit': 'M', 'net_profit': -5.7}, {'period': ""Q2 '22"", 'revenue': 0.041, 'unit': 'M', 'net_profit': -2.48}]",-10.66,-10.66,22421000,4132000,3427000,15188000,0,0,1662000,3427000,-20884000,0.2156931491480261,0.6629534124118962,0.7253285235763979,__nan__,__nan__,__nan__,0.6774006511752375
849,CMBM,Cambium Networks Corporation Ordinary Shares,"Cambium Networks Corporation, through its subsidiaries, provides wireless broadband networking infrastructure products and solutions for commercial and government network operators. Its wireless fabric includes intelligent radios, smart antennas, radio frequency (RF) algorithms, wireless-aware switches, and cloud-based network management software. The company offers point-to-point backhaul, point-to-multipoint distribution, Wi-Fi access, cnMatrix ethernet enterprise switching, cnReach IIoT, cnVision video surveillance transport, and cnMaestro and network management tools and solutions. It also offers point-to-point solutions that are connected to high-speed, high-bandwidth wireline networks; and wireless broadband backhaul to facilities or point-to-multipoint access points deployed throughout a network over distances of approximately 100 kilometers and at 2 gigabytes per second. The company also offers cnPilot and Xirrus Wi-Fi solution provides distributed access to individual users in indoor settings, such as office complexes, and outdoor settings, such as athletic stadiums and outdoor public Wi-Fi spots; cnReach solutions offer narrow-band connectivity for sensors and devices; embedded proprietary RF technology and software enables automated optimization of data flow at the outermost points in the network; cnMatrix cloud-managed wireless-aware switching solution provides the interface between wireless and wired networks; and cnVision solutions for video surveillance and CCTV deployments. It serves medium-sized wireless Internet service providers, mobile network operators, enterprises, and government agencies in North America, Europe, the Middle East, Africa, Caribbean and Latin America, and the Asia Pacific. The company was formerly known as Vector Cambium Holdings (Cayman), Ltd. and changed its name to Cambium Networks Corporation in 2018. The was founded in 2011 and is headquartered in Rolling Meadows, Illinois.",Mr. Morgan C. S. Kurk,Communication Equipment,1.1,USD,31068180,https://images.financialmodelingprep.com/symbol/CMBM.png,211508,-0.31,0.175,290640,-52100000,-77420000,"[{'period': '2023', 'revenue': 220.19, 'unit': 'M', 'net_profit': -77.42}, {'period': '2022', 'revenue': 296.9, 'unit': 'M', 'net_profit': 20.2}, {'period': '2021', 'revenue': 335.85, 'unit': 'M', 'net_profit': 37.42}, {'period': '2020', 'revenue': 278.46, 'unit': 'M', 'net_profit': 18.57}]","[{'period': ""Q3 '24"", 'revenue': 43.73, 'unit': 'M', 'net_profit': -9.68}, {'period': ""Q2 '24"", 'revenue': 45.95, 'unit': 'M', 'net_profit': -9.14}, {'period': ""Q1 '24"", 'revenue': 42.34, 'unit': 'M', 'net_profit': -26.45}, {'period': ""Q4 '23"", 'revenue': 40.21, 'unit': 'M', 'net_profit': -39.01}, {'period': ""Q3 '23"", 'revenue': 43.05, 'unit': 'M', 'net_profit': -26.2}, {'period': ""Q2 '23"", 'revenue': 59.54, 'unit': 'M', 'net_profit': -2.64}]",-2.81,-2.81,217875000,162571000,18710000,136941000,64325000,0,96328000,18710000,-28177000,-2.8883653497644075,-4.832673267326733,-4.746666666666667,__nan__,__nan__,__nan__,0.6285301204819277
850,CMCO,Columbus McKinnon Corporation Common Stock,"Columbus McKinnon Corporation designs, manufactures, and markets intelligent motion solutions to ergonomically move, lift, position, and secure materials worldwide. The company offers electric, air-powered, lever, and hand hoists; hoist trolleys, explosion-protected and custom engineered hoists, and winches; crane systems, such as crane components and kits, enclosed track rail systems, mobile and jib cranes, and fall protection systems, as well as material handling solutions; rigging equipment comprising below-the-hook lifting devices, shackles, chains and chains accessories, forestry and hand tools, lifting slings, lashing systems, and tie-downs and load binders; rotary unions and swivel joints; and mechanical and electromechanical actuators. It also provides power and motion technology products, including AC motor controls and line regenerative systems, automation and diagnostics, brakes, cable and festoon systems, collision avoidance systems, conductor bar systems, DC motor and magnet control systems, elevator drives, inverter duty motors, mining drives, pendant pushbutton stations, radio controls, and wind inverters; power delivery subsystems; overhead aluminum light rail workstations; and low profile, flexible chain, large scale, sanitary, and vertical elevation conveyor systems, as well as pallet system conveyors and accumulation systems. The company serves market verticals, including general industries, transportation, energy and utilities, process industries, industrial automation, construction and infrastructure, food and beverage, entertainment, life sciences, consumer packaged goods, and e-commerce/supply chain/warehousing. It offers its products to end users directly, as well as through distributors, independent crane builders, material handling specialists and integrators, government agencies, original equipment manufacturers, and engineering procurement and construction firms. The company was founded in 1875 and is headquartered in Buffalo, New York.",Mr. David J. Wilson,Agricultural - Machinery,35.405,USD,1015765910,https://images.financialmodelingprep.com/symbol/CMCO.png,236835,68.09,-1.535,66297,145429000,46625000,"[{'period': '2023', 'revenue': 1010.0, 'unit': 'M', 'net_profit': 46.62}, {'period': '2022', 'revenue': 936.24, 'unit': 'M', 'net_profit': 48.43}, {'period': '2021', 'revenue': 906.55, 'unit': 'M', 'net_profit': 29.66}, {'period': '2020', 'revenue': 649.64, 'unit': 'M', 'net_profit': 9.11}]","[{'period': ""Q2 '24"", 'revenue': 242.27, 'unit': 'M', 'net_profit': -15.04}, {'period': ""Q1 '24"", 'revenue': 239.73, 'unit': 'M', 'net_profit': 8.63}, {'period': ""Q4 '23"", 'revenue': 265.5, 'unit': 'M', 'net_profit': 11.81}, {'period': ""Q3 '23"", 'revenue': 254.14, 'unit': 'M', 'net_profit': 9.73}, {'period': ""Q2 '23"", 'revenue': 258.4, 'unit': 'M', 'net_profit': 15.81}, {'period': ""Q1 '23"", 'revenue': 235.49, 'unit': 'M', 'net_profit': 9.28}]",1.62,1.61,1825945000,514155000,114126000,943882000,171186000,11447000,261761000,114126000,42385000,-0.008792317286786306,-0.037250407813500176,-0.04142011834319517,"[0.07, 0.06]","['2024-11-08', '1996-04-08']",__nan__,0.5169279468987291
851,CMCSA,Comcast Corporation Class A Common Stock,"Comcast Corporation operates as a media and technology company worldwide. It operates through Cable Communications, Media, Studios, Theme Parks, and Sky segments. The Cable Communications segment offers broadband, video, voice, wireless, and other services to residential and business customers under the Xfinity brand; and advertising services. The Media segment operates NBCUniversal's television and streaming platforms, including national, regional, and international cable networks, the NBC and Telemundo broadcast, and Peacock networks. The Studios segment operates NBCUniversal's film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida; Hollywood, California; Osaka, Japan; and Beijing, China. The Sky segment offers direct-to-consumer services, such as video, broadband, voice and wireless phone services, and content business operates entertainment networks, the Sky News broadcast network, and Sky Sports networks. The company also owns the Philadelphia Flyers, as well as the Wells Fargo Center arena in Philadelphia, Pennsylvania; and provides streaming service, such as Peacock. Comcast Corporation was founded in 1963 and is headquartered in Philadelphia, Pennsylvania.",Mr. Brian L. Roberts,Telecommunications Services,37.2399,USD,142148422290,https://images.financialmodelingprep.com/symbol/CMCSA.png,19517146,10.09,-0.2501,4689863,38901000000,15388000000,"[{'period': '2023', 'revenue': 121.57, 'unit': 'B', 'net_profit': 15.39}, {'period': '2022', 'revenue': 121.43, 'unit': 'B', 'net_profit': 5.37}, {'period': '2021', 'revenue': 116.39, 'unit': 'B', 'net_profit': 14.16}, {'period': '2020', 'revenue': 103.56, 'unit': 'B', 'net_profit': 10.53}]","[{'period': ""Q3 '24"", 'revenue': 32.07, 'unit': 'B', 'net_profit': 3.63}, {'period': ""Q2 '24"", 'revenue': 29.69, 'unit': 'B', 'net_profit': 3.93}, {'period': ""Q1 '24"", 'revenue': 30.06, 'unit': 'B', 'net_profit': 3.86}, {'period': ""Q4 '23"", 'revenue': 31.25, 'unit': 'B', 'net_profit': 3.26}, {'period': ""Q3 '23"", 'revenue': 30.11, 'unit': 'B', 'net_profit': 4.05}, {'period': ""Q2 '23"", 'revenue': 30.51, 'unit': 'B', 'net_profit': 4.25}]",3.73,3.71,264811000000,23987000000,6215000000,181344000000,13813000000,9385000000,40198000000,6215000000,12961000000,0.0673892166277953,1.8655493482309125,2.0573770491803276,"[0.31, 0.1822]","['2025-01-08', '1986-03-03']",__nan__,0.6848053895042124
852,CMCT,CIM Commercial Trust Corporation Common stock,"Creative Media & Community Trust Corporation is a real estate investment trust that primarily acquires, owns, and operates Class A and creative office assets in vibrant and improving metropolitan communities throughout the United States (including improving and developing such assets). Its properties are primarily located in Los Angeles and the San Francisco Bay Area. Creative Media & Community Trust Corporation is operated by affiliates of CIM Group, L.P., a vertically-integrated owner and operator of real assets with multi-disciplinary expertise and in-house research, acquisition, credit analysis, development, finance, leasing, and onsite property management capabilities.",Mr. David A. Thompson CPA,REIT - Office,1.59,USD,18495675,https://images.financialmodelingprep.com/symbol/CMCT.png,3667070,-0.05,-0.09,356639,37539000,-48485000,"[{'period': '2023', 'revenue': 119.26, 'unit': 'M', 'net_profit': -48.48}, {'period': '2022', 'revenue': 101.91, 'unit': 'M', 'net_profit': 5.92}, {'period': '2021', 'revenue': 90930.0, 'unit': 'K', 'net_profit': -851.0}, {'period': '2020', 'revenue': 77.21, 'unit': 'M', 'net_profit': -15.02}]","[{'period': ""Q3 '24"", 'revenue': 28.62, 'unit': 'M', 'net_profit': -10.38}, {'period': ""Q2 '24"", 'revenue': 34440.0, 'unit': 'K', 'net_profit': -796.0}, {'period': ""Q1 '24"", 'revenue': 34.0, 'unit': 'M', 'net_profit': -3.73}, {'period': ""Q4 '23"", 'revenue': 33.46, 'unit': 'M', 'net_profit': -8.4}, {'period': ""Q3 '23"", 'revenue': 28.12, 'unit': 'M', 'net_profit': -15.77}, {'period': ""Q2 '23"", 'revenue': 32.76, 'unit': 'M', 'net_profit': -17.36}]",-3.33,-3.33,891200000,104517000,19290000,514431000,20104000,33505000,108350000,19290000,-1329000,0.007731336071514858,-9.192801622169652,-13.807692307692307,"[0.04, 0.24]","['2024-09-25', '1994-04-25']",__nan__,0.577234066427289
853,CME,CME Group Inc. Class A Common Stock,"CME Group Inc., together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income products. The company also provides clearing house services, including clearing, settling, and guaranteeing futures and options contracts, and cleared swaps products traded through its exchanges; and trade processing and risk mitigation services. In addition, the company offers a range of market data services, including real-time and historical data services. It serves professional traders, financial institutions, institutional and individual investors, corporations, manufacturers, producers, governments, and central banks. The company was formerly known as Chicago Mercantile Exchange Holdings Inc. and changed its name to CME Group Inc. in July 2007. CME Group Inc. was founded in 1898 and is headquartered in Chicago, Illinois.",Mr. Terrence A. Duffy,Financial - Data & Stock Exchanges,227.69,USD,82050140710,https://images.financialmodelingprep.com/symbol/CME.png,1935229,24.64,1.87,967656,3788300000,3226200000,"[{'period': '2023', 'revenue': 5.58, 'unit': 'B', 'net_profit': 3.23}, {'period': '2022', 'revenue': 5.02, 'unit': 'B', 'net_profit': 2.69}, {'period': '2021', 'revenue': 4.69, 'unit': 'B', 'net_profit': 2.64}, {'period': '2020', 'revenue': 4.88, 'unit': 'B', 'net_profit': 2.11}]","[{'period': ""Q3 '24"", 'revenue': 1580.0, 'unit': 'M', 'net_profit': 879.4}, {'period': ""Q2 '24"", 'revenue': 1530.0, 'unit': 'M', 'net_profit': 883.2}, {'period': ""Q1 '24"", 'revenue': 1490.0, 'unit': 'M', 'net_profit': 855.2}, {'period': ""Q4 '23"", 'revenue': 1440.0, 'unit': 'M', 'net_profit': 814.6}, {'period': ""Q3 '23"", 'revenue': 1340.0, 'unit': 'M', 'net_profit': 750.2}, {'period': ""Q2 '23"", 'revenue': 1360.0, 'unit': 'M', 'net_profit': 777.6}]",8.87,8.86,129706100000,94890200000,3023700000,102968200000,535600000,0,93416900000,2912000000,3377400000,0.12569458889252072,0.19888517279821627,0.19703103913630216,"[5.8, 0.14]","['2024-12-27', '2003-03-06']",__nan__,0.7938578062249964
854,CMII,CM Life Sciences II Inc. Class A Common Stock,"CM Life Sciences II Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.",Mr. Eli Decatur Casdin,Shell Companies,10.63,USD,1993401380,https://images.financialmodelingprep.com/symbol/CMII.png,66038,0,-0.6700001,121382,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
855,CMIIU,CM Life Sciences II Inc. Unit,"CM Life Sciences II Inc. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.",,Shell Companies,11.22,USD,0,https://images.financialmodelingprep.com/symbol/CMIIU.png,118536,0,-0.6399994,33735,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
856,CMIIW,CM Life Sciences II Inc. Warrant,"CM Life Sciences II Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.",Mr. Eli Decatur Casdin,Shell Companies,2.68,USD,496268038,https://images.financialmodelingprep.com/symbol/CMIIW.png,0,0,0.13,16179,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
857,CMLF,CM Life Sciences Inc. Class A Common Stock,"CM Life Sciences, Inc. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.",Mr. Eli Decatur Casdin,Shell Companies,11.6,USD,0,https://images.financialmodelingprep.com/symbol/CMLF.png,723143,-1288.888888888889,-0.87999916,489110,-192244,-192244,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -192.24}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 13.01}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -192.24}]",-0.0035,-0.0035,444135663,1371712,443858632,15593370,0,0,97120,1094681,,0,0,0,__nan__,__nan__,__nan__,0.03510947509747714
858,CMLFU,CM Life Sciences Inc. Unit,"CM Life Sciences, Inc. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.",Mr. Eli Decatur Casdin,Shell Companies,13,USD,10311794688,https://images.financialmodelingprep.com/symbol/CMLFU.png,10023,-1444.4444444444443,-0.62,1314,-192244,-192244,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -192.24}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 13.01}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -192.24}]",-0.0035,-0.0035,444135663,1371712,443858632,15593370,0,0,97120,1094681,,0,0,0,__nan__,__nan__,__nan__,0.03510947509747714
859,CMLFW,CM Life Sciences Inc. Warrant,,,,,,,,,0,-0.3234,97727,,,[],"[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 13.01}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -58.47}]",,,444135663,1371712,1094681,15593370,0,0,97120,1094681,,,,,__nan__,__nan__,__nan__,0.03510947509747714
860,CMLS,Cumulus Media Inc. Class A Common Stock,"Cumulus Media Inc., an audio-first media company, owns and operates radio stations in the United States. It owns and operates 406 stations in 86 markets, as well as approximately 9,500 affiliated stations through Westwood One. The company's content portfolio includes sports, news, talk, and entertainment programming from various brands, including the NFL, the NCAA, the Masters, CNN, the AP, the Academy of Country Music Awards, and other partners. It also provides digital marketing services, such as email marketing, geo-targeted display and video solutions, website and microsite building, hosting, social media management, reputation management, and search engine marketing and optimization. The company serves advertisers through broadcast and on-demand digital, mobile, social, and voice-activated platforms. Cumulus Media Inc. was incorporated in 2002 and is based in Atlanta, Georgia.",Ms. Mary G. Berner,Broadcasting,0.85,USD,14172560,https://images.financialmodelingprep.com/symbol/CMLS.png,64717,-0.1,0.0599,15897,35848999,-117879000,"[{'period': '2023', 'revenue': 844.55, 'unit': 'M', 'net_profit': -117.88}, {'period': '2022', 'revenue': 953.51, 'unit': 'M', 'net_profit': 16.23}, {'period': '2021', 'revenue': 916.47, 'unit': 'M', 'net_profit': 17.28}, {'period': '2020', 'revenue': 816.22, 'unit': 'M', 'net_profit': -59.72}]","[{'period': ""Q3 '24"", 'revenue': 203.6, 'unit': 'M', 'net_profit': -10.32}, {'period': ""Q2 '24"", 'revenue': 204.85, 'unit': 'M', 'net_profit': -27.7}, {'period': ""Q1 '24"", 'revenue': 200.05, 'unit': 'M', 'net_profit': -14.15}, {'period': ""Q4 '23"", 'revenue': 221.3, 'unit': 'M', 'net_profit': -98.07}, {'period': ""Q3 '23"", 'revenue': 207.42, 'unit': 'M', 'net_profit': 2.72}, {'period': ""Q2 '23"", 'revenue': 210.14, 'unit': 'M', 'net_profit': -1.07}]",-6.83,-6.83,1440301000,286897000,80660000,1153719000,182201000,0,143739000,80660000,6847000,-0.7736805618686868,-8.26079457961195,-9.228915662650603,__nan__,__nan__,__nan__,0.8010263132497999
861,CMLTU,CM Life Sciences III Inc. Unit,"CM Life Sciences III Inc. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.",Mr. Eli Decatur Casdin,Shell Companies,8.87,USD,0,https://images.financialmodelingprep.com/symbol/CMLTU.png,68320,0,-0.6199999,11702,,,[],[],,,,,,,,,,,,,,,__nan__,__nan__,__nan__,__nan__
862,CMMB,Chemomab Therapeutics Ltd. American Depositary Share,"Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.",Dr. Adi Mor George Ph.D.,Biotechnology,2.2999,USD,43368320,https://images.financialmodelingprep.com/symbol/CMMB.png,120727,-2.45,-0.1401,81046,-25392000,-24221000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.22}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -27.65}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.55}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.93}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.48}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.63}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.91}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.45}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.07}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.97}]",-2.06,-2.06,22151000,20897000,19784000,5154000,289000,0,4838000,9292000,-23614000,0.10827041264266901,0.12388772335961802,0.15226337448559674,__nan__,__nan__,__nan__,0.2326757257008713
863,CMPI,Checkmate Pharmaceuticals Inc. Common Stock,"Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 nave neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.",Mr. Barry A. Labinger,Biotechnology,10.5,USD,0,https://images.financialmodelingprep.com/symbol/CMPI.png,233019,-3.8489736070381233,0,63651,-61339000,-61405000,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -61.41}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -36.91}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.29}, {'period': '2018', 'revenue': 0.0, 'unit': 'M', 'net_profit': -20.81}]","[{'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.89}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.34}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.97}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.97}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.13}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.93}]",-6.42,-6.42,78838000,73962000,50675000,9379000,0,0,9379000,50675000,-53715000,-0.6704520697167756,-0.663731440338138,-0.6632124352331606,__nan__,__nan__,__nan__,0.11896547350262564
864,CMPR,Cimpress plc Ordinary Shares (Ireland),"Cimpress plc provides various mass customization of printing and related products in North America, Europe, and internationally. The company operates through five segments: Vistaprint, PrintBrothers, The Print Group, National Pen, and All Other Businesses. It offers printed and digital marketing products; internet-based canvas-print wall dcor, business signage, and other printed products; business cards; and marketing materials, such as flyers and postcards, digital and marketing services, writing instruments, decorated apparel, promotional products and gifts, packaging, design services, textiles, and magazines and catalogs. The company also manufactures and markets custom writing instruments and promotional products, apparels, and gifts; and provides professional desktop publishing skill sets for local printers, print resellers, graphic artists, advertising agencies, and other customers. In addition, it offers graphic design services, do-it-yourself (DIY) design services, website services, and corporate solutions under the VistaPrint, VistaCreate, 99designs by Vista, Vista Corporate Solutions, and Vista x Wix brand names; and online printing solutions. Further, the company provides promotional and packaging products, logo apparel, books and magazines, wall decors, photo merchandise, invitations and announcements, and other categories; and website design and hosting, and email marketing services, as well as order referral and other third-party offerings. The company serves various businesses, graphic designers, resellers, and printers, as well as teams, associations, groups, consumers, and families. Cimpress plc was founded in 1994 and is based in Dundalk, Ireland.",Mr. Robert S. Keane,Advertising Agencies,70.945,USD,1784515057,https://images.financialmodelingprep.com/symbol/CMPR.png,136651,12.32,-0.975,51651,400032000,173682000,"[{'period': '2024', 'revenue': 3290.0, 'unit': 'M', 'net_profit': 173.68}, {'period': '2023', 'revenue': 3080.0, 'unit': 'M', 'net_profit': -185.98}, {'period': '2022', 'revenue': 2890.0, 'unit': 'M', 'net_profit': -50.57}, {'period': '2021', 'revenue': 2590.0, 'unit': 'M', 'net_profit': -74.94}]","[{'period': ""Q1 '25"", 'revenue': 804.97, 'unit': 'M', 'net_profit': -12.55}, {'period': ""Q4 '24"", 'revenue': 832.61, 'unit': 'M', 'net_profit': 115.0}, {'period': ""Q3 '24"", 'revenue': 780.59, 'unit': 'M', 'net_profit': -3.98}, {'period': ""Q2 '24"", 'revenue': 921.36, 'unit': 'M', 'net_profit': 58.1}, {'period': ""Q1 '24"", 'revenue': 757.29, 'unit': 'M', 'net_profit': 4.55}, {'period': ""Q4 '23"", 'revenue': 788.85, 'unit': 'M', 'net_profit': 28.79}]",6.64,6.43,1892157000,457979000,208275000,2409063000,64576000,0,663963000,203775000,237488000,0.6327903379197466,1.933884653023476,1.9378531073446326,__nan__,__nan__,__nan__,1.273183462048868
865,CMPS,COMPASS Pathways Plc American Depository Shares,"COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.","Mr. Kabir Kumar Nath M.A., M.B.A.",Medical - Care Facilities,4.885,USD,334235696,https://images.financialmodelingprep.com/symbol/CMPS.png,953424,-2.1,0.135,569168,-123802000,-118464000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -118.46}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -91.5}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -71.74}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -60.33}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -38.5}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -38.1}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.19}, {'period': ""Q4 '23"", 'revenue': 3.68, 'unit': 'M', 'net_profit': -32.81}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -33.39}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -28.34}]",-2.32,-2.32,275987000,261296000,220198000,50243000,28928999,469000,19604000,220198000,-97442000,-0.1213644556760233,-0.29461778044915576,-0.07407407407407393,__nan__,__nan__,__nan__,0.18204842981734648
866,CMRX,Chimerix Inc. Common Stock,"Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.",Mr. Michael T. Andriole M.B.A.,Biotechnology,3.75,USD,337260375,https://images.financialmodelingprep.com/symbol/CMRX.png,4090769,-3.99,0.21,979257,-92974000,-82095000,"[{'period': '2023', 'revenue': 0.324, 'unit': 'M', 'net_profit': -82.09}, {'period': '2022', 'revenue': 33.82, 'unit': 'M', 'net_profit': 172.17}, {'period': '2021', 'revenue': 1.98, 'unit': 'M', 'net_profit': -255.79}, {'period': '2020', 'revenue': 5.37, 'unit': 'M', 'net_profit': -42.13}]","[{'period': ""Q3 '24"", 'revenue': 0.026000000000000002, 'unit': 'M', 'net_profit': -22.88}, {'period': ""Q2 '24"", 'revenue': 0.129, 'unit': 'M', 'net_profit': -20.68}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.87}, {'period': ""Q4 '23"", 'revenue': 0.004, 'unit': 'M', 'net_profit': -18.16}, {'period': ""Q3 '23"", 'revenue': 0.011, 'unit': 'M', 'net_profit': -23.99}, {'period': ""Q2 '23"", 'revenue': 0.026000000000000002, 'unit': 'M', 'net_profit': -18.58}]",-0.93,-0.93,212774000,189110000,182835000,19745000,1140000,21657000,18443000,27661000,-69177000,-0.5396615109462458,-1.476833539528481,-1.4720812182741116,__nan__,__nan__,__nan__,0.09279799223589348
867,CMTL,Comtech Telecommunications Corp. Common Stock,"Comtech Telecommunications Corp., together with its subsidiaries, designs, develops, produces, and markets products, systems, and services for communications solutions in the United States and internationally. It operates in two segments, Commercial Solutions and Government Solutions. The Commercial Solutions segment offers satellite ground station technologies, including single channel per carrier and time division multiple access modems, amplifiers, frequency converters, and network software to modulate, demodulate, and amplify signals, as well as to carry voice, video, and/or data over networks; and public safety and location technologies, such as 911 call handling and mapping solutions that allow cellular carriers and voice over the Internet carriers to deliver emergency calls to public safety emergency call centers. The Government Solutions segment provides tactical satellite-based networks, such as satellite modems, ruggedized routers, and solid-state drives; sustainment services for the secret Internet Protocol router and non-classified Internet Protocol router access point; and small aperture terminals. This segment also offers high-performance transmission technologies that are used in communication systems comprising electronic warfare, radar, and identification friend or foe (IFF); troposcatter technologies for satellite communication; and high-power radio frequency microwave amplifiers and related switching control technologies that are used in electronic warfare, communications, radar, IFF, and medical applications. The company serves satellite systems integrators, wireless and other communication service providers, satellite broadcasters, prime contractors and system suppliers, medical equipment companies, aviation industry system integrators, oil companies, and domestic and international defense and government customers, as well as end-customers. Comtech Telecommunications Corp. was founded in 1967 and is headquartered in Melville, New York.",Mr. John  Ratigan,Communication Equipment,4.35,USD,126692445,https://images.financialmodelingprep.com/symbol/CMTL.png,492083,-0.93,-0.13,326289,-44814000,-99985000,"[{'period': '2024', 'revenue': 540.4, 'unit': 'M', 'net_profit': -99.98}, {'period': '2023', 'revenue': 549.99, 'unit': 'M', 'net_profit': -26.9}, {'period': '2022', 'revenue': 486.24, 'unit': 'M', 'net_profit': -33.05}, {'period': '2021', 'revenue': 581.7, 'unit': 'M', 'net_profit': -73.48}]","[{'period': ""Q4 '24"", 'revenue': 126.19, 'unit': 'M', 'net_profit': -77.14}, {'period': ""Q3 '24"", 'revenue': 128.08, 'unit': 'M', 'net_profit': 2.79}, {'period': ""Q2 '24"", 'revenue': 134.22, 'unit': 'M', 'net_profit': -10.56}, {'period': ""Q1 '24"", 'revenue': 151.91, 'unit': 'M', 'net_profit': -1.44}, {'period': ""Q4 '23"", 'revenue': 148.81, 'unit': 'M', 'net_profit': -3.54}, {'period': ""Q3 '23"", 'revenue': 136.32, 'unit': 'M', 'net_profit': -7.46}]",-4.7,-4.7,960623000,336551000,32433000,426105000,195595000,824000,183547000,32433000,-77872000,-3.4018651516775646,-2.7170526785382356,-3.8958333333333335,"[0.1, 0.25]","['2023-01-17', '2010-10-20']",__nan__,0.4435715155685425
868,CNBKA,Century Bancorp Inc. Class A Common Stock,"Century Bancorp, Inc. operates as a bank holding company for Century Bank and Trust Company that provides banking products and services. The company accepts savings accounts, NOW accounts, demand deposits, time deposits, and money market accounts, as well as cash management accounts. It offers single-family and multi-family residential loans, commercial and residential real estate loans, municipal loans, and various consumer loans, as well as provides loans for the construction of residential homes, multi-family properties, commercial real estate properties, and land development. The company also provides automated lockbox collection, cash management, and account reconciliation services to corporate and institutional customers, as well as to the municipal market; and securities brokerage services. It serves commercial enterprises, state and local governments and agencies, non-profit organizations, and individuals in Massachusetts, New Hampshire, Rhode Island, Connecticut, and New York. As of March 31, 2020, the company operated 27 banking offices in 20 cities and towns in Massachusetts. Century Bancorp, Inc. was founded in 1969 and is headquartered in Medford, Massachusetts.",Mr. Barry Sloane,Banks - Regional,115.29,USD,0,https://images.financialmodelingprep.com/symbol/CNBKA.png,8905,14.288015863180071,0.0699997,11374,87753000,42209000,"[{'period': '2020', 'revenue': 124.22, 'unit': 'M', 'net_profit': 42.21}, {'period': '2019', 'revenue': 114.19, 'unit': 'M', 'net_profit': 39.7}, {'period': '2018', 'revenue': 108.82, 'unit': 'M', 'net_profit': 36.21}, {'period': '2017', 'revenue': 102.17, 'unit': 'M', 'net_profit': 22.3}]","[{'period': ""Q3 '21"", 'revenue': 34.55, 'unit': 'M', 'net_profit': 11.73}, {'period': ""Q2 '21"", 'revenue': 34.1, 'unit': 'M', 'net_profit': 10.82}, {'period': ""Q1 '21"", 'revenue': 32.77, 'unit': 'M', 'net_profit': 10.77}, {'period': ""Q4 '20"", 'revenue': 33.35, 'unit': 'M', 'net_profit': 11.6}, {'period': ""Q3 '20"", 'revenue': 31.5, 'unit': 'M', 'net_profit': 10.89}, {'period': ""Q2 '20"", 'revenue': 29.86, 'unit': 'M', 'net_profit': 10.06}]",7.58,7.58,6358834000,136735000,419183000,5988425000,13283000,2793204000,0,136735000,35999000,-0.13779144600450002,0.06322577394896597,-0.12166859791425268,"[0.18, 0.071]","['2021-09-30', '1987-07-27']",__nan__,0.9417489118288038
869,CNCE,Concert Pharmaceuticals Inc. Common Stock,"Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.",Dr. Roger D. Tung Ph.D.,Biotechnology,8.37,USD,0,https://images.financialmodelingprep.com/symbol/CNCE.png,2542039,-2.640378548895899,0,0,-73486000,-82594000,"[{'period': '2021', 'revenue': 32.58, 'unit': 'M', 'net_profit': -82.59}, {'period': '2020', 'revenue': 7.9, 'unit': 'M', 'net_profit': -74.77}, {'period': '2019', 'revenue': 1.08, 'unit': 'M', 'net_profit': -77.33}, {'period': '2018', 'revenue': 10.51, 'unit': 'M', 'net_profit': -56.02}]","[{'period': ""Q3 '22"", 'revenue': 0.008, 'unit': 'M', 'net_profit': -28.2}, {'period': ""Q2 '22"", 'revenue': 0.021, 'unit': 'M', 'net_profit': -21.41}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -39.43}, {'period': ""Q4 '21"", 'revenue': 0.02758, 'unit': 'M', 'net_profit': 22.59}, {'period': ""Q3 '21"", 'revenue': 0.543, 'unit': 'M', 'net_profit': -26.68}, {'period': ""Q2 '21"", 'revenue': 32.02, 'unit': 'M', 'net_profit': 5.42}]",-2.4,-2.4,165316000,150329000,143099000,53091000,218000,0,16120000,141636000,-55409000,-0.06752084604433597,-0.10469999732498729,0,__nan__,__nan__,__nan__,0.32114858815843594
870,CNDT,Conduent Incorporated Common Stock ,"Conduent Incorporated provides business process services with capabilities in transaction-intensive processing, analytics, and automation in the United States, Europe, and internationally. It operates through three segments: Commercial Industries, Government Services, and Transportation. The Commercial Industries segment offers business process services and customized solutions to clients in various industries; and end-user customer experience management, transaction processing services, healthcare and human resource, and learning services. The Government Services segment provides government-centric business process services to the United States federal, state, local, and foreign governments for public assistance, program administration, transaction processing, and payment services; medical management and fiscal agent care management services; and government healthcare, payment solutions, child support, and federal services. The Transportation segment offers systems and support comprising mission-critical mobility and payment solutions to government clients. This segment also provides electronic tolling, urban congestion management, and mileage-based user solutions; transit solutions; citation and permit administration, parking enforcement, and curbside demand management solutions; and computer-aided dispatch/automatic vehicle location solutions. Conduent Incorporated was founded in 2016 and is headquartered in Florham Park, New Jersey.",Mr. Clifford A. Skelton,Information Technology Services,3.94,USD,629966600,https://images.financialmodelingprep.com/symbol/CNDT.png,1139135,1.77,-0.01,325575,43000000,-296000000,"[{'period': '2023', 'revenue': 3720.0, 'unit': 'M', 'net_profit': -296.0}, {'period': '2022', 'revenue': 3860.0, 'unit': 'M', 'net_profit': -182.0}, {'period': '2021', 'revenue': 4140.0, 'unit': 'M', 'net_profit': -28.0}, {'period': '2020', 'revenue': 4160.0, 'unit': 'M', 'net_profit': -118.0}]","[{'period': ""Q3 '24"", 'revenue': 807.0, 'unit': 'M', 'net_profit': 123.0}, {'period': ""Q2 '24"", 'revenue': 828.0, 'unit': 'M', 'net_profit': 216.0}, {'period': ""Q1 '24"", 'revenue': 921.0, 'unit': 'M', 'net_profit': 99.0}, {'period': ""Q4 '23"", 'revenue': 953.0, 'unit': 'M', 'net_profit': 6.0}, {'period': ""Q3 '23"", 'revenue': 932.0, 'unit': 'M', 'net_profit': -289.0}, {'period': ""Q2 '23"", 'revenue': 915.0, 'unit': 'M', 'net_profit': -7.0}]",-1.41,-1.41,3162000000,1655000000,498000000,2387000000,783000000,0,868000000,498000000,-4000000,-0.7700534759358288,-0.6263736263736264,-0.6785714285714285,__nan__,__nan__,__nan__,0.7549019607843137
871,CNET,ZW Data Action Technologies Inc. Common Stock,"ZW Data Action Technologies Inc., through its subsidiaries, provides omni-channel advertising, precision marketing, and data analysis management systems in the People's Republic of China. It offers Internet advertising, precision marketing, and related data services through its Internet portals, including 28.com and liansuo.com that provide advertisers with tools to build sales channels in the form of franchisees, sales agents, distributors, and/or resellers. The company also develops and operates blockchain technology-based products and services. In addition, it provides other e-commerce online to offline advertising and marketing and related value-added technical services, as well as strategic corporation management services. The company was formerly known as ChinaNet Online Holdings, Inc. and changed its name to ZW Data Action Technologies Inc. in October 2020. ZW Data Action Technologies Inc. was founded in 2003 and is headquartered in Beijing, the People's Republic of China.",Mr. Handong  Cheng,Advertising Agencies,1.92,USD,4178323,https://images.financialmodelingprep.com/symbol/CNET.png,45348,-0.7,-0.03,5745,-3129000,-5974000,"[{'period': '2023', 'revenue': 30.59, 'unit': 'M', 'net_profit': -5.97}, {'period': '2022', 'revenue': 26.23, 'unit': 'M', 'net_profit': -9.79}, {'period': '2021', 'revenue': 47.33, 'unit': 'M', 'net_profit': -2.69}, {'period': '2020', 'revenue': 38.41, 'unit': 'M', 'net_profit': -5.22}]","[{'period': ""Q3 '24"", 'revenue': 3.24, 'unit': 'M', 'net_profit': -1.91}, {'period': ""Q2 '24"", 'revenue': 6420.0, 'unit': 'K', 'net_profit': -216.0}, {'period': ""Q1 '24"", 'revenue': 3530.0, 'unit': 'K', 'net_profit': -850.0}, {'period': ""Q4 '23"", 'revenue': 5.27, 'unit': 'M', 'net_profit': -1.91}, {'period': ""Q3 '23"", 'revenue': 9.18, 'unit': 'M', 'net_profit': -1.52}, {'period': ""Q2 '23"", 'revenue': 9.82, 'unit': 'M', 'net_profit': -1.4}]",-0.83,-0.83,11233000,8960000,817000,4979000,844000,794000,4855000,817000,-2093000,0.5385636336823477,0.3898478194260035,0.3941605839416059,__nan__,__nan__,__nan__,0.44324757411199145
872,CNEY,CN Energy Group Inc. Ordinary Shares,"CN Energy Group. Inc. manufactures and supplies wood-based activated carbon in China. The company's activated carbon is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production. It also produces biomass electricity for State Grid Heilongjiang, a subsidiary of State Grid Corporation of China in Heilongjiang Province. The company was incorporated in 2018 and is based in Lishui, China.",Mr. Wenhua  Liu,Chemicals - Specialty,0.4577,USD,3117971,https://images.financialmodelingprep.com/symbol/CNEY.png,4033920,-0.1,0.0966,4075541,-2375516,-5625740,"[{'period': '2023', 'revenue': 57.9, 'unit': 'M', 'net_profit': -5.63}, {'period': '2022', 'revenue': 40.21, 'unit': 'M', 'net_profit': 2.23}, {'period': '2021', 'revenue': 19.85, 'unit': 'M', 'net_profit': 1.3}, {'period': '2020', 'revenue': 12.48, 'unit': 'M', 'net_profit': 2.34}]","[{'period': ""Q2 '24"", 'revenue': 15.64, 'unit': 'M', 'net_profit': -1.48}, {'period': ""Q1 '24"", 'revenue': 15.64, 'unit': 'M', 'net_profit': -1.48}, {'period': ""Q4 '23"", 'revenue': 17610.0, 'unit': 'K', 'net_profit': -727.28}, {'period': ""Q3 '23"", 'revenue': 17610.0, 'unit': 'K', 'net_profit': -727.28}, {'period': ""Q2 '23"", 'revenue': 22.68, 'unit': 'M', 'net_profit': -4.17}, {'period': ""Q1 '23"", 'revenue': 11.34, 'unit': 'M', 'net_profit': -2.09}]",-3.12,-3.12,126195222,72449365,195502,22632988,29012866,0,22524707,195502,-30848363,-1.5604092576013324,-3.523083740113055,-2.0097087378640777,__nan__,__nan__,__nan__,0.17934900895059244
873,CNFR,Conifer Holdings Inc. Common Stock,"Conifer Holdings, Inc., an insurance holding company, engages in the sale of property and casualty insurance products. It offers insurance coverage in specialty commercial and personal product lines. The company underwrites various specialty insurance products, including property, general liability, liquor liability, automobile, and homeowners and dwelling policies. It serves the commercial insurance needs of owner-operated businesses in the markets, such as hospitality, which includes restaurants, bars, taverns, and bowling centers, as well as small grocery and convenience stores; artisan contractors comprising plumbers, painters, carpenters, electricians, and other independent contractors; and security service providers, including companies that provide security guard services, security alarm products and services, and private investigative services. The company also offers specialty homeowners insurance products, such as low- value dwelling insurance tailored for owners of lower valued homes in Illinois, Indiana, Louisiana, and Texas; and wholesale agency services comprising commercial and personal lines insurance products for its insurance company subsidiaries, as well as third party insurers. Conifer Holdings, Inc. markets and sells its insurance products through a network of approximately 4,600 independent agents in 50 states in the United States. The company was incorporated in 2009 and is headquartered in Birmingham, Michigan.","Mr. Brian Joseph Roney B.A., B.S., M.B.A.",Insurance - Property & Casualty,1.12,USD,13689648,https://images.financialmodelingprep.com/symbol/CNFR.png,16543,-0.49,-0.01,1626,-21893000,-25904000,"[{'period': '2023', 'revenue': 98.76, 'unit': 'M', 'net_profit': -25.9}, {'period': '2022', 'revenue': 104.89, 'unit': 'M', 'net_profit': -11.05}, {'period': '2021', 'revenue': 118.59, 'unit': 'M', 'net_profit': -1.92}, {'period': '2020', 'revenue': 107330.0, 'unit': 'K', 'net_profit': -244.0}]","[{'period': ""Q3 '24"", 'revenue': 16.02, 'unit': 'M', 'net_profit': 53.29}, {'period': ""Q2 '24"", 'revenue': 26.85, 'unit': 'M', 'net_profit': -3.79}, {'period': ""Q1 '24"", 'revenue': 23080.0, 'unit': 'K', 'net_profit': 231.0}, {'period': ""Q4 '23"", 'revenue': 21.14, 'unit': 'M', 'net_profit': -19.46}, {'period': ""Q3 '23"", 'revenue': 28.12, 'unit': 'M', 'net_profit': -2.71}, {'period': ""Q2 '23"", 'revenue': 24.92, 'unit': 'M', 'net_profit': -4.74}]",-2.12,-2.12,311804000,90240000,31963000,308915000,29369000,145305000,91432000,11125000,-13392000,-0.2801426733715355,-1.3444655624943433,-1.058252427184466,__nan__,__nan__,__nan__,0.9907345640209876
874,CNFRL,Conifer Holdings Inc. 6.75% Senior Unsecured Notes due 2023,,None,,24.05,USD,0,https://images.financialmodelingprep.com/symbol/CNFRL.png,3988,0,-0.73,596,-21893000,-25904000,"[{'period': '2023', 'revenue': 98.76, 'unit': 'M', 'net_profit': -25.9}, {'period': '2022', 'revenue': 104.89, 'unit': 'M', 'net_profit': -11.05}, {'period': '2021', 'revenue': 118.59, 'unit': 'M', 'net_profit': -1.92}, {'period': '2020', 'revenue': 107330.0, 'unit': 'K', 'net_profit': -244.0}]","[{'period': ""Q3 '24"", 'revenue': 16.02, 'unit': 'M', 'net_profit': 53.29}, {'period': ""Q2 '24"", 'revenue': 26.85, 'unit': 'M', 'net_profit': -3.79}, {'period': ""Q1 '24"", 'revenue': 23080.0, 'unit': 'K', 'net_profit': 231.0}, {'period': ""Q4 '23"", 'revenue': 21.14, 'unit': 'M', 'net_profit': -19.46}, {'period': ""Q3 '23"", 'revenue': 28.12, 'unit': 'M', 'net_profit': -2.71}, {'period': ""Q2 '23"", 'revenue': 24.92, 'unit': 'M', 'net_profit': -4.74}]",-2.12,-2.12,311804000,90240000,31963000,308915000,29369000,145305000,91432000,11125000,-13392000,-0.2801426733715355,-1.3444655624943433,-1.058252427184466,"[0.42188, 0.422]","['2023-09-14', '2019-03-14']",__nan__,0.9907345640209876
875,CNNB,Cincinnati Bancorp Inc. Common Stock,"Cincinnati Bancorp, Inc. operates as the holding company for Cincinnati Federal that provides various banking and financial services to individuals and businesses in the United States. The company offers various deposit accounts, including demand accounts, checking accounts, savings accounts, certificate of deposit accounts, and individual retirement accounts. Its loan portfolio comprises one- to four-family residential real estate loans; nonresidential real estate and multi-family loans; home equity loans and lines of credit; construction and land loans; commercial business loans; and consumer loans. The company also invests in securities, primarily mortgage-backed securities. It operates full-service branch offices in Miami Heights, Anderson, and Price Hill, as well as in Covington and Florence in Northern Kentucky. The company was formerly known as CF Bancorp and changed its name to Cincinnati Bancorp in March 2015. Cincinnati Bancorp was founded in 1922 and is based in Cincinnati, Ohio.",Mr. Robert A. Bedinghaus,Banks - Regional,13.1925,USD,0,https://images.financialmodelingprep.com/symbol/CNNB.png,2315,42.556451612903224,0.0425,100,3870002,1416818,"[{'period': '2022', 'revenue': 12.85, 'unit': 'M', 'net_profit': 1.42}, {'period': '2021', 'revenue': 15.44, 'unit': 'M', 'net_profit': 1.65}, {'period': '2020', 'revenue': 15.44, 'unit': 'M', 'net_profit': 3.16}, {'period': '2019', 'revenue': 8350.0, 'unit': 'K', 'net_profit': 798.47}]","[{'period': ""Q2 '23"", 'revenue': 2370.0, 'unit': 'K', 'net_profit': -434.79}, {'period': ""Q1 '23"", 'revenue': 2920.0, 'unit': 'K', 'net_profit': 287.61}, {'period': ""Q4 '22"", 'revenue': 2670.0, 'unit': 'K', 'net_profit': 134.19}, {'period': ""Q3 '22"", 'revenue': 3980.0, 'unit': 'K', 'net_profit': 867.56}, {'period': ""Q2 '22"", 'revenue': 2890.0, 'unit': 'K', 'net_profit': 66.25}, {'period': ""Q1 '22"", 'revenue': 3320.0, 'unit': 'K', 'net_profit': 348.82}]",0.52,0.51,303155338,24677364,21491260,263322318,3186104,6366581,79550,15124679,6295335,0.6602852257000008,-0.14056403711396237,-0.11864406779661009,"[1, 1]","['2022-04-29', '2022-04-29']",__nan__,0.8686052494975365
876,CNOB,ConnectOne Bancorp Inc. Common Stock,"ConnectOne Bancorp, Inc. operates as the bank holding company for ConnectOne Bank that provides commercial banking products and services for small and mid-sized businesses, local professionals, and individuals in the Northern New Jersey and New York Metropolitan area, and South Florida market. The company offers personal and business checking, retirement, money market, and time and savings accounts. It also provides consumer and commercial business loans on a secured and unsecured basis; revolving lines of credit; commercial mortgage loans; residential mortgages on primary and secondary residences; home equity loans; bridge loans; other personal purpose loans; and commercial construction and real estate loans. In addition, the company offers check cards, ATM cards, credit cards, wire transfers, access to automated teller services, Internet banking, treasury direct, automated clearing house origination, mobile banking by phone, safe deposit boxes, and remote deposit capture services. It operates through a network of eight banking offices in Bergen County, five banking offices in Union County, one banking office in Morris County, one office in Essex County, one office in Hudson County, one office in Monmouth County, one banking office in Manhattan in New York City, one office in Nassau County on Long Island, one in Astoria, and five branches in the Hudson Valley, as well as one financial center in West Palm Beach in Palm Beach County. The company was formerly known as Center Bancorp, Inc. and changed its name to ConnectOne Bancorp, Inc. in July 2014. ConnectOne Bancorp, Inc. was incorporated in 1982 and is headquartered in Englewood Cliffs, New Jersey.",Mr. Frank S. Sorrentino III,Banks - Regional,22.515,USD,863907305,https://images.financialmodelingprep.com/symbol/CNOB.png,206219,13.01,-0.565,110680,122899000,87003000,"[{'period': '2023', 'revenue': 269.11, 'unit': 'M', 'net_profit': 87.0}, {'period': '2022', 'revenue': 315.36, 'unit': 'M', 'net_profit': 125.21}, {'period': '2021', 'revenue': 277.89, 'unit': 'M', 'net_profit': 130.35}, {'period': '2020', 'revenue': 252.39, 'unit': 'M', 'net_profit': 71.29}]","[{'period': ""Q3 '24"", 'revenue': 65.62, 'unit': 'M', 'net_profit': 17.16}, {'period': ""Q2 '24"", 'revenue': 134.41, 'unit': 'M', 'net_profit': 19.06}, {'period': ""Q1 '24"", 'revenue': 133.46, 'unit': 'M', 'net_profit': 17.2}, {'period': ""Q4 '23"", 'revenue': 133.17, 'unit': 'M', 'net_profit': 19.27}, {'period': ""Q3 '23"", 'revenue': 65.92, 'unit': 'M', 'net_profit': 21.41}, {'period': ""Q2 '23"", 'revenue': 67.28, 'unit': 'M', 'net_profit': 21.39}]",2.07,2.07,9855603000,291822000,859876000,8638983000,0,635726000,13171000,242714000,85458000,-0.30475980358880367,-0.30514890864221195,-0.31683168316831684,"[0.18, 0.3]","['2024-11-15', '1994-04-12']",__nan__,0.8765554984306896
877,CNSL,Consolidated Communications Holdings Inc. Common Stock,"Consolidated Communications Holdings, Inc., together with its subsidiaries, provides broadband and business communication solutions for consumer, commercial, and carrier channels in the United States. It offers high-speed broadband Internet access and voice over Internet protocol (VoIP) phone services; commercial data connectivity services in various markets, including Ethernet services, private line data services, software defined wide area network, and multi-protocol label switching services; networking services; cloud-based services; data center and disaster recovery solutions; and wholesale services to regional and national interexchange, and wireless carriers comprising cellular backhaul and other fiber transport solutions. The company also provides voice services, such as local phone and long-distance services; and sells business equipment, as well as offers related hardware and maintenance support, video, and other miscellaneous services. In addition, it offers video services, which consist of high-definition television, digital video recorders (DVR), and/or a whole home DVR; and on-demand streaming TV services that provide endless entertainment options. Further, the company provides network access services that include interstate and intrastate switched access, network special access, and end user access; and telephone directory publishing, video advertising, billing and support, and other miscellaneous services. Consolidated Communications Holdings, Inc. was founded in 1894 and is headquartered in Mattoon, Illinois.",Mr. C. Robert Udell Jr.,Telecommunications Services,4.72,USD,559168960,https://images.financialmodelingprep.com/symbol/CNSL.png,949562,-2.31,0,0,175458000,-250514000,"[{'period': '2023', 'revenue': 1110.0, 'unit': 'M', 'net_profit': -250.51}, {'period': '2022', 'revenue': 1190.0, 'unit': 'M', 'net_profit': -177.7}, {'period': '2021', 'revenue': 1280.0, 'unit': 'M', 'net_profit': -106.69}, {'period': '2020', 'revenue': 1300.0, 'unit': 'M', 'net_profit': 36.98}]","[{'period': ""Q3 '24"", 'revenue': 271.09, 'unit': 'M', 'net_profit': -49.07}, {'period': ""Q2 '24"", 'revenue': 268.71, 'unit': 'M', 'net_profit': -54.97}, {'period': ""Q1 '24"", 'revenue': 274.68, 'unit': 'M', 'net_profit': -35.5}, {'period': ""Q4 '23"", 'revenue': 275.18, 'unit': 'M', 'net_profit': -47.3}, {'period': ""Q3 '23"", 'revenue': 283.65, 'unit': 'M', 'net_profit': -69.16}, {'period': ""Q2 '23"", 'revenue': 275.16, 'unit': 'M', 'net_profit': -108.25}]",-2.6,-2.6,3628426000,256154999,4765000,2849062001,124074000,6027000,317245000,4765000,-400448000,-0.5069299251365752,-0.40972628640885966,-0.6352201257861635,"[0.38738, 0.4089]","['2019-04-12', '2005-10-12']",__nan__,0.7852060372734624
878,CNSP,CNS Pharmaceuticals Inc. Common Stock,"CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.","Mr. John Michael Climaco Esq., J.D.",Biotechnology,0.1103,USD,6340783,https://images.financialmodelingprep.com/symbol/CNSP.png,21762750,0,-0.0085,46641840,-18860974,-18851226,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.85}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.27}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.5}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.46}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.61}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.53}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.54}, {'period': ""Q4 '23"", 'revenue': 0.00636, 'unit': 'M', 'net_profit': -5.38}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.52}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.02}]",-251.35,-250.19,1700853,1591170,548721,6132968,0,0,6132968,548721,-14143932,-0.23635136287588532,-0.23419278631443197,0.5518249736996951,__nan__,__nan__,__nan__,3.605818962602882
879,CNST,Constellation Pharmaceuticals Inc. Common Stock,"Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.",Mr. Jigar Raythatha,Biotechnology,33.99,USD,0,https://images.financialmodelingprep.com/symbol/CNST.png,1573175,0,0,1269201,-122812000,-126357000,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -126.36}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -85.55}, {'period': '2018', 'revenue': 0.0, 'unit': 'M', 'net_profit': -59.92}, {'period': '2017', 'revenue': 0.0, 'unit': 'M', 'net_profit': -35.38}]","[{'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -40.07}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -37.38}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -33.78}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -29.75}, {'period': ""Q1 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -25.44}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -24.21}]",-4.49,-4.49,441854000,428609000,421448000,31130000,0,257755000,30548000,163693000,-112370000,-0.48587468089482533,-0.4769959088252484,-0.4769736842105264,__nan__,__nan__,__nan__,0.07045313610378089
880,CNTB,Connect Biopharma Holdings Limited American Depositary Shares,"Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.",Dr. Barry D. Quart Pharm.D.,Biotechnology,1.1786,USD,65122402,https://images.financialmodelingprep.com/symbol/CNTB.png,29351,-3.02,0.0186,5069,-58372000,-59503000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -59.5}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -116.42}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -205.21}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -120.3}]","[{'period': ""Q2 '24"", 'revenue': 12.06, 'unit': 'M', 'net_profit': 3.82}, {'period': ""Q1 '24"", 'revenue': 12.06, 'unit': 'M', 'net_profit': 3.82}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -14.81}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -15.23}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.58}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -15.43}]",-1.08,-1.08,125892000,120971000,118653000,24849000,51000,0,24264000,106007000,-48224000,0.47556834624621547,0.48887256952262487,0.9255172413793104,__nan__,__nan__,__nan__,0.1973834715470403
881,CNTG,Centogene N.V. Common Shares,"Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.",Ms. Kim  Stratton,Medical - Diagnostics & Research,0.325,USD,9425033,https://images.financialmodelingprep.com/symbol/CNTG.png,0,-0.23,,0,-30867042,-34803667,"[{'period': '2023', 'revenue': 47.54, 'unit': 'M', 'net_profit': -34.8}, {'period': '2022', 'revenue': 47.47, 'unit': 'M', 'net_profit': -38.7}, {'period': '2021', 'revenue': 189.92, 'unit': 'M', 'net_profit': -46.85}, {'period': '2020', 'revenue': 128.38, 'unit': 'M', 'net_profit': -21.38}]","[{'period': ""Q3 '23"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}, {'period': ""Q2 '23"", 'revenue': 12.31, 'unit': 'M', 'net_profit': -12.23}, {'period': ""Q1 '23"", 'revenue': 12.31, 'unit': 'M', 'net_profit': -12.23}, {'period': ""Q4 '22"", 'revenue': 13.04, 'unit': 'M', 'net_profit': -7.82}, {'period': ""Q3 '22"", 'revenue': 13.04, 'unit': 'M', 'net_profit': -7.82}, {'period': ""Q2 '22"", 'revenue': 11.2, 'unit': 'M', 'net_profit': -11.89}]",-1.24,-1.24,77218611,44055292,19114746,96815755,19415000,3585954,43401753,19114746,-39194774,-0.1871026074917314,0.10075014856729453,0.13888888888888887,__nan__,__nan__,__nan__,1.2537878336091801
882,CNTY,Century Casinos Inc. Common Stock,"Century Casinos, Inc. operates as a casino entertainment company in the United States, Canada, and Poland. The company develops and operates gaming establishments, as well as related lodging, restaurant, horse racing, and entertainment facilities. As of March 8, 2022, it operated two ship-based casinos. The company was founded in 1992 and is based in Colorado Springs, Colorado.",Dr. Erwin  Haitzmann,"Gambling, Resorts & Casinos",3.05,USD,93581930,https://images.financialmodelingprep.com/symbol/CNTY.png,101225,-1.26,-0.11,49505,115360000,-28198000,"[{'period': '2023', 'revenue': 550.21, 'unit': 'M', 'net_profit': -28.2}, {'period': '2022', 'revenue': 430.53, 'unit': 'M', 'net_profit': 13.67}, {'period': '2021', 'revenue': 388.51, 'unit': 'M', 'net_profit': 20.62}, {'period': '2020', 'revenue': 304.27, 'unit': 'M', 'net_profit': -48.14}]","[{'period': ""Q3 '24"", 'revenue': 155.7, 'unit': 'M', 'net_profit': -8.12}, {'period': ""Q2 '24"", 'revenue': 146.44, 'unit': 'M', 'net_profit': -41.61}, {'period': ""Q1 '24"", 'revenue': 136.02, 'unit': 'M', 'net_profit': -13.54}, {'period': ""Q4 '23"", 'revenue': 143.76, 'unit': 'M', 'net_profit': -10.82}, {'period': ""Q3 '23"", 'revenue': 161.18, 'unit': 'M', 'net_profit': -14.18}, {'period': ""Q2 '23"", 'revenue': 136.76, 'unit': 'M', 'net_profit': -1.96}]",-0.93,-0.93,1359662000,207017000,171327000,1145221000,18253000,0,93619000,171327000,-33846000,0.1205113012733966,-3.0627651792245794,-3.0217391304347827,__nan__,__nan__,__nan__,0.8422835969527721
883,CNXC,Concentrix Corporation Common Stock,"Concentrix Corporation provides technology-infused customer experience (CX) solutions worldwide. The company provides CX process optimization, technology innovation, front- and back-office automation, analytics, and business transformation services. It also offers customer lifecycle management; customer experience/user experience strategy and design; digital transformation; and voice of the customer and analytics solutions. The company's clients include consumer electronics, technology, e-commerce, and health insurance companies, as well as global IPOs, social brands, and banks. Concentrix Corporation was incorporated in 2009 and is based in Fremont, California.",Mr. Christopher A. Caldwell,Information Technology Services,46.18,USD,2993327566,https://images.financialmodelingprep.com/symbol/CNXC.png,711501,15.39,0.19,364878,971971000,313842000,"[{'period': '2023', 'revenue': 7110.0, 'unit': 'M', 'net_profit': 313.84}, {'period': '2022', 'revenue': 6320.0, 'unit': 'M', 'net_profit': 435.05}, {'period': '2021', 'revenue': 5590.0, 'unit': 'M', 'net_profit': 405.58}, {'period': '2020', 'revenue': 4720.0, 'unit': 'M', 'net_profit': 164.81}]","[{'period': ""Q3 '24"", 'revenue': 2390.0, 'unit': 'M', 'net_profit': 16.63}, {'period': ""Q2 '24"", 'revenue': 2380.0, 'unit': 'M', 'net_profit': 66.83}, {'period': ""Q1 '24"", 'revenue': 2400.0, 'unit': 'M', 'net_profit': 52.1}, {'period': ""Q4 '23"", 'revenue': 2230.0, 'unit': 'M', 'net_profit': 69.49}, {'period': ""Q3 '23"", 'revenue': 1630.0, 'unit': 'M', 'net_profit': 77.64}, {'period': ""Q2 '23"", 'revenue': 1610.0, 'unit': 'M', 'net_profit': 78.85}]",5.72,5.7,12491827000,2858649000,295336000,8348533000,1888890000,0,2074039000,295336000,497476000,-0.009290724768267002,-0.278605398472356,-0.3141486810551559,"[0.33275, 0.25]","['2024-10-25', '2021-10-21']",__nan__,0.6683196140964809
884,CNXN,PC Connection Inc. Common Stock,"PC Connection, Inc., together with its subsidiaries, provides various information technology (IT) solutions. The company operates through three segments: Business Solutions, Enterprise Solutions, and Public Sector Solutions. It offers IT products, including computer systems, data center solutions, software and peripheral equipment, networking communications, and other products and accessories, as well as provides services related to design, configuration, and implementation of IT solutions. The company markets its products and services through its websites comprising connection.com, connection.com/enterprise, connection.com/publicsector, and macconnection.com. It serves small to medium-sized businesses (SMBs) that include small office/home office customers; government and educational institutions; and medium-to-large corporate accounts through outbound telemarketing and field sales, and marketing programs targeted to specific customer populations, as well as through digital, web, and print media advertising. The company was founded in 1982 and is headquartered in Merrimack, New Hampshire.",Mr. Timothy J. McGrath,Technology Distributors,69.48,USD,1826594460,https://images.financialmodelingprep.com/symbol/CNXN.png,70974,20.44,-0.09,16272,118223000,83271000,"[{'period': '2023', 'revenue': 2850.0, 'unit': 'M', 'net_profit': 83.27}, {'period': '2022', 'revenue': 3120.0, 'unit': 'M', 'net_profit': 89.22}, {'period': '2021', 'revenue': 2890.0, 'unit': 'M', 'net_profit': 69.91}, {'period': '2020', 'revenue': 2590.0, 'unit': 'M', 'net_profit': 55.77}]","[{'period': ""Q3 '24"", 'revenue': 724.72, 'unit': 'M', 'net_profit': 27.06}, {'period': ""Q2 '24"", 'revenue': 736.48, 'unit': 'M', 'net_profit': 26.16}, {'period': ""Q1 '24"", 'revenue': 632.02, 'unit': 'M', 'net_profit': 13.15}, {'period': ""Q4 '23"", 'revenue': 696.47, 'unit': 'M', 'net_profit': 23.78}, {'period': ""Q3 '23"", 'revenue': 693.09, 'unit': 'M', 'net_profit': 25.6}, {'period': ""Q2 '23"", 'revenue': 733.55, 'unit': 'M', 'net_profit': 19.7}]",3.17,3.15,1188381000,1048638999,297186000,347614000,611182000,0,327965000,144954000,188359000,-0.10795291632083302,-0.06666741389165985,-0.06764705882352941,"[0.1, 0.4]","['2024-11-12', '2011-11-22']",__nan__,0.2925105668973166
885,COCP,Cocrystal Pharma Inc. Common Stock,"Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.",Dr. Sam  Lee Ph.D.,Biotechnology,2.37,USD,24111906,https://images.financialmodelingprep.com/symbol/COCP.png,42751,-1.29,-0.03,10343,-19372000,-17984000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.98}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -38.84}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.19}, {'period': '2020', 'revenue': 2.01, 'unit': 'M', 'net_profit': -9.66}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.94}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.34}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.96}, {'period': ""Q4 '23"", 'revenue': 0.14400000000000002, 'unit': 'M', 'net_profit': -4.46}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.17}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.17}]",-0.0019,-0.0019,31259000,29091000,26353000,4875000,890000,0,3262000,26353000,-14784000,0.4961375399901163,0.5370317930235552,0.999601677148847,__nan__,__nan__,__nan__,0.15595508493553856
886,CODA,Coda Octopus Group Inc. Common stock,"Coda Octopus Group, Inc., together with its subsidiaries, develops and sells underwater technologies and equipment for 3D imaging, mapping, defense, and survey applications in the Americas, Europe, Australia, Asia, the Middle East, and Africa. The company operates through two segments, Marine Engineering Business and Marine Technology Business. It sells technology solutions to the subsea and underwater markets. The company's solutions include geophysical systems, a geophysical data acquisition systems, processing, and analysis software that are used primarily by survey companies, offshore renewable companies, research institutions, and salvage companies; GNSS-aided navigation systems; Echoscope and Echoscope PIPE used for real time monitoring of cable installations for offshore wind projects; and diver augmented vision display system. It offers CodaOctopus GeoSurvey products, such as hardware and software solutions for field acquisition of sidescan sonar and sub-bottom profiler; and CodaOctopus DA4G productivity suite of software that automates the tasks of analyzing, annotating, and mosaicing complex data sets. It markets its products under the CodaOctopus brand name. Coda Octopus Group, Inc. was founded in 1994 and is headquartered in Orlando, Florida.","Ms. Annmarie  Gayle LL.B, LLM",Aerospace & Defense,8.2688,USD,92573350,https://images.financialmodelingprep.com/symbol/CODA.png,47588,31.8,0.0988,66093,4088762,3124149,"[{'period': '2023', 'revenue': 19.35, 'unit': 'M', 'net_profit': 3.12}, {'period': '2022', 'revenue': 22.23, 'unit': 'M', 'net_profit': 4.3}, {'period': '2021', 'revenue': 21.33, 'unit': 'M', 'net_profit': 4.95}, {'period': '2020', 'revenue': 20.04, 'unit': 'M', 'net_profit': 3.34}]","[{'period': ""Q3 '24"", 'revenue': 5.48, 'unit': 'M', 'net_profit': 1.27}, {'period': ""Q2 '24"", 'revenue': 5.32, 'unit': 'M', 'net_profit': 1.42}, {'period': ""Q1 '24"", 'revenue': 4460.0, 'unit': 'K', 'net_profit': 629.89}, {'period': ""Q4 '23"", 'revenue': 3560.0, 'unit': 'K', 'net_profit': -320.96}, {'period': ""Q3 '23"", 'revenue': 4.89, 'unit': 'M', 'net_profit': 1.04}, {'period': ""Q2 '23"", 'revenue': 5.3, 'unit': 'M', 'net_profit': 1.01}]",0.28,0.28,51841516,40888087,24448841,3412750,4336957,0,3279368,24448841,259536,-0.28801856518248176,-0.27365996771614387,-0.3,__nan__,__nan__,__nan__,0.06583044369304324
887,CODX,Co-Diagnostics Inc. Common Stock,"Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.",Mr. Dwight H. Egan,Medical - Devices,0.82,USD,26182436,https://images.financialmodelingprep.com/symbol/CODX.png,175738,-0.59,-0.18,324040,-41475760,-35332865,"[{'period': '2023', 'revenue': 6.81, 'unit': 'M', 'net_profit': -35.33}, {'period': '2022', 'revenue': 34.22, 'unit': 'M', 'net_profit': -14.24}, {'period': '2021', 'revenue': 97.89, 'unit': 'M', 'net_profit': 36.66}, {'period': '2020', 'revenue': 74.55, 'unit': 'M', 'net_profit': 42.48}]","[{'period': ""Q3 '24"", 'revenue': 0.64114, 'unit': 'M', 'net_profit': -9.7}, {'period': ""Q2 '24"", 'revenue': 0.1611, 'unit': 'M', 'net_profit': -7.6}, {'period': ""Q1 '24"", 'revenue': 0.25275000000000003, 'unit': 'M', 'net_profit': -9.31}, {'period': ""Q4 '23"", 'revenue': 3.56, 'unit': 'M', 'net_profit': -14.68}, {'period': ""Q3 '23"", 'revenue': 2.46, 'unit': 'M', 'net_profit': -5.98}, {'period': ""Q2 '23"", 'revenue': 0.19781, 'unit': 'M', 'net_profit': -8.92}]",-1.2,-1.2,95320660,62141108,58548388,9307045,330881,773382,5747570,14916878,-23447171,-3.0234239986465634,-1.4815456591607579,-1.6666666666666665,__nan__,__nan__,__nan__,0.09763932603907695
888,COFS,ChoiceOne Financial Services Inc. Common Stock,"ChoiceOne Financial Services, Inc. operates as the bank holding company for ChoiceOne Bank that provides community banking services to corporations, partnerships, and individuals in Michigan. The company offers various deposit products, including time, savings, and demand deposits, safe deposit, and automated transaction machine services. It also provides commercial loans, such as business, industry, agricultural, construction, inventory, and real estate loans; and consumer loans comprising direct and indirect loans to consumers and purchasers of residential and real properties. In addition, the company offers safe deposit and automated transaction machine services; and alternative investment products, including annuities and mutual funds, as well as sells insurance policies, such as life and health for commercial and consumer clients. It operates 32 full-service offices in Kent, Muskegon, Newaygo, and Ottawa, Lapeer, Macomb, and St. Clair counties, Michigan. The company also operates three loan production offices. ChoiceOne Financial Services, Inc. was founded in 1898 and is headquartered in Sparta, Michigan.",Mr. Kelly J. Potes CFP,Banks - Regional,33.68,USD,301692978,https://images.financialmodelingprep.com/symbol/COFS.png,31488,10.66,-0.73,13872,0,21261000,"[{'period': '2023', 'revenue': 80.79, 'unit': 'M', 'net_profit': 21.26}, {'period': '2022', 'revenue': 81.39, 'unit': 'M', 'net_profit': 23.64}, {'period': '2021', 'revenue': 79.83, 'unit': 'M', 'net_profit': 22.04}, {'period': '2020', 'revenue': 73.77, 'unit': 'M', 'net_profit': 15.61}]","[{'period': ""Q3 '24"", 'revenue': 25.11, 'unit': 'M', 'net_profit': 7.35}, {'period': ""Q2 '24"", 'revenue': 34.1, 'unit': 'M', 'net_profit': 6.59}, {'period': ""Q1 '24"", 'revenue': 32.45, 'unit': 'M', 'net_profit': 5.63}, {'period': ""Q4 '23"", 'revenue': 31.8, 'unit': 'M', 'net_profit': 5.29}, {'period': ""Q3 '23"", 'revenue': 19.93, 'unit': 'M', 'net_profit': 5.12}, {'period': ""Q2 '23"", 'revenue': 19.58, 'unit': 'M', 'net_profit': 5.21}]",2.82,2.81,2576706000,55433000,569681000,2381072000,0,930062000,0,55433000,42248000,-1,-0.10063451776649746,-0.10476190476190479,"[0.28, 0.17001]","['2024-12-13', '2001-09-11']",__nan__,0.9240759326054272
889,COGT,Cogent Biosciences Inc. Common Stock,"Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.",Mr. Andrew R. Robbins M.B.A.,Biotechnology,8.31,USD,917939220,https://images.financialmodelingprep.com/symbol/COGT.png,1433117,-3.35,0.25,350957,-205860000,-192410000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -192.41}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -132.64}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -71.81}, {'period': '2020', 'revenue': 7.87, 'unit': 'M', 'net_profit': -66.45}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -70.63}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -58.95}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -58.35}, {'period': ""Q4 '23"", 'revenue': 5.59, 'unit': 'M', 'net_profit': -54.37}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -55.38}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -44.08}]",-2.42,-2.42,313437000,270771000,265710000,55635000,0,7460000,38168000,53229000,-156420000,-0.5321182170686871,-0.45058540593925045,-0.07079646017699122,__nan__,__nan__,__nan__,0.17749978464571828
890,COHR,Coherent Inc. Common Stock,"Coherent, Inc. provides lasers, laser-based technologies, and laser-based system solutions for a range of commercial, industrial, and scientific research applications. It operates in two segments, Original Equipment Manufacturers (OEM) Laser Sources and Industrial Lasers & Systems. The company designs, manufactures, markets, and services lasers, laser tools, precision optics, and related accessories; and laser measurement and control products. Its products are used for applications in microelectronics, materials processing, OEM components and instrumentation, and scientific research and government programs. The company markets its products through a direct sales force in the United States, as well as through direct sales personnel and independent representatives internationally. Coherent, Inc. was founded in 1966 and is headquartered in Santa Clara, California. As of July 1, 2022, Coherent, Inc. operates as a subsidiary of II-VI Incorporated.",Mr. James Robert Anderson,"Hardware, Equipment & Parts",99.03,USD,16117428897,https://images.financialmodelingprep.com/symbol/COHR.png,2397596,-80.51,-1.93,1223150,682936000,-279511000,"[{'period': '2024', 'revenue': 4710.0, 'unit': 'M', 'net_profit': -279.51}, {'period': '2023', 'revenue': 5160.0, 'unit': 'M', 'net_profit': -259.46}, {'period': '2022', 'revenue': 3320.0, 'unit': 'M', 'net_profit': 234.76}, {'period': '2021', 'revenue': 3110.0, 'unit': 'M', 'net_profit': 297.55}]","[{'period': ""Q1 '25"", 'revenue': 1350.0, 'unit': 'M', 'net_profit': 26.0}, {'period': ""Q4 '24"", 'revenue': 1310.0, 'unit': 'M', 'net_profit': -48.44}, {'period': ""Q3 '24"", 'revenue': 1210.0, 'unit': 'M', 'net_profit': -13.19}, {'period': ""Q2 '24"", 'revenue': 1130.0, 'unit': 'M', 'net_profit': -26.99}, {'period': ""Q1 '24"", 'revenue': 1050.0, 'unit': 'M', 'net_profit': -67.0}, {'period': ""Q4 '23"", 'revenue': 1210.0, 'unit': 'M', 'net_profit': -178.23}]",-1.84,-1.84,14488634000,3660099000,926033000,6542355000,848542000,0,1343767000,926033000,198915000,0.11408627392124972,-0.07728803891188554,0.026455026455026363,"[1, 1]","['2012-12-17', '2012-12-17']",__nan__,0.4515508501353544
891,COHU,Cohu Inc. Common Stock,"Cohu, Inc., through its subsidiaries, provides semiconductor test equipment and services in China, the United States, Taiwan, Malaysia, the Philippines, and internationally. The company supplies semiconductor test and inspection handlers, micro-electromechanical system (MEMS) test modules, test contactors, thermal sub-systems, and semiconductor automated test equipment for semiconductor and electronics manufacturers, and test subcontractors. It also provides semiconductor automated test equipment for wafer level and device package testing; various test handlers, including pick-and-place, turret, gravity, strip, and MEMS and thermal sub-systems; interface products comprising test contactors, and probe heads and pins; spares and kits; various parts and labor warranties on test and handling systems, and instruments; and training on the maintenance and operation of its systems, as well as application, data management software, and consulting services on its products. In addition, the company offers data analytics product that includes DI-Core, a software suite used to optimize Cohu equipment performance, which provides real-time online performance monitoring and process control. It markets its products through direct sales force and independent sales representatives. The company was formerly known as Cohu Electronics, Inc. and changed its name to Cohu, Inc. in 1972. Cohu, Inc. was incorporated in 1947 and is headquartered in Poway, California.",Dr. Luis Antonio Muller Ph.D.,Semiconductors,27.575,USD,1285372778,https://images.financialmodelingprep.com/symbol/COHU.png,308509,-25.07,0.135,103483,98942000,28156000,"[{'period': '2023', 'revenue': 636.32, 'unit': 'M', 'net_profit': 28.16}, {'period': '2022', 'revenue': 812.77, 'unit': 'M', 'net_profit': 96.85}, {'period': '2021', 'revenue': 887.21, 'unit': 'M', 'net_profit': 167.32}, {'period': '2020', 'revenue': 636.01, 'unit': 'M', 'net_profit': -13.84}]","[{'period': ""Q3 '24"", 'revenue': 95.34, 'unit': 'M', 'net_profit': -18.06}, {'period': ""Q2 '24"", 'revenue': 104.7, 'unit': 'M', 'net_profit': -15.77}, {'period': ""Q1 '24"", 'revenue': 107.61, 'unit': 'M', 'net_profit': -14.63}, {'period': ""Q4 '23"", 'revenue': 137.23, 'unit': 'M', 'net_profit': -2.03}, {'period': ""Q3 '23"", 'revenue': 150.8, 'unit': 'M', 'net_profit': 3.92}, {'period': ""Q2 '23"", 'revenue': 168.92, 'unit': 'M', 'net_profit': 10.58}]",0.59,0.59,1150352000,638818000,335698000,200182000,124624000,0,103421000,245524000,85417000,-0.44715256358678646,-0.709273389986267,-0.7064676616915423,"[0.06, 0.4032]","['2020-02-24', '1984-11-29']",__nan__,0.17401803969567575
892,COIN,Coinbase Global Inc. Class A Common Stock,"Coinbase Global, Inc. provides financial infrastructure and technology for the cryptoeconomy in the United States and internationally. The company offers the primary financial account in the cryptoeconomy for retailers; a marketplace with a pool of liquidity for transacting in crypto assets for institutions; and technology and services that enable ecosystem partners to build crypto-based applications and securely accept crypto assets as payment. Coinbase Global, Inc. was founded in 2012 and is based in Wilmington, Delaware.",Mr. Brian  Armstrong,Software - Application,269.05,USD,67356682836,https://images.financialmodelingprep.com/symbol/COIN.png,13284872,45.6,-18.71,6070067,25212000,94871000,"[{'period': '2023', 'revenue': 3110.0, 'unit': 'M', 'net_profit': 94.87}, {'period': '2022', 'revenue': 3.19, 'unit': 'B', 'net_profit': -2.62}, {'period': '2021', 'revenue': 7.84, 'unit': 'B', 'net_profit': 3.62}, {'period': '2020', 'revenue': 1280.0, 'unit': 'M', 'net_profit': 322.32}]","[{'period': ""Q3 '24"", 'revenue': 1130.0, 'unit': 'M', 'net_profit': 75.5}, {'period': ""Q2 '24"", 'revenue': 1380.0, 'unit': 'M', 'net_profit': 36.15}, {'period': ""Q1 '24"", 'revenue': 1.45, 'unit': 'B', 'net_profit': 1.18}, {'period': ""Q4 '23"", 'revenue': 953.79, 'unit': 'M', 'net_profit': 273.44}, {'period': ""Q3 '23"", 'revenue': 674.15, 'unit': 'M', 'net_profit': -2.27}, {'period': ""Q2 '23"", 'revenue': 707.91, 'unit': 'M', 'net_profit': -97.41}]",0.4,0.37,206982953000,203466531000,10286224000,200701304000,425441000,792970000,197714131000,5139351000,859749000,1.0089353178254132,1.0361420355214521,1.0338696020321763,__nan__,__nan__,__nan__,0.9696513702749231
893,COKE,Coca-Cola Consolidated Inc. Common Stock,"Coca-Cola Consolidated, Inc., together with its subsidiaries, manufactures, markets, and distributes nonalcoholic beverages primarily products of The Coca-Cola Company in the United States. The company offers sparkling beverages, such as carbonated beverages; and still beverages, including energy products, as well as noncarbonated beverages comprising bottled water, ready to drink coffee and tea, enhanced water, juices, and sports drinks. It also sells its products to other Coca-Cola bottlers; and post-mix products that are dispensed through equipment, which mixes the fountain syrup with carbonated or still water enabling fountain retailers to sell finished products to consumers in cups or glasses. In addition, the company distributes products for various other beverage brands that include Dr Pepper and Monster Energy. It sells and distributes its products directly to grocery stores, mass merchandise stores, club stores, convenience stores, and drug stores; and restaurants, schools, amusement parks, and recreational facilities, as well as through vending machine outlets. The company was formerly known as Coca-Cola Bottling Co. Consolidated and changed its name to Coca-Cola Consolidated, Inc. in January 2019. Coca-Cola Consolidated, Inc. was incorporated in 1980 and is headquartered in Charlotte, North Carolina.",Mr. J. Frank Harrison III,Beverages - Non-Alcoholic,1313.12,USD,11503821495,https://images.financialmodelingprep.com/symbol/COKE.png,0,22.9,-1.87,14783,898621000,408375000,"[{'period': '2023', 'revenue': 6650.0, 'unit': 'M', 'net_profit': 408.38}, {'period': '2022', 'revenue': 6200.0, 'unit': 'M', 'net_profit': 430.16}, {'period': '2021', 'revenue': 5560.0, 'unit': 'M', 'net_profit': 189.58}, {'period': '2020', 'revenue': 5010.0, 'unit': 'M', 'net_profit': 172.49}]","[{'period': ""Q3 '24"", 'revenue': 1770.0, 'unit': 'M', 'net_profit': 115.62}, {'period': ""Q2 '24"", 'revenue': 1800.0, 'unit': 'M', 'net_profit': 172.81}, {'period': ""Q1 '24"", 'revenue': 1590.0, 'unit': 'M', 'net_profit': 165.74}, {'period': ""Q4 '23"", 'revenue': 1630.0, 'unit': 'M', 'net_profit': 75.84}, {'period': ""Q3 '23"", 'revenue': 1710.0, 'unit': 'M', 'net_profit': 92.09}, {'period': ""Q2 '23"", 'revenue': 1740.0, 'unit': 'M', 'net_profit': 122.32}]",43.56,43.48,4288942000,1705128000,635269000,2853344000,659342000,0,1091334000,635269000,528386000,0.16481802898107378,-0.05063953245086689,-0.050566695727986055,"[2.5, 0.14]","['2024-10-25', '1985-02-25']",__nan__,0.6652792227080712
894,COLB,Columbia Banking System Inc. Common Stock,"Columbia Banking System, Inc. operates as the bank holding company for Columbia State Bank that provides a range of banking services to small and medium-sized businesses, professionals, and individuals in the United States. It offers personal banking products and services, including noninterest and interest-bearing checking, savings, money market, and certificate of deposit accounts; home mortgages for purchases and refinances, home equity loans and lines of credit, and other personal loans; debit and credit cards; and digital banking services. The company also provides business banking products and services, such as checking, savings, interest-bearing money market, and certificate of deposit accounts; agricultural, asset-based, builder, and other commercial real estate loans, as well as loans guaranteed by the small business administration; and professional banking, treasury management, merchant card, and international banking services. In addition, it offers wealth management solutions that include financial planning services, such as asset allocation, net worth analysis, estate planning and preservation, education funding, and wealth transfer; long-term care, and life and disability insurance solutions; individual retirement solutions comprising retirement planning, retirement income strategies, and traditional and Roth individual retirement accounts; and business solutions, which comprise business retirement plans, key person insurance, business succession planning, and deferred compensation plans to individuals, families, and professional businesses. Further, the company provides fiduciary, investment, and administrative trust services, such as personal and special needs trusts, estate settlement, and investment agency and charitable management. It operates a network of 153 branch locations, including 68 in the state of Washington, 59 in Oregon, 15 in Idaho, and 11 in California. The company was founded in 1993 and is headquartered in Tacoma, Washington.",Mr. Clint E. Stein CPA,Banks - Regional,27.17,USD,5692957270,https://images.financialmodelingprep.com/symbol/COLB.png,1526745,11.56,-0.24,519136,0,348715000,"[{'period': '2023', 'revenue': 1780.0, 'unit': 'M', 'net_profit': 348.71}, {'period': '2022', 'revenue': 547.56, 'unit': 'M', 'net_profit': 336.75}, {'period': '2021', 'revenue': 1280.0, 'unit': 'M', 'net_profit': 420.3}, {'period': '2020', 'revenue': 1.29, 'unit': 'B', 'net_profit': -1.52}]","[{'period': ""Q3 '24"", 'revenue': 698.9, 'unit': 'M', 'net_profit': 146.18}, {'period': ""Q2 '24"", 'revenue': 743.48, 'unit': 'M', 'net_profit': 120.14}, {'period': ""Q1 '24"", 'revenue': 733.34, 'unit': 'M', 'net_profit': 124.08}, {'period': ""Q4 '23"", 'revenue': 757.17, 'unit': 'M', 'net_profit': 93.53}, {'period': ""Q3 '23"", 'revenue': 524.86, 'unit': 'M', 'net_profit': 135.84}, {'period': ""Q2 '23"", 'revenue': 523.65, 'unit': 'M', 'net_profit': 133.38}]",1.79,1.78,52173596000,2157434000,2157434000,47178562000,0,8909165000,0,2162534000,669840000,-1,0.03552465909630826,-0.31153846153846154,"[0.36, 0.05]","['2024-11-29', '2003-05-05']",__nan__,0.9042612665609632
895,COLI,Colicity Inc. Class A Common Stock,"Colicity Inc. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus its search on identifying a prospective target business in the technology, media, and telecommunications industries in the United States and other developed countries. Colicity Inc. was incorporated in 2020 and is based in Kirkland, Washington.",Mr. Craig O. McCaw,Shell Companies,10.07,USD,0,https://images.financialmodelingprep.com/symbol/COLI.png,158484,22.886363636363637,-0.005,7445,5648973,12442392,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 12.44}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.58}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.62}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'T', 'net_profit': 10.29}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.77}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.26}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -438.53}]",0.29,0.29,1.0434040000000024,1.012239,0.732368,22.613736,0,345.031165,0.315861,0.732368,-1300181,0,0,0,__nan__,__nan__,__nan__,21.673039397970438
896,COLIU,Colicity Inc. Units,"Colicity Inc. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus its search on identifying a prospective target business in the technology, media, and telecommunications industries in the United States and other developed countries. Colicity Inc. was incorporated in 2020 and is based in Kirkland, Washington.",Mr. Craig O. McCaw,Shell Companies,10.055,USD,0,https://images.financialmodelingprep.com/symbol/COLIU.png,39004,31.226708074534162,-0.0051,3165,5648973,12442392,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 12.44}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.58}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.62}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'T', 'net_profit': 10.29}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.77}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.26}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -438.53}]",0.29,0.29,1.0434040000000024,1.012239,0.732368,22.613736,0,345.031165,0.315861,0.732368,-1300181,0,0,0,__nan__,__nan__,__nan__,21.673039397970438
897,COLIW,Colicity Inc. Warrant,,,Shell Companies,0.001,USD,0,https://images.financialmodelingprep.com/symbol/COLIW.png,0,0,0,21647,5648973,12442392,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 12.44}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.58}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.62}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'T', 'net_profit': 10.29}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 11.77}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.26}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -438.53}]",0.29,0.29,1.0434040000000024,1.012239,0.732368,22.613736,0,345.031165,0.315861,0.732368,-1300181,0,0,0,__nan__,__nan__,__nan__,21.673039397970438
898,COLL,Collegium Pharmaceutical Inc. Common Stock,"Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.",Mr. Vikram  Karnani,Drug Manufacturers - Specialty & Generic,29.56,USD,953315912,https://images.financialmodelingprep.com/symbol/COLL.png,425675,12.63,0.94,195826,308328000,48155000,"[{'period': '2023', 'revenue': 566.77, 'unit': 'M', 'net_profit': 48.16}, {'period': '2022', 'revenue': 463.93, 'unit': 'M', 'net_profit': -25.0}, {'period': '2021', 'revenue': 276.87, 'unit': 'M', 'net_profit': 71.52}, {'period': '2020', 'revenue': 310.02, 'unit': 'M', 'net_profit': 26.75}]","[{'period': ""Q3 '24"", 'revenue': 159.3, 'unit': 'M', 'net_profit': 9.34}, {'period': ""Q2 '24"", 'revenue': 145.28, 'unit': 'M', 'net_profit': 19.61}, {'period': ""Q1 '24"", 'revenue': 144.92, 'unit': 'M', 'net_profit': 27.71}, {'period': ""Q4 '23"", 'revenue': 149.75, 'unit': 'M', 'net_profit': 31.94}, {'period': ""Q3 '23"", 'revenue': 136.71, 'unit': 'M', 'net_profit': 20.63}, {'period': ""Q2 '23"", 'revenue': 135.55, 'unit': 'M', 'net_profit': 13.01}]",1.6,1.29,1143308000,537600000,310548000,947877000,179525000,0,457915000,238947000,274288000,0.8270531000195548,2.926045916326694,3.162162162162162,__nan__,__nan__,__nan__,0.8290653087357037
899,COLM,Columbia Sportswear Company Common Stock,"Columbia Sportswear Company, together with its subsidiaries, designs, sources, markets, and distributes outdoor, active, and everyday lifestyle apparel, footwear, accessories, and equipment in the United States, Latin America, the Asia Pacific, Europe, the Middle East, Africa, and Canada. The company provides apparel, accessories, and equipment that are used in various activities, such as skiing, snowboarding, hiking, climbing, mountaineering, camping, hunting, fishing, trail running, water sports, yoga, golf, and adventure travel. It also offers footwear products that include lightweight hiking boots, trail running shoes, rugged cold weather boots for activities on snow and ice, sandals and shoes for use in water activities, and function-first fashion footwear and casual shoes for everyday use. The company sells its products under the Columbia, Mountain Hardwear, SOREL, and prAna brand names through the company owned network of branded and outlet retail stores, brand-specific e-commerce sites, and concession-based arrangements with third-parties at branded outlet and shop-in-shop retail locations, as well as through independently operated specialty outdoor and sporting goods stores, sporting goods chains, department store chains, Internet retailers, and international distributors. As of December 31, 2021, it operated approximately 455 retail stores. The company was founded in 1938 and is headquartered in Portland, Oregon.",Mr. Timothy P. Boyle,Apparel - Manufacturers,82.63,USD,4725981535,https://images.financialmodelingprep.com/symbol/COLM.png,465701,23.15,-0.47,120443,462336000,251400000,"[{'period': '2023', 'revenue': 3490.0, 'unit': 'M', 'net_profit': 251.4}, {'period': '2022', 'revenue': 3460.0, 'unit': 'M', 'net_profit': 311.44}, {'period': '2021', 'revenue': 3130.0, 'unit': 'M', 'net_profit': 354.11}, {'period': '2020', 'revenue': 2500.0, 'unit': 'M', 'net_profit': 108.01}]","[{'period': ""Q3 '24"", 'revenue': 931.77, 'unit': 'M', 'net_profit': 90.16}, {'period': ""Q2 '24"", 'revenue': 570.3, 'unit': 'M', 'net_profit': -11.74}, {'period': ""Q1 '24"", 'revenue': 770.26, 'unit': 'M', 'net_profit': 42.3}, {'period': ""Q4 '23"", 'revenue': 1060.0, 'unit': 'M', 'net_profit': 93.34}, {'period': ""Q3 '23"", 'revenue': 985.68, 'unit': 'M', 'net_profit': 103.51}, {'period': ""Q2 '23"", 'revenue': 620.93, 'unit': 'M', 'net_profit': 8.35}]",4.11,4.09,2939013000,2014685000,764504000,1000403000,423079000,961000,596627000,350319000,581690000,-0.15462888300119035,-0.19278191625995375,-0.17137096774193541,"[0.3, 0.14]","['2024-11-20', '2006-11-14']",__nan__,0.34038740216528474
900,COMM,CommScope Holding Company Inc. Common Stock,"CommScope Holding Company, Inc. provides infrastructure solutions for communications and entertainment networks. It operates through four segments: Broadband Networks (Broadband), Outdoor Wireless Networks (OWN), Venue and Campus Networks (VCN), and Home Networks (Home). The Broadband segment provides converged cable access platforms, passive optical networking products, video systems, access technologies, fiber and coaxial cables, fiber and copper connectivity products, and hardened closures to the telco and cable provider broadband market. The OWN segment provides base station antennas, radio frequency filters, tower connectivity, microwave antennas, metro cell products, cabinets, steel towers, accessories, Spectrum Access System, and Comsearch products to the macro and metro cell markets. The VCN segment offers Wi-Fi and switching, distributed antenna systems, licensed and unlicensed small cells, enterprise fiber, and copper infrastructures for campuses, venues, data centers, and buildings. The Home segment provides devices and related software, and management solutions that offer residential connectivity and services to subscribers, such as digital subscriber lines, cable modems, and telephony and data gateways; and set top boxes and software that support cable, satellite, and Internet protocol television content delivery, which include digital video recorders, high definition set top boxes, and hybrid set top devices. It offers its products and services through specialized resellers and distributors, satellite video distributors, and system integrators, as well as directly to customers in the United States, Europe, the Middle East, Africa, the Asia Pacific, the Caribbean, Latin America, and Canada. The company was formerly known as Cedar I Holding Company, Inc. and changed its name to CommScope Holding Company, Inc. in January 2011. CommScope Holding Company, Inc. was founded in 1976 and is headquartered in Hickory, North Carolina.",Mr. Charles L. Treadway,Communication Equipment,5.095,USD,1099903505,https://images.financialmodelingprep.com/symbol/COMM.png,4296237,-1.72,-0.245,1403473,519100000,-1450900000,"[{'period': '2023', 'revenue': 5.79, 'unit': 'B', 'net_profit': -1.45}, {'period': '2022', 'revenue': 9.23, 'unit': 'B', 'net_profit': -1.29}, {'period': '2021', 'revenue': 8590.0, 'unit': 'M', 'net_profit': -462.6}, {'period': '2020', 'revenue': 8440.0, 'unit': 'M', 'net_profit': -573.4}]","[{'period': ""Q3 '24"", 'revenue': 1080.0, 'unit': 'M', 'net_profit': -33.0}, {'period': ""Q2 '24"", 'revenue': 1390.0, 'unit': 'M', 'net_profit': 44.4}, {'period': ""Q1 '24"", 'revenue': 1170.0, 'unit': 'M', 'net_profit': -359.2}, {'period': ""Q4 '23"", 'revenue': 1190.0, 'unit': 'M', 'net_profit': -525.1}, {'period': ""Q3 '23"", 'revenue': 1600.0, 'unit': 'M', 'net_profit': -828.7}, {'period': ""Q2 '23"", 'revenue': 1920.0, 'unit': 'M', 'net_profit': -100.4}]",-7.17,-7.17,9371900000,2862700000,543800000,11178600000,815200000,0,1409400000,543800000,236600000,5.085580304806565,-0.12743802937291165,-0.15645161290322576,__nan__,__nan__,__nan__,1.1927784120615883
901,COMS,ComSovereign Holding Corp. Common Stock,"COMSovereign Holding Corp. provides technologically-advanced telecom solutions for network operators, mobile device carriers, governmental units, and other enterprises worldwide. The company offers packet microwave solutions that transmit broadband voice, video, and data, as well as enable service providers, government agencies, enterprises, and other organizations; and in-band full-duplex technologies that alleviate the performance limitations of the principal transmission technologies. It also provides tethered drones and aerostats for use in intelligence, surveillance, and reconnaissance, as well as communication applications for national defense and security customers; and edge compute capable small cell 4G LTE and 5G access radios. In addition, the company offers maintenance and support services, as well as other professional services, such as engineering, designing, and developing a range of network systems and system components. The company was formerly known as Drone Aviation Holding Corp. and changed its name to COMSovereign Holding Corp. in November 2019. COMSovereign Holding Corp. was incorporated in 2014 and is based in Tucson, Arizona.",Mr. David A. Knight,Telecommunications Services,0.0023,USD,6199,https://images.financialmodelingprep.com/symbol/COMS.png,2472,0,0.001,2,-74474000,-79713000,"[{'period': '2022', 'revenue': 9.88, 'unit': 'M', 'net_profit': -79.71}, {'period': '2021', 'revenue': 12.64, 'unit': 'M', 'net_profit': -155.78}, {'period': '2020', 'revenue': 9.43, 'unit': 'M', 'net_profit': -37.08}, {'period': '2019', 'revenue': 4.71, 'unit': 'M', 'net_profit': -27.55}]","[{'period': ""Q3 '23"", 'revenue': 0.25, 'unit': 'M', 'net_profit': -1.42}, {'period': ""Q2 '23"", 'revenue': 3500.0, 'unit': 'K', 'net_profit': 638.0}, {'period': ""Q1 '23"", 'revenue': 0.483, 'unit': 'M', 'net_profit': -4.93}, {'period': ""Q4 '22"", 'revenue': 1.94, 'unit': 'M', 'net_profit': -40.14}, {'period': ""Q3 '22"", 'revenue': 3.8, 'unit': 'M', 'net_profit': -3.33}, {'period': ""Q2 '22"", 'revenue': 2.09, 'unit': 'M', 'net_profit': -39.73}]",-72.04,-72.04,24918000,11982000,1868000,39919000,1776000,0,27916000,1868000,-9694000,0.4009636189602889,0.4883008839332139,0.6741893175342589,__nan__,__nan__,__nan__,1.6020146079139579
902,COMSW,ComSovereign Holding Corp. Warrants,"ComSovereign Holding Corp. designs, develops, markets, and sells technologically-advanced products for telecom network operators, mobile device carriers, and other enterprises worldwide. The company designs, manufactures, and sells microwave packet radio equipment, such as backhaul telecom radios that transmit broadband voice, video, and data, as well as enable service providers, government agencies, enterprises, and other organizations to meet their increasing bandwidth requirements rapidly and affordably; and in-band full-duplex and transpositional modulation technologies that alleviate the performance limitations of the principal transmission technologies. It also offers intelligent batteries and back-up power solutions for use in cellular towers and other radio access network infrastructures, as well as automotive, aerospace, and marine vehicles; and tethered drones and aerostats for use in intelligence, surveillance, and reconnaissance, as well as communications applications for national defense and security customers. In addition, the company is developing silicon photonic devices used in data interconnects, communication networks, and computing systems. Further, it provides maintenance and support services, as well as other professional services, such as engineering, designing, and developing a range of next-generation network systems and system components. ComSovereign Holding Corp. is based in Dallas, Texas.",Mr. David A. Knight,Telecommunications Services,0.0001,USD,257,https://images.financialmodelingprep.com/symbol/COMSW.png,0,,-0.002,9392,-74474000,-79713000,"[{'period': '2022', 'revenue': 9.88, 'unit': 'M', 'net_profit': -79.71}, {'period': '2021', 'revenue': 12.64, 'unit': 'M', 'net_profit': -155.78}, {'period': '2020', 'revenue': 9.43, 'unit': 'M', 'net_profit': -37.08}, {'period': '2019', 'revenue': 4.71, 'unit': 'M', 'net_profit': -27.55}]","[{'period': ""Q3 '23"", 'revenue': 0.25, 'unit': 'M', 'net_profit': -1.42}, {'period': ""Q2 '23"", 'revenue': 3500.0, 'unit': 'K', 'net_profit': 638.0}, {'period': ""Q1 '23"", 'revenue': 0.483, 'unit': 'M', 'net_profit': -4.93}, {'period': ""Q4 '22"", 'revenue': 1.94, 'unit': 'M', 'net_profit': -40.14}, {'period': ""Q3 '22"", 'revenue': 3.8, 'unit': 'M', 'net_profit': -3.33}, {'period': ""Q2 '22"", 'revenue': 2.09, 'unit': 'M', 'net_profit': -39.73}]",-72.04,-72.04,24918000,11982000,1868000,39919000,1776000,0,27916000,1868000,-9694000,0.4009636189602889,0.4883008839332139,0.6741893175342589,__nan__,__nan__,__nan__,1.6020146079139579
903,CONE,CyrusOne Inc Common Stock,"CyrusOne (NASDAQ: CONE) is a premier global REIT specializing in design, construction and operation of more than 50 high-performance data centers worldwide. The Company provides mission-critical facilities that ensure the continued operation of IT infrastructure for approximately 1,000 customers, including approximately 200 Fortune 1000 companies. A leader in hybrid-cloud and multi-cloud deployments, CyrusOne offers colocation, hyperscale, and build-to-suit environments that help customers enhance the strategic connection of their essential data infrastructure and support achievement of sustainability goals. CyrusOne data centers offer world-class flexibility, enabling clients to modernize, simplify, and rapidly respond to changing demand. Combining exceptional financial strength with a broad global footprint, CyrusOne provides customers with long-term stability and strategic advantage at scale.",Mr. Venkatesh Durvasula,REIT - Industrial,90.36,USD,0,https://images.financialmodelingprep.com/symbol/CONE.png,2696655,451.8,0,1325394,584200000,25300000,"[{'period': '2021', 'revenue': 1210.0, 'unit': 'M', 'net_profit': 25.3}, {'period': '2020', 'revenue': 1030.0, 'unit': 'M', 'net_profit': 41.4}, {'period': '2019', 'revenue': 981.3, 'unit': 'M', 'net_profit': 41.4}, {'period': '2018', 'revenue': 821.4, 'unit': 'M', 'net_profit': 1.2}]","[{'period': ""Q4 '21"", 'revenue': 318.4, 'unit': 'M', 'net_profit': -24.4}, {'period': ""Q3 '21"", 'revenue': 304.1, 'unit': 'M', 'net_profit': 6.7}, {'period': ""Q2 '21"", 'revenue': 284.6, 'unit': 'M', 'net_profit': 7.4}, {'period': ""Q1 '21"", 'revenue': 298.6, 'unit': 'M', 'net_profit': 18.2}, {'period': ""Q4 '20"", 'revenue': 268.4, 'unit': 'M', 'net_profit': 19.0}, {'period': ""Q3 '20"", 'revenue': 262.8, 'unit': 'M', 'net_profit': -37.3}]",0.2,0.2,7452000000,981200000,346300000,4528300000,420400000,30300000,625600000,346300000,477600000,0.07212332538080382,-0.3888888888888889,-0.4285714285714285,"[0.52, 0.16]","['2022-03-25', '2013-03-29']",__nan__,0.6076623725174449
904,CONN,Conn's Inc. Common Stock,"Conn's, Inc. operates as a specialty retailer of durable consumer goods and related services in the United States. It operates through two segments, Retail and Credit. The company's stores offer furniture and mattress, including furniture and related accessories for the living room, dining room, and bedroom, as well as flat and other mattresses; and home appliances, such as refrigerators, freezers, washers, dryers, dishwashers, and ranges. Its stores also provide consumer electronics comprising LED, OLED, QLED, 4K Ultra HD, 8K televisions, gaming products, video game consoles, and home theater and portable audio equipment; and home office products, including computers, tablets, monitors, and accessories. In addition, the company offers short- and medium-term financing to its retail customers; and product support services, which comprise next-day delivery and installation services, credit insurance products, product repair services, and repair service agreements. As of July 27, 2022, it operated approximately 160 retail locations in Alabama, Arizona, Colorado, Florida, Georgia, Louisiana, Mississippi, Nevada, New Mexico, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, and Virginia. Conn's, Inc. was founded in 1890 and is headquartered in The Woodlands, Texas.",Mr. Norman L. Miller,Specialty Retail,0.0975,USD,2426385,https://images.financialmodelingprep.com/symbol/CONN.png,504248,-0.030757097791798107,-0.0844,2348765,-36152000,-76893000,"[{'period': '2024', 'revenue': 1240.0, 'unit': 'M', 'net_profit': -76.89}, {'period': '2023', 'revenue': 1340.0, 'unit': 'M', 'net_profit': -59.29}, {'period': '2022', 'revenue': 1590.0, 'unit': 'M', 'net_profit': 108.2}, {'period': '2021', 'revenue': 1390.0, 'unit': 'M', 'net_profit': -3.14}]","[{'period': ""Q4 '24"", 'revenue': 366.08, 'unit': 'M', 'net_profit': 43.3}, {'period': ""Q3 '24"", 'revenue': 280.13, 'unit': 'M', 'net_profit': -51.3}, {'period': ""Q2 '24"", 'revenue': 306.91, 'unit': 'M', 'net_profit': -33.52}, {'period': ""Q1 '24"", 'revenue': 284.57, 'unit': 'M', 'net_profit': -35.38}, {'period': ""Q4 '23"", 'revenue': 334.88, 'unit': 'M', 'net_profit': -42.8}, {'period': ""Q3 '23"", 'revenue': 321.2, 'unit': 'M', 'net_profit': -24.84}]",-3.17,-3.17,2444042000,1204096000,70753000,1946544000,780702000,402361000,466523000,70753000,-102288000,-1.638006494423267,-0.2968528637927545,-0.2886178861788618,__nan__,__nan__,__nan__,0.7964445782846612
905,CONX,CONX Corp. Class A Common Stock,"CONX Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to focus its search on identifying a prospective target operating in the technology, media, and telecommunications industries, including wireless communications industry. CONX Corp. was incorporated in 2020 and is based in Littleton, Colorado.",Mr. Kyle Jason Kiser,Shell Companies,8.79,USD,183449937,https://images.financialmodelingprep.com/symbol/CONX.png,3363,-35.16,-0.41,7394,0,-5994501,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.99}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 24.19}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 19.36}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.12}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.37}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.17}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.3}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -920.21}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.29}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -926.47}]",-0.25,-0.25,21983432,17328,8162.000000000001,40046956,0,21966104,3991456,8162.000000000001,-1789134,1,-1.2477604025666724,-1.8620689655172415,__nan__,__nan__,__nan__,1.8216880785493366
906,CONXU,CONX Corp. Unit,"CONX Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to focus its search on identifying a prospective target operating in the technology, media, and telecommunications industries, including wireless communications industry. CONX Corp. was incorporated in 2020 and is based in Littleton, Colorado.",Mr. Kyle Jason Kiser,Shell Companies,9.01,USD,183449934,https://images.financialmodelingprep.com/symbol/CONXU.png,0,36.04,-1.71,1214,0,-5994501,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.99}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 24.19}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 19.36}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.12}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.37}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.17}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.3}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -920.21}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.29}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -926.47}]",-0.25,-0.25,21983432,17328,8162.000000000001,40046956,0,21966104,3991456,8162.000000000001,-1789134,1,-1.2477604025666724,-1.8620689655172415,__nan__,__nan__,__nan__,1.8216880785493366
907,CONXW,CONX Corp. Warrant,"CONX Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to focus its search on identifying a prospective target operating in the technology, media, and telecommunications industries, including wireless communications industry. The company was incorporated in 2020 and is based in Littleton, Colorado.",Mr. Kyle Jason Kiser,Shell Companies,0.1881,USD,221235635,https://images.financialmodelingprep.com/symbol/CONXW.png,0,0,0.0284,262090,0,-5994501,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.99}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 24.19}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 19.36}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.12}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.37}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.17}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.3}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -920.21}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.29}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -926.47}]",-0.25,-0.25,21983432,17328,8162.000000000001,40046956,0,21966104,3991456,8162.000000000001,-1789134,1,-1.2477604025666724,-1.8620689655172415,__nan__,__nan__,__nan__,1.8216880785493366
908,COOL,Corner Growth Acquisition Corp. Class A Ordinary Shares,"Corner Growth Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in Palo Alto, California.",Mr. Marvin  Tien,Shell Companies,11.1,USD,111994560,https://images.financialmodelingprep.com/symbol/COOL.png,568,-31.714285714285715,-0.1,6233,-3129840,-3489963,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.49}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 37.34}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.55}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.13}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.51}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -380.48}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 681.55}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.31}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.11}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.31}]",-0.32,-0.32,4653117,99600,21631,12682079,0,4553517,4384213,21631,-9916.00000000004,0.8552242591416561,-1.0934626995784547,-1.4210526315789473,__nan__,__nan__,__nan__,2.72550185176947
909,COOLU,Corner Growth Acquisition Corp. Unit,"Corner Growth Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in Palo Alto, California.",Mr. Marvin  Tien,Shell Companies,11.4,USD,111994558,https://images.financialmodelingprep.com/symbol/COOLU.png,509,43.67816091954023,-0.1,501,-3129840,-3489963,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.49}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 37.34}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.55}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.13}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.51}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -380.48}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 681.55}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.31}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.11}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.31}]",-0.32,-0.32,4653117,99600,21631,12682079,0,4553517,4384213,21631,-9916.00000000004,0.8552242591416561,-1.0934626995784547,-1.4210526315789473,__nan__,__nan__,__nan__,2.72550185176947
910,COOLW,Corner Growth Acquisition Corp. Warrant,"Corner Growth Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in Palo Alto, California.",Mr. Marvin  Tien,Shell Companies,0.2001,USD,2154177,https://images.financialmodelingprep.com/symbol/COOLW.png,23520,0,-0.0099,7400,-3129840,-3489963,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.49}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': 37.34}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.55}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.13}]","[{'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.51}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -380.48}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 681.55}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.31}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.11}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.31}]",-0.32,-0.32,4653117,99600,21631,12682079,0,4553517,4384213,21631,-9916.00000000004,0.8552242591416561,-1.0934626995784547,-1.4210526315789473,__nan__,__nan__,__nan__,2.72550185176947
911,COOP,Mr. Cooper Group Inc. Common Stock,"Mr. Cooper Group Inc. provides servicing, origination, and transaction-based services related to single-family residences in the United States. The company operates through two segments: Servicing and Originations. The Servicing segment performs activities for underlying mortgages, including collecting and disbursing borrower payments, investor reporting, customer service, and modifying loans. The Originations segment originates residential mortgage loans through its direct-to-consumer channel, as well as originates and purchases loans from mortgage bankers and brokers. It operates primarily under the Mr. Cooper and Xome brands. The company was formerly known as WMIH Corp. and changed its name to Mr. Cooper Group Inc. in October 2018. Mr. Cooper Group Inc. was incorporated in 2015 and is based in Coppell, Texas.",Mr. Jesse K. Bray CPA,Financial - Mortgages,92.92,USD,5945365404,https://images.financialmodelingprep.com/symbol/COOP.png,0,11.94,,0,699000000,500000000,"[{'period': '2023', 'revenue': 1790.0, 'unit': 'M', 'net_profit': 500.0}, {'period': '2022', 'revenue': 2460.0, 'unit': 'M', 'net_profit': 923.0}, {'period': '2021', 'revenue': 3.32, 'unit': 'B', 'net_profit': 1.45}, {'period': '2020', 'revenue': 3070.0, 'unit': 'M', 'net_profit': 305.0}]","[{'period': ""Q3 '24"", 'revenue': 424.0, 'unit': 'M', 'net_profit': 80.0}, {'period': ""Q2 '24"", 'revenue': 572.0, 'unit': 'M', 'net_profit': 204.0}, {'period': ""Q1 '24"", 'revenue': 722.0, 'unit': 'M', 'net_profit': 181.0}, {'period': ""Q4 '23"", 'revenue': 404.0, 'unit': 'M', 'net_profit': 46.0}, {'period': ""Q3 '23"", 'revenue': 574.0, 'unit': 'M', 'net_profit': 275.0}, {'period': ""Q2 '23"", 'revenue': 603.0, 'unit': 'M', 'net_profit': 142.0}]",7.45,7.29,14196000000,2663000000,571000000,9914000000,996000000,0,6297000000,571000000,-972000000,-0.3193768257059396,-0.4582881906825569,-0.4197819314641744,__nan__,__nan__,__nan__,0.6983657368272753
912,CORE,Core Mark Holding Co Inc Common Stock,,,,,,,,,,,,160400000,63200000,"[{'period': '2020', 'revenue': 16960.0, 'unit': 'M', 'net_profit': 63.2}, {'period': '2019', 'revenue': 16670.0, 'unit': 'M', 'net_profit': 57.7}, {'period': '2018', 'revenue': 16400.0, 'unit': 'M', 'net_profit': 45.5}, {'period': '2017', 'revenue': 15690.0, 'unit': 'M', 'net_profit': 33.5}]","[{'period': ""Q2 '21"", 'revenue': 4500.0, 'unit': 'M', 'net_profit': 15.5}, {'period': ""Q1 '21"", 'revenue': 3930.0, 'unit': 'M', 'net_profit': 8.5}, {'period': ""Q4 '20"", 'revenue': 4250.0, 'unit': 'M', 'net_profit': 19.0}, {'period': ""Q3 '20"", 'revenue': 4500.0, 'unit': 'M', 'net_profit': 23.0}, {'period': ""Q2 '20"", 'revenue': 4260.0, 'unit': 'M', 'net_profit': 16.9}, {'period': ""Q1 '20"", 'revenue': 3940.0, 'unit': 'M', 'net_profit': 4.3}]",1.4,1.4,1954700000,1337200000,22800000,1322800000,468100000,0,745800000,22800000,117100000,0.15979754157628345,0.09532062391681109,0.11999999999999993,__nan__,__nan__,__nan__,0.6767278866322198
913,CORT,Corcept Therapeutics Incorporated Common Stock,"Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.",Dr. Joseph K. Belanoff M.D.,Biotechnology,50.87,USD,5329904250,https://images.financialmodelingprep.com/symbol/CORT.png,968912,39.74,-0.79,210600,108324000,106140000,"[{'period': '2023', 'revenue': 482.38, 'unit': 'M', 'net_profit': 106.14}, {'period': '2022', 'revenue': 401.86, 'unit': 'M', 'net_profit': 101.42}, {'period': '2021', 'revenue': 365.98, 'unit': 'M', 'net_profit': 112.51}, {'period': '2020', 'revenue': 353.87, 'unit': 'M', 'net_profit': 106.01}]","[{'period': ""Q3 '24"", 'revenue': 182.55, 'unit': 'M', 'net_profit': 46.69}, {'period': ""Q2 '24"", 'revenue': 163.8, 'unit': 'M', 'net_profit': 35.49}, {'period': ""Q1 '24"", 'revenue': 146.81, 'unit': 'M', 'net_profit': 27.76}, {'period': ""Q4 '23"", 'revenue': 135.41, 'unit': 'M', 'net_profit': 31.36}, {'period': ""Q3 '23"", 'revenue': 123.6, 'unit': 'M', 'net_profit': 31.38}, {'period': ""Q2 '23"", 'revenue': 117.72, 'unit': 'M', 'net_profit': 27.53}]",1.02,0.94,621517000,458636000,368221000,114812000,41123000,57176000,104505000,135551000,126900000,-0.0382655326100467,0.04655978228716796,0.07368421052631585,__nan__,__nan__,__nan__,0.1847286558533395
914,COST,Costco Wholesale Corporation Common Stock,"Costco Wholesale Corporation, together with its subsidiaries, engages in the operation of membership warehouses in the United States, Puerto Rico, Canada, the United Kingdom, Mexico, Japan, Korea, Australia, Spain, France, Iceland, China, and Taiwan. It offers branded and private-label products in a range of merchandise categories. The company offers sundries, dry groceries, candies, coolers, freezers, liquor, and tobacco and deli products; appliances, electronics, health and beauty aids, hardware, garden and patio products, sporting goods, tires, toys and seasonal products, office supplies, automotive care products, postages, tickets, apparel, small appliances, furniture, domestics, housewares, special order kiosks, and jewelry; and meat, produce, service deli, and bakery products. It also operates pharmacies, opticals, food courts, hearing-aid centers, and tire installation centers, as well as 636 gas stations; and offers business delivery, travel, same-day grocery, and various other services online in various countries. As of August 29, 2021, the company operated 815 membership warehouses, including 564 in the United States and Puerto Rico, 105 in Canada, 39 in Mexico, 30 in Japan, 29 in the United Kingdom, 16 in South Korea, 14 in Taiwan, 12 in Australia, 3 in Spain, 1 in Iceland, 1 in France, and 1 in China. It also operates e-commerce websites in the United States, Canada, the United Kingdom, Mexico, South Korea, Taiwan, Japan, and Australia. The company was formerly known as Costco Companies, Inc. and changed its name to Costco Wholesale Corporation in August 1999. Costco Wholesale Corporation was founded in 1976 and is based in Issaquah, Washington.",Mr. Ron M. Vachris,Discount Stores,921.5,USD,409052928500,https://images.financialmodelingprep.com/symbol/COST.png,1878340,54.05,-1.21,783129,12146000000,7367000000,"[{'period': '2024', 'revenue': 254.45, 'unit': 'B', 'net_profit': 7.37}, {'period': '2023', 'revenue': 242.29, 'unit': 'B', 'net_profit': 6.29}, {'period': '2022', 'revenue': 226.95, 'unit': 'B', 'net_profit': 5.84}, {'period': '2021', 'revenue': 195.93, 'unit': 'B', 'net_profit': 5.01}]","[{'period': ""Q1 '25"", 'revenue': 62.15, 'unit': 'B', 'net_profit': 1.8}, {'period': ""Q4 '24"", 'revenue': 79.7, 'unit': 'B', 'net_profit': 2.35}, {'period': ""Q3 '24"", 'revenue': 58.52, 'unit': 'B', 'net_profit': 1.68}, {'period': ""Q2 '24"", 'revenue': 58.44, 'unit': 'B', 'net_profit': 1.74}, {'period': ""Q1 '24"", 'revenue': 57.8, 'unit': 'B', 'net_profit': 1.59}, {'period': ""Q4 '23"", 'revenue': 78.94, 'unit': 'B', 'net_profit': 2.16}]",16.6,16.56,69831000000,34246000000,11144000000,46209000000,2721000000,0,35464000000,9906000000,6629000000,0.09069683908045977,0.17085187539732993,0.17066290550070534,"[1.16, 0.1]","['2024-11-01', '2004-05-06']",__nan__,0.6617261674614426
915,COUP,Coupa Software Incorporated Common Stock,"Coupa Software Incorporated provides cloud-based business spend management platform that connects its customers with suppliers worldwide. The company provides visibility into and control over how companies spend money, optimize supply chains, and manage liquidity, as well as enables businesses to achieve savings that drive profitability. Its platform offers procurement, invoicing, expense management, and payment solutions that form the transactional engine for managing a company's business spend; and specialized solutions, including strategic sourcing, contract management, contingent workforce, supplier risk management, supply chain design and planning, treasury management, and spend analysis. It serves businesses in various industries, including healthcare and pharmaceuticals, retail, financial services, manufacturing, and technology. The company markets its platform primarily through a direct sales force. Coupa Software Incorporated was incorporated in 2006 and is headquartered in San Mateo, California.",Mr. Robert  Bernshteyn,Software - Application,80.97,USD,6116578737,https://images.financialmodelingprep.com/symbol/COUP.png,2287176,-17.993333333333332,0,5078184,-102575000,-369106000,"[{'period': '2022', 'revenue': 725.29, 'unit': 'M', 'net_profit': -369.11}, {'period': '2021', 'revenue': 541.64, 'unit': 'M', 'net_profit': -180.12}, {'period': '2020', 'revenue': 389.72, 'unit': 'M', 'net_profit': -90.83}, {'period': '2019', 'revenue': 260.37, 'unit': 'M', 'net_profit': -55.52}]","[{'period': ""Q3 '23"", 'revenue': 217.34, 'unit': 'M', 'net_profit': -84.1}, {'period': ""Q2 '23"", 'revenue': 211.1, 'unit': 'M', 'net_profit': -70.6}, {'period': ""Q1 '23"", 'revenue': 196.37, 'unit': 'M', 'net_profit': -81.2}, {'period': ""Q4 '22"", 'revenue': 193.3, 'unit': 'M', 'net_profit': -93.96}, {'period': ""Q3 '22"", 'revenue': 185.82, 'unit': 'M', 'net_profit': -91.2}, {'period': ""Q2 '22"", 'revenue': 179.25, 'unit': 'M', 'net_profit': -91.47}]",-5,-5,3193179000,1015048000,729491000,2287517000,226191000,223032000,566952000,506459000,170538000,-0.2643756086136551,-1.0492568719221396,-0.9011406844106464,__nan__,__nan__,__nan__,0.7163760628514718
916,COVA,COVA Acquisition Corp. Class A Ordinary Share,"COVA Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the technology industry in Southeast Asia or the United States. The company was incorporated in 2020 and is based in San Francisco, California.",Mr. Jun Hong  Heng,Shell Companies,10.55,USD,0,https://images.financialmodelingprep.com/symbol/COVA.png,53664,527.5,0.33,38785,11607395000,23216621161,"[{'period': '2021', 'revenue': 0.0, 'unit': 'B', 'net_profit': 23.22}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.21}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.53}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'B', 'net_profit': 14.41}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'B', 'net_profit': 23.2}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.12}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.6}]",619.11,619.11,0.9253540000000058,0.795742,0.007181,22.772544000000003,0,300.053996,0.524694,0.007181,-2170645000000,0,0,0,__nan__,__nan__,__nan__,24.6095483458221
917,COVAU,COVA Acquisition Corp. Unit,"As of December 20, 2022, COVA Acquisition Corp. was acquired by ECARX Holdings, Inc., in a reverse merger transaction. COVA Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the technology industry in Southeast Asia or the United States. The company was incorporated in 2020 and is based in San Francisco, California.",Mr. Jun Hong  Heng,Shell Companies,10.5,USD,0,https://images.financialmodelingprep.com/symbol/COVAU.png,6104,18.197573656845755,0.4,4260,11607395000,23216621161,"[{'period': '2021', 'revenue': 0.0, 'unit': 'B', 'net_profit': 23.22}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.21}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.53}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'B', 'net_profit': 14.41}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'B', 'net_profit': 23.2}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.12}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.6}]",619.11,619.11,0.9253540000000058,0.795742,0.007181,22.772544000000003,0,300.053996,0.524694,0.007181,-2170645000000,0,0,0,__nan__,__nan__,__nan__,24.6095483458221
918,COVAW,COVA Acquisition Corp. Warrants to purchase Class A ordinary shares,"COVA Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded in 2020 and is based in San Francisco, California.",Mr. Jun Hong  Heng,Shell Companies,0.1,USD,0,https://images.financialmodelingprep.com/symbol/COVAW.png,0,0,0.02,22819,11607395000,23216621161,"[{'period': '2021', 'revenue': 0.0, 'unit': 'B', 'net_profit': 23.22}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.21}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 1.53}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'B', 'net_profit': 14.41}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'B', 'net_profit': 23.2}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.12}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 6.6}]",619.11,619.11,0.9253540000000058,0.795742,0.007181,22.772544000000003,0,300.053996,0.524694,0.007181,-2170645000000,0,0,0,__nan__,__nan__,__nan__,24.6095483458221
919,COWN,Cowen Inc. Class A Common Stock,"Cowen Inc., together with its subsidiaries, provides investment banking, research, sales and trading, prime brokerage, global clearing, securities financing, commission management, and investment management services in the United States and internationally. It operates in two segments, Operating Company (Op Co) and Asset Company (Asset Co). The company offers public and private capital raising, and strategic advisory services for public and private companies. It also trades common stocks, listed options, equity-linked securities, and other financial instruments on behalf of institutional investor clients. In addition, the company offers investment products and solutions in the liquidity spectrum to institutional and private clients, as well as provides investment research services. Further, it is involved in the private investment, private real estate investment, and other legacy investment activities. The company was founded in 1918 and is headquartered in New York, New York.",Mr. Jeffrey Marc Solomon,Financial - Capital Markets,38.99,USD,1099182296,https://images.financialmodelingprep.com/symbol/COWN.png,608823,17.642533936651585,0,949372,98989000,76458000,"[{'period': '2022', 'revenue': 1540.0, 'unit': 'M', 'net_profit': 76.46}, {'period': '2021', 'revenue': 2110.0, 'unit': 'M', 'net_profit': 295.61}, {'period': '2020', 'revenue': 1620.0, 'unit': 'M', 'net_profit': 216.36}, {'period': '2019', 'revenue': 1050.0, 'unit': 'M', 'net_profit': 55.87}]","[{'period': ""Q4 '22"", 'revenue': 413.93, 'unit': 'M', 'net_profit': 19.22}, {'period': ""Q3 '22"", 'revenue': 410.79, 'unit': 'M', 'net_profit': -7.7}, {'period': ""Q2 '22"", 'revenue': 302410.0, 'unit': 'K', 'net_profit': -818.0}, {'period': ""Q1 '22"", 'revenue': 410.59, 'unit': 'M', 'net_profit': 55.15}, {'period': ""Q4 '21"", 'revenue': 494.28, 'unit': 'M', 'net_profit': 59.98}, {'period': ""Q3 '21"", 'revenue': 412.24, 'unit': 'M', 'net_profit': 37.8}]",2.47,2.21,8828774000,4383085000,1139682000,7480929000,2815923000,3992836000,4371617000,1139682000,159057000,-0.7477588816577395,-0.7413560388483513,-0.7629558541266794,"[0.12, 0.04]","['2023-02-28', '2020-02-28']",__nan__,0.8473349753884288
920,COWNL,Cowen Inc. 7.75% Senior Notes due 2033,,None,,25.22,USD,0,https://images.financialmodelingprep.com/symbol/COWNL.png,7813,0,0,16479,335767000,65855000,"[{'period': '2022', 'revenue': 1540.0, 'unit': 'M', 'net_profit': 65.86}, {'period': '2021', 'revenue': 2110.0, 'unit': 'M', 'net_profit': 303.99}, {'period': '2020', 'revenue': 1620.0, 'unit': 'M', 'net_profit': 207.06}, {'period': '2019', 'revenue': 1050.0, 'unit': 'M', 'net_profit': 24.63}]","[{'period': ""Q4 '22"", 'revenue': 413.93, 'unit': 'M', 'net_profit': 19.22}, {'period': ""Q3 '22"", 'revenue': 410.79, 'unit': 'M', 'net_profit': -7.7}, {'period': ""Q2 '22"", 'revenue': 302410.0, 'unit': 'K', 'net_profit': -818.0}, {'period': ""Q1 '22"", 'revenue': 410.59, 'unit': 'M', 'net_profit': 55.15}, {'period': ""Q4 '21"", 'revenue': 1240.0, 'unit': 'M', 'net_profit': 212.05}, {'period': ""Q3 '21"", 'revenue': 412.24, 'unit': 'M', 'net_profit': 32.87}]",2.3,2.3,8828774000,3229660000,1364835000,7480929000,1864825000,49832000,859298000,1139652000,159057000,-0.4561746761103112,-0.7833652969989243,-0.7836312323612419,"[0.4844, 0.484]","['2023-02-28', '2019-08-29']",__nan__,0.8473349753884288
921,CPARU,Catalyst Partners Acquisition Corp. Unit,"Catalyst Partners Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities in the software companies. The company was incorporated in 2021 and is based in Cambridge, Massachusetts.",Dr. James Ireland Cash Jr.,Shell Companies,10,USD,0,https://images.financialmodelingprep.com/symbol/CPARU.png,9141,0,-0.02,270,,,[],"[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 4.83}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 32.88}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 18.96}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 13.65}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.83}]",,,347513577,3861462,2969044,28616378,0,0,720159,2969044,,,,,__nan__,__nan__,__nan__,0.08234607190613448
922,CPHC,Canterbury Park Holding Corporation 'New' Common Stock,"Canterbury Park Holding Corporation, through its subsidiaries, engages in horse racing, card casino, food and beverage, and real estate development businesses. The company's Horse Racing segment operates year-round simulcasting of horse races, as well as wagering on live thoroughbred and quarter horse races on a seasonal basis. Its Card Casino segment offers unbanked card games, such as poker and table games. The company's Food and Beverage segment operates concession stands, restaurants and buffets, bars, and other food venues, as well as caf style restaurants and full-service bars within the Card Casino and simulcast area. This segment also provides lounge services along with a buffet restaurant; various concession style food and beverages during live racing; and catering and events services. Its Development segment engages in various development opportunities, such as residential development, office, restaurants, hotel, entertainment, and retail operations. The company is also involved in the provision of related services and activities, such as parking, advertising signage, publication sales, and other entertainment events and activities. Canterbury Park Holding Corporation was founded in 1994 and is based in Shakopee, Minnesota.",Mr. Randall D. Sampson CPA,"Gambling, Resorts & Casinos",20.9,USD,104909849,https://images.financialmodelingprep.com/symbol/CPHC.png,2730,22.23,-0.1,1402,8313415,10563249,"[{'period': '2023', 'revenue': 61.44, 'unit': 'M', 'net_profit': 10.56}, {'period': '2022', 'revenue': 66.82, 'unit': 'M', 'net_profit': 7.51}, {'period': '2021', 'revenue': 60.4, 'unit': 'M', 'net_profit': 11.8}, {'period': '2020', 'revenue': 33.14, 'unit': 'M', 'net_profit': 1.06}]","[{'period': ""Q3 '24"", 'revenue': 19.28, 'unit': 'M', 'net_profit': 2.02}, {'period': ""Q2 '24"", 'revenue': 16200.0, 'unit': 'K', 'net_profit': 338.29}, {'period': ""Q1 '24"", 'revenue': 14100.0, 'unit': 'K', 'net_profit': 998.15}, {'period': ""Q4 '23"", 'revenue': 12.53, 'unit': 'M', 'net_profit': 1.36}, {'period': ""Q3 '23"", 'revenue': 19.27, 'unit': 'M', 'net_profit': 1.14}, {'period': ""Q2 '23"", 'revenue': 16.34, 'unit': 'M', 'net_profit': 5.29}]",2.15,2.13,104678668,36304002,26936210,22882071,4567456,24111658,11082394,21936210,3628546,-0.40699206551765016,0.406006245752332,0.38709677419354827,"[0.07, 0.25]","['2024-12-31', '2012-06-26']",__nan__,0.21859344828499347
923,CPIX,Cumberland Pharmaceuticals Inc. Common Stock,"Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.",Mr. A. J. Kazimi MBA,Drug Manufacturers - Specialty & Generic,2.4501,USD,34405039,https://images.financialmodelingprep.com/symbol/CPIX.png,1846632,-3.22,0.1601,49948,153317,-6279320,"[{'period': '2023', 'revenue': 39.55, 'unit': 'M', 'net_profit': -6.28}, {'period': '2022', 'revenue': 42.01, 'unit': 'M', 'net_profit': -5.65}, {'period': '2021', 'revenue': 35.99, 'unit': 'M', 'net_profit': -5.6}, {'period': '2020', 'revenue': 37.44, 'unit': 'M', 'net_profit': -6.63}]","[{'period': ""Q3 '24"", 'revenue': 9.09, 'unit': 'M', 'net_profit': -1.54}, {'period': ""Q2 '24"", 'revenue': 9.85, 'unit': 'M', 'net_profit': -1.09}, {'period': ""Q1 '24"", 'revenue': 8.5, 'unit': 'M', 'net_profit': -1.95}, {'period': ""Q4 '23"", 'revenue': 9.35, 'unit': 'M', 'net_profit': -6.29}, {'period': ""Q3 '23"", 'revenue': 10.09, 'unit': 'M', 'net_profit': -1.05}, {'period': ""Q2 '23"", 'revenue': 10890.0, 'unit': 'K', 'net_profit': 872.2}]",-0.44,-0.44,81776075,35714410,18321624,52516206,9758176,0,27982249,18321624,5640770,-0.5394765693757341,-0.11137639934874786,-0.12820512820512817,__nan__,__nan__,__nan__,0.6421952386440655
924,CPLP,Capital Product Partners L.P. Common Units,"Capital Product Partners L.P., a shipping company, provides marine transportation services in Greece. Its vessels transport a range of cargoes, including liquefied natural gas, containerized goods, and dry bulk cargo under short-term voyage charters, and medium to long-term time charters. As of April 27, 2022, the company owned 21 vessels, including 11 Neo-Panamax container vessels, three Panamax container vessels, one cape-size bulk carrier, and six LNG carriers. Capital GP L.L.C. serves as the general partner of the company. The company was incorporated in 2007 and is headquartered in Piraeus, Greece.",Mr. Gerasimos G. Kalogiratos,Marine Shipping,16.77,USD,979155021,https://images.financialmodelingprep.com/symbol/CPLP.png,18401,6.628458498023716,0.35,9356,247423000,47208000,"[{'period': '2023', 'revenue': 360.59, 'unit': 'M', 'net_profit': 47.21}, {'period': '2022', 'revenue': 299.07, 'unit': 'M', 'net_profit': 172.7}, {'period': '2021', 'revenue': 184.66, 'unit': 'M', 'net_profit': 77.8}, {'period': '2020', 'revenue': 140.87, 'unit': 'M', 'net_profit': 13.76}]","[{'period': ""Q2 '24"", 'revenue': 97.67, 'unit': 'M', 'net_profit': 34.18}, {'period': ""Q1 '24"", 'revenue': 104.49, 'unit': 'M', 'net_profit': 33.9}, {'period': ""Q4 '23"", 'revenue': 95.51, 'unit': 'M', 'net_profit': 12.73}, {'period': ""Q3 '23"", 'revenue': 95.53, 'unit': 'M', 'net_profit': 17.04}, {'period': ""Q2 '23"", 'revenue': 88.53, 'unit': 'M', 'net_profit': 7.41}, {'period': ""Q1 '23"", 'revenue': 81.02, 'unit': 'M', 'net_profit': -15.81}]",2.15,2.15,3140299000,225504000,192422000,1965366000,4433000,11721000,183930000,192422000,-278257000,-0.05608414338252125,-0.7266410339556214,-0.7595078299776286,"[0.15, 0.3626]","['2024-08-06', '2007-08-02']",__nan__,0.6258531432834898
925,CPRT,Copart Inc. (DE) Common Stock,"Copart, Inc. provides online auctions and vehicle remarketing services in the United States, Canada, the United Kingdom, Brazil, the Republic of Ireland, Germany, Finland, the United Arab Emirates, Oman, Bahrain, and Spain. It offers a range of services for processing and selling vehicles over the internet through its virtual bidding third generation internet auction-style sales technology to vehicle sellers, insurance companies, banks and finance companies, charities, fleet operators, dealers, vehicle rental companies, and individuals. The company's services include online seller access, salvage estimation, estimating, end-of-life vehicle processing, virtual insured exchange, transportation, vehicle inspection stations, on-demand reporting, title processing and procurement, loan payoff, flexible vehicle processing programs, buy it now, member network, sales process, and dealer services. Its services also comprise services to sell vehicles through CashForCars.com; U-Pull-It service that allows buyer to remove valuable parts and sell the remaining parts and car body; copart 360, an online technology for posting vehicle images; membership tiers for those registering to buy vehicles through Copart.com; and virtual queue to secure a place in line while visiting one of its locations. The company sells its products principally to licensed vehicle dismantlers, rebuilders, repair licensees, used vehicle dealers, and exporters, as well as to the public. The company was incorporated in 1982 and is headquartered in Dallas, Texas.",Mr. Jeffrey  Liaw,Auto - Dealerships,56.45,USD,54391155600,https://images.financialmodelingprep.com/symbol/CPRT.png,4158604,39.48,-0.13,673285,1762279000,1363020000,"[{'period': '2024', 'revenue': 4.24, 'unit': 'B', 'net_profit': 1.36}, {'period': '2023', 'revenue': 3.87, 'unit': 'B', 'net_profit': 1.24}, {'period': '2022', 'revenue': 3.5, 'unit': 'B', 'net_profit': 1.09}, {'period': '2021', 'revenue': 2690.0, 'unit': 'M', 'net_profit': 936.5}]","[{'period': ""Q1 '25"", 'revenue': 1150.0, 'unit': 'M', 'net_profit': 362.09}, {'period': ""Q4 '24"", 'revenue': 1070.0, 'unit': 'M', 'net_profit': 322.57}, {'period': ""Q3 '24"", 'revenue': 1130.0, 'unit': 'M', 'net_profit': 382.29}, {'period': ""Q2 '24"", 'revenue': 1020.0, 'unit': 'M', 'net_profit': 325.63}, {'period': ""Q1 '24"", 'revenue': 1020.0, 'unit': 'M', 'net_profit': 332.53}, {'period': ""Q4 '23"", 'revenue': 997.59, 'unit': 'M', 'net_profit': 347.79}]",1.42,1.4,8427763999,4418184000,3422158000,879209000,785877000,0,628567000,1514111000,961574000,0.18546734124013078,0.10121584402552715,0.09230769230769222,__nan__,__nan__,__nan__,0.10432292599844074
926,CPRX,Catalyst Pharmaceuticals Inc. Common Stock,"Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.",Mr. Richard John  Daly M.B.A.,Biotechnology,19.61,USD,2338943530,https://images.financialmodelingprep.com/symbol/CPRX.png,903454,16.62,-0.58,825839,119693000,71410000,"[{'period': '2023', 'revenue': 398.2, 'unit': 'M', 'net_profit': 71.41}, {'period': '2022', 'revenue': 214.2, 'unit': 'M', 'net_profit': 83.08}, {'period': '2021', 'revenue': 140.83, 'unit': 'M', 'net_profit': 39.48}, {'period': '2020', 'revenue': 119.07, 'unit': 'M', 'net_profit': 74.98}]","[{'period': ""Q3 '24"", 'revenue': 128.69, 'unit': 'M', 'net_profit': 43.88}, {'period': ""Q2 '24"", 'revenue': 122.71, 'unit': 'M', 'net_profit': 40.79}, {'period': ""Q1 '24"", 'revenue': 98.51, 'unit': 'M', 'net_profit': 23.27}, {'period': ""Q4 '23"", 'revenue': 110.57, 'unit': 'M', 'net_profit': 34.84}, {'period': ""Q3 '23"", 'revenue': 102.69, 'unit': 'M', 'net_profit': -30.76}, {'period': ""Q2 '23"", 'revenue': 99.58, 'unit': 'M', 'net_profit': 37.76}]",0.67,0.63,470114000,219329000,137636000,82233000,53514000,16489000,76063000,137636000,-54924000,0.17532748090103892,-0.14045667376834098,-0.1625,__nan__,__nan__,__nan__,0.17492140204290874
927,CPSH,CPS Technologies Corp. Common Stock,"CPS Technologies Corporation produces and sells advanced material solutions to the transportation, automotive, energy, computing/internet, telecommunication, aerospace, defense, and oil and gas markets. It primarily offers metal matrix composites that are a combination of metal and ceramic, such as baseplates for various applications, including motor controllers used in electric trains, subway cars, wind turbines, and hybrid and electric vehicles; hermetic packages for use in radar, satellite, and avionics applications; baseplates and housings used in modules built with wide band gap semiconductors; and lids and heatspreaders used with integrated circuits for use in internet switches and routers. The company also assembles housings and packages for hybrid circuits. It primarily sells its products to microelectronics systems companies in the United States, Europe, and Asia. The company was formerly known as Ceramics Process Systems Corporation and changed its name to CPS Technologies Corporation in March 2007. CPS Technologies Corporation was incorporated in 1984 and is headquartered in Norton, Massachusetts.",Mr. Brian  Mackey,"Hardware, Equipment & Parts",1.8301,USD,26584033,https://images.financialmodelingprep.com/symbol/CPSH.png,259358,-13.07,0.0201,65830,2188466,1370296,"[{'period': '2023', 'revenue': 27.55, 'unit': 'M', 'net_profit': 1.37}, {'period': '2022', 'revenue': 26.59, 'unit': 'M', 'net_profit': 2.13}, {'period': '2021', 'revenue': 22.45, 'unit': 'M', 'net_profit': 3.22}, {'period': '2020', 'revenue': 20870.0, 'unit': 'K', 'net_profit': 908.06}]","[{'period': ""Q3 '24"", 'revenue': 4.25, 'unit': 'M', 'net_profit': -1.04}, {'period': ""Q2 '24"", 'revenue': 5030.0, 'unit': 'K', 'net_profit': -954.3}, {'period': ""Q1 '24"", 'revenue': 5910.0, 'unit': 'K', 'net_profit': -143.15}, {'period': ""Q4 '23"", 'revenue': 6750.0, 'unit': 'K', 'net_profit': 139.51}, {'period': ""Q3 '23"", 'revenue': 6290.0, 'unit': 'K', 'net_profit': 171.08}, {'period': ""Q2 '23"", 'revenue': 7420.0, 'unit': 'K', 'net_profit': 600.5}]",0.0945,0.0937,21602116,18144251,8813626,4280142,4472346,0,4068774,8813626,549179,-0.18345665313140003,-0.3570911138219011,-0.37,__nan__,__nan__,__nan__,0.19813531229996173
928,CPSI,Computer Programs and Systems Inc. Common Stock,"Computer Programs and Systems, Inc. provides healthcare information technology solutions and services in the United States and the Caribbean nation of St. Maarten. Its software systems include patient management software that enables a hospital to identify a patient at various points in the healthcare delivery system, as well as to collect and maintain patient information throughout the process of patient care; and financial accounting software, which offers business office applications to track and coordinate information needed for managerial decision-making. The company also provides clinical software that automates record keeping and reporting for various clinical functions, including laboratory, radiology, physical therapy, respiratory care, and pharmacy; patient care applications; and enterprise applications that support its products for use in various areas of the hospital, and provide software applications. In addition, it offers Centriq, an intuitive user interface to centralize data from various care areas that provide the end user with a tool to view past and present patient information. Further, the company provides software solutions that promote data-driven clinical and financial outcomes for customers in the post-acute care industry; software application support, hardware maintenance, and education and related services; post-acute care support and maintenance services; revenue cycle management products and services, consulting and business management services, and managed information technology services; patient engagement, and encoder solutions. It serves community hospitals and physician clinics, skilled nursing, and assisted living facilities. Computer Programs and Systems, Inc. was founded in 1979 and is headquartered in Mobile, Alabama.",Mr. Christopher L. Fowler,Medical - Healthcare Information Services,9.19,USD,133705310,https://images.financialmodelingprep.com/symbol/CPSI.png,206653,-183.8,0.33,534996,43829000,15867000,"[{'period': '2022', 'revenue': 326.65, 'unit': 'M', 'net_profit': 15.87}, {'period': '2021', 'revenue': 280.63, 'unit': 'M', 'net_profit': 18.43}, {'period': '2020', 'revenue': 264.49, 'unit': 'M', 'net_profit': 14.25}, {'period': '2019', 'revenue': 274.63, 'unit': 'M', 'net_profit': 20.47}]","[{'period': ""Q3 '23"", 'revenue': 82.71, 'unit': 'M', 'net_profit': -3.56}, {'period': ""Q2 '23"", 'revenue': 84.62, 'unit': 'M', 'net_profit': -2.84}, {'period': ""Q1 '23"", 'revenue': 86.23, 'unit': 'M', 'net_profit': 3.08}, {'period': ""Q4 '22"", 'revenue': 83.22, 'unit': 'M', 'net_profit': 2.52}, {'period': ""Q3 '22"", 'revenue': 82.83, 'unit': 'M', 'net_profit': 2.16}, {'period': ""Q2 '22"", 'revenue': 82.73, 'unit': 'M', 'net_profit': 3.08}]",1.11,1.11,430963000,74559000,6951000,199252000,55785000,3312000,44455000,6951000,13008000,0.01670184880187432,-0.13906673901247965,-0.11904761904761897,"[0.1, 0.085]","['2020-08-14', '2003-05-07']",__nan__,0.46234131468362716
929,CPSS,Consumer Portfolio Services Inc. Common Stock,"Consumer Portfolio Services, Inc. operates as a specialty finance company in the United States. It is involved in the purchase and service of retail automobile contracts originated by franchised automobile dealers and select independent dealers in the sale of new and used automobiles, light trucks, and passenger vans. The company, through its automobile contract purchases, offers indirect financing to the customers of dealers with limited credit histories or past credit problems. It serves as an alternative source of financing for dealers, facilitating sales to customers who are not able to obtain financing from commercial banks, credit unions, and the captive finance companies. The company also acquires installment purchase contracts in four merger and acquisition transactions; purchases immaterial amounts of vehicle purchase money loans from non-affiliated lenders. and offers financing directly to sub-prime consumers to facilitate their purchase of a new or used automobile, light truck, or passenger van. It services its automobile contracts through its branches in California, Nevada, Virginia, Florida, and Illinois. The company was founded in 1991 and is based in Las Vegas, Nevada.",Mr. Charles E. Bradley Jr.,Financial - Credit Services,11.22,USD,240166344,https://images.financialmodelingprep.com/symbol/CPSS.png,29498,12.75,0.1,34500,0,45343000,"[{'period': '2023', 'revenue': 214.6, 'unit': 'M', 'net_profit': 45.34}, {'period': '2022', 'revenue': 242.19, 'unit': 'M', 'net_profit': 85.98}, {'period': '2021', 'revenue': 192.57, 'unit': 'M', 'net_profit': 47.52}, {'period': '2020', 'revenue': 169.82, 'unit': 'M', 'net_profit': 21.68}]","[{'period': ""Q3 '24"", 'revenue': 100.58, 'unit': 'M', 'net_profit': 4.8}, {'period': ""Q2 '24"", 'revenue': 90.38, 'unit': 'M', 'net_profit': 4.67}, {'period': ""Q1 '24"", 'revenue': 86.74, 'unit': 'M', 'net_profit': 4.59}, {'period': ""Q4 '23"", 'revenue': 85.98, 'unit': 'M', 'net_profit': 7.19}, {'period': ""Q3 '23"", 'revenue': 54.19, 'unit': 'M', 'net_profit': 10.38}, {'period': ""Q2 '23"", 'revenue': 49.15, 'unit': 'M', 'net_profit': 13.95}]",2.17,1.8,2903746000,6174000,6174000,2629078000,0,0,0,6174000,237421000,0,-0.4726515706593164,-0.47073170731707314,__nan__,__nan__,__nan__,0.9054090819238322
930,CPTA,Capitala Finance Corp. Common Stock,"Capitala Finance Corp. is an externally managed non-diversified, closed-end management investment company. The Company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The Company invests in first lien loans, which have a first priority security interest in all or some of the borrowers assets. In addition, its first lien loans may include positions in stretch senior secured loans, also referred to as unitranche loans, which combine characteristics of traditional first lien senior secured loans and second lien loans. It also may invest in second lien loans, which have a second priority security interest in all or substantially all of the borrowers assets. It also provides capital to lower and traditional middle-market companies in the United States. The Companys investment advisor is Capitala Investment Advisors, LLC.",Mr. Joseph Alala,Asset Management,25.4,USD,68861178,https://images.financialmodelingprep.com/symbol/CPTA.png,28256,0,0.539999,19991,-20303000,-35447000,"[{'period': '2020', 'revenue': -30.79, 'unit': 'M', 'net_profit': -35.45}, {'period': '2019', 'revenue': -22.61, 'unit': 'M', 'net_profit': -27.65}, {'period': '2018', 'revenue': -13.25, 'unit': 'M', 'net_profit': -16.03}, {'period': '2017', 'revenue': -0.043000000000000003, 'unit': 'M', 'net_profit': -6.98}]","[{'period': ""Q2 '21"", 'revenue': -5.73, 'unit': 'M', 'net_profit': -7.55}, {'period': ""Q1 '21"", 'revenue': 13.63, 'unit': 'M', 'net_profit': 12.35}, {'period': ""Q4 '20"", 'revenue': 1830.0, 'unit': 'K', 'net_profit': 538.0}, {'period': ""Q3 '20"", 'revenue': 4.16, 'unit': 'M', 'net_profit': 3.35}, {'period': ""Q2 '20"", 'revenue': 4.16, 'unit': 'M', 'net_profit': 3.1}, {'period': ""Q1 '20"", 'revenue': -40.94, 'unit': 'M', 'net_profit': -42.44}]",-13.08,-13.08,327997000,52228000,49942000,219050000,2286000,274692000,1716000,49942000,53113000,-1.0512224691856942,-0.2821282598473614,-0.27113702623906716,"[0.0139, 0.0783]","['2020-03-20', '2013-12-06']",__nan__,0.6678414741598246
931,CPTAG,Capitala Finance Corp. 5.75% Convertible Notes Due 2022,,None,Asset Management,25,USD,0,https://images.financialmodelingprep.com/symbol/CPTAG.png,4114,-24.9500998003992,0.04000092,89443,-20303000,-35447000,"[{'period': '2020', 'revenue': -30.79, 'unit': 'M', 'net_profit': -35.45}, {'period': '2019', 'revenue': -22.61, 'unit': 'M', 'net_profit': -27.65}, {'period': '2018', 'revenue': -13.25, 'unit': 'M', 'net_profit': -16.03}, {'period': '2017', 'revenue': -0.043000000000000003, 'unit': 'M', 'net_profit': -6.98}]","[{'period': ""Q2 '21"", 'revenue': -5.73, 'unit': 'M', 'net_profit': -7.55}, {'period': ""Q1 '21"", 'revenue': 13.63, 'unit': 'M', 'net_profit': 12.35}, {'period': ""Q4 '20"", 'revenue': 1830.0, 'unit': 'K', 'net_profit': 538.0}, {'period': ""Q3 '20"", 'revenue': 4.16, 'unit': 'M', 'net_profit': 3.35}, {'period': ""Q2 '20"", 'revenue': 4.16, 'unit': 'M', 'net_profit': 3.1}, {'period': ""Q1 '20"", 'revenue': -40.94, 'unit': 'M', 'net_profit': -42.44}]",-13.08,-13.08,327997000,52228000,49942000,219050000,2286000,274692000,1716000,49942000,53113000,-1.0512224691856942,-0.2821282598473614,-0.27113702623906716,"[0.359, 0.359]","['2022-05-12', '2017-08-11']",__nan__,0.6678414741598246
932,CPTAL,Capitala Finance Corp. 6% Notes Due 2022,,None,Asset Management,25,USD,0,https://images.financialmodelingprep.com/symbol/CPTAL.png,5744,-316.45569620253167,0.04000092,4022,-20303000,-35447000,"[{'period': '2020', 'revenue': -30.79, 'unit': 'M', 'net_profit': -35.45}, {'period': '2019', 'revenue': -22.61, 'unit': 'M', 'net_profit': -27.65}, {'period': '2018', 'revenue': -13.25, 'unit': 'M', 'net_profit': -16.03}, {'period': '2017', 'revenue': -0.043000000000000003, 'unit': 'M', 'net_profit': -6.98}]","[{'period': ""Q2 '21"", 'revenue': -5.73, 'unit': 'M', 'net_profit': -7.55}, {'period': ""Q1 '21"", 'revenue': 13.63, 'unit': 'M', 'net_profit': 12.35}, {'period': ""Q4 '20"", 'revenue': 1830.0, 'unit': 'K', 'net_profit': 538.0}, {'period': ""Q3 '20"", 'revenue': 4.16, 'unit': 'M', 'net_profit': 3.35}, {'period': ""Q2 '20"", 'revenue': 4.16, 'unit': 'M', 'net_profit': 3.1}, {'period': ""Q1 '20"", 'revenue': -40.94, 'unit': 'M', 'net_profit': -42.44}]",-13.08,-13.08,327997000,52228000,49942000,219050000,2286000,274692000,1716000,49942000,53113000,-1.0512224691856942,-0.2821282598473614,-0.27113702623906716,"[0.375, 0.375]","['2022-05-12', '2017-08-11']",__nan__,0.6678414741598246
933,CPZ,Calamos Long/Short Equity & Dynamic Income Trust Common Stock,"Calamos Long/Short Equity & Dynamic Income Trust is a diversified and closed-end management investment company, which engages in the business of seeking to provide current income and risk-managed capital appreciation. The firm is also involved in providing hedged market exposure through time-tested global long and short equity strategy. The company was founded on September 21, 2017 and is headquartered in Naperville, IL.",John Peter Calamos,Asset Management,15.16,USD,297624152,https://images.financialmodelingprep.com/symbol/CPZ.png,68620,5.68,,0,0,52414939,"[{'period': '2024', 'revenue': 55.87, 'unit': 'M', 'net_profit': 52.41}, {'period': '2023', 'revenue': 13.88, 'unit': 'M', 'net_profit': 11.01}, {'period': '2022', 'revenue': -38.8, 'unit': 'M', 'net_profit': -42.75}, {'period': '2021', 'revenue': 113.72, 'unit': 'M', 'net_profit': 110.64}]",[],0,0,725428851,0,0,381218930,2652696,426502625,0,0,60426377,-1,3.7599186503846354,-1,"[0.3359, 0.0422]","['2024-12-30', '2019-12-30']",__nan__,0.525508365809399
934,CRAI,CRA International Inc. Common Stock,"CRA International, Inc., together with its subsidiaries, provides economic, financial, and management consulting services in the United States, the United Kingdom, and internationally. It advises clients on economic and financial matters pertaining to litigation and regulatory proceedings; and guides corporations through business strategy and performance-related issues. The company also offers consulting services, including research and analysis, expert testimony, and support in litigation and regulatory proceedings in the areas of finance, accounting, economics, insurance, and forensic accounting and investigations to corporate clients and attorneys. In addition, it offers management consulting services comprising strategy development, performance improvement, corporate strategy and portfolio analysis, estimation of market demand, new product pricing strategies, valuation of intellectual property and other assets, assessment of competitors' actions, and analysis of new sources of supply. The company serves various industries, including communications and media; consumer, health, and wellness products; energy; entertainment and leisure; financial services; healthcare; life sciences; manufacturing and industries; natural resources; retail and distribution; technology; and transportation. CRA International, Inc. was incorporated in 1965 and is headquartered in Boston, Massachusetts.",Mr. Paul A. Maleh,Consulting Services,179.64,USD,1217907104,https://images.financialmodelingprep.com/symbol/CRAI.png,35608,29.07,-4.4,13865,81937000,38481000,"[{'period': '2023', 'revenue': 623.98, 'unit': 'M', 'net_profit': 38.48}, {'period': '2022', 'revenue': 590.9, 'unit': 'M', 'net_profit': 43.62}, {'period': '2021', 'revenue': 565.93, 'unit': 'M', 'net_profit': 41.68}, {'period': '2020', 'revenue': 508.37, 'unit': 'M', 'net_profit': 24.51}]","[{'period': ""Q3 '24"", 'revenue': 167.75, 'unit': 'M', 'net_profit': 11.44}, {'period': ""Q2 '24"", 'revenue': 171.44, 'unit': 'M', 'net_profit': 6.54}, {'period': ""Q1 '24"", 'revenue': 171.79, 'unit': 'M', 'net_profit': 13.69}, {'period': ""Q4 '23"", 'revenue': 161.61, 'unit': 'M', 'net_profit': 11.46}, {'period': ""Q3 '23"", 'revenue': 147.55, 'unit': 'M', 'net_profit': 8.6}, {'period': ""Q2 '23"", 'revenue': 161.97, 'unit': 'M', 'net_profit': 9.51}]",5.47,5.39,553211000,265476000,45586000,341110000,208315000,0,236087000,45586000,57706000,-0.05140257244405339,-0.1177927050138701,-0.09136212624584715,"[0.49, 0.14]","['2024-11-26', '2016-11-16']",__nan__,0.6166001760630212
935,CRBP,Corbus Pharmaceuticals Holdings Inc. Common Stock,"Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor  (TGF); and CRB-602, an anti-av6/av8 mAb that blocks the activation of TGF for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.",Dr. Yuval  Cohen Ph.D.,Biotechnology,12.73,USD,155045035,https://images.financialmodelingprep.com/symbol/CRBP.png,332216,-2.7,-0.13,70055,-44436700,-44603316,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -44.6}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -55.83}, {'period': '2021', 'revenue': 0.8817100000000001, 'unit': 'M', 'net_profit': -45.55}, {'period': '2020', 'revenue': 3.94, 'unit': 'M', 'net_profit': -111.3}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.78}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.0}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.9}, {'period': ""Q4 '23"", 'revenue': 1.35, 'unit': 'M', 'net_profit': -8.02}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.05}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.78}]",-10.31,-10.31,28272393,23546030,20906006,35177115,0,0,31894073,13723681,-36100473,-0.14743579150028818,0.2011326309064932,0.23002240477968633,__nan__,__nan__,__nan__,1.244221350488443
936,CRCT,Cricut Inc. Class A Common Stock,"Cricut, Inc. designs and markets a creativity platform that enables users to turn ideas into professional-looking handmade goods. It operates in three segments: Connected Machines, Subscriptions, and Accessories and Materials. The company offers connected machines, design apps, and accessories and materials for users to create personalized birthday cards, mugs, T-shirts, and large-scale interior decorations. Its connected machines include Cricut Joy, Cricut Explore, and Cricut Maker to cut, write, score, and create decorative effects using various materials, such as paper, vinyl, leather, and others; and design apps comprise Design Space app and Cricut Joy-specific app. The company also provides Cricut Access and Cricut Access Premium subscription offerings, and in-app purchases; and a software that integrates its connected machines and design apps. In addition, it offers a range of accessories and materials, such as Cricut EasyPress, Cricut Mug Press, various hand tools, machine replacement tools and blades, and project materials. The company offers its products through its third-party brick-and-mortar and online retail partners; and its website cricut.com, as well as through a network of distributors. It operates in the United States, the United Kingdom, Ireland, Australia, New Zealand, and Western Europe, as well as the Middle East, Latin America, South Africa, and Asia. The company was formerly known as Provo Craft & Novelty, Inc. and changed its name to Cricut, Inc. in March 2018. The company was incorporated in 1969 and is headquartered in South Jordan, Utah.",Mr. Ashish  Arora,Computer Hardware,5.755,USD,1234294262,https://images.financialmodelingprep.com/symbol/CRCT.png,346109,19.84,-0.065,113463,109906000,53636000,"[{'period': '2023', 'revenue': 765.15, 'unit': 'M', 'net_profit': 53.64}, {'period': '2022', 'revenue': 886.3, 'unit': 'M', 'net_profit': 60.67}, {'period': '2021', 'revenue': 1310.0, 'unit': 'M', 'net_profit': 140.47}, {'period': '2020', 'revenue': 959.03, 'unit': 'M', 'net_profit': 154.58}]","[{'period': ""Q3 '24"", 'revenue': 167.89, 'unit': 'M', 'net_profit': 11.49}, {'period': ""Q2 '24"", 'revenue': 167.95, 'unit': 'M', 'net_profit': 19.77}, {'period': ""Q1 '24"", 'revenue': 167.39, 'unit': 'M', 'net_profit': 19.65}, {'period': ""Q4 '23"", 'revenue': 231.25, 'unit': 'M', 'net_profit': 11.29}, {'period': ""Q3 '23"", 'revenue': 174.91, 'unit': 'M', 'net_profit': 17.23}, {'period': ""Q2 '23"", 'revenue': 177.76, 'unit': 'M', 'net_profit': 16.02}]",0.25,0.24,750122000,619969000,245139000,215249000,111247000,0,196464000,142187000,264380000,0.0006737562823220919,-0.11588039429004714,-0.10714285714285723,"[0.1, 0.35]","['2025-01-07', '2023-01-31']",__nan__,0.2869519891430994
937,CRDF,Cardiff Oncology Inc. Common Stock,"Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.",Dr. Mark  Erlander Ph.D.,Biotechnology,4.235,USD,281705424,https://images.financialmodelingprep.com/symbol/CRDF.png,2031890,-4.46,-0.305,739635,-45014000,-41441000,"[{'period': '2023', 'revenue': 0.488, 'unit': 'M', 'net_profit': -41.44}, {'period': '2022', 'revenue': 0.386, 'unit': 'M', 'net_profit': -37.51}, {'period': '2021', 'revenue': 0.359, 'unit': 'M', 'net_profit': -27.74}, {'period': '2020', 'revenue': 0.36599000000000004, 'unit': 'M', 'net_profit': -19.28}]","[{'period': ""Q3 '24"", 'revenue': 0.165, 'unit': 'M', 'net_profit': -11.86}, {'period': ""Q2 '24"", 'revenue': 0.163, 'unit': 'M', 'net_profit': -11.78}, {'period': ""Q1 '24"", 'revenue': 0.20500000000000002, 'unit': 'M', 'net_profit': -10.01}, {'period': ""Q4 '23"", 'revenue': 0.156, 'unit': 'M', 'net_profit': -9.34}, {'period': ""Q3 '23"", 'revenue': 0.14100000000000001, 'unit': 'M', 'net_profit': -9.73}, {'period': ""Q2 '23"", 'revenue': 0.108, 'unit': 'M', 'net_profit': -11.15}]",-0.93,-0.93,81637000,77412000,74823000,11898000,288000,0,10440000,21655000,-31469000,-0.13482579539151918,-0.1049165466858636,-0.08139534883720938,__nan__,__nan__,__nan__,0.14574273919913763
938,CREE,Cree Inc. Common Stock,"Wolfspeed, Inc. provides lighting-class light emitting diode (LED) and semiconductor products for power and radio-frequency (RF) applications in the United States, China, Europe, and internationally. It operates in two segments, Wolfspeed and LED Products. The Wolfspeed segment offers silicon carbide (SiC) materials for RF, power switching, gemstones, and other applications. It also provides SiC power device products, including SiC Schottky diodes, metal oxide semiconductor field effect transistors (MOSFETs), power modules, and gate driver boards for electric vehicles, including charging infrastructure, server power supplies, solar inverters, uninterruptible power supplies, industrial power supplies, and other applications. In addition, this segment offers gallium nitride (GaN) die, high-electron mobility transistors (HEMTs), monolithic microwave integrated circuits (MMICs), and laterally diffused MOSFET (LDMOS) power transistors for telecommunications infrastructure, military, and other commercial applications; and custom die manufacturing services for GaN HEMTs and MMICs. The LED Products segment provides blue and green LED chip products for video screens, gaming displays, function indicator lights and automotive backlights, headlamps, and directional indicators. It also offers XLamp LED components and LED modules for lighting applications; and surface mount and through-hole packaged LED products for video, signage, general illumination, transportation, gaming, and specialty lighting applications. The company was founded in 1987 and is headquartered in Durham, North Carolina.",Mr. Gregg Lowe,Semiconductors,79.12,USD,9843873040,https://images.financialmodelingprep.com/symbol/CREE.png,1398932,0,0,1325405,-356500000,-523900000,"[{'period': '2021', 'revenue': 525.6, 'unit': 'M', 'net_profit': -523.9}, {'period': '2020', 'revenue': 903.9, 'unit': 'M', 'net_profit': -191.7}, {'period': '2019', 'revenue': 1080.0, 'unit': 'M', 'net_profit': -375.1}, {'period': '2018', 'revenue': 924.9, 'unit': 'M', 'net_profit': -280.0}]","[{'period': ""Q3 '21"", 'revenue': 156.6, 'unit': 'M', 'net_profit': -70.1}, {'period': ""Q2 '21"", 'revenue': 145.8, 'unit': 'M', 'net_profit': -147.6}, {'period': ""Q1 '21"", 'revenue': 137.3, 'unit': 'M', 'net_profit': -108.9}, {'period': ""Q4 '20"", 'revenue': 127.0, 'unit': 'M', 'net_profit': -83.0}, {'period': ""Q3 '20"", 'revenue': 216.6, 'unit': 'M', 'net_profit': -184.4}, {'period': ""Q2 '20"", 'revenue': 205.7, 'unit': 'M', 'net_profit': -39.5}]",-4.66,-4.66,3446800000,1478700000,1154600000,1330300000,102300000,0,448800000,379000000,-701900000,-9.902140672782874,-1.7329160146061555,-1.6179775280898876,__nan__,__nan__,__nan__,0.38595218753626553
939,CREG,China Recycling Energy Corporation Common Stock,"Smart Powerr Corp. engages in the recycling energy business in China. The company designs, finances, constructs, installs, operates, and transfers waste energy recycling projects to mid- to large-size enterprises involved in high energy-consuming businesses. It provides waste pressure-to-energy solutions, including the Blast Furnace Top Gas Recovery Turbine Unit, a system that utilizes high pressure gas emitted from the blast furnace top to drive turbine units and generate electricity; and waste heat-to-energy solutions, such as heat power generation projects for applications in cement, steel, coking coal, and nonferrous metal industries, which collect the residual heat from various manufacturing processes. The company also offers waste gas-to-energy solutions comprising the Waste Gas Power Generation system that utilizes flammable waste gas from coal mining, petroleum exploitation, refinery processing, or other sources as a fuel source to generate electricity; and the Combined Cycle Power Plant, which employs power generating cycle to utilize the waste gas that generates electricity by burning the flammable waste gas in a gas turbine, as well as uses the waste heat from burning the gas to make steam to generate additional electricity through a steam turbine. In addition, it provides project investment, investment management, economic information consulting, technical, financial leasing, and financial leasing transactions consulting services; purchases, repairs, and disposes financial leasing assets; and sells and leases energy saving systems and equipment. The company was formerly known as China Recycling Energy Corporation and changed its name to Smart Powerr Corp. in March 2022. Smart Powerr Corp. was incorporated in 1980 and is headquartered in Xi'an, China.",Mr. Guohua  Ku,Renewable Utilities,0.7301,USD,7345682,https://images.financialmodelingprep.com/symbol/CREG.png,86016,-5.21,0.0201,282862,-797889,-746786,"[{'period': '2023', 'revenue': 0.0, 'unit': 'K', 'net_profit': -746.79}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.46}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.23}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.26}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -262.73}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -409.76}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -279.8}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -228.72}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -180.72}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -247.84}]",-0.0959,-0.0959,136469546,136465552,32370,27223879,68992421,0,23873254,32370,-68099899,0.7943814517606669,0.8324587807894731,0.8427868852459016,__nan__,__nan__,__nan__,0.19948684375340414
940,CRESY,Cresud S.A.C.I.F. y A. American Depositary Shares,"Cresud Sociedad Annima Comercial, Inmobiliaria, Financiera y Agropecuaria, an agricultural company, produces basic agricultural commodities in Brazil and other Latin American countries. It operates through Agricultural Business, and Urban Properties and Investment Business segments. The Agricultural Business segment is involved in the planting, harvesting, and sale of crops, such as wheat, corn, soybeans, cotton, and sunflower, as well as sugarcane; sale of grain derivatives, including flour and oil; breeding, purchasing, and/or fattening of cattle for sale to meat processors and local livestock auction markets; provision of agricultural services; leasing of farms to third parties; disposal and development of farmlands; and brokerage activities. The Urban Properties and Investment Business segment leases, rents, and services commercial and other spaces in shopping malls; leases offices and other rental spaces; develops, maintains, and sells undeveloped parcels of land and/or trading properties; and operates hotels, as well as engages in the entertainment activities. The company was incorporated in 1936 and is headquartered in Buenos Aires, Argentina.",Mr. Alejandro  Gustavo Elsztain,Conglomerates,13.828,USD,981159891,https://images.financialmodelingprep.com/symbol/CRESY.png,254135,-8.54,0.318,186334,103585000000,78460000000,"[{'period': '2023', 'revenue': 711.37, 'unit': 'B', 'net_profit': 78.46}, {'period': '2022', 'revenue': 190.41, 'unit': 'B', 'net_profit': 43.87}, {'period': '2021', 'revenue': 206.63, 'unit': 'B', 'net_profit': 79.95}, {'period': '2020', 'revenue': 149.93, 'unit': 'B', 'net_profit': -44.43}]","[{'period': ""Q1 '24"", 'revenue': 226.51, 'unit': 'B', 'net_profit': -39.56}, {'period': ""Q4 '23"", 'revenue': 260.56, 'unit': 'B', 'net_profit': 56.12}, {'period': ""Q3 '23"", 'revenue': 140.38, 'unit': 'B', 'net_profit': -51.65}, {'period': ""Q2 '23"", 'revenue': 101.24, 'unit': 'B', 'net_profit': -13.71}, {'period': ""Q1 '23"", 'revenue': 67.52, 'unit': 'B', 'net_profit': 78.97}, {'period': ""Q4 '22"", 'revenue': 79.92, 'unit': 'B', 'net_profit': 23.38}]",132.53,111.77,3473111000000,706400000000,260738000000,1909201000000,263962000000,147907000000,657605000000,114635000000,-11926000000,-0.08913842528270695,0.788465922042398,0.8366130820399114,"[0.58955, 0.03]","['2024-12-02', '1998-12-21']",__nan__,0.5497091800406033
941,CREX,Creative Realities Inc. Common Stock,"Creative Realities, Inc., together with its subsidiaries, provides digital marketing technology and solutions to retail companies, individual retail brands, enterprises, and organizations in the United States and internationally. Its technology and solutions include digital merchandising systems and omni-channel customer engagement systems; interactive digital shopping assistants; advisors and kiosks; and other interactive marketing technologies, such as mobile, social media, point-of-sale transactions, beaconing, and Web-based media that enables its customers to engage with their consumers. The company also provides system hardware; professional and implementation services; software design and development; and software licensing, deployment, and maintenance and support services, as well as media management and distribution software platforms and networks; device and product management; and customized software service layers, systems, experiences, workflows, and integrated solutions. The company sells its solutions to the automotive, apparel and accessories, banking, baby/children, beauty, CPG, department stores, digital out-of-home, electronics, fashion, fitness, foodservice/quick service restaurant, financial services, gaming, luxury, mass merchants, mobile operators, and pharmacy retail industries. Creative Realities, Inc. is headquartered in Louisville, Kentucky.",Mr. Richard C. Mills,Software - Application,2.96,USD,30922232,https://images.financialmodelingprep.com/symbol/CREX.png,64912,19.73,0.16,77472,3359000,-2937000,"[{'period': '2023', 'revenue': 45.17, 'unit': 'M', 'net_profit': -2.94}, {'period': '2022', 'revenue': 43.35, 'unit': 'M', 'net_profit': 1.88}, {'period': '2021', 'revenue': 18440.0, 'unit': 'K', 'net_profit': 232.0}, {'period': '2020', 'revenue': 17.46, 'unit': 'M', 'net_profit': -16.84}]","[{'period': ""Q3 '24"", 'revenue': 14440.0, 'unit': 'K', 'net_profit': 438.0}, {'period': ""Q2 '24"", 'revenue': 13120.0, 'unit': 'K', 'net_profit': -615.0}, {'period': ""Q1 '24"", 'revenue': 12290.0, 'unit': 'K', 'net_profit': -109.0}, {'period': ""Q4 '23"", 'revenue': 14.46, 'unit': 'M', 'net_profit': 1.42}, {'period': ""Q3 '23"", 'revenue': 11.57, 'unit': 'M', 'net_profit': -1.93}, {'period': ""Q2 '23"", 'revenue': 9.2, 'unit': 'M', 'net_profit': -1.43}]",-0.35,-0.35,70777000,18610000,2910000,41946000,12468000,0,20197000,2910000,1140000,2.5544973544973546,-2.5655650319829424,-1.4166666666666667,__nan__,__nan__,__nan__,0.5926501547112762
942,CREXW,Creative Realities Inc. Warrant,,None,Software - Application,0.0046,USD,0,https://images.financialmodelingprep.com/symbol/CREXW.png,0,0,0.0003,5020,3359000,-2937000,"[{'period': '2023', 'revenue': 45.17, 'unit': 'M', 'net_profit': -2.94}, {'period': '2022', 'revenue': 43.35, 'unit': 'M', 'net_profit': 1.88}, {'period': '2021', 'revenue': 18440.0, 'unit': 'K', 'net_profit': 232.0}, {'period': '2020', 'revenue': 17.46, 'unit': 'M', 'net_profit': -16.84}]","[{'period': ""Q3 '24"", 'revenue': 14440.0, 'unit': 'K', 'net_profit': 438.0}, {'period': ""Q2 '24"", 'revenue': 13120.0, 'unit': 'K', 'net_profit': -615.0}, {'period': ""Q1 '24"", 'revenue': 12290.0, 'unit': 'K', 'net_profit': -109.0}, {'period': ""Q4 '23"", 'revenue': 14.46, 'unit': 'M', 'net_profit': 1.42}, {'period': ""Q3 '23"", 'revenue': 11.57, 'unit': 'M', 'net_profit': -1.93}, {'period': ""Q2 '23"", 'revenue': 9.2, 'unit': 'M', 'net_profit': -1.43}]",-0.35,-0.35,70777000,18610000,2910000,41946000,12468000,0,20197000,2910000,1140000,2.5544973544973546,-2.5655650319829424,-1.4166666666666667,__nan__,__nan__,__nan__,0.5926501547112762
943,CRIS,Curis Inc. Common Stock,"Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.",Mr. James E. Dentzer,Biotechnology,3.5704,USD,30230434,https://images.financialmodelingprep.com/symbol/CRIS.png,120803,-0.46,0.0404,67033,-45139000,-47413000,"[{'period': '2023', 'revenue': 10.02, 'unit': 'M', 'net_profit': -47.41}, {'period': '2022', 'revenue': 10.16, 'unit': 'M', 'net_profit': -60.32}, {'period': '2021', 'revenue': 10.65, 'unit': 'M', 'net_profit': -50.64}, {'period': '2020', 'revenue': 10.84, 'unit': 'M', 'net_profit': -34.88}]","[{'period': ""Q3 '24"", 'revenue': 2.93, 'unit': 'M', 'net_profit': -10.09}, {'period': ""Q2 '24"", 'revenue': 2.55, 'unit': 'M', 'net_profit': -11.8}, {'period': ""Q1 '24"", 'revenue': 2.09, 'unit': 'M', 'net_profit': -11.88}, {'period': ""Q4 '23"", 'revenue': 2.7, 'unit': 'M', 'net_profit': -11.78}, {'period': ""Q3 '23"", 'revenue': 2.83, 'unit': 'M', 'net_profit': -12.18}, {'period': ""Q2 '23"", 'revenue': 2.2, 'unit': 'M', 'net_profit': -11.96}]",-8.96,-8.96,77282000,60908000,56334000,57612000,2794000,0,13517000,26681000,-38434000,0.10633537913284498,0.21402758437769379,0.30650154798761603,__nan__,__nan__,__nan__,0.745477601511348
944,CRKN,Crown Electrokinetics Corp. Common Stock,"Crown Electrokinetics Corp. develops and sells optical switching films. The company also focuses on commercializing electrokinetic technology for use in the smart glass market. It offers electrokinetic film technology for smart or dynamic glass. The company was formerly known as 3D Nanocolor Corp. and changed its name to Crown ElectroKinetics Corp. in October 2017. Crown ElectroKinetics Corp. was incorporated in 2015 and is based in Corvallis, Oregon.",Mr. Douglas B. Croxall,Chemicals - Specialty,0.1272,USD,8150378,https://images.financialmodelingprep.com/symbol/CRKN.png,23165517,0,-0.0058,105376374,-18336000,-28984000,"[{'period': '2023', 'revenue': 0.153, 'unit': 'M', 'net_profit': -28.98}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.37}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -37.16}, {'period': '2020', 'revenue': 0.1, 'unit': 'M', 'net_profit': -40.76}]","[{'period': ""Q3 '24"", 'revenue': 8.04, 'unit': 'M', 'net_profit': -5.86}, {'period': ""Q2 '24"", 'revenue': 4.65, 'unit': 'M', 'net_profit': -5.03}, {'period': ""Q1 '24"", 'revenue': 0.682, 'unit': 'M', 'net_profit': -4.61}, {'period': ""Q4 '23"", 'revenue': 0.094, 'unit': 'M', 'net_profit': -9.31}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.14}, {'period': ""Q2 '23"", 'revenue': 0.037, 'unit': 'M', 'net_profit': -14.62}]",-819.45,-819.45,9527000,1870000,1059000,4850000,83000,0,3776000,1059000,-18333000,-0.25546045874700446,-1.0169798190675017,-14.141352549889136,__nan__,__nan__,__nan__,0.5090794583814422
945,CRMD,CorMedix Inc. Common Stock,"CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.",Mr. Joseph  Todisco MBA,Biotechnology,10.055,USD,610109246,https://images.financialmodelingprep.com/symbol/CRMD.png,1146141,-12.57,2.125,3185726,-48887033,-46339227,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -46.34}, {'period': '2022', 'revenue': 0.06541, 'unit': 'M', 'net_profit': -29.7}, {'period': '2021', 'revenue': 0.19094, 'unit': 'M', 'net_profit': -28.21}, {'period': '2020', 'revenue': 0.23923, 'unit': 'M', 'net_profit': -22.03}]","[{'period': ""Q3 '24"", 'revenue': 11.46, 'unit': 'M', 'net_profit': -2.78}, {'period': ""Q2 '24"", 'revenue': 0.8061200000000001, 'unit': 'M', 'net_profit': -14.15}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.47}, {'period': ""Q4 '23"", 'revenue': 0.30411000000000005, 'unit': 'M', 'net_profit': -14.75}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.74}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.27}]",-0.91,-0.91,82059957,79450400,76030814,11917528,0,1,11400515,43642684,-38736780,-0.6267603037344817,-0.560153768950301,-0.2297297297297298,__nan__,__nan__,__nan__,0.14522951797305964
946,CRMT,America's Car-Mart Inc Common Stock,"America's Car-Mart, Inc., through its subsidiaries, operates as an automotive retailer in the United States. It primarily sells older model used vehicles and provides financing for its customers. As of April 30, 2022, the company operated 154 dealerships in the South-Central United States. The company was founded in 1981 and is based in Rogers, Arkansas.",Mr. Douglas  Campbell,Auto - Dealerships,47.966,USD,395844691,https://images.financialmodelingprep.com/symbol/CRMT.png,111208,-66.62,-0.474,57003,32084000,-31393000,"[{'period': '2023', 'revenue': 1390.0, 'unit': 'M', 'net_profit': -31.39}, {'period': '2022', 'revenue': 1410.0, 'unit': 'M', 'net_profit': 20.43}, {'period': '2021', 'revenue': 1210.0, 'unit': 'M', 'net_profit': 95.01}, {'period': '2020', 'revenue': 918.61, 'unit': 'M', 'net_profit': 104.82}]","[{'period': ""Q2 '24"", 'revenue': 347.27, 'unit': 'M', 'net_profit': 4.12}, {'period': ""Q1 '24"", 'revenue': 347760.0, 'unit': 'K', 'net_profit': -964.0}, {'period': ""Q4 '23"", 'revenue': 364670.0, 'unit': 'K', 'net_profit': 426.0}, {'period': ""Q3 '23"", 'revenue': 299.61, 'unit': 'M', 'net_profit': -8.54}, {'period': ""Q2 '23"", 'revenue': 361.58, 'unit': 'M', 'net_profit': -27.46}, {'period': ""Q1 '23"", 'revenue': 368.02, 'unit': 'M', 'net_profit': 4.19}]",-4.92,-4.92,1477644000,1310373000,5522000,1006494000,1108456000,0,353799000,5522000,-80044000,-0.5397371894187181,-2.5364624119028973,-2.5375,__nan__,__nan__,__nan__,0.6811478272168398
947,CRNC,Cerence Inc. Common Stock,"Cerence Inc. provides AI powered virtual assistants for the mobility/transportation market worldwide. The company offers edge software components; cloud-connected components and related toolkits and applications; and virtual assistant coexistence and professional services. It also provides conversational artificial intelligence-based solutions, including speech recognition, natural language understanding, speech signal enhancement, text-to-speech, and acoustic modeling technology. Cerence Inc. is headquartered in Burlington, Massachusetts.",Mr. Brian Matthew Krzanich,Software - Application,19.73,USD,848161132,https://images.financialmodelingprep.com/symbol/CRNC.png,6805290,-1.4,-0.45,17718732,-561427000,-588078000,"[{'period': '2024', 'revenue': 331.5, 'unit': 'M', 'net_profit': -588.08}, {'period': '2023', 'revenue': 294.48, 'unit': 'M', 'net_profit': -56.25}, {'period': '2022', 'revenue': 327.89, 'unit': 'M', 'net_profit': -310.83}, {'period': '2021', 'revenue': 387.18, 'unit': 'M', 'net_profit': 45.89}]","[{'period': ""Q4 '24"", 'revenue': 54.8, 'unit': 'M', 'net_profit': -20.42}, {'period': ""Q3 '24"", 'revenue': 70.54, 'unit': 'M', 'net_profit': -313.54}, {'period': ""Q2 '24"", 'revenue': 67.83, 'unit': 'M', 'net_profit': -277.98}, {'period': ""Q1 '24"", 'revenue': 138.34, 'unit': 'M', 'net_profit': 23.86}, {'period': ""Q4 '23"", 'revenue': 80.76, 'unit': 'M', 'net_profit': -11.55}, {'period': ""Q3 '23"", 'revenue': 61.66, 'unit': 'M', 'net_profit': -16.45}]",-14.12,-14.12,702358000,265509000,126987000,561261000,62755000,0,216808000,121485000,12200000,-99.57810820494447,-9.45397660610801,-9.085714285714285,__nan__,__nan__,__nan__,0.7991095709025882
948,CRNT,Ceragon Networks Ltd. Ordinary Shares,"Ceragon Networks Ltd. provides wireless backhaul and fronthaul solutions that enable cellular operators and other wireless service providers. Its solutions use microwave and millimeter wave radio technology to transfer telecommunication traffic between base stations, small/distributed cells, and the core of the service provider's network. The company also uses microwave technology for ultra-high speed, ultra-low latency communication for wireless 5G and 4G, 3G, and other cellular base stations. In addition, it provides IP-20 all-outdoor solutions, such as IP-20C, IP-20C-HP, IP-20S, IP-20E, and IP-20V; IP-20 split-mount/all-indoor solutions comprising IP-20N/IP-20A, IP-20F, and IP-20G; and IP-50 disaggregated solutions, including IP-50E, IP-50C, IP-50S, and IP-50FX for various short-haul, long-haul, fronthaul, and enterprise access applications. Further, the company offers network management system; and network and radio planning, site survey, solutions development, installation, network auditing and optimization, maintenance, training, and other services. It provides its services to oil and gas companies; public safety organizations; business and public institutions; broadcasters; energy utilities; and private communications networks. The company sells its products through direct sales, original equipment manufacturers, distributors, and system integrators. It operates in North America, Europe, Africa, the Asia Pacific, the Middle East, India, and Latin America. The company was formerly known as Giganet Ltd. and changed its name to Ceragon Networks Ltd. in September 2000. Ceragon Networks Ltd. was incorporated in 1996 and is headquartered in Rosh HaAyin, Israel.",Mr. Doron  Arazi,Communication Equipment,5.38,USD,461983290,https://images.financialmodelingprep.com/symbol/CRNT.png,1496870,25.62,-0.1,2814114,30247000,6220000,"[{'period': '2023', 'revenue': 347.18, 'unit': 'M', 'net_profit': 6.22}, {'period': '2022', 'revenue': 295.17, 'unit': 'M', 'net_profit': -7.4}, {'period': '2021', 'revenue': 290.77, 'unit': 'M', 'net_profit': -14.83}, {'period': '2020', 'revenue': 262.88, 'unit': 'M', 'net_profit': -16.11}]","[{'period': ""Q3 '24"", 'revenue': 102.67, 'unit': 'M', 'net_profit': 12.22}, {'period': ""Q2 '24"", 'revenue': 96.09, 'unit': 'M', 'net_profit': 7.83}, {'period': ""Q1 '24"", 'revenue': 88500.0, 'unit': 'K', 'net_profit': 403.0}, {'period': ""Q4 '23"", 'revenue': 90.36, 'unit': 'M', 'net_profit': -1.2}, {'period': ""Q3 '23"", 'revenue': 87.26, 'unit': 'M', 'net_profit': 3.37}, {'period': ""Q2 '23"", 'revenue': 86.15, 'unit': 'M', 'net_profit': 2.09}]",0.0735,0.0728,298525000,217940000,28237000,164506000,113851000,0,132953000,28237000,17988000,26.48190857785053,1.8406541424516827,1.8361774744027302,__nan__,__nan__,__nan__,0.5510627250649024
949,CRNX,Crinetics Pharmaceuticals Inc. Common Stock,"Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.",Dr. R. Scott Struthers Ph.D.,Biotechnology,50.13,USD,4648935888,https://images.financialmodelingprep.com/symbol/CRNX.png,742612,-13.55,-0.36,243408,-221510000,-214529000,"[{'period': '2023', 'revenue': 4.01, 'unit': 'M', 'net_profit': -214.53}, {'period': '2022', 'revenue': 4.74, 'unit': 'M', 'net_profit': -159.95}, {'period': '2021', 'revenue': 1.08, 'unit': 'M', 'net_profit': -106.72}, {'period': '2020', 'revenue': 0.07100000000000001, 'unit': 'M', 'net_profit': -72.86}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -76.83}, {'period': ""Q2 '24"", 'revenue': 0.399, 'unit': 'M', 'net_profit': -74.06}, {'period': ""Q1 '24"", 'revenue': 0.64, 'unit': 'M', 'net_profit': -66.93}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -60.1}, {'period': ""Q3 '23"", 'revenue': 0.34600000000000003, 'unit': 'M', 'net_profit': -57.46}, {'period': ""Q2 '23"", 'revenue': 0.988, 'unit': 'M', 'net_profit': -50.98}]",-3.69,-3.69,635353000,574153000,558555000,96247000,9351000,1770000,43942000,54897000,-170995000,-0.32720986944199787,-0.34119184265476327,-0.198051948051948,__nan__,__nan__,__nan__,0.15148586691177976
950,CRON,Cronos Group Inc. Common Share,"Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.",Mr. Michael Ryan Gorenstein J.D.,Drug Manufacturers - Specialty & Generic,2.02,USD,772235900,https://images.financialmodelingprep.com/symbol/CRON.png,1178051,-16.83,-0.01,1035422,-71800000,-73963000,"[{'period': '2023', 'revenue': 87.24, 'unit': 'M', 'net_profit': -73.96}, {'period': '2022', 'revenue': 91.9, 'unit': 'M', 'net_profit': -168.73}, {'period': '2021', 'revenue': 74.44, 'unit': 'M', 'net_profit': -396.7}, {'period': '2020', 'revenue': 46.72, 'unit': 'M', 'net_profit': -74.62}]","[{'period': ""Q3 '24"", 'revenue': 34.26, 'unit': 'M', 'net_profit': 8.35}, {'period': ""Q2 '24"", 'revenue': 27.76, 'unit': 'M', 'net_profit': -8.76}, {'period': ""Q1 '24"", 'revenue': 25.18, 'unit': 'M', 'net_profit': -2.23}, {'period': ""Q4 '23"", 'revenue': 24.58, 'unit': 'M', 'net_profit': -46.04}, {'period': ""Q3 '23"", 'revenue': 33.91, 'unit': 'M', 'net_profit': -1.64}, {'period': ""Q2 '23"", 'revenue': 19.02, 'unit': 'M', 'net_profit': -8.36}]",-0.19,-0.19,1140085000,933306000,861528000,43961000,35878000,54739000,41399000,669291000,-46258000,0.2133058684314327,0.5616591795370228,0.5777777777777778,__nan__,__nan__,__nan__,0.03855940565835003
951,CROX,Crocs Inc. Common Stock,"Crocs, Inc., together with its subsidiaries, designs, develops, manufactures, markets, and distributes casual lifestyle footwear and accessories for men, women, and children. It offers various footwear products, including clogs, sandals, slides, flip-flops, boots, flats, wedges, platforms, socks, shoe charms, loafers, sneakers, and slippers under the Crocs brand name. The company sells its products in approximately 85 countries through wholesalers, retail stores, e-commerce sites, and third-party marketplaces. As of December 31, 2021, it had 193 outlet stores, 107 retail stores, 373 company-operated stores, 73 kiosks and store-in-stores, and 14 company-operated e-commerce sites. The company serves in the Americas, the Asia Pacific, Europe, the Middle East, and Africa. Crocs, Inc. was founded in 1999 and is headquartered in Broomfield, Colorado.",Mr. Andrew  Rees,Apparel - Footwear & Accessories,110.9011,USD,6463560090,https://images.financialmodelingprep.com/symbol/CROX.png,1477561,8.06,-1.1689,336441,1091927000,792566000,"[{'period': '2023', 'revenue': 3960.0, 'unit': 'M', 'net_profit': 792.57}, {'period': '2022', 'revenue': 3550.0, 'unit': 'M', 'net_profit': 540.16}, {'period': '2021', 'revenue': 2310.0, 'unit': 'M', 'net_profit': 725.69}, {'period': '2020', 'revenue': 1390.0, 'unit': 'M', 'net_profit': 312.86}]","[{'period': ""Q3 '24"", 'revenue': 1060.0, 'unit': 'M', 'net_profit': 199.8}, {'period': ""Q2 '24"", 'revenue': 1110.0, 'unit': 'M', 'net_profit': 228.91}, {'period': ""Q1 '24"", 'revenue': 938.63, 'unit': 'M', 'net_profit': 152.45}, {'period': ""Q4 '23"", 'revenue': 960.1, 'unit': 'M', 'net_profit': 253.59}, {'period': ""Q3 '23"", 'revenue': 1050.0, 'unit': 'M', 'net_profit': 177.03}, {'period': ""Q2 '23"", 'revenue': 1070.0, 'unit': 'M', 'net_profit': 212.41}]",12.91,12.79,4643834000,910704000,149288000,3189911000,331231000,0,698296000,149288000,814819000,0.22153832385235403,0.46728278155135805,0.463718820861678,__nan__,__nan__,__nan__,0.6869132273031293
952,CRSA,Crescent Acquisition Corp Class A Common Stock,"Crescent Acquisition Corp. intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or business combination. The company was formerly known as Crescent Funding Inc. and changed its name to Crescent Acquisition Corp. in October 2018. The company was founded in 2017 and is based in Los Angeles, California.",Mr. Todd M. Purdy,Shell Companies,8.81,USD,817654338,https://images.financialmodelingprep.com/symbol/CRSA.png,381656,0,-0.30999947,216454,-28622000,-37475000,"[{'period': '2022', 'revenue': 136.03, 'unit': 'M', 'net_profit': -37.48}, {'period': '2021', 'revenue': 119.23, 'unit': 'M', 'net_profit': -103.19}, {'period': '2020', 'revenue': 102.55, 'unit': 'M', 'net_profit': -4.64}, {'period': '2019', 'revenue': 92.75, 'unit': 'M', 'net_profit': -6.91}]","[{'period': ""Q3 '23"", 'revenue': 35.35, 'unit': 'M', 'net_profit': -5.75}, {'period': ""Q2 '23"", 'revenue': 35.38, 'unit': 'M', 'net_profit': -4.39}, {'period': ""Q1 '23"", 'revenue': 36.87, 'unit': 'M', 'net_profit': -8.47}, {'period': ""Q4 '22"", 'revenue': 35.69, 'unit': 'M', 'net_profit': -5.94}, {'period': ""Q3 '22"", 'revenue': 35.25, 'unit': 'M', 'net_profit': -7.77}, {'period': ""Q2 '22"", 'revenue': 32.99, 'unit': 'M', 'net_profit': -10.78}]",-0.41,-0.41,178155000,98753000,68924000,80920000,21447000,-48133818,22352000,20742000,-24750000,0.695377771155504,0.6368490416109464,0.682170542635659,__nan__,__nan__,__nan__,0.45421122056636076
953,CRSAU,Crescent Acquisition Corp Unit,"Crescent Acquisition Corp. intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or business combination. The company was formerly known as Crescent Funding Inc. and changed its name to Crescent Acquisition Corp. in October 2018. The company was founded in 2017 and is based in Los Angeles, California.",Mr. Todd M. Purdy,Shell Companies,10.15,USD,937847891,https://images.financialmodelingprep.com/symbol/CRSAU.png,403,-27.211796246648795,0,20,-28622000,-37475000,"[{'period': '2022', 'revenue': 136.03, 'unit': 'M', 'net_profit': -37.48}, {'period': '2021', 'revenue': 119.23, 'unit': 'M', 'net_profit': -103.19}, {'period': '2020', 'revenue': 102.55, 'unit': 'M', 'net_profit': -4.64}, {'period': '2019', 'revenue': 92.75, 'unit': 'M', 'net_profit': -6.91}]","[{'period': ""Q3 '23"", 'revenue': 35.35, 'unit': 'M', 'net_profit': -5.75}, {'period': ""Q2 '23"", 'revenue': 35.38, 'unit': 'M', 'net_profit': -4.39}, {'period': ""Q1 '23"", 'revenue': 36.87, 'unit': 'M', 'net_profit': -8.47}, {'period': ""Q4 '22"", 'revenue': 35.69, 'unit': 'M', 'net_profit': -5.94}, {'period': ""Q3 '22"", 'revenue': 35.25, 'unit': 'M', 'net_profit': -7.77}, {'period': ""Q2 '22"", 'revenue': 32.99, 'unit': 'M', 'net_profit': -10.78}]",-0.41,-0.41,178155000,98753000,68924000,80920000,21447000,-48133818,22352000,20742000,-24750000,0.695377771155504,0.6368490416109464,0.682170542635659,__nan__,__nan__,__nan__,0.45421122056636076
954,CRSAW,Crescent Acquisition Corp Warrant,,None,Shell Companies,1.5982,USD,0,https://images.financialmodelingprep.com/symbol/CRSAW.png,0,-1598.2,-0.05180001,742415,-28622000,-37475000,"[{'period': '2022', 'revenue': 136.03, 'unit': 'M', 'net_profit': -37.48}, {'period': '2021', 'revenue': 119.23, 'unit': 'M', 'net_profit': -103.19}, {'period': '2020', 'revenue': 102.55, 'unit': 'M', 'net_profit': -4.64}, {'period': '2019', 'revenue': 92.75, 'unit': 'M', 'net_profit': -6.91}]","[{'period': ""Q3 '23"", 'revenue': 35.35, 'unit': 'M', 'net_profit': -5.75}, {'period': ""Q2 '23"", 'revenue': 35.38, 'unit': 'M', 'net_profit': -4.39}, {'period': ""Q1 '23"", 'revenue': 36.87, 'unit': 'M', 'net_profit': -8.47}, {'period': ""Q4 '22"", 'revenue': 35.69, 'unit': 'M', 'net_profit': -5.94}, {'period': ""Q3 '22"", 'revenue': 35.25, 'unit': 'M', 'net_profit': -7.77}, {'period': ""Q2 '22"", 'revenue': 32.99, 'unit': 'M', 'net_profit': -10.78}]",-0.41,-0.41,178155000,98753000,68924000,80920000,21447000,-48133818,22352000,20742000,-24750000,0.695377771155504,0.6368490416109464,0.682170542635659,__nan__,__nan__,__nan__,0.45421122056636076
955,CRSP,CRISPR Therapeutics AG Common Shares,"CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.",Dr. Samarth  Kulkarni Ph.D.,Biotechnology,42.53,USD,3630084355,https://images.financialmodelingprep.com/symbol/CRSP.png,1671706,-14.72,0.1,918646,-202701000,-153610000,"[{'period': '2023', 'revenue': 371.21, 'unit': 'M', 'net_profit': -153.61}, {'period': '2022', 'revenue': 0.436, 'unit': 'M', 'net_profit': -650.17}, {'period': '2021', 'revenue': 913.08, 'unit': 'M', 'net_profit': 377.66}, {'period': '2020', 'revenue': 0.543, 'unit': 'M', 'net_profit': -348.87}]","[{'period': ""Q3 '24"", 'revenue': 0.602, 'unit': 'M', 'net_profit': -85.94}, {'period': ""Q2 '24"", 'revenue': 0.517, 'unit': 'M', 'net_profit': -126.41}, {'period': ""Q1 '24"", 'revenue': 0.504, 'unit': 'M', 'net_profit': -116.59}, {'period': ""Q4 '23"", 'revenue': 200.0, 'unit': 'M', 'net_profit': 89.35}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -112.15}, {'period': ""Q2 '23"", 'revenue': 70.0, 'unit': 'M', 'net_profit': -77.74}]",-1.94,-1.94,2229571000,1908078000,1693692000,346768000,200000000,1973000,108791000,389477000,-272345000,0.6876665089855144,0.7637405313953936,0.7679425837320575,__nan__,__nan__,__nan__,0.15553126588029714
956,CRSR,Corsair Gaming Inc. Common Stock,"Corsair Gaming, Inc., together with its subsidiaries, designs, markets, and distributes gaming and streaming peripherals, components and systems in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers gamer and creator peripherals, including gaming keyboards, mice, headsets, and controllers, as well as capture cards, stream decks, USB microphones, studio accessories, and EpocCam software. It also provides gaming components and systems comprising power supply units, cooling solutions, computer cases, and DRAM modules, as well as prebuilt and custom-built gaming PCs, and others; and PC gaming software comprising iCUE for gamers and Elgato's streaming suite for streamers and content creators. In addition, the company offers coaching and training, and other services. It sells its products through a network of distributors and retailers, including online retailers, as well as directly to consumers through its website. The company was incorporated in 1994 and is headquartered in Fremont, California. Corsair Gaming, Inc. is a subsidiary of Corsair Group (Cayman), LP.",Mr. Andrew J. Paul,Computer Hardware,7.61,USD,796767000,https://images.financialmodelingprep.com/symbol/CRSR.png,487935,-8.36,0.045,352042,64639000,-2590000,"[{'period': '2023', 'revenue': 1460.0, 'unit': 'M', 'net_profit': -2.59}, {'period': '2022', 'revenue': 1380.0, 'unit': 'M', 'net_profit': -53.95}, {'period': '2021', 'revenue': 1900.0, 'unit': 'M', 'net_profit': 100.96}, {'period': '2020', 'revenue': 1700.0, 'unit': 'M', 'net_profit': 103.22}]","[{'period': ""Q3 '24"", 'revenue': 304.2, 'unit': 'M', 'net_profit': -51.71}, {'period': ""Q2 '24"", 'revenue': 261.3, 'unit': 'M', 'net_profit': -29.58}, {'period': ""Q1 '24"", 'revenue': 337.26, 'unit': 'M', 'net_profit': -12.54}, {'period': ""Q4 '23"", 'revenue': 417.29, 'unit': 'M', 'net_profit': 6.98}, {'period': ""Q3 '23"", 'revenue': 363.19, 'unit': 'M', 'net_profit': -3.08}, {'period': ""Q2 '23"", 'revenue': 325.43, 'unit': 'M', 'net_profit': -4.48}]",0.0311,0.03,1357463000,711589000,175620000,663483000,253268000,0,418487000,175620000,76392000,62.15326395458846,0.9519890260631001,1.0555357142857142,__nan__,__nan__,__nan__,0.4887669129840003
957,CRTD,Creatd Inc. Common Stock,"Creatd, Inc., a technology company, provides economic opportunities for creators. The company operated in three segments: Creatd Labs, Creatd Partners, and Creatd Ventures. Its flagship product is Vocal, a content distribution platform that delivers a digital publishing platform organized into niche-communities capable of hosting various rich media content. The company's Vocal platform enhances the visibility of content and maximizes viewership, and provides advertisers access to target markets that closely match their interests. It also offers Vocal for Brands, an internal content marketing studio that pairs leading brands with vocal creators to produce marketing campaigns; WHE Agency that focuses on representation and management of family and lifestyle-focused influencers and digital creators; and Seller's Choice, a marketing agency for direct-to-consumer and e-commerce clients, which provides design, development, strategy, and sales optimization services. In addition, the company builds, develops, and scales e-commerce brands, such as Camp and Dune Glow Remedy. Further, its Creatd studios elevates creators' stories to TV, film, books, podcasts, videos, and others. The company was formerly known as Jerrick Media Holdings, Inc. and changed its name to Creatd Inc. in September 2020. Creatd, Inc. is headquartered in New York, New York.",Mr. Jeremy Phillip Frommer,Internet Content & Information,0.455,USD,167147,https://images.financialmodelingprep.com/symbol/CRTD.png,5972,0,0,133,-14568474,-24233681,"[{'period': '2023', 'revenue': 1.92, 'unit': 'M', 'net_profit': -24.23}, {'period': '2022', 'revenue': 4.8, 'unit': 'M', 'net_profit': -36.66}, {'period': '2021', 'revenue': 4.3, 'unit': 'M', 'net_profit': -41.34}, {'period': '2020', 'revenue': 1.21, 'unit': 'M', 'net_profit': -30.28}]","[{'period': ""Q2 '24"", 'revenue': 0.37854000000000004, 'unit': 'M', 'net_profit': -3.88}, {'period': ""Q1 '24"", 'revenue': 0.42847, 'unit': 'M', 'net_profit': 1.91}, {'period': ""Q3 '23"", 'revenue': 0.43786, 'unit': 'M', 'net_profit': -2.92}, {'period': ""Q2 '23"", 'revenue': 0.69936, 'unit': 'M', 'net_profit': -4.45}, {'period': ""Q1 '23"", 'revenue': 0.98614, 'unit': 'M', 'net_profit': -15.91}, {'period': ""Q4 '22"", 'revenue': 0.79898, 'unit': 'M', 'net_profit': -11.69}]",-0.47,-0.47,2164127,73255,71105,23052635,0,0,21448447,71105,-3401763,0.49817719693272516,0.3389719129467413,0.9890595903165735,__nan__,__nan__,__nan__,10.652163666919732
958,CRTDW,Creatd Inc. Warrant,"Creatd, Inc., a technology company, provides economic opportunities for creators in the United States. It operates in four segments: Creatd Labs, Creatd Partners, Creatd Ventures, and Creatd Studios. The company's flagship product is Vocal that delivers a digital publishing platform organized into niche-communities capable of hosting various rich media content. Its Vocal platform enhances the visibility of content and maximizes viewership; and provides advertisers access to target markets that closely match its interests. The company also offers Vocal for Brands, a content marketing that fosters relationships between brands and creators through its suite of agency services; Seller's Choice, performance marketing initiatives; and WHE Agency, an influencer marketing. In addition, it builds, develops, and scales e-commerce brands, such as Camp and Dune Glow Remedy. Further, the company's Creatd studios elevates creators to develop their content for television, film, prints, and podcasts. It serves businesses and consumers. The company was formerly known as Jerrick Media Holdings, Inc. and changed its name to Creatd Inc. in September 2020. Creatd, Inc. is headquartered in New York, New York.",Mr. Jeremy Phillip Frommer,Internet Content & Information,0.0018,USD,44412,https://images.financialmodelingprep.com/symbol/CRTDW.png,0,,0.0005,10000,-14568474,-24233681,"[{'period': '2023', 'revenue': 1.92, 'unit': 'M', 'net_profit': -24.23}, {'period': '2022', 'revenue': 4.8, 'unit': 'M', 'net_profit': -36.66}, {'period': '2021', 'revenue': 4.3, 'unit': 'M', 'net_profit': -41.34}, {'period': '2020', 'revenue': 1.21, 'unit': 'M', 'net_profit': -30.28}]","[{'period': ""Q2 '24"", 'revenue': 0.37854000000000004, 'unit': 'M', 'net_profit': -3.88}, {'period': ""Q1 '24"", 'revenue': 0.42847, 'unit': 'M', 'net_profit': 1.91}, {'period': ""Q3 '23"", 'revenue': 0.43786, 'unit': 'M', 'net_profit': -2.92}, {'period': ""Q2 '23"", 'revenue': 0.69936, 'unit': 'M', 'net_profit': -4.45}, {'period': ""Q1 '23"", 'revenue': 0.98614, 'unit': 'M', 'net_profit': -15.91}, {'period': ""Q4 '22"", 'revenue': 0.79898, 'unit': 'M', 'net_profit': -11.69}]",-0.47,-0.47,2164127,73255,71105,23052635,0,0,21448447,71105,-3401763,0.49817719693272516,0.3389719129467413,0.9890595903165735,__nan__,__nan__,__nan__,10.652163666919732
959,CRTO,Criteo S.A. American Depositary Shares,"Criteo S.A., a technology company, provides marketing and monetization services on the open Internet in North and South America, Europe, the Middle East, and Africa, and the Asia-Pacific. The company's Criteo Shopper Graph, which derives clients' proprietary commerce data, such as transaction activity on their digital properties. Its Criteo AI Engine solutions include lookalike finder, recommendation, and predictive bidding algorithms; bidding engine that executes campaigns based on certain objectives set by its clients; dynamic creative optimization+, which assembles customized creative advertising content by optimizing each individual creative component in the advertisement; software systems and processes, which enable data synchronization, storage, and analysis of distributed computing infrastructure in various geographies; and experimentation platform, an offline/online testing platform to enhance the capabilities and effectiveness of prediction models. The company also provides Criteo Marketing Solutions that allow commerce companies to address various marketing goals by engaging their consumers with personalized ads across the web, mobile, and offline store environments; and Criteo Retail Media solutions, which allows retailers to generate advertising revenues from consumer brands, and/or to drive sales for themselves, by monetizing their data and audiences through personalized ads, either on their own digital property or on the open Internet. In addition, it offers real-time access to advertising inventory through its publisher partners; consulting services to companies in distance sales; and business intelligence and analytics services. It serves companies in digital retail, travel, and classifieds industries. Criteo S.A. was incorporated in 2005 and is headquartered in Paris, France.",Ms. Megan  Clarken,Advertising Agencies,38.915,USD,2131804055,https://images.financialmodelingprep.com/symbol/CRTO.png,436469,23.16,-1.545,218762,154597000,53259000,"[{'period': '2023', 'revenue': 1950.0, 'unit': 'M', 'net_profit': 53.26}, {'period': '2022', 'revenue': 2020.0, 'unit': 'M', 'net_profit': 8.95}, {'period': '2021', 'revenue': 2250.0, 'unit': 'M', 'net_profit': 134.46}, {'period': '2020', 'revenue': 2070.0, 'unit': 'M', 'net_profit': 71.68}]","[{'period': ""Q3 '24"", 'revenue': 458.89, 'unit': 'M', 'net_profit': 6.26}, {'period': ""Q2 '24"", 'revenue': 470.87, 'unit': 'M', 'net_profit': 26.99}, {'period': ""Q1 '24"", 'revenue': 449.0, 'unit': 'M', 'net_profit': 7.24}, {'period': ""Q4 '23"", 'revenue': 570.95, 'unit': 'M', 'net_profit': 61.02}, {'period': ""Q3 '23"", 'revenue': 469.19, 'unit': 'M', 'net_profit': 6.93}, {'period': ""Q2 '23"", 'revenue': 468.93, 'unit': 'M', 'net_profit': -2.88}]",0.95,0.88,2431919000,1352562000,342311000,1320528000,894239000,21869000,1180487000,336341000,131745000,-0.22331409164669652,4.9493967828418235,5.333333333333333,__nan__,__nan__,__nan__,0.5429983482180122
960,CRTX,Cortexyme Inc. Common Stock,"Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.",Ms. Casey Lynch,Biotechnology,1.95,USD,70454085,https://images.financialmodelingprep.com/symbol/CRTX.png,0,-0.6581167735403307,0.05000007,272208,-90318000,-89945000,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -89.94}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -76.85}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -36.98}, {'period': '2018', 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.48}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.56}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.71}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -89.94}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.71}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.75}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -23.09}]",-3.02,-3.02,133228000,111673000,106802000,14642000,0,19933000,14222000,69724000,-63112000,-0.14481639689199297,-0.17041210685890512,-0.14828897338403046,__nan__,__nan__,__nan__,0.10990182243972739
961,CRUS,Cirrus Logic Inc. Common Stock,"Cirrus Logic, Inc., a fabless semiconductor company, provides low-power and high-precision mixed-signal processing solutions in the United States and internationally. It offers portable products, including codecs components that integrate analog-to-digital converters (ADCs) and digital-to-analog converters (DACs) into a single integrated circuit (IC); smart codecs, a codec with digital signal processer; boosted amplifiers; digital signal processors; and SoundClear technology, which consists of a portfolio of tools, software, and algorithms that helps to enhance user experience with features, such as louder, high-fidelity sound, audio playback, voice capture, hearing augmentation, and active noise cancellation. The company's audio products are used in smartphones, tablets, wireless headsets, laptops, AR/VR headsets, home theater systems, automotive entertainment systems, and professional audio systems. It also provides high-performance mixed-signal products, such as haptic driver and sensing solutions, camera controllers, power conversion, and control ICs and fast-charging ICs used in various industrial and energy applications comprising digital utility meters, power supplies, energy control, energy measurement, and energy exploration. The company markets and sells its products through direct sales force, external sales representatives, and distributors. Cirrus Logic, Inc. was incorporated in 1984 and is headquartered in Austin, Texas.",Mr. John M. Forsyth,Semiconductors,104.7,USD,5563747530,https://images.financialmodelingprep.com/symbol/CRUS.png,676530,17.81,2.22,280712,401951000,274572000,"[{'period': '2024', 'revenue': 1790.0, 'unit': 'M', 'net_profit': 274.57}, {'period': '2023', 'revenue': 1900.0, 'unit': 'M', 'net_profit': 176.7}, {'period': '2022', 'revenue': 1780.0, 'unit': 'M', 'net_profit': 326.36}, {'period': '2021', 'revenue': 1370.0, 'unit': 'M', 'net_profit': 217.34}]","[{'period': ""Q2 '25"", 'revenue': 541.86, 'unit': 'M', 'net_profit': 102.14}, {'period': ""Q1 '25"", 'revenue': 374.03, 'unit': 'M', 'net_profit': 42.09}, {'period': ""Q4 '24"", 'revenue': 371.83, 'unit': 'M', 'net_profit': 44.84}, {'period': ""Q3 '24"", 'revenue': 618.98, 'unit': 'M', 'net_profit': 138.72}, {'period': ""Q2 '24"", 'revenue': 481.06, 'unit': 'M', 'net_profit': 75.41}, {'period': ""Q1 '24"", 'revenue': 317.02, 'unit': 'M', 'net_profit': 15.6}]",5.06,4.9,2231576000,1106192000,526542000,414562000,162478000,173374000,186393000,502764000,383329000,0.27024020579135816,0.5538615643197908,0.5911949685534589,__nan__,__nan__,__nan__,0.18577095290503215
962,CRVL,CorVel Corp. Common Stock,"CorVel Corporation provides workers' compensation, auto, liability, and health solutions for employers, third party administrators, insurance companies, and government agencies to assist them in managing the medical costs and monitoring the quality of care associated with healthcare claims. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement services, retrospective utilization review, facility claim review, professional review, pharmacy services, directed care services, Medicare solutions, clearinghouse services, independent medical examinations, and inpatient medical bill review. It also provides a range of patient management services, such as claims management, case management, 24/7 nurse triage, utilization management, vocational rehabilitation, and life care planning, as well as processing of claims for self-insured payors with respect to property and casualty insurance. The company was incorporated in 1987 and is headquartered in Fort Worth, Texas.",Mr. Michael G. Combs,Insurance - Brokers,108.115,USD,5554786528,https://images.financialmodelingprep.com/symbol/CRVL.png,120769,68.86,-0.915,26801,121353000,76252000,"[{'period': '2023', 'revenue': 795.31, 'unit': 'M', 'net_profit': 76.25}, {'period': '2022', 'revenue': 718.56, 'unit': 'M', 'net_profit': 66.36}, {'period': '2021', 'revenue': 646.23, 'unit': 'M', 'net_profit': 66.41}, {'period': '2020', 'revenue': 552.64, 'unit': 'M', 'net_profit': 46.36}]","[{'period': ""Q2 '24"", 'revenue': 224.38, 'unit': 'M', 'net_profit': 23.4}, {'period': ""Q1 '24"", 'revenue': 211.72, 'unit': 'M', 'net_profit': 21.58}, {'period': ""Q4 '23"", 'revenue': 207.23, 'unit': 'M', 'net_profit': 19.45}, {'period': ""Q3 '23"", 'revenue': 202.3, 'unit': 'M', 'net_profit': 17.09}, {'period': ""Q2 '23"", 'revenue': 195.52, 'unit': 'M', 'net_profit': 19.9}, {'period': ""Q1 '23"", 'revenue': 190.25, 'unit': 'M', 'net_profit': 19.8}]",4.45,4.4,454679000,302231000,105563000,207032000,97108000,0,184499000,105563000,69997000,0.10647823113745156,0.1489791305658103,0.16187989556135773,__nan__,__nan__,__nan__,0.4553366221004269
963,CRVS,Corvus Pharmaceuticals Inc. Common Stock,"Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.",Dr. Richard A. Miller M.D.,Biotechnology,5.84,USD,375262048,https://images.financialmodelingprep.com/symbol/CRVS.png,1180974,-5.9,,0,-26878000,-27029000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -27.03}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -50.05}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -38.2}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.82}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -40.22}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.26}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.7}, {'period': ""Q4 '23"", 'revenue': 0.246, 'unit': 'M', 'net_profit': -6.65}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.0}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.5}]",-0.56,-0.56,45553000,27956000,27149000,6869000,63000,16123000,6869000,12620000,-23969000,0.34347826086956523,0.45994924973525947,0.48148148148148145,__nan__,__nan__,__nan__,0.15079138585823107
964,CRWD,CrowdStrike Holdings Inc. Class A Common Stock,"CrowdStrike Holdings, Inc. provides cloud-delivered protection across endpoints and cloud workloads, identity, and data. It offers threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. The company primarily sells subscriptions to its Falcon platform and cloud modules through its direct sales team that leverages its network of channel partners. It serves customers worldwide. The company was incorporated in 2011 and is based in Austin, Texas.",Mr. George R. Kurtz,Software - Infrastructure,361.28,USD,88987317200,https://images.financialmodelingprep.com/symbol/CRWD.png,3559254,708.39,-5.08,1474004,293827000,89327000,"[{'period': '2024', 'revenue': 3060.0, 'unit': 'M', 'net_profit': 89.33}, {'period': '2023', 'revenue': 2240.0, 'unit': 'M', 'net_profit': -182.28}, {'period': '2022', 'revenue': 1450.0, 'unit': 'M', 'net_profit': -232.38}, {'period': '2021', 'revenue': 874.44, 'unit': 'M', 'net_profit': -92.63}]","[{'period': ""Q3 '25"", 'revenue': 1010.0, 'unit': 'M', 'net_profit': -16.82}, {'period': ""Q2 '25"", 'revenue': 963.87, 'unit': 'M', 'net_profit': 47.01}, {'period': ""Q1 '25"", 'revenue': 921.04, 'unit': 'M', 'net_profit': 42.82}, {'period': ""Q4 '24"", 'revenue': 845.34, 'unit': 'M', 'net_profit': 53.7}, {'period': ""Q3 '24"", 'revenue': 786.01, 'unit': 'M', 'net_profit': 26.66}, {'period': ""Q2 '24"", 'revenue': 731.63, 'unit': 'M', 'net_profit': 8.47}]",0.37,0.37,6646520000,4757307000,3474660000,4309431000,853105000,56244000,2697279000,3375069000,929095000,8.209770820042204,1.4900403214746138,1.4743589743589742,__nan__,__nan__,__nan__,0.6483740363378129
965,CRWS,Crown Crafts Inc Common Stock,"Crown Crafts, Inc., through its subsidiaries, operates in the consumer products industry in the United States and internationally. It provides infant, toddler, and juvenile products, including infant and toddler beddings; blankets and swaddle blankets; nursery and toddler accessories; room dcors; reusable and disposable bibs; burp cloths; hooded bath towels and washcloths; reusable and disposable placemats, and floor mats; disposable toilet seat covers and changing mats; developmental toys; feeding and care goods; and other infant, toddler, and juvenile soft goods. The company sells its products primarily to mass merchants, large chain stores, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, internet accounts, wholesale clubs and internet-based retailers through a network of sales force and independent commissioned sales representatives. Crown Crafts, Inc. was incorporated in 1957 and is headquartered in Gonzales, Louisiana.",Ms. Olivia W. Elliott CPA,"Furnishings, Fixtures & Appliances",4.515,USD,46927556,https://images.financialmodelingprep.com/symbol/CRWS.png,19683,14.11,0.015,1992,13095000,4894000,"[{'period': '2024', 'revenue': 87.63, 'unit': 'M', 'net_profit': 4.89}, {'period': '2023', 'revenue': 75.05, 'unit': 'M', 'net_profit': 5.65}, {'period': '2022', 'revenue': 87.36, 'unit': 'M', 'net_profit': 9.92}, {'period': '2021', 'revenue': 79.16, 'unit': 'M', 'net_profit': 6.08}]","[{'period': ""Q2 '25"", 'revenue': 24460.0, 'unit': 'K', 'net_profit': 860.0}, {'period': ""Q1 '25"", 'revenue': 16210.0, 'unit': 'K', 'net_profit': -322.0}, {'period': ""Q4 '24"", 'revenue': 22.58, 'unit': 'M', 'net_profit': 1.0}, {'period': ""Q3 '24"", 'revenue': 23.8, 'unit': 'M', 'net_profit': 1.7}, {'period': ""Q2 '24"", 'revenue': 24.13, 'unit': 'M', 'net_profit': 1.82}, {'period': ""Q1 '24"", 'revenue': 17120.0, 'unit': 'K', 'net_profit': 366.0}]",0.48,0.48,82706000,54824000,829000,31105000,22403000,0,10461000,829000,6298000,0.5175570749797196,-0.13380530973451327,-0.14285714285714296,"[0.08, 0.0454]","['2024-12-13', '1989-01-12']",__nan__,0.37609121466399054
966,CRZNU,Corazon Capital V838 Monoceros Corp Unit,"Corazon Capital V838 Monoceros Corp does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the education, social media and dating, and ecommerce sectors. The company was incorporated in 2021 and is based in Chicago, Illinois.",Mr. Sam  Yagan,Shell Companies,10.22,USD,263230858,https://images.financialmodelingprep.com/symbol/CRZNU.png,8057,31.349693251533743,0,100,9708074,-1096536,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.1}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.38}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.33}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.62}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.66}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.13}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -327.29}]",-0.053804779999999996,-0.053804779999999996,207688104,934801,852101,8029701,0,206753303,667536,852101,-521329,1.3141024495021547,-1.1169262739267127,-1.1461582008382978,__nan__,__nan__,__nan__,0.038662305858403904
967,CRZNW,Corazon Capital V838 Monoceros Corp Warrant,"Corazon Capital V838 Monoceros Corp is a blank check company. The company was incorporated in 2021 and is based in Chicago, Illinois.",Mr. Sam  Yagan,Shell Companies,0.0007,USD,260480863,https://images.financialmodelingprep.com/symbol/CRZNW.png,0,0,0,16400,9708074,-1096536,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.1}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 9.38}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.33}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 5.62}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.66}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.13}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -327.29}]",-0.053804779999999996,-0.053804779999999996,207688104,934801,852101,8029701,0,206753303,667536,852101,-521329,1.3141024495021547,-1.1169262739267127,-1.1461582008382978,__nan__,__nan__,__nan__,0.038662305858403904
968,CSBR,Champions Oncology Inc. Common Stock,"Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.",Dr. Ronnie  Morris M.D.,Biotechnology,10.09,USD,139435728,https://images.financialmodelingprep.com/symbol/CSBR.png,39916,-201.8,0.62,19439,-5054000,-7276000,"[{'period': '2024', 'revenue': 50.16, 'unit': 'M', 'net_profit': -7.28}, {'period': '2023', 'revenue': 53.87, 'unit': 'M', 'net_profit': -5.33}, {'period': '2022', 'revenue': 49110.0, 'unit': 'K', 'net_profit': 548.0}, {'period': '2021', 'revenue': 41040.0, 'unit': 'K', 'net_profit': 362.0}]","[{'period': ""Q2 '25"", 'revenue': 13490.0, 'unit': 'K', 'net_profit': 728.0}, {'period': ""Q1 '25"", 'revenue': 14.06, 'unit': 'M', 'net_profit': 1.31}, {'period': ""Q4 '24"", 'revenue': 14000.0, 'unit': 'K', 'net_profit': -109.0}, {'period': ""Q3 '24"", 'revenue': 12.02, 'unit': 'M', 'net_profit': -2.53}, {'period': ""Q2 '24"", 'revenue': 11.57, 'unit': 'M', 'net_profit': -2.07}, {'period': ""Q1 '24"", 'revenue': 12.56, 'unit': 'M', 'net_profit': -2.57}]",-0.54,-0.54,26132000,13639000,2618000,28035000,9526000,0,21541000,2618000,-6973000,-1.4427259545674238,-0.36382380506091844,-0.38461538461538464,__nan__,__nan__,__nan__,1.0728225929894382
969,CSCO,Cisco Systems Inc. Common Stock (DE),"Cisco Systems, Inc. designs, manufactures, and sells Internet Protocol based networking and other products related to the communications and information technology industry in the Americas, Europe, the Middle East, Africa, the Asia Pacific, Japan, and China. The company also offers switching portfolio encompasses campus switching as well as data center switching; enterprise routing portfolio interconnects public and private wireline and mobile networks, delivering highly secure, and reliable connectivity to campus, data center and branch networks; and wireless products include indoor and outdoor wireless coverage designed for seamless roaming use of voice, video, and data applications. In addition, it provides security, which comprising network security, identity and access management, secure access service edge, and threat intelligence, detection, and response offerings; collaboration products, such as Webex Suite, collaboration devices, contact center, and communication platform as a service; end-to-end collaboration solutions that can be delivered from the cloud, on-premise or within hybrid cloud environments allowing customers to transition their collaboration solutions from on-premise to the cloud; and observability offers network assurance, monitoring and analytics and observability suite. Further, the company offers a range of service and support options for its customers, including technical support and advanced services and advisory services. It serves businesses of various sizes, public institutions, governments, and service providers. The company sells its products and services directly, as well as through systems integrators, service providers, other resellers, and distributors. Cisco Systems, Inc. has strategic alliances with other companies. Cisco Systems, Inc. was incorporated in 1984 and is headquartered in San Jose, California.",Mr. Charles H. Robbins,Communication Equipment,58.915,USD,234644305400,https://images.financialmodelingprep.com/symbol/CSCO.png,18796725,25.29,0.145,7088458,15747000000,10320000000,"[{'period': '2024', 'revenue': 53.8, 'unit': 'B', 'net_profit': 10.32}, {'period': '2023', 'revenue': 57.0, 'unit': 'B', 'net_profit': 12.61}, {'period': '2022', 'revenue': 51.56, 'unit': 'B', 'net_profit': 11.81}, {'period': '2021', 'revenue': 49.82, 'unit': 'B', 'net_profit': 10.59}]","[{'period': ""Q1 '25"", 'revenue': 13.84, 'unit': 'B', 'net_profit': 2.71}, {'period': ""Q4 '24"", 'revenue': 13.64, 'unit': 'B', 'net_profit': 2.16}, {'period': ""Q3 '24"", 'revenue': 12.7, 'unit': 'B', 'net_profit': 1.89}, {'period': ""Q2 '24"", 'revenue': 12.79, 'unit': 'B', 'net_profit': 2.63}, {'period': ""Q1 '24"", 'revenue': 14.67, 'unit': 'B', 'net_profit': 3.64}, {'period': ""Q4 '23"", 'revenue': 15.2, 'unit': 'B', 'net_profit': 3.96}]",2.55,2.54,124413000000,36862000000,17854000000,78956000000,10023000000,0,40584000000,7508000000,10210000000,-0.09867780894053002,-0.18179655910568462,-0.17207792207792216,"[0.4, 0.06]","['2025-01-03', '2011-03-29']",__nan__,0.6346282140933825
970,CSCW,Color Star Technology Co. Ltd. Ordinary Shares,"Color Star Technology Co., Ltd., an entertainment and education company, provides online entertainment performances and music education services in the United States and China. The company operates Color World, an online platform of curriculum that includes music, sports, animation, painting and calligraphy, film and television, life skills, etc. Its Color World platform provides celebrity lectures, celebrity concert videos, celebrity peripheral products, and artist interactive communication services. The company was formerly known as Huitao Technology Co., Ltd. and changed its name to Color Star Technology Co., Ltd. in May 2020. Color Star Technology Co., Ltd. was founded in 2002 and is based in New York, New York.",,Entertainment,1.08,USD,10335276,https://images.financialmodelingprep.com/symbol/CSCW.png,1004847,-8.925619834710744,-0.04,312697,-22511455,-26864340,"[{'period': '2023', 'revenue': 2.83, 'unit': 'M', 'net_profit': -26.86}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -37.85}, {'period': '2021', 'revenue': 16.52, 'unit': 'M', 'net_profit': -77.21}, {'period': '2020', 'revenue': 6.78, 'unit': 'M', 'net_profit': -8.24}]","[{'period': ""Q2 '23"", 'revenue': 0.53022, 'unit': 'M', 'net_profit': -10.56}, {'period': ""Q1 '23"", 'revenue': 0.53022, 'unit': 'M', 'net_profit': -10.56}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.84}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -12.84}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.09}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.09}]",-0.71,-0.71,27591648,10473112,20218,9065904,1605000,0,9057321,20218,-2780452,0.00508333755773602,0.2902357259965181,0.8280871670702179,__nan__,__nan__,__nan__,0.3285742120224207
971,CSGP,CoStar Group Inc. Common Stock,"CoStar Group, Inc. provides information, analytics, and online marketplace services to the commercial real estate, hospitality, residential, and related professionals industries in the United States, Canada, Europe, the Asia Pacific, and Latin America. It offers CoStar Property that provides inventory of office, industrial, retail, multifamily, hospitality, and student housing properties and land; CoStar COMPS, a robust database of comparable commercial real estate sales transactions; CoStar Market Analytics to view and report on aggregated market and submarket trends; and CoStar Tenant, an online business-to-business prospecting and analytical tool that provides tenant information. The company also provides Lease Comps and Analysis, a tool to capture, manage, and maintain lease data; CoStar Lease Analysis; Public Record, a searchable database of commercially-zoned parcels; CoStar Real Estate Manager, a real estate lease administration, portfolio management, and lease accounting compliance software solution; and CoStar Risk Analytics and CoStar Investment. In addition, it offers apartment marketing sites, such as ApartmentFinder.com, ForRent.com, ApartmentHomeLiving.com, WestsideRentals.com, AFTER55.com, CorporateHousing.com, ForRentUniversity.com, Apartamentos.com, and Off Campus Partners; LoopNet Premium Lister; LoopNet Diamond, Platinum, and Gold Ads; LandsofAmerica.com, LandAndFarm.com, and LandWatch.com for rural land for-sale; BizBuySell.com, BizQuest.com, and FindaFranchise.com for operating businesses and franchises for-sale; Ten-X, an online auction platform for commercial real estate; and HomeSnap, an online and mobile software platform, as well as Homes.com, a homes for sale listings site. CoStar Group, Inc. was founded in 1987 and is headquartered in Washington, the District of Columbia.",Mr. Andrew C. Florance,Real Estate - Services,71.15,USD,29168582850,https://images.financialmodelingprep.com/symbol/CSGP.png,2861566,169.4,-0.06,729692,389800000,374700000,"[{'period': '2023', 'revenue': 2460.0, 'unit': 'M', 'net_profit': 374.7}, {'period': '2022', 'revenue': 2180.0, 'unit': 'M', 'net_profit': 369.5}, {'period': '2021', 'revenue': 1940.0, 'unit': 'M', 'net_profit': 292.6}, {'period': '2020', 'revenue': 1660.0, 'unit': 'M', 'net_profit': 227.13}]","[{'period': ""Q3 '24"", 'revenue': 692.6, 'unit': 'M', 'net_profit': 53.0}, {'period': ""Q2 '24"", 'revenue': 677.8, 'unit': 'M', 'net_profit': 19.2}, {'period': ""Q1 '24"", 'revenue': 656.4, 'unit': 'M', 'net_profit': 6.7}, {'period': ""Q4 '23"", 'revenue': 640.1, 'unit': 'M', 'net_profit': 96.47}, {'period': ""Q3 '23"", 'revenue': 624.67, 'unit': 'M', 'net_profit': 90.57}, {'period': ""Q2 '23"", 'revenue': 605.91, 'unit': 'M', 'net_profit': 100.5}]",0.92,0.92,8919700000,5476100000,5215900000,1581100000,195800000,0,455800000,5215900000,464200000,-0.4119164613604373,0.014073071718538565,-0.01075268817204302,__nan__,__nan__,__nan__,0.17725932486518606
972,CSGS,CSG Systems International Inc. Common Stock,"CSG Systems International, Inc. provides revenue management and digital monetization, customer engagement, and payment solutions primarily to the communications industry in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers Advanced Convergent Platform, a private SaaS based platform; related solutions, including field force automation, analytics, electronic bill presentment, ACH, etc. to the North American cable and satellite markets. The company also provides managed services; and professional services to implement, configure, and maintain its solutions, as well as licenses various solutions, such as mediation, partner management, rating, and charging. It serves retail, financial services, healthcare, insurance, and government entities. The company was incorporated in 1994 and is headquartered in Greenwood Village, Colorado.",Mr. Brian A. Shepherd,Software - Infrastructure,50.545,USD,1470490522,https://images.financialmodelingprep.com/symbol/CSGS.png,0,22.17,,0,194779000,66246000,"[{'period': '2023', 'revenue': 1170.0, 'unit': 'M', 'net_profit': 66.25}, {'period': '2022', 'revenue': 1090.0, 'unit': 'M', 'net_profit': 44.06}, {'period': '2021', 'revenue': 1050.0, 'unit': 'M', 'net_profit': 72.33}, {'period': '2020', 'revenue': 990.53, 'unit': 'M', 'net_profit': 58.71}]","[{'period': ""Q3 '24"", 'revenue': 295.14, 'unit': 'M', 'net_profit': 19.09}, {'period': ""Q2 '24"", 'revenue': 290.32, 'unit': 'M', 'net_profit': 13.83}, {'period': ""Q1 '24"", 'revenue': 295.13, 'unit': 'M', 'net_profit': 19.47}, {'period': ""Q4 '23"", 'revenue': 297.32, 'unit': 'M', 'net_profit': 12.67}, {'period': ""Q3 '23"", 'revenue': 286.87, 'unit': 'M', 'net_profit': 18.69}, {'period': ""Q2 '23"", 'revenue': 286.33, 'unit': 'M', 'net_profit': 13.95}]",2.21,2.2,1443046000,862226000,186264000,1169720000,351188000,0,560836000,186264000,103919000,0.3068556936206758,0.5035406264185202,0.5563380281690141,"[0.3, 0.15]","['2024-12-18', '2013-07-08']",__nan__,0.8105909305732457
973,CSII,Cardiovascular Systems Inc. Common Stock,"Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.","Mr. Scott Raymond Ward B.Sc., M.S., MS",Medical - Devices,20,USD,843960000,https://images.financialmodelingprep.com/symbol/CSII.png,677842,-20.833333333333332,0.03,387776,-34464000,-36933000,"[{'period': '2022', 'revenue': 236.22, 'unit': 'M', 'net_profit': -36.93}, {'period': '2021', 'revenue': 258.97, 'unit': 'M', 'net_profit': -13.42}, {'period': '2020', 'revenue': 236.54, 'unit': 'M', 'net_profit': -27.24}, {'period': '2019', 'revenue': 248020.0, 'unit': 'K', 'net_profit': -255.0}]","[{'period': ""Q2 '23"", 'revenue': 61.45, 'unit': 'M', 'net_profit': -7.89}, {'period': ""Q1 '23"", 'revenue': 59.67, 'unit': 'M', 'net_profit': -10.63}, {'period': ""Q4 '22"", 'revenue': 62.5, 'unit': 'M', 'net_profit': -9.69}, {'period': ""Q3 '22"", 'revenue': 56.22, 'unit': 'M', 'net_profit': -9.66}, {'period': ""Q2 '22"", 'revenue': 59.13, 'unit': 'M', 'net_profit': -8.97}, {'period': ""Q1 '22"", 'revenue': 58.37, 'unit': 'M', 'net_profit': -8.62}]",-0.94,-0.94,322677000,241846000,159833000,73197000,39678000,33425000,39954000,66424000,-28492000,-2.2158253242511896,-1.7518813799269801,-1.6857142857142857,__nan__,__nan__,__nan__,0.22684294201322064
974,CSIQ,Canadian Solar Inc. Common Shares (BC),"Canadian Solar Inc., together with its subsidiaries, designs, develops, manufactures, and sells solar ingots, wafers, cells, modules, and other solar power and battery storage products in Asia, the Americas, Europe, and internationally. The company operates through two segments, Canadian Solar Inc. (CSI) Solar and Global Energy. The CSI Solar segment offers standard solar modules and battery storage solutions, as well as solar system kits that are a ready-to-install packages comprising inverters, racking systems, and other accessories; and engineering, procurement, and construction (EPC) services. The Global Energy segment engages in the development, construction, maintenance, and sale of solar and battery storage projects; operation of solar power plants; and sale of electricity. This segment also provides operation and maintenance (O&M) services, including monitoring, inspections, repair, and replacement of plant equipment; and site management and administrative support services for solar projects, as well as asset management services. As of January 31, 2021, this segment had a fleet of solar power plants in operation with an aggregate capacity of approximately 445 MWp. The company serves distributors, system integrators, project developers, and installers/EPC companies. It sells its products primarily under its Canadian Solar brand name; and on an OEM basis. The company was incorporated in 2001 and is headquartered in Guelph, Canada.",Dr. Xiaohua  Qu Ph.D.,Solar,13.48,USD,892037639,https://images.financialmodelingprep.com/symbol/CSIQ.png,2249043,-96.29,1.13,1589684,829664000,274187000,"[{'period': '2023', 'revenue': 7610.0, 'unit': 'M', 'net_profit': 274.19}, {'period': '2022', 'revenue': 7470.0, 'unit': 'M', 'net_profit': 239.97}, {'period': '2021', 'revenue': 5280.0, 'unit': 'M', 'net_profit': 95.25}, {'period': '2020', 'revenue': 3480.0, 'unit': 'M', 'net_profit': 146.7}]","[{'period': ""Q3 '24"", 'revenue': 1510.0, 'unit': 'M', 'net_profit': -14.03}, {'period': ""Q2 '24"", 'revenue': 1640.0, 'unit': 'M', 'net_profit': 3.82}, {'period': ""Q1 '24"", 'revenue': 1330.0, 'unit': 'M', 'net_profit': 12.35}, {'period': ""Q4 '23"", 'revenue': 1700.0, 'unit': 'M', 'net_profit': -1.39}, {'period': ""Q3 '23"", 'revenue': 1850.0, 'unit': 'M', 'net_profit': 21.89}, {'period': ""Q2 '23"", 'revenue': 2360.0, 'unit': 'M', 'net_profit': 169.97}]",4.27,3.87,11895760000,6095453000,1938689000,8190516000,1209697000,277051000,5864391000,1938689000,-840845000,0.22885695200036732,0.14259817975730096,0.1447721179624664,__nan__,__nan__,__nan__,0.6885239782914249
975,CSOD,Cornerstone OnDemand Inc. Common Stock,"Cornerstone OnDemand, Inc., together with its subsidiaries, provides learning and people development solutions through software-as-a-service model worldwide. Its enterprise people development solution comprises four product suites, such as Recruiting Suite that helps organizations to attract, hire, and onboard the right employees; Learning Suite, which provides robust, a modern learning management software to supports compliance, knowledge sharing, and employee-driven development training; Performance Suite that provides tools to manage goal setting, performance reviews, competency assessments, development plans, continuous feedback, compensation management, and succession planning; and HR Suite, which provides an aggregated view of all employee data with workforce planning, self-service management, and compliance reporting capabilities. The company also offers professional services, including application configuration, system integration, business process re-engineering, change management, and training. Cornerstone OnDemand, Inc. sells its software, content, and services directly through its sales force and indirectly through its domestic and international network of distributors. It serves business services, financial services, healthcare, pharmaceuticals, insurance, manufacturing, retail, and technology industries. Cornerstone OnDemand, Inc. was founded in 1999 and is headquartered in Santa Monica, California.",Mr. Adam Miller,Software - Application,57.49,USD,0,https://images.financialmodelingprep.com/symbol/CSOD.png,1328149,0,0,3739087,93258000,-39982000,"[{'period': '2020', 'revenue': 740.92, 'unit': 'M', 'net_profit': -39.98}, {'period': '2019', 'revenue': 576.52, 'unit': 'M', 'net_profit': -4.05}, {'period': '2018', 'revenue': 537.89, 'unit': 'M', 'net_profit': -33.84}, {'period': '2017', 'revenue': 481.99, 'unit': 'M', 'net_profit': -61.34}]","[{'period': ""Q2 '21"", 'revenue': 214340.0, 'unit': 'K', 'net_profit': -371.0}, {'period': ""Q1 '21"", 'revenue': 209.27, 'unit': 'M', 'net_profit': -12.45}, {'period': ""Q4 '20"", 'revenue': 206.92, 'unit': 'M', 'net_profit': 1.56}, {'period': ""Q3 '20"", 'revenue': 199.5, 'unit': 'M', 'net_profit': -15.78}, {'period': ""Q2 '20"", 'revenue': 184.36, 'unit': 'M', 'net_profit': -11.99}, {'period': ""Q1 '20"", 'revenue': 150.14, 'unit': 'M', 'net_profit': -13.78}]",-0.6,-0.6,2134569000,451013000,161716000,1865695000,221461000,8565000,597671000,153151000,64074000,0.5091756481211768,-8.86235816477553,-7.888888888888888,__nan__,__nan__,__nan__,0.874038271894701
976,CSPI,CSP Inc. Common Stock,"CSP Inc. develops and markets IT integration solutions, security products, managed IT services, purpose built network adapters, and cluster computer systems for commercial and defense customers worldwide. It operates in two segments, Technology Solutions and High Performance Products. The Technology Solutions segment provides third-party computer hardware and software as a value added reseller to various customers in Web and infrastructure hosting, education, telecommunications, healthcare services, distribution, financial and professional services, and manufacturing industries. This segment also offers professional IT consulting services, such as planning, designing, assessment, implementation, migration, optimization, and project management; storage and virtualization solutions; enterprise security intrusion prevention, network access control, and unified threat management services; and IT security compliance services. In addition, this segment provides unified communications, wireless, and routing and switching solutions; custom software applications and solutions development and support services; optimization, maintenance, and technical support services; and managed IT services, such as monitoring, reporting, and management of alerts for the resolution and preventive general IT, as well as IT security support tasks. Further, this segment offers managed and cloud services, such as proactive monitoring and remote management of IT infrastructure, managed and hosted unified communication services, security, and backup and replication. The High Performance Products segment offers ARIA Software-Defined Security, a cybersecurity solution; Myricom network adapters; and multicomputer products for digital signal processing applications in the defense markets. CSP Inc. was incorporated in 1968 and is headquartered in Lowell, Massachusetts.",Mr. Victor J. Dellovo,Information Technology Services,17.1932,USD,169913690,https://images.financialmodelingprep.com/symbol/CSPI.png,30416,-429.83,-0.2868,18652,610000,-326000,"[{'period': '2024', 'revenue': 55220.0, 'unit': 'K', 'net_profit': -326.0}, {'period': '2023', 'revenue': 64.65, 'unit': 'M', 'net_profit': 5.2}, {'period': '2022', 'revenue': 54.36, 'unit': 'M', 'net_profit': 1.89}, {'period': '2021', 'revenue': 49210.0, 'unit': 'K', 'net_profit': 234.0}]","[{'period': ""Q4 '24"", 'revenue': 13.03, 'unit': 'M', 'net_profit': -1.66}, {'period': ""Q3 '24"", 'revenue': 13110.0, 'unit': 'K', 'net_profit': -185.0}, {'period': ""Q2 '24"", 'revenue': 13.71, 'unit': 'M', 'net_profit': 1.59}, {'period': ""Q1 '24"", 'revenue': 15380.0, 'unit': 'K', 'net_profit': -73.0}, {'period': ""Q4 '23"", 'revenue': 15.33, 'unit': 'M', 'net_profit': 1.41}, {'period': ""Q3 '23"", 'revenue': 17.71, 'unit': 'M', 'net_profit': 2.51}]",-0.0361,-0.0361,69436000,54849000,30585000,22166000,18878000,0,18682000,30585000,4017000,-0.8970985155195681,-1.0626441199077632,-1.0644642857142856,"[0.03, 0.1]","['2024-12-27', '2012-01-25']",__nan__,0.319229218272942
977,CSQ,Calamos Strategic Total Return Common Stock,"Calamos Strategic Total Return Fund is a closed ended balanced mutual fund launched by Calamos Investments LLC. The fund is managed by Calamos Advisors LLC. It invests in the public equity and fixed income markets of the United States. The fund seeks to invest in securities of companies operating across diversified sectors. It primarily invests in common and preferred stocks of companies across all market capitalizations, convertible securities, and high yield corporate bonds with an average credit rating of BB as rated by S&P. The fund employs both fundamental and quantitative analysis with a combination of bottom-up and top-down security picking approaches to create its portfolio. Calamos Strategic Total Return Fund was formed on December 31, 2003 and is domiciled in the United States.",Mr. John Peter Calamos Sr.,Asset Management,17.77,USD,2818090990,https://images.financialmodelingprep.com/symbol/CSQ.png,188304,3.31,-0.15,90630,0,861928337,"[{'period': '2024', 'revenue': 863.77, 'unit': 'M', 'net_profit': 861.93}, {'period': '2023', 'revenue': 274.34, 'unit': 'M', 'net_profit': 169.64}, {'period': '2022', 'revenue': -601.24, 'unit': 'M', 'net_profit': -602.97}, {'period': '2021', 'revenue': 1.01, 'unit': 'B', 'net_profit': 1.01}]","[{'period': ""Q2 '24"", 'revenue': 12.4, 'unit': 'M', 'net_profit': 499.07}, {'period': ""Q4 '23"", 'revenue': 202.97, 'unit': 'M', 'net_profit': -13.5}, {'period': ""Q2 '23"", 'revenue': 71.37, 'unit': 'M', 'net_profit': 183.14}, {'period': ""Q4 '22"", 'revenue': 103.44, 'unit': 'M', 'net_profit': -213.88}, {'period': ""Q2 '22"", 'revenue': 127.15, 'unit': 'M', 'net_profit': -389.09}, {'period': ""Q4 '21"", 'revenue': 114.8, 'unit': 'M', 'net_profit': 280.59}]",0,0,4167608290,0,0,1352322903,25869634,3985572163,0,0,137289263,-1,4.080932167311394,-1,"[0.1025, 0.075]","['2024-12-30', '2004-06-09']",__nan__,0.32448416667296726
978,CSSE,Chicken Soup for the Soul Entertainment Inc. Class A Common Stock,"Chicken Soup for the Soul Entertainment, Inc. operates as a streaming video-on-demand (VOD) company in the United States and internationally. It owns and operates various ad-supported and subscription-based VOD networks, including Crackle, Chicken Soup for the Soul, Popcornflix, Popcornflix Kids, Truli, Pivotshare, Espaolflix, and FrightPix. The company distributes and exhibits VOD content directly to consumers through various digital platforms, such as connected TVs, smartphones, tablets, gaming consoles, and the web through its owned and operated AVOD or FAST channel networks. It also produces and licenses movies, television series, and programs; and produces long and short-form original content. The company was founded in 2014 and is headquartered in Cos Cob, Connecticut. Chicken Soup for the Soul Entertainment, Inc. is a subsidiary of Chicken Soup for the Soul Productions, LLC.",Mr. William J. Rouhana Jr.,Entertainment,0.1055,USD,3424414,https://images.financialmodelingprep.com/symbol/CSSE.png,0,0,,0,-514759886,-622515636,"[{'period': '2023', 'revenue': 294.41, 'unit': 'M', 'net_profit': -622.52}, {'period': '2022', 'revenue': 252.81, 'unit': 'M', 'net_profit': -101.95}, {'period': '2021', 'revenue': 110.4, 'unit': 'M', 'net_profit': -50.48}, {'period': '2020', 'revenue': 66.36, 'unit': 'M', 'net_profit': -40.59}]","[{'period': ""Q1 '24"", 'revenue': 27.4, 'unit': 'M', 'net_profit': -48.7}, {'period': ""Q4 '23"", 'revenue': 39.17, 'unit': 'M', 'net_profit': -96.75}, {'period': ""Q3 '23"", 'revenue': 65.72, 'unit': 'M', 'net_profit': -429.79}, {'period': ""Q2 '23"", 'revenue': 79.91, 'unit': 'M', 'net_profit': -40.41}, {'period': ""Q1 '23"", 'revenue': 109.6, 'unit': 'M', 'net_profit': -55.69}, {'period': ""Q4 '22"", 'revenue': 113.57, 'unit': 'M', 'net_profit': -53.75}]",-21.87,-21.87,422300625,155795159,3316652,925862510,142088225,0,377861168,3316652,-29966885,-32.074944811362066,-5.10615257547221,-2.700507614213198,"[0.203, 0.45]","['2020-08-28', '2018-08-03']",__nan__,2.1924251473698386
979,CSSEN,Chicken Soup for the Soul Entertainment Inc. 9.50% Notes due 2025,"Chicken Soup for the Soul Entertainment, Inc. is an advertising-supported video-on-demand (AVOD) company. It creates, acquires, and distributes films and TV series through its Screen Media and Chicken Soup for the Soul TV Group subsidiaries. Its flagship streaming services are Redbox, Crackle, and Chicken Soup for the Soul. The company was founded on May 4, 2016 and is headquartered in Cos Cob, CT.",William J. Rouhana,Entertainment,0.8666,USD,3424413,https://images.financialmodelingprep.com/symbol/CSSEN.png,37742,,0,1037146,-514759886,-622515636,"[{'period': '2023', 'revenue': 294.41, 'unit': 'M', 'net_profit': -622.52}, {'period': '2022', 'revenue': 252.81, 'unit': 'M', 'net_profit': -101.95}, {'period': '2021', 'revenue': 110.4, 'unit': 'M', 'net_profit': -50.48}, {'period': '2020', 'revenue': 66.36, 'unit': 'M', 'net_profit': -40.59}]","[{'period': ""Q1 '24"", 'revenue': 27.4, 'unit': 'M', 'net_profit': -48.7}, {'period': ""Q4 '23"", 'revenue': 39.17, 'unit': 'M', 'net_profit': -96.75}, {'period': ""Q3 '23"", 'revenue': 65.72, 'unit': 'M', 'net_profit': -429.79}, {'period': ""Q2 '23"", 'revenue': 79.91, 'unit': 'M', 'net_profit': -40.41}, {'period': ""Q1 '23"", 'revenue': 109.6, 'unit': 'M', 'net_profit': -55.69}, {'period': ""Q4 '22"", 'revenue': 113.57, 'unit': 'M', 'net_profit': -53.75}]",-21.87,-21.87,422300625,155795159,3316652,925862510,142088225,0,377861168,3316652,-29966885,-32.074944811362066,-5.10615257547221,-2.700507614213198,"[0.59375, 0.48]","['2025-06-13', '2020-09-14']",__nan__,2.1924251473698386
980,CSSEP,Chicken Soup for the Soul Entertainment Inc. 9.75% Series A Cumulative Redeemable Perpetual Preferred Stock,"Chicken Soup for the Soul Entertainment, Inc. operates as a streaming video-on-demand (VOD) company in the United States and internationally. It owns and operates various ad-supported and subscription-based VOD networks, including Crackle, Chicken Soup for the Soul, Popcornflix, Popcornflix Kids, Truli, Pivotshare, Espaolflix, and FrightPix. The company distributes and exhibits VOD content directly to consumers through various digital platforms, such as connected TVs, smartphones, tablets, gaming consoles, and the web through its owned and operated AVOD or FAST channel networks. It also produces and licenses movies, television series, and programs; and produces long and short-form original content. The company was founded in 2014 and is headquartered in Cos Cob, Connecticut. Chicken Soup for the Soul Entertainment, Inc. is a subsidiary of Chicken Soup for the Soul Productions, LLC.",Mr. William J. Rouhana Jr.,Entertainment,0.4,USD,1404104,https://images.financialmodelingprep.com/symbol/CSSEP.png,0,-0.1,,0,-514759886,-622515636,"[{'period': '2023', 'revenue': 294.41, 'unit': 'M', 'net_profit': -622.52}, {'period': '2022', 'revenue': 252.81, 'unit': 'M', 'net_profit': -101.95}, {'period': '2021', 'revenue': 110.4, 'unit': 'M', 'net_profit': -50.48}, {'period': '2020', 'revenue': 66.36, 'unit': 'M', 'net_profit': -40.59}]","[{'period': ""Q1 '24"", 'revenue': 27.4, 'unit': 'M', 'net_profit': -48.7}, {'period': ""Q4 '23"", 'revenue': 39.17, 'unit': 'M', 'net_profit': -96.75}, {'period': ""Q3 '23"", 'revenue': 65.72, 'unit': 'M', 'net_profit': -429.79}, {'period': ""Q2 '23"", 'revenue': 79.91, 'unit': 'M', 'net_profit': -40.41}, {'period': ""Q1 '23"", 'revenue': 109.6, 'unit': 'M', 'net_profit': -55.69}, {'period': ""Q4 '22"", 'revenue': 113.57, 'unit': 'M', 'net_profit': -53.75}]",-21.87,-21.87,422300625,155795159,3316652,925862510,142088225,0,377861168,3316652,-29966885,-32.074944811362066,-5.10615257547221,-2.700507614213198,"[0.2031, 0.2031]","['2023-12-28', '2018-06-28']",__nan__,2.1924251473698386
981,CSTE,Caesarstone Ltd. Ordinary Shares,"Caesarstone Ltd., together with its subsidiaries, develops, manufactures, and markets engineered quartz and other surfaces under the Caesarstone brand in the United States, Australia, Canada, Latin America, Asia, Israel, Europe, the Middle East, and Africa. The company's engineered quartz slabs are primarily used as indoor and outdoor kitchen countertops in the renovation and remodeling construction end markets. Its products are also used in other applications, such as vanity tops, wall panels, back splashes, floor tiles, stairs, furniture, and other interior and exterior surfaces that are used in various residential and non-residential applications. The company also offers porcelain products under the Lioli brand for flooring and cladding applications, as well as resells natural stones, various ancillary fabrication tools, and installation accessories; and sells sinks and materials. It sells its products directly to fabricators, sub-distributors, and resellers; and through direct sales force and indirect network of independent distributors. The company was formerly known as Caesarstone Sdot Yam Ltd. and changed its name to Caesarstone Ltd. in June 2016. Caesarstone Ltd. was founded in 1987 and is headquartered in Menashe, Israel.",Mr. Yosef  Shiran,Construction,4.299,USD,148480152,https://images.financialmodelingprep.com/symbol/CSTE.png,45938,-2.15,-0.001,15161,-51618000,-107656000,"[{'period': '2023', 'revenue': 565.23, 'unit': 'M', 'net_profit': -107.66}, {'period': '2022', 'revenue': 690.81, 'unit': 'M', 'net_profit': -56.37}, {'period': '2021', 'revenue': 643.89, 'unit': 'M', 'net_profit': 18.97}, {'period': '2020', 'revenue': 486.41, 'unit': 'M', 'net_profit': 7.22}]","[{'period': ""Q3 '24"", 'revenue': 107.63, 'unit': 'M', 'net_profit': -4.22}, {'period': ""Q2 '24"", 'revenue': 119.43, 'unit': 'M', 'net_profit': -9.18}, {'period': ""Q1 '24"", 'revenue': 118.29, 'unit': 'M', 'net_profit': -5.09}, {'period': ""Q4 '23"", 'revenue': 128.53, 'unit': 'M', 'net_profit': -50.52}, {'period': ""Q3 '23"", 'revenue': 142390.0, 'unit': 'K', 'net_profit': -887.0}, {'period': ""Q2 '23"", 'revenue': 143.68, 'unit': 'M', 'net_profit': -52.47}]",-3.12,-3.12,579855000,319946000,91123000,257007000,83348000,0,121223000,54623000,55361000,-2.8807608450492443,-0.9099457119540149,-0.9141104294478529,"[0.199, 0.58]","['2022-08-16', '2013-11-25']",__nan__,0.4432263238223349
982,CSTL,Castle Biosciences Inc. Common Stock,"Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.",Mr. Derek J. Maetzold,Medical - Diagnostics & Research,31.63,USD,885870899,https://images.financialmodelingprep.com/symbol/CSTL.png,380106,150.62,2.27,221079,-45024000,-57466000,"[{'period': '2023', 'revenue': 219.79, 'unit': 'M', 'net_profit': -57.47}, {'period': '2022', 'revenue': 137.04, 'unit': 'M', 'net_profit': -67.14}, {'period': '2021', 'revenue': 94.08, 'unit': 'M', 'net_profit': -31.29}, {'period': '2020', 'revenue': 62.65, 'unit': 'M', 'net_profit': -10.28}]","[{'period': ""Q3 '24"", 'revenue': 85.78, 'unit': 'M', 'net_profit': 2.27}, {'period': ""Q2 '24"", 'revenue': 87.0, 'unit': 'M', 'net_profit': 8.92}, {'period': ""Q1 '24"", 'revenue': 72.97, 'unit': 'M', 'net_profit': -2.53}, {'period': ""Q4 '23"", 'revenue': 66.12, 'unit': 'M', 'net_profit': -2.58}, {'period': ""Q3 '23"", 'revenue': 61.49, 'unit': 'M', 'net_profit': -6.91}, {'period': ""Q2 '23"", 'revenue': 50.14, 'unit': 'M', 'net_profit': -18.78}]",-2.14,-2.14,453340000,295635000,243099000,62071000,38302000,0,47667000,98841000,-19247000,0.22830111065405184,0.14406148529893653,0.1705426356589147,__nan__,__nan__,__nan__,0.1369193100101469
983,CSTR,CapStar Financial Holdings Inc. Common Stock,"CapStar Financial Holdings, Inc. operates as the bank holding company for CapStar Bank that provides banking services to consumer and corporate customers located primarily in Tennessee, the United States. Its deposit products and services include demand deposits, interest-bearing transaction accounts, money market accounts, time and savings deposits, certificates of deposit, and CDARS reciprocal products. The company also provides commercial and consumer real estate, construction and land development, commercial and industrial, consumer, PPP, and other loans. In addition, it offers mortgage banking products and services; private banking and wealth management services for the owners and operators of business clients and other high net worth individuals; and correspondent banking services to community banks. Further, the company provides telephone and online banking, direct deposit, mobile banking, safe deposit box, remote deposit, and cash management services for individuals, and small and medium sized businesses. CapStar Financial Holdings, Inc. was founded in 2007 and is headquartered in Nashville, Tennessee.",Mr. Timothy K. Schools,Banks - Regional,20.11,USD,418561496,https://images.financialmodelingprep.com/symbol/CSTR.png,98498,14.26241134751773,0.01,115390,36199000,29804000,"[{'period': '2023', 'revenue': 181.16, 'unit': 'M', 'net_profit': 29.8}, {'period': '2022', 'revenue': 120.61, 'unit': 'M', 'net_profit': 39.02}, {'period': '2021', 'revenue': 133.85, 'unit': 'M', 'net_profit': 48.68}, {'period': '2020', 'revenue': 119.57, 'unit': 'M', 'net_profit': 24.7}]","[{'period': ""Q4 '23"", 'revenue': 49.38, 'unit': 'M', 'net_profit': 6.63}, {'period': ""Q3 '23"", 'revenue': 26.65, 'unit': 'M', 'net_profit': 8.93}, {'period': ""Q2 '23"", 'revenue': 28.78, 'unit': 'M', 'net_profit': 7.8}, {'period': ""Q1 '23"", 'revenue': 29.49, 'unit': 'M', 'net_profit': 6.45}, {'period': ""Q4 '22"", 'revenue': 31.24, 'unit': 'M', 'net_profit': 10.33}, {'period': ""Q3 '22"", 'revenue': 28.82, 'unit': 'M', 'net_profit': 8.19}]",1.41,1.41,3142175000,272210000,385072000,2780617000,12588000,269742000,1403064000,249611000,24315000,-0.47828781436909995,-0.23612784171002382,-0.20338983050847462,"[0.11, 0.04]","['2024-02-06', '2018-07-30']",__nan__,0.8849338435955986
984,CSWC,Capital Southwest Corporation Common Stock,"Capital Southwest Corporation is a business development company specializing in credit and private equity and venture capital investments in middle market companies, mezzanine, later stage, mature, late venture, emerging growth, buyouts, recapitalizations and growth capital investments. It does not invest in startups, publicly traded companies, real estate developments, project finance opportunities, oil and gas exploration businesses, troubled companies, turnarounds, and companies in which significant senior management is departing. In lower middle market, the firm typically invests in growth financing, bolt-on acquisitions, new platform acquisitions, refinancing, dividend recapitalizations, sponsor-led buyouts, and management buyouts situations. The investment structures are Unitranche debt, subordinated debt, senior debt, first and second lien debt, and preferred and common equity. The firm makes equity co-investments alongside debt investments, up to 20% of total check and only makes non-control investments. It prefers to invest in Industrial manufacturing and services, value-added distribution, healthcare products and services, business services, specialty chemicals, food and beverage, tech-enabled services and SaaS models. The firm seeks to invest in energy services and products, industrial technologies, and specialty chemicals and products. Within energy services and products, the firm seeks to invest in each segment of the industry, including upstream, midstream and downstream, excluding exploration and production with a focus on differentiated products and services, equipment and tool rental, consumable products, and drilling and completion chemicals. Within industrial technologies, it seeks to invest in automation and process controls, handling and packaging equipment, industrial filtration and fluid handling, measurement, monitoring and testing, professional tools, and sensors and instrumentation. Within and specialty chemicals and products, the firm seeks to invest in businesses that develop and manufacture highly differentiated chemicals and products including adhesives, coatings and sealants, catalysts and absorbents, cosmeceuticals, fine chemicals, flavors and fragrances, performance lubricants, polymers, plastics and composites, chemical dispensing and filtration equipment, professional and industrial trade consumables and tools, engineered solutions for HVAC, plumbing, and electrical installations, specified high performance materials for fire protection and oilfield applications. It may also invest in exceptional opportunities in building products. The firm seeks to invest in the United States. The firm seeks to make investments ranging from $5 to $25 million in securities. It seeks to make equity investments ranging from $5 million to $50 million and debt investments between $5 million and $20 million and co-invest in transaction size up to $40 million. It prefers to invest in companies with revenues approaching above $10 million, profitable operations, historical growth rate of at least 15 percent per year. Within the lower middle market, it seeks to invest in with less than $15 million in EBITDA and also opportunistically invests in the upper middle market, generally defined as companies with EBITDA in excess of $50 million. In addition to making direct investments, the firm allocates capital to syndicated first and second lien term loans in the upper middle market. Criteria for Upper Middle Market Syndicated 1st Lien is EBITDA Size more than $30 million, Closing Leverage greater than 4 times, investment hold size between $5 million and $7 million, investment yield greater than 6.5%. Criteria for Upper Middle Market Syndicated 2nd Lien is EBITDA Size more than $50 million, Closing Leverage greater than 6 times, investment hold size between $5 million and $7 million, investment yield greater than 9%. It prefers to take a majority and minority stake. The firm has the flexibility to hold investments for very long period in its portfolio companies. It may also invest through warrants. The firm prefers to take Board participation in its portfolio companies. Capital Southwest Corporation was founded on April 19, 1961 and is based in Dallas, Texas.",Mr. Bowen S. Diehl,Asset Management,21.9699,USD,1047672030,https://images.financialmodelingprep.com/symbol/CSWC.png,519761,13.48,-0.1901,259085,158341000,83389000,"[{'period': '2024', 'revenue': 178.13, 'unit': 'M', 'net_profit': 83.39}, {'period': '2023', 'revenue': 61.45, 'unit': 'M', 'net_profit': 33.09}, {'period': '2022', 'revenue': 83.0, 'unit': 'M', 'net_profit': 42.81}, {'period': '2021', 'revenue': 72.58, 'unit': 'M', 'net_profit': 50.88}]","[{'period': ""Q2 '25"", 'revenue': 38.42, 'unit': 'M', 'net_profit': 22.68}, {'period': ""Q1 '25"", 'revenue': 52.06, 'unit': 'M', 'net_profit': 14.04}, {'period': ""Q4 '24"", 'revenue': 26.77, 'unit': 'M', 'net_profit': 13.47}, {'period': ""Q3 '24"", 'revenue': 48.57, 'unit': 'M', 'net_profit': 23.48}, {'period': ""Q2 '24"", 'revenue': 42.78, 'unit': 'M', 'net_profit': 22.62}, {'period': ""Q1 '24"", 'revenue': 30.28, 'unit': 'M', 'net_profit': 23.81}]",2.05,2.05,1556758000,62829000,32273000,801082000,30556000,1476561000,281000,32273000,-188509000,1.2087210032222517,1.5198380322122502,0.8636363636363633,"[0.63, 0.16]","['2024-12-13', '1985-05-09']",__nan__,0.5145835126590003
985,CSWI,CSW Industrials Inc. Common Stock,"CSW Industrials, Inc. operates as a diversified industrial company in the United States and internationally. It operates through three segments: Contractor Solutions, Engineered Building Solutions, and Specialized Reliability Solutions. The Contractor Solutions segment provides cements, diffusers, grilles, registers, solvents, thread sealants, traps, and vents for use in HVAC/R, plumbing, general industrial, architecturally, and specified building products. The Engineered Building Solutions segment offers architectural railings and associated services; fire and smoke protection solutions; and pre-engineered and custom architectural building components for use in architecturally specified building products. The Specialized Reliability Solutions segment provides compounds, lubricants, lubricant management products, and sealants; and contamination control, industrial maintenance and repair, and operations solutions for use in energy, general industrial, mining, and railing markets. The company was incorporated in 2014 and is headquartered in Dallas, Texas.",Mr. Joseph Brooks Armes J.D.,Industrial - Machinery,358.365,USD,6026301677,https://images.financialmodelingprep.com/symbol/CSWI.png,106477,48.82,1.945,62716,192031000,101648000,"[{'period': '2024', 'revenue': 792.84, 'unit': 'M', 'net_profit': 101.65}, {'period': '2023', 'revenue': 757.9, 'unit': 'M', 'net_profit': 96.44}, {'period': '2022', 'revenue': 626.43, 'unit': 'M', 'net_profit': 66.39}, {'period': '2021', 'revenue': 419.2, 'unit': 'M', 'net_profit': 40.1}]","[{'period': ""Q2 '25"", 'revenue': 227.93, 'unit': 'M', 'net_profit': 36.05}, {'period': ""Q1 '25"", 'revenue': 226.18, 'unit': 'M', 'net_profit': 38.59}, {'period': ""Q4 '24"", 'revenue': 210.86, 'unit': 'M', 'net_profit': 31.76}, {'period': ""Q3 '24"", 'revenue': 174.97, 'unit': 'M', 'net_profit': 9.22}, {'period': ""Q2 '24"", 'revenue': 203.65, 'unit': 'M', 'net_profit': 30.05}, {'period': ""Q1 '24"", 'revenue': 203.36, 'unit': 'M', 'net_profit': 30.61}]",6.54,6.52,1043326000,331410000,22156000,408248000,142665000,1230000,115836000,22156000,147757000,0.0990093343482267,0.05405713693161197,0.05144694533762063,"[0.24, 0.135]","['2024-10-25', '2019-05-07']",__nan__,0.3912947630941815
986,CSX,CSX Corporation Common Stock,"CSX Corporation, together with its subsidiaries, provides rail-based freight transportation services. The company offers rail services; and transportation of intermodal containers and trailers, as well as other transportation services, such as rail-to-truck transfers and bulk commodity operations. It transports chemicals, agricultural and food products, automotive, minerals, forest products, fertilizers, and metals and equipment; and coal, coke, and iron ore to electricity-generating power plants, steel manufacturers, and industrial plants, as well as exports coal to deep-water port facilities. The company also offers intermodal transportation services through a network of approximately 30 terminals transporting manufactured consumer goods in containers; and drayage services, including the pickup and delivery of intermodal shipments. It serves the automotive industry with distribution centers and storage locations, as well as connects non-rail served customers through transferring products, such as plastics and ethanol from rail to trucks. The company operates approximately 19,500 route mile rail network, which serves various population centers in 23 states east of the Mississippi River, the District of Columbia, and the Canadian provinces of Ontario and Quebec, as well as owns and leases approximately 3,500 locomotives. It also serves production and distribution facilities through track connections. CSX Corporation was incorporated in 1978 and is headquartered in Jacksonville, Florida.",Mr. Joseph R. Hinrichs,Railroads,32.175,USD,62046913500,https://images.financialmodelingprep.com/symbol/CSX.png,12005746,17.11,0.175,6718730,7340000000,3715000000,"[{'period': '2023', 'revenue': 14.66, 'unit': 'B', 'net_profit': 3.71}, {'period': '2022', 'revenue': 14.85, 'unit': 'B', 'net_profit': 4.17}, {'period': '2021', 'revenue': 12.52, 'unit': 'B', 'net_profit': 3.78}, {'period': '2020', 'revenue': 10.58, 'unit': 'B', 'net_profit': 2.77}]","[{'period': ""Q3 '24"", 'revenue': 3620.0, 'unit': 'M', 'net_profit': 894.0}, {'period': ""Q2 '24"", 'revenue': 3700.0, 'unit': 'M', 'net_profit': 963.0}, {'period': ""Q1 '24"", 'revenue': 3680.0, 'unit': 'M', 'net_profit': 893.0}, {'period': ""Q4 '23"", 'revenue': 3680.0, 'unit': 'M', 'net_profit': 886.0}, {'period': ""Q3 '23"", 'revenue': 3570.0, 'unit': 'M', 'net_profit': 846.0}, {'period': ""Q2 '23"", 'revenue': 3700.0, 'unit': 'M', 'net_profit': 984.0}]",1.85,1.85,42408000000,3384000000,1436000000,30275000000,1393000000,2562000000,3224000000,1353000000,3268000000,-0.006765899864682003,-0.10825732117138742,-0.05128205128205122,"[0.12, 0.64]","['2024-11-29', '1981-02-17']",__nan__,0.713898321071496
987,CTAQ,Carney Technology Acquisition Corp. II Class A Common Stock,"Carney Technology Acquisition Corp. II does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company focuses on searching for a potential business combination target in the technology industry. Carney Technology Acquisition Corp. II was incorporated in 2020 and is based in Palo Alto, California.",Mr. David E. Roberson,Shell Companies,10.18,USD,0,https://images.financialmodelingprep.com/symbol/CTAQ.png,68671,56.55555555555556,0.01,344122,-9721703,7116098,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.12}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.83}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.8}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.46}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.47}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.69}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.86}]",0.14,0.14,402967373,398452,73952,24867999,0,0,265999,73952,-802930,0,0,0,__nan__,__nan__,__nan__,0.06171218978564798
988,CTAQU,Carney Technology Acquisition Corp. II Units,"Carney Technology Acquisition Corp. II does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company focuses on searching for a potential business combination target in the technology industry. Carney Technology Acquisition Corp. II was incorporated in 2020 and is based in Palo Alto, California.",Mr. David E. Roberson,Shell Companies,10.19,USD,0,https://images.financialmodelingprep.com/symbol/CTAQU.png,3100,96.13207547169812,0.04,1300,-9721703,7116098,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.12}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.83}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.8}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.46}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.47}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.69}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.86}]",0.14,0.14,402967373,398452,73952,24867999,0,0,265999,73952,-802930,0,0,0,__nan__,__nan__,__nan__,0.06171218978564798
989,CTAQW,Carney Technology Acquisition Corp. II Warrant,"Carney Technology Acquisition Corp. II intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology industry. The company was founded in 2020 and is based in Burlingame, California.",Mr. David E. Roberson,Shell Companies,0.0004,USD,0,https://images.financialmodelingprep.com/symbol/CTAQW.png,30147,0,0.0001,91522,-9721703,7116098,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.12}, {'period': '2020', 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]","[{'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.83}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 2.8}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.46}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.47}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 3.69}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.86}]",0.14,0.14,402967373,398452,73952,24867999,0,0,265999,73952,-802930,0,0,0,__nan__,__nan__,__nan__,0.06171218978564798
990,CTAS,Cintas Corporation Common Stock,"Cintas Corporation provides corporate identity uniforms and related business services primarily in the United States, Canada, and Latin America. It operates through Uniform Rental and Facility Services, First Aid and Safety Services, and All Other segments. The company rents and services uniforms and other garments, including flame resistant clothing, mats, mops and shop towels, and other ancillary items; and provides restroom cleaning services and supplies, as well as sells uniforms. It also offers first aid and safety services, and fire protection products and services. The company provides its products and services through its distribution network and local delivery routes, or local representatives to small service and manufacturing companies, as well as major corporations. Cintas Corporation was founded in 1968 and is headquartered in Cincinnati, Ohio.",Mr. Todd M. Schneider,Specialty Business Services,189.99,USD,76622777010,https://images.financialmodelingprep.com/symbol/CTAS.png,1671756,45.78,4.89,1592030,2523857000,1571592000,"[{'period': '2024', 'revenue': 9.6, 'unit': 'B', 'net_profit': 1.57}, {'period': '2023', 'revenue': 8.82, 'unit': 'B', 'net_profit': 1.35}, {'period': '2022', 'revenue': 7.85, 'unit': 'B', 'net_profit': 1.24}, {'period': '2021', 'revenue': 7.12, 'unit': 'B', 'net_profit': 1.11}]","[{'period': ""Q2 '25"", 'revenue': 2560.0, 'unit': 'M', 'net_profit': 448.5}, {'period': ""Q1 '25"", 'revenue': 2500.0, 'unit': 'M', 'net_profit': 452.03}, {'period': ""Q4 '24"", 'revenue': 2470.0, 'unit': 'M', 'net_profit': 414.31}, {'period': ""Q3 '24"", 'revenue': 2410.0, 'unit': 'M', 'net_profit': 397.58}, {'period': ""Q2 '24"", 'revenue': 2380.0, 'unit': 'M', 'net_profit': 374.61}, {'period': ""Q1 '24"", 'revenue': 2340.0, 'unit': 'M', 'net_profit': 385.08}]",3.85,3.79,9168817000,3185207000,342015000,4852445000,1244182000,302212000,1828519000,342015000,1670312000,0.1360148824581082,0.16586078738288293,0.16666666666666677,"[0.39, 6.66]","['2024-11-15', '1984-03-06']",__nan__,0.5292334878098233
991,CTBI,Community Trust Bancorp Inc. Common Stock,"Community Trust Bancorp, Inc. operates as the bank holding company for Community Trust Bank, Inc. that provides commercial and personal banking services to small and mid-sized communities. The company accepts time and demand deposits, checking accounts, savings accounts and savings certificates, individual retirement accounts and Keogh plans, and money market accounts. Its loan products include commercial, construction, mortgage, and personal loans; lease-financing, lines of credit, revolving lines of credit, and term loans, as well as other specialized loans, including asset-based financing; residential and commercial real estate loans; and consumer loans. The company also provides cash management, renting safe deposit boxes, and funds transfer services; issues letters of credit; and acts as a trustee of personal trusts, executor of estates, trustee for employee benefit trusts, and paying agent for bond and stock issues, as well as an investment agent and depositor for securities. In addition, it offers securities brokerage, and trust and wealth management services; debit cards; annuity and life insurance products; and repurchase agreements, as well as mobile, internet banking, and e-statement services. The company operates 79 banking locations in eastern, northeastern, central, south central Kentucky, southern West Virginia, and northeastern Tennessee; 4 trust offices across Kentucky; and 1 trust office in northeastern Tennessee. Community Trust Bancorp, Inc. was founded in 1903 and is headquartered in Pikeville, Kentucky.",Mr. Mark A. Gooch CTB,Banks - Regional,51,USD,920952900,https://images.financialmodelingprep.com/symbol/CTBI.png,54582,11.59,-0.64,25245,102334000,78004000,"[{'period': '2023', 'revenue': 221.32, 'unit': 'M', 'net_profit': 78.0}, {'period': '2022', 'revenue': 227.02, 'unit': 'M', 'net_profit': 81.81}, {'period': '2021', 'revenue': 223.54, 'unit': 'M', 'net_profit': 87.94}, {'period': '2020', 'revenue': 205.55, 'unit': 'M', 'net_profit': 59.5}]","[{'period': ""Q3 '24"", 'revenue': 60.03, 'unit': 'M', 'net_profit': 22.14}, {'period': ""Q2 '24"", 'revenue': 92.06, 'unit': 'M', 'net_profit': 19.5}, {'period': ""Q1 '24"", 'revenue': 90.51, 'unit': 'M', 'net_profit': 18.68}, {'period': ""Q4 '23"", 'revenue': 87.31, 'unit': 'M', 'net_profit': 18.66}, {'period': ""Q3 '23"", 'revenue': 58.64, 'unit': 'M', 'net_profit': 20.63}, {'period': ""Q2 '23"", 'revenue': 57.84, 'unit': 'M', 'net_profit': 19.4}]",4.36,4.36,5769696000,1246132000,1222557000,5067488000,23575000,1166882000,7389000,271645000,79410000,-0.019244407812769548,-0.046569046862395186,-0.05010893246187354,"[0.47, 0.21]","['2024-12-13', '1988-03-25']",__nan__,0.878293761057775
992,CTG,Computer Task Group Inc. Common Stock,"Computer Task Group, Incorporated, together with its subsidiaries, offers information and technology services in North America, South America, Western Europe, and India. It operates through three segments: North America IT Solutions and Services, Europe IT Solutions and Services, and Non-Strategic Technology Services. The company offers business process transformation solutions, which include advisory, data strategy, digital workplace, enterprise platforms, information disclosure, and regulatory and compliance services; technology transformation solutions, such as application development, automation, cloud, data management, enterprise platform implementation, and testing services; and operations transformation solutions consisting of application support, IT operations support, cloud, and infrastructure. It also provides staffing services, including managed staffing, staff augmentation, and volume staffing services. The company serves financial services, healthcare, manufacturing, and energy industries, as well as technology service providers. Computer Task Group, Incorporated was incorporated in 1966 and is headquartered in Amherst, New York.",Mr. Filip J. L. Gyd,Information Technology Services,10.5,USD,168993300,https://images.financialmodelingprep.com/symbol/CTG.png,79623,350,0.01,49163,14075000,6609000,"[{'period': '2022', 'revenue': 325.08, 'unit': 'M', 'net_profit': 6.61}, {'period': '2021', 'revenue': 392.29, 'unit': 'M', 'net_profit': 13.73}, {'period': '2020', 'revenue': 366.09, 'unit': 'M', 'net_profit': 7.64}, {'period': '2019', 'revenue': 394.17, 'unit': 'M', 'net_profit': 4.12}]","[{'period': ""Q3 '23"", 'revenue': 71290.0, 'unit': 'K', 'net_profit': -871.0}, {'period': ""Q2 '23"", 'revenue': 74590.0, 'unit': 'K', 'net_profit': -130.0}, {'period': ""Q1 '23"", 'revenue': 78200.0, 'unit': 'K', 'net_profit': 315.0}, {'period': ""Q4 '22"", 'revenue': 77.9, 'unit': 'M', 'net_profit': 1.23}, {'period': ""Q3 '22"", 'revenue': 75.0, 'unit': 'M', 'net_profit': 1.1}, {'period': ""Q2 '22"", 'revenue': 82.76, 'unit': 'M', 'net_profit': 2.04}]",0.46,0.44,181619000,99888000,25140000,75640000,70979000,116000,51933000,25140000,10412000,-0.11555862762347618,-0.5186453022578296,-0.5353535353535354,"[0.06, 0.05]","['2016-09-22', '1981-05-01']",__nan__,0.4164762497315809
993,CTHR,Charles & Colvard Ltd Common Stock,"Charles & Colvard, Ltd. operates as a fine jewelry company in the United States and internationally. The company manufactures, markets, and distributes moissanite jewels and finished moissanite jewelry under the Charles & Colvard Created Moissanite brand; and premium moissanite gemstones under the Forever One brand name. It also markets and distributes lab grown diamonds, and finished jewelry with lab grown diamonds under the Caydia brand. The company sells its products at wholesale prices to distributors, manufacturers, retailers, and designers; and to end-consumers at retail prices through charlesandcolvard.com, third-party online marketplaces, drop-ship, and other e-commerce outlets. Charles & Colvard, Ltd. was founded in 1995 and is headquartered in Morrisville, North Carolina.",Mr. Clint J. Pete CPA,Luxury Goods,1.4936,USD,4657448,https://images.financialmodelingprep.com/symbol/CTHR.png,118506,-0.25,-0.0064,5322,-13025601,-19580794,"[{'period': '2023', 'revenue': 29.95, 'unit': 'M', 'net_profit': -19.58}, {'period': '2022', 'revenue': 43.09, 'unit': 'M', 'net_profit': 2.37}, {'period': '2021', 'revenue': 39.24, 'unit': 'M', 'net_profit': 12.81}, {'period': '2020', 'revenue': 29.19, 'unit': 'M', 'net_profit': -6.16}]","[{'period': ""Q3 '24"", 'revenue': 5.26, 'unit': 'M', 'net_profit': -3.63}, {'period': ""Q2 '24"", 'revenue': 7.91, 'unit': 'M', 'net_profit': -2.87}, {'period': ""Q1 '24"", 'revenue': 4.95, 'unit': 'M', 'net_profit': -2.54}, {'period': ""Q4 '23"", 'revenue': 5.56, 'unit': 'M', 'net_profit': -9.25}, {'period': ""Q3 '23"", 'revenue': 6.64, 'unit': 'M', 'net_profit': -8.4}, {'period': ""Q2 '23"", 'revenue': 10.37, 'unit': 'M', 'net_profit': -1.04}]",-0.64,-0.64,48884088,24576396,10446532,9109502,630085,0,7061760,10446532,-5158614,-4.885325690109386,-9.248313018789636,-9.184143222506394,"[0.08, 0.05]","['2007-05-29', '2005-06-28']",__nan__,0.18634902220125288
994,CTIB,Yunhong CTI Ltd. Common Stock,"Yunhong CTI Ltd. develops, produces, distributes, and sells consumer products in the United States and internationally. It offers novelty products, including foil balloons; latex balloons under the Partyloons name; and toy balloon products, which include punch balls, water bombs, and Animal Twisties, as well as other inflatable toy items. The company also offers packaging films and custom film products for food, and other commercial and packaging applications; and container products, as well as assembles and sells Candy Blossom product line. It primarily serves various retail outlets, including general merchandise stores, discount and drugstore chains, grocery chains, card and gift shops, and party goods stores, as well as florists and balloon decorators. The company sells its products directly, as well as through a network of distributors and wholesalers, retail chains, and independent sales representatives. The company was formerly known as CTI Industries Corporation and changed its name to Yunhong CTI Ltd. in January 2020. Yunhong CTI Ltd. was founded in 1975 and is headquartered in Lake Barrington, Illinois.","Mr. Frank J. Cesario B.S., CPA, M.B.A.",Specialty Retail,2.4,USD,48232320,https://images.financialmodelingprep.com/symbol/CTIB.png,55017,-26.666666666666668,0.43,239336,-399000000,-246000000,"[{'period': '2023', 'revenue': 17800.0, 'unit': 'M', 'net_profit': -246.0}, {'period': '2022', 'revenue': 18.05, 'unit': 'M', 'net_profit': -1.81}, {'period': '2021', 'revenue': 24.09, 'unit': 'M', 'net_profit': -9.03}, {'period': '2020', 'revenue': 26.47, 'unit': 'M', 'net_profit': -2.51}]","[{'period': ""Q3 '23"", 'revenue': 1920.0, 'unit': 'K', 'net_profit': -967.0}, {'period': ""Q2 '23"", 'revenue': 4059.9999999999995, 'unit': 'K', 'net_profit': -149.0}, {'period': ""Q1 '23"", 'revenue': 5050.0, 'unit': 'K', 'net_profit': 638.0}, {'period': ""Q4 '22"", 'revenue': 5570.0, 'unit': 'K', 'net_profit': -78.0}, {'period': ""Q3 '22"", 'revenue': 2.26, 'unit': 'M', 'net_profit': -1.18}, {'period': ""Q2 '22"", 'revenue': 4420.0, 'unit': 'K', 'net_profit': -399.0}]",-0.0126,-0.0126,17247000000,13019000000,921000000,13515000000,3975000000,0,10140000000,921000000,-1338000000,-628.3375394321766,-134.61190738699008,0.9427272727272727,"[0.05, 0.05]","['2011-07-14', '2010-06-16']",__nan__,0.783614541659419
995,CTIC,CTI BioPharma Corp. (DE) Common Stock,"CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.","Dr. Adam R. Craig M.B.A., M.D., Ph.D.",Biotechnology,9.095,USD,1199448600,https://images.financialmodelingprep.com/symbol/CTIC.png,5661603,-16.84259259259259,0.005,5558437,-79853000,-91041000,"[{'period': '2022', 'revenue': 53.95, 'unit': 'M', 'net_profit': -91.04}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -99.64}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -52.95}, {'period': '2019', 'revenue': 3.35, 'unit': 'M', 'net_profit': -42.32}]","[{'period': ""Q1 '23"", 'revenue': 24.12, 'unit': 'M', 'net_profit': -21.8}, {'period': ""Q4 '22"", 'revenue': 21.08, 'unit': 'M', 'net_profit': -16.93}, {'period': ""Q3 '22"", 'revenue': 18.24, 'unit': 'M', 'net_profit': -15.63}, {'period': ""Q2 '22"", 'revenue': 12.33, 'unit': 'M', 'net_profit': -22.66}, {'period': ""Q1 '22"", 'revenue': 2.29, 'unit': 'M', 'net_profit': -37.19}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -38.21}]",-0.79,-0.79,125925000,99396000,79939000,143502000,15387000,0,81134000,30420000,-106194000,0.16236940376788486,0.08626400096350717,0.28828828828828834,__nan__,__nan__,__nan__,1.139583085169744
996,CTLP,Cantaloupe Inc. Common Stock,"Cantaloupe, Inc., a digital payment and software services company, provides technology solutions for the unattended retail market. The company offers integrated solutions for payments processing, logistics, and back-office management. It also provides ePort, an integrated payment device that is deployed in self-service, unattended market applications, such as vending, amusement, arcade, commercial laundry, air/vacuum, car wash, and others, which facilitates digital payments; and integrated software services for payment devices in the field for the wireless transfer. The company serves vending machine, car wash, electric vehicle charging, amusement, commercial laundry, micro-market, kiosk, and entertainment companies. It has strategic partnership with Bakkt Holdings, LLC to bring a cashless experience for consumers to spend digital assets at unattended retail devices: and Castles Technology to introduce a next-generation cashless device solution. The company was formerly known as USA Technologies, Inc and changed its name to Cantaloupe, Inc. Cantaloupe Inc. was incorporated in 1992 and is headquartered in Malvern, Pennsylvania.",Mr. Ravi  Venkatesan,Information Technology Services,8.82,USD,643738284,https://images.financialmodelingprep.com/symbol/CTLP.png,417317,55.13,-0.22,140824,28116000,11993000,"[{'period': '2024', 'revenue': 268.6, 'unit': 'M', 'net_profit': 11.99}, {'period': '2023', 'revenue': 243640.0, 'unit': 'K', 'net_profit': 633.0}, {'period': '2022', 'revenue': 195.2, 'unit': 'M', 'net_profit': -1.7}, {'period': '2021', 'revenue': 166.94, 'unit': 'M', 'net_profit': -8.71}]","[{'period': ""Q1 '25"", 'revenue': 70.84, 'unit': 'M', 'net_profit': 3.57}, {'period': ""Q4 '24"", 'revenue': 72.66, 'unit': 'M', 'net_profit': 2.21}, {'period': ""Q3 '24"", 'revenue': 67.9, 'unit': 'M', 'net_profit': 4.66}, {'period': ""Q2 '24"", 'revenue': 65.36, 'unit': 'M', 'net_profit': 3.12}, {'period': ""Q1 '24"", 'revenue': 62.68, 'unit': 'M', 'net_profit': 2.01}, {'period': ""Q4 '23"", 'revenue': 64.17, 'unit': 'M', 'net_profit': 2.83}]",0.16,0.15,335568000,157794000,58920000,151102000,50239000,-466000,105895000,58920000,12810000,1.3533941575290869,17.946287519747237,17.18181818181818,__nan__,__nan__,__nan__,0.4502872741143375
997,CTMX,CytomX Therapeutics Inc. Common Stock,"CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.",Dr. Sean A. McCarthy DPHIL,Biotechnology,1.035,USD,80997962,https://images.financialmodelingprep.com/symbol/CTMX.png,1189190,6.47,-0.105,1546789,-4309000,-569000,"[{'period': '2023', 'revenue': 101210.0, 'unit': 'K', 'net_profit': -569.0}, {'period': '2022', 'revenue': 53.16, 'unit': 'M', 'net_profit': -97.3}, {'period': '2021', 'revenue': 69.57, 'unit': 'M', 'net_profit': -80.65}, {'period': '2020', 'revenue': 100.36, 'unit': 'M', 'net_profit': -32.88}]","[{'period': ""Q3 '24"", 'revenue': 33.43, 'unit': 'M', 'net_profit': 5.74}, {'period': ""Q2 '24"", 'revenue': 25.11, 'unit': 'M', 'net_profit': -6.53}, {'period': ""Q1 '24"", 'revenue': 41.46, 'unit': 'M', 'net_profit': 13.79}, {'period': ""Q4 '23"", 'revenue': 26610.0, 'unit': 'K', 'net_profit': 837.0}, {'period': ""Q3 '23"", 'revenue': 26.38, 'unit': 'M', 'net_profit': 2.99}, {'period': ""Q2 '23"", 'revenue': 24.72, 'unit': 'M', 'net_profit': -1.09}]",-0.0077,-0.0077,201792000,182936000,174509000,249239000,3432000,0,155913000,17171000,-56875000,0.9564272135258666,0.9941520467836257,0.9947972972972973,__nan__,__nan__,__nan__,1.2351282508721853
998,CTRE,CareTrust REIT Inc. Common Stock,"CareTrust REIT, Inc. is a self-administered, publicly-traded real estate investment trust engaged in the ownership, acquisition, development and leasing of skilled nursing, seniors housing and other healthcare-related properties. With a nationwide portfolio of long-term net-leased properties, and a growing portfolio of quality operators leasing them, CareTrust REIT is pursuing both external and organic growth opportunities across the United States.",Mr. David M. Sedgwick,REIT - Healthcare Facilities,26.42,USD,4948994400,https://images.financialmodelingprep.com/symbol/CTRE.png,2325291,36.19,0.04,487256,145804000,53735000,"[{'period': '2023', 'revenue': 217.77, 'unit': 'M', 'net_profit': 53.73}, {'period': '2022', 'revenue': 187.51, 'unit': 'M', 'net_profit': 42.87}, {'period': '2021', 'revenue': 190.19, 'unit': 'M', 'net_profit': 48.3}, {'period': '2020', 'revenue': 175.69, 'unit': 'M', 'net_profit': 57.21}]","[{'period': ""Q3 '24"", 'revenue': 77.38, 'unit': 'M', 'net_profit': 33.44}, {'period': ""Q2 '24"", 'revenue': 68.89, 'unit': 'M', 'net_profit': 10.76}, {'period': ""Q1 '24"", 'revenue': 63.07, 'unit': 'M', 'net_profit': 28.75}, {'period': ""Q4 '23"", 'revenue': 53.47, 'unit': 'M', 'net_profit': 26.3}, {'period': ""Q3 '23"", 'revenue': 51.22, 'unit': 'M', 'net_profit': 8.7}, {'period': ""Q2 '23"", 'revenue': 47740.0, 'unit': 'K', 'net_profit': -484.0}]",0.5,0.5,2084838000,309854000,294448000,666121000,395000,0,70523000,294448000,143791000,-0.10446954481521746,0.25338216085090504,0.13636363636363635,"[0.29, 5.88]","['2024-12-31', '2014-10-29']",__nan__,0.31950731903390095
999,CTRM,Castor Maritime Inc. Common Shares,"Castor Maritime Inc. provides shipping services worldwide. The company operates through three segments: Dry Bulk, Aframax/LR2 Tanker, and Handysize Tanker. It offers seaborne transportation services for dry bulk cargo; commodities, such as iron ore, coal, soybeans, etc.; and crude oil and refined petroleum products. As of December 31, 2021, the company owned and operated a fleet of 29 vessels primarily consisting of two Handysize tanker vessels, seven Aframax/LR2 tanker vessels, and 14 dry bulk vessels. Castor Maritime Inc. was incorporated in 2017 and is based in Limassol, Cyprus.",Mr. Petros  Panagiotidis,Marine Shipping,2.78,USD,26861333,https://images.financialmodelingprep.com/symbol/CTRM.png,60800,0.75,-0.14,62039,55705947,38642488,"[{'period': '2023', 'revenue': 97.52, 'unit': 'M', 'net_profit': 38.64}, {'period': '2022', 'revenue': 262.1, 'unit': 'M', 'net_profit': 118.56}, {'period': '2021', 'revenue': 132.05, 'unit': 'M', 'net_profit': 40.5}, {'period': '2020', 'revenue': 12.49, 'unit': 'M', 'net_profit': -1.75}]","[{'period': ""Q3 '24"", 'revenue': 13.41, 'unit': 'M', 'net_profit': 2.84}, {'period': ""Q2 '24"", 'revenue': 16.28, 'unit': 'M', 'net_profit': 22.85}, {'period': ""Q1 '24"", 'revenue': 20.39, 'unit': 'M', 'net_profit': 22.33}, {'period': ""Q4 '23"", 'revenue': 26.36, 'unit': 'M', 'net_profit': 25.01}, {'period': ""Q3 '23"", 'revenue': 21.4, 'unit': 'M', 'net_profit': -5.39}, {'period': ""Q2 '23"", 'revenue': 25.28, 'unit': 'M', 'net_profit': 8.19}]",3.86,1.68,605041979,242276874,188472745,94312238,8565067,117537135,28602396,111383645,41969123,-0.38144171476165667,-0.6740699805306464,-0.6919393455706305,__nan__,__nan__,__nan__,0.15587718087904773
1000,CTRN,Citi Trends Inc. Common Stock,"Citi Trends, Inc. operates as a value retailer of fashion apparel, accessories, and home goods. It offers apparel, such as fashion sportswear and footwear for men and ladies, as well as apparel for kids, including newborns, infants, toddlers, boys, and girls; sleepwear, lingerie, and scrubs for ladies; and kids uniforms and accessories. The company also provides accessories and beauty products that include handbags, luggage, hats, belts, sunglasses, jewelry, and watches, as well as undergarments and outerwear for men and women. In addition, it offers home and lifestyle products comprising home products for the bedroom, bathroom, kitchen, and decorative accessories; and food, tech, team sports, and health products, as well as seasonal items, books, and toys. The company provides its products primarily to African American and Latinx families in the United States. As of January 29, 2022, it operated 609 stores in urban and rural markets in 33 states. The company was formerly known as Allied Fashion, Inc. and changed its name to Citi Trends, Inc. in 2001. Citi Trends, Inc. was founded in 1946 and is headquartered in Savannah, Georgia.",Mr. Kenneth Duane Seipel,Apparel - Retail,26.08,USD,227157322,https://images.financialmodelingprep.com/symbol/CTRN.png,88353,-8.52,-0.47,31097,3410000,-11979000,"[{'period': '2023', 'revenue': 747.94, 'unit': 'M', 'net_profit': -11.98}, {'period': '2022', 'revenue': 795.01, 'unit': 'M', 'net_profit': 58.89}, {'period': '2021', 'revenue': 991.6, 'unit': 'M', 'net_profit': 62.24}, {'period': '2020', 'revenue': 783.29, 'unit': 'M', 'net_profit': 23.98}]","[{'period': ""Q3 '24"", 'revenue': 179.07, 'unit': 'M', 'net_profit': -7.15}, {'period': ""Q2 '24"", 'revenue': 176.55, 'unit': 'M', 'net_profit': -18.41}, {'period': ""Q1 '24"", 'revenue': 186.29, 'unit': 'M', 'net_profit': -3.43}, {'period': ""Q4 '23"", 'revenue': 215.18, 'unit': 'M', 'net_profit': 3.55}, {'period': ""Q3 '23"", 'revenue': 179.52, 'unit': 'M', 'net_profit': -3.86}, {'period': ""Q2 '23"", 'revenue': 173.55, 'unit': 'M', 'net_profit': -5.03}]",-1.46,-1.46,518721000,225099000,79706000,361015000,4123000,0,169904000,79706000,-24452000,-0.9769973826933974,-1.2034062351422943,-1.203626220362622,"[0.08, 0.06]","['2020-03-02', '2015-08-28']",__nan__,0.6959714374393942
1001,CTSH,Cognizant Technology Solutions Corporation Class A Common Stock,"Cognizant Technology Solutions Corporation, a professional services company, provides consulting and technology, and outsourcing services in North America, Europe, and internationally. It operates through four segments: Financial Services; Healthcare; Products and Resources; and Communications, Media and Technology. The company offers customer experience enhancement, robotic process automation, analytics, and AI services in areas, such as digital lending, fraud detection, and next generation payments; the shift towards consumerism, outcome-based contracting, digital health, delivering integrated seamless, omni-channel, and patient-centered experience; and services that drive operational improvements in areas, such as clinical development, pharmacovigilance, and manufacturing, as well as claims processing, enrollment, membership, and billing to healthcare providers and payers, and life sciences companies, including pharmaceutical, biotech, and medical device companies. It also provides solution to manufacturers, retailers and travel and hospitality companies, as well as companies providing logistics, energy and utility services; and digital content, the creation of personalized user experience, and acceleration of digital engineering services to information, media and entertainment, and communications and technology companies. The company was founded in 1994 and is headquartered in Teaneck, New Jersey.",Mr. Ravi Kumar Singisetti,Information Technology Services,75.7981,USD,37582517134,https://images.financialmodelingprep.com/symbol/CTSH.png,3111772,16.77,-0.1119,610298,3347000000,2126000000,"[{'period': '2023', 'revenue': 19.35, 'unit': 'B', 'net_profit': 2.13}, {'period': '2022', 'revenue': 19.43, 'unit': 'B', 'net_profit': 2.29}, {'period': '2021', 'revenue': 18.51, 'unit': 'B', 'net_profit': 2.14}, {'period': '2020', 'revenue': 16.65, 'unit': 'B', 'net_profit': 1.39}]","[{'period': ""Q3 '24"", 'revenue': 5040.0, 'unit': 'M', 'net_profit': 582.0}, {'period': ""Q2 '24"", 'revenue': 4850.0, 'unit': 'M', 'net_profit': 566.0}, {'period': ""Q1 '24"", 'revenue': 4760.0, 'unit': 'M', 'net_profit': 546.0}, {'period': ""Q4 '23"", 'revenue': 4760.0, 'unit': 'M', 'net_profit': 558.0}, {'period': ""Q3 '23"", 'revenue': 4900.0, 'unit': 'M', 'net_profit': 525.0}, {'period': ""Q2 '23"", 'revenue': 4890.0, 'unit': 'M', 'net_profit': 463.0}]",4.21,4.21,18483000000,7506000000,2635000000,5256000000,3849000000,80000000,3333000000,2621000000,2013000000,-0.07130965593784684,-0.07161572052401746,-0.04751131221719456,"[0.3, 0.15]","['2024-11-19', '2017-05-18']",__nan__,0.28436942054861225
1002,CTSO,Cytosorbents Corporation Common Stock,"Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.","Dr. Phillip P. Chan M.D., Ph.D.",Medical - Devices,0.9925,USD,54418874,https://images.financialmodelingprep.com/symbol/CTSO.png,253835,-2.76,-0.0475,199358,-29182461,-28507394,"[{'period': '2023', 'revenue': 36.35, 'unit': 'M', 'net_profit': -28.51}, {'period': '2022', 'revenue': 29.36, 'unit': 'M', 'net_profit': -32.81}, {'period': '2021', 'revenue': 40.11, 'unit': 'M', 'net_profit': -24.56}, {'period': '2020', 'revenue': 39.45, 'unit': 'M', 'net_profit': -7.84}]","[{'period': ""Q3 '24"", 'revenue': 8.61, 'unit': 'B', 'net_profit': -2.33}, {'period': ""Q2 '24"", 'revenue': 9.89, 'unit': 'M', 'net_profit': -4.14}, {'period': ""Q1 '24"", 'revenue': 9.79, 'unit': 'M', 'net_profit': -6.36}, {'period': ""Q4 '23"", 'revenue': 8.67, 'unit': 'M', 'net_profit': -5.83}, {'period': ""Q3 '23"", 'revenue': 7.75, 'unit': 'M', 'net_profit': -9.19}, {'period': ""Q2 '23"", 'revenue': 8.07, 'unit': 'M', 'net_profit': -6.15}]",-0.64,-0.64,53260634,25702823,14131137,29985471,6057072,0,14545955,14131137,-22591372,0.027356929037506528,0.1312164690823759,0.14666666666666664,__nan__,__nan__,__nan__,0.562995006781181
1003,CTXR,Citius Pharmaceuticals Inc. Common Stock,"Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.",Mr. Leonard L. Mazur,Biotechnology,4.2,USD,32454408,https://images.financialmodelingprep.com/symbol/CTXR.png,265369,-0.7,0.29,139816,0,-39425839,"[{'period': '2024', 'revenue': 0.0, 'unit': 'M', 'net_profit': -39.43}, {'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -32.54}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -33.64}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -23.13}]","[{'period': ""Q4 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.79}, {'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -10.57}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.54}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.23}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.94}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.48}]",0,0,116651751,14220646,3251880,42549921,0,0,35814803,3251880,-28201375,1,-0.21150310703602676,1,__nan__,__nan__,__nan__,0.36476024264736495
1004,CTXRW,Citius Pharmaceuticals Inc. Warrant,"Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.",None,Biotechnology,0.1441,USD,0,https://images.financialmodelingprep.com/symbol/CTXRW.png,0,0,-0.00590001,5350,-22878727,-23054434,"[{'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -23.05}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.55}, {'period': '2019', 'revenue': 0.09, 'unit': 'M', 'net_profit': -15.56}, {'period': '2018', 'revenue': 0.075, 'unit': 'M', 'net_profit': -12.54}]","[{'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.92}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.59}, {'period': ""Q4 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -9.23}, {'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.96}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.82}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.12}]",-0.66,-0.66,142429059,72814350,70072946,9646326,0,29177000,3982292,70072946,-64257352,-0.3163788155245601,-0.3137863191339682,-0.32000000000000006,__nan__,__nan__,__nan__,0.0677272325445891
1005,CTXS,Citrix Systems Inc. Common Stock,"Citrix Systems, Inc., an enterprise software company, provides workspace, app delivery and security, and professional services worldwide. The company offers workspace services, including Citrix Workspace; Citrix Virtual Apps and Desktops; Collaborative Work Management; Citrix Content Collaboration, a cloud-based file sharing, digital transaction, and storage solution, which provides enterprise-class data services on various corporate and personal mobile devices; Citrix Analytics for Security that assesses the behavior of Citrix Virtual Apps and Desktops, and Citrix Workspace users and applies actions to protect sensitive corporate information; Citrix Analytics for Performance, which uses machine learning to quantify user experience; Citrix Secure Workspace Access that provides an end-to-end solution to implement Zero Trust principles; and Citrix Secure Internet Access, which provides a solution that protects direct internet access for branch and remote workers using unsanctioned apps. It also provides Citrix ADC that offers application delivery controller, on-premise, in-cloud, and SaaS deployment option solutions. In addition, the company provides customer services, hardware maintenance, consulting, and product training and certification services. The company serves healthcare, financial services, technology, manufacturing, consumer, and government agencies. It markets and licenses its products through resellers, distributors, systems integrators, independent software vendors, original equipment manufacturers, and service providers. The company was formerly known as Citrus Systems, Inc. and changed its name to Citrix Systems, Inc. in March 2009. Citrix Systems, Inc. was incorporated in 1989 and is headquartered in Fort Lauderdale, Florida. As of September 30, 2022, Citrix Systems, Inc. was taken private.",Mr. David Henshall,Software - Application,103.9,USD,0,https://images.financialmodelingprep.com/symbol/CTXS.png,0,0,0.04,5783859,529320000,307499000,"[{'period': '2021', 'revenue': 3220.0, 'unit': 'M', 'net_profit': 307.5}, {'period': '2020', 'revenue': 3240.0, 'unit': 'M', 'net_profit': 504.45}, {'period': '2019', 'revenue': 3010.0, 'unit': 'M', 'net_profit': 681.81}, {'period': '2018', 'revenue': 2970.0, 'unit': 'M', 'net_profit': 575.67}]","[{'period': ""Q2 '22"", 'revenue': 859.52, 'unit': 'M', 'net_profit': 115.46}, {'period': ""Q1 '22"", 'revenue': 825.34, 'unit': 'M', 'net_profit': 60.23}, {'period': ""Q4 '21"", 'revenue': 850.85, 'unit': 'M', 'net_profit': 102.9}, {'period': ""Q3 '21"", 'revenue': 778.45, 'unit': 'M', 'net_profit': 51.79}, {'period': ""Q2 '21"", 'revenue': 812.11, 'unit': 'M', 'net_profit': 62.77}, {'period': ""Q1 '21"", 'revenue': 775.77, 'unit': 'M', 'net_profit': 90.05}]",2.44,2.44,6975517000,1718985000,527179000,6428260000,885311000,14754000,2354071000,513993000,576090000,-0.3125508943773645,-0.39042236433632144,-0.39,"[0.37, 0.35]","['2021-12-07', '2018-12-07']",__nan__,0.9215460302082269
1006,CUBA,Herzfeld Caribbean Basin Fund Inc. (The) Common Stock,"The Herzfeld Caribbean Basin Fund Inc. is a closed-ended equity mutual fund launched by Thomas J. Herzfeld Advisors, Inc. The fund is managed by Herzfeld/Cuba. It invests in the public equity markets of the United States. The fund employing fundamental analysis investing in stocks of companies that are likely to benefit from economic, political, structural and technological developments in the countries in the Caribbean Basin, which consist of Cuba, Jamaica, Trinidad and Tobago, the Bahamas, the Dominican Republic, Barbados, Aruba, Haiti, the Netherlands Antilles, the Commonwealth of Puerto Rico, Mexico, Honduras, Guatemala, Belize, Costa Rica, Panama, Colombia and Venezuela. It invests in stocks of companies operating across diversified sectors. The Herzfeld Caribbean Basin Fund Inc. was formed on March 10, 1992 and is domiciled in the United States.",,Asset Management,2.34,USD,36786906,https://images.financialmodelingprep.com/symbol/CUBA.png,41864,12.32,-0.01,8576,1640201,1640201,"[{'period': '2023', 'revenue': 2.65, 'unit': 'M', 'net_profit': 1.64}, {'period': '2022', 'revenue': 8.45, 'unit': 'M', 'net_profit': 7.84}, {'period': '2021', 'revenue': -6.7, 'unit': 'M', 'net_profit': -7.45}, {'period': '2020', 'revenue': 18.38, 'unit': 'M', 'net_profit': 17.75}]","[{'period': ""Q4 '23"", 'revenue': 2220.0, 'unit': 'K', 'net_profit': -565.74}, {'period': ""Q2 '23"", 'revenue': 0.4233, 'unit': 'M', 'net_profit': 2.21}, {'period': ""Q4 '22"", 'revenue': 1.38, 'unit': 'M', 'net_profit': 5.75}, {'period': ""Q2 '22"", 'revenue': 0.00864, 'unit': 'M', 'net_profit': 2.09}, {'period': ""Q4 '21"", 'revenue': 2.08, 'unit': 'M', 'net_profit': -8.5}, {'period': ""Q2 '21"", 'revenue': 0.6519199999999999, 'unit': 'M', 'net_profit': 1.05}]",0.19,0.19,51313638,0,641709,2267719,43487,51226217,0,641709,0,-0.7907764380890229,-0.7907764380890229,-0.8318584070796461,"[0.2325, 0.012]","['2024-12-31', '1994-12-23']",__nan__,0.044193300034583397
1007,CUE,Cue Biopharma Inc. Common Stock,"Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.","Mr. Daniel R. Passeri J.D., M.Sc.",Biotechnology,1.5894,USD,100688967,https://images.financialmodelingprep.com/symbol/CUE.png,640466,-1.75,-0.1606,175242,-46052000,-50733000,"[{'period': '2023', 'revenue': 5.49, 'unit': 'M', 'net_profit': -50.73}, {'period': '2022', 'revenue': 1.25, 'unit': 'M', 'net_profit': -52.8}, {'period': '2021', 'revenue': 14.94, 'unit': 'M', 'net_profit': -44.16}, {'period': '2020', 'revenue': 3.15, 'unit': 'M', 'net_profit': -44.78}]","[{'period': ""Q3 '24"", 'revenue': 3.34, 'unit': 'M', 'net_profit': -8.66}, {'period': ""Q2 '24"", 'revenue': 2.66, 'unit': 'M', 'net_profit': -10.17}, {'period': ""Q1 '24"", 'revenue': 1.72, 'unit': 'M', 'net_profit': -12.35}, {'period': ""Q4 '23"", 'revenue': 1.82, 'unit': 'M', 'net_profit': -13.43}, {'period': ""Q3 '23"", 'revenue': 2.1, 'unit': 'M', 'net_profit': -11.01}, {'period': ""Q2 '23"", 'revenue': 1.38, 'unit': 'M', 'net_profit': -13.19}]",-1.11,-1.11,61530000,51454000,48514000,24445000,1698000,151000,17081000,48514000,-39961000,0.08790780683340295,0.03907411088595708,0.24999999999999992,__nan__,__nan__,__nan__,0.3972858768080611
1008,CUEN,Cuentas Inc. Common Stock,"Cuentas Inc., together with its subsidiaries, provides mobile banking, online banking, prepaid debit, and digital content services to the unbanked, underbanked, and underserved communities in the United States and internationally. It offers prepaid voice, text, and data mobile phone services; and domestic and international long-distance voice, text, and data telephony services. The company also provides a mobile app and general-purpose reloadable card, which are integrated into a fintech ecosystem that protects customers by depositing their funds in an FDIC insured bank account. In addition, it offers financial services, which include direct ACH deposits, ATM access, retail and online purchases, peer to peer payments, cash reloads at various retailers, prepaid long distance telecom minutes, discounted gift cards for brands, and international and domestic mobile phone recharges. The company has strategic partnerships with Sutton Bank and Interactive Communications International, Inc. Cuentas Inc. is based in Miami, Florida.",Mr. Shalom Arik Maimon,Software - Application,0.006,USD,16380,https://images.financialmodelingprep.com/symbol/CUEN.png,2795,-0.06,0,1835,-6094000,-2196000,"[{'period': '2023', 'revenue': 2.35, 'unit': 'M', 'net_profit': -2.2}, {'period': '2022', 'revenue': 2.99, 'unit': 'M', 'net_profit': -21.86}, {'period': '2021', 'revenue': 0.593, 'unit': 'M', 'net_profit': -11.01}, {'period': '2020', 'revenue': 0.558, 'unit': 'M', 'net_profit': -8.61}]","[{'period': ""Q1 '24"", 'revenue': 639.0, 'unit': 'K', 'net_profit': -445.0}, {'period': ""Q4 '23"", 'revenue': 1.35, 'unit': 'M', 'net_profit': 2.1}, {'period': ""Q3 '23"", 'revenue': 0.895, 'unit': 'M', 'net_profit': -1.19}, {'period': ""Q2 '23"", 'revenue': 0.04, 'unit': 'M', 'net_profit': -1.41}, {'period': ""Q1 '23"", 'revenue': 0.064, 'unit': 'M', 'net_profit': -1.7}, {'period': ""Q4 '22"", 'revenue': 0.787, 'unit': 'M', 'net_profit': -5.45}]",-0.95,-0.95,4720000,1760000,205000,4790000,1300000,2928000,4689000,205000,-4507000,0.43311627906976746,0.8995195607412492,0.946509009009009,__nan__,__nan__,__nan__,1.0148305084745763
1009,CUENW,Cuentas Inc. Warrant,"Cuentas Inc., together with its subsidiaries, provides mobile, prepaid debit, and digital content services to the unbanked, underbanked, and underserved communities in the United States and internationally. It offers prepaid voice, text, and data mobile phone services; and domestic and international long-distance voice, text, and data telephony services. The company also provides a mobile app and general-purpose reloadable card, which are integrated into a fintech ecosystem that protects customers by depositing their funds in an FDIC insured bank account. In addition, it offers financial services, including direct ACH deposits, ATM access, retail and online purchases, peer to peer payments, cash reloads at various retailers, prepaid long distance telecom minutes, discounted gift cards for brands, and international and domestic mobile phone recharges. The company is based in Miami Beach, Florida.",Mr. Shalom Arik Maimon,Software - Application,0.001,USD,2687,https://images.financialmodelingprep.com/symbol/CUENW.png,0,,0,21923,-6094000,-2196000,"[{'period': '2023', 'revenue': 2.35, 'unit': 'M', 'net_profit': -2.2}, {'period': '2022', 'revenue': 2.99, 'unit': 'M', 'net_profit': -21.86}, {'period': '2021', 'revenue': 0.593, 'unit': 'M', 'net_profit': -11.01}, {'period': '2020', 'revenue': 0.558, 'unit': 'M', 'net_profit': -8.61}]","[{'period': ""Q1 '24"", 'revenue': 639.0, 'unit': 'K', 'net_profit': -445.0}, {'period': ""Q4 '23"", 'revenue': 1.35, 'unit': 'M', 'net_profit': 2.1}, {'period': ""Q3 '23"", 'revenue': 0.895, 'unit': 'M', 'net_profit': -1.19}, {'period': ""Q2 '23"", 'revenue': 0.04, 'unit': 'M', 'net_profit': -1.41}, {'period': ""Q1 '23"", 'revenue': 0.064, 'unit': 'M', 'net_profit': -1.7}, {'period': ""Q4 '22"", 'revenue': 0.787, 'unit': 'M', 'net_profit': -5.45}]",-0.95,-0.95,4720000,1760000,205000,4790000,1300000,2928000,4689000,205000,-4507000,0.43311627906976746,0.8995195607412492,0.946509009009009,__nan__,__nan__,__nan__,1.0148305084745763
1010,CURI,CuriosityStream Inc. Class A Common Stock,"CuriosityStream Inc. operates as a factual content streaming service and media company. The company provides premium video programming services in various categories of factual entertainment, including science, history, society, nature, lifestyle, and technology through direct subscription video on-demand (SVoD) platforms accessible by internet connected devices, or indirectly via distribution partners who deliver CuriosityStream content via the distributor's platform or system; and through bundled content licenses for SVoD and linear offerings, partner bulk sales, brand partnerships, and content sales. It offers streaming content through devices, including televisions, set-top boxes, computers, streaming media players, game consoles, and mobile devices. As of December 31, 2021, it had approximately 23 million total paying subscribers, including direct subscribers, partner direct subscribers, and bundled MVPD subscribers. The company was founded in 2015 and is based in Silver Spring, Maryland.",Mr. Clint  Stinchcomb,Broadcasting,1.53,USD,84883176,https://images.financialmodelingprep.com/symbol/CURI.png,248312,-5.46,0,55514,-2100000,-48896000,"[{'period': '2023', 'revenue': 56.89, 'unit': 'M', 'net_profit': -48.9}, {'period': '2022', 'revenue': 78.04, 'unit': 'M', 'net_profit': -50.92}, {'period': '2021', 'revenue': 71.26, 'unit': 'M', 'net_profit': -37.63}, {'period': '2020', 'revenue': 39.62, 'unit': 'M', 'net_profit': -48.6}]","[{'period': ""Q3 '24"", 'revenue': 12.6, 'unit': 'M', 'net_profit': -3.06}, {'period': ""Q2 '24"", 'revenue': 12.39, 'unit': 'M', 'net_profit': -2.03}, {'period': ""Q1 '24"", 'revenue': 12.0, 'unit': 'M', 'net_profit': -5.04}, {'period': ""Q4 '23"", 'revenue': 14.78, 'unit': 'M', 'net_profit': -4.66}, {'period': ""Q3 '23"", 'revenue': 15.63, 'unit': 'M', 'net_profit': -26.57}, {'period': ""Q2 '23"", 'revenue': 14.1, 'unit': 'M', 'net_profit': -9.92}]",-0.92,-0.92,101022000,45290000,37715000,28376000,4760000,6354000,23398000,37715000,-16177000,0.8011363636363636,0.039692047842567316,0.04166666666666659,"[0.025, 0.025]","['2025-03-14', '2024-04-11']",__nan__,0.280889311239136
1011,CURIW,CuriosityStream Inc. Warrant,"CuriosityStream, Inc. is a media and entertainment company. It offers video and audio programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The company was founded by John S. Hendricks on June 06, 2008 and is headquartered in Silver Spring, MD.",Mr. Clint  Stinchcomb,Broadcasting,0.0257,USD,1425815,https://images.financialmodelingprep.com/symbol/CURIW.png,0,,0.0051,4672,-2100000,-48896000,"[{'period': '2023', 'revenue': 56.89, 'unit': 'M', 'net_profit': -48.9}, {'period': '2022', 'revenue': 78.04, 'unit': 'M', 'net_profit': -50.92}, {'period': '2021', 'revenue': 71.26, 'unit': 'M', 'net_profit': -37.63}, {'period': '2020', 'revenue': 39.62, 'unit': 'M', 'net_profit': -48.6}]","[{'period': ""Q3 '24"", 'revenue': 12.6, 'unit': 'M', 'net_profit': -3.06}, {'period': ""Q2 '24"", 'revenue': 12.39, 'unit': 'M', 'net_profit': -2.03}, {'period': ""Q1 '24"", 'revenue': 12.0, 'unit': 'M', 'net_profit': -5.04}, {'period': ""Q4 '23"", 'revenue': 14.78, 'unit': 'M', 'net_profit': -4.66}, {'period': ""Q3 '23"", 'revenue': 15.63, 'unit': 'M', 'net_profit': -26.57}, {'period': ""Q2 '23"", 'revenue': 14.1, 'unit': 'M', 'net_profit': -9.92}]",-0.92,-0.92,101022000,45290000,37715000,28376000,4760000,6354000,23398000,37715000,-16177000,0.8011363636363636,0.039692047842567316,0.04166666666666659,__nan__,__nan__,__nan__,0.280889311239136
1012,CUTR,Cutera Inc. Common Stock,"Cutera, Inc., a medical device company, researches, develops, manufactures, markets, and services laser and energy-based aesthetics systems for practitioners worldwide. The company offers Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truSculpt flex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; excel V+, a vascular and benign pigmented lesion treatment platform; truSculpt iD, for the non-surgical body sculpting market; and Secret RF, a fractional RF microneedling system for tissue coagulation and hemostasis. It also provides enlighten platform, a laser system that is used for tattoo removal, as well as to treat benign pigmented lesions and acne scars; excel HR platform, a hair removal solution for various skin types; and xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity. In addition, the company distributes skincare products; and offers post-warranty services through extended service contracts or direct billing. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; and Pearl and Pearl Fractional hand pieces, as well as sells hand piece refills, cycle refills, consumable tips, and marketing brochures through the company's website. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, and other qualified practitioners, as well as for physicians performing aesthetic treatments in non-medical offices. Cutera, Inc. was incorporated in 1988 and is headquartered in Brisbane, California.",Mr. Taylor C. Harris,Medical - Devices,0.6764,USD,13653743,https://images.financialmodelingprep.com/symbol/CUTR.png,683295,-0.09,0.0566,2104753,-140944000,-162833000,"[{'period': '2023', 'revenue': 212.37, 'unit': 'M', 'net_profit': -162.83}, {'period': '2022', 'revenue': 252.4, 'unit': 'M', 'net_profit': -82.34}, {'period': '2021', 'revenue': 231.27, 'unit': 'M', 'net_profit': 2.06}, {'period': '2020', 'revenue': 147.68, 'unit': 'M', 'net_profit': -23.88}]","[{'period': ""Q3 '24"", 'revenue': 32.5, 'unit': 'M', 'net_profit': -39.02}, {'period': ""Q2 '24"", 'revenue': 34.38, 'unit': 'M', 'net_profit': -24.68}, {'period': ""Q1 '24"", 'revenue': 38.79, 'unit': 'M', 'net_profit': -22.78}, {'period': ""Q4 '23"", 'revenue': 49.54, 'unit': 'M', 'net_profit': -45.23}, {'period': ""Q3 '23"", 'revenue': 46.48, 'unit': 'M', 'net_profit': -44.27}, {'period': ""Q2 '23"", 'revenue': 61.22, 'unit': 'M', 'net_profit': -31.64}]",-8.19,-8.19,346291000,269185000,143612000,518121000,49428000,0,87747000,143612000,-170880000,-1.1612205780878633,-0.9775686179256741,-0.8656036446469249,__nan__,__nan__,__nan__,1.4962011718467993
1013,CVAC,CureVac N.V. Ordinary Shares,"CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tbingen, Germany.","Dr. Alexander  Zehnder M.B.A., M.D.",Biotechnology,4.649,USD,1042798594,https://images.financialmodelingprep.com/symbol/CVAC.png,581612,7.75,,0,-234090000,-260167000,"[{'period': '2023', 'revenue': 53.76, 'unit': 'M', 'net_profit': -260.17}, {'period': '2022', 'revenue': 67.42, 'unit': 'M', 'net_profit': -249.03}, {'period': '2021', 'revenue': 102.99, 'unit': 'M', 'net_profit': -411.72}, {'period': '2020', 'revenue': 48.9, 'unit': 'M', 'net_profit': -129.07}]","[{'period': ""Q3 '24"", 'revenue': 493.9, 'unit': 'M', 'net_profit': 338.04}, {'period': ""Q2 '24"", 'revenue': 14.44, 'unit': 'M', 'net_profit': -72.54}, {'period': ""Q1 '24"", 'revenue': 12.37, 'unit': 'M', 'net_profit': -70.55}, {'period': ""Q4 '23"", 'revenue': 21.99, 'unit': 'M', 'net_profit': -84.43}, {'period': ""Q3 '23"", 'revenue': 16.48, 'unit': 'M', 'net_profit': -48.68}, {'period': ""Q2 '23"", 'revenue': 7.58, 'unit': 'M', 'net_profit': -67.41}]",-1.18,-1.18,788249000,478381000,405113000,271308000,39510000,-4000,186389000,402452000,-323087000,-0.1179830552185915,-0.04472571467580081,0.10606060606060615,__nan__,__nan__,__nan__,0.34419073160892055
1014,CVBF,CVB Financial Corporation Common Stock,"CVB Financial Corp. operates as a bank holding company for Citizens Business Bank, a state-chartered bank that provides banking and financial services to small to mid-sized businesses and individuals. It offers checking, savings, money market, and time certificates of deposit products for business and personal accounts; and serves as a federal tax depository for business customers. The company also provides commercial lending products comprising lines of credit and other working capital financing, accounts receivable lending, and letters of credit; agriculture loans to finance the operating needs of wholesale dairy farm operations, cattle feeders, livestock raisers, and farmers; lease financing services for municipal governments; commercial real estate and construction loans; and consumer financing products, including automobile leasing and financing, lines of credit, credit cards, home mortgages, and home equity loans and lines of credit. In addition, it offers various specialized services, such as treasury management systems for monitoring cash flow, merchant card processing program, armored pick-up and delivery, payroll services, remote deposit capture, electronic funds transfers, wires and automated clearinghouse, and online account access. Further, the company provides trust services through its CitizensTrust Division, such as fiduciary services, mutual funds, annuities, 401(k) plans, and individual investment accounts. As of December 31, 2021, it operated 58 banking centers located in the Inland Empire, Los Angeles County, Orange County, San Diego County, Ventura County, Santa Barbara County, and the Central Valley area of California; and three trust offices located in Ontario, Newport Beach, and Pasadena, as well as two loan production offices in California's Central Valley and the Sacramento area. The company was founded in 1974 and is headquartered in Ontario, California.",Mr. David A. Brager,Banks - Regional,20.71,USD,2892731380,https://images.financialmodelingprep.com/symbol/CVBF.png,811288,14.58,-0.46,191836,328486000,221435000,"[{'period': '2023', 'revenue': 547.32, 'unit': 'M', 'net_profit': 221.44}, {'period': '2022', 'revenue': 555.5, 'unit': 'M', 'net_profit': 235.43}, {'period': '2021', 'revenue': 461.94, 'unit': 'M', 'net_profit': 212.52}, {'period': '2020', 'revenue': 464.24, 'unit': 'M', 'net_profit': 177.16}]","[{'period': ""Q3 '24"", 'revenue': 117.28, 'unit': 'M', 'net_profit': 51.22}, {'period': ""Q2 '24"", 'revenue': 173.5, 'unit': 'M', 'net_profit': 50.03}, {'period': ""Q1 '24"", 'revenue': 171.8, 'unit': 'M', 'net_profit': 48.6}, {'period': ""Q4 '23"", 'revenue': 177.24, 'unit': 'M', 'net_profit': 48.51}, {'period': ""Q3 '23"", 'revenue': 137.68, 'unit': 'M', 'net_profit': 57.89}, {'period': ""Q2 '23"", 'revenue': 132.19, 'unit': 'M', 'net_profit': 55.77}]",1.59,1.59,16020993000,281285000,281285000,13943021000,0,222292000,13512603000,281285000,291111000,-0.03953708685176955,-0.05942444515238399,-0.05357142857142849,"[0.2, 0.088]","['2024-12-31', '1992-03-31']",__nan__,0.8702969285362024
1015,CVCO,Cavco Industries Inc. Common Stock When Issued,"Cavco Industries, Inc. designs, produces, and retails manufactured homes primarily in the United States. It operates in two segments, Factory-Built Housing and Financial Services. The company markets its manufactured homes under the Cavco, Fleetwood, Palm Harbor, Nationwide, Fairmont, Friendship, Chariot Eagle, Destiny, Commodore, Colony, Pennwest, R-Anell, Manorwood, and MidCountry brands. It also builds park model RVs; vacation cabins; and factory-built commercial structures, including apartment buildings, condominiums, hotels, workforce housing, schools, and housing for the United States military troops. In addition, the company produces various modular homes, which include single and multi-section ranch, split-level, and Cape Cod style homes, as well as two- and three-story homes, and multi-family units. Further, it provides conforming and non-conforming mortgages and home-only loans to purchasers of various brands of factory-built homes sold by company-owned retail stores, as well as various independent distributors, builders, communities, and developers. Additionally, the company offers property and casualty insurance to owners of manufactured homes. As of April 3, 2022, it operated 45 company-owned retail stores in Oregon, Arizona, Nevada, New Mexico, Texas, Indiana, Oklahoma, Florida, and New York. The company also distributes its homes through a network of independent distribution points in 48 states and Canada; and through planned community operators and residential developers. Cavco Industries, Inc. was founded in 1965 and is headquartered in Phoenix, Arizona.",Mr. William C. Boor C.F.A.,Residential Construction,442.485,USD,3587079432,https://images.financialmodelingprep.com/symbol/CVCO.png,56925,24.93,-5.755,14521,195858000,157817000,"[{'period': '2024', 'revenue': 1790.0, 'unit': 'M', 'net_profit': 157.82}, {'period': '2023', 'revenue': 2140.0, 'unit': 'M', 'net_profit': 240.55}, {'period': '2022', 'revenue': 1630.0, 'unit': 'M', 'net_profit': 197.7}, {'period': '2021', 'revenue': 1110.0, 'unit': 'M', 'net_profit': 76.65}]","[{'period': ""Q2 '25"", 'revenue': 507.46, 'unit': 'M', 'net_profit': 43.81}, {'period': ""Q1 '25"", 'revenue': 477.6, 'unit': 'M', 'net_profit': 34.43}, {'period': ""Q4 '24"", 'revenue': 419.22, 'unit': 'M', 'net_profit': 33.93}, {'period': ""Q3 '24"", 'revenue': 446.77, 'unit': 'M', 'net_profit': 35.99}, {'period': ""Q2 '24"", 'revenue': 452.03, 'unit': 'M', 'net_profit': 41.54}, {'period': ""Q1 '24"", 'revenue': 475.88, 'unit': 'M', 'net_profit': 46.36}]",18.55,18.37,1354160000,851799000,370957000,320749000,141152000,17316000,273267000,352687000,207261000,-0.3782325191586085,-0.34394356360733974,-0.3180147058823529,__nan__,__nan__,__nan__,0.23686196608967922
1016,CVCY,Central Valley Community Bancorp Common Stock,"Central Valley Community Bancorp operates as the bank holding company for the Central Valley Community Bank that provides various commercial banking services to small and middle-market businesses and individuals in the central valley area of California. The company accepts demand, savings, and time deposits; certificates of deposit; and non-interest-bearing demand deposits, as well as provides NOW and money market accounts. Its loan products include commercial and industrial loans, as well as loans secured by crop production and livestock; owner occupied and investor commercial real estate, real estate construction and other land, agricultural real estate, and other real estate loans; and equity loans and lines of credit, and installment and other consumer loans. The company also offers domestic and international wire transfer, safe deposit box, Internet banking, and other customary banking services. As of December 31, 2021, the company operated through a network of 20 full-service banking offices in Cameron Park, Clovis, Exeter, Folsom, Fresno, Gold River, Kerman, Lodi, Madera, Merced, Modesto, Oakhurst, Prather, Roseville, Sacramento, Stockton, and Visalia. Central Valley Community Bancorp was founded in 1979 and is based in Fresno, California.",Mr. James J. Kim,Banks - Regional,19.89,USD,235332513,https://images.financialmodelingprep.com/symbol/CVCY.png,26440,9.165898617511521,0.44,34540,68000,25536000,"[{'period': '2023', 'revenue': 109.04, 'unit': 'M', 'net_profit': 25.54}, {'period': '2022', 'revenue': 83.34, 'unit': 'M', 'net_profit': 26.64}, {'period': '2021', 'revenue': 80.42, 'unit': 'M', 'net_profit': 28.4}, {'period': '2020', 'revenue': 76.75, 'unit': 'M', 'net_profit': 20.35}]","[{'period': ""Q1 '24"", 'revenue': 20.13, 'unit': 'M', 'net_profit': 3.68}, {'period': ""Q4 '23"", 'revenue': 27.72, 'unit': 'M', 'net_profit': 5.89}, {'period': ""Q3 '23"", 'revenue': 21.81, 'unit': 'M', 'net_profit': 6.39}, {'period': ""Q2 '23"", 'revenue': 21.55, 'unit': 'M', 'net_profit': 6.28}, {'period': ""Q1 '23"", 'revenue': 22.56, 'unit': 'M', 'net_profit': 6.97}, {'period': ""Q4 '22"", 'revenue': 22.66, 'unit': 'M', 'net_profit': 7.63}]",2.18,2.17,2437865000,64626000,-30017000,2230801000,0,30847000,1910945000,53728000,18046000,-0.9986116782360147,-0.04162131732032276,-0.039647577092510954,"[0.12, 0.1]","['2024-05-02', '2002-03-01']",__nan__,0.9150633853802405
1017,CVET,Covetrus Inc. Common Stock,"Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software, data-driven applications, client communications tools, and related services to increase staff efficiency and enhance business health; and solutions that integrate with its software platforms, including client communication services, reminders, data backup services, hardware sales and support, and credit card processing services for veterinary practitioners and animal-health clinics. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as offers shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal, equine, and large-animal markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine. As of October 13, 2022, Covetrus, Inc. was taken private.",Mr. Benjamin Wolin,Medical - Distribution,20.99,USD,0,https://images.financialmodelingprep.com/symbol/CVET.png,1216992,-69.96666666666667,0,5300387,178000000,-86000000,"[{'period': '2021', 'revenue': 4580.0, 'unit': 'M', 'net_profit': -86.0}, {'period': '2020', 'revenue': 4340.0, 'unit': 'M', 'net_profit': -19.0}, {'period': '2019', 'revenue': 3.98, 'unit': 'B', 'net_profit': -1.02}, {'period': '2018', 'revenue': 3780.0, 'unit': 'M', 'net_profit': 100.86}]","[{'period': ""Q2 '22"", 'revenue': 1220.0, 'unit': 'M', 'net_profit': -4.0}, {'period': ""Q1 '22"", 'revenue': 1150.0, 'unit': 'M', 'net_profit': -2.0}, {'period': ""Q4 '21"", 'revenue': 1120.0, 'unit': 'M', 'net_profit': -3.0}, {'period': ""Q3 '21"", 'revenue': 1160.0, 'unit': 'M', 'net_profit': -4.0}, {'period': ""Q2 '21"", 'revenue': 1190.0, 'unit': 'M', 'net_profit': -31.0}, {'period': ""Q1 '21"", 'revenue': 1100.0, 'unit': 'M', 'net_profit': -16.0}]",-0.63,-0.63,3410000000,1351000000,183000000,1899000000,555000000,49000000,698000000,183000000,42000000,-0.15639810426540285,-3.526315789473684,-2.9374999999999996,__nan__,__nan__,__nan__,0.556891495601173
1018,CVGI,Commercial Vehicle Group Inc. Common Stock,"Commercial Vehicle Group, Inc., together with its subsidiaries, designs, manufactures, produces, and sells components and assemblies in North America, Europe, and the Asia-Pacific regions. It operates in four segments: Vehicle Solutions, Warehouse Automation, Electrical Systems, and Aftermarket & Accessories. The company offers electrical wire harness assemblies that function as current carrying devices in providing electrical interconnections for gauges, lights, control functions, power circuits, powertrain and transmission sensors, emissions systems, and other electronic applications on commercial and other vehicles; and panel assemblies. It also offers electro-mechanical assemblies, such as box builds, complex automated and robotic assemblies, and large multi-cabinet control cabinets with power distribution and cabling; vinyl or cloth-covered appliqus, armrests, map pocket compartments, and sound-reducing insulations; instrument panels; and plastics decorating and finishing products. In addition, it provides cab structures; design products, including armrests, grab handles, storage systems, floor coverings, floor mats, sleeper bunks, headliners, wall panels, and privacy curtains; and mirrors, wipers, and controls used in commercial, military and specialty recreational vehicles. Further, it offers seats and seating systems, such as mechanical and air suspension, static and military seats, and bus, as well as seats for medium-and heavy-duty trucks (MD/HD trucks); office seating products; and seats, parts, and components for the aftermarket. The company supplies its products and systems for the commercial vehicle market comprising the MD/HD truck market; and MD/HD truck, bus, construction, mining, agricultural, military, industrial, municipal, off-road recreational, and specialty vehicle markets. Commercial Vehicle Group, Inc. was incorporated in 2000 and is headquartered in New Albany, Ohio.",Mr. James R. Ray Jr.,Auto - Parts,2.275,USD,78484315,https://images.financialmodelingprep.com/symbol/CVGI.png,311072,2.77,0.015,178648,64495000,49411000,"[{'period': '2023', 'revenue': 994.68, 'unit': 'M', 'net_profit': 49.41}, {'period': '2022', 'revenue': 981.55, 'unit': 'M', 'net_profit': -21.97}, {'period': '2021', 'revenue': 971.58, 'unit': 'M', 'net_profit': 23.73}, {'period': '2020', 'revenue': 717.7, 'unit': 'M', 'net_profit': -37.05}]","[{'period': ""Q3 '24"", 'revenue': 171.77, 'unit': 'M', 'net_profit': 9.51}, {'period': ""Q2 '24"", 'revenue': 229.91, 'unit': 'M', 'net_profit': -1.6}, {'period': ""Q1 '24"", 'revenue': 232.07, 'unit': 'M', 'net_profit': 2.94}, {'period': ""Q4 '23"", 'revenue': 223.09, 'unit': 'M', 'net_profit': 23.28}, {'period': ""Q3 '23"", 'revenue': 246.69, 'unit': 'M', 'net_profit': 7.29}, {'period': ""Q2 '23"", 'revenue': 262.19, 'unit': 'M', 'net_profit': 10.14}]",1.5,1.47,483214000,327742000,37848000,310282000,133949000,1073000,145189000,37848000,18580000,0.9088137800402509,3.248919029629967,3.2058823529411766,__nan__,__nan__,__nan__,0.6421212961544989
1019,CVGW,Calavo Growers Inc. Common Stock,"Calavo Growers, Inc. markets and distributes avocados, prepared avocados, and other perishable foods to retail grocery and foodservice customers, club stores, mass merchandisers, food distributors, and wholesale customers worldwide. It operates in three segments: Fresh Products, Calavo Foods, and Renaissance Food Group (RFG). The Fresh products segment distributes avocados and other fresh produce products comprising tomatoes and papayas; and procures avocados grown in California, Mexico, Peru, and Colombia. The Calavo Foods segment is involved in purchasing, processing, packaging, and distributing prepared avocado products, including guacamole and salsa. The RFG segment manufactures, markets, and distributes fresh-cut fruits and vegetables, fresh prepared entre salads, wraps, sandwiches, and fresh snacking products, as well as ready-to-heat entrees, other hot bar and various deli items, meals kits and related components, and salad kits. The company offers its products under the Calavo and RFG brands, and related logos; and Avo Fresco, Bueno, Calavo Gold, Calavo Salsa Lisa, Salsa Lisa, Celebrate the Taste, El Dorado, Fresh Ripe, Select, Taste of Paradise, The First Name in Avocados, Tico, Mfresh, Maui Fresh International, Triggered Avocados, ProRipeVIP, RIPE NOW!, Garden Highway Fresh Cut, Garden Highway, and Garden Highway Chef Essentials trademarks. Calavo Growers, Inc. was founded in 1924 and is headquartered in Santa Paula, California.",Mr. Lecil E. Cole,Food Distribution,23.45,USD,417447520,https://images.financialmodelingprep.com/symbol/CVGW.png,132858,-48.85,-0.38,64316,18669000,-8344000,"[{'period': '2023', 'revenue': 971.95, 'unit': 'M', 'net_profit': -8.34}, {'period': '2022', 'revenue': 1190.0, 'unit': 'M', 'net_profit': -6.04}, {'period': '2021', 'revenue': 1060.0, 'unit': 'M', 'net_profit': -10.2}, {'period': '2020', 'revenue': 1060.0, 'unit': 'M', 'net_profit': -7.73}]","[{'period': ""Q3 '24"", 'revenue': 179600.0, 'unit': 'K', 'net_profit': -732.0}, {'period': ""Q2 '24"", 'revenue': 184.38, 'unit': 'M', 'net_profit': 6.06}, {'period': ""Q1 '24"", 'revenue': 127.61, 'unit': 'M', 'net_profit': -6.27}, {'period': ""Q4 '23"", 'revenue': 241.18, 'unit': 'M', 'net_profit': -7.91}, {'period': ""Q3 '23"", 'revenue': 259.88, 'unit': 'M', 'net_profit': 6.63}, {'period': ""Q2 '23"", 'revenue': 244.69, 'unit': 'M', 'net_profit': -3.9}]",-0.47,-0.47,386854000,133370000,2091000,176625000,61376000,2902000,81746000,2091000,-25160000,0.20383028114521537,-0.3819145412388208,-0.3823529411764704,"[0.2, 0.2]","['2025-01-10', '2002-11-13']",__nan__,0.456567593976022
1020,CVLG,Covenant Logistics Group Inc. Class A Common Stock,"Covenant Logistics Group, Inc., together with its subsidiaries, provides transportation and logistics services in the United States. It operates through four segments: Expedited, Dedicated, Managed Freight, and Warehousing. The Expedited segment primarily provides truckload services with high service freight and delivery standards, such as 1,000 miles in 22 hours or 15-minute delivery windows. The Dedicated segment provides customers with committed truckload capacity over contracted periods using equipment either owned or leased by the company. The Managed Freight segment offers brokerage services, including logistics capacity by outsourcing the carriage of customers' freight to third parties; and transport management services, such as logistics services on a contractual basis to customers who prefer to outsource their logistics needs. The Warehousing segment provides day-to-day warehouse management services to customers. The segment also provides shuttle and switching services to shuttling containers and trailers. The company also engages in used equipment sales and leasing business. It serves transportation companies, such as parcel freight forwarders, less-than-truckload carriers, and third-party logistics providers; and traditional truckload customers, including manufacturers, retailers, and food and beverage shippers. As of December 31, 2021, it operated 2,291 tractors and 5,331 trailers. The company was formerly known as Covenant Transportation Group, Inc. and changed its name to Covenant Logistics Group, Inc. in July 2020. Covenant Logistics Group, Inc. was founded in 1986 and is based in Chattanooga, Tennessee.",Mr. David Ray Parker,Trucking,26.77,USD,705638434,https://images.financialmodelingprep.com/symbol/CVLG.png,107767,18.09,,0,150150000,55229000,"[{'period': '2023', 'revenue': 1100.0, 'unit': 'M', 'net_profit': 55.23}, {'period': '2022', 'revenue': 1220.0, 'unit': 'M', 'net_profit': 108.68}, {'period': '2021', 'revenue': 1050.0, 'unit': 'M', 'net_profit': 60.73}, {'period': '2020', 'revenue': 838.56, 'unit': 'M', 'net_profit': -14.12}]","[{'period': ""Q3 '24"", 'revenue': 287.88, 'unit': 'M', 'net_profit': 13.03}, {'period': ""Q2 '24"", 'revenue': 287.5, 'unit': 'M', 'net_profit': 12.19}, {'period': ""Q1 '24"", 'revenue': 278.76, 'unit': 'M', 'net_profit': 3.97}, {'period': ""Q4 '23"", 'revenue': 273.99, 'unit': 'M', 'net_profit': 12.79}, {'period': ""Q3 '23"", 'revenue': 288.72, 'unit': 'M', 'net_profit': 13.51}, {'period': ""Q2 '23"", 'revenue': 274.02, 'unit': 'M', 'net_profit': 12.29}]",4.23,3.99,954438000,185945000,2294000,551018000,153610000,66327000,170291000,2294000,-132766000,0.422508123880894,-0.49182937376934543,-0.4157458563535911,"[0.055, 0.063]","['2024-12-06', '2022-03-03']",__nan__,0.5773219423367468
1021,CVLT,Commvault Systems Inc. Common Stock,"Commvault Systems, Inc. provides data protection and information management software applications and related services in the United States and internationally. The company offers Commvault Backup and Recovery, a backup and recovery solution; Commvault Disaster Recovery, a replication and disaster recovery solution; and Commvault Complete Data Protection, a data protection solution. It also provides Commvault HyperScale X, an easy-to-deploy scale-out solution; Commvault Distributed Storage Platform that offers software-defined storage built on a hyperscale architecture; Metallic Cloud Storage service, which is the easy button to adopt secure and scalable cloud storage; and Metallic Software-as-a-Service. In addition, the company provides technology and business consulting, education, and remote managed services. Further, it sells appliances that integrate the software with hardware for use in a range of business needs and use cases; and offers professional and customer support services that include data management-as-a-service under the Metallic brand. The company sells its products and services directly through its sales force, and indirectly through its network of distributors, value-added resellers, systems integrators, corporate resellers, and original equipment manufacturers to large enterprises, small and medium sized businesses, and government agencies. It supports customers in a range of industries, including banking, insurance and financial services, government, healthcare, pharmaceuticals and medical services, technology, legal, manufacturing, utilities, and energy. Commvault Systems, Inc. was founded in 1988 and is headquartered in Tinton Falls, New Jersey.",Mr. Sanjay  Mirchandani,Software - Application,154.49,USD,6755229740,https://images.financialmodelingprep.com/symbol/CVLT.png,0,39.21,-6.19,123997,90443000,168906000,"[{'period': '2024', 'revenue': 839.25, 'unit': 'M', 'net_profit': 168.91}, {'period': '2023', 'revenue': 784.59, 'unit': 'M', 'net_profit': -35.77}, {'period': '2022', 'revenue': 769.59, 'unit': 'M', 'net_profit': 33.62}, {'period': '2021', 'revenue': 723.47, 'unit': 'M', 'net_profit': -30.95}]","[{'period': ""Q2 '25"", 'revenue': 233.28, 'unit': 'M', 'net_profit': 15.56}, {'period': ""Q1 '25"", 'revenue': 224.67, 'unit': 'M', 'net_profit': 18.53}, {'period': ""Q4 '24"", 'revenue': 223.29, 'unit': 'M', 'net_profit': 126.12}, {'period': ""Q3 '24"", 'revenue': 216.81, 'unit': 'M', 'net_profit': 17.14}, {'period': ""Q2 '24"", 'revenue': 201.0, 'unit': 'M', 'net_profit': 13.02}, {'period': ""Q1 '24"", 'revenue': 198.15, 'unit': 'M', 'net_profit': 12.63}]",3.85,3.75,943913000,595126000,312754000,665828000,222683000,21789000,484928000,312754000,199712000,20.31717214865442,5.721473695980321,5.8125,__nan__,__nan__,__nan__,0.705391280764223
1022,CVLY,Codorus Valley Bancorp Inc Common Stock,"Codorus Valley Bancorp, Inc. operates as the bank holding company for the PeoplesBank that provides community banking services. The company accepts demand, money market, time, and savings deposits, as well as certificates of deposit. It also offers commercial loans, such as builder and developer, commercial and residential real estate investor, hotel/motel, wholesale and retail, agriculture, manufacturing, and other loans; consume loans, including residential mortgage, home equity, and others. In addition, the company provides mortgage and wealth management services; and sells non-deposit investment products. It operates through twenty-five full service financial centers located in South Central Pennsylvania and Central Maryland. The company was founded in 1864 and is headquartered in York, Pennsylvania.",Mr. Craig L. Kauffman,Banks - Regional,24.04,USD,232283615,https://images.financialmodelingprep.com/symbol/CVLY.png,40614,10.452173913043477,1.14,565905,-3576000,24973000,"[{'period': '2023', 'revenue': 129.7, 'unit': 'M', 'net_profit': 24.97}, {'period': '2022', 'revenue': 1.64, 'unit': 'M', 'net_profit': 20.09}, {'period': '2021', 'revenue': 78.47, 'unit': 'M', 'net_profit': 14.66}, {'period': '2020', 'revenue': 76.35, 'unit': 'M', 'net_profit': 8.44}]","[{'period': ""Q1 '24"", 'revenue': 34.02, 'unit': 'M', 'net_profit': 4.25}, {'period': ""Q4 '23"", 'revenue': 34.18, 'unit': 'M', 'net_profit': 5.45}, {'period': ""Q3 '23"", 'revenue': 23.02, 'unit': 'M', 'net_profit': 5.92}, {'period': ""Q2 '23"", 'revenue': 23.52, 'unit': 'M', 'net_profit': 6.61}, {'period': ""Q1 '23"", 'revenue': 24.06, 'unit': 'M', 'net_profit': 6.99}, {'period': ""Q4 '22"", 'revenue': 0.519, 'unit': 'M', 'net_profit': 7.93}]",2.6,2.59,2197241000,42071000,-10882000,1997636000,0,15501000,1350206000,33691000,15562000,-1.0934413378625556,0.24293251045192116,0.2322274881516589,"[0.17, 0.13]","['2024-05-06', '1994-07-20']",__nan__,0.9091565285737887
1023,CVV,CVD Equipment Corporation Common Stock,"CVD Equipment Corporation, together with its subsidiaries, designs, develops, manufactures, and sells process equipment and solutions that are used to develop and manufacture materials and coatings for research and industrial applications in the United States. It operates through three segments: CVD, SDC, and CVD Materials. The company offers chemical vapor deposition systems for use in the research, development, and manufacture of aerospace, medical components, semiconductors, LEDs, carbon nanotubes, nanowires, solar cells, and other industrial applications; and rapid thermal processing systems for use in implant activation, oxidation, silicide formation, and other processes. It also provides annealing, diffusion, and low pressure chemical vapor deposition furnaces for use in diffusion, oxidation, implant anneal, solder reflow, solar cell manufacturing, and other processes; and gas and liquid control systems, such as gas cylinder storage cabinets, custom gas and chemical delivery systems, gas and liquid valve manifold boxes, and gas isolation boxes for semiconductor fabrication processes, solar cells, LEDs, carbon nanotubes, nanowires, and industrial applications. In addition, the company offers standard and custom fabricated quartz-ware used in its equipment and other customer tools, as well as repair and replacement services for existing quartz-ware. Further, it provides MesoPlasma direct write printing, a materials deposition process that provides instrumentation, fine feature patterns, and coatings onto conformal components; and Tantaline corrosion resistant coating for valves, fittings, fasteners, vessels, bellows, and custom designed items, as well as offers carbon composites and electronic materials. The company sells its products primarily to aerospace/defense, medical, electronic component manufacturers, universities, and government and industrial laboratories. The company was incorporated in 1982 and is headquartered in Central Islip, New York.",Mr. Emmanuel N. Lakios,Industrial - Machinery,4.3844,USD,30172739,https://images.financialmodelingprep.com/symbol/CVV.png,37325,-6.85,-0.1256,48612,-3379000,-4179999,"[{'period': '2023', 'revenue': 24.11, 'unit': 'M', 'net_profit': -4.18}, {'period': '2022', 'revenue': 25810.0, 'unit': 'K', 'net_profit': -224.0}, {'period': '2021', 'revenue': 16.45, 'unit': 'M', 'net_profit': 4.75}, {'period': '2020', 'revenue': 16.92, 'unit': 'M', 'net_profit': -6.07}]","[{'period': ""Q3 '24"", 'revenue': 8189.999999999999, 'unit': 'K', 'net_profit': 203.0}, {'period': ""Q2 '24"", 'revenue': 6340.0, 'unit': 'K', 'net_profit': -761.0}, {'period': ""Q1 '24"", 'revenue': 4.92, 'unit': 'M', 'net_profit': -1.47}, {'period': ""Q4 '23"", 'revenue': 4.11, 'unit': 'M', 'net_profit': -2.27}, {'period': ""Q3 '23"", 'revenue': 6230.0, 'unit': 'K', 'net_profit': -753.0}, {'period': ""Q2 '23"", 'revenue': 5.07, 'unit': 'M', 'net_profit': -1.11}]",-0.62,-0.62,35025000,22841000,14025000,8822000,3510000,0,8554000,14025000,-624000,-6.158778625954199,-17.660709821428572,-17.618618618618616,__nan__,__nan__,__nan__,0.2518772305496074
1024,CWBC,Community West Bancshares Common Stock,"Community West Bancshares operates as the bank holding company for Community West Bank, N.A. that provides various financial products and services in California. The company offers deposit products, such as checking accounts, savings accounts, money market accounts, and fixed rate and fixed maturity certificates of deposit; and cash management products. It also provides commercial, commercial real estate, consumer, manufactured housing, and small business administration loans, as well as agricultural loans for real estate and operating lines; home equity lines of credit collateralized by residential real estate; single family real estate loans; and installment loans consisting of automobile and general-purpose loans. The company serves small to medium-sized businesses and their owners, professionals, high-net worth individuals, and non-profit organizations. It operates through a network of seven branch banking offices in Goleta, Santa Barbara, Santa Maria, Ventura, San Luis Obispo, Oxnard, and Paso Robles. Community West Bancshares was founded in 1989 and is headquartered in Goleta, California.",Mr. James J. Kim,Banks - Regional,18.65,USD,353335440,https://images.financialmodelingprep.com/symbol/CWBC.png,49004,33.91,-0.26,12646,0,25536000,"[{'period': '2023', 'revenue': 57.52, 'unit': 'M', 'net_profit': 25.54}, {'period': '2022', 'revenue': 49.79, 'unit': 'M', 'net_profit': 13.45}, {'period': '2021', 'revenue': 46.13, 'unit': 'M', 'net_profit': 13.1}, {'period': '2020', 'revenue': 40.5, 'unit': 'M', 'net_profit': 8.24}]","[{'period': ""Q3 '24"", 'revenue': 30.51, 'unit': 'M', 'net_profit': 3.38}, {'period': ""Q2 '24"", 'revenue': 45.4, 'unit': 'M', 'net_profit': -6.29}, {'period': ""Q1 '24"", 'revenue': 27.26, 'unit': 'M', 'net_profit': 3.68}, {'period': ""Q4 '23"", 'revenue': 15550.0, 'unit': 'K', 'net_profit': 479.0}, {'period': ""Q3 '23"", 'revenue': 11.6, 'unit': 'M', 'net_profit': 2.25}, {'period': ""Q2 '23"", 'revenue': 11.86, 'unit': 'M', 'net_profit': 2.12}]",2.18,2.17,2433426000,16703000,16703000,2226362000,0,906287000,1910945000,53728000,18046000,0,0.8987285300022306,0.8956521739130437,"[0.12, 0.176]","['2024-11-08', '1998-12-31']",__nan__,0.9149084459523322
1025,CWBR,CohBar Inc. Common Stock,"CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.","Dr. Pinchas  Cohen Dean, M.D., Ph.D.",Biotechnology,0.41,USD,1191841,https://images.financialmodelingprep.com/symbol/CWBR.png,0,-0.09,,0,-12065759,-11962119,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -11.96}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.41}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.63}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.65}]","[{'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.33}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.03}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.8}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.39}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -2.72}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -3.26}]",-4.13,-4.12,16365667,16218503,15737322,1033638,27500,0,1033638,5930731,-10446492,0.21664024143492353,0.22364540223458357,0.40489913544668593,__nan__,__nan__,__nan__,0.06315892899446139
1026,CWCO,Consolidated Water Co. Ltd. Ordinary Shares,"Consolidated Water Co. Ltd., together with its subsidiaries, designs, constructs, manages, and operates water production and water treatment plants primarily in the Cayman Islands, the Bahamas, and the United States. The company operates through four segments: Retail, Bulk, Services, and Manufacturing. It uses reverse osmosis technology to produce potable water from seawater. The company produces and supplies water to end-users, including residential, commercial, and government customers, as well as government-owned distributors. It also provides design, engineering, construction, procurement, and management services for desalination projects and water treatment plants, as well as management and engineering services relating to municipal water distribution and treatment. In addition, the company manufactures and services a range of water-related products, including reverse osmosis desalination equipment, membrane separation equipment, filtration equipment, piping systems, vessels, and custom fabricated components; and provides design, engineering, consulting, management, inspection, training, and equipment maintenance services for commercial, municipal, and industrial water production, supply, and treatment, as well as desalination and wastewater treatment. Consolidated Water Co. Ltd. was incorporated in 1973 and is headquartered in Grand Cayman, the Cayman Islands.",Mr. Frederick W. McTaggart,Regulated Water,25.2608,USD,400002242,https://images.financialmodelingprep.com/symbol/CWCO.png,0,15.22,-0.5592,28522,44717679,29585391,"[{'period': '2023', 'revenue': 180.21, 'unit': 'M', 'net_profit': 29.59}, {'period': '2022', 'revenue': 94.1, 'unit': 'M', 'net_profit': 9.34}, {'period': '2021', 'revenue': 66.86, 'unit': 'M', 'net_profit': 4.08}, {'period': '2020', 'revenue': 72.63, 'unit': 'M', 'net_profit': 9.34}]","[{'period': ""Q3 '24"", 'revenue': 33.39, 'unit': 'M', 'net_profit': 4.45}, {'period': ""Q2 '24"", 'revenue': 32.48, 'unit': 'M', 'net_profit': 15.85}, {'period': ""Q1 '24"", 'revenue': 39.69, 'unit': 'M', 'net_profit': 6.47}, {'period': ""Q4 '23"", 'revenue': 53.25, 'unit': 'M', 'net_profit': 9.84}, {'period': ""Q3 '23"", 'revenue': 49.85, 'unit': 'M', 'net_profit': 8.61}, {'period': ""Q2 '23"", 'revenue': 44.24, 'unit': 'M', 'net_profit': 7.32}]",1.88,1.86,218437592,112714375,42621898,26606919,59779948,1412158,23904646,42621898,2922878,1.79995645816678,2.167513931095679,2.081967213114754,"[0.11, 0.06]","['2025-01-02', '1996-09-26']",__nan__,0.12180558646700336
1027,CWST,Casella Waste Systems Inc. Class A Common Stock,"Casella Waste Systems, Inc., together with its subsidiaries, operates as a vertically integrated solid waste services company in the northeastern United States. It offers resource management services primarily in the areas of solid waste collection and disposal, transfer, recycling, and organics services to residential, commercial, municipal, institutional, and industrial customers. The company provides a range of non-hazardous solid waste services, including collections, transfer stations, and disposal facilities. It also markets recyclable metals, aluminum, plastics, and paper and corrugated cardboard that are processed at its facilities, as well as recyclables purchased from third parties. In addition, the company is involved in commodity brokerage operations. As of January 31, 2022, it owned and/or operated 50 solid waste collection operations, 65 transfer stations, 23 recycling facilities, 8 Subtitle D landfills, 3 landfill gas-to-energy facilities, and 1 landfill permitted to accept construction and demolition materials. Casella Waste Systems, Inc. was founded in 1975 and is headquartered in Rutland, Vermont.",Mr. John W. Casella,Waste Management,105.24,USD,6559125096,https://images.financialmodelingprep.com/symbol/CWST.png,311469,956.73,-0.67,94546,274170000,25399000,"[{'period': '2023', 'revenue': 1260.0, 'unit': 'M', 'net_profit': 25.4}, {'period': '2022', 'revenue': 1090.0, 'unit': 'M', 'net_profit': 53.08}, {'period': '2021', 'revenue': 889.21, 'unit': 'M', 'net_profit': 41.1}, {'period': '2020', 'revenue': 774.58, 'unit': 'M', 'net_profit': 91.11}]","[{'period': ""Q3 '24"", 'revenue': 411.63, 'unit': 'M', 'net_profit': 5.77}, {'period': ""Q2 '24"", 'revenue': 377.16, 'unit': 'M', 'net_profit': 7.01}, {'period': ""Q1 '24"", 'revenue': 341.01, 'unit': 'M', 'net_profit': -4.12}, {'period': ""Q4 '23"", 'revenue': 359.57, 'unit': 'M', 'net_profit': -1.81}, {'period': ""Q3 '23"", 'revenue': 352.74, 'unit': 'M', 'net_profit': 18.17}, {'period': ""Q2 '23"", 'revenue': 289.64, 'unit': 'M', 'net_profit': 5.49}]",0.46,0.46,2535470000,426325000,220912000,1513679000,160413000,10967000,278858000,220912000,78185000,0.10421516428105392,-0.5214868403700145,-0.5533980582524273,__nan__,__nan__,__nan__,0.5970013449182991
1028,CXDC,China XD Plastics Company Limited Common Stock,"China XD Plastics Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of modified plastics primarily for automotive applications in the People's Republic of China, and Dubai, the United Arab Emirates. Its modified plastics are used to fabricate various auto components, including exteriors consisting of automobile bumpers, rearview and sideview mirrors, and license plate parts; interiors, such as door panels, steering wheels, dashboards, glove compartments, and safety belt components; and functional components comprising air conditioner casings, heating and ventilation casings, engine covers, and air ducts. The company also offers engineered plastics and environment-friendly plastics for use in oilfield equipment, mining equipment, vessel propulsion systems, and power station equipment; and polymer composite materials. Its products are also used in high-speed railways, airplanes, ships, and electronic appliances. The company sells its products through distributors, as well as directly to end customers. China XD Plastics Company Limited was founded in 1985 and is headquartered in Harbin, the People's Republic of China.",Mr. Jie  Han,Chemicals - Specialty,0.0024,USD,0,https://images.financialmodelingprep.com/symbol/CXDC.png,5791,0,0,60,-196101414,-181700885,"[{'period': '2020', 'revenue': 1310.0, 'unit': 'M', 'net_profit': -181.7}, {'period': '2019', 'revenue': 1450.0, 'unit': 'M', 'net_profit': 3.06}, {'period': '2018', 'revenue': 1270.0, 'unit': 'M', 'net_profit': 68.31}, {'period': '2017', 'revenue': 1290.0, 'unit': 'M', 'net_profit': 31.62}]","[{'period': ""Q4 '20"", 'revenue': 593.79, 'unit': 'M', 'net_profit': -150.01}, {'period': ""Q3 '20"", 'revenue': 290.05, 'unit': 'M', 'net_profit': -38.23}, {'period': ""Q2 '20"", 'revenue': 283.22, 'unit': 'M', 'net_profit': 17.58}, {'period': ""Q1 '20"", 'revenue': 144.84, 'unit': 'M', 'net_profit': -11.04}, {'period': ""Q4 '19"", 'revenue': 310.51, 'unit': 'M', 'net_profit': -65.0}, {'period': ""Q3 '19"", 'revenue': 373.16, 'unit': 'M', 'net_profit': 16.97}]",-2.68,-2.68,2923926000,1344760833,78261679,2156711763,423946875,0,1230282394,78261679,-3031485,-2.35244266556872,-60.467253568836036,-54.599999999999994,__nan__,__nan__,__nan__,0.7376081894685433
1029,CXDO,Crexendo Inc. Common Stock,"Crexendo, Inc. provides cloud communication, unified communications as a service, call center, collaboration, and other cloud business services for businesses in the United States, Canada, and internationally. It operates through two segments, Cloud Telecommunications and Web Services. The Cloud Telecommunications segment provides telecommunications services that transmit calls using Internet protocol (IP) or cloud technology, which converts voice signals into digital data packets for transmission over the Internet or cloud; and resells broadband Internet services. This segment is also involved in the sale and lease of cloud telecommunications equipment. In addition, it offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over high-speed internet connection through various devices and user interfaces, such as desktop phones and/or mobile, and desktop applications under the Crexendo brand name. The Web Services segment provides website hosting and other professional services. The company was formerly known as iMergent, Inc. and changed its name to Crexendo, Inc. in May 2011. Crexendo, Inc. was incorporated in 1995 and is headquartered in Tempe, Arizona.",Mr. Jeffrey G. Korn,Telecommunications Services,5.635,USD,152717516,https://images.financialmodelingprep.com/symbol/CXDO.png,165714,112.7,-0.175,81422,3421000,-362000,"[{'period': '2023', 'revenue': 53200.0, 'unit': 'K', 'net_profit': -362.0}, {'period': '2022', 'revenue': 37.55, 'unit': 'M', 'net_profit': -35.41}, {'period': '2021', 'revenue': 28.09, 'unit': 'M', 'net_profit': -2.44}, {'period': '2020', 'revenue': 16.39, 'unit': 'M', 'net_profit': 7.94}]","[{'period': ""Q3 '24"", 'revenue': 15630.0, 'unit': 'K', 'net_profit': 148.0}, {'period': ""Q2 '24"", 'revenue': 14690.0, 'unit': 'K', 'net_profit': 588.0}, {'period': ""Q1 '24"", 'revenue': 14290.0, 'unit': 'K', 'net_profit': 434.0}, {'period': ""Q4 '23"", 'revenue': 14160.0, 'unit': 'K', 'net_profit': 61.0}, {'period': ""Q3 '23"", 'revenue': 13.87, 'unit': 'M', 'net_profit': 1.7}, {'period': ""Q2 '23"", 'revenue': 12670.0, 'unit': 'K', 'net_profit': -545.0}]",-0.014,-0.014,56160000,17291000,10347000,11547000,4674000,0,10261000,10347000,3407000,1.1025080154616007,0.9897777652274589,0.9909090909090909,"[0.005, 0.005]","['2023-03-30', '2022-02-17']",__nan__,0.20560897435897435
1030,CYAD,Celyad Oncology SA American Depositary Shares,"Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.",Dr. Georges  Rawadi,Biotechnology,0.47,USD,14238462,https://images.financialmodelingprep.com/symbol/CYAD.png,18057,-0.3197278911564626,-0.07,48998,-7763000,-8448000,"[{'period': '2023', 'revenue': 0.10200000000000001, 'unit': 'M', 'net_profit': -8.45}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -40.94}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.51}, {'period': '2020', 'revenue': 0.005, 'unit': 'M', 'net_profit': -17.5}]","[{'period': ""Q2 '24"", 'revenue': 0.014, 'unit': 'M', 'net_profit': -3.04}, {'period': ""Q4 '23"", 'revenue': 0.058, 'unit': 'M', 'net_profit': -4.71}, {'period': ""Q2 '23"", 'revenue': 0.044, 'unit': 'M', 'net_profit': -3.74}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -26.88}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -6.37}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -7.53}]",-0.33,-0.33,16282000,11121000,7004000,9978000,380000,0,2932000,7004000,-16101000,0.26456329658300104,-0.5440178032589016,-0.06470588235294124,__nan__,__nan__,__nan__,0.612823977398354
1031,CYAN,Cyanotech Corporation Common Stock,"Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae worldwide. The company's products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant to enhance skin, and to support eye, joint and immune health, as well as used as a human dietary supplement and dietary ingredient; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement, which is used for extra energy, strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. It also provides contract extraction services. The company sells its products through distributors, retailers, and online channels; direct to consumers; and in bulk form to manufacturers, formulators, and distributors in the health foods, nutraceuticals, and dietary supplement markets. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.",Mr. Matthew Keith Custer,Packaged Foods,0.41,USD,2933903,https://images.financialmodelingprep.com/symbol/CYAN.png,11957,-0.51,0,3400,-2511000,-5267000,"[{'period': '2023', 'revenue': 23.07, 'unit': 'M', 'net_profit': -5.27}, {'period': '2022', 'revenue': 23.18, 'unit': 'M', 'net_profit': -3.44}, {'period': '2021', 'revenue': 35.97, 'unit': 'M', 'net_profit': 2.15}, {'period': '2020', 'revenue': 32340.000000000004, 'unit': 'K', 'net_profit': 920.0}]","[{'period': ""Q2 '24"", 'revenue': 5.84, 'unit': 'M', 'net_profit': -1.15}, {'period': ""Q1 '24"", 'revenue': 5.9, 'unit': 'M', 'net_profit': -1.2}, {'period': ""Q4 '23"", 'revenue': 5.97, 'unit': 'M', 'net_profit': -2.08}, {'period': ""Q3 '23"", 'revenue': 5.58, 'unit': 'M', 'net_profit': -1.02}, {'period': ""Q2 '23"", 'revenue': 6370.0, 'unit': 'K', 'net_profit': -797.0}, {'period': ""Q1 '23"", 'revenue': 5.15, 'unit': 'M', 'net_profit': -1.37}]",-0.8,-0.81,25112000,10591000,707000,13298000,2102000,0,8554000,707000,-836000,-2.0436363636363635,-0.5311046511627907,-0.45454545454545453,__nan__,__nan__,__nan__,0.5295476266326856
1032,CYBE,CyberOptics Corporation Common Stock,"CyberOptics Corporation designs, develops, manufactures, and markets high precision sensing technology solutions and system products for inspection and metrology worldwide. It offers products based on multi-reflection suppression (MRS) technology, including multi-function systems for inspection and metrology; MX3000 memory module inspection system; 3D NanoResolution MRS sensor and WX3000 inspection and metrology system for semiconductor wafer and advanced packaging inspection and metrology; high precision 3D and 2D sensors; 3D MRS sensors; SMT electronic assembly alignment sensors; and inspection and metrology systems. The company also provides automated optical inspection (AOI) products; SQ3000 multi-function systems; QX Series 2D AOI products; MX products for inspection of memory modules; SPI Products; and semiconductor wafer and advanced packaging products. In addition, it offers general industrial metrology products and services, such as CyberGage360, a near-line or off-line metrology tool; and 3D scanning and metrology equipment, as well as semiconductor, automatic leveling, automatic gapping, automatic teaching, automatic vibration, WaferSense airborne particle, in-line particle, WaferSense auto multi, WaferSense 300mm auto resistance, and WaferSense auto vibration and leveling sensors. The company sells its products to SMT electronic assembly circuit board manufacturers, end-user customers manufacturing their own circuit boards, semiconductor manufacturers, and outsourced semiconductor assembly and test companies through independent sales representatives and distributors. CyberOptics Corporation was founded in 1984 and is headquartered in Minneapolis, Minnesota.",Dr. Subodh Kulkarni,Semiconductors,54,USD,0,https://images.financialmodelingprep.com/symbol/CYBE.png,155275,25.352112676056336,0,260186,14495000,12751000,"[{'period': '2021', 'revenue': 92.77, 'unit': 'M', 'net_profit': 12.75}, {'period': '2020', 'revenue': 70.12, 'unit': 'M', 'net_profit': 5.74}, {'period': '2019', 'revenue': 59260.0, 'unit': 'K', 'net_profit': 774.0}, {'period': '2018', 'revenue': 64.72, 'unit': 'M', 'net_profit': 2.83}]","[{'period': ""Q2 '22"", 'revenue': 27.57, 'unit': 'M', 'net_profit': 4.39}, {'period': ""Q1 '22"", 'revenue': 24.25, 'unit': 'M', 'net_profit': 3.59}, {'period': ""Q4 '21"", 'revenue': 22.08, 'unit': 'M', 'net_profit': 3.4}, {'period': ""Q3 '21"", 'revenue': 27.76, 'unit': 'M', 'net_profit': 4.8}, {'period': ""Q2 '21"", 'revenue': 25.2, 'unit': 'M', 'net_profit': 3.11}, {'period': ""Q1 '21"", 'revenue': 17.73, 'unit': 'M', 'net_profit': 1.44}]",1.69,1.69,98022000,70106000,21011000,18916000,19821000,17281000,16156000,13684000,10089000,1.4170418542604635,1.2206548241031,1.1948051948051948,__nan__,__nan__,__nan__,0.19297708677643793
1033,CYBR,CyberArk Software Ltd. Ordinary Shares,"CyberArk Software Ltd., together with its subsidiaries, develops, markets, and sales software-based security solutions and services in the United States, Europe, the Middle East, Africa, and internationally. Its solutions include Privileged Access Manager that offers risk-based credential security and session management to protect against attacks involving privileged access; Vendor Privileged Access Manager combines Privileged Access Manager and Remote Access to provide fast, easy, and secure privileged access to third-party vendors; Endpoint Privilege Manager, a SaaS solution that secures privileges on the endpoint; and Cloud Entitlements Manager, a SaaS solution, which reduces risk that arises from excessive privileges by implementing least privilege across cloud environments. The company also offers robust Identity and Access Management as a Services, such as workforce identity, which offers adaptive multi-factor authentication (MFA), single sign-on, secure Web sessions, application gateway, identity lifecycle management, and directory services; and customer identity services that provides authentication and authorization services, MFA, directory, and user management to enable organizations to provide their customers with easy and secure access to websites and applications. In addition, it offers Secrets Manager Credential Providers to provide and manage the credentials used by third-party solutions; and Secrets Manager Conjur for cloud-native applications. The company provides its products to financial services, manufacturing, insurance, healthcare, energy and utilities, transportation, retail, technology, and telecommunications industries; and government agencies through direct sales force, as well as distributors, systems integrators, value-added resellers, and managed security service providers. CyberArk Software Ltd. was founded in 1999 and is headquartered in Petah Tikva, Israel.",Mr. Matthew Lessner Cohen,Software - Infrastructure,346.94,USD,17101227704,https://images.financialmodelingprep.com/symbol/CYBR.png,459358,1119.16,1.02,220462,-43771000,-66504000,"[{'period': '2023', 'revenue': 751.89, 'unit': 'M', 'net_profit': -66.5}, {'period': '2022', 'revenue': 591.71, 'unit': 'M', 'net_profit': -130.37}, {'period': '2021', 'revenue': 502.92, 'unit': 'M', 'net_profit': -83.95}, {'period': '2020', 'revenue': 464.43, 'unit': 'M', 'net_profit': -5.76}]","[{'period': ""Q3 '24"", 'revenue': 240.1, 'unit': 'M', 'net_profit': 11.11}, {'period': ""Q2 '24"", 'revenue': 224.71, 'unit': 'M', 'net_profit': -12.92}, {'period': ""Q1 '24"", 'revenue': 221.55, 'unit': 'M', 'net_profit': 5.47}, {'period': ""Q4 '23"", 'revenue': 223.1, 'unit': 'M', 'net_profit': 8.91}, {'period': ""Q3 '23"", 'revenue': 191.24, 'unit': 'M', 'net_profit': -14.61}, {'period': ""Q2 '23"", 'revenue': 175.84, 'unit': 'M', 'net_profit': -25.78}]",-1.6,-1.6,2022208000,1211443000,993421000,1229882000,186472000,324548000,1124630000,355933000,51256000,0.6276899783951142,0.4898748159057437,0.5015576323987538,__nan__,__nan__,__nan__,0.6081876839573377
1034,CYCC,Cyclacel Pharmaceuticals Inc. Common Stock,"Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.",Mr. Spiro George Rombotis,Biotechnology,0.41,USD,2577756,https://images.financialmodelingprep.com/symbol/CYCC.png,3549004,-0.01,-0.04,986606,-25422000,-22555000,"[{'period': '2023', 'revenue': 0.42, 'unit': 'M', 'net_profit': -22.55}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.2}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.89}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.45}]","[{'period': ""Q3 '24"", 'revenue': 10.0, 'unit': 'K', 'net_profit': -1.96}, {'period': ""Q2 '24"", 'revenue': 0.004, 'unit': 'M', 'net_profit': -3.26}, {'period': ""Q1 '24"", 'revenue': 0.029, 'unit': 'M', 'net_profit': -2.95}, {'period': ""Q4 '23"", 'revenue': 0.031, 'unit': 'M', 'net_profit': -5.27}, {'period': ""Q3 '23"", 'revenue': 0.016, 'unit': 'M', 'net_profit': -6.1}, {'period': ""Q2 '23"", 'revenue': 0.373, 'unit': 'M', 'net_profit': -5.45}]",-26.75,-26.75,8805000,7444000,3378000,8198000,2933000,0,8161000,3378000,-16117999,0.07971329278887923,-0.06401547315784507,0.17002792429413582,"[0.0005, 0.0005]","['2016-07-13', '2016-07-13']",__nan__,0.9310618966496309
1035,CYCCP,Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock,"Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.",Mr. Spiro George Rombotis,Biotechnology,7.51,USD,2915405,https://images.financialmodelingprep.com/symbol/CYCCP.png,1016,-3.67,0.09,4453,-25422000,-22555000,"[{'period': '2023', 'revenue': 0.42, 'unit': 'M', 'net_profit': -22.55}, {'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.2}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.89}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.45}]","[{'period': ""Q3 '24"", 'revenue': 10.0, 'unit': 'K', 'net_profit': -1.96}, {'period': ""Q2 '24"", 'revenue': 0.004, 'unit': 'M', 'net_profit': -3.26}, {'period': ""Q1 '24"", 'revenue': 0.029, 'unit': 'M', 'net_profit': -2.95}, {'period': ""Q4 '23"", 'revenue': 0.031, 'unit': 'M', 'net_profit': -5.27}, {'period': ""Q3 '23"", 'revenue': 0.016, 'unit': 'M', 'net_profit': -6.1}, {'period': ""Q2 '23"", 'revenue': 0.373, 'unit': 'M', 'net_profit': -5.45}]",-26.75,-26.75,8805000,7444000,3378000,8198000,2933000,0,8161000,3378000,-16117999,0.07971329278887923,-0.06401547315784507,0.17002792429413582,"[0.15, 0.0125]","['2024-01-19', '2006-01-18']",__nan__,0.9310618966496309
1036,CYCN,Cyclerion Therapeutics Inc. Common Stock,"Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.",Dr. Regina  Graul Ph.D.,Biotechnology,3.265,USD,8848477,https://images.financialmodelingprep.com/symbol/CYCN.png,3177614,-1.57,0.125,54491,-12593000,-21015000,"[{'period': '2023', 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.02}, {'period': '2022', 'revenue': 0.297, 'unit': 'M', 'net_profit': -43.78}, {'period': '2021', 'revenue': 3.32, 'unit': 'M', 'net_profit': -51.66}, {'period': '2020', 'revenue': 2.3, 'unit': 'M', 'net_profit': -72.67}]","[{'period': ""Q3 '24"", 'revenue': 194.0, 'unit': 'K', 'net_profit': -723.0}, {'period': ""Q2 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.32}, {'period': ""Q1 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.54}, {'period': ""Q4 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -1.69}, {'period': ""Q3 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 7.57}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -4.18}]",-8.99,-8.99,13374000,8024000,7571000,2086000,0,5350000,2086000,7571000,-21245000,0.3073538309223915,0.5200301479992692,0.5538461538461538,__nan__,__nan__,__nan__,0.15597427845072528
1037,CYRN,CYREN Ltd. Ordinary Shares,"Cyren Ltd., together with its subsidiaries, provides cloud delivered Software-as-a-Service (SaaS) cybersecurity solutions that protect businesses, their employees, and customers against threats from email, files, and the web. It provides Cyren threat detection services, which include email security engine that offers anti-spam inbound and outbound, IP reputation, and virus outbreak detection services; malware detection engine that is used to protect email applications; Web security engine, which is used by customers to provide URL classification for web browser filtering and safe search capabilities; and threat analysis services to detect advanced cyber threats. The company also provides Cyren threat intelligence data products, which include real-time phishing intelligence, malware file intelligence, IP reputation intelligence, malware URL intelligence, and Zombie host intelligence for threat detection, threat hunting, and incident response. In addition, it offers Cyren enterprise email security products, including Cyren Email Security, a cloud-based secure email gateway; and Cyren Inbox Security, an anti-phishing and remediation product for Microsoft 365. The company sells its products through direct and indirect channels, including distributors, value added resellers, and managed service providers to enterprise customers and original equipment manufacturers. It has operations in the United States, Germany, other European countries, the Asia Pacific, Israel, and internationally. The company was formerly known as Commtouch Software Ltd. and changed its name to Cyren Ltd. in January 2014. Cyren Ltd. was incorporated in 1991 and is based in Herzliya, Israel.",Mr. Brett M. Jackson,Software - Infrastructure,0.2182,USD,1745559,https://images.financialmodelingprep.com/symbol/CYRN.png,1035629,-0.02936742934051144,0,1013508,-16737000,-23039000,"[{'period': '2021', 'revenue': 31.19, 'unit': 'M', 'net_profit': -23.04}, {'period': '2020', 'revenue': 36.39, 'unit': 'M', 'net_profit': -17.26}, {'period': '2019', 'revenue': 38.39, 'unit': 'M', 'net_profit': -18.02}, {'period': '2018', 'revenue': 35.9, 'unit': 'M', 'net_profit': -19.41}]","[{'period': ""Q3 '22"", 'revenue': 5.62, 'unit': 'M', 'net_profit': -6.12}, {'period': ""Q2 '22"", 'revenue': 5.75, 'unit': 'M', 'net_profit': -5.77}, {'period': ""Q1 '22"", 'revenue': 7.26, 'unit': 'M', 'net_profit': -6.48}, {'period': ""Q4 '21"", 'revenue': 7.36, 'unit': 'M', 'net_profit': -7.49}, {'period': ""Q3 '21"", 'revenue': 7.46, 'unit': 'M', 'net_profit': -5.79}, {'period': ""Q2 '21"", 'revenue': 7.61, 'unit': 'M', 'net_profit': -5.59}]",-5.9,-5.9,46128000,7324000,4302000,32300000,799000,0,12706000,4302000,-16799000,-0.990604186489058,-0.33458842611365347,-0.031468531468531576,__nan__,__nan__,__nan__,0.7002254595907041
1038,CYRX,CryoPort Inc. Common Stock,"Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.",Mr. Jerrell W. Shelton,Integrated Freight & Logistics,8.48,USD,419171488,https://images.financialmodelingprep.com/symbol/CYRX.png,408356,-2.5,-0.23,102298,-66358000,-99587000,"[{'period': '2022', 'revenue': 233.25, 'unit': 'M', 'net_profit': -99.59}, {'period': '2021', 'revenue': 237.28, 'unit': 'M', 'net_profit': -37.33}, {'period': '2020', 'revenue': 222.61, 'unit': 'M', 'net_profit': -275.53}, {'period': '2019', 'revenue': 78.7, 'unit': 'M', 'net_profit': -32.69}]","[{'period': ""Q3 '23"", 'revenue': 56660.0, 'unit': 'K', 'net_profit': 805.0}, {'period': ""Q2 '23"", 'revenue': 57.6, 'unit': 'M', 'net_profit': -77.99}, {'period': ""Q1 '23"", 'revenue': 54.59, 'unit': 'M', 'net_profit': -18.89}, {'period': ""Q4 '22"", 'revenue': 57.26, 'unit': 'M', 'net_profit': -62.39}, {'period': ""Q3 '22"", 'revenue': 56.16, 'unit': 'M', 'net_profit': -13.27}, {'period': ""Q2 '22"", 'revenue': 57.02, 'unit': 'M', 'net_profit': -18.36}]",-2.21,-2.21,957744000,535111999,456755000,468721000,42074000,0,45610000,46346000,-45657000,-9.725391950864717,-1.6675327458280877,-1.907894736842105,__nan__,__nan__,__nan__,0.48940113433234766
1039,CYTH,Cyclo Therapeutics Inc. Common Stock,"Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.",Mr. N. Scott Fine,Drug Manufacturers - Specialty & Generic,0.68,USD,19562308,https://images.financialmodelingprep.com/symbol/CYTH.png,36072,-0.76,0.0155,16759,-20030781,-20057302,"[{'period': '2023', 'revenue': 1.08, 'unit': 'M', 'net_profit': -20.06}, {'period': '2022', 'revenue': 1.38, 'unit': 'M', 'net_profit': -15.28}, {'period': '2021', 'revenue': 1.59, 'unit': 'M', 'net_profit': -14.31}, {'period': '2020', 'revenue': 0.90338, 'unit': 'M', 'net_profit': -8.92}]","[{'period': ""Q3 '24"", 'revenue': 0.23377, 'unit': 'M', 'net_profit': -8.83}, {'period': ""Q2 '24"", 'revenue': 0.1231, 'unit': 'M', 'net_profit': -5.98}, {'period': ""Q1 '24"", 'revenue': 0.20245, 'unit': 'M', 'net_profit': -4.34}, {'period': ""Q4 '23"", 'revenue': 0.3114, 'unit': 'M', 'net_profit': -5.64}, {'period': ""Q3 '23"", 'revenue': 0.49548000000000003, 'unit': 'M', 'net_profit': -4.77}, {'period': ""Q2 '23"", 'revenue': 0.11712, 'unit': 'M', 'net_profit': -4.64}]",-1.23,-1.23,13247538,12318257,9246592,8490531,122379,0,8468047,9246592,-16187446,-0.28382649982486674,-0.31266010422849905,0.32044198895027626,__nan__,__nan__,__nan__,0.6409138815076432
1040,CYTHW,Cyclo Therapeutics Inc. Warrant,"Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.",Mr. N. Scott Fine,Drug Manufacturers - Specialty & Generic,0.247,USD,31466788,https://images.financialmodelingprep.com/symbol/CYTHW.png,1461,,0.067,34177,-20030781,-20057302,"[{'period': '2023', 'revenue': 1.08, 'unit': 'M', 'net_profit': -20.06}, {'period': '2022', 'revenue': 1.38, 'unit': 'M', 'net_profit': -15.28}, {'period': '2021', 'revenue': 1.59, 'unit': 'M', 'net_profit': -14.31}, {'period': '2020', 'revenue': 0.90338, 'unit': 'M', 'net_profit': -8.92}]","[{'period': ""Q3 '24"", 'revenue': 0.23377, 'unit': 'M', 'net_profit': -8.83}, {'period': ""Q2 '24"", 'revenue': 0.1231, 'unit': 'M', 'net_profit': -5.98}, {'period': ""Q1 '24"", 'revenue': 0.20245, 'unit': 'M', 'net_profit': -4.34}, {'period': ""Q4 '23"", 'revenue': 0.3114, 'unit': 'M', 'net_profit': -5.64}, {'period': ""Q3 '23"", 'revenue': 0.49548000000000003, 'unit': 'M', 'net_profit': -4.77}, {'period': ""Q2 '23"", 'revenue': 0.11712, 'unit': 'M', 'net_profit': -4.64}]",-1.23,-1.23,13247538,12318257,9246592,8490531,122379,0,8468047,9246592,-16187446,-0.28382649982486674,-0.31266010422849905,0.32044198895027626,__nan__,__nan__,__nan__,0.6409138815076432
1041,CYTK,Cytokinetics Incorporated Common Stock,"Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.",Mr. Robert I. Blum,Biotechnology,48.46,USD,5718958440,https://images.financialmodelingprep.com/symbol/CYTK.png,1154412,-9.01,-0.73,494657,-456684000,-526244000,"[{'period': '2023', 'revenue': 7.53, 'unit': 'M', 'net_profit': -526.24}, {'period': '2022', 'revenue': 94.59, 'unit': 'M', 'net_profit': -402.55}, {'period': '2021', 'revenue': 70.43, 'unit': 'M', 'net_profit': -242.37}, {'period': '2020', 'revenue': 55.83, 'unit': 'M', 'net_profit': -164.13}]","[{'period': ""Q3 '24"", 'revenue': 0.463, 'unit': 'M', 'net_profit': -160.54}, {'period': ""Q2 '24"", 'revenue': 0.249, 'unit': 'M', 'net_profit': -143.32}, {'period': ""Q1 '24"", 'revenue': 0.835, 'unit': 'M', 'net_profit': -135.64}, {'period': ""Q4 '23"", 'revenue': 1.67, 'unit': 'M', 'net_profit': -136.9}, {'period': ""Q3 '23"", 'revenue': 0.378, 'unit': 'M', 'net_profit': -129.42}, {'period': ""Q2 '23"", 'revenue': 0.867, 'unit': 'M', 'net_profit': -128.64}]",-5.45,-5.45,824316000,628051000,614824000,1210639000,1283000,40534000,102678000,113024000,-415749000,-0.38641165755919854,-0.3072696198255132,-0.21651785714285707,__nan__,__nan__,__nan__,1.4686588638337725
1042,CZNC,Citizens & Northern Corp Common Stock,"Citizens & Northern Corporation operates as the bank holding company for Citizens & Northern Bank that provides a range of banking and mortgage services to individual and corporate customers. The company offers lending products include commercial, mortgage, and consumer loans, as well as specialized instruments, such as commercial letters-of-credit; and deposit products, including various types of checking accounts, passbook and statement savings accounts, money market accounts, interest checking accounts, individual retirement accounts, and certificates of deposits. It also offers wealth management services, including administration of trusts and estates, retirement plans, and other employee benefit plans, and investment management services; and a range of personal and commercial insurance products; mutual funds, annuities, educational savings accounts, and other investment products through registered agents. In addition, the company reinsures credit and mortgage, life and accident, and health insurance products. As of December 31, 2021, it had 31 branch offices, including 23 in the Northern tier/Northcentral region of Pennsylvania, 2 in the Southern tier of New York State, 4 in Southeastern Pennsylvania, and 2 in Southcentral Pennsylvania, as well as a lending office in Elmira, New York. The company was founded in 1864 and is based in Wellsboro, Pennsylvania.",Mr. J. Bradley Scovill,Banks - Regional,17.95,USD,276683095,https://images.financialmodelingprep.com/symbol/CZNC.png,28185,12.47,,0,0,24148000,"[{'period': '2023', 'revenue': 104.63, 'unit': 'M', 'net_profit': 24.15}, {'period': '2022', 'revenue': 105.96, 'unit': 'M', 'net_profit': 26.62}, {'period': '2021', 'revenue': 103.82, 'unit': 'M', 'net_profit': 30.55}, {'period': '2020', 'revenue': 90.85, 'unit': 'M', 'net_profit': 19.22}]","[{'period': ""Q3 '24"", 'revenue': 26.08, 'unit': 'M', 'net_profit': 6.37}, {'period': ""Q2 '24"", 'revenue': 39.19, 'unit': 'M', 'net_profit': 6.11}, {'period': ""Q1 '24"", 'revenue': 37.02, 'unit': 'M', 'net_profit': 5.31}, {'period': ""Q4 '23"", 'revenue': 35.91, 'unit': 'M', 'net_profit': 4.26}, {'period': ""Q3 '23"", 'revenue': 25.65, 'unit': 'M', 'net_profit': 7.59}, {'period': ""Q2 '23"", 'revenue': 26.6, 'unit': 'M', 'net_profit': 6.04}]",1.57,1.57,2515584000,66495999,537484000,2253203001,9140000,28599000,1525000,56878000,31283000,-1,-0.09279434968818093,-0.0818713450292397,"[0.28, 0.4822]","['2024-10-28', '1994-06-24']",__nan__,0.8956977787265303
1043,CZR,Caesars Entertainment Inc. Common Stock,"Caesars Entertainment, Inc. operates as a gaming and hospitality company in the United States. The company operates casinos comprising poker, keno, and race and online sportsbooks; dining venues, bars, nightclubs, and lounges; hotels; and entertainment venues. It also provides staffing and management services; accessories, souvenirs, and decorative items through retail stores; and online sports betting and iGaming services. As of December 31,2021, the company owned, leased, and managed 52 domestic properties in 16 states, consisting of approximately 55,700 slot machines, video lottery terminals, and e-tables; 2,900 table games; and 47,700 hotel rooms. Caesars Entertainment, Inc. was founded in 1937 and is based in Reno, Nevada.",Mr. Thomas Robert Reeg CFA,"Gambling, Resorts & Casinos",33.23,USD,7060710400,https://images.financialmodelingprep.com/symbol/CZR.png,3887506,-19.78,-0.16,2472983,3555000000,786000000,"[{'period': '2023', 'revenue': 11530.0, 'unit': 'M', 'net_profit': 786.0}, {'period': '2022', 'revenue': 10820.0, 'unit': 'M', 'net_profit': -524.0}, {'period': '2021', 'revenue': 9570.0, 'unit': 'M', 'net_profit': -986.0}, {'period': '2020', 'revenue': 3.47, 'unit': 'B', 'net_profit': -1.76}]","[{'period': ""Q3 '24"", 'revenue': 2870.0, 'unit': 'M', 'net_profit': -9.0}, {'period': ""Q2 '24"", 'revenue': 2830.0, 'unit': 'M', 'net_profit': -122.0}, {'period': ""Q1 '24"", 'revenue': 2740.0, 'unit': 'M', 'net_profit': -158.0}, {'period': ""Q4 '23"", 'revenue': 2830.0, 'unit': 'M', 'net_profit': -72.0}, {'period': ""Q3 '23"", 'revenue': 2990.0, 'unit': 'M', 'net_profit': 74.0}, {'period': ""Q2 '23"", 'revenue': 2880.0, 'unit': 'M', 'net_profit': 920.0}]",3.66,3.64,33366000000,2045000000,1005000000,28646000000,608000000,157000000,2690000000,1005000000,515000000,0.15949119373776907,2.5,2.4938775510204083,__nan__,__nan__,__nan__,0.8585386321405023
1044,CZWI,Citizens Community Bancorp Inc. Common Stock,"Citizens Community Bancorp, Inc. operates as a bank holding company for Citizens Community Federal N.A. that provides various traditional community banking services to businesses, agricultural operators, and consumers. The company accepts various deposit products, including demand deposits, savings and money market accounts, and certificates of deposit. It also offers various loan products comprising commercial real estate, commercial and industrial, agricultural real estate, agricultural operating, and consumer loans; and one-to-four family residential mortgages and home equity lines-of-credit. In addition, the company provides a portfolio of investments, such as mortgage-backed, corporate asset-backed, U.S. Government sponsored agency, corporate debt, and trust preferred securities. It operates through a network of 25 full-service branch in Wisconsin and Minnesota. Citizens Community Bancorp, Inc. was founded in 1938 and is based in Eau Claire, Wisconsin.",Mr. Stephen M. Bianchi,Banks - Regional,16,USD,160542400,https://images.financialmodelingprep.com/symbol/CZWI.png,24041,11.19,-0.11,9740,22058000,13059000,"[{'period': '2023', 'revenue': 58.54, 'unit': 'M', 'net_profit': 13.06}, {'period': '2022', 'revenue': 67.19, 'unit': 'M', 'net_profit': 17.76}, {'period': '2021', 'revenue': 69.69, 'unit': 'M', 'net_profit': 21.27}, {'period': '2020', 'revenue': 68.4, 'unit': 'M', 'net_profit': 12.72}]","[{'period': ""Q3 '24"", 'revenue': 14.14, 'unit': 'M', 'net_profit': 3.29}, {'period': ""Q2 '24"", 'revenue': 24.28, 'unit': 'M', 'net_profit': 3.67}, {'period': ""Q1 '24"", 'revenue': 25.8, 'unit': 'M', 'net_profit': 4.09}, {'period': ""Q4 '23"", 'revenue': 24.35, 'unit': 'M', 'net_profit': 3.69}, {'period': ""Q3 '23"", 'revenue': 14.59, 'unit': 'M', 'net_profit': 2.5}, {'period': ""Q2 '23"", 'revenue': 14.61, 'unit': 'M', 'net_profit': 3.21}]",1.25,1.25,1851391000,37138000,37138000,1678057000,0,21498000,0,37138000,11757000,-0.2010576261364048,-0.26473734587016495,-0.2603550295857988,"[0.32, 0.0262]","['2024-02-08', '2004-07-30']",__nan__,0.9063763408161755
1045,DADA,Dada Nexus Limited American Depositary Shares,"Dada Nexus Limited operates a platform of local on-demand retail and delivery in the People's Republic of China. It operates Dada Now, a local on-demand delivery platform that provides intra-city delivery and last-mile delivery services on an on-demand basis to chain merchants, small- and medium-sized enterprise merchants, and individual senders; and JDDJ, a local on-demand retail platform for consumers, retailers, and brand owner. The company was incorporated in 2014 and is headquartered in Shanghai, the People's Republic of China.",Mr. Jun  Mao,Specialty Retail,1.315,USD,347262360,https://images.financialmodelingprep.com/symbol/DADA.png,1351261,-1.2,-0.005,716923,-1446024000,-1957543000,"[{'period': '2023', 'revenue': 10.51, 'unit': 'B', 'net_profit': -1.96}, {'period': '2022', 'revenue': 9.37, 'unit': 'B', 'net_profit': -2.01}, {'period': '2021', 'revenue': 6.87, 'unit': 'B', 'net_profit': -2.47}, {'period': '2020', 'revenue': 5.74, 'unit': 'B', 'net_profit': -1.71}]","[{'period': ""Q3 '24"", 'revenue': 2430.0, 'unit': 'M', 'net_profit': -197.33}, {'period': ""Q2 '24"", 'revenue': 2350.0, 'unit': 'M', 'net_profit': -286.23}, {'period': ""Q1 '24"", 'revenue': 2450.0, 'unit': 'M', 'net_profit': -327.97}, {'period': ""Q4 '23"", 'revenue': 2.25, 'unit': 'B', 'net_profit': -1.28}, {'period': ""Q3 '23"", 'revenue': 2870.0, 'unit': 'M', 'net_profit': -165.98}, {'period': ""Q2 '23"", 'revenue': 2810.0, 'unit': 'M', 'net_profit': -158.73}]",-7.52,-7.52,7573881000,6068998000,3451347000,2016965000,386768000,0,1999572000,1893032000,-388086000,0.10850476041925475,0.025130415511913567,0.04930467762326177,__nan__,__nan__,__nan__,0.26630534596463823
1046,DAIO,Data I/O Corporation Common Stock,"Data I/O Corporation engages in the design, manufacture, and sale of programming and security deployment systems and services for electronic device manufacturers in the United States, Europe, and internationally. The company's programming system products are used to program integrated circuits (ICs) with the specific data necessary for the ICs. It offers PSV handlers offline automated programming systems; SentriX, a security deployment system; RoadRunner and RoadRunner3 series handlers, an in-line automated programming systems; LumenX Programmer; and non-automated FlashPAK III programming systems. The company also provides hardware support, system installation and repair, and device programming services. It markets and sells its products to original equipment manufacturers in automotive and consumer electronics, Internet of Things and their programming center partners, and electronic manufacturing service contract manufacturers through direct sales, and indirect sales representatives and distributors. Data I/O Corporation was incorporated in 1969 and is headquartered in Redmond, Washington.",Mr. William O. Wentworth,"Hardware, Equipment & Parts",2.981,USD,27532576,https://images.financialmodelingprep.com/symbol/DAIO.png,31654,-14.2,-0.049,28438,1056000,486000,"[{'period': '2023', 'revenue': 28060.0, 'unit': 'K', 'net_profit': 486.0}, {'period': '2022', 'revenue': 24.22, 'unit': 'M', 'net_profit': -1.12}, {'period': '2021', 'revenue': 25840.0, 'unit': 'K', 'net_profit': -555.0}, {'period': '2020', 'revenue': 20.33, 'unit': 'M', 'net_profit': -3.96}]","[{'period': ""Q3 '24"", 'revenue': 5420.0, 'unit': 'K', 'net_profit': -307.0}, {'period': ""Q2 '24"", 'revenue': 5060.0, 'unit': 'K', 'net_profit': -797.0}, {'period': ""Q1 '24"", 'revenue': 6100.0, 'unit': 'K', 'net_profit': -807.0}, {'period': ""Q4 '23"", 'revenue': 6870.0, 'unit': 'K', 'net_profit': 144.0}, {'period': ""Q3 '23"", 'revenue': 6560.0, 'unit': 'K', 'net_profit': -53.0}, {'period': ""Q2 '23"", 'revenue': 7400.0, 'unit': 'K', 'net_profit': 300.0}]",0.0544,0.0536,27401000,24613000,12341000,7082000,5707000,0,6188000,12341000,1233000,6.587301587301587,1.4339285714285714,1.4184615384615384,"[4.15, 4.15]","['1989-03-09', '1989-03-09']",__nan__,0.25845772052114885
1047,DAKT,Daktronics Inc. Common Stock,"Daktronics, Inc. designs, manufactures, markets, and sells electronic display systems and related products worldwide. It operates through five segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company offers video display systems, such as displays to show various levels of video, graphics, and animation; indoor and outdoor light emitting diodes (LED) video displays, including centerhung, landmark, ribbon board, and corporate office entrance displays, as well as video walls and hanging banners; mobile and modular display systems; architectural lighting and display products; indoor and outdoor scoreboards for various sports, digit displays, scoring and timing controllers, statistics software, and other related products; and timing systems for sports events primarily aquatics and track competitions, as well as swimming touchpads, race start systems, and relay take-off platforms. It also provides control components for video displays in live event applications; message displays; ITS dynamic message signs, including LED displays for road management; mass transit displays; and sound systems for indoor and outdoor sports venues. In addition, the company offers out-of-home advertising displays comprising digital billboards and street furniture displays; DataTime product line that consists of outdoor time and temperature displays; and Fuelight digit displays designed for the petroleum industry. Further, it provides ADFLOW DMS systems that include indoor networked solutions for retailers, convenience stores, and other businesses; and Venus Control Suite, Show Control, Vanguard, and others, as well as maintenance and professional services related to its products. The company sells its products through direct sales and resellers. Daktronics, Inc. was founded in 1968 and is headquartered in Brookings, South Dakota.",Mr. Reece A. Kurtenbach,"Hardware, Equipment & Parts",16.77,USD,787960251,https://images.financialmodelingprep.com/symbol/DAKT.png,477440,26.62,0.11,206965,104855000,34621000,"[{'period': '2024', 'revenue': 818.08, 'unit': 'M', 'net_profit': 34.62}, {'period': '2023', 'revenue': 754.2, 'unit': 'M', 'net_profit': 6.8}, {'period': '2022', 'revenue': 610970.0, 'unit': 'K', 'net_profit': 592.0}, {'period': '2021', 'revenue': 482.03, 'unit': 'M', 'net_profit': 10.93}]","[{'period': ""Q2 '25"", 'revenue': 208.33, 'unit': 'M', 'net_profit': 21.41}, {'period': ""Q1 '25"", 'revenue': 226.09, 'unit': 'M', 'net_profit': -4.95}, {'period': ""Q4 '24"", 'revenue': 215.88, 'unit': 'M', 'net_profit': 2.52}, {'period': ""Q3 '24"", 'revenue': 170.3, 'unit': 'M', 'net_profit': 10.74}, {'period': ""Q2 '24"", 'revenue': 199.37, 'unit': 'M', 'net_profit': 2.17}, {'period': ""Q1 '24"", 'revenue': 232.53, 'unit': 'M', 'net_profit': 19.2}]",0.75,0.74,527884000,401949000,81299000,289092000,173732000,2375000,192296000,81299000,46261000,1.4409293013944178,4.089826521611291,4,"[0.05, 0.1]","['2020-03-06', '2005-06-10']",__nan__,0.5476430427897038
1048,DARE,Dare Bioscience Inc. Common Stock,"Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Dar Bioscience, Inc. is headquartered in San Diego, California.",Ms. Sabrina Martucci Johnson,Biotechnology,3.37,USD,29320314,https://images.financialmodelingprep.com/symbol/DARE.png,51529,-5.81,0.01,12505,-30901517,-30161391,"[{'period': '2023', 'revenue': 2.81, 'unit': 'M', 'net_profit': -30.16}, {'period': '2022', 'revenue': 10.0, 'unit': 'M', 'net_profit': -30.95}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -38.33}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -27.4}]","[{'period': ""Q3 '24"", 'revenue': 0.04169, 'unit': 'M', 'net_profit': -4.7}, {'period': ""Q2 '24"", 'revenue': 0.02244, 'unit': 'M', 'net_profit': 12.91}, {'period': ""Q1 '24"", 'revenue': 0.009300000000000001, 'unit': 'M', 'net_profit': -6.76}, {'period': ""Q4 '23"", 'revenue': 1.81, 'unit': 'M', 'net_profit': -5.06}, {'period': ""Q3 '23"", 'revenue': 1.0, 'unit': 'M', 'net_profit': -8.3}, {'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.76}]",-4.15,-4.15,21282215,17543539,10476056,26329855,949211,335000,20480436,10476056,-39486084,0.014660400086909702,0.025408868331507784,0.054669703872437206,__nan__,__nan__,__nan__,1.2371764405161774
1049,DBDR,Roman DBDR Tech Acquisition Corp. Class A Common Stock,"As of December 27, 2021, Roman DBDR Tech Acquisition Corp. was acquired by CompoSecure, L.L.C., in a reverse merger transaction. Roman DBDR Tech Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or business combination with one or more businesses in the technology, media, and telecom industries. The company was incorporated in 2020 and is based in Las Vegas, Nevada.",,Shell Companies,9.95,USD,771491180,https://images.financialmodelingprep.com/symbol/DBDR.png,218082,0,-0.13000011,34862,-165106,-165106,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -165.11}]","[{'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 176.91}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.66}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -165.11}]",-0.0057,-0.0057,237253,1038.304,236818,8202.712,0,0,98.112,603.615,,0,0,0,__nan__,__nan__,__nan__,0.03457369137587301
1050,DBDRU,Roman DBDR Tech Acquisition Corp. Unit,"As of December 27, 2021, Roman DBDR Tech Acquisition Corp. was acquired by CompoSecure, L.L.C., in a reverse merger transaction. Roman DBDR Tech Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or business combination with one or more businesses in the technology, media, and telecom industries. The company was incorporated in 2020 and is based in Las Vegas, Nevada.",Dr. Donald G. Basile Ph.D.,Shell Companies,0,USD,0,https://images.financialmodelingprep.com/symbol/DBDRU.png,935,0,0,1822,-165106,-165106,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -165.11}]","[{'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 176.91}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.66}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -165.11}]",-0.0057,-0.0057,237253,1038.304,236818,8202.712,0,0,98.112,603.615,,0,0,0,__nan__,__nan__,__nan__,0.03457369137587301
1051,DBDRW,Roman DBDR Tech Acquisition Corp. Warrant,,,,,,,,,0,-0.01999998,20251,-165106,-165106,"[{'period': '2020', 'revenue': 0.0, 'unit': 'K', 'net_profit': -165.11}]","[{'period': ""Q3 '21"", 'revenue': 0.0, 'unit': 'K', 'net_profit': 176.91}, {'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -21.66}, {'period': ""Q1 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': 8.93}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -165.11}, {'period': ""Q3 '20"", 'revenue': 0.0, 'unit': '', 'net_profit': 0.0}]",-0.03,-0.03,237.25339300000002,1.0383040000000001,236.818704,8.202712,0,236.215089,0.09811199999999999,0.603615,-525572,0,0,0,__nan__,__nan__,__nan__,0.03457363410604627
1052,DBGI,Digital Brands Group Inc. Common Stock,"Digital Brands Group, Inc. provides apparel under various brands on direct-to-consumer and wholesale basis. The company offers denims under the DSTLD brand; and luxury men's suiting under the ACE Studios brand. It also designs, manufactures, and sells women's apparel, such as dresses, tops, jumpsuits, bottoms, sets, jackets, and rompers under the Bailey brand. It offers luxury custom and made-to- measure suiting and sportwear, as well as shirts, jackets, pants, shorts, polos, and other products that are made-to-measure under the Harper & Jones brand. The company also offers luxury T-shirts, tops, and bottoms under the Stateside brand. Digital Brands Group, Inc. sells directly to the consumer through its websites, as well as through its wholesale channel in specialty stores, select department stores, and own showrooms. The company was formerly known as Denim.LA, Inc. Digital Brands Group, Inc. was incorporated in 2012 and is headquartered in Austin, Texas.",Mr. John Hilburn Davis IV,Apparel - Retail,1.6,USD,1235629,https://images.financialmodelingprep.com/symbol/DBGI.png,0,0,,0,-755035,-10247133,"[{'period': '2023', 'revenue': 14.92, 'unit': 'M', 'net_profit': -10.25}, {'period': '2022', 'revenue': 13.97, 'unit': 'M', 'net_profit': -54.15}, {'period': '2021', 'revenue': 7.58, 'unit': 'M', 'net_profit': -32.36}, {'period': '2020', 'revenue': 5.24, 'unit': 'M', 'net_profit': -10.73}]","[{'period': ""Q3 '24"", 'revenue': 2.44, 'unit': 'M', 'net_profit': -3.54}, {'period': ""Q2 '24"", 'revenue': 3.4, 'unit': 'M', 'net_profit': -3.51}, {'period': ""Q1 '24"", 'revenue': 3580.0, 'unit': 'K', 'net_profit': -683.74}, {'period': ""Q4 '23"", 'revenue': 2.79, 'unit': 'M', 'net_profit': -3.72}, {'period': ""Q3 '23"", 'revenue': 3.26, 'unit': 'M', 'net_profit': -5.44}, {'period': ""Q2 '23"", 'revenue': 4.49, 'unit': 'M', 'net_profit': 5.04}]",-24.14,-24.14,25336033,5559687,20773,23733441,412644,0,23215407,20773,-6042617,0.9451565450195952,0.810753438459385,0.9862458763268399,__nan__,__nan__,__nan__,0.9367465301296379
1053,DBGIW,Digital Brands Group Inc. Warrant,"Digital Brands Group, Inc. provides apparel under various brands on direct-to-consumer and wholesale basis. It operates as a digitally native vertical brand that sources products from third-party manufacturers and sells directly to the end consumer through its websites, as well as through its wholesale channel in specialty stores, select department stores, and own showrooms. The company offers denims under the DSTLD brand; and luxury men's suiting under the ACE Studios brand. It also designs, manufactures, and sells women's apparel, including dresses, tops, jumpsuits, bottoms, sets, jackets, and rompers under the Bailey brand. The company was formerly known as Denim.LA, Inc. Digital Brands Group, Inc. was founded in 2012 and is headquartered in Austin, Texas.",Mr. John Hilburn Davis IV,Apparel - Retail,16,USD,30472320,https://images.financialmodelingprep.com/symbol/DBGIW.png,0,,3.39,818,-755035,-10247133,"[{'period': '2023', 'revenue': 14.92, 'unit': 'M', 'net_profit': -10.25}, {'period': '2022', 'revenue': 13.97, 'unit': 'M', 'net_profit': -54.15}, {'period': '2021', 'revenue': 7.58, 'unit': 'M', 'net_profit': -32.36}, {'period': '2020', 'revenue': 5.24, 'unit': 'M', 'net_profit': -10.73}]","[{'period': ""Q3 '24"", 'revenue': 2.44, 'unit': 'M', 'net_profit': -3.54}, {'period': ""Q2 '24"", 'revenue': 3.4, 'unit': 'M', 'net_profit': -3.51}, {'period': ""Q1 '24"", 'revenue': 3580.0, 'unit': 'K', 'net_profit': -683.74}, {'period': ""Q4 '23"", 'revenue': 2.79, 'unit': 'M', 'net_profit': -3.72}, {'period': ""Q3 '23"", 'revenue': 3.26, 'unit': 'M', 'net_profit': -5.44}, {'period': ""Q2 '23"", 'revenue': 4.49, 'unit': 'M', 'net_profit': 5.04}]",-24.14,-24.14,25336033,5559687,20773,23733441,412644,0,23215407,20773,-6042617,0.9451565450195952,0.810753438459385,0.9862458763268399,__nan__,__nan__,__nan__,0.9367465301296379
1054,DBTX,Decibel Therapeutics Inc. Common Stock,"Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.",Dr. Laurence E. Reid Ph.D.,Biotechnology,4.91,USD,123373079,https://images.financialmodelingprep.com/symbol/DBTX.png,214738,-1.9330708661417324,-0.04,1055379,-62495000,-63005000,"[{'period': '2022', 'revenue': 0.0, 'unit': 'M', 'net_profit': -63.01}, {'period': '2021', 'revenue': 0.0, 'unit': 'M', 'net_profit': -51.82}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -37.64}, {'period': '2019', 'revenue': 0.0, 'unit': 'M', 'net_profit': -41.26}]","[{'period': ""Q2 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -18.14}, {'period': ""Q1 '23"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -13.3}, {'period': ""Q4 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -15.94}, {'period': ""Q3 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -16.0}, {'period': ""Q2 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -17.05}, {'period': ""Q1 '22"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -14.02}]",-2.52,-2.52,123373000,108030000,104561000,41580000,0,0,22442000,34607000,-57361000,-0.28016305461100416,-0.21577291936012968,-0.05882352941176476,__nan__,__nan__,__nan__,0.3370267400484709
1055,DBVT,DBV Technologies S.A. American Depositary Shares,"DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.",Mr. Daniel  Tass,Biotechnology,3.39,USD,69528778,https://images.financialmodelingprep.com/symbol/DBVT.png,799958,-0.64,0.02,2392,-87464694,-72726000,"[{'period': '2023', 'revenue': 15.73, 'unit': 'M', 'net_profit': -72.73}, {'period': '2022', 'revenue': 4.8, 'unit': 'M', 'net_profit': -96.3}, {'period': '2021', 'revenue': 5.71, 'unit': 'M', 'net_profit': -97.81}, {'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -195.68}]","[{'period': ""Q3 '24"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -30.44}, {'period': ""Q2 '24"", 'revenue': 1.16, 'unit': 'M', 'net_profit': -33.12}, {'period': ""Q1 '24"", 'revenue': 1.41, 'unit': 'M', 'net_profit': -27.34}, {'period': ""Q4 '23"", 'revenue': 8.88, 'unit': 'M', 'net_profit': -11.19}, {'period': ""Q3 '23"", 'revenue': 2.4, 'unit': 'M', 'net_profit': -16.7}, {'period': ""Q2 '23"", 'revenue': 2.29, 'unit': 'M', 'net_profit': -24.24}]",-0.71,-0.71,182986000,158915000,141367000,42799000,15445000,3684424,37339000,141367000,-80330000,-0.1406555175160386,0.244797507788162,0.4274193548387097,__nan__,__nan__,__nan__,0.23389221033303095
1056,DBX,Dropbox Inc. Class A Common Stock,"Dropbox, Inc. provides a content collaboration platform worldwide. Its platform allows individuals, families, teams, and organizations to collaborate and sign up for free through its website or app, as well as upgrade to a paid subscription plan for premium features. As of December 31, 2021, the company had approximately 700 million registered users. It serves customers in professional services, technology, media, education, industrial, consumer and retail, and financial services industries. The company was formerly known as Evenflow, Inc. and changed its name to Dropbox, Inc. in October 2009. Dropbox, Inc. was incorporated in 2007 and is headquartered in San Francisco, California.",Mr. Andrew W. Houston,Software - Infrastructure,29.645,USD,9181950890,https://images.financialmodelingprep.com/symbol/DBX.png,2837022,17.14,-0.425,2067283,553500000,453600000,"[{'period': '2023', 'revenue': 2500.0, 'unit': 'M', 'net_profit': 453.6}, {'period': '2022', 'revenue': 2320.0, 'unit': 'M', 'net_profit': 553.2}, {'period': '2021', 'revenue': 2160.0, 'unit': 'M', 'net_profit': 335.8}, {'period': '2020', 'revenue': 1910.0, 'unit': 'M', 'net_profit': -256.3}]","[{'period': ""Q3 '24"", 'revenue': 638.8, 'unit': 'M', 'net_profit': 106.7}, {'period': ""Q2 '24"", 'revenue': 634.5, 'unit': 'M', 'net_profit': 110.5}, {'period': ""Q1 '24"", 'revenue': 631.3, 'unit': 'M', 'net_profit': 132.3}, {'period': ""Q4 '23"", 'revenue': 635.0, 'unit': 'M', 'net_profit': 227.3}, {'period': ""Q3 '23"", 'revenue': 633.0, 'unit': 'M', 'net_profit': 114.1}, {'period': ""Q2 '23"", 'revenue': 622.5, 'unit': 'M', 'net_profit': 43.2}]",1.33,1.31,2983500000,1516600000,1356000000,3149300000,68700000,0,1201500000,614900000,759100000,-0.19642857142857142,-0.18004338394793926,-0.130718954248366,__nan__,__nan__,__nan__,1.0555723143958438
1057,DCBO,Docebo Inc. Common Shares,"Docebo Inc. provides a cloud-based learning management system to train internal and external workforces, partners, and customers in North America, Europe, and the Asia-Pacific region. Its platform helps customers to centralize learning materials from peer enterprises and learners into one learning management system (LMS) to expedite and enrich the learning process, increase productivity, and grow teams uniformly. The company's learning platform includes Docebo Learn LMS, a cloud-based learning platform; Docebo Shape, an AI-based learning content creation tool; Docebo Content that allows to unlock the industry's best-learning content; Docebo Learning Impact, a learning measurement tool; Docebo Learning Analytics that allows learning administrators to prove their learning programs are powering their business, as well as connecting learning data to business results; Docebo Connect that connects Docebo to custom tech stack and making integrations; and Docebo Flow that allows businesses to directly inject learning into the flow of work. It also provides Docebo for Salesforce, a native integration that leverages Salesforce's application programming interface and technology architecture to produce a learning experience; and Docebo Embed (OEM) that allows original equipment manufacturers to embed and re-sell Docebo as a part of their software. In addition, the company offers Docebo Mobile App Publisher product that allows companies to create and publish own branded version of Docebo Go.Learn mobile learning applications; Docebo Extended Enterprise that breeds customer education, partner enablement, and retention; and Docebo Discover, Coach & Share that enhances the learning experience to create a culture of social learning. It serves customers in the technology, media, manufacturing, consulting and professional services, and retail industries. The company was formerly known as Docebo Canada, Inc. Docebo Inc. founded in 2005 and is based in Toronto, Canada.",Mr. Alessio  Artuffo,Software - Application,43.8524,USD,1325592273,https://images.financialmodelingprep.com/symbol/DCBO.png,64335,76.93,-0.6176,29878,8430826,2840000,"[{'period': '2023', 'revenue': 180.84, 'unit': 'M', 'net_profit': 2.84}, {'period': '2022', 'revenue': 142.91, 'unit': 'M', 'net_profit': 7.02}, {'period': '2021', 'revenue': 104.24, 'unit': 'M', 'net_profit': -13.6}, {'period': '2020', 'revenue': 62.92, 'unit': 'M', 'net_profit': -7.65}]","[{'period': ""Q3 '24"", 'revenue': 55.43, 'unit': 'M', 'net_profit': 4.96}, {'period': ""Q2 '24"", 'revenue': 53.05, 'unit': 'M', 'net_profit': 4.7}, {'period': ""Q1 '24"", 'revenue': 51.17, 'unit': 'M', 'net_profit': 5.17}, {'period': ""Q4 '23"", 'revenue': 49.28, 'unit': 'M', 'net_profit': 3.22}, {'period': ""Q3 '23"", 'revenue': 46.51, 'unit': 'M', 'net_profit': 4.05}, {'period': ""Q2 '23"", 'revenue': 43.59, 'unit': 'M', 'net_profit': -5.67}]",0.0873,0.0843,158375000,127153000,72033000,107654000,42739000,45000,100652000,71950000,15329000,-0.15630344201475413,-0.5953263037902536,-0.5635,__nan__,__nan__,__nan__,0.6797411207576953
1058,DCOM,Dime Community Bancshares Inc. Common Stock,"Dime Community Bancshares, Inc. operates as the holding company for Dime Community Bank that provides various commercial banking and financial services. It accepts time, savings, and demand deposits from the businesses, consumers, and local municipalities. The company also offers commercial real estate loans; multi-family mortgage loans; residential mortgage loans; secured and unsecured commercial and consumer loans; home equity loans; and construction and land loans. In addition, it invests in Federal Home Loan Bank, Federal National Mortgage Association, Government National Mortgage Association, and Federal Home Loan Mortgage Corporation mortgage-backed securities, collateralized mortgage obligations, and other asset backed securities; U.S. Treasury securities; New York state and local municipal obligations; U.S. government-sponsored enterprise securities; and corporate bonds. Further, the company offers certificate of deposit account registry services and insured cash sweep programs; merchant credit and debit card processing, automated teller machines, cash management services, lockbox processing, online banking services, remote deposit capture, safe deposit boxes, and individual retirement accounts; investment products and services through a third-party broker dealer; and title insurance broker services. As of December 31, 2021, it operated 60 branch locations throughout Long Island and the New York City boroughs of Brooklyn, Queens, Manhattan, and the Bronx. Dime Community Bancshares, Inc. was founded in 1910 and is headquartered in Hauppauge, New York.",Mr. Stuart H. Lubow,Banks - Regional,29.895,USD,1304731401,https://images.financialmodelingprep.com/symbol/DCOM.png,304532,19.8,-1.245,205404,0,96094000,"[{'period': '2023', 'revenue': 352.78, 'unit': 'M', 'net_profit': 96.09}, {'period': '2022', 'revenue': 418.02, 'unit': 'M', 'net_profit': 152.56}, {'period': '2021', 'revenue': 399.68, 'unit': 'M', 'net_profit': 104.0}, {'period': '2020', 'revenue': 180.48, 'unit': 'M', 'net_profit': 42.32}]","[{'period': ""Q3 '24"", 'revenue': 87.56, 'unit': 'M', 'net_profit': 13.33}, {'period': ""Q2 '24"", 'revenue': 170.14, 'unit': 'M', 'net_profit': 18.48}, {'period': ""Q1 '24"", 'revenue': 171.07, 'unit': 'M', 'net_profit': 17.69}, {'period': ""Q4 '23"", 'revenue': 82.99, 'unit': 'M', 'net_profit': 16.31}, {'period': ""Q3 '23"", 'revenue': 84.41, 'unit': 'M', 'net_profit': 14.98}, {'period': ""Q2 '23"", 'revenue': 90.62, 'unit': 'M', 'net_profit': 27.5}]",2.29,2.29,13636005000,519418000,1343787000,12409780000,55666000,0,0,457547000,85153000,-1,-0.3701067149112457,-0.38605898123324395,"[0.25, 0.21]","['2025-01-17', '1999-01-27']",__nan__,0.9100744682918495
1059,DCOMP,Dime Community Bancshares Inc. Fixed-Rate Non-Cumulative Perpetual Preferred Stock Series A,"Dime Community Bancshares, Inc. operates as the holding company for Dime Community Bank that provides various commercial banking and financial services. It accepts time, savings, and demand deposits from the businesses, consumers, and local municipalities. The company also offers commercial real estate loans; multi-family mortgage loans; residential mortgage loans; secured and unsecured commercial and consumer loans; home equity loans; and construction and land loans. In addition, it invests in Federal Home Loan Bank, Federal National Mortgage Association, Government National Mortgage Association, and Federal Home Loan Mortgage Corporation mortgage-backed securities, collateralized mortgage obligations, and other asset backed securities; U.S. Treasury securities; New York state and local municipal obligations; U.S. government-sponsored enterprise securities; and corporate bonds. Further, the company offers certificate of deposit account registry services and insured cash sweep programs; merchant credit and debit card processing, automated teller machines, cash management services, lockbox processing, online banking services, remote deposit capture, safe deposit boxes, and individual retirement accounts; investment products and services through a third-party broker dealer; and title insurance broker services. As of December 31, 2021, it operated 60 branch locations throughout Long Island and the New York City boroughs of Brooklyn, Queens, Manhattan, and the Bronx. Dime Community Bancshares, Inc. was founded in 1910 and is headquartered in Hauppauge, New York.",Mr. Stuart H. Lubow,Banks - Regional,19.8005,USD,1355586247,https://images.financialmodelingprep.com/symbol/DCOMP.png,9506,5.3,0.0205,2136,0,96094000,"[{'period': '2023', 'revenue': 352.78, 'unit': 'M', 'net_profit': 96.09}, {'period': '2022', 'revenue': 418.02, 'unit': 'M', 'net_profit': 152.56}, {'period': '2021', 'revenue': 399.68, 'unit': 'M', 'net_profit': 104.0}, {'period': '2020', 'revenue': 180.48, 'unit': 'M', 'net_profit': 42.32}]","[{'period': ""Q3 '24"", 'revenue': 87.56, 'unit': 'M', 'net_profit': 13.33}, {'period': ""Q2 '24"", 'revenue': 170.14, 'unit': 'M', 'net_profit': 18.48}, {'period': ""Q1 '24"", 'revenue': 171.07, 'unit': 'M', 'net_profit': 17.69}, {'period': ""Q4 '23"", 'revenue': 82.99, 'unit': 'M', 'net_profit': 16.31}, {'period': ""Q3 '23"", 'revenue': 84.41, 'unit': 'M', 'net_profit': 14.98}, {'period': ""Q2 '23"", 'revenue': 90.62, 'unit': 'M', 'net_profit': 27.5}]",2.29,2.29,13636005000,519418000,1343787000,12409780000,55666000,0,0,457547000,85153000,-1,-0.3701067149112457,-0.38605898123324395,"[0.34375, 0.38]","['2024-11-08', '2020-05-05']",__nan__,0.9100744682918495
1060,DCPH,Deciphera Pharmaceuticals Inc. Common Stock,"Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.",Mr. Steven L. Hoerter,Drug Manufacturers - Specialty & Generic,25.59,USD,2212920840,https://images.financialmodelingprep.com/symbol/DCPH.png,1855995,-11.57918552036199,0.02,1572857,-208858000,-194942000,"[{'period': '2023', 'revenue': 163.36, 'unit': 'M', 'net_profit': -194.94}, {'period': '2022', 'revenue': 134.04, 'unit': 'M', 'net_profit': -178.93}, {'period': '2021', 'revenue': 96.15, 'unit': 'M', 'net_profit': -296.84}, {'period': '2020', 'revenue': 42.09, 'unit': 'M', 'net_profit': -266.49}]","[{'period': ""Q1 '24"", 'revenue': 45.0, 'unit': 'M', 'net_profit': -45.08}, {'period': ""Q4 '23"", 'revenue': 48.29, 'unit': 'M', 'net_profit': -47.19}, {'period': ""Q3 '23"", 'revenue': 43.31, 'unit': 'M', 'net_profit': -49.58}, {'period': ""Q2 '23"", 'revenue': 38.3, 'unit': 'M', 'net_profit': -48.56}, {'period': ""Q1 '23"", 'revenue': 33.45, 'unit': 'M', 'net_profit': -49.61}, {'period': ""Q4 '22"", 'revenue': 36.34, 'unit': 'M', 'net_profit': -45.94}]",-2.29,-2.29,473566000,381096000,306216000,122650000,31952000,46699000,100275000,83507000,-147475000,-0.14303696325565612,-0.08948142021226059,0.03375527426160341,__nan__,__nan__,__nan__,0.25899241077273283
1061,DCRB,Decarbonization Plus Acquisition Corporation Class A Common Stock,,,,,,,,,0,0.32999992,406168,-5476998,-5476998,"[{'period': '2020', 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.48}, {'period': '2019', 'revenue': 0.0, 'unit': 'K', 'net_profit': -216.96}, {'period': '2018', 'revenue': 0.0, 'unit': '', 'net_profit': -462.0}]","[{'period': ""Q2 '21"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -8.18}, {'period': ""Q4 '20"", 'revenue': 0.0, 'unit': 'M', 'net_profit': -5.48}, {'period': ""Q2 '20"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -2.58}, {'period': ""Q4 '19"", 'revenue': 0.0, 'unit': 'K', 'net_profit': -214.12}]",-0.19,-0.19,17972571,225727721,225727721,12972568,0,0,5072192,0,-1644507,-24.244275442477875,-24.244275442477875,-23.675324675324674,__nan__,__nan__,__nan__,0.7217981222608607
